nonylphenol	B-MED
diethoxylate	I-MED
inhibits	B-MED
apoptosis	B-MED
induced	B-MED
in	O
pc12	B-MED
cells	I-MED
nonylphenol	B-MED
and	O
short-chain	B-MED
nonylphenol	I-MED
ethoxylates	I-MED
such	O
as	O
np2	B-MED
eo	I-MED
are	O
present	B-MED
in	O
aquatic	B-MED
environment	I-MED
as	O
wastewater	B-MED
contaminants	B-MED
,	O
and	O
their	O
toxic	B-MED
effects	I-MED
on	O
aquatic	B-MED
species	I-MED
have	O
been	O
reported	O
.	O
	
apoptosis	B-MED
has	O
been	O
shown	O
to	O
be	O
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
or	O
copper	B-MED
treatment	B-MED
.	O
	
to	O
understand	O
the	O
toxicity	B-MED
of	O
nonylphenol	B-MED
diethoxylate	I-MED
,	O
we	O
investigated	O
the	O
effects	B-MED
of	I-MED
np2	B-MED
eo	I-MED
on	O
apoptosis	B-MED
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
and	O
copper	B-MED
by	O
using	O
pc12	B-MED
cell	I-MED
system	I-MED
.	O
	
nonylphenol	B-MED
diethoxylate	I-MED
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-MED
viability	I-MED
from	O
apoptosis	B-MED
.	O
	
in	O
addition	O
,	O
nonylphenol	B-MED
diethoxylate	I-MED
decreased	B-MED
dna	B-MED
fragmentation	I-MED
caused	O
by	O
apoptosis	B-MED
in	O
pc12	B-MED
cells	I-MED
.	O
	
this	O
phenomenon	B-MED
was	O
confirmed	O
after	O
treating	B-MED
apoptotic	B-MED
pc12	B-MED
cells	I-MED
with	O
nonylphenol	B-MED
diethoxylate	I-MED
,	O
whereas	O
the	O
cytochrome	B-MED
c	I-MED
release	O
into	O
the	O
cytosol	B-MED
decreased	B-MED
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-MED
cells	I-MED
not	O
treated	B-MED
with	O
nonylphenol	B-MED
diethoxylate	I-MED
s	O
.	O
	
furthermore	O
,	O
bax	B-MED
contents	B-MED
in	O
apoptotic	B-MED
cells	I-MED
were	O
reduced	B-MED
after	O
exposure	B-MED
to	I-MED
nonylphenol	B-MED
diethoxylate	I-MED
.	O
	
thus	O
,	O
nonylphenol	B-MED
diethoxylate	I-MED
has	O
the	O
opposite	B-MED
effect	I-MED
on	O
apoptosis	B-MED
in	O
pc12	B-MED
cells	I-MED
compared	O
to	O
nonylphenol	B-MED
,	O
which	O
enhances	B-MED
apoptosis	B-MED
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
.	O
	
the	O
difference	B-MED
in	O
structure	B-MED
of	O
the	O
two	O
compounds	B-MED
is	O
hypothesized	B-MED
to	O
be	O
responsible	O
for	O
this	O
phenomenon	B-MED
.	O
	
these	O
results	B-MED
indicated	O
that	O
nonylphenol	B-MED
diethoxylate	I-MED
has	O
capability	B-MED
to	O
affect	O
cell	B-MED
differentiation	I-MED
and	O
development	B-MED
and	O
has	O
potentially	B-MED
harmful	B-MED
effect	I-MED
on	O
organisms	B-MED
because	O
of	O
its	O
unexpected	O
impact	B-MED
on	O
apoptosis	B-MED
.	O
	
ezh2	B-MED
and	O
zfx	B-MED
oncogenes	B-MED
in	O
malignant	B-MED
behaviour	I-MED
of	O
parathyroid	B-MED
neoplasms	I-MED
several	O
studies	B-MED
reported	O
somatic	B-MED
mutations	I-MED
of	O
many	O
genes	B-MED
men1	B-MED
,	O
ctnnb1	B-MED
,	O
cdkis	B-MED
and	O
others	O
in	O
parathyroid	B-MED
adenoma	I-MED
,	O
although	O
with	O
different	B-MED
prevalence	B-MED
.	O
	
recently	O
,	O
activating	B-MED
mutations	B-MED
of	O
the	O
ezh2	B-MED
and	O
zfx	B-MED
oncogenes	B-MED
were	O
identified	O
in	O
benign	B-MED
parathyroid	B-MED
adenoma	I-MED
by	O
whole	B-MED
exome	I-MED
sequencing	I-MED
.	O
	
the	O
same	O
mutations	B-MED
had	O
been	O
found	O
in	O
blood	B-MED
and	O
ovary	B-MED
malignant	B-MED
tumours	I-MED
.	O
	
on	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	B-MED
that	O
these	O
oncogenes	B-MED
may	O
play	O
a	O
role	O
in	O
the	O
onset	B-MED
of	O
parathyroid	B-MED
tumour	I-MED
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	B-MED
,	O
rather	O
benign	B-MED
,	O
parathyroid	B-MED
neoplasm	I-MED
.	O
	
our	O
aim	B-MED
was	O
to	O
verify	O
the	O
occurrence	B-MED
of	O
selected	O
mutations	B-MED
of	O
the	O
ezh2	B-MED
and	O
zfx	B-MED
genes	I-MED
in	O
an	O
italian	B-MED
cohort	B-MED
of	O
23	O
sporadic	B-MED
parathyroid	B-MED
carcinomas	I-MED
,	O
12	O
atypical	B-MED
and	O
45	O
typical	B-MED
adenomas	B-MED
.	O
	
dna	B-MED
was	O
extracted	B-MED
from	O
paraffin-embedded	B-MED
tissues	I-MED
,	O
pcr	B-MED
amplified	B-MED
and	O
directly	O
sequenced	B-MED
.	O
	
no	B-MED
mutations	B-MED
were	O
detected	B-MED
in	O
the	O
coding	B-MED
sequence	I-MED
and	O
boundaries	B-MED
of	O
both	O
genes	B-MED
in	O
any	O
of	O
the	O
samples	B-MED
.	O
	
two	O
polymorphisms	B-MED
of	O
the	O
ezh2	B-MED
gene	I-MED
were	O
identified	B-MED
with	O
different	B-MED
prevalence	B-MED
the	O
rs2072407	B-MED
variant	I-MED
was	O
present	B-MED
in	O
the	O
30	O
%	O
of	O
the	O
samples	B-MED
,	O
in	O
keeping	O
with	O
the	O
overall	B-MED
frequency	B-MED
in	O
larger	B-MED
populations	B-MED
,	O
while	O
the	O
rs78589034	B-MED
variant	I-MED
,	O
located	O
close	O
to	O
the	O
5'	B-MED
end	I-MED
of	O
the	O
exon	B-MED
16	I-MED
,	O
was	O
detected	B-MED
in	O
only	O
one	O
proband	B-MED
with	O
familial	B-MED
isolated	B-MED
hyperparathyroidism	B-MED
we	O
investigated	B-MED
the	O
possible	O
outcome	B-MED
on	O
the	O
splicing	B-MED
process	I-MED
.	O
	
ezh2	B-MED
and	O
zfx	B-MED
genes	I-MED
do	O
not	O
seem	O
to	O
have	O
an	O
impact	B-MED
on	O
the	O
onset	B-MED
of	O
most	O
parathyroid	B-MED
tumours	I-MED
,	O
both	O
benign	B-MED
and	O
malignant	B-MED
,	O
though	O
further	O
studies	O
on	O
larger	B-MED
cohorts	B-MED
of	O
different	B-MED
ethnicity	B-MED
patient	B-MED
-	O
physician	B-MED
discordance	B-MED
in	O
global	B-MED
assessment	I-MED
in	O
rheumatoid	B-MED
arthritis	I-MED
a	O
systematic	B-MED
literature	B-MED
review	I-MED
with	O
meta-analysis	B-MED
the	O
integration	O
of	O
the	O
patient	B-MED
in	O
therapeutic	B-MED
decision-making	B-MED
is	O
important	O
in	O
the	O
management	B-MED
of	O
rheumatoid	B-MED
arthritis	I-MED
ra	B-MED
,	O
but	O
the	O
patient	B-MED
opinion	B-MED
regarding	O
disease	B-MED
status	B-MED
may	O
differ	O
from	O
the	O
physician's	B-MED
opinion	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
in	O
the	O
published	B-MED
literature	I-MED
the	O
frequency	B-MED
and	O
drivers	O
of	O
patient	B-MED
-	O
physician	B-MED
discordance	B-MED
in	O
global	B-MED
assessment	I-MED
in	O
ra	B-MED
.	O
	
a	O
systematic	B-MED
literature	B-MED
review	I-MED
of	O
all	O
articles	B-MED
published	B-MED
up	O
to	O
january	O
2015	O
in	O
medline	B-MED
or	O
embase	B-MED
,	O
reporting	O
discordance	B-MED
in	O
ra	B-MED
,	O
was	O
conducted	O
by	O
2	O
investigators	B-MED
.	O
	
discordance	B-MED
was	O
defined	O
based	O
on	O
the	O
absolute	B-MED
difference	I-MED
of	O
patient	B-MED
global	I-MED
pga	B-MED
and	O
physician	B-MED
global	I-MED
assessments	I-MED
phga	B-MED
on	O
0-10-cm	O
scales	O
.	O
	
the	O
frequency	B-MED
of	O
discordance	B-MED
and	O
its	O
predictors	B-MED
were	O
collected	O
in	O
each	O
study	B-MED
.	O
	
frequencies	B-MED
of	O
discordance	B-MED
were	O
pooled	B-MED
by	O
meta-analysis	B-MED
using	O
random	B-MED
effect	B-MED
.	O
	
in	O
all	O
,	O
12	O
studies	B-MED
were	O
selected	O
i.e	O
,	O
11	O
patients	B-MED
weighted	B-MED
mean	I-MED
sd	O
age	B-MED
was	O
55.1	O
13.9	O
years	B-MED
,	O
weighted	B-MED
mean	I-MED
sd	O
disease	B-MED
duration	I-MED
was	O
10.4	O
9.3	O
years	B-MED
,	O
and	O
80.7	O
were	O
women	B-MED
.	O
	
the	O
value	B-MED
of	O
the	O
difference	B-MED
|	O
pga	B-MED
-	O
phga	B-MED
|	O
defining	O
discordance	B-MED
varied	O
between	O
0.5	O
cm	O
n	O
=	O
2	O
studies	O
to	O
3	O
cm	O
n	O
=	O
5	O
studies	O
the	O
weighted	B-MED
mean	I-MED
value	I-MED
was	O
2.7	O
cm	O
.	O
	
the	O
pooled	B-MED
percentage	B-MED
of	O
patients	B-MED
with	O
discordance	B-MED
was	O
43%	O
95%	O
confidence	B-MED
interval	I-MED
36%-51%	O
range	B-MED
25%-76%	O
.	O
	
pga	B-MED
was	O
usually	O
higher	B-MED
than	O
phga	B-MED
.	O
	
the	O
drivers	O
of	O
pga	B-MED
were	O
pain	B-MED
and	O
functional	B-MED
incapacity	B-MED
,	O
whereas	O
drivers	O
of	O
phga	B-MED
were	O
joint	B-MED
counts	I-MED
and	O
acute-phase	B-MED
reactants	I-MED
.	O
	
discordance	B-MED
in	O
global	B-MED
assessment	I-MED
was	O
most	O
frequently	B-MED
defined	O
as	O
a	O
difference	B-MED
of	O
3	O
points	O
or	O
more	O
even	O
with	O
such	O
a	O
stringent	O
definition	O
,	O
up	O
to	O
half	B-MED
the	O
patients	B-MED
were	O
found	O
to	O
be	O
discordant	B-MED
.	O
	
the	O
long-term	B-MED
consequences	B-MED
of	O
this	O
discordance	B-MED
a	O
randomized	B-MED
controlled	I-MED
noninferiority	I-MED
trial	I-MED
of	O
single	B-MED
dose	I-MED
of	O
oral	B-MED
dexamethasone	I-MED
versus	O
5	O
days	B-MED
of	O
oral	B-MED
prednisone	I-MED
in	O
acute	O
adult	B-MED
asthma	B-MED
oral	B-MED
dexamethasone	I-MED
demonstrates	B-MED
bioavailability	B-MED
similar	B-MED
to	O
that	O
of	O
oral	B-MED
prednisone	I-MED
but	O
has	O
a	O
longer	O
half-life	B-MED
.	O
	
we	O
evaluate	O
whether	O
a	O
single	B-MED
dose	I-MED
of	O
oral	B-MED
dexamethasone	I-MED
plus	B-MED
4	O
days	B-MED
of	O
placebo	B-MED
is	O
not	O
inferior	B-MED
to	O
5	O
days	B-MED
of	O
oral	B-MED
prednisone	I-MED
in	O
treatment	B-MED
of	O
adults	B-MED
with	O
mild	B-MED
to	O
moderate	B-MED
asthma	B-MED
exacerbations	I-MED
to	O
prevent	B-MED
relapse	B-MED
defined	O
as	O
an	O
unscheduled	B-MED
return	O
visit	O
for	O
additional	B-MED
treatment	I-MED
for	O
persistent	B-MED
or	O
worsening	B-MED
asthma	B-MED
within	O
14	O
days	B-MED
.	O
	
adult	B-MED
emergency	B-MED
department	I-MED
patients	B-MED
aged	B-MED
18	O
to	O
55	O
years	B-MED
were	O
randomized	B-MED
to	O
receive	B-MED
either	O
a	O
single	B-MED
dose	I-MED
of	O
12	O
mg	O
of	O
oral	B-MED
dexamethasone	I-MED
with	O
4	O
days	B-MED
of	O
placebo	B-MED
or	O
a	O
5-	O
day	B-MED
course	B-MED
of	O
oral	B-MED
prednisone	I-MED
60	O
mg	O
a	O
day	B-MED
.	O
	
outcomes	B-MED
including	B-MED
relapse	B-MED
were	O
assessed	B-MED
by	O
a	O
follow-up	B-MED
telephone	I-MED
interview	I-MED
at	O
2	O
weeks	B-MED
.	O
	
one	O
hundred	B-MED
seventy-three	I-MED
dexamethasone	B-MED
and	O
203	O
prednisone	B-MED
subjects	B-MED
completed	B-MED
the	O
study	O
regimen	O
and	O
telephone	B-MED
follow-up	I-MED
.	O
	
the	O
dexamethasone	B-MED
group	B-MED
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8%	O
difference	B-MED
between	O
groups	B-MED
for	O
noninferiority	B-MED
in	O
relapse	B-MED
rates	B-MED
within	O
14	O
days	B-MED
12.1	O
versus	O
9.8	O
difference	B-MED
2.3	O
95%	O
confidence	B-MED
interval	I-MED
-4	O
to	O
8.6	O
.	O
	
subjects	B-MED
in	O
the	O
2	O
groups	B-MED
had	O
similar	O
rates	B-MED
of	O
hospitalization	B-MED
for	O
their	O
relapse	B-MED
visit	B-MED
dexamethasone	B-MED
3.4	O
versus	O
prednisone	B-MED
2.9	O
difference	B-MED
0.5	O
95%	O
confidence	B-MED
interval	I-MED
-4	O
to	O
3.1	O
.	O
	
adverse	B-MED
effect	I-MED
rates	B-MED
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	B-MED
.	O
	
a	O
single	B-MED
dose	I-MED
of	O
oral	B-MED
dexamethasone	I-MED
did	O
not	O
demonstrate	B-MED
noninferiority	B-MED
to	O
prednisone	B-MED
for	O
5	O
days	B-MED
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	B-MED
of	O
adults	B-MED
with	O
mild	B-MED
to	O
moderate	B-MED
asthma	B-MED
exacerbations	I-MED
.	O
	
enhanced	B-MED
compliance	B-MED
and	O
convenience	B-MED
may	O
support	O
the	O
use	B-MED
of	O
dexamethasone	B-MED
malignancy	B-MED
is	O
associated	B-MED
with	I-MED
microcalcification	B-MED
and	O
higher	B-MED
ap/t	I-MED
ratio	I-MED
in	O
ultrasonography	B-MED
,	O
but	O
not	O
with	O
hashimoto's	B-MED
thyroiditis	I-MED
in	O
histopathology	B-MED
in	O
patients	B-MED
with	O
thyroid	B-MED
nodules	I-MED
evaluated	O
as	O
bethesda	B-MED
category	I-MED
iii	I-MED
aus	B-MED
/	O
flus	B-MED
in	O
cytology	B-MED
the	O
predictors	B-MED
of	O
malignancy	B-MED
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-MED
in	O
nodules	B-MED
with	O
atypia	B-MED
of	I-MED
undetermined	I-MED
significance	I-MED
/	O
follicular	B-MED
lesion	I-MED
of	I-MED
undetermined	I-MED
significance	I-MED
aus	B-MED
/	O
flus	B-MED
.	O
	
our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B-MED
,	O
clinical	B-MED
,	O
and	O
biochemical	B-MED
predictors	I-MED
of	O
malignancy	B-MED
in	O
these	O
patients	B-MED
.	O
	
a	O
total	O
of	O
427	O
patients	B-MED
with	O
cytologically	B-MED
bethesda	I-MED
category	I-MED
iii	I-MED
aus	B-MED
/	O
flus	B-MED
thyroid	B-MED
nodules	I-MED
were	O
included	O
in	O
this	O
retrospective	B-MED
study	I-MED
.	O
	
we	O
divided	O
the	O
nodules	B-MED
into	O
two	O
subgroups	B-MED
according	O
to	O
the	O
histopathology	B-MED
as	O
benign	B-MED
and	O
malignant	B-MED
,	O
and	O
compared	O
the	O
preoperative	B-MED
ultrasonographical	B-MED
,	O
clinical	B-MED
,	O
and	O
biochemical	B-MED
findings	I-MED
.	O
	
in	O
overall	O
,	O
427	O
patients	B-MED
with	O
449	O
aus	B-MED
/	O
flus	B-MED
nodules	B-MED
who	O
had	O
undergone	O
surgery	B-MED
,	O
the	O
rate	O
of	O
malignancy	B-MED
was	O
23.4	O
%	O
105/449	O
.	O
	
when	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-MED
was	O
25.8	O
%	O
in	O
nodules	B-MED
with	O
aus	B-MED
82/318	O
and	O
17.6	O
%	O
in	O
nodules	B-MED
with	O
flus	B-MED
23/131	O
p	O
=	O
0.061	O
.	O
	
the	O
vast	O
majority	O
of	O
malignant	B-MED
specimens	I-MED
in	O
histopathology	B-MED
consisted	O
of	O
papillary	B-MED
thyroid	I-MED
carcinoma	I-MED
ptc	B-MED
n	O
=	O
91	O
,	O
86.7	O
%	O
.	O
	
preoperative	B-MED
ultrasonographic	B-MED
features	I-MED
of	O
105	O
malignant	B-MED
nodules	I-MED
in	O
histopathology	B-MED
were	O
compared	O
with	O
the	O
344	O
benign	B-MED
nodules	I-MED
in	O
histopathology	B-MED
.	O
	
anteroposterior/transverse	B-MED
ap/t	I-MED
ratio	I-MED
was	O
significantly	O
higher	O
in	O
malignant	B-MED
group	I-MED
compared	O
to	O
benign	B-MED
group	I-MED
p	O
=	O
0.013	O
.	O
	
in	O
multiple	B-MED
logistic	I-MED
analysis	I-MED
,	O
we	O
found	O
that	O
higher	B-MED
ap/t	I-MED
ratio	I-MED
and	O
microcalcification	B-MED
were	O
independently	O
associated	B-MED
with	I-MED
malignancy	B-MED
p	O
<	O
0.05	O
.	O
	
the	O
malignancy	B-MED
-associated	O
cut-off	O
value	O
of	O
ap/t	B-MED
ratio	I-MED
at	O
maximum	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
was	O
0.81	O
.	O
	
we	O
did	O
not	O
find	O
any	O
correlation	B-MED
between	O
malignancy	B-MED
and	O
hashimoto's	B-MED
thyroiditis	I-MED
in	O
histopathology	B-MED
in	O
multivariate	B-MED
analysis	I-MED
p	O
>	O
0.05	O
.	O
	
in	O
bethesda	B-MED
category	I-MED
iii	I-MED
nodules	I-MED
with	O
higher	B-MED
ap/t	I-MED
ratio	I-MED
and	O
microcalcification	B-MED
,	O
surgery	B-MED
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle	B-MED
aspiration	I-MED
biopsy	I-MED
or	O
impact	B-MED
of	O
cofactor	B-MED
-	O
binding	B-MED
loop	I-MED
mutations	B-MED
on	O
thermotolerance	B-MED
and	O
activity	B-MED
of	O
e	B-MED
.	O
	
coli	I-MED
transketolase	B-MED
improvement	B-MED
of	O
thermostability	B-MED
in	O
engineered	B-MED
enzymes	I-MED
can	O
allow	O
biocatalysis	B-MED
on	O
substrates	B-MED
with	O
poor	O
aqueous	B-MED
solubility	B-MED
.	O
	
denaturation	B-MED
of	O
the	O
cofactor	B-MED
-	O
binding	B-MED
loops	I-MED
of	O
escherichia	B-MED
coli	I-MED
transketolase	B-MED
tk	B-MED
was	O
previously	O
linked	O
to	O
the	O
loss	B-MED
of	O
enzyme	B-MED
activity	I-MED
under	O
conditions	B-MED
of	O
high	B-MED
ph	B-MED
or	O
urea	B-MED
.	O
	
incubation	B-MED
at	O
temperatures	B-MED
just	O
below	O
the	O
thermal	B-MED
melting	I-MED
transition	I-MED
,	O
above	O
which	O
the	O
protein	B-MED
aggregates	B-MED
,	O
was	O
also	O
found	O
to	O
anneal	B-MED
the	O
enzyme	B-MED
to	O
give	O
an	O
increased	B-MED
specific	O
activity	B-MED
.	O
	
the	O
potential	O
role	B-MED
of	O
cofactor	B-MED
-	O
binding	B-MED
loop	I-MED
instability	B-MED
in	O
this	O
process	O
remained	O
unclear	O
.	O
	
in	O
this	O
work	O
,	O
the	O
two	O
cofactor	B-MED
-	O
binding	B-MED
loops	I-MED
residues	B-MED
185-192	I-MED
and	O
382-392	B-MED
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	B-MED
from	O
the	O
thermostable	B-MED
thermus	B-MED
thermophilus	I-MED
tk	B-MED
and	O
variants	B-MED
assessed	B-MED
for	O
their	O
impact	B-MED
on	O
both	O
thermostability	B-MED
and	O
activity	B-MED
.	O
	
cofactor-binding	B-MED
loop	I-MED
2	I-MED
variants	B-MED
had	O
detrimental	B-MED
effects	I-MED
on	O
specific	O
activity	B-MED
at	O
elevated	B-MED
temperatures	B-MED
,	O
whereas	O
the	O
h192p	B-MED
mutation	I-MED
in	O
cofactor-binding	B-MED
loop	I-MED
1	I-MED
resulted	O
in	O
a	O
two-fold	O
improved	O
stability	B-MED
to	O
inactivation	B-MED
at	O
elevated	B-MED
temperatures	B-MED
,	O
and	O
increased	B-MED
the	O
critical	B-MED
onset	I-MED
temperature	I-MED
for	O
aggregation	B-MED
.	O
	
the	O
specific	O
activity	B-MED
of	O
h192p	B-MED
was	O
3-fold	O
and	O
19-fold	O
higher	B-MED
than	O
that	O
for	O
wild-type	B-MED
at	O
60	O
and	O
65	O
respectively	O
,	O
and	O
also	O
remained	O
2.7	O
fold	O
higher	B-MED
after	O
re-cooling	B-MED
from	O
pre-incubations	B-MED
at	O
either	O
55	O
or	O
60	O
for	O
1h	O
.	O
	
interestingly	O
,	O
h192p	B-MED
was	O
also	O
2-times	O
more	O
active	B-MED
than	O
wild-type	B-MED
tk	B-MED
at	O
25	O
.	O
	
optimal	B-MED
activity	B-MED
was	O
achieved	O
at	O
60	O
for	O
h192p	B-MED
compared	O
to	O
55	O
for	O
wild	B-MED
type	I-MED
.	O
	
these	O
results	O
show	O
that	O
cofactor-binding	B-MED
loop	I-MED
1	I-MED
,	O
plays	O
a	O
pivotal	O
role	B-MED
in	O
partial	B-MED
denaturation	B-MED
and	O
aggregation	B-MED
at	O
elevated	B-MED
temperatures	B-MED
.	O
	
furthermore	O
,	O
a	O
single	B-MED
rigidifying	I-MED
mutation	I-MED
within	O
this	O
loop	B-MED
can	O
significantly	O
improve	O
the	O
enzyme	B-MED
specific	I-MED
activity	I-MED
,	O
as	O
well	O
as	O
the	O
stability	B-MED
to	O
thermal	B-MED
denaturation	B-MED
and	O
aggregation	B-MED
,	O
to	O
give	O
an	O
increased	B-MED
temperature	B-MED
optimum	B-MED
for	O
safety	B-MED
of	O
transradial	B-MED
diagnostic	I-MED
cardiac	I-MED
catheterization	I-MED
in	O
patients	B-MED
under	O
oral	B-MED
anticoagulant	B-MED
therapy	I-MED
cardiac	B-MED
catheterization	I-MED
in	O
anticoagulated	B-MED
patients	B-MED
is	O
usually	O
performed	B-MED
after	O
the	O
anticoagulation	B-MED
has	O
been	O
withdrawn	B-MED
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-MED
therapy	I-MED
with	I-MED
heparin	I-MED
is	O
used	O
.	O
	
a	O
prospective	O
observational	B-MED
study	I-MED
including	O
489	O
patients	B-MED
undergoing	O
transradial	B-MED
catheterization	I-MED
was	O
conducted	O
.	O
	
a	O
total	O
of	O
140	O
patients	B-MED
were	O
under	O
acenocoumarol	B-MED
group	B-MED
a	I-MED
and	O
they	O
were	O
compared	B-MED
with	O
the	O
remainder	B-MED
group	B-MED
b	I-MED
for	O
complications	B-MED
after	O
the	O
procedure	B-MED
bleeding	B-MED
and	O
vascular	B-MED
access	I-MED
complications	I-MED
.	O
	
patients	B-MED
in	O
group	B-MED
a	I-MED
were	O
older	B-MED
74	O
years	O
vs	O
.	O
	
68	O
years	O
,	O
p<0	O
and	O
the	O
main	O
indication	B-MED
for	O
anticoagulation	B-MED
was	O
atrial	B-MED
fibrillation	I-MED
58.6	O
.	O
	
no	B-MED
complications	B-MED
occurred	O
during	O
the	O
procedures	B-MED
.	O
	
there	O
were	O
no	B-MED
acute	B-MED
bleedings	I-MED
just	O
after	B-MED
the	O
bandage	B-MED
removal	B-MED
.	O
	
during	O
the	O
first	O
24h	O
,	O
only	O
3	O
2.1	O
radial	B-MED
occlusions	I-MED
in	O
group	B-MED
a	I-MED
and	O
2	O
0.6	O
in	O
group	B-MED
b	I-MED
p=0	O
were	O
recorded	B-MED
.	O
	
hematomas	B-MED
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5%	O
of	O
the	O
group	B-MED
a	I-MED
vs	O
.	O
	
4.6	O
in	O
group	B-MED
b	I-MED
.	O
	
during	O
the	O
1-month	B-MED
follow-up	B-MED
period	B-MED
,	O
one	O
more	O
radial	B-MED
occlusion	I-MED
in	O
each	O
group	B-MED
was	O
recorded	B-MED
and	O
there	O
were	O
4	O
1.1	O
additional	O
mild	B-MED
hematomas	B-MED
in	O
group	B-MED
b	I-MED
and	O
none	O
in	O
group	B-MED
a	I-MED
p=0	O
.	O
	
performing	B-MED
a	O
transradial	B-MED
diagnostic	I-MED
cardiac	I-MED
catheterization	I-MED
without	B-MED
removal	B-MED
of	O
the	O
oral	B-MED
chronic	B-MED
anticoagulation	I-MED
appears	O
safe	B-MED
in	O
patients	B-MED
under	O
acenocumarol	B-MED
therapy	B-MED
.	O
	
does	O
infrared	B-MED
visualization	B-MED
improve	O
selection	B-MED
of	O
venipuncture	B-MED
sites	B-MED
for	O
indwelling	B-MED
needle	B-MED
at	O
the	O
forearm	B-MED
in	O
second-year	O
nursing	B-MED
students	I-MED
to	O
evaluate	O
the	O
effectiveness	B-MED
of	O
a	O
vein	B-MED
visualization	I-MED
display	I-MED
system	I-MED
using	O
near-infrared	B-MED
light	I-MED
""""	O
vein	B-MED
display	I-MED
""""	O
for	O
the	O
safe	O
and	O
proper	O
selection	B-MED
of	O
venipuncture	B-MED
sites	B-MED
for	O
indwelling	B-MED
needle	B-MED
placement	O
in	O
the	O
forearm	B-MED
.	O
	
ten	O
second	O
year	O
nursing	B-MED
students	I-MED
were	O
recruited	O
to	O
apply	O
an	O
indwelling	B-MED
needle	B-MED
line	O
with	O
and	O
without	O
vein	B-MED
display	B-MED
.	O
	
another	O
ten	O
participants	B-MED
were	O
recruited	O
from	O
various	O
faculty	B-MED
to	O
serve	O
as	O
patients	B-MED
.	O
	
the	O
quality	O
of	O
the	O
venipuncture	B-MED
procedure	I-MED
at	O
various	O
selected	O
sites	B-MED
was	O
evaluated	O
according	O
to	O
a	O
scale	B-MED
developed	O
by	O
the	O
authors	B-MED
.	O
	
time	B-MED
,	O
scores	B-MED
and	O
patterns	B-MED
of	O
puncture	B-MED
-	O
site	B-MED
selection	B-MED
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
1	O
attempt	O
1	O
tourniquet	B-MED
only	O
,	O
2	O
attempt	O
2	O
vein	B-MED
display	I-MED
only	O
and	O
3	O
attempt	O
3	O
both	O
.	O
	
to	O
validate	O
the	O
effectiveness	B-MED
of	O
vein	B-MED
display	B-MED
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O
	
we	O
found	O
that	O
venipuncture	B-MED
site	B-MED
selection	B-MED
time	O
was	O
significantly	O
improved	O
with	O
the	O
vein	B-MED
display	I-MED
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	B-MED
venipuncture	B-MED
sites	B-MED
.	O
	
overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-MED
quality	B-MED
,	O
as	O
determined	O
by	O
our	O
scale	B-MED
.	O
	
these	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
vein	B-MED
display	I-MED
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	B-MED
skills	I-MED
,	O
such	O
as	O
venipuncture	B-MED
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-MED
patients	B-MED
.	O
	
elective	B-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
decreases	B-MED
other	B-MED
cause	I-MED
mortality	I-MED
relative	B-MED
to	O
radical	B-MED
nephrectomy	I-MED
only	O
in	O
specific	B-MED
subgroups	B-MED
of	O
patients	B-MED
with	O
renal	B-MED
cell	I-MED
carcinoma	I-MED
there	O
is	O
no	O
consensus	B-MED
regarding	O
a	O
protective	B-MED
effect	I-MED
on	O
mortality	B-MED
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-MED
in	O
patients	B-MED
treated	B-MED
with	I-MED
elective	B-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
relative	B-MED
to	O
their	O
radical	B-MED
nephrectomy	I-MED
counterparts	O
.	O
	
we	O
test	B-MED
whether	O
the	O
protective	B-MED
effect	I-MED
of	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
relative	B-MED
to	O
radical	B-MED
nephrectomy	I-MED
is	O
universal	B-MED
or	O
present	O
in	O
specific	B-MED
subgroups	B-MED
of	O
patients	B-MED
.	O
	
a	O
collaborative	B-MED
database	B-MED
of	O
5	O
institutions	B-MED
was	O
queried	B-MED
to	O
evaluate	B-MED
1	O
patients	B-MED
without	O
chronic	B-MED
kidney	I-MED
disease	I-MED
diagnosed	B-MED
with	O
a	O
clinical	B-MED
t1	B-MED
renal	I-MED
mass	I-MED
that	O
was	O
treated	B-MED
with	I-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
or	O
radical	B-MED
nephrectomy	I-MED
.	O
	
multivariable	B-MED
cox	I-MED
regression	I-MED
analysis	I-MED
was	O
done	O
to	O
assess	B-MED
the	O
impact	B-MED
of	O
surgery	B-MED
type	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
vs	O
radical	B-MED
nephrectomy	I-MED
on	O
other	B-MED
cause	I-MED
mortality	I-MED
after	O
adjustment	O
for	O
patient	B-MED
and	O
cancer	B-MED
characteristics	B-MED
.	O
	
interaction	B-MED
terms	O
were	O
used	O
to	O
test	B-MED
the	O
hypothesis	O
that	O
the	O
impact	B-MED
of	O
surgery	B-MED
type	O
varies	O
according	O
to	O
specific	B-MED
subcohorts	B-MED
of	O
patients	B-MED
.	O
	
ten-year	B-MED
other	B-MED
cause	I-MED
mortality	I-MED
-free	O
survival	B-MED
rates	I-MED
were	O
90%	O
and	O
88%	O
after	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
and	O
radical	B-MED
nephrectomy	I-MED
,	O
respectively	O
.	O
	
in	O
the	O
overall	B-MED
population	B-MED
radical	B-MED
nephrectomy	I-MED
was	O
not	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
other	B-MED
cause	I-MED
mortality	I-MED
on	O
multivariable	B-MED
analysis	I-MED
compared	O
to	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
hr	B-MED
0.91	O
,	O
95%	O
ci	B-MED
0.6	O
,	O
p	O
=	O
0.6	O
.	O
	
however	O
,	O
radical	B-MED
nephrectomy	I-MED
increased	B-MED
the	O
risk	B-MED
of	O
other	B-MED
cause	I-MED
mortality	I-MED
according	O
to	O
the	O
increasing	B-MED
baseline	B-MED
charlson	B-MED
comorbidity	I-MED
index	I-MED
interaction	B-MED
test	B-MED
p	O
=	O
0.0008	O
.	O
	
for	O
example	O
,	O
in	O
a	O
patient	B-MED
with	O
a	O
charlson	B-MED
comorbidity	I-MED
index	I-MED
of	O
4	O
the	O
probability	B-MED
of	O
10-year	B-MED
other	B-MED
cause	I-MED
mortality	I-MED
-free	O
survival	B-MED
was	O
86%	O
after	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
and	O
60%	O
after	O
radical	B-MED
nephrectomy	I-MED
.	O
	
elective	B-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
does	O
not	O
improve	B-MED
other	O
cause	O
survival	B-MED
relative	B-MED
to	O
radical	B-MED
nephrectomy	I-MED
consistently	O
in	O
all	O
patients	B-MED
with	O
kidney	B-MED
cancer	I-MED
.	O
	
patients	B-MED
who	O
are	O
more	O
ill	B-MED
with	O
relevant	B-MED
comorbidities	B-MED
are	O
those	O
who	O
benefit	B-MED
the	O
most	O
from	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
in	O
terms	O
of	O
other	B-MED
cause	I-MED
mortality	I-MED
.	O
	
prospective	O
study	O
of	O
dietary	B-MED
non	B-MED
enzymatic	I-MED
antioxidant	I-MED
capacity	I-MED
on	O
the	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
in	O
the	O
elderly	B-MED
dietary	B-MED
antioxidants	I-MED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-MED
loss	I-MED
and	O
associated	O
fractures	B-MED
by	O
reducing	O
levels	O
of	O
oxidative	B-MED
stress	I-MED
.	O
	
we	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-MED
non	B-MED
enzymatic	I-MED
antioxidant	I-MED
capacity	I-MED
neac	B-MED
and	O
the	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	B-MED
.	O
	
in	O
the	O
swedish	B-MED
national	I-MED
march	I-MED
cohort	I-MED
13	O
men	B-MED
and	O
women	B-MED
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-MED
,	O
cardiovascular	B-MED
disease	I-MED
or	O
hip	B-MED
fracture	I-MED
,	O
were	O
followed	O
through	O
record-linkages	B-MED
from	O
1997	O
through	O
2010	O
.	O
	
neac	B-MED
was	O
assessed	O
by	O
a	O
validated	O
food	B-MED
frequency	I-MED
questionnaire	I-MED
collected	O
at	O
baseline	B-MED
.	O
	
we	O
categorized	O
the	O
distribution	O
of	O
neac	B-MED
into	O
sex	B-MED
-	O
specific	B-MED
quartiles	B-MED
and	O
used	O
multivariable	B-MED
adjusted	I-MED
cox	I-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
models	I-MED
to	O
estimate	O
hazard	B-MED
ratios	I-MED
hrs	B-MED
with	O
95%	O
confidence	B-MED
intervals	I-MED
95%	O
ci	B-MED
.	O
	
during	O
a	O
mean	O
follow-up	B-MED
time	B-MED
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	B-MED
fracture	I-MED
.	O
	
subjects	O
in	O
the	O
highest	O
quartile	B-MED
of	O
dietary	B-MED
neac	B-MED
had	O
a	O
39%	O
lower	B-MED
risk	I-MED
of	O
incident	O
hip	B-MED
fracture	I-MED
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	B-MED
hr	B-MED
0.61	O
95%	O
ci	B-MED
0.44	O
.	O
	
the	O
association	O
was	O
non-linear	O
p	O
for	O
non-linearity	O
0.004	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	B-MED
and	O
no	O
further	O
risk	B-MED
reduction	I-MED
at	O
higher	O
levels	O
of	O
dietary	B-MED
neac	B-MED
.	O
	
due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-MED
neac	B-MED
and	O
smoking	B-MED
on	O
a	O
multiplicative	B-MED
or	O
additive	B-MED
scale	I-MED
.	O
	
higher	O
dietary	O
neac	B-MED
intake	O
is	O
associated	O
with	O
lower	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
function	B-MED
and	O
clinical	B-MED
meaningfulness	B-MED
of	O
treatments	B-MED
for	O
mild	B-MED
alzheimer's	B-MED
disease	I-MED
effectiveness	B-MED
of	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
treatments	B-MED
is	O
commonly	O
evaluated	O
with	O
coprimary	B-MED
outcomes	I-MED
cognition	B-MED
with	O
function	B-MED
to	O
ensure	O
clinical	B-MED
meaningfulness	B-MED
of	O
a	O
cognitive	B-MED
effect	B-MED
.	O
	
we	O
reviewed	B-MED
the	O
literature	B-MED
for	O
functional	B-MED
outcomes	B-MED
in	O
mild	B-MED
ad	B-MED
or	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
mci	B-MED
patients	B-MED
distinct	O
from	O
combined	O
mild-moderate	B-MED
/	O
severe	B-MED
ad	B-MED
treated	B-MED
with	I-MED
approved	O
ad	B-MED
drugs	B-MED
.	O
	
cognitive	B-MED
and	O
functional	B-MED
treatment	B-MED
differences	O
in	O
mild	B-MED
ad	B-MED
patients	B-MED
in	O
solanezumab	B-MED
expedition	B-MED
/	O
expedition2	B-MED
studies	B-MED
were	O
compared	B-MED
across	O
time	B-MED
.	O
	
seven	O
publications	B-MED
provided	O
mci	B-MED
/	O
mild	B-MED
ad	B-MED
functional	B-MED
outcomes	B-MED
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-MED
treatment	B-MED
effect	I-MED
.	O
	
secondary	B-MED
analyses	I-MED
of	O
expedition	B-MED
studies	B-MED
suggested	O
a	O
smaller	O
functional	B-MED
effect	B-MED
of	O
solanezumab	B-MED
relative	O
to	O
cognition	B-MED
.	O
	
an	O
increasing	B-MED
effect	B-MED
of	O
solanezumab	B-MED
over	O
18	O
months	B-MED
was	O
shown	O
for	O
cognition	B-MED
and	O
function	B-MED
.	O
	
function	B-MED
as	O
the	O
sole	O
measure	B-MED
to	O
demonstrate	O
clinical	B-MED
meaningfulness	B-MED
of	O
cognitive	B-MED
effects	B-MED
in	O
mild	B-MED
ad	B-MED
may	O
have	O
limitations	B-MED
.	O
	
for	O
disease	B-MED
-	O
modifying	B-MED
treatments	B-MED
,	O
point	O
differences	O
on	O
cognitive	B-MED
and	O
functional	B-MED
scales	B-MED
should	O
be	O
qualified	O
with	O
duration	B-MED
of	I-MED
treatment	I-MED
.	O
	
in	O
search	O
of	O
the	O
e	B-MED
.	O
	
coli	I-MED
compounds	B-MED
that	O
change	O
the	O
antibiotic	B-MED
production	B-MED
pattern	O
of	O
streptomyces	B-MED
coelicolor	I-MED
during	O
inter-species	B-MED
interaction	I-MED
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	B-MED
the	O
interaction	B-MED
between	O
e.coli	B-MED
and	O
streptomyces	B-MED
coelicolor	I-MED
a3	I-MED
2	I-MED
for	O
the	O
increased	B-MED
production	B-MED
of	O
undecylprodigiosin	B-MED
and	O
identify	O
the	O
e	B-MED
.	O
	
coli	I-MED
actives	B-MED
mediating	B-MED
this	O
inter-species	B-MED
interaction	I-MED
.	O
	
the	O
antibiotics	B-MED
of	O
interest	O
were	O
the	O
red-pigmented	B-MED
undecylprodigiosin	I-MED
and	O
blue-pigmented	B-MED
actinorhodin	B-MED
.	O
	
pure	O
cultures	B-MED
of	O
s	B-MED
.	O
	
coelicolor	I-MED
in	O
a	O
defined	O
medium	B-MED
produced	O
higher	O
concentrations	B-MED
of	O
actinorhodin	B-MED
compared	B-MED
to	O
those	O
of	O
undecylprodigiosin	B-MED
.	O
	
the	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-MED
and	O
antitumor	B-MED
properties	I-MED
.	O
	
as	O
a	O
strategy	O
to	O
increase	B-MED
undecylprodigiosin	B-MED
production	B-MED
,	O
we	O
added	O
separately	O
,	O
live	B-MED
cells	I-MED
and	O
heat-killed	B-MED
cells	B-MED
of	O
e	B-MED
.	O
	
coli	I-MED
c600	I-MED
,	O
and	O
the	O
cell-free	B-MED
supernatant	I-MED
of	O
e	B-MED
.	O
	
coli	I-MED
culture	B-MED
to	O
s	B-MED
.	O
	
coelicolor	I-MED
cultures	B-MED
in	I-MED
shake	I-MED
flasks	I-MED
.	O
	
the	O
interaction	B-MED
with	O
live	B-MED
cells	I-MED
of	O
e	B-MED
.	O
	
coli	I-MED
altered	O
the	O
antibiotic	B-MED
production	B-MED
pattern	O
and	O
undecylprodigiosin	B-MED
production	B-MED
was	O
enhanced	B-MED
by	O
3.5	O
compared	O
to	O
the	O
pure	B-MED
cultures	I-MED
of	O
s	B-MED
.	O
	
coelicolor	I-MED
and	O
actinorhodin	B-MED
decreased	B-MED
by	O
15-fold	O
.	O
	
the	O
heat-killed	B-MED
cells	B-MED
of	O
e	B-MED
.	O
	
coli	I-MED
however	O
,	O
had	O
no	B-MED
effect	I-MED
on	O
antibiotic	B-MED
production	B-MED
.	O
	
in	O
all	O
cases	O
,	O
growth	B-MED
and	O
glucose	B-MED
consumption	I-MED
of	O
s	B-MED
.	O
	
coelicolor	I-MED
remained	O
almost	O
the	O
same	B-MED
as	O
those	O
observed	B-MED
in	O
the	O
pure	B-MED
culture	I-MED
indicating	O
that	O
the	O
changes	B-MED
in	O
antibiotic	B-MED
production	B-MED
were	O
not	O
due	O
to	O
nutritional	B-MED
stress	B-MED
.	O
	
results	B-MED
with	O
cell-free	B-MED
supernatant	I-MED
of	O
e	B-MED
.	O
	
coli	I-MED
culture	B-MED
indicated	O
that	O
the	O
interaction	B-MED
between	O
s	B-MED
.	O
	
coelicolor	I-MED
and	O
e	B-MED
.	O
	
coli	I-MED
was	O
mediated	B-MED
via	O
diffusible	B-MED
molecule	I-MED
.	O
	
using	O
a	O
set	O
of	O
extraction	B-MED
procedures	I-MED
and	O
agar-well	B-MED
diffusion	I-MED
bioassays	I-MED
,	O
we	O
isolated	B-MED
and	O
preliminarily	O
identified	B-MED
a	O
class	B-MED
of	I-MED
compounds	I-MED
.	O
	
for	O
the	O
preliminary	O
verification	B-MED
,	O
we	O
added	O
the	O
compound	B-MED
which	O
was	O
the	O
common	O
chemical	B-MED
structural	I-MED
moiety	I-MED
in	O
this	O
class	B-MED
of	I-MED
compounds	I-MED
to	O
the	O
pure	O
s	B-MED
.	O
	
coelicolor	I-MED
cultures	B-MED
.	O
	
we	O
observed	O
similar	O
effects	B-MED
on	O
antibiotic	B-MED
production	B-MED
as	O
with	O
the	O
live	O
e	B-MED
.	O
	
coli	I-MED
cells	B-MED
and	O
their	O
supernatant	B-MED
indicating	O
that	O
this	O
class	B-MED
of	I-MED
compounds	I-MED
secreted	B-MED
by	O
e	B-MED
.	O
	
coli	I-MED
indeed	O
could	O
act	O
as	O
actives	B-MED
during	O
interspecies	B-MED
interaction	I-MED
and	O
increase	B-MED
the	O
production	B-MED
of	O
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferents	B-MED
limit	B-MED
the	O
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
during	O
whole	B-MED
body	I-MED
exercise	B-MED
in	O
humans	B-MED
the	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	B-MED
the	O
role	B-MED
of	O
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferents	B-MED
in	O
limiting	B-MED
the	O
endurance	B-MED
exercise	B-MED
-	O
induced	B-MED
metabolic	B-MED
perturbation	B-MED
assayed	B-MED
in	O
muscle	B-MED
biopsy	B-MED
samples	I-MED
taken	O
from	O
locomotor	B-MED
muscle	B-MED
.	O
	
lumbar	B-MED
intrathecal	B-MED
fentanyl	B-MED
was	O
used	O
to	O
attenuate	B-MED
the	O
central	B-MED
projection	B-MED
of	O
μ-opioid	B-MED
receptor	I-MED
-	O
sensitive	B-MED
locomotor	B-MED
muscle	B-MED
afferents	B-MED
during	O
a	O
5	O
km	O
cycling	B-MED
time	B-MED
trial	B-MED
.	O
	
the	O
findings	B-MED
suggest	O
that	O
the	O
central	B-MED
projection	B-MED
of	O
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferent	B-MED
feedback	B-MED
constrains	B-MED
voluntary	B-MED
neural	B-MED
'	O
drive	B-MED
'	O
to	O
working	B-MED
locomotor	B-MED
muscle	B-MED
and	O
limits	B-MED
the	O
exercise	B-MED
-	O
induced	B-MED
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
.	O
	
therefore	O
,	O
the	O
cns	B-MED
might	O
regulate	B-MED
the	O
degree	B-MED
of	O
metabolic	B-MED
perturbation	B-MED
within	O
locomotor	B-MED
muscle	B-MED
and	O
thereby	O
limit	B-MED
peripheral	B-MED
fatigue	B-MED
.	O
	
it	O
appears	B-MED
that	O
the	O
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferents	B-MED
are	O
an	O
important	B-MED
neural	B-MED
link	B-MED
in	O
this	O
regulatory	B-MED
mechanism	B-MED
,	O
which	O
probably	B-MED
serves	O
to	O
protect	B-MED
locomotor	B-MED
muscle	B-MED
from	O
the	O
potentially	B-MED
severe	B-MED
functional	B-MED
impairment	I-MED
as	O
a	O
consequence	B-MED
of	O
severe	B-MED
intramuscular	B-MED
metabolic	B-MED
disturbance	B-MED
.	O
	
to	O
investigate	B-MED
the	O
role	B-MED
of	O
metabo	B-MED
-	O
and	O
mechanosensitive	B-MED
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferents	B-MED
in	O
limiting	B-MED
the	O
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
during	O
whole	B-MED
body	I-MED
endurance	B-MED
exercise	B-MED
,	O
eight	O
subjects	B-MED
performed	B-MED
5	O
km	O
cycling	B-MED
time	B-MED
trials	B-MED
under	B-MED
control	I-MED
conditions	I-MED
ctrl	B-MED
and	O
with	O
lumbar	B-MED
intrathecal	B-MED
fentanyl	B-MED
impairing	B-MED
lower	B-MED
limb	I-MED
muscle	B-MED
afferent	B-MED
feedback	B-MED
fent	B-MED
.	O
	
vastus	B-MED
lateralis	I-MED
muscle	B-MED
biopsies	B-MED
were	O
obtained	B-MED
before	B-MED
and	O
immediately	B-MED
after	B-MED
exercise	B-MED
.	O
	
motoneuronal	B-MED
output	B-MED
was	I-MED
estimated	I-MED
through	O
vastus	B-MED
lateralis	I-MED
surface	I-MED
electromyography	B-MED
emg	B-MED
.	O
	
exercise	B-MED
-	O
induced	B-MED
changes	B-MED
in	O
intramuscular	B-MED
metabolites	B-MED
were	O
determine	B-MED
d	O
using	O
liquid	B-MED
and	O
gas	B-MED
chromatography-mass	I-MED
spectrometry	I-MED
.	O
	
quadriceps	B-MED
fatigue	B-MED
was	O
quantified	B-MED
by	O
pre	B-MED
-	O
to	O
post	B-MED
-	O
exercise	B-MED
changes	B-MED
in	O
potentiated	B-MED
quadriceps	I-MED
twitch	I-MED
torque	I-MED
δqtsingle	B-MED
evoked	B-MED
by	O
electrical	B-MED
femoral	B-MED
nerve	I-MED
stimulation	B-MED
.	O
	
although	O
motoneuronal	B-MED
output	B-MED
was	O
21	O
12%	O
higher	B-MED
during	O
fent	B-MED
compared	B-MED
to	O
ctrl	B-MED
p	O
<	O
0.05	O
,	O
time	B-MED
to	O
complete	B-MED
the	O
time	B-MED
trial	B-MED
was	O
similar	B-MED
8.8	O
min	O
.	O
	
compared	B-MED
to	O
ctrl	B-MED
,	O
power	B-MED
output	I-MED
during	O
fent	B-MED
was	O
10	O
4%	O
higher	B-MED
in	O
the	O
first	B-MED
half	I-MED
of	O
the	O
time	B-MED
trial	B-MED
,	O
but	O
11	O
5%	O
lower	B-MED
in	O
the	O
second	B-MED
half	I-MED
both	O
p	O
<	O
0.01	O
.	O
	
the	O
exercise	B-MED
-	O
induced	B-MED
increase	B-MED
in	O
intramuscular	B-MED
inorganic	B-MED
phosphate	I-MED
,	O
h	B-MED
,	O
adenosine	B-MED
diphosphate	I-MED
,	O
lactate	B-MED
and	O
phosphocreatine	B-MED
depletion	B-MED
was	O
55	O
30	O
,	O
62	O
18	O
,	O
129	O
63	O
,	O
47	O
14	O
p	O
<	O
0.001	O
and	O
27	O
14%	O
p	O
<	O
0.01	O
greater	B-MED
in	O
fent	B-MED
than	O
ctrl	B-MED
.	O
	
δqtsingle	B-MED
was	O
greater	B-MED
following	O
fent	B-MED
than	O
ctrl	B-MED
-52	O
2	O
vs	O
-31	O
1%	O
,	O
p	O
<	O
0.001	O
and	O
this	O
difference	B-MED
was	O
positively	B-MED
correlated	B-MED
with	O
the	O
difference	B-MED
in	O
inorganic	B-MED
phosphate	I-MED
r	O
=	O
0.79	O
p	O
<	O
0.01	O
and	O
h	O
r	O
=	O
0.92	O
p	O
<	O
0.01	O
.	O
	
in	O
conclusion	B-MED
,	O
during	O
whole	B-MED
body	I-MED
exercise	B-MED
,	O
group	B-MED
iii/iv	I-MED
muscle	I-MED
afferents	B-MED
provide	B-MED
feedback	B-MED
to	O
the	O
cns	B-MED
which	O
,	O
in	O
turn	O
,	O
constrains	B-MED
motoneuronal	B-MED
output	B-MED
to	O
the	O
active	B-MED
skeletal	B-MED
muscle	I-MED
.	O
	
this	O
regulatory	B-MED
mechanism	B-MED
limits	B-MED
the	O
exercise	B-MED
-	O
induced	B-MED
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
,	O
preventing	O
an	O
abnormal	B-MED
homeostatic	I-MED
challenge	B-MED
and	O
excessive	B-MED
peripheral	B-MED
fatigue	B-MED
.	O
	
the	O
effects	B-MED
of	I-MED
paternal	B-MED
high-fat	B-MED
diet	I-MED
exposure	B-MED
on	O
offspring	B-MED
metabolism	B-MED
with	O
epigenetic	B-MED
changes	I-MED
in	O
the	O
mouse	O
adiponectin	B-MED
and	O
leptin	B-MED
gene	B-MED
promoters	I-MED
recent	O
studies	B-MED
have	O
demonstrated	O
that	O
epigenetic	B-MED
changes	I-MED
resulting	O
from	O
malnutrition	B-MED
might	O
play	O
important	O
roles	B-MED
in	O
transgenerational	B-MED
links	I-MED
with	O
metabolic	B-MED
diseases	I-MED
.	O
	
previously	O
,	O
we	O
observed	B-MED
that	O
exposure	B-MED
to	O
a	O
high-fat	B-MED
diet	I-MED
hfd	B-MED
in	B-MED
utero	I-MED
caused	B-MED
a	O
metabolic	B-MED
syndrome	B-MED
-like	O
phenomenon	B-MED
through	B-MED
epigenetic	B-MED
modifications	I-MED
of	O
the	O
adiponectin	B-MED
and	O
leptin	B-MED
genes	I-MED
that	O
persisted	O
for	O
multiple	B-MED
generations	B-MED
.	O
	
recent	O
etiological	B-MED
studies	B-MED
indicated	B-MED
that	O
paternal	B-MED
bmi	B-MED
had	O
effects	B-MED
on	O
offspring	B-MED
bmi	B-MED
that	O
were	O
independent	B-MED
of	I-MED
but	O
additive	B-MED
to	O
maternal	B-MED
bmi	B-MED
effects	B-MED
.	O
	
thus	O
,	O
we	O
examined	O
whether	O
paternal	B-MED
hfd	B-MED
-	O
induced	B-MED
obesity	B-MED
affected	B-MED
the	O
metabolic	B-MED
status	B-MED
of	O
offspring	B-MED
through	B-MED
epigenetic	B-MED
changes	I-MED
in	O
the	O
adiponectin	B-MED
and	O
leptin	B-MED
genes	I-MED
.	O
	
additionally	O
,	O
we	O
investigated	B-MED
whether	O
a	O
normal	B-MED
diet	I-MED
during	B-MED
subsequent	B-MED
generations	I-MED
abolished	B-MED
the	O
epigenetic	B-MED
changes	I-MED
associated	B-MED
with	I-MED
paternal	B-MED
hfd	B-MED
exposure	B-MED
before	B-MED
conception	B-MED
.	O
	
we	O
observed	B-MED
the	O
effects	B-MED
of	I-MED
paternal	B-MED
hfd	B-MED
exposure	B-MED
before	B-MED
conception	B-MED
over	O
multiple	B-MED
generations	B-MED
on	O
offspring	B-MED
metabolic	B-MED
traits	B-MED
,	O
including	B-MED
weight	B-MED
and	O
fat	B-MED
gain	B-MED
,	O
glucose	B-MED
intolerance	I-MED
,	O
hypertriglyceridemia	B-MED
,	O
abnormal	B-MED
adipocytokine	I-MED
levels	B-MED
,	O
hypertension	B-MED
,	O
and	O
adiponectin	B-MED
and	O
leptin	B-MED
gene	I-MED
expression	B-MED
and	O
epigenetic	B-MED
changes	I-MED
.	O
	
normal	B-MED
diet	I-MED
consumption	O
by	O
male	O
offspring	B-MED
during	O
the	O
subsequent	O
generation	O
following	O
paternal	B-MED
hfd	B-MED
exposure	B-MED
diminished	B-MED
whereas	O
consumption	B-MED
for	O
two	O
generations	B-MED
completely	O
abolished	B-MED
the	O
effect	B-MED
of	O
paternal	B-MED
hfd	B-MED
exposure	B-MED
on	O
metabolic	B-MED
traits	B-MED
and	O
adipocytokine	B-MED
promoter	O
epigenetic	B-MED
changes	I-MED
in	O
the	O
offspring	B-MED
.	O
	
the	O
effects	B-MED
of	I-MED
paternal	B-MED
hfd	B-MED
exposure	B-MED
on	O
offspring	B-MED
were	O
relatively	O
weaker	B-MED
than	O
those	O
following	B-MED
hfd	B-MED
exposure	B-MED
in	B-MED
utero	I-MED
.	O
	
however	O
,	O
paternal	B-MED
hfd	B-MED
exposure	B-MED
had	O
an	O
additive	B-MED
metabolic	B-MED
effect	B-MED
for	O
two	O
generations	B-MED
,	O
suggesting	O
that	O
both	O
paternal	B-MED
and	O
maternal	B-MED
nutrition	B-MED
might	O
affect	B-MED
offspring	B-MED
metabolism	B-MED
through	B-MED
epigenetic	B-MED
modifications	I-MED
of	O
adipocytokine	B-MED
genes	I-MED
for	O
multiple	B-MED
generations	B-MED
.	O
	
study	B-MED
of	O
the	O
microfocus	B-MED
x-ray	B-MED
tube	I-MED
based	O
on	O
a	O
point-like	B-MED
target	I-MED
used	O
for	O
micro-computed	B-MED
tomography	I-MED
for	O
a	O
micro-computed	B-MED
tomography	I-MED
micro-ct	I-MED
system	I-MED
,	O
the	O
microfocus	B-MED
x-ray	B-MED
tube	I-MED
is	O
an	O
essential	B-MED
component	O
because	O
the	O
spatial	B-MED
resolution	B-MED
of	O
ct	B-MED
images	B-MED
,	O
in	O
theory	B-MED
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	B-MED
and	O
stability	B-MED
of	O
the	O
x-ray	B-MED
focal	B-MED
spot	I-MED
of	O
the	O
microfocus	B-MED
x-ray	B-MED
tube	I-MED
.	O
	
however	O
,	O
many	O
factors	B-MED
,	O
including	O
voltage	B-MED
fluctuations	B-MED
,	O
mechanical	B-MED
vibrations	B-MED
,	O
and	O
temperature	B-MED
changes	I-MED
,	O
can	O
cause	B-MED
the	O
size	B-MED
and	O
the	O
stability	B-MED
of	O
the	O
x-ray	B-MED
focal	B-MED
spot	I-MED
to	O
degrade	B-MED
.	O
	
a	O
new	O
microfocus	B-MED
x-ray	B-MED
tube	I-MED
based	O
on	O
a	O
point-like	B-MED
micro-target	I-MED
in	O
which	O
the	O
x-ray	B-MED
target	B-MED
is	O
irradiated	B-MED
with	O
an	O
unfocused	O
electron	B-MED
beam	I-MED
was	O
investigated	B-MED
.	O
	
egs4	B-MED
monte	I-MED
carlo	I-MED
simulation	I-MED
code	I-MED
was	O
employed	O
for	O
the	O
calculation	B-MED
of	O
the	O
x-ray	B-MED
intensity	B-MED
produced	O
from	O
the	O
point-like	B-MED
micro-target	I-MED
and	O
the	O
substrate	B-MED
.	O
	
the	O
effects	B-MED
of	I-MED
several	O
arrangements	O
of	O
the	O
target	B-MED
material	B-MED
,	O
target	B-MED
and	O
beam	B-MED
size	B-MED
were	O
studied	B-MED
.	O
	
the	O
simulation	B-MED
results	B-MED
demonstrated	O
that	O
if	O
the	O
intensity	B-MED
of	O
x-rays	B-MED
generated	B-MED
at	O
the	O
point-like	B-MED
target	I-MED
is	O
greater	B-MED
than	I-MED
half	O
of	O
the	O
x-ray	B-MED
intensity	B-MED
produced	O
on	O
the	O
substrate	B-MED
,	O
the	O
x-ray	B-MED
focal	B-MED
spot	I-MED
is	O
determined	O
in	O
part	O
by	O
the	O
point-like	B-MED
target	I-MED
rather	O
than	O
by	O
the	O
electron	B-MED
beam	I-MED
in	O
the	O
conventional	B-MED
x-ray	B-MED
tube	I-MED
.	O
	
in	O
theory	B-MED
,	O
since	O
it	O
is	O
able	O
to	O
reduce	B-MED
those	O
unfavorable	O
effects	B-MED
such	O
as	O
the	O
electron	B-MED
beam	I-MED
trajectory	I-MED
swinging	I-MED
and	O
the	O
beam	B-MED
size	B-MED
changing	B-MED
for	O
the	O
microfocus	B-MED
x-ray	B-MED
tube	I-MED
,	O
it	O
could	O
alleviate	B-MED
ct	B-MED
image	B-MED
artifacts	B-MED
caused	B-MED
by	O
the	O
x-ray	B-MED
focal	B-MED
spot	I-MED
shift	B-MED
and	O
size	B-MED
change	I-MED
.	O
	
early	B-MED
assessment	B-MED
of	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
a	O
comparison	B-MED
between	O
the	O
laparoscopic	B-MED
total	I-MED
extraperitoneal	I-MED
and	O
stoppa	B-MED
approaches	I-MED
the	O
present	B-MED
clinical	B-MED
trial	I-MED
was	O
designed	O
to	O
compare	B-MED
the	O
results	B-MED
of	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
between	O
patients	B-MED
who	O
underwent	O
the	O
conventional	B-MED
stoppa	B-MED
technique	I-MED
and	O
laparoscopic	B-MED
total	I-MED
extraperitoneal	I-MED
repair	I-MED
lte	B-MED
with	O
a	O
single	O
mesh	B-MED
and	O
without	O
staple	B-MED
fixation	I-MED
.	O
	
this	O
controlled	O
,	O
randomised	B-MED
clinical	B-MED
trial	I-MED
was	O
conducted	O
at	O
general	B-MED
surgery	I-MED
and	I-MED
trauma	I-MED
of	I-MED
the	I-MED
clinics	I-MED
hospital	I-MED
,	O
medical	B-MED
school	I-MED
,	O
the	O
university	B-MED
of	I-MED
sγo	I-MED
paulo	I-MED
between	O
september	O
2010	O
and	O
february	O
2011	O
.	O
	
totally	O
,	O
50	O
male	B-MED
patients	B-MED
,	O
with	O
a	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
,	O
older	O
than	O
25	O
years	B-MED
were	O
considered	O
eligible	B-MED
for	O
the	O
study	B-MED
.	O
	
the	O
following	O
parameters	B-MED
were	O
analysed	B-MED
during	O
the	O
early	B-MED
post-operative	B-MED
period	I-MED
1	O
the	O
intensity	B-MED
of	O
surgical	B-MED
trauma	I-MED
,	O
operation	B-MED
time	I-MED
,	O
c-reactive	B-MED
protein	I-MED
crp	B-MED
levels	B-MED
,	O
white	B-MED
blood	I-MED
cell	I-MED
count	I-MED
,	O
bleeding	B-MED
and	O
pain	B-MED
intensity	I-MED
2	O
quality	B-MED
of	I-MED
life	I-MED
assessment	B-MED
and	O
3	O
post-operative	B-MED
complications	I-MED
.	O
	
lte	B-MED
procedure	I-MED
was	O
longer	B-MED
than	O
the	O
stoppa	B-MED
procedure	I-MED
134.6	O
min	O
38.3	O
vs	O
.	O
	
90.6	O
min	O
41.3	O
p	O
<	O
0.05	O
.	O
	
the	O
levels	B-MED
of	O
crp	B-MED
were	O
higher	B-MED
in	O
the	O
stoppa	B-MED
group	B-MED
p	O
<	O
0.05	O
but	O
the	O
number	O
of	O
leucocytes	B-MED
,	O
haematocrit	B-MED
,	O
and	O
haemoglobin	B-MED
were	O
similar	B-MED
between	O
the	O
groups	B-MED
p	O
>	O
0.05	O
.	O
	
there	O
was	O
no	B-MED
difference	I-MED
in	O
pain	B-MED
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post-operative	B-MED
,	O
physical	B-MED
functioning	I-MED
,	O
physical	B-MED
limitation	I-MED
,	O
the	O
impact	B-MED
of	O
pain	B-MED
on	O
daily	B-MED
activities	I-MED
,	O
and	O
the	O
carolinas	B-MED
comfort	I-MED
scale	I-MED
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post-operative	B-MED
p	O
>	O
0.05	O
.	O
	
complications	B-MED
occurred	O
in	O
88%	O
of	O
stoppa	B-MED
group	B-MED
22	O
patients	B-MED
and	O
64%	O
in	O
lte	B-MED
group	B-MED
16	O
patients	B-MED
p	O
<	O
0.05	O
.	O
	
the	O
comparative	B-MED
study	I-MED
between	O
the	O
stoppa	B-MED
and	O
lte	B-MED
approaches	O
for	O
the	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
demonstrated	O
that	O
1	O
the	O
lte	B-MED
approach	O
showed	O
less	O
surgical	B-MED
trauma	I-MED
despite	O
the	O
longer	B-MED
operation	B-MED
time	I-MED
2	O
quality	B-MED
of	I-MED
life	I-MED
during	O
the	O
early	B-MED
post-operative	B-MED
period	I-MED
were	O
similar	B-MED
and	O
3	O
complication	B-MED
rates	B-MED
were	O
higher	B-MED
in	O
the	O
stoppa	B-MED
group	B-MED
.	O
	
morphological	B-MED
characteristics	B-MED
regulating	O
phallic	B-MED
glans	I-MED
engorgement	B-MED
in	O
the	O
american	B-MED
alligator	I-MED
the	O
distal	B-MED
part	I-MED
of	O
the	O
crocodilian	B-MED
phallus	B-MED
consists	O
of	O
a	O
bulbous	B-MED
glans	I-MED
containing	O
well-developed	O
vascular	B-MED
tissues	I-MED
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	B-MED
activity	I-MED
,	O
enlarging	B-MED
and	O
elaborating	O
the	O
glans	B-MED
into	O
a	O
complex	B-MED
,	O
though	O
still	O
functionally	B-MED
undefined	B-MED
,	O
copulatory	B-MED
structure	O
.	O
	
an	O
enlarged	B-MED
glans	B-MED
putatively	O
interacts	B-MED
with	O
the	O
female	B-MED
cloaca	B-MED
and	O
may	O
change	B-MED
the	O
shape	B-MED
of	O
her	B-MED
reproductive	I-MED
tract	I-MED
to	O
facilitate	O
insemination	B-MED
and	O
increase	B-MED
the	O
probability	B-MED
of	O
fertilization	B-MED
.	O
	
here	O
,	O
we	O
investigated	O
the	O
cellular-level	B-MED
properties	I-MED
of	O
the	O
glans	B-MED
and	O
other	O
inflatable	B-MED
phallic	I-MED
tissues	I-MED
associated	O
with	O
the	O
sperm	B-MED
-conducting	O
sulcus	B-MED
spermaticus	B-MED
in	O
the	O
american	B-MED
alligator	I-MED
alligator	B-MED
mississippiensis	I-MED
.	O
	
using	O
histochemical	B-MED
staining	I-MED
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-MED
and	O
elastin	B-MED
fiber	I-MED
densities	B-MED
and	O
orientations	B-MED
in	O
these	O
tissues	B-MED
.	O
	
extracellular	B-MED
matrix	I-MED
architectures	O
provided	O
insights	O
about	O
phallic	B-MED
glans	I-MED
material	O
properties	O
and	O
how	O
they	O
may	O
affect	B-MED
tissue	B-MED
strength	B-MED
and	O
flexibility	B-MED
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	B-MED
forces	B-MED
.	O
	
we	O
also	O
investigated	O
the	O
potential	B-MED
sources	O
of	O
fluids	B-MED
that	O
induce	B-MED
inflation	O
in	O
alligator	B-MED
phalli	B-MED
.	O
	
combining	O
serial	B-MED
sectioning	I-MED
and	O
three-dimensional	B-MED
reconstruction	I-MED
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-MED
plexus	I-MED
vascular	I-MED
bodies	B-MED
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-MED
phallus	B-MED
that	O
extend	O
distally	B-MED
adjacent	I-MED
to	O
ventro-medial	B-MED
sulcus	I-MED
tissues	I-MED
.	O
	
together	O
,	O
our	O
gross	B-MED
and	O
histological	B-MED
examination	I-MED
of	O
the	O
american	B-MED
alligator	I-MED
phallic	B-MED
glans	I-MED
suggests	O
that	O
its	O
tissues	B-MED
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-MED
inflation	O
to	O
expand	O
the	O
glans	B-MED
to	O
a	O
specific	O
and	O
repeatable	O
shape	B-MED
,	O
and	O
potentially	B-MED
release	O
secretory	B-MED
products	I-MED
into	O
the	O
female	B-MED
reproductive	I-MED
tract	I-MED
.	O
	
both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	B-MED
sexual	B-MED
selection	I-MED
,	O
by	O
mechanically	B-MED
and/or	O
chemically	O
affecting	B-MED
female	I-MED
reproductive	I-MED
physiology	I-MED
.	O
	
a	O
novel	O
role	B-MED
for	O
poly	B-MED
binding	I-MED
proteins	I-MED
in	O
programmed	B-MED
ribosomal	I-MED
frameshifting	I-MED
translational	B-MED
control	B-MED
through	O
programmed	B-MED
ribosomal	I-MED
frameshifting	I-MED
prf	B-MED
is	O
exploited	O
widely	O
by	O
viruses	B-MED
and	O
increasingly	O
documented	O
in	O
cellular	B-MED
genes	B-MED
.	O
	
frameshifting	B-MED
is	O
induced	B-MED
by	O
mrna	B-MED
secondary	I-MED
structures	I-MED
that	O
compromise	O
ribosome	B-MED
fidelity	B-MED
during	O
decoding	B-MED
of	O
a	O
heptanucleotide	B-MED
'slippery'	I-MED
sequence	I-MED
.	O
	
the	O
nsp2	B-MED
prf	B-MED
signal	B-MED
of	O
porcine	B-MED
reproductive	I-MED
and	I-MED
respiratory	I-MED
syndrome	I-MED
virus	I-MED
is	O
distinctive	O
in	O
directing	O
both	O
-2	B-MED
and	O
-1	B-MED
prf	I-MED
and	O
in	O
its	O
requirement	B-MED
for	O
a	O
trans-acting	B-MED
protein	I-MED
factor	I-MED
,	O
the	O
viral	B-MED
replicase	B-MED
subunit	I-MED
nsp1β	I-MED
.	O
	
here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	B-MED
of	O
frameshifting	B-MED
is	O
carried	O
out	O
by	O
a	O
protein	B-MED
complex	I-MED
composed	O
of	O
nsp1β	B-MED
and	O
a	O
cellular	B-MED
poly	B-MED
binding	I-MED
protein	I-MED
pcbp	B-MED
.	O
	
from	O
the	O
results	O
of	O
in	B-MED
vitro	I-MED
translation	B-MED
and	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
,	O
we	O
demonstrate	O
that	O
a	O
pcbp	B-MED
/	O
nsp1β	B-MED
complex	B-MED
binds	O
to	O
a	O
c-rich	B-MED
sequence	I-MED
downstream	B-MED
of	O
the	O
slippery	B-MED
sequence	I-MED
and	O
here	O
mimics	O
the	O
activity	B-MED
of	O
a	O
structured	O
mrna	B-MED
stimulator	B-MED
of	O
prf	B-MED
.	O
	
this	O
is	O
the	O
first	O
description	O
of	O
a	O
role	B-MED
for	O
a	O
trans-acting	B-MED
cellular	I-MED
protein	I-MED
in	O
prf	B-MED
.	O
	
the	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	B-MED
associated	B-MED
with	I-MED
poly	B-MED
binding	I-MED
proteins	I-MED
and	O
prototypes	B-MED
a	O
new	O
class	O
of	O
virus	B-MED
-	O
host	B-MED
interactions	B-MED
.	O
	
production	O
of	O
bioactive	B-MED
conjugated	B-MED
linoleic	I-MED
acid	I-MED
by	O
the	O
multifunctional	B-MED
enolase	B-MED
from	O
lactobacillus	B-MED
plantarum	I-MED
lactobacillus	B-MED
plantarum	I-MED
α-enolase	B-MED
,	O
a	O
multifunctional	B-MED
-anchorless-	O
surface	B-MED
protein	I-MED
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-MED
with	O
a	O
central	O
role	O
in	O
glycolytic	B-MED
metabolism	B-MED
,	O
was	O
characterized	B-MED
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	B-MED
metabolism	I-MED
of	O
biohydrogenation	B-MED
of	O
linoleic	B-MED
acid	I-MED
,	O
catalyzing	B-MED
the	O
formation	B-MED
of	O
bioactive	B-MED
9-cis-11-trans-cla	B-MED
through	O
dehydration	B-MED
and	O
isomerization	B-MED
of	O
10-hydroxy-12-cis-octadecenoic	B-MED
acid	I-MED
.	O
	
the	O
identity	O
of	O
the	O
enolase	B-MED
was	O
confirmed	O
through	O
mass	B-MED
spectrometric	I-MED
analysis	I-MED
that	O
showed	O
the	O
characteristic	O
442	O
amino	B-MED
acid	I-MED
sequence	I-MED
with	O
a	O
molecular	B-MED
mass	I-MED
of	O
48.03	O
kda	B-MED
.	O
	
the	O
enolase	B-MED
was	O
not	O
capable	O
of	O
using	O
linoleic	B-MED
acid	I-MED
directly	O
as	O
a	O
substrate	B-MED
but	O
instead	O
uses	O
its	O
hydroxyl	B-MED
derivative	B-MED
10-hydroxi-12-cis-octadecenoic	B-MED
acid	I-MED
to	O
finally	O
form	O
bioactive	B-MED
conjugated	B-MED
linoleic	I-MED
acid	I-MED
.	O
	
biochemical	B-MED
optimization	B-MED
studies	B-MED
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9-cis-11-trans-cla	B-MED
and	O
maximum	O
stability	B-MED
of	O
α-enolase	B-MED
when	O
catalyzing	B-MED
this	O
reaction	B-MED
.	O
	
furthermore	O
,	O
through	O
structural	B-MED
analysis	I-MED
of	O
the	O
protein	B-MED
,	O
we	O
propose	O
the	O
binding	B-MED
sites	I-MED
of	O
substrate	B-MED
and	O
product	B-MED
molecules	B-MED
that	O
were	O
characterized	B-MED
as	O
two	O
hydrophobic	B-MED
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-MED
connected	O
through	O
a	O
channel	B-MED
where	O
the	O
catalysis	B-MED
of	O
dehydration	B-MED
and	O
isomerization	B-MED
might	O
occur	O
.	O
	
these	O
results	O
prove	O
that	O
multifunctional	B-MED
α-enolase	B-MED
also	O
plays	O
a	O
role	O
in	O
cell	B-MED
detoxification	I-MED
from	O
polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
such	O
as	O
linoleic	B-MED
acid	I-MED
,	O
along	O
with	O
the	O
linoleate	B-MED
isomerase	I-MED
complex	B-MED
.	O
	
associations	B-MED
of	O
body	B-MED
mass	I-MED
index	I-MED
and	O
physical	B-MED
activity	I-MED
with	O
sexual	B-MED
dysfunction	I-MED
in	O
breast	B-MED
cancer	I-MED
survivors	B-MED
sexual	B-MED
dysfunction	I-MED
is	O
a	O
common	O
and	O
distressing	B-MED
consequence	B-MED
of	I-MED
breast	B-MED
cancer	I-MED
bc	B-MED
treatment	B-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
we	O
investigated	O
the	O
sexual	B-MED
functioning	I-MED
of	O
bc	B-MED
patients	B-MED
and	O
its	O
association	B-MED
with	O
women's	B-MED
personal	B-MED
characteristics	B-MED
and	O
cancer	B-MED
treatments	I-MED
.	O
	
in	O
this	O
cross-sectional	B-MED
study	I-MED
,	O
sexual	B-MED
function	I-MED
was	O
assessed	O
using	O
the	O
female	B-MED
sexual	I-MED
function	I-MED
index	I-MED
fsfi	B-MED
.	O
	
the	O
health-related	B-MED
quality	I-MED
of	I-MED
life	I-MED
hrqol	B-MED
was	O
measured	O
using	O
the	O
european	B-MED
organization	I-MED
for	I-MED
research	I-MED
and	I-MED
treatment	I-MED
of	I-MED
cancer	I-MED
eortc	B-MED
qlq-c30	B-MED
and	O
its	O
breast	B-MED
module	I-MED
br-23	I-MED
.	O
	
of	O
the	O
235	O
participants	B-MED
approached	O
,	O
216	O
participants	B-MED
were	O
included	O
in	O
the	O
study	O
.	O
	
of	O
these	O
,	O
63	O
patients	B-MED
reported	O
no	B-MED
sexual	I-MED
activity	I-MED
in	O
the	O
last	O
month	B-MED
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	B-MED
desire	I-MED
domain	B-MED
of	O
fsfi	B-MED
.	O
	
a	O
total	O
of	O
154	O
71.3	O
%	O
patients	B-MED
were	O
classified	O
with	O
hypoactive	B-MED
sexual	I-MED
desire	I-MED
disorder	I-MED
hsdd	B-MED
.	O
	
from	O
those	O
patients	B-MED
reporting	O
sexual	B-MED
activity	I-MED
in	O
the	O
last	O
month	B-MED
,	O
63.3	O
%	O
97	O
out	O
of	O
153	O
were	O
classified	O
with	O
sexual	B-MED
dysfunction	I-MED
.	O
	
using	O
hierarchical	B-MED
logistic	I-MED
regression	I-MED
,	O
the	O
variance	O
explained	O
change	O
in	O
r	O
2	O
by	O
the	O
addition	O
of	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
and	O
mild	O
to	O
moderate	O
physical	B-MED
activity	I-MED
in	O
the	O
prediction	B-MED
models	B-MED
of	O
sexual	B-MED
dysfunction	I-MED
and	O
hsdd	B-MED
were	O
6.8	O
and	O
7.2	O
%	O
,	O
respectively	O
.	O
	
age	B-MED
,	O
bmi	B-MED
,	O
and	O
physical	B-MED
activity	I-MED
were	O
independently	O
associated	O
with	O
sexual	B-MED
dysfunction	I-MED
and	O
hsdd	B-MED
.	O
	
additionally	O
,	O
bc	B-MED
patients	B-MED
with	O
sexual	B-MED
dysfunction	I-MED
reported	O
lower	B-MED
scores	B-MED
on	O
global	O
hrqol	B-MED
,	O
role	O
functioning	B-MED
,	O
and	O
fatigue	B-MED
.	O
	
based	O
on	O
our	O
findings	B-MED
,	O
bc	B-MED
survivors	B-MED
should	O
be	O
encouraged	O
to	O
practice	B-MED
regular	O
physical	B-MED
activity	I-MED
and	O
to	O
lose	B-MED
weight	I-MED
in	O
order	O
to	O
avoid	O
sexual	B-MED
dysfunction	I-MED
.	O
	
however	O
,	O
future	O
clinical	B-MED
trials	I-MED
are	O
needed	O
to	O
confirm	O
these	O
combination	B-MED
of	O
telmisartan	B-MED
with	O
sildenafil	B-MED
ameliorate	B-MED
progression	B-MED
of	O
diabetic	B-MED
nephropathy	I-MED
in	O
streptozotocin	B-MED
-	O
induced	B-MED
diabetic	B-MED
model	O
diabetic	B-MED
nephropathy	I-MED
dn	B-MED
is	O
a	O
leading	O
cause	O
of	O
end-stage	B-MED
renal	I-MED
disease	I-MED
in	O
the	O
world	O
.	O
	
several	O
signaling	B-MED
pathways	I-MED
are	O
involved	O
in	O
the	O
pathogenesis	B-MED
of	O
dn	B-MED
including	O
elevation	B-MED
in	O
level	O
of	O
angiotensin	B-MED
ii	I-MED
,	O
formation	B-MED
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
age	B-MED
,	O
activation	B-MED
of	O
protein	B-MED
kinase	I-MED
c	I-MED
pkc	B-MED
,	O
and	O
lipid	B-MED
accumulation	I-MED
.	O
	
these	O
pathways	B-MED
activate	B-MED
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B-MED
stress	I-MED
,	O
increasing	O
expression	B-MED
of	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta-1	I-MED
tgf-β	B-MED
1	I-MED
and	O
release	B-MED
of	O
interleukins	B-MED
and	O
adhesion	B-MED
molecules	I-MED
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-MED
pathway	B-MED
to	O
ameliorate	B-MED
the	O
progression	B-MED
of	O
dn	B-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
white	B-MED
male	I-MED
rats	I-MED
n=48	O
were	O
divided	O
into	O
six	O
groups	O
8	O
rats	B-MED
each	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	B-MED
control	I-MED
and	O
a	O
control	B-MED
vehicle	I-MED
group	I-MED
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-MED
by	O
a	O
single	O
intraperitoneal	B-MED
injection	I-MED
of	O
streptozotocin	B-MED
stz	B-MED
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
dn	B-MED
.	O
	
thereafter	O
,	O
the	O
rats	B-MED
were	O
divided	O
into	O
dn	B-MED
group	O
,	O
dn	B-MED
group	O
receiving	O
telmisartan	B-MED
or	O
sildenafil	B-MED
or	O
telmisartan	B-MED
sildenafil	B-MED
combination	B-MED
.	O
	
after	O
the	O
specified	B-MED
treatment	B-MED
period	B-MED
,	O
urine	B-MED
samples	I-MED
were	O
collected	B-MED
using	O
metabolic	B-MED
cages	I-MED
to	O
measure	O
proteinuria	B-MED
,	O
animals	B-MED
were	O
then	O
euthanized	B-MED
,	O
blood	B-MED
and	O
tissue	B-MED
samples	I-MED
were	O
collected	B-MED
for	O
measurement	B-MED
of	I-MED
blood	I-MED
glucose	I-MED
,	O
bun	B-MED
,	O
s.cr	B-MED
,	O
ldl	B-MED
,	O
no	B-MED
,	O
tgf-β1	B-MED
,	O
il-1β	B-MED
,	O
ageps	B-MED
,	O
and	O
sod	B-MED
.	O
	
the	O
combination	B-MED
therapy	I-MED
showed	O
significant	O
decrease	O
in	O
bun	B-MED
,	O
s.cr	B-MED
,	O
ldl	B-MED
,	O
tgf-β1	B-MED
,	O
il-1β	B-MED
,	O
proteinuria	B-MED
and	O
ageps	B-MED
and	O
significant	O
increase	O
in	O
sod	B-MED
and	O
no	B-MED
.	O
	
the	O
findings	O
showed	O
that	O
combination	B-MED
therapy	I-MED
was	O
able	O
to	O
ameliorate	B-MED
dn	B-MED
and	O
that	O
the	O
effects	O
were	O
superior	B-MED
to	O
the	O
single	O
drugs	B-MED
analysis	B-MED
of	O
low-biomass	B-MED
microbial	B-MED
communities	I-MED
in	O
the	O
deep	B-MED
biosphere	I-MED
over	O
the	O
past	O
few	B-MED
decades	I-MED
,	O
the	O
subseafloor	B-MED
biosphere	I-MED
has	O
been	O
explored	O
by	O
scientific	B-MED
ocean	I-MED
drilling	I-MED
to	O
depths	B-MED
of	O
about	O
2.5km	O
below	O
the	O
seafloor	B-MED
.	O
	
although	O
organic-rich	B-MED
anaerobic	I-MED
sedimentary	I-MED
habitats	I-MED
in	O
the	O
ocean	B-MED
margins	I-MED
harbor	I-MED
large	O
numbers	O
of	O
microbial	B-MED
cells	I-MED
,	O
microbial	B-MED
populations	I-MED
in	O
ultraoligotrophic	B-MED
aerobic	I-MED
sedimentary	I-MED
habitats	I-MED
in	O
the	O
open	O
ocean	B-MED
gyres	I-MED
are	O
several	O
orders	O
of	O
magnitude	B-MED
less	O
abundant	B-MED
.	O
	
despite	O
advances	O
in	O
cultivation-independent	B-MED
molecular	I-MED
ecological	I-MED
techniques	I-MED
,	O
exploring	O
the	O
low-biomass	B-MED
environment	B-MED
remains	O
technologically	B-MED
challenging	I-MED
,	O
especially	O
in	O
the	O
deep	B-MED
subseafloor	I-MED
biosphere	I-MED
.	O
	
reviewing	B-MED
the	O
historical	B-MED
background	I-MED
of	O
deep-biosphere	B-MED
analytical	B-MED
methods	I-MED
,	O
the	O
importance	B-MED
of	O
obtaining	O
clean	B-MED
samples	I-MED
and	O
tracing	B-MED
contamination	B-MED
,	O
as	O
well	O
as	O
methods	B-MED
for	O
detecting	B-MED
microbial	B-MED
life	B-MED
,	O
technological	B-MED
aspects	I-MED
of	O
molecular	B-MED
microbiology	I-MED
,	O
and	O
detecting	B-MED
subseafloor	B-MED
metabolic	B-MED
activity	I-MED
the	O
sensitivity	B-MED
and	I-MED
specifity	I-MED
of	O
dr-70	B-MED
immunoassay	B-MED
as	O
a	O
tumor	B-MED
marker	I-MED
for	O
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
lung	B-MED
cancer	I-MED
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	B-MED
related	I-MED
mortality	I-MED
.	O
	
patients	B-MED
with	O
lung	B-MED
cancer	I-MED
are	O
usually	O
diagnosed	B-MED
at	O
advanced	B-MED
or	O
locally	B-MED
advanced	I-MED
stage	I-MED
,	O
for	O
this	O
reason	O
early	B-MED
diagnosis	I-MED
of	O
lung	B-MED
cancer	I-MED
is	O
very	O
important	O
.	O
	
for	O
early	B-MED
detection	I-MED
of	O
lung	B-MED
cancer	I-MED
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-MED
computed	I-MED
tomography	I-MED
or	O
tumor	B-MED
biomarkers	I-MED
.	O
	
in	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-MED
dr-70	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
as	O
a	O
tumor	B-MED
marker	I-MED
in	O
detection	B-MED
of	O
non-small	B-MED
cell	I-MED
lung	I-MED
cancers	I-MED
.	O
	
between	O
may	B-MED
2013	O
and	O
april	B-MED
2014	O
,	O
the	O
serum	B-MED
samples	I-MED
from	O
88	O
non	B-MED
lung	I-MED
cancer	I-MED
patients	B-MED
,	O
86	O
patients	B-MED
with	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disesase	I-MED
were	O
obtained	O
.	O
	
blood	B-MED
samples	I-MED
from	O
each	O
participant	B-MED
were	O
analyzed	B-MED
for	O
dr-70	B-MED
level	B-MED
.	O
	
totally	O
174	O
patients	B-MED
were	O
enrolled	O
to	O
the	O
study	B-MED
152	O
male	B-MED
,	O
22	O
female	B-MED
.	O
	
histopathologically	B-MED
47	O
patients	B-MED
were	O
diagnosed	B-MED
with	O
squamous	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
,	O
34	O
38.6	O
with	O
adenocarcinoma	B-MED
,	O
and	O
7	O
8%	O
with	O
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
	
the	O
mean	B-MED
serum	I-MED
dr-70	I-MED
levels	B-MED
in	O
lung	B-MED
cancer	I-MED
patients	B-MED
2.43	O
1.82	O
µg/ml	O
was	O
significantly	B-MED
higher	I-MED
compared	B-MED
to	O
the	O
86	O
non-cancerous	B-MED
subjects	B-MED
1.15	O
0.70	O
µg/ml	O
p<	O
0.01	O
.	O
	
dr-70	B-MED
exhibited	O
clinical	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
of	O
54.5	O
and	O
83.7	O
,	O
respectively	O
,	O
at	O
an	O
optimal	B-MED
cut	B-MED
off	I-MED
at	O
1.98	O
µg/ml	O
.	O
	
it	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-MED
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
dr-70	B-MED
level	B-MED
is	O
1.98	O
µg/ml	O
and	O
higher	O
.	O
	
dr-70	B-MED
,	O
a	O
marker	B-MED
used	O
to	O
measure	B-MED
fibrin	B-MED
degradation	I-MED
products	I-MED
,	O
generated	O
by	O
all	O
major	O
cancers	B-MED
,	O
may	O
helps	O
to	O
find	O
high	B-MED
risk	I-MED
lung	B-MED
cancer	I-MED
patients	B-MED
.	O
	
catastrophic	B-MED
expenditure	I-MED
and	O
impoverishment	B-MED
of	O
patients	B-MED
affected	O
by	O
7	O
rare	B-MED
diseases	I-MED
in	O
china	B-MED
china	B-MED
is	O
actively	O
promoting	B-MED
regulation	O
of	O
rare	B-MED
diseases	I-MED
,	O
rare	B-MED
disease	I-MED
and	O
orphan	B-MED
drugs	I-MED
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	B-MED
planning	I-MED
.	O
	
however	O
,	O
few	O
studies	B-MED
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	B-MED
of	O
rare	B-MED
disease	I-MED
patients	B-MED
in	O
china	B-MED
.	O
	
this	O
study	O
aims	O
to	O
provide	O
policy	B-MED
recommendations	B-MED
for	O
the	O
establishment	B-MED
of	O
social	B-MED
security	I-MED
mechanism	I-MED
for	O
rare	B-MED
diseases	I-MED
in	O
china	B-MED
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	B-MED
caused	O
by	O
these	O
diseases	B-MED
.	O
	
a	O
total	O
of	O
7	O
rare	B-MED
diseases	I-MED
were	O
selected	O
by	O
delphi	B-MED
method	I-MED
.	O
	
affordability	B-MED
of	O
treatment	B-MED
for	O
the	O
7	O
rare	B-MED
diseases	I-MED
was	O
assessed	B-MED
through	O
annual	B-MED
per	I-MED
capital	I-MED
income	I-MED
,	O
catastrophic	B-MED
expenditure	I-MED
and	O
impoverishment	B-MED
expenditure	B-MED
among	O
urban	B-MED
and	O
rural	B-MED
residents	I-MED
in	O
china	B-MED
.	O
	
assessed	B-MED
through	O
annual	B-MED
per	I-MED
capital	I-MED
income	I-MED
,	O
health	B-MED
expenditure	I-MED
for	O
the	O
7	O
rare	B-MED
diseases	I-MED
are	O
all	O
rather	O
high	O
.	O
	
the	O
highest	O
health	B-MED
expenditure	I-MED
is	O
equivalent	O
to	O
income	B-MED
of	O
69.34	O
years	B-MED
of	O
one	O
urban	B-MED
resident	I-MED
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	B-MED
residents	I-MED
.	O
	
through	O
catastrophic	B-MED
expenditure	I-MED
assessment	B-MED
,	O
proportions	B-MED
of	O
the	O
population	B-MED
experiencing	O
catastrophic	B-MED
expenditure	I-MED
caused	O
by	O
the	O
7	O
rare	B-MED
diseases	I-MED
are	O
all	O
under	O
0.167	O
however	O
,	O
once	O
one	O
is	O
ill	B-MED
and	O
taking	O
medications	B-MED
,	O
he	O
will	O
suffer	O
from	O
catastrophic	B-MED
health	I-MED
expenditure	I-MED
.	O
	
through	O
impoverishment	B-MED
expenditure	B-MED
assessment	B-MED
,	O
the	O
proportions	B-MED
of	O
impoverishment	B-MED
payment	B-MED
are	O
low	O
among	O
both	O
urban	B-MED
and	O
rural	B-MED
residents	I-MED
,	O
but	O
the	O
7	O
rare	B-MED
diseases	I-MED
could	O
lead	O
nearly	O
4.6	O
million	O
people	B-MED
into	O
poverty	B-MED
on	O
a	O
national	O
scale	O
.	O
	
the	O
affordability	B-MED
of	O
treatment	B-MED
for	O
rare	B-MED
disease	I-MED
as	O
well	O
as	O
orphan	B-MED
drugs	I-MED
is	O
rather	O
poor	B-MED
.	O
	
residents	B-MED
of	O
different	O
income	B-MED
levels	I-MED
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-MED
for	O
rare	B-MED
diseases	I-MED
,	O
so	O
poverty	B-MED
caused	O
by	O
rare	B-MED
diseases	I-MED
is	O
quite	O
widespread	B-MED
.	O
	
therefore	O
,	O
social	B-MED
security	I-MED
mechanism	I-MED
for	O
rare	B-MED
disease	I-MED
patients	B-MED
should	O
be	O
established	O
and	O
specific	O
payment	B-MED
pattern	O
for	O
orphan	B-MED
drugs	I-MED
experimental	B-MED
study	I-MED
in	O
pulmonary	B-MED
artery	I-MED
sealing	B-MED
with	O
a	O
vessel-sealing	B-MED
device	I-MED
the	O
development	O
of	O
vessel-sealing	B-MED
devices	I-MED
will	O
facilitate	O
safety	B-MED
in	O
video-assisted	B-MED
thoracoscopic	I-MED
surgery	I-MED
.	O
	
our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	B-MED
and	O
safety	B-MED
of	O
sealing	B-MED
pulmonary	B-MED
arteries	I-MED
with	O
the	O
enseal	B-MED
tissue-sealing	I-MED
device	I-MED
.	O
	
pulmonary	B-MED
arteries	I-MED
from	O
beagle	B-MED
dogs	I-MED
mean	O
body	O
weight	O
13.1	O
kg	O
,	O
range	O
10.5	O
kg	O
were	O
divided	O
into	O
3	O
groups	B-MED
according	O
to	O
the	O
in-vivo	B-MED
sealing	B-MED
method	I-MED
used	O
enseal	B-MED
,	O
ligation	B-MED
,	O
and	O
proximal	B-MED
ligation	B-MED
plus	O
distal	B-MED
enseal	B-MED
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	B-MED
tolerance	B-MED
up	O
to	O
75	O
mm	O
hg	O
at	O
the	O
sealed	B-MED
end	B-MED
.	O
	
a	O
left	O
lower	O
lobectomy	B-MED
was	O
performed	O
to	O
evaluate	O
chronic-phase	B-MED
durability	O
of	O
the	O
sealed	B-MED
stumps	I-MED
in	O
a	O
survival	B-MED
model	I-MED
.	O
	
two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-MED
arteries	I-MED
in	O
each	O
dog	B-MED
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	B-MED
.	O
	
after	O
the	O
scheduled	O
survival	B-MED
period	B-MED
,	O
the	O
pulmonary	B-MED
arteries	I-MED
were	O
sampled	O
.	O
	
pressure	B-MED
tolerance	B-MED
at	O
the	O
sealed	B-MED
end	B-MED
was	O
evaluated	O
in	O
91	O
pulmonary	B-MED
artery	I-MED
sections	O
.	O
	
all	O
sealed	B-MED
ends	B-MED
showed	O
pressure	B-MED
tolerance	B-MED
>75	O
mm	O
hg	O
.	O
	
a	O
left	O
lower	O
lobectomy	B-MED
was	O
performed	O
in	O
13	O
dogs	B-MED
in	O
which	O
35	O
pulmonary	B-MED
artery	I-MED
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	B-MED
.	O
	
no	B-MED
sealing	B-MED
failure	B-MED
was	O
found	O
,	O
and	O
pathological	B-MED
findings	B-MED
showed	O
healing	B-MED
and	O
persistent	B-MED
hemostasis	B-MED
at	O
all	O
sealed	B-MED
ends	B-MED
of	O
the	O
pulmonary	B-MED
arteries	I-MED
after	O
2	O
and	O
4	O
weeks	B-MED
of	O
the	O
survival	B-MED
period	B-MED
.	O
	
pulmonary	B-MED
arteries	I-MED
sealed	B-MED
in	B-MED
vivo	I-MED
with	O
the	O
enseal	B-MED
device	I-MED
showed	O
pressure	B-MED
tolerance	B-MED
>75	O
mm	O
hg	O
in	O
the	O
acute	B-MED
phase	I-MED
,	O
and	O
persistent	B-MED
hemostasis	B-MED
after	O
2	O
or	O
4	O
weeks	B-MED
.	O
	
pulmonary	B-MED
artery	I-MED
sealing	B-MED
with	O
the	O
enseal	B-MED
device	I-MED
is	O
feasible	B-MED
and	O
safe	B-MED
in	O
thoracic	B-MED
surgery	I-MED
pathophysiology	B-MED
,	O
treatment	B-MED
and	O
prevention	B-MED
of	O
ovarian	B-MED
hyperstimulation	I-MED
syndrome	I-MED
severe	B-MED
ovarian	B-MED
hyperstimulation	I-MED
syndrome	I-MED
ohss	B-MED
is	O
an	O
iatrogenic	B-MED
condition	B-MED
that	O
affects	B-MED
1%	O
of	O
women	B-MED
that	O
undergo	O
treatment	B-MED
with	O
assisted	B-MED
reproductive	I-MED
technology	I-MED
.	O
	
the	O
review	B-MED
aims	B-MED
to	O
summarize	B-MED
recent	B-MED
evidence	B-MED
on	O
pathophysiology	B-MED
,	O
treatment	B-MED
,	O
and	O
prevention	B-MED
of	O
ohss	B-MED
.	O
	
the	O
pathophysiology	B-MED
is	O
still	O
not	O
completely	B-MED
understood	B-MED
however	O
,	O
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
is	O
likely	O
to	O
be	O
an	O
important	B-MED
mediator	O
.	O
	
human	B-MED
chorionic	I-MED
gonadotropin	I-MED
was	O
previously	O
thought	B-MED
to	O
be	O
necessary	O
for	O
ohss	B-MED
to	O
occur	B-MED
however	O
,	O
recent	B-MED
case	I-MED
reports	I-MED
have	O
proven	B-MED
otherwise	O
.	O
	
the	O
contribution	B-MED
of	O
an	O
attenuated	B-MED
anti-mullerian	B-MED
hormone	I-MED
signalling	B-MED
pathway	I-MED
and	O
cd11c	B-MED
+	O
hla-dr	B-MED
+	O
dendritic	B-MED
cells	I-MED
and	O
associated	B-MED
interleukins	B-MED
has	O
been	O
explored	O
recently	B-MED
as	O
contributors	B-MED
to	O
pathogenesis	B-MED
.	O
	
treatment	B-MED
is	O
largely	O
supportive	B-MED
and	O
is	O
based	B-MED
mainly	O
on	O
consensus	B-MED
statements	B-MED
rather	O
than	O
evidence	B-MED
.	O
	
therefore	O
,	O
it	O
is	O
important	B-MED
to	O
prevent	B-MED
this	O
condition	B-MED
by	O
identifying	B-MED
women	B-MED
at	B-MED
risk	I-MED
,	O
allowing	B-MED
the	O
clinician	B-MED
to	O
implement	B-MED
preventive	B-MED
strategies	I-MED
,	O
including	B-MED
the	O
use	O
of	O
gnrh	B-MED
antagonist	I-MED
cycles	B-MED
with	O
agonist	B-MED
triggers	O
.	O
	
more	O
research	B-MED
is	O
required	B-MED
to	O
elucidate	O
the	O
pathophysiology	B-MED
behind	O
the	O
condition	B-MED
.	O
	
clinicians	B-MED
should	O
employ	B-MED
strategies	B-MED
to	O
prevent	B-MED
ohss	B-MED
.	O
	
eosinophilic	B-MED
gastroenteritis	I-MED
as	O
a	O
rare	B-MED
cause	B-MED
of	O
recurrent	B-MED
epigastric	I-MED
pain	I-MED
eosinophilic	B-MED
gastroenteritis	I-MED
ege	B-MED
is	O
a	O
rare	O
inflammatory	B-MED
disorder	I-MED
of	O
gastrointestinal	B-MED
tract	I-MED
characterized	B-MED
by	O
eosinophilic	B-MED
infiltration	I-MED
of	O
the	O
bowel	B-MED
wall	I-MED
.	O
	
it	O
can	O
mimic	O
many	O
gastrointestinal	B-MED
disorders	I-MED
due	O
to	O
its	O
wide	B-MED
spectrum	I-MED
of	I-MED
presentations	I-MED
.	O
	
diagnose	B-MED
is	O
mostly	O
based	O
on	O
excluding	B-MED
other	B-MED
disorders	B-MED
and	O
a	O
high	B-MED
suspicion	B-MED
.	O
	
here	O
we	O
report	B-MED
a	I-MED
case	I-MED
of	O
26	O
year	B-MED
old	B-MED
man	B-MED
with	O
a	O
history	B-MED
of	O
sever	B-MED
epigastric	I-MED
pain	I-MED
followed	O
by	O
nausea	B-MED
,	O
vomiting	B-MED
since	O
a	O
few	B-MED
days	B-MED
before	B-MED
admission	B-MED
with	O
final	O
diagnosis	B-MED
of	O
comparison	O
of	O
sonoelastography	B-MED
with	O
sonourethrography	B-MED
and	O
retrograde	B-MED
urethrography	I-MED
in	O
the	O
evaluation	B-MED
of	O
male	B-MED
anterior	B-MED
urethral	I-MED
strictures	I-MED
retrograde	B-MED
urethrography	I-MED
rug	B-MED
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	B-MED
modality	I-MED
for	O
imaging	B-MED
of	O
the	O
anterior	B-MED
urethral	I-MED
strictures	I-MED
despite	O
its	O
well-known	O
limitations	B-MED
and	O
disadvantages	O
.	O
	
sonourethrography	B-MED
sug	B-MED
was	O
introduced	O
in	O
1988	O
to	O
overcome	B-MED
the	O
limitations	B-MED
of	O
rug	B-MED
and	O
to	O
provide	O
more	O
accurate	B-MED
results	I-MED
.	O
	
as	O
proper	O
selection	O
of	O
imaging	B-MED
modality	I-MED
is	O
very	O
important	O
for	O
planning	B-MED
the	I-MED
treatment	I-MED
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O
	
one	O
of	O
the	O
major	O
factors	O
for	O
recurrence	B-MED
of	O
stricture	B-MED
disease	I-MED
is	O
spongiofibrosis	B-MED
.	O
	
sonoelastography	B-MED
se	B-MED
is	O
a	O
newer	B-MED
technique	I-MED
,	O
tried	O
in	O
various	O
other	O
pathologies	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	B-MED
in	O
the	O
evaluation	O
of	O
anterior	B-MED
urethral	I-MED
stricture	I-MED
disease	I-MED
by	O
comparison	O
with	O
rug	B-MED
and	O
sug	B-MED
.	O
	
between	O
august	O
2014	O
and	O
may	O
2015	O
,	O
77	O
patients	B-MED
with	O
clinical	O
features	O
of	O
anterior	B-MED
urethral	I-MED
stricture	I-MED
disease	I-MED
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
rug	B-MED
followed	O
by	O
sug	B-MED
and	O
se	B-MED
for	O
stricture	B-MED
location	B-MED
,	O
length	B-MED
,	O
depth	B-MED
of	O
spongiofibrosis	B-MED
and	O
periurethral	B-MED
pathologies	B-MED
.	O
	
the	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	B-MED
findings	I-MED
.	O
	
overall	O
diagnostic	B-MED
accuracy	I-MED
of	O
se	B-MED
,	O
sug	B-MED
,	O
and	O
rgu	B-MED
for	O
the	O
estimation	O
of	O
stricture	B-MED
location	B-MED
,	O
and	O
length	B-MED
were	O
estimated	O
92.68	O
vs	O
.	O
	
91.54	O
,	O
79%	O
vs	O
.	O
	
78.87	O
and	O
80.48	O
vs	O
.	O
	
43.66	O
,	O
respectively	O
,	O
while	O
for	O
depth	B-MED
of	O
spongiofibrosis	B-MED
se	B-MED
,	O
and	O
sug	B-MED
had	O
accuracy	B-MED
rates	I-MED
of	O
87.3	O
,	O
48%	O
,	O
respectively	O
.	O
	
the	O
mean	O
length	O
measured	O
on	O
se	B-MED
was	O
nearest	O
to	O
the	O
mean	O
intra-operative	B-MED
stricture	B-MED
length	B-MED
21.34	O
mm	O
.	O
	
se	B-MED
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-MED
of	I-MED
bladder	I-MED
mucosa	I-MED
on	O
cystoscopic	B-MED
examination	I-MED
p=0	O
whereas	O
the	O
association	O
was	O
non-significant	O
p=0	O
for	O
difficulty	O
in	O
incision	B-MED
.	O
	
while	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
sug	B-MED
findings	O
related	O
both	O
to	O
the	O
colour	B-MED
of	I-MED
the	I-MED
bladder	I-MED
mucosa	I-MED
and	O
difficulty	O
in	O
incision	B-MED
on	O
cystoscopy	B-MED
,	O
se	B-MED
findings	O
had	O
a	O
significant	O
association	O
p<0	O
with	O
histopathology	B-MED
findings	I-MED
for	O
severe	O
degree	B-MED
of	I-MED
fibrosis	I-MED
.	O
	
sonoelastography	B-MED
estimates	O
stricture	B-MED
site	I-MED
and	I-MED
length	I-MED
better	O
in	O
comparison	O
with	O
rug	B-MED
and	O
sug	B-MED
.	O
	
it	O
estimates	O
degree	O
of	O
spongiofibrosis	B-MED
which	O
serves	O
as	O
an	O
important	O
prognostic	B-MED
factor	I-MED
for	O
stricture	B-MED
recurrence	I-MED
more	O
accurately	B-MED
than	O
changes	B-MED
in	O
risk	B-MED
factors	I-MED
for	O
young	B-MED
male	B-MED
suicide	B-MED
in	O
newcastle	B-MED
upon	I-MED
tyne	I-MED
,	O
1961-2009	O
aims	B-MED
and	O
method	B-MED
to	O
ascertain	O
differences	B-MED
in	O
patterns	B-MED
of	I-MED
suicide	I-MED
in	O
young	B-MED
men	B-MED
over	O
three	O
decades	B-MED
1960s	O
,	O
1990s	O
and	O
2000s	O
and	O
discuss	O
implications	B-MED
for	O
suicide	B-MED
prevention	B-MED
.	O
	
data	B-MED
on	O
suicides	B-MED
and	O
open	B-MED
verdicts	I-MED
in	O
men	B-MED
aged	O
15-34	O
were	O
obtained	O
from	O
coroner's	B-MED
records	I-MED
in	O
newcastle	B-MED
upon	I-MED
tyne	I-MED
and	O
analysed	B-MED
using	O
spss	B-MED
software	I-MED
.	O
	
results	B-MED
an	O
increase	B-MED
in	O
suicide	B-MED
rates	I-MED
from	O
the	O
first	O
to	O
the	O
second	O
decade	B-MED
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	B-MED
.	O
	
this	O
was	O
associated	B-MED
with	I-MED
an	O
increasing	B-MED
proportion	B-MED
of	O
single	B-MED
men	B-MED
,	O
those	O
living	B-MED
alone	I-MED
,	O
unemployment	B-MED
,	O
consumption	B-MED
of	I-MED
alcohol	I-MED
,	O
use	O
of	O
hanging	B-MED
,	O
previous	B-MED
suicide	B-MED
attempt	I-MED
and	O
history	B-MED
of	I-MED
treatment	I-MED
for	O
mental	B-MED
illness	I-MED
.	O
	
clinical	B-MED
implications	B-MED
this	O
study	B-MED
highlights	O
the	O
need	O
for	O
more	O
interventions	B-MED
and	O
focus	B-MED
to	O
be	O
given	O
to	O
young	B-MED
males	B-MED
in	O
the	O
suicide	B-MED
prevention	B-MED
area	I-MED
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	B-MED
of	I-MED
public	I-MED
health	I-MED
.	O
	
areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	B-MED
access	B-MED
to	O
means	B-MED
of	O
suicide	B-MED
,	O
reducing	B-MED
alcohol	B-MED
use	I-MED
,	O
support	B-MED
for	O
relationship	B-MED
difficulties	B-MED
,	O
engagement	B-MED
with	O
mental	B-MED
health	I-MED
services	I-MED
and	O
management	B-MED
of	O
chronic	B-MED
illness	I-MED
.	O
	
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
factor	B-MED
structure	I-MED
of	O
emotion	B-MED
processing	B-MED
and	O
theory	B-MED
of	I-MED
mind	I-MED
factor	B-MED
analytic	I-MED
studies	I-MED
examining	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
have	O
yielded	O
inconsistent	O
results	B-MED
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	B-MED
of	I-MED
measures	I-MED
.	O
	
with	O
the	O
recent	O
conclusion	O
of	O
phase	B-MED
3	I-MED
of	O
the	O
social	B-MED
cognition	I-MED
psychometric	B-MED
evaluation	I-MED
scope	I-MED
study	I-MED
,	O
the	O
most	O
psychometrically	B-MED
sound	B-MED
measures	I-MED
of	O
social	B-MED
cognition	I-MED
have	O
been	O
identified	O
.	O
	
therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	B-MED
were	O
to	O
1	O
examine	B-MED
the	O
factor	B-MED
structure	I-MED
of	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
through	O
the	O
utilization	O
of	O
psychometrically	B-MED
sound	B-MED
measures	I-MED
,	O
2	O
examine	B-MED
the	O
stability	B-MED
of	O
the	O
factor	B-MED
structure	I-MED
across	O
two	O
study	B-MED
visits	O
,	O
3	O
compare	O
the	O
factor	B-MED
structure	I-MED
of	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
to	O
that	O
in	O
healthy	B-MED
controls	I-MED
,	O
and	O
4	O
examine	B-MED
the	O
relationship	O
between	O
the	O
factors	B-MED
and	O
relevant	O
outcome	B-MED
measures	I-MED
including	O
social	B-MED
functioning	I-MED
and	O
symptoms	B-MED
.	O
	
results	B-MED
supported	O
a	O
one-factor	B-MED
model	I-MED
for	O
the	O
patient	B-MED
and	O
healthy	B-MED
control	I-MED
samples	O
at	O
both	O
visits	B-MED
.	O
	
this	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	O
symptoms	O
in	O
the	O
schizophrenia	O
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	O
at	O
both	O
study	O
visits	B-MED
assessment	B-MED
of	O
residual	B-MED
disease	I-MED
with	O
molecular	B-MED
breast	I-MED
imaging	I-MED
in	O
patients	B-MED
undergoing	O
neoadjuvant	B-MED
therapy	I-MED
association	O
with	O
molecular	B-MED
subtypes	B-MED
assessment	B-MED
of	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
therapy	I-MED
for	O
breast	B-MED
cancer	I-MED
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-MED
imaging	B-MED
.	O
	
this	O
study	B-MED
evaluates	B-MED
the	O
accuracy	B-MED
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-MED
breast	I-MED
imaging	I-MED
mbi	B-MED
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B-MED
zinc	I-MED
telluride	I-MED
detectors	B-MED
in	O
assessing	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
therapy	I-MED
in	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
.	O
	
clinical	B-MED
data	I-MED
,	O
imaging	B-MED
,	O
surgical	B-MED
,	O
and	O
pathological	B-MED
findings	B-MED
of	O
51	O
women	B-MED
with	O
breast	B-MED
cancer	I-MED
undergoing	O
neoadjuvant	B-MED
therapy	I-MED
were	O
recorded	O
.	O
	
mbi	B-MED
findings	B-MED
were	O
correlated	B-MED
with	O
surgical	B-MED
pathology	I-MED
results	I-MED
.	O
	
accuracy	B-MED
of	O
mbi	B-MED
in	O
predicting	O
complete	B-MED
pathological	I-MED
response	I-MED
and	O
size	B-MED
of	O
residual	B-MED
disease	I-MED
was	O
assessed	O
according	O
to	O
molecular	B-MED
subtypes	B-MED
.	O
	
the	O
size	B-MED
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
mbi	B-MED
correlated	B-MED
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	B-MED
r	O
=	O
0.55	O
p	O
<	O
001	O
.	O
	
this	O
correlation	B-MED
was	O
stronger	O
for	O
triple	B-MED
negative	I-MED
and	O
her2/neu	B-MED
positive	I-MED
subtypes	B-MED
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
.	O
	
sixteen	O
patients	B-MED
31%	O
had	O
complete	B-MED
pathological	I-MED
response	I-MED
.	O
	
the	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
mbi	B-MED
for	O
detecting	O
residual	B-MED
disease	I-MED
were	O
83%	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
,	O
66-93	O
and	O
69%	O
95%	O
ci	B-MED
,	O
42-88	O
,	O
respectively	O
.	O
	
for	O
triple	B-MED
negative	I-MED
or	O
her2/neu	B-MED
positive	I-MED
disease	O
the	O
sensitivity	B-MED
and	O
specificity	B-MED
were	O
88%	O
95%	O
ci	B-MED
,	O
62-98	O
and	O
75%	O
95%	O
ci	B-MED
,	O
43-93	O
,	O
respectively	O
.	O
	
the	O
accuracy	B-MED
of	O
mbi	B-MED
in	O
assessing	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
treatment	I-MED
might	O
be	O
related	O
to	O
the	O
molecular	B-MED
subtype	B-MED
.	O
	
accuracy	B-MED
is	O
highest	O
in	O
the	O
triple	B-MED
negative	I-MED
and	O
her2/neu	B-MED
positive	I-MED
subtypes	B-MED
.	O
	
the	O
relationship	B-MED
between	O
histological	B-MED
prostatitis	B-MED
and	O
lower	B-MED
urinary	I-MED
tract	I-MED
symptoms	I-MED
and	O
sexual	B-MED
function	I-MED
this	O
prospective	B-MED
analysis	I-MED
assessed	B-MED
the	O
effect	B-MED
of	O
histological	B-MED
prostatitis	B-MED
on	O
lower	B-MED
urinary	I-MED
tract	I-MED
functions	B-MED
and	O
sexual	B-MED
function	I-MED
.	O
	
the	O
patients	B-MED
were	O
separated	B-MED
into	O
two	O
groups	B-MED
as	O
histologically	B-MED
observed	B-MED
prostatitis	B-MED
group	B-MED
a	I-MED
and	O
no	B-MED
prostatitis	I-MED
group	B-MED
b	I-MED
according	O
to	O
the	O
biopsy	B-MED
outcomes	B-MED
.	O
	
international	B-MED
prostate	I-MED
symptom	I-MED
score	I-MED
,	O
international	B-MED
index	I-MED
of	I-MED
erectile	I-MED
function-5	I-MED
scores	I-MED
,	O
maximal	B-MED
and	O
average	B-MED
flow	I-MED
rate	I-MED
,	O
and	O
residual	B-MED
urine	I-MED
volumes	I-MED
were	O
compared	B-MED
statistically	O
between	O
groups	B-MED
.	O
	
there	O
was	O
no	O
significant	B-MED
difference	B-MED
p>0	O
in	O
baseline	B-MED
age	B-MED
t=0	O
,	O
body	B-MED
mass	I-MED
index	I-MED
value	I-MED
t=0	O
,	O
prostate	B-MED
volume	I-MED
t=0	O
,	O
prostate-specific	B-MED
antigen	I-MED
levels	I-MED
t=0	O
,	O
maximal	B-MED
t=0	O
and	O
average	B-MED
flow	I-MED
rate	I-MED
t=0	O
,	O
and	O
post-void	B-MED
residual	B-MED
urine	I-MED
volume	I-MED
t=0	O
.	O
	
mean	B-MED
international	B-MED
prostate	I-MED
symptom	I-MED
score	I-MED
in	O
patients	B-MED
with	O
prostatitis	B-MED
was	O
numerically	B-MED
but	O
not	O
significantly	B-MED
higher	I-MED
than	O
that	O
in	O
those	O
without	B-MED
prostatitis	B-MED
t=0	O
,	O
p=0	O
.	O
	
mean	B-MED
international	B-MED
index	I-MED
of	I-MED
erectile	I-MED
function-5	I-MED
score	I-MED
in	O
the	O
prostatitis	B-MED
group	B-MED
was	O
significantly	B-MED
lower	I-MED
than	O
that	O
in	O
those	O
without	B-MED
prostatitis	B-MED
t=1	O
,	O
p=0	O
.	O
	
histological	B-MED
prostatitis	B-MED
notably	O
affected	B-MED
sexual	B-MED
function	I-MED
of	O
patients	B-MED
and	O
may	O
serve	O
as	O
a	O
major	B-MED
risk	B-MED
factor	I-MED
for	O
sexual	B-MED
dysfunction	I-MED
while	O
having	O
little	O
effect	B-MED
on	O
lower	B-MED
urinary	I-MED
tract	I-MED
symptoms	I-MED
.	O
	
beyond	O
""""	O
median	B-MED
waiting	B-MED
time	I-MED
""""	O
development	B-MED
and	O
validation	B-MED
of	O
a	O
competing	O
risk	B-MED
model	I-MED
to	O
predict	B-MED
outcomes	B-MED
on	O
the	O
kidney	B-MED
transplant	B-MED
waiting	I-MED
list	I-MED
median	B-MED
historical	B-MED
time	B-MED
to	O
kidney	B-MED
transplant	I-MED
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	B-MED
of	O
death	B-MED
or	O
removal	B-MED
from	I-MED
the	I-MED
waiting	I-MED
list	I-MED
.	O
	
we	O
developed	O
and	O
validated	O
a	O
competing	O
risk	B-MED
model	I-MED
to	O
calculate	B-MED
likelihood	O
of	O
outcomes	B-MED
for	O
kidney	B-MED
transplant	I-MED
candidates	B-MED
and	O
demonstrate	O
how	O
this	O
information	B-MED
differs	B-MED
from	O
median	B-MED
time	B-MED
to	O
transplant	B-MED
.	O
	
data	B-MED
were	O
obtained	B-MED
from	O
the	O
us	B-MED
scientific	I-MED
registry	I-MED
of	O
transplant	B-MED
recipients	I-MED
.	O
	
the	O
retrospective	B-MED
cohort	I-MED
included	O
163	O
636	O
adults	B-MED
listed	O
for	O
kidney	B-MED
transplant	I-MED
before	O
december	O
31	O
,	O
2011	O
.	O
	
predictors	B-MED
were	O
age	B-MED
,	O
sex	B-MED
,	O
blood	B-MED
type	I-MED
,	O
calculated	B-MED
panel-reactive	B-MED
antibodies	I-MED
,	O
donation	B-MED
service	B-MED
area	I-MED
,	O
dialysis	B-MED
duration	B-MED
,	O
comorbid	B-MED
conditions	I-MED
,	O
and	O
body	B-MED
mass	I-MED
index	I-MED
.	O
	
outcomes	B-MED
were	O
deceased	O
or	O
living	B-MED
donor	I-MED
transplant	B-MED
,	O
death	B-MED
or	O
removal	B-MED
from	I-MED
the	I-MED
list	I-MED
due	B-MED
to	I-MED
deteriorating	B-MED
medical	B-MED
condition	B-MED
,	O
or	O
removal	B-MED
due	B-MED
to	I-MED
other	B-MED
reasons	I-MED
.	O
	
we	O
calculated	B-MED
hazards	B-MED
for	O
the	O
possible	B-MED
outcomes	B-MED
,	O
then	O
the	O
cumulative	B-MED
incidence	B-MED
function	B-MED
for	O
a	O
given	O
candidate	B-MED
using	O
competing	O
risk	B-MED
methodology	B-MED
.	O
	
discrimination	B-MED
and	O
calibration	B-MED
were	O
assessed	B-MED
through	B-MED
c	B-MED
statistics	I-MED
and	O
calibration	B-MED
plots	B-MED
for	O
each	B-MED
cause	B-MED
-	O
specific	B-MED
cox	B-MED
proportional	I-MED
hazard	I-MED
model	I-MED
.	O
	
c	B-MED
statistics	I-MED
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O
	
calibration	B-MED
plots	B-MED
showed	O
good	B-MED
calibration	B-MED
.	O
	
the	O
competing	O
risk	B-MED
model	I-MED
shows	O
probability	B-MED
of	O
all	O
possible	B-MED
outcomes	B-MED
for	O
up	O
to	O
12	B-MED
years	I-MED
given	O
a	O
candidate's	B-MED
characteristics	B-MED
,	O
contrasted	O
with	O
the	O
median	B-MED
waiting	B-MED
time	I-MED
for	O
that	O
candidate's	B-MED
donation	B-MED
service	B-MED
area	I-MED
.	O
	
a	O
competing	O
risk	B-MED
model	I-MED
conveys	O
more	O
relevant	B-MED
information	B-MED
than	O
the	O
median	B-MED
waiting	B-MED
time	I-MED
for	O
a	O
given	B-MED
transplant	B-MED
center	I-MED
.	O
	
this	O
model	B-MED
will	O
be	O
updated	B-MED
to	O
create	B-MED
a	O
calculator	O
reflecting	O
the	O
most	O
recent	B-MED
outcomes	B-MED
and	O
changes	B-MED
in	O
allocation	B-MED
policy	B-MED
.	O
	
it	O
illustrates	O
the	O
conversations	B-MED
that	O
should	O
be	O
initiated	B-MED
with	O
transplant	B-MED
candidates	B-MED
.	O
	
tead1	B-MED
regulates	O
the	O
expression	B-MED
of	O
peripheral	B-MED
myelin	I-MED
protein	I-MED
22	I-MED
during	O
schwann	B-MED
cell	I-MED
development	I-MED
schwann	B-MED
cells	I-MED
are	O
myelinating	B-MED
glia	I-MED
in	O
the	O
peripheral	B-MED
nervous	I-MED
system	I-MED
that	O
form	O
the	O
myelin	B-MED
sheath	I-MED
.	O
	
a	O
major	O
cause	O
of	O
peripheral	B-MED
neuropathy	I-MED
is	O
a	O
copy	B-MED
number	I-MED
variant	I-MED
involving	O
the	O
peripheral	B-MED
myelin	I-MED
protein	I-MED
22	I-MED
pmp22	I-MED
gene	I-MED
,	O
which	O
is	O
located	O
within	O
a	O
1.4	O
duplication	B-MED
on	O
chromosome	B-MED
17	I-MED
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
charcot-marie-tooth	B-MED
disease	I-MED
cmt1a	B-MED
.	O
	
rodent	B-MED
models	I-MED
of	O
cmt1a	B-MED
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
pmp22	B-MED
overexpression	B-MED
mitigates	O
several	O
aspects	O
of	O
a	O
cmt1a	B-MED
-related	O
phenotype	B-MED
.	O
	
mechanistic	B-MED
studies	B-MED
of	O
pmp22	B-MED
regulation	B-MED
identified	O
enhancers	B-MED
regulated	O
by	O
the	O
sox10	B-MED
sry	B-MED
sex	I-MED
determining	I-MED
region	I-MED
y-box	I-MED
10	I-MED
and	O
egr2	B-MED
/	O
krox20	B-MED
early	B-MED
growth	I-MED
response	I-MED
protein	I-MED
2	I-MED
transcription	B-MED
factors	I-MED
in	O
myelinated	B-MED
nerves	I-MED
.	O
	
however	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	B-MED
factors	I-MED
induce	B-MED
pmp22	B-MED
expression	B-MED
during	O
schwann	B-MED
cell	I-MED
development	I-MED
and	O
myelination	B-MED
.	O
	
here	O
,	O
we	O
examined	O
pmp22	B-MED
enhancers	B-MED
as	O
a	O
function	O
of	O
cell	B-MED
type-specificity	I-MED
,	O
nerve	B-MED
injury	I-MED
and	O
development	B-MED
.	O
	
while	O
pmp22	B-MED
enhancers	B-MED
marked	O
by	O
active	B-MED
histone	B-MED
modifications	I-MED
were	O
lost	B-MED
or	O
remodeled	O
after	O
injury	B-MED
,	O
we	O
found	O
that	O
these	O
enhancers	B-MED
were	O
permissive	O
in	O
early	O
development	B-MED
prior	O
to	O
pmp22	B-MED
upregulation	B-MED
.	O
	
pmp22	B-MED
enhancers	B-MED
contain	O
binding	B-MED
motifs	I-MED
for	O
tea	B-MED
domain	I-MED
tead	B-MED
transcription	B-MED
factors	I-MED
of	O
the	O
hippo	B-MED
signaling	I-MED
pathway	I-MED
.	O
	
we	O
discovered	O
that	O
tead1	B-MED
and	O
co-activators	O
yap	B-MED
and	O
taz	B-MED
are	O
required	O
for	O
pmp22	B-MED
expression	B-MED
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-MED
of	O
egr2	B-MED
tead1	B-MED
directly	O
binds	O
pmp22	B-MED
and	O
egr2	B-MED
enhancers	B-MED
early	O
in	O
development	B-MED
and	O
tead1	B-MED
binding	B-MED
is	O
induced	B-MED
during	O
myelination	B-MED
,	O
correlating	O
with	O
pmp22	B-MED
expression	B-MED
.	O
	
the	O
data	B-MED
identify	O
tead1	B-MED
as	O
a	O
novel	O
regulator	B-MED
of	O
pmp22	B-MED
expression	B-MED
during	O
development	B-MED
in	O
concert	O
with	O
sox10	B-MED
and	O
neutrophil	B-MED
gelatinase-associated	I-MED
lipocalin	I-MED
in	O
a	O
triphasic	B-MED
rat	B-MED
model	I-MED
of	O
adenine	B-MED
-	O
induced	B-MED
kidney	B-MED
injury	I-MED
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
ngal	B-MED
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-MED
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-MED
tubulointerstitial	I-MED
insult	I-MED
caused	O
by	O
adenine	B-MED
.	O
	
subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
ngal	B-MED
as	O
a	O
biomarker	B-MED
of	O
any	O
acute	B-MED
kidney	I-MED
injury	I-MED
,	O
on	O
top	O
of	O
chronic	B-MED
interstitial	I-MED
disease	I-MED
,	O
if	O
ngal	B-MED
levels	B-MED
are	O
stable	B-MED
through	B-MED
the	O
chronic	B-MED
phase	I-MED
of	O
our	O
adenine	B-MED
model	I-MED
.	O
	
study	B-MED
group	I-MED
rats	B-MED
were	O
fed	O
an	O
adenine	B-MED
diet	B-MED
,	O
and	O
control	B-MED
group	I-MED
rats	B-MED
were	O
fed	O
a	O
regular	B-MED
diet	I-MED
only	O
.	O
	
blood	B-MED
and	O
urine	B-MED
samples	I-MED
for	O
urea	B-MED
,	O
creatinine	B-MED
and	O
ngal	B-MED
were	O
drawn	O
from	O
each	O
rat	B-MED
at	O
the	O
beginning	B-MED
of	O
the	O
study	B-MED
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O
	
kidney	B-MED
slices	B-MED
from	O
these	O
rats	B-MED
were	O
stained	B-MED
with	O
hematoxylin-eosin	B-MED
he	B-MED
and	O
β-actin	B-MED
stainings	B-MED
.	O
	
serum	B-MED
urea	I-MED
,	O
creatinine	B-MED
and	O
ngal	B-MED
levels	B-MED
and	O
urinary	B-MED
ngal/creatinine	I-MED
ratio	I-MED
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	B-MED
and	O
than	O
in	O
the	O
control	B-MED
group	I-MED
these	O
differences	O
were	O
statistically	B-MED
significant	I-MED
in	O
some	O
of	O
the	O
intervals	B-MED
.	O
	
tubulointerstitial	B-MED
changes	O
and	O
adenine	B-MED
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-MED
.	O
	
in	O
the	O
rats	B-MED
fed	O
adenine	B-MED
,	O
serum	B-MED
urea	I-MED
,	O
creatinine	B-MED
and	O
ngal	B-MED
levels	B-MED
and	O
urinary	B-MED
ngal/creatinine	I-MED
ratio	I-MED
followed	O
a	O
triphasic	B-MED
pattern	I-MED
of	O
kidney	B-MED
injury	I-MED
an	O
acute	B-MED
phase	I-MED
while	O
on	O
the	O
adenine	B-MED
diet	B-MED
,	O
a	O
partial	B-MED
recovery	B-MED
phase	B-MED
after	O
switching	O
to	O
the	O
regular	B-MED
diet	I-MED
and	O
a	O
chronic	B-MED
kidney	I-MED
disease	I-MED
phase	B-MED
after	O
stabilization	O
of	O
renal	B-MED
function	I-MED
.	O
	
ngal	B-MED
can	O
serve	O
a	O
biomarker	B-MED
for	O
acute	B-MED
kidney	I-MED
injury	I-MED
and	O
possibly	O
for	O
chronic	B-MED
kidney	I-MED
disease	I-MED
in	O
the	O
tubulointerstitial	B-MED
rat	B-MED
model	I-MED
.	O
	
talking	B-MED
or	O
keeping	B-MED
silent	I-MED
about	O
parental	B-MED
mental	B-MED
health	I-MED
problems	I-MED
-a	O
grounded	B-MED
theory	I-MED
of	O
parents	B-MED
'	O
decision	B-MED
making	I-MED
and	O
experiences	B-MED
with	O
their	O
children	B-MED
this	O
grounded	B-MED
theory	I-MED
study	B-MED
explored	O
parents	B-MED
'	O
experiences	B-MED
of	O
responding	O
to	O
their	O
children's	B-MED
need	O
for	O
understanding	O
parental	B-MED
mental	B-MED
health	I-MED
concerns	B-MED
.	O
	
fifteen	O
parents	B-MED
with	O
severe	B-MED
and	O
enduring	O
mental	B-MED
health	I-MED
difficulties	I-MED
participated	O
in	O
the	O
study	B-MED
.	O
	
the	O
findings	B-MED
suggest	O
four	O
main	O
social	B-MED
processes	I-MED
that	O
influence	O
parents	B-MED
'	O
talk	B-MED
with	O
their	O
children	B-MED
about	O
parental	B-MED
mental	B-MED
health	I-MED
issues	I-MED
,	O
namely	O
""""	O
protecting	B-MED
and	O
being	B-MED
protected	I-MED
""""	O
""""	O
responding	B-MED
to	O
children's	B-MED
search	B-MED
for	O
understanding	B-MED
""""	O
""""	O
prioritizing	B-MED
family	B-MED
life	I-MED
""""	O
and	O
""""	O
relating	B-MED
to	I-MED
others	I-MED
""""	O
implications	O
of	O
the	O
findings	B-MED
for	O
clinical	B-MED
practice	I-MED
and	O
future	O
research	B-MED
are	O
considered	O
.	O
	
in	O
particular	O
,	O
the	O
need	O
for	O
more	O
family-orientated	B-MED
services	I-MED
where	O
parents	B-MED
experience	B-MED
parental	B-MED
mental	B-MED
health	I-MED
problems	I-MED
a	O
case	B-MED
of	O
bilateral	B-MED
pneumothoraces	B-MED
resulting	O
from	O
tracheostomy	B-MED
for	O
advanced	B-MED
laryngeal	B-MED
cancer	I-MED
pneumothorax	B-MED
is	O
a	O
possible	O
complication	B-MED
of	O
tracheostomy	B-MED
.	O
	
we	O
report	B-MED
a	O
rare	O
case	O
of	O
bilateral	B-MED
pneumothoraces	B-MED
resulting	O
from	O
tracheostomy	B-MED
in	O
an	O
advanced	B-MED
laryngeal	B-MED
cancer	I-MED
patient	B-MED
.	O
	
a	O
59-year-old	O
man	B-MED
was	O
referred	O
to	O
our	O
clinic	B-MED
for	O
evaluation	B-MED
and	O
treatment	B-MED
of	O
laryngeal	B-MED
tumor	I-MED
.	O
	
laryngeal	B-MED
endoscopy	I-MED
showed	O
limited	B-MED
movement	I-MED
of	O
bilateral	B-MED
vocal	I-MED
cords	I-MED
,	O
and	O
computed	B-MED
tomography	I-MED
revealed	O
a	O
tumor	B-MED
lesion	B-MED
extending	O
from	O
the	O
vocal	B-MED
cords	I-MED
to	O
the	O
subglottic	B-MED
area	I-MED
.	O
	
three	O
days	B-MED
after	O
the	O
first	B-MED
visit	I-MED
,	O
the	O
patient	B-MED
developed	O
respiratory	B-MED
difficulty	I-MED
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-MED
tracheostomy	I-MED
for	O
airway	B-MED
management	I-MED
.	O
	
immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-MED
,	O
he	O
began	O
hyperventilating	B-MED
,	O
and	O
complained	O
of	O
respiratory	B-MED
discomfort	I-MED
and	O
chest	B-MED
pain	I-MED
.	O
	
we	O
then	O
recognized	O
a	O
mediastinal	B-MED
air	B-MED
leak	I-MED
,	O
and	O
we	O
suspected	B-MED
pneumothorax	B-MED
resulting	O
from	O
the	O
tracheostomy	B-MED
.	O
	
chest	B-MED
x-ray	I-MED
showed	O
bilateral	B-MED
pneumothoraces	B-MED
therefore	O
,	O
we	O
inserted	B-MED
bilateral	B-MED
chest	B-MED
drainage	B-MED
tubes	I-MED
,	O
which	O
stabilized	B-MED
his	O
respiratory	B-MED
condition	I-MED
.	O
	
we	O
speculated	O
that	O
the	O
pathogenesis	B-MED
of	O
the	O
bilateral	B-MED
pneumothoraces	B-MED
was	O
weakened	B-MED
alveolar	B-MED
walls	I-MED
secondary	O
to	O
long-term	B-MED
smoking	B-MED
,	O
and	O
a	O
significant	O
rise	B-MED
in	O
airway	B-MED
pressure	I-MED
because	O
of	O
airway	B-MED
constriction	I-MED
by	O
the	O
neck-extended	B-MED
position	I-MED
and	O
hyperventilation	B-MED
,	O
during	O
arsenic	B-MED
triglutathione	I-MED
as	B-MED
transport	B-MED
by	O
multidrug	B-MED
resistance	I-MED
protein	I-MED
1	I-MED
mrp1	B-MED
/	O
abcc1	B-MED
is	O
selectively	O
modified	B-MED
by	O
phosphorylation	B-MED
of	O
tyr920/ser921	B-MED
and	O
glycosylation	B-MED
of	O
asn19/asn23	B-MED
the	O
atp-binding	B-MED
cassette	I-MED
abc	I-MED
transporter	I-MED
multidrug	B-MED
resistance	I-MED
protein	I-MED
1	I-MED
mrp1	B-MED
/	O
abcc1	B-MED
is	O
responsible	O
for	O
the	O
cellular	B-MED
export	B-MED
of	O
a	O
chemically	O
diverse	B-MED
array	B-MED
of	O
xenobiotics	B-MED
and	O
endogenous	B-MED
compounds	B-MED
.	O
	
arsenic	B-MED
,	O
a	O
human	B-MED
carcinogen	B-MED
,	O
is	O
a	O
high-affinity	B-MED
mrp1	B-MED
substrate	B-MED
as	O
arsenic	B-MED
triglutathione	I-MED
as	B-MED
.	O
	
in	O
this	O
study	O
,	O
marked	O
differences	O
in	O
as	B-MED
transport	B-MED
kinetics	B-MED
were	O
observed	O
between	O
mrp1	B-MED
-enriched	O
membrane	B-MED
vesicles	B-MED
prepared	B-MED
from	O
human	B-MED
embryonic	B-MED
kidney	B-MED
293	B-MED
hek	I-MED
km	B-MED
3.8	O
µm	O
and	O
vmax	B-MED
307	O
pmol/mg	O
per	O
minute	O
and	O
hela	B-MED
km	B-MED
0.32	O
µm	O
and	O
vmax	B-MED
42	O
pmol/mg	O
per	O
minute	O
cells	B-MED
.	O
	
mutant	B-MED
mrp1	B-MED
lacking	O
n-linked	O
glycosylation	B-MED
asn19/23/1006gln	B-MED
sugar-free	O
sf	B-MED
expressed	B-MED
in	O
either	O
hek293	B-MED
or	O
hela	B-MED
cells	I-MED
had	O
low	O
km	B-MED
and	O
vmax	B-MED
values	O
for	O
as	B-MED
,	O
similar	B-MED
to	O
hela	B-MED
wild-type	I-MED
wt	O
mrp1	B-MED
.	O
	
when	O
prepared	B-MED
in	O
the	O
presence	B-MED
of	O
phosphatase	B-MED
inhibitors	I-MED
,	O
both	O
wt-	B-MED
and	O
sf-mrp1	B-MED
-enriched	O
membrane	B-MED
vesicles	B-MED
had	O
a	O
high	O
km	B-MED
value	O
for	O
as	B-MED
3-6	O
µm	O
,	O
regardless	O
of	O
the	O
cell	B-MED
line	I-MED
.	O
	
kinetic	B-MED
parameters	I-MED
of	O
as	B-MED
for	O
hek	B-MED
-	O
asn19/23gln-mrp1	B-MED
were	O
similar	B-MED
to	O
those	O
of	O
hela	B-MED
/	O
hek	B-MED
-	O
sf-mrp1	B-MED
and	O
hela-wt	B-MED
-	O
mrp1	B-MED
,	O
whereas	O
those	O
of	O
single	B-MED
glycosylation	B-MED
mutants	B-MED
were	O
like	O
those	O
of	O
hek-wt	B-MED
-mrp1	O
.	O
	
mutation	B-MED
of	O
19	O
potential	B-MED
mrp1	O
phosphorylation	B-MED
sites	B-MED
revealed	O
that	O
hek	B-MED
-	O
tyr920phe/ser921ala-mrp1	B-MED
transported	B-MED
as	B-MED
like	O
hela-wt	B-MED
-	O
mrp1	B-MED
,	O
whereas	O
individual	O
hek	B-MED
-	O
tyr920phe-	B-MED
and	O
-	O
ser921ala-mrp1	B-MED
mutants	B-MED
were	O
similar	B-MED
to	O
hek-wt	B-MED
-	O
mrp1	B-MED
.	O
	
together	O
,	O
these	O
results	B-MED
suggest	O
that	O
asn19/asn23	B-MED
glycosylation	B-MED
and	O
tyr920/ser921	B-MED
phosphorylation	B-MED
are	O
responsible	O
for	O
altering	B-MED
the	O
kinetics	B-MED
of	O
mrp1	B-MED
-mediated	O
as	B-MED
transport	B-MED
.	O
	
the	O
kinetics	B-MED
of	O
as	B-MED
transport	B-MED
by	O
hek	B-MED
-	O
asn19/23gln/tyr920glu/ser921glu	B-MED
were	O
similar	B-MED
to	O
hek-wt	B-MED
-	O
mrp1	B-MED
,	O
indicating	O
that	O
the	O
phosphorylation	B-MED
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	B-MED
of	O
asn19/23gln	B-MED
glycosylation	B-MED
.	O
	
overall	O
,	O
these	O
data	O
suggest	O
that	O
cross-talk	O
between	O
mrp1	B-MED
glycosylation	B-MED
and	O
phosphorylation	B-MED
occurs	O
and	O
that	O
phosphorylation	B-MED
of	O
tyr920	B-MED
and	O
ser921	B-MED
can	O
switch	O
mrp1	B-MED
to	O
a	O
lower-affinity	B-MED
,	O
higher-capacity	B-MED
as	B-MED
transporter	B-MED
,	O
allowing	O
arsenic	B-MED
detoxification	B-MED
over	O
a	O
broad	B-MED
concentration	B-MED
range	B-MED
.	O
	
naphthohydroquinones	B-MED
,	O
naphthoquinones	B-MED
,	O
anthraquinones	B-MED
,	O
and	O
a	O
naphthohydroquinone	B-MED
dimer	B-MED
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
morinda	B-MED
parvifolia	I-MED
and	O
their	O
cytotoxic	B-MED
effects	I-MED
through	O
up-regulation	B-MED
of	O
p53	B-MED
five	O
unknown	B-MED
compounds	B-MED
,	O
morindaparvins	B-MED
c-g	I-MED
,	O
consisting	O
of	O
naphthohydroquinones	B-MED
,	O
a	O
naphthoquinone	B-MED
,	O
an	O
anthraquinone	B-MED
,	O
and	O
a	O
naphthohydroquinone	B-MED
dimer	B-MED
,	O
together	O
with	O
three	O
known	O
quinones	B-MED
and	O
seven	O
other	O
known	O
compounds	B-MED
,	O
were	O
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
morinda	B-MED
parvifolia	I-MED
.	O
	
the	O
structures	O
of	O
morindaparvins	B-MED
c	I-MED
,	O
d	B-MED
,	O
e	B-MED
,	O
f	B-MED
,	O
and	O
g	B-MED
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-MED
or	O
x-ray	B-MED
diffraction	I-MED
analysis	I-MED
as	O
methyl	B-MED
4-hydroxy-1	I-MED
,	O
methyl	B-MED
4	I-MED
,	O
3-amino-6-methoxy-2-methoxycarbonyl-1	B-MED
,	O
1	B-MED
,	O
and	O
dimethyl	B-MED
1	I-MED
,	O
respectively	O
.	O
	
naphthoquinones	B-MED
and	O
naphthohydroquinone	B-MED
dimers	B-MED
were	O
previously	O
unknown	B-MED
in	O
the	O
genus	B-MED
morinda	B-MED
.	O
	
in	O
addition	O
,	O
the	O
compounds	B-MED
were	O
tested	B-MED
for	O
cytotoxicity	B-MED
against	O
four	O
human	B-MED
cancer	B-MED
cell	I-MED
lines	I-MED
hela	B-MED
,	O
a2780	B-MED
,	O
ketr3	B-MED
and	O
mcf-7	B-MED
and	O
their	O
effects	B-MED
on	O
p53	B-MED
-	O
activated	B-MED
transcription	B-MED
.	O
	
three	O
naphthoquinones	B-MED
had	O
moderate	B-MED
cytotoxic	B-MED
effects	I-MED
with	O
ic50	B-MED
values	O
ranging	B-MED
from	O
1.51	O
to	O
9.56	O
μm	O
,	O
through	O
up-regulation	B-MED
of	O
p53	B-MED
transcriptional	B-MED
activity	I-MED
.	O
	
identification	B-MED
and	O
sar	B-MED
evaluation	B-MED
of	O
hemozoin	B-MED
-	O
inhibiting	B-MED
benzamides	B-MED
active	B-MED
against	O
plasmodium	B-MED
falciparum	I-MED
quinoline	B-MED
antimalarials	B-MED
target	B-MED
hemozoin	B-MED
formation	B-MED
causing	O
a	O
cytotoxic	B-MED
accumulation	B-MED
of	O
ferriprotoporphyrin	B-MED
ix	I-MED
fe	B-MED
.	O
	
well-developed	O
sar	B-MED
models	B-MED
exist	O
for	O
β-hematin	B-MED
inhibition	B-MED
,	O
parasite	B-MED
activity	B-MED
,	O
and	O
cellular	B-MED
mechanisms	I-MED
for	O
this	O
compound	B-MED
class	I-MED
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-MED
exist	O
for	O
other	O
hemozoin	B-MED
inhibiting	B-MED
chemotypes	B-MED
.	O
	
here	O
,	O
benzamide	B-MED
analogues	B-MED
based	O
on	O
previous	O
hts	B-MED
hits	O
have	O
been	O
purchased	B-MED
or	O
synthesized	B-MED
.	O
	
only	O
derivatives	B-MED
containing	I-MED
an	I-MED
electron	I-MED
deficient	I-MED
aromatic	I-MED
ring	I-MED
and	O
capable	O
of	O
adopting	O
flat	B-MED
conformations	I-MED
,	O
optimal	O
for	O
π-π	B-MED
interactions	I-MED
with	O
fe	B-MED
,	O
inhibited	B-MED
β-hematin	B-MED
formation	B-MED
.	O
	
the	O
two	O
most	O
potent	O
analogues	B-MED
showed	O
nanomolar	B-MED
parasite	B-MED
activity	B-MED
,	O
with	O
little	O
cq	B-MED
cross-resistance	B-MED
,	O
low	O
cytotoxicity	B-MED
,	O
and	O
high	O
in	B-MED
vitro	I-MED
microsomal	B-MED
stability	B-MED
.	O
	
selected	O
analogues	B-MED
inhibited	B-MED
hemozoin	B-MED
formation	B-MED
in	O
plasmodium	B-MED
falciparum	I-MED
causing	O
high	O
levels	B-MED
of	O
free	O
heme	B-MED
.	O
	
in	O
contrast	O
to	O
quinolines	B-MED
,	O
introduction	B-MED
of	O
amine	B-MED
side	I-MED
chains	I-MED
did	O
not	O
lead	O
to	O
benzamide	B-MED
accumulation	B-MED
in	O
the	O
parasite	B-MED
.	O
	
these	O
data	B-MED
reveal	O
complex	O
relationships	B-MED
between	O
heme	B-MED
binding	I-MED
,	O
free	O
heme	B-MED
levels	B-MED
,	O
cellular	B-MED
accumulation	I-MED
,	O
and	O
in	B-MED
vitro	I-MED
activity	B-MED
of	O
potential	O
novel	B-MED
antimalarials	B-MED
.	O
	
shear	B-MED
modulus	I-MED
of	O
structured	B-MED
electrorheological	B-MED
fluid	I-MED
mixtures	B-MED
some	O
immiscible	B-MED
blends	I-MED
under	O
a	O
strong	O
electric	B-MED
field	I-MED
often	O
exhibit	O
periodic	B-MED
structures	B-MED
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-MED
.	O
	
upon	O
shear	B-MED
,	O
the	O
structures	B-MED
tilt	B-MED
,	O
and	O
exhibit	O
an	O
elastic	B-MED
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	B-MED
energy	I-MED
.	O
	
assuming	O
a	O
two-dimensional	B-MED
stripe	B-MED
structure	I-MED
,	O
we	O
calculate	O
the	O
maxwell	B-MED
stress	I-MED
,	O
and	O
derive	O
an	O
expression	B-MED
for	O
the	O
shear	B-MED
modulus	I-MED
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	B-MED
field	I-MED
,	O
the	O
composition	B-MED
,	O
and	O
the	O
dielectric	B-MED
properties	I-MED
of	O
the	O
blend	B-MED
.	O
	
we	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	B-MED
tension	I-MED
,	O
which	O
renormalizes	O
the	O
effect	B-MED
of	I-MED
the	O
electric	B-MED
field	I-MED
.	O
	
this	O
leads	O
to	O
a	O
simple	O
derivation	B-MED
of	O
the	O
scaling	B-MED
law	I-MED
for	O
the	O
selection	O
of	O
the	O
wavelength	B-MED
of	O
the	O
structure	B-MED
formed	O
under	O
an	O
electric	B-MED
field	I-MED
.	O
	
sequence-specific	B-MED
dna	I-MED
binding	I-MED
by	O
long	B-MED
hairpin	I-MED
pyrrole-imidazole	B-MED
polyamides	I-MED
containing	O
an	O
8-amino-3	B-MED
acid	I-MED
unit	O
with	O
the	O
aim	O
of	O
improving	O
aqueous	B-MED
solubility	I-MED
,	O
we	O
designed	B-MED
and	O
synthesized	B-MED
five	O
n-methylpyrrole	B-MED
py	I-MED
im	I-MED
polyamides	I-MED
capable	O
of	O
recognizing	O
9-bp	B-MED
sequences	I-MED
.	O
	
their	O
dna-binding	B-MED
affinities	B-MED
and	O
sequence	B-MED
specificities	B-MED
were	O
evaluated	O
by	O
spr	B-MED
and	O
bind-n-seq	B-MED
analyses	I-MED
.	O
	
the	O
design	B-MED
of	O
polyamide	B-MED
1	I-MED
was	O
based	O
on	O
a	O
conventional	O
model	B-MED
,	O
with	O
three	O
consecutive	O
py	B-MED
or	O
im	B-MED
rings	O
separated	O
by	O
a	O
β-alanine	B-MED
to	O
match	O
the	O
curvature	O
and	O
twist	B-MED
of	O
long	O
dna	B-MED
helices	B-MED
.	O
	
polyamides	B-MED
2	I-MED
and	I-MED
3	I-MED
contained	O
an	O
8-amino-3	B-MED
acid	I-MED
ao	B-MED
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-MED
within	O
linear	O
py-im	B-MED
polyamides	I-MED
or	O
between	O
py	B-MED
-	O
im	O
hairpin	O
motifs	O
for	O
tandem	O
hairpin	O
.	O
	
it	O
is	O
demonstrated	O
herein	O
that	O
ao	O
also	O
functions	O
as	O
a	O
linker	O
element	O
that	O
can	O
extend	O
to	O
2-bp	O
in	O
hairpin	O
motifs	O
.	O
	
notably	O
,	O
although	O
the	O
ao	O
-containing	O
unit	O
can	O
fail	O
to	O
bind	O
the	O
expected	O
sequence	O
,	O
polyamide	O
4	O
,	O
which	O
has	O
two	O
ao	O
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	O
form	O
,	O
successfully	O
showed	O
the	O
expected	O
motif	O
and	O
a	O
kd	O
value	O
of	O
16nm	O
was	O
recorded	O
.	O
	
polyamide	O
5	O
,	O
containing	O
a	O
β-alanine-β-alanine	O
unit	O
instead	O
of	O
the	O
ao	O
of	O
polyamide	O
2	O
,	O
was	O
synthesized	O
for	O
comparison	O
.	O
	
the	O
aqueous	O
solubilities	O
and	O
nuclear	O
localization	O
of	O
three	O
of	O
the	O
polyamides	O
were	O
also	O
examined	O
.	O
	
the	O
results	O
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
ao	O
unit	O
in	O
the	O
core	O
of	O
py-im	O
polyamide	O
compounds	I-MED
causes	B-MED
of	I-MED
death	I-MED
among	O
children	B-MED
aged	B-MED
5	O
to	O
14	O
years	B-MED
old	B-MED
from	O
2008	O
to	O
2013	O
in	O
kersa	O
health	O
and	O
demographic	O
surveillance	O
system	O
kersa	O
hdss	O
,	O
ethiopia	B-MED
the	O
global	O
burden	O
of	O
mortality	B-MED
among	I-MED
children	I-MED
is	O
still	O
very	O
huge	O
though	O
its	O
trend	B-MED
has	O
started	O
declining	O
following	O
the	O
improvements	B-MED
in	O
the	O
living	B-MED
standard	I-MED
.	O
	
it	O
presents	O
serious	O
challenges	B-MED
to	O
the	O
well-being	O
of	O
children	B-MED
in	O
many	O
african	B-MED
countries	I-MED
.	O
	
today	O
,	O
sub-saharan	B-MED
africa	I-MED
alone	O
accounts	O
for	O
about	O
50%	O
of	O
global	B-MED
child	B-MED
mortality	I-MED
.	O
	
the	O
overall	O
objective	B-MED
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	B-MED
and	O
distribution	B-MED
of	O
causes	B-MED
of	I-MED
death	I-MED
among	O
children	B-MED
aged	B-MED
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-MED
of	O
kersa	O
hdss	O
using	O
verbal	B-MED
autopsy	B-MED
method	O
for	O
the	O
period	B-MED
2008	O
to	O
2013	O
.	O
	
kersa	O
health	O
and	O
demographic	O
surveillance	O
system	O
kersa	O
hdss	O
was	O
established	O
in	O
september	B-MED
2007	O
.	O
	
the	O
center	O
consists	O
of	O
10	O
rural	B-MED
and	O
2	O
urban	B-MED
kebeles	B-MED
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-MED
in	O
the	O
district	B-MED
.	O
	
thus	O
this	O
study	O
was	O
conducted	O
in	O
kersa	O
hdss	O
and	O
data	B-MED
was	O
taken	O
from	O
kersa	B-MED
hdss	I-MED
database	I-MED
.	O
	
the	O
study	B-MED
population	B-MED
included	O
all	O
children	B-MED
aged	B-MED
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	B-MED
of	O
2008	O
to	O
2013	O
in	O
kersa	O
hdss	O
using	O
age	B-MED
specific	O
va	O
questionnaires	B-MED
.	O
	
data	B-MED
were	O
extracted	O
from	O
spss	B-MED
database	I-MED
and	O
analyzed	O
using	O
stata	B-MED
.	O
	
a	O
total	O
of	O
229	O
deaths	B-MED
were	O
recorded	O
over	O
the	O
period	B-MED
of	O
six	O
years	O
with	O
a	O
crude	O
death	B-MED
rate	I-MED
of	O
219.6	O
per	O
100	O
population	B-MED
of	O
this	O
age	B-MED
group	I-MED
over	O
the	O
study	B-MED
period	B-MED
.	O
	
this	O
death	B-MED
rate	I-MED
was	O
217.5	O
and	O
221.5	O
per	O
100	O
populations	B-MED
for	O
females	B-MED
and	O
males	B-MED
,	O
respectively	O
.	O
	
75%	O
of	O
deaths	B-MED
took	O
place	O
at	O
home	O
.	O
	
the	O
study	B-MED
identified	O
severe	O
malnutrition	B-MED
33.9	O
,	O
intestinal	B-MED
infectious	I-MED
diseases	I-MED
13.8	O
and	O
acute	B-MED
lower	I-MED
respiratory	I-MED
infections	I-MED
9.2	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
.	O
	
in	O
broad	O
causes	B-MED
of	I-MED
death	I-MED
classification	B-MED
,	O
injuries	B-MED
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-MED
of	I-MED
death	I-MED
next	O
to	O
communicable	B-MED
diseases	I-MED
56.3	O
attributing	O
to	O
13.1	O
of	O
the	O
total	O
deaths	B-MED
.	O
	
in	O
specific	O
causes	B-MED
of	I-MED
death	I-MED
classification	B-MED
severe	O
malnutrition	B-MED
,	O
intestinal	B-MED
infectious	I-MED
diseases	I-MED
and	O
acute	B-MED
lower	I-MED
respiratory	I-MED
infections	I-MED
were	O
the	O
three	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
where	O
,	O
in	O
broad	O
causes	B-MED
of	I-MED
death	I-MED
communicable	B-MED
diseases	I-MED
and	O
injuries	B-MED
were	O
among	O
the	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
.	O
	
hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	B-MED
from	O
these	O
causes	B-MED
of	I-MED
death	I-MED
and	O
further	O
inferential	B-MED
analysis	I-MED
into	O
the	O
prevention	B-MED
and	O
management	B-MED
of	O
infectious	B-MED
diseases	I-MED
naïve	B-MED
cd8	B-MED
t	I-MED
cell	I-MED
derived	O
tumor	B-MED
-	O
specific	B-MED
cytotoxic	B-MED
effectors	I-MED
as	O
a	O
potential	O
remedy	B-MED
for	O
overcoming	O
tgf-β	B-MED
immunosuppression	B-MED
in	O
the	O
tumor	B-MED
microenvironment	I-MED
despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-MED
immunotherapy	I-MED
,	O
conventional	B-MED
approaches	B-MED
using	O
in	B-MED
vitro	I-MED
expanded	B-MED
cd8	B-MED
t	I-MED
cells	I-MED
have	O
suboptimal	B-MED
outcomes	B-MED
,	O
mostly	O
due	O
to	O
loss	B-MED
of	O
functionality	B-MED
from	O
cellular	B-MED
exhaustion	B-MED
.	O
	
we	O
therefore	O
investigated	O
the	O
phenotypic	B-MED
and	O
functional	B-MED
differences	B-MED
among	O
in	B-MED
vitro	I-MED
activated	B-MED
cd8	B-MED
t	I-MED
cells	I-MED
of	O
three	O
different	O
sources	B-MED
,	O
namely	O
naïve	B-MED
nteff	B-MED
,	O
memory	B-MED
mteff	B-MED
and	O
tumor-infiltrating	B-MED
lymphocytes	I-MED
tileff	B-MED
from	O
human	B-MED
and	O
mice	B-MED
,	O
to	O
better	O
understand	O
mechanisms	B-MED
behind	O
potent	O
effector	B-MED
functions	B-MED
and	O
potential	O
for	O
overcoming	O
current	O
limitations	B-MED
.	O
	
in	O
line	O
with	O
the	O
greater	O
proliferation	B-MED
activity	B-MED
and	O
longer	O
telomere	B-MED
lengths	B-MED
of	O
nteff	B-MED
populations	I-MED
,	O
cells	B-MED
of	O
naïve	B-MED
origin	I-MED
exhibited	O
significantly	O
less	O
amounts	O
of	O
t	B-MED
cell	I-MED
exhaustion	B-MED
markers	B-MED
than	O
those	O
of	O
mteff	B-MED
and	O
tileff	B-MED
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	B-MED
patterns	I-MED
of	O
memory-promoting	B-MED
transcription	I-MED
factors	I-MED
,	O
t-bet	B-MED
and	O
eomes	B-MED
,	O
induced	B-MED
in	O
a	O
rapid	B-MED
and	O
sustainable	B-MED
manner	B-MED
.	O
	
nteff	B-MED
cells	I-MED
appeared	O
to	O
have	O
lower	O
expression	B-MED
of	O
foxp1	B-MED
and	O
were	O
refractory	O
to	O
apoptosis	B-MED
upon	O
tgf-β	B-MED
conditioning	B-MED
,	O
implying	O
better	O
survival	B-MED
potential	B-MED
and	O
resistance	B-MED
to	O
tumor	B-MED
-	O
induced	B-MED
immune	B-MED
suppression	I-MED
.	O
	
of	O
cd8	B-MED
t	I-MED
cell	I-MED
pools	O
activated	B-MED
to	O
tumor	B-MED
-	O
specific	B-MED
ctls	B-MED
,	O
naïve	B-MED
cell	I-MED
generated	B-MED
effectors	B-MED
possessed	O
the	O
most	O
potent	O
cytotoxic	B-MED
activity	I-MED
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	B-MED
of	O
adoptive	B-MED
immunotherapy	I-MED
.	O
	
antiadipogenic	B-MED
activity	I-MED
of	O
γ-oryzanol	B-MED
and	O
its	O
stability	B-MED
in	O
pigmented	B-MED
rice	B-MED
γ-oryzanol	B-MED
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	B-MED
rice	B-MED
varieties	B-MED
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity-associated	B-MED
metabolic	I-MED
disorders	I-MED
.	O
	
antiadipogenic	B-MED
activities	I-MED
of	O
γ-oryzanol	B-MED
were	O
determined	O
in	O
human	B-MED
adipose	B-MED
-	O
derived	B-MED
mesenchymal	B-MED
stem	I-MED
cells	I-MED
and	O
mouse	B-MED
-	O
derived	B-MED
3t3-l1	B-MED
cells	I-MED
.	O
	
γ-oryzanol	B-MED
significantly	O
decreased	B-MED
lipid	B-MED
accumulation	I-MED
and	O
reduced	B-MED
glycerol-3-phosphate	B-MED
dehydrogenase	I-MED
activities	I-MED
in	O
both	O
adipocytes	B-MED
.	O
	
in	O
addition	O
,	O
γ-oryzanol	B-MED
in	O
four	O
pigmented	B-MED
rice	B-MED
varieties	B-MED
black	B-MED
with	I-MED
giant	I-MED
embryo	I-MED
,	O
brown	B-MED
,	O
sugary	B-MED
brown	I-MED
,	O
and	O
red	B-MED
was	O
stable	B-MED
when	O
stored	B-MED
at	O
4	O
and	O
also	O
at	O
room	B-MED
temperature	I-MED
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	B-MED
such	O
as	O
lutein	B-MED
and	O
β-carotene	B-MED
were	O
stable	B-MED
only	O
at	O
-80	O
.	O
	
furthermore	O
,	O
the	O
yield	B-MED
of	O
γ-oryzanol	B-MED
from	O
these	O
rice	B-MED
varieties	B-MED
was	O
significantly	O
increased	O
through	O
steaming	B-MED
and	O
roasting	B-MED
processes	I-MED
.	O
	
therefore	O
,	O
γ-oryzanol	B-MED
exerts	O
antiadipogenic	B-MED
activity	I-MED
by	O
suppressing	B-MED
adipocyte	B-MED
differentiations	I-MED
and	O
is	O
stable	B-MED
in	O
pigmented	B-MED
rice	B-MED
for	O
an	O
extended	B-MED
period	B-MED
of	I-MED
time	I-MED
during	O
storage	B-MED
and	O
after	B-MED
cooking	B-MED
.	O
	
thus	O
,	O
the	O
intake	B-MED
of	O
pigmented	B-MED
rice	B-MED
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	B-MED
obesity	B-MED
.	O
	
impact	B-MED
of	O
chemotherapy	B-MED
on	O
diet	B-MED
and	O
nutritional	B-MED
status	I-MED
of	O
women	B-MED
with	O
breast	B-MED
cancer	I-MED
a	O
prospective	B-MED
study	I-MED
certain	O
food	B-MED
groups	I-MED
are	O
often	O
rejected	B-MED
during	O
chemotherapy	B-MED
ct	B-MED
due	O
to	O
the	O
side	B-MED
effects	I-MED
of	I-MED
treatment	I-MED
,	O
which	O
may	O
interfere	B-MED
with	I-MED
adequate	B-MED
diet	I-MED
and	O
nutritional	B-MED
status	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
treatment	B-MED
impact	B-MED
on	O
the	O
diet	B-MED
and	O
nutritional	B-MED
status	I-MED
of	O
women	B-MED
with	O
breast	B-MED
cancer	I-MED
bc	B-MED
.	O
	
in	O
this	O
prospective	B-MED
longitudinal	I-MED
study	I-MED
,	O
conducted	O
in	O
2014-2015	O
,	O
55	O
women	B-MED
diagnosed	O
with	O
bc	B-MED
,	O
with	O
a	O
mean	O
age	B-MED
51.5	O
years	B-MED
,	O
were	O
followed	O
and	O
data	B-MED
were	O
collected	O
at	O
three	O
different	O
times	O
.	O
	
anthropometric	B-MED
and	O
dietary	B-MED
assessments	I-MED
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-MED
recall	I-MED
s	O
,	O
by	O
using	O
the	O
brazilian	B-MED
healthy	I-MED
eating	I-MED
index	I-MED
revised	I-MED
bhei-r	B-MED
,	O
and	O
calculating	B-MED
the	O
prevalence	B-MED
of	O
inadequacy	B-MED
by	O
the	O
ear	B-MED
cut-off	I-MED
point	I-MED
method	I-MED
.	O
	
regarding	O
the	O
bhei-r	B-MED
analysis	B-MED
,	O
the	O
majority	O
of	O
women	B-MED
had	O
a	O
""""	O
diet	B-MED
requires	O
modification	B-MED
'	O
,	O
both	O
at	O
the	O
beginning	B-MED
t0	O
,	O
58.2	O
,	O
n	O
=	O
32	O
and	O
during	B-MED
treatment	I-MED
t1	O
,	O
54.5	O
,	O
n	O
=	O
30	O
.	O
	
however	O
,	O
after	O
the	O
end	O
of	O
the	O
ct	B-MED
,	O
the	O
greater	B-MED
percentage	I-MED
of	O
patients	B-MED
t2	O
,	O
49.1	O
,	O
n	O
=	O
27	O
were	O
classified	O
as	O
having	O
an	O
""""	O
inadequate	B-MED
diet	I-MED
""""	O
,	O
since	O
the	O
total	B-MED
fruit	B-MED
consumption	B-MED
as	O
well	O
as	O
the	O
dark	B-MED
green	I-MED
and	O
orange	B-MED
vegetable	I-MED
and	O
legume	B-MED
consumption	B-MED
decreased	B-MED
significantly	I-MED
during	B-MED
treatment	I-MED
p	O
=	O
0.043	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
.	O
	
there	O
was	O
a	O
significant	B-MED
reduction	I-MED
in	O
the	O
intake	B-MED
of	O
macro	B-MED
and	O
micronutrients	B-MED
,	O
with	O
a	O
high	O
prevalence	B-MED
of	O
inadequacy	B-MED
,	O
of	O
up	O
to	O
100%	O
,	O
for	O
calcium	B-MED
,	O
iron	B-MED
,	O
phosphorus	B-MED
,	O
magnesium	B-MED
,	O
niacin	B-MED
,	O
riboflavin	B-MED
,	O
thiamin	B-MED
,	O
vitamin	B-MED
b6	I-MED
,	O
vitamin	B-MED
c	I-MED
and	O
zinc	B-MED
.	O
	
assessment	B-MED
of	O
the	O
nutritional	B-MED
status	I-MED
indicated	O
that	O
56%	O
n	O
=	O
31	O
of	O
patients	B-MED
were	O
overweight	B-MED
at	O
these	O
three	O
different	O
times	O
.	O
	
weight	B-MED
,	O
bmi	B-MED
and	O
waist	B-MED
circumference	I-MED
increased	B-MED
significantly	I-MED
,	O
indicating	O
a	O
worse	B-MED
nutritional	B-MED
status	I-MED
,	O
and	O
there	O
was	O
a	O
correlation	B-MED
between	O
poor	B-MED
diet	I-MED
quality	I-MED
and	O
higher	B-MED
values	I-MED
for	O
bmi	B-MED
,	O
waist-hip	B-MED
ratio	I-MED
and	O
waist-to-height	B-MED
ratio	I-MED
.	O
	
chemotherapy	B-MED
interferes	B-MED
in	O
the	O
patients	B-MED
'	O
diet	B-MED
generating	O
a	O
negative	B-MED
impact	I-MED
on	O
the	O
quality	B-MED
and	O
intake	B-MED
of	O
micro	B-MED
and	O
macronutrients	B-MED
,	O
as	O
well	O
as	O
an	O
impact	B-MED
on	O
their	O
nutritional	B-MED
status	I-MED
,	O
with	O
an	O
increase	O
in	O
anthropometric	B-MED
measurements	I-MED
.	O
	
benefit	O
and	O
risk	B-MED
in	O
short	O
term	O
after	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
by	O
direct	B-MED
anterior	I-MED
approach	I-MED
combined	O
with	O
dual	B-MED
mobility	I-MED
cup	I-MED
no	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-MED
associated	O
with	O
the	O
dual	B-MED
mobility	I-MED
cup	I-MED
dmc	B-MED
in	O
primary	O
tha	B-MED
via	O
direct	B-MED
anterior	I-MED
approach	I-MED
daa	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
compare	O
the	O
safety	B-MED
and	O
rate	O
of	O
early	O
postoperative	B-MED
complication	I-MED
of	O
the	O
daa	B-MED
with	O
the	O
dmc	B-MED
for	O
tha	B-MED
with	O
those	O
of	O
the	O
daa	B-MED
with	O
a	O
single	B-MED
standard	I-MED
cup	I-MED
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
	
we	O
retrospectively	O
investigated	O
60	O
hips	B-MED
treated	B-MED
in	O
the	O
single-	O
daa	B-MED
group	B-MED
and	O
60	O
hips	B-MED
treated	B-MED
in	O
the	O
dual-	O
daa	B-MED
group	B-MED
.	O
	
a	O
primary	B-MED
/	O
secondary	B-MED
outcome	B-MED
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-MED
-	O
or	O
perioperative	B-MED
complication	B-MED
within	O
the	O
first	O
6	O
months	B-MED
/the	O
operative	B-MED
time	I-MED
and	O
hip	O
function	O
at	O
6	O
months	B-MED
postoperatively	B-MED
.	O
	
we	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
	
no	B-MED
intraoperative	B-MED
complications	I-MED
were	O
observed	O
in	O
either	O
group	B-MED
.	O
	
one	O
anterior	B-MED
dislocation	I-MED
and	O
one	O
periprosthetic	B-MED
hip	I-MED
fracture	I-MED
were	O
occurred	O
in	O
the	O
single-	O
daa	B-MED
group	B-MED
.	O
	
the	O
surgical	B-MED
times	I-MED
in	O
the	O
single-	O
daa	B-MED
and	O
dual-	O
daa	B-MED
groups	B-MED
were	O
112.0	O
20.9	O
and	O
121.0	O
26.9	O
min	O
p	O
<	O
0.001	O
.	O
	
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6-	O
month	B-MED
postoperative	B-MED
hip	B-MED
function	I-MED
scores	I-MED
between	O
the	O
two	O
groups	B-MED
.	O
	
there	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
	
we	O
have	O
demonstrated	O
the	O
short-term	O
safety	B-MED
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
dmc	B-MED
in	O
the	O
daa	B-MED
compared	O
with	O
the	O
standard	B-MED
single	I-MED
mobility	I-MED
cup	I-MED
.	O
	
diffuse	B-MED
traumatic	I-MED
brain	I-MED
injury	I-MED
affects	O
chronic	B-MED
corticosterone	B-MED
function	B-MED
in	O
the	O
rat	B-MED
as	O
many	O
as	O
20-55%	O
of	O
patients	B-MED
with	O
a	O
history	B-MED
of	O
traumatic	B-MED
brain	I-MED
injury	I-MED
tbi	B-MED
experience	O
chronic	B-MED
endocrine	B-MED
dysfunction	I-MED
,	O
leading	O
to	O
impaired	B-MED
quality	I-MED
of	I-MED
life	I-MED
,	O
impaired	B-MED
rehabilitation	B-MED
efforts	B-MED
and	O
lowered	B-MED
life	I-MED
expectancy	I-MED
.	O
	
endocrine	B-MED
dysfunction	I-MED
after	O
tbi	B-MED
is	O
thought	O
to	O
result	B-MED
from	O
acceleration	B-MED
-	O
deceleration	B-MED
forces	B-MED
to	O
the	O
brain	B-MED
within	O
the	O
skull	B-MED
,	O
creating	O
enduring	O
hypothalamic	B-MED
and	O
pituitary	B-MED
neuropathology	B-MED
,	O
and	O
subsequent	O
hypothalamic	B-MED
-pituitary	O
endocrine	O
hpe	O
dysfunction	O
.	O
	
these	O
experiments	O
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	O
tbi	O
results	O
in	O
chronic	O
dysfunction	O
of	O
corticosterone	O
cort	O
,	O
a	O
glucocorticoid	O
released	O
in	O
response	O
to	O
stress	O
and	O
testosterone	O
.	O
	
we	O
used	O
a	O
rodent	O
model	O
of	O
diffuse	O
tbi	O
induced	O
by	O
midline	O
fluid	O
percussion	O
injury	O
mfpi	O
.	O
	
at	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	O
control	O
animals	O
,	O
circulating	O
levels	O
of	O
cort	O
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	O
stress	O
and	O
in	O
response	O
to	O
dexamethasone	O
,	O
a	O
synthetic	O
glucocorticoid	O
commonly	O
used	O
to	O
test	O
hpe	O
axis	O
regulation	O
.	O
	
testosterone	O
was	O
evaluated	O
at	O
rest	O
.	O
	
further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	O
-	O
induced	O
neuron	O
morphology	O
golgi	O
stain	O
,	O
neuropathology	O
silver	O
stain	O
and	O
activated	O
astrocytes	O
gfap	O
in	O
the	O
paraventricular	O
nucleus	O
pvn	O
of	O
the	O
hypothalamus	O
.	O
	
resting	O
plasma	O
cort	O
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
cort	O
increase	O
in	O
response	O
to	O
restraint	O
induced	O
stress	O
.	O
	
no	O
changes	O
in	O
testosterone	O
were	O
measured	O
.	O
	
these	O
changes	O
in	O
cort	O
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	O
processes	O
in	O
the	O
pvn	O
over	O
time	O
,	O
devoid	O
of	O
neuropathology	O
or	O
astrocytosis	O
.	O
	
results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	O
tbi	O
leads	O
to	O
changes	O
in	O
cort	O
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	O
of	O
symptoms	O
related	O
to	O
endocrine	O
dysfunction	O
.	O
	
future	O
experiments	O
aim	O
to	O
evaluate	O
additional	O
hp-related	O
hormones	O
and	O
endocrine	O
circuit	O
pathology	O
following	O
diffuse	O
tbi	I-MED
methamphetamine	B-MED
,	O
3	B-MED
mdma	B-MED
and	O
3	B-MED
mdpv	B-MED
induce	B-MED
differential	B-MED
cytotoxic	B-MED
effects	I-MED
in	O
bovine	B-MED
brain	B-MED
microvessel	B-MED
endothelial	B-MED
cells	I-MED
designer	B-MED
drugs	I-MED
such	O
as	O
synthetic	B-MED
psychostimulants	I-MED
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-MED
of	O
drug	B-MED
abuse	I-MED
and	O
addiction	B-MED
.	O
	
in	O
addition	O
to	O
methamphetamine	B-MED
meth	B-MED
,	O
these	O
drugs	B-MED
include	O
3	B-MED
mdma	B-MED
and	O
commercial	B-MED
preparations	B-MED
of	O
synthetic	B-MED
cathinones	I-MED
including	O
3	B-MED
mdpv	B-MED
,	O
typically	O
referred	O
to	O
as	O
""""	O
bath	B-MED
salts	I-MED
""""	O
these	O
psychostimulants	B-MED
exert	O
neurotoxic	B-MED
effects	I-MED
by	O
altering	B-MED
monoamine	B-MED
systems	I-MED
in	O
the	O
brain	B-MED
.	O
	
additionally	O
,	O
meth	B-MED
and	O
mdma	B-MED
adversely	B-MED
affect	I-MED
the	O
integrity	B-MED
of	O
the	O
blood-brain	B-MED
barrier	I-MED
bbb	B-MED
there	O
are	O
no	O
current	O
reports	B-MED
on	O
the	O
effects	B-MED
of	I-MED
mdpv	B-MED
on	O
the	O
bbb	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
effects	B-MED
of	I-MED
meth	B-MED
,	O
mdma	B-MED
and	O
mdpv	B-MED
on	O
bovine	B-MED
brain	B-MED
microvessel	B-MED
endothelial	B-MED
cells	I-MED
bbmvecs	B-MED
,	O
an	O
accepted	O
in	B-MED
vitro	I-MED
model	I-MED
of	O
the	O
bbb	B-MED
.	O
	
confluent	B-MED
bbmvec	B-MED
monolayers	B-MED
were	O
treated	B-MED
with	O
meth	B-MED
,	O
mdma	B-MED
and	O
mdpv	B-MED
0.5mm	O
for	O
24h	O
.	O
	
meth	B-MED
and	O
mdma	B-MED
increased	B-MED
lactate	B-MED
dehydrogenase	I-MED
release	B-MED
only	O
at	O
the	O
highest	B-MED
concentration	B-MED
2.5mm	O
,	O
whereas	O
mdpv	B-MED
induced	B-MED
cytotoxicity	B-MED
at	O
all	O
concentration	B-MED
s	O
.	O
	
mdma	B-MED
and	O
meth	B-MED
decreased	B-MED
cellular	B-MED
proliferation	I-MED
only	O
at	O
2.5mm	O
,	O
with	O
similar	O
effects	B-MED
observed	O
after	O
mdpv	B-MED
exposures	B-MED
starting	O
at	O
1mm	O
.	O
	
only	O
mdpv	B-MED
increased	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
production	B-MED
at	O
all	O
concentrations	B-MED
tested	B-MED
whereas	O
all	O
3	O
drugs	B-MED
increased	B-MED
nitric	B-MED
oxide	I-MED
production	B-MED
.	O
	
morphological	B-MED
analysis	I-MED
revealed	O
different	B-MED
patterns	O
of	O
compound	B-MED
-	O
induced	B-MED
cell	B-MED
damage	I-MED
.	O
	
meth	B-MED
induced	B-MED
vacuole	B-MED
formatio	B-MED
n	O
at	O
1mm	O
and	O
disruption	B-MED
of	O
the	O
monolayer	B-MED
at	O
2.5mm	O
.	O
	
mdma	B-MED
induced	B-MED
disruption	B-MED
of	O
the	O
endothelial	B-MED
monolayer	B-MED
from	O
1mm	O
without	O
vacuolization	B-MED
.	O
	
on	O
the	O
other	O
hand	O
,	O
mdpv	B-MED
induced	B-MED
monolayer	B-MED
disruption	B-MED
at	O
doses	B-MED
0.5mm	O
without	O
vacuole	B-MED
formation	B-MED
at	O
2.5mm	O
,	O
the	O
few	O
remaining	O
cells	B-MED
lacked	O
endothelial	B-MED
morphology	I-MED
.	O
	
these	O
data	B-MED
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-MED
psychostimulants	I-MED
alter	O
monoaminergic	B-MED
systems	I-MED
,	O
they	O
each	O
induce	B-MED
bbb	B-MED
toxicity	B-MED
by	O
different	B-MED
mechanisms	B-MED
with	O
mdpv	B-MED
being	O
the	O
most	O
alleviation	B-MED
of	O
hepatic	B-MED
fat	B-MED
accumulation	I-MED
by	O
betaine	B-MED
involves	O
reduction	B-MED
of	O
homocysteine	B-MED
via	O
up-regulation	B-MED
of	O
betaine-homocysteine	B-MED
methyltransferase	I-MED
bhmt	B-MED
we	O
investigated	B-MED
the	O
anti-lipogenic	B-MED
effect	I-MED
of	O
betaine	B-MED
in	O
rats	B-MED
fed	O
methionine	B-MED
and	O
choline	B-MED
-	O
deficient	B-MED
diet	B-MED
mcd	B-MED
.	O
	
intake	O
of	O
mcd	B-MED
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	B-MED
accumulation	B-MED
of	O
hepatic	B-MED
lipids	B-MED
,	O
which	O
was	O
prevented	B-MED
by	O
betaine	B-MED
supplementation	B-MED
in	O
drinking	B-MED
water	I-MED
1%	O
.	O
	
phosphorylation	B-MED
of	O
amp-activated	B-MED
protein	I-MED
kinase	I-MED
ampk	B-MED
,	O
acetyl-coa	B-MED
carboxylase	I-MED
acc	B-MED
,	O
sterol	B-MED
regulatory	I-MED
element-binding	I-MED
protein	I-MED
1c	I-MED
srebp-1c	B-MED
,	O
and	O
liver	B-MED
kinase	I-MED
b1	I-MED
lkb1	B-MED
was	O
inhibited	B-MED
by	O
mcd	B-MED
intake	B-MED
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	B-MED
by	O
betaine	B-MED
feeding	B-MED
.	O
	
meanwhile	O
,	O
betaine	B-MED
supplementation	B-MED
reversed	B-MED
the	O
reduction	B-MED
of	O
methionine	B-MED
and	I-MED
s-adenosylmethionine	I-MED
sam	B-MED
,	O
and	O
the	O
elevation	B-MED
of	O
homocysteine	B-MED
levels	I-MED
in	O
the	O
liver	B-MED
,	O
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-MED
of	O
betaine-homocysteine	B-MED
methyltransfease	I-MED
bhmt	B-MED
and	O
methionine	B-MED
adenosyltransferase	I-MED
mat	B-MED
.	O
	
different	B-MED
cell	B-MED
lines	I-MED
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-MED
on	O
activation	B-MED
of	O
the	O
ampk	B-MED
pathway	B-MED
.	O
	
homocysteine	B-MED
treatment	B-MED
decreased	B-MED
pampk	B-MED
,	O
pacc	B-MED
,	O
psrebp-1c	B-MED
and	O
plkb1	B-MED
in	O
hepg2	B-MED
cells	I-MED
.	O
	
metformin	B-MED
-	O
induced	B-MED
activation	B-MED
of	O
ampk	B-MED
was	O
also	O
inhibited	B-MED
by	O
homocysteine	B-MED
.	O
	
treatment	B-MED
with	O
hydroxylamine	B-MED
,	O
a	O
cystathionine	B-MED
β-synthase	I-MED
inhibitor	B-MED
,	O
resulted	O
in	O
a	O
reduction	B-MED
of	O
pampk	B-MED
,	O
pacc	B-MED
and	O
psrebp-1c	B-MED
,	O
accompanied	O
by	O
an	O
elevation	B-MED
of	O
intracellular	B-MED
homocysteine	B-MED
.	O
	
betaine	B-MED
treatment	B-MED
prevented	B-MED
the	O
homocysteine	B-MED
-	O
induced	B-MED
reduction	B-MED
of	O
pampk	B-MED
,	O
pacc	B-MED
,	O
psrebp-1c	B-MED
and	O
plkb1	B-MED
in	O
h4iie	B-MED
cells	I-MED
,	O
but	O
not	O
in	O
hepg2	B-MED
cells	I-MED
.	O
	
also	O
the	O
elevation	B-MED
of	O
cellular	O
homocysteine	B-MED
and	O
inhibition	B-MED
of	O
protein	B-MED
expression	I-MED
of	O
bhmt	B-MED
were	O
prevented	B-MED
by	O
betaine	B-MED
only	O
in	O
h4iie	B-MED
cells	I-MED
which	O
express	B-MED
bhmt	B-MED
.	O
	
the	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-MED
against	O
hepatic	B-MED
lipid	B-MED
accumulation	B-MED
may	O
be	O
attributed	B-MED
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	B-MED
of	O
homocysteine	B-MED
via	O
up-regulation	B-MED
of	O
bhmt	B-MED
in	O
dual-color	B-MED
sted	I-MED
microscopy	I-MED
reveals	O
a	O
sandwich	B-MED
structure	I-MED
of	O
bassoon	B-MED
and	O
piccolo	B-MED
in	O
active	B-MED
zones	I-MED
of	O
adult	B-MED
and	O
aged	B-MED
mice	B-MED
presynaptic	B-MED
active	I-MED
zones	I-MED
play	O
a	O
pivotal	O
role	O
as	O
synaptic	B-MED
vesicle	I-MED
release	B-MED
sites	I-MED
for	O
synaptic	B-MED
transmission	I-MED
,	O
but	O
the	O
molecular	B-MED
architecture	I-MED
of	O
active	B-MED
zones	I-MED
in	O
mammalian	B-MED
neuromuscular	B-MED
junctions	I-MED
nmjs	B-MED
at	O
sub-diffraction	B-MED
limited	I-MED
resolution	I-MED
remains	O
unknown	O
.	O
	
bassoon	B-MED
and	O
piccolo	B-MED
are	O
active	B-MED
zone	I-MED
specific	O
cytosolic	B-MED
proteins	B-MED
essential	O
for	O
active	B-MED
zone	I-MED
assembly	I-MED
in	O
nmjs	B-MED
,	O
ribbon	B-MED
synapses	I-MED
,	O
and	O
brain	B-MED
synapses	B-MED
.	O
	
these	O
proteins	B-MED
are	O
thought	O
to	O
colocalize	B-MED
and	O
share	O
some	O
functions	O
at	O
active	B-MED
zones	I-MED
.	O
	
here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non-overlapping	B-MED
localization	I-MED
of	O
these	O
two	O
proteins	B-MED
in	O
mouse	B-MED
nmjs	B-MED
revealed	O
using	O
dual-color	B-MED
stimulated	I-MED
emission	I-MED
depletion	I-MED
sted	B-MED
super	B-MED
resolution	I-MED
microscopy	I-MED
.	O
	
piccolo	B-MED
puncta	B-MED
sandwiched	O
bassoon	B-MED
puncta	B-MED
and	O
aligned	B-MED
in	O
a	O
piccolo	B-MED
-	O
bassoon	B-MED
-	O
piccolo	B-MED
structure	B-MED
in	O
adult	B-MED
nmjs	B-MED
.	O
	
p/q-type	B-MED
voltage-gated	I-MED
calcium	I-MED
channel	I-MED
vgcc	B-MED
puncta	B-MED
colocalized	B-MED
with	O
bassoon	B-MED
puncta	B-MED
.	O
	
the	O
p/q-type	B-MED
vgcc	I-MED
and	O
bassoon	B-MED
protein	B-MED
levels	I-MED
decreased	B-MED
significantly	O
in	O
nmjs	B-MED
from	O
aged	B-MED
mouse	B-MED
.	O
	
in	O
contrast	O
,	O
the	O
piccolo	B-MED
levels	B-MED
in	O
nmjs	B-MED
from	O
aged	B-MED
mice	B-MED
were	O
comparable	O
to	O
levels	B-MED
in	O
adult	B-MED
mice	B-MED
.	O
	
this	O
study	O
revealed	O
the	O
molecular	B-MED
architecture	I-MED
of	O
active	B-MED
zones	I-MED
in	O
mouse	B-MED
nmjs	B-MED
at	O
sub-diffraction	B-MED
limited	I-MED
resolution	I-MED
,	O
and	O
described	O
the	O
selective	B-MED
degeneration	I-MED
mechanism	I-MED
of	O
active	B-MED
zone	I-MED
proteins	B-MED
in	O
nmjs	B-MED
from	O
aged	B-MED
mice	B-MED
.	O
	
interestingly	O
,	O
the	O
localization	B-MED
pattern	I-MED
of	O
active	B-MED
zone	I-MED
proteins	B-MED
described	O
herein	O
is	O
similar	O
to	O
active	B-MED
zone	I-MED
structures	B-MED
described	O
using	O
electron	B-MED
microscope	I-MED
tomography	I-MED
.	O
	
molecular	B-MED
serum	B-MED
signature	B-MED
of	O
treatment	B-MED
resistant	I-MED
depression	I-MED
a	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-MED
depressive	I-MED
disorder	I-MED
mdd	B-MED
do	O
not	O
respond	O
to	O
multiple	B-MED
trials	B-MED
of	O
anti-depressants	B-MED
,	O
develop	O
a	O
chronic	B-MED
course	B-MED
of	I-MED
disease	I-MED
and	O
become	O
treatment	B-MED
resistant	B-MED
.	O
	
most	O
of	O
the	O
studies	O
investigating	O
molecular	B-MED
changes	B-MED
in	O
treatment-resistant	B-MED
depression	I-MED
trd	B-MED
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B-MED
.	O
	
consequently	O
,	O
biomarkers	B-MED
associated	O
with	O
trd	B-MED
are	O
still	O
lacking	O
.	O
	
this	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high-throughput	B-MED
proteomic	I-MED
platforms	I-MED
to	O
identify	O
peripheral	B-MED
biomarkers	B-MED
of	O
trd	B-MED
defined	O
by	O
two	O
staging	B-MED
models	I-MED
,	O
the	O
thase	B-MED
and	I-MED
rush	I-MED
staging	I-MED
model	I-MED
trm	B-MED
and	O
the	O
maudsley	B-MED
staging	I-MED
model	I-MED
msm	B-MED
.	O
	
serum	B-MED
collected	O
from	O
an	O
inpatient	B-MED
cohort	O
of	O
65	O
individuals	B-MED
suffering	O
from	O
mdd	B-MED
was	O
analysed	O
using	O
two	O
different	O
mass	B-MED
spectrometric-based	I-MED
platforms	I-MED
,	O
label-free	B-MED
liquid	I-MED
chromatography	I-MED
mass	I-MED
spectrometry	I-MED
lc-ms	B-MED
and	O
selective	B-MED
reaction	I-MED
monitoring	I-MED
srm	B-MED
,	O
as	O
well	O
as	O
a	O
multiplex	B-MED
bead	I-MED
based	I-MED
assay	I-MED
.	O
	
in	O
the	O
lc-ms	B-MED
analysis	I-MED
,	O
proteins	B-MED
involved	O
in	O
the	O
acute	B-MED
phase	I-MED
response	I-MED
and	O
complement	B-MED
activation	I-MED
and	O
coagulation	B-MED
were	O
significantly	O
different	O
between	O
the	O
staging	B-MED
groups	I-MED
in	O
both	O
models	B-MED
.	O
	
in	O
the	O
multiplex	B-MED
bead-based	I-MED
assay	I-MED
analysis	O
tnf-α	B-MED
levels	I-MED
log	B-MED
=	O
-4	O
,	O
p	O
=	O
0.045	O
were	O
significantly	B-MED
different	B-MED
in	O
the	O
trm	B-MED
comparison	B-MED
.	O
	
using	O
srm	B-MED
,	O
significant	B-MED
changes	B-MED
of	O
three	O
apolipoproteins	B-MED
a-i	I-MED
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
,	O
m	B-MED
β	O
=	O
-0	O
,	O
p	O
=	O
0.009	O
and	O
f	B-MED
β	O
=	O
-0	O
,	O
p	O
=	O
0.024	O
were	O
associated	O
with	O
the	O
trm	B-MED
but	O
not	O
the	O
msm	B-MED
.	O
	
overall	O
,	O
our	O
findings	B-MED
suggest	O
that	O
proteins	B-MED
,	O
which	O
are	O
involved	O
in	O
immune	B-MED
and	O
complement	B-MED
activation	I-MED
,	O
may	O
represent	O
potential	O
biomarkers	B-MED
that	O
could	O
be	O
used	O
by	O
clinicians	B-MED
to	O
identify	O
high-risk	B-MED
patients	B-MED
.	O
	
nevertheless	O
,	O
given	O
that	O
the	O
molecular	B-MED
changes	B-MED
between	O
the	O
staging	B-MED
groups	I-MED
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	B-MED
benchmark	O
study	B-MED
on	O
fine-mode	B-MED
aerosol	I-MED
in	O
a	O
big	B-MED
urban	I-MED
area	I-MED
and	O
relevant	B-MED
doses	I-MED
deposited	B-MED
in	O
the	O
human	B-MED
respiratory	B-MED
tract	I-MED
it	O
is	O
well-known	O
that	O
the	O
health	B-MED
effects	B-MED
of	O
pm	B-MED
increase	O
as	O
particle	B-MED
size	I-MED
decreases	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
ultrafine	B-MED
particles	I-MED
ufps	B-MED
.	O
	
starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	B-MED
of	I-MED
atmospheric	B-MED
aerosol	B-MED
in	O
rome	B-MED
is	O
characterized	O
by	O
significant	O
levels	B-MED
of	O
pm2.5	B-MED
almost	O
75%	O
of	O
pm10	B-MED
fraction	O
is	O
pm2.5	B-MED
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	B-MED
particles	I-MED
in	O
such	O
great	B-MED
urban	I-MED
area	I-MED
.	O
	
the	O
daytime	B-MED
/	O
nighttime	B-MED
,	O
work-	B-MED
/	O
weekdays	B-MED
and	O
cold	B-MED
/	O
hot	B-MED
seasonal	B-MED
trends	I-MED
of	O
submicron	B-MED
particles	I-MED
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
nox	B-MED
and	O
total	O
pah	B-MED
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
ufps	B-MED
from	O
combustion	B-MED
processes	I-MED
.	O
	
furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	B-MED
of	O
submicron	B-MED
particles	I-MED
deposited	B-MED
in	O
the	O
respiratory	B-MED
system	I-MED
i.e	O
,	O
head	B-MED
,	O
tracheobronchial	B-MED
and	O
alveolar	B-MED
regions	I-MED
in	O
different	O
lung	B-MED
lobes	I-MED
has	O
been	O
estimated	O
.	O
	
dosimeter	B-MED
estimates	B-MED
were	O
performed	O
with	O
the	O
multiple-path	B-MED
particle	I-MED
dosimetry	I-MED
model	I-MED
mppd	B-MED
v.2	I-MED
.	O
	
the	O
paper	O
discusses	O
the	O
aerosol	B-MED
doses	B-MED
deposited	B-MED
in	O
the	O
respiratory	B-MED
system	I-MED
of	O
individuals	B-MED
exposed	B-MED
in	O
proximity	O
of	O
traffic	B-MED
.	O
	
during	O
traffic	B-MED
peak	O
hours	B-MED
,	O
about	O
6.6	O
10	O
particles	B-MED
are	O
deposited	B-MED
into	O
the	O
respiratory	B-MED
system	I-MED
.	O
	
such	O
dose	B-MED
is	O
almost	O
entirely	O
made	O
of	O
ufps	B-MED
.	O
	
according	O
to	O
the	O
greater	O
dose	B-MED
estimated	B-MED
,	O
right	B-MED
lung	I-MED
lobes	I-MED
are	O
expected	O
to	O
be	O
more	O
susceptible	B-MED
to	O
respiratory	B-MED
pathologies	B-MED
than	O
left	B-MED
lobes	I-MED
.	O
	
international	B-MED
liver	I-MED
transplant	I-MED
society	I-MED
practice	I-MED
guidelines	I-MED
diagnosis	B-MED
and	O
management	B-MED
of	O
hepatopulmonary	B-MED
syndrome	I-MED
and	O
portopulmonary	B-MED
hypertension	I-MED
two	O
distinct	O
pulmonary	B-MED
vascular	I-MED
disorders	I-MED
,	O
hepatopulmonary	B-MED
syndrome	I-MED
hps	B-MED
and	O
portopulmonary	B-MED
hypertension	I-MED
poph	B-MED
may	O
occur	O
as	O
a	O
consequence	B-MED
of	I-MED
hepatic	B-MED
parenchymal	I-MED
or	O
vascular	B-MED
abnormalities	I-MED
.	O
	
hps	B-MED
and	O
poph	B-MED
have	O
major	O
clinical	B-MED
implications	B-MED
for	O
liver	B-MED
transplantation	I-MED
.	O
	
a	O
european	B-MED
respiratory	I-MED
society	I-MED
task	I-MED
force	I-MED
on	O
pulmonary-hepatic	B-MED
disorders	I-MED
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-MED
and	O
guide	B-MED
management	I-MED
of	O
these	O
disorders	B-MED
.	O
	
these	O
international	B-MED
liver	I-MED
transplant	I-MED
society	I-MED
diagnostic	I-MED
and	I-MED
management	I-MED
guidelines	I-MED
are	O
based	O
on	O
that	O
task	B-MED
force	I-MED
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	B-MED
experience	O
dictates	O
.	O
	
based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
hps	B-MED
and	O
poph	B-MED
articles	O
identified	O
via	O
a	O
medline	B-MED
search	I-MED
1985-2015	O
,	O
clinical	B-MED
guidelines	I-MED
were	O
based	O
on	O
,	O
selected	B-MED
single	I-MED
care	I-MED
reports	I-MED
,	O
small	B-MED
series	I-MED
,	O
registries	B-MED
,	O
databases	B-MED
,	O
and	O
expert	B-MED
opinion	I-MED
.	O
	
the	O
paucity	O
of	O
randomized	B-MED
,	O
controlled	I-MED
trials	I-MED
in	O
either	O
of	O
these	O
disorders	B-MED
was	O
noted	O
.	O
	
guidelines	B-MED
are	O
presented	O
in	O
5	O
parts	O
i	O
.	O
	
definitions	B-MED
/	O
diagnostic	B-MED
criteria	I-MED
ii	O
.	O
	
hepatopulmonary	B-MED
syndrome	I-MED
iii	O
.	O
	
portopulmonary	B-MED
hypertension	I-MED
iv	O
.	O
	
implications	B-MED
for	O
liver	B-MED
transplantation	I-MED
and	O
v	O
.	O
	
suggestions	B-MED
for	O
future	O
clinical	B-MED
research	I-MED
.	O
	
uveitis	B-MED
in	O
children	B-MED
the	O
review	O
provides	O
updates	O
on	O
novel	B-MED
risk	B-MED
markers	I-MED
for	O
the	O
development	B-MED
of	O
pediatric	B-MED
inflammatory	B-MED
uveitis	I-MED
and	O
a	O
severe	B-MED
disease	I-MED
course	I-MED
,	O
on	O
treatment	B-MED
of	O
refractory	B-MED
disease	I-MED
,	O
and	O
on	O
the	O
measurement	B-MED
of	O
visual	B-MED
outcomes	I-MED
.	O
	
there	O
are	O
several	O
new	O
genetic	B-MED
markers	I-MED
,	O
biomarkers	B-MED
,	O
and	O
clinical	B-MED
factors	B-MED
that	O
may	O
influence	O
a	O
child's	B-MED
uveitis	B-MED
disease	B-MED
course	I-MED
.	O
	
it	O
is	O
important	O
to	O
identify	O
children	B-MED
at	O
risk	B-MED
for	O
poor	B-MED
visual	I-MED
outcomes	I-MED
and	O
who	O
are	O
refractory	B-MED
to	O
traditional	B-MED
therapy	I-MED
.	O
	
racial	B-MED
disparities	I-MED
have	O
recently	O
been	O
reported	B-MED
.	O
	
we	O
describe	O
agents	B-MED
of	O
potential	B-MED
benefit	I-MED
.	O
	
in	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	B-MED
reported	I-MED
outcomes	I-MED
in	O
this	O
population	B-MED
.	O
	
uveitis	B-MED
can	O
lead	O
to	O
vision-threatening	B-MED
complications	I-MED
.	O
	
timely	B-MED
and	I-MED
aggressive	I-MED
treatment	I-MED
of	O
children	B-MED
identified	O
to	O
be	O
at	O
risk	B-MED
for	O
a	O
severe	B-MED
uveitis	I-MED
course	I-MED
may	O
lead	O
to	O
improved	B-MED
outcomes	I-MED
.	O
	
utility	B-MED
of	O
a	O
mhealth	B-MED
app	I-MED
for	O
self-management	B-MED
and	O
education	B-MED
of	O
cardiac	B-MED
diseases	I-MED
in	O
spanish	B-MED
urban	B-MED
and	I-MED
rural	I-MED
areas	I-MED
analyze	B-MED
the	O
utility	B-MED
of	O
a	O
mobile	B-MED
health	I-MED
app	I-MED
named	O
heartkeeper	B-MED
in	O
several	B-MED
groups	I-MED
of	I-MED
population	I-MED
and	O
obtain	B-MED
conclusions	B-MED
to	O
be	O
applied	B-MED
to	O
other	B-MED
similar	I-MED
apps	I-MED
.	O
	
a	O
questionnaire	B-MED
has	O
been	O
designed	B-MED
to	O
evaluate	O
the	O
usage	B-MED
and	O
utility	B-MED
of	O
the	O
heartkeeper	B-MED
app	I-MED
.	O
	
the	O
questionnaire	B-MED
information	B-MED
was	O
collected	B-MED
by	O
collaborating	O
cardiologists	B-MED
from	O
32	O
patients	B-MED
before	B-MED
and	I-MED
after	I-MED
they	O
used	B-MED
the	O
app	B-MED
.	O
	
patients	B-MED
were	O
randomly	B-MED
selected	I-MED
with	O
established	O
quotas	B-MED
within	O
interest	B-MED
groups	I-MED
,	O
so	O
that	O
men	B-MED
and	O
women	B-MED
,	O
patients	B-MED
older	B-MED
or	O
younger	B-MED
than	O
60	O
years	B-MED
old	I-MED
and	O
patients	B-MED
living	O
in	O
urban	B-MED
or	I-MED
rural	I-MED
areas	I-MED
were	O
equally	B-MED
represented	I-MED
.	O
	
using	O
the	O
appropriate	O
statistical	B-MED
techniques	I-MED
we	O
see	O
that	O
the	O
heartkeeper	B-MED
app	I-MED
was	O
useful	O
for	O
patients	B-MED
as	O
they	O
qualify	B-MED
with	O
70	O
points	O
out	O
of	O
100	O
the	O
overall	B-MED
opinion	I-MED
of	O
the	O
app	B-MED
,	O
it	O
helps	O
them	O
remember	B-MED
more	O
easily	O
taking	O
their	O
pills	B-MED
with	O
a	O
mean	O
improvement	B-MED
of	O
20.94	O
points	O
p	O
<	O
0.001	O
and	O
they	O
perceive	O
a	O
global	B-MED
improvement	I-MED
of	O
their	O
health	O
8.28	O
points	O
,	O
p	O
<	O
0.001	O
.	O
	
we	O
also	O
observe	B-MED
that	O
these	O
improvements	B-MED
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	B-MED
urban	I-MED
or	I-MED
rural	I-MED
where	O
the	O
patient	B-MED
comes	O
from	O
or	O
on	O
their	O
sex	B-MED
.	O
	
although	O
older	B-MED
patients	I-MED
needed	B-MED
more	O
help	O
to	O
use	B-MED
the	O
app	B-MED
and	O
used	B-MED
it	O
slightly	O
less	B-MED
frequently	I-MED
,	O
the	O
improvements	B-MED
on	O
several	B-MED
measures	I-MED
considered	O
,	O
such	O
as	O
remembering	B-MED
taking	O
pills	B-MED
,	O
breathing	B-MED
problems	I-MED
or	O
trouble	B-MED
developing	I-MED
activities	I-MED
,	O
depend	O
significantly	O
p	O
<	O
0.05	O
on	O
age	O
with	O
older	B-MED
patients	I-MED
reporting	O
higher	B-MED
improvements	B-MED
than	O
younger	B-MED
ones	I-MED
.	O
	
the	O
results	B-MED
obtained	O
with	O
the	O
sample	B-MED
of	O
patients	B-MED
considered	O
in	O
this	O
research	B-MED
prove	O
the	O
utility	B-MED
of	O
the	O
heartkeeper	B-MED
app	I-MED
.	O
	
this	O
utility	B-MED
is	O
similar	O
in	O
urban	B-MED
and	I-MED
rural	I-MED
areas	I-MED
and	O
for	O
patients	B-MED
of	O
both	B-MED
sexes	I-MED
and	O
,	O
to	B-MED
some	I-MED
extent	I-MED
,	O
depends	O
on	O
the	O
age	B-MED
of	O
the	O
patient	B-MED
with	O
older	B-MED
patients	I-MED
reporting	O
slightly	B-MED
lower	I-MED
frequency	I-MED
of	O
use	B-MED
but	O
higher	B-MED
health	B-MED
improvements	I-MED
than	O
younger	B-MED
ones	I-MED
.	O
	
a	O
holistic	B-MED
approach	I-MED
to	O
age	B-MED
estimation	B-MED
in	O
refugee	B-MED
children	B-MED
many	O
refugee	B-MED
children	B-MED
arriving	O
in	O
australia	B-MED
have	O
an	O
inaccurately	B-MED
documented	B-MED
date	B-MED
of	I-MED
birth	I-MED
dob	B-MED
.	O
	
a	O
medical	B-MED
assessment	I-MED
of	O
a	O
child's	B-MED
age	I-MED
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	B-MED
that	O
their	O
documented	B-MED
dob	B-MED
is	O
incorrect	B-MED
.	O
	
this	O
study's	O
aim	O
was	O
to	O
assess	B-MED
the	O
accuracy	B-MED
a	O
holistic	B-MED
age	I-MED
assessment	I-MED
tool	I-MED
aat	B-MED
in	O
estimating	B-MED
the	O
age	B-MED
of	O
refugee	B-MED
children	B-MED
newly	O
settled	O
in	O
australia	B-MED
.	O
	
a	O
holistic	B-MED
aat	I-MED
that	O
combines	O
medical	B-MED
and	O
non-medical	B-MED
approaches	I-MED
was	O
used	O
to	O
estimate	B-MED
the	O
ages	B-MED
of	O
60	O
refugee	B-MED
children	B-MED
with	O
a	O
known	O
dob	B-MED
.	O
	
the	O
tool	B-MED
used	O
four	O
components	B-MED
to	O
assess	B-MED
age	B-MED
an	O
oral	B-MED
narrative	B-MED
,	O
developmental	B-MED
assessment	B-MED
,	O
anthropometric	B-MED
measures	I-MED
and	O
pubertal	B-MED
assessment	B-MED
.	O
	
assessors	B-MED
were	O
blinded	B-MED
to	O
the	O
true	B-MED
age	B-MED
of	O
the	O
child	B-MED
.	O
	
correlation	B-MED
coefficients	I-MED
for	O
the	O
actual	B-MED
and	O
estimated	B-MED
age	B-MED
were	O
calculated	B-MED
for	O
the	O
tool	B-MED
overall	B-MED
and	I-MED
individual	I-MED
components	I-MED
.	O
	
the	O
correlation	B-MED
coefficient	I-MED
between	O
the	O
actual	B-MED
and	O
estimated	B-MED
age	B-MED
from	O
the	O
aat	B-MED
was	O
very	O
strong	O
at	O
0.9802	O
boys	B-MED
0.9748	O
,	O
girls	B-MED
0.9876	O
.	O
	
the	O
oral	B-MED
narrative	B-MED
component	B-MED
of	O
the	O
tool	B-MED
performed	O
best	O
r	O
=	O
0.9603	O
.	O
	
overall	O
,	O
86.7	O
of	O
age	B-MED
estimates	B-MED
were	O
within	O
1	O
year	B-MED
of	O
the	O
true	B-MED
age	B-MED
.	O
	
the	O
range	O
of	O
differences	O
was	O
-1	O
to	O
3.92	O
years	B-MED
with	O
a	O
standard	B-MED
deviation	I-MED
of	O
0.77	O
years	B-MED
9.24	O
months	B-MED
.	O
	
the	O
aat	B-MED
is	O
a	O
holistic	B-MED
,	O
simple	B-MED
and	O
safe	B-MED
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-MED
age	B-MED
in	O
refugee	B-MED
children	B-MED
with	O
results	O
comparable	O
with	O
radiological	B-MED
methods	I-MED
caged-opossum	B-MED
motif	B-MED
enrichment	I-MED
analysis	I-MED
from	O
cage	B-MED
-derived	O
tsss	B-MED
with	O
the	O
emergence	O
of	O
large-scale	B-MED
cap	I-MED
analysis	I-MED
of	I-MED
gene	I-MED
expression	I-MED
cage	I-MED
datasets	I-MED
from	O
individual	B-MED
labs	I-MED
and	O
the	O
fantom	B-MED
consortium	I-MED
,	O
one	O
can	O
now	O
analyze	O
the	O
cis-regulatory	B-MED
regions	I-MED
associated	O
with	O
gene	B-MED
transcription	I-MED
at	O
an	O
unprecedented	B-MED
level	I-MED
of	I-MED
refinement	I-MED
.	O
	
by	O
coupling	O
transcription	B-MED
factor	I-MED
binding	I-MED
site	I-MED
tfbs	B-MED
enrichment	B-MED
analysis	I-MED
with	O
cage	B-MED
-derived	O
genomic	B-MED
regions	I-MED
,	O
caged-opossum	B-MED
can	O
identify	B-MED
tfs	B-MED
that	O
act	O
as	O
key	B-MED
regulators	B-MED
of	O
genes	B-MED
involved	O
in	O
specific	B-MED
mammalian	B-MED
cell	I-MED
and	O
tissue	B-MED
types	I-MED
.	O
	
the	O
webtool	B-MED
allows	O
for	O
the	O
analysis	B-MED
of	O
cage	B-MED
-derived	O
transcription	B-MED
start	I-MED
sites	I-MED
tsss	B-MED
either	O
provided	O
by	O
the	O
user	B-MED
or	O
selected	O
from	O
1300	O
mammalian	B-MED
samples	B-MED
from	O
the	O
fantom5	B-MED
project	I-MED
with	O
pre-computed	B-MED
tfbs	B-MED
predicted	O
with	O
jaspar	B-MED
tf	I-MED
binding	I-MED
profiles	I-MED
.	O
	
the	O
tool	B-MED
helps	O
power	O
insights	B-MED
into	O
the	O
regulation	B-MED
of	I-MED
genes	I-MED
through	O
the	O
study	B-MED
of	O
the	O
specific	B-MED
usage	B-MED
of	O
tsss	B-MED
within	O
specific	B-MED
cell	B-MED
types	I-MED
and/or	O
under	O
specific	B-MED
conditions	I-MED
.	O
	
the	O
caged-oposum	B-MED
web	I-MED
tool	I-MED
is	O
implemented	O
in	O
perl	B-MED
,	O
mysql	B-MED
and	O
apache	B-MED
and	O
is	O
available	O
at	O
http	B-MED
contacts	O
anthony.mathelier	B-MED
or	O
wyeth	B-MED
supplementary	B-MED
information	I-MED
supplementary	B-MED
data	I-MED
are	O
available	O
at	O
bioinformatics	B-MED
online	B-MED
.	O
	
self-assembled	B-MED
polymeric	B-MED
vectors	B-MED
mixtures	B-MED
characterization	B-MED
of	O
the	O
polymorphism	B-MED
and	O
existence	O
of	O
synergistic	B-MED
effects	B-MED
in	O
photodynamic	B-MED
therapy	I-MED
the	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	B-MED
of	O
polymeric	B-MED
self-assemblies	B-MED
vectors	B-MED
solution	B-MED
and	O
their	O
photodynamic	B-MED
therapeutic	I-MED
efficiency	B-MED
.	O
	
for	O
this	O
,	O
several	O
amphiphilic	B-MED
block	B-MED
copolymers	I-MED
of	O
poly	B-MED
have	O
been	O
used	O
to	O
form	O
self-assemblies	B-MED
with	O
different	O
morphologies	B-MED
micelles	B-MED
,	O
worm-like	B-MED
micelles	I-MED
or	O
vesicles	B-MED
.	O
	
in	O
a	O
first	O
step	O
,	O
controlled	B-MED
mixtures	I-MED
of	O
preformed	O
micelles	B-MED
and	O
vesicles	B-MED
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-MED
light	I-MED
scattering	I-MED
and	O
asymmetrical	B-MED
flow	I-MED
field	I-MED
flow	I-MED
fractionation	I-MED
asflfff	B-MED
.	O
	
for	O
this	O
,	O
a	O
custom-made	B-MED
program	B-MED
,	O
storms	B-MED
,	O
was	O
developed	O
to	O
analyze	O
dls	B-MED
data	B-MED
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	B-MED
.	O
	
this	O
showed	O
that	O
dls	B-MED
only	O
sensed	O
the	O
larger	B-MED
vesicles	B-MED
when	O
the	O
micelles	B-MED
/	O
vesicles	B-MED
ratio	B-MED
was	O
80/20	O
w/w	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
asflfff	B-MED
allowed	O
clear	O
detection	B-MED
of	O
the	O
presence	O
of	O
micelles	B-MED
when	O
this	O
same	O
ratio	B-MED
was	O
as	O
low	O
as	O
10/90	O
.	O
	
subsequently	O
,	O
the	O
photodynamic	B-MED
therapy	I-MED
efficiency	B-MED
of	O
various	O
controlled	B-MED
mixtures	I-MED
was	O
assessed	O
using	O
multicellular	O
spheroids	B-MED
when	O
a	O
photosensitizer	B-MED
,	O
pheophorbide	B-MED
a	I-MED
,	O
was	O
encapsulated	B-MED
in	O
the	O
polymer	B-MED
self-assemblies	B-MED
.	O
	
some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	B-MED
as	O
monomorphous	B-MED
systems	I-MED
.	O
	
in	O
some	O
cases	O
,	O
mixtures	B-MED
were	O
found	O
to	O
exhibit	O
a	O
higher	O
pdt	B-MED
efficiency	B-MED
compared	O
to	O
the	O
individual	O
nano	B-MED
-	O
objects	B-MED
,	O
revealing	O
a	O
synergistic	B-MED
effect	B-MED
for	O
the	O
efficient	O
delivery	B-MED
of	O
the	O
photosensitizer	B-MED
.	O
	
polymorphous	B-MED
vectors	B-MED
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	B-MED
applications	I-MED
.	O
	
fuzheng	B-MED
qingjie	I-MED
granules	I-MED
inhibit	B-MED
growth	B-MED
of	O
hepatoma	B-MED
cells	I-MED
via	O
inducing	B-MED
mitochondria	B-MED
-mediated	O
apoptosis	B-MED
and	O
enhancing	B-MED
immune	B-MED
function	I-MED
fuzheng	B-MED
qingjie	I-MED
fzqj	B-MED
granules	I-MED
,	O
a	O
compound	B-MED
chinese	B-MED
medicine	I-MED
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-MED
therapy	I-MED
for	O
alimentary	B-MED
tract	I-MED
cancers	B-MED
.	O
	
however	O
,	O
the	O
underlying	O
anticancer	B-MED
mechanisms	B-MED
are	O
still	O
not	O
well	O
understood	O
.	O
	
in	O
the	O
present	B-MED
study	B-MED
,	O
hepg2	B-MED
cells	I-MED
were	O
treated	B-MED
with	O
fzqj	B-MED
-	O
containing	B-MED
serum	B-MED
.	O
	
cell	B-MED
proliferation	I-MED
was	O
evaluated	B-MED
using	O
mtt	B-MED
assay	I-MED
.	O
	
apoptosis	B-MED
was	O
analyzed	B-MED
using	O
a	O
flow	B-MED
cytometer	I-MED
.	O
	
cell	B-MED
ultrastructure	I-MED
was	O
observed	B-MED
under	O
a	O
transmission	B-MED
electron	I-MED
microscope	I-MED
.	O
	
the	O
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
δψ	B-MED
was	O
examined	B-MED
with	O
jc-1	B-MED
dye	I-MED
.	O
	
in	O
h22	B-MED
tumor-bearing	I-MED
mice	I-MED
,	O
cd4	B-MED
t	I-MED
cells	I-MED
,	O
cd8	B-MED
t	I-MED
cells	I-MED
,	O
cd3	B-MED
t	I-MED
cells	I-MED
,	O
and	O
natural	B-MED
killer	I-MED
cells	I-MED
nk	B-MED
in	O
peripheral	B-MED
blood	I-MED
were	O
evaluated	O
cytometrically	B-MED
.	O
	
interleukin	B-MED
il	I-MED
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
tnf	B-MED
levels	B-MED
were	O
measured	B-MED
using	O
radioimmunoassay	B-MED
the	O
mrna	B-MED
levels	B-MED
of	O
bax	B-MED
and	O
bcl-2	B-MED
were	O
examined	B-MED
by	O
reverse	B-MED
transcription-polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
	
the	O
protein	B-MED
levels	B-MED
of	O
bax	B-MED
,	O
bcl-2	B-MED
,	O
cytochrome	B-MED
c	I-MED
,	O
caspase	B-MED
3	I-MED
and	O
9	B-MED
,	O
parp	B-MED
,	O
and	O
cd69	B-MED
were	O
examined	B-MED
by	O
western	B-MED
blotting	I-MED
.	O
	
the	O
apoptotic	B-MED
cells	B-MED
in	O
tissues	B-MED
were	O
observed	B-MED
using	O
tunel	B-MED
method	I-MED
.	O
	
alanine	B-MED
transaminase	I-MED
alt	B-MED
,	O
aspartate	B-MED
transaminase	I-MED
ast	B-MED
,	O
blood	B-MED
urea	I-MED
nitrogen	I-MED
bun	B-MED
,	O
and	O
creatinine	B-MED
cre	B-MED
were	O
detected	B-MED
by	O
an	O
automatic	B-MED
biochemical	B-MED
analyzer	B-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
fzqj	B-MED
-	O
containing	B-MED
serum	B-MED
remarkably	O
inhibited	B-MED
proliferation	B-MED
of	O
hepg2	B-MED
cells	I-MED
in	O
dose	B-MED
-	O
and	O
time	B-MED
-	O
dependent	B-MED
manners	O
,	O
induced	B-MED
hepg2	B-MED
cell	I-MED
apoptosis	B-MED
and	O
caused	O
a	O
decrease	B-MED
of	O
δψ	B-MED
.	O
	
analysis	B-MED
of	O
tumor	B-MED
tissue	I-MED
showed	O
that	O
fzqj	B-MED
-	O
induced	B-MED
apoptosis	B-MED
was	O
accompanied	O
by	O
downregulation	B-MED
of	O
bcl-2	B-MED
and	O
upregulation	B-MED
of	O
bax	B-MED
,	O
release	B-MED
of	O
cytochrome	B-MED
c	I-MED
,	O
activation	B-MED
of	O
caspase	B-MED
3	I-MED
and	O
9	B-MED
,	O
and	O
cleavage	B-MED
of	O
parp	B-MED
.	O
	
in	O
addition	O
,	O
fzqj	B-MED
increased	B-MED
the	O
percentages	B-MED
of	O
cd4	B-MED
t	I-MED
and	O
nk	B-MED
cells	I-MED
,	O
the	O
ratio	B-MED
of	O
cd4	B-MED
/	O
cd8	B-MED
t	I-MED
cells	I-MED
as	O
well	O
as	O
the	O
levels	B-MED
of	O
serum	B-MED
tnf-α	B-MED
.	O
	
fzqj	B-MED
also	O
increased	B-MED
cd69	B-MED
expression	B-MED
in	O
tumor	B-MED
tissue	I-MED
.	O
	
no	B-MED
hepatorenal	I-MED
toxicity	I-MED
was	O
observed	B-MED
in	O
h22	B-MED
tumor-bearing	I-MED
mice	I-MED
.	O
	
these	O
results	B-MED
indicated	B-MED
that	O
fzqj	B-MED
could	O
inhibit	B-MED
the	O
growth	B-MED
of	O
hepatoma	B-MED
cells	I-MED
via	O
regulating	O
immune	B-MED
function	I-MED
and	O
inducing	B-MED
mitochondria	B-MED
mediated	O
professional	B-MED
reinventions	I-MED
swedish	B-MED
psychologists	B-MED
,	O
1990-2010	O
since	O
the	O
early	O
20th	B-MED
century	I-MED
,	O
the	O
swedish	B-MED
psychology	B-MED
profession	I-MED
has	O
undergone	O
several	O
changes	B-MED
in	O
its	O
essential	B-MED
tasks	I-MED
,	O
epistemological	B-MED
foundations	I-MED
,	O
and	O
social	B-MED
roles	I-MED
.	O
	
these	O
changes	B-MED
occurred	B-MED
through	O
an	O
ongoing	O
"""tuning"""	O
with	O
swedish	B-MED
society	B-MED
,	O
in	O
which	O
the	O
profession	B-MED
strove	O
to	O
appear	O
relevant	O
to	O
society's	B-MED
concerns	B-MED
and	O
problems	B-MED
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession's	B-MED
goals	B-MED
and	O
aims	B-MED
.	O
	
studying	O
the	O
history	B-MED
of	O
the	O
profession	B-MED
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	B-MED
definitions	B-MED
and	O
contours	B-MED
of	O
the	O
psychology	B-MED
profession	I-MED
itself	O
as	O
well	O
as	O
on	O
the	O
organization	B-MED
of	O
the	O
society	B-MED
in	O
which	O
it	O
acts	O
.	O
	
this	O
article	B-MED
examines	O
the	O
history	B-MED
of	O
the	O
swedish	B-MED
psychology	B-MED
profession	I-MED
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	B-MED
of	O
the	O
discussions	B-MED
and	O
debates	B-MED
taking	O
place	O
in	O
the	O
swedish	B-MED
psychological	B-MED
association's	I-MED
journal	I-MED
.	O
	
the	O
analytical	B-MED
framework	I-MED
used	O
draws	O
on	O
work	O
done	O
within	O
actor-network	B-MED
theory	I-MED
and	O
science	B-MED
studies	I-MED
.	O
	
we	O
argue	O
that	O
the	O
profession's	B-MED
institutional	B-MED
connections	I-MED
,	O
defining	O
tasks	B-MED
,	O
epistemological	B-MED
underpinnings	B-MED
,	O
and	O
social	B-MED
position	I-MED
have	O
changed	B-MED
in	O
major	O
ways	O
during	O
these	O
2	O
decades	B-MED
.	O
	
overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-MED
,	O
the	O
profession	B-MED
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	B-MED
itself	O
to	O
politicians	B-MED
,	O
the	O
media	B-MED
,	O
patients	B-MED
,	O
and	O
customers	B-MED
through	O
means	O
such	O
as	O
a	O
more	O
economized	B-MED
vocabulary	B-MED
and	O
novel	B-MED
forms	O
of	O
empirical	B-MED
research	I-MED
.	O
	
these	O
changes	B-MED
have	O
led	O
to	O
a	O
more	O
socialized	B-MED
profession	B-MED
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-MED
in	O
swedish	B-MED
society	B-MED
,	O
leading	O
to	O
conflicts	B-MED
within	O
the	O
profession	B-MED
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	B-MED
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	B-MED
of	I-MED
autonomy	I-MED
.	O
	
psycinfo	B-MED
database	I-MED
record	I-MED
personally	B-MED
meaningful	I-MED
rituals	I-MED
a	O
way	O
to	O
increase	B-MED
compassion	B-MED
and	O
decrease	B-MED
burnout	B-MED
among	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
rituals	B-MED
can	O
increase	B-MED
a	O
sense	B-MED
of	I-MED
connectedness	I-MED
,	O
meaning	B-MED
,	O
and	O
support	B-MED
,	O
especially	O
after	O
the	O
death	B-MED
of	O
those	O
for	O
whom	O
we	O
care	O
.	O
	
hospice	B-MED
staff	B-MED
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	B-MED
rituals	I-MED
as	O
they	O
cope	B-MED
with	I-MED
the	O
frequent	B-MED
deaths	I-MED
of	O
their	O
patients	B-MED
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	B-MED
care	I-MED
while	O
minimizing	O
burnout	B-MED
.	O
	
this	O
study	O
investigated	O
the	O
role	O
of	O
personally	B-MED
meaningful	I-MED
rituals	I-MED
in	O
increasing	B-MED
compassion	B-MED
and	O
decreasing	B-MED
burnout	B-MED
among	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
.	O
	
an	O
online	B-MED
survey	I-MED
was	O
completed	O
by	O
members	O
of	O
the	O
national	B-MED
hospice	I-MED
and	I-MED
palliative	I-MED
care	I-MED
organization	I-MED
nhpco	O
which	O
inquired	O
about	O
personal	O
ritual	O
practices	O
,	O
and	O
included	O
the	O
professional	O
quality	O
of	O
life	O
proqol	O
scale	O
to	O
measure	O
current	O
levels	O
of	O
compassion	O
satisfaction	O
,	O
burnout	O
,	O
and	O
secondary	O
traumatic	O
stress	O
.	O
	
three	O
hundred	O
ninety	O
hospice	O
staff	O
and	O
volunteers	O
from	O
across	O
38	O
states	O
completed	O
the	O
online	O
survey	O
.	O
	
the	O
majority	O
of	O
participants	O
were	O
caucasian	O
and	O
female	O
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	O
and	O
palliative	O
care	O
.	O
	
the	O
majority	O
of	O
hospice	O
staff	O
and	O
volunteers	O
used	O
personally	O
meaningful	O
rituals	O
after	O
the	O
death	O
of	O
their	O
patients	O
to	O
help	O
them	O
cope	O
71%	O
.	O
	
those	O
who	O
used	O
rituals	O
demonstrated	O
significantly	O
higher	O
compassion	O
satisfaction	O
and	O
significantly	O
lower	O
burnout	O
as	O
measured	O
by	O
the	O
proqol	O
,	O
with	O
professional	O
support	O
,	O
social	O
support	O
,	O
and	O
age	O
playing	O
significant	O
roles	O
as	O
well	O
.	O
	
rituals	O
may	O
be	O
an	O
important	O
way	O
to	O
increase	O
compassion	O
and	O
decrease	O
burnout	O
among	O
hospice	O
staff	O
and	O
volunteers	O
.	O
	
organizations	O
may	O
benefit	O
from	O
providing	O
training	O
and	O
support	O
for	O
personalized	O
rituals	O
among	O
team	O
members	O
,	O
especially	O
new	O
staff	O
who	O
may	O
be	O
at	O
greater	O
risk	O
for	O
burnout	B-MED
activation	B-MED
of	O
the	O
orphan	B-MED
receptor	I-MED
gpr55	I-MED
by	O
lysophosphatidylinositol	B-MED
promotes	B-MED
metastasis	B-MED
in	O
triple-negative	B-MED
breast	I-MED
cancer	I-MED
the	O
orphan	B-MED
g	I-MED
protein-coupled	I-MED
receptor	I-MED
gpr55	B-MED
has	O
been	O
directly	B-MED
or	O
indirectly	B-MED
related	B-MED
to	O
basic	O
alterations	B-MED
that	O
drive	O
malignant	B-MED
growth	B-MED
uncontrolled	B-MED
cancer	O
cell	B-MED
proliferation	I-MED
,	O
sustained	B-MED
angiogenesis	I-MED
,	O
and	O
cancer	O
cell	B-MED
adhesion	I-MED
and	O
migration	B-MED
.	O
	
however	O
,	O
little	B-MED
is	O
known	B-MED
about	O
the	O
involvement	B-MED
of	O
this	O
receptor	B-MED
in	O
metastasis	B-MED
.	O
	
here	O
,	O
we	O
show	O
that	O
elevated	B-MED
gpr55	B-MED
expression	I-MED
in	O
human	B-MED
tumors	B-MED
is	O
associated	B-MED
with	I-MED
the	O
aggressive	B-MED
basal	I-MED
/	O
triple-negative	B-MED
breast	I-MED
cancer	I-MED
population	B-MED
,	O
higher	B-MED
probability	I-MED
to	O
develop	O
metastases	B-MED
,	O
and	O
therefore	O
poor	B-MED
patient	B-MED
prognosis	B-MED
.	O
	
activation	B-MED
of	O
gpr55	B-MED
by	O
its	O
proposed	O
endogenous	B-MED
ligand	B-MED
lysophosphatidylinositol	B-MED
confers	O
pro-invasive	B-MED
features	B-MED
on	O
breast	B-MED
cancer	I-MED
cells	I-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
specifically	O
,	O
this	O
effect	B-MED
is	O
elicited	B-MED
by	I-MED
coupling	B-MED
to	O
gq/11	B-MED
heterotrimeric	I-MED
proteins	I-MED
and	O
the	O
subsequent	B-MED
activation	B-MED
,	O
through	O
erk	B-MED
,	O
of	O
the	O
transcription	B-MED
factor	I-MED
etv4	I-MED
/	O
pea3	B-MED
.	O
	
together	B-MED
,	O
these	O
data	B-MED
show	O
that	O
gpr55	B-MED
promotes	B-MED
breast	B-MED
cancer	I-MED
metastasis	B-MED
,	O
and	O
supports	B-MED
the	O
notion	O
that	O
this	O
orphan	B-MED
receptor	I-MED
may	O
constitute	O
a	O
new	B-MED
therapeutic	B-MED
target	B-MED
and	O
potential	B-MED
biomarker	B-MED
in	O
the	O
highly	O
aggressive	B-MED
triple-negative	I-MED
subtype	I-MED
.	O
	
effect	B-MED
of	O
ultrasonic	B-MED
processing	B-MED
on	O
the	O
changes	O
in	O
activity	B-MED
,	O
aggregation	B-MED
and	O
the	O
secondary	B-MED
and	O
tertiary	B-MED
structure	I-MED
of	O
polyphenol	B-MED
oxidase	I-MED
in	O
oriental	B-MED
sweet	B-MED
melon	I-MED
cucumis	B-MED
melo	I-MED
var	I-MED
.	O
	
makuwa	I-MED
makino	I-MED
polyphenol	B-MED
oxidase	I-MED
ppo	B-MED
mainly	O
contributes	B-MED
to	O
the	O
browning	B-MED
reaction	I-MED
of	O
fruits	B-MED
and	O
vegetables	B-MED
and	O
causes	O
serious	B-MED
damage	B-MED
to	O
the	O
quality	B-MED
of	O
sweet	B-MED
melon	I-MED
products	B-MED
.	O
	
however	O
,	O
traditional	B-MED
methods	B-MED
to	O
inactivate	B-MED
browning	B-MED
may	O
induce	B-MED
more	O
unexpected	B-MED
risks	B-MED
than	O
ultrasonic	B-MED
processing	B-MED
.	O
	
meanwhile	O
,	O
there	O
are	O
no	O
reports	B-MED
on	O
the	O
effect	B-MED
of	O
ultrasound	B-MED
on	O
ppo	B-MED
directly	O
purified	B-MED
from	O
sweet	B-MED
melon	I-MED
.	O
	
the	O
ppo	B-MED
in	O
the	O
original	B-MED
juice	B-MED
was	O
less	O
inactivated	B-MED
than	O
the	O
purified	B-MED
form	O
when	O
treated	B-MED
with	I-MED
ultrasound	B-MED
.	O
	
as	O
for	O
purified	B-MED
ppo	B-MED
,	O
superior	O
to	O
thermal	B-MED
treatment	I-MED
,	O
less	O
heat	B-MED
was	O
needed	O
to	O
inactivate	B-MED
the	O
ppo	B-MED
with	O
ultrasonic	B-MED
treatment	B-MED
.	O
	
at	O
intensity	B-MED
lower	I-MED
than	O
200	O
w	O
,	O
ultrasound	B-MED
did	O
not	O
significantly	B-MED
affect	O
the	O
structure	B-MED
and	O
activity	B-MED
of	O
ppo	B-MED
p	O
>	O
0.05	O
,	O
and	O
latent	B-MED
ppo	B-MED
was	O
activated	B-MED
.	O
	
at	O
intensity	B-MED
higher	I-MED
than	O
200	O
w	O
,	O
ultrasound	B-MED
inactivated	B-MED
ppo	B-MED
,	O
induced	B-MED
aggregation	B-MED
and	O
dissociation	B-MED
of	O
ppo	B-MED
particles	B-MED
and	O
significantly	B-MED
decreased	I-MED
the	O
α-helix	B-MED
structure	I-MED
content	O
.	O
	
low-frequency	B-MED
high-intensity	B-MED
ultrasound	B-MED
caused	O
an	O
inactivation	B-MED
effect	B-MED
and	O
conformational	B-MED
changes	I-MED
of	O
purified	B-MED
ppo	B-MED
from	O
oriental	B-MED
sweet	B-MED
melons	I-MED
.	O
	
changes	B-MED
in	O
the	O
ppo	B-MED
structure	B-MED
induced	B-MED
by	O
ultrasound	B-MED
eventually	O
inactivated	B-MED
the	O
enzyme	B-MED
.	O
	
ultrasound	B-MED
may	O
be	O
a	O
potential	B-MED
method	B-MED
to	O
inactivate	B-MED
ppo	B-MED
in	O
oriental	B-MED
sweet	B-MED
melons	I-MED
.	O
	
phylogeography	B-MED
of	O
the	O
spanish	B-MED
moon	B-MED
moth	I-MED
graellsia	B-MED
isabellae	I-MED
lepidoptera	B-MED
,	O
saturniidae	B-MED
geographic	B-MED
and	O
demographic	B-MED
factors	I-MED
as	O
well	O
as	O
specialisation	B-MED
to	O
a	O
new	O
host-plant	B-MED
may	O
lead	O
to	O
host	B-MED
-	O
associated	B-MED
differentiation	B-MED
in	O
plant	B-MED
-feeding	O
insects	B-MED
.	O
	
we	O
explored	O
the	O
phylogeography	B-MED
of	O
a	O
protected	B-MED
moth	B-MED
,	O
graellsia	B-MED
isabellae	I-MED
,	O
and	O
its	O
two	O
recognised	O
host-plant	B-MED
species	B-MED
pinus	B-MED
sylvestris	I-MED
and	O
p	B-MED
.	O
	
nigra	I-MED
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	B-MED
history	I-MED
of	O
this	O
iconic	O
lepidopteran	B-MED
.	O
	
dna	B-MED
variation	B-MED
in	O
one	O
mitochondrial	B-MED
marker	B-MED
and	O
nine	O
nuclear	B-MED
microsatellite	B-MED
loci	I-MED
revealed	O
a	O
strong	O
phylogeographic	B-MED
pattern	I-MED
across	O
28	O
populations	O
of	O
g	B-MED
.	O
	
isabellae	I-MED
studied	O
in	O
spain	B-MED
and	O
france	B-MED
comprising	O
six	O
groups	B-MED
mostly	O
distributed	B-MED
along	O
different	B-MED
mountain	B-MED
ranges	I-MED
.	O
	
reanalysis	B-MED
of	O
a	O
previously	O
published	O
chloroplast	B-MED
microsatellite	B-MED
dataset	I-MED
revealed	B-MED
a	O
three	O
and	O
two-	O
group	B-MED
structure	I-MED
for	O
spanish	B-MED
p	B-MED
.	O
	
sylvestris	I-MED
and	O
p	B-MED
.	O
	
nigra	I-MED
,	O
respectively	O
.	O
	
overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	B-MED
moth	B-MED
did	O
not	O
match	B-MED
the	O
ones	O
of	O
p	B-MED
.	O
	
sylvestris	I-MED
and	O
p	B-MED
.	O
	
nigra	I-MED
.	O
	
there	O
was	O
no	B-MED
evidence	I-MED
of	I-MED
host	B-MED
-	O
associated	B-MED
differentiation	B-MED
between	O
populations	O
using	O
p	B-MED
.	O
	
sylvestris	I-MED
and	O
the	O
ones	O
inhabiting	B-MED
p	B-MED
.	O
	
nigra	I-MED
.	O
	
the	O
two	O
major	B-MED
mitochondrial	B-MED
clades	B-MED
of	O
g	B-MED
.	O
	
isabellae	I-MED
likely	O
diverged	O
before	O
the	O
last	B-MED
glacial	I-MED
maximum	I-MED
and	O
geographically	B-MED
separated	B-MED
the	O
species	B-MED
into	O
a	O
""""	O
southern	B-MED
""""	O
central	B-MED
and	I-MED
southern	I-MED
iberian	I-MED
clusters	I-MED
and	O
a	O
""""	O
northern	B-MED
""""	O
lineage	B-MED
eastern	B-MED
iberian	I-MED
,	O
pyrenean	B-MED
and	O
french	B-MED
alpine	I-MED
clusters	I-MED
.	O
	
the	O
eastern	B-MED
iberian	I-MED
system	I-MED
,	O
where	O
this	O
insect	B-MED
uses	O
both	O
host-plants	B-MED
,	O
harboured	O
the	O
highest	B-MED
level	B-MED
of	O
genetic	B-MED
diversity	B-MED
.	O
	
such	O
a	O
group	B-MED
independently	O
colonised	B-MED
the	O
west	B-MED
and	O
east	B-MED
parts	I-MED
of	O
the	O
pyrenees	B-MED
.	O
	
our	O
results	O
point	O
to	O
a	O
native	B-MED
origin	B-MED
for	O
the	O
french	B-MED
populations	I-MED
occurring	B-MED
in	O
the	O
alps	B-MED
,	O
genetically	B-MED
related	O
to	O
the	O
eastern	B-MED
iberian	I-MED
and	O
pyrenean	B-MED
sites	I-MED
.	O
	
the	O
central	B-MED
iberian	I-MED
group	I-MED
derived	O
from	O
southern	B-MED
iberian	I-MED
ancestors	B-MED
.	O
	
secondary	B-MED
contacts	B-MED
were	O
inferred	O
between	O
the	O
southern/central	B-MED
iberian	I-MED
populations	I-MED
and	O
eastern	B-MED
iberian	I-MED
cluster	I-MED
as	O
well	O
as	O
between	O
the	O
two	O
pyrenean	B-MED
ones	I-MED
.	O
	
the	O
mito-nuclear	B-MED
discordance	I-MED
observed	O
with	O
regard	O
to	O
the	O
eastern	B-MED
iberian	I-MED
cluster	I-MED
is	O
congruent	B-MED
with	O
a	O
secondary	B-MED
contact	B-MED
after	O
the	O
evolution	B-MED
of	O
mito-nuclear	B-MED
incompatibilities	I-MED
in	O
geographically	B-MED
isolated	I-MED
areas	I-MED
.	O
	
prevalence	B-MED
of	O
physical	B-MED
activity	I-MED
and	O
sitting	B-MED
time	B-MED
among	O
south	B-MED
korean	I-MED
adolescents	B-MED
results	B-MED
from	O
the	O
korean	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
,	O
2013	O
this	O
study	O
aimed	O
to	O
describe	O
physical	B-MED
activity	I-MED
pa	B-MED
and	O
sitting	B-MED
time	B-MED
,	O
and	O
to	O
examine	O
associations	B-MED
between	O
sociodemographic	B-MED
factors	I-MED
,	O
weight	B-MED
status	B-MED
,	O
pa	B-MED
,	O
and	O
sitting	B-MED
time	B-MED
among	O
south	B-MED
korean	I-MED
adolescents	B-MED
12-18	O
years	B-MED
.	O
	
findings	B-MED
are	O
based	O
on	O
self-report	B-MED
data	I-MED
from	O
638	O
participants	B-MED
in	O
the	O
2013	O
korea	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
.	O
	
only	O
4.9	O
of	O
adolescents	B-MED
accumulated	O
60	O
minutes	B-MED
of	O
moderate-to-vigorous	B-MED
pa	I-MED
daily	B-MED
.	O
	
adolescents	B-MED
spent	O
532.4	O
9.3	O
mins/d	B-MED
sitting	B-MED
.	O
	
after	O
controlling	O
for	O
age	B-MED
and	O
sex	B-MED
,	O
individuals	B-MED
in	O
higher	B-MED
income	I-MED
groups	I-MED
compared	B-MED
with	O
the	O
lowest	B-MED
income	I-MED
group	I-MED
,	O
living	B-MED
in	O
nonmetro	B-MED
seoul	B-MED
compared	B-MED
with	O
metro	B-MED
seoul	B-MED
,	O
and	O
who	O
were	O
overweight	B-MED
compared	B-MED
with	O
nonoverweight	B-MED
were	O
more	O
likely	O
to	O
meet	O
pa	B-MED
guidelines	B-MED
.	O
	
participants	B-MED
in	O
the	O
highest	B-MED
income	I-MED
group	I-MED
compared	B-MED
with	O
lowest	B-MED
income	I-MED
group	I-MED
,	O
and	O
residing	B-MED
in	O
nonmetro	B-MED
seoul	B-MED
compared	B-MED
with	O
metro	B-MED
seoul	B-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-MED
time	B-MED
group	B-MED
>720	O
min/d	B-MED
p	O
<	O
05	O
.	O
	
increasing	B-MED
pa	B-MED
and	O
reducing	B-MED
sitting	B-MED
should	O
be	O
a	O
public	B-MED
health	I-MED
priority	B-MED
in	O
south	B-MED
korea	I-MED
.	O
	
graphene	B-MED
/	O
nafion	B-MED
composite	B-MED
film	I-MED
modified	O
glassy	B-MED
carbon	B-MED
electrode	I-MED
for	O
simultaneous	B-MED
determination	B-MED
of	O
paracetamol	B-MED
,	O
aspirin	B-MED
and	O
caffeine	B-MED
in	O
pharmaceutical	B-MED
formulations	I-MED
a	O
graphene	B-MED
-	O
nafion	B-MED
composite	B-MED
film	I-MED
was	O
fabricated	B-MED
on	O
the	O
glassy	B-MED
carbon	B-MED
electrode	I-MED
gr-nf/gce	B-MED
,	O
and	O
used	O
for	O
simultaneous	B-MED
determination	B-MED
of	O
paracetamol	B-MED
par	B-MED
,	O
aspirin	B-MED
asa	B-MED
and	O
caffeine	B-MED
caf	B-MED
.	O
	
the	O
electrochemical	B-MED
behaviors	I-MED
of	O
par	B-MED
,	O
asa	B-MED
and	O
caf	B-MED
were	O
investigated	B-MED
by	O
cyclic	B-MED
voltammetry	I-MED
and	O
square-wave	B-MED
adsorptive	I-MED
anodic	I-MED
stripping	I-MED
voltammetry	I-MED
.	O
	
by	O
using	O
stripping	B-MED
one	O
for	O
simultaneous	B-MED
determination	B-MED
of	O
par	B-MED
,	O
asa	B-MED
and	O
caf	B-MED
,	O
their	O
electrochemical	B-MED
oxidation	I-MED
peaks	I-MED
appeared	B-MED
at	O
+0	O
,	O
1.04	O
and	O
1.44v	O
,	O
and	O
good	B-MED
linear	B-MED
current	I-MED
responses	I-MED
were	O
obtained	B-MED
with	O
the	O
detection	B-MED
limits	I-MED
of	O
18ngml	O
1.2	O
,	O
11.7ngml	O
6.5	O
and	O
7.3ngml	O
3.8	O
,	O
respectively	O
.	O
	
finally	O
,	O
the	O
proposed	B-MED
electrochemical	B-MED
sensor	I-MED
was	O
successfully	B-MED
applied	B-MED
for	O
quantifying	B-MED
par	B-MED
,	O
asa	B-MED
and	O
caf	B-MED
in	O
commercial	B-MED
tablet	B-MED
formulations	I-MED
.	O
	
long-term	B-MED
antibiofilm	B-MED
activity	I-MED
of	O
carboxymethyl	B-MED
chitosan	I-MED
on	O
mixed	B-MED
biofilm	I-MED
on	O
silicone	B-MED
silicone	B-MED
voice	B-MED
prostheses	I-MED
are	O
most	O
frequently	B-MED
used	O
in	O
voice	B-MED
rehabilitation	I-MED
of	O
laryngectomized	B-MED
patients	B-MED
.	O
	
however	O
,	O
the	O
functional	B-MED
device	I-MED
lifetimes	B-MED
are	O
limited	B-MED
due	B-MED
to	I-MED
formation	B-MED
of	O
mixed	B-MED
biofilms	I-MED
.	O
	
existing	O
in	B-MED
vitro	I-MED
models	I-MED
simulating	O
biofilm	B-MED
formation	I-MED
are	O
restricted	B-MED
to	O
only	O
short-term	B-MED
periods	B-MED
.	O
	
the	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
the	O
effect	B-MED
of	O
carboxymethyl	B-MED
chitosan	I-MED
on	O
mixed	B-MED
biofilm	I-MED
formation	I-MED
of	O
fungi	B-MED
and	O
bacteria	B-MED
on	O
silicone	B-MED
over	O
a	O
long-term	B-MED
period	B-MED
.	O
	
mixed	O
species	B-MED
biofilms	B-MED
of	O
candida	B-MED
albicans	I-MED
,	O
candida	B-MED
tropicalis	I-MED
,	O
lactobacillus	B-MED
gasseri	I-MED
,	O
streptococcus	B-MED
salivarius	I-MED
,	O
rothia	B-MED
dentocariosa	I-MED
,	O
and	O
staphylococcus	B-MED
epidermidis	I-MED
were	O
cultivated	B-MED
on	O
the	O
surfaces	B-MED
of	O
medical-grade	B-MED
silicone	I-MED
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-MED
chitosan	I-MED
.	O
	
biofilm	B-MED
kinetics	I-MED
was	O
monitored	O
using	O
specially	O
designed	B-MED
image	I-MED
analysis	I-MED
software	I-MED
to	O
calculate	B-MED
the	O
percentual	B-MED
surface	I-MED
covering	I-MED
of	O
each	O
platelet	B-MED
.	O
	
biofilm	B-MED
architecture	I-MED
was	O
investigated	B-MED
by	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
.	O
	
a	O
cover	B-MED
of	O
living	B-MED
mixed	B-MED
biofilm	I-MED
could	O
be	O
generated	O
over	O
22	O
days	B-MED
on	O
silicone	B-MED
and	O
the	O
maximum	B-MED
of	O
22%	O
biofilm	B-MED
surface	B-MED
covering	I-MED
at	O
day	B-MED
22	O
.	O
	
however	O
,	O
less	B-MED
than	I-MED
4%	O
surface	B-MED
coverage	I-MED
was	O
observed	B-MED
on	O
the	O
carboxymethyl	B-MED
chitosan	I-MED
-	O
treated	B-MED
plates	O
in	O
the	O
testing	B-MED
period	B-MED
.	O
	
scanning	B-MED
electron	I-MED
microscopy	I-MED
confirms	B-MED
that	O
,	O
on	O
surfaces	B-MED
treated	B-MED
by	O
carboxymethyl	B-MED
chitosan	I-MED
,	O
the	O
biofilm	B-MED
was	O
less	B-MED
dense	B-MED
.	O
	
in	O
addition	O
,	O
there	O
were	O
fewer	B-MED
layers	O
of	O
cells	B-MED
and	O
profuse	B-MED
cellular	I-MED
debris	I-MED
,	O
together	B-MED
with	O
degrading	O
and	O
morphologically	B-MED
altered	I-MED
yeast	B-MED
cells	O
.	O
	
carboxymethyl	O
chitosan	O
may	O
serve	O
as	O
a	O
possible	O
antibiofilm	O
agent	O
to	O
limit	O
biofilm	O
formation	O
on	O
voice	O
prostheses	O
.	O
	
na	O
laryngoscope	O
,	O
126	O
,	O
spectral	B-MED
fingerprints	I-MED
of	O
large-scale	O
cortical	B-MED
dynamics	B-MED
during	B-MED
ambiguous	B-MED
motion	B-MED
perception	I-MED
ambiguous	B-MED
stimuli	B-MED
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-MED
correlates	B-MED
of	O
consciousness	B-MED
.	O
	
recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-MED
perception	B-MED
might	O
arise	O
from	O
the	O
dynamic	B-MED
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-MED
areas	I-MED
.	O
	
while	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	B-MED
coupling	I-MED
as	O
a	O
correlate	B-MED
of	O
cortical	B-MED
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	B-MED
modes	I-MED
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	B-MED
functions	I-MED
.	O
	
here	O
,	O
we	O
studied	O
two	O
coupling	B-MED
modes	I-MED
,	O
namely	O
phase	B-MED
and	I-MED
envelope	I-MED
coupling	I-MED
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	B-MED
.	O
	
therefore	O
,	O
we	O
recorded	O
128-channel	O
eeg	B-MED
while	O
participants	B-MED
performed	O
a	O
bistable	B-MED
motion	I-MED
task	I-MED
and	O
utilized	O
state-of-the-art	O
source-space	O
connectivity	B-MED
analysis	B-MED
techniques	B-MED
to	O
study	O
the	O
functional	B-MED
relevance	I-MED
of	O
different	O
coupling	B-MED
modes	I-MED
for	O
cortical	B-MED
communication	O
.	O
	
our	O
results	O
indicate	O
that	O
gamma-band	B-MED
phase	I-MED
coupling	I-MED
in	O
extrastriate	B-MED
visual	B-MED
cortex	I-MED
might	O
mediate	O
the	O
integration	O
of	O
visual	B-MED
tokens	I-MED
into	O
a	O
moving	B-MED
stimulus	B-MED
during	O
ambiguous	B-MED
visual	B-MED
stimulation	I-MED
.	O
	
furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long-range	O
fronto-occipital	O
gamma-band	O
envelope	B-MED
coupling	I-MED
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	B-MED
motion	B-MED
perception	I-MED
.	O
	
additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-MED
parieto-occipital	I-MED
alpha-band	B-MED
phase	I-MED
coupling	I-MED
controls	O
the	O
inter-	O
hemispheric	B-MED
information	B-MED
transfer	I-MED
.	O
	
these	O
findings	O
provide	O
correlative	B-MED
evidence	B-MED
for	O
the	O
notion	O
that	O
synchronized	B-MED
oscillatory	O
brain	B-MED
activity	I-MED
reflects	O
the	O
processing	B-MED
of	I-MED
sensory	I-MED
input	O
as	O
well	O
as	O
the	O
information	B-MED
integration	I-MED
across	O
several	O
spatiotemporal	B-MED
scales	I-MED
.	O
	
the	O
results	O
indicate	O
that	O
distinct	B-MED
coupling	I-MED
modes	I-MED
are	O
involved	O
in	O
different	O
cortical	B-MED
computations	B-MED
and	O
that	O
the	O
rich	O
spatiotemporal	B-MED
correlation	I-MED
structure	B-MED
of	I-MED
the	I-MED
brain	I-MED
might	O
constitute	O
the	O
functional	B-MED
architecture	O
for	O
cortical	B-MED
beneficial	B-MED
effects	I-MED
of	O
voglibose	B-MED
administration	B-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
via	O
gastrointestinal	B-MED
bile	B-MED
acid	I-MED
modification	B-MED
this	O
study	B-MED
was	O
designed	O
with	O
the	O
goal	B-MED
of	O
examining	O
the	O
effects	B-MED
of	O
voglibose	B-MED
administration	B-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
and	O
underlying	O
mechanism	B-MED
high	B-MED
fat	I-MED
diet	I-MED
-induced	O
obese	B-MED
mice	I-MED
.	O
	
male	B-MED
c57bl/6	B-MED
mice	I-MED
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-MED
a	O
control	B-MED
diet	I-MED
ctl	B-MED
,	O
high-fat	B-MED
diet	I-MED
hf	B-MED
,	O
high-fat	B-MED
diet	I-MED
supplemented	I-MED
with	I-MED
voglibose	I-MED
vo	B-MED
,	O
and	O
high	B-MED
fat	I-MED
diet	I-MED
pair-fed	I-MED
group	I-MED
pf	B-MED
.	O
	
after	O
12	O
weeks	B-MED
,	O
the	O
following	O
characteristics	B-MED
were	O
investigated	O
serum	B-MED
lipid	I-MED
and	O
glucose	B-MED
levels	I-MED
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	B-MED
levels	I-MED
of	O
genes	B-MED
involved	O
in	O
lipid	B-MED
and	O
bile	B-MED
acid	I-MED
metabolism	I-MED
.	O
	
in	O
addition	O
,	O
pyrosequencing	B-MED
was	O
used	O
to	O
analyze	O
the	O
composition	B-MED
of	O
gut	B-MED
microbiota	I-MED
found	O
in	O
feces	B-MED
.	O
	
total	B-MED
body	I-MED
weight	I-MED
gain	I-MED
was	O
significantly	B-MED
lower	I-MED
in	O
the	O
vo	B-MED
group	I-MED
than	O
in	O
the	O
ctl	B-MED
,	O
hf	B-MED
,	O
and	O
pf	B-MED
groups	I-MED
.	O
	
the	O
vo	B-MED
group	I-MED
exhibited	O
improved	O
metabolic	B-MED
profiles	I-MED
including	O
those	O
of	O
blood	B-MED
glucose	I-MED
,	O
triglyceride	B-MED
,	O
and	O
total	B-MED
cholesterol	I-MED
levels	I-MED
.	O
	
the	O
12-	O
week	B-MED
voglibose	B-MED
administration	B-MED
decreased	O
the	O
ratio	O
of	O
firmicutes	B-MED
to	O
bacteroidetes	B-MED
found	O
in	O
feces	B-MED
.	O
	
circulating	O
levels	B-MED
of	O
taurocholic	B-MED
and	O
cholic	B-MED
acid	I-MED
were	O
significantly	B-MED
higher	I-MED
in	O
the	O
vo	B-MED
group	I-MED
than	O
in	O
the	O
hf	B-MED
and	O
ctl	B-MED
groups	I-MED
.	O
	
deoxycholic	B-MED
acid	I-MED
levels	B-MED
tended	O
to	O
be	O
higher	O
in	O
the	O
vo	B-MED
group	I-MED
than	O
in	O
the	O
hf	B-MED
group	I-MED
.	O
	
voglibose	B-MED
administration	B-MED
downregulated	B-MED
expression	B-MED
levels	I-MED
of	O
cyp8b1	B-MED
and	O
hnf4α	B-MED
genes	I-MED
and	O
upregulated	B-MED
those	O
of	O
pgc1α	B-MED
,	O
whereas	O
fxrα	B-MED
was	O
not	O
affected	O
.	O
	
voglibose	B-MED
administration	B-MED
elicits	O
changes	O
in	O
the	O
composition	B-MED
of	O
the	O
intestinal	B-MED
microbiota	I-MED
and	O
circulating	B-MED
metabolites	I-MED
,	O
which	O
ultimately	O
has	O
systemic	B-MED
effects	I-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
in	O
supramolecular	B-MED
recognition	I-MED
of	O
amino	B-MED
acids	I-MED
by	O
twisted	B-MED
cucurbit	I-MED
binding	B-MED
interactions	B-MED
between	B-MED
twisted	B-MED
cucurbit	I-MED
tq	B-MED
and	O
twenty	O
standard	B-MED
amino	B-MED
acids	I-MED
aas	B-MED
have	O
been	O
investigated	B-MED
by	O
nmr	B-MED
spectroscopy	I-MED
and	O
isothermal	B-MED
titration	I-MED
calorimetry	I-MED
itc	B-MED
in	O
aqueous	B-MED
hcl	B-MED
solutions	I-MED
and	O
in	O
dmso	B-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
tq	B-MED
displays	B-MED
clear	O
binding	B-MED
affinity	B-MED
for	O
aas	B-MED
with	O
a	O
positively	B-MED
charged	I-MED
side	I-MED
chain	I-MED
or	O
containing	B-MED
an	O
aromatic	B-MED
ring	I-MED
,	O
but	O
weaker	B-MED
binding	B-MED
affinity	B-MED
for	O
aas	B-MED
with	O
hydrophobic	B-MED
or	O
polar	B-MED
side	I-MED
chains	I-MED
,	O
with	O
the	O
binding	B-MED
mode	B-MED
depending	O
on	O
the	O
type	O
of	O
side	B-MED
chain	I-MED
present	O
in	O
the	O
comparison	B-MED
of	O
alkaline	B-MED
phosphatase	I-MED
activity	I-MED
of	O
mc3t3-e1	B-MED
cells	I-MED
cultured	O
on	O
different	O
ti	B-MED
surfaces	B-MED
modified	O
sandblasted	B-MED
with	O
large	O
grit	B-MED
and	O
acid-etched	B-MED
msla	B-MED
,	O
laser-treated	B-MED
,	O
and	O
laser	B-MED
and	I-MED
acid-treated	I-MED
ti	B-MED
surfaces	B-MED
in	O
this	O
study	B-MED
,	O
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
effect	O
of	O
implant	O
surface	B-MED
treatment	O
on	O
cell	B-MED
differentiation	I-MED
of	O
osteoblast	B-MED
cells	I-MED
.	O
	
for	O
this	O
purpose	O
,	O
three	O
surfaces	B-MED
were	O
compared	O
1	O
a	O
modified	O
sla	O
msla	O
sand-blasted	O
with	O
large	O
grit	B-MED
,	O
acid-etched	O
,	O
and	O
immersed	O
in	O
0.9	O
nacl	B-MED
,	O
2	O
a	O
laser	B-MED
treatment	I-MED
lt	B-MED
laser	B-MED
treatment	I-MED
titanium	B-MED
surface	B-MED
and	O
3	O
a	O
laser	B-MED
and	I-MED
acid-treated	I-MED
lat	O
laser	B-MED
treatment	I-MED
,	O
acid-etched	I-MED
titanium	B-MED
surface	B-MED
.	O
	
the	O
msla	B-MED
surfaces	B-MED
were	O
considered	O
as	O
the	O
control	B-MED
group	I-MED
,	O
and	O
lt	B-MED
and	O
lat	B-MED
surfaces	B-MED
as	O
test	B-MED
groups	I-MED
.	O
	
alkaline	B-MED
phosphatase	I-MED
expression	B-MED
alp	B-MED
was	O
used	O
to	O
quantify	O
osteoblastic	B-MED
differentiation	I-MED
of	O
mc3t3-e1	B-MED
cell	I-MED
.	O
	
surface	B-MED
roughness	B-MED
was	O
evaluated	B-MED
by	O
a	O
contact	B-MED
profilometer	I-MED
urfpak-sv	O
mitutoyo	O
,	O
kawasaki	O
,	O
japan	B-MED
and	O
characterized	O
by	O
two	O
parameters	O
mean	B-MED
roughness	I-MED
ra	B-MED
and	O
maximum	B-MED
peak-to-valley	I-MED
height	I-MED
rt	B-MED
.	O
	
scanning	B-MED
electron	I-MED
microscope	I-MED
revealed	O
that	O
msla	O
control	B-MED
group	I-MED
surface	B-MED
was	O
not	O
as	O
rough	B-MED
as	O
lt	B-MED
,	O
lat	B-MED
surface	B-MED
test	B-MED
groups	I-MED
.	O
	
alkaline	B-MED
phosphatase	I-MED
expression	B-MED
,	O
the	O
measure	O
of	O
osteoblastic	B-MED
differentiation	I-MED
,	O
and	O
total	O
alp	B-MED
expression	B-MED
by	O
surface-adherent	B-MED
cells	I-MED
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	B-MED
for	O
all	O
three	O
surfaces	B-MED
tested	O
p<	O
.	O
	
furthermore	O
,	O
alp	B-MED
expression	B-MED
levels	B-MED
of	O
msla	B-MED
and	O
lat	B-MED
surfaces	B-MED
were	O
significantly	O
higher	O
than	O
expression	B-MED
levels	B-MED
of	O
lt	B-MED
surface-adherent	B-MED
cells	I-MED
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-MED
,	O
respectively	O
p<	O
.	O
	
however	O
,	O
alp	B-MED
expression	B-MED
levels	B-MED
between	O
msla	B-MED
and	O
lat	B-MED
surface	B-MED
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-MED
p>	O
.	O
	
this	O
study	B-MED
suggested	O
that	O
msla	B-MED
and	O
lat	B-MED
surfaces	B-MED
exhibited	O
more	O
favorable	B-MED
environment	B-MED
for	O
osteoblast	B-MED
differentiation	I-MED
when	O
compared	O
with	O
lt	B-MED
surface	B-MED
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-MED
surface	B-MED
modification	B-MED
studies	B-MED
.	O
	
overcoming	B-MED
structural	B-MED
inequalities	B-MED
in	O
oral	B-MED
health	I-MED
the	O
role	O
of	O
dental	B-MED
curricula	B-MED
to	O
date	O
the	O
role	O
of	O
health	B-MED
professional	I-MED
schools	I-MED
in	O
addressing	O
oral	B-MED
health	I-MED
inequalities	B-MED
have	O
been	O
minimal	O
,	O
as	O
attempts	B-MED
have	O
focused	B-MED
principally	O
upon	O
systemic	B-MED
reform	B-MED
and	O
broader	O
societal	B-MED
obligations	I-MED
.	O
	
professionalism	B-MED
is	O
a	O
broad	O
competency	B-MED
that	O
is	O
taught	O
throughout	O
dental	B-MED
schools	I-MED
and	O
encompasses	O
a	O
range	B-MED
of	O
attributes	O
.	O
	
professionalism	B-MED
as	O
a	O
competency	B-MED
draws	O
some	O
debate	B-MED
and	O
appears	O
to	O
be	O
a	O
shifting	B-MED
phenomenon	I-MED
.	O
	
we	O
may	O
ask	O
if	O
professionalism	B-MED
in	O
the	O
dental	B-MED
curricula	B-MED
may	O
be	O
better	O
addressed	O
by	O
social	B-MED
accountability	I-MED
social	B-MED
accountability	I-MED
directs	O
oral	B-MED
health	I-MED
professional	B-MED
curricula	I-MED
education	B-MED
,	O
research	B-MED
,	O
and	O
service	B-MED
activities	I-MED
towards	O
addressing	O
the	O
priority	B-MED
health	B-MED
concerns	B-MED
of	O
the	O
community	B-MED
,	O
in	O
our	O
case	O
oral	B-MED
health	I-MED
inequalities	B-MED
.	O
	
although	O
working	O
toward	O
dental	B-MED
schools	I-MED
becoming	O
more	O
socially	B-MED
accountable	I-MED
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	B-MED
oral	B-MED
health	I-MED
inequalities	B-MED
,	O
it	O
might	O
have	O
limitations	O
.	O
	
we	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-MED
curricula	B-MED
by	O
considering	O
some	O
of	O
the	O
political	B-MED
,	O
structural	B-MED
,	O
social	B-MED
and	O
ethical	B-MED
factors	B-MED
that	O
influence	B-MED
our	O
institutions	B-MED
and	O
our	O
function	B-MED
analysis	B-MED
of	O
mef2c	B-MED
promoter	B-MED
in	O
muscle	B-MED
differentiation	I-MED
regeneration	B-MED
of	I-MED
adult	I-MED
skeletal	I-MED
muscle	I-MED
following	O
injury	B-MED
occurs	O
through	O
the	O
activation	B-MED
of	O
satellite	B-MED
cells	I-MED
,	O
that	O
proliferates	B-MED
,	O
differentiates	B-MED
,	O
and	O
fuses	B-MED
with	O
injured	B-MED
myofibers	B-MED
.	O
	
myocyte	B-MED
enhancer	I-MED
factor	I-MED
2	I-MED
mef2	I-MED
proteins	I-MED
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	B-MED
muscle	B-MED
regeneration	I-MED
.	O
	
in	O
order	O
to	O
further	O
understand	O
mef2c	B-MED
gene	I-MED
,	O
the	O
promoter	B-MED
of	O
pig	B-MED
mef2c	B-MED
gene	I-MED
was	O
analyzed	O
in	O
this	O
paper	O
.	O
	
quantitative	B-MED
real-time	I-MED
pcr	I-MED
qrt-pcr	B-MED
revealed	O
the	O
expression	B-MED
pattern	O
of	O
mef2c	B-MED
gene	I-MED
in	O
muscle	B-MED
of	O
eight	O
tissues	B-MED
.	O
	
the	O
mef2c	B-MED
promoter	B-MED
had	O
the	O
higher	O
transcriptional	B-MED
activity	I-MED
in	O
differentiated	B-MED
c2c12	B-MED
cells	I-MED
than	O
that	O
in	O
proliferating	B-MED
c2c12	B-MED
cells	I-MED
,	O
which	O
was	O
accompanied	O
by	O
the	O
up-regulation	B-MED
of	O
mrna	B-MED
expression	I-MED
of	O
mef2c	B-MED
gene	I-MED
.	O
	
function	B-MED
deletion	B-MED
and	O
mutation	B-MED
analyses	B-MED
showed	O
that	O
myod	B-MED
and	O
mef2	B-MED
binding	B-MED
sites	I-MED
within	O
the	O
mef2c	B-MED
promoter	B-MED
were	O
responsible	O
for	O
the	O
regulation	B-MED
of	O
mef2c	B-MED
transcription	B-MED
.	O
	
mef2c	B-MED
could	O
up-regulate	B-MED
the	I-MED
transcriptional	I-MED
activities	I-MED
of	O
mef2c	B-MED
promoter	B-MED
constructs	I-MED
which	O
contained	O
a	O
3'-end	B-MED
nucleotide	I-MED
sequence	I-MED
with	O
p300	B-MED
binding	B-MED
site	I-MED
.	O
	
the	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
emsa	B-MED
and	O
chromatin	B-MED
immunoprecipitation	I-MED
chip	I-MED
assays	I-MED
determined	O
the	O
myod	B-MED
binding	B-MED
site	I-MED
in	O
mef2c	B-MED
promoter	B-MED
.	O
	
these	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-MED
of	O
the	O
pig	B-MED
mef2c	B-MED
gene	I-MED
.	O
	
and	O
the	O
study	O
of	O
mef2c	B-MED
promoter	B-MED
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	B-MED
mechanisms	I-MED
of	O
mef2c	B-MED
in	O
muscle	B-MED
differentiation	I-MED
or	O
muscle	B-MED
repair	I-MED
and	O
regeneration	B-MED
.	O
	
novel	O
insights	O
into	O
development	O
of	O
diabetic	B-MED
bladder	B-MED
disorder	I-MED
provided	O
by	O
metabolomic	B-MED
analysis	I-MED
of	O
the	O
rat	B-MED
nondiabetic	O
and	O
diabetic	B-MED
detrusor	B-MED
and	O
urothelial	B-MED
layer	I-MED
there	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	B-MED
in	O
bladder	B-MED
metabolism	B-MED
resulting	O
from	O
diabetes	B-MED
.	O
	
such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-MED
bladder	B-MED
disorder	I-MED
dbd	I-MED
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	B-MED
of	O
detrusor	B-MED
and	O
urothelial	B-MED
layer	I-MED
in	O
a	O
1-mo	O
streptozotocin	B-MED
-induced	O
rat	B-MED
model	B-MED
of	O
type	B-MED
1	I-MED
diabetes	I-MED
with	O
nondiabetic	B-MED
controls	I-MED
.	O
	
our	O
studies	O
revealed	O
that	O
diabetes	B-MED
caused	O
both	O
common	O
and	O
differential	O
changes	B-MED
in	O
the	O
detrusor	B-MED
and	O
urothelial	B-MED
layer's	I-MED
metabolome	B-MED
.	O
	
diabetes	B-MED
resulted	O
in	O
similar	O
changes	B-MED
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-MED
markers	B-MED
in	O
both	O
tissues	B-MED
,	O
such	O
as	O
glucose	B-MED
,	O
lactate	B-MED
,	O
2-hydroxybutyrate	B-MED
,	O
branched-chain	B-MED
amino	I-MED
acid	I-MED
degradation	I-MED
products	I-MED
,	O
bile	B-MED
acids	I-MED
,	O
and	O
1	B-MED
,	O
as	O
well	O
as	O
markers	B-MED
of	O
oxidative	B-MED
stress	I-MED
.	O
	
in	O
the	O
detrusor	B-MED
but	O
not	O
the	O
urothelial	B-MED
layer	I-MED
,	O
diabetes	B-MED
caused	O
activation	O
of	O
the	O
pentose-phosphate	B-MED
and	O
polyol	B-MED
pathways	B-MED
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
tca	B-MED
cycle	I-MED
and	O
β-oxidation	B-MED
.	O
	
changes	B-MED
in	O
detrusor	B-MED
energy-generating	B-MED
pathways	I-MED
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-MED
that	O
,	O
through	O
generation	O
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
dbd	B-MED
.	O
	
in	O
the	O
diabetic	B-MED
urothelial	B-MED
layer	I-MED
there	O
was	O
decreased	O
flux	B-MED
of	O
glucose	B-MED
via	O
glycolysis	B-MED
and	O
changes	B-MED
in	O
lipid	O
metabolism	O
,	O
particularly	O
prostaglandin	O
synthesis	O
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	O
dysfunction	B-MED
proximal	B-MED
soil	I-MED
sensing	I-MED
-	O
a	O
contribution	B-MED
for	O
species	B-MED
habitat	B-MED
distribution	B-MED
modelling	B-MED
of	O
earthworms	B-MED
in	O
agricultural	B-MED
soils	B-MED
earthworms	B-MED
are	O
important	O
for	O
maintaining	O
soil	B-MED
ecosystem	B-MED
functioning	B-MED
and	O
serve	O
as	O
indicators	B-MED
of	O
soil	B-MED
fertility	B-MED
.	O
	
however	O
,	O
detection	O
of	O
earthworms	B-MED
is	O
time-consuming	B-MED
,	O
which	O
hinders	O
the	O
assessment	B-MED
of	O
earthworm	B-MED
abundances	B-MED
with	O
high	O
sampling	B-MED
density	B-MED
over	O
entire	O
fields	B-MED
.	O
	
recent	O
developments	O
of	O
mobile	B-MED
terrestrial	I-MED
sensor	I-MED
platforms	I-MED
for	O
proximal	B-MED
soil	I-MED
sensing	I-MED
pss	B-MED
provided	O
new	O
tools	B-MED
for	O
collecting	O
dense	O
spatial	O
information	B-MED
of	O
soils	B-MED
using	O
various	O
sensing	B-MED
principles	I-MED
.	O
	
yet	O
,	O
the	O
potential	O
of	O
pss	B-MED
for	O
assessing	B-MED
earthworm	B-MED
habitats	B-MED
is	O
largely	O
unexplored	O
.	O
	
this	O
study	B-MED
investigates	B-MED
whether	O
pss	B-MED
data	B-MED
contribute	O
to	O
the	O
spatial	O
prediction	B-MED
of	O
earthworm	B-MED
abundances	B-MED
in	O
species	B-MED
distribution	B-MED
models	B-MED
of	O
agricultural	B-MED
soils	B-MED
.	O
	
proximal	B-MED
soil	I-MED
sensing	I-MED
data	B-MED
,	O
e.g	O
,	O
soil	B-MED
electrical	B-MED
conductivity	I-MED
ec	B-MED
,	O
ph	B-MED
,	O
and	O
near	B-MED
infrared	I-MED
absorbance	I-MED
nir	B-MED
,	O
were	O
collected	B-MED
in	O
real-time	B-MED
in	O
a	O
field	B-MED
with	O
two	O
management	B-MED
strategies	I-MED
reduced	B-MED
tillage	B-MED
/	O
conventional	O
tillage	B-MED
and	O
sandy	B-MED
to	O
loam	B-MED
soils	I-MED
.	O
	
pss	B-MED
was	O
related	O
to	O
observations	B-MED
from	O
a	O
long-term	B-MED
11	O
years	B-MED
earthworm	B-MED
observation	B-MED
study	I-MED
conducted	O
at	O
42	O
plots	B-MED
.	O
	
earthworms	B-MED
were	O
sampled	B-MED
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	B-MED
blocks	O
and	O
identified	B-MED
to	O
species	B-MED
level	B-MED
.	O
	
sensor	B-MED
data	B-MED
were	O
highly	O
correlated	O
with	O
earthworm	B-MED
abundances	B-MED
observed	B-MED
in	O
reduced	B-MED
tillage	B-MED
but	O
less	O
correlated	B-MED
with	O
earthworm	B-MED
abundances	B-MED
observed	B-MED
in	O
conventional	B-MED
tillage	I-MED
.	O
	
this	O
may	O
indicate	O
that	O
management	B-MED
influences	B-MED
the	O
sensor	B-MED
-	O
earthworm	B-MED
relationship	O
.	O
	
generalized	O
additive	O
models	B-MED
and	O
state-space	B-MED
models	I-MED
showed	O
that	O
modelling	B-MED
based	O
on	O
data	B-MED
fusion	O
from	O
ec	B-MED
,	O
ph	B-MED
,	O
and	O
nir	B-MED
sensors	B-MED
produced	O
better	O
results	B-MED
than	O
modelling	B-MED
without	O
sensor	B-MED
data	B-MED
or	O
data	B-MED
from	O
just	O
a	O
single	O
sensor	B-MED
.	O
	
regarding	O
the	O
individual	O
earthworm	B-MED
species	B-MED
,	O
particular	O
sensor	B-MED
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	B-MED
requirements	B-MED
of	O
the	O
earthworms	B-MED
.	O
	
earthworm	B-MED
species	B-MED
with	O
soil	B-MED
-specific	O
habitat	B-MED
preferences	B-MED
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	B-MED
by	O
pss	B-MED
than	O
more	O
ubiquitous	B-MED
species	B-MED
.	O
	
our	O
findings	B-MED
suggest	O
that	O
pss	B-MED
contributes	O
to	O
the	O
spatial	O
modelling	B-MED
of	O
earthworm	B-MED
abundances	B-MED
at	O
field	B-MED
scale	I-MED
and	O
that	O
it	O
will	O
support	O
species	B-MED
distribution	B-MED
modelling	B-MED
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	B-MED
-	O
earthworm	B-MED
relationships	O
in	O
size	B-MED
matters	O
to	O
function	O
brain	B-MED
volume	I-MED
correlates	B-MED
with	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
across	O
healthy	B-MED
individuals	B-MED
a	O
fundamental	O
issue	O
in	O
neuroscience	B-MED
is	O
to	O
understand	O
the	O
structural	B-MED
substrates	B-MED
of	O
neural	O
activities	O
.	O
	
intrinsic	B-MED
brain	B-MED
activity	I-MED
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	B-MED
functions	I-MED
.	O
	
structurally	O
,	O
cognitive	B-MED
functions	I-MED
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
.	O
	
therefore	O
,	O
an	O
association	B-MED
between	O
intrinsic	B-MED
brain	B-MED
activities	I-MED
and	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
can	O
be	O
hypothesized	O
,	O
and	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
may	O
impact	B-MED
intrinsic	B-MED
brain	B-MED
activity	I-MED
in	O
human	B-MED
brains	B-MED
.	O
	
the	O
present	O
study	B-MED
aimed	O
to	O
explicitly	O
investigate	B-MED
this	O
brain	B-MED
structure	I-MED
-	O
function	B-MED
relationship	B-MED
using	O
two	O
large	O
independent	O
cohorts	B-MED
of	O
176	O
and	O
236	O
young	B-MED
adults	I-MED
.	O
	
structural	B-MED
-	O
mri	B-MED
was	O
performed	B-MED
to	O
estimate	B-MED
the	O
brain	B-MED
volume	I-MED
,	O
and	O
resting-state	B-MED
functional-mri	I-MED
was	O
applied	O
to	O
extract	O
the	O
amplitude	B-MED
of	I-MED
low-frequency	I-MED
fluctuations	I-MED
alff	B-MED
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
.	O
	
intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	B-MED
correlation	B-MED
between	O
whole-brain	B-MED
size	I-MED
and	O
alff	B-MED
.	O
	
moreover	O
,	O
specific	B-MED
brain	B-MED
lobes	I-MED
/	O
regions	B-MED
,	O
including	O
the	O
frontal	B-MED
lobe	I-MED
,	O
the	O
left	B-MED
middle	I-MED
frontal	I-MED
gyrus	I-MED
,	O
anterior	B-MED
cingulate	I-MED
gyrus	I-MED
,	O
rolandic	B-MED
operculum	I-MED
,	O
and	O
insula	B-MED
,	O
also	O
showed	O
a	O
reliable	B-MED
,	O
positive	B-MED
volume	B-MED
-	O
alff	B-MED
correlation	B-MED
in	O
the	O
two	O
cohorts	B-MED
.	O
	
these	O
findings	O
offer	O
direct	B-MED
,	O
empirical	B-MED
evidence	B-MED
of	I-MED
a	O
strong	B-MED
association	B-MED
between	O
brain	B-MED
size	I-MED
/	O
volume	B-MED
and	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	B-MED
substrates	B-MED
of	O
the	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
of	O
the	O
human	B-MED
brain	B-MED
.	O
	
on	O
the	O
control	B-MED
of	O
social	B-MED
approach-avoidance	B-MED
behavior	I-MED
neural	B-MED
and	O
endocrine	B-MED
mechanisms	B-MED
the	O
ability	B-MED
to	O
control	B-MED
our	O
automatic	B-MED
action	B-MED
tendencies	B-MED
is	O
crucial	B-MED
for	O
adequate	B-MED
social	B-MED
interactions	I-MED
.	O
	
emotional	B-MED
events	B-MED
trigger	B-MED
automatic	B-MED
approach	B-MED
and	I-MED
avoidance	I-MED
tendencies	B-MED
.	O
	
although	O
these	O
actions	B-MED
may	O
be	O
generally	O
adaptive	B-MED
,	O
the	O
capacity	B-MED
to	O
override	B-MED
these	O
emotional	B-MED
reactions	I-MED
may	O
be	O
key	B-MED
to	O
flexible	B-MED
behavior	B-MED
during	O
social	B-MED
interaction	I-MED
.	O
	
the	O
present	B-MED
chapter	B-MED
provides	B-MED
a	O
review	B-MED
of	O
the	O
neuroendocrine	B-MED
mechanisms	B-MED
underlying	O
this	O
ability	B-MED
and	O
their	O
relation	B-MED
to	O
social	B-MED
psychopathologies	B-MED
.	O
	
aberrant	B-MED
social	B-MED
behavior	I-MED
,	O
such	O
as	O
observed	B-MED
in	O
social	B-MED
anxiety	I-MED
or	O
psychopathy	B-MED
,	O
is	O
marked	B-MED
by	O
abnormalities	B-MED
in	O
approach-avoidance	B-MED
tendencies	B-MED
and	O
the	O
ability	B-MED
to	O
control	B-MED
them	O
.	O
	
key	B-MED
neural	B-MED
regions	B-MED
involved	B-MED
in	O
the	O
regulation	B-MED
of	O
approach-avoidance	B-MED
behavior	I-MED
are	O
the	O
amygdala	B-MED
,	O
widely	O
implicated	B-MED
in	O
automatic	B-MED
emotional	B-MED
processing	B-MED
,	O
and	O
the	O
anterior	B-MED
prefrontal	B-MED
cortex	I-MED
,	O
which	O
exerts	B-MED
control	B-MED
over	O
the	O
amygdala	B-MED
.	O
	
hormones	B-MED
,	O
especially	O
testosterone	B-MED
and	O
cortisol	B-MED
,	O
have	O
been	O
shown	O
to	O
affect	B-MED
approach-avoidance	B-MED
behavior	I-MED
and	O
the	O
associated	B-MED
neural	B-MED
mechanisms	B-MED
.	O
	
the	O
present	B-MED
chapter	B-MED
also	O
discusses	O
ways	O
to	O
directly	B-MED
influence	B-MED
social	B-MED
approach	B-MED
and	I-MED
avoidance	I-MED
behavior	I-MED
and	O
will	O
end	O
with	O
a	O
research	B-MED
agenda	B-MED
to	O
further	O
advance	B-MED
this	O
important	B-MED
research	B-MED
field	I-MED
.	O
	
control	B-MED
over	O
approach-avoidance	B-MED
tendencies	B-MED
may	O
serve	O
as	O
an	O
exemplar	B-MED
of	O
emotional	B-MED
action	B-MED
regulation	B-MED
and	O
might	O
have	O
a	O
great	B-MED
value	B-MED
in	O
understanding	B-MED
the	O
underlying	O
mechanisms	B-MED
of	O
the	O
development	B-MED
of	O
affective	B-MED
disorders	I-MED
.	O
	
high	O
occurrence	O
of	O
non-clear	B-MED
cell	I-MED
renal	I-MED
cell	I-MED
carcinoma	I-MED
in	O
oman	B-MED
it	O
is	O
conventionally	O
accepted	O
that	O
renal	B-MED
cell	I-MED
carcinoma	I-MED
rcc	B-MED
occurs	O
in	O
older	B-MED
patients	I-MED
and	O
the	O
clear	B-MED
cell	I-MED
type	I-MED
is	O
the	O
most	O
common	O
histology	B-MED
.	O
	
however	O
,	O
ethnic	B-MED
variations	I-MED
exist	O
and	O
this	O
study	B-MED
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	B-MED
pattern	I-MED
of	O
rcc	B-MED
in	O
oman	B-MED
.	O
	
ninety	O
rcc	B-MED
patients	B-MED
who	O
presented	B-MED
to	O
a	O
tertiary	B-MED
care	I-MED
center	I-MED
in	O
the	O
sultanate	B-MED
of	I-MED
oman	I-MED
from	O
2010	O
to	O
2014	O
were	O
studied	B-MED
.	O
	
the	O
main	B-MED
findings	I-MED
were	O
that	O
the	O
median	B-MED
age	I-MED
of	O
presentation	B-MED
was	O
low	B-MED
,	O
more	O
patients	B-MED
presented	B-MED
with	O
localized	B-MED
stage	B-MED
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non-clear	B-MED
especially	O
papillary	B-MED
histology	B-MED
.	O
	
data	B-MED
from	O
other	O
gulf	B-MED
countries	I-MED
patient	B-MED
mobility	I-MED
for	O
elective	B-MED
secondary	B-MED
health	I-MED
care	I-MED
services	I-MED
in	O
response	B-MED
to	O
patient	B-MED
choice	I-MED
policies	I-MED
a	O
systematic	B-MED
review	I-MED
our	O
review	O
establishes	O
the	O
empirical	B-MED
evidence	B-MED
for	O
patient	B-MED
mobility	I-MED
for	O
elective	B-MED
secondary	I-MED
care	I-MED
services	I-MED
in	O
countries	B-MED
that	O
allow	O
patients	B-MED
to	O
choose	O
their	O
health	B-MED
care	I-MED
provider	I-MED
.	O
	
pubmed	B-MED
and	O
embase	B-MED
were	O
searched	O
for	O
relevant	O
articles	B-MED
between	O
1990	O
and	O
2015	O
.	O
	
of	O
5	O
titles	B-MED
/	O
abstracts	B-MED
reviewed	B-MED
,	O
26	O
studies	B-MED
were	O
included	O
.	O
	
the	O
studies	B-MED
used	O
three	O
main	O
methodological	B-MED
models	B-MED
to	O
establish	O
mobility	B-MED
.	O
	
variation	B-MED
in	O
the	O
extent	O
of	O
patient	B-MED
mobility	I-MED
was	O
observed	O
across	O
the	O
studies	O
.	O
	
mobility	B-MED
was	O
positively	O
associated	B-MED
with	I-MED
lower	B-MED
waiting	I-MED
times	I-MED
,	O
indicators	B-MED
of	O
better	B-MED
service	I-MED
quality	I-MED
,	O
and	O
access	O
to	O
advanced	B-MED
technology	I-MED
.	O
	
it	O
was	O
negatively	O
associated	O
with	O
advanced	B-MED
age	I-MED
or	O
lower	O
socioeconomic	B-MED
backgrounds	O
.	O
	
from	O
a	O
policy	B-MED
perspective	B-MED
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	B-MED
of	O
patients	B-MED
are	O
prepared	O
to	O
travel	B-MED
beyond	O
their	O
nearest	O
provider	B-MED
for	O
elective	B-MED
services	I-MED
.	O
	
as	O
a	O
consequence	O
,	O
some	O
providers	B-MED
are	O
likely	O
to	O
be	O
""""	O
winners	B-MED
""""	O
and	O
others	O
""""	O
losers	B-MED
""""	O
which	O
could	O
result	O
in	O
overall	O
decreased	B-MED
provider	B-MED
capacity	B-MED
or	O
inefficient	B-MED
utilization	O
of	O
existing	O
services	B-MED
.	O
	
equity	B-MED
new	B-MED
breast	B-MED
pain	I-MED
chart	B-MED
for	O
objective	B-MED
record	I-MED
of	O
mastalgia	B-MED
mastalgia	B-MED
is	O
the	O
commonest	B-MED
affliction	B-MED
of	O
mammary	B-MED
gland	I-MED
among	O
ladies	B-MED
of	O
the	O
reproductive	B-MED
age	B-MED
group	I-MED
.	O
	
since	O
etiopathogenesis	B-MED
and	O
therapy	B-MED
are	O
different	B-MED
for	O
cyclical	B-MED
and	O
noncyclical	B-MED
pain	I-MED
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O
	
this	O
is	O
usually	O
done	O
in	O
the	O
breast	B-MED
clinics	I-MED
by	O
advising	O
the	O
patient	B-MED
to	O
fill	O
a	O
pain	B-MED
diary	I-MED
over	O
a	O
period	B-MED
of	O
2	O
months	B-MED
over	O
two	O
menstrual	B-MED
cycles	I-MED
.	O
	
the	O
cardiff	B-MED
pain	I-MED
chart	I-MED
records	I-MED
the	O
severity	B-MED
of	O
pain	B-MED
in	O
the	O
form	O
of	O
a	O
triangle	B-MED
for	O
mild	B-MED
to	O
moderate	B-MED
pain	I-MED
and	O
a	O
square	B-MED
for	O
severe	B-MED
pain	I-MED
.	O
	
moreover	O
,	O
cardiff	B-MED
pain	I-MED
chart	I-MED
does	O
not	O
allow	O
a	O
patient	B-MED
to	O
record	B-MED
the	O
severity	B-MED
of	O
pain	B-MED
on	O
days	B-MED
of	O
menses	B-MED
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"""p"""	O
in	O
the	O
box	O
.	O
	
these	O
problems	B-MED
have	O
been	O
resolved	B-MED
in	O
the	O
new	B-MED
breast	B-MED
pain	I-MED
chart	B-MED
.	O
	
in	O
the	O
new	B-MED
pain	B-MED
chart	I-MED
,	O
the	O
lady	B-MED
records	B-MED
pain	B-MED
severity	B-MED
in	O
the	O
form	O
of	O
visual	B-MED
linear	I-MED
analogue	I-MED
scale	I-MED
score	I-MED
on	O
every	B-MED
day	I-MED
of	O
menstrual	B-MED
cycle	I-MED
.	O
	
she	O
enters	O
her	O
menstrual	B-MED
experience	B-MED
on	O
a	O
separate	O
part	O
of	O
chart	B-MED
,	O
which	O
allows	O
us	O
to	O
visualize	B-MED
the	O
full	O
month's	B-MED
pain	B-MED
severity	B-MED
the	O
demand	O
for	O
cigarettes	B-MED
in	O
tanzania	B-MED
and	O
implications	B-MED
for	O
tobacco	B-MED
taxation	B-MED
policy	I-MED
the	O
study	B-MED
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-MED
in	O
tanzania	B-MED
and	O
presents	O
simulation	B-MED
results	B-MED
on	O
the	O
effect	B-MED
of	O
the	O
cigarette	B-MED
excise	B-MED
tax	I-MED
on	O
smoking	B-MED
participation	B-MED
,	O
government	B-MED
revenue	I-MED
,	O
and	O
related	O
topics	O
.	O
	
after	O
briefly	O
summarizing	O
the	O
magnitude	B-MED
and	O
spread	O
of	O
cigarette	B-MED
consumption	I-MED
in	O
the	O
country	B-MED
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
african	B-MED
and	O
other	O
countries	B-MED
.	O
	
the	O
2008	O
tanzanian	B-MED
household	B-MED
budget	I-MED
survey	B-MED
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-MED
in	O
tanzania	B-MED
.	O
	
the	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	B-MED
prevalence	O
for	O
tanzania	B-MED
is	O
15.35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	B-MED
income	I-MED
groups	I-MED
.	O
	
smoking	B-MED
intensity	O
and	O
per	B-MED
capita	I-MED
consumption	I-MED
were	O
estimated	O
at	O
7.08	O
cigarettes	B-MED
and	O
1.33	O
cigarettes	B-MED
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O
	
a	O
two-part	B-MED
demand	I-MED
equation	I-MED
model	I-MED
was	O
used	O
to	O
estimate	O
various	O
elasticities	B-MED
.	O
	
for	O
the	O
overall	O
equation	B-MED
,	O
the	O
price	B-MED
elasticities	I-MED
of	O
smoking	B-MED
participation	B-MED
,	O
smoking	B-MED
intensity	O
,	O
and	O
total	O
elasticity	B-MED
were	O
estimated	O
at	O
-0	O
,	O
-0	O
,	O
and	O
-1	O
,	O
respectively	O
.	O
	
compared	O
to	O
similar	O
results	O
in	O
other	O
developing	B-MED
countries	I-MED
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O
	
when	O
estimated	O
by	O
expenditure	B-MED
income	I-MED
groups	I-MED
,	O
the	O
magnitude	B-MED
of	O
the	O
elasticity	B-MED
appears	O
higher	O
among	O
high	B-MED
expenditure	I-MED
groups	I-MED
than	O
among	O
low	B-MED
expenditure	I-MED
groups	I-MED
.	O
	
two	O
simulation	B-MED
exercises	O
were	O
undertaken	O
.	O
	
first	O
,	O
the	O
effect	B-MED
of	O
different	O
excise	B-MED
rates	B-MED
on	O
smoking	B-MED
participation	B-MED
rate	I-MED
,	O
cigarette	B-MED
consumption	I-MED
,	O
tax	B-MED
revenue	I-MED
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O
	
second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	B-MED
of	O
a	O
given	O
increase	B-MED
in	O
the	O
cigarette	B-MED
excise	B-MED
tax	I-MED
on	O
various	O
expenditure	B-MED
groups	I-MED
.	O
	
the	O
overall	O
results	B-MED
suggest	O
that	O
an	O
increase	B-MED
in	O
the	O
excise	B-MED
tax	I-MED
on	O
cigarettes	B-MED
in	O
tanzania	B-MED
would	O
reduce	O
cigarette	B-MED
consumption	I-MED
and	O
increase	B-MED
government	B-MED
tax	I-MED
revenue	I-MED
.	O
	
physicians'	B-MED
knowledge	O
on	O
the	O
work-related	B-MED
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
copd	B-MED
may	O
be	O
induced	O
by	O
the	O
work	B-MED
environment	I-MED
conditions	B-MED
.	O
	
according	O
to	O
the	O
estimates	B-MED
,	O
10-20%	O
of	O
all	O
copd	B-MED
cases	B-MED
are	O
associated	B-MED
with	I-MED
occupational	B-MED
exposure	I-MED
to	O
dusts	B-MED
and	O
irritant	B-MED
gases	B-MED
.	O
	
however	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	B-MED
of	O
work-related	B-MED
copd	B-MED
were	O
recognized	O
in	O
poland	B-MED
.	O
	
the	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
analyze	B-MED
the	O
reasons	O
for	O
the	O
low	B-MED
incidence	B-MED
of	O
work-related	B-MED
copd	B-MED
in	O
the	O
context	B-MED
of	O
pulmonologists	B-MED
'	O
knowledge	O
about	O
occupational	B-MED
risk	B-MED
factors	I-MED
and	O
procedures	B-MED
on	O
reporting	B-MED
suspected	B-MED
occupational	B-MED
diseases	I-MED
.	O
	
a	O
survey	B-MED
included	O
94	O
pulmonologists	B-MED
randomly	B-MED
selected	O
out	O
of	O
225	O
specialists	B-MED
registered	O
at	O
the	O
local	B-MED
physicians	I-MED
chamber	I-MED
in	O
łódź	B-MED
.	O
	
the	O
study	B-MED
was	O
performed	B-MED
anonymously	B-MED
with	O
the	O
use	O
of	O
original	O
questionnaire	B-MED
.	O
	
more	O
than	O
a	O
half	O
of	O
the	O
surveyed	B-MED
pulmonologists	B-MED
identified	B-MED
environmental	B-MED
risk	B-MED
factors	I-MED
for	O
copd	B-MED
correctly	O
,	O
while	O
only	O
23.4	O
properly	O
identified	B-MED
the	O
main	O
occupational	B-MED
risk	B-MED
factors	I-MED
as	O
the	O
cause	B-MED
of	O
copd	B-MED
.	O
	
only	O
58.5	O
of	O
the	O
pulmonologists	B-MED
always	O
asked	O
their	O
patients	B-MED
suffering	B-MED
from	O
copd	B-MED
about	O
their	O
job	B-MED
/	O
profession	B-MED
and	O
60.6	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	B-MED
on	O
reporting	B-MED
suspected	B-MED
occupational	B-MED
diseases	I-MED
.	O
	
the	O
physicians	B-MED
rarely	B-MED
ask	O
patients	B-MED
suffering	B-MED
from	O
copd	B-MED
about	O
their	O
job	B-MED
/	O
profession	B-MED
and	O
the	O
relationship	B-MED
between	O
their	O
ailments	B-MED
and	O
occupational	B-MED
exposure	I-MED
.	O
	
what	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	B-MED
regulations	I-MED
on	O
proper	O
referral	B-MED
of	I-MED
a	I-MED
patient	I-MED
with	O
a	O
suspected	B-MED
case	B-MED
of	O
occupational	B-MED
disease	I-MED
.	O
	
the	O
results	B-MED
of	O
the	O
study	B-MED
clearly	O
indicate	B-MED
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	B-MED
pulmonologists	B-MED
'	O
knowledge	O
on	O
work-related	B-MED
copd	B-MED
.	O
	
case	B-MED
report	I-MED
of	O
necrotizing	B-MED
fasciitis	I-MED
associated	B-MED
with	I-MED
streptococcus	B-MED
pneumoniae	I-MED
necrotizing	B-MED
fasciitis	I-MED
,	O
caused	O
by	O
streptococcus	B-MED
pneumoniae	I-MED
,	O
is	O
an	O
extremely	B-MED
rare	I-MED
and	O
life-threatening	B-MED
bacterial	B-MED
soft	B-MED
tissue	I-MED
infection	I-MED
.	O
	
we	O
report	B-MED
a	O
case	B-MED
of	O
early	O
necrotizing	B-MED
fasciitis	I-MED
associated	B-MED
with	I-MED
streptococcus	B-MED
pneumoniae	I-MED
infection	B-MED
in	O
a	O
26-	O
year	B-MED
-old	O
man	B-MED
who	O
was	O
immunocompromised	B-MED
with	O
mixed	B-MED
connective	I-MED
tissue	I-MED
disease	I-MED
.	O
	
the	O
patient	B-MED
presented	O
with	O
acute	B-MED
,	O
painful	B-MED
,	O
erythematous	B-MED
,	O
and	O
edematous	B-MED
skin	I-MED
lesions	B-MED
of	O
his	O
right	B-MED
lower	I-MED
back	I-MED
,	O
which	O
rapidly	O
progressed	B-MED
to	O
the	O
right	B-MED
knee	I-MED
.	O
	
the	O
patient	B-MED
underwent	O
surgical	B-MED
exploration	I-MED
,	O
and	O
a	O
diagnosis	B-MED
of	O
necrotizing	B-MED
fasciitis	I-MED
was	O
confirmed	O
by	O
pathological	B-MED
evidence	B-MED
of	O
necrosis	B-MED
of	O
the	O
fascia	B-MED
and	O
neutrophil	B-MED
infiltration	I-MED
in	O
tissue	B-MED
biopsies	I-MED
.	O
	
cultures	B-MED
of	O
fascial	B-MED
tissue	B-MED
biopsies	I-MED
and	O
blood	B-MED
samples	I-MED
were	O
positive	B-MED
for	O
streptococcus	B-MED
pneumoniae	I-MED
.	O
	
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-MED
of	O
necrotizing	B-MED
fasciitis	I-MED
resulting	O
from	O
streptococcus	B-MED
pneumoniae	I-MED
diagnosed	B-MED
at	O
early	O
phase	B-MED
the	O
patient	B-MED
recovered	I-MED
well	O
without	O
surgical	B-MED
debridement	I-MED
.	O
	
a	O
comparative	B-MED
study	I-MED
of	O
the	O
efficacy	B-MED
of	O
iv	B-MED
dexketoprofen	B-MED
,	O
lornoxicam	B-MED
,	O
and	O
diclophenac	B-MED
sodium	I-MED
on	O
postoperative	B-MED
analgesia	I-MED
and	O
tramadol	B-MED
consumption	B-MED
in	O
patients	B-MED
receiving	O
patient-controlled	B-MED
tramadol	B-MED
this	O
study	B-MED
was	O
designed	B-MED
to	O
compare	B-MED
the	O
effects	B-MED
of	I-MED
dexketoprofen	B-MED
,	O
lornoxicam	B-MED
,	O
and	O
diclophenac	B-MED
sodium	I-MED
on	O
postoperative	B-MED
analgesia	I-MED
and	O
tramadol	B-MED
consumption	B-MED
in	O
patients	B-MED
receiving	O
postoperative	B-MED
patient-controlled	B-MED
tramadol	B-MED
after	O
a	O
major	B-MED
abdominal	B-MED
surgery	I-MED
.	O
	
eighty	O
patients	B-MED
were	O
randomized	B-MED
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-MED
drugs	B-MED
.	O
	
patients	B-MED
in	O
group	B-MED
dexketoprofen	B-MED
dt	B-MED
received	O
iv	B-MED
50	O
mg	O
dexketoprofen	B-MED
,	O
group	B-MED
lornoxicam	B-MED
lr	B-MED
received	O
iv	B-MED
8	O
mg	O
lornoxicam	B-MED
,	O
group	B-MED
diclophenac	B-MED
sodium	I-MED
ds	B-MED
received	O
75	O
mg	O
iv	B-MED
diclophenac	B-MED
sodium	I-MED
and	O
group	B-MED
saline	B-MED
s	B-MED
received	O
0.9	O
saline	B-MED
in	O
2	O
ml	O
syringes	B-MED
,	O
20	O
min	B-MED
before	O
the	O
end	O
of	O
anaesthesia	B-MED
.	O
	
a	O
standardized	B-MED
1	O
mg	O
kg	O
dose	B-MED
of	O
tramadol	B-MED
was	O
routinely	B-MED
administered	B-MED
to	O
all	O
patients	B-MED
as	O
the	O
loading	B-MED
dose	I-MED
at	O
the	O
end	O
of	O
surgery	B-MED
.	O
	
postoperatively	B-MED
,	O
whenever	O
patients	B-MED
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-MED
patient-controlled	B-MED
analgesia	I-MED
device	I-MED
giving	O
a	O
bolus	B-MED
dose	I-MED
0.2	O
mg	O
kg	O
of	O
tramadol	B-MED
.	O
	
pain	B-MED
,	O
discomfort	B-MED
,	O
and	O
sedation	B-MED
scores	B-MED
,	O
cumulative	B-MED
tramadol	B-MED
consumption	B-MED
,	O
supplemental	B-MED
meperidine	B-MED
requirement	B-MED
,	O
and	O
side	B-MED
effects	I-MED
were	O
recorded	O
.	O
	
visual	B-MED
rating	I-MED
scale	I-MED
and	O
patient	B-MED
discomfort	B-MED
scores	B-MED
were	O
significantly	B-MED
lower	B-MED
in	O
dt	B-MED
,	O
lr	B-MED
and	O
ds	B-MED
groups	B-MED
compared	O
to	O
those	O
in	O
in	O
group	B-MED
s	B-MED
p<0	O
.	O
	
cumulative	B-MED
tramadol	B-MED
consumption	B-MED
was	O
significantly	B-MED
lower	B-MED
in	O
non-steroidal	B-MED
anti-inflammatory	I-MED
drug	I-MED
nsaid	B-MED
treated	B-MED
groups	B-MED
at	O
each	O
study	B-MED
period	I-MED
after	O
the	O
second	O
postoperative	B-MED
hour	B-MED
than	O
in	O
group	B-MED
s	B-MED
p<0	O
.	O
	
supplemental	B-MED
meperidine	B-MED
requirement	B-MED
was	O
significantly	B-MED
higher	O
in	O
group	B-MED
s	B-MED
at	O
each	O
study	B-MED
period	I-MED
after	O
postoperative	B-MED
30	O
min	B-MED
than	O
in	O
nsaid	B-MED
-	O
treated	B-MED
groups	B-MED
p<0	O
.	O
	
after	O
major	B-MED
abdominal	B-MED
surgery	I-MED
,	O
adding	O
iv	B-MED
diclophenac	B-MED
,	O
lornoxicam	B-MED
or	O
dexketoprofen	B-MED
to	O
patient-controlled	B-MED
tramadol	B-MED
resulted	O
in	O
lower	B-MED
pain	B-MED
scores	B-MED
,	O
smaller	B-MED
tramadol	B-MED
consumption	B-MED
,	O
less	O
rescue	O
supplemental	B-MED
analgesic	B-MED
requirement	B-MED
,	O
and	O
fewer	O
side	B-MED
effects	I-MED
compared	O
with	O
the	O
tramadol	B-MED
alone	O
perioperative	B-MED
management	I-MED
of	O
severe	B-MED
hypertension	I-MED
during	O
laparoscopic	B-MED
surgery	I-MED
for	O
pheochromocytoma	B-MED
phaeochromocytoma	B-MED
is	O
a	O
catecholamine-secreting	B-MED
vascular	B-MED
tumour	I-MED
that	O
is	O
derived	O
from	O
chromaffin	B-MED
cell	I-MED
.	O
	
lethal	B-MED
cardiovascular	B-MED
complications	I-MED
,	O
such	O
as	O
serious	O
hypertension	B-MED
,	O
myocardial	B-MED
infarction	I-MED
and	O
aortic	B-MED
dissection	I-MED
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-MED
catecholamine	I-MED
release	I-MED
.	O
	
each	O
stage	B-MED
of	O
anaesthesia	B-MED
management	I-MED
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-MED
catecholamine	I-MED
secretion	I-MED
that	O
may	O
occur	O
during	O
induction	B-MED
,	O
perioperative	B-MED
stage	I-MED
and	O
surgical	B-MED
manipulation	I-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-MED
preparation	I-MED
and	O
severe	B-MED
,	O
persistent	I-MED
hypertension	I-MED
attack	I-MED
management	I-MED
with	O
a	O
combination	O
of	O
α-adrenergic	B-MED
blockade	I-MED
,	O
β-adrenergic	B-MED
blockade	I-MED
,	O
sodium	B-MED
nitroprusside	I-MED
and	O
remifentanil	B-MED
in	O
a	O
patient	B-MED
who	O
underwent	O
laparoscopic	B-MED
surgery	I-MED
for	O
a	O
case	B-MED
based	O
reflection	B-MED
on	O
communicating	B-MED
end	I-MED
of	O
life	B-MED
information	B-MED
in	O
non-english	B-MED
speaking	I-MED
patients	B-MED
mr	O
x	O
was	O
a	O
56	O
year	B-MED
old	I-MED
chinese	B-MED
man	B-MED
non-english	B-MED
speaking	I-MED
,	O
who	O
presented	O
to	O
the	O
emergency	B-MED
department	I-MED
with	O
a	O
range	O
of	O
non-specific	B-MED
symptoms	B-MED
.	O
	
on	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-MED
with	O
an	O
advanced	B-MED
cancer	I-MED
of	I-MED
the	I-MED
pancreas	I-MED
.	O
	
it	O
was	O
an	O
aggressive	B-MED
,	O
highly	O
treatment	B-MED
resistant	I-MED
cancer	I-MED
,	O
with	O
an	O
alarmingly	O
poor	B-MED
prognosis	I-MED
.	O
	
before	O
the	O
diagnosis	B-MED
had	O
been	O
made	O
,	O
the	O
family	B-MED
had	O
informed	O
our	O
team	B-MED
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	B-MED
issues	B-MED
with	O
mr	O
x	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-MED
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O
	
they	O
reported	O
that	O
mr	O
x	O
was	O
in	O
support	B-MED
of	O
this	O
arrangement	O
.	O
	
eventually	O
we	O
told	O
the	O
family	B-MED
about	O
mr	O
x's	O
diagnosis	B-MED
,	O
and	O
they	O
asserted	O
their	O
collective	B-MED
will	I-MED
to	O
keep	O
this	O
information	B-MED
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	B-MED
discussion	B-MED
go	O
through	O
them	O
.	O
	
however	O
,	O
the	O
doctor	B-MED
in	I-MED
charge	I-MED
explained	O
the	O
diagnosis	B-MED
to	O
mr	O
x	O
using	O
an	O
interpreter	B-MED
while	O
his	O
family	B-MED
were	O
away	O
from	O
his	O
bed	B-MED
.	O
	
in	O
this	O
discussion	O
,	O
i	O
consider	O
this	O
case	B-MED
from	O
the	O
perspective	O
of	O
respecting	B-MED
patients'	I-MED
and	I-MED
families'	I-MED
preferences	I-MED
around	O
medical	B-MED
treatment	I-MED
and	I-MED
care	I-MED
.	O
	
difference-in-differences	B-MED
method	I-MED
in	O
comparative	B-MED
effectiveness	I-MED
research	I-MED
utility	O
with	O
unbalanced	B-MED
groups	I-MED
comparative	B-MED
effectiveness	I-MED
research	I-MED
cer	B-MED
often	O
includes	O
observational	B-MED
studies	I-MED
utilizing	O
administrative	B-MED
data	I-MED
.	O
	
multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
cer	B-MED
to	O
adjust	O
for	O
group	B-MED
differences	B-MED
,	O
including	O
difference-in-differences	B-MED
did	I-MED
estimation	I-MED
.	O
	
this	O
study	O
presents	O
did	B-MED
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B-MED
to	O
estimate	O
treatment	B-MED
outcomes	I-MED
in	O
the	O
cer	B-MED
setting	O
by	O
utilizing	O
the	O
marketscan	B-MED
databases	I-MED
for	O
multiple	B-MED
sclerosis	I-MED
ms	B-MED
patients	B-MED
receiving	O
different	O
therapies	B-MED
.	O
	
the	O
sample	O
included	O
6762	O
patients	B-MED
,	O
with	O
363	O
in	O
the	O
test	B-MED
cohort	I-MED
glatiramer	B-MED
acetate	I-MED
ga	B-MED
switched	B-MED
to	O
fingolimod	B-MED
fty	B-MED
and	O
6399	O
in	O
the	O
control	B-MED
cohort	I-MED
ga	B-MED
only	O
,	O
no	B-MED
switch	I-MED
from	O
a	O
us	B-MED
administrative	I-MED
claims	I-MED
database	I-MED
.	O
	
a	O
trend	B-MED
analysis	I-MED
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B-MED
to	O
the	O
mean	B-MED
and	O
to	O
compare	O
relapse	B-MED
rates	O
among	O
treatment	B-MED
cohorts	I-MED
.	O
	
did	B-MED
analysis	I-MED
was	O
used	O
to	O
enable	O
comparisons	B-MED
among	O
the	O
test	B-MED
and	O
control	B-MED
cohorts	I-MED
.	O
	
logistic	B-MED
regression	I-MED
was	O
used	O
to	O
estimate	O
the	O
probability	B-MED
of	O
relapse	B-MED
after	O
switching	B-MED
from	O
ga	B-MED
to	O
fty	B-MED
,	O
and	O
to	O
compare	B-MED
group	B-MED
differences	B-MED
in	O
the	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
index	B-MED
periods	I-MED
.	O
	
crude	O
did	B-MED
analysis	I-MED
showed	O
that	O
in	O
the	O
pre	B-MED
-	O
index	B-MED
period	I-MED
more	O
patients	B-MED
in	O
the	O
test	B-MED
cohort	I-MED
experienced	O
an	O
ms	B-MED
relapse	B-MED
and	O
had	O
a	O
higher	O
mean	B-MED
number	I-MED
of	O
relapses	B-MED
than	O
in	O
the	O
control	B-MED
cohort	I-MED
.	O
	
during	O
the	O
pre	B-MED
-	O
index	B-MED
period	I-MED
,	O
numeric	B-MED
and	O
relative	O
data	O
for	O
ms	B-MED
relapses	B-MED
in	O
patients	B-MED
in	O
the	O
test	B-MED
cohort	I-MED
were	O
significantly	O
higher	O
than	O
in	O
the	O
control	B-MED
cohort	I-MED
,	O
while	O
no	B-MED
significant	I-MED
between-	O
group	B-MED
differences	B-MED
emerged	O
during	O
the	O
post	B-MED
-	O
index	B-MED
period	I-MED
.	O
	
generalized	O
linear	B-MED
modeling	I-MED
with	O
did	B-MED
regression	B-MED
estimation	I-MED
showed	O
that	O
the	O
mean	O
number	O
of	O
ms	B-MED
relapses	B-MED
decreased	O
significantly	O
in	O
the	O
post	B-MED
-	O
index	B-MED
period	I-MED
among	O
patients	B-MED
in	O
the	O
test	B-MED
cohort	I-MED
compared	O
with	O
patients	B-MED
in	O
the	O
control	B-MED
cohort	I-MED
.	O
	
in	O
this	O
study	O
,	O
an	O
ms	B-MED
population	B-MED
was	O
utilized	O
to	O
demonstrate	O
how	O
did	B-MED
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-MED
effects	I-MED
in	O
a	O
heterogeneous	B-MED
population	B-MED
,	O
where	O
the	O
test	B-MED
and	O
control	B-MED
cohorts	I-MED
varied	O
greatly	O
.	O
	
the	O
results	O
show	O
that	O
did	B-MED
offers	O
a	O
robust	O
method	O
for	O
comparing	B-MED
diverse	B-MED
cohorts	B-MED
when	O
other	O
risk-adjustment	B-MED
methods	I-MED
metabolomic	B-MED
analysis	B-MED
of	O
glycerophospholipid	B-MED
signatures	O
of	O
inflammation	B-MED
treated	B-MED
with	I-MED
non-steroidal	B-MED
anti-inflammatory	I-MED
drugs	I-MED
-induced-	O
raw264.7	B-MED
cells	I-MED
using	O
1	B-MED
nmr	I-MED
and	O
u-hplc	B-MED
/	O
q-tof-ms	B-MED
non-destructive	B-MED
proton	I-MED
nuclear	I-MED
magnetic	I-MED
resonance	I-MED
1	I-MED
nmr	I-MED
spectroscopy	I-MED
and	O
highly	B-MED
sensitive	I-MED
ultra-performance	B-MED
liquid	I-MED
chromatography	I-MED
quadrupole	B-MED
time-of-flight	I-MED
mass	I-MED
spectrometry	I-MED
u-hplc	B-MED
/	O
q-tof-ms	B-MED
coupled	O
to	O
data	B-MED
processing	I-MED
methods	B-MED
were	O
applied	O
to	O
analyze	O
the	O
metabolic	B-MED
profiling	I-MED
changes	O
of	O
glycerophospholipids	B-MED
gpls	B-MED
in	O
raw264.7	B-MED
cells	I-MED
from	O
inflammation	B-MED
to	O
prognosis	B-MED
.	O
	
analysis	B-MED
of	O
1	B-MED
nmr	I-MED
was	O
shown	O
that	O
the	O
models	B-MED
were	O
grouped	B-MED
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	B-MED
.	O
	
based	O
on	O
the	O
highly	B-MED
simple	I-MED
,	O
accurate	B-MED
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
1	B-MED
nmr	I-MED
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	B-MED
drugs	I-MED
in	O
the	O
metabolic	B-MED
profiling	I-MED
of	O
gpls	B-MED
.	O
	
58	O
gpls	B-MED
were	O
identified	B-MED
by	O
u-hplc	B-MED
/	O
q-tof-ms	B-MED
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	B-MED
in	O
this	O
study	B-MED
compared	O
with	O
our	O
previous	O
results	O
.	O
	
in	O
addition	O
,	O
ten	O
potential	B-MED
biomarkers	B-MED
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-MED
pc	B-MED
16	O
and	O
18	O
changed	B-MED
consistently	O
in	O
three	O
drug-induced	B-MED
groups	B-MED
and	O
might	O
be	O
the	O
important	O
biomarkers	B-MED
.	O
	
compared	O
with	O
1	B-MED
nmr	I-MED
,	O
u-hplc	B-MED
/	O
q-tof-ms	B-MED
showed	O
higher	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-MED
of	O
biomarkers	B-MED
apart	O
from	O
the	O
deficiency	B-MED
of	O
time-consuming	B-MED
sample	B-MED
preparation	I-MED
steps	I-MED
and	O
unambiguous	O
metabolite	B-MED
identification	B-MED
.	O
	
therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	B-MED
of	O
gpls	B-MED
during	O
inflammation	B-MED
by	O
combining	O
1	B-MED
nmr	I-MED
spectroscopy	I-MED
with	O
u-hplc	B-MED
/	O
q-tof-ms	B-MED
.	O
	
the	O
metabolic	B-MED
profiling	I-MED
of	O
gpls	B-MED
provides	O
valuable	O
evidence	B-MED
for	O
inflammation	B-MED
diagnosis	B-MED
and	O
prognosis	B-MED
,	O
and	O
might	O
unravel	O
the	O
mechanisms	B-MED
involved	O
in	O
inflammation	B-MED
progression	B-MED
.	O
	
characterization	B-MED
of	O
novel	B-MED
deor-family	B-MED
member	B-MED
from	O
the	O
streptomyces	B-MED
ahygroscopicus	I-MED
strain	B-MED
ck-15	I-MED
that	O
acts	O
as	O
a	O
repressor	B-MED
of	O
morphological	B-MED
development	B-MED
wuyiencin	B-MED
is	O
produced	B-MED
by	O
streptomyces	B-MED
ahygroscopicus	I-MED
var	I-MED
.	O
	
wuyiensis	I-MED
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
china	B-MED
as	O
an	O
industrially	B-MED
produced	B-MED
biopesticide	B-MED
to	O
control	B-MED
various	O
fungal	B-MED
diseases	I-MED
.	O
	
although	O
its	O
mechanism	B-MED
of	O
action	B-MED
,	O
breeding	B-MED
,	O
and	O
fermentation	B-MED
had	O
been	O
extensively	O
characterized	B-MED
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	B-MED
functions	I-MED
that	O
affect	O
its	O
biosynthesis	B-MED
or	O
morphological	B-MED
development	B-MED
.	O
	
the	O
wysr3	B-MED
gene	I-MED
of	O
s	B-MED
.	O
	
ahygroscopicus	I-MED
strain	B-MED
ck-15	I-MED
,	O
a	O
novel	B-MED
member	B-MED
of	O
the	O
deor	B-MED
family	I-MED
of	O
regulatory	B-MED
genes	I-MED
,	O
was	O
assessed	B-MED
to	O
determine	O
its	O
function	B-MED
by	O
gene	B-MED
knockdown	I-MED
.	O
	
herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
deor	B-MED
family	I-MED
proteins	I-MED
derived	O
from	O
the	O
same	O
source	B-MED
are	O
likely	O
to	O
be	O
a	O
single	B-MED
branch	B-MED
in	O
a	O
phylogenetic	B-MED
tree	I-MED
and	O
show	O
that	O
wysr3	B-MED
acts	O
as	O
a	O
repressor	B-MED
for	O
its	O
morphological	B-MED
development	B-MED
without	O
effecting	O
wuyiencin	B-MED
production	B-MED
.	O
	
we	O
found	O
that	O
the	O
δwysr3	B-MED
strain	B-MED
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	B-MED
stage	B-MED
of	O
maximum	O
biomass	B-MED
at	O
60	O
h	O
,	O
which	O
is	O
12	O
h	O
faster	B-MED
than	O
the	O
wild-type	B-MED
strain	B-MED
.	O
	
in	O
the	O
industrial	B-MED
fermentation	B-MED
production	B-MED
process	B-MED
,	O
the	O
δwysr3	B-MED
strain	B-MED
can	O
reduce	B-MED
consumption	B-MED
and	O
save	O
both	O
time	B-MED
and	O
targeting	B-MED
the	O
ecology	B-MED
within	O
the	O
role	B-MED
of	O
the	O
gut-brain	B-MED
axis	I-MED
and	O
human	B-MED
microbiota	B-MED
in	O
drug	B-MED
addiction	I-MED
despite	O
major	B-MED
advances	I-MED
in	O
our	O
understanding	B-MED
of	O
the	O
brain	B-MED
using	B-MED
traditional	B-MED
neuroscience	I-MED
,	O
reliable	B-MED
and	O
efficacious	B-MED
treatments	B-MED
for	O
drug	B-MED
addiction	I-MED
have	O
remained	B-MED
elusive	I-MED
.	O
	
hence	O
,	O
the	O
time	B-MED
has	O
come	O
to	O
utilize	B-MED
novel	B-MED
approaches	B-MED
,	O
particularly	O
those	O
drawing	B-MED
upon	O
contemporary	B-MED
advances	B-MED
in	O
fields	B-MED
outside	O
of	O
established	B-MED
neuroscienc	B-MED
e	O
and	O
psychiatry	B-MED
.	O
	
put	O
another	O
way	O
,	O
the	O
time	B-MED
has	O
come	O
for	O
a	O
paradigm	B-MED
shift	I-MED
in	O
the	O
addiction	B-MED
sciences	B-MED
.	O
	
apropos	B-MED
,	O
a	O
revolution	B-MED
in	O
the	O
area	B-MED
of	O
human	B-MED
health	B-MED
is	O
underway	B-MED
,	O
which	O
is	O
occurring	B-MED
at	O
the	O
nexus	B-MED
between	O
enteric	B-MED
microbiology	B-MED
and	O
neuroscience	B-MED
.	O
	
it	O
has	O
become	O
increasingly	B-MED
clear	B-MED
that	O
the	O
human	B-MED
microbiota	B-MED
the	O
vast	O
ecology	B-MED
of	O
bacteria	B-MED
residing	B-MED
within	O
the	O
human	B-MED
organism	B-MED
,	O
plays	O
an	O
important	B-MED
role	B-MED
in	O
health	B-MED
and	O
disease	B-MED
.	O
	
this	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	B-MED
that	O
bacteria	B-MED
living	B-MED
in	O
the	O
human	B-MED
body	I-MED
approximately	B-MED
1kg	O
of	O
mass	B-MED
,	O
roughly	O
equivalent	B-MED
to	O
that	O
of	O
the	O
human	B-MED
brain	B-MED
outnumber	O
human	B-MED
cells	I-MED
10	O
to	O
1	O
.	O
	
while	O
advances	O
in	O
the	O
understanding	B-MED
of	O
the	O
role	B-MED
of	O
microbiota	B-MED
in	O
other	O
areas	B-MED
of	O
human	B-MED
health	B-MED
have	O
yielded	B-MED
intriguing	B-MED
results	B-MED
e.g	O
,	O
clostridium	B-MED
difficile	I-MED
,	O
irritable	B-MED
bowel	I-MED
syndrome	I-MED
,	O
autism	B-MED
,	O
etc	O
,	O
to	O
date	B-MED
,	O
no	O
systematic	B-MED
programs	B-MED
of	O
research	B-MED
have	O
examined	B-MED
the	O
role	B-MED
of	O
microbiota	B-MED
in	O
drug	B-MED
addiction	I-MED
.	O
	
the	O
current	B-MED
hypothesis	B-MED
,	O
therefore	O
,	O
is	O
that	O
gut	B-MED
dysbiosis	I-MED
plays	O
a	O
key	O
role	B-MED
in	O
addictive	B-MED
disorders	B-MED
.	O
	
in	O
the	O
context	B-MED
of	O
this	O
hypothesis	B-MED
,	O
this	O
paper	B-MED
provides	B-MED
a	O
rationale	B-MED
for	O
future	B-MED
research	B-MED
to	O
target	B-MED
the	O
""""	O
gut	B-MED
-	O
brain	B-MED
axis	B-MED
""""	O
in	O
addiction	B-MED
.	O
	
a	O
brief	O
background	B-MED
of	O
the	O
gut	B-MED
-	O
brain	B-MED
axis	B-MED
is	O
provided	B-MED
,	O
along	O
with	O
a	O
series	B-MED
of	O
hypothesis-driven	B-MED
ideas	B-MED
outlining	O
potential	B-MED
treatments	B-MED
for	O
addiction	B-MED
via	O
manipulations	B-MED
of	O
the	O
""""	O
ecology	B-MED
homogeneous	B-MED
synthesis	B-MED
of	O
ag	B-MED
nanoparticles	I-MED
-doped	O
water-soluble	B-MED
cellulose	I-MED
acetate	I-MED
for	O
versatile	B-MED
applications	B-MED
we	O
report	B-MED
a	O
facile	B-MED
and	O
efficient	B-MED
approach	B-MED
for	O
synthesis	B-MED
of	O
well-dispersed	B-MED
and	O
stable	B-MED
silver	B-MED
nanoparticles	I-MED
ag	B-MED
nps	I-MED
using	O
water-soluble	B-MED
cellulose	I-MED
acetate	I-MED
ca	B-MED
as	O
both	O
reductant	B-MED
and	O
stabilizer	B-MED
.	O
	
partially	B-MED
substituted	O
ca	B-MED
with	O
highly	B-MED
active	B-MED
hydroxyl	B-MED
groups	I-MED
and	O
excellent	B-MED
water-solubility	B-MED
is	O
able	B-MED
to	O
reduce	B-MED
silver	B-MED
ions	I-MED
in	O
homogeneous	B-MED
aqueous	B-MED
medium	B-MED
effectively	B-MED
.	O
	
the	O
synthesized	B-MED
ag	B-MED
nps	I-MED
were	O
characterized	B-MED
by	O
uv-vis	B-MED
spectroscopy	I-MED
,	O
x-ray	B-MED
diffraction	I-MED
,	O
x-ray	B-MED
photoelectron	I-MED
spectroscopy	I-MED
,	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
and	O
energy	B-MED
dispersive	I-MED
x-ray	I-MED
spectroscope	I-MED
analysis	B-MED
.	O
	
the	O
as-	O
prepared	B-MED
ag	B-MED
nps	I-MED
were	O
well-dispersed	B-MED
,	O
showing	O
a	O
surface	B-MED
plasmon	I-MED
resonance	I-MED
peak	B-MED
at	O
426	O
nm	B-MED
.	O
	
the	O
resulted	O
ag	B-MED
nps	I-MED
ca	B-MED
nanohybrids	B-MED
exhibit	O
high	B-MED
catalytic	B-MED
activity	I-MED
for	O
the	O
reduction	B-MED
of	O
4-nitrophenol	B-MED
to	O
4-aminophenol	B-MED
in	O
the	O
presence	O
of	O
nabh4	B-MED
.	O
	
meanwhile	O
,	O
the	O
nanohybrids	B-MED
are	O
also	O
effective	B-MED
in	O
inhibiting	B-MED
the	O
growth	B-MED
of	O
bacterial	B-MED
.	O
	
this	O
environmentally	B-MED
friendly	I-MED
method	I-MED
promotes	B-MED
the	O
use	B-MED
of	I-MED
renewable	B-MED
natural	I-MED
resources	I-MED
to	O
prepare	B-MED
a	O
variety	B-MED
of	O
inorganic-organic	B-MED
materials	I-MED
for	O
catalysis	B-MED
,	O
antibacterial	B-MED
,	O
sensors	B-MED
and	O
other	O
isx-9	B-MED
can	O
potentiate	O
cell	B-MED
proliferation	I-MED
and	O
neuronal	B-MED
commitment	B-MED
in	O
the	O
rat	B-MED
dentate	B-MED
gyrus	I-MED
adult	B-MED
hippocampal	B-MED
neurogenesis	B-MED
can	O
be	O
modulated	B-MED
by	O
various	O
physiological	B-MED
and	O
pathological	B-MED
conditions	I-MED
,	O
including	O
stress	B-MED
,	O
affective	B-MED
disorders	I-MED
,	O
and	O
several	O
neurological	B-MED
conditions	B-MED
.	O
	
given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	B-MED
plasticity	I-MED
in	O
the	O
functioning	B-MED
of	O
the	O
hippocampus	B-MED
namely	O
learning	B-MED
and	O
memory	B-MED
and	O
affective	B-MED
behaviors	B-MED
,	O
it	O
is	O
believed	O
that	O
alterations	B-MED
in	O
hippocampal	B-MED
neurogenesis	B-MED
might	O
underlie	O
some	O
of	O
the	O
behavioral	B-MED
deficits	B-MED
associated	B-MED
with	I-MED
these	O
psychiatric	B-MED
and	O
neurological	B-MED
conditions	B-MED
.	O
	
thus	O
,	O
the	O
search	B-MED
for	O
compounds	B-MED
that	O
can	O
reverse	B-MED
these	O
deficits	B-MED
with	O
minimal	B-MED
side	B-MED
effects	I-MED
has	O
become	O
a	O
recognized	O
priority	O
.	O
	
in	O
the	O
present	O
study	B-MED
we	O
tested	B-MED
the	O
pro-neurogenic	B-MED
effects	B-MED
of	O
isoxazole	B-MED
9	I-MED
isx-9	B-MED
,	O
a	O
small	O
synthetic	B-MED
molecule	B-MED
that	O
has	O
been	O
recently	O
identified	B-MED
through	O
the	O
screening	B-MED
of	I-MED
chemical	I-MED
libraries	I-MED
in	O
stem	B-MED
cell-based	I-MED
assays	I-MED
.	O
	
we	O
found	O
that	O
administration	B-MED
of	O
isx-9	B-MED
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	B-MED
proliferation	I-MED
and	O
increase	B-MED
the	O
number	B-MED
of	O
immature	B-MED
neurons	B-MED
in	O
the	O
hippocampal	B-MED
dg	B-MED
of	O
adult	B-MED
rats	B-MED
.	O
	
in	B-MED
addition	I-MED
,	O
isx-9	B-MED
treatment	B-MED
was	O
able	O
to	O
completely	B-MED
reverse	B-MED
the	O
marked	B-MED
reduction	B-MED
in	O
these	O
initial	B-MED
stages	B-MED
of	O
the	O
neurogenic	B-MED
process	I-MED
observed	B-MED
in	O
vehicle	B-MED
-	O
treated	B-MED
animals	B-MED
which	O
were	O
submitted	O
to	O
repeated	B-MED
handling	B-MED
and	O
exposure	B-MED
to	I-MED
daily	B-MED
intraperitoneal	B-MED
injections	I-MED
.	O
	
based	O
on	O
these	O
results	B-MED
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-MED
studies	B-MED
that	O
require	O
repeated	B-MED
handling	B-MED
and	O
manipulation	B-MED
of	O
animals	B-MED
should	O
include	O
a	O
naïve	O
non-manipulated	O
control	B-MED
to	O
determine	O
the	O
baseline	B-MED
levels	B-MED
of	O
hippocampal	B-MED
cell	B-MED
proliferation	I-MED
and	O
neuronal	B-MED
differentiation	B-MED
.	O
	
overall	O
,	O
these	O
findings	B-MED
demonstrate	O
that	O
isx-9	B-MED
is	O
a	O
promising	O
synthetic	B-MED
compound	B-MED
for	O
the	O
mitigation	B-MED
of	O
stress	B-MED
-	O
induced	B-MED
deficits	B-MED
in	O
adult	B-MED
hippocampal	B-MED
neurogenesis	B-MED
.	O
	
future	O
studies	B-MED
are	O
thus	O
warranted	O
to	O
evaluate	B-MED
the	O
pro-neurogenic	B-MED
properties	B-MED
of	O
isx-9	B-MED
in	O
animal	B-MED
models	I-MED
of	O
affective	B-MED
and	O
neurological	B-MED
disorders	I-MED
associated	B-MED
with	I-MED
impaired	B-MED
hippocampal	B-MED
structural	B-MED
plasticity	I-MED
.	O
	
changes	B-MED
in	O
parenting	B-MED
strategies	B-MED
after	O
a	O
young	B-MED
person's	B-MED
self-harm	B-MED
a	O
qualitative	B-MED
study	I-MED
when	O
faced	O
with	O
the	O
discovery	B-MED
of	O
their	O
child's	B-MED
self-harm	B-MED
,	O
mothers	B-MED
and	O
fathers	B-MED
may	O
re-evaluate	B-MED
their	O
parenting	B-MED
strategies	B-MED
.	O
	
this	O
can	O
include	O
changes	B-MED
to	O
the	O
amount	O
of	O
support	B-MED
they	O
provide	O
their	O
child	B-MED
and	O
changes	B-MED
to	O
the	O
degree	B-MED
to	O
which	O
they	O
control	B-MED
and	O
monitor	B-MED
their	O
child	B-MED
.	O
	
we	O
conducted	O
an	O
in-depth	B-MED
qualitative	I-MED
study	I-MED
with	O
37	O
parents	B-MED
of	O
young	B-MED
people	B-MED
who	O
had	O
self-harmed	B-MED
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	B-MED
changed	B-MED
after	O
the	O
discovery	B-MED
of	O
self-harm	B-MED
.	O
	
early	B-MED
on	O
,	O
parents	B-MED
often	O
found	O
themselves	O
"""walking"	O
on	O
"eggshells"""	O
so	O
as	O
not	O
to	O
upset	B-MED
their	O
child	B-MED
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	B-MED
.	O
	
parents	B-MED
'	O
reactions	B-MED
to	O
the	O
self-harm	B-MED
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
as	O
part	O
of	O
adolescence	B-MED
,	O
as	O
a	O
mental	B-MED
health	I-MED
issue	I-MED
or	O
as	O
""""	O
naughty	B-MED
behaviour	I-MED
""""	O
.	O
	
parenting	B-MED
of	O
other	O
children	B-MED
in	O
the	O
family	B-MED
could	O
also	O
be	O
affected	O
,	O
with	O
parents	B-MED
worrying	O
about	O
less	O
of	O
their	O
time	B-MED
being	O
available	O
for	O
siblings	B-MED
.	O
	
many	O
parents	B-MED
developed	O
specific	O
strategies	B-MED
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	B-MED
,	O
such	O
as	O
learning	B-MED
to	O
avoid	O
blaming	B-MED
themselves	O
or	O
their	O
child	B-MED
for	O
the	O
self-harm	B-MED
and	O
developing	O
new	O
ways	O
to	O
communicate	B-MED
with	O
their	O
child	B-MED
.	O
	
parents	B-MED
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	B-MED
on	O
to	O
other	O
people	B-MED
in	O
the	O
same	O
situation	B-MED
.	O
	
parents	B-MED
reported	O
changes	B-MED
in	O
their	O
parenting	B-MED
behaviours	B-MED
after	O
the	O
discovery	B-MED
of	O
a	O
child	B-MED
's	O
self-harm	B-MED
.	O
	
professionals	B-MED
involved	O
in	O
the	O
care	B-MED
of	O
young	B-MED
people	B-MED
who	O
self-harm	B-MED
might	O
use	O
this	O
information	B-MED
in	O
supporting	B-MED
and	O
advising	B-MED
parents	B-MED
.	O
	
optimizing	B-MED
survival	B-MED
of	O
patients	B-MED
with	O
marginally	B-MED
operable	I-MED
stage	B-MED
iiia	I-MED
non-small-cell	I-MED
lung	I-MED
cancer	I-MED
receiving	O
chemoradiotherapy	B-MED
with	B-MED
or	O
without	B-MED
surgery	B-MED
for	O
marginally	B-MED
operable	I-MED
stage	B-MED
iiia	I-MED
non-small-cell	I-MED
lung	I-MED
cancer	I-MED
nsclc	B-MED
,	O
surgery	B-MED
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-MED
concurrent	B-MED
chemoradiotherapy	I-MED
ccrt	B-MED
for	O
reasons	O
unresectable	B-MED
or	O
medically	B-MED
inoperable	I-MED
conditions	B-MED
,	O
or	O
patient	B-MED
refusal	I-MED
.	O
	
this	O
study	B-MED
aims	O
to	O
investigate	B-MED
the	O
outcomes	B-MED
of	O
a	O
phased	B-MED
ccrt	I-MED
protocol	I-MED
established	O
to	O
maximize	O
the	O
operability	B-MED
of	O
marginally	B-MED
operable	I-MED
stage	B-MED
iiia	I-MED
nsclc	I-MED
and	O
to	O
care	O
for	O
reassessed	B-MED
inoperable	B-MED
patients	I-MED
,	O
in	O
comparison	O
with	O
continuous-course	B-MED
definitive	I-MED
ccrt	I-MED
.	O
	
forty-seven	O
patients	B-MED
with	O
marginally	B-MED
operable	I-MED
stage	B-MED
iiia	I-MED
nsclc	I-MED
receiving	O
ccrt	B-MED
were	O
included	O
.	O
	
twenty-eight	O
patients	B-MED
were	O
treated	B-MED
with	O
our	O
phased	B-MED
ccrt	I-MED
protocol	I-MED
,	O
including	O
neoadjuvant	B-MED
ccrt	B-MED
followed	O
by	O
surgery	B-MED
group	B-MED
a	I-MED
,	O
n	O
=	O
16	O
or	O
,	O
for	O
reassessed	B-MED
inoperable	B-MED
patients	I-MED
,	O
maintenance	O
chemotherapy	O
and	O
split-course	O
ccrt	O
boost	O
group	O
b	O
,	O
n	O
=	O
12	O
.	O
	
the	O
other	O
19	O
were	O
treated	O
with	O
continuous-course	O
definitive	O
ccrt	O
group	O
c	O
.	O
	
overall	O
survival	O
os	O
and	O
progression-free	O
survival	O
pfs	O
were	O
analyzed	O
.	O
	
among	O
all	O
,	O
median	O
os	O
and	O
pfs	O
were	O
35.6	O
and	O
12.8	O
months	O
,	O
respectively	O
median	O
follow-up	O
,	O
22.3	O
months	O
.	O
	
the	O
median	O
os	O
of	O
group	O
a	O
not	O
reached	O
was	O
better	O
than	O
that	O
of	O
group	O
b	O
34.4	O
months	O
and	O
group	O
c	O
15.2	O
months	O
p	O
=	O
009	O
.	O
	
on	O
multivariate	O
analysis	O
,	O
performance	O
status	O
0	O
to	O
1	O
hazard	O
ratio	O
hr	O
,	O
0.026	O
p	O
<	O
001	O
,	O
adenocarcinoma	O
hr	O
,	O
0.156	O
p	O
=	O
003	O
,	O
and	O
group	O
a	O
hr	O
,	O
0.199	O
p	O
=	O
033	O
were	O
independent	O
prognostic	O
factors	O
.	O
	
the	O
os	O
of	O
group	O
b	O
hr	O
,	O
0.450	O
95%	O
confidence	O
interval	O
,	O
0.118	O
p	O
=	O
243	O
was	O
not	O
statistically	O
different	O
from	O
that	O
of	O
group	O
c	O
.	O
	
for	O
marginally	O
operable	O
stage	O
iiia	O
nsclc	O
,	O
our	O
phased	O
ccrt	O
strategy	O
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	B-MED
by	O
split-course	O
ccrt	O
boost	O
following	O
maintenance	B-MED
chemotherapy	I-MED
.	O
	
evaluation	O
of	O
three	B-MED
protein-extraction	B-MED
methods	I-MED
for	O
proteome	B-MED
analysis	B-MED
of	O
maize	B-MED
leaf	B-MED
midrib	B-MED
,	O
a	O
compound	B-MED
tissue	I-MED
rich	O
in	O
sclerenchyma	B-MED
cells	I-MED
leaf	B-MED
morphology	B-MED
is	O
closely	O
related	O
to	O
the	O
growth	B-MED
and	I-MED
development	I-MED
of	O
maize	B-MED
zea	I-MED
mays	I-MED
l	I-MED
plants	I-MED
and	O
final	O
kernel	B-MED
production	O
.	O
	
as	O
an	O
important	O
part	O
of	O
the	O
maize	B-MED
leaf	B-MED
,	O
the	O
midrib	B-MED
holds	O
leaf	B-MED
blades	O
in	O
the	O
aerial	B-MED
position	I-MED
for	O
maximum	O
sunlight	B-MED
capture	O
.	O
	
leaf	B-MED
midrib	B-MED
s	O
of	O
adult	B-MED
plants	B-MED
contain	O
substantial	O
sclerenchyma	B-MED
cells	I-MED
with	O
heavily	B-MED
thickened	I-MED
and	O
lignified	B-MED
secondary	B-MED
walls	I-MED
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-MED
,	O
making	O
protein	B-MED
extraction	I-MED
and	O
proteome	B-MED
analysis	B-MED
difficult	O
in	O
leaf	B-MED
midrib	B-MED
tissue	O
.	O
	
in	O
the	O
present	O
study	O
,	O
three	O
protein-extraction	B-MED
methods	I-MED
that	O
are	O
commonly	O
used	O
in	O
plant	B-MED
proteomics	B-MED
,	O
i.e	O
,	O
phenol	B-MED
extraction	B-MED
,	O
tca	B-MED
/	O
acetone	B-MED
extraction	B-MED
,	O
and	O
tca	B-MED
/	O
acetone	B-MED
/	O
phenol	B-MED
extraction	B-MED
,	O
were	O
qualitatively	B-MED
and	O
quantitatively	B-MED
evaluated	I-MED
based	O
on	O
2de	O
maps	O
and	O
ms/ms	B-MED
analysis	I-MED
using	O
the	O
midribs	B-MED
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-MED
of	O
maize	B-MED
plants	I-MED
.	O
	
microscopy	B-MED
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-MED
underneath	O
maize	B-MED
midrib	B-MED
epidermises	B-MED
particularly	O
abaxial	B-MED
epidermises	B-MED
.	O
	
the	O
spot-number	O
order	O
obtained	O
via	O
2de	B-MED
mapping	I-MED
was	O
as	O
follows	O
phenol	B-MED
extraction	B-MED
655	O
>	O
tca	B-MED
/	O
acetone	B-MED
extraction	B-MED
589	O
>	O
tca	B-MED
/	O
acetone	B-MED
/	O
phenol	B-MED
extraction	B-MED
545	O
.	O
	
ms/ms	B-MED
analysis	I-MED
identified	O
a	O
total	O
of	O
17	O
spots	B-MED
that	O
exhibited	O
2-fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	B-MED
methods	O
using	O
phenol	B-MED
extraction	B-MED
as	O
a	O
control	B-MED
.	O
	
sixteen	O
of	O
the	O
proteins	B-MED
identified	O
were	O
hydrophilic	B-MED
,	O
with	O
gravy	B-MED
values	I-MED
ranging	O
from	O
-0	O
to	O
-0	O
.	O
	
for	O
all	O
three	B-MED
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high-quality	O
protein	B-MED
samples	O
and	O
good	O
2de	B-MED
maps	I-MED
for	O
the	O
maize	B-MED
leaf	B-MED
midrib	B-MED
.	O
	
however	O
,	O
phenol	B-MED
extraction	B-MED
produced	O
a	O
better	O
2de	B-MED
map	I-MED
with	O
greater	O
resolution	B-MED
between	O
spots	B-MED
,	O
and	O
tca	B-MED
/	O
acetone	B-MED
extraction	B-MED
produced	O
higher	O
protein	B-MED
yields	B-MED
.	O
	
thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	B-MED
protein	B-MED
extraction	I-MED
among	O
the	O
three	B-MED
methods	O
.	O
	
this	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-MED
extraction	I-MED
methods	O
for	O
the	O
proteome	B-MED
analysis	B-MED
of	O
recalcitrant	O
plant	B-MED
tissues	I-MED
that	O
are	O
rich	O
in	O
sclerenchyma	B-MED
cells	I-MED
.	O
	
dominant	B-MED
and	O
non-	O
dominant	B-MED
frequency	B-MED
structure	O
of	O
evoked	B-MED
ventricular	B-MED
fibrillation	I-MED
in	O
dogs	B-MED
with	O
myocardial	B-MED
ischemia	I-MED
the	O
first	O
10	O
min	O
of	O
electrically	B-MED
provoked	I-MED
ventricular	B-MED
fibrillation	I-MED
in	O
dogs	B-MED
with	O
ischemic	B-MED
heart	I-MED
disease	I-MED
were	O
characterized	B-MED
by	O
organized	B-MED
myocardial	B-MED
activity	I-MED
evidenced	O
by	O
the	O
dominant	B-MED
ecg	I-MED
frequency	I-MED
structure	O
.	O
	
during	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-MED
fibrillation	I-MED
,	O
low-frequency	B-MED
oscillations	I-MED
4-7	O
hz	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-MED
,	O
the	O
dominant	B-MED
frequencies	I-MED
were	O
low	B-MED
and	O
medium	B-MED
4-12	O
hz	O
.	O
	
after	O
10-min	O
fibrillation	B-MED
,	O
the	O
oscillations	B-MED
became	O
non-	O
dominant	B-MED
.	O
	
thus	O
,	O
ischemic	B-MED
myocardium	I-MED
maintains	B-MED
the	O
organized	B-MED
structure	I-MED
of	O
ventricular	B-MED
fibrillation	I-MED
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	B-MED
of	O
automatic	B-MED
diagnostics	I-MED
of	O
abnormal	B-MED
cardiac	I-MED
activity	I-MED
in	O
adverse	B-MED
events	I-MED
risk	B-MED
associated	B-MED
with	I-MED
angiogenesis	B-MED
inhibitors	I-MED
addition	O
to	O
therapy	B-MED
in	O
ovarian	B-MED
cancer	I-MED
a	O
meta-analysis	B-MED
of	O
randomized	B-MED
controlled	I-MED
trials	I-MED
inhibition	B-MED
of	I-MED
angiogenesis	I-MED
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-MED
strategy	I-MED
for	O
advanced	B-MED
or	O
recurrent	B-MED
ovarian	I-MED
cancer	I-MED
.	O
	
we	O
conduct	O
this	O
meta-analysis	B-MED
to	O
investigate	B-MED
the	O
risk	B-MED
of	O
adverse	B-MED
events	I-MED
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-MED
inhibitors	I-MED
ais	B-MED
in	O
ovarian	B-MED
cancer	I-MED
.	O
	
databases	B-MED
from	O
pubmed	B-MED
,	O
web	B-MED
of	I-MED
science	I-MED
and	O
cochrane	B-MED
library	I-MED
up	O
to	O
december	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	B-MED
studies	B-MED
.	O
	
eligible	O
studies	B-MED
included	O
prospective	B-MED
randomized	I-MED
controlled	I-MED
phase	I-MED
ii/iii	I-MED
clinical	I-MED
trials	I-MED
evaluating	B-MED
therapy	B-MED
with	O
or	O
without	O
ais	B-MED
for	O
ovarian	B-MED
cancer	I-MED
.	O
	
summary	O
relative	B-MED
risk	I-MED
rr	B-MED
and	O
95%	O
confidence	B-MED
intervals	I-MED
cis	B-MED
were	O
calculated	B-MED
using	O
random-effects	B-MED
or	O
fixed-effects	B-MED
according	O
to	O
the	O
heterogeneity	B-MED
among	O
included	O
trials	B-MED
.	O
	
a	O
total	O
of	O
7	O
patients	B-MED
from	O
ten	O
clinical	B-MED
trials	I-MED
were	O
included	O
in	O
the	O
meta-analysis	B-MED
.	O
	
pooled	B-MED
rr	B-MED
showed	O
that	O
the	O
use	B-MED
of	I-MED
ais	B-MED
was	O
associated	B-MED
with	I-MED
a	O
statistically	O
increased	B-MED
risk	B-MED
in	O
four	O
of	O
the	O
adverse	B-MED
outcomes	B-MED
studied	O
arterial	B-MED
thromboembolic	I-MED
events	B-MED
rr	B-MED
=	O
2.0	O
,	O
gastrointestinal	B-MED
gi	I-MED
perforation	I-MED
rr	B-MED
=	O
3.86	O
,	O
proteinuria	B-MED
rr	B-MED
=	O
2.44	O
,	O
and	O
hypertension	B-MED
rr	B-MED
=	O
5.39	O
.	O
	
no	B-MED
statistically	I-MED
significant	I-MED
differences	B-MED
were	O
found	O
for	O
hemorrhagic	B-MED
events	B-MED
p	O
=	O
0.07	O
,	O
venous	B-MED
thromboembolic	I-MED
events	B-MED
p	O
=	O
0.13	O
,	O
or	O
fatal	B-MED
adverse	B-MED
events	I-MED
p	O
=	O
0.26	O
.	O
	
the	O
addition	O
of	O
ais	B-MED
to	O
therapy	B-MED
in	O
ovarian	B-MED
cancer	I-MED
did	O
significantly	O
increase	B-MED
the	O
risk	B-MED
of	O
arterial	B-MED
thromboembolic	I-MED
events	B-MED
,	O
gi	B-MED
perforation	I-MED
,	O
proteinuria	B-MED
and	O
hypertension	B-MED
,	O
but	O
not	O
for	O
venous	B-MED
thromboembolic	I-MED
events	B-MED
,	O
hemorrhagic	B-MED
events	B-MED
,	O
or	O
fatal	B-MED
adverse	B-MED
events	I-MED
.	O
	
relationship	B-MED
between	O
lrrk2	B-MED
r1628p	B-MED
polymorphism	I-MED
and	O
parkinson's	B-MED
disease	I-MED
in	O
asian	B-MED
populations	I-MED
although	O
the	O
leucine-rich	B-MED
repeat	I-MED
kinase	I-MED
2	I-MED
lrrk2	B-MED
r1628p	B-MED
polymorphism	I-MED
has	O
been	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
parkinson's	B-MED
disease	I-MED
pd	B-MED
in	O
taiwan	B-MED
,	O
china	B-MED
,	O
and	O
singapore	B-MED
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	B-MED
.	O
	
thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta-analysis	B-MED
was	O
to	O
evaluate	O
the	O
associations	B-MED
between	O
the	O
lrrk2	B-MED
r1628p	B-MED
polymorphism	I-MED
rs33949390	B-MED
and	O
pd	B-MED
in	O
asian	B-MED
populations	I-MED
.	O
	
a	O
search	O
for	O
eligible	O
studies	B-MED
was	O
performed	O
in	O
pubmed	B-MED
,	O
embase	B-MED
,	O
sinomed	B-MED
,	O
and	O
the	O
china	B-MED
knowledge	I-MED
resource	I-MED
integrated	I-MED
database	I-MED
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95%	O
confidence	B-MED
intervals	I-MED
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	B-MED
between	O
the	O
r1628p	B-MED
polymorphism	I-MED
and	O
pd	B-MED
.	O
	
this	O
meta-analysis	B-MED
assessed	O
19	O
studies	B-MED
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9	O
pd	B-MED
patients	B-MED
and	O
8	O
controls	B-MED
and	O
found	O
that	O
the	O
r1628p	B-MED
polymorphism	I-MED
was	O
significantly	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
pd	B-MED
in	O
asian	B-MED
populations	I-MED
.	O
	
moreover	O
,	O
stratification	B-MED
analyses	I-MED
indicated	O
that	O
the	O
r1628p	B-MED
polymorphism	I-MED
was	O
significantly	O
associated	B-MED
with	I-MED
an	O
increased	O
risk	B-MED
of	O
pd	B-MED
among	O
chinese	B-MED
as	O
well	O
as	O
non-chinese	B-MED
asian	I-MED
populations	I-MED
and	O
an	O
increased	O
risk	B-MED
of	O
pd	B-MED
in	O
chinese	B-MED
patients	I-MED
from	O
china	B-MED
,	O
taiwan	B-MED
,	O
and	O
singapore	B-MED
.	O
	
in	O
a	O
stratified	B-MED
analysis	I-MED
conducted	O
according	O
to	O
age	B-MED
,	O
significant	O
associations	B-MED
were	O
found	O
for	O
both	O
late-onset	O
pd	B-MED
and	O
early-onset	O
pd	B-MED
.	O
	
the	O
present	O
data	O
indicate	O
that	O
the	O
r1628p	B-MED
polymorphism	I-MED
of	O
the	O
lrrk2	B-MED
gene	I-MED
contributes	O
to	O
pd	B-MED
susceptibility	B-MED
in	O
asian	B-MED
,	O
especially	O
chinese	B-MED
,	O
populations	B-MED
.	O
	
efficacy	B-MED
and	O
safety	B-MED
of	O
cisplatin	B-MED
,	O
dexamethasone	B-MED
,	O
gemcitabine	B-MED
and	O
pegaspargase	B-MED
ddgp	B-MED
regimen	B-MED
in	O
newly	B-MED
diagnosed	I-MED
,	O
advanced-stage	B-MED
extranodal	B-MED
natural	I-MED
killer/t-cell	I-MED
lymphoma	I-MED
interim	B-MED
analysis	B-MED
of	O
a	O
phase	B-MED
4	I-MED
study	B-MED
nct01501149	O
to	O
explore	O
a	O
more	O
effective	B-MED
treatment	B-MED
for	O
newly	B-MED
diagnosed	I-MED
,	O
advanced-stage	B-MED
extranodal	B-MED
natural	I-MED
killer/t-cell	I-MED
lymphoma	I-MED
,	O
nasal	I-MED
type	I-MED
enktl	B-MED
,	O
we	O
conducted	O
a	O
phase	B-MED
4	I-MED
study	B-MED
of	O
the	O
cisplatin	B-MED
,	O
dexamethasone	B-MED
,	O
gemcitabine	B-MED
,	O
pegaspargase	B-MED
ddgp	B-MED
regimen	B-MED
.	O
	
the	O
primary	O
end	B-MED
point	I-MED
was	O
the	O
2-year	O
progression-free	B-MED
survival	I-MED
pfs	B-MED
after	O
the	O
protocol	B-MED
treatment	I-MED
.	O
	
secondary	O
endpoints	B-MED
included	O
response	B-MED
rate	I-MED
rr	B-MED
,	O
overall	B-MED
survival	I-MED
os	B-MED
and	O
median	B-MED
survival	I-MED
time	I-MED
mst	B-MED
.	O
	
the	O
interim	B-MED
analysis	B-MED
included	O
data	B-MED
only	O
from	O
march	O
2011	O
to	O
september	O
2013	O
,	O
who	O
received	B-MED
six	O
cycles	O
of	O
ddgp	B-MED
chemotherapy	B-MED
.	O
	
a	O
total	O
of	O
25	O
eligible	B-MED
patients	B-MED
were	O
enrolled	O
.	O
	
seventeen	O
patients	B-MED
17/24	O
,	O
70.83	O
achieved	O
complete	B-MED
response	I-MED
cr	B-MED
and	O
four	O
4/24	O
,	O
16.67	O
achieved	O
partial	B-MED
response	I-MED
pr	B-MED
,	O
three	O
3/24	O
,	O
12.50	O
had	O
progressive	B-MED
disease	I-MED
pd	B-MED
.	O
	
the	O
rr	B-MED
after	O
treatment	B-MED
was	O
87.50	O
.	O
	
after	O
a	O
median	B-MED
follow-up	B-MED
duration	B-MED
of	O
24.67	O
months	B-MED
range	O
4-48	O
months	B-MED
.	O
	
the	O
2-year	O
pfs	B-MED
and	O
os	B-MED
rate	I-MED
were	O
61.80	O
95%	O
ci	B-MED
,	O
42.00	O
to	O
81.60	O
and	O
68.50	O
%	O
95%	O
ci	B-MED
,	O
48.70	O
to	O
88.30	O
,	O
respectively	O
.	O
	
the	O
mst	B-MED
was	O
36.55	O
months	B-MED
95%	O
ci	B-MED
,	O
29.41	O
months	B-MED
to	O
43.70	O
months	B-MED
.	O
	
grade	B-MED
3/4	O
leukopenia	B-MED
occurred	B-MED
in	O
fourteen	O
patients	B-MED
58.33	O
and	O
grade	B-MED
3/4	O
thrombocytopenia	B-MED
occurred	B-MED
in	O
eleven	O
patients	B-MED
45.83	O
.	O
	
twelve	O
patients	B-MED
50.00	O
experienced	O
activated	B-MED
partial	I-MED
phromboplastin	I-MED
ptime	I-MED
aptt	B-MED
elongation	B-MED
and	O
fourteen	O
patients	B-MED
58.33	O
experienced	O
hypofibrinogenemia	B-MED
.	O
	
in	O
conclusion	O
,	O
ddgp	B-MED
regimen	B-MED
is	O
an	O
effective	B-MED
and	O
tolerated	B-MED
treatment	B-MED
for	O
newly	B-MED
diagnosed	I-MED
,	O
advanced-stage	B-MED
enktl	B-MED
.	O
	
this	O
trial	B-MED
was	O
registered	B-MED
at	O
www.clinicaltrials	B-MED
effect	B-MED
of	O
hepatitis	B-MED
c	I-MED
virus	I-MED
coinfection	I-MED
on	O
the	O
content	O
of	O
cd4	B-MED
and	I-MED
cd8	I-MED
t	B-MED
cell	I-MED
subpopulations	B-MED
in	O
hiv	B-MED
-	O
infected	B-MED
patients	B-MED
receiving	B-MED
antiretroviral	B-MED
therapy	I-MED
we	O
studied	O
the	O
effect	B-MED
of	O
hepatitis	B-MED
c	I-MED
virus	I-MED
coinfection	I-MED
on	O
t	B-MED
cell	I-MED
subpopulations	B-MED
in	O
hiv	B-MED
-	O
infected	B-MED
patients	B-MED
receiving	O
antiretroviral	B-MED
therapy	I-MED
.	O
	
coinfection	B-MED
with	O
hepatitis	B-MED
c	I-MED
virus	I-MED
was	O
followed	O
by	O
a	O
decrease	B-MED
in	O
the	O
number	O
of	O
naive	B-MED
cd4	I-MED
t	I-MED
cells	I-MED
and	O
an	O
increase	B-MED
in	O
the	O
count	B-MED
of	O
central	O
cd8	B-MED
memory	I-MED
t	I-MED
cells	I-MED
in	O
these	O
patients	B-MED
.	O
	
hepatitis	B-MED
c	I-MED
virus	I-MED
had	O
no	B-MED
effect	I-MED
on	O
the	O
number	O
of	O
cd4	B-MED
memory	I-MED
t	I-MED
cells	I-MED
main	O
target	O
for	O
hiv	B-MED
.	O
	
this	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-MED
effect	B-MED
of	O
hepatitis	B-MED
c	I-MED
virus	I-MED
on	O
the	O
course	B-MED
of	O
hiv	B-MED
infection	B-MED
.	O
	
examining	B-MED
the	O
contribution	B-MED
of	O
motor	B-MED
movement	I-MED
and	O
language	B-MED
dominance	B-MED
to	O
increased	B-MED
left	B-MED
lateralization	B-MED
during	O
sign	B-MED
generation	B-MED
in	O
native	B-MED
signers	B-MED
the	O
neural	B-MED
systems	I-MED
supporting	O
speech	B-MED
and	O
sign	B-MED
processing	B-MED
are	O
very	O
similar	B-MED
,	O
although	O
not	O
identical	O
.	O
	
in	O
a	O
previous	O
ftcd	B-MED
study	I-MED
of	O
hearing	B-MED
native	B-MED
signers	B-MED
gutierrez-sigut	O
,	O
daws	O
,	O
et	O
al	O
,	O
2015	O
we	O
found	O
stronger	O
left	B-MED
lateralization	B-MED
for	O
sign	B-MED
than	O
speech	B-MED
.	O
	
given	O
that	O
this	O
increased	B-MED
lateralization	B-MED
could	O
not	O
be	O
explained	O
by	O
hand	B-MED
movement	B-MED
alone	O
,	O
the	O
contribution	O
of	O
motor	B-MED
movement	I-MED
versus	O
'	O
linguistic	B-MED
'	O
processes	B-MED
to	O
the	O
strength	B-MED
of	O
hemispheric	B-MED
lateralization	B-MED
during	O
sign	B-MED
production	B-MED
remains	O
unclear	O
.	O
	
here	O
we	O
directly	O
contrast	B-MED
lateralization	B-MED
strength	B-MED
of	O
covert	B-MED
versus	O
overt	B-MED
signing	B-MED
during	O
phonological	B-MED
and	O
semantic	B-MED
fluency	B-MED
tasks	B-MED
.	O
	
to	O
address	O
the	O
possibility	O
that	O
hearing	B-MED
native	B-MED
signers	B-MED
'	O
elevated	B-MED
lateralization	B-MED
indices	I-MED
lis	B-MED
were	O
due	O
to	O
performing	O
a	O
task	B-MED
in	O
their	O
less	O
dominant	B-MED
language	B-MED
,	O
here	O
we	O
test	O
deaf	B-MED
native	B-MED
signers	B-MED
,	O
whose	O
dominant	B-MED
language	B-MED
is	O
british	B-MED
sign	I-MED
language	I-MED
bsl	B-MED
.	O
	
signers	B-MED
were	O
more	O
strongly	O
left	B-MED
lateralized	B-MED
for	O
overt	B-MED
than	O
covert	B-MED
sign	B-MED
generation	O
.	O
	
however	O
,	O
the	O
strength	B-MED
of	O
lateralization	B-MED
was	O
not	O
correlated	B-MED
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-MED
of	O
the	O
right	B-MED
hand	I-MED
.	O
	
comparisons	B-MED
with	O
previous	O
data	B-MED
from	O
hearing	B-MED
native	B-MED
english	B-MED
speakers	B-MED
suggest	O
stronger	O
laterality	B-MED
indices	I-MED
for	O
sign	B-MED
than	O
speech	B-MED
in	O
both	O
covert	B-MED
and	O
overt	B-MED
tasks	B-MED
.	O
	
this	O
increased	B-MED
left	B-MED
lateralization	B-MED
may	O
be	O
driven	O
by	O
specific	O
properties	B-MED
of	O
sign	B-MED
production	B-MED
such	O
as	O
the	O
increased	B-MED
use	B-MED
of	O
self-monitoring	B-MED
mechanisms	B-MED
or	O
the	O
nature	B-MED
of	O
phonological	B-MED
encoding	I-MED
of	O
hard	B-MED
ticks	I-MED
acari	B-MED
ixodidae	I-MED
of	O
livestock	B-MED
in	O
nicaragua	B-MED
,	O
with	O
notes	B-MED
about	O
distribution	B-MED
we	O
document	B-MED
the	O
species	B-MED
of	O
ticks	B-MED
that	O
parasitize	B-MED
livestock	B-MED
in	O
nicaragua	B-MED
.	O
	
the	O
study	B-MED
was	O
based	O
on	O
tick	B-MED
collection	B-MED
on	O
cattle	B-MED
and	O
horses	B-MED
from	O
437	O
farms	B-MED
in	O
nine	O
departments	B-MED
.	O
	
of	O
4841	O
animals	B-MED
examined	O
4481	O
cows	B-MED
and	O
360	O
horses	B-MED
,	O
3299	O
were	O
parasitized	B-MED
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-MED
and	O
67	O
%	O
of	O
the	O
equines	B-MED
in	O
study	B-MED
59	O
cows	B-MED
and	O
25	O
horses	B-MED
were	O
parasitized	B-MED
by	O
more	O
than	O
one	O
species	B-MED
.	O
	
in	O
addition	O
,	O
280	O
specimens	B-MED
of	O
the	O
entomological	B-MED
museum	B-MED
in	O
león	B-MED
were	O
examined	O
.	O
	
the	O
ticks	B-MED
found	O
on	O
cattle	B-MED
were	O
rhipicephalus	B-MED
microplus	I-MED
75.2	O
%	O
of	O
the	O
ticks	B-MED
collected	B-MED
,	O
amblyomma	B-MED
mixtum	I-MED
20.8	O
%	O
,	O
a	B-MED
.	O
	
parvum	I-MED
2.6	O
%	O
,	O
a	B-MED
.	O
	
tenellum	I-MED
0.7	O
%	O
,	O
a	B-MED
.	O
	
maculatum	I-MED
0.7	O
%	O
.	O
	
while	O
the	O
ticks	B-MED
collected	B-MED
from	O
the	O
horses	B-MED
were	O
dermacentor	B-MED
nitens	I-MED
41.5	O
%	O
,	O
a	B-MED
.	O
	
mixtum	I-MED
31.7	O
%	O
,	O
r	B-MED
.	O
	
microplus	I-MED
13.8	O
%	O
,	O
a	B-MED
.	O
	
parvum	I-MED
6.5	O
%	O
,	O
a	B-MED
.	O
	
tenellum	I-MED
3.3	O
%	O
,	O
d	B-MED
.	O
	
dissimilis	I-MED
2.4	O
%	O
and	O
a	B-MED
.	O
	
maculatum	I-MED
assessment	B-MED
the	O
exposure	B-MED
level	B-MED
of	O
rare	B-MED
earth	I-MED
elements	I-MED
in	O
workers	B-MED
producing	B-MED
cerium	B-MED
,	O
lanthanum	B-MED
oxide	I-MED
ultrafine	B-MED
and	O
nanoparticles	B-MED
in	O
order	O
to	O
assess	B-MED
occupational	B-MED
exposure	B-MED
level	B-MED
of	O
15	O
rare	B-MED
earth	I-MED
elements	I-MED
rees	B-MED
and	O
identify	B-MED
the	O
associated	B-MED
influence	B-MED
,	O
we	O
used	O
inductively	B-MED
coupled	I-MED
plasma	I-MED
mass	I-MED
spectrometry	I-MED
icp-ms	B-MED
based	B-MED
on	O
closed	B-MED
-	O
vessel	B-MED
microwave	B-MED
-	O
assisted	B-MED
wet	B-MED
digestion	I-MED
procedure	I-MED
to	O
determinate	B-MED
the	O
concentration	B-MED
of	O
y	B-MED
,	O
la	B-MED
,	O
ce	B-MED
,	O
pr	B-MED
,	O
nd	B-MED
,	O
sm	B-MED
,	O
eu	B-MED
,	O
gd	B-MED
,	O
tb	B-MED
,	O
dy	B-MED
,	O
ho	B-MED
,	O
er	B-MED
,	O
tm	B-MED
,	O
yb	B-MED
and	O
lu	B-MED
in	O
urinary	B-MED
samples	I-MED
obtained	B-MED
from	O
workers	B-MED
producing	B-MED
ultrafine	B-MED
and	O
nanoparticles	B-MED
containing	O
cerium	B-MED
and	O
lanthanum	B-MED
oxide	I-MED
.	O
	
the	O
results	B-MED
suggest	B-MED
that	O
la	B-MED
and	O
ce	B-MED
were	O
the	O
primary	B-MED
component	B-MED
,	O
together	O
accounting	B-MED
for	O
97	O
%	O
of	O
total	O
rees	B-MED
in	O
workers	B-MED
.	O
	
the	O
urinary	B-MED
levels	B-MED
of	O
la	B-MED
,	O
and	O
ce	B-MED
among	O
the	O
workers	B-MED
6.36	O
,	O
15.32	O
μg.g	O
creatinine	B-MED
,	O
respectively	O
were	O
significantly	B-MED
enriched	B-MED
compared	B-MED
to	O
those	O
levels	B-MED
measured	B-MED
in	O
the	O
control	B-MED
subjects	B-MED
1.52	O
,	O
4.04	O
μg.g	O
creatinine	B-MED
,	O
respectively	O
p	O
<	O
0.05	O
.	O
	
this	O
study	B-MED
simultaneously	B-MED
identified	B-MED
the	O
associated	B-MED
individual	B-MED
factors	B-MED
,	O
the	O
results	B-MED
indicate	B-MED
that	O
the	O
concentrations	B-MED
in	O
over	O
5	O
years	O
group	B-MED
11.64	O
10.93	O
for	O
la	B-MED
,	O
27.83	O
24.38	O
for	O
ce	B-MED
were	O
significantly	B-MED
elevated	B-MED
compared	B-MED
to	O
1-5	O
years	O
group	B-MED
2.58	O
1.51	O
for	O
la	B-MED
,	O
6.87	O
3.90	O
for	O
ce	B-MED
p	O
<	O
0.05	O
.	O
	
compared	B-MED
the	O
urinary	B-MED
levels	B-MED
of	O
la	B-MED
and	O
ce	B-MED
at	O
the	O
separation	B-MED
and	O
packaging	B-MED
locations	B-MED
9.10	O
9.51	O
for	O
la	B-MED
,	O
22.29	O
21.01	O
for	O
ce	B-MED
with	O
the	O
other	O
locations	B-MED
2.85	O
0.98	O
for	O
la	B-MED
,	O
6.37	O
2.12	O
for	O
ce	B-MED
,	O
the	O
results	B-MED
show	O
urinary	B-MED
concentrations	B-MED
were	O
significantly	B-MED
higher	B-MED
in	O
workers	B-MED
at	O
separation	B-MED
and	O
packaging	B-MED
locations	B-MED
p	O
<	O
0.01	O
.	O
	
inter	B-MED
-	O
individual	B-MED
variation	B-MED
in	O
levels	B-MED
of	O
la	B-MED
and	O
ce	B-MED
in	O
urine	B-MED
is	O
the	O
result	B-MED
of	O
multi-factorial	B-MED
comprehensive	B-MED
action	B-MED
.	O
	
further	O
researches	B-MED
should	O
focus	B-MED
on	O
the	O
multiple	B-MED
factors	B-MED
contributing	B-MED
to	O
the	O
rees	B-MED
levels	B-MED
of	O
the	O
occupationally	B-MED
exposed	B-MED
workers	B-MED
.	O
	
two	O
known	B-MED
and	O
one	O
new	B-MED
species	B-MED
of	O
draconematidae	B-MED
and	O
epsilonematida	B-MED
nematoda	B-MED
,	O
desmodorida	B-MED
from	O
the	O
white	B-MED
sea	I-MED
,	O
north	B-MED
russia	I-MED
morphological	B-MED
descriptions	B-MED
of	O
three	O
""""	O
walking	B-MED
nematode	I-MED
""""	O
species	B-MED
found	O
for	O
the	O
first	O
time	O
in	O
the	O
white	B-MED
sea	I-MED
are	O
presented	O
.	O
	
draconema	B-MED
ophicephalum	I-MED
claparède	B-MED
,	O
1863	O
draconematidae	B-MED
and	O
epsilonema	B-MED
steineri	I-MED
chitwood	B-MED
,	O
1935	O
epsilonematidae	B-MED
,	O
both	O
known	O
from	O
insufficient	B-MED
material	O
and	O
females	B-MED
only	O
,	O
are	O
re-described	O
and	O
problems	B-MED
of	O
their	O
taxonomic	B-MED
identification	B-MED
as	O
well	O
as	O
species	B-MED
compositions	B-MED
of	O
respective	O
genera	B-MED
are	O
discussed	O
.	O
	
the	O
new	B-MED
species	B-MED
prochaetosoma	B-MED
marisalbi	I-MED
sp	I-MED
.	O
	
n	O
.	O
	
draconematidae	B-MED
differs	O
from	O
other	O
prochaetosoma	B-MED
species	I-MED
except	O
p	B-MED
.	O
	
longicapitatum	I-MED
allgén	B-MED
,	O
1935	O
in	O
that	O
the	O
pharyngeal	B-MED
bulb	B-MED
lumen	B-MED
is	O
not	B-MED
cuticularised	I-MED
,	O
from	O
p	B-MED
.	O
	
longicapitatum	I-MED
by	O
shape	B-MED
of	I-MED
body	I-MED
and	O
rostrum	B-MED
,	O
greater	B-MED
number	O
of	O
cephalic	B-MED
adhesive	B-MED
tubes	I-MED
,	O
and	O
from	O
p	B-MED
.	O
	
maertensi	I-MED
decraemer	B-MED
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	B-MED
tail	B-MED
,	O
fewer	O
anterior	B-MED
adhesive	B-MED
tubes	I-MED
and	O
longer	B-MED
spicules	B-MED
,	O
besides	O
lacking	O
cuticular	B-MED
thickening	I-MED
in	O
the	O
pharyngeal	B-MED
bulb	B-MED
.	O
	
draconema	B-MED
hoonsooi	I-MED
,	O
d	B-MED
.	O
	
youngeouni	I-MED
,	O
p.rochaetosoma	B-MED
beomseomense	I-MED
,	O
p	B-MED
.	O
	
brevicaudatum	I-MED
,	O
p	B-MED
.	O
	
byungilli	I-MED
,	O
p	B-MED
.	O
	
cracense	I-MED
,	O
p	B-MED
.	O
	
saheungi	I-MED
,	O
p	B-MED
.	O
	
sujungi	I-MED
,	O
p	B-MED
.	O
	
supseomense	I-MED
erected	B-MED
by	O
rho	B-MED
min	B-MED
2011	O
are	O
considered	O
as	O
invalid	B-MED
species	B-MED
while	O
prochaetosoma	B-MED
arcticum	I-MED
,	O
p	B-MED
.	O
	
lugubre	I-MED
and	O
epsilonema	B-MED
cygnoides	I-MED
are	O
assumed	O
as	O
species	B-MED
inquirenda	I-MED
.	O
	
from	O
a	O
phylogenetic	B-MED
tree	I-MED
based	O
on	O
the	O
18s	B-MED
rrna	I-MED
gene	I-MED
,	O
all	O
three	O
white	B-MED
sea	I-MED
species	B-MED
adjoin	B-MED
to	O
unidentified	B-MED
species	B-MED
of	O
their	O
respective	O
differential	B-MED
effects	B-MED
of	I-MED
crude	B-MED
oil	I-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
,	O
and	O
the	O
impact	B-MED
on	O
n2o	B-MED
production	B-MED
denitrification	B-MED
and	O
anammox	B-MED
are	O
key	O
processes	B-MED
for	O
reducing	B-MED
the	O
external	B-MED
nitrogen	B-MED
loads	O
delivered	B-MED
to	O
coastal	B-MED
ecosystems	B-MED
,	O
and	O
these	O
processes	B-MED
can	O
be	O
affected	B-MED
by	O
pollutants	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
effect	B-MED
of	I-MED
crude	B-MED
oil	I-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
.	O
	
controlled	B-MED
laboratory	I-MED
experiments	I-MED
were	O
performed	O
using	O
sediment	B-MED
slurries	B-MED
from	O
the	O
lima	B-MED
estuary	B-MED
nw	B-MED
portugal	B-MED
.	O
	
anammox	B-MED
and	O
denitrification	B-MED
rates	B-MED
were	O
measured	O
using	O
15	B-MED
no3	B-MED
,	O
and	O
the	O
production	B-MED
of	O
29	B-MED
and	O
30	B-MED
quantified	O
by	O
membrane	B-MED
inlet	I-MED
mass	I-MED
spectrometry	I-MED
.	O
	
results	O
revealed	O
that	O
while	O
denitrification	B-MED
rates	B-MED
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	B-MED
oil	I-MED
amendment	B-MED
,	O
anammox	B-MED
activity	B-MED
was	O
partially	O
between	O
2	O
and	O
5	O
times	O
or	O
completely	B-MED
inhibited	B-MED
by	O
the	O
addition	B-MED
of	O
crude	B-MED
oil	I-MED
when	O
comparing	O
to	O
rates	B-MED
in	O
unamended	B-MED
controls	I-MED
.	O
	
similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	B-MED
sediment	B-MED
types	B-MED
,	O
despite	O
their	O
different	O
physical-chemical	B-MED
characteristics	I-MED
.	O
	
moreover	O
,	O
n2o	B-MED
production	B-MED
was	O
reduced	B-MED
by	O
2-36	O
times	O
following	O
crude	B-MED
oil	I-MED
addition	B-MED
.	O
	
further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	B-MED
of	O
the	O
observed	B-MED
reduction	B-MED
in	O
n2o	B-MED
production	B-MED
.	O
	
this	O
study	B-MED
represents	O
one	O
of	O
the	O
first	O
contributions	B-MED
to	O
the	O
understanding	O
of	O
the	O
impact	B-MED
of	O
crude	B-MED
oil	I-MED
pollution	B-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
,	O
with	O
profound	O
implications	O
for	O
the	O
management	B-MED
of	O
aquatic	B-MED
ecosystems	B-MED
regarding	O
eutrophication	B-MED
n-removal	B-MED
.	O
	
shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	B-MED
leadership	B-MED
-	O
a	O
qualitative	B-MED
study	I-MED
in	O
australia	B-MED
purpose	O
the	O
paper	O
aims	B-MED
to	O
explore	O
the	O
beliefs	B-MED
of	O
doctors	B-MED
in	O
leadership	B-MED
roles	O
of	O
the	O
concept	B-MED
of	O
"""the"	O
dark	O
"side"""	O
,	O
using	O
data	B-MED
collected	O
from	O
interviews	B-MED
carried	O
out	O
with	O
45	O
doctors	B-MED
in	O
medical	B-MED
leadership	B-MED
roles	O
across	O
australia	B-MED
.	O
	
the	O
paper	O
looks	O
at	O
the	O
beliefs	B-MED
from	O
the	O
perspectives	B-MED
of	O
doctors	B-MED
who	O
are	O
already	O
in	O
leadership	B-MED
roles	O
themselves	O
to	O
identify	O
potential	O
barriers	B-MED
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better-informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-MED
in	O
the	O
leadership	B-MED
of	O
the	O
australian	B-MED
health	B-MED
system	I-MED
.	O
	
the	O
research	B-MED
question	O
is	O
"""what"	O
are	O
the	O
beliefs	B-MED
of	O
medical	B-MED
leaders	B-MED
that	O
form	O
the	O
key	O
themes	B-MED
or	O
dimensions	B-MED
of	O
the	O
negative	O
perception	O
of	O
the	O
'dark	O
side'	O
.	O
	
design/methodology/approach	O
the	O
paper	O
analysed	O
data	B-MED
from	O
two	O
similar	O
qualitative	B-MED
studies	I-MED
examining	O
medical	B-MED
leadership	B-MED
and	O
engagement	O
in	O
australia	B-MED
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	B-MED
with	O
other	O
researchers	B-MED
,	O
which	O
used	O
in-depth	O
semi-structured	B-MED
interviews	I-MED
with	O
45	O
purposively	O
sampled	O
senior	O
medical	B-MED
leaders	B-MED
in	O
leadership	B-MED
roles	O
across	O
australia	B-MED
in	O
health	B-MED
services	I-MED
,	O
private	B-MED
and	O
public	B-MED
hospitals	I-MED
,	O
professional	B-MED
associations	I-MED
and	O
health	B-MED
departments	I-MED
.	O
	
the	O
data	B-MED
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	B-MED
through	O
a	O
coding	B-MED
framework	O
based	O
on	O
the	O
interview	B-MED
data	B-MED
and	O
literature	B-MED
review	I-MED
,	O
with	O
all	O
sections	O
of	O
coded	B-MED
data	B-MED
grouped	B-MED
into	O
themes	B-MED
.	O
	
findings	O
medical	B-MED
leaders	B-MED
had	O
four	O
key	O
beliefs	B-MED
about	O
the	O
"""dark"	O
"side"""	O
as	O
perceived	O
through	O
the	O
eyes	B-MED
of	O
their	O
own	O
past	O
clinical	B-MED
experience	I-MED
and/or	O
their	O
clinical	B-MED
colleagues	B-MED
.	O
	
these	O
four	O
beliefs	B-MED
or	O
dimensions	B-MED
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"""the"	O
dark	O
"side"""	O
are	O
the	O
belief	B-MED
that	O
they	O
lack	O
both	O
managerial	B-MED
and	O
clinical	B-MED
credibility	B-MED
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	B-MED
with	O
clinicians	B-MED
,	O
their	O
clinical	B-MED
colleagues	B-MED
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	B-MED
leadership	B-MED
and	O
,	O
as	O
a	O
result	O
,	O
doctors	B-MED
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	B-MED
practice	I-MED
to	O
medical	B-MED
leadership	B-MED
roles	O
in	O
the	O
first	O
place	O
.	O
	
research	O
limitations/implications	O
this	O
research	B-MED
was	O
conducted	O
within	O
the	O
western	B-MED
developed-nation	B-MED
setting	O
of	O
australia	B-MED
and	O
only	O
involved	O
interviews	B-MED
with	O
doctors	B-MED
in	O
medical	B-MED
leadership	B-MED
roles	O
.	O
	
the	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-MED
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	B-MED
.	O
	
future	O
research	B-MED
involving	O
doctors	B-MED
who	O
have	O
not	O
chosen	O
to	O
transition	B-MED
to	O
leadership	B-MED
roles	O
,	O
or	O
other	O
health	B-MED
practitioners	I-MED
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	B-MED
.	O
	
also	O
,	O
this	O
research	B-MED
was	O
exploratory	O
and	O
descriptive	B-MED
in	O
nature	O
using	O
qualitative	B-MED
methods	I-MED
,	O
and	O
quantitative	B-MED
research	I-MED
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-MED
for	O
statistical	B-MED
generalisation	I-MED
.	O
	
practical	O
implications	O
the	O
paper	O
includes	O
implications	O
for	O
health	B-MED
organisations	I-MED
,	O
training	O
providers	O
,	O
medical	B-MED
employers	B-MED
and	O
health	B-MED
departments	I-MED
and	O
describes	O
a	O
multi-prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O
	
originality/value	O
this	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-MED
the	O
concept	B-MED
of	O
"""moving"	O
to	O
the	O
dark	O
"side"""	O
as	O
a	O
negative	O
perception	O
of	O
medical	B-MED
leadership	B-MED
and	O
contributes	O
to	O
the	O
evidence	B-MED
in	O
this	O
under-	O
researched	B-MED
area	O
.	O
	
this	O
paper	O
has	O
used	O
data	B-MED
from	O
two	O
similar	O
studies	B-MED
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	B-MED
and	O
coding	B-MED
,	O
looking	O
at	O
the	O
concept	B-MED
erlotinib	B-MED
plus	O
gemcitabine	B-MED
versus	O
gemcitabine	B-MED
for	O
pancreatic	B-MED
cancer	I-MED
real	B-MED
-	O
world	B-MED
analysis	B-MED
of	O
korean	B-MED
national	B-MED
database	B-MED
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
has	O
found	O
that	O
the	O
addition	B-MED
of	O
erlotinib	B-MED
to	O
gemcitabine	B-MED
gem	B-MED
-	O
e	B-MED
for	O
pancreatic	B-MED
cancer	I-MED
led	O
to	O
a	O
modest	B-MED
increase	B-MED
in	O
survival	B-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
national	B-MED
population	B-MED
-	O
based	B-MED
retrospective	B-MED
study	I-MED
was	O
to	O
compare	B-MED
the	O
effectiveness	B-MED
of	O
gem	B-MED
-	O
e	B-MED
to	O
gem	B-MED
alone	O
for	O
pancreatic	B-MED
cancer	I-MED
patients	B-MED
in	O
real	B-MED
clinical	I-MED
practice	I-MED
.	O
	
patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
icd-10	B-MED
c25	O
with	O
prescription	B-MED
claims	O
of	O
gemcitabine	B-MED
or	O
erlotinib	B-MED
between	O
jan	O
1	O
,	O
2007	O
and	O
dec	O
31	O
,	O
2012	O
were	O
retrospectively	B-MED
identified	B-MED
from	O
the	O
korean	B-MED
health	B-MED
insurance	I-MED
claims	O
database	B-MED
.	O
	
to	O
be	O
included	O
in	O
the	O
study	B-MED
population	B-MED
,	O
patients	B-MED
were	O
required	B-MED
to	O
have	O
had	O
a	O
histological	B-MED
or	O
cytological	B-MED
diagnosis	I-MED
within	O
one	O
year	O
before	O
chemotherapy	B-MED
.	O
	
patients	B-MED
treated	B-MED
with	I-MED
prior	O
radiotherapy	B-MED
,	O
surgery	B-MED
,	O
or	O
chemotherapy	B-MED
were	O
excluded	B-MED
to	O
reduce	B-MED
heterogeneity	B-MED
.	O
	
overall	O
survival	B-MED
from	O
the	O
initiation	B-MED
of	O
therapy	B-MED
and	O
the	O
medical	B-MED
costs	I-MED
of	O
gem	B-MED
-	O
e	B-MED
and	O
gem	B-MED
were	O
compared	B-MED
.	O
	
a	O
total	O
of	O
4	O
patients	B-MED
were	O
included	O
in	O
the	O
analysis	B-MED
.	O
	
overall	O
survival	B-MED
was	O
not	O
significantly	B-MED
longer	B-MED
in	O
patients	B-MED
treated	B-MED
with	O
gem	B-MED
-	O
e	B-MED
median	B-MED
6.77	O
months	O
for	O
gem	B-MED
-	O
e	B-MED
vs	O
.	O
	
6.68	O
months	O
for	O
gem	B-MED
,	O
p	O
=	O
0.0977	O
.	O
	
there	O
was	O
also	O
no	B-MED
significant	I-MED
difference	B-MED
in	O
the	O
respective	O
one-year	O
survival	B-MED
rates	I-MED
27.0	O
%	O
vs	O
.	O
	
27.3	O
%	O
p	O
=	O
0.5988	O
.	O
	
multivariate	B-MED
analysis	I-MED
using	O
age	B-MED
,	O
gender	B-MED
,	O
and	O
comorbidities	B-MED
as	O
covariates	B-MED
did	O
not	O
reveal	B-MED
any	O
significant	B-MED
differences	B-MED
in	O
survival	B-MED
.	O
	
based	B-MED
on	O
this	O
relative	B-MED
effectiveness	I-MED
,	O
the	O
incremental	B-MED
cost	B-MED
per	O
life	B-MED
year	B-MED
gained	B-MED
over	O
gem	B-MED
was	O
estimated	B-MED
at	O
usd	B-MED
70	O
for	O
gem	B-MED
-	O
e	B-MED
.	O
	
gem	B-MED
-	O
e	B-MED
for	O
pancreatic	B-MED
cancer	I-MED
is	O
not	O
more	O
effective	B-MED
than	O
gem	B-MED
in	O
a	O
real	B-MED
-	O
world	B-MED
setting	B-MED
,	O
and	O
it	O
does	O
not	O
provide	B-MED
reasonable	B-MED
cost-effectiveness	B-MED
over	O
development	O
of	O
a	O
novel	O
quantitative	B-MED
structure-activity	I-MED
relationship	I-MED
model	B-MED
to	O
accurately	O
predict	O
pulmonary	B-MED
absorption	I-MED
and	O
replace	O
routine	O
use	O
of	O
the	O
isolated	B-MED
perfused	B-MED
respiring	B-MED
rat	B-MED
lung	I-MED
model	B-MED
we	O
developed	O
and	O
tested	O
a	O
novel	O
quantitative	B-MED
structure-activity	I-MED
relationship	I-MED
qsar	B-MED
model	B-MED
to	O
better	O
understand	O
the	O
physicochemical	B-MED
drivers	O
of	O
pulmonary	B-MED
absorption	I-MED
,	O
and	O
to	O
facilitate	O
compound	B-MED
design	I-MED
through	O
improved	O
prediction	B-MED
of	O
absorption	B-MED
.	O
	
the	O
model	B-MED
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-MED
.	O
	
pulmonary	B-MED
absorption	I-MED
data	O
was	O
generated	O
using	O
the	O
isolated	B-MED
perfused	B-MED
respiring	B-MED
rat	B-MED
lung	I-MED
iprlu	B-MED
model	B-MED
for	O
82	O
drug	B-MED
discovery	I-MED
compounds	B-MED
and	O
17	O
marketed	B-MED
drugs	I-MED
.	O
	
this	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
qsar	B-MED
model	B-MED
based	O
on	O
calculated	O
physicochemical	B-MED
properties	I-MED
.	O
	
a	O
further	O
9	O
compounds	B-MED
were	O
used	O
to	O
test	O
the	O
model's	B-MED
predictive	O
capability	B-MED
.	O
	
the	O
qsar	B-MED
model	B-MED
performed	O
well	O
on	O
the	O
9	O
compounds	B-MED
in	O
the	O
""""	O
test	B-MED
set	I-MED
""""	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	B-MED
of	O
r	O
=	O
0.85	O
,	O
and	O
>65%	O
of	O
compounds	B-MED
correctly	O
categorised	O
.	O
	
calculated	O
descriptors	O
associated	O
with	O
permeability	B-MED
and	O
hydrophobicity	B-MED
positively	O
correlated	O
with	O
pulmonary	B-MED
absorption	I-MED
,	O
whereas	O
those	O
associated	O
with	O
charge	B-MED
,	O
ionisation	B-MED
and	O
size	B-MED
negatively	O
correlated	O
.	O
	
the	O
novel	O
qsar	B-MED
model	B-MED
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
iprlu	B-MED
model	B-MED
data	O
for	O
ranking	B-MED
and	O
classifying	B-MED
compounds	B-MED
prior	O
to	O
synthesis	B-MED
.	O
	
it	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	B-MED
drug	I-MED
discovery	I-MED
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	B-MED
drivers	O
of	O
pulmonary	B-MED
absorption	I-MED
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-MED
dataset	B-MED
.	O
	
the	O
epiderm	B-MED
3d	B-MED
human	I-MED
reconstructed	I-MED
skin	I-MED
micronucleus	I-MED
rsmn	I-MED
assay	I-MED
historical	B-MED
control	I-MED
data	B-MED
and	O
proof	B-MED
of	O
principle	B-MED
studies	I-MED
for	O
mechanistic	B-MED
assay	I-MED
adaptations	O
the	O
in	B-MED
vitro	I-MED
human	I-MED
reconstructed	I-MED
skin	I-MED
micronucleus	I-MED
rsmn	I-MED
assay	I-MED
in	O
epiderm	B-MED
is	O
a	O
promising	O
novel	O
animal	B-MED
alternative	I-MED
for	O
evaluating	O
genotoxicity	B-MED
of	O
topically	B-MED
applied	I-MED
chemicals	B-MED
.	O
	
it	O
is	O
particularly	O
useful	O
for	O
assessing	B-MED
cosmetic	B-MED
ingredients	I-MED
that	O
can	O
no	O
longer	O
be	O
tested	B-MED
using	O
in	B-MED
vivo	I-MED
assays	B-MED
.	O
	
to	O
advance	O
the	O
use	O
of	O
this	O
test	B-MED
especially	O
for	O
regulatory	B-MED
decision-making	B-MED
,	O
we	O
have	O
established	O
the	O
rsmn	B-MED
assay	I-MED
in	O
our	O
laboratory	B-MED
according	O
to	O
good	B-MED
laboratory	I-MED
practice	I-MED
and	O
following	O
the	O
principles	O
of	O
the	O
oecd	B-MED
test	B-MED
guideline	I-MED
487	I-MED
in	B-MED
vitro	I-MED
mammalian	B-MED
cell	I-MED
micronucleus	B-MED
test	I-MED
.	O
	
proficiency	O
with	O
the	O
assay	B-MED
was	O
established	O
by	O
correctly	O
identifying	O
direct-acting	B-MED
genotoxins	I-MED
and	O
genotoxins	B-MED
requiring	O
metabolism	B-MED
,	O
as	O
well	O
as	O
non-genotoxic	B-MED
/	O
non-carcinogenic	B-MED
chemicals	B-MED
.	O
	
we	O
also	O
report	B-MED
the	O
analysis	B-MED
of	O
our	O
historical	B-MED
control	I-MED
data	B-MED
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	B-MED
control	I-MED
values	B-MED
for	O
%	O
micronuclei	B-MED
in	O
binucleated	B-MED
cells	I-MED
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O
	
technical	B-MED
issues	I-MED
including	O
evaluating	O
various	O
solvents	B-MED
with	O
both	O
48h	O
and	O
72h	O
treatment	B-MED
regimens	I-MED
were	O
investigated	B-MED
.	O
	
for	O
the	O
first	O
time	O
,	O
mechanistic	B-MED
studies	I-MED
using	O
crest	B-MED
analysis	I-MED
revealed	O
that	O
the	O
rsmn	B-MED
assay	I-MED
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-MED
and	O
clastogens	B-MED
.	O
	
moreover	O
,	O
the	O
assay	B-MED
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-MED
as	O
markers	B-MED
for	O
proliferative	B-MED
and	O
toxic	B-MED
effects	I-MED
of	O
wnt-5a	B-MED
/	O
frizzled9	B-MED
receptor	B-MED
signaling	I-MED
through	O
the	O
gαo	B-MED
/	O
gβγ	B-MED
complex	I-MED
regulates	B-MED
dendritic	B-MED
spine	I-MED
formation	B-MED
wnt	B-MED
ligands	I-MED
play	O
crucial	O
roles	O
in	O
the	O
development	B-MED
and	O
regulation	B-MED
of	I-MED
synapse	I-MED
structure	I-MED
and	I-MED
function	I-MED
.	O
	
specifically	O
,	O
wnt-5a	B-MED
acts	O
as	O
a	O
secreted	B-MED
growth	I-MED
factor	I-MED
that	O
regulates	B-MED
dendritic	B-MED
spine	I-MED
formation	B-MED
in	O
rodent	B-MED
hippocampal	B-MED
neurons	B-MED
,	O
resulting	O
in	O
postsynaptic	B-MED
development	B-MED
that	O
promotes	O
the	O
clustering	B-MED
of	I-MED
the	I-MED
postsynaptic	I-MED
density	I-MED
protein-95	I-MED
psd-95	I-MED
.	O
	
here	O
,	O
we	O
focused	O
on	O
the	O
early	B-MED
events	B-MED
occurring	O
after	O
the	O
interaction	B-MED
between	O
wnt-5a	B-MED
and	O
its	O
frizzled	B-MED
receptor	I-MED
at	O
the	O
neuronal	B-MED
cell	B-MED
surface	I-MED
.	O
	
additionally	O
,	O
we	O
studied	O
the	O
role	B-MED
of	O
heterotrimeric	B-MED
g	I-MED
proteins	I-MED
in	O
wnt-5a	B-MED
-dependent	O
synaptic	B-MED
development	B-MED
.	O
	
we	O
report	O
that	O
frizzled9	B-MED
fzd9	B-MED
,	O
a	O
wnt	B-MED
receptor	B-MED
related	O
to	O
williams'	B-MED
syndrome	I-MED
,	O
is	O
localized	O
in	O
the	O
postsynaptic	B-MED
region	I-MED
,	O
where	O
it	O
interacts	B-MED
with	O
wnt-5a	B-MED
.	O
	
functionally	O
,	O
fzd9	B-MED
is	O
required	O
for	O
the	O
wnt-5a	B-MED
-mediated	O
increase	B-MED
in	O
dendritic	B-MED
spine	I-MED
density	I-MED
.	O
	
fzd9	B-MED
forms	O
a	O
pre-coupled	B-MED
complex	I-MED
with	O
gαo	B-MED
under	O
basal	B-MED
conditions	I-MED
that	O
dissociates	B-MED
after	O
wnt-5a	B-MED
stimulation	B-MED
.	O
	
accordingly	O
,	O
we	O
found	O
that	O
g-protein	B-MED
inhibition	I-MED
abrogates	I-MED
wnt-5a	B-MED
-dependent	O
pathway	B-MED
in	O
hippocampal	B-MED
neurons	B-MED
.	O
	
in	O
particular	O
,	O
the	O
activation	B-MED
of	O
gαo	B-MED
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	B-MED
the	O
wnt-5a	B-MED
-	O
induced	B-MED
dendritic	B-MED
spine	I-MED
density	I-MED
.	O
	
in	O
addition	O
,	O
we	O
found	O
that	O
gβγ	B-MED
is	O
required	O
for	O
the	O
wnt-5a	B-MED
-mediated	O
increase	B-MED
in	O
cytosolic	B-MED
calcium	B-MED
levels	B-MED
and	O
spinogenesis	B-MED
.	O
	
our	O
findings	B-MED
reveal	O
that	O
fzd9	B-MED
and	O
heterotrimeric	B-MED
g	I-MED
proteins	I-MED
regulate	B-MED
wnt-5a	B-MED
signaling	B-MED
and	O
dendritic	B-MED
spines	I-MED
in	O
cultured	B-MED
hippocampal	B-MED
neurons	B-MED
.	O
	
a	O
delayed	B-MED
diagnosis	B-MED
of	O
chronic	B-MED
mesenteric	I-MED
ischaemia	I-MED
the	O
role	O
of	O
clinicians	B-MED
'	O
cognitive	B-MED
errors	B-MED
chronic	B-MED
diarrhoeal	B-MED
illnesses	I-MED
with	O
nausea	B-MED
and	O
weight	B-MED
loss	I-MED
are	O
a	O
common	B-MED
indication	B-MED
for	O
gastroenterology	B-MED
review	B-MED
.	O
	
while	O
many	O
such	O
cases	O
have	O
intra-luminal	B-MED
aetiologies	B-MED
,	O
such	O
as	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
,	O
coeliac	B-MED
disease	I-MED
or	O
other	O
malabsorptive	B-MED
conditions	I-MED
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	B-MED
gut	B-MED
disorders	B-MED
or	O
systemic	B-MED
malignancy	B-MED
,	O
clinicians	B-MED
must	O
also	O
keep	O
vascular	B-MED
disorders	I-MED
in	O
mind	O
.	O
	
here	O
we	O
report	O
a	O
patient	B-MED
with	O
a	O
delayed	B-MED
diagnosis	B-MED
of	O
chronic	B-MED
mesenteric	I-MED
ischaemia	I-MED
after	O
6	O
months	B-MED
of	O
gastrointestinal	B-MED
symptoms	I-MED
strongly	O
mimicking	O
an	O
alternative	B-MED
diagnosis	B-MED
such	O
as	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
due	O
an	O
atypical	B-MED
predominance	B-MED
of	O
nausea	B-MED
and	O
diarrhoea	B-MED
rather	O
than	O
pain	B-MED
.	O
	
we	O
briefly	O
review	B-MED
the	O
literature	B-MED
on	O
treatment	B-MED
of	O
this	O
condition	B-MED
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	B-MED
of	O
cognitive	B-MED
errors	B-MED
made	O
by	O
clinicians	B-MED
that	O
led	O
to	O
a	O
diagnostic	B-MED
delay	B-MED
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	B-MED
can	O
be	O
minimised	B-MED
in	O
their	O
evaluation	B-MED
of	O
choroidal	B-MED
thickness	B-MED
in	O
patients	B-MED
with	O
pseudoexfoliation	B-MED
syndrome	I-MED
and	O
pseudoexfoliation	B-MED
glaucoma	I-MED
purpose	B-MED
.	O
	
to	O
compare	B-MED
the	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thickness	B-MED
in	O
eyes	B-MED
with	O
pseudoexfoliation	B-MED
pex	I-MED
syndrome	I-MED
and	O
pex	B-MED
glaucoma	I-MED
with	O
the	O
normal	B-MED
eyes	B-MED
of	O
healthy	B-MED
controls	B-MED
.	O
	
materials	O
and	O
methods	O
.	O
	
in	O
this	O
prospective	B-MED
study	I-MED
,	O
30	O
eyes	B-MED
of	O
30	O
patients	B-MED
with	O
pex	B-MED
syndrome	I-MED
,	O
28	O
eyes	B-MED
of	O
28	O
patients	B-MED
with	O
pex	B-MED
glaucoma	I-MED
,	O
and	O
30	O
eyes	B-MED
of	O
30	O
age	B-MED
-matched	O
healthy	B-MED
subjects	B-MED
were	O
enrolled	O
.	O
	
choroidal	B-MED
thicknesses	B-MED
in	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
areas	B-MED
were	O
measured	B-MED
by	O
using	O
spectral	B-MED
domain	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
.	O
	
results	O
.	O
	
gender	B-MED
,	O
age	B-MED
,	O
and	O
axial	B-MED
length	I-MED
did	O
not	B-MED
significantly	I-MED
differ	O
between	O
the	O
groups	B-MED
all	O
,	O
p	O
>	O
0.05	O
.	O
	
the	O
mean	B-MED
values	I-MED
of	O
choroidal	B-MED
thickness	B-MED
in	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
areas	B-MED
except	B-MED
the	O
superior	B-MED
quadrant	B-MED
in	O
the	O
patients	B-MED
with	O
pex	B-MED
syndrome	I-MED
and	O
pex	B-MED
glaucoma	I-MED
were	O
lower	B-MED
compared	B-MED
with	O
controls	B-MED
all	O
p	O
<	O
0.05	O
.	O
	
the	O
mean	B-MED
values	I-MED
of	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thickness	B-MED
in	O
the	O
pex	B-MED
glaucoma	I-MED
group	B-MED
were	O
lower	B-MED
compared	B-MED
with	O
pex	B-MED
syndrome	I-MED
group	B-MED
however	O
this	O
difference	B-MED
was	O
not	B-MED
significant	I-MED
.	O
	
conclusions	O
.	O
	
the	O
findings	B-MED
of	O
this	O
study	B-MED
revealed	B-MED
that	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thicknesses	B-MED
were	O
decreased	B-MED
in	O
pex	B-MED
syndrome	I-MED
and	O
pex	B-MED
glaucoma	I-MED
cases	B-MED
.	O
	
the	O
role	O
of	O
choroid	B-MED
in	O
the	O
development	B-MED
of	O
glaucomatous	B-MED
damage	B-MED
in	O
patients	B-MED
with	O
pex	B-MED
syndrome	I-MED
remains	O
clinical	B-MED
features	I-MED
and	O
complications	B-MED
of	O
the	O
hla-b27	B-MED
-associated	O
acute	B-MED
anterior	I-MED
uveitis	I-MED
a	O
metanalysis	B-MED
in	O
this	O
article	B-MED
,	O
we	O
report	O
a	O
literature-based	B-MED
metanalysis	B-MED
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-MED
features	I-MED
of	O
the	O
hla-b27	B-MED
acute	B-MED
anterior	I-MED
uveitis	I-MED
aau	B-MED
.	O
	
the	O
examined	B-MED
material	O
was	O
based	O
on	O
observational	B-MED
studies	I-MED
in	O
which	O
participants	B-MED
were	O
affected	O
by	O
acute	B-MED
anterior	I-MED
uveitis	I-MED
and	O
divided	O
into	O
hla	B-MED
b27+	I-MED
and	O
hla	B-MED
b27-	I-MED
.	O
	
we	O
performed	O
a	O
search	O
on	O
articles	B-MED
with	O
the	O
words	O
""""	O
hla	B-MED
b27	I-MED
uveitis	I-MED
""""	O
dated	O
before	O
may	O
2014	O
.	O
	
among	O
these	O
,	O
29	O
articles	B-MED
were	O
selected	O
for	O
a	O
second	O
review	B-MED
.	O
	
after	O
a	O
further	O
evaluation	O
,	O
22	O
articles	B-MED
were	O
analyzed	B-MED
.	O
	
the	O
clinical	B-MED
characteristics	I-MED
studied	O
in	O
the	O
metanalysis	B-MED
were	O
1	O
systemic	B-MED
disease	I-MED
2	O
sex	B-MED
distribution	I-MED
3	O
laterality	B-MED
4	O
visual	B-MED
acuity	I-MED
5	O
hypopion	B-MED
6	O
anterior	B-MED
chamber's	I-MED
fibrin	I-MED
7	O
elevated	B-MED
intraocular	I-MED
pressure	I-MED
iop	B-MED
during	O
inflammation	B-MED
8	O
glaucoma	B-MED
9	O
posterior	B-MED
synechiae	I-MED
10	O
cataract	B-MED
11	O
cystoid	B-MED
macular	I-MED
edema	I-MED
12	O
papillitis	B-MED
.	O
	
we	O
have	O
calculated	O
a	O
relative	B-MED
risk	I-MED
rr	B-MED
for	O
each	O
outcome	B-MED
measured	I-MED
.	O
	
the	O
results	B-MED
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
hla	B-MED
b27	I-MED
acute	B-MED
anterior	I-MED
uveitis	I-MED
,	O
such	O
as	O
strong	O
association	B-MED
with	I-MED
ankylosing	B-MED
spondylitis	I-MED
rr	B-MED
=	O
6.80	O
and	O
systemic	B-MED
diseases	I-MED
rr	B-MED
=	O
9.9	O
,	O
male	B-MED
prevalence	B-MED
rr	B-MED
=	O
1.2	O
,	O
unilateral	B-MED
rr	B-MED
=	O
1.1	O
or	O
alternating	O
bilateral	B-MED
rr	B-MED
=	O
2.2	O
involvement	B-MED
,	O
hypopion	B-MED
rr	B-MED
=	O
5.5	O
,	O
fibrinous	B-MED
reaction	B-MED
and	O
even	O
papillitis	B-MED
r	O
=	O
7.7	O
.	O
	
simultaneous	O
bilateral	B-MED
rr	B-MED
=	O
0.3	O
aau	B-MED
is	O
more	O
frequent	B-MED
in	O
hla-b27	B-MED
negative	B-MED
form	O
.	O
	
we	O
report	O
higher	O
risk	B-MED
of	O
elevated	B-MED
iop	I-MED
and	O
glaucoma	B-MED
rr	B-MED
=	O
0.6	O
in	O
b27-	B-MED
acute	I-MED
anterior	I-MED
uveitis	I-MED
.	O
	
no	O
significant	O
difference	O
between	O
hla	B-MED
b	I-MED
27	I-MED
positive	I-MED
and	O
negative	B-MED
aau	B-MED
was	O
observed	B-MED
according	O
to	O
final	O
visual	B-MED
acuity	I-MED
and	O
complications	B-MED
such	O
as	O
posterior	B-MED
synechiae	I-MED
,	O
cataract	B-MED
,	O
and	O
maculare	B-MED
edema	I-MED
.	O
	
we	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-MED
evaluation	I-MED
and	O
therapeutic	B-MED
decision	B-MED
in	O
addressing	O
a	O
still	O
ill-defined	O
ophthalmologic	B-MED
condition	B-MED
.	O
	
a	O
case	O
presenting	O
with	O
splenic	B-MED
infarct	I-MED
diagnosed	B-MED
as	O
primary	B-MED
bone	I-MED
marrow	I-MED
cd5	B-MED
positive	I-MED
dlbcl	B-MED
a	O
clinicopathological	B-MED
correlation	I-MED
de	B-MED
novo	I-MED
cd5+	B-MED
diffuse	B-MED
large	I-MED
b	I-MED
cell	I-MED
lymphoma	I-MED
dlbcl	B-MED
is	O
a	O
rare	B-MED
and	O
aggressive	B-MED
subtype	I-MED
of	O
dlbcl	B-MED
.	O
	
it	O
is	O
a	O
distinct	O
clinicopathologic	B-MED
entity	B-MED
with	O
complex	B-MED
molecular	I-MED
profile	I-MED
and	O
poor	B-MED
prognosis	I-MED
.	O
	
a	O
59	O
year	B-MED
old	O
female	B-MED
presented	B-MED
with	I-MED
pyrexia	B-MED
of	I-MED
unknown	I-MED
origin	I-MED
since	O
1	O
month	B-MED
.	O
	
on	O
examination	B-MED
,	O
there	O
was	O
severe	B-MED
pallor	I-MED
,	O
hepatosplenomegaly	B-MED
and	O
no	B-MED
palpable	I-MED
lymphadenopathy	B-MED
.	O
	
complete	B-MED
blood	I-MED
count	I-MED
revealed	B-MED
bicytopenia	B-MED
with	O
normal	B-MED
total	I-MED
leucocyte	I-MED
count	I-MED
.	O
	
liver	B-MED
and	O
renal	B-MED
function	I-MED
tests	I-MED
were	O
normal	B-MED
.	O
	
ultrasonography	B-MED
abdomen	I-MED
revealed	B-MED
splenic	B-MED
enlargement	I-MED
with	O
two	B-MED
focal	I-MED
lesions	I-MED
attributed	O
to	O
either	O
splenic	B-MED
abscess	I-MED
or	O
infarcts	B-MED
.	O
	
patient	B-MED
was	O
being	O
managed	O
as	O
splenic	B-MED
infarct	I-MED
but	O
continued	O
to	O
have	O
bicytopenia	B-MED
.	O
	
further	O
investigation	B-MED
showed	O
elevated	B-MED
serum	I-MED
ferritin	I-MED
,	O
triglycerides	B-MED
and	O
ldh	B-MED
.	O
	
with	O
a	O
clinical	B-MED
suspicion	B-MED
of	O
infection	B-MED
and	O
haemophagocytic	B-MED
lymphohistiocytosis	I-MED
bone	B-MED
marrow	I-MED
aspiration	I-MED
bma	O
and	O
biopsy	O
bmbx	O
was	O
done	O
.	O
	
bma	O
showed	O
extensive	O
haemophagocytosis	O
and	O
7.4	O
%	O
large	O
lymphoma-like	O
cells	O
.	O
	
on	O
this	O
basis	O
pet-ct	O
was	O
suggested	O
which	O
showed	O
enlarged	O
spleen	O
with	O
diffuse	O
uptake	O
.	O
	
bmbx	O
showed	O
nodular	O
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O
	
on	O
immunohistochemistry	O
,	O
these	O
cells	O
were	O
positive	O
for	O
cd20	O
,	O
cd5	O
,	O
mum1	O
,	O
bcl-2	O
,	O
bcl-6	O
and	O
negative	O
for	O
cd3	O
,	O
cd10	O
and	O
cd23	O
.	O
	
cd34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O
	
the	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	O
of	O
de	O
novo	O
cd5+	O
dlbcl	O
,	O
with	O
primary	O
hepatosplenic	O
pattern	O
of	O
involvement	O
.	O
	
cd5+	O
dlbcl	O
presenting	O
as	O
splenic	O
infarct	O
is	O
very	O
rare	O
.	O
	
this	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	O
of	O
a	O
primary	O
aggressive	O
lymphoma	O
with	O
haemophagocytosis	O
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	O
and	O
splenic	O
infarct	O
without	O
lymphadenopathy	O
.	O
	
this	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	B-MED
marrow	I-MED
aspirate	O
and	O
biopsy	O
to	O
make	O
a	O
correct	O
diagnosis	B-MED
the	O
cost-effectiveness	B-MED
of	O
family	B-MED
/	O
family-based	B-MED
therapy	I-MED
for	O
treatment	B-MED
of	O
externalizing	B-MED
disorders	I-MED
,	O
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
a	O
systematic	O
review	B-MED
family	B-MED
therapy	I-MED
and	O
family-based	B-MED
treatment	I-MED
has	O
been	O
commonly	O
applied	O
in	O
children	B-MED
and	O
adolescents	B-MED
in	O
mental	B-MED
health	I-MED
care	I-MED
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O
	
there	O
is	O
an	O
increased	O
interest	O
in	O
economic	B-MED
evaluations	I-MED
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-MED
.	O
	
the	O
aim	O
of	O
this	O
systematic	O
review	B-MED
is	O
to	O
summarize	O
and	O
evaluate	B-MED
the	O
evidence	O
on	O
cost-effectiveness	B-MED
of	O
family	B-MED
/	O
family-based	B-MED
therapy	I-MED
for	O
externalizing	B-MED
disorders	I-MED
,	O
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
.	O
	
a	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
pubmed	B-MED
,	O
education	B-MED
resource	I-MED
information	I-MED
centre	I-MED
eric	B-MED
,	O
psycinfo	B-MED
and	O
cochrane	B-MED
reviews	B-MED
including	O
studies	B-MED
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
august	O
of	O
2013	O
.	O
	
full	O
economic	B-MED
evaluations	I-MED
investigating	O
family	B-MED
/	O
family-based	B-MED
interventions	I-MED
for	O
adolescents	B-MED
between	O
10	O
and	O
20	O
years	B-MED
treated	B-MED
for	O
substance	B-MED
use	I-MED
disorders	I-MED
,	O
delinquency	B-MED
or	O
externalizing	B-MED
disorders	I-MED
were	O
included	O
.	O
	
seven	O
hundred	O
thirty-one	O
articles	B-MED
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-MED
were	O
initially	O
selected	O
.	O
	
the	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-MED
.	O
	
the	O
quality	B-MED
of	O
these	O
studies	B-MED
was	O
assessed	B-MED
.	O
	
within	O
the	O
identified	O
studies	B-MED
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	B-MED
/	O
family-based	B-MED
interventions	I-MED
and	O
disorders	B-MED
.	O
	
according	O
to	O
the	O
outcomes	B-MED
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	B-MED
of	O
the	O
economic	B-MED
evaluations	I-MED
was	O
low	O
.	O
	
results	O
varied	O
by	O
study	B-MED
.	O
	
due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta-analysis	B-MED
.	O
	
the	O
quality	B-MED
of	O
the	O
identified	O
economic	B-MED
evaluations	I-MED
of	O
family	B-MED
/	O
family-based	B-MED
therapy	I-MED
for	O
treatment	B-MED
of	O
externalizing	B-MED
disorders	I-MED
,	O
adolescent	B-MED
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
was	O
insufficient	O
to	O
determine	O
the	O
cost-effectiveness	B-MED
.	O
	
although	O
commonly	O
applied	O
,	O
family	B-MED
/	O
family-based	B-MED
therapy	I-MED
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	B-MED
regulation	B-MED
of	O
abca1	B-MED
and	O
abcg1	B-MED
gene	B-MED
expression	I-MED
in	O
the	O
intraabdominal	B-MED
adipose	I-MED
tissue	I-MED
tissue	B-MED
specific	I-MED
expression	I-MED
of	I-MED
genes	I-MED
encoding	B-MED
cholesterol	B-MED
transporters	B-MED
abca1	B-MED
and	O
abcg1	B-MED
as	O
well	O
as	O
genes	B-MED
encoding	B-MED
the	O
most	O
important	O
transcriptional	B-MED
regulators	B-MED
of	O
adipogenesis	B-MED
-	O
lxra	B-MED
,	O
lxrb	B-MED
,	O
pparg	B-MED
and	O
rora	B-MED
has	O
been	O
investigated	B-MED
in	O
intraabdominal	B-MED
adipose	I-MED
tissue	I-MED
iat	B-MED
samples	B-MED
a	O
direct	O
correlation	B-MED
between	O
the	O
content	O
of	O
abca1	B-MED
and	O
abcg1	B-MED
proteins	I-MED
with	O
rora	B-MED
protein	I-MED
level	B-MED
r=0	O
,	O
p<0	O
r=0	O
,	O
p<0	O
,	O
respectively	O
suggests	B-MED
the	O
role	O
of	O
the	O
transcription	B-MED
factor	I-MED
rora	B-MED
in	O
the	O
regulation	B-MED
of	O
iat	B-MED
abca1	B-MED
and	O
abcg1	B-MED
protein	I-MED
levels	B-MED
.	O
	
abca1	B-MED
and	O
abcg1	B-MED
gene	B-MED
expression	I-MED
positively	O
correlated	B-MED
with	O
obesity	B-MED
indicators	B-MED
such	O
as	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
r=0	O
,	O
p=0	O
r=0	O
,	O
p=0	O
,	O
respectively	O
and	O
waist	B-MED
circumference	I-MED
r=0	O
,	O
p=0	O
r=0	O
,	O
p=0	O
,	O
respectively	O
.	O
	
the	O
development	B-MED
of	O
obesity	B-MED
is	O
associated	B-MED
with	I-MED
decreased	B-MED
iat	B-MED
levels	B-MED
of	O
rora	B-MED
and	O
lxrb	B-MED
mrna	B-MED
p=0	O
and	O
p=0	O
,	O
respectively	O
.	O
	
these	O
data	B-MED
suggest	B-MED
that	O
the	O
nuclear	B-MED
factor	I-MED
rora	I-MED
can	O
play	O
a	O
significant	B-MED
role	O
in	O
the	O
regulation	B-MED
of	O
cholesterol	B-MED
metabolism	I-MED
and	O
control	B-MED
iat	B-MED
expression	B-MED
of	O
abca1	B-MED
and	O
abcg1	B-MED
,	O
while	O
the	O
level	B-MED
of	O
iat	B-MED
lxrb	B-MED
gene	B-MED
expression	I-MED
may	O
be	O
an	O
important	O
factor	O
associated	B-MED
with	I-MED
the	O
development	B-MED
of	O
triterpenoids	B-MED
from	O
the	O
stems	B-MED
of	O
tripterygium	B-MED
regelii	I-MED
three	O
new	O
triterpenoids	B-MED
,	O
triregelolides	B-MED
a	O
,	O
b	O
1	O
,	O
2	O
,	O
and	O
triregeloic	B-MED
acid	I-MED
3	O
,	O
were	O
isolated	B-MED
from	O
the	O
stems	B-MED
of	O
tripterygium	B-MED
regelii	I-MED
along	O
with	O
twenty	O
known	O
triterpene	B-MED
analogues	B-MED
4-23	O
.	O
	
the	O
structures	O
of	O
three	O
new	O
compounds	B-MED
were	O
identified	O
by	O
analyzing	O
their	O
nmr	B-MED
spectroscopic	I-MED
and	O
hresims	B-MED
data	O
.	O
	
compounds	B-MED
4	B-MED
,	O
7	B-MED
,	O
8	B-MED
,	O
10	B-MED
,	O
13	B-MED
,	O
14	B-MED
,	O
17	B-MED
,	O
21-23	B-MED
were	O
isolated	B-MED
from	O
t	B-MED
.	O
	
regelii	I-MED
for	O
the	O
first	O
time	O
.	O
	
compounds	B-MED
3	B-MED
,	O
5	B-MED
,	O
6	B-MED
,	O
8	B-MED
,	O
9	B-MED
,	O
10	B-MED
,	O
14	B-MED
and	O
16	B-MED
showed	O
inhibitory	B-MED
effects	I-MED
on	I-MED
the	I-MED
proliferation	I-MED
of	O
human	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
mcf-7	B-MED
by	O
24.1	O
,	O
69.6	O
,	O
72.8	O
,	O
21.6	O
,	O
23.1	O
,	O
43.3	O
,	O
25.5	O
and	O
23.5	O
p<0	O
at	O
a	O
concentration	B-MED
biochemical	B-MED
evidence	O
for	O
a	O
mitochondrial	B-MED
genetic	B-MED
modifier	B-MED
in	O
the	O
phenotypic	B-MED
manifestation	B-MED
of	O
leber's	B-MED
hereditary	I-MED
optic	I-MED
neuropathy	I-MED
-associated	O
mitochondrial	B-MED
dna	I-MED
mutation	I-MED
leber's	B-MED
hereditary	I-MED
optic	I-MED
neuropathy	I-MED
lhon	B-MED
is	O
the	O
most	O
common	O
mitochondrial	B-MED
disease	I-MED
.	O
	
mitochondrial	B-MED
modifiers	B-MED
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	B-MED
expression	I-MED
of	O
primary	O
lhon	B-MED
-associated	O
mitochondrial	B-MED
dna	I-MED
mtdna	B-MED
mutations	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
demonstrated	O
that	O
the	O
lhon	B-MED
susceptibility	B-MED
allele	B-MED
m.14502t	B-MED
>	I-MED
c	I-MED
,	O
p	B-MED
.	O
	
58i	I-MED
>	I-MED
v	I-MED
in	O
the	O
nd6	B-MED
gene	I-MED
modulated	B-MED
the	O
phenotypic	B-MED
expression	I-MED
of	O
primary	O
lhon	B-MED
-associated	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
.	O
	
twenty-two	O
han	B-MED
chinese	I-MED
pedigrees	B-MED
carrying	O
m.14502t	B-MED
>	I-MED
c	I-MED
and	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutations	I-MED
exhibited	O
significantly	O
higher	O
penetrance	B-MED
of	O
optic	B-MED
neuropathy	I-MED
than	O
those	O
carrying	O
only	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
.	O
	
we	O
performed	O
functional	B-MED
assays	B-MED
using	O
the	O
cybrid	B-MED
cell	I-MED
models	I-MED
,	O
generated	O
by	O
fusing	O
mtdna-less	B-MED
ρ	I-MED
cells	I-MED
with	O
enucleated	B-MED
cells	I-MED
from	O
lhon	B-MED
patients	B-MED
carrying	O
both	O
m.11778g	B-MED
>	I-MED
a	I-MED
and	O
m.14502t	B-MED
>	I-MED
c	I-MED
mutations	I-MED
,	O
only	O
m.14502t	B-MED
>	I-MED
c	I-MED
or	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtdna	B-MED
haplogroup	B-MED
.	O
	
these	O
cybrids	B-MED
cell	I-MED
lines	I-MED
bearing	O
m.14502t	B-MED
>	I-MED
c	I-MED
mutation	I-MED
exhibited	O
mild	O
effects	B-MED
on	O
mitochondrial	B-MED
functions	B-MED
compared	O
with	O
those	O
carrying	O
only	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
.	O
	
however	O
,	O
more	O
severe	O
mitochondrial	B-MED
dysfunctions	B-MED
were	O
observed	O
in	O
cell	B-MED
lines	I-MED
bearing	O
both	O
m.14502t	B-MED
>	I-MED
c	I-MED
and	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutations	I-MED
than	O
those	O
carrying	O
only	O
m.11778g	B-MED
>	I-MED
a	I-MED
or	O
m.14502t	B-MED
>	I-MED
c	I-MED
mutation	I-MED
.	O
	
in	O
particular	O
,	O
the	O
m.14502t	B-MED
>	I-MED
c	I-MED
mutation	I-MED
altered	O
assemble	O
of	O
complex	B-MED
i	I-MED
,	O
thereby	O
aggravating	O
the	O
respiratory	B-MED
phenotypes	B-MED
associated	O
with	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
,	O
resulted	O
in	O
a	O
more	O
defective	B-MED
complex	B-MED
i	I-MED
.	O
	
furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-MED
atp	B-MED
and	O
increasing	O
production	O
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
were	O
also	O
observed	O
in	O
mutant	B-MED
cells	B-MED
bearing	O
both	O
m.14502t	B-MED
>	I-MED
c	I-MED
and	O
m.11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
than	O
those	O
carrying	O
only	O
11778g	B-MED
>	I-MED
a	I-MED
mutation	I-MED
.	O
	
our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	B-MED
of	O
lhon	B-MED
that	O
were	O
manifested	B-MED
by	I-MED
interaction	O
between	O
primary	O
and	O
secondary	O
mtdna	B-MED
mutations	B-MED
.	O
	
improving	B-MED
care	B-MED
transitions	I-MED
across	O
healthcare	B-MED
settings	B-MED
through	O
a	O
human	B-MED
factors	I-MED
approach	O
after	O
more	O
than	O
two	O
decades	B-MED
of	O
research	B-MED
focused	O
on	O
care	B-MED
transition	I-MED
improvement	B-MED
and	O
intervention	B-MED
development	B-MED
,	O
unfavorable	B-MED
outcome	I-MED
measures	B-MED
associated	B-MED
with	I-MED
care	B-MED
transitions	I-MED
across	O
healthcare	B-MED
settings	B-MED
persist	O
.	O
	
readmissions	B-MED
rates	B-MED
remain	O
an	O
important	O
outcome	B-MED
to	O
target	B-MED
for	O
intervention	B-MED
,	O
adverse	B-MED
events	I-MED
associated	B-MED
with	I-MED
care	B-MED
transitions	I-MED
continue	O
to	O
be	O
an	O
issue	B-MED
,	O
and	O
patients	B-MED
are	O
often	O
dissatisfied	B-MED
with	O
the	O
quality	B-MED
of	O
their	O
care	B-MED
.	O
	
currently	O
,	O
interventions	B-MED
to	O
improve	O
care	B-MED
transitions	I-MED
are	O
disease	B-MED
specific	B-MED
,	O
require	O
substantial	B-MED
financial	B-MED
investments	I-MED
in	O
training	B-MED
allied	B-MED
healthcare	I-MED
professionals	I-MED
,	O
or	O
focus	O
primarily	O
on	O
hospital-based	B-MED
discharge	I-MED
planning	I-MED
with	O
mixed	O
results	O
.	O
	
this	O
complex	B-MED
situation	I-MED
requires	O
a	O
method	B-MED
of	I-MED
evaluation	I-MED
that	O
can	O
provide	O
a	O
comprehensive	B-MED
,	O
in-depth	B-MED
,	O
and	O
context-driven	B-MED
investigation	B-MED
of	O
potential	B-MED
risks	I-MED
to	O
safe	O
care	B-MED
transitions	I-MED
across	O
healthcare	B-MED
settings	B-MED
,	O
which	O
can	O
lead	O
to	O
the	O
creation	B-MED
of	O
effective	B-MED
,	O
usable	B-MED
,	O
and	O
sustainable	B-MED
interventions	B-MED
.	O
	
a	O
systems'	O
approach	O
known	O
as	O
human	B-MED
factors	I-MED
and	I-MED
ergonomics	I-MED
hfe	B-MED
evaluates	B-MED
the	O
factors	B-MED
in	O
a	O
system	O
that	O
affect	O
human	B-MED
performance	I-MED
.	O
	
this	O
article	B-MED
describes	O
how	O
hfe	B-MED
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	B-MED
care	B-MED
transitions	I-MED
.	O
	
adenosine	B-MED
and	O
the	O
adenosine	B-MED
a2a	I-MED
receptor	I-MED
agonist	I-MED
,	O
cgs21680	B-MED
,	O
upregulate	B-MED
cd39	B-MED
and	O
cd73	B-MED
expression	B-MED
through	O
e2f-1	B-MED
and	O
creb	B-MED
in	O
regulatory	B-MED
t	I-MED
cells	I-MED
isolated	B-MED
from	O
septic	B-MED
mice	B-MED
the	O
number	O
of	O
regulatory	B-MED
t	I-MED
cells	I-MED
treg	B-MED
cells	I-MED
and	O
the	O
expression	B-MED
of	O
ectonucleoside	B-MED
triphosphate	I-MED
diphosphohydrolase	I-MED
1	I-MED
entpd1	B-MED
also	O
known	O
as	O
cd39	B-MED
and	O
5'-ectonucleotidase	B-MED
nt5e	B-MED
also	O
known	O
as	O
cd73	B-MED
on	O
the	O
treg	B-MED
cell	I-MED
surface	B-MED
are	O
increased	B-MED
during	O
sepsis	B-MED
.	O
	
in	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	B-MED
leading	O
to	O
the	O
high	B-MED
expression	B-MED
of	O
cd39	B-MED
and	O
cd73	B-MED
,	O
and	O
the	O
regulation	B-MED
of	I-MED
the	O
cd39	B-MED
/	O
cd73	B-MED
/	O
adenosine	B-MED
pathway	B-MED
in	O
treg	B-MED
cells	I-MED
under	O
septic	B-MED
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-MED
model	I-MED
of	O
sepsis	B-MED
and	O
separated	O
the	O
treg	B-MED
cells	I-MED
using	O
a	O
flow	B-MED
cytometer	I-MED
.	O
	
the	O
treg	B-MED
cells	I-MED
isolated	B-MED
from	O
the	O
peritoneal	B-MED
lavage	I-MED
and	O
splenocytes	B-MED
of	O
the	O
mice	B-MED
were	O
treated	B-MED
with	I-MED
adenosine	B-MED
or	O
the	O
specific	O
adenosine	B-MED
a2a	I-MED
receptor	I-MED
agonist	I-MED
,	O
cgs21680	B-MED
,	O
and	O
were	O
transfected	B-MED
with	O
specific	O
sirna	B-MED
targeting	B-MED
e2f	B-MED
transcription	I-MED
factor	I-MED
1	I-MED
e2f-1	B-MED
or	O
cyclic	B-MED
adenosine	I-MED
monophosphate	I-MED
camp	I-MED
response	I-MED
element-binding	I-MED
protein	I-MED
creb	B-MED
,	O
which	O
are	O
predicted	O
transcription	B-MED
regulatory	I-MED
factors	I-MED
of	O
cd39	B-MED
or	O
cd73	B-MED
.	O
	
the	O
regulatory	B-MED
relationships	O
among	O
these	O
factors	B-MED
were	O
then	O
determined	O
by	O
western	B-MED
blot	I-MED
analysis	I-MED
and	O
dual-luciferase	B-MED
reporter	I-MED
assay	I-MED
.	O
	
in	O
addition	O
,	O
changes	B-MED
in	O
adenosine	B-MED
metabolism	I-MED
were	O
measured	O
in	O
the	O
treated	B-MED
cells	B-MED
.	O
	
the	O
results	O
revealed	O
that	O
adenosine	B-MED
and	O
cgs21680	B-MED
significantly	O
upregulated	B-MED
cd39	B-MED
and	O
cd73	B-MED
expression	B-MED
p<0	O
.	O
	
e2f-1	B-MED
and	O
creb	B-MED
induced	O
cd39	B-MED
and	O
cd73	B-MED
expression	B-MED
,	O
and	O
were	O
upregulated	B-MED
by	O
adenosine	B-MED
and	O
cgs21680	B-MED
.	O
	
adenosine	B-MED
triphosphate	I-MED
atp	I-MED
hydrolysis	I-MED
and	O
adenosine	B-MED
generation	B-MED
were	O
inhibited	B-MED
by	O
the	O
knockdown	B-MED
of	O
e2f-1	B-MED
or	O
creb	B-MED
,	O
and	O
were	O
accelerated	B-MED
in	O
the	O
presence	O
of	O
cgs21680	B-MED
.	O
	
based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-MED
,	O
the	O
adenosine	B-MED
a2a	I-MED
receptor	I-MED
agonist	I-MED
,	O
e2f-1	B-MED
and	O
creb	B-MED
are	O
the	O
possible	O
factors	B-MED
contributing	O
to	O
the	O
high	B-MED
expression	B-MED
of	O
cd39	B-MED
and	O
cd73	B-MED
on	O
the	O
treg	B-MED
cell	I-MED
surface	B-MED
during	O
sepsis	B-MED
.	O
	
adenosine	B-MED
and	O
its	O
a2a	B-MED
receptor	I-MED
agonist	I-MED
served	O
as	O
the	O
signal	B-MED
transducer	I-MED
factors	B-MED
of	O
the	O
cd39	B-MED
/	O
cd73	B-MED
/	O
adenosine	B-MED
pathway	B-MED
,	O
accelerating	B-MED
adenosine	B-MED
generation	B-MED
.	O
	
our	O
study	O
may	O
benefit	O
further	O
research	B-MED
on	O
adenosine	B-MED
metabolism	I-MED
for	O
the	O
treatment	B-MED
of	O
exploring	O
consumer	B-MED
and	O
patient	B-MED
knowledge	B-MED
,	O
behavior	B-MED
,	O
and	O
attitude	B-MED
toward	B-MED
medicinal	B-MED
and	O
lifestyle	B-MED
products	I-MED
purchased	B-MED
from	O
the	O
internet	B-MED
a	O
web	B-MED
-	O
based	B-MED
survey	B-MED
in	O
recent	O
years	O
,	O
lifestyle	B-MED
products	I-MED
have	O
emerged	O
to	O
help	O
improve	B-MED
people's	B-MED
physical	B-MED
and	O
mental	B-MED
performance	B-MED
.	O
	
the	O
internet	B-MED
plays	O
a	O
major	B-MED
role	B-MED
in	O
the	O
spread	B-MED
of	O
these	O
products	B-MED
.	O
	
however	O
,	O
the	O
literature	B-MED
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	B-MED
of	O
medicines	B-MED
purchased	B-MED
from	O
the	O
internet	B-MED
and	O
the	O
impact	B-MED
of	O
counterfeit	B-MED
medicines	I-MED
on	O
public	B-MED
health	B-MED
.	O
	
little	O
or	O
no	B-MED
data	I-MED
are	I-MED
available	I-MED
on	O
the	O
authenticity	B-MED
of	O
lifestyle	B-MED
products	I-MED
and	O
actual	O
toxicity	B-MED
associated	B-MED
with	I-MED
their	O
use	B-MED
and	O
misuse	B-MED
.	O
	
our	O
aim	O
was	O
to	O
investigate	B-MED
consumer	B-MED
and	O
patient	B-MED
attitudes	I-MED
toward	B-MED
the	O
purchase	B-MED
of	O
lifestyle	B-MED
products	I-MED
from	O
the	O
internet	B-MED
,	O
their	O
knowledge	B-MED
of	O
product	B-MED
authenticity	B-MED
and	O
toxicity	B-MED
,	O
and	O
their	O
experiences	B-MED
with	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
.	O
	
a	O
web	B-MED
-	O
based	B-MED
study	B-MED
was	O
performed	B-MED
between	O
may	O
2014	O
and	O
may	O
2015	O
.	O
	
uniform	B-MED
collection	B-MED
of	I-MED
data	I-MED
was	O
performed	B-MED
through	B-MED
an	O
anonymous	B-MED
online	B-MED
questionnaire	B-MED
.	O
	
participants	B-MED
were	O
invited	O
worldwide	B-MED
via	O
email	B-MED
,	O
social	B-MED
media	I-MED
,	O
or	O
personal	B-MED
communication	I-MED
to	O
complete	B-MED
the	O
online	B-MED
questionnaire	B-MED
.	O
	
a	O
total	B-MED
of	O
320	O
participants	B-MED
completed	B-MED
the	O
questionnaire	B-MED
.	O
	
the	O
results	B-MED
of	O
the	O
questionnaire	B-MED
showed	O
that	O
208	O
65.0	O
participants	B-MED
purchased	B-MED
lifestyle	B-MED
products	I-MED
from	O
the	O
internet	B-MED
mainly	B-MED
due	B-MED
to	I-MED
convenience	B-MED
and	O
reduced	B-MED
cost	B-MED
.	O
	
more	B-MED
than	I-MED
half	B-MED
55.6	O
,	O
178/320	O
of	O
participants	B-MED
purchased	B-MED
cosmetic	B-MED
products	I-MED
,	O
whereas	O
only	O
a	O
minority	B-MED
purchased	B-MED
medicinal	B-MED
products	I-MED
.	O
	
yet	O
,	O
62.8	O
201/320	O
of	O
participants	B-MED
were	O
aware	B-MED
of	O
the	O
presence	B-MED
of	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
from	O
the	O
internet	B-MED
,	O
and	O
11.9	O
38/320	O
experienced	B-MED
counterfeit	B-MED
products	B-MED
.	O
	
in	O
only	O
0.9	O
3/320	O
of	O
those	O
cases	B-MED
were	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
reported	B-MED
to	O
authorities	B-MED
.	O
	
moreover	O
,	O
7.2	O
23/320	O
of	O
the	O
participants	B-MED
experienced	B-MED
adverse	B-MED
effects	I-MED
due	O
to	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
.	O
	
in	O
summary	O
,	O
patients	B-MED
experienced	B-MED
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
that	O
resulted	B-MED
in	I-MED
adverse	B-MED
effects	I-MED
on	O
their	O
health	B-MED
.	O
	
although	O
certain	O
adverse	B-MED
effects	I-MED
were	O
reported	B-MED
in	O
this	O
study	B-MED
,	O
counterfeit	B-MED
products	B-MED
were	O
underreported	B-MED
to	O
authorities	B-MED
.	O
	
further	O
public	B-MED
awareness	I-MED
campaigns	I-MED
and	O
patient	B-MED
education	I-MED
are	O
it's	O
not	O
all	O
doom	O
and	O
gloom	O
prune	B-MED
belly	I-MED
syndrome	I-MED
associated	B-MED
with	I-MED
vacterl	I-MED
prune	B-MED
belly	I-MED
syndrome	I-MED
is	O
a	O
rare	B-MED
abnormality	B-MED
its	O
association	B-MED
with	I-MED
vacterl	I-MED
is	O
even	O
rarer	B-MED
.	O
	
this	O
association	B-MED
has	O
been	O
reported	B-MED
in	O
literature	B-MED
a	O
few	O
times	O
since	O
first	O
reported	B-MED
in	O
1993	O
and	O
so	O
far	O
the	O
majority	B-MED
have	O
either	O
been	O
stillbirths	B-MED
or	I-MED
died	I-MED
shortly	I-MED
after	I-MED
birth	I-MED
.	O
	
we	O
present	O
a	O
case	B-MED
of	O
prune	B-MED
belly	I-MED
syndrome	I-MED
associated	B-MED
with	I-MED
vacterl	I-MED
changes	B-MED
in	O
cardiovascular	B-MED
health	B-MED
status	I-MED
and	O
the	O
risk	B-MED
of	I-MED
new-onset	B-MED
hypertension	I-MED
in	O
kailuan	B-MED
cohort	B-MED
study	I-MED
american	B-MED
heart	I-MED
association	I-MED
cardiovascular	B-MED
health	B-MED
metrics	I-MED
are	O
intimately	O
related	O
to	O
cardiovascular	B-MED
diseases	I-MED
.	O
	
acting	O
as	O
a	O
key	B-MED
independent	O
risk	B-MED
factor	I-MED
for	O
high	B-MED
morbidity	B-MED
and	O
mortality	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
,	O
hypertension	B-MED
and	O
its	O
relationship	B-MED
between	O
health	B-MED
status	I-MED
get	O
urgent	O
attention	B-MED
.	O
	
while	O
the	O
influence	B-MED
of	O
individual	B-MED
health	B-MED
status	I-MED
changes	B-MED
and	O
the	O
future	O
risk	B-MED
of	I-MED
new-onset	B-MED
hypertension	I-MED
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-MED
the	O
changes	B-MED
of	O
cardiovascular	B-MED
health	B-MED
status	I-MED
and	O
the	O
morbidity	B-MED
of	O
hypertension	B-MED
in	O
kailuan	B-MED
cohort	B-MED
study	I-MED
in	O
north	B-MED
china	B-MED
.	O
	
the	O
cardiovascular	B-MED
health	B-MED
score	I-MED
chs	B-MED
was	O
evaluated	B-MED
by	O
the	O
follow-ups	B-MED
of	O
2006-2007	O
,	O
2008-2009	O
,	O
2010-2011	O
and	O
2012-2013	O
.	O
	
the	O
study	B-MED
population	I-MED
n	O
=	O
19381	O
was	O
divided	B-MED
into	O
5	O
groups	B-MED
based	O
on	O
the	O
changes	B-MED
in	O
their	O
chs	B-MED
score	I-MED
between	O
the	O
first	O
two	O
follow-ups	B-MED
chs	O
of	O
2006-2007	O
and	O
2008-2009	O
-2	O
,	O
-1	O
,	O
0	O
,	O
1	O
,	O
2	O
.	O
	
the	O
morbidity	B-MED
of	O
hypertension	B-MED
was	O
collected	B-MED
during	B-MED
2010-2011	O
and	O
2012-2013	O
follow-ups	B-MED
.	O
	
data	B-MED
analysis	I-MED
showed	O
that	O
during	B-MED
a	O
median	B-MED
follow-up	B-MED
of	O
3.79	O
years	O
,	O
morbidity	B-MED
of	O
hypertension	B-MED
had	O
a	O
graded	O
relationship	B-MED
with	O
chs	O
.	O
	
as	O
chs	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	B-MED
morbidity	B-MED
of	O
hypertension	B-MED
for	O
all	O
participants	B-MED
were	O
81.40	O
,	O
75.47	O
,	O
68.37	O
,	O
71.43	O
and	O
83.13	O
per	O
1000	O
person-year	O
,	O
respectively	O
.	O
	
an	O
increased	B-MED
chs	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10%	O
decrease	B-MED
in	O
the	O
future	B-MED
risk	B-MED
of	I-MED
new-onset	B-MED
hypertension	I-MED
hr	O
0.90	O
,	O
95%	O
ci	B-MED
0.88	O
.	O
	
in	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	B-MED
between	O
the	O
incidence	O
of	O
new-onset	B-MED
hypertension	I-MED
and	O
elevation	B-MED
of	O
cardiovascular	B-MED
health	B-MED
metrics	I-MED
.	O
	
population	B-MED
-wide	O
prevention	B-MED
,	O
especially	O
the	O
promotion	B-MED
of	O
lifestyle	B-MED
improvements	B-MED
,	O
is	O
critical	B-MED
to	O
reducing	B-MED
the	O
morbidity	B-MED
of	O
new-onset	B-MED
hypertension	I-MED
.	O
	
an	O
hiv	B-MED
-	O
tailored	B-MED
quit	B-MED
-	O
smoking	B-MED
counselling	B-MED
pilot	B-MED
intervention	B-MED
targeting	B-MED
depressive	B-MED
symptoms	I-MED
plus	O
nicotine	B-MED
replacement	I-MED
therapy	I-MED
cardiovascular	B-MED
disease	I-MED
cvd	B-MED
rates	B-MED
among	O
people	B-MED
living	B-MED
with	I-MED
hiv/aids	I-MED
phas	B-MED
are	O
high	B-MED
.	O
	
rates	B-MED
of	O
cigarette	B-MED
smoking	I-MED
,	O
a	O
leading	B-MED
contributor	B-MED
to	O
cvd	B-MED
among	O
phas	B-MED
,	O
are	O
40-70%	O
2-3	O
times	O
higher	B-MED
than	O
the	O
general	B-MED
population	I-MED
.	O
	
furthermore	O
,	O
phas	B-MED
have	O
high	B-MED
rates	B-MED
of	O
depression	B-MED
40-60%	O
,	O
a	O
risk	B-MED
factor	I-MED
for	O
smoking	B-MED
cessation	B-MED
relapse	B-MED
.	O
	
the	O
current	O
pilot	B-MED
study	I-MED
examined	B-MED
the	O
effectiveness	B-MED
of	O
a	O
specifically	O
tailored	B-MED
5-	O
session	B-MED
smoking	B-MED
cessation	B-MED
counselling	B-MED
programme	I-MED
for	O
phas	B-MED
,	O
which	O
addressed	O
depression	B-MED
,	O
in	O
combination	O
with	O
nicotine	B-MED
replacement	I-MED
therapy	I-MED
nrt	B-MED
in	O
a	O
cohort	B-MED
of	O
pha	B-MED
smokers	B-MED
n	O
=	O
50	O
.	O
	
at	O
6-	O
month	B-MED
follow-up	B-MED
,	O
28%	O
of	O
participants	B-MED
demonstrated	O
biochemically	B-MED
verified	B-MED
abstinence	B-MED
from	O
smoking	B-MED
.	O
	
this	O
result	B-MED
compares	B-MED
favourably	O
to	O
other	O
quit	B-MED
-	O
smoking	B-MED
intervention	B-MED
studies	B-MED
,	O
particularly	O
given	O
the	O
high	B-MED
percentage	B-MED
of	O
hiv+	B-MED
smokers	B-MED
with	O
depression	B-MED
.	O
	
at	O
study	B-MED
baseline	B-MED
,	O
52%	O
of	O
hiv+	B-MED
smokers	B-MED
scored	O
above	O
the	O
clinical	B-MED
cut-off	B-MED
for	O
depression	B-MED
on	O
the	O
centre	B-MED
for	I-MED
epidemiological	I-MED
studies	I-MED
-	I-MED
depression	I-MED
ces-d	I-MED
scale	I-MED
.	O
	
hiv+	B-MED
smokers	B-MED
with	O
depression	B-MED
at	O
study	B-MED
baseline	B-MED
demonstrated	O
quantitatively	B-MED
lower	B-MED
depression	B-MED
at	O
6-	O
month	B-MED
follow-up	B-MED
with	O
a	O
large	B-MED
effect	B-MED
size	I-MED
d	O
=	O
1	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	B-MED
significance	I-MED
p	O
=	O
058	O
.	O
	
furthermore	O
,	O
those	O
with	O
depression	B-MED
were	O
no	O
more	O
likely	O
to	O
relapse	B-MED
than	O
those	O
without	O
depression	B-MED
p	O
=	O
33	O
,	O
suggesting	O
that	O
our	O
counselling	B-MED
programme	I-MED
adequately	B-MED
addressed	O
this	O
significant	B-MED
barrier	B-MED
to	O
smoking	B-MED
cessation	B-MED
among	O
phas	B-MED
.	O
	
our	O
pilot	B-MED
study	I-MED
indicates	O
the	O
importance	B-MED
of	O
tailored	B-MED
programmes	I-MED
to	O
help	O
phas	B-MED
quit	B-MED
smoking	B-MED
,	O
the	O
significance	B-MED
of	O
addressing	O
depressive	B-MED
symptoms	I-MED
,	O
and	O
the	O
need	O
for	O
tailored	B-MED
counselling	I-MED
programmes	I-MED
to	O
enhance	B-MED
quit	B-MED
rates	B-MED
among	O
effects	B-MED
of	I-MED
complex	B-MED
life	B-MED
cycles	I-MED
on	O
genetic	B-MED
diversity	I-MED
cyclical	B-MED
parthenogenesis	I-MED
neutral	O
patterns	O
of	O
population	B-MED
genetic	B-MED
diversity	I-MED
in	O
species	B-MED
with	O
complex	B-MED
life	B-MED
cycles	I-MED
are	O
difficult	O
to	O
anticipate	B-MED
.	O
	
cyclical	B-MED
parthenogenesis	I-MED
cp	B-MED
,	O
in	O
which	O
organisms	B-MED
undergo	O
several	O
rounds	O
of	O
clonal	B-MED
reproduction	B-MED
followed	O
by	O
a	O
sexual	B-MED
event	I-MED
,	O
is	O
one	O
such	O
life	B-MED
cycle	I-MED
.	O
	
many	O
species	B-MED
,	O
including	O
crop	B-MED
pests	B-MED
aphids	B-MED
,	O
human	B-MED
parasites	I-MED
trematodes	B-MED
or	O
models	B-MED
used	O
in	O
evolutionary	B-MED
science	I-MED
daphnia	B-MED
,	O
are	O
cyclical	B-MED
parthenogens	I-MED
.	O
	
it	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	B-MED
cycle	I-MED
on	O
neutral	O
genetic	B-MED
diversity	I-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
describe	O
distributions	B-MED
of	O
genetic	B-MED
diversity	I-MED
under	O
conditions	B-MED
of	O
cp	B-MED
with	O
various	O
clonal	B-MED
phase	B-MED
lengths	B-MED
.	O
	
using	O
a	O
markov	B-MED
chain	I-MED
model	I-MED
of	O
cp	B-MED
for	O
a	O
single	B-MED
locus	B-MED
and	O
individual-based	O
simulations	B-MED
for	O
two	B-MED
loci	B-MED
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	B-MED
from	O
full	O
sexuality	B-MED
are	O
observed	O
after	O
only	O
a	O
few	O
generations	B-MED
of	O
clonality	B-MED
.	O
	
the	O
convergence	B-MED
towards	O
predictions	B-MED
made	O
under	O
conditions	O
of	O
full	O
clonality	B-MED
during	O
the	O
clonal	B-MED
phase	B-MED
depends	O
on	O
the	O
balance	O
between	O
mutations	B-MED
and	O
genetic	B-MED
drift	I-MED
.	O
	
second	O
,	O
the	O
sexual	B-MED
event	I-MED
of	O
cp	B-MED
usually	O
resets	O
the	O
genetic	B-MED
diversity	I-MED
at	O
a	O
single	B-MED
locus	B-MED
towards	O
predictions	B-MED
made	O
under	O
full	O
sexuality	B-MED
.	O
	
however	O
,	O
this	O
single	O
recombination	B-MED
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	B-MED
phases	I-MED
towards	O
full-sexuality	B-MED
predictions	B-MED
.	O
	
finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	B-MED
,	O
cp	B-MED
and	O
acyclic	O
partial	B-MED
clonality	B-MED
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-MED
are	O
clonally	B-MED
produced	O
within	O
each	O
generation	B-MED
differentially	O
affect	O
the	O
distribution	B-MED
of	O
genetic	B-MED
diversity	I-MED
.	O
	
overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	B-MED
of	O
neutral	O
genetic	B-MED
diversity	I-MED
that	O
may	O
serve	O
as	O
a	O
null	B-MED
model	I-MED
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-MED
or	O
demographic	B-MED
processes	B-MED
in	O
cyclical	B-MED
parthenogens	I-MED
recent	B-MED
advances	B-MED
in	O
chitosan	B-MED
-based	O
nanoparticulate	B-MED
pulmonary	B-MED
drug	B-MED
delivery	I-MED
the	O
advent	O
of	O
biodegradable	B-MED
polymer	I-MED
-	O
encapsulated	B-MED
drug	B-MED
nanoparticles	B-MED
has	O
made	O
the	O
pulmonary	B-MED
route	B-MED
of	I-MED
administration	I-MED
an	O
exciting	O
area	O
of	O
drug	B-MED
delivery	I-MED
research	B-MED
.	O
	
chitosan	B-MED
,	O
a	O
natural	B-MED
biodegradable	B-MED
and	O
biocompatible	B-MED
polysaccharide	B-MED
has	O
received	B-MED
enormous	O
attention	O
as	O
a	O
carrier	B-MED
for	O
drug	B-MED
delivery	I-MED
.	O
	
recently	O
,	O
nanoparticles	B-MED
of	O
chitosan	B-MED
cs	B-MED
and	O
its	O
synthetic	B-MED
derivatives	I-MED
have	O
been	O
investigated	B-MED
for	O
the	O
encapsulation	B-MED
and	O
delivery	B-MED
of	O
many	O
drugs	B-MED
with	O
improved	B-MED
targeting	B-MED
and	O
controlled	B-MED
release	I-MED
.	O
	
herein	O
,	O
recent	B-MED
advances	B-MED
in	O
the	O
preparation	B-MED
and	O
use	B-MED
of	I-MED
micro-	B-MED
/	O
nanoparticles	B-MED
of	O
chitosan	B-MED
and	O
its	O
derivatives	B-MED
for	O
pulmonary	B-MED
delivery	B-MED
of	O
various	O
therapeutic	B-MED
agents	I-MED
drugs	B-MED
,	O
genes	B-MED
,	O
vaccines	B-MED
are	O
reviewed	B-MED
.	O
	
although	O
chitosan	B-MED
has	O
wide	O
applications	B-MED
in	O
terms	O
of	O
formulations	B-MED
and	O
routes	B-MED
of	I-MED
drug	I-MED
delivery	I-MED
,	O
this	O
review	B-MED
is	O
focused	O
on	O
pulmonary	B-MED
delivery	B-MED
of	I-MED
drug-encapsulated	I-MED
nanoparticles	I-MED
of	O
chitosan	B-MED
and	O
its	O
derivatives	B-MED
.	O
	
in	O
addition	O
,	O
the	O
controversial	B-MED
toxicological	B-MED
effects	I-MED
of	O
chitosan	B-MED
nanoparticles	B-MED
for	O
lung	B-MED
delivery	B-MED
form	B-MED
and	O
function	B-MED
in	O
gene	B-MED
regulatory	I-MED
networks	I-MED
the	O
structure	B-MED
of	O
network	B-MED
motifs	I-MED
determines	O
fundamental	B-MED
properties	I-MED
of	O
their	O
dynamical	B-MED
state	I-MED
space	I-MED
network	B-MED
motifs	I-MED
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	B-MED
,	O
such	O
as	O
the	O
feed-forward	B-MED
loop	I-MED
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	B-MED
networks	I-MED
.	O
	
recent	B-MED
studies	B-MED
have	O
used	O
boolean	B-MED
network	B-MED
motifs	B-MED
to	O
explore	O
the	O
link	O
between	O
form	B-MED
and	O
function	B-MED
in	O
gene	B-MED
regulatory	I-MED
networks	I-MED
and	O
have	O
found	O
that	O
the	O
structure	B-MED
of	O
a	O
motif	B-MED
does	O
not	O
strongly	O
determine	O
its	O
function	B-MED
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	B-MED
expression	I-MED
patterns	B-MED
the	O
motif	B-MED
can	O
produce	O
.	O
	
here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	B-MED
-	O
level	B-MED
definition	B-MED
of	O
the	O
'	O
function	B-MED
'	O
of	O
a	O
motif	B-MED
,	O
in	O
terms	O
of	O
two	O
fundamental	B-MED
properties	I-MED
of	O
its	O
dynamical	B-MED
state	I-MED
space	I-MED
as	O
a	O
boolean	B-MED
network	B-MED
.	O
	
one	O
is	O
the	O
basin	B-MED
entropy	I-MED
,	O
which	O
is	O
a	O
complexity	B-MED
measure	B-MED
of	O
the	O
dynamics	B-MED
of	O
boolean	B-MED
networks	B-MED
.	O
	
the	O
other	O
is	O
the	O
diversity	B-MED
of	O
cyclic	B-MED
attractor	I-MED
lengths	I-MED
that	O
a	O
given	O
motif	B-MED
can	O
produce	O
.	O
	
using	O
these	O
two	O
measures	B-MED
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three-node	B-MED
motifs	B-MED
and	O
show	O
that	O
the	O
structural	B-MED
properties	B-MED
of	O
a	O
motif	B-MED
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	B-MED
loops	I-MED
and	O
feed-forward	B-MED
loops	I-MED
,	O
predict	O
fundamental	B-MED
characteristics	I-MED
of	O
its	O
dynamical	B-MED
state	I-MED
space	I-MED
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	B-MED
versatility	I-MED
.	O
	
we	O
also	O
show	O
that	O
these	O
higher	B-MED
-	O
level	B-MED
properties	B-MED
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	B-MED
networks	I-MED
,	O
as	O
both	O
basin	B-MED
entropy	I-MED
and	O
cycle	B-MED
length	I-MED
diversity	B-MED
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	B-MED
,	O
in	O
neural	B-MED
and	O
genetic	B-MED
regulatory	I-MED
networks	I-MED
,	O
of	O
the	O
13	O
connected	O
motifs	B-MED
without	O
self-interactions	B-MED
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
jak1	B-MED
-	O
stat3	B-MED
signals	B-MED
are	O
essential	B-MED
effectors	B-MED
of	O
the	O
usp6	B-MED
/	O
tre17	B-MED
oncogene	I-MED
in	O
tumorigenesis	B-MED
bone	B-MED
and	O
soft	B-MED
tissue	I-MED
tumors	I-MED
bstt	B-MED
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	B-MED
of	O
effective	B-MED
therapies	B-MED
.	O
	
here	O
we	O
report	B-MED
a	O
role	O
for	O
the	O
ubiquitin-specific	B-MED
protease	I-MED
6	I-MED
usp6	B-MED
tre17	B-MED
oncogene	I-MED
,	O
which	O
is	O
overexpressed	B-MED
upon	O
chromosome	B-MED
translocation	I-MED
in	O
various	O
human	B-MED
tumors	B-MED
,	O
including	O
aneurysmal	B-MED
bone	I-MED
cyst	I-MED
abc	B-MED
,	O
and	O
the	O
related	O
benign	B-MED
lesion	B-MED
nodular	B-MED
fasciitis	I-MED
.	O
	
ectopic	B-MED
expression	I-MED
of	O
usp6	B-MED
is	O
known	O
to	O
drive	O
formation	B-MED
of	O
tumors	B-MED
,	O
which	O
recapitulate	O
key	B-MED
features	I-MED
of	O
abc	B-MED
and	O
nodular	B-MED
fasciitis	I-MED
however	O
,	O
the	O
identity	B-MED
of	O
usp6's	B-MED
relevant	O
substrates	B-MED
has	O
been	O
obscure	O
.	O
	
here	O
we	O
report	B-MED
that	O
the	O
jak1	B-MED
-	O
stat3	B-MED
signaling	B-MED
pathway	I-MED
serves	O
as	O
an	O
essential	B-MED
effector	B-MED
of	O
usp6	B-MED
in	O
bstt	B-MED
formation	B-MED
.	O
	
we	O
found	O
that	O
usp6	B-MED
directly	O
deubiquitinated	B-MED
jak1	B-MED
,	O
leading	B-MED
to	O
its	O
stabilization	B-MED
and	O
activation	B-MED
of	O
stat3	B-MED
.	O
	
the	O
tumorigenic	B-MED
potential	B-MED
of	O
usp6	B-MED
was	O
attenuated	B-MED
significantly	I-MED
by	I-MED
crispr	B-MED
-mediated	O
deletion	B-MED
of	O
jak1	B-MED
or	O
stat3	B-MED
,	O
or	O
by	O
administration	B-MED
of	O
a	O
jak	B-MED
family	I-MED
inhibitor	B-MED
.	O
	
analysis	B-MED
of	O
primary	B-MED
clinical	I-MED
samples	I-MED
of	O
nodular	B-MED
fasciitis	I-MED
confirmed	B-MED
the	O
activation	B-MED
of	O
a	O
jak1	B-MED
-	O
stat3	B-MED
gene	B-MED
signature	I-MED
in	B-MED
vivo	I-MED
together	O
,	O
our	O
studies	B-MED
highlight	O
jak1	B-MED
as	O
the	O
first	O
identified	O
substrate	B-MED
for	O
usp6	B-MED
,	O
and	O
they	O
offer	O
a	O
mechanistic	B-MED
rationale	I-MED
for	O
the	O
clinical	B-MED
investigation	I-MED
of	O
jak	B-MED
and	O
stat3	B-MED
inhibitors	B-MED
as	O
therapeutics	B-MED
for	O
the	O
treatment	B-MED
of	O
bone	B-MED
and	O
soft	B-MED
tissue	I-MED
tumors	I-MED
along	O
with	O
other	O
neoplasms	B-MED
driven	O
by	O
usp6	B-MED
overexpression	B-MED
.	O
	
the	O
evidence	B-MED
behind	O
integrating	B-MED
palliative	B-MED
care	I-MED
into	O
oncology	B-MED
practice	B-MED
palliative	B-MED
care	I-MED
services	I-MED
provided	B-MED
alongside	O
traditional	B-MED
oncology	B-MED
care	I-MED
have	O
been	O
shown	O
to	O
be	O
beneficial	B-MED
to	O
patients	B-MED
and	O
families	B-MED
.	O
	
this	O
article	B-MED
provides	O
a	O
brief	B-MED
history	B-MED
of	O
palliative	B-MED
care	I-MED
,	O
a	O
pathway	O
to	O
implementing	B-MED
these	O
services	B-MED
into	O
currently	B-MED
established	B-MED
oncology	B-MED
programs	I-MED
,	O
and	O
a	O
brief	O
discussion	B-MED
of	O
common	B-MED
barriers	I-MED
.	O
	
secondary	B-MED
ossification	I-MED
center	I-MED
appearance	B-MED
and	O
closure	B-MED
in	I-MED
the	I-MED
pelvis	I-MED
and	O
proximal	B-MED
femur	I-MED
variable	O
ossification	B-MED
patterns	B-MED
of	O
the	O
pelvis	B-MED
in	O
skeletally	B-MED
immature	B-MED
patients	B-MED
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-MED
radiographs	B-MED
challenging	O
.	O
	
inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	B-MED
comparisons	B-MED
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-MED
ossification	I-MED
centers	I-MED
.	O
	
this	O
study	O
evaluates	B-MED
the	O
chronology	B-MED
and	O
sex	B-MED
differences	I-MED
for	O
appearance	B-MED
and	O
closure	B-MED
of	I-MED
pelvic	I-MED
and	O
proximal	B-MED
femoral	I-MED
secondary	B-MED
ossification	I-MED
centers	I-MED
using	O
computed	B-MED
tomography	I-MED
ct	B-MED
.	O
	
patients	B-MED
who	O
underwent	O
abdominal	B-MED
and	O
pelvic	B-MED
ct	I-MED
scans	I-MED
between	O
january	O
2009	O
and	O
december	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	B-MED
centers	I-MED
were	O
retrospectively	B-MED
reviewed	B-MED
.	O
	
patients	B-MED
between	O
the	O
ages	B-MED
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-MED
of	O
the	O
pelvis	B-MED
and	O
proximal	B-MED
femurs	I-MED
were	O
included	O
.	O
	
patients	B-MED
with	O
a	O
history	O
of	O
orthopaedic	B-MED
trauma	I-MED
or	O
pathology	B-MED
affecting	B-MED
ossification	B-MED
were	O
excluded	O
.	O
	
ct	B-MED
scans	I-MED
were	O
assessed	B-MED
for	O
the	O
appearance	B-MED
and	O
closure	B-MED
of	O
the	O
following	O
secondary	B-MED
ossification	I-MED
centers	I-MED
anterior	B-MED
inferior	I-MED
iliac	I-MED
spine	I-MED
aiis	B-MED
,	O
anterior	B-MED
superior	I-MED
iliac	I-MED
spine	I-MED
asis	B-MED
,	O
femoral	B-MED
head	I-MED
fh	B-MED
,	O
greater	B-MED
trochanter	I-MED
gt	B-MED
,	O
iliac	B-MED
crest	I-MED
ic	B-MED
,	O
ischial	B-MED
tuberosity	I-MED
it	B-MED
,	O
lesser	B-MED
trochanter	I-MED
lt	B-MED
,	O
posterior	B-MED
superior	I-MED
iliac	I-MED
spine	I-MED
psis	B-MED
,	O
symphysis	B-MED
pubis	I-MED
sp	B-MED
,	O
and	O
triradiate	B-MED
cartilage	I-MED
trc	B-MED
.	O
	
basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O
	
a	O
total	O
of	O
496	O
ct	B-MED
scans	I-MED
met	O
inclusion	B-MED
criteria	I-MED
240	O
males	B-MED
and	O
256	O
females	B-MED
.	O
	
the	O
order	O
of	O
appearance	B-MED
of	O
the	O
secondary	B-MED
ossification	I-MED
centers	I-MED
was	O
male	B-MED
gt	B-MED
,	O
lt	B-MED
,	O
aiis	B-MED
,	O
it	B-MED
,	O
asis	B-MED
,	O
psis	B-MED
,	O
ic	B-MED
,	O
and	O
sp	B-MED
female	B-MED
gt	B-MED
,	O
lt	B-MED
,	O
it	B-MED
,	O
aiis	B-MED
,	O
psis	B-MED
,	O
ic	B-MED
,	O
asis	B-MED
,	O
and	O
sp	B-MED
.	O
	
the	O
order	O
of	O
closure	B-MED
was	O
similar	O
male	B-MED
trc	B-MED
,	O
lt	B-MED
,	O
fh	B-MED
,	O
aiis	B-MED
,	O
gt	B-MED
,	O
asis	B-MED
,	O
psis	B-MED
,	O
it	B-MED
,	O
ic	B-MED
,	O
and	O
sp	B-MED
female	B-MED
lt	B-MED
,	O
trc	B-MED
,	O
aiis	B-MED
,	O
fh	B-MED
,	O
gt	B-MED
,	O
asis	B-MED
,	O
psis	B-MED
,	O
it	B-MED
,	O
ic	B-MED
,	O
and	O
sp	B-MED
.	O
	
female	B-MED
ossification	B-MED
centers	I-MED
appeared	O
1	O
to	O
2	O
years	O
before	O
males	B-MED
in	O
all	O
locations	B-MED
.	O
	
female	B-MED
ossification	B-MED
centers	I-MED
closed	O
1	O
to	O
2	O
years	O
before	O
males	B-MED
in	O
all	O
locations	B-MED
except	O
trc	B-MED
,	O
ic	B-MED
,	O
and	O
sp	B-MED
.	O
	
the	O
appearance	B-MED
and	O
closure	B-MED
of	I-MED
the	I-MED
pelvis	I-MED
and	O
proximal	B-MED
femur	I-MED
secondary	B-MED
ossification	I-MED
centers	I-MED
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	B-MED
than	O
males	B-MED
.	O
	
knowledge	O
of	O
more	O
precise	O
ages	B-MED
of	I-MED
developmen	I-MED
t	O
and	O
sex	B-MED
differences	I-MED
better	O
characterize	O
this	O
complex	O
skeletal	B-MED
development	I-MED
.	O
	
future	O
studies	O
may	O
use	O
secondary	B-MED
ossification	I-MED
centers	I-MED
to	O
further	O
evaluate	B-MED
skeletal	B-MED
maturity	I-MED
,	O
assess	O
pediatric	B-MED
pathology	B-MED
,	O
and	O
aid	O
surgical	B-MED
management	I-MED
.	O
	
pediatric	B-MED
orthopaedic	B-MED
trauma	B-MED
and	O
associated	B-MED
injuries	I-MED
of	O
snowmobile	B-MED
,	O
atv	B-MED
,	O
and	O
dirtbike	B-MED
accidents	I-MED
a	O
19-year	B-MED
experience	O
at	O
a	O
level	O
1	O
pediatric	B-MED
trauma	B-MED
center	I-MED
the	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
type	B-MED
and	O
severity	B-MED
of	O
orthopaedic	B-MED
and	O
associated	B-MED
injuries	I-MED
for	O
snowmobile	B-MED
,	O
all-terrain	B-MED
vehicles	I-MED
atv	B-MED
and	O
motorized	B-MED
dirtbike	I-MED
accidents	I-MED
in	O
a	O
pediatric	B-MED
patient	B-MED
population	I-MED
.	O
	
a	O
total	O
of	O
758	O
patients	B-MED
who	O
presented	O
following	O
either	O
snowmobile	B-MED
n=87	O
,	O
atv-related	B-MED
n=308	O
or	O
dirtbike	B-MED
n=363	I-MED
trauma	I-MED
at	O
our	O
institution	B-MED
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	B-MED
.	O
	
a	O
total	O
of	O
441	O
axial	B-MED
and	O
appendicular	B-MED
fractures	I-MED
occurred	O
requiring	O
533	O
procedures	B-MED
.	O
	
snowmobile	B-MED
and	O
dirtbike	B-MED
accidents	I-MED
were	O
associated	B-MED
with	I-MED
a	O
higher	O
rate	O
of	O
fractures	B-MED
63%	O
,	O
64%	O
than	O
the	O
atv	B-MED
group	I-MED
50%	O
p=0	O
.	O
	
snowmobile	B-MED
injuries	I-MED
had	O
the	O
highest	O
rate	O
of	O
spinal	B-MED
23%	O
and	O
lower	B-MED
extremity	I-MED
fractures	I-MED
53%	O
p=0	O
.	O
	
snowmobile	B-MED
and	O
dirtbike	B-MED
cohorts	I-MED
had	O
higher	O
rate	O
of	O
femur	B-MED
fractures	I-MED
22%	O
,	O
17%	O
,	O
p=0	O
whereas	O
the	O
atv	B-MED
cohort	I-MED
had	O
higher	O
rates	O
of	O
upper	B-MED
extremity	I-MED
18%	O
,	O
hand	B-MED
11%	O
,	O
scapula	B-MED
4.6	O
,	O
and	O
open	B-MED
fractures	I-MED
28.6	O
p<0	O
.	O
	
head	B-MED
trauma	I-MED
was	O
the	O
most	O
commonly	O
associated	B-MED
injury	I-MED
in	O
275	O
patients	B-MED
with	O
the	O
highest	O
rate	O
in	O
the	O
atv	B-MED
group	I-MED
44%	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
76%	O
.	O
	
snowmobile	B-MED
and	O
atv	B-MED
patients	I-MED
had	O
higher	O
injury	B-MED
severity	I-MED
score	I-MED
11.3	O
,	O
9.6	O
than	O
dirtbike	B-MED
patients	I-MED
7.8	O
p=0	O
.	O
	
atv	B-MED
patients	I-MED
were	O
found	O
to	O
be	O
younger	B-MED
11.8	O
y	O
compared	O
with	O
snowmobile	B-MED
13.2	O
y	O
and	O
dirtbike	B-MED
13.5	O
y	O
p<0	O
.	O
	
pediatric	B-MED
snowmobile	B-MED
,	O
atv	B-MED
and	O
dirtbike	B-MED
accidents	I-MED
result	O
in	O
severe	B-MED
orthopaedic	B-MED
and	O
associated	B-MED
injuries	I-MED
with	O
each	O
vehicle	B-MED
demonstrating	O
significantly	O
different	O
injury	B-MED
patterns	B-MED
.	O
	
injury	B-MED
prevention	I-MED
should	O
focus	O
on	O
improved	O
safety	B-MED
mechanisms	I-MED
,	O
protective	B-MED
gear	I-MED
,	O
safe	O
areas	O
for	O
off-road	B-MED
vehicle	I-MED
use	O
and	O
strict	B-MED
laws	I-MED
with	O
minimum	O
age	B-MED
hospitalist	B-MED
co-management	B-MED
of	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
at	O
a	O
community	B-MED
hospital	I-MED
the	O
benefits	O
of	O
hospitalist	B-MED
co-management	B-MED
of	O
pediatric	B-MED
surgical	B-MED
patients	I-MED
include	O
bettering	B-MED
patient	B-MED
safety	I-MED
,	O
decreasing	B-MED
negative	B-MED
patient	B-MED
outcomes	I-MED
,	O
providing	O
comprehensive	B-MED
medical	I-MED
care	I-MED
,	O
and	O
establishing	O
a	O
dedicated	B-MED
resource	I-MED
to	O
patients	B-MED
for	O
postoperative	B-MED
care	I-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
characterize	B-MED
the	O
nature	B-MED
of	O
patients	B-MED
co-managed	O
by	O
a	O
pediatric	B-MED
hospitalist	B-MED
.	O
	
the	O
authors	B-MED
hypothesize	B-MED
that	O
hospitalist	B-MED
co-management	B-MED
is	O
safe	B-MED
and	O
efficacious	B-MED
in	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
who	O
are	O
admitted	B-MED
to	O
a	O
community	B-MED
hospital	I-MED
.	O
	
a	O
retrospective	B-MED
review	I-MED
was	O
performed	O
of	O
all	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
admitted	B-MED
to	O
a	O
community	B-MED
hospital	I-MED
who	O
were	O
co-managed	O
by	O
a	O
pediatric	B-MED
hospitalist	B-MED
.	O
	
indications	O
for	O
hospitalization	B-MED
included	O
pain	B-MED
control	I-MED
,	O
antibiotic	B-MED
infusion	I-MED
,	O
and	O
need	O
for	O
neurovascular	B-MED
monitoring	I-MED
.	O
	
parameters	B-MED
of	O
postoperative	B-MED
care	I-MED
and	O
co-management	B-MED
were	O
assessed	B-MED
,	O
including	O
presence	B-MED
of	O
complications	B-MED
,	O
medication	B-MED
introduction	I-MED
or	O
adjustment	O
by	O
the	O
hospitalist	B-MED
,	O
follow-up	B-MED
adherence	B-MED
,	O
and	O
readmission	B-MED
/	O
complication	B-MED
rates	B-MED
after	O
discharge	B-MED
.	O
	
thirty-two	O
patients	B-MED
were	O
assessed	B-MED
with	O
an	O
average	B-MED
age	I-MED
of	O
8.8	O
years	B-MED
.	O
	
twenty-five	O
percent	B-MED
of	O
patients	B-MED
had	O
an	O
associated	B-MED
comorbidity	I-MED
,	O
including	O
asthma	B-MED
,	O
attention	B-MED
deficit	I-MED
disorder	I-MED
,	O
and/or	O
autism	B-MED
.	O
	
the	O
pediatric	B-MED
hospitalist	B-MED
added	O
pain	B-MED
medication	I-MED
to	O
the	O
original	O
postoperative	B-MED
orders	I-MED
placed	O
by	O
the	O
orthopaedics	B-MED
team	I-MED
in	O
44	O
percent	B-MED
of	O
patients	B-MED
14	O
of	O
the	O
32	O
either	O
for	O
breakthrough	B-MED
pain	I-MED
or	O
better	O
long-term	O
coverage	O
.	O
	
additionally	O
,	O
25	O
percent	B-MED
of	O
patients	B-MED
had	O
pain	B-MED
medication	I-MED
adjusted	O
from	O
the	O
original	O
dosing	B-MED
and	O
schedule	B-MED
.	O
	
the	O
hospitalist	B-MED
team	B-MED
contacted	O
the	O
surgeon	B-MED
about	O
the	O
four	O
patients	B-MED
12.5	O
percent	B-MED
.	O
	
in	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	B-MED
was	O
contacted	O
to	O
discuss	O
pain	B-MED
medication	I-MED
,	O
and	O
one	O
patient	B-MED
woke	O
up	O
agitated	O
from	O
anesthesia	B-MED
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-MED
on	O
the	O
pediatrics	O
floor	O
.	O
	
the	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	B-MED
.	O
	
the	O
hospitalists	B-MED
rounded	O
on	O
and	O
discharged	B-MED
patients	I-MED
the	O
subsequent	O
morning	O
.	O
	
all	O
patients	B-MED
were	O
given	O
a	O
follow-up	B-MED
appointment	I-MED
and	I-MED
schedule	I-MED
by	O
the	O
hospitalist	B-MED
team	O
,	O
and	O
every	B-MED
patient	I-MED
followed	B-MED
up	I-MED
accordingly	O
within	O
ten	O
days	B-MED
of	O
discharge	B-MED
.	O
	
no	O
complications	B-MED
or	O
hospital	B-MED
readmissions	I-MED
occurred	O
within	O
thirty	O
days	B-MED
of	O
discharge	B-MED
.	O
	
hospitalist	B-MED
co-management	B-MED
of	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
in	O
a	O
community	O
hospital	O
allows	O
for	O
better	O
medical	O
comorbidity	O
and	O
medication	O
management	O
.	O
	
hospitalist	O
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	O
stay	O
and	O
help	O
streamline	O
communication	O
between	O
providers	O
and	O
patients	B-MED
while	O
allowing	O
the	O
surgeon	O
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O
	
co-management	O
is	O
safe	O
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	O
surgical	O
patients	O
who	O
are	O
admitted	O
to	O
a	O
community	B-MED
hospital	I-MED
.	O
	
extra	O
carbohydrate	B-MED
binding	I-MED
module	I-MED
contributes	B-MED
to	O
the	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
of	O
a	O
non-modular	B-MED
hydrolase	I-MED
family	O
5	B-MED
endoglucanase	I-MED
from	O
fomitiporia	B-MED
mediterranea	I-MED
mf3/22	I-MED
fmeg	B-MED
from	O
fomitiporia	B-MED
mediterranea	I-MED
is	O
a	O
non-modular	B-MED
endoglucanase	I-MED
composed	O
of	O
a	O
24-amino	B-MED
acids	I-MED
extension	B-MED
and	O
13-amino	B-MED
acids	I-MED
linker-like	B-MED
peptide	I-MED
at	O
the	O
n-terminus	B-MED
and	O
a	O
312-amino	B-MED
acids	I-MED
gh5	B-MED
catalytic	I-MED
domain	I-MED
cd	B-MED
at	O
the	O
c-terminus	B-MED
.	O
	
in	O
this	O
study	O
,	O
six	O
fmeg	B-MED
derivatives	O
with	O
deletion	B-MED
of	O
n-terminal	B-MED
fragments	I-MED
or	O
fusion	B-MED
with	O
an	O
extra	O
family	B-MED
1	I-MED
carbohydrate-binding	I-MED
module	I-MED
cbm1	B-MED
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	B-MED
of	O
cbm1	B-MED
to	O
fmeg	B-MED
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
.	O
	
fmeg	B-MED
showed	O
a	O
weak	O
processivity	B-MED
and	O
released	O
cellobiose	B-MED
g2	B-MED
and	O
cellotriose	B-MED
g3	B-MED
as	O
main	B-MED
end	I-MED
products	I-MED
,	O
and	O
cellotriose	B-MED
g4	B-MED
as	O
minor	B-MED
end	I-MED
product	I-MED
from	O
filter	B-MED
paper	I-MED
fp	B-MED
,	O
but	O
more	O
amount	O
of	O
g4	B-MED
was	O
released	O
from	O
regenerated	B-MED
amorphous	I-MED
cellulose	I-MED
rac	B-MED
.	O
	
all	O
derivatives	B-MED
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-MED
cmc	B-MED
with	O
the	O
same	B-MED
optimal	I-MED
ph	B-MED
7.0	O
and	O
temperature	B-MED
50	O
.	O
	
however	O
,	O
fusing	O
an	O
extra	O
cbm1	B-MED
to	O
fmeg	B-MED
or	O
fmeg	B-MED
with	O
flexible	B-MED
peptide	I-MED
significantly	O
improved	O
its	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
to	O
fp	B-MED
and	O
rac	B-MED
.	O
	
overall	O
,	O
1.79	O
and	O
1.84	O
increases	O
in	O
the	O
soluble	B-MED
/insoluble	O
product	O
ratio	B-MED
on	O
fp	B-MED
,	O
and	O
1.38	O
and	O
1.39	O
increases	O
on	O
rac	B-MED
,	O
compared	O
to	O
fmeg	B-MED
,	O
were	O
recorded	O
for	O
cbm1	B-MED
-	O
fmeg	B-MED
and	O
cbm1	B-MED
-linker-	O
fmeg	B-MED
,	O
respectively	O
.	O
	
meanwhile	O
,	O
they	O
displayed	O
2.64	O
and	O
2.67	B-MED
more	I-MED
activity	I-MED
on	O
rac	B-MED
,	O
and	O
1.68	O
and	O
1.77	O
on	O
fp	B-MED
,	O
respectively	O
.	O
	
similar	O
improvement	O
was	O
also	O
obtained	O
for	O
cbm1	B-MED
-linker-	O
fmeg	B-MED
as	O
compared	O
with	O
fmeg	B-MED
.	O
	
interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
cbm1	B-MED
with	O
fmeg	B-MED
also	O
caused	O
an	O
alteration	B-MED
of	O
cleavage	B-MED
pattern	I-MED
on	O
insoluble	B-MED
celluloses	I-MED
.	O
	
our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
may	O
arise	O
from	O
cbm1	B-MED
binding	B-MED
affinity	I-MED
.	O
	
the	O
n-terminal	B-MED
24-	I-MED
or	I-MED
37-amino	I-MED
acids	I-MED
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	B-MED
separation	I-MED
of	O
the	O
two	B-MED
domains	I-MED
required	O
for	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
.	O
	
in	O
addition	O
,	O
deletion	B-MED
of	O
the	O
n-terminal	B-MED
24-	I-MED
or	I-MED
37-amino	I-MED
acids	I-MED
led	O
to	O
significant	B-MED
reduction	I-MED
in	O
thermostability	B-MED
but	O
not	O
the	O
enzymatic	B-MED
activity	I-MED
.	O
	
overnight	B-MED
switching	B-MED
from	O
oxcarbazepine	B-MED
to	O
eslicarbazepine	B-MED
acetate	I-MED
an	O
observational	B-MED
study	I-MED
there	O
are	O
clinical	B-MED
situations	I-MED
where	O
it	O
might	O
be	O
appropriate	B-MED
to	O
switch	B-MED
patients	B-MED
from	O
immediate-release	B-MED
oxcarbazepine	B-MED
oxc	B-MED
to	O
eslicarbazepine	B-MED
acetate	I-MED
esl	B-MED
.	O
	
we	O
investigated	B-MED
the	O
effects	B-MED
of	I-MED
transitioning	O
patients	B-MED
overnight	B-MED
from	O
oxc	B-MED
to	O
esl	B-MED
.	O
	
a	O
retrospective	B-MED
,	O
single-center	B-MED
study	I-MED
was	O
conducted	O
in	O
which	O
patients	B-MED
with	O
drug-resistant	B-MED
focal	B-MED
epilepsy	I-MED
on	O
a	O
stable	O
dose	B-MED
of	O
immediate-release	B-MED
oxc	B-MED
for	O
at	O
least	O
4	B-MED
weeks	I-MED
were	O
switched	B-MED
overnight	B-MED
to	O
esl	B-MED
.	O
	
patients	B-MED
were	O
switched	B-MED
because	O
they	O
experienced	O
persistent	B-MED
seizures	B-MED
with	O
oxc	B-MED
but	O
were	O
unable	B-MED
to	O
tolerate	B-MED
increased	O
oxc	B-MED
dosing	B-MED
due	O
to	O
adverse	B-MED
events	I-MED
.	O
	
tolerability	B-MED
was	O
assessed	B-MED
using	O
the	O
adverse	B-MED
events	I-MED
profile	I-MED
aep	B-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
was	O
assessed	B-MED
using	O
the	O
quality	B-MED
of	I-MED
life	I-MED
in	I-MED
epilepsy	I-MED
inventory	I-MED
10	I-MED
qolie-10	B-MED
,	O
and	O
alertness	B-MED
was	O
assessed	B-MED
as	O
reaction	B-MED
time	I-MED
using	O
a	O
subtest	O
of	O
the	O
test	B-MED
battery	I-MED
for	I-MED
attention	I-MED
performance	I-MED
version	I-MED
2.3	I-MED
.	O
	
assessments	B-MED
were	O
performed	B-MED
immediately	B-MED
prior	B-MED
to	I-MED
and	O
5	B-MED
days	I-MED
after	O
switching	B-MED
from	O
oxc	B-MED
to	O
esl	B-MED
days	B-MED
0	O
and	O
5	O
,	O
respectively	O
.	O
	
the	O
analysis	B-MED
included	O
21	O
patients	B-MED
12	O
women	B-MED
,	O
9	O
men	B-MED
mean	B-MED
age	I-MED
36	I-MED
years	I-MED
.	O
	
after	O
switching	B-MED
from	O
oxc	B-MED
to	O
esl	B-MED
,	O
there	O
were	O
significant	O
improvements	B-MED
in	O
mean	B-MED
scores	I-MED
for	O
aep	B-MED
p<	O
,	O
qolie-10	B-MED
p=	O
,	O
and	O
alertness	B-MED
p<	O
.	O
	
adverse	B-MED
events	I-MED
profile	I-MED
total	B-MED
scores	I-MED
improved	B-MED
for	O
21/21	O
100.0	O
patients	B-MED
,	O
qolie-10	B-MED
total	B-MED
scores	I-MED
improved	B-MED
for	O
17/21	O
81.0	O
patients	B-MED
,	O
and	O
alertness	B-MED
scores	B-MED
improved	B-MED
for	O
16/21	O
76.2	O
patients	B-MED
.	O
	
in	O
this	O
short-term	B-MED
,	O
single-center	B-MED
study	I-MED
,	O
an	O
overnight	B-MED
switch	B-MED
from	O
twice-daily	B-MED
oxc	B-MED
to	O
once-daily	B-MED
esl	B-MED
in	O
patients	B-MED
with	O
drug-resistant	B-MED
focal	B-MED
epilepsies	I-MED
resulted	B-MED
in	O
improvements	B-MED
in	O
side	B-MED
effects	I-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
,	O
and	O
complete	B-MED
genome	B-MED
sequences	B-MED
of	O
three	O
outbreak	B-MED
-associated	O
legionella	B-MED
pneumophila	I-MED
isolates	B-MED
we	O
report	O
here	O
the	O
complete	B-MED
genome	B-MED
sequences	B-MED
of	O
three	O
legionella	B-MED
pneumophila	I-MED
isolates	B-MED
that	O
are	O
associated	B-MED
with	I-MED
a	O
legionnaires'	B-MED
disease	I-MED
outbreak	B-MED
in	O
new	B-MED
york	I-MED
in	O
2012	O
.	O
	
two	O
clinical	B-MED
isolates	B-MED
d7630	B-MED
and	O
d7632	B-MED
and	O
one	O
environmental	B-MED
isolate	B-MED
d7631	B-MED
were	O
recovered	B-MED
from	O
this	O
outbreak	B-MED
.	O
	
a	O
single	O
isolate-specific	B-MED
virulence	B-MED
gene	B-MED
was	O
found	O
in	O
d7632	B-MED
.	O
	
these	O
isolates	B-MED
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-MED
the	O
genomic	B-MED
resolution	B-MED
of	O
various	O
bioinformatics	B-MED
approaches	B-MED
for	O
l	B-MED
.	O
	
pneumophila	I-MED
serogroup	B-MED
1	I-MED
isolates	B-MED
.	O
	
complete	O
genome	B-MED
sequence	I-MED
analysis	I-MED
of	O
a	O
naturally	O
reassorted	O
infectious	B-MED
bursal	I-MED
disease	I-MED
virus	I-MED
from	O
india	B-MED
the	O
novel	O
infectious	B-MED
bursal	I-MED
disease	I-MED
virus	I-MED
ibdv	B-MED
isolate	B-MED
bge14/abt1/mvc/india	B-MED
is	O
a	O
very	O
virulent	B-MED
ibdv	B-MED
that	O
was	O
isolated	B-MED
from	O
broiler	B-MED
flocks	I-MED
in	O
southern	O
parts	O
of	O
india	B-MED
during	O
2014	O
.	O
	
here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
india	B-MED
,	O
the	O
complete	O
genome	B-MED
sequence	I-MED
of	O
bge14/abt1/mvc/india	B-MED
,	O
a	O
reassortment	O
strain	B-MED
with	O
segments	B-MED
a	I-MED
and	I-MED
b	I-MED
derived	O
from	O
a	O
very	O
virulent	B-MED
ibdv	B-MED
strain	B-MED
and	O
an	O
attenuated	B-MED
ibdv	B-MED
,	O
respectively	O
.	O
	
the	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	B-MED
exchange	I-MED
between	O
attenuated	B-MED
and	O
very	O
virulent	B-MED
strains	B-MED
of	O
ibdv	B-MED
circulating	B-MED
in	B-MED
the	I-MED
field	I-MED
.	O
	
patient	B-MED
satisfaction	I-MED
with	O
postpartum	B-MED
teaching	B-MED
methods	B-MED
postpartum	B-MED
discharge	B-MED
instructions	I-MED
are	O
a	O
crucial	O
part	O
of	O
a	O
mother's	B-MED
birth	B-MED
experience	B-MED
.	O
	
finding	B-MED
the	O
method	B-MED
to	O
provide	O
those	O
discharge	B-MED
instructions	I-MED
in	O
a	O
manner	O
that	O
increases	B-MED
the	O
mother's	B-MED
satisfaction	B-MED
with	O
her	O
hospital	B-MED
experience	B-MED
is	O
important	O
.	O
	
this	O
quasi-experimental	B-MED
study	I-MED
examined	B-MED
the	O
relationship	B-MED
between	O
new	B-MED
mothers'	B-MED
interaction	B-MED
with	O
nurses	B-MED
providing	O
postpartum	B-MED
instructions	B-MED
by	O
the	O
traditional	B-MED
and	O
class	O
methods	B-MED
and	O
their	O
satisfaction	B-MED
with	O
discharge	B-MED
teaching	I-MED
.	O
	
the	O
results	O
indicated	O
new	B-MED
mothers	B-MED
were	O
satisfied	B-MED
with	O
both	O
methods	B-MED
of	O
discharge	B-MED
teaching	I-MED
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	B-MED
with	O
overall	O
satisfaction	B-MED
with	O
the	O
traditional	B-MED
method	B-MED
of	O
discharge	B-MED
teaching	I-MED
than	O
with	O
attending	B-MED
the	O
discharge	B-MED
class	I-MED
.	O
	
splicing	B-MED
variants	O
of	O
adar2	B-MED
and	O
adar2	B-MED
-mediated	O
rna	B-MED
editing	I-MED
in	O
glioma	B-MED
the	O
roles	O
of	O
alternative	B-MED
splicing	I-MED
and	O
rna	B-MED
editing	I-MED
in	O
gene	B-MED
regulation	I-MED
and	O
transcriptome	B-MED
diversity	O
are	O
well	O
documented	O
.	O
	
adenosine	B-MED
deaminases	I-MED
acting	O
on	O
rna	B-MED
adars	B-MED
are	O
responsible	O
for	O
adenosine-to-inosine	B-MED
a-to-i	I-MED
editing	I-MED
and	O
exemplify	O
the	O
complex	O
association	O
between	O
rna	B-MED
editing	I-MED
and	O
alternative	B-MED
splicing	I-MED
.	O
	
the	O
self-editing	B-MED
activity	O
of	O
adar2	B-MED
,	O
which	O
acts	O
on	O
its	O
own	O
pre-mrna	B-MED
,	O
leads	O
to	O
its	O
alternative	B-MED
splicing	I-MED
.	O
	
alternative	B-MED
splicing	I-MED
occurs	O
independently	O
at	O
nine	O
splicing	B-MED
sites	O
on	O
adar2	B-MED
pre-mrna	B-MED
,	O
generating	O
numerous	O
alternative	B-MED
splicing	I-MED
variants	O
with	O
various	O
catalytic	B-MED
activities	I-MED
.	O
	
a-to-i	B-MED
rna	I-MED
editing	I-MED
is	O
important	O
in	O
a	O
range	O
of	O
physiological	B-MED
processes	I-MED
in	O
humans	B-MED
and	O
is	O
associated	O
with	O
several	O
diseases	B-MED
,	O
including	O
amyotrophic	B-MED
lateral	I-MED
sclerosis	I-MED
,	O
mood	B-MED
disorders	I-MED
,	O
epilepsy	B-MED
and	O
glioma	B-MED
.	O
	
reduced	O
editing	B-MED
at	O
the	O
glutamine	B-MED
/	O
arginine	B-MED
site	O
of	O
the	O
ampa	B-MED
receptor	I-MED
subunit	I-MED
glua2	I-MED
in	O
glioma	B-MED
,	O
without	O
any	O
alteration	O
in	O
adar2	B-MED
expression	B-MED
,	O
is	O
a	O
notable	O
phenomenon	O
.	O
	
several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	B-MED
in	O
the	O
catalytic	B-MED
activity	I-MED
of	O
adar2	B-MED
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O
	
the	O
present	O
review	B-MED
summarizes	O
the	O
relevant	O
literature	B-MED
and	O
shares	O
experimental	B-MED
results	I-MED
concerning	O
adar2	B-MED
alternative	B-MED
splicing	I-MED
.	O
	
in	O
particular	O
,	O
the	O
present	O
review	B-MED
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-MED
variants	O
of	O
adar2	B-MED
may	O
reduce	O
the	O
adar2	B-MED
editing	B-MED
activity	O
in	O
glioma	B-MED
.	O
	
dominant	O
expression	B-MED
of	O
adar2	B-MED
splicing	B-MED
variant	O
with	O
low	O
enzyme	B-MED
activity	I-MED
causes	O
reduced	O
rna	B-MED
editing	I-MED
of	O
glua2	B-MED
subunit	I-MED
at	O
the	O
glutamine	B-MED
/	O
arginine	B-MED
site	O
in	O
heat-shock	B-MED
protein	I-MED
60	I-MED
of	O
porphyromonas	B-MED
gingivalis	I-MED
may	O
induce	O
dysfunction	B-MED
of	O
human	B-MED
umbilical	I-MED
endothelial	I-MED
cells	I-MED
via	O
regulation	B-MED
of	O
endothelial-nitric	B-MED
oxide	I-MED
synthase	I-MED
and	O
vascular	B-MED
endothelial-cadherin	I-MED
accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-MED
was	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
coronary	B-MED
heart	I-MED
disease	I-MED
cad	B-MED
.	O
	
porphyromonus	B-MED
gingivalis	I-MED
p	B-MED
.	O
	
gingivalis	I-MED
,	O
a	O
major	O
periodontal	B-MED
pathogen	B-MED
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	B-MED
response	I-MED
of	O
cad	B-MED
in	B-MED
vivo	I-MED
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
identify	O
whether	O
p	B-MED
.	O
	
gingivalis	I-MED
heat-shock	B-MED
protein	I-MED
60	I-MED
hsp60	B-MED
induced	O
the	O
dysfunction	B-MED
of	O
human	B-MED
umbilical	I-MED
vein	I-MED
endothelial	I-MED
cells	I-MED
huvecs	B-MED
in	B-MED
vitro	I-MED
.	O
	
huvecs	B-MED
were	O
stimulated	B-MED
with	O
a	O
range	O
of	O
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
concentrations	B-MED
1	O
,	O
10	O
and	O
100	O
ng/l	O
at	O
different	O
time-points	B-MED
.	O
	
the	O
levels	B-MED
of	O
vascular	B-MED
endothelial	I-MED
ve	I-MED
,	O
endothelial	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
enos	B-MED
and	O
cysteinyl	B-MED
aspartate-specific	I-MED
protease-3	I-MED
caspase-3	B-MED
were	O
measured	O
using	O
western	B-MED
blot	I-MED
analysis	B-MED
.	O
	
the	O
apoptotic	B-MED
rate	B-MED
of	O
huvecs	B-MED
was	O
detected	O
using	O
flow	B-MED
cytometry	I-MED
.	O
	
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
at	O
a	O
concentration	B-MED
of	O
10	O
ng/l	O
significantly	O
decreased	O
the	O
expression	B-MED
levels	B-MED
of	O
ve-cadherin	B-MED
and	O
enos	B-MED
protein	I-MED
at	O
24	O
h	B-MED
stimulation	B-MED
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-MED
was	O
identified	O
following	O
a	O
low	B-MED
dose	I-MED
of	O
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
1	O
ng/l	O
.	O
	
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
at	O
100	O
ng/l	O
significantly	O
downregulated	B-MED
the	O
expression	B-MED
levels	B-MED
of	O
ve-cadherin	B-MED
and	O
enos	B-MED
protein	I-MED
at	O
12	O
h	O
in	O
huvecs	B-MED
.	O
	
however	O
,	O
the	O
cleavage	B-MED
of	O
caspase-3	B-MED
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	B-MED
.	O
	
consistently	O
,	O
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
induced	O
apoptosis	B-MED
of	O
huvecs	B-MED
in	O
a	O
concentration	B-MED
-	O
dependent	B-MED
manner	O
.	O
	
these	O
results	B-MED
indicated	O
that	O
p	B-MED
.	O
	
gingivalis	I-MED
hsp60	B-MED
may	O
induce	O
dysfunction	B-MED
and	O
apoptosis	B-MED
in	O
huvecs	B-MED
via	O
downregulating	B-MED
the	O
expression	B-MED
levels	B-MED
of	O
ve-cadherin	B-MED
and	O
enos	B-MED
,	O
and	O
promoting	O
the	O
cleavage	B-MED
of	O
estradiol	B-MED
prodrugs	B-MED
ep	B-MED
for	O
efficient	O
oral	B-MED
estrogen	B-MED
treatment	I-MED
and	O
abolished	O
effects	O
on	O
estrogen	B-MED
modulated	O
liver	B-MED
functions	I-MED
oral	B-MED
compared	O
to	O
parenteral	B-MED
estrogen	B-MED
administration	I-MED
is	O
characterized	O
by	O
reduced	O
systemic	B-MED
but	O
prominent	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
on	O
lipids	B-MED
,	O
hemostatic	B-MED
factors	I-MED
,	O
gh	B-MED
-/	O
igf	B-MED
i	I-MED
axis	O
,	O
angiotensinogen	B-MED
.	O
	
in	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	B-MED
effects	I-MED
of	O
oral	B-MED
treatment	I-MED
,	O
estradiol	B-MED
e2	B-MED
prodrugs	B-MED
ep	B-MED
were	O
designed	O
which	O
bypass	O
the	O
liver	B-MED
tissue	I-MED
as	O
inactive	O
molecules	O
.	O
	
carbone17-oh	B-MED
sulfonamide	I-MED
-o2-nh2	I-MED
substituted	I-MED
esters	I-MED
of	O
e2	B-MED
ec508	B-MED
,	O
others	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B-MED
anhydrase	I-MED
ii	I-MED
ca-ii	B-MED
binding	B-MED
.	O
	
ca	B-MED
ii	I-MED
in	O
erythrocytes	B-MED
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
ep	B-MED
from	O
portal	B-MED
vein	I-MED
blood	I-MED
during	O
liver	B-MED
passage	B-MED
.	O
	
ovariectomized	B-MED
ovx	B-MED
,	O
day	O
minus	O
14	O
rats	B-MED
were	O
orally	B-MED
treated	I-MED
once	O
daily	O
from	O
day	O
1-3	O
.	O
	
sacrifice	O
day	O
4	O
.	O
	
uteri	B-MED
were	O
dissected	B-MED
and	O
weighed	B-MED
.	O
	
cholesterol	B-MED
fractions	I-MED
and	O
angiotensinogen	B-MED
were	O
determined	O
in	O
plasma	B-MED
.	O
	
oral	B-MED
e2	I-MED
and	O
ethinyl	B-MED
estradiol	I-MED
ee	B-MED
generated	O
dose	O
related	O
uterine	B-MED
growth	B-MED
and	O
important	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
.	O
	
ep	B-MED
induced	O
uterine	B-MED
growth	I-MED
at	O
about	O
hundred-fold	O
lower	O
doses	O
.	O
	
this	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-MED
cholesterol	B-MED
or	O
angiotensinogen	B-MED
.	O
	
preliminary	O
pharmacokinetic	B-MED
studies	I-MED
with	O
ec508	B-MED
used	O
intravenous	B-MED
and	O
oral	B-MED
administration	I-MED
in	O
male	B-MED
rats	B-MED
.	O
	
resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-MED
bioavailability	B-MED
.	O
	
further	O
high	O
blood	B-MED
-	O
but	O
low	O
plasma	B-MED
concentrations	O
indicated	O
erythrocyte	B-MED
binding	B-MED
of	O
ec508	B-MED
in	B-MED
vivo	I-MED
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-MED
passage	B-MED
.	O
	
very	O
high	O
systemic	B-MED
estrogenicity	B-MED
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
is	O
evidence	O
for	O
a	O
systemic	B-MED
release	O
of	O
e2	B-MED
from	O
sulfonamide	B-MED
ep	I-MED
.	O
	
in	O
conclusion	O
,	O
tested	O
oral	B-MED
ep	B-MED
bypass	O
the	O
liver	B-MED
in	O
erythrocytes	B-MED
furnishing	O
systemic	B-MED
estradiol	B-MED
at	O
hydrolysis	B-MED
.	O
	
this	O
mechanism	O
avoids	O
the	O
hepatic	B-MED
estrogenic	B-MED
impact	O
of	O
conventional	O
oral	B-MED
estrogen	B-MED
therapy	I-MED
.	O
	
differences	B-MED
in	O
pain	B-MED
experience	B-MED
and	O
cooperation	B-MED
between	O
consecutive	B-MED
surgeries	I-MED
in	O
patients	B-MED
undergoing	O
phacoemulsification	B-MED
the	O
purpose	O
of	O
this	O
study	B-MED
is	O
to	O
compare	O
pain	B-MED
experience	B-MED
and	O
cooperation	B-MED
between	O
consecutive	B-MED
surgeries	I-MED
in	O
patients	B-MED
undergoing	O
phacoemulsification	B-MED
in	O
both	O
eyes	B-MED
,	O
using	O
sub-tenon's	B-MED
local	I-MED
anesthesia	I-MED
without	O
sedation	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
268	O
patients	B-MED
with	O
bilateral	B-MED
senile	I-MED
cataracts	I-MED
were	O
recruited	O
.	O
	
all	O
operations	B-MED
were	O
performed	O
without	O
sedation	B-MED
,	O
using	O
a	O
clear	O
corneal	B-MED
phacoemulsification	B-MED
technique	I-MED
and	O
sub-tenon's	B-MED
local	I-MED
anesthesia	I-MED
,	O
by	O
one	O
of	O
four	O
surgeons	B-MED
.	O
	
the	O
first	O
surgery	B-MED
was	O
performed	O
on	O
the	O
eye	B-MED
with	O
the	O
higher	O
grade	O
cataract	B-MED
.	O
	
the	O
other	O
eye	B-MED
was	O
operated	B-MED
on	O
within	O
3	B-MED
months	I-MED
by	O
the	O
same	O
surgeon	B-MED
mean	O
interval	O
1.9	O
1.1	O
months	B-MED
.	O
	
all	O
patients	B-MED
were	O
asked	O
to	O
grade	O
their	O
pain	B-MED
experience	B-MED
during	O
induction	B-MED
and	O
maintenance	B-MED
of	O
anesthesia	B-MED
and	O
also	O
during	O
the	O
phacoemulsification	B-MED
surgery	I-MED
,	O
using	O
a	O
visual	B-MED
analogue	I-MED
scale	I-MED
vas	B-MED
from	O
0	O
no	B-MED
pain	I-MED
to	O
10	O
unbearable	B-MED
pain	I-MED
administered	O
after	O
the	O
surgery	B-MED
.	O
	
the	O
cooperation	B-MED
of	O
the	O
patient	B-MED
was	O
graded	O
from	O
0	O
no	O
event	O
to	O
3	O
markedeye	B-MED
and	O
head	B-MED
movement	I-MED
and	O
lid	B-MED
squeezing	I-MED
by	O
the	O
attending	O
surgeon	B-MED
.	O
	
the	O
vas	B-MED
scores	I-MED
and	O
cooperation	B-MED
scores	B-MED
of	O
the	O
patients	B-MED
were	O
the	O
outcome	B-MED
measurements	I-MED
.	O
	
the	O
mean	B-MED
pain	I-MED
score	I-MED
was	O
2.11	O
0.79	O
in	O
the	O
first	O
eye	B-MED
and	O
3.33	O
0.80	O
in	O
the	O
second	O
eye	B-MED
during	O
the	O
administration	B-MED
of	O
sub-tenon's	B-MED
anesthesia	I-MED
,	O
and	O
1.50	O
0.60	O
in	O
the	O
first	O
eye	B-MED
and	O
2.10	O
0.57	O
in	O
the	O
second	O
eye	B-MED
during	O
the	O
phacoemulsification	B-MED
surgery	I-MED
.	O
	
the	O
patient	B-MED
cooperation	I-MED
score	B-MED
was	O
1.60	O
0.75	O
in	O
the	O
first	O
surgery	B-MED
and	O
2.08	O
0.72	O
in	O
the	O
second	O
surgery	B-MED
.	O
	
the	O
differences	B-MED
between	O
the	O
first	O
and	O
second	O
surgeries	B-MED
were	O
statistically	O
significant	O
for	O
all	O
outcome	B-MED
measures	I-MED
p	O
<	O
0.01	O
.	O
	
patients	B-MED
who	O
previously	O
underwent	O
phaco	B-MED
surgery	I-MED
in	O
one	O
eye	B-MED
experienced	O
more	O
pain	B-MED
and	O
showed	O
worse	B-MED
cooperation	B-MED
during	O
the	O
phaco	B-MED
surgery	I-MED
in	O
the	O
second	O
eye	B-MED
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-MED
,	O
viz	O
,	O
less	O
than	O
3	O
months	B-MED
.	O
	
therefore	O
,	O
if	O
the	O
surgeon	B-MED
has	O
difficulty	B-MED
in	O
the	O
first	O
operation	B-MED
gaining	O
the	O
patient's	B-MED
cooperation	I-MED
,	O
the	O
surgeon	B-MED
must	O
be	O
careful	O
if	O
contralateral	B-MED
eye	I-MED
surgery	I-MED
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-MED
/	O
analgesia	B-MED
should	O
be	O
considered	O
or	O
the	O
surgery	B-MED
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	B-MED
of	O
recent	B-MED
memory	I-MED
on	O
the	O
patient's	B-MED
subsequent	O
pain	B-MED
experience	B-MED
.	O
	
co-chip	B-MED
enables	O
genome-wide	B-MED
mapping	I-MED
of	O
histone	B-MED
mark	I-MED
co-occurrence	B-MED
at	O
single-molecule	B-MED
resolution	I-MED
histone	B-MED
modifications	I-MED
play	O
an	O
important	B-MED
role	B-MED
in	O
chromatin	B-MED
organization	I-MED
and	O
transcriptional	B-MED
regulation	I-MED
,	O
but	O
despite	O
the	O
large	B-MED
amount	I-MED
of	O
genome-wide	B-MED
histone	B-MED
modification	I-MED
data	B-MED
collected	B-MED
in	O
different	B-MED
cells	B-MED
and	O
tissues	B-MED
,	O
little	O
is	O
known	O
about	O
co-occurrence	B-MED
of	O
modifications	B-MED
on	O
the	O
same	O
nucleosome	B-MED
.	O
	
here	O
we	O
present	B-MED
a	O
genome-wide	B-MED
quantitative	I-MED
method	I-MED
for	O
combinatorial	B-MED
indexed	I-MED
chromatin	B-MED
immunoprecipitation	I-MED
co-chip	B-MED
to	O
characterize	O
co-occurrence	B-MED
of	O
histone	B-MED
modifications	I-MED
on	O
nucleosomes	B-MED
.	O
	
using	O
co-chip	B-MED
,	O
we	O
study	B-MED
the	O
genome-wide	B-MED
co-occurrence	B-MED
of	O
14	O
chromatin	B-MED
marks	I-MED
70	O
pairwise	B-MED
combinations	I-MED
,	O
and	O
find	O
previously	O
undescribed	O
co-occurrence	B-MED
patterns	B-MED
,	O
including	O
the	O
co-occurrence	B-MED
of	O
h3k9me1	B-MED
and	O
h3k27ac	B-MED
in	O
super-enhancers	B-MED
.	O
	
finally	O
,	O
we	O
apply	B-MED
co-chip	B-MED
to	O
measure	B-MED
the	O
distribution	B-MED
of	O
the	O
bivalent	B-MED
h3k4me3	B-MED
-	O
h3k27me3	B-MED
domains	B-MED
in	O
two	O
distinct	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cell	I-MED
mesc	B-MED
states	O
and	O
in	O
four	O
adult	B-MED
tissues	I-MED
.	O
	
we	O
observe	B-MED
dynamic	B-MED
changes	B-MED
in	O
5	O
regions	O
and	O
discover	B-MED
both	O
loss	B-MED
and	O
de	B-MED
novo	I-MED
gain	B-MED
of	O
bivalency	B-MED
in	O
key	O
tissue-specific	B-MED
regulatory	B-MED
genes	I-MED
,	O
suggesting	B-MED
a	O
functional	B-MED
role	I-MED
for	O
bivalent	B-MED
domains	B-MED
during	O
different	O
stages	B-MED
of	O
development	B-MED
.	O
	
these	O
results	B-MED
show	O
that	O
co-chip	B-MED
can	O
reveal	B-MED
the	O
complex	B-MED
interactions	I-MED
between	O
histone	B-MED
modifications	I-MED
.	O
	
hand-assisted	B-MED
laparoscopic	I-MED
versus	O
standard	B-MED
laparoscopic	I-MED
colectomy	I-MED
are	O
outcomes	B-MED
and	O
operative	B-MED
time	I-MED
different	O
hal	B-MED
colectomy	B-MED
is	O
a	O
technique	B-MED
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-MED
surgery	I-MED
while	O
improving	O
tactile	O
feedback	O
and	O
operative	B-MED
time	I-MED
.	O
	
published	O
data	B-MED
are	O
largely	O
limited	O
to	O
small	O
,	O
single-institution	B-MED
studies	I-MED
.	O
	
the	O
2012-2013	O
national	B-MED
surgical	I-MED
quality	I-MED
improvement	I-MED
program	I-MED
participant	I-MED
data	I-MED
use	I-MED
file	I-MED
was	O
queried	O
for	O
patients	B-MED
undergoing	O
elective	O
sl	B-MED
or	O
hal	B-MED
colectomy	B-MED
.	O
	
patients	B-MED
underwent	O
1	O
propensity	O
matching	O
and	O
had	O
outcomes	B-MED
compared	O
.	O
	
an	O
additional	O
subgroup	B-MED
analysis	I-MED
was	O
performed	O
for	O
patients	B-MED
undergoing	O
segmental	B-MED
resections	B-MED
only	O
.	O
	
13	O
patients	B-MED
were	O
identified	O
,	O
of	O
whom	O
6084	O
43.6	O
%	O
underwent	O
hal	B-MED
colectomy	B-MED
.	O
	
patients	B-MED
undergoing	O
hal	B-MED
versus	O
sl	B-MED
colectomy	I-MED
had	O
higher	O
rates	B-MED
of	O
postoperative	B-MED
ileus	I-MED
8.7	O
vs	O
.	O
	
6.3	O
%	O
,	O
p	O
<	O
0.001	O
,	O
wound	B-MED
complication	I-MED
8.8	O
vs	O
.	O
	
6.8	O
%	O
,	O
p	O
=	O
0.006	O
,	O
and	O
30-	O
day	B-MED
readmission	B-MED
7.5	O
vs	O
.	O
	
6.0	O
%	O
,	O
p	O
=	O
0.002	O
,	O
without	O
any	O
differences	O
in	O
operative	B-MED
time	I-MED
156	O
vs	O
.	O
	
157	O
min	O
,	O
p	O
=	O
0.713	O
.	O
	
amongst	O
segmental	B-MED
colectomies	B-MED
,	O
hal	B-MED
remained	O
associated	O
with	O
higher	O
rates	B-MED
of	O
wound	B-MED
complications	I-MED
8.6	O
vs	O
.	O
	
6.5	O
%	O
,	O
p	O
=	O
0.016	O
,	O
postoperative	B-MED
ileus	I-MED
8.9	O
vs	O
.	O
	
6.3	O
%	O
,	O
p	O
<	O
0.001	O
,	O
and	O
30-	O
day	B-MED
readmission	B-MED
7.1	O
vs	O
.	O
	
5.9	O
%	O
,	O
p	O
=	O
0.041	O
with	O
no	O
difference	O
in	O
operative	B-MED
time	I-MED
between	O
hal	B-MED
and	O
sl	O
145	O
vs	O
.	O
	
145	O
min	O
,	O
p	O
=	O
0.334	O
.	O
	
use	O
of	O
hal	B-MED
colectomy	B-MED
is	O
associated	O
with	O
increased	O
risk	B-MED
of	O
wound	B-MED
complications	I-MED
,	O
postoperative	B-MED
ileus	I-MED
,	O
and	O
readmissions	B-MED
.	O
	
importantly	O
,	O
this	O
technique	B-MED
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	B-MED
time	I-MED
.	O
	
safety	B-MED
and	O
immunogenecity	B-MED
of	O
a	O
live	O
attenuated	B-MED
rift	B-MED
valley	I-MED
fever	I-MED
vaccine	I-MED
cl13t	B-MED
in	O
camels	B-MED
rift	B-MED
valley	I-MED
fever	I-MED
is	O
an	O
emerging	O
zoonotic	B-MED
viral	B-MED
disease	I-MED
,	O
enzootic	B-MED
and	O
endemic	B-MED
in	O
africa	B-MED
and	O
the	O
arabian	B-MED
peninsula	I-MED
,	O
which	O
poses	O
a	O
significant	B-MED
threat	B-MED
to	O
both	O
human	B-MED
and	O
animal	B-MED
health	B-MED
.	O
	
the	O
disease	B-MED
is	O
most	O
severe	B-MED
in	O
ruminants	B-MED
causing	B-MED
abortions	B-MED
in	O
pregnant	B-MED
animals	B-MED
,	O
especially	O
sheep	B-MED
animals	I-MED
and	O
high	O
mortality	B-MED
in	O
young	B-MED
populations	B-MED
.	O
	
high	O
mortality	B-MED
rates	I-MED
and	O
severe	B-MED
clinical	B-MED
manifestation	B-MED
have	O
also	O
been	O
reported	B-MED
among	O
camel	B-MED
populations	B-MED
in	O
africa	B-MED
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	B-MED
available	B-MED
live	B-MED
vaccines	I-MED
against	O
rvf	B-MED
have	O
been	O
tested	B-MED
for	O
safety	B-MED
and	O
efficacy	B-MED
in	O
this	O
species	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
the	O
safety	B-MED
and	O
efficacy	B-MED
through	O
a	O
neutralizing	B-MED
antibody	I-MED
response	B-MED
of	O
the	O
thermostable	B-MED
live	I-MED
attenuated	I-MED
rvf	B-MED
cl13t	I-MED
vaccine	I-MED
were	O
evaluated	B-MED
in	O
camels	B-MED
in	O
two	O
different	B-MED
preliminary	B-MED
experiments	B-MED
involving	O
16	O
camels	B-MED
,	O
that	O
12	O
camels	B-MED
and	O
4	O
pregnant	B-MED
camels	B-MED
.	O
	
the	O
study	B-MED
revealed	B-MED
that	O
the	O
cl13t	B-MED
vaccine	I-MED
was	O
safe	B-MED
to	O
use	B-MED
in	O
camels	B-MED
and	O
no	O
abortions	B-MED
or	O
teratogenic	B-MED
effects	I-MED
were	O
observed	B-MED
.	O
	
the	O
single	O
dose	B-MED
of	O
the	O
vaccine	B-MED
stimulated	O
a	O
strong	B-MED
and	O
long-lasting	O
neutralizing	B-MED
antibody	I-MED
response	B-MED
for	O
up	O
to	O
12	O
months	B-MED
.	O
	
the	O
presence	B-MED
of	O
neutralization	B-MED
antibodies	I-MED
is	O
likely	O
to	O
correlate	B-MED
with	I-MED
protection	B-MED
however	O
protection	B-MED
would	O
need	O
to	O
be	O
confirmed	B-MED
by	I-MED
challenge	O
experiments	B-MED
using	O
the	O
virulent	B-MED
rvf	B-MED
virus	I-MED
.	O
	
autoantibodies	B-MED
to	O
mog	B-MED
in	O
a	O
distinct	O
subgroup	B-MED
of	O
adult	B-MED
multiple	B-MED
sclerosis	I-MED
to	O
evaluate	B-MED
the	O
presence	O
of	O
antibodies	B-MED
to	O
conformation	B-MED
-intact	O
myelin	B-MED
oligodendrocyte	I-MED
glycoprotein	I-MED
mog	B-MED
in	O
a	O
subgroup	B-MED
of	O
adult	B-MED
patients	B-MED
with	O
clinically	B-MED
definite	O
multiple	B-MED
sclerosis	I-MED
ms	B-MED
preselected	O
for	O
a	O
specific	O
clinical	B-MED
phenotype	B-MED
including	O
severe	B-MED
spinal	B-MED
cord	I-MED
,	O
optic	B-MED
nerve	I-MED
,	O
and	O
brainstem	B-MED
involvement	O
.	O
	
antibodies	B-MED
to	O
mog	B-MED
were	O
investigated	B-MED
using	O
a	O
cell-based	B-MED
assay	I-MED
in	O
3	O
groups	B-MED
of	O
patients	B-MED
104	O
preselected	O
patients	B-MED
with	O
ms	B-MED
group	B-MED
1	I-MED
,	O
55	O
age	B-MED
-	O
and	O
sex	B-MED
-matched	O
,	O
otherwise	O
unselected	O
patients	B-MED
with	O
ms	B-MED
group	B-MED
2	I-MED
,	O
and	O
in	O
22	O
brain-biopsied	B-MED
patients	B-MED
with	O
demyelinating	B-MED
diseases	I-MED
of	O
the	O
cns	B-MED
n	O
=	O
19	O
with	O
ms	B-MED
,	O
4	O
of	O
whom	O
classified	B-MED
as	O
ms	B-MED
type	I-MED
ii	I-MED
group	B-MED
3	I-MED
.	O
	
recognized	O
epitopes	B-MED
were	O
identified	O
with	O
mutated	B-MED
variants	B-MED
of	O
mog	B-MED
.	O
	
antibodies	B-MED
to	O
mog	B-MED
were	O
found	O
in	O
about	O
5%	O
5/104	O
of	O
preselected	O
adult	B-MED
patients	B-MED
with	O
ms	B-MED
.	O
	
in	O
contrast	O
,	O
in	O
groups	B-MED
2	I-MED
and	O
3	B-MED
,	O
none	O
of	O
the	O
patients	B-MED
tested	B-MED
positive	O
for	O
mog	B-MED
antibodies	B-MED
.	O
	
patients	B-MED
with	O
ms	B-MED
with	O
antibodies	B-MED
to	O
mog	B-MED
predominantly	O
manifested	B-MED
with	O
concomitant	B-MED
severe	B-MED
brainstem	B-MED
and	O
spinal	B-MED
cord	I-MED
involvement	O
and	O
had	O
a	O
severe	B-MED
disease	B-MED
course	I-MED
with	O
high	O
relapse	B-MED
rates	B-MED
and	O
failure	B-MED
to	O
several	O
disease-modifying	B-MED
therapies	I-MED
.	O
	
three	O
of	O
them	O
had	O
been	O
treated	B-MED
with	I-MED
plasma	B-MED
exchange	I-MED
with	O
a	O
favorable	B-MED
response	I-MED
.	O
	
all	O
anti-mog	B-MED
-positive	O
patients	B-MED
with	O
ms	B-MED
showed	O
typical	O
ms	B-MED
lesions	B-MED
on	O
brain	B-MED
mri	I-MED
.	O
	
longitudinal	B-MED
analysis	I-MED
up	O
to	O
9	O
years	B-MED
revealed	O
fluctuations	B-MED
and	O
reappearance	O
of	O
anti-mog	B-MED
reactivity	I-MED
.	O
	
epitope	B-MED
mapping	I-MED
indicated	O
interindividual	B-MED
heterogeneity	I-MED
,	O
yet	O
intraindividual	B-MED
stability	I-MED
of	O
the	O
antibody	B-MED
response	I-MED
.	O
	
antibodies	B-MED
to	O
mog	B-MED
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B-MED
of	O
adult	B-MED
ms	B-MED
with	O
a	O
specific	O
clinical	B-MED
phenotype	B-MED
and	O
may	O
indicate	O
disease	B-MED
heterogeneity	B-MED
.	O
	
acute	B-MED
ph-negative	I-MED
lymphoblastic	I-MED
leukemias	I-MED
in	O
adults	B-MED
risk	B-MED
factors	I-MED
in	O
the	O
use	O
of	O
the	O
all-2009	B-MED
protocol	I-MED
to	O
analyze	O
well-known	O
risk	B-MED
factors	I-MED
rfs	B-MED
,	O
such	O
as	O
age	B-MED
,	O
immunophenotype	B-MED
,	O
baseline	B-MED
leukocytosis	B-MED
,	O
enhanced	B-MED
lactate	B-MED
dehydrogenase	I-MED
ldh	B-MED
activity	B-MED
,	O
time	O
to	O
achieve	O
complete	O
remission	B-MED
,	O
a	O
risk	B-MED
group	I-MED
,	O
and	O
cytogenetic	B-MED
abnormalities	I-MED
in	O
patients	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
all	B-MED
in	O
the	O
use	O
of	O
the	O
all-2009	B-MED
protocol	I-MED
.	O
	
the	O
protocol	B-MED
covered	O
298	O
patients	B-MED
137	O
women	B-MED
including	B-MED
13	O
pregnant	B-MED
women	I-MED
and	O
161	O
men	B-MED
aged	O
15	O
to	O
55	O
years	O
median	O
age	O
28	O
years	O
with	O
ph-negative	B-MED
all	I-MED
.	O
	
the	O
phenotype	B-MED
was	O
unknown	O
in	O
6	O
patients	B-MED
.	O
	
three	O
1%	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O
	
182	O
62.4	O
patients	B-MED
were	O
found	O
to	O
have	O
b-cell	B-MED
all	I-MED
early	O
pre-b	B-MED
all	I-MED
n=51	O
common	O
all	B-MED
n=92	O
,	O
and	O
pre-b	B-MED
all	I-MED
n=39	O
107	O
36.6	O
patients	B-MED
had	O
t-cell	B-MED
all	I-MED
early	O
t-all	B-MED
n=56	O
thymic	B-MED
t-all	B-MED
n=41	O
,	O
and	O
mature	B-MED
t-all	B-MED
n=10	O
.	O
	
according	O
to	O
the	O
baseline	B-MED
clinical	B-MED
and	O
laboratory	B-MED
parameters	B-MED
leukocytosis	B-MED
of	O
30	O
and	O
more	O
for	O
b-all	B-MED
and	O
that	O
of	O
100	O
and	O
more	O
for	O
t-all	B-MED
phenotype	B-MED
в-i	O
for	O
b-all	B-MED
,	O
phenotype	B-MED
т-i-ii-iv	O
for	O
t-all	B-MED
ldh	B-MED
activity	B-MED
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
the	O
presence	B-MED
of	O
translocation	B-MED
t	I-MED
,	O
the	O
high-risk	B-MED
group	I-MED
included	B-MED
most	O
patients	B-MED
with	O
b-all	B-MED
n=110	O
72.8	O
and	O
t-all	B-MED
n=76	O
76%	O
.	O
	
thirty-five	O
patients	B-MED
with	O
t-all	B-MED
underwent	O
autologous	B-MED
bone	I-MED
marrow	I-MED
transplantation	I-MED
bmt	B-MED
.	O
	
allogeneic	B-MED
bmt	I-MED
was	O
performed	B-MED
in	O
18	O
7%	O
of	O
the	O
258	O
patients	B-MED
who	O
had	O
undergone	O
an	O
induction	B-MED
phase	I-MED
.	O
	
five-year	O
overall	B-MED
survival	I-MED
for	O
all	O
the	O
patients	B-MED
included	B-MED
in	O
the	O
investigation	B-MED
was	O
59%	O
relapse-free	B-MED
survival	O
was	O
65%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	B-MED
with	O
b-all	B-MED
and	O
in	O
those	O
with	O
t-all	B-MED
the	O
overall	B-MED
survival	I-MED
rates	I-MED
were	O
53.3	O
and	O
67.5	O
p=0	O
the	O
relapse-free	O
survival	O
was	O
56	O
and	O
79%	O
p=0	O
,	O
respectively	O
.	O
	
multivariate	B-MED
analysis	I-MED
including	B-MED
the	O
well-known	O
rfs	B-MED
demonstrated	O
that	O
the	O
latter	O
for	O
t-all	B-MED
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient's	B-MED
age	B-MED
was	O
identified	O
for	O
b-all	B-MED
p=0	O
.	O
	
a	O
lower	O
chemotherapeutic	B-MED
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-MED
bmts	I-MED
did	O
not	O
affect	O
total	O
positive	O
treatment	B-MED
results	B-MED
in	O
adult	B-MED
patients	B-MED
with	O
all	B-MED
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-MED
effects	B-MED
and	O
by	O
preserving	B-MED
the	O
total	O
cytostatic	B-MED
loading	B-MED
dose	I-MED
.	O
	
the	O
results	B-MED
of	O
the	O
russian	B-MED
investigation	B-MED
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-MED
bmts	I-MED
in	O
adult	B-MED
patients	B-MED
with	O
multidetector	B-MED
ct	I-MED
of	O
expected	B-MED
findings	B-MED
and	O
complications	B-MED
after	O
contemporary	B-MED
inguinal	B-MED
hernia	I-MED
repair	I-MED
surgery	B-MED
inguinal	B-MED
hernia	I-MED
repair	I-MED
ihr	B-MED
with	O
prosthetic	B-MED
mesh	B-MED
implantation	B-MED
is	O
the	O
most	O
common	O
procedure	B-MED
in	O
general	B-MED
surgery	I-MED
,	O
and	O
may	O
be	O
performed	B-MED
using	O
either	O
an	O
open	B-MED
or	O
laparoscopic	B-MED
approach	I-MED
.	O
	
this	O
paper	B-MED
provides	O
an	O
overview	B-MED
of	O
contemporary	B-MED
tension-free	O
ihr	B-MED
techniques	B-MED
and	O
materials	B-MED
,	O
and	O
illustrates	O
the	O
expected	B-MED
postoperative	B-MED
imaging	B-MED
findings	I-MED
and	O
iatrogenic	B-MED
injuries	I-MED
.	O
	
emphasis	O
is	O
placed	O
on	O
multidetector	B-MED
ct	I-MED
,	O
which	O
represents	O
the	O
ideal	B-MED
modality	B-MED
to	O
comprehensively	O
visualize	O
the	O
operated	B-MED
groin	B-MED
region	I-MED
and	O
deeper	B-MED
intra-abdominal	B-MED
structures	I-MED
.	O
	
ct	B-MED
consistently	O
depicts	O
seroma	B-MED
,	O
mesh	B-MED
infections	I-MED
,	O
hemorrhages	B-MED
,	O
bowel	B-MED
complications	B-MED
and	O
urinary	B-MED
bladder	I-MED
injuries	B-MED
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	B-MED
basis	O
for	O
therapeutic	B-MED
choice	B-MED
.	O
	
since	O
radiologists	B-MED
are	O
increasingly	B-MED
requested	O
to	O
investigate	B-MED
suspected	B-MED
iatrogenic	B-MED
complications	B-MED
,	O
this	O
paper	B-MED
aims	O
to	O
provide	O
an	O
increased	B-MED
familiarity	B-MED
with	O
early	B-MED
ct	B-MED
studies	B-MED
after	O
ihr	B-MED
,	O
including	O
complications	B-MED
and	O
normal	B-MED
postoperative	B-MED
appearances	B-MED
such	O
as	O
focal	B-MED
pseudolesions	B-MED
,	O
in	O
order	O
to	O
avoid	B-MED
misinterpretation	I-MED
and	O
inappropriate	B-MED
management	B-MED
.	O
	
the	O
transcription	B-MED
factors	I-MED
ms188	B-MED
and	O
ams	B-MED
form	O
a	O
complex	B-MED
to	O
activate	B-MED
the	O
expression	B-MED
of	O
cyp703a2	B-MED
for	O
sporopollenin	B-MED
biosynthesis	I-MED
in	O
arabidopsis	B-MED
thaliana	I-MED
the	O
sexine	B-MED
layer	I-MED
of	O
pollen	B-MED
grain	I-MED
is	O
mainly	O
composed	O
of	O
sporopollenins	B-MED
.	O
	
the	O
sporophytic	B-MED
secretory	I-MED
tapetum	I-MED
is	O
required	B-MED
for	O
the	O
biosynthesis	B-MED
of	I-MED
sporopollenin	I-MED
.	O
	
although	O
several	O
enzymes	B-MED
involved	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
have	O
been	O
reported	O
,	O
the	O
regulatory	B-MED
mechanism	I-MED
of	O
these	O
enzymes	B-MED
in	O
tapetal	B-MED
layer	I-MED
remains	O
elusive	O
.	O
	
aborted	B-MED
microspores	I-MED
ams	B-MED
and	O
male	B-MED
sterile	I-MED
188	I-MED
/	O
myb103	B-MED
/	O
myb80	B-MED
ms188	B-MED
/	O
myb103	B-MED
/	O
myb80	B-MED
are	O
two	O
tapetal	B-MED
cell	I-MED
-specific	O
transcription	B-MED
factors	I-MED
required	B-MED
for	O
pollen	B-MED
wall	I-MED
formation	I-MED
.	O
	
ams	B-MED
functions	B-MED
upstream	B-MED
of	O
ms188	B-MED
.	O
	
here	O
we	O
report	O
that	O
ams	B-MED
and	O
ms188	B-MED
target	B-MED
the	O
cyp703a2	B-MED
gene	I-MED
,	O
which	O
is	O
involved	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
.	O
	
we	O
found	O
that	O
ams	B-MED
and	O
ms188	B-MED
were	O
localized	B-MED
in	O
tapetum	B-MED
while	O
cyp703a2	B-MED
was	O
localized	B-MED
in	O
both	O
tapetum	B-MED
and	O
locule	B-MED
.	O
	
chromatin	B-MED
immunoprecipitation	I-MED
chip	B-MED
showed	O
that	O
ms188	B-MED
directly	O
bound	B-MED
to	O
the	O
promoter	B-MED
of	O
cyp703a2	B-MED
and	O
luciferase-inducible	B-MED
assay	B-MED
showed	O
that	O
ms188	B-MED
activated	B-MED
the	O
expression	B-MED
of	O
cyp703a2	B-MED
.	O
	
yeast	B-MED
two-hybrid	I-MED
and	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
emsas	B-MED
further	O
demonstrated	O
that	O
ms188	B-MED
complexed	B-MED
with	O
ams	B-MED
.	O
	
the	O
expression	B-MED
of	O
cyp703a2	B-MED
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	B-MED
levels	I-MED
of	O
ms188	B-MED
in	O
the	O
ams	B-MED
mutant	B-MED
.	O
	
therefore	O
,	O
our	O
data	B-MED
reveal	B-MED
that	O
ms188	B-MED
coordinates	B-MED
with	O
ams	B-MED
to	O
activate	B-MED
cyp703a2	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
of	O
plant	B-MED
tapetum	B-MED
.	O
	
activation	B-MED
of	O
ephrinb-ephb	B-MED
receptor	I-MED
signalling	I-MED
in	O
rat	B-MED
spinal	I-MED
cord	I-MED
contributes	O
to	O
maintenance	B-MED
of	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
dnp	B-MED
is	O
severe	B-MED
and	O
intractable	B-MED
in	O
clinic	B-MED
.	O
	
the	O
specific	B-MED
cellular	B-MED
and	O
molecular	B-MED
mechanisms	B-MED
underlying	O
dnp	B-MED
remain	O
elusive	O
and	O
its	O
treatment	B-MED
are	O
limited	B-MED
.	O
	
we	O
investigated	B-MED
roles	B-MED
of	O
ephb1	B-MED
receptor	I-MED
in	O
the	O
development	O
of	O
dnp	B-MED
.	O
	
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
was	O
produced	O
in	O
male	B-MED
,	O
adult	B-MED
,	O
sprague-dawley	B-MED
rats	I-MED
by	O
a	O
single	O
i.p	O
.	O
	
streptozotocin	B-MED
stz	B-MED
or	O
alloxan	B-MED
.	O
	
western	B-MED
blot	I-MED
analysis	I-MED
and	O
immunohistochemistry	B-MED
were	O
used	O
to	O
analyse	O
expression	B-MED
of	O
ephb1	B-MED
receptor	I-MED
as	O
well	O
as	O
the	O
activation	B-MED
of	O
the	O
glial	B-MED
cells	I-MED
and	O
the	O
pro-inflammatory	B-MED
cytokines	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
.	O
	
dnp	B-MED
manifested	B-MED
as	O
mechanical	B-MED
allodynia	I-MED
,	O
which	O
was	O
determined	O
by	O
measuring	B-MED
incidence	B-MED
of	O
foot	B-MED
withdrawal	B-MED
in	O
response	B-MED
to	O
mechanical	B-MED
indentation	I-MED
of	O
the	O
hind	B-MED
paw	B-MED
by	O
an	O
electro	B-MED
von	I-MED
frey	I-MED
filament	I-MED
.	O
	
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
and	O
high	B-MED
blood	I-MED
glucose	I-MED
were	O
exhibited	O
simultaneously	B-MED
in	O
around	O
70%	O
of	O
animals	B-MED
that	O
received	O
i.p	O
.	O
	
stz	B-MED
or	O
alloxan	B-MED
.	O
	
phosphorylation	B-MED
of	O
ephb1	B-MED
,	O
activation	B-MED
of	O
the	O
astrocytes	B-MED
and	O
microglial	B-MED
cells	I-MED
,	O
and	O
level	B-MED
of	O
tumour	B-MED
necrosis	I-MED
factor	I-MED
tnf	B-MED
and	O
interleukin	B-MED
il	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
were	O
significantly	O
increased	O
in	O
rats	B-MED
with	O
dnp	B-MED
.	O
	
spinal	B-MED
blocking	B-MED
ephb1	B-MED
receptor	I-MED
activation	B-MED
in	O
the	O
late	O
phase	O
after	O
stz	B-MED
injection	B-MED
significantly	O
suppressed	B-MED
the	O
established	O
mechanical	B-MED
allodynia	I-MED
as	O
well	O
as	O
activation	B-MED
of	O
the	O
astrocytes	B-MED
and	O
microglial	B-MED
cells	I-MED
and	O
activity	B-MED
of	O
tnf-α	B-MED
and	O
il-1β	B-MED
.	O
	
however	O
,	O
spinal	B-MED
treatment	B-MED
of	O
ephb1	B-MED
-	O
fc	B-MED
in	O
the	O
early	B-MED
phase	I-MED
after	O
stz	B-MED
injection	B-MED
did	O
not	O
prevent	O
the	O
induction	B-MED
of	O
dnp	B-MED
.	O
	
ephb1	B-MED
receptor	I-MED
activation	B-MED
in	O
the	O
spinal	B-MED
cord	I-MED
is	O
critical	B-MED
to	O
the	O
maintenance	B-MED
,	O
but	O
not	O
induction	B-MED
of	O
diabetic	B-MED
pain	B-MED
.	O
	
ephb1	B-MED
receptor	I-MED
may	O
be	O
a	O
potential	B-MED
target	B-MED
for	O
relieving	B-MED
the	O
established	O
diabetic	B-MED
pain	B-MED
.	O
	
activation	B-MED
of	O
ephb1	B-MED
receptor	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
is	O
critical	B-MED
to	O
maintaining	B-MED
the	O
established	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
,	O
but	O
not	O
to	O
diabetic	B-MED
pain	B-MED
induction	B-MED
.	O
	
spinal	B-MED
blocking	B-MED
ephb1	B-MED
receptor	I-MED
activation	B-MED
suppresses	B-MED
ongoing	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
.	O
	
conservation	B-MED
of	O
the	O
red	B-MED
kite	I-MED
milvus	B-MED
milvus	I-MED
aves	B-MED
accipitriformes	B-MED
is	O
not	O
affected	B-MED
by	O
the	O
establishment	O
of	O
a	O
broad	O
hybrid	B-MED
zone	B-MED
with	O
the	O
black	B-MED
kite	I-MED
milvus	B-MED
migrans	I-MED
migrans	I-MED
in	O
central	B-MED
europe	I-MED
among	O
accipitriformes	B-MED
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	B-MED
have	O
been	O
reported	B-MED
to	O
form	O
hybrid	B-MED
zones	B-MED
these	O
include	O
the	O
red	B-MED
kite	I-MED
milvus	B-MED
milvus	I-MED
and	O
black	B-MED
kite	I-MED
milvus	B-MED
migrans	I-MED
migrans	I-MED
.	O
	
m	B-MED
.	O
	
milvus	I-MED
is	O
endemic	B-MED
to	O
the	O
western	B-MED
palearctic	I-MED
and	O
has	O
an	O
estimated	O
total	O
population	B-MED
of	O
20-24	O
breeding	B-MED
pairs	B-MED
.	O
	
the	O
species	B-MED
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	B-MED
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-MED
of	O
rodenticide-treated	B-MED
baits	I-MED
,	O
illegal	B-MED
poisoning	B-MED
and	O
changes	O
in	O
agricultural	B-MED
practices	I-MED
,	O
particularly	O
in	O
its	O
core	B-MED
range	B-MED
.	O
	
whereas	O
f1	B-MED
m	B-MED
.	O
	
milvus	I-MED
m	B-MED
.	O
	
migr	I-MED
.	O
	
migrans	I-MED
hybrid	B-MED
offspring	B-MED
have	O
been	O
found	O
,	O
f2	B-MED
and	O
f3	B-MED
hybrids	B-MED
have	O
only	O
rarely	O
been	O
reported	B-MED
,	O
with	O
low	O
nesting	B-MED
success	B-MED
rates	B-MED
of	O
f1	B-MED
hybrids	B-MED
and	O
partial	B-MED
hybrid	B-MED
sterility	O
likely	O
playing	O
a	O
role	O
.	O
	
here	O
,	O
we	O
analyzed	B-MED
the	O
mitochondrial	B-MED
co1	B-MED
and	O
cytb	B-MED
and	O
nuclear	B-MED
myc	B-MED
dna	B-MED
loci	B-MED
of	O
184	O
m	B-MED
.	O
	
milvus	I-MED
,	O
124	O
m	B-MED
.	O
	
migr	I-MED
.	O
	
migrans	I-MED
and	O
3	O
f1	B-MED
hybrid	B-MED
individuals	O
collected	O
across	O
central	B-MED
europe	I-MED
.	O
	
in	O
agreement	B-MED
with	O
previous	O
studies	B-MED
,	O
we	O
found	O
low	O
heterozygosity	B-MED
in	O
m	B-MED
.	O
	
milvus	I-MED
regardless	O
of	O
locus	B-MED
.	O
	
we	O
found	O
that	O
populations	B-MED
of	O
both	O
examined	B-MED
species	B-MED
were	O
characterized	B-MED
by	O
a	O
high	O
gene	B-MED
flow	I-MED
within	O
populations	B-MED
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	B-MED
distributed	O
across	O
the	O
entire	O
examined	B-MED
area	B-MED
.	O
	
few	O
haplotypes	B-MED
displayed	O
statistically	B-MED
significant	I-MED
aggregation	B-MED
in	O
one	O
region	B-MED
over	O
another	O
.	O
	
we	O
did	O
not	O
find	O
mitochondrial	B-MED
dna	I-MED
of	O
one	O
species	B-MED
in	O
individuals	O
with	O
the	O
plumage	B-MED
of	O
the	O
other	O
species	B-MED
,	O
except	O
in	O
f1	B-MED
hybrids	B-MED
,	O
which	O
agrees	O
with	O
haldane	B-MED
rule	I-MED
.	O
	
it	O
remains	O
to	O
be	O
investigated	B-MED
by	O
genomic	B-MED
methods	B-MED
whether	O
occasional	O
gene	B-MED
flow	I-MED
occurs	O
through	O
the	O
paternal	B-MED
line	O
,	O
as	O
the	O
examined	B-MED
myc	B-MED
gene	I-MED
displayed	O
only	O
marginal	O
divergence	B-MED
between	O
m	B-MED
.	O
	
milvus	I-MED
and	O
m	B-MED
.	O
	
migr	I-MED
.	O
	
migrans	I-MED
.	O
	
the	O
central	B-MED
europe	I-MED
an	O
population	B-MED
of	O
m	B-MED
.	O
	
milvus	I-MED
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	B-MED
flow	I-MED
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	B-MED
of	O
individuals	O
in	O
m	B-MED
.	O
	
milvus	I-MED
extracellular	B-MED
potassium	B-MED
and	O
seizures	B-MED
excitation	B-MED
,	O
inhibition	B-MED
and	O
the	O
role	O
of	O
ih	B-MED
seizure	B-MED
activity	I-MED
leads	O
to	O
increases	O
in	O
extracellular	B-MED
potassium	B-MED
concentration	B-MED
k	B-MED
formula	O
see	O
text	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-MED
passive	B-MED
and	O
active	B-MED
membrane	B-MED
properties	O
as	O
well	O
as	O
in	O
population	B-MED
activities	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
examined	O
how	O
extracellular	B-MED
potassium	B-MED
modulates	O
seizure	B-MED
activities	I-MED
using	O
an	O
acute	O
4-ap	B-MED
induced	O
seizure	B-MED
model	B-MED
in	O
the	O
neocortex	B-MED
,	O
both	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
.	O
	
moderately	O
elevated	O
k	B-MED
formula	O
see	O
text	O
up	O
to	O
9	O
see	O
text	O
prolonged	B-MED
seizure	B-MED
durations	B-MED
and	O
shortened	B-MED
interictal	I-MED
intervals	I-MED
as	O
well	O
as	O
depolarized	B-MED
the	O
neuronal	B-MED
resting	B-MED
membrane	I-MED
potential	I-MED
rmp	B-MED
.	O
	
however	O
,	O
when	O
k	B-MED
formula	O
see	O
text	O
reached	O
higher	O
than	O
9	O
see	O
text	O
,	O
seizure	B-MED
like	I-MED
events	I-MED
sles	B-MED
were	O
blocked	B-MED
and	O
neurons	B-MED
went	O
into	O
a	O
depolarization	B-MED
-	O
blocked	B-MED
state	O
.	O
	
spreading	B-MED
depression	B-MED
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-MED
events	I-MED
could	O
be	O
reversed	O
within	O
1-2	O
see	O
text	O
after	O
the	O
raised	O
k	B-MED
formula	O
see	O
text	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O
	
this	O
concentration	B-MED
-dependent	O
dual	O
effect	O
of	O
k	B-MED
formula	O
see	O
text	O
was	O
observed	O
using	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
mouse	B-MED
brain	I-MED
preparations	I-MED
as	O
well	O
as	O
in	O
human	B-MED
neocortical	B-MED
tissue	B-MED
resected	O
during	O
epilepsy	B-MED
surgery	B-MED
.	O
	
blocking	B-MED
the	O
ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization-activated	B-MED
cyclic	I-MED
nucleotide-gated	I-MED
hcn	I-MED
channels	I-MED
,	O
modulated	O
the	O
elevated	O
k	B-MED
formula	O
see	O
text	O
influence	B-MED
on	O
sles	B-MED
by	O
promoting	O
the	O
high	O
k	B-MED
formula	O
see	O
text	O
inhibitory	B-MED
actions	I-MED
.	O
	
these	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
k	B-MED
formula	O
see	O
text	O
on	O
neuronal	B-MED
excitability	B-MED
and	O
seizure	B-MED
activity	I-MED
.	O
	
activation	B-MED
of	O
general	B-MED
control	I-MED
nonderepressible	I-MED
2	I-MED
kinase	I-MED
protects	B-MED
human	B-MED
glomerular	B-MED
endothelial	I-MED
cells	I-MED
from	O
harmful	O
high-glucose	B-MED
-	O
induced	B-MED
molecular	B-MED
pathways	I-MED
considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-MED
restriction	B-MED
on	O
diabetic	B-MED
nephropathy	I-MED
dn	B-MED
and	O
the	O
role	O
of	O
renal	B-MED
endothelium	B-MED
in	O
its	O
pathogenesis	B-MED
,	O
we	O
evaluated	B-MED
the	O
effect	O
of	O
general	B-MED
control	I-MED
nonderepressible	I-MED
2	I-MED
gcn2	I-MED
kinase	I-MED
activation	B-MED
,	O
a	O
sensor	B-MED
of	O
amino	B-MED
acid	I-MED
deprivation	B-MED
,	O
on	O
known	O
detrimental	O
molecular	B-MED
pathways	I-MED
in	O
primary	O
human	B-MED
glomerular	B-MED
endothelial	I-MED
cells	I-MED
genc	B-MED
.	O
	
genc	B-MED
were	O
cultured	B-MED
under	O
normal	O
or	O
high	B-MED
-glucose	O
conditions	O
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
gcn2	O
kinase	O
activator	O
,	O
tryptophanol	O
.	O
	
glucose	O
transporter	O
1	O
glut1	O
expression	O
was	O
assessed	O
by	O
western	O
blotting	O
and	O
reactive	O
oxygen	O
species	O
ros	O
using	O
a	O
fluorogenic	O
probe	O
.	O
	
activities	O
of	O
glyceraldehyde	O
3-phosphate	O
dehydrogenase	O
gapdh	O
and	O
protein	O
kinase	O
c	O
pkc	O
were	O
assessed	O
by	O
commercial	O
activity	O
assays	O
,	O
sorbitol	O
colorimetrically	O
,	O
methylglyoxal	O
by	O
elisa	O
and	O
o-linked	O
β-n-acetyl	O
glucosamine	O
o-glcnac	O
proteins	O
by	O
western	O
blotting	O
.	O
	
high	O
glucose	O
induced	O
glut1	O
expression	O
,	O
increased	O
ros	O
and	O
inhibited	O
gapdh	O
.	O
	
also	O
it	O
increased	O
the	O
polyol	O
pathway	O
product	O
sorbitol	O
,	O
pkc	O
activity	O
,	O
the	O
level	O
of	O
the	O
o-glcnac-modified	O
proteins	O
that	O
produced	O
by	O
the	O
hexosamine	O
pathway	O
and	O
the	O
advanced	O
glycation	O
endproducts'	O
precursor	O
methylglyoxal	O
.	O
	
co-treatment	O
of	O
genc	O
with	O
tryptophanol	O
restored	O
the	O
above	O
high-glucose	O
-	O
induced	O
alterations	O
.	O
	
activation	O
of	O
gcn2	O
kinase	O
protects	O
genc	O
from	O
high-glucose	O
-	O
induced	O
harmful	O
molecular	O
pathways	O
.	O
	
by	O
inhibiting	O
concurrently	O
many	O
pathways	O
involved	O
in	O
dn	O
pathogenesis	O
,	O
gcn2	O
kinase	O
may	O
serve	O
as	O
a	O
pharmaceutical	O
target	O
for	O
the	O
treatment	O
of	O
dn	B-MED
juicer	B-MED
provides	B-MED
a	O
one-click	O
system	O
for	O
analyzing	B-MED
loop-resolution	B-MED
hi-c	I-MED
experiments	I-MED
hi-c	B-MED
experiments	I-MED
explore	O
the	O
3d	B-MED
structure	I-MED
of	O
the	O
genome	B-MED
,	O
generating	B-MED
terabases	B-MED
of	I-MED
data	I-MED
to	O
create	O
high-resolution	B-MED
contact	B-MED
maps	I-MED
.	O
	
here	O
,	O
we	O
introduce	O
juicer	B-MED
,	O
an	O
open-source	B-MED
tool	I-MED
for	O
analyzing	O
terabase-scale	B-MED
hi-c	B-MED
datasets	I-MED
.	O
	
juicer	B-MED
allows	O
users	B-MED
without	B-MED
a	O
computational	B-MED
background	B-MED
to	O
transform	B-MED
raw	B-MED
sequence	I-MED
data	I-MED
into	O
normalized	O
contact	B-MED
maps	I-MED
with	O
one	O
click	O
.	O
	
juicer	B-MED
produces	O
a	O
hic	B-MED
file	I-MED
containing	O
compressed	B-MED
contact	B-MED
matrices	I-MED
at	O
many	O
resolutions	B-MED
,	O
facilitating	O
visualization	B-MED
and	O
analysis	B-MED
at	O
multiple	B-MED
scales	I-MED
.	O
	
structural	B-MED
features	I-MED
,	O
such	O
as	O
loops	B-MED
and	O
domains	B-MED
,	O
are	O
automatically	B-MED
annotated	B-MED
.	O
	
juicer	B-MED
is	O
available	O
as	O
open	B-MED
source	B-MED
software	B-MED
bjn	B-MED
awards	I-MED
2016	O
iv	B-MED
therapy	I-MED
claire	O
rickard	O
professor	B-MED
of	O
nursing	B-MED
,	O
national	O
health	O
and	O
medical	O
research	O
council	O
nhmrc	O
centre	B-MED
of	I-MED
research	I-MED
excellence	I-MED
in	O
nursing	B-MED
,	O
griffith	O
university	O
,	O
was	O
awarded	B-MED
second	O
place	O
in	O
the	O
bjn	B-MED
awards	I-MED
2016	O
for	O
iv	B-MED
therapy	I-MED
nurse	B-MED
of	O
the	O
year	B-MED
.	O
	
here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
stressful	B-MED
life	B-MED
events	I-MED
and	O
leucocyte	B-MED
telomere	I-MED
length	I-MED
do	O
lifestyle	B-MED
factors	I-MED
,	O
somatic	B-MED
and	O
mental	B-MED
health	I-MED
,	O
or	O
low	B-MED
grade	I-MED
inflammation	I-MED
mediate	O
this	O
relationship	B-MED
results	O
from	O
a	O
cohort	B-MED
of	O
danish	B-MED
men	I-MED
born	B-MED
in	O
1953	O
exposure	B-MED
to	I-MED
psychosocial	B-MED
stress	B-MED
is	O
associated	B-MED
with	I-MED
increased	O
risk	B-MED
of	O
a	O
number	O
of	O
somatic	B-MED
and	O
mental	B-MED
disorders	I-MED
with	O
relation	B-MED
to	O
immune	O
system	O
functioning	O
.	O
	
we	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	O
telomere	O
length	O
tl	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	O
burden	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
occurring	O
during	O
the	O
life	O
course	O
.	O
	
we	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	B-MED
between	O
stressful	O
life	O
events	O
and	O
tl	O
is	O
mediated	O
through	O
somatic	O
and	O
mental	O
health	O
,	O
lifestyle	O
,	O
and	O
markers	O
of	O
low-grade	O
inflammation	O
.	O
	
a	O
cohort	O
of	O
danish	O
men	O
born	O
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	O
in	O
the	O
metropolit	O
cohort	O
.	O
	
these	O
men	O
underwent	O
a	O
health	O
examination	O
including	O
blood	O
sampling	O
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	O
pcr-based	O
measurement	O
of	O
tl	O
.	O
	
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
tl	O
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	O
health	O
cardiovascular	O
disease	O
,	O
body	O
mass	O
and	O
depressive	O
mood	O
,	O
lifestyle	O
factors	O
,	O
and	O
low	O
grade	O
inflammation	O
c-reactive	O
protein	O
crp	O
,	O
interleukin	O
il	O
and	O
il-10	O
.	O
	
total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
tl	O
.	O
	
in	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	O
tl	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=-0	O
p=0	O
.	O
	
this	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
β=-0	O
p<0	O
.	O
	
thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
tl	O
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	O
mood	O
16%	O
and	O
crp	O
9%	O
.	O
	
this	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	O
tl	O
in	O
middle-aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	O
mood	O
and	O
low	O
grade	O
inflammation	B-MED
description	B-MED
of	O
ancylomarina	B-MED
subtilis	I-MED
gen	I-MED
.	O
	
nov	I-MED
,	O
sp	I-MED
.	O
	
nov	I-MED
,	O
isolated	B-MED
from	O
coastal	B-MED
sediment	I-MED
,	O
proposal	B-MED
of	O
marinilabiliales	B-MED
ord	I-MED
.	O
	
nov	I-MED
.	O
	
and	O
transfer	B-MED
of	O
marinilabiliaceae	B-MED
,	O
prolixibacteraceae	B-MED
and	O
marinifilaceae	B-MED
to	O
the	O
order	B-MED
marinilabiliales	B-MED
a	O
gram-stain-negative	B-MED
,	O
facultatively	B-MED
anaerobic	I-MED
,	O
moderately	B-MED
halophilic	I-MED
,	O
filamentous	B-MED
,	O
non-motile	B-MED
bacterium	I-MED
,	O
designated	B-MED
fa102t	B-MED
,	O
was	O
isolated	B-MED
from	O
marine	B-MED
sediment	I-MED
of	O
the	O
coast	B-MED
of	O
weihai	B-MED
,	O
china	I-MED
.	O
	
phylogenetic	B-MED
analysis	I-MED
based	B-MED
on	O
16s	B-MED
rrna	I-MED
gene	I-MED
sequences	I-MED
showed	B-MED
that	O
strain	B-MED
fa102t	B-MED
formed	O
a	O
distinct	B-MED
evolutionary	B-MED
lineage	B-MED
within	O
the	O
family	B-MED
marinifilaceae	B-MED
and	O
its	O
closest	B-MED
relative	I-MED
was	O
marinifilum	B-MED
fragile	I-MED
jcm	I-MED
15579t	I-MED
93.2	O
sequence	B-MED
similarity	I-MED
.	O
	
the	O
dna	B-MED
g+c	B-MED
content	I-MED
of	O
the	O
novel	B-MED
strain	B-MED
was	O
36.5	O
mol%	O
.	O
	
the	O
predominant	B-MED
cellular	B-MED
fatty	B-MED
acids	I-MED
and	O
respiratory	B-MED
quinone	B-MED
were	O
iso-c15	B-MED
and	O
iso-c15	B-MED
3-oh	I-MED
,	O
and	O
mk-7	B-MED
,	O
respectively	B-MED
.	O
	
on	O
the	O
basis	B-MED
of	O
the	O
phylogenetic	B-MED
,	O
phenotypic	B-MED
and	O
physiological	B-MED
data	B-MED
,	O
strain	B-MED
fa102t	B-MED
represents	B-MED
a	O
novel	B-MED
genus	B-MED
and	O
species	B-MED
,	O
for	O
which	O
the	O
name	O
ancylomarina	B-MED
subtilis	I-MED
gen	I-MED
.	O
	
nov	I-MED
,	O
sp	I-MED
.	O
	
nov	I-MED
.	O
	
is	O
proposed	B-MED
.	O
	
the	O
type	B-MED
strain	B-MED
of	O
ancylomarina	B-MED
subtilis	I-MED
is	O
fa102t	B-MED
=	O
kctc	B-MED
42257t	I-MED
=	O
dsm	B-MED
28825t	I-MED
=	O
cicc	B-MED
10902t	I-MED
.	O
	
furthermore	O
,	O
a	O
new	B-MED
order	B-MED
named	O
marinilabiliales	B-MED
is	O
proposed	B-MED
to	O
accommodate	B-MED
three	O
families	B-MED
previously	B-MED
classified	B-MED
in	O
the	O
order	B-MED
bacteroidales	B-MED
.	O
	
marinilabiliales	B-MED
ord	I-MED
.	O
	
nov	I-MED
.	O
	
encompasses	O
the	O
families	B-MED
marinilabiliaceae	B-MED
,	O
prolixibacteraceae	B-MED
and	O
treatment	B-MED
for	O
rheumatoid	B-MED
arthritis	I-MED
and	O
risk	B-MED
of	O
alzheimer's	B-MED
disease	I-MED
a	O
nested	B-MED
case-control	I-MED
analysis	I-MED
it	O
is	O
increasingly	B-MED
becoming	O
accepted	B-MED
that	O
inflammation	B-MED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-MED
of	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
,	O
as	O
several	B-MED
immune	B-MED
-related	O
genes	B-MED
have	O
been	O
associated	B-MED
with	I-MED
ad	B-MED
.	O
	
among	O
these	O
is	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
tnf	I-MED
,	O
a	O
proinflammatory	B-MED
cytokine	I-MED
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-MED
disorders	I-MED
,	O
including	O
rheumatoid	B-MED
arthritis	I-MED
ra	B-MED
.	O
	
although	O
ad	B-MED
and	O
ra	B-MED
appear	O
to	O
involve	O
similar	B-MED
pathological	B-MED
mechanisms	I-MED
through	O
the	O
production	B-MED
of	O
tnf-α	B-MED
,	O
the	O
relationship	B-MED
between	O
ad	B-MED
and	O
ra	B-MED
remains	O
unknown	B-MED
.	O
	
to	O
determine	O
the	O
relative	B-MED
risk	I-MED
of	O
ad	B-MED
among	O
ra	B-MED
patients	B-MED
and	O
non-	O
ra	B-MED
patients	B-MED
,	O
and	O
whether	O
anti-tnf	B-MED
therapy	I-MED
for	O
ra	B-MED
was	O
associated	B-MED
with	I-MED
a	O
lower	B-MED
risk	B-MED
of	O
ad	B-MED
in	O
ra	B-MED
patients	B-MED
.	O
	
we	O
performed	O
a	O
nested	B-MED
case-control	I-MED
study	I-MED
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	B-MED
adults	B-MED
aged	O
18	O
years	O
in	O
all	O
50	O
us	B-MED
states	I-MED
,	O
puerto	B-MED
rico	I-MED
,	O
and	O
us	B-MED
virgin	I-MED
islands	I-MED
in	O
the	O
verisk	B-MED
health	I-MED
claims	I-MED
database	I-MED
.	O
	
we	O
derived	O
a	O
sub-cohort	B-MED
of	O
subjects	O
with	O
a	O
diagnosis	B-MED
of	O
ra	B-MED
controls	B-MED
,	O
or	O
ra	B-MED
and	O
ad	B-MED
cases	B-MED
,	O
matching	B-MED
cases	B-MED
and	O
controls	O
based	O
on	O
age	B-MED
,	O
sex	B-MED
,	O
exposure	B-MED
assessment	I-MED
period	I-MED
,	O
and	O
methotrexate	B-MED
treatment	I-MED
.	O
	
we	O
also	O
assessed	B-MED
relative	I-MED
risk	I-MED
of	O
ad	B-MED
following	O
exposure	B-MED
to	I-MED
standard	B-MED
ra	B-MED
therapies	B-MED
,	O
including	O
anti-tnf	B-MED
agents	I-MED
infliximab	B-MED
,	O
adalimumab	B-MED
,	O
etanercept	B-MED
,	O
methotrexate	B-MED
,	O
prednisone	B-MED
,	O
sulfasalazine	B-MED
,	O
and	O
rituximab	B-MED
.	O
	
odds	B-MED
ratios	I-MED
were	O
adjusted	O
for	O
comorbidities	B-MED
,	O
including	O
coronary	B-MED
artery	I-MED
disease	I-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
peripheral	B-MED
vascular	I-MED
disease	I-MED
.	O
	
ad	B-MED
was	O
more	O
prevalent	B-MED
p	O
<	O
0.0001	O
among	O
ra	B-MED
patients	B-MED
0.79	O
%	O
than	O
among	O
those	O
without	B-MED
ra	B-MED
0.11	O
%	O
.	O
	
chronic	B-MED
conditions	I-MED
such	O
as	O
coronary	B-MED
artery	I-MED
disease	I-MED
odds	B-MED
ratio	I-MED
or	B-MED
1.48	O
95	O
%	O
confidence	B-MED
interval	I-MED
ci	B-MED
1.04	O
p	O
=	O
0.03	O
,	O
diabetes	B-MED
or	B-MED
1.86	O
95	O
%	O
ci	B-MED
1.32	O
p	O
=	O
0.0004	O
,	O
and	O
peripheral	B-MED
vascular	I-MED
disease	I-MED
or	B-MED
1.61	O
95	O
%	O
ci	B-MED
1.06	O
p	O
=	O
0.02	O
significantly	O
increased	O
the	O
relative	B-MED
risk	I-MED
of	O
ad	B-MED
among	O
ra	B-MED
patients	B-MED
.	O
	
exposure	B-MED
to	I-MED
anti-tnf	B-MED
agents	I-MED
as	O
a	O
class	B-MED
,	O
but	O
not	O
other	O
immunosuppressive	B-MED
drugs	I-MED
studied	O
,	O
was	O
associated	B-MED
with	I-MED
lowered	B-MED
risk	B-MED
of	O
ad	B-MED
among	O
ra	B-MED
patients	B-MED
unadjusted	O
or	B-MED
0.44	O
95	O
%	O
ci	B-MED
0.22	O
p	O
=	O
0.02	O
adjusted	O
or	B-MED
0.45	O
95	O
%	O
ci	B-MED
0.23	O
p	O
=	O
0.02	O
.	O
	
sub-group	B-MED
analysis	I-MED
demonstrated	O
that	O
of	O
the	O
three	O
anti-tnf	B-MED
agents	I-MED
studied	O
,	O
only	O
etanercept	B-MED
unadjusted	O
or	B-MED
,	O
0.33	O
95	O
%	O
ci	B-MED
0.08	O
p	O
=	O
0.03	O
adjusted	O
or	B-MED
0.30	O
95	O
%	O
ci	B-MED
0.08	O
p	O
=	O
0.02	O
was	O
associated	B-MED
with	I-MED
a	O
decreased	B-MED
risk	B-MED
of	O
ad	B-MED
in	O
ra	B-MED
patients	B-MED
.	O
	
there	O
is	O
an	O
increased	B-MED
risk	B-MED
of	O
ad	B-MED
in	O
the	O
studied	O
ra	B-MED
population	B-MED
.	O
	
the	O
relative	B-MED
risk	I-MED
of	O
ad	B-MED
among	O
ra	B-MED
subjects	O
was	O
lowered	B-MED
in	O
those	O
exposed	B-MED
to	I-MED
etanercept	B-MED
.	O
	
anti-tnf	B-MED
therapy	I-MED
with	O
etanercept	B-MED
shows	O
promise	B-MED
as	O
a	O
potential	B-MED
treatment	B-MED
for	O
dimerization	B-MED
of	O
egfr	B-MED
and	O
her2	B-MED
induces	O
breast	B-MED
cancer	I-MED
cell	B-MED
motility	I-MED
through	O
stat1	B-MED
-dependent	O
acta2	B-MED
induction	B-MED
the	O
dimerization	B-MED
of	O
egfr	B-MED
and	O
her2	B-MED
is	O
associated	O
with	O
poor	O
prognosis	B-MED
such	O
as	O
induction	B-MED
of	O
tumor	B-MED
growth	I-MED
and	O
cell	B-MED
invasion	I-MED
compared	B-MED
to	O
when	O
egfr	B-MED
remains	O
as	O
a	O
homodimer	B-MED
.	O
	
however	O
,	O
the	O
mechanism	B-MED
for	O
events	O
after	O
dimerization	B-MED
in	O
breast	B-MED
cancer	I-MED
models	B-MED
is	O
not	O
clear	O
.	O
	
we	O
found	O
that	O
expressions	B-MED
of	O
alpha-smooth	B-MED
muscle	I-MED
actin	I-MED
acta2	B-MED
and	O
signal	B-MED
transducer	I-MED
and	I-MED
activator	I-MED
of	I-MED
transcription	I-MED
1	I-MED
stat1	B-MED
significantly	O
increased	B-MED
with	O
transient	O
or	O
stable	O
overexpression	B-MED
of	O
her2	B-MED
in	O
egfr	B-MED
-	O
positive	B-MED
breast	B-MED
cancer	I-MED
cells	B-MED
.	O
	
acta2	B-MED
and	O
stat1	B-MED
expression	B-MED
was	O
also	O
increased	B-MED
in	O
her2	B-MED
-	O
positive	B-MED
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
	
in	O
contrast	O
,	O
acta2	B-MED
expression	B-MED
was	O
decreased	B-MED
by	O
her2	B-MED
sirna	I-MED
.	O
	
next	O
,	O
we	O
investigated	O
the	O
co-relation	O
between	O
stat1	B-MED
and	O
acta2	B-MED
expression	B-MED
.	O
	
basal	O
acta2	B-MED
expression	B-MED
was	O
significantly	O
decreased	B-MED
by	O
treatment	B-MED
with	O
the	O
stat1	B-MED
inhibitor	I-MED
fludarabine	B-MED
or	O
the	O
jak2	B-MED
inhibitor	I-MED
ag490	B-MED
.	O
	
in	O
contrast	O
,	O
acta2	B-MED
expression	B-MED
was	O
increased	B-MED
by	O
stat1	B-MED
overexpression	B-MED
.	O
	
levels	O
of	O
acta2	B-MED
,	O
stat1	B-MED
,	O
and	O
her2	B-MED
were	O
increased	B-MED
and	O
relapse	O
free	B-MED
survival	I-MED
was	O
decreased	B-MED
in	O
high-risk	B-MED
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
	
we	O
also	O
investigated	B-MED
the	O
effect	O
of	O
acta2	B-MED
on	O
cell	B-MED
motility	I-MED
,	O
which	O
was	O
suppressed	B-MED
by	O
acta2	B-MED
shrna	I-MED
overexpression	B-MED
in	O
mda-mb231	B-MED
her2	B-MED
and	O
4t1	B-MED
mammary	I-MED
carcinoma	I-MED
cells	I-MED
.	O
	
the	O
number	O
of	O
lung	B-MED
metastatic	I-MED
nodules	I-MED
was	O
significantly	O
decreased	B-MED
in	O
acta2	B-MED
knockdown	B-MED
mice	I-MED
.	O
	
taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	B-MED
of	O
acta2	B-MED
by	O
egfr	B-MED
and	O
her2	B-MED
dimerization	B-MED
was	O
regulated	O
through	O
a	O
jak2	B-MED
/	O
stat1	B-MED
signaling	B-MED
pathway	I-MED
,	O
and	O
aberrant	O
acta2	B-MED
expression	B-MED
accelerated	O
the	O
invasiveness	O
and	O
metastasis	O
of	O
breast	O
cancer	O
cells	B-MED
intensive	O
social	B-MED
cognitive	B-MED
treatment	I-MED
can	O
do	O
treatment	B-MED
with	O
participation	B-MED
of	O
support	O
partners	B-MED
in	O
persons	B-MED
with	O
relapsing	B-MED
remitting	I-MED
multiple	I-MED
sclerosis	I-MED
observation	B-MED
of	O
improved	B-MED
self-efficacy	B-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
,	O
anxiety	B-MED
and	O
depression	B-MED
1	O
year	B-MED
later	O
in	O
persons	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
ms	B-MED
self-efficacy	B-MED
positively	B-MED
affects	O
health-related	B-MED
quality	I-MED
of	I-MED
life	I-MED
hrqol	B-MED
and	O
physical	B-MED
activity	I-MED
.	O
	
in	O
a	O
previous	O
study	O
we	O
observed	B-MED
that	O
6	O
months	B-MED
after	O
an	O
intensive	O
3-	O
day	B-MED
social	B-MED
cognitive	B-MED
treatment	I-MED
can	O
do	O
treatment	B-MED
with	O
the	O
participation	B-MED
of	O
support	O
partners	B-MED
,	O
self-efficacy	B-MED
and	O
hrqol	B-MED
had	O
improved	B-MED
in	O
persons	B-MED
with	O
relapsing	B-MED
remitting	I-MED
ms	I-MED
rrms	B-MED
.	O
	
given	O
the	O
chronic	B-MED
nature	B-MED
of	I-MED
the	I-MED
disease	I-MED
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	B-MED
changes	B-MED
may	O
last	O
.	O
	
can	O
do	O
treatment	B-MED
was	O
given	O
to	O
60	O
persons	B-MED
with	O
ms	B-MED
and	O
their	O
support	O
partners	B-MED
.	O
	
at	O
baseline	B-MED
and	O
12	O
months	B-MED
after	O
treatment	B-MED
self-efficacy	B-MED
control	B-MED
,	O
self-efficacy	B-MED
function	B-MED
,	O
physical	B-MED
and	O
mental	B-MED
hrqol	B-MED
,	O
anxiety	B-MED
,	O
depression	B-MED
and	O
fatigue	B-MED
were	O
assessed	B-MED
via	O
self-report	B-MED
questionnaires	B-MED
.	O
	
differences	B-MED
were	O
tested	B-MED
via	O
a	O
paired	B-MED
t	I-MED
test	I-MED
.	O
	
of	O
the	O
57	O
persons	B-MED
with	O
ms	B-MED
that	O
completed	B-MED
the	O
baseline	B-MED
assessment	B-MED
and	O
the	O
3-	O
day	B-MED
treatment	B-MED
,	O
38	O
filled	O
in	O
the	O
12th	O
month	B-MED
questionnaires	B-MED
response	B-MED
rate	B-MED
66.7	O
%	O
,	O
22	O
with	O
rrms	B-MED
and	O
14	O
with	O
progressive	B-MED
ms	B-MED
.	O
	
in	O
the	O
rr	B-MED
group	B-MED
self-efficacy	B-MED
control	B-MED
had	O
increased	B-MED
by	O
20.2	O
%	O
and	O
physical	B-MED
hrqol	B-MED
by	O
15.0	O
%	O
,	O
and	O
depression	B-MED
and	O
anxiety	B-MED
had	O
decreased	B-MED
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
all	O
p	O
<	O
0.05	O
the	O
changes	B-MED
in	O
mental	B-MED
hrqol	B-MED
+17	O
%	O
and	O
fatigue	B-MED
-20	O
%	O
failed	B-MED
to	O
be	O
statistically	B-MED
significant	I-MED
p	O
=	O
0.087	O
,	O
p	O
=	O
0.080	O
,	O
respectively	O
.	O
	
in	O
the	O
progressive	B-MED
group	B-MED
no	O
changes	B-MED
suggestive	B-MED
of	I-MED
improvement	B-MED
were	O
seen	O
.	O
	
the	O
findings	B-MED
suggest	B-MED
that	O
a	O
3-	O
day	B-MED
intensive	O
social	B-MED
cognitive	B-MED
treatment	I-MED
can	O
do	O
treatment	B-MED
with	O
the	O
participation	B-MED
of	O
support	O
partners	B-MED
may	O
have	O
long	B-MED
lasting	I-MED
beneficial	B-MED
effects	B-MED
on	O
the	O
self-efficacy	B-MED
and	O
hrqol	B-MED
in	O
persons	B-MED
with	O
rrms	B-MED
and	O
that	O
improvements	B-MED
in	O
anxiety	B-MED
and	O
depression	B-MED
,	O
not	O
seen	O
in	O
the	O
6-	O
month	B-MED
study	O
,	O
may	O
yet	O
develop	B-MED
at	O
12	O
perineal	B-MED
injuries	I-MED
and	O
birth	B-MED
positions	I-MED
among	O
2992	O
women	B-MED
with	O
a	O
low	B-MED
risk	I-MED
pregnancy	I-MED
who	O
opted	O
for	O
a	O
homebirth	B-MED
whether	O
certain	O
birth	B-MED
positions	I-MED
are	O
associated	B-MED
with	I-MED
perineal	B-MED
injuries	I-MED
and	O
severe	B-MED
perineal	I-MED
trauma	I-MED
spt	B-MED
is	O
still	O
unclear	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
describe	O
the	O
prevalence	B-MED
of	O
perineal	B-MED
injuries	I-MED
of	O
different	O
severity	B-MED
in	O
a	O
low-risk	B-MED
population	B-MED
of	O
women	B-MED
who	O
planned	O
to	O
give	O
birth	B-MED
at	I-MED
home	I-MED
and	O
to	O
compare	O
the	O
prevalence	B-MED
of	O
perineal	B-MED
injuries	I-MED
,	O
spt	B-MED
and	O
episiotomy	B-MED
in	O
different	O
birth	B-MED
positions	I-MED
in	O
four	O
nordic	B-MED
countries	I-MED
.	O
	
a	O
population	B-MED
-based	O
prospective	B-MED
cohort	I-MED
study	I-MED
of	O
planned	O
home	B-MED
births	I-MED
in	O
four	O
nordic	B-MED
countries	I-MED
.	O
	
to	O
assess	B-MED
medical	I-MED
outcomes	I-MED
a	O
questionnaire	B-MED
completed	O
after	O
birth	B-MED
by	O
the	O
attending	O
midwife	B-MED
was	O
used	O
.	O
	
descriptive	B-MED
statistics	I-MED
,	O
bivariate	B-MED
analysis	I-MED
and	O
logistic	B-MED
regression	I-MED
were	O
used	O
to	O
analyze	O
the	O
data	B-MED
.	O
	
two	O
thousand	O
nine	O
hundred	O
ninety-two	O
women	B-MED
with	O
planned	O
home	B-MED
births	I-MED
,	O
who	O
birthed	O
spontaneously	O
at	O
home	B-MED
or	O
after	O
transfer	B-MED
to	I-MED
hospital	I-MED
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O
	
the	O
prevalence	B-MED
of	O
spt	B-MED
was	O
0.7	O
%	O
and	O
the	O
prevalence	B-MED
of	O
episiotomy	B-MED
was	O
1.0	O
%	O
.	O
	
there	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-MED
characteristics	B-MED
.	O
	
no	O
association	O
between	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
and	O
sutured	B-MED
perineal	B-MED
injuries	I-MED
was	O
found	O
or	B-MED
1.02	O
95	O
%	O
ci	B-MED
0.86	O
or	O
spt	B-MED
or	B-MED
0.68	O
ci	B-MED
95	O
%	O
0.26	O
.	O
	
flexible	B-MED
sacrum	B-MED
positions	B-MED
were	O
associated	B-MED
with	I-MED
fewer	O
episiotomies	B-MED
or	B-MED
0.20	O
ci	B-MED
95	O
%	O
0.10	O
.	O
	
a	O
low	O
prevalence	B-MED
of	O
spt	B-MED
and	O
episiotomy	B-MED
was	O
found	O
among	O
women	B-MED
opting	O
for	O
a	O
home	B-MED
birth	I-MED
in	O
four	O
nordic	B-MED
countries	I-MED
.	O
	
women	B-MED
used	O
a	O
variety	O
of	O
birth	B-MED
positions	I-MED
and	O
a	O
majority	O
gave	O
birth	B-MED
in	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
.	O
	
no	O
associations	O
were	O
found	O
between	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
and	O
spt	B-MED
.	O
	
flexible	B-MED
sacrum	B-MED
positions	B-MED
were	O
associated	B-MED
with	I-MED
fewer	O
parallel-processing	B-MED
continuous-flow	B-MED
device	I-MED
for	O
optimization	B-MED
-	O
free	B-MED
polymerase	B-MED
chain	I-MED
reaction	I-MED
a	O
parallel-processing	B-MED
four-station	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
pcr	B-MED
device	B-MED
has	O
been	O
developed	O
,	O
which	O
performs	B-MED
continuous-flow	B-MED
pcr	B-MED
without	O
optimization	B-MED
of	O
the	O
annealing	B-MED
temperature	B-MED
.	O
	
since	O
the	O
annealing	B-MED
temperature	B-MED
of	O
each	O
station	B-MED
can	O
be	O
controlled	B-MED
independently	B-MED
,	O
the	O
device	B-MED
covers	B-MED
an	O
annealing	B-MED
temperature	B-MED
range	B-MED
of	O
50-68	O
c	O
,	O
which	O
is	O
wide	B-MED
enough	O
to	O
perform	B-MED
pcr	B-MED
for	O
any	O
dna	B-MED
fragment	I-MED
regardless	O
of	O
its	O
optimum	B-MED
annealing	B-MED
condition	B-MED
.	O
	
this	O
arrangement	B-MED
lets	O
us	O
continuously	B-MED
obtain	B-MED
an	O
amplified	B-MED
amount	B-MED
of	O
a	O
dna	B-MED
fragment	I-MED
at	O
least	O
from	O
one	O
of	O
the	O
stations	B-MED
.	O
	
the	O
device	B-MED
consists	O
of	O
four	O
identical	B-MED
cylindrical	B-MED
stations	B-MED
diameter	B-MED
20	O
mm	O
,	O
height	B-MED
55	O
mm	O
.	O
	
a	O
polytetrafluoroethylene	B-MED
capillary	B-MED
reactor	I-MED
length	B-MED
2	O
m	O
,	O
i.d	O
.	O
	
100	O
μm	O
,	O
o.d	O
.	O
	
400	O
μm	O
is	O
wound	B-MED
helically	I-MED
up	B-MED
around	B-MED
each	O
station	B-MED
.	O
	
the	O
whole	O
assembly	B-MED
is	O
designed	B-MED
to	O
minimize	B-MED
the	O
number	B-MED
of	O
heating	B-MED
blocks	I-MED
for	O
providing	B-MED
temperatures	B-MED
of	O
denaturation	B-MED
,	O
annealing	B-MED
,	O
and	O
extension	B-MED
to	O
be	O
seven	O
and	O
to	O
shape	B-MED
a	O
compact	B-MED
cube	B-MED
height	B-MED
55	O
mm	O
,	O
base	B-MED
60	O
mm	O
60	O
mm	O
.	O
	
the	O
reproducibility	B-MED
for	O
continuous-flow	B-MED
pcr	B-MED
is	O
reasonably	O
high	B-MED
run	B-MED
-to-	O
run	B-MED
and	O
station	B-MED
-to-	O
station	B-MED
relative	O
standard	B-MED
deviation	I-MED
of	O
their	O
amplification	B-MED
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
.	O
	
performance	B-MED
on	O
the	O
optimization	B-MED
-	O
free	B-MED
dna	B-MED
amplification	I-MED
has	O
been	O
evaluated	B-MED
with	O
four	O
dna	B-MED
samples	I-MED
with	O
different	B-MED
annealing	B-MED
conditions	B-MED
and	O
product	B-MED
sizes	B-MED
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
,	O
which	O
has	O
demonstrated	B-MED
that	O
in	O
all	O
cases	B-MED
,	O
pcr	B-MED
is	O
successful	B-MED
at	O
least	O
on	O
one	O
station	B-MED
.	O
	
in	O
addition	B-MED
,	O
three	O
dna	B-MED
fragment	I-MED
s	O
with	O
different	B-MED
lengths	B-MED
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
have	O
been	O
successfully	B-MED
amplified	B-MED
in	O
a	O
segmented	B-MED
-	O
flow	B-MED
mode	B-MED
without	O
the	O
carry-over	O
contamination	B-MED
between	O
segments	B-MED
.	O
	
this	O
result	B-MED
suggests	O
that	O
this	O
device	B-MED
could	O
serve	O
as	O
the	O
pcr	B-MED
module	B-MED
of	O
a	O
continuous-flow	B-MED
high-throughput	B-MED
on-line	I-MED
total	I-MED
dna	I-MED
analysis	I-MED
system	B-MED
integrating	B-MED
all	O
necessary	O
modules	B-MED
from	O
cell	B-MED
lysis	B-MED
/	O
dna	B-MED
extraction	I-MED
to	O
pcr	B-MED
product	B-MED
analysis	B-MED
.	O
	
assessing	B-MED
sex-differences	B-MED
and	O
the	O
effect	B-MED
of	O
timing	B-MED
of	O
vaccination	B-MED
on	O
immunogenicity	B-MED
,	O
reactogenicity	B-MED
and	O
efficacy	B-MED
of	I-MED
vaccines	I-MED
in	O
young	B-MED
children	B-MED
study	B-MED
protocol	I-MED
for	O
an	O
individual	B-MED
participant	B-MED
data	B-MED
meta-analysis	B-MED
of	O
randomised	B-MED
controlled	I-MED
trials	I-MED
disease	B-MED
incidence	B-MED
differs	O
between	O
males	B-MED
and	O
females	B-MED
for	O
some	O
infectious	B-MED
or	O
inflammatory	B-MED
diseases	I-MED
.	O
	
sex-differences	B-MED
in	O
immune	B-MED
responses	I-MED
to	O
some	O
vaccines	B-MED
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-MED
vaccines	I-MED
in	O
adults	B-MED
.	O
	
little	O
evidence	B-MED
is	O
available	B-MED
on	O
whether	O
sex-differences	B-MED
occur	O
in	O
response	B-MED
to	O
immunisation	B-MED
in	O
infancy	B-MED
even	O
though	O
this	O
is	O
the	O
age	B-MED
group	I-MED
in	O
which	O
most	O
vaccines	B-MED
are	O
administered	B-MED
.	O
	
factors	B-MED
other	O
than	O
sex	B-MED
,	O
such	O
as	O
timing	B-MED
or	O
coadministration	B-MED
of	O
other	O
vaccines	B-MED
,	O
can	O
also	O
influence	B-MED
the	O
immune	B-MED
response	I-MED
to	O
vaccination	B-MED
.	O
	
individual	B-MED
participant	B-MED
data	B-MED
meta-analysis	B-MED
of	O
randomised	B-MED
controlled	I-MED
trials	I-MED
of	O
vaccines	B-MED
in	O
healthy	O
infants	B-MED
and	O
young	B-MED
children	B-MED
will	O
be	O
conducted	O
.	O
	
fully	O
anonymised	O
data	B-MED
from	O
170	O
randomised	B-MED
controlled	I-MED
trials	I-MED
of	O
v	O
accines	B-MED
for	O
diphtheria	B-MED
,	O
tetanus	B-MED
,	O
bordetella	B-MED
pertussis	I-MED
,	O
polio	B-MED
,	O
haemophilus	B-MED
influenzae	I-MED
type	I-MED
b	I-MED
,	O
hepatitis	B-MED
b	I-MED
,	O
streptococcus	B-MED
pneumoniae	I-MED
,	O
neisseria	B-MED
meningitidis	I-MED
,	O
measles	B-MED
,	O
mumps	B-MED
,	O
rubella	B-MED
,	O
varicella	B-MED
and	O
rotavirus	B-MED
will	O
be	O
combined	O
for	O
analysis	B-MED
.	O
	
outcomes	B-MED
include	O
measures	B-MED
of	O
immunogenicity	B-MED
immunoglobulins	B-MED
,	O
reactogenicity	B-MED
,	O
safety	B-MED
and	O
disease	B-MED
-specific	O
clinical	B-MED
efficacy	I-MED
.	O
	
data	B-MED
from	O
trials	B-MED
of	O
vaccines	B-MED
containing	O
similar	O
components	B-MED
will	O
be	O
combined	O
in	O
hierarchical	B-MED
models	B-MED
and	O
the	O
effect	B-MED
of	O
sex	B-MED
and	O
timing	B-MED
of	O
vaccinations	B-MED
estimated	O
for	O
each	O
outcome	B-MED
separately	O
.	O
	
systematic	B-MED
reviews	I-MED
of	O
published	B-MED
estimates	O
of	O
sex-differences	B-MED
cannot	O
adequately	O
answer	B-MED
questions	I-MED
in	O
this	O
field	B-MED
since	O
such	O
comparisons	B-MED
are	O
never	O
the	O
main	O
purpose	B-MED
of	O
a	O
clinical	B-MED
trial	I-MED
,	O
thus	O
a	O
large	B-MED
degree	B-MED
of	O
reporting	B-MED
bias	B-MED
exists	B-MED
in	O
the	O
published	B-MED
literature	B-MED
.	O
	
recent	O
improvements	B-MED
in	O
the	O
widespread	B-MED
availability	B-MED
of	I-MED
individual	B-MED
participant	B-MED
data	B-MED
from	O
randomised	B-MED
controlled	I-MED
trials	I-MED
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	B-MED
individual	B-MED
participant	B-MED
data	B-MED
meta-analyses	B-MED
which	O
were	O
previously	B-MED
impossible	B-MED
,	O
thereby	O
reducing	B-MED
the	O
effect	B-MED
of	O
publication	B-MED
or	O
reporting	B-MED
bias	B-MED
on	O
the	O
understanding	B-MED
of	O
the	O
infant	B-MED
immune	B-MED
response	I-MED
.	O
	
preliminary	B-MED
results	I-MED
will	O
be	O
available	B-MED
in	O
2016	O
with	O
final	O
results	B-MED
available	B-MED
in	O
2019	O
.	O
	
no	B-MED
ethics	B-MED
review	B-MED
is	O
required	O
for	O
secondary	B-MED
analyses	I-MED
of	O
anonymised	O
an	O
ultrasensitive	B-MED
electrochemiluminescence	B-MED
sensor	B-MED
based	O
on	O
reduced	B-MED
graphene	I-MED
oxide	I-MED
-	O
copper	B-MED
sulfide	I-MED
composite	B-MED
coupled	O
with	O
capillary	B-MED
electrophoresis	I-MED
for	O
determination	B-MED
of	O
amlodipine	B-MED
besylate	I-MED
in	O
mice	B-MED
plasma	B-MED
a	O
new	O
electrochemiluminescence	B-MED
ecl	B-MED
sensor	B-MED
based	O
on	O
reduced	B-MED
graphene	I-MED
oxide	I-MED
-	O
copper	B-MED
sulfide	I-MED
rgo	B-MED
-	O
cus	B-MED
composite	B-MED
coupled	O
with	O
capillary	B-MED
electrophoresis	I-MED
ce	B-MED
was	O
constructed	O
for	O
the	O
ultrasensitive	B-MED
detection	B-MED
of	O
amlodipine	B-MED
besylate	I-MED
aml	B-MED
for	O
the	O
first	O
time	O
.	O
	
in	O
this	O
work	O
,	O
rgo	B-MED
-	O
cus	B-MED
composite	B-MED
was	O
synthesized	O
by	O
one-pot	O
hydrothermal	B-MED
method	I-MED
and	O
used	O
for	O
electrode	B-MED
modification	B-MED
.	O
	
the	O
electrochemical	B-MED
and	O
ecl	B-MED
behaviors	O
of	O
the	O
sensor	B-MED
were	O
investigated	B-MED
.	O
	
more	O
than	O
5-fold	O
enhance	B-MED
in	O
ecl	B-MED
intensity	B-MED
was	O
observed	B-MED
after	O
modified	O
with	O
rgo	B-MED
-	O
cus	B-MED
composite	B-MED
.	O
	
the	O
results	B-MED
can	O
be	O
ascribed	O
to	O
the	O
presence	B-MED
of	O
rgo	B-MED
-	O
cus	B-MED
composite	B-MED
on	O
the	O
electrode	B-MED
surface	B-MED
that	O
facilitates	O
the	O
electron	B-MED
transfer	I-MED
rate	I-MED
between	O
the	O
electroactive	B-MED
center	B-MED
of	O
ru	B-MED
and	O
the	O
electrode	B-MED
.	O
	
the	O
ecl	B-MED
sensor	B-MED
was	O
coupled	B-MED
with	O
ce	B-MED
to	O
improve	O
the	O
selectivity	B-MED
and	O
the	O
ce	B-MED
-	O
ecl	B-MED
parameters	B-MED
that	O
affect	O
separation	B-MED
and	O
detection	B-MED
were	O
optimized	O
.	O
	
under	O
the	O
optimum	B-MED
conditions	O
,	O
the	O
linear	B-MED
ranges	I-MED
for	O
aml	B-MED
was	O
0.008	O
with	O
a	O
detection	B-MED
limit	I-MED
of	O
2.8ng	O
s/n=3	O
.	O
	
the	O
method	B-MED
displayed	O
the	O
advantages	O
of	O
high	B-MED
sensitivity	I-MED
,	O
good	B-MED
selectivity	I-MED
,	O
wide	O
linear	B-MED
range	I-MED
,	O
low	O
detection	B-MED
limit	I-MED
and	O
fine	B-MED
reproducibility	I-MED
,	O
and	O
was	O
used	O
to	O
analyze	O
aml	B-MED
in	O
mice	B-MED
plasma	B-MED
with	O
a	O
satisfactory	O
result	B-MED
,	O
which	O
holds	O
a	O
great	O
potential	B-MED
in	O
the	O
field	O
of	O
pharmaceutical	B-MED
analysis	I-MED
.	O
	
estrogen	B-MED
and	O
progesterone	B-MED
hormone	B-MED
receptor	B-MED
expression	I-MED
in	O
oral	B-MED
cavity	I-MED
cancer	I-MED
recent	O
studies	O
have	O
shown	O
an	O
increase	B-MED
in	O
the	O
incidence	B-MED
of	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
oscc	B-MED
in	O
younger	B-MED
patients	B-MED
.	O
	
the	O
hypothesis	B-MED
that	O
tumors	B-MED
could	O
be	O
hormonally	B-MED
induced	B-MED
during	O
pregnancy	B-MED
or	O
in	O
young	B-MED
female	B-MED
patients	B-MED
without	O
the	O
well-known	O
risk	B-MED
factors	I-MED
alcohol	B-MED
or	O
tobacco	B-MED
abuse	I-MED
seems	O
to	O
be	O
plausible	O
.	O
	
estrogen	B-MED
receptor	I-MED
alpha	I-MED
erα	B-MED
and	O
progesterone	B-MED
receptor	I-MED
pr	B-MED
expression	B-MED
were	O
analyzed	B-MED
in	O
normal	O
oral	B-MED
mucosa	I-MED
n=5	O
,	O
oral	B-MED
precursor	I-MED
lesions	I-MED
simple	B-MED
hyperplasia	I-MED
,	O
n=11	O
squamous	B-MED
intraepithelial	I-MED
neoplasia	I-MED
,	O
sin	B-MED
i-iii	I-MED
,	O
n=35	O
,	O
and	O
oscc	B-MED
specimen	B-MED
.	O
	
osccs	B-MED
were	O
stratified	B-MED
in	O
a	O
young	B-MED
female	B-MED
n=7	O
study	O
cohort	B-MED
and	O
older	B-MED
patients	B-MED
n=46	O
.	O
	
in	O
the	O
young	B-MED
female	B-MED
study	O
cohort	B-MED
three	O
patients	B-MED
n=3/7	O
developed	O
oscc	B-MED
during	O
or	O
shortly	O
after	O
pregnancy	B-MED
.	O
	
breast	B-MED
cancer	I-MED
tissues	B-MED
were	O
used	O
as	O
positive	B-MED
control	I-MED
for	O
erα	B-MED
and	O
pr	B-MED
expression	B-MED
.	O
	
erα	B-MED
expression	B-MED
was	O
found	O
in	O
four	O
oral	B-MED
precursor	I-MED
lesions	I-MED
squamous	B-MED
intraepithelial	I-MED
neoplasia	I-MED
,	O
sin	B-MED
i-iii	I-MED
,	O
n=4/35	O
,	O
11%	O
and	O
in	O
five	O
oscc	B-MED
specimen	B-MED
n=5/46	O
,	O
11%	O
.	O
	
the	O
five	O
erα	B-MED
positive	B-MED
oscc	B-MED
samples	B-MED
were	O
older	B-MED
male	B-MED
patients	B-MED
.	O
	
all	O
patients	B-MED
within	O
the	O
young	B-MED
female	B-MED
study	O
cohort	B-MED
were	O
negatively	B-MED
stained	O
for	O
both	O
erα	B-MED
and	O
pr	B-MED
.	O
	
er	B-MED
expression	B-MED
could	O
be	O
regarded	O
as	O
a	O
seldom	B-MED
risk	B-MED
factor	I-MED
for	O
oscc	B-MED
.	O
	
pr	B-MED
expression	B-MED
seems	O
to	O
be	O
not	O
relevant	B-MED
for	O
the	O
development	B-MED
of	O
studying	B-MED
neuroprotective	B-MED
effect	I-MED
of	O
atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
drug	B-MED
on	O
high	B-MED
glucose	I-MED
-	O
induced	B-MED
neurotoxicity	B-MED
in	O
undifferentiated	B-MED
pc12	B-MED
cells	I-MED
role	B-MED
of	O
nadph	B-MED
oxidase	I-MED
overproduction	B-MED
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
ros	B-MED
by	O
nadph	B-MED
oxidase	I-MED
nox	B-MED
activation	B-MED
has	O
been	O
considered	B-MED
the	O
essential	B-MED
mechanism	B-MED
induced	B-MED
by	O
hyperglycemia	B-MED
in	O
various	O
tissues	B-MED
.	O
	
however	O
,	O
there	O
is	O
no	B-MED
comprehensive	I-MED
study	B-MED
on	O
the	O
role	B-MED
of	O
noxs	B-MED
in	O
high	B-MED
glucose	I-MED
hg	B-MED
induced	B-MED
toxic	B-MED
effect	I-MED
in	O
neural	B-MED
tissues	I-MED
.	O
	
recently	O
,	O
a	O
therapeutic	B-MED
strategy	B-MED
in	O
oxidative	B-MED
related	B-MED
pathologies	B-MED
has	O
been	O
introduced	B-MED
by	O
blocking	B-MED
the	O
undesirable	B-MED
actions	I-MED
of	O
nox	B-MED
enzymes	I-MED
by	O
small	B-MED
molecules	I-MED
.	O
	
the	O
protective	B-MED
roles	B-MED
of	O
statins	B-MED
in	O
ameliorating	B-MED
oxidative	B-MED
stress	I-MED
by	O
nox	B-MED
inhibition	B-MED
have	O
been	O
shown	O
in	O
some	O
tissues	B-MED
except	O
neural	B-MED
.	O
	
we	O
hypothesized	B-MED
then	O
,	O
that	O
different	B-MED
noxs	B-MED
may	O
have	O
role	B-MED
in	O
hg	B-MED
-	O
induced	B-MED
neural	B-MED
cell	I-MED
injury	I-MED
.	O
	
furthermore	O
,	O
we	O
postulate	B-MED
that	O
atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
may	O
modulate	B-MED
this	O
noxs	B-MED
activity	I-MED
to	O
protect	B-MED
neural	B-MED
cells	I-MED
.	O
	
undifferentiated	B-MED
pc12	B-MED
cells	I-MED
were	O
treated	B-MED
with	I-MED
hg	B-MED
140	O
mm/	O
24	B-MED
h	I-MED
in	O
the	O
presence	B-MED
and	O
absence	B-MED
of	O
atorvastatin	B-MED
1	O
μm/	O
96	B-MED
h	I-MED
.	O
	
the	O
cell	B-MED
viability	I-MED
was	O
measured	B-MED
by	O
mtt	B-MED
assay	I-MED
and	O
the	O
gene	B-MED
and	O
protein	B-MED
expressions	I-MED
profile	I-MED
of	O
nox	B-MED
1-4	O
were	O
determined	B-MED
by	I-MED
rt-pcr	B-MED
and	O
western	B-MED
blotting	I-MED
,	O
respectively	O
.	O
	
levels	B-MED
of	O
ros	B-MED
and	O
malondialdehyde	B-MED
mda	B-MED
were	O
also	O
evaluated	B-MED
.	O
	
gene	B-MED
and	O
protein	B-MED
expression	I-MED
levels	B-MED
of	O
nox	B-MED
1-4	O
and	O
consequently	B-MED
ros	B-MED
and	O
mda	B-MED
levels	B-MED
were	O
elevated	B-MED
in	O
hg	B-MED
-	O
treated	B-MED
pc12	B-MED
cells	I-MED
.	O
	
atorvastatin	B-MED
could	O
significantly	B-MED
decrease	B-MED
hg	B-MED
-	O
induced	B-MED
noxs	B-MED
,	O
ros	B-MED
and	O
mda	B-MED
elevation	B-MED
and	O
improve	B-MED
impaired	B-MED
cell	B-MED
viability	I-MED
.	O
	
it	O
can	O
be	O
concluded	B-MED
that	O
hg	B-MED
could	O
elevate	B-MED
noxs	B-MED
activity	I-MED
,	O
ros	B-MED
and	O
mda	B-MED
levels	B-MED
in	O
neural	B-MED
tissues	I-MED
and	O
atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
nox	B-MED
inhibitor	I-MED
drug	I-MED
may	O
prevent	B-MED
and	O
delay	B-MED
diabetic	B-MED
complications	I-MED
,	O
particularly	O
intravascular	B-MED
inflammation	B-MED
triggers	B-MED
intracerebral	B-MED
activated	B-MED
microglia	B-MED
and	O
contributes	O
to	O
secondary	B-MED
brain	I-MED
injury	I-MED
after	O
experimental	B-MED
subarachnoid	B-MED
hemorrhage	I-MED
esah	B-MED
activation	B-MED
of	O
innate	B-MED
immunity	I-MED
contributes	O
to	O
secondary	B-MED
brain	I-MED
injury	I-MED
after	O
experimental	B-MED
subarachnoid	B-MED
hemorrhage	I-MED
esah	B-MED
.	O
	
microglia	B-MED
accumulation	B-MED
and	O
activation	B-MED
within	O
the	O
brain	B-MED
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	B-MED
cell	I-MED
death	I-MED
after	O
esah	B-MED
.	O
	
in	O
isolated	B-MED
mouse	B-MED
brain	B-MED
capillaries	B-MED
after	O
esah	B-MED
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	B-MED
expression	I-MED
for	O
intercellular	B-MED
adhesion	I-MED
molecule-1	I-MED
icam-1	B-MED
and	O
p-selectin	B-MED
.	O
	
hence	O
,	O
we	O
hypothesized	B-MED
that	O
extracerebral	B-MED
intravascular	B-MED
inflammatory	B-MED
processes	I-MED
might	O
initiate	O
the	O
previously	O
reported	B-MED
microglia	B-MED
accumulation	B-MED
within	O
the	O
brain	B-MED
tissue	I-MED
.	O
	
we	O
therefore	O
induced	O
esah	B-MED
in	O
knockout	B-MED
mice	I-MED
for	O
icam-1	B-MED
icam-1	B-MED
and	O
p-selectin	B-MED
glycoprotein	I-MED
ligand-1	I-MED
psgl-1	B-MED
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-MED
-	O
endothelial	B-MED
interaction	B-MED
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-MED
in	O
a	O
chronic	B-MED
cranial	B-MED
window	B-MED
model	I-MED
.	O
	
this	O
inhibition	B-MED
of	O
neutrophil	B-MED
recruitment	I-MED
to	O
the	O
endothelium	B-MED
results	O
in	O
significantly	O
ameliorated	B-MED
microglia	B-MED
accumulation	B-MED
and	O
neuronal	B-MED
cell	I-MED
death	I-MED
in	O
knockout	B-MED
animals	I-MED
in	O
comparison	O
to	O
controls	O
.	O
	
our	O
results	O
suggest	O
an	O
outside-in	O
activation	B-MED
of	O
the	O
cns	B-MED
innate	I-MED
immune	B-MED
system	I-MED
at	O
the	O
vessel	B-MED
/	O
brain	B-MED
interface	O
following	O
esah	B-MED
.	O
	
microglia	B-MED
cells	B-MED
,	O
as	O
part	O
of	O
the	O
brain's	B-MED
innate	B-MED
immune	I-MED
system	I-MED
,	O
are	O
triggered	B-MED
by	O
an	O
inflammatory	B-MED
reaction	I-MED
in	O
the	O
microvasculature	B-MED
after	O
esah	B-MED
,	O
thus	O
contributing	O
to	O
neuronal	B-MED
cell	I-MED
death	I-MED
.	O
	
this	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-MED
targets	B-MED
,	O
as	O
well	O
as	O
possible	O
therapy	B-MED
options	O
for	O
patients	B-MED
suffering	O
from	O
amphetamine	B-MED
withdrawal	I-MED
differentially	O
increases	O
the	O
expression	B-MED
of	O
organic	B-MED
cation	I-MED
transporter	I-MED
3	I-MED
and	O
serotonin	B-MED
transporter	I-MED
in	O
limbic	B-MED
brain	B-MED
regions	I-MED
amphetamine	B-MED
withdrawal	I-MED
increases	O
anxiety	B-MED
and	O
stress	B-MED
sensitivity	O
related	O
to	O
blunted	B-MED
ventral	B-MED
hippocampus	B-MED
vhipp	B-MED
and	O
enhances	O
the	O
central	B-MED
nucleus	I-MED
of	I-MED
the	I-MED
amygdala	I-MED
cea	B-MED
serotonin	B-MED
responses	B-MED
.	O
	
extracellular	B-MED
serotonin	B-MED
levels	B-MED
are	O
regulated	O
by	O
the	O
serotonin	B-MED
transporter	I-MED
sert	B-MED
and	O
organic	B-MED
cation	I-MED
transporter	I-MED
3	I-MED
oct3	B-MED
,	O
and	O
vhipp	B-MED
oct3	B-MED
expression	B-MED
is	O
enhanced	O
during	O
24	B-MED
hours	I-MED
of	O
amphetamine	B-MED
withdrawal	I-MED
,	O
while	O
sert	B-MED
expression	B-MED
is	O
unaltered	O
.	O
	
here	O
,	O
we	O
tested	O
whether	O
oct3	B-MED
and	O
sert	B-MED
expression	B-MED
in	O
the	O
cea	B-MED
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-MED
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-MED
serotonergic	B-MED
neurotransmission	I-MED
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	B-MED
weeks	I-MED
of	O
withdrawal	B-MED
.	O
	
we	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-MED
expression	B-MED
were	O
confined	O
to	O
these	O
regions	O
.	O
	
male	B-MED
rats	B-MED
received	O
amphetamine	B-MED
or	O
saline	B-MED
for	O
two	B-MED
weeks	I-MED
followed	O
by	O
24	B-MED
hours	I-MED
or	O
two	B-MED
weeks	I-MED
of	O
withdrawal	B-MED
,	O
with	O
transporter	B-MED
expression	B-MED
measured	O
using	O
western	B-MED
immunoblot	I-MED
.	O
	
oct3	B-MED
and	O
sert	B-MED
expression	B-MED
increased	O
in	O
the	O
cea	B-MED
at	O
both	O
withdrawal	B-MED
timepoints	O
.	O
	
in	O
the	O
vhipp	B-MED
,	O
oct3	B-MED
expression	B-MED
increased	O
only	O
at	O
24	B-MED
hours	I-MED
of	O
withdrawal	B-MED
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-MED
hypothalamus	I-MED
.	O
	
no	B-MED
changes	I-MED
were	O
evident	O
in	O
any	O
other	O
regions	B-MED
sampled	O
.	O
	
these	O
regionally	O
specific	O
changes	O
in	O
limbic	B-MED
oct3	B-MED
and	O
sert	B-MED
expression	B-MED
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-MED
imbalance	B-MED
and	O
negative	B-MED
affect	I-MED
during	O
amphetamine	B-MED
withdrawal	I-MED
.	O
	
nutritional	B-MED
aspects	I-MED
of	O
night	B-MED
eating	B-MED
and	O
its	O
association	B-MED
with	I-MED
weight	B-MED
status	B-MED
among	O
korean	B-MED
adolescents	B-MED
a	O
growing	B-MED
body	O
of	O
research	B-MED
has	O
indicated	O
that	O
night	B-MED
eating	B-MED
could	O
be	O
associated	B-MED
with	I-MED
poor	B-MED
diet	I-MED
quality	B-MED
and	O
negative	B-MED
health	B-MED
outcomes	I-MED
.	O
	
this	O
study	B-MED
examined	O
the	O
nutritional	B-MED
aspects	I-MED
of	O
night	B-MED
eating	B-MED
,	O
its	O
related	O
factors	B-MED
,	O
and	O
the	O
association	B-MED
between	O
night	B-MED
eating	B-MED
and	O
body	B-MED
weight	I-MED
among	O
korean	B-MED
adolescents	B-MED
.	O
	
this	O
study	B-MED
analysed	O
the	O
data	B-MED
from	O
a	O
one	O
day	B-MED
24-hour	O
dietary	B-MED
recall	I-MED
as	O
well	O
as	O
a	O
demographic	B-MED
survey	I-MED
of	O
1	O
korean	B-MED
adolescents	B-MED
aged	O
12	O
to	O
18-	O
years	B-MED
-old	O
obtained	O
from	O
the	O
2010-2012	O
korea	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
.	O
	
'	O
night	B-MED
eating	B-MED
'	O
was	O
defined	O
as	O
consuming	O
25%	O
or	O
more	O
of	O
one's	O
daily	B-MED
energy	I-MED
intake	I-MED
between	O
21	O
and	O
06	O
.	O
	
subjects	B-MED
complying	O
with	O
the	O
preceding	O
condition	B-MED
were	O
classified	O
as	O
'	O
night	B-MED
eaters	B-MED
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non-night	B-MED
eaters	I-MED
'	O
.	O
	
logistic	B-MED
regression	I-MED
analysis	I-MED
examined	O
factors	B-MED
related	O
to	O
night	B-MED
eating	B-MED
.	O
	
multiple	B-MED
linear	I-MED
regression	I-MED
analyses	I-MED
were	O
used	O
to	O
examine	O
the	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
bmi	B-MED
z-scores	B-MED
,	O
whereas	O
multinomial	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
examine	O
the	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
weight	B-MED
status	B-MED
.	O
	
about	O
21%	O
of	O
korean	B-MED
adolescents	B-MED
appeared	O
to	O
be	O
night	B-MED
eaters	B-MED
.	O
	
night	B-MED
eaters	B-MED
showed	O
increased	B-MED
breakfast	B-MED
skipping	B-MED
p	O
=	O
0.001	O
,	O
higher	O
energy	B-MED
intake	I-MED
from	O
snacks	B-MED
p	O
<	O
0.001	O
,	O
greater	O
proportion	B-MED
of	I-MED
energy	I-MED
intake	I-MED
from	I-MED
fat	I-MED
p	O
=	O
0.029	O
,	O
and	O
lower	B-MED
dietary	I-MED
diversity	I-MED
scores	I-MED
p	O
=	O
0.008	O
than	O
non-night	B-MED
eaters	I-MED
.	O
	
male	B-MED
adolescents	B-MED
presented	O
1.9	O
times	B-MED
higher	O
odds	O
of	O
being	O
night	B-MED
eaters	B-MED
than	O
females	B-MED
.	O
	
adolescents	B-MED
whose	O
both	O
parents	B-MED
were	O
night	B-MED
eaters	B-MED
were	O
4.4	O
times	B-MED
as	O
likely	O
to	O
be	O
night	B-MED
eaters	B-MED
as	O
those	O
whose	O
neither	O
parents	B-MED
were	O
.	O
	
female	B-MED
adolescents	B-MED
showed	O
a	O
significant	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
bmi	B-MED
z-scores	B-MED
β	O
=	O
0.28	O
,	O
p	O
=	O
0.004	O
.	O
	
however	O
,	O
night	B-MED
eating	B-MED
did	O
not	O
increase	B-MED
odds	O
of	O
being	O
overweight	B-MED
or	O
obese	B-MED
in	O
adolescents	B-MED
.	O
	
night	B-MED
eating	B-MED
in	O
korean	B-MED
adolescents	B-MED
was	O
related	O
to	O
undesirable	B-MED
dietary	I-MED
behaviours	I-MED
and	O
low	B-MED
diet	I-MED
quality	I-MED
in	O
general	O
as	O
well	O
as	O
higher	O
bmi	B-MED
z-scores	B-MED
in	O
females	B-MED
.	O
	
male	B-MED
gender	B-MED
and	O
parental	B-MED
night	B-MED
eating	B-MED
appeared	O
to	O
be	O
the	O
factors	B-MED
that	O
significantly	O
increased	B-MED
odds	O
of	O
night	B-MED
eating	B-MED
.	O
	
these	O
results	O
suggest	O
that	O
night	B-MED
eating	B-MED
should	O
be	O
considered	O
when	O
designing	O
nutrition	B-MED
education	I-MED
or	O
intervention	B-MED
programs	I-MED
targeting	O
a	O
randomized	B-MED
trial	I-MED
of	O
plasma-lyte	B-MED
a	I-MED
and	O
0.9	B-MED
%	I-MED
sodium	I-MED
chloride	I-MED
in	O
acute	B-MED
pediatric	I-MED
gastroenteritis	I-MED
compare	O
the	O
efficacy	B-MED
and	O
safety	O
of	O
plasma-lyte	B-MED
a	I-MED
pla	B-MED
versus	O
0.9	B-MED
%	I-MED
sodium	I-MED
chloride	I-MED
nacl	B-MED
intravenous	B-MED
iv	I-MED
fluid	I-MED
replacement	I-MED
in	O
children	B-MED
with	O
moderate	O
to	O
severe	B-MED
dehydration	I-MED
secondary	O
to	O
acute	B-MED
gastroenteritis	I-MED
age	B-MED
.	O
	
prospective	B-MED
,	O
randomized	B-MED
,	O
double-blind	B-MED
study	I-MED
conducted	O
at	O
eight	O
pediatric	B-MED
emergency	B-MED
departments	I-MED
eds	B-MED
in	O
the	O
us	B-MED
and	O
canada	B-MED
nct	O
.	O
	
the	O
primary	B-MED
outcome	I-MED
measure	I-MED
was	O
serum	B-MED
bicarbonate	I-MED
level	I-MED
at	O
4	O
h	O
.	O
	
secondary	B-MED
outcomes	I-MED
included	O
safety	O
and	O
tolerability	B-MED
.	O
	
the	O
hypothesis	B-MED
was	O
that	O
pla	B-MED
would	O
be	O
superior	O
to	O
0.9	B-MED
%	I-MED
nacl	I-MED
in	O
improvement	B-MED
of	I-MED
4-h	I-MED
bicarbonate	I-MED
.	O
	
patients	B-MED
n	O
=	O
100	O
aged	O
6	O
months	O
to	O
<11	O
years	O
with	O
age	B-MED
-induced	O
moderate-to-	O
severe	B-MED
dehydration	I-MED
were	O
enrolled	O
.	O
	
patients	B-MED
with	O
a	O
baseline	B-MED
bicarbonate	B-MED
level	I-MED
22	O
meq/l	O
formed	B-MED
the	O
modified	B-MED
intent	B-MED
to	I-MED
treat	I-MED
mitt	B-MED
group	B-MED
.	O
	
at	O
baseline	B-MED
,	O
the	O
treatment	B-MED
groups	B-MED
were	O
comparable	O
except	O
that	O
the	O
pla	B-MED
group	B-MED
was	O
older	O
.	O
	
at	O
hour	O
4	O
,	O
the	O
pla	B-MED
group	B-MED
had	O
greater	O
increases	B-MED
in	I-MED
serum	I-MED
bicarbonate	I-MED
from	O
baseline	B-MED
than	O
did	O
the	O
0.9	B-MED
%	I-MED
nacl	I-MED
group	B-MED
mean	O
sd	O
at	O
4	O
h	O
18	O
3.74	O
vs	O
18.0	O
3.67	O
change	O
from	O
baseline	B-MED
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
p	O
=	O
004	O
.	O
	
both	O
treatment	B-MED
groups	B-MED
received	O
similar	O
fluid	B-MED
volumes	I-MED
.	O
	
the	O
pla	B-MED
group	B-MED
had	O
less	O
abdominal	B-MED
pain	I-MED
and	O
better	O
dehydration	B-MED
scores	O
at	O
hour	O
2	O
both	O
p	O
=	O
03	O
but	O
not	O
at	O
hour	O
4	O
p	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
.	O
	
no	O
patient	B-MED
experienced	O
clinically	B-MED
relevant	I-MED
worsening	I-MED
of	O
laboratory	B-MED
findings	I-MED
or	O
physical	B-MED
examination	I-MED
,	O
and	O
hospital	B-MED
admission	I-MED
rates	I-MED
were	O
similar	B-MED
.	O
	
one	O
patient	B-MED
in	O
each	O
treatment	B-MED
group	B-MED
developed	O
hyponatremia	B-MED
.	O
	
four	O
patients	B-MED
developed	O
hyperkalemia	B-MED
pla	B-MED
1	O
,	O
0.9	B-MED
%	I-MED
nacl	I-MED
3	O
.	O
	
in	O
comparison	B-MED
with	O
0.9	B-MED
%	I-MED
nacl	I-MED
,	O
pla	B-MED
for	O
rehydration	B-MED
in	O
children	B-MED
with	O
age	B-MED
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-MED
in	I-MED
serum	I-MED
bicarbonate	I-MED
and	O
dehydration	B-MED
the	O
relationships	B-MED
between	O
symptoms	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
over	O
the	O
course	B-MED
of	O
cognitive-behavioral	B-MED
therapy	I-MED
for	O
panic	B-MED
disorder	I-MED
in	O
japan	B-MED
this	O
study	B-MED
examined	B-MED
the	O
relationships	B-MED
between	O
changes	B-MED
in	O
symptoms	B-MED
and	O
changes	B-MED
in	O
quality	B-MED
of	I-MED
life	I-MED
qol	B-MED
during	O
cognitive-behavioral	B-MED
therapy	I-MED
cbt	B-MED
for	O
panic	B-MED
disorder	I-MED
pd	B-MED
.	O
	
we	O
treated	B-MED
198	O
pd	B-MED
patients	B-MED
with	O
group	O
cbt	B-MED
in	O
japan	B-MED
.	O
	
using	O
multiple	B-MED
regression	I-MED
analysis	I-MED
,	O
we	O
examined	B-MED
the	O
associations	B-MED
between	O
changes	B-MED
in	O
qol	B-MED
and	O
changes	B-MED
in	O
pd	B-MED
symptoms	B-MED
or	O
comorbid	B-MED
psychological	I-MED
symptoms	I-MED
during	O
cbt	B-MED
.	O
	
changes	B-MED
in	O
anticipatory	B-MED
anxiety	I-MED
,	O
agoraphobic	B-MED
fear	I-MED
/	O
avoidance	B-MED
,	O
and	O
somatization	B-MED
were	O
significant	O
predictors	B-MED
of	O
changes	B-MED
in	O
some	O
aspects	O
of	O
qol	B-MED
.	O
	
it	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-MED
,	O
anticipatory	B-MED
anxiety	I-MED
,	O
and	O
agoraphobic	B-MED
fear	I-MED
to	O
improve	O
qol	B-MED
in	O
cbt	B-MED
for	O
coupling	B-MED
of	O
trpv6	B-MED
and	O
tmem16a	B-MED
in	O
epithelial	B-MED
principal	I-MED
cells	I-MED
of	O
the	O
rat	B-MED
epididymis	I-MED
the	O
epididymis	B-MED
establishes	O
a	O
congenial	B-MED
environment	B-MED
for	O
sperm	B-MED
maturation	I-MED
and	O
protection	B-MED
.	O
	
its	O
fluid	B-MED
is	O
acidic	B-MED
,	O
and	O
the	O
calcium	B-MED
concentration	B-MED
is	O
low	B-MED
and	O
declines	O
along	O
the	O
length	B-MED
of	O
the	O
epididymal	B-MED
tubule	I-MED
.	O
	
however	O
,	O
our	O
knowledge	O
of	O
ionic	B-MED
currents	I-MED
and	O
mechanisms	B-MED
of	O
calcium	B-MED
homeostasis	I-MED
in	O
rat	B-MED
epididymal	I-MED
epithelial	B-MED
cells	I-MED
remains	O
enigmatic	O
.	O
	
in	O
this	O
study	B-MED
,	O
to	O
better	O
understand	O
calcium	B-MED
regulation	I-MED
in	O
the	O
epididymis	B-MED
,	O
we	O
use	O
the	O
patch-clamp	B-MED
method	I-MED
to	O
record	O
from	O
single	O
rat	B-MED
cauda	B-MED
epididymal	I-MED
principal	B-MED
cells	I-MED
.	O
	
we	O
detect	B-MED
a	O
constitutively	O
active	B-MED
ca	B-MED
current	B-MED
with	O
characteristics	B-MED
that	O
match	O
the	O
epithelial	B-MED
calcium	B-MED
channel	I-MED
trpv6	B-MED
.	O
	
electrophysiological	B-MED
and	O
pharmacological	B-MED
data	I-MED
also	O
reveal	O
a	O
constitutively	O
active	B-MED
calcium-activated	I-MED
chloride	I-MED
conductance	I-MED
cacc	B-MED
.	O
	
removal	O
of	O
extracellular	B-MED
calcium	B-MED
attenuates	B-MED
not	O
only	O
the	O
trpv6	B-MED
-like	O
conductance	B-MED
,	O
but	O
also	O
the	O
cacc	B-MED
.	O
	
lanthanide	B-MED
block	B-MED
is	O
time	B-MED
dependent	B-MED
such	O
that	O
the	O
trpv6	B-MED
-like	O
component	O
is	O
inhibited	B-MED
first	O
,	O
followed	O
by	O
the	O
cacc	B-MED
.	O
	
the	O
putative	O
cacc	B-MED
blocker	B-MED
niflumic	B-MED
acid	I-MED
partially	O
inhibits	B-MED
whole-cell	B-MED
currents	B-MED
,	O
whereas	O
la	B-MED
almost	O
abolishes	O
whole-cell	B-MED
currents	B-MED
in	O
principal	B-MED
cells	I-MED
.	O
	
membrane	B-MED
potential	I-MED
measurements	B-MED
reveal	O
an	O
interplay	O
between	O
la	B-MED
-	O
sensitive	B-MED
ion	I-MED
channels	I-MED
and	O
those	O
that	O
are	O
sensitive	B-MED
to	O
the	O
specific	B-MED
tmem16a	B-MED
inhibitor	B-MED
tannic	B-MED
acid	I-MED
.	O
	
in	B-MED
vivo	I-MED
perfusion	B-MED
of	O
the	O
cauda	B-MED
epididymal	I-MED
tubule	I-MED
shows	O
a	O
substantial	O
rate	O
of	O
ca	B-MED
reabsorption	B-MED
from	O
the	O
luminal	B-MED
side	I-MED
,	O
which	O
is	O
dose-dependently	O
suppressed	B-MED
by	O
ruthenium	B-MED
red	I-MED
,	O
a	O
putative	O
blocker	B-MED
of	O
epithelial	B-MED
ca	B-MED
channels	I-MED
and	O
cacc	B-MED
.	O
	
finally	O
,	O
we	O
discover	O
messenger	B-MED
rna	I-MED
for	O
both	O
trpv6	B-MED
and	O
tmem16a	B-MED
in	O
the	O
rat	B-MED
epididymis	I-MED
and	O
show	O
that	O
their	O
proteins	B-MED
colocalize	B-MED
in	O
the	O
apical	B-MED
membrane	I-MED
of	O
principal	B-MED
cells	I-MED
.	O
	
collectively	O
,	O
these	O
data	B-MED
provide	O
evidence	B-MED
for	O
a	O
coupling	B-MED
mechanism	B-MED
between	O
trpv6	B-MED
and	O
tmem16a	B-MED
in	O
principal	B-MED
cells	I-MED
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	B-MED
of	I-MED
calcium	I-MED
homeostasis	I-MED
in	O
the	O
voices	O
a	O
conversation	B-MED
with	O
allen	B-MED
j	I-MED
.	O
	
wilcox	I-MED
allen	B-MED
james	I-MED
wilcox	I-MED
was	O
born	O
on	O
30	O
september	O
1946	O
in	O
columbus	B-MED
,	O
oh	I-MED
.	O
	
he	O
studied	O
medicine	B-MED
at	O
the	O
university	B-MED
of	I-MED
michigan	I-MED
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	B-MED
,	O
he	O
completed	B-MED
a	I-MED
master's	I-MED
degree	I-MED
in	O
maternal	B-MED
and	I-MED
child	I-MED
health	I-MED
1976	O
and	O
a	O
phd	B-MED
in	O
epidemiology	B-MED
1979	O
at	O
the	O
university	B-MED
of	I-MED
north	I-MED
carolina	I-MED
in	O
chapel	B-MED
hill	I-MED
.	O
	
after	O
graduation	B-MED
,	O
he	O
went	O
to	O
work	B-MED
at	O
the	O
national	B-MED
institute	I-MED
of	I-MED
environmental	I-MED
health	I-MED
sciences	I-MED
niehs	B-MED
,	O
one	O
of	O
the	O
us	B-MED
national	I-MED
institutes	I-MED
of	I-MED
health	I-MED
in	O
durham	B-MED
,	O
nc	I-MED
,	O
where	O
he	O
has	O
spent	O
his	O
career	B-MED
.	O
	
he	O
developed	O
a	O
research	B-MED
program	I-MED
in	O
reproductive	O
and	O
perinatal	B-MED
epidemiology	I-MED
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O
	
his	O
studies	O
include	O
the	O
early	B-MED
pregnancy	I-MED
study	O
,	O
which	O
documented	B-MED
the	O
extent	O
of	O
subclinical	B-MED
pregnancy	B-MED
loss	I-MED
in	O
humans	B-MED
and	O
established	B-MED
the	O
fertile	B-MED
days	I-MED
of	O
a	O
woman's	B-MED
menstrual	B-MED
cycle	I-MED
.	O
	
he	O
served	O
as	O
the	O
chief	B-MED
of	I-MED
the	O
epidemiology	B-MED
branch	B-MED
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
editor-in-chief	B-MED
of	O
the	O
journal	B-MED
epidemiology	B-MED
from	O
2001	O
to	O
2014	O
.	O
	
his	O
textbook	B-MED
,	O
fertility	B-MED
and	I-MED
pregnancy-an	I-MED
epidemiologic	I-MED
perspective	I-MED
,	O
was	O
published	B-MED
by	O
oxford	B-MED
university	I-MED
press	I-MED
in	O
2010	O
.	O
	
he	O
was	O
elected	B-MED
to	O
the	O
american	B-MED
epidemiological	I-MED
society	I-MED
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	B-MED
in	O
2003	O
.	O
	
he	O
also	O
served	O
as	O
president	B-MED
of	O
the	O
society	B-MED
of	I-MED
pediatric	I-MED
and	I-MED
perinatal	I-MED
epidemiological	I-MED
research	I-MED
1996	O
and	O
the	O
president	B-MED
of	O
the	O
society	B-MED
of	I-MED
epidemiological	I-MED
research	I-MED
1998	O
.	O
	
he	O
holds	O
adjunct	O
teaching	B-MED
appointments	B-MED
at	O
the	O
university	B-MED
of	I-MED
north	I-MED
carolina	I-MED
,	O
harvard	B-MED
university	I-MED
,	O
and	O
the	O
university	B-MED
of	I-MED
bergen	I-MED
norway	B-MED
,	O
which	O
awarded	B-MED
him	O
an	O
honorary	B-MED
doctoral	B-MED
degree	I-MED
evaluation	B-MED
of	O
spontaneous	B-MED
bone	B-MED
regeneration	I-MED
after	O
enucleation	B-MED
of	O
large	B-MED
cysts	B-MED
of	O
the	O
jaws	B-MED
using	O
radiographic	B-MED
computed	B-MED
software	B-MED
spontaneous	B-MED
regeneration	B-MED
of	I-MED
bone	I-MED
is	O
commonly	B-MED
seen	O
in	O
the	O
small	B-MED
surgical	B-MED
defects	B-MED
caused	O
by	O
enucleation	B-MED
of	O
cysts	B-MED
.	O
	
however	O
,	O
in	O
case	O
of	O
large	B-MED
surgical	B-MED
defects	B-MED
caused	O
by	O
the	O
enucleation	B-MED
,	O
spontaneous	B-MED
regeneration	B-MED
of	I-MED
bone	I-MED
is	O
a	O
rare	B-MED
phenomenon	B-MED
and	O
it	O
depends	B-MED
on	O
factors	B-MED
,	O
such	O
as	O
age	B-MED
of	O
the	O
patient	B-MED
,	O
intact	B-MED
periosteum	B-MED
,	O
and	O
proper	O
stabilization	B-MED
.	O
	
the	O
study	B-MED
included	B-MED
16	O
patients	B-MED
,	O
who	O
reported	B-MED
to	O
the	O
department	B-MED
of	I-MED
oral	I-MED
and	I-MED
maxillofacial	I-MED
surgery	I-MED
with	O
the	O
complaint	B-MED
of	O
pain	B-MED
and	O
swelling	B-MED
in	O
the	O
jaws	B-MED
diagnosed	B-MED
as	O
cyst	B-MED
.	O
	
the	O
sample	B-MED
included	B-MED
equal	O
numbers	B-MED
of	O
male	B-MED
and	O
female	B-MED
subjects	B-MED
aged	B-MED
between	O
15	O
and	O
40	O
years	O
.	O
	
panoramic	B-MED
radiographs	I-MED
were	O
taken	O
pre-	B-MED
and	O
postoperatively	B-MED
on	O
day	O
2	O
of	O
the	O
enucleation	B-MED
.	O
	
the	O
dimensions	B-MED
of	O
the	O
cyst	B-MED
were	O
evaluated	B-MED
on	O
the	O
radiograph	B-MED
according	O
to	O
the	O
proforma	B-MED
.	O
	
subsequent	B-MED
radiographs	B-MED
were	O
taken	O
at	O
regular	B-MED
intervals	B-MED
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	B-MED
parameters	B-MED
and	O
were	O
analyzed	B-MED
using	O
mcid	B-MED
analysis	I-MED
software	B-MED
of	O
imaging	B-MED
research	I-MED
.	O
	
mean	B-MED
reduction	B-MED
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60%	O
in	O
the	O
cystic	B-MED
cavity	B-MED
size	B-MED
and	O
increase	B-MED
in	O
the	O
mean	B-MED
density	B-MED
up	O
to	O
59	O
and	O
90.2	O
at	O
3	O
and	O
6	O
months	O
intervals	B-MED
respectively	O
.	O
	
spontaneous	B-MED
bone	B-MED
regeneration	I-MED
was	O
seen	O
even	O
after	O
primary	B-MED
closure	B-MED
of	O
the	O
large	B-MED
cystic	B-MED
defect	B-MED
without	O
the	O
need	B-MED
for	O
placement	B-MED
of	O
foreign	B-MED
substances	I-MED
or	O
grafts	B-MED
and	O
it	O
also	O
eliminated	B-MED
the	O
complications	B-MED
resulting	B-MED
from	I-MED
placement	B-MED
of	O
foreign	B-MED
substance	I-MED
.	O
	
further	O
studies	B-MED
are	O
required	B-MED
in	O
a	O
larger	B-MED
sample	B-MED
with	O
longer	B-MED
follow-up	B-MED
durations	B-MED
to	O
confirm	B-MED
the	O
outcome	B-MED
of	I-MED
the	I-MED
present	I-MED
work	I-MED
for	O
the	O
benefit	B-MED
of	O
patients	B-MED
.	O
	
the	O
present	B-MED
study	B-MED
depicted	O
that	O
spontaneous	B-MED
bone	B-MED
regeneration	I-MED
can	O
occur	O
with	O
accepted	B-MED
results	B-MED
after	O
simple	B-MED
enucleation	B-MED
of	O
jaw	B-MED
cyst	B-MED
without	O
the	O
aid	B-MED
of	O
any	O
graft	B-MED
material	I-MED
.	O
	
hence	O
,	O
simple	B-MED
enucleation	B-MED
may	O
be	O
considered	B-MED
as	O
a	O
first	B-MED
line	I-MED
of	I-MED
treatment	I-MED
modality	B-MED
for	O
cystic	B-MED
lesion	B-MED
of	O
the	O
jaws	B-MED
.	O
	
this	O
simplifies	O
the	O
surgical	B-MED
procedure	I-MED
,	O
decreases	B-MED
the	O
economic	B-MED
and	O
biologic	B-MED
costs	B-MED
,	O
and	O
reduces	B-MED
the	O
risk	B-MED
of	O
postoperative	B-MED
complications	I-MED
.	O
	
follow-up	B-MED
is	O
necessary	O
along	O
with	O
patient's	B-MED
compliance	B-MED
for	O
the	O
success	B-MED
of	I-MED
treatment	I-MED
.	O
	
membrane	B-MED
protein	I-MED
solubilization	I-MED
and	O
composition	B-MED
of	O
protein	B-MED
detergent	B-MED
complexes	B-MED
membrane	B-MED
proteins	I-MED
are	O
typically	B-MED
expressed	I-MED
in	O
heterologous	B-MED
systems	B-MED
with	O
a	O
view	O
to	O
in	B-MED
vitro	I-MED
characterization	B-MED
.	O
	
a	O
critical	B-MED
step	I-MED
in	O
the	O
preparation	B-MED
of	O
membrane	B-MED
proteins	I-MED
after	O
expression	B-MED
in	O
any	O
system	B-MED
is	O
the	O
solubilization	B-MED
of	I-MED
the	I-MED
protein	I-MED
in	O
aqueous	B-MED
solution	I-MED
,	O
typically	O
using	O
detergents	B-MED
and	O
lipids	B-MED
,	O
to	O
obtain	O
the	O
protein	B-MED
in	O
a	O
form	O
suitable	B-MED
for	O
purification	B-MED
,	O
structural	B-MED
or	O
functional	B-MED
analysis	B-MED
.	O
	
this	O
process	B-MED
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-MED
in	O
an	O
unnatural	B-MED
environment	B-MED
,	O
a	O
protein	B-MED
detergent	B-MED
complex	B-MED
,	O
separating	O
it	O
from	O
its	O
natural	B-MED
lipid	B-MED
partners	O
while	O
causing	O
the	O
minimum	B-MED
destabilization	B-MED
or	O
modification	B-MED
of	O
the	O
structure	B-MED
.	O
	
although	O
the	O
process	B-MED
is	O
difficult	B-MED
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	B-MED
number	O
of	O
membrane	B-MED
proteins	I-MED
have	O
been	O
successfully	B-MED
isolated	I-MED
after	O
expression	B-MED
in	O
a	O
wide	O
variety	O
of	O
systems	B-MED
.	O
	
in	O
this	O
chapter	O
we	O
give	O
a	O
general	B-MED
protocol	I-MED
for	O
preparing	O
protein	B-MED
detergent	B-MED
complexes	B-MED
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	B-MED
steps	I-MED
.	O
	
in	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-MED
the	O
composition	B-MED
of	O
protein	B-MED
detergent	B-MED
complexes	B-MED
this	O
analysis	B-MED
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	B-MED
variation	B-MED
can	O
we	O
predict	B-MED
burnout	B-MED
among	O
student	B-MED
nurses	I-MED
an	O
exploration	O
of	O
the	O
icwr-1	B-MED
model	I-MED
of	O
individual	B-MED
psychological	B-MED
resilience	I-MED
the	O
nature	O
of	O
nursing	B-MED
work	I-MED
is	O
demanding	B-MED
and	O
can	O
be	O
stressful	B-MED
.	O
	
previous	O
studies	O
have	O
shown	O
a	O
high	B-MED
rate	B-MED
of	O
burnout	B-MED
among	O
employed	B-MED
nurses	B-MED
.	O
	
recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	B-MED
in	O
determining	O
the	O
psychological	B-MED
adjustment	I-MED
of	O
employed	B-MED
nurses	B-MED
.	O
	
a	O
theoretical	B-MED
model	I-MED
of	O
resilience	B-MED
was	O
proposed	O
recently	O
that	O
includes	B-MED
several	B-MED
constructs	B-MED
identified	O
in	O
the	O
literature	B-MED
related	O
to	O
resilience	B-MED
and	O
to	O
psychological	B-MED
functioning	I-MED
.	O
	
as	O
nursing	B-MED
students	I-MED
are	O
the	O
future	B-MED
of	O
the	O
nursing	B-MED
workforce	B-MED
it	O
is	O
important	B-MED
to	O
advance	B-MED
our	O
understanding	O
of	O
the	O
determinants	B-MED
of	O
resilience	B-MED
in	O
this	O
population	B-MED
.	O
	
student	B-MED
nurses	I-MED
who	O
had	O
completed	B-MED
their	O
final	B-MED
practicum	B-MED
were	O
invited	O
to	O
participate	O
in	O
an	O
online	B-MED
survey	I-MED
measuring	B-MED
the	O
key	O
constructs	B-MED
of	O
the	O
icwr-1	B-MED
model	I-MED
.	O
	
422	O
students	B-MED
from	O
across	O
australia	B-MED
and	O
canada	B-MED
completed	B-MED
the	O
survey	B-MED
between	O
july	O
2014	O
and	O
july	O
2015	O
.	O
	
as	O
well	O
as	O
several	B-MED
key	O
demographics	B-MED
,	O
trait	B-MED
negative	I-MED
affect	I-MED
,	O
mindfulness	B-MED
,	O
self-efficacy	B-MED
,	O
coping	B-MED
,	O
resilience	B-MED
,	O
and	O
burnout	B-MED
were	O
measured	B-MED
.	O
	
we	O
used	O
structural	B-MED
equation	I-MED
modeling	I-MED
and	O
found	O
support	O
for	O
the	O
major	B-MED
pathways	B-MED
of	O
the	O
model	B-MED
namely	O
that	O
resilience	B-MED
had	O
a	O
significant	B-MED
influence	B-MED
on	O
the	O
relationship	B-MED
between	O
mindfulness	B-MED
,	O
self-efficacy	B-MED
and	O
coping	B-MED
,	O
and	O
psychological	B-MED
adjustment	I-MED
burnout	B-MED
scores	B-MED
.	O
	
furthermore	O
,	O
as	O
predicted	B-MED
,	O
neuroticism	B-MED
moderated	O
the	O
relationship	B-MED
between	O
coping	B-MED
and	O
burnout	B-MED
.	O
	
results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	B-MED
approaches	B-MED
to	O
supporting	O
nursing	B-MED
students	I-MED
who	O
may	O
be	O
at	B-MED
risk	I-MED
of	O
medication	B-MED
intervention	I-MED
for	O
chronic	B-MED
kidney	I-MED
disease	I-MED
patients	B-MED
transitioning	B-MED
from	O
hospital	B-MED
to	O
home	B-MED
study	B-MED
design	I-MED
and	O
baseline	B-MED
characteristics	B-MED
the	O
hospital	B-MED
readmission	I-MED
rate	B-MED
in	O
the	O
population	B-MED
with	O
chronic	B-MED
kidney	I-MED
disease	I-MED
ckd	B-MED
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	B-MED
are	O
urgently	O
needed	B-MED
.	O
	
the	O
ckd	B-MED
-	O
medication	B-MED
intervention	I-MED
trial	I-MED
ckd	B-MED
-	O
mit	B-MED
www.clinicaltrials	B-MED
ncto1459770	I-MED
is	O
a	O
single-blind	B-MED
investigators	B-MED
,	O
randomized	B-MED
,	O
clinical	B-MED
trial	I-MED
conducted	O
at	O
providence	B-MED
health	I-MED
care	I-MED
in	O
spokane	B-MED
,	O
washington	I-MED
.	O
	
study	B-MED
participants	I-MED
are	O
hospitalized	B-MED
patients	I-MED
with	O
ckd	B-MED
stages	B-MED
3-5	O
not	O
treated	B-MED
with	I-MED
kidney	B-MED
replacement	I-MED
therapy	I-MED
and	O
acute	B-MED
illness	I-MED
.	O
	
the	O
study	B-MED
intervention	I-MED
is	O
a	O
pharmacist-led	B-MED
,	O
home-based	B-MED
,	O
medication	B-MED
management	I-MED
intervention	B-MED
delivered	B-MED
within	O
7	O
days	B-MED
after	O
hospital	B-MED
discharge	I-MED
.	O
	
the	O
primary	B-MED
outcome	I-MED
is	O
a	O
composite	O
of	O
hospital	B-MED
readmissions	I-MED
and	O
visits	O
to	O
emergency	B-MED
departments	I-MED
and	O
urgent	B-MED
care	I-MED
centers	I-MED
for	O
90	O
days	B-MED
following	O
hospital	B-MED
discharge	I-MED
.	O
	
secondary	B-MED
outcomes	I-MED
are	O
achievements	B-MED
of	O
guideline-based	B-MED
targets	B-MED
for	O
ckd	B-MED
risk	B-MED
factors	I-MED
and	O
complications	B-MED
.	O
	
enrollment	B-MED
began	O
in	O
february	B-MED
2012	O
and	O
ended	O
in	O
may	B-MED
2015	O
.	O
	
at	O
baseline	B-MED
,	O
the	O
age	B-MED
of	O
participants	B-MED
was	O
69	O
11	O
years	B-MED
mean	O
sd	O
,	O
50%	O
77	O
of	O
155	O
were	O
women	B-MED
,	O
83%	O
117	O
of	O
141	O
had	O
hypertension	B-MED
and	O
56%	O
79	O
of	O
141	O
had	O
diabetes	B-MED
.	O
	
at	O
baseline	B-MED
,	O
the	O
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	B-MED
was	O
41	O
14	O
ml/min/1	O
m2	O
and	O
urine	B-MED
albumin-to-creatinine	I-MED
ratio	I-MED
was	O
43	O
mg/g	O
interquartile	B-MED
range	I-MED
8-528	O
mg/g	O
.	O
	
the	O
most	O
frequent	O
diagnosis	B-MED
category	I-MED
for	O
the	O
index	O
hospital	B-MED
admission	I-MED
was	O
cardiovascular	B-MED
diseases	I-MED
at	O
34%	O
53	O
of	O
155	O
,	O
but	O
the	O
most	O
common	O
single	B-MED
diagnosis	I-MED
for	O
admission	B-MED
was	O
community-acquired	B-MED
acute	B-MED
kidney	I-MED
injury	I-MED
at	O
10%	O
16	O
of	O
155	O
.	O
	
participants	B-MED
in	O
ckd	B-MED
-	O
mit	B-MED
are	O
typical	O
of	O
acutely	B-MED
ill	I-MED
hospitalized	B-MED
patients	I-MED
with	O
ckd	B-MED
.	O
	
a	O
medication	B-MED
management	I-MED
intervention	B-MED
after	O
hospital	B-MED
discharge	I-MED
is	O
under	O
study	B-MED
to	O
reduce	B-MED
post	B-MED
-	O
hospitalization	B-MED
acute	B-MED
care	I-MED
utilization	B-MED
and	O
to	O
improve	O
ckd	B-MED
management	B-MED
.	O
	
direct	B-MED
repair	B-MED
of	O
lumbar	B-MED
pars	I-MED
interarticularis	I-MED
defects	B-MED
by	O
utilizing	B-MED
intraoperative	B-MED
o-arm-based	I-MED
navigation	I-MED
and	O
microendoscopic	B-MED
techniques	I-MED
a	O
retrospective	B-MED
analysis	I-MED
of	O
the	O
clinical	B-MED
outcomes	I-MED
of	O
eight	O
patients	B-MED
with	O
the	O
lumbar	B-MED
pars	I-MED
interarticulars	I-MED
defects	B-MED
treated	B-MED
by	O
direct	B-MED
repair	B-MED
with	O
the	O
aid	B-MED
of	O
intraoperative	B-MED
o-arm	I-MED
based	I-MED
navigation	I-MED
and	O
microendoscopic	B-MED
techniques	I-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
direct	B-MED
screw	B-MED
repair	B-MED
by	O
using	B-MED
minimally	B-MED
invasive	I-MED
surgery	I-MED
for	O
the	O
lumbar	B-MED
pars	I-MED
interarticulars	I-MED
defects	B-MED
in	O
a	O
pilot	B-MED
study	I-MED
.	O
	
direct	B-MED
repair	B-MED
of	O
pars	B-MED
interarticulars	I-MED
defects	B-MED
has	O
been	O
used	B-MED
to	O
treat	B-MED
young	B-MED
adult	I-MED
patients	B-MED
.	O
	
reports	B-MED
concerning	B-MED
direct	B-MED
repair	B-MED
by	O
minimally	B-MED
invasive	I-MED
techniques	I-MED
for	O
pars	B-MED
interarticulars	I-MED
defects	B-MED
are	O
quite	O
rare	B-MED
.	O
	
review	B-MED
of	O
medical	B-MED
records	I-MED
identified	B-MED
eight	O
consecutive	B-MED
patients	B-MED
treated	B-MED
with	O
intraoperative	B-MED
o-arm	I-MED
based	I-MED
navigation	I-MED
and	O
microendoscopic	B-MED
techniques	I-MED
.	O
	
debridement	B-MED
and	O
autograft	B-MED
of	O
pars	B-MED
interarticularis	I-MED
defects	B-MED
was	O
performed	B-MED
under	O
microendoscopic	B-MED
procedure	I-MED
.	O
	
then	O
,	O
percutaneous	B-MED
bilateral	B-MED
intralaminar	B-MED
screws	B-MED
were	O
inserted	B-MED
by	O
utilizing	B-MED
intraoperative	B-MED
navigation	I-MED
.	O
	
the	O
clinical	B-MED
and	O
radiological	B-MED
data	B-MED
were	O
collected	B-MED
and	O
analyzed	B-MED
retrospectively	B-MED
.	O
	
eight	O
patients	B-MED
had	O
a	O
mean	B-MED
age	B-MED
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	B-MED
at	O
the	O
time	B-MED
of	O
treatment	B-MED
.	O
	
symptoms	B-MED
included	B-MED
axial	B-MED
back	B-MED
pain	I-MED
in	O
100%	O
of	O
patients	B-MED
without	O
concomitant	B-MED
radiculopathy	B-MED
.	O
	
autograft	B-MED
was	O
used	B-MED
in	O
all	O
cases	B-MED
.	O
	
the	O
average	B-MED
follow-up	B-MED
duration	B-MED
was	O
27.4	O
months	O
with	O
a	O
range	B-MED
of	O
20	O
to	O
33	O
months	O
.	O
	
symptoms	B-MED
resolved	B-MED
completely	B-MED
or	O
partially	B-MED
in	O
all	O
patients	B-MED
.	O
	
low	B-MED
back	I-MED
pain	I-MED
visual	B-MED
analog	I-MED
scores	I-MED
decrease	B-MED
from	O
preoperative	B-MED
6.8	O
to	O
postoperative	B-MED
1.4	O
of	O
eight	O
cases	B-MED
.	O
	
of	O
16	O
pars	B-MED
defects	B-MED
,	O
healing	B-MED
was	O
observed	B-MED
in	O
13	O
81.3	O
at	O
last	O
radiological	B-MED
follow-up	B-MED
.	O
	
one	O
patient	B-MED
with	O
bilateral	B-MED
fusion	I-MED
failure	I-MED
refused	B-MED
revision	B-MED
surgery	I-MED
because	O
of	O
mild	B-MED
complaint	I-MED
.	O
	
no	B-MED
complications	I-MED
such	O
as	O
dural	B-MED
tear	I-MED
,	O
nerve	B-MED
root	I-MED
injury	I-MED
,	O
and	O
infection	B-MED
occurred	B-MED
.	O
	
minimally	B-MED
invasive	I-MED
direct	B-MED
repair	B-MED
of	O
the	O
pars	B-MED
interarticularis	I-MED
defects	B-MED
with	O
intralaminar	B-MED
screws	B-MED
by	O
using	B-MED
microendoscopic	B-MED
system	I-MED
and	O
navigation	B-MED
procedure	I-MED
can	O
provide	B-MED
safe	O
and	O
effective	B-MED
treatment	B-MED
of	O
spondylolysis	B-MED
with	O
satisfactory	B-MED
clinical	B-MED
and	O
radiological	B-MED
outcomes	B-MED
,	O
which	O
need	B-MED
some	O
special	B-MED
tools	I-MED
with	O
steep	B-MED
learning	B-MED
curve	I-MED
.	O
	
evidence	B-MED
-based	O
review	B-MED
and	O
survey	B-MED
of	O
expert	B-MED
opinion	I-MED
of	O
reconstruction	B-MED
of	O
metastatic	B-MED
spine	I-MED
tumors	I-MED
systematic	B-MED
review	B-MED
and	O
consensus	B-MED
expert	B-MED
opinion	I-MED
.	O
	
to	O
provide	O
surgeons	B-MED
and	O
other	O
health	B-MED
care	I-MED
professionals	I-MED
with	O
guidelines	B-MED
for	O
surgical	B-MED
reconstruction	I-MED
of	O
metastatic	B-MED
spine	B-MED
disease	I-MED
based	O
on	O
evidence	B-MED
and	O
expert	B-MED
opinion	I-MED
.	O
	
the	O
surgical	B-MED
treatment	I-MED
of	O
spinal	B-MED
metastases	I-MED
is	O
controversial	O
.	O
	
specifically	O
two	O
aspects	O
of	O
surgical	B-MED
reconstruction	I-MED
are	O
addressed	O
in	O
this	O
study	O
i	O
choice	O
of	O
bone	B-MED
graft	I-MED
used	O
during	B-MED
surgery	B-MED
for	O
metastatic	B-MED
spine	I-MED
tumors	I-MED
and	O
ii	O
the	O
design	B-MED
of	O
reconstruction	B-MED
or	O
construct	B-MED
to	O
stabilize	B-MED
.	O
	
a	O
systematic	B-MED
review	B-MED
of	O
the	O
available	B-MED
medical	B-MED
literature	B-MED
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	B-MED
with	O
consensus	B-MED
expert	B-MED
opinion	I-MED
from	O
a	O
recent	O
survey	B-MED
of	O
spine	B-MED
surgeons	B-MED
who	O
treat	B-MED
metastatic	B-MED
spine	I-MED
tumors	I-MED
.	O
	
there	O
is	O
very	O
little	O
evidence	B-MED
in	O
the	O
literature	B-MED
to	O
provide	O
guidance	B-MED
on	O
the	O
use	B-MED
of	I-MED
bone	B-MED
graft	I-MED
in	O
metastatic	B-MED
tumor	I-MED
reconstruction	B-MED
.	O
	
there	O
is	O
little	O
evidence	B-MED
in	O
the	O
literature	B-MED
to	O
support	O
the	O
preferential	O
use	B-MED
of	I-MED
one	O
graft	B-MED
type	I-MED
over	O
the	O
other	O
.	O
	
approximately	O
,	O
41%	O
of	O
respondents	B-MED
said	O
they	O
used	O
bone	B-MED
graft	I-MED
or	O
bone	B-MED
graft	I-MED
substitutes	B-MED
to	O
accomplish	O
fusion	B-MED
.	O
	
there	O
were	O
17	O
studies	B-MED
that	O
described	O
the	O
use	B-MED
of	I-MED
a	O
prefabricated	B-MED
prosthetic	I-MED
,	O
10	O
studies	B-MED
describing	O
the	O
use	B-MED
of	I-MED
polymethyl	B-MED
methacrylate	I-MED
pmma	B-MED
bone	B-MED
cement	I-MED
,	O
and	O
only	O
three	O
studies	B-MED
describing	O
the	O
use	B-MED
of	I-MED
bone	B-MED
graft	I-MED
for	O
anterior	B-MED
column	B-MED
reconstruction	B-MED
.	O
	
the	O
use	B-MED
of	I-MED
structural	B-MED
allograft	I-MED
was	O
most	O
popular	O
among	O
the	O
experts	B-MED
for	O
anterior	B-MED
reconstruction	B-MED
,	O
followed	B-MED
by	I-MED
cage	B-MED
reconstruction	B-MED
,	O
and	O
pmma	B-MED
bone	B-MED
cement	I-MED
.	O
	
achieving	O
bony	B-MED
union	I-MED
may	O
be	O
of	O
importance	B-MED
for	O
the	O
maintenance	B-MED
of	O
spinal	B-MED
stability	B-MED
in	O
the	O
long	B-MED
term	I-MED
after	O
reconstruction	B-MED
.	O
	
whether	O
bony	B-MED
union	I-MED
is	O
required	B-MED
for	O
patients	B-MED
with	O
shorter	B-MED
life	B-MED
expectancies	I-MED
is	O
debatable	O
.	O
	
the	O
literature	B-MED
supports	O
the	O
use	B-MED
of	I-MED
anterior	B-MED
reconstruction	B-MED
with	O
either	O
a	O
prefabricated	B-MED
prosthetic	I-MED
or	O
pmma	B-MED
bone	B-MED
cement	I-MED
.	O
	
it	O
also	O
supports	O
the	O
use	B-MED
of	I-MED
an	O
anterior	B-MED
construct	B-MED
reinforced	O
with	O
bilateral	B-MED
posterior	B-MED
instrumentation	B-MED
when	O
performing	B-MED
a	O
three-column	B-MED
reconstruction	I-MED
.	O
	
the	O
value	O
of	O
transesophageal	B-MED
echocardiography	I-MED
for	O
embolic	B-MED
strokes	I-MED
of	I-MED
undetermined	I-MED
source	I-MED
our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-MED
yield	I-MED
of	O
transesophageal	B-MED
echocardiography	I-MED
tee	B-MED
in	O
consecutive	O
patients	B-MED
with	O
ischemic	B-MED
stroke	I-MED
is	B-MED
fulfilling	O
the	O
diagnostic	B-MED
criteria	I-MED
of	O
embolic	B-MED
strokes	I-MED
of	I-MED
undetermined	I-MED
source	I-MED
esus	B-MED
.	O
	
we	O
prospectively	O
evaluated	O
consecutive	O
patients	B-MED
with	O
acute	O
is	B-MED
satisfying	O
esus	B-MED
criteria	O
who	O
underwent	O
in-	O
hospital	B-MED
tee	B-MED
examination	I-MED
in	O
3	O
tertiary	B-MED
care	I-MED
stroke	I-MED
centers	I-MED
during	B-MED
a	I-MED
12-month	I-MED
period	I-MED
.	O
	
we	O
also	O
performed	O
a	O
systematic	B-MED
review	I-MED
and	O
meta-analysis	B-MED
estimating	I-MED
the	O
cumulative	O
effect	O
of	O
tee	B-MED
findings	B-MED
on	O
therapeutic	B-MED
management	I-MED
for	O
secondary	B-MED
stroke	I-MED
prevention	I-MED
among	O
different	O
is	B-MED
subgroups	O
.	O
	
we	O
identified	O
61	O
patients	B-MED
with	O
esus	B-MED
who	O
underwent	B-MED
investigation	I-MED
with	O
tee	B-MED
mean	O
age	O
44	O
12	O
years	O
,	O
49%	O
men	B-MED
,	O
median	O
nih	B-MED
stroke	I-MED
scale	I-MED
score	I-MED
=	O
5	O
points	O
interquartile	B-MED
range	I-MED
3-8	O
.	O
	
tee	B-MED
revealed	O
additional	O
findings	B-MED
in	O
52%	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
40%-65%	O
of	O
the	O
study	B-MED
population	I-MED
.	O
	
tee	B-MED
findings	B-MED
changed	O
management	O
initiation	B-MED
of	O
anticoagulation	B-MED
therapy	I-MED
,	O
administration	B-MED
of	O
iv	B-MED
antibiotic	I-MED
therapy	I-MED
,	O
and	O
patent	B-MED
foramen	I-MED
ovale	I-MED
closure	I-MED
in	O
10	O
16%	O
95%	O
ci	B-MED
9%-28%	O
patients	B-MED
.	O
	
the	O
pooled	B-MED
rate	I-MED
of	O
reported	O
anticoagulation	B-MED
therapy	I-MED
attributed	O
to	O
abnormal	B-MED
tee	B-MED
findings	B-MED
among	O
3	O
acute	O
is	B-MED
patients	B-MED
included	O
in	O
the	O
meta-analysis	B-MED
12	O
studies	O
was	O
8.7	O
95%	O
ci	B-MED
7.3	O
.	O
	
in	O
subgroup	B-MED
analysis	I-MED
,	O
the	O
rates	O
of	O
initiation	B-MED
of	O
anticoagulation	B-MED
therapy	I-MED
on	O
the	O
basis	O
of	O
tee	B-MED
investigation	O
did	O
not	O
differ	O
p	O
=	O
0.315	O
among	O
patients	B-MED
with	O
cryptogenic	B-MED
stroke	I-MED
6.9	O
95%	O
ci	B-MED
4.9	O
,	O
esus	B-MED
8.1	O
95%	O
ci	B-MED
3.4	O
,	O
and	O
is	B-MED
9.4	O
95%	O
ci	B-MED
7.5	O
.	O
	
abnormal	O
tee	B-MED
findings	B-MED
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	B-MED
therapeutic	B-MED
strategy	I-MED
in	O
approximately	O
1	O
of	O
7	O
patients	B-MED
with	O
simultaneous	B-MED
thrombosis	B-MED
of	O
multiple	B-MED
coronary	I-MED
arteries	I-MED
in	O
a	O
patient	B-MED
with	O
rheumatoid	B-MED
arthritis	I-MED
we	O
present	O
a	O
case	B-MED
of	O
simultaneous	B-MED
coronary	B-MED
thrombosis	I-MED
of	I-MED
the	I-MED
left	I-MED
main	I-MED
,	O
the	O
left	B-MED
anterior	I-MED
descending	I-MED
artery	I-MED
and	O
the	O
right	B-MED
coronary	I-MED
artery	I-MED
in	O
a	O
patient	B-MED
,	O
recently	O
diagnosed	B-MED
with	O
rheumatoid	B-MED
arthritis	I-MED
.	O
	
unintentional	B-MED
injuries	I-MED
in	O
children	B-MED
up	O
to	O
six	O
years	B-MED
of	O
age	B-MED
and	O
related	O
parental	B-MED
knowledge	B-MED
,	O
attitudes	B-MED
,	O
and	O
behaviors	B-MED
in	O
italy	B-MED
to	O
describe	O
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
unintentional	B-MED
injuries	I-MED
among	O
children	B-MED
aged	O
<6	O
years	B-MED
and	O
to	O
examine	O
parents	B-MED
'	O
level	O
of	O
knowledge	B-MED
,	O
attitudes	B-MED
,	O
and	O
behaviors	B-MED
about	O
pediatric	B-MED
injuries	B-MED
and	O
related	O
preventive	B-MED
measures	I-MED
.	O
	
a	O
cross-sectional	B-MED
survey	I-MED
was	O
conducted	O
between	O
may	B-MED
and	O
july	B-MED
2015	O
on	O
a	O
random	B-MED
sample	I-MED
of	O
794	O
parents	B-MED
of	O
3-	O
to	O
6-year-old	O
children	B-MED
through	O
a	O
self-administered	B-MED
anonymous	B-MED
questionnaire	I-MED
.	O
	
a	O
total	O
of	O
409	O
parents	B-MED
participated	O
.	O
	
two-thirds	O
of	O
the	O
children	B-MED
had	O
experienced	O
at	O
least	O
1	O
unintentional	B-MED
injury	I-MED
in	O
the	O
previous	O
12	O
months	B-MED
.	O
	
more	O
than	O
one-half	O
of	O
these	O
children	B-MED
were	O
boys	B-MED
.	O
	
the	O
leading	B-MED
cause	I-MED
was	O
falls	B-MED
the	O
injuries	B-MED
occurred	O
mainly	O
at	O
home	B-MED
,	O
and	O
only	O
9.2	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	B-MED
department	I-MED
.	O
	
parents	B-MED
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	B-MED
injuries	I-MED
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	B-MED
injured	B-MED
.	O
	
approximately	O
70%	O
of	O
respondents	B-MED
were	O
aware	B-MED
of	O
security	B-MED
measures	I-MED
to	O
prevent	O
pediatric	B-MED
injuries	B-MED
,	O
and	O
this	O
knowledge	B-MED
was	O
more	O
prevalent	O
in	O
older	O
parents	B-MED
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	B-MED
level	I-MED
of	I-MED
education	I-MED
compared	O
with	O
those	O
with	O
a	O
middle	B-MED
school	I-MED
education	I-MED
.	O
	
the	O
perceived	B-MED
utility	O
of	O
education	B-MED
about	O
preventive	B-MED
measures	I-MED
of	O
pediatric	B-MED
injuries	B-MED
had	O
a	O
mean	B-MED
value	I-MED
of	O
8.9	O
on	O
a	O
likert	B-MED
scale	I-MED
of	O
1-10	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	B-MED
.	O
	
this	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-MED
health	I-MED
educational	B-MED
programs	I-MED
for	O
parents	B-MED
regarding	O
prevention	B-MED
of	O
unintentional	B-MED
injuries	I-MED
in	O
children	B-MED
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	B-MED
and	O
injury	B-MED
prevention	I-MED
and	O
to	O
reduce	B-MED
risks	B-MED
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-MED
occur	O
at	O
truncated	B-MED
bovine	I-MED
integrin	B-MED
alpha-v/beta-6	I-MED
as	O
a	O
universal	B-MED
capture	I-MED
ligand	I-MED
for	O
fmd	B-MED
diagnosis	B-MED
foot-and-mouth	B-MED
disease	I-MED
fmd	B-MED
is	O
endemic	B-MED
in	O
many	O
regions	B-MED
of	O
the	O
world	B-MED
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	B-MED
animal	B-MED
diseases	I-MED
.	O
	
fmd	B-MED
affects	O
livestock	B-MED
,	O
such	O
as	O
cattle	B-MED
,	O
sheep	B-MED
,	O
goats	B-MED
and	O
pigs	B-MED
,	O
and	O
causes	O
enormous	B-MED
economic	I-MED
losses	I-MED
due	O
to	O
reduced	O
productivity	B-MED
and	O
trade	B-MED
restrictions	I-MED
.	O
	
preparedness	B-MED
and	O
early	B-MED
diagnosis	I-MED
are	O
essential	B-MED
for	O
effective	B-MED
control	I-MED
of	O
fmd	B-MED
.	O
	
many	O
diagnostic	B-MED
assays	I-MED
are	O
dependent	B-MED
on	O
raising	O
high-affinity	B-MED
,	O
anti-fmd	B-MED
virus	I-MED
fmdv	B-MED
serotype-specific	B-MED
antibodies	I-MED
in	O
small	O
animals	B-MED
rabbits	B-MED
and	O
guinea	B-MED
pigs	I-MED
that	O
give	O
broad	O
virus	B-MED
coverage	O
.	O
	
here	O
we	O
show	O
that	O
soluble	B-MED
,	O
truncated	B-MED
forms	I-MED
of	O
bovine	B-MED
αvβ6	B-MED
bind	B-MED
fmdv	B-MED
in	O
an	O
authentic	O
rgd	B-MED
and	O
divalent	B-MED
cation	I-MED
dependent	I-MED
interaction	I-MED
and	O
can	O
be	O
used	O
as	O
the	O
trapping	B-MED
reagent	I-MED
in	O
a	O
fmdv	B-MED
sandwich	B-MED
elisa	I-MED
.	O
	
in	O
addition	O
,	O
inclusion	B-MED
of	O
flag	B-MED
or	O
his	B-MED
tags	I-MED
facilitates	O
simple	O
purification	B-MED
without	O
the	O
loss	B-MED
of	O
virus	B-MED
binding	I-MED
.	O
	
we	O
also	O
provide	O
evidence	B-MED
that	O
when	O
combined	B-MED
with	O
a	O
guinea	B-MED
pig	I-MED
polyclonal	B-MED
serum	I-MED
,	O
or	O
serotype-specific	B-MED
monoclonal	I-MED
antibodies	I-MED
,	O
the	O
integrin	B-MED
can	O
be	O
used	O
to	O
detect	B-MED
viruses	B-MED
representative	O
of	O
all	O
fmdv	B-MED
serotypes	I-MED
.	O
	
we	O
also	O
show	O
that	O
recombinant	B-MED
fmdv	I-MED
empty	B-MED
capsids	I-MED
,	O
with	O
stabilising	B-MED
disulphide	I-MED
bonds	I-MED
,	O
can	O
serve	O
as	O
an	O
antigen	B-MED
in	O
the	O
elisa	B-MED
and	O
can	O
therefore	O
replace	O
inactivated	B-MED
virus	I-MED
antigen	I-MED
as	O
a	O
positive	B-MED
control	I-MED
for	O
the	O
assay	B-MED
.	O
	
our	O
results	B-MED
demonstrate	O
the	O
potential	B-MED
use	O
of	O
bovine	B-MED
αvβ6	B-MED
and	O
fmdv	B-MED
empty	B-MED
capsids	I-MED
in	O
fmd	B-MED
diagnostic	B-MED
assays	I-MED
.	O
	
stress	B-MED
and	O
binge	B-MED
drinking	I-MED
a	O
toxic	B-MED
combination	O
for	O
the	O
teenage	B-MED
brain	B-MED
young	B-MED
adult	I-MED
university	B-MED
students	I-MED
frequently	O
binge	B-MED
on	O
alcohol	B-MED
and	O
have	O
high	B-MED
stress	B-MED
levels	I-MED
.	O
	
based	O
on	O
findings	O
in	O
rodents	B-MED
,	O
we	O
predicted	O
that	O
heavy	B-MED
current	I-MED
alcohol	I-MED
use	I-MED
and	O
elevated	B-MED
stress	B-MED
and	O
depression	B-MED
scores	I-MED
would	O
be	O
associated	B-MED
with	I-MED
deficits	B-MED
on	O
high	B-MED
interference	B-MED
memory	B-MED
tasks	B-MED
,	O
while	O
early	B-MED
onset	I-MED
,	O
prolonged	O
binge	B-MED
patterns	B-MED
would	O
lead	O
to	O
broader	O
cognitive	B-MED
deficits	I-MED
on	O
tests	O
of	O
associative	B-MED
encoding	I-MED
and	O
executive	B-MED
functions	I-MED
.	O
	
we	O
developed	O
the	O
concentration	B-MED
memory	B-MED
task	B-MED
,	O
a	O
novel	O
computerized	B-MED
version	I-MED
of	O
the	O
concentration	B-MED
card	B-MED
game	I-MED
with	O
a	O
high	B-MED
degree	O
of	O
interference	B-MED
.	O
	
we	O
found	O
that	O
young	B-MED
adults	I-MED
with	O
elevated	B-MED
stress	B-MED
,	O
depression	B-MED
,	O
and	O
alcohol	B-MED
consumption	I-MED
scores	I-MED
were	O
impaired	B-MED
in	O
the	O
concentration	B-MED
memory	B-MED
task	B-MED
.	O
	
we	O
also	O
analyzed	B-MED
data	I-MED
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	B-MED
alcohol	B-MED
consumption	I-MED
scores	I-MED
were	O
associated	B-MED
with	I-MED
impaired	B-MED
performance	B-MED
on	O
another	O
high	B-MED
interference	B-MED
memory	B-MED
task	B-MED
,	O
based	O
on	O
kirwan	B-MED
and	I-MED
stark's	I-MED
mnemonic	I-MED
similarity	I-MED
test	I-MED
.	O
	
on	O
the	O
other	O
hand	O
,	O
adolescent	B-MED
onset	B-MED
of	O
binge	B-MED
drinking	I-MED
predicted	O
poorer	B-MED
performance	B-MED
on	O
broader	O
range	O
of	O
memory	B-MED
tests	B-MED
,	O
including	O
a	O
more	O
systematic	B-MED
test	I-MED
of	I-MED
spatial	I-MED
recognition	I-MED
memory	I-MED
,	O
and	O
an	O
associative	B-MED
learning	I-MED
task	B-MED
.	O
	
our	O
results	B-MED
are	O
broadly	O
consistent	B-MED
with	I-MED
findings	O
in	O
rodents	B-MED
that	O
acute	B-MED
alcohol	I-MED
and	O
stress	B-MED
exposure	O
suppress	B-MED
neurogenesis	B-MED
in	O
the	O
adult	B-MED
hippocampus	B-MED
,	O
which	O
in	O
turn	O
impairs	B-MED
performance	B-MED
in	O
high	B-MED
interference	B-MED
memory	B-MED
tasks	B-MED
,	O
while	O
adolescent	B-MED
onset	B-MED
binge	B-MED
drinking	I-MED
causes	O
more	O
extensive	B-MED
brain	B-MED
damage	I-MED
and	O
cognitive	B-MED
deficits	I-MED
.	O
	
of	O
kindlins	B-MED
and	O
cancer	B-MED
kindlins	B-MED
are	O
4.1	B-MED
ferm	I-MED
domain	I-MED
containing	O
proteins	B-MED
.	O
	
there	O
are	O
three	O
kindlins	B-MED
in	O
mammals	B-MED
,	O
which	O
share	O
high	B-MED
sequence	B-MED
identity	O
.	O
	
kindlin-1	B-MED
is	O
expressed	B-MED
primarily	O
in	O
epithelial	B-MED
cells	I-MED
,	O
kindlin-2	B-MED
is	O
widely	O
distributed	B-MED
and	O
is	O
particularly	O
abundant	B-MED
in	O
adherent	B-MED
cells	I-MED
,	O
and	O
kindlin-3	B-MED
is	O
expressed	B-MED
primarily	O
in	O
hematopoietic	B-MED
cells	I-MED
.	O
	
these	O
distributions	B-MED
are	O
not	O
exclusive	B-MED
some	O
cells	B-MED
express	B-MED
multiple	B-MED
kindlins	B-MED
,	O
and	O
transformed	B-MED
cells	I-MED
often	B-MED
exhibit	O
aberrant	B-MED
expression	B-MED
,	O
both	O
in	O
the	O
isoforms	B-MED
and	O
the	O
levels	B-MED
of	O
kindlins	B-MED
.	O
	
great	O
interest	O
in	O
the	O
kindlins	B-MED
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	B-MED
roles	B-MED
in	O
controlling	B-MED
integrin	B-MED
function	B-MED
.	O
	
in	B-MED
vitro	I-MED
studies	I-MED
,	O
in	B-MED
vivo	I-MED
studies	I-MED
of	O
mice	B-MED
deficient	B-MED
in	O
kindlins	B-MED
,	O
and	O
studies	B-MED
of	O
patients	B-MED
with	O
genetic	B-MED
deficiencies	B-MED
of	O
kindlins	B-MED
have	O
clearly	O
established	B-MED
that	O
they	O
regulate	O
the	O
capacity	B-MED
of	O
integrins	B-MED
to	O
mediate	B-MED
their	O
functions	B-MED
.	O
	
kindlins	B-MED
are	O
adaptor	B-MED
proteins	I-MED
their	O
function	B-MED
emanate	B-MED
from	O
their	O
interaction	B-MED
with	O
binding	B-MED
partners	O
,	O
including	O
the	O
cytoplasmic	B-MED
tails	I-MED
of	O
integrins	B-MED
and	O
components	O
of	O
the	O
actin	B-MED
cytoskeleton	I-MED
.	O
	
the	O
purpose	B-MED
of	O
this	O
review	B-MED
is	O
to	O
provide	O
a	O
brief	B-MED
overview	B-MED
of	O
kindlin	B-MED
structure	B-MED
and	O
function	B-MED
,	O
a	O
consideration	B-MED
of	O
their	O
binding	B-MED
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	B-MED
of	O
each	O
kindlin	B-MED
family	B-MED
member	B-MED
with	O
cancer	B-MED
.	O
	
in	O
view	B-MED
of	O
many	O
correlations	B-MED
of	O
kindlin	B-MED
expression	B-MED
levels	B-MED
and	O
neoplasia	B-MED
and	O
the	O
known	O
association	B-MED
of	O
integrins	B-MED
with	O
tumor	B-MED
progression	I-MED
and	O
metastasis	B-MED
,	O
we	O
consider	B-MED
whether	O
regulation	O
of	O
kindlins	B-MED
or	O
their	O
function	B-MED
would	O
be	O
attractive	B-MED
targets	B-MED
for	O
treatment	B-MED
of	I-MED
cancer	I-MED
.	O
	
preclinical	B-MED
fibrinolysis	B-MED
in	O
patients	B-MED
with	O
st-segment	B-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
in	O
a	O
rural	B-MED
region	I-MED
in	O
the	O
current	B-MED
guidelines	I-MED
for	O
the	O
treatment	B-MED
of	O
patients	B-MED
with	O
st-segment	B-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
stemi	B-MED
,	O
the	O
european	O
society	O
of	O
cardiology	O
esc	O
recommends	B-MED
preclinical	B-MED
fibrinolysis	B-MED
as	O
a	O
reperfusion	B-MED
therapy	I-MED
if	O
,	O
due	O
to	O
long	O
transportation	B-MED
times	B-MED
,	O
no	O
cardiac	B-MED
catheterisation	I-MED
is	O
available	B-MED
within	O
90-120	O
min	B-MED
.	O
	
however	O
,	O
there	O
is	O
little	O
remaining	B-MED
in-depth	O
expertise	B-MED
in	O
this	O
method	B-MED
because	O
fibrinolysis	B-MED
is	O
presently	B-MED
only	O
rarely	B-MED
indicated	B-MED
.	O
	
in	O
a	O
rural	B-MED
area	I-MED
in	O
southwestern	B-MED
germany	B-MED
,	O
where	O
an	O
emergency	B-MED
primary	I-MED
percutaneous	I-MED
coronary	I-MED
intervention	I-MED
was	O
not	O
routinely	B-MED
available	B-MED
within	O
90-120	O
min	B-MED
,	O
156	O
stemi	B-MED
patients	B-MED
underwent	O
fibrinolysis	B-MED
with	O
the	O
plasminogen	B-MED
activator	I-MED
reteplase	I-MED
,	O
performed	B-MED
by	I-MED
trained	O
emergency	B-MED
physicians	B-MED
.	O
	
the	O
practicality	B-MED
of	O
the	O
treatment	B-MED
,	O
as	O
well	O
as	O
complications	B-MED
and	O
the	O
mortality	B-MED
of	O
the	O
patients	B-MED
in	O
the	O
preclinical	B-MED
phase	B-MED
until	O
arrival	B-MED
at	O
the	O
hospital	B-MED
,	O
were	O
retrospectively	B-MED
studied	I-MED
.	O
	
the	O
mean	B-MED
time	I-MED
from	O
onset	B-MED
of	I-MED
the	O
symptoms	B-MED
to	O
first	O
medical	B-MED
contact	I-MED
was	O
114	O
116	O
min	B-MED
.	O
	
the	O
mean	B-MED
interval	I-MED
to	O
the	O
start	B-MED
of	O
fibrinolysis	B-MED
of	O
13.5	O
6.4	O
min	B-MED
was	O
within	O
the	O
30	O
min	B-MED
mandated	B-MED
by	O
the	O
esc	O
.	O
	
patients	B-MED
with	O
inferior	B-MED
stemi	I-MED
represented	B-MED
the	O
largest	B-MED
subgroup	B-MED
.	O
	
occurring	O
in	O
39	O
cases	B-MED
25	O
%	O
,	O
complications	B-MED
due	O
to	O
infarction	B-MED
were	O
relatively	O
common	B-MED
during	O
the	O
prehospital	B-MED
phase	B-MED
,	O
including	O
15	O
cases	B-MED
9.6	O
%	O
of	O
cardiogenic	B-MED
shock	I-MED
,	O
but	O
in	O
all	O
cases	B-MED
the	O
complications	B-MED
were	O
manageable	B-MED
.	O
	
no	O
patient	B-MED
died	B-MED
before	O
arrival	B-MED
at	O
the	O
hospital	B-MED
.	O
	
as	O
lysis	B-MED
-	O
associated	B-MED
adverse	B-MED
effects	I-MED
,	O
merely	O
two	O
uncomplicated	B-MED
mucosal	B-MED
haemorrhages	I-MED
and	O
one	O
case	O
of	O
mild	B-MED
allergic	I-MED
skin	I-MED
reactions	I-MED
were	O
seen	B-MED
.	O
	
in	O
emergency	B-MED
situations	I-MED
with	O
long	O
transportation	B-MED
times	B-MED
to	O
the	O
nearest	O
suitable	B-MED
cardiac	B-MED
catheterisation	I-MED
laboratory	B-MED
,	O
preclinical	B-MED
fibrinolysis	B-MED
in	O
stemi	B-MED
still	O
represents	O
a	O
workable	B-MED
method	I-MED
.	O
	
success	B-MED
of	O
this	O
strategy	B-MED
requires	O
particularly	O
strong	B-MED
training	I-MED
of	O
the	O
emergency	B-MED
physicians	B-MED
in	O
ecg	B-MED
and	O
lysis	B-MED
therapy	B-MED
,	O
and	O
co-operation	B-MED
with	O
nearby	O
cardiac	B-MED
centres	I-MED
.	O
	
a	O
method	B-MED
of	O
providing	B-MED
engaging	O
formative	B-MED
feedback	I-MED
to	O
large	B-MED
cohort	B-MED
first-year	B-MED
physiology	B-MED
and	O
anatomy	B-MED
students	B-MED
a	O
growing	O
body	O
of	O
evidence	B-MED
demonstrates	B-MED
a	O
critical	B-MED
role	O
for	O
effective	B-MED
,	O
meaningful	B-MED
feedback	B-MED
to	O
enhance	B-MED
student	B-MED
learning	B-MED
.	O
	
effective	B-MED
feedback	B-MED
can	O
become	O
part	B-MED
of	I-MED
the	O
learning	B-MED
cycle	B-MED
that	O
is	O
not	O
only	O
a	O
learning	B-MED
opportunity	B-MED
for	O
the	O
student	B-MED
but	O
can	O
also	O
be	O
used	O
to	O
inform	B-MED
the	O
teacher	B-MED
and	O
ongoing	B-MED
curriculum	B-MED
development	I-MED
.	O
	
feedback	B-MED
is	O
considered	B-MED
particularly	O
important	B-MED
during	B-MED
the	O
first	B-MED
year	I-MED
of	O
university	B-MED
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	B-MED
strategy	O
that	O
can	O
help	O
attenuate	B-MED
student	B-MED
performance	B-MED
anxieties	I-MED
and	O
solidify	B-MED
perceptions	B-MED
of	O
academic	B-MED
support	I-MED
.	O
	
unfortunately	O
,	O
the	O
provision	O
of	O
individualized	B-MED
,	O
timely	B-MED
feedback	B-MED
can	O
be	O
particularly	O
challenging	O
in	O
first-year	B-MED
courses	B-MED
as	O
they	O
tend	O
to	O
be	O
large	B-MED
and	O
diverse	B-MED
cohort	B-MED
classes	B-MED
that	O
pose	O
challenges	O
of	O
time	B-MED
and	O
logistics	B-MED
.	O
	
various	O
forms	O
of	O
generic	O
feedback	B-MED
can	O
provide	B-MED
rapid	B-MED
and	O
cost-effect	B-MED
feedback	B-MED
to	O
large	B-MED
cohorts	B-MED
but	O
may	O
be	O
of	O
limited	B-MED
benefit	B-MED
to	O
students	B-MED
other	O
than	O
signaling	O
weaknesses	B-MED
in	O
knowledge	B-MED
.	O
	
the	O
present	B-MED
study	B-MED
describes	B-MED
a	O
method	B-MED
that	O
was	O
used	O
to	O
provide	B-MED
formative	B-MED
task-related	I-MED
feedback	I-MED
to	O
a	O
large	B-MED
cohort	B-MED
of	O
first-year	B-MED
physiology	B-MED
and	O
anatomy	B-MED
students	B-MED
.	O
	
based	O
on	O
student	B-MED
evaluations	B-MED
presented	B-MED
in	O
this	O
study	B-MED
,	O
this	O
method	B-MED
provided	B-MED
feedback	B-MED
in	O
a	O
manner	O
that	O
engaged	O
students	B-MED
,	O
uncovered	B-MED
underlying	B-MED
misconceptions	I-MED
,	O
facilitated	O
peer	B-MED
discussion	B-MED
,	O
and	O
provided	B-MED
opportunity	O
for	O
new	B-MED
instruction	B-MED
while	O
allowing	B-MED
the	O
lecturer	B-MED
to	O
recognize	B-MED
common	B-MED
gaps	B-MED
in	O
knowledge	B-MED
and	O
inform	O
ongoing	B-MED
curriculum	B-MED
development	I-MED
.	O
	
sirt2	B-MED
deacetylates	B-MED
and	O
inhibits	B-MED
the	I-MED
peroxidase	I-MED
activity	I-MED
of	O
peroxiredoxin-1	B-MED
to	O
sensitize	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
oxidant	B-MED
stress	I-MED
-	O
inducing	B-MED
agents	O
sirt2	B-MED
is	O
a	O
protein	B-MED
deacetylase	I-MED
with	O
tumor	B-MED
suppressor	I-MED
activity	I-MED
in	O
breast	B-MED
and	O
liver	B-MED
tumors	I-MED
where	O
it	O
is	O
mutated	B-MED
however	O
,	O
the	O
critical	O
substrates	B-MED
mediating	O
its	O
antitumor	B-MED
activity	I-MED
are	O
not	O
fully	O
defined	O
.	O
	
here	O
we	O
demonstrate	O
that	O
sirt2	B-MED
binds	B-MED
,	O
deacetylates	B-MED
,	O
and	O
inhibits	B-MED
the	I-MED
peroxidase	I-MED
activity	I-MED
of	O
the	O
antioxidant	B-MED
protein	I-MED
peroxiredoxin	I-MED
prdx-1	B-MED
in	O
breast	B-MED
cancer	I-MED
cells	I-MED
.	O
	
ectopic	B-MED
overexpression	B-MED
of	O
sirt2	B-MED
,	O
but	O
not	O
its	O
catalytically	B-MED
dead	I-MED
mutant	I-MED
,	O
increased	B-MED
intracellular	B-MED
levels	I-MED
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
ros	B-MED
induced	B-MED
by	I-MED
hydrogen	I-MED
peroxide	I-MED
,	O
which	O
led	O
to	O
increased	B-MED
levels	B-MED
of	O
an	O
overoxidized	B-MED
and	I-MED
multimeric	I-MED
form	I-MED
of	I-MED
prdx-1	I-MED
with	O
activity	B-MED
as	I-MED
a	I-MED
molecular	I-MED
chaperone	I-MED
.	O
	
elevated	B-MED
levels	B-MED
of	O
sirt2	B-MED
sensitized	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
intracellular	B-MED
dna	I-MED
damage	I-MED
and	O
cell	B-MED
death	I-MED
induced	I-MED
by	I-MED
oxidative	I-MED
stress	I-MED
,	O
as	O
associated	O
with	O
increased	B-MED
levels	B-MED
of	O
nuclear	B-MED
foxo3a	I-MED
and	O
the	O
proapoptotic	B-MED
bim	I-MED
protein	I-MED
.	O
	
in	O
addition	O
,	O
elevated	B-MED
levels	B-MED
of	O
sirt2	B-MED
sensitized	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
arsenic	B-MED
trioxide	I-MED
,	O
an	O
approved	O
therapeutic	B-MED
agent	I-MED
,	O
along	O
with	O
other	O
intracellular	B-MED
ros	I-MED
-	O
inducing	B-MED
agents	I-MED
.	O
	
conversely	O
,	O
antisense	B-MED
rna	I-MED
-	O
mediated	B-MED
attenuation	I-MED
of	O
sirt2	B-MED
reversed	B-MED
ros	B-MED
-	O
induced	B-MED
toxicity	I-MED
as	O
demonstrated	O
in	O
a	O
zebrafish	B-MED
embryo	B-MED
model	I-MED
system	I-MED
.	O
	
collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	B-MED
suppressor	I-MED
activity	I-MED
of	O
sirt2	B-MED
requires	O
its	O
ability	O
to	O
restrict	B-MED
the	O
antioxidant	B-MED
activity	I-MED
of	O
prdx-1	B-MED
,	O
thereby	O
sensitizing	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
ros	B-MED
-	O
induced	B-MED
dna	I-MED
damage	I-MED
and	O
cell	B-MED
cytotoxicity	I-MED
.	O
	
on	O
the	O
development	B-MED
of	O
conjunctival	B-MED
hyperemia	I-MED
computer-assisted	B-MED
diagnosis	I-MED
tools	I-MED
influence	O
of	O
feature	B-MED
selection	B-MED
and	O
class	B-MED
imbalance	I-MED
in	O
automatic	O
gradings	O
the	O
sudden	O
increase	O
of	O
blood	B-MED
flow	I-MED
in	O
the	O
bulbar	B-MED
conjunctiva	I-MED
,	O
known	O
as	O
hyperemia	B-MED
,	O
is	O
associated	O
to	O
a	O
red	B-MED
hue	I-MED
of	O
variable	B-MED
intensity	B-MED
.	O
	
experts	O
measure	O
hyperemia	B-MED
using	O
levels	O
in	O
a	O
grading	B-MED
scale	I-MED
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non-repeatable	O
and	O
time	B-MED
consuming	I-MED
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	B-MED
.	O
	
however	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	B-MED
due	O
to	O
data	O
issues	O
such	O
as	O
class	B-MED
imbalance	I-MED
or	O
correlated	B-MED
features	B-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	B-MED
of	O
hyperemia	B-MED
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	B-MED
framework	I-MED
for	O
hyperemia	B-MED
grading	B-MED
.	O
	
oversampling	B-MED
,	O
undersampling	B-MED
and	O
smote	B-MED
approaches	I-MED
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	B-MED
imbalance	I-MED
.	O
	
25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	B-MED
methods	I-MED
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	B-MED
scale	I-MED
.	O
	
the	O
values	O
and	O
relationships	O
among	O
features	B-MED
and	O
experts'	B-MED
values	I-MED
were	O
analysed	O
,	O
and	O
five	O
feature	B-MED
selection	B-MED
techniques	O
were	O
subsequently	O
studied	O
.	O
	
the	O
lowest	B-MED
mean	I-MED
square	I-MED
error	I-MED
mse	B-MED
for	O
the	O
regression	B-MED
systems	I-MED
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales	O
.	O
	
multi-layer	B-MED
perceptron	I-MED
mlp	B-MED
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	B-MED
forest	I-MED
rf	I-MED
method	I-MED
.	O
	
when	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
mlp	B-MED
.	O
	
correlation	B-MED
based	I-MED
feature	I-MED
selection	I-MED
cfs	B-MED
and	O
m5	O
provide	O
the	O
best	O
results	O
,	O
mse	B-MED
=0	O
and	O
mse	B-MED
=0	O
respectively	O
.	O
	
finally	O
,	O
the	O
class	B-MED
imbalance	I-MED
problem	I-MED
is	O
minimised	O
with	O
the	O
smote	B-MED
approach	I-MED
for	O
both	O
scales	O
mse	B-MED
<0	O
.	O
	
machine	B-MED
learning	I-MED
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-MED
grading	B-MED
,	O
removing	O
both	O
intra-	B-MED
and	I-MED
inter-expert	I-MED
subjectivity	I-MED
while	O
providing	O
a	O
gain	O
in	O
computation	B-MED
time	B-MED
.	O
	
smote	B-MED
and	O
oversampling	B-MED
approaches	I-MED
minimise	O
the	O
class	B-MED
imbalance	I-MED
problem	I-MED
,	O
while	O
feature	B-MED
selection	B-MED
reduces	O
the	O
number	O
of	O
features	B-MED
from	O
25	O
to	O
3-5	O
without	O
worsening	O
the	O
mse	B-MED
.	O
	
as	O
the	O
differences	O
between	O
the	O
system	B-MED
and	O
a	O
human	B-MED
expert	I-MED
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	B-MED
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	B-MED
behaves	O
like	O
an	O
medication	B-MED
,	O
rehabilitation	B-MED
and	O
health	B-MED
care	I-MED
consumption	I-MED
in	O
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
a	O
population	B-MED
based	I-MED
study	I-MED
to	O
evaluate	O
medication	B-MED
,	O
rehabilitation	B-MED
and	O
healthcare	B-MED
consumption	I-MED
in	O
adults	B-MED
with	O
cp	B-MED
as	O
a	O
function	B-MED
of	O
gross	B-MED
motor	I-MED
function	I-MED
classification	I-MED
system	I-MED
gmfcs	B-MED
level	O
.	O
	
questionnaire	B-MED
-based	O
cross-sectional	B-MED
study	I-MED
.	O
	
brittany	B-MED
,	O
a	O
french	B-MED
county	I-MED
.	O
	
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
.	O
	
questionnaires	B-MED
relating	O
to	O
drugs	B-MED
,	O
orthotic	B-MED
devices	I-MED
,	O
mobility	B-MED
aids	I-MED
,	O
rehabilitation	B-MED
and	O
medical	B-MED
input	I-MED
were	O
sent	B-MED
to	O
435	O
members	B-MED
of	O
a	O
unique	B-MED
regional	B-MED
french	I-MED
network	B-MED
dedicated	O
to	O
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
.	O
	
the	O
questionnaire	B-MED
was	O
completed	B-MED
by	O
the	O
participant	B-MED
or	O
a	O
helper	B-MED
if	O
necessary	O
.	O
	
of	O
the	O
282	O
responders	B-MED
,	O
7.8	O
had	O
a	O
gmfcs	B-MED
level	I-MED
of	O
i	O
,	O
14.2	O
ii	O
,	O
17.7	O
iii	O
,	O
29.1	O
iv	O
and	O
31.2	O
v	O
.	O
	
participants	B-MED
consumed	O
a	O
large	B-MED
amount	I-MED
of	I-MED
healthcare	I-MED
.	O
	
almost	B-MED
three-quarters	I-MED
took	O
orally	B-MED
administered	I-MED
drugs	I-MED
,	O
of	O
which	O
antispastic	B-MED
and	O
antiepileptic	B-MED
drugs	I-MED
were	O
among	O
the	O
most	B-MED
frequent	I-MED
.	O
	
nearly	O
all	O
patients	B-MED
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	B-MED
,	O
87.2	O
had	O
physiotherapy	B-MED
,	O
78%	O
used	O
at	O
least	O
one	O
mobility	B-MED
aid	I-MED
and	O
69.5	O
used	O
at	O
least	O
one	O
orthotic	B-MED
device	I-MED
.	O
	
the	O
frequency	B-MED
of	O
numerous	O
inputs	O
increased	O
with	O
gmfcs	B-MED
level	I-MED
.	O
	
specificities	B-MED
were	O
found	B-MED
for	O
each	O
gmfcs	B-MED
level	I-MED
,	O
e.g	O
.	O
	
participants	B-MED
with	O
gmfcs	B-MED
level	I-MED
iv	O
and	O
v	O
had	O
a	O
high	B-MED
level	I-MED
of	O
medical	B-MED
input	I-MED
and	O
a	O
greater	B-MED
use	I-MED
of	I-MED
trunk-supporting	B-MED
devices	I-MED
,	O
antireflux	B-MED
and	O
laxative	B-MED
.	O
	
profiles	B-MED
could	O
be	O
established	O
based	O
on	O
gmfcs	B-MED
levels	I-MED
.	O
	
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
use	O
a	O
large	B-MED
amount	I-MED
of	O
drugs	B-MED
,	O
mobility	B-MED
aids	I-MED
,	O
orthotic	B-MED
devices	I-MED
,	O
rehabilitation	B-MED
and	O
medical	B-MED
input	I-MED
.	O
	
healthcare	B-MED
is	O
targeted	B-MED
at	O
cerebral	B-MED
palsy	I-MED
-related	O
issues	O
.	O
	
gmfcs	O
is	O
a	O
determinant	O
of	O
healthcare	O
consumption	O
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical	O
practice	O
to	O
target	O
care	O
appropriately	B-MED
transcriptome	B-MED
sequencing	I-MED
and	O
de	B-MED
novo	I-MED
characterization	B-MED
of	O
korean	B-MED
endemic	O
land	B-MED
snail	I-MED
,	O
koreanohadra	B-MED
kurodana	I-MED
for	O
functional	O
transcripts	B-MED
and	O
ssr	B-MED
markers	B-MED
the	O
korean	B-MED
endemic	O
land	B-MED
snail	I-MED
koreanohadra	B-MED
kurodana	I-MED
gastropoda	B-MED
bradybaenidae	B-MED
found	O
in	O
humid	B-MED
areas	I-MED
of	O
broadleaf	B-MED
forests	I-MED
and	O
shrubs	B-MED
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	B-MED
are	O
declining	O
in	O
recent	O
years	B-MED
.	O
	
the	O
species	B-MED
is	O
poorly	O
characterized	O
at	O
the	O
genomic	B-MED
level	I-MED
that	O
limits	O
the	O
understanding	O
of	O
functions	B-MED
at	O
the	O
molecular	B-MED
and	O
genetics	B-MED
level	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
we	O
performed	O
de	B-MED
novo	I-MED
transcriptome	B-MED
sequencing	I-MED
to	O
produce	O
a	O
comprehensive	O
transcript	B-MED
dataset	B-MED
of	O
visceral	B-MED
mass	I-MED
tissue	I-MED
of	O
k	B-MED
.	O
	
kurodana	I-MED
by	O
the	O
illumina	B-MED
paired-end	I-MED
sequencing	I-MED
technology	I-MED
.	O
	
over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315	O
contigs	B-MED
and	O
191	O
unigenes	B-MED
,	O
with	O
an	O
average	O
and	O
n50	B-MED
length	B-MED
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O
	
overall	O
,	O
36.32	O
%	O
of	O
the	O
unigenes	B-MED
found	O
matches	O
to	O
known	O
protein	B-MED
/	O
nucleotide	B-MED
sequences	I-MED
in	O
the	O
public	B-MED
databases	I-MED
.	O
	
the	O
direction	B-MED
of	O
the	O
unigenes	B-MED
to	O
functional	O
categories	O
was	O
determined	O
using	O
cog	B-MED
,	O
go	B-MED
,	O
kegg	B-MED
,	O
and	O
interproscan	B-MED
protein	B-MED
domain	I-MED
search	B-MED
.	O
	
the	O
go	B-MED
analysis	B-MED
search	O
resulted	O
in	O
22	O
unigenes	B-MED
12.02	O
%	O
being	O
categorized	O
into	O
40	O
functional	B-MED
groups	I-MED
.	O
	
the	O
kegg	B-MED
annotation	I-MED
revealed	O
that	O
metabolism	B-MED
pathway	I-MED
genes	B-MED
were	O
enriched	O
.	O
	
the	O
most	O
prominent	O
protein	B-MED
motifs	I-MED
include	O
the	O
zinc	B-MED
finger	I-MED
,	O
ribonuclease	B-MED
h	I-MED
,	O
reverse	B-MED
transcriptase	I-MED
,	O
and	O
ankyrin	B-MED
repeat	I-MED
domains	I-MED
.	O
	
the	O
simple	B-MED
sequence	I-MED
repeats	I-MED
ssrs	B-MED
identified	O
from	O
>1	O
kb	O
length	B-MED
of	O
unigenes	B-MED
show	O
a	O
dominancy	O
of	O
dinucleotide	B-MED
repeat	I-MED
motifs	I-MED
followed	O
with	O
tri-	B-MED
and	O
tetranucleotide	B-MED
motifs	I-MED
.	O
	
a	O
number	O
of	O
unigenes	B-MED
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	B-MED
and	O
defense	B-MED
mechanisms	I-MED
including	O
heat	B-MED
shock	I-MED
proteins	I-MED
70	I-MED
,	O
toll-like	B-MED
receptor	I-MED
4	I-MED
,	O
amp-activated	B-MED
protein	I-MED
kinase	I-MED
,	O
aquaporin-2	B-MED
,	O
etc	O
.	O
	
our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	B-MED
and	O
functional	O
characterization	B-MED
of	O
new	O
genes	B-MED
and	O
candidate	O
polymorphic	B-MED
ssr	B-MED
markers	B-MED
in	O
k	B-MED
.	O
	
kurodana	I-MED
.	O
	
the	O
availability	O
of	O
transcriptome	B-MED
information	O
http	B-MED
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	B-MED
study	I-MED
and	O
genetic	B-MED
diversity	I-MED
assessment	B-MED
.	O
	
prediction	B-MED
of	O
estrogenic	B-MED
bioactivity	B-MED
of	O
environmental	B-MED
chemical	I-MED
metabolites	B-MED
the	O
us	B-MED
environmental	I-MED
protection	I-MED
agency's	I-MED
epa	B-MED
endocrine	B-MED
disruptor	I-MED
screening	I-MED
program	I-MED
edsp	B-MED
is	O
using	O
in	B-MED
vitro	I-MED
data	I-MED
generated	O
from	O
toxcast	B-MED
/	O
tox21	B-MED
high-throughput	B-MED
screening	I-MED
assays	I-MED
to	O
assess	O
the	O
endocrine	B-MED
activity	B-MED
of	O
environmental	B-MED
chemicals	I-MED
.	O
	
considering	O
that	O
in	B-MED
vitro	I-MED
assays	I-MED
may	O
have	O
limited	O
metabolic	B-MED
capacity	I-MED
,	O
inactive	B-MED
chemicals	I-MED
that	O
are	O
biotransformed	B-MED
into	O
metabolites	B-MED
with	O
endocrine	B-MED
bioactivity	B-MED
may	O
be	O
missed	O
for	O
further	O
screening	B-MED
and	O
testing	B-MED
.	O
	
therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	B-MED
and	O
endocrine	B-MED
activity	B-MED
of	O
both	O
parent	B-MED
chemicals	I-MED
and	O
their	O
associated	O
metabolites	B-MED
.	O
	
we	O
used	O
commercially	O
available	O
software	B-MED
to	O
predict	O
metabolites	B-MED
of	O
50	O
parent	B-MED
compounds	I-MED
,	O
out	O
of	O
which	O
38	O
chemicals	B-MED
are	O
known	O
to	O
have	O
estrogenic	B-MED
metabolites	B-MED
,	O
and	O
12	O
compounds	B-MED
and	O
their	O
metabolites	B-MED
are	O
negative	O
for	O
estrogenic	B-MED
activity	B-MED
.	O
	
three	O
er	B-MED
qsar	B-MED
models	B-MED
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-MED
bioactivity	B-MED
of	O
the	O
parent	B-MED
compounds	I-MED
and	O
predicted	O
metabolites	B-MED
,	O
the	O
outputs	O
of	O
the	O
models	B-MED
were	O
averaged	O
,	O
and	O
the	O
chemicals	B-MED
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	B-MED
of	O
the	O
parent	B-MED
chemical	I-MED
and	O
metabolites	B-MED
.	O
	
the	O
metabolite	B-MED
prediction	I-MED
software	I-MED
correctly	O
identified	O
known	O
estrogenic	B-MED
metabolites	B-MED
for	O
26	O
out	O
of	O
27	O
parent	B-MED
chemicals	I-MED
with	O
associated	O
metabolite	B-MED
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-MED
metabolites	B-MED
were	O
predicted	O
as	O
potential	O
biotransformation	B-MED
products	B-MED
derived	O
from	O
the	O
parent	B-MED
chemical	I-MED
.	O
	
the	O
qsar	B-MED
models	B-MED
estimated	O
stronger	O
estrogenic	B-MED
activity	B-MED
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-MED
metabolites	B-MED
compared	O
to	O
their	O
parent	B-MED
chemicals	I-MED
.	O
	
finally	O
,	O
the	O
three	O
models	B-MED
identified	O
a	O
similar	O
set	O
of	O
parent	B-MED
compounds	I-MED
as	O
top	O
ranked	O
chemicals	B-MED
based	O
on	O
the	O
estrogenicity	B-MED
of	O
putative	O
metabolites	B-MED
.	O
	
this	O
proposed	O
in	B-MED
silico	I-MED
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-MED
of	O
chemicals	B-MED
with	O
estrogenic	B-MED
metabolites	B-MED
and	O
may	O
reduce	O
potential	O
false	B-MED
negative	I-MED
results	O
from	O
in	B-MED
vitro	I-MED
assays	I-MED
.	O
	
effects	B-MED
of	I-MED
application	B-MED
of	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
the	O
health	B-MED
belief	I-MED
model	I-MED
in	O
promoting	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
among	O
targeted	B-MED
women	B-MED
in	O
sisaket	B-MED
province	I-MED
,	O
thailand	B-MED
cervical	B-MED
cancer	I-MED
is	O
a	O
major	B-MED
public	B-MED
health	I-MED
problem	I-MED
in	O
thailand	B-MED
,	O
being	O
ranked	B-MED
second	O
only	O
to	O
breast	B-MED
cancer	I-MED
.	O
	
thai	B-MED
women	B-MED
have	O
been	O
reported	B-MED
to	O
have	O
a	O
low	B-MED
rate	B-MED
of	O
cervical	B-MED
cancer	I-MED
screening	I-MED
27.7	O
of	O
the	O
80%	O
goal	B-MED
of	O
who	B-MED
.	O
	
we	O
therefore	O
aimed	B-MED
to	O
apply	B-MED
the	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
health	B-MED
belief	I-MED
model	I-MED
in	O
promoting	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
in	O
kanthararom	B-MED
district	I-MED
,	O
sisaket	B-MED
province	I-MED
.	O
	
a	O
total	B-MED
of	O
92	O
from	O
974	O
targeted	B-MED
women	B-MED
aged	B-MED
3060	O
years	B-MED
were	O
randomly	B-MED
divided	B-MED
into	O
two	O
groups	B-MED
.	O
	
the	O
experimental	B-MED
group	I-MED
underwent	O
application	B-MED
of	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
a	O
health	B-MED
belief	I-MED
model	I-MED
program	B-MED
promoting	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
while	O
the	O
control	B-MED
group	I-MED
received	B-MED
normal	B-MED
services	I-MED
.	O
	
two	O
research	B-MED
tools	I-MED
were	O
used	O
1	O
application	B-MED
of	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
health	B-MED
belief	I-MED
model	I-MED
program	B-MED
and	O
2	O
questionnaire	B-MED
used	O
to	O
evaluate	B-MED
perceptions	B-MED
of	O
cervical	B-MED
cancer	I-MED
.	O
	
descriptive	B-MED
and	O
inferential	B-MED
statistics	I-MED
including	B-MED
paired	B-MED
sample	B-MED
ttest	I-MED
and	O
independent	B-MED
ttest	B-MED
were	O
used	O
to	O
analyze	B-MED
the	I-MED
data	I-MED
.	O
	
after	O
the	O
program	B-MED
had	O
been	O
used	O
,	O
the	O
mean	B-MED
score	I-MED
of	O
perception	B-MED
of	O
cervical	B-MED
cancer	I-MED
of	O
experimental	B-MED
group	I-MED
was	O
at	O
a	O
higher	B-MED
level	B-MED
x=4	O
s.d	B-MED
.	O
	
=0	O
,	O
than	O
in	O
the	O
control	B-MED
group	I-MED
x=3	O
s.d	B-MED
.	O
	
=0	O
with	O
statistical	B-MED
significance	I-MED
p<0	O
.	O
	
this	O
research	B-MED
demonstrated	O
an	O
appropriate	B-MED
communication	B-MED
process	B-MED
in	O
behavioral	B-MED
modification	B-MED
to	O
prevent	O
cervical	B-MED
cancer	I-MED
.	O
	
it	O
can	O
be	O
recommended	B-MED
that	O
this	O
program	B-MED
featuring	B-MED
social	B-MED
marketing	I-MED
and	O
the	O
health	B-MED
belief	I-MED
model	I-MED
be	O
used	O
to	O
promote	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
in	O
targeted	B-MED
women	B-MED
and	O
it	O
can	O
be	O
promoted	B-MED
as	O
a	O
guideline	B-MED
for	O
other	O
health	B-MED
services	I-MED
,	O
especially	O
in	O
health	B-MED
promotion	I-MED
and	O
disease	B-MED
prevention	I-MED
.	O
	
visualization	B-MED
of	O
the	O
intimal	B-MED
flap	I-MED
in	O
intracranial	B-MED
arterial	I-MED
dissection	I-MED
using	O
high-resolution	B-MED
3t	B-MED
mri	I-MED
presence	B-MED
of	O
an	O
intimal	B-MED
flap	I-MED
is	O
a	O
critical	B-MED
imaging	B-MED
finding	I-MED
in	O
diagnosing	B-MED
intracranial	B-MED
artery	I-MED
dissection	I-MED
icad	B-MED
.	O
	
recent	O
reports	B-MED
showed	O
that	O
high-resolution	B-MED
magnetic	B-MED
resonance	I-MED
imaging	I-MED
mri	B-MED
was	O
better	B-MED
at	O
identifying	O
intimal	B-MED
flaps	I-MED
as	O
compared	B-MED
with	O
routine	O
mri	B-MED
techniques	I-MED
used	O
in	O
clinical	B-MED
settings	I-MED
.	O
	
however	O
,	O
no	O
current	O
standardized	O
sequence	B-MED
for	O
high-resolution	B-MED
mri	B-MED
without	O
gadolinium	B-MED
enhancement	B-MED
produces	O
images	B-MED
of	O
satisfactory	O
quality	B-MED
with	O
clinically	O
tolerable	O
scanning	B-MED
times	B-MED
.	O
	
this	O
study	O
evaluated	B-MED
a	O
nonenhanced	B-MED
high-resolution	I-MED
fast	I-MED
spin	I-MED
echo	I-MED
hr-fse	I-MED
mri	I-MED
sequence	B-MED
for	O
visualizing	O
intimal	B-MED
flaps	I-MED
in	O
patients	B-MED
with	O
icad	B-MED
.	O
	
three	O
patients	B-MED
with	O
icad	B-MED
underwent	O
plain	O
mri	B-MED
examination	O
using	O
a	O
2-dimensional	B-MED
t2-weighted	B-MED
fse	I-MED
imaging	I-MED
sequence	B-MED
optimized	O
for	O
our	O
3t	B-MED
system	I-MED
in-plane	O
pixel	O
size	O
,	O
23	O
mm	O
23	O
mm	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
,	O
as	O
well	O
as	O
scanning	B-MED
with	O
conventional	B-MED
modalities	B-MED
,	O
including	O
ct	B-MED
angiography	I-MED
,	O
magnetic	B-MED
resonance	I-MED
angiography	I-MED
,	O
and	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
.	O
	
we	O
assessed	B-MED
whether	O
these	O
imaging	B-MED
methods	I-MED
could	O
visualize	O
an	O
intimal	B-MED
flap	I-MED
and/or	O
double	B-MED
lumen	I-MED
sign	I-MED
in	O
the	O
participants	B-MED
and	O
compared	B-MED
the	O
results	B-MED
between	O
hr-fse	B-MED
and	O
the	O
other	O
modalities	B-MED
.	O
	
hr-fse	B-MED
images	B-MED
clearly	O
showed	O
intimal	B-MED
flaps	I-MED
and	O
double	B-MED
lumen	I-MED
signs	I-MED
in	O
all	O
3	O
patients	B-MED
,	O
whereas	O
the	O
conventional	B-MED
modalities	B-MED
identified	B-MED
a	O
double	B-MED
lumen	I-MED
sign	I-MED
in	O
only	O
2	O
of	O
the	O
3	O
patients	B-MED
.	O
	
the	O
present	O
method	O
of	O
optimized	O
hr-fse	B-MED
imaging	I-MED
with	O
a	O
3t	B-MED
system	I-MED
improved	B-MED
visualization	B-MED
of	O
intimal	B-MED
flaps	I-MED
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	B-MED
patients	B-MED
with	O
suspected	B-MED
icad	B-MED
that	O
cannot	O
be	O
definitively	O
diagnosed	B-MED
by	O
conventional	B-MED
imaging	B-MED
modalities	I-MED
.	O
	
quantification	B-MED
of	O
intact	B-MED
plasma	B-MED
agt	B-MED
consisting	O
of	O
oxidized	O
and	O
reduced	B-MED
conformations	I-MED
using	O
a	O
modified	O
elisa	B-MED
the	O
pleiotropic	B-MED
actions	I-MED
of	O
the	O
renin-angiotensin	B-MED
system	I-MED
ras	B-MED
depend	O
on	O
the	O
availability	B-MED
of	I-MED
angiotensinogen	B-MED
agt	B-MED
which	O
generates	B-MED
angiotensin	B-MED
i	I-MED
ang	B-MED
i	I-MED
when	O
cleaved	B-MED
by	O
renin	B-MED
.	O
	
thus	O
,	O
quantification	B-MED
of	O
the	O
intact	B-MED
agt	B-MED
iagt	B-MED
concentrations	B-MED
is	O
important	B-MED
to	O
evaluate	O
the	O
actual	B-MED
renin	B-MED
substrate	I-MED
available	B-MED
.	O
	
the	O
iagt	B-MED
conformation	B-MED
exists	O
as	O
oxidized	B-MED
agt	I-MED
oxi-agt	B-MED
and	O
reduced	B-MED
agt	I-MED
red-agt	B-MED
in	O
a	O
disulfide	B-MED
bond	I-MED
,	O
and	O
oxi-agt	B-MED
has	O
a	O
higher	B-MED
affinity	B-MED
for	O
renin	B-MED
,	O
which	O
may	O
exacerbate	O
ras	B-MED
-	O
associated	B-MED
diseases	I-MED
.	O
	
accordingly	O
,	O
we	O
determined	B-MED
iagt	B-MED
,	O
oxi-agt	B-MED
,	O
and	O
red-agt	B-MED
levels	B-MED
in	O
plasma	B-MED
from	O
rats	B-MED
and	O
mice	B-MED
.	O
	
blood	B-MED
samples	I-MED
were	O
obtained	B-MED
by	O
cardiac	B-MED
puncture	I-MED
and	O
then	O
immediately	B-MED
mixed	B-MED
with	O
an	O
inhibitor	B-MED
solution	B-MED
containing	B-MED
a	O
renin	B-MED
inhibitor	I-MED
.	O
	
total	B-MED
agt	B-MED
tagt	B-MED
levels	B-MED
were	O
measured	B-MED
by	O
tagt	B-MED
elisa	B-MED
which	O
detects	B-MED
both	O
cleaved	B-MED
and	O
iagt	B-MED
.	O
	
iagt	B-MED
levels	B-MED
were	O
determined	B-MED
by	I-MED
iagt	B-MED
elisa	B-MED
which	O
was	O
found	O
to	O
only	O
detect	B-MED
red-agt	B-MED
.	O
	
thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	B-MED
with	O
dithiothreitol	B-MED
,	O
a	O
reducing	B-MED
agent	I-MED
,	O
to	O
quantify	B-MED
total	B-MED
iagt	B-MED
concentration	B-MED
.	O
	
tagt	B-MED
levels	B-MED
in	O
rat	B-MED
and	O
mouse	B-MED
plasma	B-MED
were	O
1	O
139	O
and	O
1	O
77	O
ng/ml	O
,	O
respectively	O
.	O
	
iagt	B-MED
levels	B-MED
were	O
53%	O
of	O
tagt	B-MED
in	O
rat	B-MED
plasma	B-MED
but	O
only	O
22%	O
in	O
mouse	B-MED
plasma	B-MED
,	O
probably	O
reflecting	O
the	O
greater	B-MED
plasma	B-MED
renin	B-MED
activity	B-MED
in	O
mice	B-MED
.	O
	
the	O
ratios	B-MED
of	O
oxi-agt	B-MED
and	O
red-agt	B-MED
were	O
4	O
rat	B-MED
and	O
16	O
mouse	B-MED
.	O
	
plasma	B-MED
iagt	B-MED
consists	O
of	O
oxi-agt	B-MED
and	O
red-agt	B-MED
,	O
suggesting	B-MED
that	O
oxidative	B-MED
stress	I-MED
can	O
influence	B-MED
ang	B-MED
i	I-MED
generation	B-MED
by	O
the	O
agt	B-MED
conformation	B-MED
switch	O
.	O
	
furthermore	O
,	O
the	O
lower	B-MED
availability	B-MED
of	I-MED
plasma	B-MED
iagt	B-MED
in	O
mice	B-MED
suggests	B-MED
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	B-MED
factor	B-MED
in	O
ang	B-MED
i	I-MED
formation	B-MED
in	O
this	O
carbon	B-MED
monoxide	I-MED
improves	B-MED
efficacy	B-MED
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
during	B-MED
sepsis	B-MED
by	O
production	O
of	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
are	O
being	O
investigated	B-MED
as	O
a	O
cell-based	B-MED
therapy	I-MED
for	O
a	O
number	O
of	O
disease	B-MED
processes	I-MED
,	O
with	O
promising	O
results	B-MED
in	O
animal	B-MED
models	I-MED
of	O
systemic	B-MED
inflammation	I-MED
and	O
sepsis	B-MED
.	O
	
studies	B-MED
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-MED
the	O
therapeutic	B-MED
potential	B-MED
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
.	O
	
a	O
gas	B-MED
molecule	B-MED
that	O
improves	B-MED
outcome	B-MED
in	O
experimental	B-MED
sepsis	B-MED
is	O
carbon	B-MED
monoxide	I-MED
.	O
	
we	O
hypothesized	O
that	O
preconditioning	B-MED
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
with	O
carbon	B-MED
monoxide	I-MED
ex	B-MED
vivo	I-MED
would	O
promote	B-MED
further	O
therapeutic	B-MED
benefit	B-MED
when	O
cells	B-MED
are	O
administered	B-MED
in	B-MED
vivo	I-MED
after	O
the	O
onset	B-MED
of	I-MED
polymicrobial	B-MED
sepsis	B-MED
in	O
mice	B-MED
.	O
	
animal	B-MED
study	I-MED
and	O
primary	B-MED
cell	I-MED
culture	I-MED
.	O
	
laboratory	B-MED
investigation	B-MED
.	O
	
balb/c	B-MED
mice	I-MED
.	O
	
polymicrobial	B-MED
sepsis	B-MED
was	O
induced	B-MED
by	O
cecal	B-MED
ligation	B-MED
and	O
puncture	B-MED
.	O
	
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
,	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
-	O
conditioned	B-MED
with	O
carbon	B-MED
monoxide	I-MED
,	O
fibroblasts	B-MED
,	O
or	O
fibroblasts	B-MED
-	O
conditioned	B-MED
with	O
carbon	B-MED
monoxide	I-MED
were	O
delivered	B-MED
by	O
tail	B-MED
vein	I-MED
injections	B-MED
to	O
septic	B-MED
mice	B-MED
.	O
	
the	O
mice	B-MED
were	O
assessed	B-MED
for	O
survival	B-MED
,	O
bacterial	B-MED
clearance	B-MED
,	O
and	O
the	O
inflammatory	B-MED
response	I-MED
during	B-MED
sepsis	B-MED
in	O
each	O
of	O
the	O
groups	B-MED
.	O
	
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
were	O
also	O
assessed	B-MED
for	O
their	O
ability	B-MED
to	O
promote	B-MED
bacterial	B-MED
phagocytosis	B-MED
by	O
neutrophils	B-MED
,	O
the	O
production	O
of	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
,	O
and	O
their	O
importance	O
for	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
function	B-MED
using	O
gene	B-MED
silencing	I-MED
.	O
	
ex	B-MED
vivo	I-MED
preconditioning	B-MED
with	O
carbon	B-MED
monoxide	I-MED
allowed	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
to	O
be	O
administered	B-MED
later	O
after	O
the	O
onset	B-MED
of	I-MED
sepsis	B-MED
6	O
hr	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	B-MED
effect	I-MED
with	O
increased	B-MED
survival	B-MED
.	O
	
carbon	B-MED
monoxide	I-MED
preconditioned	B-MED
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
were	O
also	O
able	O
to	O
alleviate	O
organ	B-MED
injury	I-MED
,	O
improve	B-MED
bacterial	B-MED
clearance	B-MED
,	O
and	O
promote	B-MED
the	O
resolution	B-MED
of	O
inflammation	B-MED
.	O
	
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
exposed	B-MED
to	I-MED
carbon	B-MED
monoxide	I-MED
,	O
with	O
docosahexaenoic	B-MED
acid	I-MED
substrate	B-MED
,	O
produced	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
,	O
particularly	O
d-series	B-MED
resolvins	B-MED
,	O
which	O
promoted	B-MED
survival	B-MED
.	O
	
silencing	B-MED
of	O
lipoxygenase	B-MED
pathways	I-MED
5-lipoxygenase	B-MED
and	O
12	B-MED
/	O
15-lipoxygenase	B-MED
,	O
which	O
are	O
important	B-MED
enzymes	B-MED
for	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediator	I-MED
biosynthesis	B-MED
,	O
resulted	B-MED
in	O
a	O
loss	O
of	O
therapeutic	B-MED
benefit	B-MED
bestowed	O
on	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
by	O
carbon	B-MED
monoxide	I-MED
.	O
	
taken	O
together	O
,	O
these	O
data	B-MED
suggest	O
that	O
production	O
of	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
contribute	B-MED
to	O
improved	B-MED
mesenchymal	B-MED
stromal	I-MED
cell	I-MED
efficacy	B-MED
when	O
exposed	B-MED
to	I-MED
carbon	B-MED
monoxide	I-MED
,	O
resulting	O
in	O
an	O
improved	B-MED
therapeutic	B-MED
response	I-MED
during	B-MED
sepsis	B-MED
.	O
	
effect	B-MED
of	O
primary	B-MED
health	I-MED
care	I-MED
reforms	B-MED
in	O
turkey	B-MED
on	O
health	B-MED
service	I-MED
utilization	I-MED
and	O
user	B-MED
satisfaction	I-MED
strengthening	B-MED
primary	B-MED
health	I-MED
care	I-MED
phc	B-MED
is	O
considered	O
a	O
priority	O
for	O
efficient	B-MED
and	O
responsive	B-MED
health	B-MED
systems	I-MED
,	O
but	O
empirical	B-MED
evidence	B-MED
from	O
low-	O
and	O
middle-	O
income	B-MED
countries	B-MED
is	O
limited	B-MED
.	O
	
the	O
stepwise	B-MED
introduction	I-MED
of	O
family	B-MED
medicine	I-MED
across	O
all	O
81	O
provinces	B-MED
of	O
turkey	B-MED
a	O
middle-income	B-MED
country	B-MED
between	O
2005	O
and	O
2010	O
,	O
aimed	O
at	O
phc	B-MED
strengthening	B-MED
,	O
presents	O
a	O
natural	B-MED
experiment	I-MED
for	O
assessing	B-MED
the	O
effect	B-MED
of	O
family	B-MED
medicine	I-MED
on	O
health	B-MED
service	I-MED
utilization	I-MED
and	O
user	B-MED
satisfaction	I-MED
the	O
effect	B-MED
of	O
health	B-MED
system	I-MED
reforms	B-MED
,	O
that	O
introduced	O
family	B-MED
medicine	I-MED
,	O
on	O
utilization	B-MED
was	O
assessed	B-MED
using	O
longitudinal	B-MED
,	O
province-level	B-MED
data	I-MED
for	O
12	O
years	B-MED
and	O
multivariate	B-MED
regression	I-MED
models	I-MED
adjusting	O
for	O
supply-side	B-MED
variables	I-MED
,	O
demographics	B-MED
,	O
socio-economic	B-MED
development	I-MED
and	O
underlying	O
yearly	B-MED
trends	B-MED
.	O
	
user	B-MED
satisfaction	I-MED
with	O
primary	B-MED
and	O
secondary	B-MED
care	I-MED
services	B-MED
was	O
explored	O
using	O
data	B-MED
from	O
annual	B-MED
life	I-MED
satisfaction	I-MED
surveys	I-MED
.	O
	
trends	B-MED
in	O
preferred	O
first	O
point	O
of	O
contact	B-MED
primary	B-MED
vs	O
secondary	B-MED
,	O
public	B-MED
vs	O
.	O
	
private	B-MED
,	O
reason	B-MED
for	I-MED
choice	I-MED
and	O
health	B-MED
services	I-MED
issues	B-MED
,	O
were	O
described	B-MED
and	O
stratified	B-MED
by	O
patient	B-MED
characteristics	I-MED
,	O
provider	B-MED
type	I-MED
,	O
and	O
rural/urban	B-MED
settings	I-MED
between	O
2002	O
and	O
2013	O
,	O
the	O
average	B-MED
number	I-MED
of	O
phc	B-MED
consultations	B-MED
increased	B-MED
from	O
1.75	O
to	O
2.83	O
per	O
person	B-MED
per	O
year	B-MED
.	O
	
in	O
multivariate	B-MED
models	I-MED
,	O
family	B-MED
medicine	I-MED
introduction	B-MED
was	O
associated	B-MED
with	I-MED
an	O
increase	B-MED
of	O
0.37	O
phc	B-MED
consultations	B-MED
per	O
person	B-MED
p	O
<	O
0.001	O
,	O
and	O
slower	B-MED
annual	B-MED
growth	I-MED
in	O
phc	B-MED
and	O
secondary	B-MED
care	I-MED
consultations	B-MED
.	O
	
following	O
family	B-MED
medicine	I-MED
introduction	B-MED
,	O
the	O
growth	B-MED
of	O
phc	B-MED
and	O
secondary	B-MED
care	I-MED
consultations	B-MED
per	O
person	B-MED
was	O
0.08	O
and	O
0.30	O
,	O
respectively	O
,	O
a	O
year	B-MED
.	O
	
phc	B-MED
increased	B-MED
as	O
preferred	O
provider	B-MED
by	O
9.5	O
over	O
7	O
years	B-MED
with	O
the	O
reasons	O
of	O
proximity	B-MED
and	O
service	B-MED
satisfaction	I-MED
,	O
which	O
increased	B-MED
by	O
14.9	O
and	O
11.8	O
,	O
respectively	O
.	O
	
reporting	B-MED
of	O
poor	B-MED
facility	I-MED
hygiene	I-MED
,	O
difficulty	B-MED
getting	I-MED
an	I-MED
appointment	I-MED
,	O
poor	B-MED
physician	B-MED
behaviour	B-MED
and	O
high	B-MED
costs	B-MED
of	I-MED
health	I-MED
care	I-MED
all	O
declined	B-MED
p	O
<	O
0.001	O
in	O
phc	B-MED
settings	B-MED
,	O
but	O
remained	O
higher	B-MED
among	O
urban	B-MED
,	O
low-income	B-MED
and	O
working-age	B-MED
populations	B-MED
.	O
	
laparoscopic	B-MED
radical	B-MED
lymph	I-MED
node	I-MED
dissection	I-MED
for	O
advanced	B-MED
colon	I-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
complete	B-MED
mesocolic	I-MED
excision	I-MED
is	O
currently	O
recognized	O
as	O
a	O
standard	B-MED
procedure	I-MED
for	O
colon	B-MED
cancer	I-MED
.	O
	
gastroepiploic	B-MED
,	O
infrapyloric	B-MED
,	O
and	O
superficial	B-MED
pancreatic	I-MED
head	I-MED
lymph	I-MED
node	I-MED
metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
have	O
been	O
reported	O
for	O
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
	
we	O
sought	O
to	O
investigate	O
metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
in	O
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
	
this	O
was	O
a	O
single-center	B-MED
retrospective	I-MED
study	I-MED
.	O
	
all	O
patients	B-MED
with	O
t2	B-MED
or	O
deeper	O
invasive	B-MED
colon	B-MED
cancer	I-MED
in	O
the	O
relevant	O
tumor	B-MED
location	I-MED
who	O
underwent	O
laparoscopic	B-MED
right	I-MED
hemicolectomy	I-MED
or	O
extended	B-MED
right	I-MED
hemicolectomy	I-MED
at	O
our	O
institution	B-MED
between	O
1	O
april	B-MED
2011	O
and	O
31	O
march	B-MED
2015	O
were	O
included	O
.	O
	
lymph	B-MED
node	I-MED
dissection	I-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
was	O
performed	O
in	O
35	O
cases	O
.	O
	
complications	B-MED
occurred	O
in	O
11	O
patients	B-MED
31%	O
and	O
were	O
grades	O
i	O
and	O
ii	O
according	O
to	O
the	O
clavien-dindo	B-MED
classification	I-MED
.	O
	
lymph	B-MED
node	I-MED
metastases	I-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
were	O
found	O
in	O
only	O
three	O
patients	B-MED
9%	O
.	O
	
each	O
metastasis	B-MED
was	O
larger	O
than	O
9	O
mm	B-MED
.	O
	
metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
occurred	O
in	O
9%	O
of	O
patients	B-MED
with	O
t2	B-MED
or	O
deeper	O
invasive	B-MED
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
	
laparoscopy	B-MED
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	B-MED
ligament	I-MED
resection	I-MED
.	O
	
this	O
study	B-MED
included	O
a	O
small	O
sample	B-MED
and	O
lacked	O
an	O
extended	B-MED
follow-up	B-MED
.	O
	
further	O
studies	B-MED
are	O
needed	O
to	O
determine	O
the	O
clinical	B-MED
relevance	I-MED
of	O
this	O
finding	B-MED
,	O
particularly	O
in	O
terms	O
of	O
recurrence	B-MED
and	O
long-term	B-MED
survival	B-MED
.	O
	
smartphone	B-MED
-based	O
psychotherapeutic	B-MED
micro-interventions	B-MED
to	O
improve	O
mood	B-MED
in	O
a	O
real-world	B-MED
setting	I-MED
using	O
mobile	B-MED
communication	B-MED
technology	I-MED
as	O
new	O
personalized	O
approach	B-MED
to	O
treat	B-MED
mental	B-MED
disorders	I-MED
or	O
to	O
more	O
generally	O
improve	O
quality	B-MED
of	I-MED
life	I-MED
is	O
highly	O
promising	O
.	O
	
knowledge	B-MED
about	O
intervention	B-MED
components	B-MED
that	O
target	O
key	O
psychopathological	B-MED
processes	B-MED
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-MED
approaches	B-MED
is	O
urgently	O
needed	O
.	O
	
we	O
explored	O
the	O
use	O
of	O
smartphone	B-MED
-based	O
micro-interventions	B-MED
based	O
on	O
psychotherapeutic	B-MED
techniques	I-MED
,	O
guided	O
by	O
short	O
video-clips	B-MED
,	O
to	O
elicit	O
mood	B-MED
changes	I-MED
.	O
	
as	O
part	O
of	O
a	O
larger	O
neurofeedback	B-MED
study	B-MED
,	O
all	O
subjects	B-MED
-after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-MED
condition	B-MED
-underwent	O
daily	B-MED
smartphone	B-MED
-based	O
micro-interventions	B-MED
for	O
13	O
consecutive	O
days	B-MED
.	O
	
they	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	B-MED
,	O
including	O
viscerosensory	B-MED
attention	B-MED
,	O
emotional	B-MED
imagery	B-MED
,	O
facial	B-MED
expression	I-MED
,	O
and	O
contemplative	B-MED
repetition	B-MED
.	O
	
changes	B-MED
in	O
mood	B-MED
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
multidimensional	B-MED
mood	I-MED
state	I-MED
questionnaire	I-MED
scales	O
good	B-MED
-	O
bad	B-MED
,	O
gb	O
awake	B-MED
-	O
tired	B-MED
,	O
at	O
and	O
calm	B-MED
-	O
nervous	B-MED
,	O
cn	O
.	O
	
twenty-seven	O
men	B-MED
participated	O
on	O
at	O
least	O
11	O
days	B-MED
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	B-MED
.	O
	
altogether	O
,	O
they	O
underwent	O
335	O
,	O
generally	O
well-tolerated	O
,	O
micro-intervention	B-MED
sessions	I-MED
,	O
with	O
viscerosensory	B-MED
attention	B-MED
178	O
sessions	B-MED
,	O
53.13	O
and	O
contemplative	B-MED
repetition	B-MED
68	O
sessions	B-MED
,	O
20.30	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	B-MED
.	O
	
mixed	O
models	B-MED
indicated	O
that	O
subjects	B-MED
showed	O
better	O
mood	B-MED
gb	O
b	O
=	O
0.464	O
,	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
0.068	O
,	O
0.860	O
,	O
t	O
613.3	O
=	O
2.298	O
,	O
p	O
=	O
0.022	O
and	O
became	O
more	O
awake	B-MED
at	O
b	O
=	O
0.514	O
,	O
95%	O
ci	B-MED
0.103	O
,	O
0.925	O
,	O
t	O
612.4	O
=	O
2.456	O
,	O
p	O
=	O
0.014	O
and	O
calmer	B-MED
cn	O
b	O
=	O
0.685	O
,	O
95%	O
ci	B-MED
0.360	O
,	O
1.010	O
,	O
t	O
612.3	O
=	O
4.137	O
,	O
p	O
<	O
0.001	O
from	O
pre	B-MED
-	O
to	O
post-micro-intervention	B-MED
.	O
	
these	O
mood	B-MED
improvements	B-MED
from	O
pre	B-MED
-	O
to	O
post-micro-intervention	B-MED
were	O
associated	O
with	O
changes	B-MED
in	I-MED
mood	I-MED
from	O
the	O
1st	O
day	B-MED
until	O
the	O
last	O
day	B-MED
with	O
regard	O
to	O
gb	B-MED
mood	I-MED
r	O
=	O
0.614	O
,	O
95%	O
ci	B-MED
0.297	O
,	O
0.809	O
,	O
p	O
<	O
0.001	O
,	O
but	O
not	O
at	B-MED
mood	I-MED
r	O
=	O
0.279	O
,	O
95%	O
ci	B-MED
-0	O
,	O
0.602	O
,	O
p	O
=	O
0.167	O
and	O
cn	B-MED
mood	I-MED
r	O
=	O
0.277	O
,	O
95%	O
ci	B-MED
0.124	O
,	O
0.601	O
,	O
p	O
=	O
0.170	O
.	O
	
our	O
findings	B-MED
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	B-MED
-based	O
micro-interventions	B-MED
eliciting	O
short-term	B-MED
mood	B-MED
changes	I-MED
,	O
based	O
on	O
techniques	B-MED
used	O
in	O
psychotherapeutic	B-MED
approaches	B-MED
,	O
such	O
as	O
mindfulness	B-MED
-based	O
psychotherapy	B-MED
,	O
transcendental	B-MED
meditation	I-MED
,	O
and	O
other	O
contemplative	B-MED
therapies	B-MED
.	O
	
the	O
results	O
encourage	O
exploring	O
these	O
techniques	B-MED
'	O
capability	B-MED
to	O
improve	O
mood	B-MED
in	O
randomized	O
controlled	B-MED
studies	I-MED
and	O
patients	B-MED
.	O
	
smartphone	B-MED
-based	O
micro-interventions	B-MED
are	O
promising	O
to	O
modify	O
mood	B-MED
in	O
real-world	B-MED
settings	I-MED
,	O
complementing	O
other	O
psychotherapeutic	B-MED
interventions	I-MED
,	O
in	O
line	O
with	O
the	O
precision	B-MED
medicine	B-MED
approach	I-MED
.	O
	
the	O
here	O
presented	O
data	B-MED
were	O
collected	O
within	O
a	O
randomized	B-MED
trial	I-MED
,	O
primary	B-MED
pituitary	B-MED
diffuse	B-MED
large	I-MED
b-cell	I-MED
lymphoma	I-MED
with	O
somatotroph	B-MED
hyperplasia	I-MED
and	O
acromegaly	B-MED
case	B-MED
report	I-MED
diffuse	B-MED
large	I-MED
b-cell	I-MED
lymphoma	I-MED
dlbcl	B-MED
is	O
the	O
most	O
common	B-MED
type	B-MED
of	O
non-hodgkin	B-MED
lymphoma	I-MED
and	O
comprises	O
approximately	O
30%	O
of	O
all	O
lymphomas	B-MED
.	O
	
patients	B-MED
typically	O
present	B-MED
with	O
a	O
nonpainful	B-MED
mass	B-MED
in	O
the	O
neck	B-MED
,	O
groin	B-MED
,	O
or	O
abdomen	B-MED
associated	B-MED
with	I-MED
constitutional	B-MED
symptoms	I-MED
.	O
	
in	O
this	O
report	B-MED
,	O
however	O
,	O
the	O
authors	B-MED
describe	O
a	O
rare	B-MED
case	B-MED
of	O
a	O
61-	O
year	B-MED
-old	O
woman	B-MED
with	O
hyperprolactinemia	B-MED
,	O
hypothyroidism	B-MED
,	O
and	O
acromegaly	B-MED
elevation	B-MED
of	O
insulin-like	B-MED
growth	I-MED
factor-1	I-MED
igf-1	B-MED
with	O
elevated	B-MED
growth	B-MED
hormone-releasing	I-MED
hormone	I-MED
ghrh	B-MED
in	O
whom	O
an	O
mri	B-MED
demonstrated	B-MED
diffuse	B-MED
enlargement	I-MED
of	I-MED
the	I-MED
pituitary	I-MED
gland	I-MED
.	O
	
despite	O
medical	B-MED
treatment	I-MED
,	O
the	O
patient	B-MED
had	O
persistent	B-MED
elevation	B-MED
of	O
igf-1	B-MED
.	O
	
she	O
underwent	O
a	O
transsphenoidal	B-MED
biopsy	I-MED
,	O
which	O
yielded	B-MED
a	O
diagnosis	B-MED
of	O
dlbcl	B-MED
with	O
an	O
activated	B-MED
b-cell	B-MED
immunophenotype	B-MED
with	O
somatotroph	B-MED
hyperplasia	I-MED
.	O
	
after	O
stereo-tactic	B-MED
radiation	I-MED
therapy	I-MED
in	O
combination	B-MED
with	O
chemotherapy	B-MED
,	O
she	O
is	O
currently	B-MED
in	O
remission	B-MED
from	O
her	O
lymphoma	B-MED
and	O
has	O
normalized	B-MED
igf-1	B-MED
levels	B-MED
without	O
medical	B-MED
therapy	I-MED
,	O
8	O
months	B-MED
after	O
her	O
histopathological	B-MED
diagnosis	B-MED
.	O
	
this	O
is	O
the	O
only	O
reported	B-MED
case	B-MED
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-MED
diagnosis	I-MED
,	O
multidisciplinary	B-MED
evaluation	I-MED
,	O
and	O
critical	B-MED
intraoperative	B-MED
decision-making	B-MED
when	O
treating	B-MED
atypical	O
sellar	B-MED
lesions	B-MED
.	O
	
doctor	B-MED
competence	B-MED
and	O
the	O
demand	B-MED
for	O
healthcare	B-MED
evidence	B-MED
from	O
rural	B-MED
china	I-MED
the	O
agency	B-MED
problem	B-MED
between	O
patients	B-MED
and	O
doctors	B-MED
has	O
long	O
been	O
emphasised	O
in	O
the	O
health	B-MED
economics	I-MED
literature	I-MED
,	O
but	O
the	O
empirical	B-MED
evidence	B-MED
on	O
whether	O
patients	B-MED
can	O
evaluate	B-MED
and	O
respond	O
to	O
better	B-MED
quality	B-MED
care	I-MED
remains	O
mixed	B-MED
and	O
inconclusive	B-MED
.	O
	
using	O
household	B-MED
data	B-MED
linked	O
to	O
an	O
assessment	B-MED
of	O
village	B-MED
doctors'	B-MED
clinical	B-MED
competence	I-MED
in	O
rural	B-MED
china	I-MED
,	O
we	O
show	O
that	O
there	O
is	O
no	B-MED
correlation	I-MED
between	O
doctor	B-MED
competence	B-MED
and	O
patients'	B-MED
healthcare	B-MED
utilisation	B-MED
,	O
with	O
confidence	B-MED
intervals	I-MED
reasonably	O
tight	O
around	O
zero	O
.	O
	
household	B-MED
perceptions	B-MED
of	O
quality	B-MED
are	O
an	O
important	B-MED
determinant	B-MED
of	O
care-seeking	B-MED
behaviour	I-MED
,	O
yet	O
patients	B-MED
appear	B-MED
unable	B-MED
to	O
recognise	B-MED
more	O
competent	B-MED
doctors	B-MED
-	O
there	O
is	O
no	O
relationship	B-MED
between	O
doctor	B-MED
competence	B-MED
and	O
perceptions	B-MED
of	O
quality	B-MED
.	O
	
unintentional	B-MED
insecticide	B-MED
poisoning	I-MED
by	O
age	B-MED
an	O
analysis	B-MED
of	O
queensland	O
poisons	O
information	O
centre	O
calls	B-MED
data	B-MED
from	O
the	O
queensland	O
poisons	O
information	O
centre	O
qpic	O
was	O
assessed	B-MED
to	O
determine	B-MED
mechanisms	B-MED
of	O
acute	O
insecticide	B-MED
poisoning	I-MED
in	O
young	B-MED
children	I-MED
<5	B-MED
years	I-MED
and	O
whether	O
age	B-MED
affects	B-MED
insecticide-poisoning	B-MED
patterns	B-MED
.	O
	
records	B-MED
of	O
all	O
insecticide-related	B-MED
calls	I-MED
placed	O
to	O
qpic	O
in	O
2014	O
were	O
obtained	B-MED
.	O
	
a	O
stratified	B-MED
analysis	B-MED
of	O
call	B-MED
patterns	B-MED
by	O
age	B-MED
was	O
conducted	B-MED
.	O
	
of	O
743	O
insecticide-related	B-MED
calls	I-MED
received	B-MED
by	I-MED
qpic	O
364	O
49.0	O
were	O
for	O
young	B-MED
children	I-MED
.	O
	
the	O
number	O
of	O
calls	B-MED
peaked	B-MED
in	O
children	B-MED
aged	B-MED
one	I-MED
.	O
	
ant	B-MED
and	O
cockroach	B-MED
baits	B-MED
accounted	B-MED
for	O
39.0	O
of	O
calls	B-MED
.	O
	
sprays	B-MED
,	O
which	O
were	O
found	B-MED
to	O
contain	O
not	O
only	O
pyrethroids	B-MED
,	O
pyrethrins	B-MED
and/or	O
piperonly	B-MED
butoxide	I-MED
but	O
also	O
the	O
organophosphate	B-MED
diazinon	I-MED
,	O
accounted	B-MED
for	O
25.8	O
of	O
calls	B-MED
.	O
	
mouthing	B-MED
or	O
ingesting	B-MED
a	O
pest-control	B-MED
product	I-MED
and	O
consuming	B-MED
an	O
item/insect	O
after	O
treatment	B-MED
were	O
common	O
mechanisms	B-MED
for	O
children	B-MED
under	O
the	O
age	B-MED
of	I-MED
two	I-MED
.	O
	
topical	B-MED
exposure	B-MED
to	I-MED
sprays	B-MED
,	O
via	O
direct	B-MED
application	B-MED
,	O
typically	O
by	O
the	O
child	B-MED
or	O
an	O
older	B-MED
sibling	I-MED
,	O
peaked	B-MED
in	O
children	B-MED
aged	B-MED
two	I-MED
.	O
	
in	O
12.3	O
of	O
calls	B-MED
medical	B-MED
attention	I-MED
for	O
the	O
child	B-MED
was	O
already	O
sought	B-MED
or	O
advised	B-MED
by	I-MED
qpic	O
.	O
	
normal	B-MED
behaviours	I-MED
associated	B-MED
with	I-MED
child	B-MED
development	I-MED
,	O
particularly	O
mouthing	B-MED
behaviours	B-MED
,	O
explained	O
the	O
peak	B-MED
of	I-MED
exposure	I-MED
in	O
one-year	B-MED
-	O
olds	B-MED
.	O
	
this	O
finding	B-MED
should	O
guide	O
strategies	B-MED
to	O
minimise	B-MED
poisonings	B-MED
in	O
this	O
vulnerable	B-MED
population	I-MED
.	O
	
investigating	O
synthetic	B-MED
oligonucleotide	B-MED
targeting	O
of	O
mir31	B-MED
in	O
duchenne	B-MED
muscular	I-MED
dystrophy	I-MED
exon-skipping	B-MED
via	O
synthetic	B-MED
antisense	B-MED
oligonucleotides	I-MED
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-MED
for	O
duchenne	B-MED
muscular	I-MED
dystrophy	I-MED
dmd	B-MED
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence-specific	B-MED
and	O
thus	O
each	O
oligonucleotide	B-MED
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	B-MED
.	O
	
the	O
discovery	B-MED
that	O
dystrophin	B-MED
mrna	B-MED
is	O
subject	O
to	O
translational	B-MED
suppression	I-MED
by	O
the	O
microrna	B-MED
mir31	B-MED
,	O
and	O
that	O
mir31	B-MED
is	O
elevated	O
in	O
the	O
muscle	B-MED
of	O
dmd	B-MED
patients	B-MED
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	B-MED
chemistries	O
employed	O
for	O
exon	B-MED
skipping	I-MED
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	B-MED
block	I-MED
.	O
	
this	O
approach	O
would	O
act	O
synergistically	B-MED
with	O
exon	B-MED
skipping	I-MED
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'utr	B-MED
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
dmd	B-MED
patients	B-MED
who	O
express	O
low	O
levels	O
of	O
in-frame	B-MED
transcript	B-MED
.	O
	
we	O
here	O
present	O
investigations	B-MED
into	O
the	O
feasibility	O
of	O
combining	O
exon	B-MED
skipping	I-MED
with	O
several	O
different	O
strategies	O
for	O
mir31	B-MED
-	O
modulation	B-MED
,	O
using	O
both	O
in	B-MED
vitro	I-MED
models	B-MED
and	O
the	O
mdx	B-MED
mouse	I-MED
the	O
classical	O
animal	B-MED
model	I-MED
of	O
dmd	B-MED
,	O
and	O
monitoring	B-MED
effects	B-MED
on	O
dystrophin	B-MED
at	O
the	O
transcriptional	B-MED
and	O
translational	B-MED
level	O
.	O
	
we	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-MED
culture	I-MED
model	B-MED
,	O
our	O
in	B-MED
vivo	I-MED
data	B-MED
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	B-MED
of	O
dystrophin	B-MED
translation	B-MED
,	O
suggesting	O
that	O
mir31	B-MED
-	O
modulation	B-MED
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	B-MED
approaches	O
.	O
	
possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	B-MED
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
in	O
the	O
kenya	B-MED
aids	I-MED
indicator	I-MED
survey	I-MED
2012	I-MED
relevance	B-MED
to	O
targets	B-MED
for	O
hiv	B-MED
diagnosis	I-MED
and	O
treatment	B-MED
in	O
kenya	B-MED
to	O
assess	B-MED
the	O
impact	B-MED
of	O
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
antiretroviral	B-MED
arv	I-MED
therapy	I-MED
art	B-MED
on	O
national	B-MED
estimates	B-MED
of	O
diagnosed	B-MED
hiv	I-MED
and	O
art	B-MED
coverage	B-MED
in	O
kenya	B-MED
.	O
	
hiv-positive	B-MED
dried	B-MED
blood	I-MED
spot	I-MED
samples	I-MED
from	O
kenya's	B-MED
second	I-MED
aids	I-MED
indicator	I-MED
survey	I-MED
were	O
tested	B-MED
for	O
an	O
arv	B-MED
biomarker	B-MED
by	O
liquid	B-MED
chromatography-tandem	I-MED
mass	I-MED
spectrometry	I-MED
.	O
	
estimates	B-MED
of	O
diagnosed	B-MED
hiv	I-MED
and	O
art	B-MED
use	B-MED
based	O
on	O
self-report	B-MED
were	O
compared	B-MED
with	O
those	O
corrected	O
for	O
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
based	O
on	O
arv	B-MED
testing	O
.	O
	
multivariate	B-MED
analysis	I-MED
determined	B-MED
factors	B-MED
associated	B-MED
with	I-MED
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
among	O
persons	B-MED
on	O
art	B-MED
.	O
	
among	O
559	O
hiv-positive	B-MED
samples	B-MED
,	O
the	O
arv	B-MED
biomarker	B-MED
was	O
detected	B-MED
in	O
42.5	O
ci	O
37.4	O
.	O
	
arv	B-MED
drugs	I-MED
were	O
present	O
in	O
90.7	O
ci	O
86.1	O
reporting	B-MED
hiv-positive	I-MED
status	O
and	O
receiving	B-MED
art	B-MED
,	O
66.7	O
ci	O
59.9	O
reporting	B-MED
hiv-positive	I-MED
status	O
irrespective	O
of	O
art	B-MED
use	B-MED
,	O
21.0	O
ci	O
13.4	O
reporting	B-MED
hiv-negative	B-MED
status	I-MED
,	O
and	O
19.3	O
ci	O
9.0	O
reporting	B-MED
no	B-MED
previous	B-MED
hiv	B-MED
test	I-MED
.	O
	
after	O
correcting	O
for	O
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
,	O
diagnosed	B-MED
hiv	I-MED
increased	B-MED
from	O
46.9	O
to	O
57.2	O
and	O
art	B-MED
coverage	B-MED
increased	B-MED
from	O
31.8	O
to	O
42.8	O
.	O
	
undisclosed	B-MED
hiv	B-MED
infection	I-MED
on	O
art	B-MED
was	O
associated	B-MED
with	I-MED
being	O
aged	B-MED
25-39	O
years	O
and	O
not	O
visiting	O
a	O
health	B-MED
provider	I-MED
in	O
the	O
past	O
year	O
,	O
while	O
younger	B-MED
age	I-MED
and	O
higher	B-MED
wealth	I-MED
was	O
associated	B-MED
with	I-MED
undisclosed	B-MED
art	B-MED
use	B-MED
.	O
	
substantial	B-MED
levels	B-MED
of	O
undisclosed	B-MED
hiv	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
while	O
on	O
art	B-MED
were	O
observed	B-MED
,	O
resulting	B-MED
in	I-MED
diagnosed	B-MED
hiv	I-MED
underestimated	O
by	O
112	O
persons	B-MED
and	O
art	B-MED
coverage	B-MED
by	O
131	O
persons	B-MED
.	O
	
supplementing	O
self-reported	B-MED
art	B-MED
status	B-MED
with	O
objective	B-MED
measures	I-MED
of	O
art	B-MED
use	B-MED
in	O
national	B-MED
population	B-MED
-based	O
sero-surveys	B-MED
can	O
improve	B-MED
monitoring	B-MED
of	O
treatment	B-MED
targets	B-MED
in	O
differential	O
control	B-MED
and	O
function	B-MED
of	O
arabidopsis	B-MED
prodh1	B-MED
and	O
prodh2	B-MED
genes	I-MED
on	O
infection	B-MED
with	O
biotrophic	B-MED
and	O
necrotrophic	B-MED
pathogens	B-MED
arabidopsis	B-MED
contains	O
two	O
proline	B-MED
dehydrogenase	I-MED
prodh	I-MED
genes	I-MED
,	O
prodh1	B-MED
and	O
prodh2	B-MED
,	O
encoding	B-MED
for	O
homologous	B-MED
and	O
functional	B-MED
isoenzymes	B-MED
.	O
	
although	O
prodh1	B-MED
has	O
been	O
studied	O
extensively	O
,	O
especially	O
under	O
abiotic	B-MED
stress	I-MED
,	O
prodh2	B-MED
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	B-MED
.	O
	
these	O
genes	B-MED
display	O
distinctive	O
expression	B-MED
patterns	B-MED
and	O
show	O
weak	B-MED
transcriptional	B-MED
co-regulation	I-MED
,	O
but	O
are	O
both	O
activated	B-MED
in	O
pathogen	B-MED
-	O
infected	B-MED
tissues	B-MED
.	O
	
we	O
have	O
demonstrated	O
previously	O
that	O
arabidopsis	B-MED
plants	I-MED
with	O
silenced	B-MED
prodh1	B-MED
/	O
2	B-MED
expression	B-MED
fail	B-MED
to	O
trigger	O
defences	B-MED
against	O
the	O
hemibiotrophic	B-MED
bacterial	B-MED
pathogen	B-MED
pseudomonas	B-MED
syringae	I-MED
pv	I-MED
.	O
	
tomato	I-MED
avrrpm1	I-MED
pst-avrrpm1	B-MED
,	O
and	O
that	O
prodh1	B-MED
and	O
prodh2	B-MED
are	O
differentially	O
regulated	B-MED
by	O
salicylic	B-MED
acid	I-MED
sa	B-MED
.	O
	
in	O
the	O
current	O
work	O
,	O
we	O
used	O
prodh1	B-MED
and	O
prodh2	B-MED
single-	O
mutant	B-MED
plants	B-MED
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	B-MED
to	O
resistance	B-MED
against	O
pst-avrrpm1	B-MED
and	O
the	O
necrotrophic	B-MED
fungal	B-MED
pathogen	I-MED
botrytis	B-MED
cinerea	I-MED
.	O
	
in	O
addition	O
,	O
we	O
studied	O
the	O
sensitivity	B-MED
of	O
prodh1	B-MED
and	O
prodh2	B-MED
to	O
the	O
jasmonic	B-MED
acid	I-MED
ja	B-MED
defence	B-MED
pathway	B-MED
.	O
	
we	O
found	O
that	O
prodh1	B-MED
and	O
prodh2	B-MED
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	B-MED
against	O
pst-avrrpm1	B-MED
and	O
b	B-MED
.	O
	
cinerea	I-MED
.	O
	
however	O
,	O
prodh2	B-MED
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	B-MED
of	O
b	B-MED
.	O
	
cinerea	I-MED
growth	B-MED
.	O
	
interestingly	O
,	O
prodh1	B-MED
is	O
up-regulated	B-MED
by	O
sa	B-MED
and	O
ja	B-MED
,	O
whereas	O
prodh2	B-MED
is	O
only	O
activated	B-MED
by	O
ja	B-MED
,	O
and	O
both	O
genes	B-MED
display	O
transcriptional	B-MED
inter-regulation	I-MED
at	O
basal	B-MED
and	O
infection	B-MED
conditions	B-MED
.	O
	
these	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
prodh2	B-MED
to	O
disease	B-MED
resistance	I-MED
,	O
and	O
describe	O
the	O
differential	O
regulation	B-MED
and	O
non-redundant	O
but	O
complementary	B-MED
function	I-MED
of	O
both	O
enzyme	B-MED
isoforms	I-MED
in	O
infected	B-MED
tissues	B-MED
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
prodh	B-MED
in	O
the	O
control	O
of	O
biotrophic	B-MED
and	O
necrotrophic	B-MED
pathogens	B-MED
.	O
	
effect	B-MED
of	O
protein	B-MED
repetitiveness	B-MED
on	O
protein-protein	B-MED
interaction	I-MED
prediction	B-MED
results	B-MED
using	O
support	B-MED
vector	I-MED
machines	I-MED
there	O
are	O
many	O
computational	B-MED
approaches	I-MED
to	O
predict	O
the	O
protein-protein	B-MED
interactions	I-MED
using	O
support	B-MED
vector	I-MED
machines	I-MED
svms	B-MED
with	O
high	O
performance	O
.	O
	
in	O
fact	O
,	O
performance	O
of	O
currently	O
reported	O
methods	B-MED
are	O
significantly	O
over-estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	B-MED
in	O
the	O
datasets	B-MED
used	O
.	O
	
to	O
study	B-MED
the	O
effect	O
of	O
object	O
repetitiveness	B-MED
of	O
datasets	B-MED
on	O
predicting	B-MED
results	B-MED
.	O
	
we	O
present	O
novel	O
methods	B-MED
to	O
construct	O
different	O
positive	B-MED
datasets	B-MED
with	O
or	O
without	O
repeating	O
proteins	B-MED
using	O
graph	B-MED
maximum	O
matching	O
in	O
the	O
protein-protein	B-MED
interaction	I-MED
datasets	B-MED
and	O
corresponding	O
series	O
of	O
negative	B-MED
datasets	B-MED
with	O
different	O
proteins	B-MED
repetitiveness	B-MED
are	O
constructed	O
using	O
graph	B-MED
adjacency	B-MED
matrix	I-MED
.	O
	
the	O
relationship	B-MED
between	O
the	O
svm	B-MED
prediction	B-MED
results	B-MED
and	O
the	O
repeated	B-MED
proteins	B-MED
repeat	O
numbers	O
and	O
repeat	O
rates	O
and	O
the	O
distributions	B-MED
of	O
repeated	B-MED
proteins	B-MED
in	O
the	O
datasets	B-MED
are	O
analyzed	O
.	O
	
protein	B-MED
repetitiveness	B-MED
of	O
positive	B-MED
and	O
negative	B-MED
datasets	B-MED
can	O
affect	O
the	O
prediction	B-MED
result	B-MED
high	O
protein	B-MED
repetitiveness	B-MED
of	O
positive	B-MED
or	O
negative	B-MED
datasets	B-MED
yield	O
high	O
performance	O
prediction	O
result	B-MED
.	O
	
this	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	B-MED
of	O
datasets	B-MED
is	O
a	O
key	O
issue	O
in	O
protein-protein	B-MED
interactions	I-MED
prediction	B-MED
using	O
svms	B-MED
since	O
real	O
world	O
data	B-MED
contain	O
certain	O
degrees	O
of	O
repeat	B-MED
proteins	B-MED
.	O
	
from	O
'	O
sense	B-MED
of	I-MED
number	I-MED
'	O
to	O
'	O
sense	B-MED
of	I-MED
magnitude	B-MED
'	O
-	O
the	O
role	O
of	O
continuous	B-MED
magnitudes	B-MED
in	O
numerical	B-MED
cognition	B-MED
in	O
this	O
review	O
,	O
we	O
are	O
pitting	B-MED
two	O
theories	B-MED
against	O
each	O
other	O
the	O
more	O
accepted	O
theory	B-MED
-the	O
'	O
number	B-MED
sense	I-MED
'	O
theory	B-MED
-suggesting	O
that	O
a	O
sense	B-MED
of	I-MED
number	I-MED
is	O
innate	B-MED
and	O
non-symbolic	B-MED
numerosity	I-MED
is	O
being	O
processed	O
independently	O
of	O
continuous	B-MED
magnitudes	B-MED
e.g	O
,	O
size	B-MED
,	O
area	B-MED
,	O
density	B-MED
and	O
the	O
newly	O
emerging	O
theory	B-MED
suggesting	O
that	O
1	O
both	O
numerosities	B-MED
and	O
continuous	B-MED
magnitudes	B-MED
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	B-MED
,	O
and	O
2	O
a	O
sense	B-MED
of	I-MED
number	I-MED
might	O
not	O
be	O
innate	B-MED
.	O
	
in	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	B-MED
sense	I-MED
'	O
theory	B-MED
.	O
	
against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	B-MED
between	O
numerosities	B-MED
and	O
continuous	B-MED
magnitudes	B-MED
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non-symbolic	B-MED
numerosity	I-MED
processing	I-MED
in	O
isolation	O
from	O
continuous	B-MED
magnitudes	B-MED
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	B-MED
and	O
imaging	B-MED
studies	I-MED
with	O
infants	B-MED
,	O
adults	B-MED
and	O
animals	B-MED
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	B-MED
magnitudes	B-MED
.	O
	
in	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	B-MED
of	I-MED
magnitude	B-MED
'	O
theory	B-MED
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	O
magnitudes	O
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	O
.	O
	
finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O
	
our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	O
sense	O
theory	B-MED
anymore	O
.	O
	
therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	O
sense	O
is	O
simply	O
innate	O
,	O
but	O
to	O
put	O
this	O
hypothesis	O
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	O
of	O
numerosity	O
and	O
continuous	B-MED
magnitudes	B-MED
.	O
	
how	O
integrated	B-MED
management	I-MED
strategies	I-MED
promote	B-MED
protein	B-MED
quality	B-MED
of	O
cotton	B-MED
embryos	I-MED
high	B-MED
levels	B-MED
of	O
soil	B-MED
available	B-MED
n	B-MED
,	O
n	B-MED
assimilation	B-MED
and	O
protein	B-MED
accumulation	B-MED
rate	B-MED
cottonseed	B-MED
is	O
widely	O
used	O
as	O
a	O
source	B-MED
of	O
ruminant	B-MED
feed	B-MED
and	O
for	O
industrial	B-MED
purposes	B-MED
.	O
	
therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-MED
the	O
nutritional	B-MED
value	I-MED
of	O
cotton	B-MED
embryos	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
a	O
conventional	B-MED
management	I-MED
cm	B-MED
and	O
two	O
integrated	O
cotton	B-MED
management	B-MED
strategies	I-MED
ims1	B-MED
,	O
ims2	B-MED
were	O
performed	B-MED
at	O
two	O
soil	B-MED
fertility	B-MED
levels	B-MED
to	O
study	B-MED
the	O
relationships	B-MED
among	O
soil	B-MED
n	B-MED
,	O
n	B-MED
assimilation	B-MED
,	O
embryonic	B-MED
protein	B-MED
accumulation	B-MED
and	O
protein	B-MED
quality	B-MED
.	O
	
the	O
levels	B-MED
of	I-MED
proteins	I-MED
,	O
essential	B-MED
amino	I-MED
acids	I-MED
,	O
and	O
semi-essential	B-MED
amino	I-MED
acids	I-MED
,	O
especially	O
those	O
of	O
glutamate	B-MED
,	O
lysine	B-MED
,	O
and	O
methionine	B-MED
,	O
were	O
higher	B-MED
in	O
ims1	B-MED
and	O
ims2	B-MED
embryos	B-MED
than	O
in	O
cm	B-MED
embryos	B-MED
.	O
	
these	O
changes	B-MED
were	O
significantly	O
positively	B-MED
correlated	B-MED
with	O
the	O
soil	B-MED
-	O
available	B-MED
n	B-MED
content	I-MED
,	O
glutamine	B-MED
synthetase	I-MED
activity	I-MED
and	O
peak	B-MED
value	O
of	O
protein	B-MED
accumulation	B-MED
rate	B-MED
and	O
were	O
negatively	B-MED
correlated	B-MED
with	O
the	O
free	B-MED
amino	B-MED
acid	I-MED
level	I-MED
.	O
	
these	O
results	B-MED
illustrated	O
that	O
integrated	B-MED
management	I-MED
strategies	I-MED
,	O
especially	O
the	O
rates	B-MED
and	O
timing	B-MED
of	O
n	B-MED
application	B-MED
,	O
raise	B-MED
the	O
level	B-MED
of	O
soil	B-MED
available	B-MED
n	B-MED
,	O
which	O
is	O
beneficial	O
for	O
n	B-MED
assimilation	B-MED
in	O
developing	O
cotton	B-MED
embryos	I-MED
.	O
	
the	O
protein	B-MED
content	I-MED
was	O
limited	B-MED
by	O
the	O
rate	B-MED
of	O
protein	B-MED
accumulation	B-MED
rather	O
than	O
by	O
the	O
free	B-MED
amino	B-MED
acid	I-MED
content	I-MED
.	O
	
the	O
combination	B-MED
of	O
target	B-MED
yield	I-MED
fertilization	B-MED
,	O
a	O
growth	B-MED
-driven	O
n	B-MED
application	B-MED
schedule	O
,	O
a	O
high	B-MED
plant	B-MED
density	B-MED
and	O
the	O
seedling	B-MED
raising	O
with	O
bio-organic	B-MED
fertilizer	I-MED
can	O
substantially	O
improve	B-MED
protein	B-MED
quality	B-MED
in	O
cotton	B-MED
embryos	I-MED
,	O
especially	O
at	O
a	O
soil	B-MED
with	O
low	O
soil	B-MED
organic	B-MED
matter	I-MED
and	O
total	B-MED
nitrogen	B-MED
.	O
	
help	O
end	O
the	O
hiv	B-MED
epidemic	B-MED
after	O
many	O
delays	O
,	O
the	O
public	B-MED
consultation	I-MED
on	O
hiv	B-MED
prevention	I-MED
tool	B-MED
prep	B-MED
pre-exposure	B-MED
prophylaxis	I-MED
is	O
finally	O
here	O
.	O
	
now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
hiv	B-MED
epidemic	B-MED
by	O
responding	O
to	O
this	O
nhs	B-MED
england	I-MED
consultation	I-MED
before	O
23	O
osseointegration	B-MED
behavior	O
of	O
novel	B-MED
ti-nb-zr-ta-si	B-MED
alloy	I-MED
for	O
dental	B-MED
implants	I-MED
an	O
in	B-MED
vivo	I-MED
study	B-MED
this	O
study	O
aimed	O
to	O
evaluate	B-MED
the	O
effects	B-MED
of	I-MED
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
on	O
mineral	B-MED
apposition	I-MED
rate	I-MED
and	O
new	O
bic	B-MED
contact	I-MED
in	O
rabbits	B-MED
.	O
	
twelve	O
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
were	O
fabricated	B-MED
and	O
placed	B-MED
into	O
the	O
right	B-MED
femur	B-MED
sites	B-MED
in	O
six	O
rabbits	B-MED
,	O
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
were	O
used	O
as	O
controls	B-MED
in	O
the	O
left	B-MED
femur	B-MED
.	O
	
tetracycline	B-MED
and	O
alizarin	B-MED
red	I-MED
were	O
administered	O
3	O
weeks	B-MED
and	O
1	O
week	B-MED
before	O
euthanization	B-MED
,	O
respectively	O
.	O
	
at	O
4	O
weeks	B-MED
and	O
8	O
weeks	B-MED
after	O
implantation	B-MED
,	O
animals	B-MED
were	O
euthanized	B-MED
,	O
respectively	O
.	O
	
surface	B-MED
characterization	B-MED
and	O
implant-bone	B-MED
contact	I-MED
surface	B-MED
analysis	B-MED
were	O
performed	B-MED
by	O
using	O
a	O
scanning	B-MED
electron	I-MED
microscope	I-MED
and	O
an	O
energy	B-MED
dispersive	I-MED
x-ray	I-MED
detector	I-MED
.	O
	
mineral	B-MED
apposition	I-MED
rate	I-MED
was	O
evaluated	B-MED
using	O
a	O
confocal	B-MED
laser	I-MED
scanning	I-MED
microscope	I-MED
.	O
	
toluidine	B-MED
blue	I-MED
staining	I-MED
was	O
performed	B-MED
on	O
undecalcified	B-MED
sections	B-MED
for	O
histology	B-MED
and	O
histomorphology	B-MED
evaluation	O
.	O
	
scanning	B-MED
electron	I-MED
microscope	I-MED
and	O
histomorphology	B-MED
observation	B-MED
revealed	B-MED
a	O
direct	B-MED
contact	I-MED
between	O
implants	B-MED
and	O
bone	B-MED
of	O
all	O
groups	B-MED
.	O
	
after	O
a	O
healing	B-MED
period	B-MED
of	O
4	O
weeks	B-MED
,	O
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
showed	O
significantly	O
higher	O
mineral	B-MED
apposition	I-MED
rate	I-MED
compared	O
to	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
p	O
<	O
0.05	O
,	O
whereas	O
there	O
was	O
no	B-MED
significant	I-MED
difference	O
between	O
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
p	O
>	O
0.05	O
at	O
8	O
weeks	B-MED
.	O
	
no	B-MED
significant	I-MED
difference	O
of	O
bone-to-implant	B-MED
contact	I-MED
was	O
observed	B-MED
between	O
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
implants	B-MED
after	O
a	O
healing	B-MED
period	B-MED
of	O
4	O
weeks	B-MED
and	O
8	O
weeks	B-MED
.	O
	
this	O
study	O
showed	O
that	O
ti-nb-zr-ta-si	B-MED
alloy	I-MED
implants	B-MED
could	O
establish	O
a	O
close	B-MED
direct	I-MED
contact	I-MED
comparedto	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
implants	B-MED
,	O
improved	B-MED
mineral	B-MED
matrix	I-MED
apposition	I-MED
rate	I-MED
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	B-MED
as	O
a	O
material	B-MED
for	O
dental	B-MED
implants	I-MED
.	O
	
simultaneous	B-MED
edited	B-MED
mrs	B-MED
of	O
gaba	B-MED
and	O
glutathione	B-MED
edited	B-MED
mrs	B-MED
allows	O
the	O
detection	B-MED
of	O
low	B-MED
-	O
concentration	B-MED
metabolites	B-MED
,	O
whose	O
signals	B-MED
are	O
not	B-MED
resolved	B-MED
in	O
the	O
mr	B-MED
spectrum	I-MED
.	O
	
tailored	B-MED
acquisitions	I-MED
can	O
be	O
designed	B-MED
to	O
detect	B-MED
,	O
for	O
example	B-MED
,	O
the	O
inhibitory	B-MED
neurotransmitter	B-MED
γ-aminobutyric	B-MED
acid	I-MED
gaba	B-MED
,	O
or	O
the	O
reduction-oxidation	B-MED
redox	B-MED
compound	O
glutathione	B-MED
gsh	B-MED
,	O
and	O
single	B-MED
-	O
voxel	B-MED
edited	B-MED
experiments	B-MED
are	O
generally	O
acquired	O
at	O
a	O
rate	B-MED
of	O
one	B-MED
metabolite	B-MED
-	O
per-experiment	B-MED
.	O
	
we	O
demonstrate	O
that	O
simultaneous	B-MED
detection	B-MED
of	O
the	O
overlapping	B-MED
signals	B-MED
of	O
gaba	B-MED
and	O
gsh	B-MED
is	O
possible	O
using	B-MED
hadamard	B-MED
encoding	I-MED
and	I-MED
reconstruction	I-MED
of	I-MED
mega-edited	I-MED
spectroscopy	I-MED
hermes	B-MED
.	O
	
hermes	B-MED
applies	B-MED
orthogonal	B-MED
editing	I-MED
encoding	I-MED
following	B-MED
a	O
hadamard	B-MED
scheme	I-MED
,	O
such	O
that	O
gsh-	B-MED
and	O
gaba	B-MED
-	O
edited	B-MED
difference	B-MED
spectra	B-MED
can	O
be	O
reconstructed	O
from	O
a	O
single	B-MED
multiplexed	I-MED
experiment	I-MED
.	O
	
at	O
a	O
te	B-MED
of	O
80ms	O
,	O
20-ms	O
editing	B-MED
pulses	B-MED
are	O
applied	B-MED
at	O
4.56ppm	O
on	O
gsh	B-MED
on	O
gaba	B-MED
,	O
both	B-MED
offsets	B-MED
using	O
a	O
dual-lobe	B-MED
cosine-modulated	I-MED
pulse	I-MED
or	O
neither	O
.	O
	
hadamard	B-MED
combinations	I-MED
of	O
the	O
four	O
sub-experiments	B-MED
yield	O
gaba	B-MED
and	O
gsh	B-MED
difference	B-MED
spectra	B-MED
.	O
	
it	O
is	O
shown	O
that	O
hermes	B-MED
gives	O
excellent	B-MED
separation	B-MED
of	O
the	O
edited	B-MED
gaba	B-MED
and	O
gsh	B-MED
signals	B-MED
in	O
phantoms	B-MED
,	O
and	O
resulting	O
edited	B-MED
lineshapes	B-MED
agree	B-MED
well	B-MED
with	O
separate	B-MED
mescher-garwood	B-MED
point-resolved	I-MED
spectroscopy	I-MED
mega-press	B-MED
acquisitions	B-MED
.	O
	
in	B-MED
vivo	I-MED
,	O
the	O
quality	B-MED
and	O
signal-to-noise	B-MED
ratio	I-MED
snr	B-MED
of	O
hermes	B-MED
spectra	B-MED
are	O
similar	B-MED
to	O
those	O
of	O
sequentially	B-MED
acquired	B-MED
mega-press	B-MED
spectra	B-MED
,	O
with	O
the	O
benefit	B-MED
of	O
saving	O
half	O
the	O
acquisition	B-MED
time	B-MED
.	O
	
chitosan	B-MED
-functionalised	O
poly	B-MED
methacrylate	I-MED
core-shell	B-MED
microgels	I-MED
as	O
drug	B-MED
delivery	I-MED
carriers	I-MED
salicylic	B-MED
acid	I-MED
loading	B-MED
and	I-MED
release	I-MED
this	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-MED
-functionalised	O
poly	B-MED
methacrylate	I-MED
cs	B-MED
/	O
phema	B-MED
core-shell	B-MED
microgels	I-MED
as	O
drug	B-MED
delivery	I-MED
carriers	I-MED
.	O
	
cs	B-MED
/	O
phema	B-MED
microgels	B-MED
were	O
prepared	O
by	O
emulsifier-free	B-MED
emulsion	I-MED
polymerisation	I-MED
with	O
n	B-MED
'-methylenebisacrylamide	I-MED
mba	B-MED
as	O
a	O
crosslinker	B-MED
.	O
	
the	O
study	B-MED
on	I-MED
drug	I-MED
loading	I-MED
,	O
using	O
salicylic	B-MED
acid	I-MED
sa	B-MED
as	O
a	O
model	B-MED
drug	I-MED
,	O
was	O
performed	O
.	O
	
the	O
results	O
showed	O
that	O
the	O
encapsulation	B-MED
efficiency	I-MED
ee	B-MED
increased	O
as	O
drug	B-MED
-to-	O
microgel	O
ratio	B-MED
was	O
increased	O
.	O
	
higher	O
ee	B-MED
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	B-MED
,	O
by	O
increasing	O
the	O
amount	O
of	O
mba	B-MED
from	O
0.01	O
g	O
to	O
0.03	O
g	O
.	O
	
in	O
addition	O
,	O
the	O
highest	O
ee	B-MED
61.1	O
was	O
observed	O
at	O
ph	B-MED
3	O
.	O
	
the	O
highest	O
release	B-MED
of	I-MED
sa	I-MED
60%	O
was	O
noticed	O
at	O
ph	B-MED
2.4	O
,	O
while	O
the	O
lowest	O
one	O
49.4	O
was	O
obtained	O
at	O
ph	B-MED
7.4	O
.	O
	
moreover	O
,	O
the	O
highest	O
release	B-MED
of	I-MED
sa	I-MED
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0.2	O
m	O
nacl	B-MED
.	O
	
the	O
ph	B-MED
-	O
and	O
ionic-sensitivity	B-MED
of	O
cs	B-MED
/	O
phema	B-MED
could	O
be	O
useful	O
as	O
a	O
sustained	B-MED
release	I-MED
delivery	I-MED
device	I-MED
,	O
especially	O
for	O
oral	B-MED
delivery	I-MED
.	O
	
breast	B-MED
augmentation	I-MED
after	O
conservation	B-MED
surgery	I-MED
and	O
radiation	B-MED
therapy	I-MED
there	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	B-MED
undergoing	O
breast	B-MED
augmentation	I-MED
with	O
implants	B-MED
after	O
breast	B-MED
conservation	I-MED
surgery	I-MED
bcs	B-MED
and	O
radiotherapy	B-MED
.	O
	
this	O
retrospective	B-MED
study	I-MED
examined	O
outcomes	O
for	O
patients	B-MED
with	O
breast	B-MED
implant	I-MED
-only	O
augmentation	B-MED
after	O
bcs	B-MED
and	O
radiotherapy	B-MED
.	O
	
between	O
june	O
1998	O
and	O
december	O
2010	O
,	O
671	O
women	B-MED
underwent	O
prosthetic	B-MED
breast	B-MED
reconstruction	I-MED
.	O
	
nineteen	O
patients	B-MED
2.8	O
underwent	O
an	O
augmentation	B-MED
after	O
bcs	B-MED
and	O
radiotherapy	B-MED
.	O
	
the	O
mean	B-MED
age	B-MED
was	O
55.8	O
years	B-MED
range	B-MED
,	O
40-69	O
years	B-MED
.	O
	
sixteen	O
of	O
these	O
patients	B-MED
underwent	O
one-stage	B-MED
implant	I-MED
-only	O
breast	B-MED
augmentation	I-MED
,	O
whereas	O
3	O
patients	B-MED
underwent	O
two-stage	B-MED
expander	I-MED
and	O
then	O
implant	B-MED
augmentation	I-MED
.	O
	
all	O
surgeries	B-MED
were	O
successful	O
.	O
	
the	O
average	O
size	O
of	O
breast	B-MED
implant	I-MED
used	O
was	O
258.7	O
.	O
	
seven	O
patients	B-MED
also	O
received	O
contralateral	B-MED
augmentation	B-MED
with	O
an	O
average	O
implant	O
size	O
of	O
232.2	O
.	O
	
one	O
patient	B-MED
received	O
oral	B-MED
antibiotics	B-MED
for	O
minor	O
wound	B-MED
infection	I-MED
.	O
	
patients	B-MED
were	O
judged	O
to	O
have	O
an	O
excellent	O
14/19	O
73.7	O
,	O
good	O
3/19	O
15.8	O
,	O
or	O
fair	O
2/19	O
10.5	O
cosmetic	B-MED
result	B-MED
.	O
	
the	O
breasts	B-MED
of	O
selected	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
after	O
bcs	B-MED
and	O
radiotherapy	B-MED
.	O
	
with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	B-MED
with	O
breast	B-MED
implants	I-MED
mitochondrial	B-MED
pyruvate	I-MED
dehydrogenase	I-MED
phosphatase	I-MED
1	I-MED
regulates	O
the	O
early	O
differentiation	B-MED
of	I-MED
cardiomyocytes	I-MED
from	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
mitochondria	B-MED
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	B-MED
stem	I-MED
cells	I-MED
escs	B-MED
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	B-MED
into	O
diverse	O
cell	B-MED
lineages	I-MED
,	O
including	O
cardiomyocytes	B-MED
.	O
	
however	O
,	O
mitochondrial	B-MED
regulators	I-MED
that	O
manage	O
the	O
rate	B-MED
of	I-MED
differentiation	I-MED
or	O
cell	B-MED
fate	I-MED
have	O
been	O
rarely	O
identified	O
.	O
	
this	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	B-MED
factor	I-MED
that	O
controls	O
the	O
differentiation	B-MED
of	I-MED
escs	I-MED
into	O
cardiac	B-MED
myocytes	I-MED
.	O
	
we	O
induced	O
cardiomyocyte	B-MED
differentiation	I-MED
from	O
mouse	B-MED
escs	I-MED
mescs	B-MED
and	O
performed	O
microarray	B-MED
assays	I-MED
to	O
assess	O
messenger	B-MED
rna	I-MED
mrna	B-MED
expression	B-MED
changes	O
at	O
differentiation	B-MED
day	I-MED
8	I-MED
d8	B-MED
compared	O
with	O
undifferentiated	B-MED
mescs	B-MED
d0	O
.	O
	
among	O
the	O
differentially	O
expressed	B-MED
genes	I-MED
,	O
pdp1	B-MED
expression	B-MED
was	O
significantly	O
decreased	O
27-fold	O
on	O
d8	B-MED
compared	O
to	O
d0	B-MED
,	O
which	O
was	O
accompanied	O
by	O
suppressed	B-MED
mitochondrial	B-MED
indices	B-MED
,	O
including	O
atp	B-MED
levels	O
,	O
membrane	B-MED
potential	I-MED
,	O
ros	B-MED
and	O
mitochondrial	B-MED
ca	I-MED
.	O
	
notably	O
,	O
pdp1	B-MED
overexpression	B-MED
significantly	O
enhanced	O
the	O
mitochondrial	B-MED
indices	B-MED
and	O
pyruvate	B-MED
dehydrogenase	I-MED
activity	I-MED
and	O
reduced	O
the	O
expression	B-MED
of	O
cardiac	B-MED
differentiation	I-MED
marker	B-MED
mrna	I-MED
and	O
the	O
cardiac	B-MED
differentiation	I-MED
rate	B-MED
compared	O
to	O
a	O
mock	O
control	O
.	O
	
in	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	B-MED
of	O
the	O
pdp1	B-MED
gene	I-MED
promoted	O
the	O
expression	B-MED
of	O
cardiac	B-MED
differentiation	I-MED
marker	B-MED
mrna	I-MED
and	O
the	O
cardiac	B-MED
differentiation	I-MED
rate	B-MED
.	O
	
in	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	B-MED
pdp1	I-MED
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	B-MED
differentiation	I-MED
at	O
an	O
early	O
differentiation	B-MED
stage	I-MED
in	O
thermo-reversible	B-MED
capture	I-MED
and	I-MED
release	I-MED
of	O
dna	B-MED
by	O
zwitterionic	B-MED
surfactants	I-MED
the	O
thermo-reversible	B-MED
capture	I-MED
and	I-MED
release	I-MED
of	O
dna	B-MED
were	O
studied	O
by	O
the	O
protonation	B-MED
and	O
deprotonation	B-MED
of	O
alkyldimethylamine	B-MED
oxide	I-MED
cndmao	B-MED
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
in	O
tris-hcl	B-MED
buffer	B-MED
solution	I-MED
.	O
	
dna	B-MED
/	O
c14dmao	B-MED
in	O
tris-hcl	B-MED
buffer	B-MED
solution	I-MED
with	O
ph	B-MED
=	O
7.2	O
is	O
transparent	B-MED
at	O
25	O
c	O
,	O
indicating	O
that	O
dna	B-MED
molecules	B-MED
exist	O
mainly	O
in	O
individuals	B-MED
and	O
the	O
binding	B-MED
of	O
c14dmao	B-MED
is	O
weak	B-MED
.	O
	
with	O
the	O
increase	B-MED
of	O
temperature	B-MED
,	O
the	O
ph	B-MED
of	O
the	O
buffer	B-MED
solution	I-MED
continuously	O
decreases	B-MED
,	O
which	O
leads	O
to	O
protonation	B-MED
of	O
c14dmao	B-MED
c14dmao	B-MED
+	O
h	B-MED
c14dmaoh	B-MED
and	O
an	O
obvious	O
increase	B-MED
of	I-MED
the	I-MED
turbidity	I-MED
of	O
the	O
samples	B-MED
.	O
	
this	O
indicates	O
a	O
stronger	O
binding	B-MED
of	O
the	O
protonated	B-MED
c14dmaoh	B-MED
to	O
dna	B-MED
.	O
	
further	O
investigations	O
demonstrated	O
the	O
formation	B-MED
of	O
dna	B-MED
/	O
c14dmaoh	B-MED
complexes	B-MED
,	O
in	O
which	O
the	O
stretched	O
dna	B-MED
molecules	B-MED
are	O
effectively	O
compacted	B-MED
as	O
evidenced	O
from	O
uv-vis	B-MED
absorptions	O
,	O
circular	O
dichroism	O
cd	O
measurements	O
,	O
atomic	O
force	O
microscopy	O
afm	O
observations	O
,	O
dynamic	O
light	O
scattering	O
dls	O
measurements	O
and	O
agarose	O
gel	O
electrophoresis	O
age	O
.	O
	
interestingly	O
,	O
when	O
the	O
temperature	O
is	O
turned	O
back	O
to	O
25	O
c	O
,	O
the	O
compacted	O
dna	O
molecules	O
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O
	
this	O
cycle	O
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	O
of	O
efficiency	O
.	O
	
the	O
effect	O
of	O
the	O
chain	O
length	O
of	O
cndmao	O
has	O
also	O
been	O
investigated	O
.	O
	
when	O
c14dmao	O
was	O
replaced	O
by	O
c12dmao	O
,	O
similar	O
phenomena	O
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	O
critical	O
surfactant	O
concentration	O
for	O
dna	O
compaction	O
and	O
a	O
slightly	O
lower	O
ph	O
of	O
tris-hcl	O
buffer	O
solution	O
with	O
ph	O
=	O
6.8	O
.	O
	
for	O
the	O
dna	O
/	O
c10dmao	O
system	O
,	O
however	O
,	O
no	O
dna	O
compaction	O
was	O
observed	O
even	O
in	O
tris-hcl	O
buffer	O
solution	O
with	O
a	O
much	O
lower	O
ph	O
and	O
a	O
much	O
higher	O
c10dmao	O
concentration	O
.	O
	
the	O
negative	O
charges	O
of	O
dna	O
molecules	O
can	O
easily	O
be	O
neutralized	O
by	O
positive	O
charges	O
of	O
cationic	O
cndmaoh	O
n	O
=	O
12	O
and	O
14	O
micelles	O
.	O
	
dna	O
was	O
compacted	O
and	O
then	O
insoluble	O
dna	O
/	O
cndmaoh	O
complexes	O
were	O
formed	O
.	O
	
because	O
of	O
the	O
much	O
higher	O
critical	O
micelle	O
concentration	O
cmc	O
of	O
the	O
shorter	O
chain	O
length	O
c10dmaoh	O
,	O
cationic	O
c10dmaoh	O
micelles	O
cannot	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	O
dna	O
.	O
	
the	O
strategy	O
may	O
provide	O
an	O
efficient	O
and	O
alternative	O
approach	O
for	O
stimuli-responsive	O
gene	O
therapy	O
and	O
drug	O
release	I-MED
collaborating	B-MED
for	O
systems	B-MED
change	B-MED
a	O
social	B-MED
science	I-MED
framework	I-MED
for	O
academic	B-MED
roles	I-MED
in	O
community	B-MED
partnerships	I-MED
environmental	B-MED
health	I-MED
researchers	B-MED
,	O
government	B-MED
agencies	I-MED
,	O
and	O
community	B-MED
groups	I-MED
have	O
endorsed	O
long-term	O
community	B-MED
-	O
academic	B-MED
partnerships	B-MED
as	O
an	O
effective	B-MED
strategy	I-MED
to	O
support	B-MED
science	B-MED
-based	O
improvements	B-MED
in	O
environmental	B-MED
health	I-MED
.	O
	
social	B-MED
sciences	I-MED
concepts	B-MED
,	O
approaches	B-MED
,	O
and	O
methods	B-MED
are	O
fundamental	O
to	O
these	O
translational	B-MED
partnerships	I-MED
.	O
	
however	O
,	O
appropriate	B-MED
roles	B-MED
for	O
academic	B-MED
partners	B-MED
vary	O
throughout	O
the	O
process	B-MED
of	O
changing	B-MED
systems	B-MED
policies	B-MED
,	O
practices	B-MED
,	O
programs	B-MED
,	O
etc	O
.	O
	
this	O
can	O
complicate	O
planning	B-MED
,	O
evaluating	B-MED
,	O
and	O
sustaining	B-MED
such	O
partnerships	B-MED
.	O
	
we	O
set	O
forth	O
a	O
conceptual	B-MED
framework	I-MED
for	O
academic	B-MED
partners	B-MED
'	O
roles	O
at	O
different	B-MED
stages	I-MED
of	O
systems	B-MED
change	B-MED
.	O
	
we	O
apply	O
this	O
framework	B-MED
to	O
three	O
longstanding	O
academic	B-MED
-	O
community	B-MED
partnerships	B-MED
involving	O
national	B-MED
institute	I-MED
of	I-MED
environmental	I-MED
health	I-MED
sciences	I-MED
community	B-MED
outreach	I-MED
and	I-MED
engagement	I-MED
cores	I-MED
.	O
	
we	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	B-MED
can	O
help	O
academic	B-MED
partners	B-MED
tap	O
appropriate	B-MED
expertise	B-MED
,	O
redefine	O
their	O
roles	O
,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	B-MED
efforts	O
to	O
improve	B-MED
environmental	B-MED
health	I-MED
.	O
	
a	O
novel	B-MED
mechanical	B-MED
simulator	I-MED
for	O
cannulation	B-MED
and	O
sphincterotomy	B-MED
after	O
billroth	B-MED
ii	I-MED
or	O
roux-en-y	B-MED
reconstruction	I-MED
in	O
patients	B-MED
with	O
billroth	B-MED
ii	I-MED
b	B-MED
ii	I-MED
or	O
roux-en-y	B-MED
anatomy	B-MED
,	O
endoscopic	B-MED
retrograde	I-MED
cholangiopancreatography	I-MED
ercp	B-MED
is	O
demanding	O
.	O
	
here	O
,	O
we	O
describe	O
a	O
novel	B-MED
simulator	B-MED
with	O
simulated	B-MED
fluoroscopy	B-MED
for	O
cannulation	B-MED
and	O
sphincterotomy	B-MED
training	B-MED
in	O
such	O
situations	O
.	O
	
a	O
custom-made	O
simulation	B-MED
system	I-MED
was	O
built	B-MED
based	O
upon	O
a	O
common	B-MED
chassis	B-MED
of	O
a	O
series	B-MED
of	O
previously	B-MED
described	O
ercp	B-MED
simulators	B-MED
.	O
	
the	O
papilla	B-MED
is	O
made	O
out	O
of	O
organic	B-MED
material	B-MED
and	O
can	O
be	O
cut	B-MED
by	O
high	B-MED
frequency	I-MED
current	B-MED
.	O
	
the	O
advancement	B-MED
of	O
guidewires	B-MED
and	O
other	O
instruments	B-MED
within	O
transparent	B-MED
mock	O
bile	B-MED
ducts	I-MED
can	O
be	O
viewed	O
in	O
the	O
window	B-MED
of	O
the	O
simulator	B-MED
without	O
the	O
need	O
for	O
fluoroscopy	B-MED
.	O
	
the	O
ercp	B-MED
b	B-MED
ii	I-MED
/	O
roux-en-y	B-MED
simulation	B-MED
system	I-MED
was	O
first	O
evaluated	B-MED
during	O
an	O
ercp	B-MED
course	B-MED
.	O
	
there	O
were	O
no	O
technical	B-MED
problems	I-MED
related	O
to	O
the	O
novel	B-MED
simulator	B-MED
during	O
the	O
course	B-MED
.	O
	
after	O
sphincterotomy	B-MED
,	O
the	O
organic	B-MED
papillae	B-MED
could	O
easily	O
be	O
exchanged	B-MED
within	O
a	O
few	O
seconds	B-MED
.	O
	
overall	O
,	O
the	O
novel	B-MED
b	B-MED
ii	I-MED
/	O
roux-en-y	B-MED
simulator	B-MED
achieved	O
favorable	B-MED
results	B-MED
by	O
trainees	B-MED
and	O
expert	B-MED
endoscopists	B-MED
in	O
all	O
categories	B-MED
assessed	B-MED
.	O
	
the	O
new	O
b	B-MED
ii	I-MED
/	O
roux-en-y	B-MED
mechanical	B-MED
simulator	I-MED
is	O
simple	B-MED
and	O
practicable	B-MED
.	O
	
a	O
first	O
evaluation	B-MED
during	O
an	O
ercp	B-MED
course	B-MED
showed	O
promising	O
a	O
thermophilic	B-MED
-like	O
ene-reductase	B-MED
originating	O
from	O
an	O
acidophilic	B-MED
iron	B-MED
oxidizer	I-MED
ene-reductases	B-MED
originating	O
from	O
extremophiles	B-MED
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	B-MED
due	O
to	O
higher	B-MED
-	O
stability	B-MED
properties	B-MED
.	O
	
the	O
genome	B-MED
of	O
the	O
acidophilic	B-MED
iron-oxidizing	B-MED
bacterium	I-MED
""""	O
"ferrovum"""	B-MED
sp	I-MED
.	O
	
ja12	I-MED
was	O
found	O
to	O
harbor	O
a	O
thermophilic	B-MED
-like	O
ene-reductase	B-MED
foye-1	B-MED
.	O
	
the	O
foye-1	B-MED
gene	I-MED
was	O
ligated	O
into	O
a	O
pet16bp	B-MED
expression	B-MED
vector	B-MED
system	I-MED
,	O
and	O
the	O
enzyme	B-MED
was	O
produced	O
in	O
escherichia	B-MED
coli	I-MED
bl21	B-MED
de3	I-MED
plyss	I-MED
cells	I-MED
in	O
yields	O
of	O
10	O
mg	O
l	O
.	O
	
foye-1	B-MED
showed	O
remarkable	O
activity	B-MED
and	O
rates	B-MED
on	O
n-phenylmaleimide	B-MED
and	O
n-phenyl-2-methylmaleimide	B-MED
up	O
to	O
89	O
u	O
mg	O
,	O
>97	O
%	O
conversion	B-MED
,	O
95	O
%	O
r	O
with	O
both	O
nicotinamide	B-MED
cofactors	I-MED
,	O
nadph	B-MED
and	O
nadh	B-MED
.	O
	
the	O
catalytic	B-MED
efficiency	B-MED
with	O
nadph	B-MED
was	O
27	O
times	O
higher	B-MED
compared	O
to	O
nadh	B-MED
.	O
	
at	O
the	O
temperature	B-MED
maximum	B-MED
50	O
c	O
and	O
ph	B-MED
optimum	I-MED
6.5	O
,	O
activity	B-MED
was	O
almost	O
doubled	B-MED
to	O
160	O
u	O
mg	O
.	O
	
these	O
findings	B-MED
accomplish	O
foye-1	B-MED
for	O
a	O
valuable	O
biocatalyst	B-MED
in	O
the	O
synthesis	B-MED
of	O
succinimides	B-MED
.	O
	
the	O
appearance	O
of	O
a	O
thermophilic	B-MED
-like	O
ene-reductase	B-MED
in	O
an	O
acidic	B-MED
habitat	I-MED
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	B-MED
neighborhood	B-MED
of	O
the	O
encoding	B-MED
gene	B-MED
,	O
awarding	O
foye-1	B-MED
a	O
putative	O
involvement	O
in	O
a	O
quorum-sensing	B-MED
a	O
tanshinone	B-MED
i	I-MED
derivative	B-MED
enhances	O
the	O
activities	B-MED
of	O
antibiotics	B-MED
against	O
staphylococcus	B-MED
aureus	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
infections	B-MED
caused	O
by	O
staphylococcus	B-MED
aureus	I-MED
are	O
prevalent	O
.	O
	
the	O
dramatically	O
reduced	O
discovery	B-MED
of	O
new	O
antibiotics	B-MED
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant	B-MED
bacteria	I-MED
,	O
represents	O
a	O
major	O
health	B-MED
problem	B-MED
in	O
both	O
hospital	B-MED
and	O
community	B-MED
settings	I-MED
.	O
	
using	O
antibiotic	B-MED
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-MED
is	O
an	O
attractive	O
strategy	O
.	O
	
in	O
this	O
study	B-MED
,	O
16-aldehyde	B-MED
tanshinone	I-MED
i	I-MED
alt	B-MED
was	O
synthesized	B-MED
and	O
bacteriostatic	B-MED
activity	I-MED
was	O
explored	O
.	O
	
in	O
addition	O
,	O
synergistic	B-MED
or	O
additive	B-MED
activity	B-MED
between	O
alt	B-MED
and	O
aminoglycoside	B-MED
antibiotics	I-MED
or	O
β-lactam	B-MED
antibiotics	I-MED
in	B-MED
vitro	I-MED
was	O
identified	O
.	O
	
moreover	O
,	O
alt	B-MED
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-MED
str	B-MED
and	O
ampicillin	B-MED
amp	B-MED
against	O
s	B-MED
.	O
	
aureus	I-MED
in	O
a	O
murine	B-MED
infection	I-MED
model	I-MED
.	O
	
primary	O
mechanistic	B-MED
insight	I-MED
indicated	O
that	O
alt	B-MED
could	O
damage	B-MED
the	O
bacterial	B-MED
cell	B-MED
membrane	I-MED
,	O
leading	O
to	O
accumulation	B-MED
of	O
antibiotics	B-MED
inside	O
bacterial	B-MED
cells	I-MED
.	O
	
this	O
finding	O
might	O
be	O
useful	O
for	O
treating	B-MED
infections	B-MED
caused	O
by	O
s	B-MED
.	O
	
aureus	I-MED
and	O
expand	O
the	O
scope	O
of	O
application	B-MED
of	O
investigation	O
of	O
argyrophilic	B-MED
nucleolar	B-MED
organizing	I-MED
region	I-MED
ischemia/reperfusion	B-MED
i/r	I-MED
injury	I-MED
is	O
a	O
complex	B-MED
event	I-MED
frequently	O
observed	B-MED
in	O
vascular	B-MED
surgery	I-MED
and	O
can	O
cause	O
functional	B-MED
and	O
structural	B-MED
cell	B-MED
damage	I-MED
.	O
	
nucleolar-organizing	B-MED
regions	I-MED
nors	B-MED
are	O
sites	B-MED
of	O
the	O
ribosomal	B-MED
genes	I-MED
located	O
on	O
chromosomes	B-MED
and	O
can	O
be	O
stained	B-MED
with	O
silver	B-MED
when	O
they	O
are	O
active	B-MED
.	O
	
thus	O
these	O
proteins	B-MED
are	O
named	O
as	O
argyrophilic-nor	B-MED
agnor	I-MED
proteins	I-MED
.	O
	
we	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	B-MED
of	I-MED
renal	B-MED
i/r	B-MED
injury	I-MED
on	O
the	O
nor	B-MED
protein	I-MED
synthesis	B-MED
and	O
association	O
between	O
the	O
agnor	B-MED
proteins	I-MED
amount	B-MED
and	O
histopathological	B-MED
injuring	I-MED
score	I-MED
.	O
	
nine	O
female	B-MED
wistar-albino	B-MED
rats	I-MED
with	O
weight	O
of	O
200-250g	O
were	O
included	O
into	O
the	O
study	O
.	O
	
the	O
animals	B-MED
were	O
randomly	B-MED
divided	B-MED
in	O
two	O
groups	B-MED
,	O
a	O
control	B-MED
group	I-MED
and	O
an	O
i/r	B-MED
group	B-MED
.	O
	
in	O
i/r	B-MED
group	B-MED
,	O
rats	B-MED
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	B-MED
pedicle	I-MED
occlusion	B-MED
followed	O
by	O
24	O
hours	O
of	O
reperfusion	B-MED
.	O
	
in	O
the	O
control	B-MED
group	I-MED
no	O
drug	B-MED
injections	I-MED
or	O
ischemia	B-MED
reperfusion	I-MED
were	O
performed	B-MED
in	O
animals	B-MED
.	O
	
then	O
histopathological	B-MED
injury	I-MED
score	I-MED
,	O
mean	B-MED
agnor	I-MED
number	I-MED
and	O
total	B-MED
agnor	I-MED
area	I-MED
/	O
nuclear	B-MED
area	I-MED
taa	B-MED
/	O
na	B-MED
were	O
detected	B-MED
for	O
each	O
rat	B-MED
.	O
	
the	O
differences	O
between	O
control	B-MED
and	O
i/r	B-MED
groups	B-MED
were	O
significant	B-MED
for	O
histopathological	B-MED
injury	I-MED
scores	I-MED
p	O
=	O
0.016	O
.	O
	
also	O
the	O
differences	O
between	O
control	B-MED
group	I-MED
and	O
i/r	B-MED
group	B-MED
were	O
significant	B-MED
for	O
mean	B-MED
agnor	I-MED
number	I-MED
p	O
=	O
0.000	O
and	O
taa/na	B-MED
ratio	I-MED
p	O
=	O
0.000	O
.	O
	
additionally	O
,	O
there	O
was	O
a	O
positive	B-MED
correlation	I-MED
between	O
taa/na	B-MED
ratio	I-MED
and	O
histopathological	B-MED
injury	I-MED
score	I-MED
r	O
=	O
0.728	O
p	O
=	O
0.026	O
and	O
between	O
mean	B-MED
agnor	I-MED
number	I-MED
and	O
histopathological	B-MED
injury	I-MED
score	I-MED
r	O
=	O
0.670	O
p	O
=	O
0.048	O
.	O
	
the	O
detection	B-MED
of	O
agnor	B-MED
proteins	I-MED
amount	B-MED
may	O
be	O
used	O
as	O
an	O
indicator	B-MED
to	O
obtain	O
information	B-MED
about	O
the	O
cellular	B-MED
behaviour	I-MED
self-protective	B-MED
mechanism	O
of	O
tubular	B-MED
epithelial	I-MED
cells	I-MED
against	O
i/r	B-MED
injury	I-MED
and	O
cellular	B-MED
damage	I-MED
levels	B-MED
when	O
emotion	B-MED
and	O
expression	B-MED
diverge	O
the	O
social	B-MED
costs	I-MED
of	O
parkinson's	B-MED
disease	I-MED
patients	B-MED
with	O
parkinson's	B-MED
disease	I-MED
pd	B-MED
are	O
perceived	B-MED
more	O
negatively	B-MED
than	O
their	O
healthy	B-MED
peers	B-MED
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	B-MED
contribute	B-MED
to	O
this	O
negative	B-MED
social	B-MED
perception	I-MED
.	O
	
based	O
on	O
a	O
cohort	B-MED
of	O
17	O
pd	B-MED
patients	B-MED
and	O
20	O
healthy	B-MED
controls	I-MED
,	O
we	O
assessed	B-MED
how	O
naïve	O
raters	O
judge	O
the	O
emotion	B-MED
and	O
emotional	B-MED
intensity	B-MED
displayed	B-MED
in	O
dynamic	B-MED
facial	B-MED
expressions	I-MED
as	O
adults	B-MED
with	O
and	O
without	O
pd	B-MED
watched	B-MED
emotionally	B-MED
evocative	O
films	B-MED
experiment	B-MED
1	O
,	O
and	O
how	O
age	B-MED
-matched	O
peers	B-MED
naïve	O
to	O
patients	B-MED
'	O
disease	B-MED
status	O
judge	O
their	O
social	B-MED
desirability	I-MED
along	O
various	O
dimensions	B-MED
from	O
audiovisual	B-MED
stimuli	B-MED
interview	B-MED
excerpts	I-MED
recorded	O
after	O
certain	O
films	B-MED
experiment	B-MED
2	O
.	O
	
in	O
experiment	B-MED
1	O
,	O
participants	B-MED
with	O
pd	B-MED
were	O
rated	B-MED
as	O
significantly	B-MED
more	I-MED
facially	B-MED
expressive	I-MED
than	O
healthy	B-MED
controls	I-MED
moreover	O
,	O
ratings	B-MED
demonstrated	O
that	O
pd	B-MED
patients	B-MED
were	O
routinely	O
mistaken	O
for	O
experiencing	B-MED
a	O
negative	B-MED
emotion	B-MED
,	O
whereas	O
controls	B-MED
were	O
rated	B-MED
as	O
displaying	B-MED
a	O
more	O
positive	B-MED
emotion	B-MED
than	O
they	O
reported	B-MED
feeling	B-MED
.	O
	
in	O
experiment	B-MED
2	O
,	O
results	B-MED
showed	O
that	O
age-peers	B-MED
rated	B-MED
pd	B-MED
patients	B-MED
as	O
significantly	B-MED
less	I-MED
socially	B-MED
desirable	I-MED
than	O
control	B-MED
participants	B-MED
.	O
	
specifically	O
,	O
pd	B-MED
patients	B-MED
were	O
rated	B-MED
as	O
less	O
involved	B-MED
,	O
interested	B-MED
,	O
friendly	B-MED
,	O
intelligent	O
,	O
optimistic	B-MED
,	O
attentive	O
,	O
and	O
physically	B-MED
attractive	I-MED
than	O
healthy	B-MED
controls	I-MED
.	O
	
taken	O
together	O
,	O
our	O
results	B-MED
point	O
to	O
a	O
disconnect	O
between	O
how	O
pd	B-MED
patients	B-MED
report	B-MED
feeling	B-MED
and	O
attributions	B-MED
that	O
others	O
make	O
about	O
their	O
emotions	B-MED
and	O
social	B-MED
characteristics	I-MED
,	O
underlining	O
significant	B-MED
social	B-MED
challenges	I-MED
of	O
the	O
disease	B-MED
.	O
	
in	O
particular	O
,	O
changes	B-MED
in	O
the	O
ability	B-MED
to	O
modulate	B-MED
the	O
expression	B-MED
of	O
negative	B-MED
emotions	B-MED
may	O
contribute	B-MED
to	O
the	O
negative	B-MED
social	B-MED
impressions	B-MED
that	O
many	O
pd	B-MED
patients	B-MED
establishing	O
in-	O
hospital	B-MED
geriatrics	B-MED
services	I-MED
in	O
africa	B-MED
insights	O
from	O
the	O
university	B-MED
of	I-MED
benin	I-MED
teaching	I-MED
hospital	I-MED
geriatrics	B-MED
project	B-MED
unawareness	O
of	O
the	O
peculiar	O
healthcare	B-MED
needs	B-MED
of	O
the	O
elderly	B-MED
and	O
resource	B-MED
constraints	B-MED
may	O
be	O
some	O
reasons	O
why	O
until	O
recently	O
,	O
nigerian	B-MED
hospitals	B-MED
have	O
not	O
been	O
equipped	O
with	O
the	O
human	B-MED
and	O
infrastructural	B-MED
resources	I-MED
required	O
to	O
meet	O
older	B-MED
adults	I-MED
'	O
special	O
healthcare	B-MED
needs	B-MED
.	O
	
there	O
is	O
paucity	O
of	O
specialized	O
health	B-MED
services	I-MED
for	O
the	O
elderly	B-MED
in	O
africa	B-MED
.	O
	
nigeria	B-MED
,	O
with	O
a	O
population	B-MED
of	O
over	O
170	O
million	O
,	O
did	O
not	O
have	O
any	O
healthcare	B-MED
facility	I-MED
with	O
dedicated	O
services	B-MED
for	O
the	O
elderly	B-MED
until	O
2012	O
.	O
	
the	O
university	B-MED
of	I-MED
benin	I-MED
teaching	I-MED
hospital	I-MED
ubth	B-MED
in	O
nigeria	B-MED
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	B-MED
unit	O
in	O
october	O
2013	O
.	O
	
a	O
prepared	O
environment	O
and	O
trained	B-MED
interdisciplinary	I-MED
teams	I-MED
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare	B-MED
services	I-MED
for	O
the	O
elderly	B-MED
.	O
	
the	O
ongoing	O
ubth	B-MED
geriatrics	B-MED
project	B-MED
aims	O
to	O
provide	O
specialized	O
interdisciplinary	B-MED
health	B-MED
services	I-MED
to	O
older	B-MED
adults	I-MED
and	O
to	O
provide	O
training	B-MED
and	O
continuing	O
professional	B-MED
development	I-MED
in	O
geriatrics	B-MED
for	O
healthcare	B-MED
staff	I-MED
.	O
	
in	O
developing	O
our	O
inpatient	B-MED
services	B-MED
,	O
we	O
adopted	O
the	O
acute	B-MED
care	I-MED
for	I-MED
elders	I-MED
ace	B-MED
model	B-MED
and	O
worked	O
in	O
tandem	O
with	O
the	O
"""abcs"""	O
of	O
implementing	O
ace	B-MED
units	I-MED
.	O
	
in	O
the	O
face	O
of	O
limited	O
resources	B-MED
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics	B-MED
unit	I-MED
with	O
a	O
trained	O
interdisciplinary	B-MED
team	I-MED
.	O
	
family	B-MED
participation	B-MED
is	O
central	O
in	O
our	O
practice	B-MED
.	O
	
since	O
october	O
2013	O
,	O
residents	B-MED
and	O
house	B-MED
officers	I-MED
in	O
internal	B-MED
medicine	I-MED
have	O
been	O
undertaking	O
4-	O
and	O
12-	O
weekly	B-MED
rotations	B-MED
,	O
respectively	O
.	O
	
there	O
is	O
also	O
a	O
robust	O
academic	B-MED
program	I-MED
,	O
which	O
includes	O
once-	O
weekly	B-MED
geriatric	B-MED
pharmacotherapy	B-MED
seminars	B-MED
,	O
once-	O
weekly	B-MED
interdisciplinary	O
seminars	B-MED
,	O
and	O
2-	O
weekly	B-MED
journal	B-MED
club	I-MED
meetings	I-MED
alternating	O
with	O
seminars	B-MED
on	O
geriatric	B-MED
assessment	I-MED
tools	I-MED
.	O
	
it	O
is	O
possible	O
to	O
establish	O
geriatric	B-MED
services	I-MED
and	O
achieve	O
best	O
practices	B-MED
in	O
resource-limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human	B-MED
resources	I-MED
and	O
infrastructure	B-MED
.	O
	
we	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	B-MED
in	O
other	O
parts	O
of	O
engaging	B-MED
adolescent	B-MED
girls	I-MED
in	O
transactional	B-MED
sex	I-MED
through	B-MED
compensated	B-MED
dating	B-MED
transactional	B-MED
sex	I-MED
through	B-MED
so-called	O
compensated	B-MED
dating	B-MED
in	O
adolescent	B-MED
girls	I-MED
is	O
a	O
problem	B-MED
in	O
need	B-MED
of	O
public	B-MED
concern	B-MED
.	O
	
compensated	B-MED
dating	B-MED
typically	O
involves	O
the	O
use	B-MED
of	I-MED
information	B-MED
communication	I-MED
technology	I-MED
to	O
advertise	B-MED
,	O
search	B-MED
,	O
bargain	B-MED
,	O
and	O
eventually	O
arrange	O
for	O
transactional	B-MED
sex	I-MED
.	O
	
the	O
technology	B-MED
enables	B-MED
the	O
sexual	B-MED
partners	I-MED
to	O
maintain	B-MED
privacy	B-MED
and	O
secrecy	B-MED
in	O
transactional	B-MED
sex	I-MED
.	O
	
such	O
secrecy	B-MED
necessitates	B-MED
the	O
girls	B-MED
'	O
disclosure	B-MED
about	O
their	O
life	B-MED
experiences	I-MED
in	O
order	B-MED
to	O
address	O
the	O
concern	B-MED
.	O
	
the	O
disclosure	B-MED
is	O
the	O
focus	B-MED
of	O
the	O
present	O
qualitative	B-MED
study	I-MED
of	O
27	O
girls	B-MED
practicing	B-MED
the	O
dating	B-MED
in	O
hong	B-MED
kong	I-MED
,	O
china	B-MED
.	O
	
based	B-MED
on	O
the	O
disclosure	B-MED
,	O
the	O
study	B-MED
presents	O
a	O
grounded	B-MED
theory	I-MED
that	O
epitomizes	O
engagement	B-MED
in	O
compensated	B-MED
dating	B-MED
by	O
referential	B-MED
choice	I-MED
.	O
	
such	O
a	O
referential	B-MED
choice	I-MED
theory	I-MED
unravels	O
that	O
choice	B-MED
with	O
reference	B-MED
to	O
the	O
family	B-MED
push	B-MED
and	O
social	B-MED
norms	I-MED
sustains	B-MED
the	O
engagement	B-MED
.	O
	
meanwhile	O
,	O
the	O
choice	B-MED
rests	O
on	O
expectancy	B-MED
and	O
reinforcement	B-MED
from	O
experiential	B-MED
learning	I-MED
about	O
compensated	B-MED
dating	B-MED
.	O
	
the	O
theory	B-MED
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-MED
through	B-MED
diverting	B-MED
the	O
referential	B-MED
choice	I-MED
of	O
the	O
numerical	B-MED
simulation	I-MED
of	O
emitted	B-MED
particle	I-MED
characteristics	B-MED
and	O
airway	B-MED
deposition	B-MED
distribution	B-MED
of	O
symbicort	B-MED
turbuhaler	I-MED
dry	B-MED
powder	I-MED
fixed	O
combination	B-MED
aerosol	B-MED
drug	I-MED
one	O
of	O
the	O
most	O
widespread	O
dry	B-MED
powder	I-MED
fixed	O
combinations	B-MED
used	O
in	O
asthma	B-MED
and	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
copd	B-MED
management	B-MED
is	O
symbicort	B-MED
turbuhaler	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
simulate	B-MED
the	O
deposition	B-MED
distribution	B-MED
of	O
both	O
components	B-MED
of	O
this	O
drug	B-MED
within	O
the	O
airways	B-MED
based	O
on	O
realistic	O
airflow	B-MED
measurements	I-MED
.	O
	
breathing	B-MED
parameters	B-MED
of	O
25	O
healthy	B-MED
adults	I-MED
11	O
females	B-MED
and	O
14	O
males	B-MED
were	O
acquired	B-MED
while	O
inhaling	B-MED
through	O
turbuhaler	B-MED
.	O
	
individual	B-MED
specific	O
emitted	B-MED
doses	I-MED
and	O
particle	B-MED
size	I-MED
distributions	B-MED
of	O
symbicort	B-MED
turbuhaler	I-MED
were	O
determined	B-MED
.	O
	
a	O
self-developed	O
particle	B-MED
deposition	B-MED
model	B-MED
was	O
adapted	B-MED
and	O
validated	B-MED
to	O
simulate	B-MED
the	O
deposition	B-MED
of	O
budesonide	B-MED
inhaled	B-MED
corticosteroid	I-MED
ics	B-MED
and	O
formoterol	B-MED
long	B-MED
acting	I-MED
β2	I-MED
agonist	I-MED
laba	B-MED
in	O
the	O
upper	B-MED
airways	I-MED
and	O
lungs	B-MED
of	O
the	O
healthy	B-MED
volunteers	I-MED
.	O
	
based	O
on	O
current	B-MED
simulations	B-MED
the	O
emitted	B-MED
doses	I-MED
varied	O
between	O
50.4	O
and	O
92.5	O
of	O
the	O
metered	O
dose	B-MED
for	O
the	O
ics	B-MED
,	O
and	O
between	O
38%	O
and	O
96.1	O
in	O
case	O
of	O
laba	B-MED
component	B-MED
depending	O
on	O
the	O
individual	B-MED
inhalation	B-MED
flow	I-MED
rate	I-MED
.	O
	
this	O
variability	B-MED
induced	B-MED
a	O
notable	O
inter-	O
individual	B-MED
spread	B-MED
of	O
the	O
deposited	B-MED
lung	B-MED
doses	B-MED
mean	O
33.6	O
,	O
range	B-MED
20.4	O
for	O
budesonide	B-MED
and	O
mean	O
29.8	O
,	O
range	B-MED
16.4	O
for	O
formoterol	B-MED
.	O
	
significant	B-MED
inter-gender	B-MED
differences	B-MED
were	O
also	O
observed	B-MED
.	O
	
average	O
lung	B-MED
dose	B-MED
of	O
budesonide	B-MED
was	O
29.2	O
of	O
the	O
metered	O
dose	B-MED
for	O
females	B-MED
and	O
37%	O
for	O
males	B-MED
,	O
while	O
formoterol	B-MED
deposited	B-MED
with	O
26.4	O
efficiency	B-MED
for	O
females	B-MED
and	O
32.5	O
for	O
males	B-MED
.	O
	
present	O
results	B-MED
also	O
highlighted	O
the	O
importance	B-MED
of	O
breath-holding	B-MED
after	O
inhalation	B-MED
of	O
the	O
drug	B-MED
.	O
	
about	O
a	O
half	O
of	O
the	O
total	O
lung	B-MED
deposition	B-MED
occurred	B-MED
during	O
breath-hold	B-MED
at	O
9.6s	O
average	O
breath-hold	B-MED
time	B-MED
.	O
	
calculated	O
depositions	B-MED
confirmed	B-MED
appropriate	B-MED
lung	B-MED
deposition	B-MED
of	O
symbicort	B-MED
turbuhaler	I-MED
for	O
both	O
genders	B-MED
,	O
however	O
more	O
effort	O
for	O
optimal	B-MED
inhalation	I-MED
technique	I-MED
is	O
advised	B-MED
for	O
persons	B-MED
with	O
low	B-MED
vital	I-MED
capacity	I-MED
.	O
	
this	O
study	B-MED
demonstrated	O
the	O
possibility	O
of	O
personalized	B-MED
prediction	B-MED
of	O
airway	B-MED
deposition	B-MED
of	O
aerosol	B-MED
drugs	I-MED
by	O
numerical	B-MED
simulations	I-MED
.	O
	
the	O
methodology	B-MED
developed	O
in	O
this	O
study	B-MED
will	O
be	O
applicable	B-MED
also	O
to	O
other	O
marketed	B-MED
drugs	B-MED
in	O
the	O
nutrient	B-MED
intake	I-MED
of	O
infants	B-MED
and	O
toddlers	B-MED
in	O
the	O
united	B-MED
arab	I-MED
emirates	I-MED
the	O
feeding	O
infants	B-MED
and	O
toddlers	B-MED
study	O
this	O
descriptive	O
study	O
evaluated	O
the	O
nutrient	B-MED
adequacy	I-MED
of	O
the	O
diet	B-MED
of	O
infants	B-MED
aged	O
6-11	O
months	O
and	O
toddlers	B-MED
aged	O
12-24	O
months	O
in	O
the	O
united	B-MED
arab	I-MED
emirates	I-MED
.	O
	
a	O
random	O
sample	O
of	O
1000	O
infants	B-MED
and	O
toddlers	B-MED
was	O
recruited	O
from	O
2	O
cities	O
al	B-MED
ain	I-MED
and	O
dubai	B-MED
from	O
march	B-MED
2011	O
to	O
february	B-MED
2012	O
and	O
their	O
usual	O
nutrient	B-MED
intake	I-MED
was	O
determined	O
using	O
24-hour	O
recall	O
.	O
	
in	O
all	O
,	O
54.2	O
of	O
infants	B-MED
and	O
25.2	O
of	O
toddlers	B-MED
were	O
breastfeeding	B-MED
.	O
	
mean	O
energy	B-MED
intake	I-MED
of	O
infant	B-MED
girls	I-MED
in	O
al	B-MED
ain	I-MED
and	O
dubai	B-MED
was	O
747	O
sd	O
189	O
kcal	B-MED
and	O
773	O
sd	O
215	O
kcal	B-MED
respectively	O
and	O
810.5	O
sd	O
232.2	O
kcal	B-MED
and	O
821.9	O
sd	O
262	O
kcal	B-MED
for	O
boys	B-MED
.	O
	
in	O
toddlers	B-MED
,	O
mean	O
energy	B-MED
intake	I-MED
for	O
girls	B-MED
in	O
al	O
ain	O
and	O
dubai	O
was	O
1032.8	O
sd	O
252	O
kcal	B-MED
and	O
1013	O
sd	O
339.1	O
kcal	B-MED
respectively	O
and	O
1057.2	O
sd	O
201.8	O
kcal	B-MED
and	O
1030.3	O
sd	O
341.7	O
kcal	B-MED
for	O
boys	B-MED
.	O
	
iron	B-MED
intake	I-MED
was	O
low	B-MED
in	O
both	O
groups	O
.	O
	
mean	O
body	B-MED
mass	I-MED
index	I-MED
and	O
body	B-MED
weight	I-MED
and	O
height	B-MED
were	O
similar	O
to	O
world	B-MED
health	I-MED
organization	I-MED
figures	O
but	O
significant	O
numbers	O
of	O
infants	B-MED
and	O
toddlers	B-MED
of	O
both	O
sexes	O
were	O
over	B-MED
-	O
or	O
underweight	B-MED
.	O
	
although	O
mean	O
energy	O
and	O
macronutrient	B-MED
intakes	B-MED
were	O
comparable	O
to	O
the	O
rda	B-MED
,	O
significant	O
numbers	O
were	O
over	B-MED
-	O
or	O
estimation	O
of	O
the	O
hiv-1	B-MED
backward	B-MED
mutation	B-MED
rate	I-MED
from	O
transmitted	B-MED
drug-resistant	I-MED
strains	B-MED
one	O
of	O
the	O
serious	O
threats	B-MED
facing	O
the	O
administration	O
of	O
antiretroviral	B-MED
therapy	I-MED
to	O
human	B-MED
immunodeficiency	I-MED
virus	I-MED
hiv-1	B-MED
infected	B-MED
patients	B-MED
is	O
the	O
reported	O
increasing	B-MED
prevalence	I-MED
of	O
transmitted	B-MED
drug	I-MED
resistance	I-MED
.	O
	
however	O
,	O
given	O
that	O
hiv-1	B-MED
drug-resistant	B-MED
strains	B-MED
are	O
often	O
less	O
fit	O
than	O
the	O
wild-type	B-MED
strains	B-MED
,	O
it	O
is	O
expected	O
that	O
drug-resistant	B-MED
strains	B-MED
that	O
are	O
present	O
during	O
the	O
primary	B-MED
phase	B-MED
of	O
the	O
hiv-1	B-MED
infection	I-MED
are	O
replaced	B-MED
by	O
the	O
fitter	O
wild-type	B-MED
strains	B-MED
.	O
	
this	O
replacement	B-MED
of	O
hiv-1	B-MED
resistant	I-MED
mutations	B-MED
involves	O
the	O
emergence	O
of	O
wild-type	B-MED
strains	B-MED
by	O
a	O
process	B-MED
of	O
backward	B-MED
mutation	B-MED
.	O
	
how	O
quickly	O
the	O
replacement	B-MED
happens	O
is	O
dependent	B-MED
on	O
the	O
class	O
of	O
hiv-1	B-MED
mutation	B-MED
group	B-MED
.	O
	
we	O
estimate	O
the	O
backward	B-MED
mutation	B-MED
rates	I-MED
and	O
relative	O
fitness	O
of	O
various	O
mutational	B-MED
groups	B-MED
known	O
to	O
confer	O
hiv-1	B-MED
drug	B-MED
resistance	I-MED
.	O
	
we	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	B-MED
model	I-MED
to	O
data	B-MED
for	O
individuals	B-MED
who	O
were	O
originally	O
infected	B-MED
by	O
an	O
hiv-1	B-MED
strain	B-MED
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	B-MED
resistance	I-MED
-conferring	O
mutations	B-MED
and	O
observed	O
over	O
a	O
period	B-MED
of	I-MED
time	I-MED
to	O
see	O
whether	O
the	O
resistant	B-MED
strain	B-MED
is	O
replaced	B-MED
.	O
	
to	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	B-MED
,	O
generated	O
from	O
simulations	B-MED
of	O
the	O
stochastic	B-MED
model	I-MED
,	O
that	O
best	O
describes	O
the	O
observed	B-MED
clinical	B-MED
data	I-MED
replacement	B-MED
times	B-MED
of	O
a	O
given	O
mutation	B-MED
.	O
	
we	O
found	O
that	O
lamivudine/emtricitabine	B-MED
-associated	O
mutations	B-MED
have	O
a	O
distinctly	O
higher	O
,	O
backward	B-MED
mutation	B-MED
rate	I-MED
and	O
low	O
relative	B-MED
fitness	B-MED
compared	O
to	O
the	O
other	O
classes	B-MED
as	O
has	O
been	O
reported	O
before	O
while	O
protease	B-MED
inhibitors	I-MED
-associated	O
mutations	B-MED
have	O
a	O
slower	O
backward	B-MED
mutation	B-MED
rate	I-MED
and	O
high	O
relative	B-MED
fitness	B-MED
.	O
	
for	O
the	O
other	O
mutation	B-MED
classes	B-MED
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
modeling	B-MED
the	O
hospital	B-MED
safety	B-MED
partnership	B-MED
preferences	B-MED
of	I-MED
patients	I-MED
and	O
their	O
families	B-MED
a	O
discrete	B-MED
choice	B-MED
conjoint	B-MED
experiment	I-MED
patients	B-MED
and	O
their	O
families	B-MED
play	O
an	O
important	O
role	B-MED
in	O
efforts	O
to	O
improve	B-MED
health	B-MED
service	I-MED
safety	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
is	O
to	O
understand	O
the	O
safety	B-MED
partnership	B-MED
preferences	B-MED
of	I-MED
patients	I-MED
and	O
their	O
families	B-MED
.	O
	
we	O
used	O
a	O
discrete	B-MED
choice	B-MED
conjoint	B-MED
experiment	I-MED
to	O
model	O
the	O
safety	B-MED
partnership	B-MED
preferences	B-MED
of	O
1	O
patients	B-MED
or	O
those	O
such	O
as	O
parents	B-MED
acting	O
on	O
their	O
behalf	O
.	O
	
participants	B-MED
made	O
choices	B-MED
between	O
hypothetical	O
safety	B-MED
partnerships	B-MED
composed	O
by	O
experimentally	O
varying	O
15	O
four-level	O
partnership	B-MED
design	B-MED
attributes	B-MED
.	O
	
participants	B-MED
preferred	B-MED
an	O
approach	B-MED
to	O
safety	B-MED
based	O
on	O
partnerships	B-MED
between	O
patients	B-MED
and	O
staff	B-MED
rather	O
than	O
a	O
model	O
delegating	O
responsibility	B-MED
for	O
safety	B-MED
to	O
hospital	B-MED
staff	I-MED
.	O
	
they	O
valued	O
the	O
opportunity	B-MED
to	I-MED
participate	I-MED
in	O
point	O
of	O
service	O
safety	B-MED
partnerships	B-MED
,	O
such	O
as	O
identity	O
and	O
medication	B-MED
double	I-MED
checks	I-MED
,	O
that	O
might	O
afford	O
an	O
immediate	B-MED
risk	B-MED
reduction	I-MED
.	O
	
latent	O
class	O
analysis	B-MED
yielded	O
two	O
segments	O
.	O
	
actively	B-MED
engaged	I-MED
participants	I-MED
73.3	O
comprised	O
outpatients	B-MED
with	O
higher	B-MED
education	I-MED
,	O
who	O
anticipated	B-MED
more	O
benefits	B-MED
to	O
safety	B-MED
partnerships	B-MED
,	O
were	O
more	B-MED
confident	I-MED
in	O
their	O
ability	B-MED
to	O
contribute	B-MED
,	O
and	O
were	O
more	O
intent	B-MED
on	O
participating	B-MED
.	O
	
they	O
were	O
more	O
likely	O
to	O
prefer	B-MED
a	O
personal	O
engagement	B-MED
strategy	B-MED
,	O
valued	O
scientific	B-MED
evidence	I-MED
,	O
preferred	B-MED
a	O
more	O
active	O
approach	B-MED
to	O
safety	B-MED
education	I-MED
,	O
and	O
advocated	O
disclosure	B-MED
of	I-MED
errors	I-MED
.	O
	
the	O
passively	O
engaged	O
segment	O
26.7	O
anticipated	B-MED
fewer	B-MED
benefits	B-MED
,	O
were	O
less	O
confident	B-MED
in	O
their	O
ability	B-MED
to	O
contribute	B-MED
,	O
and	O
were	O
less	O
intent	O
on	O
participating	B-MED
.	O
	
they	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-MED
strategy	B-MED
based	O
on	O
signage	B-MED
.	O
	
they	O
preferred	B-MED
that	O
staff	B-MED
explain	O
why	O
they	O
thought	O
patients	B-MED
should	O
help	O
make	O
care	B-MED
safer	O
and	O
decide	O
whether	O
errors	B-MED
were	O
disclosed	O
.	O
	
inpatients	B-MED
,	O
those	O
with	O
immigrant	B-MED
backgrounds	I-MED
,	O
and	O
those	O
with	O
less	B-MED
education	I-MED
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment	O
.	O
	
health	B-MED
services	I-MED
need	O
to	O
communicate	O
information	B-MED
regarding	O
risks	B-MED
,	O
ask	O
about	O
partnership	B-MED
preferences	B-MED
,	O
create	O
opportunities	B-MED
respecting	O
individual	B-MED
differences	I-MED
,	O
and	O
ensure	O
a	O
positive	B-MED
response	I-MED
when	O
patients	B-MED
raise	O
safety	B-MED
concerns	B-MED
.	O
	
influence	O
of	O
ozone	B-MED
and	O
paracetic	B-MED
acid	I-MED
disinfection	B-MED
on	O
adhesion	B-MED
of	I-MED
resilient	B-MED
liners	I-MED
to	O
acrylic	B-MED
resin	I-MED
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	B-MED
acid	I-MED
paa	B-MED
and	O
ozone	B-MED
disinfection	B-MED
on	O
the	O
tensile	B-MED
bond	I-MED
strength	I-MED
tbs	B-MED
of	O
silicone-based	B-MED
resilient	B-MED
liners	I-MED
to	O
acrylic	B-MED
resins	I-MED
.	O
	
one	O
hundred	O
and	O
twenty	O
dumbbell	B-MED
shaped	I-MED
heat-polymerized	B-MED
acrylic	B-MED
resins	I-MED
were	O
prepared	O
.	O
	
from	O
the	O
mid	O
segment	O
of	O
the	O
specimens	B-MED
,	O
3	O
mm	O
of	O
acrylic	B-MED
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	B-MED
liners	I-MED
.	O
	
the	O
specimens	B-MED
were	O
divided	O
into	O
2	B-MED
control	I-MED
control1	B-MED
,	O
control7	B-MED
and	O
4	O
test	O
groups	O
of	O
paa	B-MED
and	O
ozone	B-MED
disinfection	B-MED
paa1	B-MED
,	O
paa7	B-MED
,	O
ozone1	B-MED
and	O
ozone7	B-MED
n=10	O
.	O
	
while	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	B-MED
water	I-MED
for	O
10	O
min	O
control1	B-MED
and	O
7	O
days	O
control7	B-MED
,	O
test	O
groups	O
were	O
subjected	O
to	O
paa	B-MED
16	O
g/l	O
or	O
ozone	B-MED
rich	O
water	B-MED
4	O
mg/l	O
for	O
1	O
cycle	O
10	O
min	O
for	O
paa	B-MED
and	O
60	O
min	O
for	O
ozone	B-MED
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	B-MED
tests	B-MED
.	O
	
measurements	O
of	O
the	O
tbs	B-MED
were	O
analyzed	O
using	O
3-way	O
anova	B-MED
and	O
tukey's	B-MED
hsd	I-MED
test	I-MED
.	O
	
adhesive	B-MED
strength	B-MED
of	O
mollosil	B-MED
decreased	O
significantly	O
by	O
application	O
of	O
ozone	B-MED
disinfection	B-MED
.	O
	
paa	B-MED
disinfection	B-MED
had	O
no	O
negative	O
effect	O
on	O
the	O
tbs	B-MED
values	O
of	O
mollosil	B-MED
and	O
molloplast	B-MED
b	I-MED
to	O
acrylic	B-MED
resin	I-MED
.	O
	
single	O
application	O
of	O
ozone	B-MED
disinfection	B-MED
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
tbs	B-MED
values	O
of	O
molloplast	B-MED
b	I-MED
,	O
but	O
prolonged	B-MED
exposure	B-MED
to	I-MED
ozone	I-MED
decreased	O
its	O
adhesive	B-MED
strength	B-MED
.	O
	
the	O
adhesion	B-MED
of	O
resilient	B-MED
liners	I-MED
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
paa	B-MED
disinfection	B-MED
.	O
	
immersion	O
in	O
ozonated	B-MED
water	B-MED
significantly	O
decreased	O
tbs	B-MED
of	O
mollosil	B-MED
.	O
	
prolonged	O
exposure	O
to	O
ozone	B-MED
negatively	O
affects	O
adhesion	B-MED
of	O
molloplast	B-MED
b	I-MED
to	O
denture	B-MED
base	I-MED
materials	I-MED
.	O
	
the	O
construction	B-MED
of	O
three-dimensional	B-MED
composite	B-MED
fibrous	B-MED
macrostructures	B-MED
with	B-MED
nanotextures	I-MED
for	O
biomedical	B-MED
applications	B-MED
the	O
development	O
of	O
modern	O
biomedical	B-MED
nanotechnology	B-MED
requires	O
three-dimensional	B-MED
macrostructures	B-MED
with	B-MED
nanotextures	I-MED
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	B-MED
in	O
intricate	O
biological	B-MED
systems	I-MED
.	O
	
additionally	O
,	O
the	O
restoration	B-MED
and	O
regeneration	B-MED
of	O
some	O
specific	O
body	B-MED
tissues	I-MED
and	O
organs	B-MED
rely	O
on	O
the	O
function	O
of	O
conductive	B-MED
polymers	I-MED
,	O
which	O
can	O
provide	O
electrical	B-MED
cues	B-MED
for	O
cells	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
fabricated	O
three-dimensional	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
of	O
polycaprolactone	B-MED
pcl	B-MED
with	O
different	O
concentrations	B-MED
of	O
polyaniline	B-MED
pani	B-MED
by	O
employing	O
an	O
improved	O
electrospinning	B-MED
technology	I-MED
with	O
a	O
specially	O
designed	O
collector	O
.	O
	
the	O
3d	B-MED
structures	B-MED
possessed	O
cap-like	B-MED
macrostructures	I-MED
with	O
centimetre-scale	B-MED
thickness	B-MED
and	O
interconnected	O
pore	B-MED
nanotextures	I-MED
with	O
nanometre-scale	B-MED
nanofibres	B-MED
.	O
	
to	O
estimate	O
the	O
biocompatibility	B-MED
of	O
the	O
3d	B-MED
pcl	B-MED
/	O
pani	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
,	O
mouse	B-MED
myoblasts	B-MED
c2c12	B-MED
cells	I-MED
were	O
cultured	O
as	O
model	B-MED
cells	B-MED
.	O
	
the	O
initial	O
responses	O
of	O
c2c12	B-MED
cells	I-MED
to	O
the	O
3d	B-MED
pcl	B-MED
/	O
pani	B-MED
composite	B-MED
macrostructures	B-MED
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
pcl	B-MED
,	O
that	O
is	O
,	O
the	O
cells	B-MED
exhibited	O
typical	O
myoblast-like	B-MED
morphologies	I-MED
with	O
obvious	O
pseudopodia	B-MED
and	O
the	O
moderate	O
incorporation	O
less	O
than	O
2.0	O
wt%	O
of	O
conductive	O
pani	B-MED
facilitated	O
cell	B-MED
proliferation	I-MED
,	O
which	O
indicated	O
that	O
pani	B-MED
has	O
appreciable	O
cell	B-MED
affinity	I-MED
.	O
	
moreover	O
,	O
the	O
addition	O
of	O
conductive	B-MED
pani	B-MED
to	O
the	O
3d	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
considerably	O
enhanced	O
myoblast	B-MED
differentiation	I-MED
and	O
myotube	B-MED
maturation	I-MED
.	O
	
these	O
results	O
suggest	O
that	O
electrospun	B-MED
3d	B-MED
pcl	B-MED
/	O
pani	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
would	O
have	O
promising	O
applications	O
in	O
tissue	O
engineering	I-MED
mechanisms	B-MED
of	O
replacement	B-MED
of	O
circulating	B-MED
viruses	B-MED
by	O
seasonal	B-MED
and	O
pandemic	B-MED
influenza	I-MED
a	I-MED
viruses	I-MED
seasonal	B-MED
influenza	I-MED
causes	O
annual	O
epidemics	B-MED
by	O
the	O
accumulation	B-MED
of	O
antigenic	B-MED
changes	I-MED
.	O
	
pandemic	B-MED
influenza	I-MED
occurs	O
through	O
a	O
major	O
antigenic	B-MED
change	I-MED
of	O
the	O
influenza	B-MED
a	I-MED
virus	I-MED
,	O
which	O
can	O
originate	B-MED
from	O
other	O
hosts	B-MED
.	O
	
although	O
new	O
antigenic	B-MED
variants	I-MED
of	O
the	O
influenza	B-MED
a	I-MED
virus	I-MED
replace	O
formerly	O
circulating	B-MED
seasonal	B-MED
and	O
pandemic	B-MED
viruses	I-MED
,	O
replacement	B-MED
mechanisms	B-MED
remain	O
poorly	O
understood	O
.	O
	
a	O
stochastic	B-MED
individual-based	I-MED
seir	I-MED
susceptible-exposed-infectious-recovered	I-MED
model	I-MED
with	O
two	O
viral	B-MED
strains	I-MED
formerly	O
circulating	B-MED
old	B-MED
strain	I-MED
and	O
newly	B-MED
emerged	I-MED
strain	I-MED
was	O
developed	O
for	O
simulations	B-MED
to	O
elucidate	O
the	O
replacement	B-MED
mechanisms	B-MED
.	O
	
factors	B-MED
and	O
conditions	B-MED
of	O
virus	B-MED
and	O
host	B-MED
populations	O
affecting	O
the	O
replacement	B-MED
were	O
identified	O
.	O
	
replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical	B-MED
regions	I-MED
than	O
temperate	B-MED
regions	I-MED
.	O
	
the	O
magnitude	B-MED
of	O
the	O
ongoing	O
epidemic	B-MED
by	O
the	O
old	B-MED
strain	I-MED
,	O
herd	B-MED
immunity	I-MED
against	O
the	O
old	B-MED
strain	I-MED
,	O
and	O
timing	B-MED
of	O
appearance	B-MED
of	O
the	O
new	B-MED
strain	I-MED
are	O
not	O
that	O
important	O
for	O
replacement	B-MED
.	O
	
it	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	B-MED
by	O
a	O
pandemic	B-MED
virus	I-MED
is	O
higher	O
than	O
a	O
seasonal	B-MED
virus	I-MED
because	O
of	O
the	O
high	O
initial	O
susceptibility	B-MED
and	O
high	O
basic	O
reproductive	B-MED
number	O
of	O
the	O
pandemic	B-MED
virus	I-MED
.	O
	
the	O
findings	O
of	O
this	O
study	O
on	O
replacement	B-MED
mechanisms	B-MED
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus	B-MED
transmission	I-MED
dynamics	B-MED
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	B-MED
strategy	O
to	O
mitigate	B-MED
the	O
impact	O
of	O
seasonal	B-MED
and	O
pandemic	B-MED
influenza	I-MED
.	O
	
request	B-MED
and	O
fulfillment	B-MED
of	O
postpartum	B-MED
tubal	B-MED
ligation	I-MED
in	O
patients	B-MED
after	O
high-risk	B-MED
pregnancy	I-MED
female	B-MED
sterilization	I-MED
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	B-MED
of	O
contraception	B-MED
in	O
the	O
united	B-MED
states	I-MED
.	O
	
prior	O
studies	B-MED
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	B-MED
tubal	B-MED
ligation	I-MED
pptl	B-MED
requests	B-MED
go	O
unfulfilled	B-MED
.	O
	
this	O
study	B-MED
seeks	O
to	O
establish	O
whether	O
obstetric	B-MED
or	O
medical	B-MED
risk	I-MED
status	B-MED
influences	O
patients	B-MED
'	O
request	B-MED
for	O
or	O
subsequent	O
completion	B-MED
of	O
pptl	B-MED
.	O
	
this	O
study	B-MED
was	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
of	O
women	B-MED
delivering	B-MED
at	O
a	O
university	B-MED
hospital	I-MED
in	O
2009-2010	O
who	O
received	O
prenatal	B-MED
care	I-MED
in	O
the	O
faculty	B-MED
and	O
resident	B-MED
clinics	I-MED
.	O
	
high-risk	B-MED
status	B-MED
was	O
defined	O
by	O
society	B-MED
for	I-MED
maternal-fetal	I-MED
medicine	I-MED
guidelines	I-MED
.	O
	
documentation	B-MED
of	O
contraceptive	B-MED
plan	I-MED
and	O
administration	B-MED
of	O
contraceptive	B-MED
methods	I-MED
was	O
abstracted	B-MED
from	O
patient	B-MED
records	I-MED
.	O
	
subsequent	O
pregnancies	B-MED
through	O
march	O
1	O
,	O
2013	O
,	O
were	O
abstracted	B-MED
.	O
	
of	O
3063	O
participants	B-MED
2048	O
low	B-MED
risk	I-MED
and	O
1015	O
high	B-MED
risk	I-MED
,	O
231	O
requested	B-MED
pptl	B-MED
7.5	O
.	O
	
this	O
was	O
more	O
likely	O
among	O
high-risk	B-MED
patients	B-MED
than	O
low-risk	B-MED
patients	B-MED
10.0	O
vs	O
.	O
	
6.3	O
,	O
p<	O
,	O
those	O
with	O
public	B-MED
insurance	I-MED
13.8	O
vs	O
.	O
	
3.2	O
,	O
p<	O
and	O
those	O
with	O
an	O
unintended	B-MED
index	I-MED
pregnancy	I-MED
13.8	O
vs	O
.	O
	
4.1	O
,	O
p<	O
.	O
	
of	O
the	O
patients	B-MED
requesting	B-MED
pptl	B-MED
,	O
118	O
51.1	O
underwent	O
the	O
procedure	B-MED
immediately	O
postpartum	B-MED
.	O
	
completion	B-MED
was	O
not	O
associated	O
with	O
high-risk	B-MED
status	B-MED
54.0	O
,	O
or	O
with	O
race	B-MED
,	O
insurance	B-MED
status	I-MED
or	O
parity	B-MED
.	O
	
among	O
113	O
women	B-MED
with	O
an	O
unfulfilled	B-MED
pptl	B-MED
request	B-MED
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	B-MED
15.0	O
during	O
the	O
27	O
months	B-MED
of	O
follow-up	B-MED
.	O
	
though	O
women	B-MED
with	O
high-risk	B-MED
pregnancies	I-MED
were	O
more	O
likely	O
to	O
request	B-MED
pptl	B-MED
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-MED
the	O
procedure	B-MED
.	O
	
over	O
one	O
third	O
of	O
high-risk	B-MED
patients	B-MED
'	O
requests	B-MED
were	O
unfulfilled	B-MED
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain	O
.	O
	
though	O
women	B-MED
with	O
high-risk	B-MED
pregnancies	I-MED
were	O
more	O
likely	O
to	O
request	B-MED
pptl	B-MED
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-MED
the	O
procedure	B-MED
.	O
	
providers	O
should	O
consider	O
these	O
procedures	B-MED
urgent	B-MED
,	O
especially	O
in	O
high-risk	B-MED
women	B-MED
,	O
and	O
advocate	O
for	O
their	O
patients	B-MED
'	O
access	O
to	O
this	O
gut	B-MED
microbiota	I-MED
after	O
roux-en-y	B-MED
gastric	I-MED
bypass	I-MED
and	O
sleeve	B-MED
gastrectomy	I-MED
in	O
a	O
diabetic	B-MED
rat	B-MED
model	B-MED
increased	O
diversity	B-MED
and	O
associations	O
of	O
discriminant	B-MED
genera	B-MED
with	O
metabolic	B-MED
changes	B-MED
recent	O
work	O
with	O
gut	B-MED
microbiota	I-MED
after	O
bariatric	B-MED
surgery	I-MED
is	O
limited	O
,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement	O
.	O
	
given	O
the	O
role	O
of	O
the	O
gut	B-MED
microbiota	I-MED
in	O
regulating	O
host	B-MED
metabolism	B-MED
,	O
we	O
explored	O
the	O
effect	O
of	O
roux-en-y	B-MED
gastric	I-MED
bypass	I-MED
rygb	B-MED
and	O
sleeve	B-MED
gastrectomy	I-MED
sg	B-MED
on	O
the	O
modifications	O
of	O
gut	B-MED
microbiota	I-MED
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	B-MED
intake	B-MED
and/or	O
weight	B-MED
loss	B-MED
and	O
examined	O
their	O
links	O
with	O
host	O
metabolism	O
.	O
	
zucker	O
diabetic	O
fatty	O
rats	O
were	O
divided	O
into	O
the	O
following	O
groups	O
rygb	O
sham-operated	O
with	O
pair-fed	O
as	O
rygb	O
sham-operated	O
fed	O
ad	O
libitum	O
and	O
sg	O
.	O
	
the	O
metabolic	O
effects	O
and	O
gut	O
microbiota	O
profile	O
were	O
analyzed	O
10	O
weeks	O
postoperatively	O
.	O
	
associations	O
between	O
discriminating	O
genera	O
and	O
metabolic	O
markers	O
after	O
rygb	O
were	O
explored	O
.	O
	
the	O
2	O
procedures	O
induced	O
similar	O
glucose	O
improvement	O
and	O
increased	O
flora	O
diversity	O
after	O
10	O
weeks	O
compared	O
with	O
sham-operated	O
groups	O
.	O
	
rygb	O
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
proteobacteria	O
/	O
gammaproteobacteria	O
and	O
betaproteobacteria	O
and	O
increased	O
emergence	O
of	O
fusobacteria	O
and	O
clostridium	O
,	O
whereas	O
sg	O
resulted	O
in	O
more	O
abundant	O
actinobacteria	O
compared	O
with	O
other	O
groups	O
.	O
	
most	O
of	O
the	O
12	O
discriminant	O
genera	O
correlated	O
with	O
changes	O
in	O
metabolic	O
phenotype	O
,	O
but	O
only	O
28.6	O
of	O
these	O
correlations	O
were	O
independent	O
of	O
weight	O
,	O
and	O
4	O
discriminant	O
genera	O
still	O
negatively	O
correlated	O
with	O
serum	O
insulin	O
level	O
independent	O
of	O
food	O
intake	O
and	O
weight	O
loss	B-MED
after	O
rygb	O
.	O
	
these	O
data	O
demonstrate	O
that	O
rygb	O
and	O
sg	O
surgery	O
produced	O
similar	O
diversity	O
but	O
different	O
microbiota	O
compositions	O
changes	O
in	O
zucker	O
diabetic	O
fatty	O
rats	O
.	O
	
these	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	O
of	O
the	O
discriminate	O
microbiota	O
and	O
the	O
mechanisms	O
linking	O
postsurgical	O
modulation	O
of	O
gut	O
microbiota	O
and	O
improvements	O
in	O
insulin	O
resistance	I-MED
ocular	B-MED
toxicity	I-MED
of	O
auy922	B-MED
in	O
pigmented	B-MED
and	O
albino	B-MED
rats	I-MED
auy922	B-MED
,	O
a	O
heat	B-MED
shock	I-MED
protein	I-MED
90	I-MED
inhibitor	B-MED
is	O
associated	O
with	O
ocular	B-MED
adverse	B-MED
events	I-MED
aes	B-MED
.	O
	
to	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-MED
aes	B-MED
in	O
patients	B-MED
,	O
4	O
investigative	B-MED
studies	I-MED
were	O
performed	O
in	O
a	O
step-wise	B-MED
approach	I-MED
to	O
assess	O
retinal	B-MED
structure	I-MED
and	O
function	O
in	O
pigmented	B-MED
brown	B-MED
norway	I-MED
and	O
albino	B-MED
wistar	I-MED
rats	I-MED
.	O
	
in	O
rats	O
administered	O
30mg/kg	O
of	O
auy922	O
,	O
the	O
auc	O
0-24	O
h	O
and	O
cmax	O
are	O
comparable	O
to	O
that	O
in	O
patients	O
at	O
70mg/m	O
.	O
	
auy922	O
at	O
30mg/kg	O
was	O
poorly	O
tolerated	O
by	O
rats	O
with	O
morbidity	O
or	O
mortality	O
generally	O
after	O
the	O
third	O
weekly	O
treatment	O
.	O
	
electroretinography	O
erg	O
changes	O
were	O
observed	O
at	O
doses	O
30mg/kg	O
.	O
	
the	O
erg	O
changes	O
were	O
dose	O
dependent	O
,	O
consistent	O
with	O
an	O
effect	O
on	O
the	O
photoreceptors	O
,	O
and	O
fully	O
reversible	O
.	O
	
the	O
erg	O
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
cmax	O
while	O
maintaining	O
auc	O
.	O
	
histopathological	O
changes	O
were	O
seen	O
mainly	O
when	O
rats	O
were	O
administered	O
auy922	O
at	O
100mg/kg	O
.	O
	
the	O
2-	O
hour	O
infusion	O
of	O
auy922	O
at	O
100mg/kg	O
caused	O
disorganization	O
of	O
the	O
outer	O
segment	O
photoreceptor	O
morphology	O
in	O
male	O
brown	O
norway	O
rats	O
the	O
severity	O
of	O
the	O
disorganization	O
increased	O
with	O
the	O
number	O
of	O
administrations	O
,	O
but	O
was	O
reversible	O
during	O
a	O
4-	O
week	O
posttreatment	O
period	O
.	O
	
there	O
was	O
no	O
major	O
difference	O
in	O
ocular	O
response	O
between	O
brown	O
norway	O
and	O
wistar	B-MED
rats	B-MED
.	O
	
no	O
changes	O
in	O
serum	O
iron	O
levels	O
,	O
and	O
no	O
changes	O
in	O
rhodopsin	O
,	O
pde6α	O
,	O
β-transducin	O
concentrations	O
,	O
or	O
retinal	O
pigment	O
epithelium-specific	O
protein	O
rpe65	O
expression	O
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	O
of	O
auy922	O
at	O
100mg/kg	O
compared	O
to	O
vehicle-treated	O
controls	O
.	O
	
auy922	O
retinal	O
toxicity	O
in	O
rats	O
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	O
and	O
is	O
shown	O
to	O
be	O
reversible	O
,	O
while	O
a	O
precise	O
molecular	O
mechanism	O
for	O
the	O
effect	O
was	O
not	O
assessment	B-MED
of	O
cerebral	B-MED
blood	B-MED
perfusion	I-MED
reserve	O
with	O
acetazolamide	B-MED
using	O
3d	B-MED
spiral	I-MED
asl	I-MED
mri	I-MED
preliminary	O
experience	O
in	O
pediatric	B-MED
patients	B-MED
to	O
demonstrate	O
the	O
clinical	B-MED
feasibility	I-MED
of	O
a	O
new	O
non-cartesian	B-MED
cylindrically-distributed	I-MED
spiral	I-MED
3d	I-MED
pseudo-continuous	I-MED
arterial	I-MED
spin	I-MED
labeling	I-MED
pcasl	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
mri	I-MED
pulse	B-MED
sequence	I-MED
in	O
pediatric	B-MED
patients	B-MED
in	O
quantifying	B-MED
cerebral	B-MED
blood	I-MED
flow	I-MED
cbf	B-MED
response	O
to	O
an	O
acetazolamide	B-MED
acz	I-MED
vasodilator	I-MED
challenge	O
.	O
	
mri	B-MED
exams	I-MED
were	O
performed	O
on	O
two	O
3	B-MED
tesla	I-MED
philips	I-MED
ingenia	I-MED
systems	I-MED
using	I-MED
32	I-MED
channel	I-MED
head	I-MED
coil	I-MED
arrays	I-MED
.	O
	
after	O
local	O
institutional	B-MED
review	I-MED
board	I-MED
approval	I-MED
,	O
the	O
3d	B-MED
spiral-based	I-MED
pcasl	I-MED
technique	I-MED
was	O
added	O
to	O
a	O
standard	O
brain	B-MED
mri	I-MED
exam	I-MED
and	O
evaluated	O
in	O
13	O
pediatric	B-MED
patients	B-MED
average	O
age	O
11.7	O
,	O
range	O
1.4	O
.	O
	
all	O
patients	B-MED
were	O
administered	B-MED
acz	B-MED
for	O
clinically	B-MED
indicated	I-MED
reasons	O
.	O
	
quantitative	O
whole-brain	B-MED
cbf	I-MED
measurements	I-MED
were	O
computed	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
acz	B-MED
to	O
assess	O
cerebrovascular	B-MED
reserve	I-MED
.	O
	
3d	B-MED
spiral	I-MED
pcasl	I-MED
data	B-MED
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B-MED
.	O
	
in	O
11	O
patients	B-MED
,	O
cbf	B-MED
increased	O
2.8	O
to	O
93.2	O
after	O
administration	B-MED
of	I-MED
acz	B-MED
.	O
	
in	O
the	O
two	O
remaining	O
patients	B-MED
,	O
cbf	B-MED
decreased	O
by	O
2.4	O
to	O
6.0	O
after	O
acz	B-MED
.	O
	
the	O
group	O
average	O
change	O
in	O
cbf	B-MED
due	O
to	O
acz	B-MED
was	O
approximately	O
25.0	O
and	O
individual	O
changes	O
were	O
statistically	B-MED
significant	I-MED
p<0	O
in	O
all	O
patients	B-MED
using	O
a	O
paired	O
t-test	B-MED
analysis	I-MED
.	O
	
cbf	B-MED
perfusion	B-MED
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
mr	B-MED
angiography	I-MED
and	O
clinical	B-MED
findings	I-MED
.	O
	
3d	B-MED
cylindrically-distributed	I-MED
spiral	I-MED
pcasl	I-MED
mri	I-MED
provides	O
a	O
robust	O
approach	O
to	O
assess	B-MED
cerebral	B-MED
blood	I-MED
flow	I-MED
and	O
reserve	O
in	O
pediatric	B-MED
patients	B-MED
.	O
	
assessing	B-MED
the	O
learning	B-MED
potential	B-MED
of	O
an	O
interactive	B-MED
digital	B-MED
game	I-MED
versus	O
an	O
interactive-style	B-MED
didactic	B-MED
lecture	B-MED
the	O
continued	O
importance	O
of	O
didactic	B-MED
teaching	B-MED
in	O
medical	B-MED
student	I-MED
education	B-MED
games	B-MED
with	O
educational	B-MED
intent	O
offer	O
a	O
possible	B-MED
advantage	O
of	O
being	O
more	O
interactive	B-MED
and	O
increasing	B-MED
learner	B-MED
satisfaction	B-MED
.	O
	
we	O
conducted	O
a	O
two-armed	B-MED
experiment	I-MED
to	O
evaluate	B-MED
student	B-MED
satisfaction	B-MED
and	O
content	B-MED
mastery	B-MED
for	O
an	O
introductory	O
pediatric	B-MED
radiology	I-MED
topic	B-MED
,	O
taught	B-MED
by	O
either	O
an	O
interactive	B-MED
digital	B-MED
game	I-MED
or	O
with	O
a	O
traditional	B-MED
didactic	B-MED
lecture	B-MED
.	O
	
medical	B-MED
students	I-MED
participating	B-MED
in	O
a	O
fourth-year	O
radiology	B-MED
elective	B-MED
were	O
invited	O
to	O
participate	B-MED
.	O
	
student	B-MED
cohorts	B-MED
were	O
alternatively	B-MED
given	O
a	O
faculty	B-MED
-	O
supervised	B-MED
1h	O
session	B-MED
playing	B-MED
a	O
simple	O
interactive	B-MED
digital	B-MED
tic-tac-toe	B-MED
quiz	B-MED
module	I-MED
on	O
pediatric	B-MED
gastrointestinal	I-MED
radiology	I-MED
or	O
a	O
1h	O
didactic	B-MED
introductory	O
lecture	B-MED
on	O
the	O
same	O
topic	B-MED
.	O
	
survey	B-MED
questions	B-MED
assessed	B-MED
the	O
learners'	B-MED
perceived	B-MED
ability	B-MED
to	I-MED
recall	I-MED
the	O
material	B-MED
as	O
well	O
as	O
their	O
satisfaction	B-MED
with	O
the	O
educational	B-MED
experience	B-MED
.	O
	
results	O
of	O
an	O
end-of-rotation	B-MED
exam	B-MED
were	O
reviewed	B-MED
to	O
evaluate	B-MED
a	O
quantitative	B-MED
measure	I-MED
of	O
learning	B-MED
between	O
groups	B-MED
.	O
	
survey	B-MED
responses	B-MED
were	O
analyzed	B-MED
with	O
a	O
chi-squared	B-MED
test	I-MED
.	O
	
exam	B-MED
results	O
for	O
both	O
groups	B-MED
were	O
analyzed	B-MED
with	O
a	O
paired	O
student's	B-MED
t-test	I-MED
.	O
	
students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
had	O
higher	B-MED
test	B-MED
scores	I-MED
compared	B-MED
to	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
4.0	O
versus	O
3.6	O
,	O
p	O
=	O
0.045	O
.	O
	
students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
reported	B-MED
greater	B-MED
understanding	B-MED
and	O
recall	B-MED
of	O
the	O
material	B-MED
than	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
p	O
<	O
0.001	O
and	O
p	O
=	O
0.004	O
,	O
respectively	O
.	O
	
students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
perceived	B-MED
the	O
lecture	B-MED
to	O
be	O
more	O
enjoyable	B-MED
and	O
a	O
better	O
use	O
of	O
their	O
time	B-MED
compared	B-MED
to	O
those	O
in	O
the	O
game	B-MED
group	B-MED
p	O
=	O
0.04	O
and	O
p	O
<	O
0.001	O
,	O
respectively	O
.	O
	
there	O
was	O
no	O
statistically	B-MED
significant	I-MED
difference	B-MED
between	O
the	O
lecture	B-MED
and	O
game	B-MED
group	B-MED
in	O
ability	B-MED
to	O
maintain	O
interest	B-MED
p	O
=	O
0.187	O
.	O
	
in	O
comparison	O
to	O
pre-survey	B-MED
results	O
,	O
there	O
was	O
a	O
statistically	B-MED
significant	I-MED
decrease	B-MED
in	O
interest	B-MED
for	O
further	O
digital	B-MED
interactive	B-MED
materials	B-MED
reported	B-MED
by	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
p	O
=	O
0.146	O
.	O
	
our	O
experience	B-MED
supported	O
the	O
use	O
of	O
a	O
traditional	B-MED
lecture	B-MED
over	O
a	O
digital	B-MED
game	I-MED
module	O
.	O
	
while	O
these	O
results	O
might	O
be	O
affected	B-MED
by	O
the	O
specific	B-MED
lecture	B-MED
and	O
digital	B-MED
content	B-MED
in	O
any	O
given	O
comparison	B-MED
,	O
a	O
digital	B-MED
module	B-MED
predictors	B-MED
of	O
30-	O
day	B-MED
mortality	B-MED
in	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
intracerebral	B-MED
hemorrhage	I-MED
intracerebral	B-MED
hemorrhage	I-MED
ich	B-MED
is	O
a	O
life	B-MED
threatening	I-MED
entity	O
,	O
and	O
an	O
early	B-MED
outcome	I-MED
assessment	I-MED
is	O
mandatory	O
for	O
optimizing	O
therapeutic	B-MED
efforts	I-MED
.	O
	
we	O
retrospectively	B-MED
analyzed	B-MED
data	B-MED
from	O
342	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
ich	B-MED
to	O
evaluate	O
possible	O
predictors	B-MED
of	O
30-	O
day	B-MED
mortality	B-MED
considering	O
clinical	B-MED
,	O
radiological	B-MED
,	O
and	O
therapeutical	B-MED
parameters	B-MED
.	O
	
we	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-MED
grading	I-MED
scoring	I-MED
systems	I-MED
ich	B-MED
score	I-MED
,	O
func	B-MED
score	I-MED
and	O
intracerebral	B-MED
hemorrhage	I-MED
grading	I-MED
scale	I-MED
ich-gs	B-MED
on	O
our	O
population	B-MED
to	O
evaluate	O
the	O
correlation	B-MED
of	O
these	O
scores	B-MED
with	O
the	O
30-	O
day	B-MED
mortality	B-MED
in	O
our	O
study	B-MED
.	O
	
we	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-MED
grading	I-MED
scoring	I-MED
systems	I-MED
ich	B-MED
score	I-MED
,	O
func	B-MED
score	I-MED
and	O
intracerebral	B-MED
hemorrhage	I-MED
grading	I-MED
scale	I-MED
ich-gs	B-MED
on	O
our	O
population	B-MED
to	O
evaluate	O
the	O
correlation	B-MED
of	O
these	O
scores	B-MED
with	O
the	O
30-	O
day	B-MED
mortality	B-MED
in	O
our	O
study	B-MED
.	O
	
from	O
342	O
patients	B-MED
mean	O
age	B-MED
67	O
years	B-MED
,	O
mean	O
glasgow	B-MED
coma	I-MED
scale	I-MED
gcs	B-MED
on	O
admission	B-MED
9	O
,	O
mean	O
ich	B-MED
volume	B-MED
62.19	O
ml	O
,	O
most	O
common	O
hematoma	B-MED
location	B-MED
basal	B-MED
ganglia	I-MED
43.9	O
,	O
102	O
received	O
surgical	B-MED
and	O
240	O
conservative	B-MED
treatment	I-MED
.	O
	
the	O
30-	O
day	B-MED
mortality	B-MED
was	O
25.15	O
.	O
	
in	O
a	O
multivariate	B-MED
analysis	I-MED
,	O
gcs	B-MED
odds	B-MED
ratio	I-MED
or	B-MED
=0	O
,	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
=0	O
,	O
p	O
<	O
0.001	O
,	O
bleeding	B-MED
volume	B-MED
or	B-MED
=	O
1.012	O
per	O
ml	O
,	O
95%	O
ci	B-MED
=	O
1.007	O
-	O
1.017	O
,	O
p	O
<	O
0.001	O
,	O
and	O
infratentorial	B-MED
hematoma	B-MED
location	B-MED
or	B-MED
=	O
5.381	O
,	O
95%	O
ci	B-MED
=	O
2.166	O
,	O
p	O
=	O
0.009	O
were	O
significant	O
predictors	B-MED
for	O
the	O
30-	O
day	B-MED
mortality	B-MED
.	O
	
after	O
receiver	B-MED
operating	I-MED
characteristics	I-MED
analysis	B-MED
,	O
we	O
defined	O
a	O
""""	O
high-risk	B-MED
group	I-MED
""""	O
for	O
an	O
unfavorable	O
short-term	B-MED
outcome	B-MED
with	O
gcs	B-MED
<11	O
and	O
ich	B-MED
volume	B-MED
>32	O
ml	O
supratentorially	B-MED
or	O
21	O
ml	O
infratentorially	B-MED
.	O
	
using	O
pearson	B-MED
correlation	I-MED
,	O
we	O
found	O
a	O
correlation	B-MED
of	O
0.986	O
between	O
ich	B-MED
score	I-MED
and	O
30-	O
day	B-MED
mortality	B-MED
p	O
<	O
0.001	O
,	O
0.853	O
between	O
func	B-MED
score	I-MED
and	O
30-	O
day	B-MED
mortality	B-MED
p	O
=	O
0.001	O
,	O
and	O
0.924	O
between	O
ich-gs	B-MED
and	O
30-	O
day	B-MED
mortality	B-MED
p	O
=	O
0.001	O
.	O
	
gcs	B-MED
score	B-MED
on	O
admission	B-MED
together	O
with	O
the	O
baseline	B-MED
volume	B-MED
and	O
localization	B-MED
of	O
the	O
hemorrhage	B-MED
are	O
strong	O
predictors	B-MED
for	O
30-	O
day	B-MED
mortality	B-MED
in	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
intracerebral	B-MED
hemorrhage	I-MED
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high-risk	B-MED
patients	B-MED
with	O
poor	O
short-term	B-MED
outcome	B-MED
.	O
	
the	O
ich	B-MED
score	I-MED
and	O
the	O
ich-gs	B-MED
accurately	B-MED
predict	B-MED
the	O
30-	O
day	B-MED
mortality	B-MED
.	O
	
gga-mir-21	B-MED
inhibits	B-MED
chicken	B-MED
pre-adipocyte	B-MED
proliferation	B-MED
in	O
part	O
by	O
down-regulating	B-MED
kruppel-like	B-MED
factor	I-MED
5	I-MED
gga-mir-21	B-MED
is	O
abundantly	O
expressed	B-MED
in	O
chicken	B-MED
pre-adipocytes	B-MED
,	O
but	O
its	O
role	O
is	O
unclear	O
.	O
	
the	O
present	O
study	O
investigated	B-MED
the	O
role	O
of	O
gga-mir-21	B-MED
in	O
chicken	B-MED
pre-adipocyte	B-MED
proliferation	B-MED
.	O
	
cell	B-MED
proliferation	I-MED
assay	I-MED
and	O
gene	B-MED
expression	I-MED
analysis	I-MED
of	O
proliferating	B-MED
cell	I-MED
nuclear	I-MED
antigen	I-MED
pcna	B-MED
showed	O
that	O
the	O
gga-mir-21	B-MED
mimic	B-MED
inhibited	B-MED
pre-adipocyte	B-MED
proliferation	B-MED
.	O
	
in	O
contrast	O
,	O
the	O
gga-mir-21	B-MED
inhibitor	B-MED
enhanced	B-MED
pre-adipocyte	B-MED
proliferation	B-MED
.	O
	
the	O
subsequent	O
investigation	B-MED
identified	O
kruppel-like	B-MED
factor	I-MED
5	I-MED
klf5	B-MED
mrna	B-MED
as	O
a	O
target	B-MED
of	O
gga-mir-21	B-MED
.	O
	
the	O
gga-mir-21	B-MED
mimic	B-MED
inhibited	B-MED
klf5	B-MED
3	B-MED
reporter	B-MED
activity	B-MED
and	O
decreased	B-MED
endogenous	B-MED
klf5	B-MED
expression	B-MED
in	O
primary	B-MED
pre-adipocytes	B-MED
.	O
	
klf5	B-MED
knockdown	B-MED
using	O
rnai	B-MED
had	O
a	O
similar	O
effect	B-MED
to	O
that	O
of	O
the	O
gga-mir-21	B-MED
mimic	B-MED
on	O
cell	B-MED
proliferation	I-MED
.	O
	
the	O
promoting	B-MED
effect	B-MED
of	O
the	O
gga-mir-21	B-MED
inhibitor	B-MED
on	O
pre-adipocyte	B-MED
proliferation	B-MED
was	O
partially	O
attenuated	B-MED
by	O
klf5	B-MED
knockdown	B-MED
.	O
	
taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
mir-21	B-MED
inhibits	O
chicken	B-MED
pre-adipocyte	B-MED
proliferation	B-MED
,	O
at	O
least	O
in	O
part	O
,	O
by	O
targeting	B-MED
klf5	B-MED
.	O
	
the	O
application	B-MED
of	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
to	O
reflective	B-MED
writing	I-MED
for	O
medical	B-MED
humanities	I-MED
literature	B-MED
study	I-MED
to	O
enhance	B-MED
students'	B-MED
empathy	B-MED
,	O
critical	B-MED
thinking	I-MED
,	O
and	O
reflective	B-MED
writing	I-MED
to	O
facilitate	O
interdisciplinary	B-MED
collaboration	I-MED
and	O
to	O
make	O
connections	B-MED
between	O
patients'	B-MED
diseases	B-MED
and	O
their	O
social	B-MED
/	O
cultural	B-MED
contexts	I-MED
,	O
the	O
study	B-MED
examined	B-MED
whether	O
the	O
use	O
of	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
in	O
reflective	B-MED
writing	I-MED
for	O
medical	B-MED
humanities	I-MED
literature	O
acquisition	B-MED
could	O
have	O
positive	B-MED
effects	I-MED
on	O
medical	B-MED
university	I-MED
students	B-MED
in	O
terms	O
of	O
empathy	B-MED
,	O
critical	B-MED
thinking	I-MED
,	O
and	O
reflective	B-MED
writing	I-MED
.	O
	
a	O
15-week	B-MED
quasi-experimental	B-MED
design	I-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
learning	B-MED
outcomes	I-MED
.	O
	
after	O
conducting	O
cluster	B-MED
algorithms	I-MED
,	O
heterogeneous	B-MED
learning	I-MED
clusters	I-MED
experimental	B-MED
group	I-MED
n	O
=	O
43	O
and	O
non-heterogeneous	B-MED
learning	I-MED
clusters	I-MED
control	B-MED
group	I-MED
n	O
=	O
43	O
were	O
derived	O
for	O
a	O
medical	B-MED
humanities	I-MED
literature	B-MED
study	I-MED
.	O
	
before	O
and	O
after	O
the	O
intervention	B-MED
,	O
an	O
empathy	B-MED
scale	I-MED
in	O
patient	B-MED
care	I-MED
es	B-MED
-	O
pc	B-MED
,	O
a	O
critical	B-MED
thinking	I-MED
disposition	I-MED
assessment	I-MED
ctda-r	B-MED
,	O
and	O
a	O
reflective	B-MED
writing	I-MED
test	I-MED
were	O
administered	B-MED
to	O
both	O
groups	B-MED
.	O
	
the	O
findings	O
showed	O
that	O
on	O
the	O
empathy	B-MED
scale	I-MED
,	O
significant	O
differences	O
in	O
the	O
""""	O
behavioral	B-MED
empathy	I-MED
""""	O
""""	O
affective	B-MED
empathy	I-MED
""""	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post-test	B-MED
mean	I-MED
scores	I-MED
of	O
the	O
experimental	B-MED
group	I-MED
and	O
those	O
of	O
the	O
control	B-MED
group	I-MED
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
""""	O
intelligent	B-MED
empathy	I-MED
""""	O
regarding	O
critical	B-MED
thinking	I-MED
,	O
there	O
were	O
significant	O
differences	O
in	O
""""	O
systematicity	B-MED
and	O
analyticity	B-MED
""""	O
""""	O
skepticism	B-MED
and	O
well-informed	B-MED
""""	O
""""	O
maturity	B-MED
and	O
skepticism	B-MED
""""	O
and	O
overall	O
sections	O
.	O
	
as	O
for	O
reflective	B-MED
writing	I-MED
,	O
significant	O
differences	O
existed	O
in	O
""""	O
ideas	B-MED
""""	O
""""	O
voice	B-MED
and	O
point	B-MED
of	I-MED
view	I-MED
""""	O
""""	O
critical	B-MED
thinking	I-MED
and	O
representation	B-MED
""""	O
""""	O
depth	B-MED
of	I-MED
reflection	I-MED
on	O
personal	B-MED
growth	I-MED
""""	O
and	O
overall	O
sections	O
,	O
but	O
not	O
in	O
""""	O
focus	B-MED
and	O
context	B-MED
structure	I-MED
""""	O
and	O
""""	O
language	B-MED
and	O
conventions	B-MED
""""	O
this	O
study	B-MED
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
in	O
reflective	B-MED
writing	I-MED
about	O
medical	B-MED
humanities	I-MED
literature	O
to	O
facilitate	O
interdisciplinary	B-MED
cooperation	I-MED
to	O
provide	O
more	O
humanizing	O
medical	B-MED
care	I-MED
.	O
	
the	O
usefulness	O
of	O
employing	B-MED
an	O
electronic	B-MED
traction	I-MED
table	I-MED
to	O
determine	O
flexibility	B-MED
in	O
adolescent	B-MED
idiopathic	I-MED
scoliosis	I-MED
the	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
develop	B-MED
new	O
equipment	B-MED
for	O
the	O
assessment	B-MED
of	O
the	O
flexibility	B-MED
of	O
the	O
spine	B-MED
with	O
different	O
forces	B-MED
.	O
	
this	O
new	O
system	B-MED
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	B-MED
idiopathic	I-MED
scoliosis	I-MED
ais	B-MED
for	O
the	O
selection	B-MED
of	O
fusion	B-MED
levels	I-MED
and	O
surgical	B-MED
success	B-MED
.	O
	
eighteen	O
patients	B-MED
suffering	O
from	O
ais	B-MED
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	B-MED
instrumented	B-MED
spinal	I-MED
fusion	I-MED
in	O
our	O
clinic	B-MED
were	O
recruited	O
in	O
this	O
study	B-MED
.	O
	
the	O
electronic	B-MED
traction	I-MED
table	I-MED
ett	B-MED
that	O
was	O
designed	O
in	O
our	O
clinic	B-MED
was	O
used	O
to	O
evaluate	O
the	O
radiogical	B-MED
and	O
clinical	B-MED
parameters	B-MED
of	O
the	O
spine	B-MED
.	O
	
the	O
significant	O
prescriptive	B-MED
angle	I-MED
of	O
major	O
cobb	B-MED
angles	I-MED
between	O
postoperative	B-MED
angles	I-MED
were	O
longitudinal	B-MED
traction	B-MED
and	O
lateral	B-MED
pushing	I-MED
cobb	I-MED
angles	I-MED
.	O
	
longitudinal	B-MED
traction	B-MED
and	O
lateral	B-MED
pushing	I-MED
angles	I-MED
were	O
more	O
correlated	O
with	O
correction	B-MED
ratios	I-MED
.	O
	
there	O
was	O
a	O
significant	B-MED
difference	O
between	O
longitudinal	B-MED
traction	B-MED
minor	O
cobb	B-MED
angle	I-MED
,	O
longitudinal	B-MED
traction	B-MED
lateral	B-MED
pushing	I-MED
minor	I-MED
cobb	I-MED
angle	I-MED
and	O
postoperative	B-MED
minor	I-MED
cobb	I-MED
angles	I-MED
.	O
	
the	O
deformity	B-MED
is	O
needed	O
to	O
balance	O
both	O
tractional	B-MED
and	O
rotational	B-MED
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	O
.	O
	
electronic	O
traction	O
table	O
is	O
a	O
new	O
device	O
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	O
traction	O
and	O
lateral	O
pushing	O
radiographs	O
.	O
	
it	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	O
and	O
distal	O
end	O
of	O
the	O
vertebral	O
column	I-MED
the	O
messaging	B-MED
for	I-MED
diabetes	I-MED
intervention	B-MED
reduced	O
barriers	B-MED
to	O
medication	B-MED
adherence	I-MED
among	O
low-income	B-MED
,	O
diverse	O
adults	B-MED
with	O
type	B-MED
2	I-MED
nonadherence	B-MED
to	O
diabetes	B-MED
medication	B-MED
is	O
prevalent	O
and	O
costly	O
.	O
	
messaging	B-MED
for	I-MED
diabetes	I-MED
med	B-MED
,	O
a	O
mobile	B-MED
health	I-MED
mhealth	B-MED
intervention	B-MED
,	O
identified	O
and	O
addressed	O
user	B-MED
-specific	O
barriers	B-MED
to	O
medication	B-MED
adherence	I-MED
.	O
	
we	O
assessed	O
whether	O
med	B-MED
reduced	O
users	B-MED
'	O
targeted	O
barriers	B-MED
and	O
if	O
barrier	B-MED
reductions	O
were	O
associated	O
with	O
within-participant	B-MED
improvements	O
in	O
adherence	B-MED
or	O
glycemic	B-MED
control	I-MED
hba1c	B-MED
.	O
	
adults	B-MED
n	O
=	O
80	O
with	O
type	B-MED
2	I-MED
diabetes	I-MED
completed	O
self-report	O
measures	O
identifying	O
barriers	B-MED
to	O
adherence	B-MED
at	O
baseline	O
and	O
monthly	B-MED
for	O
3	O
months	B-MED
.	O
	
at	O
each	O
assessment	B-MED
,	O
17	O
barriers	B-MED
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	B-MED
.	O
	
each	O
subsequent	O
month	B-MED
,	O
users	B-MED
received	O
daily	O
text	B-MED
messages	I-MED
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	B-MED
.	O
	
targeted	O
barriers	B-MED
were	O
different	O
for	O
each	O
participant	B-MED
and	O
could	O
change	O
monthly	B-MED
.	O
	
paired	O
t-tests	B-MED
assessed	O
within-participant	B-MED
improvement	O
in	O
targeted	O
barriers	B-MED
each	O
month	B-MED
,	O
and	O
nested	O
regression	B-MED
models	I-MED
assessed	O
if	O
changes	O
in	O
a	O
participant's	B-MED
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	B-MED
and	O
hba1c	B-MED
.	O
	
participants	B-MED
were	O
69%	O
non-white	O
and	O
82%	O
had	O
incomes	O
<	O
.	O
	
average	O
hba1c	B-MED
was	O
8.2	O
2.0	O
.	O
	
assessment	O
completion	O
rates	O
were	O
100%	O
at	O
baseline	O
,	O
59%	O
at	O
1	O
month	B-MED
,	O
30%	O
at	O
2	O
months	B-MED
,	O
and	O
65%	O
at	O
3	O
months	B-MED
.	O
	
the	O
most	O
commonly	O
reported	O
barriers	B-MED
were	O
the	O
cost	B-MED
of	O
medications	B-MED
76%	O
,	O
believing	O
medications	B-MED
are	O
harmful	O
58%	O
,	O
and	O
lacking	O
information	O
about	O
medications	B-MED
53%	O
.	O
	
participants	B-MED
'	O
barrier	B-MED
scores	O
improved	O
each	O
month	B-MED
and	O
barrier	B-MED
improvement	O
predicted	O
adherence	B-MED
assessed	O
via	O
nightly	O
adherence	B-MED
assessment	O
text	B-MED
messages	I-MED
p	O
<	O
001	O
.	O
	
among	O
participants	B-MED
who	O
completed	O
assessments	O
each	O
month	B-MED
,	O
barrier	B-MED
improvement	O
in	O
months	B-MED
2	O
and	O
3	O
p	O
<	O
05	O
predicted	O
hba1c	B-MED
improvement	O
.	O
	
iterative	O
,	O
individual	O
tailoring	O
may	O
overcome	O
users	B-MED
'	O
barriers	B-MED
to	O
adherence	B-MED
.	O
	
attrition	O
is	O
a	O
challenge	O
for	O
mhealth	B-MED
interventions	B-MED
among	O
low-income	B-MED
patients	B-MED
.	O
	
macular	B-MED
ganglion	B-MED
cell	I-MED
-	O
inner	B-MED
plexiform	I-MED
layer	I-MED
thickness	B-MED
is	O
associated	B-MED
with	I-MED
clinical	B-MED
progression	I-MED
in	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
and	O
alzheimers	B-MED
disease	I-MED
we	O
investigated	O
the	O
association	O
of	O
the	O
macular	B-MED
ganglion	B-MED
cell	I-MED
-	O
inner	B-MED
plexiform	I-MED
layer	I-MED
gcipl	B-MED
and	O
peripapillary	B-MED
retinal	I-MED
nerve	I-MED
fiber	I-MED
layer	I-MED
rnfl	B-MED
thicknesses	B-MED
with	O
disease	B-MED
progression	I-MED
in	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
mci	B-MED
and	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
.	O
	
we	O
recruited	O
42	O
patients	B-MED
with	O
ad	B-MED
,	O
26	O
with	O
mci	B-MED
,	O
and	O
66	O
normal	O
elderly	B-MED
controls	I-MED
.	O
	
the	O
thicknesses	B-MED
of	O
the	O
rnfl	B-MED
and	O
gcipl	B-MED
were	O
measured	O
via	O
spectral-domain	B-MED
optic	I-MED
coherent	I-MED
tomography	I-MED
in	O
all	O
participants	B-MED
at	O
baseline	B-MED
.	O
	
the	O
patients	B-MED
with	O
mci	B-MED
or	O
ad	B-MED
underwent	O
clinical	B-MED
and	O
neuropsychological	B-MED
tests	I-MED
at	O
baseline	B-MED
and	O
once	B-MED
every	I-MED
year	I-MED
thereafter	I-MED
for	I-MED
2	I-MED
years	I-MED
.	O
	
the	O
clinical	B-MED
dementia	I-MED
rating	I-MED
scale-sum	I-MED
of	I-MED
boxes	I-MED
cdr-sb	B-MED
score	B-MED
exhibited	O
significant	O
negative	B-MED
relationships	B-MED
with	O
the	O
average	B-MED
gcipl	I-MED
thickness	B-MED
β	O
=	O
-0	O
,	O
p	O
<	O
0.05	O
and	O
the	O
gcipl	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
superonasal	B-MED
,	O
and	O
inferonasal	B-MED
sectors	I-MED
.	O
	
the	O
composite	B-MED
memory	I-MED
score	I-MED
exhibited	O
significant	O
positive	B-MED
associations	B-MED
with	O
the	O
average	B-MED
gcipl	I-MED
thickness	B-MED
and	O
the	O
gcipl	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
inferonasal	B-MED
,	O
and	O
inferotemporal	B-MED
sectors	I-MED
.	O
	
the	O
temporal	B-MED
rnfl	I-MED
thickness	B-MED
,	O
the	O
average	O
and	O
minimum	O
gcipl	B-MED
thicknesses	B-MED
,	O
and	O
the	O
gcipl	B-MED
thickness	B-MED
in	O
the	O
inferonasal	B-MED
,	O
inferior	B-MED
,	O
and	O
inferotemporal	B-MED
sectors	I-MED
at	O
baseline	B-MED
were	O
significantly	O
reduced	B-MED
in	O
mci	B-MED
patients	B-MED
who	O
were	O
converted	O
to	O
ad	B-MED
compared	O
to	O
stable	O
mci	B-MED
patients	B-MED
.	O
	
the	O
change	O
of	O
cdr-sb	B-MED
from	O
baseline	B-MED
to	O
2	O
years	B-MED
exhibited	O
significant	O
negative	B-MED
associations	B-MED
with	O
the	O
average	O
β	O
=	O
-0	O
,	O
p	O
=	O
0.006	O
and	O
minimum	B-MED
gcipl	I-MED
thicknesses	B-MED
as	O
well	O
as	O
gcipl	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
superior	B-MED
,	O
superonasal	B-MED
,	O
and	O
inferonasal	B-MED
sectors	I-MED
at	O
baseline	B-MED
.	O
	
our	O
data	O
suggest	O
that	O
macular	O
gcipl	B-MED
thickness	B-MED
represents	O
a	O
promising	O
biomarker	B-MED
for	O
monitoring	O
the	O
progression	B-MED
of	O
mci	B-MED
and	O
green	B-MED
and	O
rapid	B-MED
synthesis	B-MED
of	O
silver	B-MED
nanoparticles	B-MED
using	O
borago	B-MED
officinalis	I-MED
leaf	B-MED
extract	B-MED
anticancer	B-MED
and	O
antibacterial	B-MED
activities	I-MED
this	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	B-MED
effective	B-MED
,	O
and	O
ecofriendly	B-MED
synthesis	B-MED
of	O
silver	B-MED
nanoparticles	B-MED
agnps	B-MED
using	O
borago	B-MED
officinalis	I-MED
leaves	B-MED
extract	B-MED
efficiently	B-MED
.	O
	
the	O
biosynthesis	B-MED
of	O
agnps	B-MED
was	O
verified	B-MED
by	O
uv-vis	B-MED
spectrum	I-MED
which	O
showed	O
the	O
surface	B-MED
plasmon	I-MED
resonance	I-MED
spr	B-MED
band	O
at	O
422	O
nm	O
.	O
	
transmission	B-MED
electron	I-MED
microscope	I-MED
tem	I-MED
analysis	I-MED
revealed	O
that	O
the	O
particles	B-MED
were	O
spherical	B-MED
,	O
hexagonal	B-MED
,	O
and	O
irregular	B-MED
in	O
shape	B-MED
and	O
had	O
size	B-MED
ranging	B-MED
from	O
30	O
to	O
80	O
nm	O
.	O
	
the	O
energy	B-MED
dispersive	I-MED
x-ray	I-MED
spectroscopy	I-MED
edx	B-MED
and	O
elemental	B-MED
mapping	I-MED
have	O
displayed	O
the	O
purity	B-MED
and	O
maximum	B-MED
distribution	B-MED
of	O
silver	B-MED
in	O
the	O
agnps	B-MED
.	O
	
the	O
crystalline	B-MED
nature	O
of	O
agnps	B-MED
had	O
been	O
identified	B-MED
using	O
x-ray	B-MED
diffraction	I-MED
xrd	B-MED
and	O
selected	B-MED
area	I-MED
diffraction	I-MED
pattern	I-MED
saed	O
.	O
	
the	O
particle	B-MED
size	I-MED
analysis	B-MED
revealed	O
that	O
the	O
z-average	B-MED
diameter	B-MED
of	O
the	O
agnps	B-MED
was	O
50.86	O
nm	O
with	O
polydispersity	B-MED
index	I-MED
pdi	B-MED
0.136	O
.	O
	
zeta	B-MED
potential	I-MED
analysis	B-MED
displayed	O
the	O
colloidal	B-MED
stability	I-MED
of	O
agnps	B-MED
.	O
	
this	O
work	O
also	O
showed	O
the	O
efficacy	B-MED
of	O
agnps	B-MED
against	O
lung	B-MED
cancer	B-MED
cell	I-MED
lines	I-MED
a549	B-MED
and	O
cervical	B-MED
cancer	B-MED
cell	I-MED
line	I-MED
hela	B-MED
,	O
in	B-MED
vitro	I-MED
.	O
	
the	O
agnps	B-MED
showed	O
cytotoxicity	B-MED
to	O
the	O
a549	B-MED
and	O
hela	B-MED
cancer	B-MED
cell	I-MED
line	I-MED
at	O
the	O
concentrations	B-MED
5	O
and	O
2	O
μg/ml	O
.	O
	
the	O
agnps	B-MED
were	O
also	O
explored	O
for	O
the	O
antibacterial	B-MED
activity	I-MED
including	O
biofilm	B-MED
inhibition	B-MED
against	O
pathogenic	B-MED
bacteria	B-MED
.	O
	
the	O
b	B-MED
.	O
	
officinalis	I-MED
leaves	B-MED
extract	B-MED
can	O
be	O
used	O
efficiently	B-MED
for	O
green	O
synthesis	B-MED
agnps	B-MED
.	O
	
the	O
biosynthesized	O
agnps	B-MED
demonstrated	O
potentials	B-MED
as	O
anticancer	B-MED
and	O
antibacterial	B-MED
agents	I-MED
.	O
	
this	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	B-MED
of	O
new	O
anticancer	B-MED
and	O
antimicrobial	B-MED
agents	I-MED
.	O
	
genotyping	B-MED
of	O
staphylococcus	B-MED
aureus	I-MED
in	O
bovine	B-MED
mastitis	I-MED
and	O
correlation	O
to	O
phenotypic	B-MED
characteristics	B-MED
reducing	O
the	O
prevalence	O
of	O
mastitis	B-MED
caused	O
by	O
staphylococcus	B-MED
aureus	I-MED
s	B-MED
.	O
	
aureus	I-MED
is	O
essential	O
to	O
improve	O
animal	B-MED
health	B-MED
and	O
reduce	O
economic	O
losses	O
for	O
farmers	B-MED
.	O
	
the	O
clinical	O
outcome	O
of	O
acute	B-MED
mastitis	I-MED
and	O
risk	B-MED
of	O
progression	O
to	O
persistent	B-MED
mastitis	B-MED
can	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
be	O
related	O
to	O
genetic	B-MED
variants	I-MED
of	O
the	O
strain	B-MED
causing	O
the	O
infection	B-MED
.	O
	
in	O
the	O
present	O
study	B-MED
we	O
have	O
used	O
microarrays	B-MED
to	O
investigate	O
the	O
presence	O
of	O
virulence	B-MED
genes	B-MED
in	O
s	B-MED
.	O
	
aureus	I-MED
isolates	O
from	O
dairy	B-MED
cows	I-MED
with	O
acute	B-MED
clinical	I-MED
mastitis	I-MED
n=70	O
and	O
correlated	O
the	O
findings	B-MED
to	O
other	O
genotypic	B-MED
and	O
phenotypic	B-MED
characteristics	B-MED
.	O
	
among	O
the	O
most	O
commonly	O
found	O
virulence	B-MED
factors	I-MED
were	O
genes	B-MED
encoding	B-MED
several	O
hemolysin	B-MED
types	B-MED
,	O
leukocidins	B-MED
d	I-MED
and	O
lukm	B-MED
/	O
lukf-p83	B-MED
,	O
clumping	B-MED
factors	I-MED
a	I-MED
and	O
b	B-MED
,	O
fibrinogen	B-MED
binding	I-MED
protein	I-MED
and	O
fibronectin-binding	B-MED
protein	I-MED
a	I-MED
.	O
	
some	O
virulence	B-MED
factors	I-MED
e.g	O
.	O
	
fibronectin-binding	B-MED
protein	I-MED
b	I-MED
and	O
staphylococcus	B-MED
aureus	I-MED
surface	B-MED
protein	I-MED
g	I-MED
were	O
less	O
common	O
.	O
	
genes	B-MED
coding	O
for	O
several	O
staphylococcal	B-MED
enterotoxins	I-MED
and	O
toxic	B-MED
shock	I-MED
syndrome	I-MED
toxin-1	I-MED
tsst-1	B-MED
were	O
commonly	O
found	O
,	O
especially	O
in	O
one	O
major	O
pulsotype	B-MED
.	O
	
no	B-MED
beta-lactamase	B-MED
genes	I-MED
were	O
found	O
in	O
any	O
common	O
pulsotype	B-MED
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	B-MED
,	O
indicated	O
to	O
be	O
of	O
human	B-MED
origin	I-MED
.	O
	
production	O
of	O
tsst-1	B-MED
,	O
enterotoxins	B-MED
,	O
hemolysins	B-MED
and	O
beta-lactamase	B-MED
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	B-MED
.	O
	
this	O
study	B-MED
reveals	O
a	O
number	O
of	O
genotypic	B-MED
differences	B-MED
and	O
similarities	B-MED
among	O
common	O
and	O
rare	O
pulsotypes	B-MED
of	O
s	B-MED
.	O
	
aureus	I-MED
from	O
cases	O
of	O
mastitis	B-MED
in	O
sweden	B-MED
.	O
	
the	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic	B-MED
tools	I-MED
to	O
guide	O
on-farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-MED
health	B-MED
from	O
a	O
specific	O
s	B-MED
.	O
	
aureus	I-MED
genotype	B-MED
.	O
	
uveitis	B-MED
in	O
spondyloarthritis	B-MED
patients	B-MED
and	O
its	O
association	B-MED
with	I-MED
hla-b27	B-MED
histocompatibility	I-MED
antigen	I-MED
prospective	B-MED
study	I-MED
t	O
o	O
perform	O
a	O
prospective	B-MED
study	I-MED
of	O
clinical	B-MED
presentation	I-MED
and	O
course	B-MED
of	O
uveitis	B-MED
in	O
spondyloarthritis	B-MED
spa	B-MED
patients	B-MED
as	O
well	O
as	O
its	O
association	B-MED
with	I-MED
the	O
hla-b27	B-MED
histocompatibility	I-MED
antigen	I-MED
.	O
	
the	O
study	B-MED
included	O
219	O
patients	B-MED
with	O
uveitis	B-MED
,	O
all	O
tested	B-MED
for	O
hla-b27	B-MED
antigen	I-MED
and	O
various	O
infections	B-MED
viral	B-MED
,	O
bacterial	B-MED
,	O
and	O
parasitic	B-MED
as	O
well	O
as	O
examined	B-MED
for	O
locomotive	B-MED
system	I-MED
involvement	B-MED
.	O
	
the	O
presence	B-MED
of	O
the	O
hla-b27	B-MED
antigen	I-MED
was	O
determined	B-MED
in	O
142	O
64.8	O
out	O
of	O
219	O
patients	B-MED
,	O
of	O
them	O
87	O
were	O
diagnosed	B-MED
with	O
an	O
entity	B-MED
of	O
the	O
spa	B-MED
group	B-MED
.	O
	
the	O
remaining	B-MED
77	O
35.2	O
patients	B-MED
appeared	O
to	O
be	O
hla-b27	B-MED
-	O
negative	B-MED
,	O
but	O
13	O
were	O
still	O
diagnosed	B-MED
with	O
an	O
entity	B-MED
of	O
the	O
spa	B-MED
group	B-MED
.	O
	
there	O
were	O
10	O
4.6	O
patients	B-MED
with	O
2	O
or	O
more	O
diseases	B-MED
from	O
the	O
spa	B-MED
group	B-MED
clinical	O
decussation	O
.	O
	
when	O
comparing	B-MED
the	O
two	O
groups	B-MED
of	O
hla-b27-positive	B-MED
and	O
negative	B-MED
patients	B-MED
having	O
both	O
spa	B-MED
and	O
uveitis	B-MED
,	O
no	O
statistically	B-MED
significant	I-MED
difference	B-MED
was	O
found	O
as	O
to	O
the	O
age	B-MED
of	I-MED
onset	I-MED
,	O
site	B-MED
,	O
frequency	B-MED
of	I-MED
attacks	I-MED
,	O
and	O
uni	B-MED
-	O
or	O
bilateral	B-MED
involvement	B-MED
p>0	O
.	O
	
we	O
also	O
performed	B-MED
a	O
comparison	B-MED
of	O
hla-b27-positive	B-MED
and	O
negative	B-MED
patients	B-MED
with	O
no	O
account	O
to	O
their	O
spa	B-MED
status	B-MED
and	O
revealed	B-MED
a	O
higher	B-MED
complication	B-MED
rate	B-MED
in	O
those	O
that	O
were	O
negative	B-MED
p<0	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
hla-b27	B-MED
-	O
negative	B-MED
patients	B-MED
often	O
have	O
autoimmune	B-MED
or	O
infectious	B-MED
uveitis	I-MED
of	O
different	B-MED
origin	O
notable	O
for	O
long	B-MED
attacks	O
and	O
short	B-MED
remissions	B-MED
.	O
	
assessing	B-MED
the	O
site	B-MED
and	O
course	B-MED
of	O
uveitis	B-MED
as	O
well	O
as	O
hla-b27	B-MED
testing	B-MED
of	O
uveitis	B-MED
patients	B-MED
has	O
proved	O
important	B-MED
for	O
etiological	B-MED
diagnosis	B-MED
.	O
	
diseases	B-MED
of	O
the	O
spa	B-MED
group	B-MED
have	O
been	O
shown	O
to	O
be	O
6.7	O
times	B-MED
more	O
common	O
in	O
hla-b27-positive	B-MED
patients	B-MED
as	O
compared	B-MED
to	O
hla-b27	B-MED
-	O
negative	B-MED
ones	O
.	O
	
clinical	B-MED
presentation	I-MED
of	O
uveitis	B-MED
in	O
the	O
presence	B-MED
of	O
spa	B-MED
in	O
both	O
hla-b27-positive	B-MED
and	O
negative	B-MED
patients	B-MED
resembles	O
that	O
of	O
idiopathic	B-MED
uveitis	I-MED
-	O
an	O
independent	O
hla-b27	B-MED
-	O
associated	B-MED
syndrome	B-MED
р>0	O
.	O
	
cases	O
of	O
decussation	O
between	O
entities	B-MED
of	O
the	O
spa	B-MED
group	B-MED
are	O
usually	O
more	O
severe	B-MED
in	O
terms	O
of	O
clinical	B-MED
presentation	I-MED
and	O
course	B-MED
of	O
uveitis	B-MED
and	O
are	O
associated	B-MED
with	I-MED
a	O
worse	B-MED
prognosis	I-MED
.	O
	
complications	B-MED
of	O
uveitis	B-MED
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non-spa	B-MED
hla-b27	B-MED
-	O
negative	B-MED
patients	B-MED
human	B-MED
brucellosis	B-MED
in	O
south	B-MED
africa	I-MED
public	B-MED
health	I-MED
and	O
diagnostic	B-MED
pitfalls	I-MED
human	B-MED
brucellosis	B-MED
in	O
south	B-MED
africa	I-MED
sa	B-MED
is	O
under-diagnosed	B-MED
and	O
under-reported	B-MED
.	O
	
this	O
is	O
because	O
many	O
clinicians	B-MED
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected	B-MED
patients	I-MED
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	B-MED
and	O
insidious	B-MED
nature	B-MED
of	I-MED
the	I-MED
disease	I-MED
.	O
	
a	O
case	B-MED
of	O
human	B-MED
brucellosis	B-MED
caused	O
by	O
brucella	B-MED
melitensis	I-MED
in	O
a	O
patient	B-MED
from	O
the	O
western	B-MED
cape	I-MED
province	I-MED
of	O
sa	B-MED
is	O
described	B-MED
,	O
and	O
the	O
resulting	B-MED
exposure	O
of	O
staff	B-MED
members	I-MED
at	O
two	O
medical	B-MED
microbiology	I-MED
laboratories	I-MED
,	O
as	O
well	O
as	O
the	O
public	B-MED
health	I-MED
investigation	I-MED
that	O
was	O
conducted	O
,	O
are	O
discussed	O
.	O
	
this	O
article	B-MED
aims	B-MED
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	B-MED
between	O
public	B-MED
health	I-MED
,	O
medical	B-MED
and	O
veterinary	B-MED
services	B-MED
and	O
exposing	B-MED
deficiencies	I-MED
in	O
public	B-MED
health	I-MED
,	O
veterinary	B-MED
and	O
laboratory	B-MED
survey	B-MED
of	O
trichinella	B-MED
infection	I-MED
from	O
domestic	B-MED
pigs	I-MED
in	O
the	O
historical	B-MED
endemic	B-MED
areas	I-MED
of	O
henan	B-MED
province	I-MED
,	O
central	B-MED
china	I-MED
the	O
aim	B-MED
of	O
this	O
work	B-MED
was	O
to	O
investigate	B-MED
the	O
current	B-MED
situation	I-MED
of	O
trichinella	B-MED
infection	I-MED
from	O
domestic	B-MED
pigs	I-MED
in	O
the	O
historical	B-MED
endemic	B-MED
areas	I-MED
of	O
henan	B-MED
province	I-MED
,	O
central	B-MED
china	I-MED
.	O
	
a	O
total	O
of	O
823	O
diaphragm	B-MED
samples	I-MED
from	O
the	O
indoor-raised	B-MED
pigs	I-MED
were	O
collected	B-MED
in	O
five	B-MED
cities	B-MED
of	O
henan	B-MED
during	O
2014-2015	O
and	O
examined	B-MED
by	O
artificial	B-MED
digestion	I-MED
method	I-MED
.	O
	
the	O
overall	B-MED
prevalence	I-MED
of	O
trichinella	B-MED
infection	I-MED
in	O
pigs	B-MED
was	O
0.61	O
%	O
5/823	O
.	O
	
trichinella	B-MED
larvae	I-MED
were	O
detected	B-MED
in	O
0.91	O
%	O
5/550	O
of	O
pigs	B-MED
from	O
nanyang	B-MED
city	I-MED
of	O
henan	B-MED
.	O
	
the	O
larval	B-MED
burden	B-MED
in	O
infected	B-MED
animals	I-MED
was	O
0.03	O
larvae	B-MED
per	O
gram	O
lpg	O
of	O
muscles	B-MED
with	O
a	O
range	B-MED
from	O
0.02	O
to	O
0.05	O
lpg	O
.	O
	
the	O
larvae	B-MED
were	O
identified	B-MED
as	O
trichinella	B-MED
spiralis	I-MED
by	O
multiple	B-MED
pcr	I-MED
.	O
	
our	O
study	B-MED
confirms	B-MED
the	O
existence	B-MED
of	O
swine	B-MED
trichinellosis	B-MED
in	O
henan	B-MED
,	O
but	O
the	O
infection	B-MED
level	B-MED
was	O
under	O
the	O
minimum	B-MED
level	I-MED
for	O
defining	O
infectious	B-MED
sources	I-MED
for	O
humans	B-MED
.	O
	
however	O
,	O
the	O
prevalence	B-MED
of	O
swine	B-MED
trichinella	B-MED
infection	I-MED
in	O
henan	B-MED
need	O
to	O
be	O
further	O
evaluated	B-MED
with	O
a	O
large	B-MED
scale	I-MED
of	O
pork	B-MED
samples	I-MED
for	O
ensuring	O
meat	B-MED
food	B-MED
safety	I-MED
.	O
	
voriconazole	B-MED
metabolism	B-MED
is	O
influenced	B-MED
by	O
severe	B-MED
inflammation	B-MED
a	O
prospective	B-MED
study	I-MED
during	O
an	O
infection	B-MED
or	O
inflammation	B-MED
,	O
several	B-MED
drug	B-MED
-	O
metabolizing	B-MED
enzymes	B-MED
in	O
the	O
liver	B-MED
are	O
down-regulated	B-MED
,	O
including	O
cytochrome	B-MED
p450	I-MED
iso-enzymes	I-MED
.	O
	
since	O
voriconazole	B-MED
is	O
extensively	B-MED
metabolized	B-MED
by	O
cytochrome	B-MED
p450	I-MED
iso-enzymes	I-MED
,	O
the	O
metabolism	B-MED
of	O
voriconazole	B-MED
can	O
be	O
influenced	B-MED
during	O
inflammation	B-MED
via	O
reduced	B-MED
clearance	B-MED
of	I-MED
the	I-MED
drug	I-MED
,	O
resulting	O
in	O
higher	B-MED
voriconazole	B-MED
trough	B-MED
concentrations	I-MED
.	O
	
to	O
investigate	O
prospectively	O
the	O
influence	B-MED
of	O
inflammation	B-MED
on	O
voriconazole	B-MED
metabolism	B-MED
and	O
voriconazole	B-MED
trough	B-MED
concent	I-MED
ratio	I-MED
ns	I-MED
.	O
	
a	O
prospective	O
observational	O
study	O
was	O
performed	O
at	O
the	O
university	O
medical	O
center	O
groningen	O
.	O
	
patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
18	O
years	O
old	O
and	O
treated	O
with	O
voriconazole	O
.	O
	
voriconazole	O
and	O
voriconazole-n-oxide	O
concentrations	O
were	O
determined	O
in	O
discarded	O
blood	O
samples	O
.	O
	
to	O
determine	O
the	O
degree	O
of	O
inflammation	O
,	O
c-reactive	O
protein	O
crp	O
concentrations	O
were	O
used	O
.	O
	
subsequently	O
,	O
a	O
longitudinal	O
data	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
inflammation	O
on	O
the	O
metabolic	O
ratio	B-MED
and	O
voriconazole	O
trough	O
concentration	O
.	O
	
thirty-four	O
patients	O
were	O
included	O
.	O
	
in	O
total	O
489	O
voriconazole	O
trough	O
concentrations	O
were	O
included	O
in	O
the	O
longitudinal	O
data	O
analysis	O
.	O
	
this	O
analysis	O
showed	O
that	O
inflammation	O
,	O
reflected	O
by	O
crp	O
concentrations	O
,	O
significantly	O
influence	O
d	O
the	O
metabolic	O
ratio	O
,	O
voriconazole	O
trough	O
concentration	O
and	O
voriconazole-n-oxide	O
concentration	O
all	O
p	O
<	O
0.001	O
,	O
when	O
corrected	O
for	O
other	O
factors	O
that	O
could	O
influence	O
voriconazole	O
metabolism	O
.	O
	
the	O
metabolic	O
ratio	O
was	O
decreased	O
by	O
0.99229	O
and	O
the	O
voriconazole-n-oxide	O
concentration	O
by	O
0.99775	O
,	O
while	O
the	O
voriconazole	O
trough	O
concentration	O
was	O
increased	O
by	O
1.005321	O
,	O
where	O
n	O
is	O
the	O
difference	O
in	O
crp	O
units	O
in	O
mg/l	O
.	O
	
this	O
study	O
shows	O
that	O
voriconazole	O
metabolism	O
is	O
decreased	O
during	O
inflammation	O
,	O
resulting	O
in	O
higher	O
voriconazole	O
trough	O
concentration	O
s	O
.	O
	
therefore	O
,	O
frequent	O
monitoring	O
of	O
voriconazole	O
serum	O
concentrations	O
is	O
recommended	O
during	O
and	O
following	O
severe	O
inflammation	B-MED
neoadjuvant	B-MED
chemotherapy	I-MED
of	O
ovarian	B-MED
cancer	I-MED
results	O
in	O
three	O
patterns	O
of	O
tumor-infiltrating	B-MED
lymphocyte	I-MED
response	B-MED
with	O
distinct	O
implications	O
for	O
immunotherapy	B-MED
purpose	O
some	O
forms	O
of	O
chemotherapy	B-MED
can	O
enhance	O
antitumor	B-MED
immunity	B-MED
through	O
immunogenic	B-MED
cell	B-MED
death	I-MED
,	O
resulting	O
in	O
increased	O
t-cell	B-MED
activation	I-MED
and	O
tumor	B-MED
infiltration	I-MED
.	O
	
such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-MED
to	O
immunotherapies	B-MED
,	O
including	O
checkpoint	B-MED
blockade	I-MED
.	O
	
we	O
investigated	O
whether	O
platinum	B-MED
-	O
and	O
taxane	B-MED
-based	O
chemotherapy	B-MED
for	O
ovarian	B-MED
cancer	I-MED
induces	O
immunologic	B-MED
changes	O
consistent	O
with	O
this	O
possibility	O
.	O
	
experimental	B-MED
design	I-MED
matched	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
neoadjuvant	B-MED
chemotherapy	I-MED
tumor	B-MED
samples	I-MED
from	O
26	O
high-grade	B-MED
serous	I-MED
carcinoma	I-MED
hgsc	B-MED
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-MED
ihc	B-MED
for	O
a	O
large	O
panel	O
of	O
immune	B-MED
cells	I-MED
and	O
associated	O
factors	O
.	O
	
the	O
prognostic	O
significance	O
of	O
post	B-MED
-	O
chemotherapy	B-MED
til	B-MED
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B-MED
n	O
=	O
90	O
neoadjuvant	B-MED
chemotherapy	I-MED
was	O
associated	O
with	O
increased	O
densities	O
of	O
cd3	B-MED
+	O
,	O
cd8	B-MED
+	O
,	O
cd8	B-MED
+	O
tia-1	B-MED
+	O
,	O
pd-1	B-MED
+	O
and	O
cd20	B-MED
+	O
til	B-MED
.	O
	
other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
cd79a	B-MED
+	O
cd138	B-MED
+	O
plasma	B-MED
cells	I-MED
,	O
cd68	B-MED
+	O
macrophages	B-MED
,	O
and	O
mhc	B-MED
class	I-MED
i	I-MED
on	O
tumor	B-MED
cells	I-MED
.	O
	
immunosuppressive	B-MED
cell	B-MED
types	O
were	O
also	O
unchanged	O
,	O
including	O
foxp3	B-MED
+	O
pd-1	B-MED
+	O
cells	B-MED
putative	O
regulatory	B-MED
t	I-MED
cells	I-MED
,	O
ido-1	B-MED
+	O
cells	O
,	O
and	O
pd-l1	B-MED
+	O
cells	O
both	O
macrophages	B-MED
and	O
tumor	B-MED
cells	I-MED
.	O
	
hierarchical	B-MED
clustering	I-MED
revealed	O
three	O
response	O
patterns	O
i	O
til	B-MED
high	O
tumors	B-MED
showed	O
increases	O
in	O
multiple	O
immune	B-MED
markers	I-MED
after	O
chemotherapy	B-MED
ii	O
til	B-MED
low	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
and	O
iii	O
til	B-MED
negative	B-MED
cases	O
generally	O
remained	O
negative	B-MED
.	O
	
despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	B-MED
til	B-MED
showed	O
limited	O
prognostic	O
significance.conclusions	O
chemotherapy	B-MED
augments	O
pre-existing	O
til	B-MED
responses	B-MED
but	O
fails	O
to	O
relieve	O
major	O
immune-suppressive	B-MED
mechanisms	I-MED
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O
	
our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-MED
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	B-MED
microenvironment	I-MED
.	O
	
the	O
adder	B-MED
vipera	B-MED
berus	I-MED
in	O
southern	B-MED
altay	I-MED
mountains	I-MED
population	B-MED
characteristics	I-MED
,	O
distribution	B-MED
,	O
morphology	B-MED
and	O
phylogenetic	B-MED
position	I-MED
as	O
the	O
most	O
widely	O
distributed	B-MED
snake	B-MED
in	O
eurasia	B-MED
,	O
the	O
adder	B-MED
vipera	B-MED
berus	I-MED
has	O
been	O
extensively	B-MED
investigated	B-MED
in	O
europe	B-MED
but	O
poorly	O
understood	O
in	O
asia	B-MED
.	O
	
the	O
southern	B-MED
altay	I-MED
mountains	I-MED
represent	O
the	O
adder's	B-MED
southern	B-MED
distribution	B-MED
limit	B-MED
in	O
central	B-MED
asia	I-MED
,	O
whereas	O
its	O
population	B-MED
status	I-MED
has	O
never	O
been	O
assessed	B-MED
.	O
	
we	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	B-MED
surveys	I-MED
for	O
the	O
adder	B-MED
at	O
two	O
areas	B-MED
of	O
southern	B-MED
altay	I-MED
mountains	I-MED
using	O
a	O
combination	B-MED
of	O
line	B-MED
transects	I-MED
and	O
random	B-MED
searches	B-MED
.	O
	
we	O
also	O
described	O
the	O
morphological	B-MED
characteristics	I-MED
of	O
the	O
collected	B-MED
specimens	I-MED
and	O
conducted	O
analyses	B-MED
of	O
external	B-MED
morphology	B-MED
and	O
molecular	B-MED
phylogeny	I-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
the	O
adder	B-MED
distributed	B-MED
in	O
both	O
survey	B-MED
sites	B-MED
and	O
we	O
recorded	B-MED
a	O
total	O
of	O
34	O
sightings	B-MED
.	O
	
in	O
kanas	B-MED
river	I-MED
valley	I-MED
,	O
the	O
estimated	B-MED
encounter	B-MED
rate	B-MED
over	O
a	O
total	O
of	O
137	O
km	O
transects	B-MED
was	O
0.15	O
0.05	O
sightings	B-MED
/km	O
.	O
	
the	O
occurrence	B-MED
of	O
melanism	B-MED
was	O
only	O
17%	O
.	O
	
the	O
small	B-MED
size	I-MED
was	O
typical	B-MED
for	O
the	O
adders	B-MED
in	O
southern	B-MED
altay	I-MED
mountains	I-MED
in	O
contrast	O
to	O
other	O
geographic	B-MED
populations	I-MED
of	O
the	O
nominate	B-MED
subspecies	B-MED
.	O
	
a	O
phylogenetic	B-MED
tree	I-MED
obtained	B-MED
by	O
bayesian	B-MED
inference	I-MED
based	O
on	O
dna	B-MED
sequences	I-MED
of	O
the	O
mitochondrial	B-MED
cytochrome	I-MED
b	I-MED
1	O
bp	O
grouped	B-MED
them	O
within	O
the	O
northern	B-MED
clade	I-MED
of	O
the	O
species	B-MED
but	O
failed	O
to	O
separate	B-MED
them	O
from	O
the	O
subspecies	B-MED
v	B-MED
.	O
	
b	I-MED
.	O
	
sachalinensis	I-MED
.	O
	
our	O
discovery	B-MED
extends	O
the	O
distribution	B-MED
range	B-MED
of	O
v	B-MED
.	O
	
berus	I-MED
and	O
provides	O
a	O
basis	B-MED
for	O
further	O
researches	B-MED
.	O
	
we	O
discuss	O
the	O
hypothesis	B-MED
that	O
the	O
adder	B-MED
expands	B-MED
its	O
distribution	B-MED
border	B-MED
to	O
the	O
southwest	B-MED
along	O
the	O
mountains	B-MED
'	O
elevation	B-MED
gradient	B-MED
,	O
but	O
the	O
population	B-MED
abundance	B-MED
declines	B-MED
gradually	B-MED
due	O
to	O
a	O
drying	B-MED
climate	I-MED
.	O
	
binding	B-MED
of	O
pollutants	B-MED
to	O
biomolecules	B-MED
a	O
simulation	B-MED
study	I-MED
a	O
number	O
of	O
cases	B-MED
around	O
the	O
world	B-MED
have	O
been	O
reported	O
where	O
animals	B-MED
were	O
found	B-MED
dead	I-MED
or	O
dying	B-MED
with	O
symptoms	B-MED
resembling	O
a	O
thiamine	B-MED
vitamin	B-MED
b	I-MED
deficiency	I-MED
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	B-MED
has	O
been	O
suggested	O
.	O
	
here	O
,	O
we	O
investigate	B-MED
whether	O
biomolecules	B-MED
involved	O
in	O
thiamin	B-MED
binding	I-MED
and	O
transport	B-MED
could	O
be	O
blocked	B-MED
by	O
a	O
range	O
of	O
different	O
pollutants	B-MED
.	O
	
we	O
used	O
in	B-MED
silico	I-MED
docking	B-MED
of	O
five	O
compound	B-MED
classes	B-MED
25	O
compounds	B-MED
in	O
total	O
to	O
each	O
of	O
five	O
targets	O
prion	B-MED
protein	I-MED
,	O
ecf-type	B-MED
abc	I-MED
transporter	I-MED
,	O
thi-box	B-MED
riboswitch	I-MED
receptor	I-MED
,	O
thiamin	B-MED
pyrophosphokinase	I-MED
,	O
and	O
ykof	B-MED
protein	I-MED
and	O
subsequently	O
performed	O
molecular	B-MED
dynamics	I-MED
md	I-MED
simulations	I-MED
to	O
assess	O
the	O
stability	B-MED
of	O
the	O
complexes	B-MED
.	O
	
the	O
compound	B-MED
classes	B-MED
were	O
thiamin	B-MED
analogues	B-MED
control	B-MED
,	O
pesticides	B-MED
,	O
veterinary	B-MED
medicines	B-MED
,	O
polychlorinated	B-MED
biphenyls	I-MED
,	O
and	O
dioxins	B-MED
,	O
all	O
of	O
which	O
are	O
prevalent	B-MED
in	O
the	O
environment	B-MED
to	O
some	O
extent	O
.	O
	
a	O
few	O
anthropogenic	O
compounds	B-MED
were	O
found	O
to	O
bind	B-MED
the	O
ecf-type	B-MED
abc	I-MED
transporter	I-MED
,	O
but	O
none	B-MED
binds	I-MED
stably	I-MED
to	O
prion	B-MED
protein	I-MED
.	O
	
for	O
the	O
riboswitch	B-MED
,	O
most	O
compounds	B-MED
remained	O
in	O
their	O
binding	B-MED
pockets	I-MED
during	O
50	O
ns	O
of	O
md	B-MED
simulation	I-MED
,	O
indicating	O
that	O
rna	B-MED
provides	O
a	O
promiscuous	O
binding	B-MED
site	I-MED
.	O
	
in	O
both	O
ykof	B-MED
and	O
thiamin	B-MED
pyrophosphokinase	I-MED
tpk	B-MED
,	O
most	O
compounds	B-MED
remain	O
tightly	B-MED
bound	I-MED
.	O
	
however	O
,	O
tpk	B-MED
biomolecules	B-MED
undergo	O
pollutant	B-MED
-	O
induced	B-MED
conformational	B-MED
changes	I-MED
.	O
	
although	O
most	O
compounds	B-MED
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	B-MED
methods	I-MED
like	O
free	B-MED
energy	I-MED
perturbation	I-MED
calculations	B-MED
before	O
firm	O
conclusions	B-MED
can	O
be	O
drawn	O
.	O
	
this	O
study	B-MED
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large-scale	O
quantitative	B-MED
computational	B-MED
screening	I-MED
of	O
interactions	B-MED
between	O
biological	B-MED
entities	I-MED
and	O
pollutant	B-MED
molecules	I-MED
.	O
	
characterisation	B-MED
of	O
methicillin-resistant	B-MED
staphylococcus	I-MED
aureus	I-MED
clinical	B-MED
isolates	B-MED
from	O
animals	B-MED
in	O
new	B-MED
zealand	I-MED
,	O
2012-2013	O
,	O
and	O
subclinical	B-MED
colonisation	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
in	O
auckland	B-MED
to	O
characterise	B-MED
methicillin-resistant	B-MED
staphylococcus	I-MED
aureus	I-MED
mrsa	B-MED
isolates	B-MED
from	O
infection	B-MED
sites	I-MED
in	O
animals	B-MED
in	O
new	B-MED
zealand	I-MED
and	O
assess	O
the	O
prevalence	B-MED
of	O
subclinical	B-MED
mrsa	B-MED
colonisation	I-MED
in	O
dogs	B-MED
and	O
cats	B-MED
attending	O
veterinary	B-MED
clinics	I-MED
in	O
auckland	B-MED
.	O
	
mrsa	B-MED
isolates	B-MED
from	O
clinical	B-MED
specimens	B-MED
obtained	O
by	O
the	O
main	O
new	B-MED
zealand	I-MED
veterinary	B-MED
diagnostic	I-MED
laboratories	I-MED
between	O
june	B-MED
2012	O
and	O
june	B-MED
2013	O
,	O
were	O
genotypically	B-MED
characterised	I-MED
by	O
dna	B-MED
microarray	I-MED
hybridisation	I-MED
analysis	I-MED
and	O
spa	B-MED
typing	B-MED
.	O
	
in	O
addition	O
,	O
nasal	B-MED
or	O
perineal	B-MED
skin	I-MED
swabs	B-MED
collected	O
from	O
a	O
cross-sectional	B-MED
sample	I-MED
of	O
dogs	B-MED
n=361	O
and	O
cats	B-MED
n=225	O
attending	O
29	O
veterinary	B-MED
clinics	I-MED
in	O
auckland	B-MED
during	O
the	O
same	O
period	B-MED
were	O
analysed	B-MED
for	O
mrsa	B-MED
by	O
culture	B-MED
.	O
	
eight	O
mrsa	B-MED
clinical	B-MED
isolates	B-MED
were	O
submitted	O
for	O
characterisation	B-MED
by	O
the	O
participating	O
laboratories	B-MED
.	O
	
the	O
isolates	B-MED
originated	O
from	O
five	O
dogs	B-MED
,	O
including	O
two	O
isolates	B-MED
from	O
the	O
same	O
dog	B-MED
,	O
one	O
foal	B-MED
,	O
and	O
one	O
isolate	B-MED
had	O
no	O
identification	O
of	O
the	O
source	B-MED
.	O
	
the	O
strain	B-MED
-	O
types	B-MED
identified	B-MED
were	O
ak3	B-MED
st-5	I-MED
sccmeciv	I-MED
t045	O
n=1	O
,	O
usa500	B-MED
st8	I-MED
sccmeciv	I-MED
t064	O
n=1	O
,	O
wspp	B-MED
st30	I-MED
sccmeciv	I-MED
t019	O
n=1	O
,	O
rhine	B-MED
hesse	I-MED
st5	I-MED
sccmecii	I-MED
t002	O
n=2	O
,	O
and	O
emrsa-15	B-MED
st22	I-MED
sccmeciv	I-MED
t032	O
n=3	O
.	O
	
no	O
mrsa	B-MED
were	O
isolated	B-MED
from	O
586	O
cultured	B-MED
swabs	I-MED
.	O
	
methicillin-susceptible	B-MED
s	I-MED
.	O
	
aureus	I-MED
were	O
detected	B-MED
in	O
9/257	O
3.5	O
swabs	B-MED
and	O
non-aureus	B-MED
staphylococci	I-MED
in	O
22/257	O
8.5	O
swabs	B-MED
.	O
	
the	O
estimated	O
true	O
mrsa	B-MED
subclinical	B-MED
colonisation	B-MED
prevalence	B-MED
was	O
0%	O
,	O
with	O
an	O
upper	O
95%	O
ci	B-MED
boundary	O
of	O
1.9	O
for	O
cats	B-MED
and	O
1.4	O
for	O
dogs	B-MED
.	O
	
the	O
modest	B-MED
number	I-MED
of	O
mrsa	B-MED
isolates	B-MED
submitted	O
for	O
this	O
study	B-MED
by	O
the	O
participating	O
laboratories	B-MED
suggests	O
clinical	B-MED
mrsa	B-MED
infection	I-MED
in	O
animals	B-MED
in	O
new	B-MED
zealand	I-MED
continues	O
to	O
be	O
sporadic	B-MED
.	O
	
the	O
wide	O
variety	O
of	O
strain	B-MED
-	O
types	B-MED
found	O
mirrored	O
the	O
evolving	O
strain	B-MED
-	O
type	B-MED
diversity	B-MED
observed	O
in	O
humans	B-MED
.	O
	
we	O
cannot	O
rule	O
out	O
bias	B-MED
due	O
to	O
the	O
non-random	B-MED
sampling	I-MED
of	O
dogs	B-MED
and	O
cats	B-MED
,	O
but	O
the	O
apparent	O
colonisation	B-MED
prevalence	B-MED
of	O
0%	O
was	O
consistent	B-MED
with	I-MED
the	O
low	O
prevalence	B-MED
of	O
subclinical	B-MED
colonisation	B-MED
in	O
humans	B-MED
in	O
new	B-MED
zealand	I-MED
.	O
	
these	O
similarities	B-MED
indicate	O
the	O
epidemiology	B-MED
of	O
animal	B-MED
and	O
human	B-MED
mrsa	B-MED
infections	I-MED
are	O
linked	O
.	O
	
in	O
the	O
last	O
decade	B-MED
,	O
the	O
prevalence	B-MED
of	O
human	B-MED
mrsa	B-MED
infections	I-MED
in	O
new	B-MED
zealand	I-MED
has	O
steadily	O
increased	B-MED
.	O
	
this	O
is	O
the	O
second	O
published	O
study	B-MED
of	O
mrsa	B-MED
in	O
animals	B-MED
in	O
new	B-MED
zealand	I-MED
.	O
	
the	O
results	O
indicate	O
clinical	B-MED
mrsa	B-MED
infection	I-MED
in	O
animals	B-MED
remains	O
sporadic	B-MED
,	O
but	O
the	O
diversification	B-MED
of	O
the	O
strain	B-MED
-	O
types	B-MED
may	O
pose	O
new	O
therapeutic	B-MED
challenges	O
to	O
veterinarians	B-MED
,	O
due	O
to	O
their	O
diverse	O
cloud-based	B-MED
motifsim	I-MED
detecting	B-MED
similarity	B-MED
in	O
large	O
dna	B-MED
motif	I-MED
data	B-MED
sets	I-MED
we	O
developed	O
the	O
cloud-based	B-MED
motifsim	I-MED
on	O
amazon	B-MED
web	I-MED
services	I-MED
aws	B-MED
cloud	B-MED
.	O
	
the	O
tool	B-MED
is	O
an	O
extended	O
version	B-MED
from	O
our	O
web-based	B-MED
tool	I-MED
version	I-MED
2.0	I-MED
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	B-MED
for	O
detecting	B-MED
similarity	B-MED
in	O
multiple	O
dna	B-MED
motif	I-MED
data	B-MED
sets	I-MED
.	O
	
this	O
cloud	B-MED
-based	O
version	B-MED
further	O
allows	O
researchers	B-MED
to	O
exploit	O
the	O
computing	B-MED
resources	I-MED
available	O
from	O
aws	B-MED
to	O
detect	B-MED
similarity	B-MED
in	O
multiple	O
large-scale	O
dna	B-MED
motif	I-MED
data	B-MED
sets	I-MED
resulting	O
from	O
the	O
next-generation	B-MED
sequencing	I-MED
technology	I-MED
.	O
	
the	O
tool	B-MED
is	O
highly	O
scalable	O
with	O
expandable	O
utilization	B-MED
and	O
outcomes	B-MED
of	O
sentinel	B-MED
lymph	I-MED
node	I-MED
biopsy	I-MED
for	O
vulvar	B-MED
cancer	I-MED
to	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
in	O
women	B-MED
with	O
vulvar	B-MED
cancer	I-MED
.	O
	
the	O
perspective	B-MED
database	I-MED
,	O
an	O
all-payer	B-MED
database	I-MED
that	O
collects	B-MED
data	I-MED
from	O
more	O
than	O
500	O
hospitals	B-MED
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
of	O
women	B-MED
with	O
vulvar	B-MED
cancer	I-MED
who	O
underwent	O
vulvectomy	B-MED
and	O
lymph	B-MED
node	I-MED
assessment	I-MED
from	O
2006	O
to	O
2015	O
.	O
	
multivariable	B-MED
models	I-MED
were	O
used	O
to	O
determine	O
factors	B-MED
associated	O
with	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
.	O
	
length	B-MED
of	I-MED
stay	I-MED
and	O
cost	B-MED
were	O
compared	O
between	O
women	B-MED
who	O
underwent	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
and	O
lymphadenectomy	B-MED
.	O
	
among	O
2	O
women	B-MED
,	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
was	O
utilized	O
in	O
618	O
27.2	O
and	O
1	O
72.8	O
underwent	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
.	O
	
performance	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
increased	O
from	O
17.0	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
12.0	O
in	O
2006	O
to	O
39.1	O
95%	O
ci	B-MED
27.1	O
in	O
2015	O
.	O
	
in	O
a	O
multivariable	B-MED
model	I-MED
,	O
women	B-MED
treated	B-MED
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
,	O
whereas	O
women	B-MED
with	O
more	O
comorbidities	B-MED
and	O
those	O
treated	B-MED
at	O
rural	B-MED
hospitals	I-MED
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-MED
.	O
	
the	O
median	B-MED
length	B-MED
of	I-MED
stay	I-MED
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
median	B-MED
2	O
days	O
,	O
interquartile	B-MED
range	I-MED
1-3	O
compared	O
with	O
women	B-MED
who	O
underwent	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
median	O
3	O
days	O
,	O
interquartile	B-MED
range	I-MED
2-4	O
.	O
	
the	O
cost	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
was	O
7	O
interquartile	B-MED
range	I-MED
5	O
compared	O
with	O
8	O
interquartile	B-MED
range	I-MED
5	O
for	O
lymphadenectomy	B-MED
.	O
	
the	O
use	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
for	O
vulvar	B-MED
cancer	I-MED
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O
	
sentinel	B-MED
lymph	I-MED
node	I-MED
biopsy	I-MED
is	O
associated	O
with	O
a	O
shorter	B-MED
hospital	I-MED
stay	I-MED
and	O
decreased	B-MED
cost	I-MED
compared	O
with	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
.	O
	
condition	B-MED
-	O
dependent	B-MED
co-regulation	B-MED
of	O
genomic	B-MED
clusters	I-MED
of	O
virulence	B-MED
factors	I-MED
in	O
the	O
grapevine	B-MED
trunk	I-MED
pathogen	B-MED
neofusicoccum	B-MED
parvum	I-MED
the	O
ascomycete	B-MED
neofusicoccum	B-MED
parvum	I-MED
,	O
one	O
of	O
the	O
causal	B-MED
agents	I-MED
of	O
botryosphaeria	B-MED
dieback	I-MED
,	O
is	O
a	O
destructive	O
wood	B-MED
-	O
infecting	B-MED
fungus	B-MED
and	O
a	O
serious	O
threat	B-MED
to	O
grape	B-MED
production	O
worldwide	B-MED
.	O
	
the	O
capability	B-MED
of	O
colonizing	B-MED
woody	B-MED
tissue	I-MED
combined	B-MED
with	O
the	O
secretion	B-MED
of	O
phytotoxic	B-MED
compounds	B-MED
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	B-MED
and	O
virulence	B-MED
.	O
	
here	O
,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence	B-MED
factors	I-MED
and	O
their	O
transcriptional	B-MED
dynamics	B-MED
as	O
the	O
fungus	B-MED
feeds	B-MED
on	O
different	O
substrates	B-MED
and	O
colonizes	B-MED
the	O
woody	B-MED
stem	I-MED
.	O
	
we	O
assembled	B-MED
and	O
annotated	B-MED
a	O
highly	B-MED
contiguous	B-MED
genome	B-MED
using	O
single	B-MED
molecule	I-MED
real-time	I-MED
dna	I-MED
sequencing	I-MED
.	O
	
transcriptome	B-MED
profiling	I-MED
by	O
rna-sequencing	B-MED
determined	O
the	O
genome	B-MED
-wide	O
patterns	B-MED
of	O
expression	B-MED
of	O
virulence	B-MED
factors	I-MED
both	O
in	B-MED
vitro	I-MED
potato	B-MED
dextrose	B-MED
agar	I-MED
or	O
medium	B-MED
amended	B-MED
with	O
grape	B-MED
wood	B-MED
as	O
substrate	B-MED
and	O
in	O
planta	B-MED
.	O
	
pairwise	B-MED
statistical	I-MED
testing	I-MED
of	O
differential	B-MED
expression	B-MED
followed	O
by	O
co-expression	B-MED
network	I-MED
analysis	I-MED
revealed	O
that	O
physically	B-MED
clustered	B-MED
genes	I-MED
coding	B-MED
for	O
putative	O
virulence	B-MED
functions	B-MED
were	O
induced	O
depending	O
on	O
substrate	B-MED
or	O
stage	B-MED
of	O
plant	B-MED
infection	B-MED
.	O
	
co-expressed	B-MED
gene	B-MED
clusters	I-MED
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	B-MED
associated	B-MED
with	I-MED
secondary	B-MED
metabolism	I-MED
,	O
but	O
also	O
with	O
cell	B-MED
wall	I-MED
degradation	I-MED
,	O
suggesting	O
that	O
dynamic	B-MED
co-regulation	B-MED
of	O
transcriptional	B-MED
networks	I-MED
contribute	O
to	O
multiple	O
aspects	O
of	O
n	B-MED
.	O
	
parvum	I-MED
virulence	B-MED
.	O
	
in	O
most	O
of	O
the	O
co-expressed	B-MED
clusters	B-MED
,	O
all	O
genes	B-MED
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter	B-MED
region	I-MED
indicative	O
of	O
co-regulation	B-MED
by	O
the	O
same	O
transcription	B-MED
factor	I-MED
.	O
	
co-expression	B-MED
analysis	I-MED
also	O
identified	O
chromatin	B-MED
regulators	B-MED
with	O
correlated	B-MED
expression	B-MED
with	O
inducible	B-MED
clusters	B-MED
of	O
virulence	B-MED
factors	I-MED
,	O
suggesting	O
a	O
complex	O
,	O
multi-layered	O
regulation	B-MED
of	O
the	O
virulence	B-MED
repertoire	O
of	O
n	B-MED
.	O
	
parvum	I-MED
.	O
	
congenital	B-MED
anomalies	I-MED
following	O
use	O
of	O
isotretinoin	B-MED
emphasis	O
on	O
its	O
legal	B-MED
aspects	I-MED
we	O
described	O
a	O
neonate	B-MED
with	O
severe	B-MED
and	O
multiple	B-MED
abnormalities	I-MED
following	O
use	O
of	O
isotretinoin	B-MED
,	O
in	O
spite	O
of	O
the	O
mother	B-MED
's	O
previous	O
knowledge	B-MED
of	O
drug	B-MED
complications	I-MED
.	O
	
initial	O
physical	B-MED
examination	I-MED
after	O
delivery	B-MED
showed	O
congenital	B-MED
absence	I-MED
of	O
both	B-MED
eyes	I-MED
and	O
both	O
auricles	B-MED
as	O
well	O
as	O
anal	B-MED
atresia	I-MED
and	O
a	O
cleft	B-MED
palate	I-MED
.	O
	
due	O
to	O
severe	B-MED
respiratory	B-MED
distress	I-MED
and	O
atresia	B-MED
of	O
the	O
anus	B-MED
,	O
the	O
neonate	B-MED
was	O
admitted	O
to	O
a	O
neonatal	B-MED
intensive	B-MED
care	I-MED
unit	I-MED
and	O
underwent	O
reconstructive	B-MED
surgery	I-MED
.	O
	
the	O
drug	B-MED
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	B-MED
.	O
	
using	O
this	O
drug	B-MED
within	O
pregnancy	B-MED
with	O
awareness	O
of	O
its	O
side	B-MED
effects	I-MED
may	O
have	O
legal	B-MED
consequences	B-MED
.	O
	
functional	B-MED
adaptation	I-MED
of	O
crustacean	B-MED
exoskeletal	B-MED
elements	B-MED
through	O
structural	B-MED
and	O
compositional	B-MED
diversity	B-MED
a	O
combined	B-MED
experimental	B-MED
and	O
theoretical	B-MED
study	I-MED
the	O
crustacean	B-MED
cuticle	B-MED
is	O
a	O
composite	B-MED
material	B-MED
that	O
covers	O
the	O
whole	O
animal	B-MED
and	O
forms	O
the	O
continuous	B-MED
exoskeleton	I-MED
.	O
	
nano-fibers	B-MED
composed	O
of	O
chitin	B-MED
and	O
protein	B-MED
molecules	I-MED
form	O
most	O
of	O
the	O
organic	B-MED
matrix	B-MED
of	O
the	O
cuticle	B-MED
that	O
,	O
at	O
the	O
macroscale	B-MED
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	B-MED
levels	B-MED
.	O
	
at	O
least	O
two	O
of	O
them	O
,	O
the	O
exo-	B-MED
and	O
endocuticle	B-MED
,	O
contain	O
a	O
mineral	B-MED
phase	I-MED
of	O
mainly	O
mg	B-MED
-	O
calcite	B-MED
,	O
amorphous	B-MED
calcium	B-MED
carbonate	I-MED
and	O
phosphate	B-MED
.	O
	
the	O
high	O
number	O
of	O
hierarchical	B-MED
levels	B-MED
and	O
the	O
compositional	B-MED
diversity	B-MED
provide	O
a	O
high	O
degree	B-MED
of	I-MED
freedom	I-MED
for	O
varying	B-MED
the	O
physical	B-MED
,	O
in	O
particular	O
mechanical	B-MED
,	O
properties	B-MED
of	O
the	O
material	B-MED
.	O
	
this	O
makes	O
the	O
cuticle	B-MED
a	O
versatile	B-MED
material	I-MED
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	B-MED
elements	B-MED
that	O
are	O
adapted	B-MED
to	O
different	O
functions	B-MED
and	O
the	O
eco-physiological	B-MED
strains	I-MED
of	O
individual	B-MED
species	I-MED
.	O
	
this	O
review	B-MED
presents	O
our	O
recent	O
analytical	B-MED
,	O
experimental	B-MED
and	O
theoretical	B-MED
studies	I-MED
on	O
the	O
cuticle	B-MED
,	O
summarising	O
at	O
which	O
hierarchical	B-MED
levels	B-MED
structure	B-MED
and	O
composition	B-MED
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical	B-MED
properties	I-MED
.	O
	
we	O
describe	O
our	O
multi-scale	B-MED
hierarchical	I-MED
modeling	I-MED
approach	I-MED
based	O
on	O
the	O
results	B-MED
from	O
these	O
studies	B-MED
,	O
aiming	O
at	O
systematically	B-MED
predicting	B-MED
the	O
structure	B-MED
-	O
composition	B-MED
-	O
property	B-MED
relations	B-MED
of	O
cuticle	B-MED
composites	B-MED
from	O
the	O
molecular	B-MED
level	B-MED
to	O
the	O
macro-scale	B-MED
.	O
	
this	O
modeling	B-MED
approach	I-MED
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	B-MED
of	O
optimized	O
biomimetic	B-MED
materials	I-MED
within	O
a	O
knowledge-based	B-MED
design	I-MED
approach	I-MED
.	O
	
draft	B-MED
genome	I-MED
sequences	I-MED
of	O
15	O
isolates	B-MED
of	O
listeria	B-MED
monocytogenes	I-MED
serotype	I-MED
1/2a	I-MED
,	O
subgroup	B-MED
st204	B-MED
listeria	B-MED
monocytogenes	I-MED
sequence	B-MED
type	I-MED
204	I-MED
st204	I-MED
strains	I-MED
have	O
been	O
isolated	B-MED
from	O
a	O
range	B-MED
of	I-MED
food	I-MED
,	O
environmental	B-MED
,	O
and	O
clinical	B-MED
sources	B-MED
in	O
australia	B-MED
.	O
	
this	O
study	O
describes	O
the	O
draft	B-MED
genome	I-MED
sequences	I-MED
of	O
15	O
isolates	O
collected	O
from	O
meat	B-MED
and	O
dairy	B-MED
associated	I-MED
sources	I-MED
.	O
	
high	O
transferability	B-MED
of	O
homoeolog-specific	B-MED
markers	I-MED
between	O
bread	B-MED
wheat	B-MED
and	O
newly	O
synthesized	B-MED
hexaploid	B-MED
wheat	I-MED
lines	I-MED
bread	B-MED
wheat	B-MED
triticum	B-MED
aestivum	I-MED
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
aabbdd	O
has	O
a	O
complex	O
allohexaploid	B-MED
genome	I-MED
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	B-MED
between	O
the	O
homoeologous	B-MED
sequences	I-MED
and	O
assign	O
them	O
to	O
the	O
chromosome	B-MED
a	I-MED
,	O
b	B-MED
,	O
or	O
d	B-MED
subgenomes	B-MED
.	O
	
the	O
chromosome	B-MED
-based	O
draft	O
genome	B-MED
sequence	B-MED
of	O
the	O
'	O
chinese	B-MED
spring	I-MED
'	O
common	O
wheat	B-MED
cultivar	I-MED
enables	O
the	O
large-scale	O
development	B-MED
of	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
pcr	B-MED
markers	B-MED
specific	O
for	O
homoeologs	O
.	O
	
based	O
on	O
high-confidence	O
'	O
chinese	B-MED
spring	I-MED
'	O
genes	B-MED
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog-specific	B-MED
markers	I-MED
for	O
chromosomes	B-MED
4b	I-MED
and	O
7b	B-MED
.	O
	
these	O
markers	B-MED
were	O
used	O
in	O
pcr	B-MED
assays	I-MED
for	O
the	O
4b	B-MED
and	O
7b	B-MED
nullisomes	O
and	O
their	O
euploid	O
synthetic	B-MED
hexaploid	I-MED
wheat	I-MED
shw	I-MED
line	I-MED
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	B-MED
between	O
triticum	B-MED
turgidum	I-MED
aabb	O
and	O
the	O
wild	O
diploid	B-MED
species	I-MED
aegilops	B-MED
tauschii	I-MED
dd	O
.	O
	
up	O
to	O
64%	O
of	O
the	O
markers	B-MED
for	O
chromosomes	B-MED
4b	I-MED
or	O
7b	B-MED
in	O
the	O
shw	B-MED
background	O
were	O
confirmed	O
to	O
be	O
homoeolog-specific	O
.	O
	
thus	O
,	O
these	O
markers	B-MED
were	O
highly	O
transferable	O
between	O
the	O
'	O
chinese	B-MED
spring	I-MED
'	O
bread	B-MED
wheat	B-MED
and	O
shw	B-MED
lines	I-MED
.	O
	
homoeolog-specific	B-MED
markers	I-MED
designed	O
using	O
genes	B-MED
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-MED
investigations	I-MED
involving	O
homoeologous	O
chromosome	B-MED
tracking	O
and	O
homoeolog	O
expression	B-MED
participation	B-MED
in	O
and	O
adherence	B-MED
to	O
physical	B-MED
exercise	I-MED
after	O
completion	B-MED
of	O
primary	B-MED
cancer	I-MED
treatment	B-MED
the	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
identify	B-MED
demographic	B-MED
,	O
clinical	B-MED
,	O
psychosocial	B-MED
,	O
physical	B-MED
and	O
environmental	B-MED
factors	B-MED
that	O
are	O
associated	B-MED
with	I-MED
participation	B-MED
in	O
and	O
adherence	B-MED
to	O
a	O
combined	B-MED
resistance	B-MED
and	O
endurance	B-MED
exercise	I-MED
program	B-MED
among	O
cancer	B-MED
survivors	I-MED
,	O
shortly	O
after	O
completion	B-MED
of	O
primary	B-MED
cancer	I-MED
treatment	B-MED
.	O
	
data	B-MED
from	O
the	O
randomized	B-MED
controlled	B-MED
resistance	B-MED
and	I-MED
endurance	I-MED
exercise	I-MED
after	I-MED
chemotherapy	I-MED
react	B-MED
study	B-MED
were	O
used	O
for	O
this	O
study	B-MED
.	O
	
the	O
participants	B-MED
of	O
the	O
react	B-MED
study	B-MED
were	O
randomly	B-MED
allocated	B-MED
to	O
either	O
a	O
high	B-MED
intensity	I-MED
hi	B-MED
or	O
low	B-MED
-to-	O
moderate	B-MED
intensity	I-MED
lmi	B-MED
exercise	B-MED
program	B-MED
.	O
	
patients	B-MED
'	O
participation	B-MED
rate	B-MED
was	O
defined	O
as	O
the	O
cancer	B-MED
survivors	I-MED
'	O
decision	O
to	O
participate	B-MED
in	O
the	O
react	B-MED
study	B-MED
.	O
	
exercise	B-MED
adherence	B-MED
reflected	B-MED
participants	B-MED
'	O
attendance	B-MED
to	O
the	O
scheduled	B-MED
exercise	B-MED
sessions	B-MED
and	O
their	O
compliance	B-MED
to	O
the	O
prescribed	B-MED
exercises	B-MED
.	O
	
high	B-MED
session	B-MED
attendance	B-MED
rates	B-MED
were	O
defined	O
as	O
attending	B-MED
at	O
least	O
80	O
%	O
of	O
the	O
sessions	B-MED
.	O
	
high	B-MED
compliance	B-MED
rates	B-MED
were	O
defined	O
as	O
performing	B-MED
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	B-MED
exercise	B-MED
across	O
all	O
sessions	B-MED
.	O
	
correlates	B-MED
of	O
exercise	B-MED
adherence	B-MED
were	O
studied	B-MED
separately	B-MED
for	O
hi	B-MED
and	O
lmi	B-MED
exercise	B-MED
.	O
	
demographic	B-MED
,	O
clinical	B-MED
,	O
and	O
physical	B-MED
factors	B-MED
were	O
assessed	B-MED
using	O
self-reported	B-MED
questionnaires	B-MED
.	O
	
relevant	B-MED
clinical	B-MED
information	I-MED
was	O
extracted	B-MED
from	O
medical	B-MED
records	I-MED
.	O
	
multivariable	B-MED
logistic	I-MED
regression	I-MED
analyses	I-MED
were	O
applied	B-MED
to	O
identify	B-MED
correlates	B-MED
that	O
were	O
significantly	B-MED
associated	B-MED
with	I-MED
participation	B-MED
,	O
high	B-MED
session	B-MED
attendance	B-MED
,	O
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
high	B-MED
compliance	B-MED
with	O
endurance	B-MED
exercises	I-MED
.	O
	
participants	B-MED
were	O
more	B-MED
likely	I-MED
to	O
have	O
higher	B-MED
education	I-MED
,	O
be	O
non-smokers	B-MED
,	O
have	O
lower	B-MED
psychological	B-MED
distress	I-MED
,	O
higher	B-MED
outcome	B-MED
expectations	B-MED
,	O
and	O
perceive	B-MED
more	B-MED
exercise	B-MED
barriers	B-MED
than	O
non-participants	B-MED
.	O
	
in	O
hi	B-MED
exercise	B-MED
,	O
higher	B-MED
self-efficacy	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
session	B-MED
attendance	B-MED
and	O
high	B-MED
compliance	B-MED
with	O
endurance	B-MED
exercises	I-MED
,	O
and	O
lower	B-MED
psychological	B-MED
distress	I-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
exercise	B-MED
s	O
.	O
	
in	O
lmi	B-MED
exercise	B-MED
,	O
being	O
a	O
non-smoker	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
exercises	B-MED
and	O
higher	B-MED
bmi	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
endurance	B-MED
exercises	I-MED
.	O
	
furthermore	O
,	O
breast	B-MED
cancer	I-MED
survivors	I-MED
were	O
less	B-MED
likely	B-MED
to	O
report	B-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
endurance	B-MED
exercises	I-MED
in	O
lmi	B-MED
exercise	B-MED
compared	B-MED
to	O
survivors	B-MED
of	O
other	O
types	O
of	O
cancer	B-MED
.	O
	
the	O
discriminative	B-MED
ability	B-MED
of	O
the	O
multivariable	B-MED
models	B-MED
ranged	B-MED
from	O
0.62	O
to	O
0.75	O
.	O
	
several	O
demographic	B-MED
,	O
clinical	B-MED
and	O
psychosocial	B-MED
factors	B-MED
were	O
associated	B-MED
with	I-MED
participation	B-MED
in	O
and	O
adherence	B-MED
to	O
exercise	B-MED
among	O
cancer	B-MED
survivors	I-MED
.	O
	
psychosocial	B-MED
factors	B-MED
were	O
more	B-MED
strongly	B-MED
associated	B-MED
with	I-MED
adherence	B-MED
in	O
hi	B-MED
than	O
lmi	B-MED
exercise	B-MED
.	O
	
this	O
study	B-MED
was	O
registered	B-MED
at	O
the	O
netherlands	B-MED
trial	I-MED
register	I-MED
ntr2153	B-MED
in	B-MED
situ	I-MED
stabilization	B-MED
of	O
heavy	B-MED
metals	I-MED
in	O
multiple-	O
metal	B-MED
contaminated	B-MED
paddy	B-MED
soil	B-MED
using	O
different	O
steel	B-MED
slag	B-MED
-based	O
silicon	B-MED
fertilizer	B-MED
steel	B-MED
slag	B-MED
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	B-MED
fertilizer	B-MED
to	O
alleviate	O
the	O
mobility	B-MED
and	O
bioavailability	B-MED
of	O
heavy	B-MED
metals	I-MED
in	O
soil	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
influence	B-MED
of	O
particle	B-MED
size	I-MED
,	O
composition	B-MED
,	O
and	O
application	O
rate	O
of	O
slag	B-MED
on	O
metal	B-MED
immobilization	B-MED
in	O
acidic	B-MED
soil	B-MED
,	O
metals	B-MED
uptake	B-MED
by	O
rice	B-MED
and	O
rice	B-MED
growth	B-MED
.	O
	
the	O
results	O
indicated	O
that	O
application	O
of	O
slag	B-MED
increased	O
soil	B-MED
ph	B-MED
,	O
plant	B-MED
-available	O
silicon	B-MED
concentrations	B-MED
in	O
soil	B-MED
,	O
and	O
decreased	B-MED
the	O
bioavailability	B-MED
of	O
metals	B-MED
compared	O
with	O
control	B-MED
treatment	I-MED
,	O
whereas	O
pulverous	B-MED
slag	I-MED
s1	B-MED
was	O
more	B-MED
effective	I-MED
than	O
granular	B-MED
slag	B-MED
s2	O
and	O
s3	O
.	O
	
the	O
acid	B-MED
-	O
extractable	B-MED
fraction	I-MED
of	I-MED
cd	B-MED
in	O
the	O
spiked	O
soil	B-MED
was	O
significantly	O
decreased	B-MED
with	O
application	O
of	O
s1	B-MED
at	O
rates	O
of	O
1	O
and	O
3	O
%	O
,	O
acid-extractable	O
fractions	O
of	O
cu	B-MED
and	O
zn	B-MED
were	O
decreased	B-MED
when	O
treated	B-MED
at	O
3	O
%	O
.	O
	
use	O
of	O
s1	B-MED
at	O
both	O
rates	O
resulted	O
in	O
significantly	B-MED
lower	I-MED
cd	B-MED
,	O
cu	B-MED
,	O
and	O
zn	B-MED
concentrations	B-MED
in	O
rice	B-MED
tissues	B-MED
than	O
in	O
controls	B-MED
by	O
82.6	O
,	O
88.4	O
,	O
and	O
67.4	O
%	O
,	O
respectively	O
.	O
	
however	O
,	O
use	O
of	O
pulverous	B-MED
slag	I-MED
at	O
1	O
%	O
significantly	O
promotes	B-MED
rice	B-MED
growth	B-MED
,	O
restricted	O
rice	B-MED
growth	B-MED
when	O
treated	B-MED
at	O
3	O
%	O
.	O
	
thus	O
,	O
the	O
results	O
explained	O
that	O
reduced	B-MED
particle	B-MED
size	I-MED
and	O
suitable	O
application	O
rate	O
of	O
slag	B-MED
could	O
be	O
beneficial	O
to	O
rice	B-MED
growth	B-MED
and	O
metals	B-MED
stabilization	B-MED
.	O
	
plasmodium	B-MED
falciparum	I-MED
choline	B-MED
kinase	I-MED
inhibition	B-MED
leads	O
to	O
a	O
major	O
decrease	B-MED
in	O
phosphatidylethanolamine	B-MED
causing	O
parasite	B-MED
death	B-MED
malaria	B-MED
is	O
a	O
life-threatening	B-MED
disease	B-MED
caused	O
by	O
different	O
species	B-MED
of	O
the	O
protozoan	B-MED
parasite	I-MED
plasmodium	B-MED
,	O
with	O
p	B-MED
.	O
	
falciparum	I-MED
being	O
the	O
deadliest	O
.	O
	
increasing	B-MED
parasitic	B-MED
resistance	B-MED
to	O
existing	O
antimalarials	B-MED
makes	O
the	O
necessity	O
of	O
novel	B-MED
avenues	O
to	O
treat	B-MED
this	O
disease	B-MED
an	O
urgent	O
priority	O
.	O
	
the	O
enzymes	B-MED
responsible	O
for	O
the	O
synthesis	B-MED
of	O
phosphatidylcholine	B-MED
and	O
phosphatidylethanolamine	B-MED
are	O
attractive	O
drug	B-MED
targets	I-MED
to	O
treat	B-MED
malaria	B-MED
as	O
their	O
selective	O
inhibition	B-MED
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite's	B-MED
growth	B-MED
and	O
cures	B-MED
malaria	B-MED
in	O
a	O
mouse	B-MED
model	I-MED
.	O
	
we	O
present	O
here	O
a	O
detailed	O
study	B-MED
that	O
reveals	O
a	O
mode	B-MED
of	I-MED
action	I-MED
for	O
two	O
p	B-MED
.	O
	
falciparum	I-MED
choline	B-MED
kinase	I-MED
inhibitors	B-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
the	O
compounds	B-MED
present	O
distinct	O
binding	B-MED
modes	O
to	O
the	O
choline	B-MED
/	O
ethanolamine	B-MED
-	O
binding	B-MED
site	I-MED
of	O
p	B-MED
.	O
	
falciparum	I-MED
choline	B-MED
kinase	I-MED
,	O
reflecting	O
different	O
types	O
of	O
inhibition	B-MED
.	O
	
strikingly	O
,	O
these	O
compounds	B-MED
primarily	O
inhibit	O
the	O
ethanolamine	B-MED
kinase	I-MED
activity	I-MED
of	O
the	O
p	B-MED
.	O
	
falciparum	I-MED
choline	B-MED
kinase	I-MED
,	O
leading	O
to	O
a	O
severe	O
decrease	B-MED
in	O
the	O
phosphatidylethanolamine	B-MED
levels	B-MED
within	O
p	B-MED
.	O
	
falciparum	I-MED
,	O
which	O
explains	O
the	O
resulting	O
growth	B-MED
phenotype	I-MED
and	O
the	O
parasites	B-MED
death	B-MED
.	O
	
these	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode	B-MED
of	I-MED
action	I-MED
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial	B-MED
development	I-MED
efforts	O
selectively	O
targeting	O
p	B-MED
.	O
	
falciparum	I-MED
choline	B-MED
kinase	I-MED
.	O
	
anti-cd45rb	B-MED
and	O
donor-specific	B-MED
spleen	I-MED
cells	I-MED
transfusion	I-MED
inhibition	B-MED
allograft	B-MED
skin	I-MED
rejection	I-MED
mediated	O
by	O
memory	B-MED
t	I-MED
cells	I-MED
donor-reactive	O
memory	B-MED
t	I-MED
tm	I-MED
mediate	O
accelerated	O
rejection	B-MED
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted	B-MED
organs	I-MED
.	O
	
selective	O
interference	O
with	O
the	O
anti-cd45rb	B-MED
monoclonal	I-MED
antibody	I-MED
α-cd45rb	I-MED
reliably	O
induces	O
donor	B-MED
-	O
specific	B-MED
tolerance	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
pre-sensitization	B-MED
to	O
female	B-MED
c57bl/6	B-MED
mice	I-MED
with	O
the	O
skin	B-MED
of	O
female	B-MED
blab/c	B-MED
mice	I-MED
generated	O
a	O
large	O
number	O
of	O
tm	B-MED
cells	I-MED
and	O
resulted	O
in	O
rapid	O
rejection	B-MED
of	O
the	O
secondly	B-MED
transplanted	B-MED
allografts	B-MED
.	O
	
α-cd45rb	B-MED
did	O
induce	O
the	O
tolerance	B-MED
to	O
skin	B-MED
allograft	I-MED
primarily	B-MED
transplanted	B-MED
but	O
failed	O
to	O
induce	O
tolerance	B-MED
in	O
the	O
pre-sensitized	B-MED
mice	I-MED
.	O
	
donor-specific	B-MED
spleen	I-MED
cell	I-MED
transfusion	I-MED
dst	B-MED
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	B-MED
in	O
the	O
pre-sensitized	B-MED
recipients	B-MED
.	O
	
interestingly	O
,	O
combination	O
of	O
α-cd45rb	B-MED
with	O
dst	B-MED
inhibited	O
the	O
rejection	B-MED
induced	O
by	O
memory	B-MED
t	I-MED
cells	I-MED
in	O
the	O
pre-sensitized	B-MED
mice	I-MED
.	O
	
cd25+	B-MED
t-cell	I-MED
depletion	B-MED
in	O
α-cd45rb	B-MED
combined	O
with	O
dst	B-MED
therapy	B-MED
recipients	B-MED
could	O
prevent	O
skin	B-MED
allograft	I-MED
tolerance	B-MED
from	O
establishing	O
.	O
	
in	O
addition	O
,	O
adoptive	B-MED
transfer	I-MED
of	O
donor	B-MED
-primed	O
memory	B-MED
t	I-MED
cells	I-MED
into	O
the	O
tolerant	B-MED
recipients	B-MED
markedly	O
broke	O
the	O
established	O
tolerance	B-MED
.	O
	
our	O
findings	B-MED
indicate	O
that	O
α-cd45rb	B-MED
and	O
dst	B-MED
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	B-MED
mediated	O
by	O
memory	B-MED
t	I-MED
cells	I-MED
and	O
induce	O
long-term	O
skin	B-MED
allograft	I-MED
acceptance	B-MED
in	O
recruitment	B-MED
of	O
minority	B-MED
adolescents	B-MED
and	O
young	B-MED
adults	I-MED
into	O
randomised	B-MED
clinical	I-MED
trials	I-MED
testing	B-MED
the	O
design	B-MED
of	O
the	O
technology	B-MED
enhanced	I-MED
community	I-MED
health	I-MED
nursing	I-MED
tech-n	B-MED
pelvic	B-MED
inflammatory	I-MED
disease	I-MED
trial	O
pelvic	B-MED
inflammatory	I-MED
disease	I-MED
pid	B-MED
disproportionately	B-MED
affects	O
adolescent	B-MED
and	O
young	B-MED
adult	I-MED
aya	B-MED
women	B-MED
and	O
can	O
negatively	O
influence	B-MED
reproductive	B-MED
health	I-MED
trajectories	O
.	O
	
few	O
randomized	B-MED
controlled	I-MED
trials	I-MED
rcts	B-MED
have	O
focused	O
on	O
strategies	O
to	O
improve	B-MED
outpatient	B-MED
adherence	B-MED
or	O
to	O
reduce	B-MED
reproductive	B-MED
morbidity	B-MED
in	O
this	O
population	B-MED
.	O
	
this	O
paper	O
describes	O
the	O
research	B-MED
methods	I-MED
and	O
preliminary	B-MED
effectiveness	B-MED
of	O
recruitment	B-MED
,	O
retention	B-MED
,	O
and	O
intervention	B-MED
strategies	O
employed	O
in	O
a	O
novel	O
rct	B-MED
designed	O
to	O
test	O
a	O
technology-enhanced	B-MED
community-health	I-MED
nursing	I-MED
tech-n	B-MED
intervention	B-MED
among	O
urban	O
aya	B-MED
with	O
pid	B-MED
.	O
	
aya	B-MED
women	B-MED
aged	B-MED
13-25	O
years	B-MED
were	O
recruited	B-MED
during	O
acute	B-MED
pid	I-MED
visits	B-MED
in	O
outpatient	B-MED
clinics	I-MED
and	O
emergency	B-MED
departments	I-MED
ed	B-MED
to	O
participate	B-MED
in	O
this	O
irb-approved	B-MED
trial	O
.	O
	
participants	B-MED
completed	B-MED
an	O
audio-computerized	B-MED
self-interview	I-MED
acasi	B-MED
,	O
provided	O
vaginal	B-MED
specimens	I-MED
,	O
and	O
were	O
randomized	B-MED
to	O
standard	B-MED
treatment	B-MED
or	O
the	O
intervention	B-MED
.	O
	
intervention	B-MED
participants	B-MED
received	B-MED
text-messaging	B-MED
support	B-MED
for	O
30	O
days	B-MED
and	O
a	O
community	B-MED
health	I-MED
nurse	I-MED
chn	I-MED
interventionist	I-MED
performed	B-MED
a	O
home	B-MED
visit	I-MED
with	I-MED
clinical	I-MED
assessment	I-MED
within	O
5	O
days	B-MED
after	O
enrollment	B-MED
.	O
	
all	O
patients	B-MED
received	O
a	O
full	O
course	B-MED
of	O
medications	B-MED
and	O
completed	B-MED
research	O
visits	B-MED
at	O
14-	O
days	B-MED
adherence	B-MED
,	O
30	O
days	B-MED
and	O
90	O
days	B-MED
with	O
by	O
an	O
outreach	B-MED
worker	I-MED
.	O
	
sti	B-MED
testing	B-MED
performed	B-MED
at	O
the	O
30-and	O
90-	O
day	B-MED
visits	B-MED
.	O
	
exploratory	B-MED
analyses	I-MED
using	O
descriptive	B-MED
statistics	I-MED
were	O
conducted	O
to	O
examine	O
recruitment	B-MED
,	O
retention	B-MED
,	O
and	O
follow-up	B-MED
data	B-MED
to	O
test	O
the	O
overall	O
design	B-MED
of	O
the	O
intervention	B-MED
.	O
	
in	O
the	O
first	O
48	O
months	B-MED
,	O
64%	O
of	O
463	O
patients	B-MED
were	O
eligible	B-MED
for	O
the	O
study	O
and	O
81.2	O
of	O
293	O
eligible	B-MED
patients	B-MED
were	O
recruited	B-MED
for	O
the	O
study	O
63.3	O
238	O
81.2	O
of	O
eligible	B-MED
patients	B-MED
were	O
enrolled	B-MED
.	O
	
most	O
participants	B-MED
were	O
african	B-MED
american	I-MED
95.6	O
with	O
a	O
mean	B-MED
age	B-MED
of	O
18.6	O
2.3	O
.	O
	
ninety-four	O
percent	O
of	O
individuals	B-MED
assigned	O
to	O
the	O
tech-n	B-MED
intervention	I-MED
completed	B-MED
the	O
nursing	B-MED
visits	I-MED
.	O
	
all	O
completed	B-MED
visits	B-MED
have	O
been	O
within	O
the	O
5-	O
day	B-MED
window	B-MED
and	O
over	O
90%	O
of	O
patients	B-MED
in	O
both	O
arms	O
have	O
been	O
retained	B-MED
over	O
the	O
3-	O
month	B-MED
follow-up	B-MED
period	B-MED
.	O
	
biological	B-MED
data	B-MED
suggests	O
a	O
shift	B-MED
in	I-MED
the	I-MED
biological	I-MED
milieu	I-MED
with	O
the	O
predominance	O
of	O
chlamydia	B-MED
trachomatis	I-MED
,	O
mycoplasma	B-MED
genitalium	I-MED
,	O
and	O
trichomonas	B-MED
vaginalis	I-MED
infections	I-MED
.	O
	
preliminary	B-MED
data	B-MED
from	O
the	O
tech-n	B-MED
study	O
demonstrated	O
that	O
urban	B-MED
,	O
low-income	B-MED
,	O
minority	B-MED
aya	B-MED
with	O
pid	B-MED
can	O
effectively	O
be	O
recruited	B-MED
and	O
retained	B-MED
to	O
participate	B-MED
in	O
sexual	B-MED
and	O
reproductive	B-MED
health	I-MED
rcts	B-MED
with	O
sufficient	B-MED
investment	B-MED
in	O
the	O
design	B-MED
and	O
infrastructure	B-MED
of	I-MED
the	I-MED
study	I-MED
.	O
	
community	B-MED
-based	O
sexual	B-MED
health	I-MED
interventions	B-MED
appear	O
to	O
be	O
both	O
feasible	B-MED
and	O
acceptable	B-MED
in	O
this	O
extended	O
use	O
of	O
prostate	B-MED
health	I-MED
index	I-MED
and	O
percentage	O
of	O
-2	B-MED
antigen	I-MED
in	O
chinese	B-MED
men	B-MED
with	O
prostate	B-MED
specific	I-MED
antigen	I-MED
10-20	O
ng/ml	O
and	O
normal	B-MED
digital	B-MED
rectal	I-MED
examination	I-MED
we	O
investigated	O
the	O
extended	O
use	O
of	O
prostate	B-MED
health	I-MED
index	I-MED
phi	B-MED
and	O
percentage	O
of	O
-2	B-MED
antigen	I-MED
%p2psa	B-MED
in	O
chinese	B-MED
men	B-MED
with	O
prostate-specific	B-MED
antigen	I-MED
psa	B-MED
10-20	O
ng/ml	O
and	O
normal	B-MED
digital	B-MED
rectal	I-MED
examination	I-MED
dre	B-MED
.	O
	
all	O
consecutive	O
chinese	B-MED
men	B-MED
with	O
psa	B-MED
10-20	O
ng/ml	O
and	O
normal	B-MED
dre	B-MED
who	O
agreed	O
for	O
transrectal	B-MED
ultrasound	I-MED
trus	B-MED
10-core	O
prostate	B-MED
biopsy	I-MED
were	O
recruited	O
.	O
	
blood	B-MED
samples	I-MED
were	O
taken	O
immediately	O
before	O
trus	B-MED
-guided	O
prostate	B-MED
biopsy	I-MED
.	O
	
the	O
performances	O
of	O
total	B-MED
psa	I-MED
tpsa	B-MED
,	O
%	O
free-to-total	B-MED
psa	I-MED
%	O
fpsa	B-MED
,	O
%p2psa	B-MED
,	O
and	O
phi	B-MED
were	O
compared	O
using	O
logistic	B-MED
regression	I-MED
,	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
,	O
and	O
decision	B-MED
curve	I-MED
analyses	I-MED
dca	B-MED
.	O
	
from	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
chinese	B-MED
men	B-MED
were	O
included	O
.	O
	
among	O
them	O
,	O
53	O
out	O
of	O
312	O
17.0	O
men	B-MED
were	O
diagnosed	B-MED
to	O
have	O
prostate	B-MED
cancer	I-MED
on	O
biopsy	B-MED
.	O
	
the	O
proportions	O
of	O
men	B-MED
with	O
positive	B-MED
biopsies	I-MED
were	O
6.7	O
in	O
phi	O
<35	O
,	O
22.8	O
in	O
phi	O
35-55	O
,	O
and	O
54.5	O
in	O
phi	O
>55	O
chi-square	O
test	O
,	O
p<0	O
.	O
	
the	O
area	O
under	O
curves	O
auc	O
of	O
the	O
base	O
model	O
including	O
age	O
,	O
tpsa	O
and	O
status	O
of	O
initial/repeated	O
biopsy	O
was	O
0.64	O
.	O
	
adding	O
%p2psa	O
and	O
phi	O
to	O
the	O
base	O
model	O
improved	O
the	O
auc	O
to	O
0.79	O
p<0	O
and	O
0.78	O
p<0	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
dca	O
.	O
	
the	O
positive	O
biopsy	O
rates	O
of	O
gleason	O
7	O
or	O
above	O
prostate	O
cancers	O
were	O
2.2	O
for	O
phi	O
<35	O
,	O
7.9	O
for	O
phi	O
35-55	O
,	O
and	O
36.4	O
for	O
phi	O
>55	O
chi-square	O
test	O
,	O
p<0	O
.	O
	
by	O
utilizing	O
the	O
phi	O
cutoff	O
of	O
35	O
to	O
men	O
with	O
psa	O
10-20	O
ng/ml	O
and	O
normal	O
dre	O
,	O
57.1	O
178	O
of	O
312	O
biopsies	B-MED
could	O
be	O
avoided	O
.	O
	
both	O
phi	B-MED
and	O
%p2psa	O
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	O
and	O
high	O
grade	O
prostate	O
cancer	O
.	O
	
the	O
use	O
of	O
phi	B-MED
and	O
%p2psa	O
should	O
be	O
extended	O
to	O
chinese	O
men	O
with	O
psa	O
10-20	O
ng/ml	O
and	O
normal	O
dre	B-MED
a	O
pilot	B-MED
study	I-MED
exploring	O
the	O
relationship	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
self	B-MED
-	O
judgement	B-MED
,	O
self	B-MED
-	O
kindness	B-MED
,	O
compassion	B-MED
,	O
professional	B-MED
quality	I-MED
of	I-MED
life	I-MED
and	O
wellbeing	B-MED
among	O
uk	B-MED
community	B-MED
nurses	I-MED
compassion	B-MED
fatigue	I-MED
and	O
burnout	B-MED
can	O
impact	B-MED
on	O
performance	B-MED
of	O
nurses	B-MED
.	O
	
this	O
paper	O
explores	O
the	O
relationship	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
self	B-MED
-	O
judgement	B-MED
,	O
self	B-MED
-	O
kindness	B-MED
,	O
compassion	B-MED
,	O
professional	B-MED
quality	I-MED
of	I-MED
life	I-MED
,	O
and	O
wellbeing	B-MED
among	O
community	B-MED
nurses	I-MED
.	O
	
to	O
measure	B-MED
associations	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
compassion	B-MED
fatigue	I-MED
,	O
wellbeing	B-MED
,	O
and	O
burnout	B-MED
in	O
community	B-MED
nurses	I-MED
.	O
	
quantitative	B-MED
data	B-MED
were	O
collected	B-MED
using	O
standardised	B-MED
psychometric	B-MED
questionnaires	I-MED
1	O
professional	B-MED
quality	I-MED
of	I-MED
life	I-MED
scale	I-MED
2	O
self-compassion	B-MED
scale	I-MED
3	O
short	B-MED
warwick	I-MED
edinburgh	I-MED
mental	I-MED
wellbeing	I-MED
scale	I-MED
4	O
compassion	B-MED
for	I-MED
others	I-MED
scale	I-MED
,	O
used	O
to	O
measure	B-MED
relationships	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
compassion	B-MED
fatigue	I-MED
,	O
wellbeing	B-MED
,	O
and	O
burnout	B-MED
.	O
	
a	O
cross	B-MED
sectional	I-MED
sample	O
of	O
registered	B-MED
community	I-MED
nurses	I-MED
n=37	O
studying	O
for	O
a	O
postgraduate	B-MED
diploma	B-MED
at	O
a	O
university	B-MED
in	O
the	O
north	B-MED
of	I-MED
england	I-MED
took	O
part	O
in	O
this	O
study	B-MED
.	O
	
results	B-MED
show	O
that	O
community	B-MED
nurses	I-MED
who	O
score	B-MED
high	B-MED
on	O
measures	B-MED
of	O
self	B-MED
-	O
compassion	B-MED
and	O
wellbeing	B-MED
,	O
also	O
report	O
less	B-MED
burnout	B-MED
.	O
	
greater	B-MED
compassion	B-MED
satisfaction	B-MED
was	O
also	O
positively	B-MED
associated	B-MED
with	I-MED
compassion	B-MED
for	O
others	O
,	O
and	O
wellbeing	B-MED
,	O
whilst	O
also	O
being	O
negatively	B-MED
correlated	B-MED
with	O
burnout	B-MED
.	O
	
high	B-MED
levels	B-MED
of	O
self	B-MED
-	O
compassion	B-MED
were	O
linked	O
with	O
lower	B-MED
levels	B-MED
of	O
burnout	B-MED
.	O
	
furthermore	O
when	O
community	B-MED
nurses	I-MED
have	O
greater	B-MED
compassion	B-MED
satisfaction	B-MED
they	O
also	O
report	O
more	O
compassion	B-MED
for	O
others	O
,	O
increased	B-MED
wellbeing	B-MED
,	O
and	O
less	B-MED
burnout	B-MED
.	O
	
the	O
implications	B-MED
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	B-MED
for	O
the	O
promotion	B-MED
of	O
greater	B-MED
compassion	B-MED
cd169	B-MED
identifies	B-MED
an	O
activated	B-MED
cd8	B-MED
t	I-MED
cell	I-MED
subset	B-MED
in	O
regional	B-MED
lymph	I-MED
nodes	I-MED
that	O
predicts	B-MED
favorable	B-MED
prognosis	B-MED
in	O
colorectal	B-MED
cancer	I-MED
patients	B-MED
cd169	B-MED
was	O
first	O
identified	O
on	O
macrophages	B-MED
mϕ	B-MED
and	O
linked	O
to	O
antigen	B-MED
presentation	I-MED
.	O
	
here	O
,	O
we	O
showed	O
cd169	B-MED
expression	I-MED
on	O
some	O
cd8	B-MED
t	I-MED
lymphocytes	I-MED
in	O
regional	B-MED
lymph	I-MED
nodes	I-MED
lns	B-MED
and	O
investigated	B-MED
the	O
function	B-MED
and	O
clinical	B-MED
relevance	I-MED
of	O
cd169	B-MED
t	I-MED
cells	I-MED
in	O
tumor-draining	B-MED
lns	I-MED
of	O
colorectal	B-MED
cancer	I-MED
crc	B-MED
patients	B-MED
.	O
	
fresh	B-MED
tumor-draining	I-MED
ln	I-MED
tissues	I-MED
from	O
39	O
randomly	B-MED
enrolled	B-MED
patients	I-MED
were	O
assessed	B-MED
by	O
flow	B-MED
cytometry	I-MED
for	O
activation	B-MED
and	O
differentiation	B-MED
of	O
cd169	B-MED
t	I-MED
cells	I-MED
and	O
t	B-MED
cell-mediated	I-MED
killing	I-MED
of	I-MED
tumor	I-MED
cells	I-MED
.	O
	
in	O
total	O
,	O
114	O
tumor-draining	B-MED
ln	I-MED
paraffin	O
sections	O
from	O
crc	B-MED
patients	B-MED
were	O
analyzed	O
by	O
multiple-color	B-MED
immunofluorescence	I-MED
for	O
cd169	B-MED
t	I-MED
cell	I-MED
distribution	B-MED
and	O
clinical	O
values	O
.	O
	
the	O
prognostic	B-MED
significance	B-MED
of	O
cd169	B-MED
t	I-MED
cells	I-MED
was	O
evaluated	B-MED
by	O
kaplan-meier	B-MED
analysis	I-MED
.	O
	
a	O
fraction	B-MED
of	I-MED
cd8	B-MED
t	I-MED
cells	I-MED
in	O
regional	B-MED
lns	I-MED
,	O
but	O
not	O
peripheral	B-MED
blood	I-MED
,	O
tonsils	B-MED
,	O
or	O
tumors	B-MED
,	O
expressed	B-MED
surface	I-MED
cd169	I-MED
.	O
	
in	B-MED
situ	I-MED
detection	B-MED
of	O
draining	B-MED
lns	I-MED
revealed	B-MED
preferential	O
localization	B-MED
of	O
cd169	B-MED
t	I-MED
cells	I-MED
to	O
subcapsular	B-MED
sinus	I-MED
and	O
interfollicular	B-MED
regions	I-MED
,	O
closely	O
associated	B-MED
with	I-MED
cd169	B-MED
mϕ	I-MED
.	O
	
cd169	B-MED
t	I-MED
cell	I-MED
ratios	B-MED
were	O
significantly	O
lower	O
in	O
peri-tumor	B-MED
lns	B-MED
than	O
distant-tumor	B-MED
lns	B-MED
.	O
	
cd169	B-MED
t	I-MED
cells	I-MED
predominantly	B-MED
expressed	O
activation	B-MED
markers	I-MED
cd69	B-MED
,	O
hla-dr	B-MED
,	O
pd-1	B-MED
with	O
slightly	O
lower	O
cd45ra	B-MED
and	O
cd62l	B-MED
levels	B-MED
.	O
	
they	O
produced	O
high	B-MED
granzyme	B-MED
b	I-MED
,	O
perforin	B-MED
,	O
tnf-α	B-MED
,	O
and	O
ifnγ	B-MED
levels	B-MED
,	O
and	O
promoted	O
tumor-killing	B-MED
efficiency	I-MED
ex	B-MED
vitro	I-MED
.	O
	
moreover	O
,	O
cd169	B-MED
t	I-MED
cells	I-MED
infiltrating	B-MED
tumor-draining	B-MED
lns	I-MED
decreased	B-MED
with	O
disease	B-MED
progression	I-MED
and	O
were	O
strongly	O
associated	B-MED
with	I-MED
crc	B-MED
patient	B-MED
survival	B-MED
.	O
	
we	O
identified	B-MED
novel	O
activated	B-MED
/	O
cytolytic	B-MED
cd169	I-MED
t	I-MED
cells	I-MED
selectively	O
present	O
in	O
regional	B-MED
lns	I-MED
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	B-MED
factor	I-MED
and	O
indicator	B-MED
for	O
selecting	B-MED
patients	B-MED
for	O
appearance	B-MED
differences	B-MED
between	O
lots	B-MED
and	O
brands	B-MED
of	O
similar	O
shade	B-MED
designations	B-MED
of	O
dental	B-MED
composite	I-MED
resins	I-MED
the	O
purposes	B-MED
of	O
this	O
study	B-MED
were	O
to	O
investigate	B-MED
differences	B-MED
in	O
two	O
inherent	B-MED
appearance	B-MED
characteristics	B-MED
between	O
lots	B-MED
of	O
an	O
enamel	B-MED
dental	I-MED
composite	I-MED
resin	I-MED
of	O
the	O
same	O
shade	B-MED
and	O
brand	B-MED
,	O
and	O
to	O
further	O
compare	B-MED
these	O
differences	B-MED
to	O
those	O
of	O
similar	O
shade	B-MED
designation	B-MED
of	O
a	O
different	B-MED
brand	B-MED
of	O
dental	B-MED
composite	I-MED
resins	I-MED
.	O
	
appearance	B-MED
analyses	B-MED
proceeded	B-MED
for	O
three	O
different	O
lots	B-MED
of	O
shades	B-MED
a1	B-MED
,	O
b2	B-MED
,	O
and	O
d3	B-MED
manufactured	B-MED
by	O
one	O
company	B-MED
and	O
for	O
one	O
lot	B-MED
of	O
shade	B-MED
ea1	B-MED
manufactured	B-MED
by	O
another	O
.	O
	
samples	B-MED
were	O
measured	B-MED
on	O
black	B-MED
,	O
white	B-MED
,	O
and	O
gray	B-MED
backings	B-MED
using	O
spectroradiometry	B-MED
.	O
	
kubelka-munk	B-MED
theory	I-MED
was	O
used	O
to	O
determine	O
reflectivity	B-MED
of	O
each	O
lot	B-MED
studied	B-MED
.	O
	
cielab	B-MED
values	I-MED
and	O
color	B-MED
differences	B-MED
between	O
shades	B-MED
and	O
lots	B-MED
were	O
analyzed	B-MED
.	O
	
translucency	B-MED
indicators	B-MED
were	O
compared	B-MED
between	O
lots	B-MED
over	O
thicknesses	B-MED
from	O
0.5	O
to	O
3.0	O
mm	O
.	O
	
differences	B-MED
in	O
inherent	B-MED
color	B-MED
between	O
some	O
lots	B-MED
of	O
same	O
shade	B-MED
designations	B-MED
within	O
a	O
brand	B-MED
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	B-MED
threshold	B-MED
.	O
	
color	B-MED
difference	B-MED
between	O
an	O
enamel	B-MED
composite	I-MED
resin	I-MED
of	O
shade	B-MED
a1	B-MED
and	O
a	O
composite	B-MED
resin	I-MED
of	O
shade	B-MED
ea1	B-MED
was	O
also	O
above	O
the	O
acceptability	B-MED
threshold	B-MED
.	O
	
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
translucency	B-MED
were	O
found	O
between	O
some	O
lots	B-MED
of	O
one	O
shade	B-MED
over	O
the	O
entire	O
range	B-MED
of	O
thicknesses	B-MED
studied	B-MED
.	O
	
appearance	B-MED
analyses	B-MED
indicate	B-MED
substantial	O
variation	B-MED
between	O
lots	B-MED
of	O
same	O
shade	B-MED
designations	B-MED
as	O
well	O
as	O
between	O
brands	B-MED
of	O
similar	O
shade	B-MED
designations	B-MED
.	O
	
optical	B-MED
principles	O
applied	B-MED
to	O
important	B-MED
clinical	B-MED
appearance	B-MED
attributes	O
are	O
described	O
which	O
characterize	B-MED
inherent	B-MED
appearance	B-MED
attributes	O
and	O
provide	O
aid	B-MED
in	O
the	O
appearance	B-MED
matching	B-MED
process	B-MED
for	O
dental	B-MED
composite	I-MED
resins	I-MED
used	O
in	O
restorative	B-MED
and	O
operative	B-MED
dental	I-MED
procedures	I-MED
.	O
	
patient	B-MED
preferences	I-MED
in	O
treatment	B-MED
choices	B-MED
for	O
early-stage	B-MED
lung	B-MED
cancer	I-MED
decision-making	B-MED
for	O
lung	B-MED
cancer	I-MED
treatment	B-MED
can	O
be	O
complex	B-MED
because	O
it	O
involves	O
both	O
provider	B-MED
recommendations	B-MED
based	O
on	O
the	O
patient's	B-MED
clinical	B-MED
condition	B-MED
and	O
patient	B-MED
preferences	I-MED
.	O
	
this	O
study	B-MED
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-MED
in	O
lung	B-MED
cancer	I-MED
treatment	B-MED
from	O
the	O
patient's	B-MED
perspective	B-MED
.	O
	
a	O
conjoint	B-MED
preference	I-MED
experiment	I-MED
began	O
by	O
asking	O
respondents	B-MED
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-MED
with	O
lung	B-MED
cancer	I-MED
.	O
	
respondents	B-MED
then	O
chose	B-MED
among	O
procedures	B-MED
that	O
differed	O
regarding	O
treatment	B-MED
modalities	B-MED
,	O
the	O
potential	O
for	O
treatment	B-MED
-related	O
complications	B-MED
,	O
the	O
likelihood	B-MED
of	O
recurrence	B-MED
,	O
provider	B-MED
case	B-MED
volume	B-MED
,	O
and	O
distance	B-MED
needed	B-MED
to	O
travel	B-MED
for	O
treatment	B-MED
.	O
	
conjoint	B-MED
analysis	I-MED
derived	O
relative	O
weights	O
for	O
these	O
attributes	B-MED
.	O
	
a	O
total	O
of	O
225	O
responses	B-MED
were	O
analyzed	B-MED
.	O
	
respondents	B-MED
were	O
most	O
willing	O
to	O
accept	O
minimally	B-MED
invasive	B-MED
operations	I-MED
for	O
treatment	B-MED
of	O
their	O
hypothetical	O
lung	B-MED
cancer	I-MED
,	O
followed	O
by	O
stereotactic	B-MED
body	I-MED
radiation	I-MED
therapy	I-MED
sbrt	B-MED
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-MED
.	O
	
treatment	B-MED
type	O
and	O
risk	B-MED
of	I-MED
recurrence	I-MED
were	O
the	O
most	O
important	O
attributes	B-MED
from	O
the	O
conjoint	B-MED
experiment	I-MED
each	O
with	O
a	O
relative	O
weight	O
of	O
0.23	O
,	O
followed	O
by	O
provider	B-MED
volume	B-MED
relative	O
weight	O
of	O
0.21	O
,	O
risk	B-MED
of	O
major	O
complications	B-MED
relative	O
weight	O
of	O
0.18	O
,	O
and	O
distance	B-MED
needed	B-MED
to	O
travel	B-MED
for	O
treatment	B-MED
relative	O
weight	O
of	O
0.15	O
.	O
	
procedural	B-MED
and	O
treatment	B-MED
preferences	B-MED
did	O
not	O
vary	O
with	O
demographics	B-MED
,	O
self-reported	B-MED
health	B-MED
status	I-MED
,	O
or	O
familiarity	B-MED
with	O
the	O
procedures	B-MED
.	O
	
survey	B-MED
respondents	B-MED
preferred	O
minimally	B-MED
invasive	B-MED
operations	I-MED
over	O
sbrt	B-MED
or	O
thoracotomy	B-MED
for	O
treatment	B-MED
of	O
early-stage	B-MED
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
	
treatment	B-MED
modality	B-MED
and	O
risk	B-MED
of	O
cancer	B-MED
recurrence	I-MED
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-MED
preferences	B-MED
.	O
	
provider	B-MED
experience	B-MED
outweighed	O
the	O
potential	O
need	B-MED
to	O
travel	B-MED
for	O
lung	B-MED
cancer	I-MED
treatment	B-MED
.	O
	
suppressed	B-MED
translation	B-MED
and	O
ulk1	B-MED
degradation	B-MED
as	O
potential	B-MED
mechanisms	B-MED
of	O
autophagy	B-MED
limitation	O
under	O
prolonged	B-MED
starvation	B-MED
macroautophagy	B-MED
/	O
autophagy	B-MED
is	O
a	O
well-organized	O
process	O
of	O
intracellular	B-MED
degradation	I-MED
,	O
which	O
is	O
rapidly	O
activated	B-MED
under	O
starvation	B-MED
conditions	O
.	O
	
recent	O
data	B-MED
demonstrate	O
a	O
transcriptional	B-MED
upregulation	B-MED
of	O
several	O
autophagy	B-MED
genes	B-MED
as	O
a	O
mechanism	B-MED
that	O
controls	B-MED
autophagy	B-MED
in	O
response	O
to	O
starvation	B-MED
.	O
	
here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	B-MED
of	O
mrna	B-MED
of	O
the	O
essential	O
autophagy	B-MED
initiation	B-MED
gene	I-MED
ulk1	B-MED
,	O
its	O
protein	B-MED
level	B-MED
is	O
rapidly	O
reduced	B-MED
under	O
starvation	B-MED
.	O
	
although	O
both	O
autophagic	B-MED
and	O
proteasomal	B-MED
systems	I-MED
contribute	O
to	O
the	O
degradation	B-MED
of	O
ulk1	B-MED
,	O
under	O
prolonged	B-MED
nitrogen	B-MED
deprivation	B-MED
,	O
its	O
level	B-MED
was	O
still	O
reduced	B-MED
in	O
atg7	B-MED
knockout	B-MED
cells	I-MED
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	B-MED
treated	B-MED
with	O
the	O
lysosomal	B-MED
or	O
proteasomal	B-MED
inhibitors	I-MED
.	O
	
we	O
demonstrate	O
that	O
under	O
starvation	B-MED
,	O
protein	B-MED
translation	I-MED
is	O
rapidly	O
diminished	B-MED
and	O
,	O
similar	O
to	O
treatments	B-MED
with	O
the	O
proteosynthesis	B-MED
inhibitors	I-MED
cycloheximide	B-MED
or	O
anisomycin	B-MED
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	B-MED
of	O
ulk1	B-MED
.	O
	
furthermore	O
,	O
it	O
was	O
found	O
that	O
inhibition	B-MED
of	O
the	O
mitochondrial	B-MED
respiratory	B-MED
complexes	I-MED
or	O
the	O
mitochondrial	B-MED
atp	B-MED
synthase	I-MED
function	I-MED
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	B-MED
of	O
substrates	B-MED
,	O
promote	O
upregulation	B-MED
of	O
ulk1	B-MED
mrna	I-MED
and	O
protein	B-MED
expression	I-MED
in	O
an	O
ampk	B-MED
-	O
dependent	B-MED
manner	O
in	O
u1810	B-MED
lung	I-MED
cancer	I-MED
cells	I-MED
growing	O
in	O
complete	O
culture	B-MED
medium	I-MED
.	O
	
these	O
inhibitors	B-MED
could	O
also	O
drastically	O
increase	B-MED
the	O
ulk1	B-MED
protein	I-MED
in	O
u1810	B-MED
cells	I-MED
with	O
knockout	O
of	O
atg13	B-MED
,	O
where	O
the	O
ulk1	B-MED
expression	B-MED
is	O
significantly	O
diminished	B-MED
.	O
	
however	O
,	O
such	O
upregulation	B-MED
of	O
ulk1	B-MED
protein	I-MED
is	O
negligible	O
under	O
starvation	B-MED
conditions	O
,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	B-MED
and	O
suggesting	O
that	O
transcriptional	B-MED
upregulation	B-MED
of	O
ulk1	B-MED
protein	I-MED
will	O
be	O
diminished	B-MED
under	O
such	O
conditions	O
.	O
	
thus	O
,	O
we	O
propose	O
a	O
model	B-MED
where	O
inhibition	B-MED
of	O
protein	B-MED
translation	I-MED
,	O
together	O
with	O
the	O
degradation	B-MED
systems	O
,	O
limit	O
autophagy	B-MED
during	O
neuroprotective	B-MED
role	I-MED
of	O
microrna-22	B-MED
in	O
a	O
6-hydroxydopamine	B-MED
-	O
induced	B-MED
cell	B-MED
model	B-MED
of	O
parkinson's	B-MED
disease	I-MED
via	O
regulation	B-MED
of	O
its	O
target	B-MED
gene	B-MED
trpm7	B-MED
parkinson's	B-MED
disease	I-MED
pd	B-MED
,	O
the	O
second	O
most	O
prevalent	B-MED
neurodegenerative	B-MED
disorder	I-MED
with	O
only	O
symptomatic	B-MED
treatment	B-MED
available	B-MED
,	O
is	O
characterized	B-MED
by	O
a	O
progressive	B-MED
loss	B-MED
of	O
dopaminergic	B-MED
neurons	I-MED
in	O
the	O
midbrain	B-MED
.	O
	
ample	O
evidence	O
indicated	O
that	O
micrornas	B-MED
mirs	B-MED
could	O
regulate	B-MED
post-transcriptional	I-MED
gene	B-MED
expression	I-MED
and	O
neuronal	B-MED
disease	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
we	O
have	O
evaluated	O
the	O
effects	B-MED
and	O
mechanism	B-MED
of	O
mir-22	B-MED
in	O
pc12	B-MED
pheochromocytoma	I-MED
cells	I-MED
treated	B-MED
with	O
6-hydroxydopamine	B-MED
6-ohda	B-MED
to	O
mimic	O
pd	B-MED
.	O
	
rt-pcr	B-MED
results	B-MED
showed	O
that	O
the	O
expression	B-MED
of	O
mir-22	B-MED
is	O
downregulated	B-MED
in	O
6-ohda	B-MED
-	O
treated	B-MED
pc12	B-MED
cells	I-MED
,	O
and	O
the	O
overexpression	B-MED
of	O
mir-22	B-MED
significantly	O
promoted	B-MED
the	O
survival	B-MED
and	O
proliferation	B-MED
of	O
6-ohda	B-MED
-	O
induced	B-MED
pc12	B-MED
cells	I-MED
,	O
whereas	O
mir-22	B-MED
inhibitor	B-MED
reversed	B-MED
these	O
effects	B-MED
.	O
	
in	O
addition	O
,	O
pc12	B-MED
cells	I-MED
were	O
treated	B-MED
with	O
mir-22	B-MED
mimics	I-MED
or	O
inhibitor	B-MED
following	B-MED
6-ohda	B-MED
administration	B-MED
,	O
which	O
medicated	O
ros	B-MED
production	B-MED
and	O
upregulation	B-MED
or	O
downregulation	B-MED
of	O
caspase-3	B-MED
activity	I-MED
,	O
respectively	O
.	O
	
a	O
luciferase	B-MED
reporter	O
assay	B-MED
revealed	B-MED
that	O
transient	B-MED
receptor	I-MED
potential	I-MED
melastatin	I-MED
7	I-MED
trpm7	B-MED
is	O
a	O
direct	B-MED
target	B-MED
gene	B-MED
of	O
mir-22	B-MED
,	O
and	O
mir-22	B-MED
overexpression	B-MED
markedly	O
downregulated	B-MED
the	O
level	B-MED
of	O
trpm7	B-MED
.	O
	
strikingly	O
,	O
further	O
analysis	B-MED
showed	O
that	O
mir-22	B-MED
mediated	O
6-ohda	B-MED
-	O
induced	B-MED
pc12	B-MED
cell	B-MED
survival	I-MED
and	O
proliferation	B-MED
by	O
targeting	B-MED
trpm7	B-MED
.	O
	
taken	O
together	O
,	O
the	O
present	O
study	B-MED
showed	O
that	O
mir-22	B-MED
overexpression	B-MED
exhibited	O
neuroprotective	B-MED
and	O
reversal	B-MED
effects	B-MED
on	O
the	O
6-ohda	B-MED
-	O
induced	B-MED
pc12	B-MED
cell	B-MED
growth	I-MED
and	O
apoptosis	B-MED
by	O
targeting	B-MED
trpm7	B-MED
.	O
	
obstacle	B-MED
course	I-MED
runs	I-MED
review	B-MED
of	O
acquired	O
injuries	B-MED
and	O
illnesses	B-MED
at	O
a	O
series	B-MED
of	O
canadian	B-MED
events	B-MED
race	B-MED
the	O
growing	O
popularity	O
of	O
obstacle	B-MED
course	I-MED
runs	I-MED
ocrs	B-MED
has	O
led	O
to	O
significant	B-MED
concerns	B-MED
regarding	O
their	O
safety	B-MED
.	O
	
the	O
influx	O
of	O
injuries	B-MED
and	O
illnesses	B-MED
in	O
rural	B-MED
areas	I-MED
where	O
ocrs	B-MED
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency	B-MED
medical	I-MED
services	I-MED
ems	B-MED
and	O
local	O
eds	O
.	O
	
literature	B-MED
concerning	B-MED
the	O
safety	B-MED
of	O
these	O
events	B-MED
is	O
minimal	B-MED
and	O
mostly	O
consists	O
of	O
media	B-MED
reports	B-MED
.	O
	
we	O
sought	O
to	O
characterise	B-MED
the	O
injury	B-MED
and	O
illness	B-MED
profile	O
of	O
ocrs	B-MED
and	O
the	O
level	B-MED
of	O
medical	B-MED
care	I-MED
required	O
.	O
	
this	O
study	B-MED
analysed	B-MED
ocr	B-MED
events	B-MED
occurring	O
in	O
eight	O
locations	O
across	O
canada	B-MED
from	O
may	O
to	O
august	O
2015	O
total	O
45	O
285	O
participants	B-MED
.	O
	
data	B-MED
were	O
extracted	B-MED
from	O
event	B-MED
medical	B-MED
charts	I-MED
of	O
patients	B-MED
presenting	O
to	O
the	O
onsite	B-MED
medical	B-MED
team	I-MED
,	O
including	O
injury	B-MED
or	O
illness	B-MED
type	O
,	O
onsite	O
treatment	B-MED
and	O
disposition	B-MED
.	O
	
there	O
were	O
557	O
race	B-MED
participants	I-MED
treated	B-MED
at	O
eight	O
ocr	B-MED
events	B-MED
1.2	O
of	O
all	O
participants	B-MED
.	O
	
there	O
were	O
609	O
medical	B-MED
complaints	I-MED
in	O
total	O
.	O
	
three	O
quarters	O
of	O
injuries	B-MED
were	O
musculoskeletal	B-MED
in	O
nature	O
.	O
	
eighty-nine	O
per	O
cent	O
returned	O
to	O
the	O
event	B-MED
with	O
no	O
need	O
for	O
further	O
medical	B-MED
care	I-MED
.	O
	
the	O
majority	O
of	O
treatments	B-MED
were	O
completed	O
with	O
first	B-MED
aid	I-MED
and	O
basic	O
medical	B-MED
equipment	I-MED
.	O
	
eleven	O
patients	B-MED
2%	O
of	O
patients	B-MED
required	O
transfer	O
to	O
hospital	B-MED
by	O
ems	B-MED
for	O
presentations	O
including	O
fracture	B-MED
,	O
dislocation	B-MED
,	O
head	B-MED
injury	I-MED
,	O
chest	B-MED
pain	I-MED
,	O
fall	B-MED
from	I-MED
height	I-MED
,	O
and	O
abdominal	B-MED
pain	I-MED
.	O
	
we	O
found	O
that	O
1.2	O
of	O
race	B-MED
participants	I-MED
presented	O
to	O
onsite	O
medical	B-MED
services	I-MED
.	O
	
the	O
majority	O
of	O
complaints	O
were	O
minor	B-MED
and	O
musculoskeletal	B-MED
in	O
nature	O
.	O
	
only	O
2%	O
of	O
those	O
treated	B-MED
were	O
transferred	O
to	O
hospital	B-MED
through	O
ems	B-MED
.	O
	
this	O
is	O
consistent	B-MED
with	I-MED
other	O
types	O
of	O
mass	B-MED
gathering	I-MED
events	B-MED
.	O
	
is	O
modern	B-MED
medical	B-MED
management	I-MED
changing	B-MED
ultimate	O
patient	B-MED
outcomes	I-MED
in	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
the	O
impact	B-MED
of	O
modern	B-MED
medical	B-MED
management	I-MED
of	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
ibd	B-MED
on	O
surgical	B-MED
necessity	I-MED
and	O
outcomes	B-MED
remains	O
unclear	B-MED
.	O
	
we	O
hypothesized	O
that	O
surgery	B-MED
rates	B-MED
have	O
decreased	B-MED
while	O
outcomes	B-MED
have	O
worsened	B-MED
due	O
to	O
operating	B-MED
on	O
""""	O
sicker	B-MED
""""	O
patients	B-MED
since	O
the	O
introduction	B-MED
of	O
biologic	B-MED
medications	I-MED
.	O
	
the	O
nationwide	O
inpatient	B-MED
sample	B-MED
and	O
icd-9-cm	B-MED
codes	I-MED
were	O
used	O
to	O
identify	O
inpatient	B-MED
admissions	B-MED
for	O
crohn's	B-MED
disease	I-MED
and	O
ulcerative	B-MED
colitis	I-MED
.	O
	
trends	B-MED
in	O
ibd	B-MED
nutrition	B-MED
,	O
surgeries	B-MED
,	O
and	O
postoperative	B-MED
complications	I-MED
were	O
determined	O
.	O
	
there	O
were	O
191	O
admissions	B-MED
for	O
ibd	B-MED
during	O
the	O
study	B-MED
period	B-MED
.	O
	
surgery	B-MED
rates	B-MED
were	O
largely	O
unchanged	B-MED
over	O
the	O
study	B-MED
period	B-MED
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-MED
in	O
both	O
crohn's	B-MED
disease	I-MED
and	O
ulcerative	B-MED
colitis	I-MED
.	O
	
the	O
rate	B-MED
of	O
poor	B-MED
nutrition	I-MED
increased	B-MED
by	O
67	O
%	O
in	O
ulcerative	B-MED
colitis	I-MED
and	O
by	O
83	O
%	O
in	O
crohn's	B-MED
disease	I-MED
.	O
	
rates	B-MED
of	O
postoperative	B-MED
anastomotic	B-MED
leak	I-MED
10.2	O
%	O
were	O
unchanged	B-MED
over	O
the	O
years	O
.	O
	
postoperative	B-MED
infection	I-MED
rates	B-MED
decreased	B-MED
by	O
17	O
%	O
in	O
crohn's	B-MED
disease	I-MED
18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012	O
p	O
<	O
0.001	O
but	O
did	O
not	O
show	O
a	O
trend	B-MED
in	O
any	O
direction	O
in	O
ulcerative	B-MED
colitis	I-MED
.	O
	
rates	B-MED
of	O
ibd	B-MED
surgery	B-MED
have	O
remained	O
stable	B-MED
while	O
postoperative	B-MED
infectious	I-MED
complications	I-MED
have	O
remained	O
stable	B-MED
or	O
decreased	B-MED
since	O
the	O
implementation	B-MED
of	O
biologic	B-MED
therapies	I-MED
.	O
	
we	O
identified	O
an	O
increase	B-MED
in	O
poor	B-MED
nutrition	I-MED
in	O
surgical	B-MED
patients	I-MED
.	O
	
clinical	B-MED
experience	B-MED
with	O
the	O
subcutaneous	B-MED
implantable	I-MED
cardioverter-defibrillator	I-MED
in	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
sudden	B-MED
cardiac	I-MED
death	I-MED
is	O
a	O
major	O
contributor	O
to	O
mortality	B-MED
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
.	O
	
the	O
subcutaneous	B-MED
implantable	B-MED
cardioverter-defibrillator	I-MED
icd	B-MED
has	O
emerged	O
as	O
a	O
novel	B-MED
tool	B-MED
for	O
prevention	B-MED
of	O
sudden	B-MED
cardiac	I-MED
death	I-MED
,	O
but	O
clinical	B-MED
performance	I-MED
data	B-MED
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
are	O
limited	O
.	O
	
a	O
retrospective	B-MED
study	I-MED
involving	O
7	O
centers	O
over	O
a	O
5-	O
year	B-MED
period	B-MED
beginning	O
in	O
2011	O
was	O
performed	B-MED
.	O
	
twenty-one	O
patients	B-MED
median	B-MED
33.9	O
years	B-MED
were	O
identified	O
.	O
	
the	O
most	O
common	O
diagnosis	B-MED
was	O
single	B-MED
ventricle	I-MED
physiology	B-MED
52%	O
,	O
9	O
palliated	B-MED
by	O
fontan	B-MED
operation	I-MED
and	O
2	O
by	O
aortopulmonary	B-MED
shunts	I-MED
d-transposition	B-MED
of	I-MED
the	I-MED
great	I-MED
arteries	I-MED
after	O
mustard	B-MED
/	O
senning	B-MED
n=2	O
,	O
tetralogy	B-MED
of	I-MED
fallot	I-MED
n=2	O
,	O
aortic	B-MED
valve	I-MED
disease	I-MED
n=2	O
,	O
and	O
other	O
biventricular	B-MED
surgery	B-MED
n=4	O
.	O
	
a	O
prior	O
cardiac	B-MED
device	I-MED
had	O
been	O
implanted	B-MED
in	O
7	O
33%	O
.	O
	
the	O
icd	B-MED
indication	B-MED
was	O
primary	B-MED
prevention	I-MED
in	O
67%	O
and	O
secondary	B-MED
in	O
33%	O
patient	B-MED
s	I-MED
.	O
	
the	O
most	O
common	O
reason	O
for	O
subcutaneous	B-MED
icd	B-MED
placement	B-MED
was	O
limited	O
transvenous	B-MED
access	I-MED
for	O
ventricular	B-MED
lead	I-MED
placement	B-MED
n=10	O
followed	O
by	O
intracardiac	B-MED
right-to-left	I-MED
shunt	I-MED
n=5	O
.	O
	
ventricular	B-MED
arrhythmia	I-MED
was	O
induced	B-MED
in	O
17	O
81%	O
and	O
was	O
converted	O
with	O
80	O
joules	B-MED
in	O
all	O
.	O
	
there	O
was	O
one	O
implant	B-MED
complication	I-MED
related	I-MED
to	I-MED
infection	I-MED
,	O
not	B-MED
requiring	O
device	B-MED
removal	I-MED
.	O
	
over	O
a	O
median	B-MED
follow-up	B-MED
of	O
14	O
months	B-MED
,	O
4	O
patients	B-MED
21%	O
received	O
inappropriate	B-MED
and	O
1	O
5%	O
patient	B-MED
received	O
appropriate	B-MED
shocks	I-MED
.	O
	
there	O
was	O
one	O
arrhythmic	B-MED
death	I-MED
related	O
to	O
asystole	B-MED
in	O
a	O
single	B-MED
ventricle	I-MED
patient	B-MED
.	O
	
subcutaneous	B-MED
icd	B-MED
implantation	B-MED
is	O
feasible	O
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
patients	B-MED
.	O
	
most	O
candidates	B-MED
have	O
single	B-MED
ventricle	I-MED
heart	B-MED
disease	I-MED
and	O
limited	O
transvenous	B-MED
options	I-MED
for	O
icd	B-MED
placement	B-MED
.	O
	
despite	O
variable	B-MED
anatomy	B-MED
,	O
this	O
study	B-MED
demonstrates	O
successful	B-MED
conversion	B-MED
of	O
induced	B-MED
ventricular	B-MED
arrhythmia	I-MED
and	O
reasonable	B-MED
rhythm	B-MED
discrimination	B-MED
during	O
interaction	B-MED
of	O
multiple	B-MED
gene	B-MED
variants	I-MED
and	O
their	O
effects	B-MED
on	O
schizophrenia	B-MED
phenotypes	B-MED
schizophrenia	B-MED
is	O
a	O
clinically	B-MED
heterogeneous	B-MED
disorder	I-MED
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic	B-MED
architecture	I-MED
.	O
	
many	O
schizophrenia	B-MED
susceptibility	B-MED
genes	B-MED
were	O
identified	B-MED
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	B-MED
or	O
contradictory	B-MED
genetic	B-MED
association	I-MED
studies	I-MED
.	O
	
this	O
confusion	O
may	O
,	O
in	O
part	O
,	O
be	O
because	O
symptoms	B-MED
result	O
from	O
the	O
combined	O
interaction	B-MED
of	O
many	O
genes	B-MED
and	O
these	O
interacting	B-MED
genes	B-MED
are	O
associated	B-MED
with	I-MED
specific	B-MED
sub-phenotypes	B-MED
of	O
schizophrenia	B-MED
rather	O
than	O
schizophrenia	B-MED
as	O
a	O
whole	O
.	O
	
this	O
study	O
investigates	B-MED
the	O
relationship	B-MED
between	O
schizophrenia	B-MED
susceptibility	B-MED
genes	B-MED
and	O
schizophrenia	B-MED
sub-phenotypes	B-MED
by	O
identifying	B-MED
multiple	B-MED
gene	B-MED
variant	I-MED
interactions	B-MED
.	O
	
fifty	O
snps	B-MED
from	O
21	O
genes	B-MED
were	O
genotyped	B-MED
in	O
235	O
australian	B-MED
participants	B-MED
with	O
schizophrenia	B-MED
screened	B-MED
for	O
various	O
phenotypes	B-MED
.	O
	
schizophrenia	B-MED
participants	B-MED
were	O
grouped	O
into	O
relevant	B-MED
phenotype	B-MED
clusters	B-MED
using	O
cluster	B-MED
analysis	I-MED
and	O
normalized	B-MED
phenotype	B-MED
cluster	B-MED
scores	B-MED
were	O
calculated	O
for	O
each	O
patient	B-MED
.	O
	
the	O
relationship	B-MED
between	O
genotypes	B-MED
and	O
normalized	B-MED
phenotype	B-MED
cluster	B-MED
scores	B-MED
were	O
analyzed	O
by	O
linear	B-MED
regression	I-MED
analysis	I-MED
.	O
	
three	O
phenotype	B-MED
clusters	B-MED
were	O
identified	B-MED
.	O
	
there	O
was	O
some	O
overlap	O
in	O
symptoms	B-MED
between	O
phenotype	B-MED
clusters	B-MED
,	O
particularly	O
for	O
depression	B-MED
.	O
	
however	O
,	O
cluster	B-MED
1	I-MED
appears	O
to	O
be	O
characterized	O
by	O
speech	B-MED
disorder	I-MED
and	O
affective	O
behavior	B-MED
symptoms	I-MED
,	O
cluster	B-MED
2	I-MED
has	O
predominantly	O
hallucination	B-MED
symptoms	B-MED
and	O
cluster	B-MED
3	I-MED
has	O
mainly	O
delusion	B-MED
symptoms	B-MED
.	O
	
interaction	B-MED
of	O
five	O
snps	B-MED
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster	B-MED
1	I-MED
symptoms	B-MED
ten	O
snps	B-MED
on	O
cluster	B-MED
2	I-MED
symptoms	B-MED
and	O
eight	O
snps	B-MED
on	O
cluster	B-MED
3	I-MED
symptoms	B-MED
.	O
	
the	O
interaction	B-MED
of	O
specific	B-MED
susceptibility	B-MED
genes	B-MED
is	O
likely	O
to	O
lead	O
to	O
specific	B-MED
clinical	B-MED
sub-phenotypes	B-MED
of	O
schizophrenia	B-MED
.	O
	
larger	O
patient	B-MED
cohorts	B-MED
with	O
more	O
extensive	O
clinical	B-MED
data	B-MED
will	O
improve	O
the	O
detection	B-MED
of	O
gene	B-MED
interactions	I-MED
and	O
the	O
resultant	O
schizophrenia	B-MED
clinical	B-MED
phenotypes	B-MED
.	O
	
evaluation	O
of	O
dnmt1	B-MED
gene	B-MED
expression	I-MED
profile	I-MED
and	O
methylation	B-MED
of	O
its	O
promoter	B-MED
region	I-MED
in	O
patients	B-MED
with	O
ankylosing	B-MED
spondylitis	I-MED
ankylosing	B-MED
spondylitis	I-MED
as	B-MED
is	O
an	O
autoimmune	B-MED
disease	I-MED
with	O
a	O
chronic	B-MED
inflammatory	I-MED
arthritis	I-MED
.	O
	
the	O
critical	O
role	O
of	O
methylation	B-MED
in	O
the	O
biology	B-MED
of	O
immunocytes	B-MED
has	O
increasingly	O
been	O
surveyed	B-MED
to	O
discover	O
disease	B-MED
etiology	B-MED
.	O
	
dna	B-MED
methyltransferase	I-MED
1	I-MED
dnmt1	B-MED
is	O
an	O
enzyme	B-MED
,	O
which	O
establishes	O
and	O
regulates	B-MED
patterns	B-MED
of	O
methylated	B-MED
cytosine	I-MED
residues	O
.	O
	
the	O
aim	B-MED
of	O
the	O
current	O
investigation	B-MED
was	O
to	O
unveil	O
if	O
methylation	B-MED
circumstances	O
of	O
cpg	B-MED
sites	B-MED
in	O
dnmt1	B-MED
promoter	B-MED
could	O
affect	O
the	O
mrna	B-MED
expression	I-MED
level	B-MED
of	O
this	O
gene	B-MED
in	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
pbmcs	B-MED
from	O
as	B-MED
patients	B-MED
.	O
	
pbmcs	B-MED
were	O
isolated	O
from	O
whole	B-MED
blood	I-MED
of	O
40	O
as	B-MED
patients	B-MED
and	O
40	O
healthy	B-MED
individuals	B-MED
.	O
	
total	O
rna	B-MED
and	O
dna	B-MED
contents	O
of	O
leukocytes	B-MED
were	O
extracted	B-MED
.	O
	
afterward	O
,	O
quantitative	B-MED
analysis	I-MED
was	O
carried	O
out	O
by	O
real-time	B-MED
pcr	I-MED
using	O
the	O
sybr	B-MED
green	I-MED
pcr	I-MED
master	I-MED
mix	I-MED
.	O
	
finally	O
,	O
to	O
determine	O
the	O
methylation	B-MED
level	B-MED
,	O
pcr	B-MED
products	B-MED
of	O
bisulfite-treated	B-MED
dna	I-MED
from	O
patients	B-MED
and	O
controls	B-MED
were	O
sequenced	B-MED
.	O
	
compared	O
with	O
healthy	B-MED
controls	B-MED
,	O
expression	B-MED
level	I-MED
of	O
dnmt1	B-MED
in	O
as	B-MED
patients	B-MED
was	O
significantly	O
downregulated	B-MED
.	O
	
methylation	B-MED
of	O
dnmt1	B-MED
promoter	B-MED
was	O
significantly	O
higher	O
in	O
as	B-MED
patients	B-MED
in	O
comparison	O
to	O
controls	B-MED
.	O
	
while	O
a	O
negative	B-MED
correlation	B-MED
between	O
methylation	B-MED
and	O
expression	B-MED
level	I-MED
of	O
dnmt1	B-MED
was	O
observed	O
in	O
as	B-MED
patients	B-MED
,	O
both	O
methylation	B-MED
and	O
expression	B-MED
level	I-MED
of	O
dnmt1	B-MED
did	O
not	O
correlate	B-MED
with	O
clinical	B-MED
manifestations	B-MED
.	O
	
considering	O
the	O
observation	O
that	O
decreased	B-MED
expression	B-MED
level	I-MED
of	O
dnmt1	B-MED
was	O
associated	O
with	O
hypermethylation	B-MED
of	O
dnmt1	B-MED
promoter	B-MED
in	O
pbmcs	B-MED
from	O
as	B-MED
patients	B-MED
,	O
this	O
survey	B-MED
suggests	O
that	O
dysregulation	O
of	O
dnmt1	B-MED
expression	B-MED
through	O
altered	B-MED
methylation	B-MED
level	B-MED
of	O
other	O
target	B-MED
genes	B-MED
would	O
probably	O
contribute	O
to	O
as	B-MED
antibacterial	B-MED
activity	B-MED
of	O
polyaniline	B-MED
coated	B-MED
silver	B-MED
nanoparticles	B-MED
synthesized	B-MED
from	O
piper	B-MED
betle	I-MED
leaves	I-MED
extract	I-MED
plants	B-MED
or	O
natural	B-MED
resources	I-MED
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	B-MED
method	B-MED
for	O
nanoparticles	B-MED
synthesis	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
polyaniline	B-MED
coated	B-MED
silver	B-MED
nanoparticles	B-MED
agnps	B-MED
synthesized	B-MED
from	O
piper	B-MED
betle	I-MED
leaves	I-MED
extract	I-MED
were	O
investigated	O
for	O
their	O
antibacterial	B-MED
activity	B-MED
.	O
	
silver	O
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	O
nitrate	O
and	O
nabh4	O
was	O
used	O
as	O
reducing	O
agent	O
.	O
	
silver	O
nanoparticles	O
and	O
extracts	O
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	O
.	O
	
prepared	O
nanoparticles	O
were	O
characterized	O
by	O
visual	O
inspection	O
,	O
ultraviolet-visible	O
spectroscopy	O
uv	O
,	O
fourier	O
transform	O
infrared	O
spectroscopy	O
ft-ir	O
,	O
transmission	O
electron	O
microscopy	O
tem	O
techniques	O
.	O
	
antibacterial	O
activities	O
of	O
the	O
synthesized	O
silver	O
nanoparticles	O
were	O
tested	O
against	O
staphylococcus	O
aureus	O
atcc	O
25923	O
,	O
salmonella	O
typhi	O
atcc	O
14028	O
,	O
escherichia	O
coli	O
atcc	O
25922	O
and	O
pseudomonas	O
aeruginosa	O
atcc	O
27853	O
.	O
	
uv-vis	O
spectrum	O
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O
	
the	O
ft-ir	O
results	O
imply	O
that	O
ag-nps	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio-compounds	O
present	O
in	O
p	O
.	O
	
betle	O
.	O
	
tem	O
image	O
showed	O
that	O
ag-nps	O
formed	O
were	O
well	O
dispersed	O
with	O
a	O
spherical	O
structures	O
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O
	
the	O
result	O
revealed	O
that	O
ag-extract	O
nps	O
showed	O
32.78	O
mm	O
zone	O
of	O
inhibition	O
against	O
s	O
.	O
	
aureus	O
,	O
whereas	O
norfloxacin	O
positive	O
control	O
showed	O
maximum	O
32.15	O
mm	O
zone	O
of	O
inhibition	O
for	O
s	O
.	O
	
aureus	O
.	O
	
again	O
,	O
maximum	O
zone	O
of	O
inhibition	O
29.55	O
mm	O
was	O
found	O
for	O
s	O
.	O
	
typhi	O
,	O
27.12	O
mm	O
for	O
e	O
.	O
	
coli	O
and	O
21.95	O
mm	O
for	O
p	O
.	O
	
aeruginosa	O
.	O
	
the	O
results	O
obtained	O
by	O
this	O
study	O
can't	O
be	O
directly	O
extrapolated	O
to	O
human	O
so	O
further	O
studies	O
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	O
activity	B-MED
of	O
ag-extract	O
nps	O
for	O
drug	O
development	O
program	I-MED
clinical	B-MED
pearls	I-MED
in	O
tremor	B-MED
and	O
other	O
hyperkinetic	B-MED
movement	I-MED
disorders	B-MED
hyperkinetic	B-MED
movements	I-MED
,	O
such	O
as	O
tremor	B-MED
,	O
myoclonus	B-MED
,	O
chorea	B-MED
,	O
and	O
dystonia	B-MED
,	O
occur	O
in	O
many	O
neurologic	B-MED
and	O
medical	B-MED
conditions	I-MED
.	O
	
accurate	O
clinical	B-MED
evaluation	I-MED
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	B-MED
and	O
treatment	B-MED
of	O
patients	B-MED
with	O
abnormal	B-MED
movements	I-MED
.	O
	
tracking	O
children	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
who	O
abandoned	B-MED
therapy	B-MED
experience	B-MED
,	O
challenges	B-MED
,	O
parental	B-MED
perspectives	B-MED
,	O
and	O
impact	O
of	O
treatment	B-MED
subsidies	B-MED
and	O
intensified	B-MED
counseling	I-MED
refusal	B-MED
for	I-MED
treatment	I-MED
and	O
therapy	B-MED
abandonment	B-MED
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
all	B-MED
in	O
resource	B-MED
-poor	O
countries	B-MED
.	O
	
the	O
present	O
study	B-MED
,	O
conducted	O
on	O
children	B-MED
with	O
all	B-MED
whose	O
treatment	B-MED
was	O
abandoned	B-MED
,	O
attempted	O
to	O
track	O
all	O
these	O
children	B-MED
to	O
ascertain	O
the	O
causes	O
and	O
outcome	B-MED
of	O
therapy	B-MED
abandonment	B-MED
/	O
refusal	B-MED
.	O
	
in	O
order	O
to	O
improve	O
outcome	B-MED
of	O
all	B-MED
,	O
measures	O
to	O
prevent	O
abandonment	B-MED
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-MED
subsidies	B-MED
and	O
intensified	B-MED
multistage	I-MED
counseling	I-MED
.	O
	
of	O
the	O
77	O
of	O
418	O
children	B-MED
abandoning	O
therapy	B-MED
,	O
17	O
22%	O
refused	B-MED
upfront	I-MED
,	O
whereas	O
the	O
rest	O
abandoned	B-MED
during	O
various	O
phases	O
of	O
chemotherapy	B-MED
.	O
	
only	O
39	O
50.6	O
of	O
these	O
77	O
families	B-MED
could	O
be	O
subsequently	O
contacted	O
.	O
	
financial	B-MED
problems	I-MED
,	O
too	O
many	O
dependents	B-MED
at	O
home	B-MED
,	O
and	O
wrong	O
perceptions	B-MED
about	O
cancer	B-MED
led	O
to	O
abandonment	B-MED
in	O
majority	O
.	O
	
children	B-MED
abandoning	I-MED
treatment	I-MED
before	O
completion	O
of	O
induction	B-MED
had	O
a	O
significantly	O
shorter	O
survival	B-MED
than	O
who	O
abandoned	B-MED
post	B-MED
induction	I-MED
p	O
<	O
0001	O
.	O
	
intensified	B-MED
preabandonment	I-MED
counseling	I-MED
and	O
subsidized	O
treatment	B-MED
led	O
to	O
significant	O
reduction	B-MED
in	O
abandonment	B-MED
rates	I-MED
effect	B-MED
of	O
new-onset	B-MED
left	B-MED
bundle	I-MED
branch	I-MED
block	I-MED
after	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
corevalve	B-MED
on	O
mortality	B-MED
,	O
frequency	B-MED
of	O
re-hospitalization	B-MED
,	O
and	O
need	O
for	O
pacemaker	B-MED
new-onset	B-MED
conduction	B-MED
disturbances	I-MED
are	O
common	O
after	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
tavi	B-MED
.	O
	
the	O
most	O
common	O
complication	B-MED
is	O
left	B-MED
bundle	I-MED
branch	I-MED
block	I-MED
lbbb	B-MED
.	O
	
the	O
clinical	B-MED
impact	B-MED
of	O
new-onset	B-MED
lbbb	B-MED
after	O
tavi	B-MED
remains	O
controversial	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	B-MED
impact	B-MED
of	O
new-onset	B-MED
lbbb	B-MED
in	O
terms	O
of	O
mortality	B-MED
and	O
morbidity	B-MED
need	O
for	O
pacemakers	B-MED
and	O
admissions	B-MED
for	O
heart	B-MED
failure	I-MED
at	O
long-term	B-MED
follow-up	I-MED
.	O
	
from	O
april	O
2008	O
to	O
december	O
2014	O
,	O
220	O
patients	B-MED
who	O
had	O
severe	O
aortic	B-MED
stenosis	I-MED
were	O
treated	B-MED
with	I-MED
the	O
implantation	B-MED
of	O
a	O
corevalve	B-MED
prosthesis	I-MED
.	O
	
sixty-seven	O
of	O
these	O
patients	B-MED
were	O
excluded	O
from	O
the	O
analysis	B-MED
,	O
including	O
22	O
patients	B-MED
with	O
pre-existing	B-MED
lbbb	B-MED
and	O
45	O
with	O
a	O
permanent	B-MED
pacemaker	I-MED
,	O
implanted	B-MED
previously	O
or	O
within	O
72	O
hours	B-MED
of	O
implantation	B-MED
.	O
	
the	O
remaining	O
153	O
patients	B-MED
were	O
divided	O
into	O
2	O
groups	B-MED
group	B-MED
1	O
n	O
=	O
80	O
,	O
those	O
with	O
persistent	B-MED
new-onset	B-MED
lbbb	B-MED
,	O
and	O
group	B-MED
2	O
n	O
=	O
73	O
,	O
those	O
without	O
conduction	B-MED
disturbances	I-MED
after	O
treatment	B-MED
.	O
	
both	O
groups	B-MED
were	O
followed	B-MED
up	I-MED
at	O
1	O
month	B-MED
,	O
6	O
months	B-MED
,	O
12	O
months	B-MED
,	O
and	O
yearly	B-MED
thereafter	O
.	O
	
persistent	B-MED
new-onset	B-MED
lbbb	B-MED
occurred	O
in	O
80	O
patients	B-MED
36%	O
immediately	O
after	O
tavi	B-MED
73	O
patients	B-MED
33%	O
did	O
not	O
develop	O
conduction	B-MED
disturbances	I-MED
.	O
	
the	O
mean	O
follow-up	B-MED
time	B-MED
of	O
both	O
groups	B-MED
was	O
32	O
22	O
months	B-MED
range	O
3	O
to	O
82	O
months	B-MED
,	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	B-MED
between	O
the	O
groups	B-MED
.	O
	
there	O
were	O
no	O
differences	O
in	O
mortality	B-MED
between	O
the	O
groups	B-MED
39%	O
vs	O
48%	O
,	O
p	O
=	O
0.58	O
.	O
	
no	O
differences	O
were	O
observed	O
between	O
the	O
groups	B-MED
in	O
re-hospitalizations	B-MED
for	O
heart	B-MED
failure	I-MED
11%	O
vs	O
16%	O
,	O
p	O
=	O
0.55	O
.	O
	
group	B-MED
1	O
did	O
not	O
require	O
pacemaker	B-MED
implantation	I-MED
more	O
often	O
at	O
follow-up	B-MED
10%	O
vs	O
13%	O
,	O
p	O
=	O
0.38	O
than	O
group	B-MED
2	O
.	O
	
in	O
conclusion	O
,	O
new-onset	B-MED
lbbb	B-MED
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	B-MED
incidence	B-MED
of	O
late	O
need	O
for	O
a	O
permanent	B-MED
pacemaker	I-MED
after	O
corevalve	B-MED
implantation	B-MED
.	O
	
in	O
addition	O
,	O
it	O
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	O
risk	O
of	O
late	O
mortality	B-MED
or	O
the	O
relationship	B-MED
between	O
polymorphisms	B-MED
of	O
bdnfos	B-MED
and	O
bdnf	B-MED
genes	I-MED
and	O
heroin	B-MED
addiction	I-MED
in	O
the	O
han	B-MED
chinese	I-MED
population	I-MED
the	O
number	O
of	O
heroin	B-MED
addicts	B-MED
is	O
increasing	B-MED
in	O
the	O
world	B-MED
.	O
	
both	O
environmental	B-MED
and	O
genetic	B-MED
factors	I-MED
both	O
play	O
critical	B-MED
roles	O
in	O
the	O
process	B-MED
of	O
heroin	B-MED
addiction	I-MED
.	O
	
we	O
aimed	B-MED
to	O
investigate	B-MED
the	O
associations	B-MED
between	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
snps	B-MED
in	O
lin7c	B-MED
,	O
bdnfos	B-MED
and	O
bdnf	B-MED
genes	I-MED
and	O
drug	B-MED
addiction	I-MED
in	O
the	O
han	B-MED
chinese	I-MED
population	I-MED
.	O
	
we	O
conducted	O
a	O
case-control	B-MED
study	I-MED
among	O
692	O
cases	B-MED
and	O
700	O
healthy	B-MED
controls	I-MED
from	O
xi'an	B-MED
,	O
china	B-MED
.	O
	
eight	O
snps	B-MED
were	O
selected	B-MED
and	O
genotyped	B-MED
using	O
massarray	B-MED
technology	I-MED
sequenom	B-MED
,	O
san	B-MED
diego	I-MED
,	O
ca	I-MED
,	O
usa	B-MED
.	O
	
odds	B-MED
ratios	I-MED
or	B-MED
and	O
95%	O
confidence	B-MED
intervals	I-MED
cis	B-MED
were	O
calculated	B-MED
by	O
unconditional	B-MED
logistic	I-MED
regression	I-MED
adjusting	O
for	O
age	B-MED
and	O
sex	B-MED
.	O
	
using	O
the	O
chi-squared	B-MED
test	I-MED
,	O
we	O
found	O
that	O
rs7481311	B-MED
or	B-MED
=1	O
,	O
95%	O
ci	B-MED
=	O
1.087	O
,	O
p	O
=	O
0.009	O
and	O
rs11030096	B-MED
or	B-MED
=1	O
,	O
95%	O
ci	B-MED
=	O
1.049	O
,	O
p	O
=	O
0.011	O
in	O
the	O
bndfos	B-MED
were	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
.	O
	
by	O
contrast	O
,	O
rs988712	B-MED
located	O
in	O
bdnfos	B-MED
showed	O
a	O
decreased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
or	B-MED
=0	O
,	O
95%	O
ci	B-MED
=	O
0.582	O
,	O
p	O
=	O
0.003	O
.	O
	
by	O
genetic	B-MED
model	I-MED
analysis	B-MED
,	O
we	O
found	O
that	O
the	O
't'	B-MED
allele	I-MED
of	O
rs988712	B-MED
in	O
bdnfos	B-MED
had	O
a	O
protective	O
role	O
for	O
heroin	B-MED
addiction	I-MED
in	O
the	O
additive	B-MED
model	I-MED
and	O
dominant	B-MED
model	I-MED
p	O
<	O
0.05	O
.	O
	
by	O
contrast	O
,	O
the	O
allele	B-MED
't'	I-MED
of	O
rs7481311	B-MED
in	O
bdnfos	B-MED
significantly	O
elevated	B-MED
the	O
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
in	O
the	O
additive	B-MED
model	I-MED
,	O
recessive	B-MED
model	I-MED
and	O
dominant	B-MED
model	I-MED
p	O
<	O
0.05	O
.	O
	
we	O
also	O
found	O
that	O
allele	B-MED
'c	I-MED
'	O
of	O
rs11030096	B-MED
was	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
addiction	B-MED
in	O
the	O
dominant	B-MED
model	I-MED
and	O
additive	B-MED
model	I-MED
p	O
<	O
0.05	O
.	O
	
additionally	O
,	O
we	O
found	O
that	O
rs6265	B-MED
,	O
rs11030104	B-MED
and	O
rs10767664	B-MED
in	O
bdnf	B-MED
were	O
associated	B-MED
with	I-MED
a	O
decreased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
p	O
<	O
0.05	O
.	O
	
however	O
,	O
only	O
rs7481311	B-MED
in	O
bdnfos	B-MED
remained	O
significant	B-MED
after	O
bonferroni	B-MED
correction	I-MED
p	O
<	O
0.00625	O
.	O
	
these	O
results	B-MED
suggest	O
that	O
polymorphisms	B-MED
of	O
bdnfos	B-MED
play	O
an	O
important	B-MED
role	O
in	O
heroin	B-MED
addiction	I-MED
susceptibility	B-MED
in	O
the	O
chinese	B-MED
han	I-MED
population	I-MED
.	O
	
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
associated	B-MED
with	I-MED
adolescent	B-MED
girls'	I-MED
substance	B-MED
use	I-MED
data	B-MED
from	O
a	O
nationwide	O
facebook	B-MED
sample	O
despite	O
overall	O
reductions	B-MED
in	O
teenage	B-MED
substance	B-MED
use	I-MED
,	O
adolescent	B-MED
girls	I-MED
'	O
rates	B-MED
of	O
substance	B-MED
use	I-MED
remain	O
unacceptably	B-MED
high	I-MED
.	O
	
this	O
article	B-MED
examines	O
whether	O
girls	B-MED
'	O
substance	B-MED
use	I-MED
is	O
associated	B-MED
with	I-MED
general	O
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
goal	B-MED
setting	I-MED
,	O
problem	B-MED
solving	I-MED
,	O
refusal	B-MED
skills	I-MED
,	O
peer	B-MED
use	I-MED
,	O
and	O
self-efficacy	B-MED
and	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
communication	B-MED
style	I-MED
,	O
coping	B-MED
skills	I-MED
,	O
self-esteem	B-MED
,	O
body	B-MED
image	I-MED
,	O
perceived	B-MED
stress	I-MED
,	O
anxiety	B-MED
,	O
and	O
depression	B-MED
.	O
	
cross-sectional	B-MED
data	I-MED
were	O
collected	O
in	O
2013	O
via	O
online	B-MED
surveys	I-MED
from	O
a	O
nationwide	O
sample	O
of	O
adolescent	B-MED
girls	I-MED
n	O
=	O
788	O
,	O
aged	O
13	O
and	O
14	O
years	O
,	O
who	O
were	O
recruited	O
through	O
facebook	B-MED
.	O
	
in	O
multivariate	B-MED
analyses	I-MED
,	O
controlling	O
for	O
correlates	B-MED
of	O
adolescent	B-MED
substance	B-MED
use	I-MED
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
were	O
consistently	O
associated	B-MED
with	I-MED
past-month	O
alcohol	B-MED
,	O
cigarette	B-MED
,	O
and	O
other	O
drug	B-MED
use	I-MED
in	O
the	O
expected	O
direction	O
past-month	B-MED
marijuana	I-MED
use	I-MED
was	O
associated	B-MED
with	I-MED
8	O
of	O
the	O
13	O
factors	B-MED
.	O
	
refusal	B-MED
skill	I-MED
s	O
,	O
peer	B-MED
use	I-MED
,	O
coping	B-MED
,	O
and	O
depressive	B-MED
mood	I-MED
were	O
most	O
consistently	O
and	O
strongly	O
associated	B-MED
with	I-MED
substance	B-MED
use	I-MED
.	O
	
substance	B-MED
abuse	I-MED
prevention	I-MED
programs	B-MED
targeting	O
adolescent	B-MED
girls	I-MED
should	O
focus	O
on	O
such	O
general	O
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
as	O
problem	B-MED
solving	I-MED
,	O
refusal	B-MED
skill	I-MED
s	O
,	O
peer	B-MED
influences	I-MED
,	O
and	O
self-efficacy	B-MED
,	O
as	O
well	O
as	O
such	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
as	O
communication	B-MED
style	I-MED
,	O
coping	B-MED
,	O
self-esteem	B-MED
,	O
body	B-MED
image	I-MED
,	O
perceived	B-MED
stress	I-MED
,	O
and	O
mood	B-MED
management	I-MED
.	O
	
ethics	B-MED
hype	B-MED
there	O
has	O
been	O
growing	O
concern	B-MED
about	O
the	O
phenomenon	B-MED
of	O
science	B-MED
hype	B-MED
,	O
the	O
tendency	O
to	O
exaggerate	B-MED
the	O
value	O
or	O
near	B-MED
-	O
future	B-MED
application	B-MED
of	O
research	B-MED
results	I-MED
.	O
	
although	O
this	O
is	O
a	O
problem	B-MED
that	O
touches	O
every	O
area	B-MED
of	I-MED
biomedicine	I-MED
,	O
the	O
topic	B-MED
of	O
genetics	B-MED
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	B-MED
predictions	B-MED
.	O
	
the	O
world	B-MED
has	O
been	O
told	O
for	O
over	O
two	O
decades	B-MED
-by	O
the	O
media	B-MED
,	O
researchers	B-MED
,	O
politicians	B-MED
,	O
and	O
the	O
biotech	B-MED
industry	B-MED
-that	O
a	O
genome	B-MED
-driven	O
health	B-MED
care	I-MED
revolution	B-MED
is	O
just	O
around	O
the	O
corner	O
.	O
	
and	O
while	O
the	O
revolution	B-MED
never	O
seems	O
to	O
arrive	O
,	O
the	O
hopeful	O
rhetoric	B-MED
continues	O
.	O
	
it	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
""""	O
genohype	B-MED
""""	O
is	O
having	O
a	O
range	O
of	O
adverse	B-MED
social	B-MED
consequences	I-MED
,	O
including	O
misleading	O
the	O
public	B-MED
and	O
hurting	B-MED
the	O
long-term	B-MED
legitimacy	B-MED
of	O
the	O
field	B-MED
.	O
	
while	O
we	O
need	O
more	O
good	O
data	B-MED
on	O
the	O
nature	B-MED
and	O
magnitude	B-MED
of	O
these	O
possible	O
harms	B-MED
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	B-MED
that	O
sustained	B-MED
science	B-MED
hype	B-MED
is	O
a	O
bad	O
thing	O
.	O
	
we	O
all	O
benefit	B-MED
from	O
robust	B-MED
science	B-MED
and	O
accurate	B-MED
public	B-MED
representations	B-MED
of	O
biomedical	B-MED
research	I-MED
.	O
	
but	O
,	O
to	O
date	O
,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-MED
of	O
the	O
degree	B-MED
to	O
which	O
the	O
scholarship	B-MED
on	O
the	O
related	O
ethical	B-MED
,	O
legal	B-MED
,	O
and	O
social	B-MED
issues	I-MED
has	O
been	O
hyped	O
.	O
	
are	O
the	O
conclusions	B-MED
from	O
elsi	B-MED
scholarship	I-MED
also	O
lubiprostone	B-MED
accelerates	B-MED
intestinal	B-MED
transit	I-MED
and	O
alleviates	B-MED
small	B-MED
intestinal	I-MED
bacterial	I-MED
overgrowth	I-MED
in	O
patients	B-MED
with	O
chronic	B-MED
constipation	I-MED
lubiprostone	B-MED
is	O
an	O
effective	B-MED
treatment	B-MED
for	O
chronic	B-MED
constipation	I-MED
cc	B-MED
.	O
	
the	O
mechanism	B-MED
of	I-MED
action	I-MED
of	O
lubiprostone	B-MED
is	O
through	O
increasing	B-MED
fluid	B-MED
secretion	I-MED
and	O
lubrication	B-MED
of	O
the	O
intestinal	B-MED
lumen	I-MED
.	O
	
the	O
effects	B-MED
of	O
lubiprostone	B-MED
on	O
gastrointestinal	B-MED
transit	I-MED
and	O
small	B-MED
intestinal	I-MED
bacterial	I-MED
overgrowth	I-MED
sibo	B-MED
have	O
not	O
been	O
adequately	O
explored	O
.	O
	
the	O
current	O
study	B-MED
was	O
designed	O
to	O
investigate	B-MED
whether	O
lubiprostone	B-MED
1	O
alters	O
gastrointestinal	B-MED
transit	I-MED
and	O
2	O
affects	O
sibo	B-MED
in	O
patients	B-MED
with	O
constipation	B-MED
.	O
	
a	O
total	O
of	O
29	O
female	B-MED
patients	I-MED
mean	B-MED
age	I-MED
=	O
39	O
years	B-MED
range	B-MED
19-64	O
with	O
cc	B-MED
received	B-MED
2	O
weeks	B-MED
of	O
lubiprostone	B-MED
24mcg	O
b.i	O
,	O
p.o	O
.	O
	
stool	B-MED
consistency	I-MED
based	O
on	O
bristol	B-MED
stool	I-MED
scale	I-MED
and	O
the	O
frequency	B-MED
of	I-MED
bowel	I-MED
movements	I-MED
bms	B-MED
were	O
recorded	O
.	O
	
gastric	B-MED
emptying	I-MED
time	I-MED
,	O
small	B-MED
bowel	I-MED
transit	I-MED
time	I-MED
,	O
colon	B-MED
transit	B-MED
time	I-MED
ctt	B-MED
,	O
combined	O
small	B-MED
and	I-MED
large	I-MED
bowel	I-MED
transit	I-MED
time	I-MED
slbtt	B-MED
and	O
whole	O
gut	B-MED
transit	B-MED
time	I-MED
were	O
measured	B-MED
using	O
wireless	B-MED
motility	I-MED
capsule	I-MED
.	O
	
the	O
sibo	B-MED
status	B-MED
was	O
assessed	O
by	O
the	O
lactulose	B-MED
breath	I-MED
test	I-MED
.	O
	
data	B-MED
were	O
analyzed	B-MED
using	O
wilcoxon	B-MED
rank	I-MED
,	O
mann-whitney	B-MED
u	I-MED
,	O
spearman	B-MED
rank	I-MED
correlation	I-MED
and	O
chi-square	B-MED
tests	I-MED
.	O
	
lubiprostone	B-MED
significantly	O
softened	B-MED
the	O
stool	B-MED
and	O
increased	B-MED
the	O
frequency	B-MED
of	I-MED
bm	I-MED
from	O
median	B-MED
of	O
2	O
to	O
4	O
times	B-MED
per	O
week	B-MED
.	O
	
the	O
ctt	B-MED
and	O
slbtt	B-MED
were	O
significantly	O
shorter	B-MED
in	O
responders	B-MED
to	O
lubiprostone	B-MED
i.e	O
,	O
those	O
with	O
2	O
times	B-MED
increase	B-MED
in	O
the	O
number	B-MED
of	O
their	O
weekly	B-MED
bm	B-MED
compared	B-MED
with	O
nonresponders	B-MED
.	O
	
the	O
higher	B-MED
frequency	B-MED
of	I-MED
bm	I-MED
after	O
treatment	B-MED
was	O
significantly	O
correlated	B-MED
with	O
the	O
acceleration	B-MED
of	O
ctt	B-MED
,	O
slbtt	B-MED
and	O
whole	O
gut	B-MED
transit	B-MED
time	I-MED
.	O
	
in	O
all	O
,	O
17	O
out	O
of	O
25	O
68%	O
patients	B-MED
,	O
who	O
were	O
tested	B-MED
for	O
sibo	B-MED
at	O
baseline	B-MED
,	O
were	O
positive	B-MED
.	O
	
in	O
addition	O
,	O
7	O
out	O
of	O
17	O
41%	O
sibo	B-MED
-	O
positive	B-MED
patients	B-MED
became	O
sibo	B-MED
-	O
negative	B-MED
after	O
lubiprostone	B-MED
treatment	B-MED
p	O
<	O
0.05	O
.	O
	
in	O
cc	B-MED
,	O
lubiprostone	B-MED
improves	O
the	O
frequency	B-MED
of	I-MED
bms	I-MED
,	O
softens	B-MED
the	O
stool	B-MED
,	O
accelerates	B-MED
intestinal	B-MED
transit	I-MED
and	O
decreases	B-MED
accompanying	O
sibo	B-MED
.	O
	
the	O
improvement	B-MED
of	O
sibo	B-MED
could	O
be	O
explained	O
by	O
the	O
cleansing	B-MED
effect	B-MED
of	O
increased	B-MED
intestinal	B-MED
fluid	I-MED
and	O
mucus	B-MED
combined	O
with	O
enhanced	B-MED
intestinal	B-MED
motility	I-MED
with	O
minimally	B-MED
invasive	I-MED
treatment	I-MED
of	O
difficult	O
bleeding	B-MED
lesions	B-MED
of	O
the	O
small	B-MED
bowel	I-MED
bleeding	B-MED
lesions	B-MED
of	O
the	O
small	B-MED
bowel	I-MED
are	O
often	O
difficult	O
to	O
identify	B-MED
due	O
to	O
the	O
obscure	B-MED
symptomatology	B-MED
.	O
	
localizing	B-MED
these	O
lesions	B-MED
requires	O
specific	B-MED
techniques	B-MED
.	O
	
the	O
double-balloon	B-MED
enteroscopy	I-MED
dbe	B-MED
could	O
be	O
used	O
to	O
precisely	O
localize	B-MED
and	O
mark	O
lesions	B-MED
,	O
so	O
that	O
a	O
minimally	B-MED
invasive	I-MED
surgical	I-MED
treatment	I-MED
could	O
be	O
performed	O
.	O
	
twenty	O
robot	B-MED
-	O
assisted	B-MED
small	B-MED
bowel	I-MED
procedures	I-MED
are	O
presented	O
using	O
a	O
combination	B-MED
of	O
dbe	B-MED
for	O
localization	B-MED
and	O
robotic	B-MED
resection	I-MED
.	O
	
there	O
were	O
10	O
jejunal	B-MED
resections	I-MED
and	O
10	O
ileal	B-MED
resections	I-MED
.	O
	
mean	O
age	B-MED
was	O
58.7	O
years	B-MED
.	O
	
mean	O
operative	B-MED
time	I-MED
was	O
153.4	O
minutes	B-MED
,	O
mean	O
blood	B-MED
loss	I-MED
of	O
46	O
ml	O
.	O
	
no	O
conversion-to-open	B-MED
and	O
there	O
were	O
4	O
post-operative	B-MED
complications	B-MED
.	O
	
the	O
90-	O
day	B-MED
mortality	B-MED
was	O
nil	O
and	O
the	O
median	O
length	B-MED
of	I-MED
stay	I-MED
was	O
4.1	O
days	B-MED
.	O
	
final	O
pathology	B-MED
was	O
consistent	B-MED
with	I-MED
malignancy	B-MED
in	O
10	O
cases	B-MED
.	O
	
the	O
combination	B-MED
of	O
double-balloon	B-MED
enteroscopy	I-MED
and	O
robotic	B-MED
technology	I-MED
allows	O
accurate	B-MED
identification	B-MED
and	O
selective	O
treatment	B-MED
of	O
lesions	B-MED
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	B-MED
in	O
a	O
minimally	B-MED
invasive	I-MED
fashion	I-MED
.	O
	
kinematic	B-MED
and	O
emg	B-MED
responses	B-MED
to	O
pelvis	B-MED
and	O
leg	B-MED
assistance	B-MED
force	B-MED
during	O
treadmill	B-MED
walking	I-MED
in	O
children	B-MED
with	O
cerebral	B-MED
palsy	I-MED
treadmill	B-MED
training	I-MED
has	O
been	O
used	O
for	O
improving	O
locomotor	B-MED
function	I-MED
in	O
children	B-MED
with	O
cerebral	B-MED
palsy	I-MED
cp	B-MED
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	B-MED
.	O
	
the	O
understanding	O
of	O
the	O
kinematic	B-MED
and	O
emg	B-MED
responses	B-MED
to	O
force	B-MED
s	O
applied	O
to	O
the	O
body	B-MED
of	O
subjects	O
during	O
treadmill	B-MED
walking	I-MED
is	O
crucial	O
for	O
improving	O
current	O
paradigms	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
the	O
kinematic	B-MED
s	O
and	O
emg	B-MED
responses	B-MED
to	O
the	O
pelvis	B-MED
and/or	O
leg	B-MED
assistance	B-MED
force	B-MED
.	O
	
ten	O
children	B-MED
with	O
spastic	B-MED
cp	I-MED
were	O
recruited	O
to	O
participate	B-MED
in	O
this	O
study	B-MED
.	O
	
a	O
controlled	O
assistance	B-MED
force	B-MED
was	O
applied	O
to	O
the	O
pelvis	B-MED
and/or	O
legs	B-MED
during	O
stance	B-MED
and	O
swing	B-MED
phase	I-MED
of	I-MED
gait	I-MED
through	O
a	O
custom	O
designed	O
robotic	B-MED
system	I-MED
during	O
walking	B-MED
.	O
	
muscle	B-MED
activities	B-MED
and	O
spatial	B-MED
-	O
temporal	B-MED
gait	B-MED
parameters	I-MED
were	O
measured	O
at	O
different	O
loading	B-MED
conditions	I-MED
during	O
walking	B-MED
.	O
	
in	O
addition	O
,	O
the	O
spatial-temporal	B-MED
gait	I-MED
parameters	I-MED
during	O
overground	O
walking	B-MED
before	O
and	O
after	O
treadmill	B-MED
training	I-MED
were	O
also	O
collected	O
.	O
	
applying	O
pelvis	B-MED
assistance	B-MED
improved	B-MED
step	B-MED
height	I-MED
and	O
applying	O
leg	B-MED
assistance	B-MED
improved	B-MED
step	B-MED
length	I-MED
during	O
walking	B-MED
,	O
but	O
applying	O
leg	B-MED
assistance	B-MED
also	O
reduced	B-MED
muscle	B-MED
activation	B-MED
of	O
ankle	B-MED
flexor	I-MED
during	O
the	O
swing	B-MED
phase	I-MED
of	I-MED
gait	I-MED
.	O
	
in	O
addition	O
,	O
step	B-MED
length	I-MED
and	O
self-selected	O
walking	B-MED
speed	I-MED
significantly	O
improved	B-MED
after	O
one	O
session	B-MED
of	O
treadmill	B-MED
training	I-MED
with	O
combined	O
pelvis	B-MED
and	O
leg	B-MED
assistance	B-MED
.	O
	
outlining	O
a	O
population	B-MED
"""at"	I-MED
"risk"""	I-MED
of	O
parkinson's	B-MED
disease	I-MED
evidence	B-MED
from	O
a	O
case-control	B-MED
study	I-MED
the	O
multifactorial	B-MED
pathogenesis	I-MED
of	O
parkinson's	B-MED
disease	I-MED
pd	B-MED
requires	O
a	O
careful	O
identification	O
of	O
populations	B-MED
"""at"	I-MED
"risk"""	I-MED
of	O
developing	O
the	O
disease	B-MED
.	O
	
in	O
this	O
case-control	B-MED
study	I-MED
we	O
analyzed	B-MED
a	O
large	O
italian	B-MED
population	B-MED
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	B-MED
criteria	I-MED
to	O
define	O
a	O
population	B-MED
"""at"	I-MED
"risk"""	I-MED
of	O
pd	B-MED
.	O
	
we	O
enrolled	O
300	O
pd	B-MED
patients	B-MED
and	O
300	O
controls	B-MED
,	O
gender	B-MED
and	O
age	B-MED
matched	B-MED
,	O
from	O
the	O
same	O
urban	B-MED
geographical	B-MED
area	I-MED
.	O
	
all	O
subjects	B-MED
were	O
interviewed	B-MED
on	O
demographics	B-MED
,	O
family	B-MED
history	I-MED
of	O
pd	B-MED
,	O
occupational	B-MED
and	I-MED
environmental	I-MED
toxicants	I-MED
exposure	I-MED
,	O
smoking	B-MED
status	I-MED
,	O
and	O
alcohol	B-MED
consumption	I-MED
.	O
	
a	O
sample	O
of	O
65	O
patients	B-MED
and	O
65	O
controls	B-MED
also	O
underwent	O
serum	B-MED
dosing	B-MED
of	O
iron	B-MED
,	O
copper	B-MED
,	O
mercury	B-MED
,	O
and	O
manganese	B-MED
by	O
means	O
of	O
inductively	B-MED
coupled-plasma-mass-spectrometry	I-MED
icp-ms	B-MED
.	O
	
positive	B-MED
family	B-MED
history	I-MED
,	O
toxicants	B-MED
exposure	I-MED
,	O
non-current-smoker	B-MED
,	O
and	O
alcohol	B-MED
nonconsumer	I-MED
status	I-MED
occurred	O
as	O
significant	O
risk	B-MED
factors	I-MED
in	O
our	O
population	B-MED
.	O
	
the	O
number	O
of	O
concurring	B-MED
risk	I-MED
factors	I-MED
overlapping	B-MED
in	O
the	O
same	B-MED
subject	I-MED
impressively	O
increased	B-MED
the	O
overall	B-MED
risk	I-MED
.	O
	
no	B-MED
significant	I-MED
differences	I-MED
were	O
measured	B-MED
in	O
the	O
metal	B-MED
serum	B-MED
levels	B-MED
.	O
	
our	O
findings	B-MED
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	B-MED
pd	B-MED
-	O
risk	B-MED
factors	I-MED
defines	O
a	O
condition	O
""""	O
at	B-MED
risk	I-MED
""""	O
of	O
pd	B-MED
.	O
	
a	O
simple	O
stratification	B-MED
,	O
based	O
on	O
these	O
questionnaires	B-MED
,	O
might	O
be	O
of	O
help	O
in	O
identifying	B-MED
subjects	I-MED
suitable	O
for	O
neuroprotective	B-MED
strategies	I-MED
.	O
	
work	B-MED
process	B-MED
,	O
performance	B-MED
and	O
professional	B-MED
profile	I-MED
of	O
a	O
hearing	B-MED
health	I-MED
network	I-MED
reference	B-MED
for	O
satisfaction	B-MED
to	O
analyze	B-MED
the	O
correlation	B-MED
between	O
the	O
satisfaction	B-MED
of	O
professionals	B-MED
from	O
the	O
hearing	B-MED
health	I-MED
care	I-MED
network	I-MED
in	O
two	O
micro	B-MED
-	O
regions	B-MED
of	O
minas	B-MED
gerais	I-MED
state	I-MED
and	O
the	O
sociodemographic	B-MED
profile	I-MED
,	O
work	B-MED
process	B-MED
,	O
and	O
work	B-MED
performance	I-MED
in	O
the	O
health	B-MED
service	I-MED
.	O
	
this	O
is	O
a	O
cross-sectional	B-MED
,	O
observational	B-MED
,	O
analytic	B-MED
study	I-MED
with	O
a	O
non-probabilistic	B-MED
sample	I-MED
including	O
34	O
professionals	B-MED
from	O
the	O
hearing	B-MED
health	I-MED
care	I-MED
services	I-MED
.	O
	
data	B-MED
collection	I-MED
occurred	O
through	O
individual	B-MED
interviews	B-MED
in	O
the	O
municipality	B-MED
of	O
professional	B-MED
practice	I-MED
.	O
	
associations	B-MED
between	O
the	O
professional	B-MED
satisfaction	I-MED
variable	B-MED
and	O
the	O
explanatory	B-MED
variables	B-MED
sociodemographic	B-MED
data	I-MED
,	O
work	B-MED
routine	I-MED
,	O
and	O
developed	B-MED
actions	B-MED
were	O
conducted	O
.	O
	
professionals	B-MED
with	O
graduate	B-MED
studies	I-MED
were	O
more	O
satisfied	B-MED
with	O
the	O
human	B-MED
resources	I-MED
policy	I-MED
and	O
the	O
activities	B-MED
developed	B-MED
,	O
whereas	O
health	B-MED
civil	B-MED
servants	I-MED
showed	O
more	O
satisfaction	B-MED
with	O
the	O
wage	B-MED
policy	B-MED
and	O
the	O
work	B-MED
schedule	I-MED
.	O
	
the	O
correlation	B-MED
analysis	I-MED
between	O
work	B-MED
process	B-MED
and	O
satisfaction	B-MED
revealed	B-MED
a	O
moderate	B-MED
positive	B-MED
correlation	B-MED
between	O
items	O
such	O
as	O
health	B-MED
promotion	I-MED
actions	B-MED
,	O
satisfaction	B-MED
with	O
diagnostic	B-MED
equipment	I-MED
,	O
and	O
satisfaction	B-MED
with	O
maintenance	B-MED
equipment	I-MED
.	O
	
the	O
present	O
study	B-MED
revealed	O
a	O
higher	B-MED
level	B-MED
of	O
satisfaction	B-MED
among	O
professionals	B-MED
with	O
graduate	B-MED
studies	I-MED
human	B-MED
resources	I-MED
policy	I-MED
and	O
activities	B-MED
developed	B-MED
and	O
civil	B-MED
servants	I-MED
wage	B-MED
policy	B-MED
and	O
work	B-MED
schedule	I-MED
.	O
	
the	O
relevance	B-MED
of	O
this	O
study	B-MED
lies	O
on	O
the	O
important	O
role	O
that	O
health	B-MED
professionals	I-MED
play	O
on	O
the	O
health	B-MED
care	I-MED
network	I-MED
.	O
	
additionally	O
,	O
the	O
study	B-MED
of	O
satisfaction	B-MED
level	B-MED
can	O
provide	O
a	O
search	O
for	O
improvements	B-MED
,	O
considering	O
that	O
satisfied	B-MED
professionals	B-MED
not	O
only	O
improve	B-MED
service	B-MED
quality	I-MED
,	O
but	O
also	O
show	B-MED
greater	I-MED
creativity	I-MED
,	O
commitment	B-MED
,	O
and	O
application	B-MED
of	O
laparoscopic	B-MED
lumbar	B-MED
discectomy	I-MED
and	O
artificial	B-MED
disc	I-MED
replacement	I-MED
at	O
least	O
two	O
years	O
of	O
follow-up	B-MED
this	O
prospective	B-MED
observational	B-MED
study	I-MED
included	O
22	O
patients	B-MED
who	O
were	O
diagnosed	B-MED
with	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
treated	O
via	O
artificial	B-MED
disc	I-MED
replacement	I-MED
adr	B-MED
with	O
a	O
laparoscopic	B-MED
technique	B-MED
.	O
	
the	O
current	O
study	B-MED
aimed	B-MED
to	O
assess	B-MED
the	O
safety	B-MED
and	O
efficacy	B-MED
of	O
adr	B-MED
using	O
a	O
laparoscopic	B-MED
technique	B-MED
for	O
lumbar	B-MED
disc	I-MED
herniation	I-MED
.	O
	
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
is	O
the	O
major	O
cause	O
of	O
low	B-MED
back	I-MED
pain	I-MED
with	O
lumbar	B-MED
segmental	B-MED
instability	B-MED
.	O
	
adr	B-MED
has	O
increased	B-MED
in	O
popularity	B-MED
as	O
an	O
alternative	B-MED
treatment	I-MED
for	O
lumbar	B-MED
disc	I-MED
herniation	I-MED
.	O
	
however	O
,	O
the	O
traditional	B-MED
approach	B-MED
to	O
spinal	B-MED
surgery	I-MED
carries	O
the	O
risk	B-MED
of	O
catastrophic	B-MED
bleeding	B-MED
from	O
injury	B-MED
to	O
major	O
vessels	B-MED
,	O
as	O
well	O
as	O
iatrogenic	B-MED
injury	B-MED
to	O
the	O
viscera	B-MED
and	O
associated	B-MED
structures	I-MED
.	O
	
therefore	O
,	O
laparoscopic	B-MED
lumbar	B-MED
discectomy	I-MED
and	O
adr	B-MED
may	O
represent	B-MED
a	O
useful	O
alternative	B-MED
.	O
	
twenty-two	O
patients	B-MED
8	O
males	B-MED
and	O
14	O
females	B-MED
who	O
were	O
diagnosed	B-MED
with	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
were	O
included	O
in	O
this	O
study	B-MED
.	O
	
seven	O
cases	B-MED
involved	O
the	O
l4/5	O
level	O
,	O
and	O
15	O
cases	B-MED
involved	O
the	O
l5/s1	O
level	O
.	O
	
all	O
patients	B-MED
were	O
ineffective	B-MED
after	O
at	O
least	O
6	O
months	O
of	O
conservative	B-MED
treatments	I-MED
all	O
patients	B-MED
were	O
informed	O
of	O
the	O
surgery	B-MED
before	O
the	O
operation	B-MED
and	O
provided	O
consent	B-MED
.	O
	
three-dimensional	B-MED
computed	B-MED
tomographic	I-MED
angiography	I-MED
3d	B-MED
-	O
cta	B-MED
of	O
the	O
iliac	B-MED
great	O
blood	B-MED
vessels	I-MED
was	O
completed	B-MED
before	O
the	O
surgery	B-MED
.	O
	
all	O
surgical	B-MED
procedures	I-MED
were	O
performed	O
under	O
a	O
laparoscope	B-MED
.	O
	
all	O
patients	B-MED
were	O
followed	B-MED
up	I-MED
.	O
	
all	O
surgeries	B-MED
were	O
successfully	B-MED
completed	B-MED
.	O
	
the	O
average	B-MED
operation	B-MED
time	B-MED
was	O
120	O
minutes	O
range	B-MED
110-150	O
min	O
,	O
and	O
the	O
average	B-MED
hemorrhage	B-MED
was	O
145	O
ml	O
range	B-MED
80-360	O
ml	O
.	O
	
all	O
cases	B-MED
underwent	O
x-rays	B-MED
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	B-MED
follow-up	B-MED
.	O
	
the	O
outcome	B-MED
indicated	O
that	O
there	O
was	O
no	O
mobilization	B-MED
,	O
displacement	B-MED
,	O
or	O
subsidence	B-MED
in	O
all	O
patients	B-MED
with	O
the	O
exception	B-MED
of	O
one	O
case	B-MED
with	O
prosthesis	B-MED
migration	I-MED
.	O
	
the	O
follow-up	B-MED
time	O
was	O
43.8	O
months	O
range	B-MED
24-64	O
months	O
.	O
	
the	O
mean	B-MED
visual	B-MED
analog	I-MED
scale	I-MED
vas	B-MED
and	O
oswestry	B-MED
scores	I-MED
were	O
decreased	B-MED
postoperatively	B-MED
.	O
	
the	O
mean	B-MED
improvement	B-MED
rate	B-MED
of	O
the	O
vas	B-MED
score	I-MED
was	O
73.5	O
.	O
	
lumbar	B-MED
adr	B-MED
using	O
a	O
laparoscope	B-MED
represents	O
a	O
novel	O
,	O
minimally	B-MED
invasive	I-MED
treatment	B-MED
for	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
and	O
severe	B-MED
lumbar	B-MED
discogenic	I-MED
pain	I-MED
.	O
	
low	B-MED
literacy	I-MED
and	O
written	B-MED
drug	I-MED
information	I-MED
information-seeking	B-MED
,	O
leaflet	B-MED
evaluation	B-MED
and	O
preferences	B-MED
,	O
and	O
roles	O
for	O
images	B-MED
background	O
low-literate	B-MED
patients	B-MED
are	O
at	O
risk	B-MED
to	O
misinterpret	O
written	B-MED
drug	I-MED
information	I-MED
.	O
	
for	O
the	O
co-	O
design	O
of	O
targeted	O
patient	B-MED
information	I-MED
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	B-MED
in	O
determining	O
their	O
communication	B-MED
barriers	I-MED
and	O
information	B-MED
needs	O
.	O
	
objective	O
to	O
gain	O
insight	O
into	O
how	O
people	B-MED
with	O
low	B-MED
literacy	I-MED
use	O
and	O
evaluate	O
written	B-MED
drug	I-MED
information	I-MED
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	B-MED
leaflet	B-MED
can	O
be	O
improved	O
,	O
and	O
in	O
particular	O
how	O
images	B-MED
could	O
be	O
used	O
.	O
	
setting	O
food	B-MED
banks	I-MED
and	O
an	O
education	B-MED
institution	I-MED
for	O
dutch	B-MED
language	I-MED
training	B-MED
in	O
the	O
netherlands	B-MED
.	O
	
method	O
semi-structured	O
focus	B-MED
groups	I-MED
and	O
individual	B-MED
interviews	B-MED
were	O
held	O
with	O
low-literate	B-MED
participants	I-MED
n	O
=	O
45	O
.	O
	
the	O
thematic	B-MED
framework	I-MED
approach	I-MED
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	B-MED
.	O
	
main	O
outcome	B-MED
measure	O
low-literate	B-MED
people's	I-MED
experience	B-MED
with	O
patient	B-MED
information	I-MED
leaflets	B-MED
,	O
ideas	B-MED
for	O
improvements	B-MED
,	O
and	O
perceptions	B-MED
on	O
possible	O
uses	O
for	O
visuals	B-MED
.	O
	
results	O
patient	B-MED
information	I-MED
leaflets	B-MED
were	O
considered	O
discouraging	O
to	O
use	O
,	O
and	O
information	B-MED
difficult	O
to	O
find	O
and	O
understand	B-MED
.	O
	
many	O
rely	O
on	O
alternative	O
information	B-MED
sources	I-MED
.	O
	
the	O
leaflet	B-MED
should	O
be	O
shorter	O
,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	B-MED
,	O
legibility	B-MED
and	O
readability	B-MED
.	O
	
participants	B-MED
thought	O
images	B-MED
could	O
increase	O
the	O
leaflet's	B-MED
appeal	O
,	O
help	O
ask	O
questions	B-MED
,	O
provide	O
an	O
overview	B-MED
,	O
help	O
understand	O
textual	B-MED
information	B-MED
,	O
aid	O
recall	B-MED
,	O
reassure	O
,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	B-MED
,	O
empowerment	B-MED
and	O
feeling	O
of	O
safety	B-MED
.	O
	
conclusion	O
already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	B-MED
and	O
maintaining	O
interest	O
in	O
the	O
message	O
,	O
low-literate	B-MED
patients	I-MED
experience	B-MED
barriers	B-MED
in	I-MED
the	I-MED
communication	I-MED
process	O
through	O
written	B-MED
drug	I-MED
information	I-MED
.	O
	
short	O
,	O
structured	O
,	O
visual	B-MED
/	O
textual	B-MED
explanations	B-MED
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	B-MED
,	O
improve	B-MED
understanding	B-MED
,	O
and	O
empower	O
the	O
low-literate	B-MED
target	I-MED
group	I-MED
.	O
	
establishment	O
and	O
application	O
of	O
a	O
flow	B-MED
cytometry	I-MED
-based	O
method	B-MED
for	O
detecting	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
histone	B-MED
deacetylase	I-MED
inhibitors	I-MED
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
aids	B-MED
and	O
other	O
diseases	B-MED
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B-MED
drugs	I-MED
developed	O
in	O
recent	O
years	O
.	O
	
however	O
,	O
there	O
is	O
still	O
a	O
lack	B-MED
of	O
a	O
unified	B-MED
and	O
reliable	B-MED
method	B-MED
for	O
detecting	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
in	O
basic	B-MED
and	O
clinical	B-MED
research	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
developed	O
a	O
flow	B-MED
cytometry	I-MED
-based	O
method	B-MED
to	O
detect	B-MED
histone	O
acetylation	O
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
on	O
ice	O
vs	O
.	O
	
room	O
temperature	O
,	O
permeabilization	O
method	O
intracellular	O
vs	O
.	O
	
nuclear	O
,	O
antibody	O
dose	O
antibody	O
titration	O
and	O
antibody	O
incubation	O
time	O
time	O
gradient	O
using	O
whole	O
blood	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
	
in	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	O
of	O
chidamide	O
the	O
only	O
china	O
fda	O
approved	O
hdaci	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	O
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I-MED
performance	B-MED
and	O
safety	B-MED
of	O
collagenated	B-MED
xenogeneic	I-MED
bone	I-MED
block	I-MED
for	O
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
staged	B-MED
implant	I-MED
placement	I-MED
.	O
	
a	O
monocenter	B-MED
,	O
prospective	I-MED
single-arm	I-MED
clinical	I-MED
study	I-MED
to	O
assess	B-MED
the	O
clinical	B-MED
safety	I-MED
and	O
performance	B-MED
of	O
collagenated	B-MED
xenogeneic	I-MED
bone	I-MED
block	I-MED
cxbb	B-MED
for	O
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
two-stage	B-MED
implant	B-MED
placement	I-MED
.	O
	
in	O
ten	O
patients	B-MED
exhibiting	B-MED
a	O
single	B-MED
-	O
tooth	B-MED
gap	B-MED
,	O
the	O
surgical	B-MED
procedure	I-MED
included	B-MED
the	O
preparation	B-MED
of	O
mucoperiosteal	B-MED
flaps	I-MED
,	O
a	O
rigid	B-MED
fixation	I-MED
of	O
cxbb	B-MED
geistlich	B-MED
bio-graft	I-MED
using	O
an	O
osteosynthesis	B-MED
screw	I-MED
,	O
and	O
contour	B-MED
augmentation	B-MED
.	O
	
after	O
24	O
weeks	O
of	O
submerged	B-MED
healing	I-MED
,	O
the	O
primary	B-MED
endpoint	I-MED
was	O
defined	O
as	O
the	O
final	B-MED
ridge	B-MED
width	B-MED
sufficient	B-MED
to	O
place	O
an	O
adequately	B-MED
dimensioned	B-MED
titanium	B-MED
implant	I-MED
at	O
the	O
respective	O
sites	B-MED
.	O
	
secondary	B-MED
outcomes	I-MED
included	B-MED
,	O
for	O
example	O
,	O
the	O
gain	B-MED
in	O
ridge	B-MED
width	B-MED
mm	O
.	O
	
clinical	B-MED
parameters	I-MED
e.g	O
,	O
bleeding	B-MED
on	I-MED
probing	I-MED
-	O
bop	B-MED
,	O
probing	B-MED
depth	I-MED
-	O
pd	B-MED
,	O
mucosal	B-MED
recession	I-MED
-	O
mr	B-MED
were	O
assessed	B-MED
immediately	O
after	O
the	O
cementation	B-MED
of	I-MED
the	I-MED
crown	I-MED
and	O
at	O
the	O
final	B-MED
visit	I-MED
.	O
	
at	O
24	O
weeks	O
,	O
implant	B-MED
placement	I-MED
could	O
be	O
achieved	B-MED
in	O
8	O
of	O
10	O
patients	B-MED
exhibiting	B-MED
a	O
mean	B-MED
gain	B-MED
in	O
ridge	B-MED
width	B-MED
mean	B-MED
sd	B-MED
of	O
3.88	O
1.75	O
mm	O
.	O
	
histological	B-MED
analysis	B-MED
has	O
pointed	O
to	O
a	O
homogeneous	B-MED
osseous	B-MED
organization	B-MED
of	O
cxbb	B-MED
.	O
	
the	O
changes	B-MED
of	O
mean	B-MED
bop	B-MED
,	O
pd	B-MED
,	O
and	O
mr	B-MED
values	B-MED
at	O
the	O
final	B-MED
visit	I-MED
amounted	B-MED
to	O
16.62	O
32.02	O
,	O
0.04	O
0.21	O
mm	O
,	O
and	O
-0	O
0.12	O
mm	O
,	O
respectively	O
.	O
	
cxbb	B-MED
may	O
be	O
successfully	B-MED
used	O
to	O
support	B-MED
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
two-stage	B-MED
implant	B-MED
placement	I-MED
.	O
	
the	O
link	O
between	O
self-perceptions	B-MED
of	O
aging	B-MED
,	O
cancer	B-MED
view	O
and	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
of	O
older	B-MED
people	I-MED
with	O
cancer	B-MED
a	B-MED
cross-sectional	I-MED
study	I-MED
older	B-MED
people	I-MED
may	O
suffer	O
from	O
stigmas	B-MED
linked	O
to	O
cancer	B-MED
and	O
aging	B-MED
.	O
	
although	O
some	O
studies	B-MED
suggested	O
that	O
a	O
negative	B-MED
view	B-MED
of	O
cancer	B-MED
may	O
increase	O
the	O
level	B-MED
of	I-MED
depression	I-MED
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	B-MED
in	O
the	O
elderly	B-MED
population	I-MED
.	O
	
similarly	O
,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-MED
self-perception	B-MED
of	O
aging	B-MED
has	O
deleterious	O
consequences	B-MED
on	O
mental	B-MED
and	O
physical	B-MED
health	I-MED
in	O
normal	O
aging	B-MED
,	O
the	O
influence	O
in	O
pathological	B-MED
contexts	B-MED
,	O
such	O
as	O
oncology	B-MED
,	O
has	O
not	O
been	O
studied	O
.	O
	
the	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	B-MED
the	O
effect	O
of	O
these	O
two	O
stigmas	B-MED
on	O
the	O
health	B-MED
of	O
elderly	B-MED
oncology	B-MED
patients	B-MED
.	O
	
101	O
patients	B-MED
suffering	O
from	O
a	O
cancer	B-MED
breast	B-MED
,	O
gynecological	B-MED
,	O
lung	B-MED
or	O
hematological	B-MED
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-MED
.	O
	
their	O
self-perception	B-MED
of	O
age	B-MED
,	O
cancer	B-MED
view	O
and	O
health	B-MED
physical	B-MED
and	O
mental	B-MED
was	O
assessed	O
.	O
	
multiple	O
regressions	B-MED
showed	O
that	O
patients	B-MED
with	O
a	O
more	O
negative	B-MED
self-perception	B-MED
of	O
aging	B-MED
and/or	O
more	O
negative	B-MED
cancer	B-MED
view	O
reported	O
poorer	B-MED
global	B-MED
health	I-MED
.	O
	
we	O
also	O
observed	O
that	O
negative	B-MED
self-perception	B-MED
of	O
aging	B-MED
was	O
associated	B-MED
with	I-MED
worse	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
,	O
whereas	O
negative	B-MED
cancer	B-MED
views	O
were	O
only	O
linked	O
to	O
worse	O
mental	B-MED
health	I-MED
.	O
	
no	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-MED
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	B-MED
.	O
	
older	O
patients	B-MED
with	O
cancer	B-MED
face	O
double	O
stigmatization	B-MED
,	O
due	O
to	O
negative	B-MED
self-perception	B-MED
of	O
aging	B-MED
and	O
cancer	B-MED
,	O
and	O
these	O
stigmas	B-MED
have	O
impacts	O
on	O
global	O
and	O
mental	B-MED
health	I-MED
.	O
	
self-perception	B-MED
of	O
aging	B-MED
is	O
also	O
linked	O
to	O
physical	B-MED
health	I-MED
.	O
	
longitudinal	B-MED
studies	I-MED
will	O
be	O
necessary	O
to	O
analyze	B-MED
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	B-MED
and	O
the	O
aortic	B-MED
root	I-MED
natural	B-MED
history	I-MED
after	O
root-sparing	B-MED
ascending	I-MED
replacement	I-MED
in	O
nonsyndromic	B-MED
aneurysmal	B-MED
patients	I-MED
leaving	O
native	B-MED
aortic	B-MED
tissue	I-MED
in	B-MED
situ	I-MED
in	O
root-sparing	B-MED
ascending	I-MED
aortic	I-MED
replacement	I-MED
raises	O
concern	B-MED
regarding	O
potential	B-MED
later	B-MED
need	B-MED
for	O
root	B-MED
reoperation	B-MED
or	O
for	O
the	O
potential	B-MED
occurrence	B-MED
of	O
localized	B-MED
dissections	B-MED
or	O
rupture	B-MED
in	O
the	O
residual	B-MED
root	B-MED
.	O
	
the	O
purpose	B-MED
of	I-MED
this	I-MED
study	I-MED
was	O
to	O
evaluate	B-MED
the	O
natural	B-MED
growth	I-MED
of	O
the	O
aortic	B-MED
root	I-MED
after	O
root-sparing	B-MED
aortic	I-MED
replacement	I-MED
.	O
	
in	O
all	O
,	O
102	O
consecutive	B-MED
patients	B-MED
mean	B-MED
age	B-MED
61.8	O
12.5	O
years	B-MED
60%	O
male	B-MED
who	O
had	O
undergone	O
root-sparing	B-MED
aortic	I-MED
replacement	I-MED
had	O
sufficient	B-MED
retrievable	B-MED
information	I-MED
regarding	O
their	O
aortic	B-MED
root	I-MED
diameter	B-MED
at	O
postoperative	B-MED
baseline	B-MED
and	O
follow-up	B-MED
imaging	B-MED
by	O
computed	B-MED
tomography	I-MED
or	O
echocardiography	B-MED
.	O
	
the	O
annual	B-MED
growth	B-MED
rate	I-MED
was	O
evaluated	B-MED
and	O
also	O
compared	B-MED
according	O
to	O
the	O
influence	B-MED
of	O
valve	B-MED
morphology	I-MED
and	O
concomitant	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
.	O
	
furthermore	O
,	O
the	O
years	B-MED
of	O
natural	B-MED
history	I-MED
that	O
would	O
require	B-MED
for	O
root	B-MED
enlargement	B-MED
to	O
meet	O
a	O
50	O
mm	B-MED
threshold	B-MED
of	O
the	O
root	B-MED
diameter	B-MED
were	O
calculated	B-MED
.	O
	
the	O
estimated	B-MED
growth	B-MED
rate	I-MED
of	O
the	O
aortic	B-MED
root	I-MED
after	O
root-sparing	B-MED
aortic	I-MED
replacement	I-MED
is	O
between	O
0.27	O
and	O
0.51	O
mm	B-MED
per	B-MED
year	I-MED
mean	B-MED
0.41	O
mm	B-MED
,	O
varying	O
according	O
to	O
the	O
underlying	B-MED
diameter	I-MED
and	O
therefore	O
fivefold	O
less	B-MED
than	I-MED
other	O
aortic	B-MED
regions	I-MED
.	O
	
accordingly	O
,	O
a	O
root	B-MED
aneurysm	I-MED
indicating	O
reoperation	B-MED
would	O
not	O
be	O
expected	B-MED
for	O
29.1	O
years	B-MED
on	O
average	B-MED
.	O
	
only	O
patients	B-MED
with	O
a	O
diameter	B-MED
of	O
45	O
mm	B-MED
or	O
more	O
are	O
at	B-MED
risk	I-MED
for	O
reoperation	B-MED
,	O
and	O
not	O
until	B-MED
at	O
least	O
after	B-MED
10.4	O
years	B-MED
have	B-MED
passed	I-MED
.	O
	
neither	B-MED
the	O
valve	B-MED
morphology	I-MED
p	O
=	O
0.62	O
nor	O
concomitant	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
p	O
=	O
0.86	O
influenced	B-MED
rate	B-MED
of	O
root	B-MED
dilation	I-MED
.	O
	
in	O
nonsyndromic	B-MED
patients	B-MED
,	O
the	O
aortic	B-MED
root	I-MED
is	O
the	O
slowest	B-MED
growing	B-MED
portion	B-MED
of	O
the	O
thoracic	B-MED
aorta	I-MED
.	O
	
leaving	O
the	O
native	B-MED
root	B-MED
,	O
as	O
in	O
root-sparing	B-MED
ascending	I-MED
aortic	I-MED
replacement	I-MED
,	O
is	O
a	O
safe	B-MED
approach	I-MED
regarding	O
secondary	B-MED
root	I-MED
intervention	B-MED
for	O
aortic	B-MED
root	I-MED
diameters	B-MED
of	O
45	O
mm	B-MED
physical	B-MED
exercise	I-MED
for	O
late-life	B-MED
depression	B-MED
effects	B-MED
on	O
heart	B-MED
rate	I-MED
variability	B-MED
late-life	B-MED
major	B-MED
depression	I-MED
is	O
associated	B-MED
with	I-MED
increased	B-MED
cardiovascular	B-MED
risk	I-MED
and	O
impaired	B-MED
autonomic	I-MED
control	I-MED
of	I-MED
the	I-MED
heart	I-MED
,	O
as	O
evident	O
from	O
reduced	B-MED
heart	B-MED
rate	I-MED
variability	B-MED
hrv	B-MED
.	O
	
moreover	O
,	O
antidepressant	B-MED
drug	I-MED
therapy	B-MED
also	O
might	O
be	O
associated	B-MED
with	I-MED
further	O
reductions	B-MED
of	O
hrv	B-MED
.	O
	
in	O
the	O
seeds	B-MED
study	I-MED
,	O
we	O
investigated	O
whether	O
sertraline	B-MED
associated	B-MED
with	I-MED
physical	B-MED
exercise	I-MED
protocols	O
led	O
to	O
improvements	B-MED
of	O
hrv	B-MED
,	O
compared	O
with	O
antidepressant	B-MED
drug	I-MED
therapy	B-MED
alone	O
.	O
	
single-blind	B-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
	
psychiatric	B-MED
consultation	I-MED
-liaison	O
program	O
for	O
primary	B-MED
care	I-MED
.	O
	
patients	B-MED
aged	O
65-85	O
years	O
with	O
major	B-MED
depression	I-MED
,	O
recruited	O
from	O
primary	B-MED
care	I-MED
.	O
	
sertraline	B-MED
plus	O
structured	O
,	O
tailored	B-MED
group	I-MED
physical	B-MED
exercise	I-MED
s	B-MED
+	I-MED
ex	I-MED
versus	O
sertraline	B-MED
alone	O
s	O
for	O
24	O
weeks	B-MED
.	O
	
hrv	B-MED
indices	B-MED
rr	O
,	O
percentage	B-MED
of	I-MED
nn	I-MED
intervals	I-MED
greater	I-MED
than	I-MED
50	I-MED
msec	I-MED
pnn50	B-MED
,	O
square	B-MED
root	I-MED
of	I-MED
the	I-MED
mean	I-MED
squared	I-MED
differences	I-MED
of	I-MED
successive	I-MED
nn	I-MED
intervals	I-MED
rmssd	B-MED
,	O
standard	B-MED
deviation	I-MED
of	O
heart	B-MED
rate	I-MED
sdhr	B-MED
,	O
standard	B-MED
deviation	I-MED
of	I-MED
the	I-MED
nn	I-MED
interval	I-MED
sdnn	B-MED
,	O
high-frequency	B-MED
band	I-MED
hf	B-MED
,	O
low-frequency	B-MED
band	I-MED
lf	B-MED
,	O
and	O
their	O
ratio	B-MED
lf/hf	B-MED
were	O
measured	B-MED
at	O
baseline	B-MED
,	O
week	B-MED
12	O
,	O
and	O
week	B-MED
24	O
.	O
	
psychiatric	B-MED
and	O
medical	B-MED
assessments	I-MED
.	O
	
participants	B-MED
displayed	O
significant	O
improvements	B-MED
of	O
most	O
hrv	B-MED
indices	B-MED
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
pnn50	B-MED
,	O
rmssd	B-MED
,	O
sdhr	B-MED
,	O
sdnn	B-MED
,	O
hf	B-MED
,	O
lf	B-MED
,	O
and	O
lf/hf	B-MED
.	O
	
moreover	O
,	O
patients	B-MED
in	O
the	O
s	B-MED
+	I-MED
ex	I-MED
group	I-MED
displayed	O
greater	O
increases	B-MED
of	O
different	O
hrv	B-MED
indices	B-MED
rr	B-MED
,	O
pnn50	B-MED
,	O
rmssd	B-MED
,	O
sdhr	B-MED
,	O
sdnn	B-MED
,	O
hf	B-MED
,	O
and	O
lf	B-MED
compared	O
with	O
those	O
in	O
the	O
s	B-MED
group	I-MED
.	O
	
the	O
combination	B-MED
of	O
structured	O
physical	B-MED
exercise	I-MED
and	O
sertraline	B-MED
might	O
exert	O
positive	B-MED
effects	B-MED
on	O
the	O
autonomic	B-MED
control	I-MED
of	I-MED
the	I-MED
heart	I-MED
among	O
older	O
patients	B-MED
with	O
major	B-MED
depression	I-MED
.	O
	
genome-wide	B-MED
snp	I-MED
linkage	I-MED
mapping	I-MED
and	O
qtl	B-MED
analysis	B-MED
for	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
in	O
the	O
upland	B-MED
cotton	I-MED
recombinant	B-MED
inbred	I-MED
lines	I-MED
population	O
it	O
is	O
of	O
significance	O
to	O
discover	O
genes	B-MED
related	O
to	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
and	O
tightly	O
linked	O
markers	B-MED
for	O
marker-assisted	B-MED
selection	I-MED
mas	B-MED
in	O
cotton	B-MED
breeding	B-MED
.	O
	
in	O
this	O
study	O
,	O
188	B-MED
f8	I-MED
recombinant	B-MED
inbred	I-MED
lines	I-MED
rils	B-MED
,	O
derived	O
from	O
a	O
intraspecific	B-MED
cross	B-MED
between	O
hs46	B-MED
and	O
marcabucag8us-1-88	B-MED
were	O
genotyped	B-MED
by	O
the	O
cotton	B-MED
63k	O
single	B-MED
nucleotide	I-MED
polymorphism	I-MED
snp	I-MED
assay	I-MED
.	O
	
field	B-MED
trials	I-MED
were	O
conducted	O
in	O
sanya	B-MED
,	O
hainan	I-MED
province	I-MED
,	O
during	O
the	O
2014-2015	O
cropping	B-MED
seasons	B-MED
under	O
standard	B-MED
conditions	B-MED
.	O
	
results	O
revealed	O
significant	B-MED
differences	B-MED
p	O
<	O
0.05	O
among	O
rils	B-MED
,	O
environments	B-MED
and	O
replications	B-MED
for	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
.	O
	
broad-sense	O
heritabilities	B-MED
of	O
all	O
traits	B-MED
including	O
fiber	B-MED
length	B-MED
,	O
fiber	B-MED
uniformity	B-MED
,	O
micronaire	B-MED
,	O
fiber	B-MED
elongation	B-MED
,	O
fiber	B-MED
strength	B-MED
,	O
boll	B-MED
weight	B-MED
,	O
and	O
lint	B-MED
percentage	B-MED
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O
	
a	O
1784.28	O
cm	B-MED
centimorgans	B-MED
linkage	B-MED
map	I-MED
,	O
harboring	O
2618	O
polymorphic	B-MED
snp	B-MED
markers	B-MED
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cm	B-MED
per	O
marker	B-MED
density	O
.	O
	
seventy-one	O
quantitative	B-MED
trait	I-MED
locus	I-MED
qtls	B-MED
for	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
were	O
detected	O
on	O
21	O
chromosomes	B-MED
,	O
explaining	O
4.70	O
phenotypic	B-MED
variance	B-MED
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	B-MED
qtls	B-MED
across	O
two	O
environments	B-MED
.	O
	
meanwhile	O
,	O
12	O
certain	O
regions	B-MED
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
hotspot	B-MED
or	O
more	O
cluster	B-MED
traits	B-MED
,	O
mainly	O
focused	O
on	O
chr05	B-MED
,	O
chr09	B-MED
,	O
chr10	B-MED
,	O
chr14	B-MED
,	O
chr19	B-MED
,	O
and	O
chr20	B-MED
.	O
	
nineteen	O
pairs	O
of	O
epistatic	B-MED
qtls	B-MED
e-qtls	B-MED
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	B-MED
qtls	B-MED
.	O
	
these	O
additive	B-MED
qtls	B-MED
,	O
e-qtls	B-MED
,	O
and	O
qtl	B-MED
clusters	B-MED
were	O
tightly	O
linked	O
to	O
snp	B-MED
markers	B-MED
,	O
which	O
may	O
serve	O
as	O
target	B-MED
regions	B-MED
for	O
map-based	B-MED
cloning	I-MED
,	O
gene	B-MED
discovery	I-MED
,	O
and	O
mas	B-MED
in	O
cotton	B-MED
breeding	B-MED
.	O
	
effects	B-MED
of	O
an	O
early	O
intervention	B-MED
using	O
human	B-MED
amniotic	B-MED
epithelial	B-MED
cells	I-MED
in	O
a	O
copd	B-MED
rat	B-MED
model	B-MED
the	O
study	B-MED
aimed	O
to	O
investigate	B-MED
the	O
effect	B-MED
of	O
an	O
early	O
intervention	B-MED
using	O
human	B-MED
amniotic	B-MED
epithelial	B-MED
cell	I-MED
haec	B-MED
in	O
a	O
rat	B-MED
model	B-MED
of	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
copd	B-MED
.	O
	
twenty-four	O
specific	B-MED
pathogen-free	I-MED
wistar	B-MED
rats	I-MED
were	O
randomized	B-MED
to	O
the	O
control	B-MED
,	O
copd	B-MED
,	O
and	O
copd	B-MED
+	O
haec	B-MED
groups	B-MED
.	O
	
copd	B-MED
was	O
established	O
by	O
intratracheal	B-MED
lps	B-MED
injection	O
combined	O
with	O
smoke	B-MED
fumigation	B-MED
over	O
30	O
days	B-MED
.	O
	
on	O
the	O
first	O
day	B-MED
of	O
model	B-MED
establishment	O
rats	B-MED
in	O
the	O
aec	B-MED
group	B-MED
also	O
received	O
intratracheal	B-MED
instillation	I-MED
of	O
500	O
haecs	B-MED
isolated	O
from	O
the	O
placenta	B-MED
of	O
healthy	B-MED
donors	B-MED
.	O
	
the	O
mean	B-MED
linear	I-MED
intercept	I-MED
mli	B-MED
and	O
mean	B-MED
alveolar	I-MED
number	I-MED
man	B-MED
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	B-MED
emphysema	I-MED
.	O
	
il-8	B-MED
was	O
measured	O
using	O
a	O
radioimmunoassay	B-MED
,	O
surfactant	B-MED
protein	I-MED
d	I-MED
sp-d	B-MED
was	O
measured	O
by	O
elisa	B-MED
,	O
and	O
matrix	B-MED
metalloproteinase	I-MED
mmp	I-MED
and	O
mmp8	B-MED
expression	B-MED
was	O
assessed	O
by	O
pcr	B-MED
.	O
	
smoke	B-MED
fumigation	B-MED
combined	O
to	O
lps	B-MED
injection	O
successfully	O
established	O
a	O
copd	B-MED
rat	B-MED
model	B-MED
with	O
significant	O
emphysema	B-MED
and	O
airway	B-MED
inflammation	I-MED
,	O
elevated	B-MED
mli	B-MED
and	O
man	B-MED
,	O
elevated	B-MED
systemic	B-MED
and	O
lung	B-MED
tissue	B-MED
levels	B-MED
of	O
il-8	B-MED
and	O
sp-d	B-MED
p<0	O
,	O
and	O
high	O
expression	B-MED
of	O
mmp2	B-MED
and	O
mmp8	B-MED
.	O
	
rats	B-MED
in	O
the	O
copd	B-MED
+	O
haec	B-MED
group	B-MED
exhibited	O
alleviated	B-MED
lung	B-MED
damage	B-MED
,	O
mli	B-MED
and	O
man	B-MED
p<0	O
,	O
reduced	B-MED
systemic	B-MED
and	O
lung	B-MED
tissue	B-MED
levels	B-MED
of	O
il-8	B-MED
and	O
sp-d	B-MED
p<0	O
and	O
mmp2	B-MED
and	O
mmp8	B-MED
expression	B-MED
p<0	O
.	O
	
early	O
intervention	B-MED
using	O
haecs	B-MED
could	O
delay	O
disease	B-MED
progression	I-MED
in	O
rats	B-MED
with	O
systematic	B-MED
identification	B-MED
of	O
pharmacological	B-MED
targets	B-MED
from	O
small-molecule	B-MED
phenotypic	B-MED
screens	I-MED
phenotypic	B-MED
drug	B-MED
discovery	I-MED
offers	O
some	O
advantages	B-MED
over	O
target	B-MED
-	O
based	B-MED
methods	B-MED
,	O
mainly	O
because	O
it	O
allows	O
drug	B-MED
leads	I-MED
to	O
be	O
tested	B-MED
in	O
systems	B-MED
that	O
more	B-MED
closely	B-MED
model	B-MED
distinct	B-MED
disease	B-MED
states	I-MED
.	O
	
however	O
,	O
a	O
potential	B-MED
disadvantage	B-MED
is	O
the	O
difficulty	B-MED
of	O
linking	B-MED
the	O
observed	B-MED
phenotype	B-MED
to	O
a	O
specific	B-MED
cellular	B-MED
target	B-MED
.	O
	
to	O
address	O
this	O
problem	B-MED
,	O
we	O
developed	B-MED
depick	B-MED
,	O
a	O
computational	B-MED
target	O
de-convolution	B-MED
tool	B-MED
to	O
determine	B-MED
targets	B-MED
specifically	B-MED
linked	B-MED
to	O
small-molecule	B-MED
phenotypic	B-MED
screens	I-MED
.	O
	
we	O
applied	B-MED
depick	B-MED
to	O
eight	O
publicly	B-MED
available	O
screens	B-MED
and	O
predicted	B-MED
59	O
drug	B-MED
target	B-MED
-	O
phenotype	B-MED
associations	B-MED
.	O
	
in	O
addition	O
to	O
literature	B-MED
-	O
based	B-MED
evidence	B-MED
for	O
our	O
predictions	B-MED
,	O
we	O
provide	B-MED
experimental	B-MED
support	B-MED
for	O
seven	O
predicted	B-MED
associations	B-MED
.	O
	
interestingly	B-MED
,	O
our	O
analysis	B-MED
led	O
to	O
the	O
discovery	B-MED
of	O
a	O
previously	B-MED
unrecognized	B-MED
connection	B-MED
between	O
the	O
wnt	B-MED
signaling	I-MED
pathway	I-MED
and	O
an	O
aromatase	B-MED
,	O
cyp19a1	B-MED
.	O
	
these	O
results	B-MED
demonstrate	B-MED
that	O
the	O
depick	B-MED
approach	O
can	O
not	O
only	O
accelerate	B-MED
target	B-MED
de-convolution	B-MED
but	O
also	O
aid	B-MED
in	O
discovery	B-MED
of	O
new	O
functionally	B-MED
relevant	B-MED
biological	B-MED
relationships	B-MED
.	O
	
'	O
yarn	B-MED
with	O
me'	O
applying	O
clinical	B-MED
yarning	I-MED
to	O
improve	O
clinician	B-MED
-	O
patient	B-MED
communication	B-MED
in	O
aboriginal	B-MED
health	B-MED
care	I-MED
although	O
successful	O
communication	B-MED
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	B-MED
consultation	I-MED
,	O
communication	B-MED
between	O
aboriginal	B-MED
patients	B-MED
and	O
practitioners	B-MED
such	O
as	O
doctors	B-MED
,	O
nurses	B-MED
and	O
allied	B-MED
health	I-MED
professionals	I-MED
,	O
continues	O
to	O
be	O
problematic	B-MED
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	B-MED
care	I-MED
to	O
aboriginal	B-MED
people	I-MED
.	O
	
this	O
paper	O
presents	O
an	O
overarching	B-MED
framework	I-MED
for	O
practitioners	B-MED
to	O
help	O
them	O
reorientate	O
their	O
communication	B-MED
with	O
aboriginal	B-MED
patients	B-MED
using	O
'	O
clinical	B-MED
yarning	I-MED
'	O
.	O
	
clinical	B-MED
yarning	I-MED
is	O
a	O
patient	B-MED
-centred	O
approach	O
that	O
marries	O
aboriginal	B-MED
cultural	B-MED
communication	I-MED
preferences	O
with	O
biomedical	B-MED
understandings	O
of	O
health	B-MED
and	I-MED
disease	I-MED
.	O
	
clinical	B-MED
yarning	I-MED
consists	O
of	O
three	O
interrelated	O
areas	O
the	O
social	B-MED
yarn	B-MED
,	O
in	O
which	O
the	O
practitioner	B-MED
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	B-MED
relationship	I-MED
the	O
diagnostic	B-MED
yarn	B-MED
,	O
in	O
which	O
the	O
practitioner	B-MED
facilitates	O
the	O
patient's	B-MED
health	B-MED
story	I-MED
while	O
interpreting	O
it	O
through	O
a	O
biomedical	B-MED
or	O
scientific	B-MED
lens	I-MED
and	O
the	O
management	O
yarn	B-MED
,	O
that	O
employs	B-MED
stories	I-MED
and	O
metaphors	B-MED
as	O
tools	O
for	O
patients	B-MED
to	O
help	O
them	O
understand	O
a	O
health	B-MED
issue	I-MED
so	O
a	O
collaborative	B-MED
management	I-MED
approach	I-MED
can	O
be	O
adopted	O
.	O
	
there	O
is	O
cultural	B-MED
and	O
research	B-MED
evidence	B-MED
that	O
supports	O
this	O
approach	O
.	O
	
clinical	B-MED
yarning	I-MED
has	O
the	O
potential	O
to	O
improve	O
outcomes	B-MED
for	O
patients	B-MED
and	O
effect	O
of	O
single-dose	B-MED
carbapenem	B-MED
exposure	B-MED
on	O
transcriptional	B-MED
expression	I-MED
of	O
blandm-1	B-MED
and	O
mexa	B-MED
in	O
pseudomonas	B-MED
aeruginosa	I-MED
the	O
therapeutic	B-MED
option	I-MED
of	O
a	O
carbapenem	B-MED
antibiotic	I-MED
is	O
compromised	O
in	O
pseudomonas	B-MED
aeruginosa	I-MED
owing	O
both	O
to	O
acquired	B-MED
and	O
intrinsic	B-MED
resistance	I-MED
mechanisms	O
.	O
	
in	O
recent	O
years	O
,	O
new	B-MED
delhi	I-MED
metallo-β-lactamase	I-MED
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	B-MED
resistance	I-MED
determinant	I-MED
.	O
	
however	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
p	B-MED
.	O
	
aeruginosa	I-MED
strain	B-MED
possessing	O
both	O
blandm-1	B-MED
and	O
an	O
overexpressed	B-MED
mexab-oprm	B-MED
system	O
during	O
carbapenem	B-MED
therapy	B-MED
.	O
	
this	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	B-MED
isolates	I-MED
of	O
p	B-MED
.	O
	
aeruginosa	I-MED
when	O
exposed	O
to	O
meropenem	B-MED
.	O
	
five	O
strains	B-MED
were	O
used	O
i	O
strain	B-MED
overexpressing	I-MED
mexab-oprm	B-MED
but	O
with	O
no	B-MED
blandm-1	B-MED
ii	O
strain	O
harbouring	O
blandm-1	B-MED
but	O
expressing	B-MED
mexab-oprm	B-MED
at	O
basal	O
level	O
iii	O
strain	B-MED
possessing	O
blandm-1	B-MED
and	O
overexpressing	B-MED
mexab-oprm	B-MED
iv	O
p	B-MED
.	O
	
aeruginosa	I-MED
pao1	I-MED
and	O
v	O
p	B-MED
.	O
	
aeruginosa	I-MED
k2733-pao1	I-MED
δmexab-oprm	B-MED
δmexcd-oprj	B-MED
δmexef-oprn	B-MED
δmexxy-oprm	B-MED
into	O
which	O
blandm-1	B-MED
was	O
cloned	B-MED
.	O
	
strains	B-MED
were	O
incubated	O
in	O
luria-bertani	B-MED
broth	I-MED
with	O
and	O
without	O
1μg/ml	O
meropenem	B-MED
.	O
	
total	B-MED
rna	I-MED
was	O
isolated	O
at	O
45-min	O
intervals	O
and	O
was	O
immediately	O
reverse	B-MED
transcribed	I-MED
to	O
cdna	B-MED
.	O
	
this	O
was	O
repeated	O
for	O
6h	O
.	O
	
quantitative	B-MED
real-time	I-MED
pcr	I-MED
was	O
performed	O
for	O
both	O
resistance	B-MED
mechanisms	I-MED
.	O
	
meropenem	B-MED
exposure	B-MED
did	O
not	O
significantly	O
elevate	B-MED
transcription	I-MED
of	O
either	O
the	O
blandm-1	B-MED
or	O
mexa	B-MED
gene	I-MED
.	O
	
however	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single-dose	B-MED
exposure	B-MED
to	I-MED
carbapenem	I-MED
,	O
the	O
efflux	B-MED
pump	I-MED
system	I-MED
played	O
a	O
major	O
role	B-MED
in	I-MED
bacterial	I-MED
survival	I-MED
compared	O
with	O
ndm-1	B-MED
.	O
	
this	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	B-MED
response	I-MED
to	I-MED
carbapenem	I-MED
antibiotic	I-MED
when	O
two	O
different	O
resistance	B-MED
mechanisms	I-MED
coexist	O
.	O
	
this	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
inducible	B-MED
expression	B-MED
of	O
both	O
ermb	B-MED
and	O
ermt	B-MED
conferred	O
high	B-MED
macrolide	B-MED
resistance	I-MED
in	O
streptococcus	B-MED
gallolyticus	I-MED
subsp	I-MED
.	O
	
pasteurianus	I-MED
isolates	B-MED
in	O
china	B-MED
streptococcus	B-MED
gallolyticus	I-MED
subsp	I-MED
.	O
	
pasteurianus	I-MED
is	O
an	O
under-recognized	O
pathogen	B-MED
and	O
zoonotic	B-MED
agent	I-MED
causing	O
opportunistic	B-MED
infections	I-MED
in	O
humans	B-MED
.	O
	
despite	O
increasing	O
recognition	B-MED
of	O
this	O
subspecies	B-MED
as	O
a	O
cause	O
for	O
human	B-MED
infectious	B-MED
diseases	I-MED
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic	B-MED
resistance	I-MED
mechanism	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular	B-MED
mechanism	I-MED
underlying	O
the	O
high	O
macrolide	B-MED
resistance	I-MED
of	O
six	O
s	B-MED
.	O
	
gallolyticus	I-MED
subsp	I-MED
.	O
	
pasteurianus	I-MED
isolates	B-MED
from	O
dead	B-MED
ducklings	B-MED
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
china	B-MED
during	O
2010-2013	O
.	O
	
all	O
isolates	B-MED
exhibited	O
multi-drug	B-MED
resistance	I-MED
including	O
high	O
macrolide	B-MED
resistance	I-MED
mic	B-MED
1024	O
mg/l	O
for	O
erythromycin	O
,	O
and	O
512	O
mg/l	O
for	O
clarithromycin	O
.	O
	
efflux-encoding	O
mefa	O
and	O
mefe	O
genes	O
were	O
not	O
detectable	O
in	O
these	O
isolates	O
.	O
	
the	O
presence	O
of	O
23s	O
rrna	O
mutations	O
in	O
specific	O
isolates	O
did	O
not	O
significantly	O
change	O
macrolide	O
mic	B-MED
s	O
.	O
	
no	O
nucleotide	O
substitutions	O
were	O
found	O
in	O
genes	O
encoding	O
ribosomal	O
proteins	O
l4	O
or	O
l22	O
.	O
	
the	O
ermb	O
and	O
ermt	O
genes	O
were	O
found	O
in	O
the	O
genomes	O
of	O
all	O
isolates	O
.	O
	
these	O
two	O
genes	O
were	O
acquired	O
independently	O
in	O
one	O
highly	O
virulent	O
isolate	O
al101002	O
,	O
and	O
clustered	O
with	O
tn916	O
and	O
is1216	O
,	O
respectively	O
.	O
	
the	O
expression	O
of	O
both	O
ermb	O
and	O
ermt	O
in	O
all	O
isolates	O
was	O
erythromycin	B-MED
inducible	O
and	O
yielded	O
comparable	O
macrolide	O
mics	O
in	O
all	O
six	O
isolates	O
.	O
	
taken	O
together	O
,	O
inducible	O
expression	O
of	O
both	O
ermb	O
and	O
ermt	O
conferred	O
high	O
macrolide	O
resistance	O
in	O
these	O
s	O
.	O
	
gallolyticus	O
subsp	O
.	O
	
pasterianus	O
isolates	O
.	O
	
our	O
findings	O
reveal	O
new	O
macrolide	O
resistance	O
features	O
in	O
s	O
.	O
	
gallolyticus	O
subsp	O
.	O
	
pasteurianus	O
by	O
both	O
ermb	O
and	O
ermt	B-MED
bilateral	B-MED
c1	B-MED
laminar	I-MED
hooks	I-MED
combined	O
with	O
c2	B-MED
pedicle	I-MED
screw	I-MED
fixation	B-MED
in	O
the	O
treatment	B-MED
of	O
atlantoaxial	B-MED
subluxation	I-MED
after	O
grisel	B-MED
syndrome	I-MED
many	O
etiologies	B-MED
can	O
lead	O
to	O
atlantoaxial	B-MED
subluxaion	I-MED
.	O
	
in	O
grisel	B-MED
syndrome	I-MED
gs	B-MED
,	O
this	O
subluxation	B-MED
occurs	O
spontaneously	B-MED
after	O
inflammatory	B-MED
processes	B-MED
of	O
the	O
head	B-MED
and	O
neck	B-MED
.	O
	
diagnosis	B-MED
is	O
typically	O
based	O
on	O
clinical	B-MED
history	I-MED
and	O
a	O
strong	O
suspicion	B-MED
of	O
this	O
syndrome	B-MED
.	O
	
nonsurgical	B-MED
treatment	I-MED
most	O
often	O
resolves	B-MED
the	O
symptoms	B-MED
however	O
,	O
in	O
some	O
cases	B-MED
surgical	B-MED
treatment	I-MED
is	O
necessary	O
to	O
repair	B-MED
the	O
subluxation	B-MED
.	O
	
various	O
surgical	B-MED
techniques	I-MED
and	O
instrumentation	B-MED
systems	I-MED
have	O
been	O
used	O
to	O
treat	B-MED
atlantoaxial	B-MED
subluxation	I-MED
,	O
although	O
there	O
is	O
no	O
consensus	B-MED
regarding	O
the	O
best	O
treatment	B-MED
method	I-MED
for	O
the	O
pediatric	B-MED
population	B-MED
.	O
	
to	O
describe	O
a	O
case	B-MED
of	O
atlantoaxial	B-MED
subluxation	I-MED
in	O
a	O
child	B-MED
with	O
gs	B-MED
treated	B-MED
surgically	B-MED
with	O
an	O
alternative	B-MED
construct	B-MED
.	O
	
this	O
is	O
a	O
case	B-MED
report	I-MED
and	O
literature	B-MED
review	I-MED
.	O
	
our	O
case	B-MED
study	I-MED
involves	O
a	O
5-	O
year	B-MED
-old	O
girl	B-MED
with	O
a	O
6-	O
month	B-MED
history	B-MED
of	O
unresolved	B-MED
fielding	B-MED
type	I-MED
ii	I-MED
atlantoaxial	I-MED
subluxation	I-MED
caused	O
by	O
gs	B-MED
.	O
	
despite	O
conservative	B-MED
treatment	I-MED
,	O
the	O
patient's	B-MED
symptoms	B-MED
continued	B-MED
to	O
progress	B-MED
.	O
	
after	O
two	O
failed	B-MED
closed	B-MED
reduction	I-MED
attempts	B-MED
,	O
open	B-MED
reduction	I-MED
and	O
c1-c2	B-MED
fusion	I-MED
were	O
performed	B-MED
with	O
atlas	B-MED
laminar	I-MED
hook	I-MED
and	O
axis	B-MED
pedicle	I-MED
polyaxial	I-MED
screws	I-MED
.	O
	
a	O
literature	B-MED
review	I-MED
of	O
the	O
surgical	B-MED
treatment	I-MED
of	O
gs	B-MED
was	O
also	O
performed	B-MED
.	O
	
after	O
surgery	B-MED
,	O
the	O
patient	B-MED
exhibited	O
full	O
clinical	B-MED
and	O
functional	B-MED
recovery	I-MED
with	O
complete	B-MED
resolution	I-MED
of	O
symptoms	B-MED
.	O
	
at	O
the	O
36-	O
month	B-MED
follow-up	B-MED
examination	B-MED
,	O
there	O
was	O
continual	B-MED
evidence	B-MED
of	O
satisfactory	B-MED
reduction	B-MED
and	O
fusion	B-MED
.	O
	
no	O
complications	B-MED
were	O
observed	B-MED
.	O
	
upon	O
completion	B-MED
of	O
the	O
literature	B-MED
review	I-MED
,	O
eight	O
gs	B-MED
cases	B-MED
were	O
found	O
to	O
have	O
been	O
treated	B-MED
surgically	B-MED
with	O
the	O
minimum	O
patient	B-MED
age	B-MED
being	O
9	O
years	B-MED
.	O
	
conservative	B-MED
management	I-MED
of	O
gs	B-MED
is	O
the	O
most	O
common	B-MED
and	O
effective	B-MED
treatment	B-MED
however	O
,	O
a	O
few	O
surgical	B-MED
cases	I-MED
have	O
been	O
reported	B-MED
in	O
the	O
literature	B-MED
with	O
good	O
results	B-MED
.	O
	
satisfactory	B-MED
clinical	B-MED
results	I-MED
and	O
fusion	B-MED
at	O
36	O
months	B-MED
post	B-MED
surgery	I-MED
were	O
seen	O
in	O
a	O
pediatric	B-MED
patient	B-MED
with	O
atlantoaxial	B-MED
subluxation	I-MED
and	O
instability	B-MED
using	O
atlas	B-MED
laminar	I-MED
hook	I-MED
and	O
axis	B-MED
pedicle	I-MED
polyaxial	I-MED
screws	I-MED
.	O
	
caries	B-MED
with	O
dental	B-MED
fluorosis	I-MED
and	O
oral	B-MED
health	I-MED
behaviour	I-MED
among	O
12-year	B-MED
school	B-MED
children	I-MED
in	O
moderate-fluoride	B-MED
drinking	I-MED
water	I-MED
community	I-MED
in	O
quetta	B-MED
,	O
pakistan	B-MED
to	O
determine	O
the	O
prevalence	B-MED
of	O
dental	B-MED
caries	I-MED
and	O
its	O
relationship	B-MED
with	O
dental	B-MED
fluorosis	I-MED
,	O
oral	B-MED
health	I-MED
behaviour	I-MED
and	O
dietary	B-MED
behaviour	I-MED
among	O
12-year	B-MED
school	B-MED
children	I-MED
in	O
moderate-fluoride	B-MED
drinking	I-MED
water	I-MED
community	I-MED
in	O
quetta	B-MED
,	O
pakistan	B-MED
.	O
	
cross-sectional	B-MED
study	I-MED
.	O
	
government	B-MED
and	O
private	B-MED
schools	I-MED
of	O
quetta	B-MED
,	O
from	O
november	B-MED
2012	O
to	O
february	B-MED
2013	O
.	O
	
atotal	O
of	O
349	O
children	B-MED
aged	O
12-year	B-MED
from	O
14	O
randomly	O
selected	O
schools	B-MED
were	O
included	O
.	O
	
the	O
data	B-MED
collection	I-MED
was	O
done	O
on	O
questionnaire	B-MED
designed	O
for	O
children	B-MED
.	O
	
dental	B-MED
caries	I-MED
status	B-MED
was	O
examined	O
by	O
using	O
who	O
criteria	O
.	O
	
dental	O
caries	O
was	O
found	O
in	O
81	O
children	O
23.2	O
with	O
mean	O
dmft	O
0.61	O
.	O
	
boys	O
had	O
1.6	O
times	O
more	O
chance	O
to	O
have	O
dental	O
caries	O
than	O
girls	O
.	O
	
dental	O
fluorosis	O
was	O
found	O
in	O
63.6	O
of	O
children	O
with	O
majority	O
of	O
moderate	O
degree	O
50.5	O
.	O
	
dental	O
fluorosis	O
status	B-MED
was	O
found	O
significantly	O
associated	O
with	O
dental	O
caries	O
status	O
in	O
children	O
.	O
	
the	O
children	O
who	O
had	O
mild	O
,	O
moderate	O
and	O
severe	O
fluorosis	O
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	O
caries	O
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	O
.	O
	
there	O
was	O
no	O
significant	O
association	O
between	O
children's	O
caries	O
status	O
and	O
use	O
of	O
paste	O
,	O
brushing	O
habit	O
,	O
miswak	O
,	O
and	O
visit	O
to	O
the	O
dentist	O
.	O
	
the	O
use	O
of	O
pastries	O
and	O
juices	O
had	O
a	O
direct	O
relation	O
with	O
the	O
children's	O
dental	O
caries	O
status	O
.	O
	
dental	O
caries	O
in	O
children	O
of	O
quetta	O
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	O
deficient	O
countries	O
.	O
	
however	O
,	O
the	O
high	O
prevalence	O
of	O
moderate	O
dental	O
fluorosis	O
and	O
consumption	O
of	O
pastries	O
and	O
juices	O
resulted	O
in	O
dental	O
caries	I-MED
proteomics	B-MED
analysis	B-MED
of	O
the	O
endogenous	B-MED
,	O
constitutive	O
,	O
leaf	B-MED
sumoylome	B-MED
sumoylation	B-MED
is	O
a	O
post-translational	B-MED
modification	I-MED
which	O
regulates	B-MED
a	O
number	O
of	O
critical	B-MED
biological	B-MED
processes	I-MED
in	O
,	O
for	O
example	O
mammals	B-MED
,	O
yeast	B-MED
and	O
plants	B-MED
.	O
	
in	O
order	O
to	O
fully	O
understand	B-MED
the	O
functional	B-MED
effects	I-MED
of	O
sumoylation	B-MED
an	O
essential	B-MED
first	O
step	O
is	O
the	O
identification	B-MED
of	O
endogenous	B-MED
targets	B-MED
for	O
sumoylation	B-MED
.	O
	
here	O
we	O
report	B-MED
the	O
results	B-MED
of	O
using	O
a	O
recently	O
developed	O
proteomic	B-MED
approach	I-MED
based	O
on	O
the	O
use	O
of	O
3d	B-MED
gels	B-MED
to	O
identify	O
the	O
endogenous	B-MED
sumo	B-MED
targets	B-MED
in	O
leaves	B-MED
of	O
solanum	B-MED
tuberosum	I-MED
.	O
	
by	O
using	O
3d	B-MED
gels	B-MED
we	O
avoid	O
the	O
problem	O
of	O
co-migration	B-MED
of	O
proteins	B-MED
,	O
which	O
is	O
a	O
major	B-MED
limitation	B-MED
of	O
2d	B-MED
gels	B-MED
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	B-MED
sensitive	I-MED
cydye	B-MED
dige	I-MED
fluor	I-MED
saturation	I-MED
dyes	I-MED
.	O
	
using	O
this	O
new	O
method	O
we	O
have	O
identified	B-MED
39	O
individual	B-MED
proteins	I-MED
as	O
probable	B-MED
sumo	B-MED
targets	B-MED
in	O
leaves	B-MED
of	O
solanum	B-MED
tuberosum	I-MED
.	O
	
the	O
advantages	O
of	O
this	O
method	B-MED
compared	O
with	O
other	O
approaches	B-MED
are	O
discussed	O
,	O
and	O
possible	B-MED
future	B-MED
developments	B-MED
are	O
outlined	O
.	O
	
the	O
authors	B-MED
have	O
no	O
conflicts	B-MED
of	I-MED
interest	I-MED
to	O
declare	O
.	O
	
all	O
authors	B-MED
have	O
approved	B-MED
the	O
manuscript	B-MED
and	O
agree	B-MED
with	O
submission	B-MED
to	O
journal	B-MED
of	I-MED
proteomics	I-MED
.	O
	
antenatal	B-MED
consultation	B-MED
following	B-MED
limb	B-MED
malformation	I-MED
discovery	B-MED
using	O
ultrasound	B-MED
scan	I-MED
our	O
unit	B-MED
has	O
been	O
providing	B-MED
antenatal	B-MED
consultations	B-MED
for	O
30	O
years	O
following	B-MED
the	O
discovery	B-MED
of	O
limb	B-MED
malformation	I-MED
with	O
the	O
fetus	B-MED
.	O
	
each	O
of	O
these	O
consultations	B-MED
is	O
specific	B-MED
and	O
carried	B-MED
out	I-MED
by	O
a	O
multi-professional	B-MED
team	I-MED
.	O
	
it	O
requires	B-MED
a	O
physical	O
and	O
rehabilitation	B-MED
doctor	B-MED
,	O
an	O
orthopedic	B-MED
surgeon	I-MED
,	O
an	O
occupational	B-MED
therapist	I-MED
for	O
upper	B-MED
limb	I-MED
malformation	I-MED
,	O
a	O
physiotherapist	B-MED
for	O
lower	B-MED
malformation	I-MED
and	O
a	O
psychologist	B-MED
.	O
	
this	O
multidisciplinary	B-MED
consultation	B-MED
is	O
unique	B-MED
because	O
of	O
each	O
pregnancy	B-MED
story	O
,	O
because	O
of	O
each	O
patient	B-MED
life	B-MED
story	I-MED
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	B-MED
when	O
announcing	O
the	O
diagnosis	B-MED
.	O
	
we	O
deal	O
with	O
couples	B-MED
shocked	B-MED
by	O
the	O
prenatal	B-MED
diagnosis	I-MED
.	O
	
we	O
help	O
them	O
get	O
acceptance	B-MED
of	O
the	O
child	B-MED
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	B-MED
child	B-MED
.	O
	
medical	B-MED
information	I-MED
is	O
often	O
perceived	B-MED
as	O
being	O
"""a"	O
surfeit	B-MED
of	O
information	B-MED
""""	O
difficult	B-MED
to	O
handle	O
by	O
the	O
couple	B-MED
stunned	B-MED
by	O
the	O
overwhelming	B-MED
diagnosis	B-MED
.	O
	
we	O
must	O
stress	O
that	O
it	O
is	O
critical	B-MED
to	O
not	O
only	O
have	O
a	O
good	O
medical	B-MED
description	I-MED
of	O
the	O
malformations	B-MED
and	O
potential	B-MED
treatments	I-MED
but	O
also	O
a	O
good	O
psychological	B-MED
support	I-MED
parents	B-MED
personal	B-MED
life	B-MED
story	I-MED
,	O
self-defense	B-MED
mechanism	I-MED
,	O
guilt	B-MED
feeling	I-MED
.	O
	
the	O
ethical	B-MED
aspect	I-MED
of	O
this	O
consultation	B-MED
is	O
also	O
important	B-MED
.	O
	
team	B-MED
members	B-MED
must	O
be	O
as	O
neutral	B-MED
as	O
possible	B-MED
in	O
their	O
assessments	B-MED
in	O
order	O
to	O
let	O
the	O
couple	B-MED
take	O
the	O
final	O
decision	B-MED
the	O
continuation	B-MED
of	O
the	O
pregnancy	B-MED
or	O
a	O
request	B-MED
of	O
voluntary	B-MED
termination	B-MED
of	I-MED
pregnancy	I-MED
.	O
	
these	O
prenatal	B-MED
consultations	B-MED
highlight	O
the	O
importance	B-MED
of	O
the	O
multidisciplinary	B-MED
global	B-MED
care	B-MED
.	O
	
bending	B-MED
rules	I-MED
the	O
shape	B-MED
of	O
the	O
perceptual	B-MED
generalisation	B-MED
gradient	B-MED
is	O
sensitive	B-MED
to	O
inference	B-MED
rules	I-MED
generalising	B-MED
what	O
is	O
learned	B-MED
about	O
one	O
stimulus	B-MED
to	O
other	O
but	O
perceptually	B-MED
related	O
stimuli	B-MED
is	O
a	O
basic	O
behavioural	B-MED
phenomenon	B-MED
.	O
	
we	O
evaluated	B-MED
whether	O
a	O
rule	B-MED
learning	B-MED
mechanism	B-MED
may	O
serve	O
to	O
explain	O
such	O
generalisation	B-MED
.	O
	
to	O
this	O
end	O
,	O
we	O
assessed	B-MED
whether	O
inference	B-MED
rules	I-MED
communicated	B-MED
through	O
verbal	B-MED
instructions	I-MED
affect	O
generalisation	B-MED
.	O
	
expectancy	B-MED
ratings	B-MED
,	O
but	O
not	O
valence	O
ratings	B-MED
,	O
proved	O
sensitive	B-MED
to	O
this	O
manipulation	B-MED
.	O
	
in	O
addition	O
to	O
revealing	O
a	O
role	B-MED
for	O
inference	B-MED
rules	I-MED
in	O
generalisation	B-MED
,	O
our	O
study	B-MED
has	O
clinical	B-MED
implications	B-MED
as	O
well	O
.	O
	
more	O
specifically	O
,	O
we	O
argue	O
that	O
targeting	B-MED
inference	B-MED
rules	I-MED
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	B-MED
to	O
affect	O
the	O
excessive	B-MED
generalisation	B-MED
that	O
is	O
often	O
observed	O
in	O
neuroticism	B-MED
and	O
fatigue	B-MED
3	B-MED
months	I-MED
after	O
ischemic	B-MED
stroke	I-MED
a	O
cross-sectional	B-MED
study	I-MED
to	O
examine	B-MED
the	O
relation	O
between	O
neuroticism	B-MED
and	O
fatigue	B-MED
in	O
chinese	B-MED
patients	B-MED
with	O
stroke	B-MED
.	O
	
cross-sectional	B-MED
study	I-MED
.	O
	
acute	B-MED
stroke	B-MED
unit	I-MED
.	O
	
survivors	B-MED
of	O
ischemic	B-MED
stroke	I-MED
n=191	O
recruited	O
from	O
the	O
acute	B-MED
stroke	B-MED
unit	I-MED
between	O
may	O
1	O
,	O
2010	O
,	O
and	O
september	O
1	O
,	O
2011	O
.	O
	
not	O
applicable	O
.	O
	
the	O
personality	B-MED
trait	I-MED
of	O
neuroticism	B-MED
was	O
measured	B-MED
with	O
the	O
neuroticism	B-MED
subscale	B-MED
of	O
the	O
chinese	B-MED
version	B-MED
of	O
the	O
neo	B-MED
five-factor	I-MED
inventory	I-MED
.	O
	
the	O
level	B-MED
of	O
fatigue	B-MED
was	O
measured	B-MED
with	O
the	O
fatigue	B-MED
assessment	I-MED
scale	I-MED
.	O
	
the	O
national	B-MED
institutes	I-MED
of	I-MED
health	I-MED
stroke	I-MED
scale	I-MED
,	O
geriatric	B-MED
depression	I-MED
scale	I-MED
,	O
barthel	B-MED
index	I-MED
,	O
and	O
mini-mental	B-MED
state	I-MED
examination	I-MED
were	O
administered	B-MED
to	O
obtain	O
demographic	B-MED
and	O
clinical	B-MED
information	I-MED
.	O
	
fatigue	B-MED
severity	I-MED
3	B-MED
months	I-MED
after	O
stroke	B-MED
positively	O
correlated	B-MED
with	O
geriatric	B-MED
depression	I-MED
scale	I-MED
and	O
neo	B-MED
five-factor	I-MED
inventory	I-MED
neuroticism	B-MED
scores	B-MED
and	O
negatively	B-MED
correlated	B-MED
with	O
the	O
barthel	B-MED
index	I-MED
score	I-MED
.	O
	
neuroticism	B-MED
,	O
independent	B-MED
of	O
depressive	B-MED
symptoms	I-MED
,	O
is	O
a	O
predictor	O
of	O
fatigue	B-MED
severity	I-MED
3	B-MED
months	I-MED
after	O
stroke	B-MED
.	O
	
interventions	O
such	O
as	O
psychological	B-MED
screening	B-MED
programs	I-MED
are	O
warranted	O
for	O
early	O
detection	B-MED
of	O
patients	B-MED
at	O
high	B-MED
risk	I-MED
of	I-MED
poststroke	B-MED
depression	I-MED
.	O
	
hematological	B-MED
,	O
biochemical	B-MED
,	O
and	O
toxicopathic	B-MED
effects	I-MED
of	O
subchronic	B-MED
acetamiprid	B-MED
toxicity	B-MED
in	O
wistar	B-MED
rats	I-MED
acetamiprid	B-MED
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B-MED
.	O
	
this	O
study	O
investigates	B-MED
toxic	B-MED
effects	I-MED
of	O
repeated	O
oral	B-MED
administration	I-MED
of	O
three	O
doses	B-MED
of	O
acetamiprid	B-MED
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
ld50	B-MED
during	O
60	O
days	B-MED
.	O
	
for	O
this	O
,	O
male	B-MED
wistar	B-MED
rats	I-MED
were	O
divided	O
into	O
four	O
different	O
groups	B-MED
.	O
	
hematological	B-MED
,	O
biochemical	B-MED
,	O
and	O
toxicopathic	B-MED
effects	I-MED
of	O
acetamiprid	B-MED
were	O
evaluated	B-MED
.	O
	
according	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	B-MED
in	O
the	O
body	B-MED
weight	I-MED
gain	I-MED
at	O
the	O
highest	O
dose	B-MED
1/5	O
of	O
ld50	B-MED
of	O
acetamiprid	B-MED
was	O
noticed	O
.	O
	
an	O
increase	B-MED
in	O
the	O
relative	O
liver	B-MED
weight	B-MED
was	O
also	O
observed	O
at	O
this	O
dose	B-MED
level	B-MED
.	O
	
the	O
hematological	B-MED
constituents	I-MED
were	O
affected	O
.	O
	
a	O
significant	O
decrease	B-MED
in	O
rbc	B-MED
,	O
hgb	B-MED
,	O
and	O
hct	B-MED
in	O
rats	B-MED
treated	B-MED
with	O
higher	O
doses	B-MED
of	O
acetamiprid	B-MED
1/10	O
and	O
1/5	O
of	O
ld50	B-MED
was	O
noted	O
.	O
	
however	O
,	O
a	O
significant	O
increase	B-MED
in	O
wbc	B-MED
and	O
plt	B-MED
were	O
observed	O
at	O
the	O
same	O
doses	B-MED
.	O
	
furthermore	O
,	O
acetamiprid	B-MED
induced	B-MED
liver	I-MED
toxicity	I-MED
measured	O
by	O
the	O
increased	B-MED
activities	B-MED
of	O
aspartate	B-MED
aminotransferase	I-MED
ast	B-MED
,	O
alanine	B-MED
aminotransferase	I-MED
alt	B-MED
,	O
alkaline	B-MED
phosphates	I-MED
alps	B-MED
,	O
and	O
lactate	B-MED
dehydrogenase	I-MED
ldh	B-MED
which	O
may	O
be	O
due	O
to	O
the	O
loss	B-MED
of	O
hepatic	B-MED
membrane	I-MED
architecture	I-MED
and	O
hepatocellular	B-MED
damage	I-MED
.	O
	
in	O
addition	O
,	O
exposure	B-MED
to	I-MED
acetamiprid	B-MED
resulted	O
in	O
a	O
significant	O
decrease	B-MED
in	O
the	O
levels	B-MED
of	O
superoxide	B-MED
dismutase	I-MED
and	O
catalase	B-MED
activities	B-MED
p	O
0.01	O
with	O
concomitant	B-MED
increase	B-MED
in	O
lipid	B-MED
peroxidation	I-MED
in	O
rat	B-MED
liver	B-MED
.	O
	
these	O
findings	B-MED
highlight	O
the	O
subchronic	B-MED
hepatotoxicity	B-MED
of	O
sustained	B-MED
delivery	I-MED
of	O
vincristine	B-MED
inside	O
an	O
orthotopic	B-MED
mouse	B-MED
sarcoma	I-MED
model	O
decreases	B-MED
tumor	B-MED
growth	I-MED
sarcoma	B-MED
accounts	O
for	O
20%	O
of	O
solid	B-MED
tumors	I-MED
in	O
children	B-MED
.	O
	
surgery	B-MED
has	O
significant	O
morbidity	B-MED
.	O
	
we	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-MED
directly	O
into	O
tumors	B-MED
through	O
sustained	B-MED
release	I-MED
silk	B-MED
systems	O
could	O
slow	O
tumor	B-MED
growth	I-MED
.	O
	
human	B-MED
ewing	B-MED
sarcoma	I-MED
cells	B-MED
a673	I-MED
were	O
cultured	B-MED
with	O
vincristine	B-MED
and	O
doxorubicin	B-MED
to	O
determine	O
half	B-MED
maximal	I-MED
inhibitory	I-MED
concentration	I-MED
ic50	B-MED
.	O
	
cells	B-MED
were	O
injected	O
into	O
mouse	B-MED
hind	B-MED
leg	I-MED
to	O
create	O
orthotopic	B-MED
tumors	B-MED
.	O
	
tumor	B-MED
volumes	I-MED
were	O
measured	O
using	O
ultrasound	B-MED
.	O
	
when	O
volume	O
reached	O
>250mm	O
interventions	B-MED
included	O
implantation	B-MED
of	O
drug-free	B-MED
silk	B-MED
foam	O
control	B-MED
-f	O
,	O
doxorubicin	B-MED
400μg	O
foam	O
dox400	B-MED
-f	O
,	O
vincristine	B-MED
50μg	O
foam	O
vin50	B-MED
-f	O
,	O
drug-free	B-MED
silk	B-MED
gel	B-MED
control	B-MED
-g	O
,	O
vincristine	B-MED
50μg	O
gel	B-MED
vin50	B-MED
-g	O
,	O
or	O
single	O
dose	O
intravenous	B-MED
vincristine	B-MED
50μg	O
vin50	B-MED
-iv	O
.	O
	
end-point	B-MED
was	O
volume>1000mm	O
.	O
	
kaplan	B-MED
meier	I-MED
and	O
anova	B-MED
were	O
used	O
.	O
	
ic50	B-MED
for	O
vincristine	B-MED
and	O
doxorubicin	B-MED
was	O
0.5ng	O
and	O
200ng/ml	O
,	O
respectively	O
.	O
	
there	O
was	O
no	O
difference	O
between	O
dox400	B-MED
-f	O
6	O
1days	B-MED
to	O
end	B-MED
point	I-MED
dtep	B-MED
and	O
control	B-MED
-f	O
5	O
dtep	B-MED
.	O
	
vin50	B-MED
-f	O
12.4	O
dtep	B-MED
had	O
slower	B-MED
growth	I-MED
compared	O
to	O
control	B-MED
-f	O
p<0	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
vin50	B-MED
-f	O
and	O
vin50	B-MED
-iv	O
14	O
dtep	B-MED
.	O
	
growth	B-MED
was	I-MED
slowest	I-MED
with	O
vin50	B-MED
-g	O
,	O
28	O
dtep	B-MED
compared	O
to	O
all	O
other	O
treatment	O
groups	O
p<0	O
.	O
	
sustained	B-MED
delivery	I-MED
of	O
vincristine	B-MED
inside	O
the	O
sarcoma	B-MED
tumor	B-MED
with	O
silk	B-MED
gel	B-MED
decreased	B-MED
tumor	B-MED
growth	I-MED
.	O
	
applying	O
this	O
intratumoral	B-MED
treatment	I-MED
strategy	O
may	O
potentially	O
decrease	B-MED
the	O
extent	O
of	O
surgical	B-MED
excision	I-MED
.	O
	
spinal	B-MED
load	B-MED
in	O
nurses	B-MED
during	O
emergency	B-MED
lifting	B-MED
of	O
obese	B-MED
patients	B-MED
preliminary	B-MED
results	I-MED
nurses	B-MED
are	O
exposed	O
to	O
the	O
risk	B-MED
of	O
injury	B-MED
while	O
handling	B-MED
patients	B-MED
.	O
	
this	O
is	O
particularly	O
true	O
for	O
obese	B-MED
patients	B-MED
.	O
	
the	O
goal	B-MED
of	O
this	O
paper	O
is	O
to	O
estimate	B-MED
the	O
spinal	B-MED
loads	B-MED
and	O
the	O
related	O
risk	B-MED
of	O
injury	B-MED
to	O
nurses	B-MED
while	O
lifting	B-MED
obese	B-MED
patients	B-MED
from	O
the	O
floor	B-MED
with	O
a	O
bariatric	B-MED
sheet	I-MED
during	O
a	O
hospital	B-MED
emergency	B-MED
.	O
	
six	O
male	B-MED
nurses	B-MED
participated	O
in	O
this	O
study	B-MED
.	O
	
the	O
biomechanical	B-MED
analysis	I-MED
focused	O
on	O
the	O
lifting	B-MED
strategy	O
.	O
	
thirty	O
obese	B-MED
in-patients	B-MED
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	B-MED
study	I-MED
and	O
divided	O
into	O
three	O
groups	B-MED
according	O
to	O
their	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
.	O
	
three-dimensional	B-MED
motion	I-MED
analysis	I-MED
was	O
conducted	O
using	O
an	O
optoelectronic	B-MED
system	I-MED
.	O
	
the	O
trunk	B-MED
kinematics	B-MED
and	O
the	O
loading	B-MED
on	O
the	O
spines	B-MED
of	O
the	O
operating	O
nurses	B-MED
were	O
computed	B-MED
.	O
	
our	O
data	B-MED
showed	O
that	O
when	O
the	O
nurse	B-MED
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	B-MED
was	O
more	O
flexed	B-MED
at	O
the	O
end	O
of	O
the	O
lift	B-MED
with	O
a	O
reduced	B-MED
range	B-MED
of	I-MED
motion	I-MED
.	O
	
the	O
values	B-MED
were	O
higher	B-MED
when	O
the	O
nurse	B-MED
lifted	O
patients	B-MED
with	O
higher	B-MED
bmis	B-MED
.	O
	
all	O
kinetic	B-MED
parameters	I-MED
and	O
tension	B-MED
in	O
the	O
lumbar	B-MED
muscles	I-MED
at	O
the	O
end	O
of	O
the	O
movement	B-MED
were	O
characterised	O
by	O
lower	B-MED
values	B-MED
for	O
the	O
nurse	B-MED
placed	O
beside	O
the	O
patient's	B-MED
head	B-MED
or	O
feet	B-MED
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	B-MED
groups	I-MED
.	O
	
our	O
preliminary	O
data	B-MED
suggest	O
that	O
only	O
the	O
reaction	O
load	B-MED
on	O
the	O
spine	B-MED
of	O
the	O
nurse	B-MED
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient's	B-MED
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	B-MED
safety	B-MED
limits	B-MED
.	O
	
expectations	B-MED
for	O
the	O
methodology	B-MED
and	O
translation	B-MED
of	O
animal	B-MED
research	I-MED
a	O
survey	B-MED
of	O
the	O
general	B-MED
public	I-MED
,	O
medical	B-MED
students	I-MED
and	O
animal	B-MED
researchers	B-MED
in	O
north	B-MED
america	I-MED
to	O
determine	O
what	O
are	O
considered	O
acceptable	B-MED
standards	B-MED
for	O
animal	B-MED
research	I-MED
ar	B-MED
methodology	B-MED
and	O
translation	B-MED
rate	I-MED
to	O
humans	B-MED
,	O
a	O
validated	O
survey	B-MED
was	O
sent	O
to	O
a	O
a	O
sample	O
of	O
the	O
general	B-MED
public	I-MED
,	O
via	O
sampling	B-MED
survey	I-MED
international	I-MED
ssi	B-MED
canada	B-MED
,	O
amazon	B-MED
mechanical	I-MED
turk	I-MED
amt	B-MED
usa	B-MED
,	O
a	O
canadian	B-MED
city	I-MED
festival	B-MED
cf	B-MED
and	O
a	O
canadian	B-MED
children's	B-MED
hospital	I-MED
ch	B-MED
b	O
a	O
sample	O
of	O
medical	B-MED
students	I-MED
two	O
first-year	O
classes	O
and	O
c	O
a	O
sample	O
of	O
scientists	B-MED
corresponding	O
authors	B-MED
and	O
academic	B-MED
paediatricians	B-MED
.	O
	
there	O
were	O
1379	O
responses	B-MED
from	O
the	O
general	B-MED
public	I-MED
sample	O
ssi	B-MED
,	O
n	O
=	O
557	O
amt	B-MED
,	O
n	O
=	O
590	O
cf	B-MED
,	O
n	O
=	O
195	O
ch	B-MED
,	O
n	O
=	O
102	O
,	O
205/330	O
62%	O
medical	B-MED
student	I-MED
responses	B-MED
,	O
and	O
23/323	O
7%	O
,	O
too	O
few	O
to	O
report	O
scientist	B-MED
responses	B-MED
.	O
	
asked	O
about	O
methodological	B-MED
quality	I-MED
,	O
most	O
of	O
the	O
general	B-MED
public	I-MED
and	O
medical	B-MED
student	I-MED
respondents	B-MED
expect	O
that	O
ar	B-MED
is	O
of	O
high	B-MED
quality	I-MED
e.g	O
.	O
	
anaesthesia	B-MED
and	O
analgesia	B-MED
are	O
monitored	O
,	O
even	O
overnight	O
,	O
and	O
'humane'	O
euthanasia	B-MED
,	O
optimal	B-MED
statistical	B-MED
design	I-MED
,	O
comprehensive	B-MED
literature	B-MED
review	I-MED
,	O
randomisation	B-MED
and	O
blinding	B-MED
,	O
are	O
performed	O
,	O
and	O
costs	B-MED
and	O
difficulty	O
are	O
not	O
acceptable	B-MED
justifications	B-MED
for	O
lower	B-MED
quality	I-MED
e.g	O
.	O
	
costs	B-MED
of	O
expert	O
consultation	B-MED
,	O
or	O
more	O
laboratory	B-MED
staff	I-MED
.	O
	
asked	O
about	O
their	O
expectations	B-MED
of	O
translation	B-MED
to	O
humans	B-MED
of	O
toxicity	B-MED
,	O
carcinogenicity	B-MED
,	O
teratogenicity	B-MED
and	O
treatment	B-MED
findings	B-MED
,	O
most	O
expect	O
translation	B-MED
more	O
than	O
60%	O
of	O
the	O
time	O
.	O
	
if	O
translation	B-MED
occurred	O
less	O
than	O
20%	O
of	O
the	O
time	O
,	O
a	O
minority	B-MED
disagreed	O
that	O
this	O
would	O
"""significantly"	O
reduce	O
your	O
support	O
for	O
ar	B-MED
""""	O
.	O
	
medical	B-MED
students	I-MED
were	O
more	O
supportive	B-MED
of	O
ar	B-MED
,	O
even	O
if	O
translation	B-MED
occurred	O
less	O
than	O
20%	O
of	O
the	O
time	O
.	O
	
expectations	B-MED
for	O
ar	B-MED
are	O
much	O
higher	O
than	O
empirical	B-MED
data	I-MED
predicting	B-MED
violence	B-MED
and	O
recidivism	B-MED
in	O
a	O
large	O
sample	O
of	O
males	B-MED
on	O
probation	B-MED
or	O
parole	B-MED
this	O
study	B-MED
evaluated	B-MED
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
iowa	B-MED
violence	B-MED
and	O
victimization	B-MED
instrument	B-MED
in	O
a	O
sample	O
of	O
1961	O
males	B-MED
from	O
the	O
state	O
of	O
iowa	B-MED
who	O
were	O
on	O
probation	B-MED
or	O
released	B-MED
from	I-MED
prison	I-MED
to	O
parole	B-MED
supervision	B-MED
.	O
	
this	O
is	O
the	O
first	O
study	B-MED
to	O
examine	O
the	O
potential	B-MED
of	O
the	O
iowa	B-MED
violence	B-MED
and	O
victimization	B-MED
instrument	B-MED
to	O
predict	B-MED
criminal	B-MED
offenses	I-MED
.	O
	
the	O
males	B-MED
were	O
followed	O
for	O
30	O
months	B-MED
immediately	O
following	O
their	O
admission	B-MED
to	O
probation	B-MED
or	O
parole	B-MED
.	O
	
auc	B-MED
analyses	B-MED
indicated	O
fair	O
to	O
good	O
predictive	B-MED
power	O
for	O
the	O
iowa	B-MED
violence	B-MED
and	O
victimization	B-MED
instrument	B-MED
for	O
charges	O
of	O
violence	B-MED
and	O
victimization	B-MED
,	O
but	O
chance	O
predictive	B-MED
power	O
for	O
drug	B-MED
offenses	I-MED
.	O
	
notably	O
,	O
both	O
scales	O
of	O
the	O
instrument	B-MED
performed	O
equally	O
well	O
at	O
the	O
30-	O
month	B-MED
follow-up	B-MED
.	O
	
items	O
on	O
the	O
iowa	B-MED
violence	B-MED
and	O
victimization	B-MED
instrument	B-MED
not	O
only	O
predicted	B-MED
violence	B-MED
,	O
but	O
are	O
straightforward	O
to	O
score	O
.	O
	
violence	B-MED
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	B-MED
findings	B-MED
,	O
including	O
the	O
potential	B-MED
to	O
expand	B-MED
the	O
measure	O
to	O
other	O
jurisdictions	B-MED
and	O
prognostic	B-MED
significance	I-MED
of	O
non-hpv16	B-MED
genotypes	I-MED
in	O
oropharyngeal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
opscc	B-MED
positive	B-MED
for	O
hpv16	B-MED
genotype	I-MED
have	O
better	B-MED
overall	B-MED
survival	I-MED
compared	B-MED
with	O
cases	O
positive	O
for	O
other	O
hpv	B-MED
genotypes	I-MED
.	O
	
we	O
sought	O
to	O
further	O
replicate	B-MED
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	B-MED
by	I-MED
expression	B-MED
of	O
p16	B-MED
tumor	I-MED
suppressor	I-MED
protein	I-MED
.	O
	
we	O
identified	O
238	O
opscc	B-MED
cases	O
from	O
the	O
carolina	B-MED
head	I-MED
and	I-MED
neck	I-MED
cancer	I-MED
study	I-MED
chance	B-MED
study	O
,	O
a	O
population	B-MED
based	I-MED
case-control	I-MED
study	I-MED
.	O
	
tumors	B-MED
that	O
tested	O
positive	B-MED
solely	I-MED
for	O
hpv16	B-MED
genotype	I-MED
and	O
no	O
other	O
genotypes	B-MED
with	O
pcr	B-MED
were	O
classified	B-MED
as	O
hpv16-positive	B-MED
.	O
	
tumors	B-MED
positive	B-MED
for	I-MED
any	O
other	O
high-risk	B-MED
hpv	B-MED
genotype	I-MED
were	O
classified	B-MED
as	O
non-hpv16-positive	B-MED
.	O
	
expression	B-MED
of	O
p16	B-MED
in	O
the	O
tumor	B-MED
was	O
determined	B-MED
with	O
immunohistochemistry	B-MED
.	O
	
follow-up	O
time	O
was	O
calculated	O
from	O
the	O
date	B-MED
of	I-MED
diagnosis	I-MED
to	O
date	B-MED
of	I-MED
death	I-MED
or	O
december	O
31	O
,	O
2013	O
.	O
	
overall	B-MED
survival	I-MED
was	O
compared	O
with	O
the	O
kaplan-meier	B-MED
curves	I-MED
and	O
log-rank	B-MED
test	I-MED
.	O
	
hazard	B-MED
ratios	I-MED
hr	B-MED
adjusted	O
for	O
smoking	B-MED
,	O
alcohol	B-MED
use	I-MED
,	O
sex	B-MED
,	O
race	B-MED
,	O
and	O
age	B-MED
was	O
calculated	O
with	O
the	O
cox	B-MED
proportional	I-MED
hazard	I-MED
regression	I-MED
.	O
	
cases	O
with	O
hpv16-positive	B-MED
opscc	B-MED
had	O
better	B-MED
overall	B-MED
survival	I-MED
than	O
cases	O
with	O
non-hpv16-positive	B-MED
opscc	B-MED
log-rank	O
p-value	O
0.010	O
.	O
	
when	O
restricted	O
to	O
opscc	B-MED
cases	O
positive	B-MED
for	O
p16	B-MED
expression	I-MED
,	O
the	O
same	O
trend	B-MED
continued	O
log-rank	O
p-value	O
0.002	O
.	O
	
in	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non-hpv16-positive	B-MED
opscc	B-MED
had	O
greater	B-MED
risk	I-MED
of	I-MED
death	B-MED
compared	O
to	O
cases	O
with	O
hpv16-positive	B-MED
tumors	B-MED
hr	B-MED
1.92	O
95%	O
ci	O
1.03	O
,	O
3.60	O
.	O
	
this	O
finding	B-MED
indicates	B-MED
that	O
hpv	B-MED
genotyping	B-MED
carries	O
valuable	B-MED
prognostic	I-MED
significance	I-MED
in	O
addition	O
to	O
p16	B-MED
status	B-MED
and	O
future	O
survival	O
studies	O
of	O
opscc	B-MED
should	O
take	O
into	O
account	O
differing	O
hpv	B-MED
genotypes	I-MED
.	O
	
randomized	B-MED
trials	I-MED
of	O
the	O
teen	B-MED
outreach	B-MED
program	I-MED
in	O
louisiana	B-MED
and	O
rochester	B-MED
,	O
new	B-MED
york	I-MED
to	O
evaluate	B-MED
the	O
teen	B-MED
outreach	B-MED
program	I-MED
,	O
a	O
pregnancy	B-MED
prevention	I-MED
program	B-MED
,	O
in	O
2	O
community	B-MED
-based	O
settings	O
.	O
	
we	O
evaluated	B-MED
the	O
teen	B-MED
outreach	B-MED
program	I-MED
,	O
a	O
9-month	O
positive	B-MED
youth	I-MED
development	I-MED
program	I-MED
,	O
in	O
3	O
cohorts	B-MED
of	O
youths	B-MED
from	O
2012	O
to	O
2015	O
in	O
2	O
states	B-MED
.	O
	
in	O
louisiana	B-MED
,	O
7	O
agencies	B-MED
participated	O
in	O
an	O
individualized	B-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
,	O
with	O
youths	B-MED
randomly	O
assigned	O
to	O
a	O
treatment	B-MED
or	O
control	B-MED
condition	I-MED
.	O
	
fourteen	O
agencies	B-MED
in	O
rochester	B-MED
,	O
new	B-MED
york	I-MED
,	O
participated	O
in	O
a	O
cluster	B-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
	
we	O
found	O
no	B-MED
differences	I-MED
between	O
the	O
intervention	B-MED
and	O
control	B-MED
youths	I-MED
on	O
delay	B-MED
of	O
sexual	B-MED
onset	B-MED
in	O
louisiana	B-MED
adjusted	B-MED
odds	I-MED
ratio	I-MED
aor	B-MED
=	O
0.80	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
=	O
0.62	O
,	O
1.03	O
or	O
in	O
rochester	B-MED
,	O
new	B-MED
york	I-MED
aor	B-MED
=	O
0.89	O
95%	O
ci	B-MED
=	O
0.45	O
,	O
1.77	O
,	O
or	O
for	O
sex	B-MED
with	O
no	O
effective	O
means	O
of	O
birth	B-MED
control	I-MED
louisiana	B-MED
,	O
aor	B-MED
=	O
1.18	O
95%	O
ci	B-MED
=	O
0.78	O
,	O
1.78	O
rochester	B-MED
,	O
aor	B-MED
=	O
0.41	O
95%	O
ci	B-MED
=	O
0.13	O
,	O
1.27	O
after	O
controlling	B-MED
for	O
relevant	O
covariates	B-MED
.	O
	
we	O
found	O
no	B-MED
short-term	B-MED
effects	B-MED
for	O
the	O
offer	O
of	O
the	O
intervention	B-MED
.	O
	
research	B-MED
might	O
be	O
needed	O
for	O
the	O
long-term	B-MED
and	O
intermediate	B-MED
impacts	I-MED
of	O
youth	B-MED
development	I-MED
programs	I-MED
on	O
these	O
and	O
other	O
adolescent	B-MED
risk	B-MED
behaviors	I-MED
.	O
	
a	O
single	B-MED
session	I-MED
of	O
exhaustive	B-MED
exercise	I-MED
markedly	O
decreases	B-MED
circulating	B-MED
levels	O
of	O
guanidinoacetic	B-MED
acid	I-MED
in	O
healthy	B-MED
men	B-MED
and	O
women	B-MED
we	O
evaluated	B-MED
the	O
effects	B-MED
of	I-MED
exercise	B-MED
on	O
circulating	B-MED
concentrations	B-MED
of	O
guanidinoacetic	B-MED
acid	I-MED
gaa	B-MED
and	O
creatine	B-MED
in	O
23	O
healthy	B-MED
volunteers	I-MED
subjected	O
to	O
running	B-MED
to	O
exhaustion	B-MED
and	O
free-weight	B-MED
bench-press	I-MED
to	O
volitional	B-MED
failure	I-MED
.	O
	
blood	B-MED
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	B-MED
session	B-MED
.	O
	
running	B-MED
induced	B-MED
a	O
significant	O
decrease	B-MED
in	O
serum	B-MED
gaa	B-MED
by	O
20.1	O
p	O
<	O
0.001	O
,	O
while	O
free-weight	B-MED
exercise	I-MED
reduced	B-MED
gaa	B-MED
by	O
11.7	O
p	O
<	O
0.001	O
,	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	B-MED
gaa	B-MED
as	O
a	O
novel	O
biomarker	B-MED
of	O
anti-helminthic	B-MED
activity	B-MED
of	O
momordica	B-MED
charantia	I-MED
l	I-MED
.	O
	
against	O
fasciola	B-MED
hepatica	I-MED
eggs	I-MED
after	O
twelve	O
days	B-MED
of	O
incubation	B-MED
in	B-MED
vitro	I-MED
fasciolosis	B-MED
,	O
a	O
parasitic	B-MED
disease	I-MED
caused	O
by	O
the	O
trematode	B-MED
fasciola	B-MED
hepatica	I-MED
underreported	O
is	O
expanding	O
both	O
in	O
human	B-MED
and	O
animal	B-MED
population	I-MED
,	O
throughout	O
the	O
world	B-MED
.	O
	
the	O
constant	O
use	O
of	O
synthetic	B-MED
drugs	I-MED
to	O
treat	B-MED
this	O
condition	B-MED
has	O
led	O
to	O
the	O
natural	B-MED
selection	I-MED
of	O
resistant	B-MED
strains	B-MED
of	O
the	O
parasite	B-MED
.	O
	
hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti-helminthic	B-MED
properties	B-MED
of	O
medicinal	B-MED
plants	I-MED
and	O
phytopharmaceuticals	B-MED
.	O
	
the	O
current	O
study	B-MED
assessed	O
the	O
potential	O
anti-fasciolicide	B-MED
action	B-MED
of	O
momordica	B-MED
charantia	I-MED
leaf	B-MED
extracts	B-MED
and	O
fractions	B-MED
on	O
the	O
eggs	B-MED
of	I-MED
f	I-MED
.	O
	
hepatica	I-MED
parasites	I-MED
.	O
	
the	O
lyophilized	B-MED
crude	B-MED
extract	I-MED
ce	B-MED
of	O
m	B-MED
.	O
	
charantia	I-MED
leaves	I-MED
and	O
its	O
sub-fractions	B-MED
,	O
obtained	O
from	O
liquid-liquid	B-MED
partitioning	I-MED
with	O
organic	B-MED
solvents	I-MED
,	O
were	O
analysed	B-MED
by	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
hplc	B-MED
,	O
suspended	B-MED
in	O
1%	O
dmso	B-MED
and	O
used	O
in	B-MED
in	O
vitro	I-MED
tests	B-MED
.	O
	
quadruplicates	B-MED
of	O
50	O
f	B-MED
.	O
	
hepatica	I-MED
eggs	I-MED
were	O
incubated	B-MED
at	O
23	O
with	O
m	B-MED
.	O
	
charantia	I-MED
leaf	B-MED
ce	B-MED
in	O
different	O
concentrations	B-MED
.	O
	
after	O
12	O
days	B-MED
no	O
larvae	B-MED
were	O
formed	O
in	O
eggs	B-MED
incubated	B-MED
with	O
ce	B-MED
concentrations	B-MED
above	O
12.5mg	O
.	O
	
eggs	B-MED
incubated	B-MED
with	O
ce	B-MED
sub-fractions	B-MED
at	O
concentrations	B-MED
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg	O
affected	B-MED
embryonic	B-MED
development	I-MED
,	O
with	O
n-butanol	B-MED
presenting	O
the	O
strongest	O
inhibition	B-MED
of	O
miracidia	B-MED
formation	B-MED
.	O
	
in	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90%	O
of	O
the	O
miracidia	B-MED
hatched	B-MED
in	O
the	O
control	B-MED
experiments	I-MED
using	O
0.03	O
dmso	B-MED
whereas	O
embryogenesis	B-MED
was	O
completely	O
abolished	B-MED
with	O
any	O
concentration	B-MED
of	O
albendazole	B-MED
sulphoxide	I-MED
abz	B-MED
.	O
	
chemical	B-MED
analysis	I-MED
of	O
the	O
ce	B-MED
and	O
sub-fractions	B-MED
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	B-MED
.	O
	
hplc-ms	B-MED
confirmed	O
quercetin	B-MED
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	B-MED
present	O
in	O
the	O
ce	B-MED
and	O
the	O
n-butanol	B-MED
subfraction	B-MED
.	O
	
this	O
is	O
the	O
first	O
study	B-MED
to	O
analyse	B-MED
the	O
potential	O
anti-fasciolicide	B-MED
action	B-MED
of	O
m	B-MED
.	O
	
charantia	I-MED
leaf	B-MED
ce	B-MED
and	O
dabigatran	B-MED
a	O
new	O
oral	B-MED
anticoagulant	I-MED
.	O
	
guidelines	B-MED
to	O
follow	O
in	O
oral	B-MED
surgery	I-MED
procedures	I-MED
.	O
	
a	O
systematic	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
dabigatran	B-MED
is	O
a	O
newly	O
commercialized	O
drug	B-MED
that	O
is	O
replacing	O
other	O
anticoagulants	B-MED
in	O
the	O
prevention	O
of	O
venous	B-MED
thromboembolism	I-MED
,	O
stroke	B-MED
and	O
systemic	B-MED
arterial	I-MED
valve	I-MED
embolism	I-MED
.	O
	
it	O
acts	O
directly	O
on	O
thrombin	B-MED
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	B-MED
.	O
	
therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	B-MED
the	O
risk	B-MED
of	I-MED
bleeding	I-MED
involved	O
before	O
any	O
dental	B-MED
treatment	I-MED
.	O
	
we	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	B-MED
search	I-MED
in	O
pubmed	B-MED
/	O
medline	B-MED
along	O
with	O
the	O
cochrane	B-MED
library	I-MED
.	O
	
we	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-MED
other	O
than	O
dabigatran	B-MED
,	O
and	O
works	O
about	O
surgical	B-MED
treatments	I-MED
in	O
anatomical	B-MED
locations	I-MED
other	O
than	O
the	O
oral	B-MED
cavity	I-MED
.	O
	
we	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
,	O
9	O
narrative	B-MED
literature	I-MED
reviews	I-MED
,	O
1	O
case	B-MED
series	I-MED
,	O
2	O
clinical	B-MED
cases	I-MED
and	O
1	O
expert	B-MED
opinion	I-MED
.	O
	
because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	B-MED
trials	I-MED
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta-analysis	B-MED
.	O
	
currently	O
,	O
there	O
is	O
no	O
consensus	B-MED
on	O
the	O
procedure	B-MED
to	O
be	O
followed	O
in	O
patients	B-MED
taking	O
dabigatran	B-MED
.	O
	
however	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	B-MED
of	O
embolism	B-MED
,	O
postoperative	B-MED
bleeding	I-MED
and	O
renal	B-MED
function	I-MED
.	O
	
also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-MED
interventions	I-MED
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti-hemolytic	B-MED
measures	I-MED
.	O
	
did	O
fidelis	B-MED
projects	B-MED
contribute	B-MED
to	O
the	O
detection	B-MED
of	O
new	O
smear	B-MED
-	O
positive	B-MED
pulmonary	B-MED
tuberculosis	I-MED
cases	O
in	O
china	B-MED
setting	O
the	O
first	B-MED
phase	I-MED
of	I-MED
the	I-MED
fund	I-MED
for	I-MED
innovative	I-MED
dots	I-MED
expansion	I-MED
through	I-MED
local	I-MED
initiatives	I-MED
to	I-MED
stop	I-MED
tb	I-MED
fidelis	B-MED
projects	B-MED
in	O
china	B-MED
started	O
in	O
2003	O
.	O
	
objective	O
to	O
determine	O
whether	O
the	O
fidelis	B-MED
projects	B-MED
contribute	B-MED
d	O
to	O
the	O
increased	B-MED
case	B-MED
detection	B-MED
rate	B-MED
for	O
new	O
smear	B-MED
-	O
positive	B-MED
pulmonary	B-MED
tuberculosis	I-MED
ptb	B-MED
in	O
china	B-MED
.	O
	
methods	O
we	O
compared	B-MED
the	O
case	B-MED
notification	I-MED
rates	I-MED
cnrs	B-MED
in	O
the	O
intervention	B-MED
year	I-MED
with	O
those	O
of	O
the	O
previous	B-MED
year	B-MED
in	O
the	O
fidelis	B-MED
areas	B-MED
,	O
then	O
compared	B-MED
the	O
difference	B-MED
between	O
the	O
cnrs	B-MED
of	O
the	O
intervention	B-MED
year	I-MED
and	O
the	O
previous	B-MED
year	B-MED
in	O
the	O
fidelis	B-MED
areas	B-MED
with	O
those	O
in	O
the	O
non-fi-delis	B-MED
areas	B-MED
within	O
the	O
province	B-MED
.	O
	
results	O
there	O
was	O
an	O
increase	B-MED
in	O
the	O
cnr	B-MED
in	O
the	O
intervention	B-MED
year	I-MED
compared	B-MED
with	O
the	O
previous	B-MED
year	B-MED
for	O
all	O
the	O
project	B-MED
sites	O
.	O
	
the	O
differences	B-MED
between	O
the	O
cnr	B-MED
in	O
the	O
intervention	B-MED
year	I-MED
and	O
the	O
previous	B-MED
year	B-MED
ranged	B-MED
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	B-MED
in	O
the	O
fidelis	B-MED
areas	B-MED
and	O
from	O
2.9	O
to	O
20.4	O
000	O
in	O
the	O
non-fidelis	B-MED
areas	B-MED
.	O
	
differences	B-MED
-in-	O
differences	B-MED
analysis	B-MED
shows	O
that	O
the	O
differences	B-MED
in	O
the	O
cnrs	B-MED
in	O
the	O
fidelis	B-MED
areas	B-MED
were	O
not	O
statistically	B-MED
significantly	I-MED
different	B-MED
from	O
those	O
in	O
the	O
non-	O
fidelis	B-MED
areas	B-MED
p	O
=	O
0.393	O
.	O
	
conclusion	O
the	O
fidelis	B-MED
projects	B-MED
may	O
have	O
contributed	B-MED
to	O
the	O
increase	B-MED
in	O
case	B-MED
detection	B-MED
of	O
new	O
smear	B-MED
-	O
positive	B-MED
ptb	B-MED
in	O
china	B-MED
,	O
but	O
the	O
level	B-MED
of	O
evidence	B-MED
is	O
liver	B-MED
fatty	I-MED
acid	I-MED
binding	I-MED
protein	I-MED
deficiency	B-MED
provokes	O
oxidative	B-MED
stress	I-MED
,	O
inflammation	B-MED
,	O
and	O
apoptosis	B-MED
-mediated	O
hepatotoxicity	B-MED
induced	B-MED
by	O
pyrazinamide	B-MED
in	O
zebrafish	B-MED
larvae	B-MED
pyrazinamide	B-MED
pza	B-MED
is	O
an	O
essential	B-MED
antitubercular	B-MED
drug	I-MED
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	B-MED
potential	B-MED
.	O
	
this	O
study	O
examined	O
the	O
effects	B-MED
of	I-MED
pza	B-MED
exposure	B-MED
on	O
zebrafish	B-MED
danio	B-MED
rerio	I-MED
larvae	B-MED
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	B-MED
.	O
	
a	O
transgenic	B-MED
line	I-MED
of	O
zebrafish	B-MED
larvae	B-MED
that	O
expressed	B-MED
enhanced	B-MED
green	I-MED
fluorescent	I-MED
protein	I-MED
egfp	B-MED
in	O
the	O
liver	B-MED
was	O
incubated	B-MED
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mm	O
pza	B-MED
from	O
72	O
h	O
postfertilization	B-MED
hpf	O
.	O
	
different	O
endpoints	B-MED
such	O
as	O
mortality	B-MED
,	O
morphology	B-MED
changes	B-MED
in	O
the	O
size	B-MED
and	O
shape	B-MED
of	O
the	O
liver	B-MED
,	O
histological	B-MED
changes	B-MED
,	O
transaminase	B-MED
analysis	I-MED
and	O
apoptosis	B-MED
,	O
markers	B-MED
of	O
oxidative	B-MED
and	O
genetic	B-MED
damage	I-MED
,	O
as	O
well	O
as	O
the	O
expression	B-MED
of	O
certain	O
genes	B-MED
were	O
selected	O
to	O
evaluate	B-MED
pza	B-MED
-	O
induced	B-MED
hepatotoxicity	B-MED
.	O
	
our	O
results	O
confirm	B-MED
the	O
manner	O
of	O
pza	B-MED
dose-dependent	B-MED
hepatotoxicity	B-MED
.	O
	
pza	B-MED
was	O
found	O
to	O
induce	B-MED
marked	B-MED
injury	B-MED
in	O
zebrafish	B-MED
larvae	B-MED
,	O
such	O
as	O
liver	B-MED
atrophy	I-MED
,	O
elevations	B-MED
of	I-MED
transaminase	I-MED
levels	I-MED
,	O
oxidative	B-MED
stress	I-MED
,	O
and	O
hepatocyte	B-MED
apoptosis	I-MED
.	O
	
to	O
further	O
understand	O
the	O
mechanism	O
behind	O
pza	B-MED
-	O
induced	B-MED
hepatotoxicity	B-MED
,	O
changes	B-MED
in	O
gene	B-MED
expression	I-MED
levels	I-MED
in	O
zebrafish	B-MED
larvae	B-MED
exposed	B-MED
to	I-MED
pza	B-MED
for	O
72	O
h	O
postexposure	B-MED
hpe	O
were	O
determined	O
.	O
	
the	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
pza	B-MED
decreased	B-MED
the	O
expression	B-MED
levels	I-MED
of	O
liver	B-MED
fatty	I-MED
acid	I-MED
binding	I-MED
protein	I-MED
l-fabp	B-MED
and	O
its	O
target	B-MED
gene	I-MED
,	O
peroxisome	B-MED
proliferator-activated	I-MED
receptor	I-MED
α	I-MED
ppar-α	B-MED
,	O
and	O
provoked	O
more	O
severe	B-MED
oxidative	B-MED
stress	I-MED
and	O
hepatitis	B-MED
via	O
the	O
upregulation	B-MED
of	O
inflammatory	B-MED
cytokines	I-MED
such	O
as	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
alpha	I-MED
tnf-α	B-MED
and	O
transforming	B-MED
growth	I-MED
factor	I-MED
β	I-MED
tgf-β	B-MED
.	O
	
these	O
findings	O
suggest	O
that	O
l-fabp	B-MED
-mediated	O
ppar-α	B-MED
downregulation	B-MED
appears	O
to	O
be	O
a	O
hepatotoxic	B-MED
response	I-MED
resulting	O
from	O
zebrafish	B-MED
larva	B-MED
liver	B-MED
cell	I-MED
apoptosis	B-MED
,	O
and	O
l-fabp	B-MED
can	O
be	O
used	O
as	O
a	O
biomarker	B-MED
for	O
the	O
early	B-MED
detection	I-MED
of	O
pza	B-MED
-	O
induced	B-MED
liver	B-MED
damage	I-MED
in	O
zebrafish	B-MED
larvae	B-MED
.	O
	
smooth	B-MED
versus	O
textured	B-MED
surfaces	B-MED
feature	B-MED
-based	O
category	B-MED
selectivity	B-MED
in	O
human	B-MED
visual	B-MED
cortex	I-MED
in	O
fmri	B-MED
studies	I-MED
,	O
human	B-MED
lateral	B-MED
occipital	I-MED
lo	I-MED
cortex	I-MED
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	B-MED
of	O
objects	B-MED
,	O
compared	B-MED
with	O
nonobjects	B-MED
.	O
	
however	O
,	O
it	O
remains	O
unresolved	B-MED
whether	O
all	O
objects	B-MED
evoke	O
equivalent	B-MED
levels	B-MED
of	O
activity	B-MED
in	O
lo	B-MED
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	B-MED
features	I-MED
produce	O
stronger	B-MED
activation	B-MED
.	O
	
here	O
,	O
we	O
used	O
an	O
unbiased	B-MED
parametric	I-MED
texture	I-MED
model	I-MED
to	O
predict	B-MED
preferred	B-MED
versus	O
nonpreferred	B-MED
stimuli	I-MED
in	O
lo	B-MED
.	O
	
observation	B-MED
and	O
psychophysical	B-MED
results	I-MED
showed	O
that	O
predicted	B-MED
preferred	B-MED
stimuli	B-MED
both	O
objects	B-MED
and	O
nonobjects	B-MED
had	O
smooth	B-MED
rather	O
than	O
textured	B-MED
surfaces	B-MED
.	O
	
these	O
predictions	B-MED
were	O
confirmed	B-MED
using	O
fmri	B-MED
,	O
for	O
objects	B-MED
and	O
nonobjects	B-MED
.	O
	
similar	O
preferences	B-MED
were	O
also	O
found	O
in	O
the	O
fusiform	B-MED
face	I-MED
area	I-MED
ffa	B-MED
.	O
	
consistent	B-MED
with	I-MED
this	O
1	O
ffa	B-MED
and	O
lo	B-MED
responded	O
more	O
strongly	O
to	O
nonfreckled	B-MED
smooth	B-MED
faces	B-MED
,	O
compared	B-MED
with	O
otherwise	O
identical	O
freckled	B-MED
textured	B-MED
faces	B-MED
and	O
2	O
strong	O
functional	B-MED
connections	B-MED
were	O
found	O
between	O
lo	B-MED
and	O
ffa	B-MED
.	O
	
thus	O
,	O
lo	B-MED
and	O
ffa	B-MED
may	O
be	O
part	O
of	O
an	O
information	B-MED
-	O
processing	B-MED
stream	O
distinguished	O
by	O
feature	B-MED
-based	O
category	B-MED
selectivity	B-MED
smooth	B-MED
>	O
high-fructose	B-MED
diet	I-MED
is	O
as	O
detrimental	O
as	O
high-fat	B-MED
diet	I-MED
in	O
the	O
induction	B-MED
of	O
insulin	B-MED
resistance	I-MED
and	O
diabetes	B-MED
mediated	O
by	O
hepatic	B-MED
/	O
pancreatic	B-MED
endoplasmic	B-MED
reticulum	I-MED
er	I-MED
stress	I-MED
in	O
the	O
context	B-MED
of	O
high	B-MED
human	B-MED
consumption	B-MED
of	O
fructose	B-MED
diets	B-MED
,	O
there	O
is	O
an	O
imperative	O
need	B-MED
to	O
understand	B-MED
how	O
dietary	B-MED
fructose	B-MED
intake	I-MED
influence	B-MED
cellular	B-MED
and	O
molecular	B-MED
mechanisms	B-MED
and	O
thereby	O
affect	B-MED
β-cell	B-MED
dysfunction	I-MED
and	O
insulin	B-MED
resistance	I-MED
.	O
	
while	O
evidence	B-MED
exists	B-MED
for	O
a	O
relationship	B-MED
between	O
high	B-MED
-	O
fat	B-MED
-	O
induced	B-MED
insulin	B-MED
resistance	I-MED
and	O
metabolic	B-MED
disorders	I-MED
,	O
there	O
is	O
lack	B-MED
of	I-MED
studies	B-MED
in	O
relation	O
to	O
high-fructose	B-MED
diet	I-MED
.	O
	
therefore	O
,	O
we	O
attempted	O
to	O
study	B-MED
the	O
effect	B-MED
of	O
different	B-MED
diets	B-MED
viz	O
,	O
high-fat	B-MED
diet	I-MED
hfd	B-MED
,	O
high-fructose	B-MED
diet	I-MED
hfs	B-MED
,	O
and	O
a	O
combination	B-MED
hfs	B-MED
+	O
hfd	B-MED
diet	B-MED
on	O
glucose	B-MED
homeostasis	I-MED
and	O
insulin	B-MED
sensitivity	I-MED
in	O
male	B-MED
wistar	B-MED
rats	I-MED
compared	B-MED
to	O
control	B-MED
animals	I-MED
fed	B-MED
with	O
normal	B-MED
pellet	B-MED
diet	B-MED
.	O
	
investigations	B-MED
include	O
oral	B-MED
glucose	I-MED
tolerance	I-MED
test	I-MED
,	O
insulin	B-MED
tolerance	I-MED
test	I-MED
,	O
histopathology	B-MED
by	O
h	B-MED
and	O
masson's	B-MED
trichrome	I-MED
staining	I-MED
,	O
mrna	B-MED
expression	I-MED
by	O
real-time	B-MED
pcr	I-MED
,	O
protein	B-MED
expression	I-MED
by	O
western	B-MED
blot	I-MED
,	O
and	O
caspase-3	B-MED
activity	I-MED
by	O
colorimetry	B-MED
.	O
	
rats	B-MED
subjected	O
to	O
high-fat	B-MED
/	O
fructose	B-MED
diets	I-MED
became	O
glucose	B-MED
intolerant	B-MED
,	O
insulin-resistant	B-MED
,	O
and	O
dyslipidemic	B-MED
.	O
	
compared	B-MED
to	O
control	B-MED
animals	I-MED
,	O
rats	B-MED
subjected	O
to	O
different	B-MED
combination	B-MED
of	O
fat	B-MED
/	O
fructose	B-MED
diets	I-MED
showed	O
increased	B-MED
mrna	B-MED
and	O
protein	B-MED
expression	I-MED
of	O
a	O
battery	O
of	O
er	B-MED
stress	I-MED
markers	B-MED
both	O
in	O
pancreas	B-MED
and	O
liver	B-MED
.	O
	
transcription	B-MED
factors	I-MED
of	O
β-cell	B-MED
function	I-MED
insig1	B-MED
,	O
srebp1c	B-MED
and	O
pdx1	B-MED
as	O
well	O
as	O
hepatic	B-MED
gluconeogenesis	B-MED
foxo1	B-MED
and	O
pepck	B-MED
were	O
adversely	B-MED
affected	I-MED
in	O
diet	B-MED
-	O
induced	B-MED
insulin-resistant	B-MED
rats	B-MED
.	O
	
the	O
convergence	B-MED
of	O
chronic	B-MED
er	B-MED
stress	I-MED
towards	O
apoptosis	B-MED
in	O
pancreas	B-MED
/	O
liver	B-MED
was	O
also	O
indicated	B-MED
by	O
increased	B-MED
levels	B-MED
of	O
chop	B-MED
mrna	I-MED
increased	B-MED
activity	O
of	O
both	O
jnk	B-MED
and	O
caspase-3	B-MED
in	O
rats	B-MED
subjected	O
to	O
high-fat	B-MED
/	O
fructose	B-MED
diets	I-MED
.	O
	
our	O
study	B-MED
exposes	O
the	O
experimental	B-MED
support	B-MED
in	O
that	O
high-fructose	B-MED
diet	I-MED
is	O
equally	B-MED
detrimental	O
in	O
causing	B-MED
metabolic	B-MED
disorders	I-MED
.	O
	
immature	B-MED
stages	B-MED
and	O
larval	B-MED
chaetotaxy	B-MED
of	O
notofairchildia	B-MED
stenygros	I-MED
quate	O
alexander	O
diptera	B-MED
psychodidae	B-MED
bruchomyiinae	B-MED
some	O
authors	O
have	O
hypothesized	O
that	O
bruchomyiinae	B-MED
is	O
"""the"	O
most	O
plesiomorphic	B-MED
subfamily	I-MED
of	O
psychodidae	B-MED
""""	O
and	O
its	O
members	B-MED
"""are"	O
among	O
the	O
most	O
primitive	B-MED
living	B-MED
diptera	B-MED
""""	O
.	O
	
although	O
bruchomyiinae	B-MED
is	O
of	O
no	B-MED
medical	B-MED
importance	B-MED
,	O
it	O
is	O
of	O
great	O
evolutionary	B-MED
significance	B-MED
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	B-MED
group	I-MED
of	O
phlebotominae	B-MED
.	O
	
in	O
general	O
,	O
species	B-MED
of	O
this	O
subfamily	B-MED
are	O
rarely	O
collected	O
in	O
their	O
natural	B-MED
environment	I-MED
therefore	O
,	O
adults	B-MED
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	B-MED
stages	B-MED
of	O
these	O
flies	B-MED
are	O
poorly	O
known	O
.	O
	
we	O
describe	O
the	O
egg	B-MED
,	O
larvae	B-MED
and	O
pupae	B-MED
of	O
notofairchildia	B-MED
stenygros	I-MED
and	O
provide	O
nomenclatural	B-MED
notes	I-MED
on	O
larval	B-MED
chaetotaxy	B-MED
based	O
on	O
analyses	O
using	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
sem	B-MED
and	O
optic	B-MED
microscopy	I-MED
.	O
	
the	O
morphology	B-MED
of	O
immature	B-MED
nt	B-MED
.	O
	
stenygros	I-MED
is	O
compared	O
with	O
other	O
bruchomyiinae	B-MED
and	O
psychodidae	B-MED
species	B-MED
,	O
especially	O
with	O
species	B-MED
of	O
phlebotominae	B-MED
that	O
are	O
superficially	O
similar	B-MED
to	O
bruchomyiinae	B-MED
.	O
	
results	B-MED
of	O
this	O
study	B-MED
revealed	O
striking	O
morphological	B-MED
differences	B-MED
between	O
the	O
immature	B-MED
stages	B-MED
of	O
bruchomyiinae	B-MED
and	O
phlebotominae	B-MED
the	O
former	O
are	O
lacking	O
abdominal	B-MED
pseudopods	B-MED
and	O
microtrichia	B-MED
on	O
the	O
cephalic	B-MED
integument	B-MED
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	B-MED
of	O
phlebotominae	B-MED
.	O
	
these	O
morphological	B-MED
differences	B-MED
observed	O
in	O
the	O
immature	B-MED
stages	B-MED
between	O
members	B-MED
of	O
the	O
two	O
subfamilies	B-MED
support	O
the	O
findings	B-MED
of	O
recent	O
molecular	B-MED
studies	I-MED
indicating	O
that	O
bruchomyiinae	B-MED
and	O
phlebtominae	B-MED
are	O
evolutionarily	B-MED
not	B-MED
closely	I-MED
related	I-MED
.	O
	
notofairchildia	B-MED
stenygros	I-MED
is	O
now	O
the	O
fourth	B-MED
species	B-MED
of	O
bruchomyiinae	B-MED
for	O
which	O
the	O
immature	B-MED
stages	B-MED
initial	O
clinical	B-MED
results	I-MED
with	O
the	O
thermocool	B-MED
smarttouch	I-MED
surround	I-MED
flow	I-MED
catheter	I-MED
the	O
biosense	B-MED
webster	I-MED
thermocool	I-MED
smarttouch	I-MED
surround	I-MED
flow	I-MED
stsf	I-MED
catheter	I-MED
is	O
a	O
recently	O
developed	O
ablation	B-MED
catheter	B-MED
incorporating	O
surround	B-MED
flow	I-MED
sf	B-MED
technology	B-MED
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	B-MED
tissue	B-MED
contact	B-MED
.	O
	
in	O
our	O
unit	O
,	O
it	O
superseded	O
the	O
thermocool	B-MED
sf	I-MED
catheter	I-MED
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
may	O
2015	O
.	O
	
procedure	B-MED
-related	O
data	B-MED
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation	B-MED
procedures	I-MED
performed	O
in	O
our	O
department	O
using	O
the	O
stsf	B-MED
catheter	I-MED
.	O
	
from	O
a	O
database	B-MED
of	O
654	O
procedures	B-MED
performed	O
in	O
our	O
unit	O
using	O
the	O
sf	B-MED
catheter	I-MED
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
stsf	B-MED
procedure	I-MED
,	O
matching	O
for	O
procedure	B-MED
type	I-MED
,	O
operator	B-MED
experience	B-MED
,	O
patient	B-MED
age	I-MED
,	O
and	O
gender	B-MED
.	O
	
the	O
groups	B-MED
were	O
well	O
matched	O
for	O
patient	B-MED
age	I-MED
,	O
gender	B-MED
,	O
and	O
procedure	B-MED
type	I-MED
.	O
	
procedure	B-MED
duration	I-MED
was	O
similar	O
in	O
both	O
groups	B-MED
mean	O
225.5	O
vs	O
.	O
	
221.4	O
min	O
,	O
iqr	B-MED
106.5	O
vs	O
.	O
	
91.5	O
,	O
p	O
=	O
0.55	O
,	O
but	O
fluoroscopy	B-MED
duration	I-MED
was	O
shorter	B-MED
in	O
the	O
stsf	B-MED
group	I-MED
mean	O
25.8	O
vs	O
.	O
	
30.0	O
,	O
iqr	B-MED
19.6	O
vs	O
.	O
	
18.5	O
,	O
p	O
=	O
0.03	O
.	O
	
no	B-MED
complication	I-MED
occurred	O
in	O
the	O
stsf	B-MED
group	I-MED
.	O
	
complications	B-MED
occurred	O
in	O
two	O
cases	B-MED
in	O
the	O
sf	B-MED
group	I-MED
one	O
pericardial	B-MED
effusion	I-MED
requiring	O
drainage	B-MED
and	O
one	O
need	O
for	O
permanent	B-MED
pacing	B-MED
.	O
	
complete	B-MED
procedural	I-MED
success	I-MED
was	O
achieved	O
in	O
98	O
cases	B-MED
in	O
the	O
stsf	B-MED
group	I-MED
and	O
94	O
cases	B-MED
in	O
the	O
sf	B-MED
group	I-MED
p	O
=	O
0.15	O
.	O
	
the	O
composite	O
endpoint	O
of	O
procedure	O
failure	B-MED
or	O
acute	B-MED
complication	B-MED
was	O
less	O
common	O
in	O
the	O
stsf	B-MED
group	I-MED
2	O
vs	O
.	O
	
8	O
,	O
p	O
=	O
0.05	O
.	O
	
the	O
stsf	B-MED
catheter	I-MED
is	O
safe	O
and	O
effective	B-MED
in	O
treating	B-MED
a	O
range	O
of	O
arrhythmias	B-MED
.	O
	
compared	O
with	O
the	O
sf	B-MED
catheter	I-MED
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	B-MED
-	O
efficacy	B-MED
low	B-MED
birth	I-MED
weight	I-MED
and	O
features	B-MED
of	O
neuroticism	B-MED
and	O
mood	B-MED
disorder	I-MED
in	O
83	O
545	O
participants	B-MED
of	O
the	O
uk	B-MED
biobank	B-MED
cohort	B-MED
low	B-MED
birth	I-MED
weight	I-MED
has	O
been	O
inconsistently	O
associated	O
with	O
risk	B-MED
of	O
developing	O
affective	B-MED
disorders	I-MED
,	O
including	O
major	B-MED
depressive	I-MED
disorder	I-MED
mdd	B-MED
.	O
	
to	O
date	O
,	O
studies	B-MED
investigating	B-MED
possible	O
associations	B-MED
between	O
birth	B-MED
weight	I-MED
and	O
bipolar	B-MED
disorder	I-MED
bd	B-MED
,	O
or	O
personality	B-MED
traits	I-MED
known	O
to	O
predispose	B-MED
to	O
affective	B-MED
disorders	I-MED
such	O
as	O
neuroticism	B-MED
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	B-MED
.	O
	
to	O
assess	B-MED
whether	O
very	B-MED
low	I-MED
birth	I-MED
weight	I-MED
<1500	O
g	O
and	O
low	B-MED
birth	I-MED
weight	I-MED
1500-2490	O
g	O
were	O
associated	B-MED
with	I-MED
higher	B-MED
neuroticism	I-MED
scores	B-MED
assessed	B-MED
in	O
middle	B-MED
age	I-MED
,	O
and	O
lifetime	B-MED
history	I-MED
of	O
either	O
mdd	B-MED
or	O
bd	B-MED
.	O
	
we	O
controlled	O
for	O
possible	O
confounding	B-MED
factors	I-MED
.	O
	
retrospective	B-MED
cohort	B-MED
study	I-MED
using	O
baseline	B-MED
data	B-MED
on	O
the	O
83	O
545	O
uk	B-MED
biobank	B-MED
participants	B-MED
with	O
detailed	O
mental	B-MED
health	I-MED
and	O
birth	B-MED
weight	I-MED
data	B-MED
.	O
	
main	O
outcomes	B-MED
were	O
prevalent	O
mdd	B-MED
and	O
bd	B-MED
,	O
and	O
neuroticism	B-MED
assessed	B-MED
using	O
the	O
eysenck	B-MED
personality	I-MED
inventory	I-MED
neuroticism	I-MED
scale	I-MED
-	I-MED
revised	I-MED
epin-r	B-MED
.	O
	
referent	O
to	O
normal	B-MED
birth	I-MED
weight	I-MED
,	O
very	B-MED
low	I-MED
/	O
low	B-MED
birth	I-MED
weight	I-MED
were	O
associated	O
with	O
higher	B-MED
neuroticism	I-MED
scores	B-MED
,	O
increased	B-MED
mdd	B-MED
and	O
bd	B-MED
.	O
	
the	O
associations	B-MED
between	O
birth	B-MED
weight	I-MED
category	B-MED
and	O
mdd	B-MED
were	O
partially	O
mediated	O
by	O
higher	B-MED
neuroticism	I-MED
.	O
	
these	O
findings	B-MED
suggest	O
that	O
intrauterine	B-MED
programming	B-MED
may	O
play	O
a	O
role	B-MED
in	O
lifetime	B-MED
vulnerability	B-MED
to	O
affective	B-MED
disorders	I-MED
.	O
	
dna	B-MED
annealing	I-MED
by	O
redβ	B-MED
is	O
insufficient	O
for	O
homologous	B-MED
recombination	I-MED
and	O
the	O
additional	O
requirements	O
involve	O
intra-	B-MED
and	I-MED
inter-molecular	I-MED
interactions	I-MED
single	B-MED
strand	I-MED
annealing	I-MED
proteins	I-MED
ssaps	B-MED
like	O
redβ	B-MED
initiate	O
homologous	B-MED
recombination	I-MED
by	O
annealing	B-MED
complementary	I-MED
dna	I-MED
strands	I-MED
.	O
	
we	O
show	O
that	O
c-terminally	B-MED
truncated	I-MED
redβ	B-MED
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	B-MED
and	O
nucleoprotein	B-MED
filament	I-MED
formation	I-MED
,	O
is	O
unable	O
to	O
mediate	O
homologous	B-MED
recombination	I-MED
.	O
	
mutations	B-MED
of	O
the	O
c-terminal	B-MED
domain	I-MED
were	O
evaluated	O
using	O
both	O
single	B-MED
-	O
and	O
double	B-MED
stranded	I-MED
ss	B-MED
and	O
ds	B-MED
substrates	O
in	O
recombination	B-MED
assays	B-MED
.	O
	
mutations	B-MED
of	O
critical	B-MED
amino	I-MED
acids	I-MED
affected	O
either	O
dsdna	B-MED
recombination	B-MED
or	O
both	O
ssdna	B-MED
and	O
dsdna	B-MED
recombination	I-MED
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsdna	B-MED
recombination	I-MED
and	O
the	O
second	O
for	O
recombination	B-MED
per	O
se	O
.	O
	
as	O
evaluated	O
by	O
co-immunoprecipitation	B-MED
experiments	I-MED
,	O
the	O
dsdna	B-MED
recombination	I-MED
function	I-MED
relates	O
to	O
the	O
redα	B-MED
-	O
redβ	B-MED
protein-protein	B-MED
interaction	I-MED
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
c-terminal	B-MED
domain	I-MED
but	O
also	O
a	O
region	O
near	O
the	O
n-terminus	B-MED
.	O
	
because	O
the	O
nucleoprotein	B-MED
filament	I-MED
formed	I-MED
with	O
c-terminally	B-MED
truncated	I-MED
redβ	B-MED
has	O
altered	O
properties	O
,	O
the	O
second	O
c-terminal	B-MED
function	I-MED
could	O
be	O
due	O
to	O
an	O
interaction	B-MED
required	O
for	O
functional	B-MED
filaments	B-MED
.	O
	
alternatively	O
the	O
second	O
c-terminal	B-MED
function	I-MED
could	O
indicate	O
a	O
requirement	O
for	O
a	O
redβ	B-MED
-	O
host	B-MED
factor	I-MED
interaction	I-MED
.	O
	
these	O
data	O
further	O
advance	O
the	O
model	O
for	O
red	B-MED
recombination	I-MED
and	O
the	O
proposition	O
that	O
redβ	B-MED
and	O
rad52	B-MED
ssaps	B-MED
multi-drug-resistant	B-MED
acinetobacter	B-MED
calcoaceticus-acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
infection	B-MED
outbreak	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
in	O
a	O
veterinary	B-MED
hospital	I-MED
members	O
of	O
the	O
acinetobacter	B-MED
calcoaceticus-acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
cause	O
severe	B-MED
outbreaks	B-MED
in	O
humans	B-MED
,	O
and	O
are	O
increasingly	B-MED
reported	B-MED
in	O
animals	B-MED
.	O
	
a	O
retrospective	B-MED
study	I-MED
,	O
describing	O
a	O
severe	B-MED
outbreak	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
caused	O
by	O
a	O
multidrug	B-MED
resistant	I-MED
member	I-MED
of	O
the	O
acinetobacter	B-MED
calcoaceticus-acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
in	O
a	O
veterinary	B-MED
hospital	I-MED
,	O
between	O
july	O
2010	O
and	O
november	O
2012	O
.	O
	
the	O
study	B-MED
included	B-MED
19	O
dogs	B-MED
and	O
4	O
cats	B-MED
.	O
	
acinetobacter	B-MED
calcoaceticus-acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
bacteria	I-MED
were	O
isolated	B-MED
from	O
urine	B-MED
9	O
animals	B-MED
,	O
respiratory	B-MED
tract	I-MED
11	O
,	O
tissues	B-MED
3	O
and	O
blood	B-MED
1	O
.	O
	
the	O
most	B-MED
common	B-MED
infection	B-MED
-	O
associated	B-MED
findings	I-MED
included	B-MED
fever	B-MED
,	O
purulent	B-MED
discharge	I-MED
from	O
endotracheal	B-MED
tubes	I-MED
,	O
hypotension	B-MED
,	O
and	O
neutropaenia	B-MED
.	O
	
infection	B-MED
s	O
led	O
to	O
pneumonia	B-MED
,	O
urinary	B-MED
tract	I-MED
infection	I-MED
,	O
cellulitis	B-MED
and	O
sepsis	B-MED
.	O
	
infection	B-MED
was	O
transmitted	B-MED
in	O
the	O
intensive	B-MED
care	I-MED
unit	I-MED
,	O
where	O
22	O
of	O
23	O
animals	B-MED
were	O
initially	B-MED
hospitalised	B-MED
.	O
	
the	O
mortality	B-MED
rate	I-MED
was	O
70%	O
16	O
of	O
23	O
animals	B-MED
,	O
and	O
was	O
higher	B-MED
in	O
cases	O
of	O
respiratory	B-MED
infection	I-MED
compared	B-MED
to	O
other	O
infections	B-MED
.	O
	
aggressive	O
environmental	B-MED
cleaning	B-MED
and	O
disinfection	B-MED
,	O
with	O
staff	B-MED
education	I-MED
for	O
personal	B-MED
hygiene	I-MED
and	O
antisepsis	B-MED
,	O
sharply	O
decreased	B-MED
the	O
infection	B-MED
incidence	B-MED
.	O
	
health	B-MED
care	I-MED
-	O
associated	B-MED
outbreaks	B-MED
with	O
multidrug	B-MED
resistant	I-MED
acinetobacter	B-MED
calcoaceticus-acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
in	O
dogs	B-MED
and	O
cats	B-MED
are	O
potentially	O
highly	B-MED
fatal	B-MED
and	O
difficult	B-MED
to	O
eradicate	B-MED
,	O
warranting	O
monitoring	B-MED
,	O
antiseptic	B-MED
techniques	B-MED
and	O
judicious	O
antibiotic	B-MED
use	B-MED
.	O
	
manipulation	O
of	O
an	O
existing	O
crystal	B-MED
form	I-MED
unexpectedly	B-MED
results	I-MED
in	O
interwoven	B-MED
packing	I-MED
networks	I-MED
with	O
pseudo-translational	B-MED
symmetry	I-MED
nonribosomal	B-MED
peptide	I-MED
synthetases	I-MED
nrpss	B-MED
are	O
multimodular	B-MED
enzymes	I-MED
that	O
synthesize	B-MED
a	O
myriad	B-MED
of	O
diverse	B-MED
molecules	I-MED
.	O
	
tailoring	B-MED
domains	I-MED
have	O
been	O
co-opted	O
into	O
nrpss	B-MED
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal	B-MED
peptide	I-MED
products	I-MED
.	O
	
linear	B-MED
gramicidin	I-MED
synthetase	I-MED
contains	B-MED
a	O
unique	O
formylation	B-MED
-	O
tailoring	B-MED
domain	I-MED
in	O
its	O
initiation	B-MED
module	I-MED
f-a	B-MED
-	O
pcp	B-MED
.	O
	
the	O
structure	O
of	O
the	O
f-a	B-MED
di-domain	B-MED
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal	B-MED
form	I-MED
which	O
had	O
large	O
solvent	B-MED
channels	B-MED
and	O
no	B-MED
density	I-MED
for	O
the	O
minor	O
asub	B-MED
subdomain	I-MED
.	O
	
an	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	B-MED
by	O
removing	B-MED
the	O
asub	B-MED
subdomain	I-MED
from	O
the	O
construct	O
f-a	B-MED
δ	O
sub	B-MED
in	O
order	O
to	O
produce	O
a	O
crystal	B-MED
that	O
could	O
accommodate	O
the	O
pcp	B-MED
domain	I-MED
.	O
	
in	O
the	O
resulting	O
crystal	B-MED
the	O
original	B-MED
packing	I-MED
network	I-MED
was	O
still	O
present	O
,	O
but	O
a	O
second	B-MED
network	I-MED
with	O
the	O
same	O
packing	B-MED
and	O
almost	O
no	O
contact	O
with	O
the	O
original	B-MED
network	I-MED
took	O
the	O
place	O
of	O
the	O
solvent	B-MED
channels	B-MED
and	O
changed	O
the	O
space	B-MED
group	I-MED
of	I-MED
the	I-MED
crystal	I-MED
.	O
	
folate	B-MED
-based	O
single	B-MED
cell	I-MED
screening	I-MED
using	O
surface	B-MED
enhanced	I-MED
raman	I-MED
microimaging	I-MED
recent	O
progress	O
in	O
nanotechnology	B-MED
and	O
its	O
application	O
to	O
biomedical	B-MED
settings	I-MED
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-MED
cancer	I-MED
diagnosis	I-MED
.	O
	
the	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	B-MED
cells	I-MED
,	O
such	O
as	O
the	O
expression	B-MED
of	O
particular	O
plasma	B-MED
membrane	I-MED
molecular	B-MED
receptors	I-MED
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	B-MED
the	I-MED
stage	I-MED
of	I-MED
development	I-MED
of	I-MED
the	I-MED
disease	I-MED
.	O
	
here	O
we	O
report	O
a	O
single	B-MED
cell	I-MED
screening	I-MED
approach	O
based	O
on	O
surface	B-MED
enhanced	I-MED
raman	I-MED
scattering	I-MED
sers	I-MED
microimaging	I-MED
.	O
	
we	O
fabricated	O
a	O
sers-labelled	O
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	O
acid	O
.	O
	
after	O
treating	O
the	O
cells	O
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
three	O
different	O
cell	O
populations	O
from	O
different	O
cell	O
lines	O
cancer	O
hela	O
and	O
pc-3	O
,	O
and	O
normal	O
hacat	O
lines	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	O
binding	O
proteins	O
.	O
	
the	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	O
cell	O
lines	O
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
sers	B-MED
signal	O
measured	O
on	O
cancer	O
cells	O
.	O
	
these	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	O
cell	O
diagnostics	O
and	O
,	O
potentially	O
,	O
in	O
theranostics	B-MED
self-reported	B-MED
occupational	B-MED
injuries	I-MED
among	O
industrial	B-MED
beef	B-MED
slaughterhouse	B-MED
workers	B-MED
in	O
the	O
midwestern	B-MED
united	I-MED
states	I-MED
although	O
workers	B-MED
in	O
meatpacking	B-MED
facilities	I-MED
in	O
the	O
united	B-MED
states	I-MED
experience	O
high	B-MED
rates	I-MED
of	O
occupational	B-MED
injury	I-MED
,	O
their	O
injury	B-MED
experiences	O
have	O
received	O
limited	O
research	B-MED
attention	O
.	O
	
prior	O
research	B-MED
indicates	I-MED
underreporting	B-MED
in	O
injury	B-MED
rates	I-MED
in	O
this	O
industry	B-MED
as	O
well	O
significant	O
variation	O
in	O
injury	B-MED
rates	I-MED
among	O
facilities	O
.	O
	
to	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational	B-MED
injury	I-MED
among	O
meatpacking	B-MED
workers	B-MED
,	O
we	O
conducted	O
a	O
cross-sectional	B-MED
study	I-MED
of	O
workers	B-MED
employed	O
at	O
an	O
industrial	B-MED
beefpacking	I-MED
plant	I-MED
in	O
nebraska	B-MED
,	O
united	B-MED
states	I-MED
n	O
=	O
137	O
and	O
interviewed	O
workers	B-MED
about	O
recent	O
injury	B-MED
experiences	O
.	O
	
we	O
assessed	O
frequency	O
,	O
cause	O
and	O
nature	O
of	O
self-reported	B-MED
injury	B-MED
.	O
	
we	O
estimated	O
annual	B-MED
incidence	I-MED
rates	I-MED
of	O
self-reported	B-MED
injuries	B-MED
using	O
the	O
osha	B-MED
formula	B-MED
and	O
compared	O
these	O
rates	O
to	O
industry-wide	B-MED
data	I-MED
.	O
	
we	O
also	O
evaluated	O
psychological	B-MED
distress	I-MED
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
kessler-6	B-MED
scale	I-MED
to	O
assess	O
whether	O
distress	B-MED
was	O
associated	B-MED
with	I-MED
recent	O
occupational	B-MED
injury	I-MED
.	O
	
in	O
this	O
study	O
,	O
15.1	O
of	O
workers	O
experienced	O
occupational	O
injuries	O
that	O
required	O
time	O
off	O
work	O
,	O
job	O
transfer	O
,	O
or	O
restriction	O
during	O
the	O
past	O
three	O
months	O
.	O
	
the	O
estimated	O
annual	O
incidence	O
rate	O
was	O
15.2	O
injuries	O
per	O
100	O
full-time	O
workers	O
for	O
these	O
injuries	O
at	O
this	O
plant	O
.	O
	
rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50%	O
of	O
injuries	O
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20%	O
of	O
injuries	O
.	O
	
use	O
of	O
metal	O
mesh	O
sleeves	O
por	O
0.10	O
p	O
=	O
0.008	O
and	O
metal	O
mesh	O
gloves	O
por	O
0.41	O
p	O
=	O
0.05	O
were	O
associated	O
with	O
reduced	O
risk	O
of	O
injury	B-MED
.	O
	
use	O
of	O
a	O
carbon	O
steel	O
for	O
knife	O
sharpening	O
por	O
5.2	O
p	O
=	O
0.02	O
was	O
associated	O
with	O
elevated	O
risk	O
of	O
moderate	O
and	O
severe	O
injury	O
.	O
	
there	O
were	O
no	O
associations	O
between	O
self-reported	O
occupational	O
injury	O
and	O
overall	O
measures	O
of	O
psychological	O
distress	O
.	O
	
self-reported	O
incidence	O
rate	O
of	O
severe	O
injury	O
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry	O
estimates	O
.	O
	
worker	O
self-reports	O
may	O
illustrate	O
key	O
areas	O
for	O
injury	O
prevention	I-MED
the	O
effect	B-MED
of	O
l-arginine	B-MED
on	O
dural	B-MED
healing	I-MED
after	O
experimentally	O
induced	B-MED
dural	B-MED
defect	B-MED
in	O
a	O
rat	B-MED
model	B-MED
incomplete	B-MED
repair	B-MED
of	O
the	O
dura	B-MED
mater	I-MED
may	O
result	B-MED
in	O
numerous	B-MED
complications	B-MED
such	O
as	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
and	O
meningitis	B-MED
.	O
	
for	O
this	O
reason	O
,	O
accurate	B-MED
repair	B-MED
of	O
the	O
dura	B-MED
mater	I-MED
is	O
essential	B-MED
.	O
	
in	O
this	O
study	O
,	O
the	O
effect	B-MED
of	O
systemic	B-MED
and	O
local	B-MED
supplementation	B-MED
of	O
l-arginine	B-MED
on	O
dural	B-MED
healing	I-MED
was	O
evaluated	O
.	O
	
thirty	O
male	B-MED
wistar	B-MED
rats	I-MED
were	O
used	O
and	O
divided	B-MED
into	O
control	B-MED
,	O
local	B-MED
,	O
and	O
systemic	B-MED
l-arginine	B-MED
groups	B-MED
,	O
with	O
10	O
rats	B-MED
in	O
each	O
.	O
	
in	O
each	O
group	B-MED
,	O
a	O
5-mm	O
experimental	B-MED
incision	I-MED
was	O
made	O
at	O
the	O
lumbar	B-MED
segment	I-MED
of	I-MED
the	I-MED
dura	I-MED
mater	I-MED
and	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
was	O
induced	B-MED
.	O
	
each	O
group	B-MED
was	O
divided	B-MED
into	O
2	O
subgroups	B-MED
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-MED
,	O
the	O
rats	B-MED
were	O
killed	B-MED
and	O
the	O
damaged	B-MED
segments	B-MED
of	O
the	O
dura	B-MED
were	O
separated	B-MED
,	O
histologically	B-MED
evaluated	O
and	O
the	O
dural	B-MED
healing	I-MED
indicators	B-MED
including	O
cell	B-MED
types	I-MED
,	O
granulation	B-MED
tissue	I-MED
formation	B-MED
,	O
collagen	B-MED
deposit	B-MED
,	O
and	O
vascularization	B-MED
were	O
compared	B-MED
between	O
groups	B-MED
.	O
	
the	O
systematic	B-MED
supplementation	B-MED
of	O
l-arginine	B-MED
showed	O
a	O
significant	B-MED
effect	B-MED
in	O
dural	B-MED
healing	I-MED
compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
.	O
	
after	O
the	O
first	O
week	B-MED
,	O
granulation	B-MED
formation	B-MED
increased	B-MED
considerably	O
p	O
<	O
0.031	O
,	O
and	O
after	O
6	O
weeks	B-MED
,	O
collagen	B-MED
deposition	B-MED
and	O
neovascularization	B-MED
were	O
significantly	O
different	B-MED
compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
p	O
<	O
0.030	O
p	O
<	O
0.009	O
.	O
	
in	O
comparison	B-MED
between	O
different	B-MED
groups	B-MED
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-MED
,	O
maximum	B-MED
changes	B-MED
in	O
healing	B-MED
indicators	B-MED
were	O
observed	B-MED
in	O
the	O
systemic	B-MED
group	B-MED
and	O
the	O
least	O
variations	B-MED
were	O
related	O
to	O
the	O
control	B-MED
group	I-MED
.	O
	
the	O
systemic	B-MED
supplementation	B-MED
of	O
l-arginine	B-MED
may	O
accelerate	B-MED
dural	B-MED
healing	I-MED
by	O
increasing	B-MED
the	O
level	B-MED
of	O
granulation	B-MED
tissue	I-MED
formation	B-MED
,	O
collagen	B-MED
deposition	B-MED
,	O
and	O
birth	B-MED
preparedness	I-MED
and	I-MED
complication	I-MED
readiness	I-MED
practice	I-MED
and	O
associated	B-MED
factors	B-MED
among	O
pregnant	B-MED
women	I-MED
,	O
northwest	B-MED
ethiopia	I-MED
background	O
.	O
	
little	O
is	O
known	O
about	O
birth	B-MED
preparedness	I-MED
and	I-MED
complication	I-MED
readiness	I-MED
bpcr	B-MED
plan	B-MED
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal	B-MED
mortality	I-MED
.	O
	
therefore	O
,	O
this	O
study	B-MED
was	O
done	O
to	O
assess	B-MED
the	O
status	B-MED
of	O
bpcr	B-MED
and	O
associated	B-MED
factors	B-MED
among	O
pregnant	B-MED
women	I-MED
in	O
south	B-MED
wollo	I-MED
,	O
northwest	B-MED
ethiopia	I-MED
,	O
by	O
involving	O
819	O
pregnant	B-MED
women	I-MED
from	O
march	O
to	O
april	O
,	O
2014	O
.	O
	
data	B-MED
were	O
collected	O
by	O
using	O
pretested	O
interviewer	B-MED
administered	B-MED
questionnaire	I-MED
and	O
analyzed	B-MED
using	O
a	O
computer	B-MED
program	I-MED
of	O
spss	B-MED
version	I-MED
20.00	I-MED
.	O
	
results	B-MED
.	O
	
pregnant	B-MED
women	I-MED
who	O
were	O
prepared	B-MED
for	O
at	O
least	O
three	O
elements	B-MED
of	O
bpcr	B-MED
were	O
24.1	O
.	O
	
pregnant	B-MED
women	I-MED
knowing	O
at	O
least	O
three	O
key	O
danger	B-MED
signs	I-MED
during	O
pregnancy	B-MED
,	O
delivery	B-MED
,	O
and	O
postnatal	B-MED
period	I-MED
were	O
23.2	O
,	O
22.6	O
,	O
and	O
9.6	O
,	O
respectively	O
.	O
	
women	B-MED
having	O
secondary	B-MED
education	I-MED
and	O
higher	O
were	O
6.20	O
95%	O
ci	B-MED
=	O
1.36	O
,	O
28.120	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-MED
than	O
illiterates	B-MED
.	O
	
women	B-MED
having	O
a	O
lifetime	B-MED
history	I-MED
of	O
stillbirth	B-MED
5.80	O
1.13	O
,	O
29.63	O
,	O
attending	B-MED
anc	B-MED
for	O
last	O
child	B-MED
pregnancy	B-MED
5.44	O
2.07	O
,	O
14.27	O
,	O
participating	B-MED
in	O
community	B-MED
bpcr	B-MED
group	B-MED
discussion	I-MED
4.36	O
1.17	O
,	O
16.26	O
,	O
and	O
having	O
their	O
male	B-MED
partner	B-MED
involved	O
in	O
bpcr	B-MED
counseling	B-MED
during	O
anc	B-MED
follow-up	B-MED
4.45	O
1.95	O
,	O
10.16	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-MED
.	O
	
conclusions	B-MED
.	O
	
bpcr	B-MED
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health	B-MED
communication	I-MED
by	O
involving	O
partner	B-MED
in	O
bpcr	B-MED
counseling	B-MED
.	O
	
fluoranthene	B-MED
degradation	B-MED
and	O
binding	B-MED
mechanism	B-MED
study	B-MED
based	O
on	O
the	O
active-site	B-MED
structure	B-MED
of	O
ring-hydroxylating	B-MED
dioxygenase	I-MED
in	O
microbacterium	B-MED
paraoxydans	I-MED
jpm1	I-MED
in	O
this	O
study	B-MED
,	O
a	O
gram-positive	B-MED
fluoranthene-degrading	I-MED
bacterial	I-MED
strain	B-MED
was	O
isolated	B-MED
from	O
crude	B-MED
oil	I-MED
in	O
dagang	B-MED
oilfield	I-MED
and	O
identified	B-MED
as	O
microbacterium	B-MED
paraoxydans	I-MED
jpm1	I-MED
by	O
the	O
analysis	B-MED
of	O
16s	B-MED
rdna	I-MED
sequence	B-MED
.	O
	
after	O
25	O
days	B-MED
of	O
incubation	B-MED
,	O
the	O
strain	B-MED
jpm1	B-MED
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	B-MED
amount	B-MED
of	O
fluoranthene	B-MED
.	O
	
moreover	O
,	O
four	O
metabolites	B-MED
9-fluorenone-1-carboxylic	B-MED
acid	I-MED
,	O
9-fluorenone	B-MED
,	O
phthalic	B-MED
acid	I-MED
,	O
and	O
benzoic	B-MED
acid	I-MED
were	O
detected	O
in	O
the	O
culture	B-MED
solution	I-MED
.	O
	
the	O
gene	B-MED
sequence	I-MED
encoding	B-MED
the	O
aromatic-ring-hydroxylating	B-MED
dioxygenase	I-MED
was	O
amplified	B-MED
in	O
the	O
strain	B-MED
jpm1	B-MED
by	O
pcr	B-MED
.	O
	
based	O
on	O
the	O
translated	O
protein	B-MED
sequence	I-MED
,	O
a	O
homology	B-MED
modeling	I-MED
method	I-MED
was	O
applied	O
to	O
build	O
the	O
crystal	B-MED
structure	I-MED
of	O
dioxygenase	B-MED
.	O
	
subsequently	O
,	O
the	O
interaction	B-MED
mechanism	B-MED
between	O
fluoranthene	B-MED
and	O
the	O
active	B-MED
site	I-MED
of	O
dioxygenase	B-MED
was	O
simulated	B-MED
and	O
analyzed	B-MED
by	O
molecular	B-MED
docking	I-MED
.	O
	
consequently	O
,	O
a	O
feasible	O
degrading	B-MED
pathway	B-MED
of	O
fluoranthene	B-MED
in	O
the	O
strain	B-MED
jpm1	B-MED
was	O
proposed	O
based	O
on	O
the	O
metabolites	B-MED
and	O
the	O
interaction	B-MED
analyses	I-MED
.	O
	
additionally	O
,	O
the	O
thermodynamic	B-MED
analysis	I-MED
showed	O
that	O
the	O
strain	B-MED
jpm1	B-MED
had	O
high	B-MED
tolerance	B-MED
for	O
fluoranthene	B-MED
,	O
and	O
the	O
influence	B-MED
of	O
fluoranthene	B-MED
for	O
the	O
bacterial	B-MED
growth	B-MED
activity	O
was	O
negligible	B-MED
under	O
100	O
to	O
400	O
mg	O
l	O
concentrations	B-MED
.	O
	
taken	O
together	O
,	O
this	O
study	B-MED
indicates	O
that	O
the	O
strain	B-MED
jpm1	B-MED
has	O
high	O
potential	B-MED
for	O
further	O
study	B-MED
in	O
bioremediation	B-MED
of	O
polycyclic	B-MED
aromatic	I-MED
hydrocarbon	I-MED
pah	B-MED
contaminated	B-MED
sites	B-MED
.	O
	
ultrasonography	B-MED
for	O
acute	B-MED
appendicitis	I-MED
-	O
the	O
way	O
it	O
looks	O
today	O
despite	O
sophisticated	O
physical	B-MED
examination	I-MED
and	O
laboratory	B-MED
support	I-MED
,	O
diagnosis	B-MED
of	O
acute	B-MED
appendicitis	I-MED
remained	O
challenging	O
in	O
clinical	B-MED
practice	I-MED
with	O
a	O
negative	B-MED
appendectomy	I-MED
rate	B-MED
of	O
15	O
-	O
30	O
%	O
.	O
	
as	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-MED
us	B-MED
has	O
been	O
proven	O
a	O
reliable	B-MED
diagnostic	B-MED
method	I-MED
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	B-MED
presentation	B-MED
and	O
enables	O
to	O
rule	B-MED
out	I-MED
many	O
differential	B-MED
diagnoses	I-MED
recent	O
publications	B-MED
emphasized	O
the	O
role	O
of	O
multidetector	B-MED
computed	I-MED
tomography	I-MED
ct	B-MED
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	B-MED
negative	I-MED
findings	I-MED
at	O
operation	B-MED
.	O
	
extensive	B-MED
as	O
well	O
as	O
uncritical	B-MED
application	I-MED
of	O
this	O
method	O
even	O
in	O
children	B-MED
inevitably	O
causes	O
substantial	O
radiation	B-MED
exposure	I-MED
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	B-MED
performance	B-MED
of	O
us	B-MED
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-MED
or	O
economic	B-MED
preponderance	B-MED
recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
us	B-MED
and	O
ct	B-MED
in	O
acute	B-MED
appendicitis	I-MED
.	O
	
therefore	O
,	O
1	O
generation	O
after	O
us	B-MED
with	I-MED
graded	I-MED
compression	I-MED
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-MED
acute	B-MED
appendicitis	I-MED
puylaert	O
,	O
a	O
visual	B-MED
arousal	B-MED
fostering	B-MED
its	O
role	O
and	O
performance	O
in	O
clinical	B-MED
medicine	I-MED
mesenchymal	B-MED
stem	I-MED
cells	I-MED
enhance	B-MED
the	O
oncolytic	B-MED
effect	B-MED
of	O
newcastle	B-MED
disease	I-MED
virus	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
glioma	B-MED
stem	B-MED
cells	I-MED
via	O
the	O
secretion	B-MED
of	O
trail	B-MED
newcastle	B-MED
disease	I-MED
virus	I-MED
ndv	B-MED
is	O
an	O
avian	B-MED
paramyxovirus	I-MED
,	O
which	O
selectively	O
exerts	B-MED
oncolytic	B-MED
effects	B-MED
in	O
cancer	B-MED
cells	I-MED
.	O
	
mesenchymal	B-MED
stem	I-MED
cells	I-MED
mscs	B-MED
have	O
been	O
reported	O
to	O
affect	O
tumor	B-MED
growth	I-MED
and	O
deliver	B-MED
anti-tumor	B-MED
agents	I-MED
to	O
experimental	B-MED
glioblastoma	B-MED
gbm	B-MED
.	O
	
here	O
,	O
we	O
explored	O
the	O
effects	B-MED
of	I-MED
ndv	B-MED
-	O
infected	B-MED
mscs	B-MED
derived	O
from	O
different	O
sources	B-MED
,	O
on	O
glioma	B-MED
cells	B-MED
and	O
glioma	B-MED
stem	B-MED
cells	I-MED
gscs	B-MED
and	O
the	O
mechanisms	B-MED
involved	O
in	O
their	O
effects	B-MED
.	O
	
the	O
glioma	B-MED
cell	B-MED
lines	I-MED
a172	B-MED
and	O
u87	B-MED
and	O
primary	B-MED
gscs	B-MED
that	O
were	O
generated	B-MED
from	O
gbm	B-MED
tumors	B-MED
were	O
used	O
in	O
this	O
study	B-MED
.	O
	
mscs	B-MED
derived	B-MED
from	O
bone	B-MED
marrow	I-MED
,	O
adipose	B-MED
tissue	I-MED
or	O
umbilical	B-MED
cord	I-MED
were	O
infected	B-MED
with	O
ndv	B-MED
mth-68/h	B-MED
.	O
	
the	O
ability	B-MED
of	O
these	O
cells	B-MED
to	O
deliver	B-MED
the	O
virus	B-MED
to	O
glioma	B-MED
cell	B-MED
lines	I-MED
and	O
gscs	B-MED
and	O
the	O
effects	B-MED
of	I-MED
ndv	B-MED
-	O
infected	B-MED
mscs	B-MED
on	O
cell	B-MED
death	I-MED
and	O
on	O
the	O
stemness	B-MED
and	O
self-renewal	B-MED
of	O
gscs	B-MED
were	O
examined	B-MED
.	O
	
the	O
mechanisms	B-MED
involved	B-MED
in	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
the	O
ndv	B-MED
-	O
infected	B-MED
mscs	B-MED
and	O
their	O
influence	B-MED
on	O
the	O
radiation	B-MED
sensitivity	I-MED
of	O
gscs	B-MED
were	O
examined	B-MED
as	O
well	O
.	O
	
ndv	B-MED
induced	B-MED
a	O
dose-dependent	B-MED
cell	B-MED
death	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
a	O
low	B-MED
level	B-MED
of	O
apoptosis	B-MED
and	O
inhibition	B-MED
of	O
self-renewal	B-MED
in	O
gscs	B-MED
.	O
	
mscs	B-MED
derived	B-MED
from	O
bone	B-MED
marrow	I-MED
,	O
adipose	B-MED
and	O
umbilical	B-MED
cord	I-MED
that	O
were	O
infected	B-MED
with	O
ndv	B-MED
delivered	B-MED
the	O
virus	B-MED
to	O
co-cultured	B-MED
glioma	B-MED
cells	B-MED
and	O
gscs	B-MED
.	O
	
conditioned	B-MED
medium	I-MED
of	O
ndv	B-MED
-	O
infected	B-MED
mscs	B-MED
induced	B-MED
higher	B-MED
level	B-MED
of	O
apoptosis	B-MED
in	O
the	O
tumor	B-MED
cells	I-MED
compared	B-MED
with	O
the	O
apoptosis	B-MED
induced	B-MED
by	O
their	O
direct	B-MED
infection	I-MED
with	O
similar	B-MED
virus	B-MED
titers	I-MED
.	O
	
these	O
results	B-MED
suggest	B-MED
that	O
factor	B-MED
secreted	B-MED
by	O
the	O
infected	B-MED
mscs	B-MED
sensitized	B-MED
the	O
glioma	B-MED
cells	B-MED
to	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
ndv	B-MED
.	O
	
we	O
identified	B-MED
trail	B-MED
as	O
a	O
mediator	B-MED
of	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
the	O
infected	B-MED
mscs	B-MED
and	O
demonstrated	B-MED
that	O
trail	B-MED
synergized	O
with	O
ndv	B-MED
in	O
the	O
induction	B-MED
of	O
cell	B-MED
death	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
gscs	B-MED
.	O
	
moreover	O
,	O
conditioned	B-MED
medium	B-MED
of	O
infected	B-MED
mscs	B-MED
enhanced	B-MED
the	O
sensitivity	O
of	O
gscs	B-MED
to	O
γ-radiation	B-MED
.	O
	
ndv	B-MED
-	O
infected	B-MED
umbilical	B-MED
cord	I-MED
-	O
derived	B-MED
mscs	B-MED
may	O
provide	O
a	O
novel	B-MED
effective	B-MED
therapeutic	B-MED
approach	B-MED
for	O
targeting	B-MED
gscs	B-MED
and	O
gbm	B-MED
and	O
for	O
sensitizing	O
these	O
tumors	B-MED
to	O
importance	B-MED
of	O
ecological	B-MED
factors	I-MED
and	O
colony	B-MED
handling	B-MED
for	O
optimizing	B-MED
health	B-MED
status	I-MED
of	O
apiaries	B-MED
in	O
mediterranean	B-MED
ecosystems	B-MED
we	O
analyzed	B-MED
six	O
apiaries	B-MED
in	O
several	O
natural	B-MED
environments	I-MED
with	O
a	O
mediterranean	B-MED
ecosystem	B-MED
in	O
madrid	B-MED
,	O
central	B-MED
spain	I-MED
,	O
in	O
order	O
to	O
understand	B-MED
how	O
landscape	B-MED
and	O
management	B-MED
characteristics	B-MED
may	O
influence	B-MED
apiary	B-MED
health	B-MED
and	O
bee	B-MED
production	O
in	O
the	O
long	B-MED
term	I-MED
.	O
	
we	O
focused	B-MED
on	O
five	O
criteria	B-MED
habitat	B-MED
quality	B-MED
,	O
landscape	B-MED
heterogeneity	B-MED
,	O
climate	B-MED
,	O
management	B-MED
and	O
health	B-MED
,	O
as	O
well	O
as	O
30	O
subcriteria	B-MED
,	O
and	O
we	O
used	O
the	O
analytic	B-MED
hierarchy	I-MED
process	I-MED
ahp	B-MED
to	O
rank	B-MED
them	O
according	O
to	O
relevance	B-MED
.	O
	
habitat	B-MED
quality	B-MED
proved	O
to	O
have	O
the	O
highest	O
relevance	B-MED
,	O
followed	O
by	O
beehive	B-MED
management	B-MED
.	O
	
within	O
habitat	B-MED
quality	B-MED
,	O
the	O
following	O
subcriteria	B-MED
proved	O
to	O
be	O
most	O
relevant	B-MED
orographic	B-MED
diversity	I-MED
,	O
elevation	B-MED
range	B-MED
and	O
important	B-MED
plant	B-MED
species	B-MED
located	B-MED
1.5	O
km	O
from	O
the	O
apiary	B-MED
.	O
	
the	O
most	O
important	B-MED
subcriteria	B-MED
under	O
beehive	B-MED
management	B-MED
were	O
honey	B-MED
production	B-MED
,	O
movement	O
of	O
the	O
apiary	B-MED
to	O
a	O
location	B-MED
with	O
a	O
higher	O
altitude	B-MED
and	O
wax	B-MED
renewal	B-MED
.	O
	
temperature	B-MED
was	O
the	O
most	O
important	O
subcriterion	B-MED
under	O
climate	B-MED
,	O
while	O
pathogen	B-MED
and	O
varroa	B-MED
loads	B-MED
were	O
the	O
most	O
significant	B-MED
under	O
health	B-MED
.	O
	
two	O
of	O
the	O
six	O
apiaries	B-MED
showed	O
the	O
best	B-MED
values	I-MED
in	O
the	O
ahp	B-MED
analysis	B-MED
and	O
showed	O
annual	B-MED
honey	B-MED
production	B-MED
of	O
70	O
and	O
28	O
kg/	O
colony	B-MED
.	O
	
this	O
high	O
productivity	B-MED
was	O
due	O
primarily	O
to	O
high	O
elevation	B-MED
range	B-MED
and	O
high	O
orographic	B-MED
diversity	I-MED
,	O
which	O
favored	O
high	O
habitat	B-MED
quality	B-MED
.	O
	
in	O
addition	O
,	O
one	O
of	O
these	O
apiaries	B-MED
showed	O
the	O
best	B-MED
value	I-MED
for	O
beehive	B-MED
management	B-MED
,	O
while	O
the	O
other	O
showed	O
the	O
best	B-MED
value	I-MED
for	O
health	B-MED
,	O
reflected	O
in	O
the	O
low	B-MED
pathogen	B-MED
load	B-MED
and	O
low	B-MED
average	B-MED
number	B-MED
of	O
viruses	B-MED
.	O
	
these	O
results	B-MED
highlight	O
the	O
importance	B-MED
of	O
environmental	B-MED
factors	I-MED
and	O
good	O
sanitary	B-MED
practices	I-MED
to	O
maximize	O
apiary	B-MED
health	B-MED
and	O
honey	B-MED
productivity	B-MED
.	O
	
chordoma	B-MED
dedifferentiation	I-MED
after	O
proton	B-MED
beam	I-MED
therapy	I-MED
a	O
case	B-MED
report	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
chordoma	B-MED
is	O
a	O
rare	B-MED
invasive	B-MED
bone	B-MED
tumor	I-MED
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	B-MED
.	O
	
a	O
total	O
of	O
three	O
primary	B-MED
histological	B-MED
varieties	I-MED
have	O
been	O
identified	B-MED
conventional	B-MED
,	O
chondroid	B-MED
,	O
and	O
dedifferentiated	B-MED
.	O
	
we	O
report	B-MED
a	O
case	B-MED
of	O
an	O
8-year-old	O
white	B-MED
girl	B-MED
who	O
presented	O
with	O
conventional	B-MED
chordoma	I-MED
,	O
was	O
treated	B-MED
with	O
surgical	B-MED
resection	I-MED
and	O
mixed	B-MED
proton	B-MED
and	O
photon	B-MED
beam	I-MED
therapy	I-MED
,	O
and	O
had	O
a	O
recurrence	B-MED
in	O
the	O
resection	B-MED
cavity	I-MED
2.5	O
years	O
later	O
with	O
dedifferentiated	B-MED
morphology	I-MED
.	O
	
the	O
recurrent	B-MED
tumor	I-MED
did	O
not	O
express	B-MED
brachyury	B-MED
,	O
a	O
recently	B-MED
identified	B-MED
protein	B-MED
specific	B-MED
to	O
tissue	B-MED
of	O
notochordal	B-MED
origin	B-MED
.	O
	
the	O
short	B-MED
time	B-MED
period	I-MED
between	O
radiation	B-MED
therapy	I-MED
and	O
dedifferentiation	B-MED
,	O
low	B-MED
dose	I-MED
of	O
photons	B-MED
,	O
and	O
rarity	B-MED
of	O
dedifferentiated	B-MED
skull	I-MED
base	I-MED
chordomas	I-MED
in	O
pediatric	B-MED
patients	B-MED
should	O
alert	B-MED
clinicians	B-MED
to	O
the	O
possibility	B-MED
of	O
chordoma	B-MED
dedifferentiation	I-MED
after	O
proton	B-MED
beam	I-MED
therapy	I-MED
.	O
	
volumetric	B-MED
absorptive	I-MED
microsampling	I-MED
at	O
home	B-MED
as	O
an	O
alternative	B-MED
tool	B-MED
for	O
the	O
monitoring	B-MED
of	O
hba1c	B-MED
in	O
diabetes	B-MED
patients	B-MED
microsampling	B-MED
techniques	I-MED
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-MED
collection	I-MED
.	O
	
dried	B-MED
blood	I-MED
spot	I-MED
dbs	I-MED
sampling	I-MED
and	O
blood	B-MED
collection	I-MED
with	O
heparinized	B-MED
capillaries	I-MED
are	O
the	O
standard	B-MED
techniques	B-MED
.	O
	
volumetric	B-MED
absorptive	I-MED
microsampling	I-MED
vams	B-MED
is	O
a	O
novel	O
technique	B-MED
that	O
collects	O
a	O
fixed	O
volume	B-MED
of	O
blood	B-MED
by	O
applying	O
an	O
absorbent	O
tip	B-MED
to	O
a	O
blood	B-MED
drop	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
we	O
explored	O
the	O
feasibility	O
of	O
hba1c	B-MED
monitoring	B-MED
with	O
vams	B-MED
sampling	I-MED
at	O
home	B-MED
and	O
analysis	B-MED
in	O
the	O
laboratory	B-MED
.	O
	
diabetic	B-MED
patients	B-MED
were	O
enrolled	O
in	O
this	O
study	B-MED
during	O
consultation	B-MED
with	O
the	O
endocrinologist	B-MED
.	O
	
a	O
venous	B-MED
adults	B-MED
or	O
capillary	B-MED
children	I-MED
sample	I-MED
was	O
taken	O
for	O
immediate	O
hba1c	B-MED
analysis	B-MED
.	O
	
dbs	B-MED
n=1	O
and	O
dried	B-MED
vams	I-MED
n=2	O
were	O
collected	O
at	O
home	B-MED
and	O
sent	O
to	O
the	O
laboratory	B-MED
.	O
	
for	O
25	O
pediatric	B-MED
patients	B-MED
one	O
vams	B-MED
was	O
collected	O
during	O
consultation	B-MED
for	O
immediate	O
analysis	B-MED
without	O
drying	O
,	O
referred	O
to	O
as	O
""""	O
wet	B-MED
vams	I-MED
""""	O
.	O
	
hba1c	B-MED
analyses	B-MED
were	O
performed	O
on	O
a	O
tosoh	B-MED
hlc-723	I-MED
g8	I-MED
high-performance	I-MED
liquid	I-MED
chromatography	I-MED
hplc	I-MED
analyzer	I-MED
.	O
	
the	O
median	O
time	O
between	O
sampling	B-MED
at	O
home	B-MED
and	O
analysis	B-MED
was	O
3	O
days	B-MED
.	O
	
results	B-MED
of	O
hba1c	B-MED
in	O
dried	O
vams	B-MED
showed	O
a	O
poor	O
agreement	O
with	O
venous	B-MED
/	O
capillary	B-MED
blood	I-MED
collected	O
in	O
hospital	B-MED
concordance	B-MED
correlation	I-MED
coefficient	I-MED
ccc	B-MED
=0	O
.	O
	
similar	O
observations	O
were	O
found	O
with	O
standard	B-MED
dbs	B-MED
.	O
	
an	O
excellent	O
agreement	O
was	O
obtained	O
between	O
hba1c	B-MED
results	B-MED
on	O
wet	B-MED
vams	I-MED
ccc	B-MED
=0	O
and	O
standard	B-MED
blood	B-MED
samples	I-MED
.	O
	
patients	B-MED
experienced	O
vams	B-MED
and	O
dbs	B-MED
as	O
easy	B-MED
and	O
convenient	B-MED
to	O
use	B-MED
.	O
	
utilizing	O
equipment	B-MED
standard	B-MED
available	O
in	O
the	O
clinical	B-MED
laboratory	B-MED
,	O
the	O
use	O
of	O
home	B-MED
-sampled	O
dried	B-MED
vams	I-MED
and	O
dbs	B-MED
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-MED
of	O
hba1c	B-MED
.	O
	
however	O
,	O
perfect	O
agreement	O
between	O
hba1c	B-MED
measured	O
on	O
wet	B-MED
vams	I-MED
and	O
capillary	B-MED
microsamples	I-MED
are	O
eyes	B-MED
a	O
mirror	B-MED
of	O
the	O
soul	B-MED
what	O
eye	B-MED
wrinkles	B-MED
reveal	B-MED
about	O
a	O
horse's	B-MED
emotional	B-MED
state	I-MED
finding	O
valid	B-MED
indicators	B-MED
of	O
emotional	B-MED
states	I-MED
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal	B-MED
welfare	I-MED
science	I-MED
.	O
	
here	O
,	O
we	O
investigated	B-MED
in	O
horses	B-MED
whether	O
variation	B-MED
in	O
the	O
expression	B-MED
of	O
eye	B-MED
wrinkles	B-MED
caused	O
by	O
contraction	B-MED
of	O
the	O
inner	B-MED
eyebrow	I-MED
raiser	O
reflects	B-MED
emotional	B-MED
valence	I-MED
.	O
	
by	O
confronting	O
horses	B-MED
with	O
positive	B-MED
and	O
negative	B-MED
conditions	B-MED
,	O
we	O
aimed	O
to	O
induce	B-MED
positive	B-MED
and	O
negative	B-MED
emotional	B-MED
states	I-MED
,	O
hypothesising	B-MED
that	O
positive	B-MED
emotions	B-MED
would	O
reduce	B-MED
whereas	O
negative	B-MED
emotions	B-MED
would	O
increase	B-MED
eye	B-MED
wrinkle	B-MED
expression	B-MED
.	O
	
sixteen	O
horses	B-MED
were	O
individually	O
exposed	B-MED
in	O
a	O
balanced	B-MED
order	O
to	O
two	O
positive	B-MED
grooming	B-MED
,	O
food	B-MED
anticipation	I-MED
and	O
two	O
negative	B-MED
condition	B-MED
s	O
food	B-MED
competition	B-MED
,	O
waving	B-MED
a	O
plastic	B-MED
bag	I-MED
.	O
	
each	O
condition	B-MED
lasted	O
for	O
60	O
seconds	B-MED
and	O
was	O
preceded	O
by	O
a	O
60	O
second	B-MED
control	B-MED
phase	I-MED
.	O
	
throughout	O
both	O
phases	B-MED
,	O
pictures	B-MED
of	O
the	O
eyes	B-MED
were	O
taken	O
,	O
and	O
for	O
each	O
horse	B-MED
four	O
pictures	B-MED
per	O
condition	B-MED
and	O
phase	B-MED
were	O
randomly	B-MED
selected	I-MED
.	O
	
pictures	B-MED
were	O
scored	O
in	O
random	B-MED
order	I-MED
and	O
by	O
two	O
experimenters	B-MED
blind	B-MED
to	O
condition	B-MED
and	O
phase	B-MED
for	O
six	O
outcome	B-MED
measures	I-MED
qualitative	B-MED
impression	B-MED
,	O
eyelid	B-MED
shape	B-MED
,	O
markedness	B-MED
of	O
the	O
wrinkles	B-MED
,	O
presence	B-MED
of	O
eye	B-MED
white	I-MED
,	O
number	B-MED
of	O
wrinkles	B-MED
,	O
and	O
the	O
angle	B-MED
between	O
the	O
line	O
through	O
the	O
eyeball	B-MED
and	O
the	O
highest	B-MED
wrinkle	B-MED
.	O
	
the	O
angle	B-MED
decreased	B-MED
during	O
grooming	B-MED
and	O
increased	B-MED
during	O
food	B-MED
competition	B-MED
compared	B-MED
to	O
control	B-MED
phase	I-MED
s	O
,	O
whereas	O
the	O
two	O
phases	B-MED
did	O
not	O
differ	O
during	O
food	B-MED
anticipation	I-MED
and	O
the	O
plastic	B-MED
bag	I-MED
condition	B-MED
.	O
	
no	B-MED
effects	I-MED
on	O
the	O
other	O
outcome	B-MED
measures	I-MED
were	O
detected	B-MED
.	O
	
taken	O
together	O
,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	B-MED
to	O
assess	B-MED
eye	B-MED
wrinkle	B-MED
expression	B-MED
reliably	O
,	O
of	O
which	O
one	O
measure	B-MED
was	O
affected	B-MED
by	O
the	O
conditions	B-MED
the	O
horses	B-MED
were	O
exposed	B-MED
to	I-MED
.	O
	
variation	B-MED
in	O
eye	B-MED
wrinkle	B-MED
expression	B-MED
might	O
provide	B-MED
valuable	O
information	B-MED
on	O
horse	B-MED
welfare	B-MED
but	O
further	O
validation	B-MED
of	O
specific	B-MED
measures	B-MED
across	O
different	B-MED
conditions	B-MED
effective	B-MED
mercury	B-MED
bioremoval	B-MED
from	O
aqueous	B-MED
solution	I-MED
,	O
and	O
its	O
electrochemical	B-MED
determination	I-MED
this	O
work	O
proposed	O
mercury	B-MED
elimination	B-MED
using	O
agricultural	B-MED
waste	B-MED
allium	B-MED
cepa	I-MED
l	I-MED
the	O
biomass	B-MED
removed	B-MED
99.4	O
of	O
mercury	B-MED
,	O
following	O
a	O
pseudo-second	B-MED
order	I-MED
kinetics	I-MED
r	O
=	O
0.9999	O
.	O
	
the	O
langmuir	B-MED
model	I-MED
was	O
adequately	B-MED
fitted	O
to	O
the	O
adsorption	B-MED
isotherm	I-MED
,	O
thereby	O
obtaining	O
the	O
maximum	B-MED
mercury	B-MED
adsorption	B-MED
capacity	B-MED
of	O
111.1	O
0.3	O
mg	O
g	O
.	O
	
the	O
biomass	B-MED
showed	O
high	B-MED
density	B-MED
of	O
strong	B-MED
mercury	B-MED
chelating	B-MED
groups	I-MED
,	O
thus	O
making	O
it	O
economically	B-MED
attractive	B-MED
.	O
	
also	O
,	O
the	O
implementation	B-MED
of	O
a	O
mercury	B-MED
-	O
selective	B-MED
electrode	I-MED
for	O
continuous	B-MED
determination	B-MED
in	O
real	B-MED
time	I-MED
is	O
proposed	B-MED
this	O
electrode	B-MED
replaces	B-MED
techniques	B-MED
like	O
atomic	B-MED
absorption	I-MED
spectroscopy	I-MED
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	B-MED
time	I-MED
studies	B-MED
.	O
	
this	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	B-MED
for	O
removing	B-MED
mercury	B-MED
from	O
contaminated	B-MED
water	I-MED
for	O
environmental	B-MED
remediation	I-MED
.	O
	
modeling	B-MED
nurse-patient	B-MED
assignments	I-MED
considering	O
patient	B-MED
acuity	I-MED
and	O
travel	B-MED
distance	B-MED
metrics	B-MED
balancing	B-MED
workload	B-MED
among	O
nurses	B-MED
on	O
a	O
hospital	B-MED
unit	I-MED
is	O
important	O
for	O
the	O
satisfaction	B-MED
and	O
safety	B-MED
of	O
nurses	B-MED
and	O
patients	B-MED
.	O
	
to	O
balance	B-MED
nurse	B-MED
workloads	B-MED
,	O
direct	B-MED
patient	B-MED
care	I-MED
activities	I-MED
,	O
indirect	B-MED
patient	B-MED
care	I-MED
activities	I-MED
,	O
and	O
non-patient	B-MED
care	I-MED
activities	I-MED
that	O
occur	O
throughout	O
a	O
shift	B-MED
must	O
be	O
considered	O
.	O
	
the	O
layout	O
of	O
a	O
hospital	B-MED
unit	I-MED
and	O
the	O
location	B-MED
of	O
a	O
nurse's	B-MED
assigned	B-MED
patients	B-MED
relative	B-MED
to	O
other	O
resources	B-MED
on	O
the	O
unit	B-MED
are	O
also	O
important	B-MED
factors	I-MED
in	O
achieving	B-MED
workload	B-MED
balance	B-MED
.	O
	
in	O
most	O
hospitals	B-MED
,	O
a	O
unit	O
charge	O
nurse	B-MED
is	O
responsible	B-MED
for	O
the	O
shift	B-MED
assignment	B-MED
of	O
patients	B-MED
to	O
nurses	B-MED
based	O
on	O
experience	B-MED
and	O
past	B-MED
practices	I-MED
.	O
	
the	O
nurse-patient	B-MED
assignment	I-MED
process	B-MED
is	O
also	O
often	O
a	O
manual	B-MED
process	I-MED
in	O
which	O
the	O
charge	O
nurse	B-MED
must	O
sort	B-MED
through	O
multiple	B-MED
decision	I-MED
criteria	I-MED
in	O
a	O
limited	O
amount	O
of	O
time	B-MED
.	O
	
in	O
this	O
paper	O
,	O
a	O
methodology	B-MED
for	O
the	O
construction	O
of	O
balanced	B-MED
nurse-patient	B-MED
workload	I-MED
assignments	I-MED
is	O
proposed	B-MED
.	O
	
through	O
the	O
illustration	O
of	O
this	O
methodology	B-MED
new	O
scoring	B-MED
metrics	B-MED
are	O
developed	B-MED
using	O
measures	B-MED
currently	O
available	B-MED
on	O
,	O
or	O
from	O
,	O
the	O
hospital	B-MED
unit	I-MED
.	O
	
it	O
was	O
demonstrated	B-MED
that	O
the	O
complex	B-MED
scheduling	I-MED
problem	B-MED
can	O
be	O
captured	O
.	O
	
while	O
the	O
methodology	B-MED
was	O
illustrated	O
for	O
a	O
scheduling	B-MED
problem	B-MED
commonly	O
encountered	O
on	O
a	O
hospital	B-MED
unit	I-MED
,	O
the	O
approach	B-MED
can	O
be	O
adapted	O
to	O
other	O
workforce	B-MED
scheduling	B-MED
problems	B-MED
in	O
which	O
measures	B-MED
of	O
workload	B-MED
are	O
required	B-MED
and	O
composed	O
of	O
elements	B-MED
imposed	O
by	O
the	O
work	B-MED
environment	I-MED
,	O
variability	B-MED
within	O
the	O
required	B-MED
tasks	B-MED
,	O
and	O
a	O
measurable	B-MED
perception	B-MED
of	O
the	O
relative	B-MED
intensity	B-MED
of	O
the	O
work	B-MED
elements	I-MED
.	O
	
effect	B-MED
of	I-MED
alpha	B-MED
lipoic	I-MED
acid	I-MED
on	O
in	B-MED
vitro	I-MED
development	B-MED
of	O
bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
the	O
present	O
study	B-MED
aimed	O
to	O
evaluate	B-MED
the	O
in	B-MED
vitro	I-MED
effect	B-MED
of	I-MED
alpha	B-MED
lipoic	I-MED
acid	I-MED
ala	B-MED
addition	O
to	O
the	O
culture	B-MED
medium	I-MED
on	O
the	O
development	B-MED
of	O
the	O
bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
.	O
	
bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
were	O
collected	B-MED
and	O
divided	B-MED
into	O
two	O
groups	B-MED
depending	O
on	O
their	O
size	B-MED
80-100	O
μm	O
and	O
100-110	O
μm	O
.	O
	
they	O
were	O
cultured	O
in	B-MED
vitro	I-MED
for	O
15	O
days	O
d	O
using	O
different	O
media	B-MED
including	O
at	O
three	O
different	O
doses	B-MED
of	O
ala	B-MED
.	O
	
the	O
genes	B-MED
expression	I-MED
levels	B-MED
of	O
follicle-stimulating	B-MED
hormone	I-MED
beta-subunit	I-MED
fshr	B-MED
,	O
insulin-like	B-MED
growth	I-MED
factor	I-MED
igf-1	B-MED
,	O
activin	B-MED
,	O
luteinizing	B-MED
hormone/choriogonadotropin	I-MED
receptor	I-MED
,	O
bone	B-MED
morphogenetic	I-MED
protein	I-MED
receptor	I-MED
type	I-MED
ia	I-MED
,	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
receptor	I-MED
1	I-MED
,	O
growth	B-MED
differentiation	I-MED
factor	I-MED
9	I-MED
,	O
bcl2-associated	B-MED
x	I-MED
protein	I-MED
bax	B-MED
,	O
and	O
c-myc	B-MED
were	O
studied	O
using	O
real-time	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
	
the	O
protein	B-MED
expression	I-MED
levels	B-MED
of	O
fshr	B-MED
,	O
igf-1	B-MED
,	O
and	O
bax	B-MED
were	O
measured	O
using	O
western	B-MED
blot	I-MED
analysis	I-MED
.	O
	
the	O
results	B-MED
of	O
the	O
present	O
work	O
revealed	O
that	O
in	B-MED
vitro	I-MED
addition	O
of	O
ala	B-MED
-	O
induced	B-MED
significant	B-MED
increase	B-MED
in	I-MED
the	I-MED
growth	I-MED
and	O
development	B-MED
of	O
secondary	B-MED
preantral	I-MED
follicles	I-MED
throughout	O
the	O
culture	B-MED
period	B-MED
as	O
compared	B-MED
to	O
control	B-MED
.	O
	
the	O
fshr	B-MED
,	O
igf-1	B-MED
,	O
luteinizing	B-MED
hormone/choriogonadotropin	I-MED
receptor	I-MED
,	O
bone	B-MED
morphogenetic	I-MED
protein	I-MED
receptor	I-MED
type	I-MED
ia	I-MED
,	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
receptor	I-MED
1	I-MED
,	O
growth	B-MED
differentiation	I-MED
factor	I-MED
9	I-MED
,	O
and	O
activin	B-MED
a	I-MED
genes	I-MED
were	O
upregulated	B-MED
in	O
ala	B-MED
-	O
treated	B-MED
follicles	B-MED
as	O
compared	B-MED
to	O
the	O
control	B-MED
.	O
	
on	O
contrary	O
,	O
preapoptotic	B-MED
genes	I-MED
bax	B-MED
and	O
c-myc	B-MED
were	O
downregulated	B-MED
in	O
treated	B-MED
follicles	B-MED
compared	B-MED
to	O
control	B-MED
ones	O
.	O
	
the	O
protein	B-MED
levels	I-MED
of	O
fshr	B-MED
and	O
igf-1	B-MED
were	O
highly	O
expressed	B-MED
in	O
treated	B-MED
follicles	B-MED
compared	B-MED
to	O
control	B-MED
however	O
,	O
bax	B-MED
protein	I-MED
was	O
downregulated	B-MED
in	O
the	O
treated	B-MED
follicles	B-MED
groups	B-MED
.	O
	
the	O
addition	O
of	O
ala	B-MED
to	O
the	O
culture	B-MED
medium	I-MED
enhances	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
development	B-MED
and	O
how	O
should	O
proxies	B-MED
of	O
cognitive	B-MED
reserve	I-MED
be	O
evaluated	B-MED
in	O
a	O
population	B-MED
of	O
healthy	B-MED
older	B-MED
adults	I-MED
while	O
some	O
tools	B-MED
have	O
been	O
developed	O
to	O
estimate	B-MED
an	O
individual's	B-MED
cognitive	B-MED
reserve	I-MED
cr	B-MED
,	O
no	O
study	O
has	O
assessed	B-MED
the	O
adequacy	B-MED
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
cr	B-MED
proxy	B-MED
indicators	O
.	O
	
therefore	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	B-MED
method	O
to	O
estimate	B-MED
cr	B-MED
by	O
comparing	O
two	O
approaches	O
1	O
the	O
common	B-MED
assessment	B-MED
of	O
cr	B-MED
proxies	B-MED
in	O
the	O
literature	B-MED
e.g	O
.	O
	
years	B-MED
of	I-MED
education	I-MED
and	O
2	O
the	O
calculation	B-MED
of	O
a	O
comprehensive	B-MED
index	B-MED
based	O
on	O
most	B-MED
significant	I-MED
parameters	B-MED
used	O
in	O
the	O
estimation	B-MED
of	O
cr	B-MED
.	O
	
data	O
on	O
cr	B-MED
proxies	B-MED
i.e	O
.	O
	
education	B-MED
,	O
occupation	B-MED
,	O
and	O
leisure	B-MED
activities	I-MED
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older	B-MED
adults	I-MED
.	O
	
regression	B-MED
analyses	I-MED
were	O
used	O
to	O
develop	O
the	O
two	O
indices	B-MED
of	O
cr	B-MED
i.e	O
.	O
	
icr-standard	B-MED
and	O
icr-detailed	B-MED
and	O
to	O
determine	O
which	O
index	B-MED
best	O
represented	O
the	O
level	O
of	O
one's	O
cr	B-MED
.	O
	
the	O
icr-standard	B-MED
was	O
calculated	B-MED
using	O
a	O
combination	B-MED
of	O
the	O
three	O
most	O
common	B-MED
measures	B-MED
of	O
reserve	B-MED
in	O
the	O
literature	B-MED
number	B-MED
of	I-MED
schooling	I-MED
years	I-MED
,	O
complexity	B-MED
of	O
the	O
primary	O
occupation	B-MED
,	O
and	O
amount	O
of	O
current	B-MED
participation	B-MED
in	O
stimulating	B-MED
activities	B-MED
.	O
	
the	O
icr-detailed	B-MED
was	O
calculated	B-MED
using	O
the	O
most	B-MED
significant	I-MED
parameters	B-MED
established	O
in	O
initial	B-MED
analyses	B-MED
of	O
cr	B-MED
highest	B-MED
level	I-MED
of	I-MED
education	I-MED
combined	B-MED
with	O
the	O
number	O
of	O
training	B-MED
courses	I-MED
,	O
last	B-MED
occupation	B-MED
,	O
and	O
amount	B-MED
of	O
current	O
participation	B-MED
in	O
social	B-MED
and	O
intellectual	B-MED
activities	I-MED
.	O
	
the	O
comparison	B-MED
of	O
both	O
indices	B-MED
showed	O
that	O
higher	O
levels	O
of	O
icr-standard	B-MED
and	O
icr-detailed	B-MED
were	O
associated	B-MED
with	I-MED
a	O
greater	B-MED
minimization	B-MED
of	O
the	O
effects	B-MED
of	I-MED
age	B-MED
on	O
cognition	B-MED
.	O
	
however	O
,	O
the	O
icr-detailed	B-MED
was	O
more	O
strongly	O
associated	B-MED
to	O
this	O
minimization	B-MED
than	O
the	O
icr-standard	B-MED
,	O
suggesting	O
that	O
the	O
icr-detailed	B-MED
best	O
reflect	O
one's	O
cr	B-MED
.	O
	
this	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	B-MED
importance	B-MED
to	O
question	O
methods	O
measuring	B-MED
cr	B-MED
proxies	B-MED
in	O
order	O
to	O
develop	O
a	O
clinical	B-MED
tool	I-MED
allowing	O
a	O
comprehensive	B-MED
and	O
accurate	B-MED
estimation	B-MED
of	O
discordance	B-MED
in	O
pathology	B-MED
report	I-MED
after	O
central	B-MED
pathology	I-MED
review	I-MED
implications	O
for	O
breast	B-MED
cancer	I-MED
adjuvant	B-MED
treatment	I-MED
pathological	B-MED
predictive	B-MED
factors	I-MED
are	O
the	O
most	O
important	O
markers	B-MED
when	O
selecting	O
early	O
breast	B-MED
cancer	I-MED
adjuvant	B-MED
therapy	I-MED
.	O
	
in	O
randomized	B-MED
clinical	I-MED
trials	I-MED
the	O
variability	B-MED
in	O
pathology	B-MED
report	I-MED
after	O
central	B-MED
pathology	I-MED
review	I-MED
is	O
noteworthy	O
.	O
	
we	O
evaluated	O
the	O
discordance	B-MED
rate	B-MED
dr	B-MED
and	O
inter-rater	B-MED
agreement	I-MED
between	O
local	B-MED
and	O
central	B-MED
histopathological	B-MED
report	I-MED
and	O
the	O
clinical	B-MED
implication	O
on	O
treatment	B-MED
decision	I-MED
.	O
	
a	O
retrospective	B-MED
analysis	I-MED
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B-MED
cancer	I-MED
tumors	I-MED
diagnosed	O
by	O
local	B-MED
pathologists	I-MED
and	O
subsequently	O
reviewed	B-MED
at	O
the	O
pathology	B-MED
division	I-MED
of	O
european	B-MED
institute	I-MED
of	I-MED
oncology	I-MED
.	O
	
the	O
inter-rater	B-MED
agreement	I-MED
k	O
between	O
local	O
and	O
central	B-MED
pathology	I-MED
was	O
calculated	O
for	O
ki-67	B-MED
,	O
grading	B-MED
,	O
hormone	B-MED
receptors	I-MED
er	B-MED
/	O
pgr	B-MED
and	O
her2/neu	B-MED
.	O
	
the	O
bland-altman	B-MED
plots	I-MED
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
ki-67	B-MED
,	O
er	B-MED
and	O
pgr	B-MED
.	O
	
dr	B-MED
was	O
calculated	O
for	O
er	B-MED
/	O
pgr	B-MED
and	O
her2	B-MED
.	O
	
from	O
2007	O
to	O
2013	O
,	O
187	O
pathology	B-MED
specimens	I-MED
from	O
10	O
cancer	B-MED
centers	I-MED
were	O
reviewed	B-MED
.	O
	
substantial	O
agreement	O
was	O
observed	O
for	O
er	B-MED
k0.612	O
95%	O
ci	B-MED
,	O
0538-0	O
,	O
pgr	B-MED
k0.659	O
95%	O
ci	B-MED
,	O
0580-0	O
,	O
ki-67	B-MED
k0.609	O
95%	O
ci	B-MED
,	O
0.534	O
and	O
grading	B-MED
k0.669	O
95%	O
ci	B-MED
,	O
0.569	O
.	O
	
moderate	O
agreement	O
was	O
found	O
for	O
her2	B-MED
k0.546	O
95%	O
ci	B-MED
,	O
0444-0	O
.	O
	
dr	B-MED
was	O
9.5	O
negativity	O
to	O
positivity	O
and	O
31.7	O
positivity	O
to	O
negativity	O
for	O
her2	B-MED
and	O
26.2	O
negativity	O
to	O
positivity	O
and	O
12.5	O
positivity	O
to	O
negativity	O
for	O
er	B-MED
/	O
pgr	B-MED
.	O
	
according	O
to	O
changes	O
in	O
her2	B-MED
and	O
er	B-MED
/	O
pgr	B-MED
status	O
,	O
23	O
12.2	O
and	O
33	O
17.6	O
systemic	B-MED
prescription	B-MED
were	O
respectively	O
modified	O
.	O
	
in	O
our	O
retrospective	B-MED
analysis	I-MED
,	O
central	B-MED
pathological	I-MED
review	I-MED
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making	B-MED
process	I-MED
in	O
early	O
breast	B-MED
cancer	I-MED
,	O
as	O
shown	O
in	O
clinical	B-MED
trials	I-MED
.	O
	
implementing	B-MED
non-invasive	B-MED
prenatal	B-MED
diagnosis	I-MED
nipd	B-MED
in	O
a	O
national	B-MED
health	I-MED
service	I-MED
laboratory	I-MED
from	O
dominant	B-MED
to	O
recessive	B-MED
disorders	B-MED
our	O
uk	B-MED
national	I-MED
health	I-MED
service	I-MED
regional	I-MED
genetics	I-MED
laboratory	I-MED
offers	O
nipd	B-MED
for	O
autosomal	B-MED
dominant	I-MED
and	O
de	B-MED
novo	I-MED
conditions	B-MED
achondroplasia	B-MED
,	O
thanataphoric	B-MED
dysplasia	I-MED
,	O
apert	B-MED
syndrome	I-MED
,	O
paternal	B-MED
mutation	B-MED
exclusion	B-MED
for	O
cystic	B-MED
fibrosis	I-MED
and	O
a	O
range	O
of	O
bespoke	B-MED
tests	I-MED
.	O
	
nipd	B-MED
avoids	O
the	O
risks	B-MED
associated	B-MED
with	I-MED
invasive	B-MED
testing	I-MED
,	O
making	O
prenatal	B-MED
diagnosis	I-MED
more	B-MED
accessible	O
to	O
families	B-MED
at	O
high	B-MED
genetic	B-MED
risk	I-MED
.	O
	
however	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	B-MED
diagnosis	B-MED
for	O
autosomal	B-MED
recessive	I-MED
diseases	I-MED
,	O
which	O
is	O
complicated	B-MED
by	O
the	O
predominance	B-MED
of	O
the	O
maternal	B-MED
mutant	B-MED
allele	B-MED
in	O
the	O
cell-free	B-MED
dna	I-MED
sample	B-MED
and	O
thus	O
requires	O
a	O
variety	B-MED
of	O
different	B-MED
approaches	B-MED
.	O
	
validation	B-MED
and	O
diagnostic	B-MED
implementation	B-MED
for	O
nipd	B-MED
of	O
congenital	B-MED
adrenal	I-MED
hyperplasia	I-MED
cah	B-MED
is	O
further	O
complicated	B-MED
by	O
presence	B-MED
of	O
a	O
pseudogene	B-MED
that	O
requires	O
a	O
different	B-MED
approach	B-MED
.	O
	
we	O
have	O
used	O
an	O
assay	B-MED
targeting	B-MED
approximately	B-MED
6700	O
heterozygous	B-MED
snps	B-MED
around	O
the	O
cah	B-MED
gene	I-MED
cyp21a2	B-MED
to	O
construct	O
the	O
high-risk	B-MED
parental	B-MED
haplotypes	B-MED
and	O
tested	O
this	O
approach	B-MED
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	B-MED
of	O
the	O
parental	B-MED
alleles	B-MED
can	O
be	O
correctly	O
identified	B-MED
using	O
nipd	B-MED
.	O
	
we	O
are	O
evaluating	O
various	O
measures	B-MED
of	O
the	O
fetal	B-MED
fraction	O
to	O
help	O
determine	O
inheritance	B-MED
of	O
parental	B-MED
mutations	B-MED
.	O
	
we	O
are	O
currently	O
exploring	O
the	O
utility	B-MED
of	O
an	O
nipd	B-MED
multi-disorder	B-MED
panel	I-MED
for	O
autosomal	B-MED
recessive	I-MED
disease	I-MED
,	O
to	O
make	O
testing	B-MED
more	O
widely	O
applicable	B-MED
to	O
families	B-MED
with	O
a	O
variety	O
of	O
serious	B-MED
genetic	B-MED
conditions	I-MED
.	O
	
silk	B-MED
fibroin	I-MED
based	O
carrier	B-MED
system	I-MED
for	O
delivery	B-MED
of	O
fibrinogen	B-MED
and	O
thrombin	B-MED
as	O
coagulant	B-MED
supplements	B-MED
the	O
control	B-MED
of	O
bleeding	B-MED
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-MED
after	O
a	O
traumatic	B-MED
injury	I-MED
.	O
	
hemostatic	B-MED
devices	I-MED
delivering	B-MED
blood	B-MED
clotting	I-MED
accelerating	O
agents	B-MED
such	O
as	O
fibrinogen	B-MED
are	O
increasingly	B-MED
used	O
due	O
to	O
their	O
efficacy	B-MED
and	O
their	O
ease	O
of	O
application	B-MED
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	B-MED
to	O
incorporate	B-MED
the	O
coagulant	B-MED
supplements	B-MED
fibrinogen	B-MED
and	O
thrombin	B-MED
in	O
silk	B-MED
protein	I-MED
sponges	B-MED
by	O
mixing	O
the	O
coagulants	B-MED
with	O
an	O
aqueous	B-MED
silk	B-MED
solution	O
,	O
followed	O
by	O
molding	B-MED
,	O
freeze-drying	B-MED
and	O
water	B-MED
annealing	I-MED
.	O
	
in	O
this	O
combination	B-MED
system	B-MED
we	O
demonstrate	O
the	O
delivery	B-MED
of	O
fibrinogen	B-MED
while	O
maintaining	O
its	O
hemostatic	B-MED
potential	I-MED
.	O
	
concentration	B-MED
ratios	I-MED
of	O
silk	B-MED
to	O
fibrinogen	B-MED
of	O
1.0	O
,	O
2.3	O
and	O
3.0	O
were	O
used	O
.	O
	
the	O
thrombin	B-MED
-induced	O
fibrin	B-MED
polymeric	B-MED
network	B-MED
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-MED
spongy	B-MED
structure	I-MED
but	O
also	O
remained	O
interconnected	B-MED
to	O
the	O
silk	B-MED
,	O
providing	O
an	O
intact	B-MED
network	B-MED
.	O
	
the	O
mechanical	B-MED
characterization	I-MED
of	O
the	O
fibrinogen-releasing	B-MED
silk	B-MED
sponges	B-MED
before	O
and	O
after	O
the	O
induction	B-MED
of	O
the	O
fibrinogen	B-MED
polymerization	B-MED
demonstrated	O
that	O
the	O
fibrin	B-MED
network	B-MED
resulted	O
in	O
reduced	B-MED
permanent	B-MED
deformation	B-MED
from	O
21.1	O
to	O
6.5	O
,	O
19.6	O
to	O
5.7	O
and	O
12.7	O
to	O
9.4	O
for	O
the	O
2.8	O
,	O
1.5	O
and	O
0.8	O
fibrinogen	B-MED
-containing	O
silk	B-MED
sponges	B-MED
,	O
respectively	O
.	O
	
moreover	O
,	O
the	O
fibrin	B-MED
formation	B-MED
lead	O
to	O
a	O
more	O
linear	B-MED
elastic	B-MED
behavior	I-MED
over	O
longer	O
strain	O
ranges	O
.	O
	
in	O
combination	O
,	O
the	O
calcein-am	B-MED
/	O
pi	B-MED
stainings	B-MED
and	O
mtt	B-MED
assay	I-MED
results	O
indicate	O
uniform	B-MED
cell	B-MED
adhesion	I-MED
on	O
the	O
surface	B-MED
and	O
cytocompatibility	B-MED
of	O
the	O
silk	B-MED
/	O
fibrin	B-MED
sponges	B-MED
,	O
respectively	O
.	O
	
moreover	O
,	O
the	O
co-delivery	B-MED
of	O
thrombin	B-MED
with	O
fibrinogen	B-MED
via	O
silk	B-MED
as	O
carrier	B-MED
material	I-MED
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	B-MED
robust	B-MED
and	O
durable	B-MED
system	I-MED
while	O
preserving	B-MED
hemostatic	B-MED
features	I-MED
of	O
the	O
coagulant	B-MED
substances	I-MED
for	O
the	O
generation	B-MED
of	O
hemostatic	B-MED
devices	I-MED
.	O
	
adoptively	O
transferred	O
natural	B-MED
killer	I-MED
cells	I-MED
maintain	O
long-term	O
antitumor	B-MED
activity	I-MED
by	O
epigenetic	B-MED
imprinting	I-MED
and	O
cd4	B-MED
t	I-MED
cell	I-MED
help	O
natural	B-MED
killer	I-MED
nk	I-MED
cell	I-MED
infusions	B-MED
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	B-MED
with	O
different	O
types	O
of	O
cancer	B-MED
.	O
	
the	O
optimal	O
strategies	O
for	O
nk	B-MED
cell	I-MED
activation	B-MED
prior	O
to	O
infusion	B-MED
are	O
still	O
under	O
debate	O
.	O
	
there	O
is	O
recent	O
evidence	O
that	O
nk	B-MED
cells	I-MED
can	O
acquire	O
long-term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B-MED
il-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
.	O
	
the	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long-term	O
nk	B-MED
cell	I-MED
antitumor	B-MED
activity	I-MED
are	O
incompletely	O
under-stood	O
.	O
	
here	O
,	O
we	O
show	O
that	O
nk	B-MED
cells	I-MED
preactivated	O
in	B-MED
vitro	I-MED
with	O
il-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
,	O
but	O
not	O
with	O
il-15	B-MED
alone	O
,	O
maintained	O
high	O
antitumor	B-MED
activity	I-MED
even	O
1	B-MED
mo	I-MED
after	O
transfer	O
into	O
lymphopenic	B-MED
rag-2	B-MED
γc	O
mice	B-MED
.	O
	
the	O
nk	B-MED
cell	I-MED
intrinsic	O
ability	O
for	O
ifnγ	B-MED
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	B-MED
sequence	I-MED
cns	B-MED
1	O
in	O
the	O
ifng	B-MED
locus	B-MED
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B-MED
of	O
ifng	B-MED
.	O
	
in	O
a	O
xenograft	B-MED
melanoma	I-MED
mouse	I-MED
model	I-MED
,	O
human	B-MED
il-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
-preactivated	O
nk	B-MED
cells	I-MED
rejected	O
tumors	B-MED
more	O
efficiently	O
.	O
	
in	O
rag-2	B-MED
γc	O
mice	B-MED
,	O
co-transfer	O
of	O
cd4	B-MED
t	I-MED
cells	I-MED
further	O
improved	O
the	O
long-term	O
competence	O
of	O
nk	B-MED
cells	I-MED
for	O
ifnγ	B-MED
production	O
that	O
was	O
dependent	O
on	O
il-2	B-MED
.	O
	
cd4	B-MED
t	I-MED
cell	I-MED
activation	B-MED
during	O
homeostatic	B-MED
proliferation	I-MED
required	O
macrophages	B-MED
and	O
further	O
promoted	O
the	O
long-term	O
nk	B-MED
cell	I-MED
antitumor	B-MED
activity	I-MED
.	O
	
thus	O
,	O
nk	B-MED
cells	I-MED
can	O
"""remember"""	O
a	O
previous	O
exposure	O
to	O
cytokines	B-MED
by	O
epigenetic	B-MED
imprinting	I-MED
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
ifnγ	B-MED
-producing	O
phenotype	B-MED
after	O
adoptive	O
transfer	O
.	O
	
in	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B-MED
-preactivated	O
nk	B-MED
cells	I-MED
with	O
cd4	B-MED
t	I-MED
cell	I-MED
activation	B-MED
upon	O
lymphopenic	B-MED
conditioning	O
to	O
achieve	O
long-term	O
nk	B-MED
cell	I-MED
effector	O
function	O
for	O
cancer	B-MED
immunotherapy	I-MED
.	O
	
survey	B-MED
of	O
neonatal	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
nurse	B-MED
attitudes	B-MED
toward	O
therapeutic	B-MED
hypothermia	I-MED
treatment	I-MED
the	O
traumatic	B-MED
experiences	O
of	O
parent	B-MED
s	O
of	O
babies	B-MED
treated	B-MED
with	I-MED
therapeutic	B-MED
hypothermia	I-MED
th	B-MED
have	O
been	O
described	O
.	O
	
no	O
research	B-MED
has	O
assessed	B-MED
neonatal	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
nicu	B-MED
nurse	B-MED
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-MED
babies	B-MED
and	O
emotional	O
support	O
to	O
their	O
parents	B-MED
.	O
	
to	O
assess	O
nicu	B-MED
nurse	B-MED
attitudes	B-MED
to	O
the	O
provision	O
of	O
th	B-MED
with	O
respect	O
to	O
perceptions	B-MED
about	O
baby	B-MED
pain	B-MED
/	O
sedation	B-MED
,	O
need	O
for	O
nurse	B-MED
and	O
parent	B-MED
education	B-MED
,	O
decision	B-MED
making	I-MED
about	O
initiation	B-MED
of	O
th	B-MED
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O
	
a	O
survey	B-MED
was	O
electronically	O
sent	O
to	O
219	O
nurses	B-MED
at	O
2	O
affiliated	O
academic	O
level	O
iii	O
nicus	B-MED
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O
	
there	O
were	O
17	O
questions	O
where	O
responses	B-MED
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	B-MED
to	O
provide	O
free	O
text	O
responses	B-MED
.	O
	
the	O
response	B-MED
rate	O
was	O
38%	O
n	O
=	O
83	O
.	O
	
overwhelming	B-MED
similarities	O
between	O
the	O
urban	B-MED
and	O
rural	B-MED
institutions	I-MED
were	O
found	O
with	O
nicu	B-MED
nurses	B-MED
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
th	B-MED
,	O
agreement	O
that	O
th	B-MED
improves	O
long-term	B-MED
outcomes	B-MED
and	O
that	O
the	O
benefits	O
of	O
th	B-MED
outweigh	O
the	O
risks	O
.	O
	
nurses	B-MED
at	O
the	O
urban	B-MED
institution	I-MED
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-MED
of	O
baby	B-MED
pain	B-MED
/	O
sedation	B-MED
,	O
and	O
nurses	B-MED
at	O
both	O
institutions	B-MED
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	B-MED
and	O
parent	B-MED
education	B-MED
about	O
th	B-MED
and	O
improved	O
timeliness	O
of	O
decision	B-MED
making	I-MED
for	O
initiation	B-MED
of	O
th	B-MED
.	O
	
nicu	B-MED
nurses	B-MED
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	B-MED
of	O
babies	B-MED
after	O
treatment	B-MED
with	O
th	B-MED
and	O
feel	O
that	O
parents	B-MED
need	O
more	O
education	B-MED
about	O
th	B-MED
.	O
	
research	B-MED
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
th	B-MED
treatment	I-MED
for	O
parent	B-MED
-	O
baby	B-MED
pharmacological	B-MED
venous	I-MED
thromboembolism	I-MED
prophylaxis	I-MED
in	O
meningioma	B-MED
patients	B-MED
should	O
it	O
be	O
earlier	O
than	O
clinical	B-MED
practice	I-MED
we	O
read	O
the	O
report	B-MED
by	O
çeltikçi	O
et	O
al	O
in	O
the	O
turkish	B-MED
neurosurgery	I-MED
with	O
great	O
interest	O
.	O
	
in	O
this	O
single-center	O
retrospective	B-MED
study	I-MED
,	O
they	O
analysed	O
449	O
intracranial	B-MED
meningioma	I-MED
patients	B-MED
underwent	O
open	B-MED
surgery	I-MED
.	O
	
they	O
stated	O
that	O
venous	B-MED
thromboembolism	I-MED
vte	B-MED
had	O
been	O
seen	O
in	O
21	O
4.6	O
of	O
their	O
patients	B-MED
.	O
	
this	O
is	O
an	O
important	O
issue	O
because	O
vte	B-MED
,	O
including	O
deep	B-MED
vein	I-MED
thrombosis	I-MED
dvt	B-MED
and	O
pulmonary	B-MED
embolism	I-MED
pe	B-MED
,	O
is	O
the	O
most	O
common	O
overall	O
complication	B-MED
in	O
meningioma	B-MED
surgery	I-MED
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	B-MED
2	O
.	O
	
we	O
suppose	O
that	O
prophylaxis	B-MED
of	O
vte	B-MED
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological	B-MED
prophylaxis	I-MED
are	O
combined	O
.	O
	
we	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical	B-MED
extrapolation	I-MED
.	O
	
best	B-MED
next-generation	B-MED
biomedical	B-MED
entity	I-MED
search	I-MED
tool	I-MED
for	O
knowledge	B-MED
discovery	B-MED
from	O
biomedical	B-MED
literature	I-MED
as	O
the	O
volume	B-MED
of	O
publications	B-MED
rapidly	B-MED
increases	B-MED
,	O
searching	B-MED
for	O
relevant	B-MED
information	B-MED
from	O
the	O
literature	B-MED
becomes	O
more	O
challenging	B-MED
.	O
	
to	O
complement	O
standard	B-MED
search	B-MED
engines	I-MED
such	O
as	O
pubmed	B-MED
,	O
it	O
is	O
desirable	B-MED
to	O
have	O
an	O
advanced	B-MED
search	I-MED
tool	I-MED
that	O
directly	B-MED
returns	B-MED
relevant	B-MED
biomedical	B-MED
entities	B-MED
such	O
as	O
targets	B-MED
,	O
drugs	B-MED
,	O
and	O
mutations	B-MED
rather	O
than	O
a	O
long	O
list	O
of	O
articles	O
.	O
	
some	O
existing	B-MED
tools	B-MED
submit	B-MED
a	O
query	B-MED
to	O
pubmed	B-MED
and	O
process	B-MED
retrieved	O
abstracts	B-MED
to	O
extract	O
information	B-MED
at	O
query	B-MED
time	B-MED
,	O
resulting	B-MED
in	O
a	O
slow	B-MED
response	O
time	B-MED
and	O
limited	B-MED
coverage	B-MED
of	O
only	O
a	O
fraction	B-MED
of	I-MED
the	O
pubmed	B-MED
corpus	I-MED
.	O
	
other	O
tools	B-MED
preprocess	B-MED
the	O
pubmed	B-MED
corpus	I-MED
to	O
speed	O
up	O
the	O
response	O
time	B-MED
however	O
,	O
they	O
are	O
not	O
constantly	B-MED
updated	B-MED
,	O
and	O
thus	O
produce	B-MED
outdated	B-MED
results	B-MED
.	O
	
further	O
,	O
most	O
existing	O
tools	B-MED
cannot	O
process	B-MED
sophisticated	B-MED
queries	B-MED
such	O
as	O
searches	B-MED
for	O
mutations	B-MED
that	O
co-occur	B-MED
with	O
query	B-MED
terms	O
in	O
the	O
literature	B-MED
.	O
	
to	O
address	O
these	O
problems	B-MED
,	O
we	O
introduce	B-MED
best	B-MED
,	O
a	O
biomedical	B-MED
entity	I-MED
search	I-MED
tool	I-MED
.	O
	
best	B-MED
returns	B-MED
,	O
as	O
a	O
result	B-MED
,	O
a	O
list	O
of	O
10	O
different	B-MED
types	O
of	O
biomedical	B-MED
entities	B-MED
including	B-MED
genes	B-MED
,	O
diseases	B-MED
,	O
drugs	B-MED
,	O
targets	B-MED
,	O
transcription	B-MED
factors	I-MED
,	O
mirnas	B-MED
,	O
and	O
mutations	B-MED
that	O
are	O
relevant	B-MED
to	O
a	O
user's	O
query	B-MED
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	B-MED
,	O
best	B-MED
is	O
the	O
only	O
system	B-MED
that	O
processes	B-MED
free	O
text	B-MED
queries	B-MED
and	O
returns	B-MED
up-to-date	B-MED
results	B-MED
in	O
real	B-MED
time	I-MED
including	B-MED
mutation	B-MED
information	B-MED
in	O
the	O
results	B-MED
.	O
	
best	B-MED
alanine	B-MED
to	O
serine	B-MED
variant	B-MED
at	O
position	O
986	O
of	O
calcium	B-MED
sensing	I-MED
receptor	I-MED
and	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
with	O
regard	O
to	O
the	O
effect	B-MED
of	O
calcium	B-MED
against	O
colorectal	B-MED
cancer	I-MED
crc	B-MED
and	O
considering	O
the	O
key	O
role	B-MED
of	O
calcium	B-MED
sensing	I-MED
receptor	I-MED
casr	B-MED
in	O
calcium	B-MED
homeostasis	I-MED
,	O
this	O
study	O
investigated	B-MED
whether	O
casr	B-MED
gene	I-MED
rs1801725	B-MED
or	O
a986s	B-MED
variant	I-MED
was	O
associated	B-MED
with	I-MED
susceptibility	B-MED
to	O
crc	B-MED
risk	B-MED
.	O
	
this	O
study	O
was	O
conducted	O
as	O
a	O
case-control	B-MED
study	I-MED
and	O
303	O
cases	B-MED
with	O
crc	B-MED
and	O
354	O
controls	B-MED
were	O
enrolled	O
.	O
	
all	O
657	O
subjects	B-MED
were	O
genotyped	B-MED
for	O
casr	B-MED
gene	I-MED
a986s	B-MED
variant	I-MED
using	O
pcr	B-MED
-	O
rflp	B-MED
method	I-MED
.	O
	
no	B-MED
significant	I-MED
difference	B-MED
was	O
observed	B-MED
for	O
the	O
a986s	B-MED
variant	I-MED
of	O
casr	B-MED
gene	I-MED
in	O
either	O
genotype	B-MED
or	O
allele	B-MED
frequencies	I-MED
between	O
the	O
cases	B-MED
and	O
the	O
controls	B-MED
and	O
this	O
lack	B-MED
of	O
difference	B-MED
remained	O
non-significant	O
even	O
after	O
adjustment	B-MED
for	O
age	B-MED
,	O
bmi	B-MED
,	O
sex	B-MED
,	O
smoking	B-MED
status	I-MED
,	O
and	O
family	B-MED
history	I-MED
of	O
crc	B-MED
.	O
	
no	B-MED
evidence	I-MED
for	O
the	O
effect	B-MED
modification	B-MED
of	O
the	O
association	B-MED
a986s	B-MED
variant	I-MED
and	O
crc	B-MED
by	O
bmi	B-MED
,	O
sex	B-MED
,	O
or	O
tumor	B-MED
site	I-MED
was	O
also	O
observed	B-MED
.	O
	
furthermore	O
,	O
the	O
risk	B-MED
of	O
obesity	B-MED
in	O
relation	B-MED
to	O
the	O
a986s	B-MED
variant	I-MED
in	O
the	O
controls	B-MED
and	O
the	O
cases	B-MED
was	O
separately	O
analyzed	B-MED
and	O
we	O
observed	O
no	B-MED
significant	I-MED
difference	I-MED
between	O
normal	B-MED
weight	I-MED
bmi	B-MED
<	O
25kg/m	O
and	O
overweight	B-MED
/	O
obese	B-MED
bmi	B-MED
25kg/m	O
subjects	B-MED
.	O
	
our	O
findings	B-MED
do	O
not	O
support	O
a	O
role	O
for	O
effect	B-MED
of	O
the	O
casr	B-MED
gene	I-MED
a986s	B-MED
variant	I-MED
on	O
crc	B-MED
risk	B-MED
nevertheless	O
,	O
this	O
finding	B-MED
requires	O
confirmation	B-MED
and	O
the	O
role	B-MED
of	O
the	O
gene	B-MED
variant	I-MED
in	O
carcinogenesis	B-MED
needs	O
to	O
be	O
further	O
treatment	B-MED
of	O
erythematotelangiectatic	B-MED
rosacea	I-MED
with	O
the	O
fractionation	B-MED
of	O
high-fluence	B-MED
,	O
long-pulsed	O
595-nm	O
pulsed	B-MED
dye	I-MED
laser	I-MED
various	O
lasers	B-MED
have	O
been	O
used	O
for	O
the	O
treatment	B-MED
of	O
erythematotelangiectatic	B-MED
rosacea	I-MED
etr	B-MED
that	O
does	O
not	O
respond	O
to	O
systemic	B-MED
or	O
topical	B-MED
therapy	I-MED
.	O
	
the	O
pulsed	B-MED
dye	I-MED
lasers	I-MED
pdls	B-MED
are	O
an	O
effective	O
option	O
for	O
etr	B-MED
,	O
and	O
the	O
purpuragenic	B-MED
fluence	B-MED
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O
	
given	O
that	O
purpura	B-MED
and	O
subsequent	O
possible	O
postinflammatory	B-MED
hyperpigmentation	I-MED
pih	B-MED
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	B-MED
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-MED
fluence	B-MED
were	O
reported	O
.	O
	
to	O
deliver	O
the	O
sufficient	O
high	B-MED
fluence	I-MED
of	O
a	O
pdl	B-MED
without	O
generating	O
purpura	B-MED
,	O
we	O
designed	O
the	O
fractionation	B-MED
of	O
high	B-MED
fluence	I-MED
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
6	O
milliseconds	O
of	O
a	O
pdl	B-MED
in	O
succession	O
.	O
	
a	O
total	O
of	O
eight	O
patients	B-MED
with	O
etr	B-MED
were	O
enrolled	O
in	O
this	O
study	O
all	O
patients	B-MED
were	O
treated	O
with	O
pdl	B-MED
10	O
times	O
at	O
2-week	O
intervals	O
.	O
	
erythema	B-MED
and	O
telangiectasia	B-MED
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	B-MED
using	O
the	O
digital	B-MED
photographs	I-MED
.	O
	
moderate-to-marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	B-MED
,	O
and	O
erythema	B-MED
and	O
telangiectasia	B-MED
scores	O
were	O
significantly	O
decreased	O
.	O
	
purpura	B-MED
and	O
pih	B-MED
were	O
not	O
reported	O
in	O
all	O
patients	B-MED
.	O
	
the	O
fractionation	B-MED
of	O
high-fluence	B-MED
,	O
long-pulsed	O
595	O
nm	O
pdl	B-MED
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-MED
for	O
propulsion	B-MED
strategy	I-MED
in	O
the	O
gait	B-MED
of	O
primary	B-MED
school	I-MED
children	B-MED
the	O
effect	B-MED
of	O
age	B-MED
and	O
speed	B-MED
the	O
strategy	B-MED
used	O
to	O
generate	B-MED
power	B-MED
for	O
forward	O
propulsion	B-MED
in	O
walking	B-MED
and	O
running	B-MED
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	B-MED
of	O
gait	B-MED
maturation	B-MED
and	O
elastic	B-MED
energy	I-MED
recycling	B-MED
.	O
	
this	O
study	B-MED
investigated	B-MED
ankle	B-MED
and	O
hip	B-MED
power	B-MED
generation	B-MED
as	O
a	O
propulsion	B-MED
strategy	I-MED
ps	B-MED
during	O
the	O
late	B-MED
stance	I-MED
/	O
early	B-MED
swing	I-MED
phases	I-MED
of	O
walking	B-MED
and	O
running	B-MED
in	O
typically	B-MED
developing	I-MED
td	B-MED
children	B-MED
15	O
six	O
to	O
nine	O
years	B-MED
17	O
nine	O
to	O
13	O
years	B-MED
using	O
three-dimensional	B-MED
gait	B-MED
analysis	I-MED
.	O
	
peak	B-MED
ankle	B-MED
power	B-MED
generation	B-MED
at	O
push-off	B-MED
peaka2	B-MED
,	O
peak	B-MED
hip	B-MED
power	B-MED
generation	B-MED
in	O
early	B-MED
swing	I-MED
peakh3	B-MED
and	O
propulsion	B-MED
strategy	I-MED
ps	B-MED
peaka2	B-MED
/	O
peaka2+peakh3	B-MED
were	O
calculated	B-MED
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	B-MED
power	B-MED
to	O
total	O
propulsion	B-MED
.	O
	
mean	B-MED
ps	B-MED
values	B-MED
decreased	B-MED
as	O
speed	B-MED
increased	B-MED
for	O
comfortable	B-MED
walking	I-MED
p<0	O
,	O
fast	B-MED
walking	B-MED
p<0	O
and	O
fast	B-MED
running	B-MED
p<0	O
,	O
and	O
less	O
consistently	O
during	O
jogging	B-MED
p=0	O
.	O
	
ps	B-MED
varied	O
with	O
age	B-MED
p<0	O
only	O
during	O
fast	B-MED
walking	B-MED
.	O
	
at	O
any	O
speed	B-MED
of	O
fast	B-MED
walking	B-MED
,	O
older	B-MED
children	I-MED
generated	B-MED
more	O
peaka2	B-MED
p=0	O
and	O
less	O
peakh3	B-MED
p=0	O
than	O
younger	B-MED
children	I-MED
.	O
	
while	O
the	O
kinetics	B-MED
of	O
running	B-MED
propulsion	B-MED
appear	O
to	O
be	O
developed	O
by	O
age	B-MED
six	O
years	B-MED
,	O
the	O
skills	B-MED
of	O
fast	B-MED
walking	B-MED
appeared	O
to	O
require	O
additional	O
neuromuscular	B-MED
maturity	B-MED
.	O
	
these	O
findings	B-MED
support	O
the	O
concept	O
that	O
running	B-MED
is	O
a	O
skill	B-MED
that	O
matures	B-MED
early	B-MED
for	O
td	B-MED
children	B-MED
.	O
	
the	O
relationship	B-MED
between	O
anthropometry	B-MED
and	O
body	B-MED
composition	I-MED
from	O
computed	B-MED
tomography	I-MED
the	O
mediators	O
of	O
atherosclerosis	B-MED
in	O
south	B-MED
asians	I-MED
living	B-MED
in	O
america	B-MED
study	O
few	O
studies	O
examine	O
the	O
relationships	B-MED
between	O
anthropometry	B-MED
and	O
the	O
body	B-MED
composition	I-MED
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	B-MED
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	B-MED
in	O
south	B-MED
asians	I-MED
living	O
in	O
the	O
us	B-MED
.	O
	
we	O
conducted	O
a	O
cross-sectional	B-MED
study	I-MED
of	O
871	O
participants	B-MED
in	O
the	O
mediators	O
of	O
atherosclerosis	B-MED
in	O
south	B-MED
asians	I-MED
living	B-MED
in	O
america	B-MED
masala	B-MED
study	I-MED
who	O
had	O
bmi	B-MED
<	O
40	O
kg/m	O
and	O
underwent	O
abdominal	B-MED
ct	I-MED
scans	I-MED
for	O
measurement	B-MED
of	O
visceral	B-MED
and	O
subcutaneous	B-MED
fat	I-MED
.	O
	
linear	B-MED
regression	I-MED
was	O
used	O
to	O
model	B-MED
the	O
associations	O
between	O
anthropometric	B-MED
measures	I-MED
and	O
naturally	O
log-transformed	O
body	B-MED
composition	I-MED
measures	O
.	O
	
all	O
measures	O
of	O
anthropometry	B-MED
,	O
except	O
height	B-MED
,	O
were	O
significantly	O
associated	B-MED
with	I-MED
visceral	B-MED
fat	I-MED
and	O
had	O
a	O
significant	B-MED
non-linear	O
component	O
p	O
<	O
05	O
.	O
	
the	O
only	O
associations	O
for	O
visceral	B-MED
fat	I-MED
that	O
exhibited	O
significant	B-MED
heterogeneity	B-MED
by	O
sex	B-MED
were	O
waist	B-MED
circumference	I-MED
%	O
difference	O
in	O
visceral	B-MED
fat	I-MED
slope	O
women	B-MED
1.92	O
,	O
men	B-MED
2.74	O
,	O
p	O
=	O
007	O
for	O
interaction	O
and	O
waist-to-hip	B-MED
ratio	I-MED
women	B-MED
25.9	O
,	O
men	B-MED
717.4	O
,	O
p	O
<	O
001	O
.	O
	
except	O
for	O
height	B-MED
,	O
all	O
measures	O
of	O
anthropometry	B-MED
were	O
significantly	O
associated	B-MED
with	I-MED
subcutaneous	B-MED
fat	I-MED
,	O
had	O
a	O
significant	B-MED
quadratic	O
component	O
,	O
and	O
significant	B-MED
heterogeneity	B-MED
by	O
sex	B-MED
weight	B-MED
kg	O
2.74	O
for	O
women	B-MED
,	O
4.08	O
for	O
men	B-MED
bmi	B-MED
kg/m	O
10.3	O
,	O
14.0	O
waist	B-MED
circumference	I-MED
cm	O
1.51	O
,	O
3.36	O
hip	B-MED
circumference	I-MED
cm	O
2.53	O
,	O
4.50	O
with	O
p	O
<	O
001	O
for	O
each	O
.	O
	
in	O
masala	O
participants	B-MED
,	O
the	O
relationships	B-MED
of	O
anthropometric	B-MED
measures	I-MED
with	O
visceral	B-MED
and	O
subcutaneous	B-MED
fat	I-MED
appear	O
similar	O
to	O
other	O
race	B-MED
/	O
ethnic	B-MED
groups	I-MED
,	O
but	O
with	O
weaker	B-MED
non-linearity	O
and	O
heterogeneity	B-MED
by	O
sex	B-MED
.	O
	
given	O
these	O
results	O
,	O
researchers	B-MED
should	O
consider	O
separate	O
models	O
by	O
sex	B-MED
for	O
us	O
south	B-MED
asians	I-MED
when	O
approximating	O
subcutaneous	B-MED
fat	I-MED
or	O
when	O
using	O
waist	B-MED
circumference	I-MED
to	O
approximate	O
visceral	B-MED
fat	I-MED
.	O
	
active	B-MED
packaging	B-MED
of	O
chicken	B-MED
meats	I-MED
with	O
modified	B-MED
atmosphere	B-MED
including	O
oxygen	B-MED
scavengers	B-MED
the	O
effects	B-MED
of	I-MED
modified	B-MED
atmosphere	B-MED
packaging	B-MED
map	B-MED
-70%	O
co2	B-MED
/30%	O
n2	B-MED
and	O
iron	B-MED
-based	O
oxygen	B-MED
scavengers	B-MED
os	B-MED
with	O
various	O
absorption	O
capacities	O
ageless	O
ss100	O
,	O
ss300	O
,	O
and	O
ss500	O
as	O
an	O
active	O
packaging	B-MED
system	I-MED
on	O
microbiological	B-MED
and	O
oxidative	B-MED
changes	B-MED
in	O
chicken	B-MED
thigh	I-MED
meats	I-MED
were	O
evaluated	O
during	O
refrigerated	B-MED
storage	I-MED
4	O
for	O
19	O
d	O
at	O
3-	O
day	B-MED
intervals	B-MED
.	O
	
total	B-MED
aerobic	I-MED
mesophilic	I-MED
bacteria	I-MED
counts	I-MED
exceeded	O
the	O
acceptability	B-MED
limit	I-MED
at	O
d	O
7	O
in	O
the	O
control	B-MED
group	I-MED
without	O
map	B-MED
air	B-MED
,	O
and	O
at	O
d	O
19	O
in	O
map	B-MED
and	O
os	B-MED
containing	O
samples	B-MED
.	O
	
os	B-MED
utilization	B-MED
resulted	O
in	O
around	O
1.5	O
and	O
1.0	O
log	O
unit	O
reductions	B-MED
in	O
pseudomonas	B-MED
spp	I-MED
.	O
	
counts	B-MED
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	B-MED
,	O
respectively	O
,	O
as	O
compared	O
with	O
air	B-MED
and	O
map	B-MED
groups	B-MED
p	O
<	O
0.05	O
.	O
	
map	B-MED
and	O
os	B-MED
groups	B-MED
had	O
fewer	O
p	O
<	O
0.05	O
coliform	B-MED
counts	I-MED
than	O
did	O
the	O
air	B-MED
group	B-MED
,	O
with	O
an	O
approximately	O
1.0	O
log	O
reduction	B-MED
observed	O
at	O
d	O
10	O
.	O
	
although	O
in	O
some	O
cases	B-MED
os	B-MED
utilization	B-MED
resulted	O
in	O
lower	O
tbars	B-MED
values	B-MED
and	O
carbonyl	B-MED
and	O
sulphydryl	B-MED
contents	I-MED
,	O
particularly	O
during	O
later	O
stages	B-MED
of	O
refrigerated	B-MED
storage	I-MED
as	O
compared	O
to	O
air	B-MED
and	O
map	B-MED
groups	B-MED
,	O
in	O
general	O
,	O
these	O
effects	B-MED
were	O
not	O
always	O
apparent	O
.	O
	
the	O
results	O
of	O
this	O
study	O
suggested	O
that	O
map	B-MED
suppressed	B-MED
microbiological	B-MED
growth	I-MED
and	O
retarded	O
lipid	B-MED
and	O
protein	B-MED
oxidation	I-MED
in	O
chicken	B-MED
thigh	I-MED
meats	I-MED
,	O
with	O
a	O
9-	O
day	B-MED
shelf-life	B-MED
extention	O
with	O
insignificant	O
effects	B-MED
of	I-MED
os	B-MED
.	O
	
multidrug	B-MED
resistance	I-MED
of	O
acinetobacter	B-MED
baumannii	I-MED
in	O
ladoke	B-MED
akintola	I-MED
university	I-MED
teaching	I-MED
hospital	I-MED
,	O
osogbo	B-MED
,	O
nigeria	I-MED
acinetobacter	B-MED
baumannii	I-MED
is	O
a	O
ubiquitous	O
pathogen	B-MED
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare-associated	B-MED
infections	I-MED
at	O
ladoke	B-MED
akintola	I-MED
university	I-MED
teaching	I-MED
hospital	I-MED
.	O
	
isolates	B-MED
were	O
assayed	B-MED
according	O
to	O
standard	B-MED
protocol	I-MED
.	O
	
the	O
isolates	B-MED
were	O
subjected	O
to	O
molecular	B-MED
techniques	I-MED
to	O
detect	O
blaoxa	B-MED
,	O
blatem	I-MED
,	O
blactx-m	I-MED
,	O
and	I-MED
blashv	I-MED
genes	I-MED
in	O
strains	B-MED
of	O
the	O
a	B-MED
.	O
	
baumannii	I-MED
isolates	B-MED
.	O
	
the	O
prevalence	O
of	O
a	B-MED
.	O
	
baumannii	I-MED
was	O
8.5	O
and	O
was	O
most	O
prevalent	O
among	O
patients	B-MED
in	O
the	O
age	B-MED
group	I-MED
51-60	O
36%	O
the	O
male	B-MED
patients	B-MED
63.6	O
were	O
more	O
infected	B-MED
than	O
their	O
female	B-MED
counterparts	O
.	O
	
patients	B-MED
72.7	O
in	O
the	O
intensive	B-MED
care	I-MED
unit	I-MED
icu	B-MED
were	O
most	O
infected	B-MED
with	O
this	O
organism	B-MED
.	O
	
the	O
isolates	B-MED
showed	O
100%	O
resistance	B-MED
to	O
both	O
amikacin	B-MED
and	O
ciprofloxacin	B-MED
and	O
90.9	O
to	O
both	O
ceftriaxone	B-MED
and	O
ceftazidime	B-MED
,	O
while	O
resistance	B-MED
to	O
the	O
other	O
antibiotics	B-MED
used	O
in	O
this	O
study	B-MED
were	O
piperacillin	B-MED
81.8	O
,	O
imipenem	B-MED
72.7	O
,	O
gentamycin	B-MED
72.2	O
,	O
and	O
meropenem	B-MED
63.6	O
.	O
	
none	O
of	O
the	O
isolates	B-MED
was	O
,	O
however	O
,	O
resistant	B-MED
to	O
colistin	B-MED
.	O
	
pcr	B-MED
results	B-MED
showed	O
that	O
blaoxa	B-MED
,	O
blatem	I-MED
,	O
and	I-MED
blactx-m	I-MED
genes	I-MED
were	O
positive	B-MED
in	O
some	O
isolates	B-MED
,	O
while	O
blashv	B-MED
was	O
not	B-MED
detected	I-MED
in	O
any	O
of	O
the	O
isolates	B-MED
.	O
	
this	O
study	B-MED
has	O
revealed	B-MED
that	O
the	O
strains	B-MED
of	O
a	B-MED
.	O
	
baumannii	I-MED
isolated	B-MED
are	O
multiple	B-MED
drug	I-MED
resistant	I-MED
.	O
	
regular	O
monitoring	B-MED
,	O
judicious	O
prescription	B-MED
,	O
and	O
early	O
detection	B-MED
of	O
resistance	B-MED
to	O
these	O
antibiotics	B-MED
are	O
,	O
therefore	O
,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
dataset	B-MED
of	O
the	O
molecular	B-MED
dynamics	I-MED
simulations	I-MED
of	O
bilayers	B-MED
consisting	O
of	O
short	O
amyloidogenic	B-MED
peptide	I-MED
vdswnvlvag	B-MED
from	O
bgl2p-glucantransferase	B-MED
of	O
s	B-MED
.	O
	
cerevisiae	I-MED
cell	B-MED
wall	I-MED
the	O
amyloidogenic	B-MED
peptide	I-MED
vdswnvlvag	B-MED
from	O
bgl2p-glucantransferase	B-MED
of	O
saccharomyces	B-MED
cerevisiae	I-MED
cell	B-MED
wall	I-MED
and	O
its	O
modifying	O
analog	B-MED
veswnvlvag	B-MED
were	O
taken	O
for	O
the	O
construction	O
of	O
four	B-MED
types	O
of	O
bilayers	B-MED
which	O
differ	O
by	O
orientation	B-MED
of	O
the	O
peptides	B-MED
in	O
the	O
layers	B-MED
and	O
of	O
the	O
layers	B-MED
relative	O
to	O
each	O
other	O
.	O
	
these	O
bilayers	B-MED
were	O
used	O
as	O
starting	O
models	B-MED
for	O
the	O
molecular	B-MED
dynamics	I-MED
md	B-MED
at	O
three	O
charge	O
states	O
neutral	O
,	O
ph3	O
,	O
and	O
ph5	O
.	O
	
the	O
changes	B-MED
of	O
the	O
fraction	O
of	O
secondary	B-MED
structure	I-MED
during	O
1	O
ns	O
simulations	B-MED
were	O
received	O
for	O
96	O
md	O
trajectories	O
.	O
	
the	O
data	B-MED
article	B-MED
contains	O
the	O
necessary	O
information	B-MED
for	O
the	O
construction	O
of	O
models	B-MED
of	O
β-strands	B-MED
organization	B-MED
in	O
the	O
oligomer	B-MED
structure	B-MED
.	O
	
these	O
results	B-MED
were	O
used	O
in	O
the	O
associated	O
research	B-MED
article	I-MED
""""	O
structural	B-MED
model	I-MED
of	O
amyloid	B-MED
fibrils	I-MED
for	O
amyloidogenic	B-MED
peptide	I-MED
from	O
bgl2p-glucantransferase	B-MED
of	O
s	B-MED
.	O
	
cerevisiae	I-MED
cell	B-MED
wall	I-MED
and	O
its	O
modifying	O
analog	B-MED
.	O
	
new	O
morphology	B-MED
of	O
amyloid	B-MED
fibrils	I-MED
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
popliteal	B-MED
artery	I-MED
for	O
vascular	B-MED
access	I-MED
the	O
saphenous	B-MED
vein	I-MED
is	O
commonly	O
used	O
as	O
a	O
vascular	B-MED
graft	I-MED
in	O
peripheral	B-MED
artery	I-MED
surgery	B-MED
but	O
rarely	B-MED
used	O
for	O
vascular	B-MED
access	I-MED
.	O
	
the	O
literature	B-MED
on	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
is	O
scarce	B-MED
.	O
	
here	O
we	O
present	O
two	O
cases	O
of	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
for	O
vascular	B-MED
access	I-MED
,	O
the	O
surgical	B-MED
technique	I-MED
and	O
respective	O
follow-up	B-MED
.	O
	
two	O
young	B-MED
men	B-MED
,	O
aged	O
29	O
and	O
36	O
years	B-MED
,	O
were	O
chosen	O
for	O
lower-limb	B-MED
vascular	I-MED
access	I-MED
for	O
hemodialysis	B-MED
.	O
	
the	O
first	O
patient	B-MED
was	O
paraplegic	B-MED
since	O
birth	O
.	O
	
he	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	B-MED
extremity	I-MED
vascular	I-MED
access	I-MED
was	O
avoided	O
.	O
	
the	O
second	O
patient	B-MED
presented	O
with	O
an	O
infected	B-MED
upper	B-MED
extremity	I-MED
arteriovenous	I-MED
graft	I-MED
avg	B-MED
and	O
after	O
multiple	O
closed	B-MED
avfs	B-MED
he	O
had	O
no	O
more	O
available	O
arm	B-MED
veins	I-MED
.	O
	
both	O
patients	B-MED
received	B-MED
autologous	B-MED
lower	B-MED
extremity	I-MED
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transpositions	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
under	O
spinal	B-MED
anesthesia	I-MED
in	O
may	O
and	O
october	O
2012	O
,	O
respectively	O
.	O
	
cannulation	B-MED
of	O
the	O
fistula	B-MED
was	O
allowed	O
after	O
one	O
month	B-MED
.	O
	
there	O
were	O
no	B-MED
early	I-MED
complications	I-MED
.	O
	
slight	B-MED
swelling	I-MED
on	O
the	O
leg	B-MED
appeared	B-MED
in	O
one	O
of	O
the	O
patients	B-MED
.	O
	
both	O
fistulas	B-MED
were	O
still	O
functional	B-MED
after	O
36	O
and	O
32	O
months	B-MED
,	O
respectively	O
.	O
	
the	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
popliteal	B-MED
artery	I-MED
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	B-MED
and	I-MED
straight	I-MED
segment	I-MED
for	O
cannulation	B-MED
and	O
may	O
be	O
a	O
suitable	O
autologous	B-MED
vascular	B-MED
access	I-MED
in	O
selected	O
inhibited	B-MED
temperament	B-MED
and	O
hippocampal	B-MED
volume	B-MED
in	O
offspring	B-MED
of	O
parents	B-MED
with	O
bipolar	B-MED
disorder	I-MED
prior	O
studies	O
have	O
suggested	B-MED
that	O
inhibited	B-MED
temperament	B-MED
may	O
be	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
for	O
developing	O
anxiety	B-MED
or	O
mood	B-MED
disorder	I-MED
,	O
including	O
bipolar	B-MED
disorder	I-MED
.	O
	
however	O
,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	B-MED
risk	B-MED
is	O
unknown	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-MED
temperament	B-MED
in	O
symptomatic	B-MED
and	O
asymptomatic	B-MED
child	B-MED
offspring	B-MED
of	O
parents	B-MED
with	O
bipolar	B-MED
disorder	I-MED
obd	B-MED
and	O
to	O
investigate	B-MED
whether	O
inhibited	B-MED
temperament	O
is	O
associated	O
with	O
aberrant	O
hippocampal	O
volumes	O
compared	O
with	O
healthy	O
control	O
hc	O
youth	O
.	O
	
the	O
obd	O
group	O
consisted	O
of	O
45	O
youth	O
,	O
24	O
of	O
whom	O
had	O
current	O
psychiatric	O
symptoms	O
obd	O
and	O
21	O
without	O
any	O
psychiatric	O
symptoms	O
obd	O
,	O
and	O
were	O
compared	O
with	O
24	O
hc	O
youth	O
.	O
	
temperament	O
characteristics	O
were	O
measured	O
by	O
using	O
the	O
revised	O
dimensions	O
of	O
temperament	O
survey	O
.	O
	
magnetic	O
resonance	O
imaging	O
was	O
used	O
to	O
measure	O
hippocampal	O
volumes	O
.	O
	
the	O
association	O
between	O
temperament	O
and	O
hippocampal	O
volumes	O
was	O
tested	O
by	O
using	O
multiple	O
regression	O
analysis	O
.	O
	
compared	O
with	O
the	O
obd	O
group	O
,	O
the	O
obd	O
group	O
had	O
significantly	O
more	O
inhibited	B-MED
temperament	B-MED
traits	O
,	O
less	O
flexibility	O
,	O
more	O
negative	O
mood	O
,	O
and	O
less	O
regular	O
rhythm	O
in	O
their	O
daily	O
routines	O
.	O
	
in	O
contrast	O
,	O
the	O
obd	O
group	O
was	O
more	O
likely	O
to	O
approach	O
novel	O
situations	O
compared	O
with	O
obd	O
or	O
hc	O
groups	O
.	O
	
within	O
the	O
obd	O
group	O
,	O
a	O
more	O
inhibited	O
temperament	O
was	O
associated	B-MED
with	I-MED
smaller	O
right	O
hippocampal	O
volumes	O
.	O
	
in	O
this	O
study	O
,	O
symptomatic	O
obd	O
were	O
characterized	O
by	O
an	O
inhibited	O
temperament	O
that	O
was	O
inversely	O
correlated	O
with	O
hippocampal	O
volume	O
.	O
	
additional	O
longitudinal	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
inverse	O
correlations	O
between	O
hippocampal	O
volume	O
and	O
inhibited	O
temperament	O
represent	O
early	O
markers	O
of	O
risk	O
for	O
later	O
developing	O
bipolar	O
disorder	I-MED
dynamic	B-MED
disorder	B-MED
can	O
explain	O
non-exponential	B-MED
kinetics	B-MED
of	O
fast	O
protein	B-MED
mechanical	I-MED
unfolding	I-MED
protein	B-MED
unfolding	I-MED
often	O
does	O
not	O
obey	O
a	O
simple	O
two-state	O
behavior	O
.	O
	
previous	O
single	B-MED
molecule	I-MED
force	I-MED
spectroscopy	I-MED
studies	B-MED
demonstrated	O
stretched	B-MED
exponential	I-MED
kinetics	B-MED
of	O
protein	B-MED
unfolding	I-MED
under	O
a	O
constant	B-MED
pulling	I-MED
force	I-MED
,	O
the	O
molecular	B-MED
origin	B-MED
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O
	
we	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	B-MED
unfolding	I-MED
of	O
ubiquitin	B-MED
and	O
nug2	B-MED
by	O
molecular	B-MED
dynamics	I-MED
md	I-MED
simulations	I-MED
.	O
	
both	O
proteins	B-MED
show	O
kinetics	B-MED
best	O
fit	O
by	O
stretched	B-MED
exponentials	I-MED
,	O
with	O
stretching	B-MED
exponents	I-MED
similar	O
to	O
those	O
found	O
in	O
experiments	B-MED
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	B-MED
in	O
our	O
short	O
md	B-MED
simulations	I-MED
.	O
	
instead	O
,	O
we	O
can	O
ascribe	O
non-exponential	B-MED
kinetics	B-MED
to	O
dynamic	B-MED
disorder	B-MED
,	O
due	O
to	O
conformational	B-MED
fluctuations	B-MED
on	O
the	O
nanosecond	B-MED
timescale	I-MED
.	O
	
our	O
study	B-MED
highlights	O
the	O
general	O
role	O
of	O
dynamic	B-MED
disorder	B-MED
in	O
protein	B-MED
kinetics	I-MED
on	O
a	O
broad	O
range	O
of	O
time	B-MED
scales	I-MED
even	O
including	O
those	O
probed	O
in	O
md	B-MED
simulations	I-MED
.	O
	
identification	O
and	O
functional	O
analysis	O
of	O
the	O
gtpv	B-MED
bidirectional	B-MED
promoter	B-MED
region	I-MED
the	O
goat	B-MED
pox	I-MED
chick	I-MED
embryo-attenuated	I-MED
virus	I-MED
gtpv	B-MED
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-MED
that	O
can	O
elicit	O
protective	O
immune	B-MED
responses	I-MED
.	O
	
it	O
possesses	O
a	O
large	O
genome	B-MED
and	O
a	O
robust	O
ability	O
to	O
express	B-MED
exogenous	B-MED
genes	B-MED
.	O
	
thus	O
,	O
this	O
virus	B-MED
is	O
an	O
ideal	B-MED
vector	B-MED
for	O
recombinant	B-MED
live	I-MED
vaccines	I-MED
for	O
infectious	B-MED
diseases	I-MED
in	O
ruminant	B-MED
animals	I-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	B-MED
promoter	B-MED
region	I-MED
of	O
gtpv	B-MED
through	O
screening	O
named	O
pbvv	B-MED
.	O
	
pbvv	B-MED
is	O
located	O
between	O
etf-l	B-MED
and	O
vitf-3	B-MED
,	O
which	O
are	O
transcribed	B-MED
in	O
opposite	B-MED
directions	B-MED
.	O
	
a	O
new	O
recombinant	B-MED
goat	I-MED
pox	I-MED
virus	I-MED
rgtpv	B-MED
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
pbvv	B-MED
was	O
used	O
as	O
a	O
promoter	B-MED
element	O
to	O
enhance	B-MED
brucella	B-MED
omp31	I-MED
expression	B-MED
,	O
and	O
duplicate	O
pbvv	B-MED
-	O
was	O
used	O
as	O
a	O
promoter	B-MED
element	I-MED
to	O
regulate	O
enhanced	B-MED
green	I-MED
fluorescent	I-MED
protein	I-MED
egfp	B-MED
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O
	
pbvv	B-MED
promoter	I-MED
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
p7.5	B-MED
promoter	I-MED
of	O
vaccinia	B-MED
virus	I-MED
,	O
as	O
measured	O
by	O
egfp	B-MED
expression	B-MED
the	O
fluorescence	B-MED
intensity	I-MED
of	O
egfp	B-MED
expressed	B-MED
in	O
cells	B-MED
was	O
confirmed	O
by	O
fluorescence	B-MED
microscopy	I-MED
and	O
flow	B-MED
cytometry	I-MED
.	O
	
pbvv	B-MED
promoter	I-MED
activity	O
was	O
measured	O
by	O
brucella	B-MED
omp31	I-MED
expression	B-MED
.	O
	
interaction	O
with	O
the	O
anti-brucella-omp31	B-MED
monoclonal	I-MED
antibody	I-MED
was	O
confirmed	O
by	O
western	B-MED
blotting	I-MED
,	O
and	O
omp31	B-MED
mrna	B-MED
expression	I-MED
was	O
assessed	O
by	O
qrt-pcr	B-MED
.	O
	
the	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	B-MED
multivalent	B-MED
vaccines	I-MED
based	O
on	O
rgtpv	B-MED
.	O
	
this	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	B-MED
of	O
exogenous	B-MED
genes	B-MED
.	O
	
psychometric	B-MED
analysis	I-MED
of	O
the	O
patient	B-MED
health	I-MED
questionnaire	I-MED
in	O
danish	B-MED
patients	B-MED
with	O
an	O
implantable	B-MED
cardioverter	I-MED
defibrillator	I-MED
the	O
defib-women	B-MED
study	I-MED
to	O
assess	O
the	O
psychometric	B-MED
properties	I-MED
of	O
the	O
patient	B-MED
health	I-MED
questionnaire	I-MED
phq-9	B-MED
,	O
a	O
measure	B-MED
of	O
depressive	B-MED
symptoms	I-MED
,	O
in	O
a	O
large	B-MED
danish	B-MED
national	B-MED
cohort	I-MED
of	O
patients	B-MED
with	O
heart	B-MED
disease	I-MED
,	O
implanted	B-MED
with	O
an	O
implantable	B-MED
cardioverter	I-MED
defibrillator	I-MED
icd	B-MED
,	O
using	O
item	B-MED
response	I-MED
theory	I-MED
.	O
	
a	O
prospective	B-MED
cohort	I-MED
of	O
patients	B-MED
implanted	B-MED
with	O
an	O
icd	B-MED
n=1531	O
80.4	O
men	B-MED
completed	O
the	O
phq-9	B-MED
at	O
the	O
time	O
of	O
implant	B-MED
.	O
	
data	B-MED
were	O
analyzed	B-MED
using	O
two	O
item	B-MED
response	I-MED
theory	I-MED
models	I-MED
,	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
and	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
.	O
	
the	O
analysis	B-MED
showed	O
disordered	B-MED
response	I-MED
thresholds	B-MED
in	O
eight	O
of	O
nine	O
items	B-MED
for	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
and	O
five	O
of	O
nine	O
items	B-MED
for	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
,	O
indicating	O
that	O
respondents	B-MED
have	O
difficulty	B-MED
discriminating	B-MED
between	O
response	B-MED
options	O
.	O
	
when	O
collapsing	O
response	B-MED
options	B-MED
2	O
and	O
3	O
,	O
the	O
rescored	B-MED
phq-9	B-MED
had	O
a	O
better	O
fit	O
to	O
both	O
models	B-MED
.	O
	
the	O
unidimensionality	B-MED
and	O
the	O
precision	B-MED
of	O
the	O
rescored	B-MED
phq-9	B-MED
were	O
confirmed	O
.	O
	
items	B-MED
did	O
not	O
have	O
any	O
differential	B-MED
functioning	I-MED
dif	B-MED
across	O
educational	B-MED
level	I-MED
,	O
age	B-MED
,	O
indication	B-MED
for	O
icd	B-MED
implantation	B-MED
,	O
and	O
severity	B-MED
of	O
heart	B-MED
failure	I-MED
that	O
influence	B-MED
depression	B-MED
outcomes	B-MED
in	O
patients	B-MED
with	O
an	O
icd	B-MED
.	O
	
one	O
item	O
exhibited	O
dif	B-MED
by	O
gender	B-MED
.	O
	
three	O
items	B-MED
did	O
not	O
fit	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
,	O
but	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
could	O
be	O
fitted	O
to	O
the	O
full	O
item	B-MED
set	I-MED
.	O
	
the	O
unidimensionality	B-MED
and	O
reliability	B-MED
of	O
the	O
danish	B-MED
version	I-MED
of	O
the	O
phq-9	B-MED
were	O
confirmed	B-MED
.	O
	
however	O
,	O
the	O
associated	B-MED
consequences	B-MED
of	O
the	O
number	O
of	O
response	B-MED
options	B-MED
3-point	O
versus	O
4-point	O
likert	B-MED
scale	I-MED
need	O
to	O
be	O
further	O
examined	B-MED
for	O
the	O
phq-9	B-MED
both	O
as	O
a	O
screening	B-MED
tool	B-MED
and	O
outcome	B-MED
measure	I-MED
.	O
	
geographical	B-MED
variations	I-MED
in	O
incidence	B-MED
,	O
management	B-MED
and	O
survival	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
in	O
a	O
western	B-MED
country	I-MED
information	B-MED
on	O
the	O
incidence	B-MED
,	O
management	B-MED
,	O
and	O
prognosis	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
hcc	B-MED
is	O
derived	O
from	O
population	B-MED
samples	I-MED
,	O
regional	B-MED
data	B-MED
,	O
or	O
registries	B-MED
.	O
	
comprehensive	B-MED
national	B-MED
evaluations	B-MED
within	O
a	O
given	O
country	B-MED
are	O
lacking	B-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
investigate	B-MED
regional	B-MED
variations	B-MED
in	O
hcc	B-MED
care	B-MED
within	O
france	B-MED
.	O
	
this	O
observational	B-MED
study	I-MED
analysed	O
data	B-MED
from	O
french	B-MED
administrative	B-MED
databases	I-MED
for	O
more	O
than	O
30	O
patients	B-MED
with	O
hcc	B-MED
diagnosed	B-MED
between	O
2009	O
and	O
2012	O
,	O
and	O
followed-up	O
until	O
2013	O
.	O
	
the	O
incidence	B-MED
of	O
hcc	B-MED
,	O
access	B-MED
to	O
surgery	B-MED
,	O
and	O
survival	B-MED
,	O
at	O
both	O
the	O
national	B-MED
level	I-MED
and	O
two	O
geographical	B-MED
levels	I-MED
the	O
21	O
french	B-MED
regions	I-MED
and	O
95	O
french	B-MED
departments	B-MED
into	O
which	O
france	B-MED
is	O
divided	B-MED
administratively	I-MED
,	O
were	O
determined	O
.	O
	
the	O
influence	B-MED
on	O
outcome	B-MED
of	O
the	O
structure	O
of	O
the	O
hospital	B-MED
where	O
hcc	B-MED
was	O
first	O
managed	B-MED
was	O
assessed	B-MED
.	O
	
at	O
the	O
national	B-MED
level	I-MED
,	O
the	O
median	B-MED
survival	I-MED
was	O
9.4	O
months	B-MED
and	O
only	O
22.8	O
of	O
patients	B-MED
had	O
curative	B-MED
treatment	I-MED
.	O
	
there	O
were	O
marked	O
variations	O
between	O
regions	B-MED
and	O
departments	B-MED
in	O
incidence	B-MED
,	O
access	B-MED
to	O
curative	B-MED
treatment	I-MED
range	O
1.3	O
and	O
8.1	O
respectively	O
,	O
and	O
in	O
median	B-MED
survival	I-MED
range	B-MED
5.7	O
and	O
4.3	O
months	B-MED
respectively	O
.	O
	
the	O
administrative	B-MED
type	I-MED
and	O
annual	B-MED
hcc	B-MED
-	O
caseload	B-MED
of	O
the	O
hospital	B-MED
where	O
patients	B-MED
were	O
first	O
admitted	B-MED
also	O
had	O
an	O
independent	B-MED
influence	B-MED
on	O
treatment	B-MED
and	O
survival	B-MED
.	O
	
despite	O
full	O
insurance	B-MED
coverage	I-MED
for	O
all	O
citizens	B-MED
,	O
national	B-MED
measures	B-MED
to	O
reduce	B-MED
inequities	I-MED
in	O
the	O
management	B-MED
of	O
cancer	B-MED
patients	I-MED
,	O
standardised	O
recommendations	B-MED
for	O
hcc	B-MED
surveillance	B-MED
and	O
management	B-MED
,	O
the	O
percentage	B-MED
of	O
patients	B-MED
undergoing	O
curative	B-MED
treatment	I-MED
and	O
their	O
survival	B-MED
may	O
vary	O
four-fold	O
depending	O
on	O
their	O
postcode	B-MED
.	O
	
the	O
hospital	B-MED
in	O
which	O
patients	B-MED
are	O
first	O
managed	B-MED
has	O
a	O
clear	O
influence	B-MED
on	O
accessibility	B-MED
to	O
both	O
good	B-MED
care	I-MED
and	O
survival	B-MED
.	O
	
population-based	B-MED
studies	I-MED
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B-MED
in	O
the	O
survival	B-MED
of	O
patients	B-MED
with	O
malignancy	B-MED
.	O
	
as	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	B-MED
of	O
health	B-MED
systems	I-MED
,	O
in	O
addition	O
to	O
the	O
incidence	B-MED
of	O
the	O
cancer	B-MED
or	O
quality	B-MED
of	O
registration	B-MED
,	O
variations	O
within	O
a	O
given	O
country	B-MED
should	O
be	O
minimal	B-MED
.	O
	
however	O
,	O
similar	O
to	O
between	O
countries	B-MED
differences	O
,	O
this	O
study	B-MED
shows	O
differences	O
within	O
the	O
same	O
country	B-MED
in	O
the	O
incidence	B-MED
,	O
curative	B-MED
treatment	I-MED
rate	B-MED
,	O
and	O
survival	B-MED
of	O
patients	B-MED
with	O
hcc	B-MED
.	O
	
evidence	B-MED
that	O
access	O
to	O
care	B-MED
and	O
survival	B-MED
varies	O
within	O
a	O
country	B-MED
can	O
strengthen	B-MED
the	I-MED
impetus	I-MED
for	O
government	B-MED
and	O
clinicians	B-MED
to	O
address	O
these	O
identification	B-MED
of	O
potential	O
predictive	B-MED
markers	B-MED
of	O
dexamethasone	B-MED
resistance	B-MED
in	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
response	B-MED
to	O
dexamethasone	B-MED
dexa	B-MED
,	O
as	O
a	O
hallmark	B-MED
drug	I-MED
in	O
the	O
treatment	B-MED
of	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
all	B-MED
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	B-MED
factors	I-MED
in	O
the	O
prediction	B-MED
of	I-MED
outcome	I-MED
in	O
all	B-MED
.	O
	
identification	B-MED
of	O
predictive	B-MED
markers	B-MED
of	O
chemoresistance	B-MED
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	B-MED
protocol	I-MED
with	O
the	O
lowest	O
effect	B-MED
adverse	I-MED
.	O
	
hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	B-MED
targets	I-MED
using	O
the	O
2de	B-MED
/	O
ms	B-MED
proteomics	B-MED
study	I-MED
of	O
a	O
dexa	B-MED
-	O
resistant	B-MED
cell	I-MED
line	I-MED
reh	B-MED
as	O
a	O
model	B-MED
for	O
poor	O
dexa	B-MED
responding	O
patients	B-MED
before	O
and	O
after	O
drug	B-MED
treatment	I-MED
.	O
	
using	O
the	O
proteomic	B-MED
methods	I-MED
,	O
three	O
differentially	O
expressed	B-MED
proteins	B-MED
were	O
detected	B-MED
,	O
including	O
voltage	B-MED
dependent	I-MED
anion	I-MED
channel	I-MED
1	I-MED
vdac1	B-MED
,	O
sorting	B-MED
nexin	I-MED
3	I-MED
snx3	B-MED
,	O
and	O
prefoldin	B-MED
subunit	I-MED
6	I-MED
pfdn6	B-MED
.	O
	
we	O
observed	O
low	O
expression	B-MED
of	O
three	O
proteins	B-MED
after	O
dexa	B-MED
treatment	B-MED
in	O
reh	B-MED
cells	I-MED
.	O
	
we	O
subsequently	O
verified	O
low	O
expression	B-MED
of	O
resulted	O
proteins	B-MED
at	O
the	O
mrna	B-MED
level	B-MED
using	O
the	O
quantitative	B-MED
pcr	I-MED
method	I-MED
.	O
	
these	O
proteins	B-MED
are	O
promising	O
proteins	B-MED
because	O
of	O
their	O
important	O
roles	B-MED
in	O
drug	B-MED
resistance	I-MED
and	O
regulation	B-MED
of	I-MED
apoptosis	I-MED
vdac1	B-MED
,	O
protein	B-MED
trafficking	I-MED
snx3	B-MED
,	O
and	O
protein	B-MED
folding	I-MED
pfdn6	B-MED
.	O
	
additionally	O
,	O
mrna	B-MED
expression	B-MED
level	I-MED
of	O
these	O
proteins	B-MED
was	O
assessed	B-MED
in	O
17	O
bone	B-MED
marrow	I-MED
samples	I-MED
from	O
children	B-MED
with	O
newly	B-MED
diagnosed	I-MED
all	B-MED
and	O
7	O
non-cancerous	B-MED
samples	I-MED
as	O
controls	B-MED
.	O
	
the	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	B-MED
subtypes	I-MED
of	O
leukemia	B-MED
,	O
mrna	B-MED
expression	B-MED
of	O
vdac1	B-MED
,	O
snx3	B-MED
,	O
and	O
pfdn6	B-MED
decreased	O
in	O
all	B-MED
samples	B-MED
compared	O
with	O
non-cancerous	B-MED
samples	I-MED
particularly	O
in	O
vdac1	B-MED
p	O
<	O
0.001	O
.	O
	
additionally	O
,	O
mrna	B-MED
expression	B-MED
of	O
three	O
proteins	B-MED
was	O
also	O
declined	O
in	O
high-risk	B-MED
samples	B-MED
compared	O
with	O
standard	B-MED
risk	B-MED
cases	B-MED
.	O
	
these	O
results	O
demonstrated	O
diagnostic	B-MED
and	O
prognostic	B-MED
value	B-MED
of	O
these	O
proteins	B-MED
in	O
childhood	B-MED
all	B-MED
.	O
	
furthermore	O
,	O
investigation	B-MED
of	O
protein-protein	B-MED
interaction	I-MED
using	O
string	B-MED
database	B-MED
indicated	O
that	O
these	O
proteins	B-MED
involved	O
in	O
the	O
signaling	B-MED
pathway	I-MED
of	O
nr3c1	B-MED
as	O
dexamethasone	B-MED
target	B-MED
.	O
	
in	O
conclusion	O
,	O
our	O
proteomic	B-MED
study	I-MED
in	O
dexa	B-MED
resistant	B-MED
leukemic	B-MED
cells	I-MED
revealed	O
vdac1	B-MED
,	O
snx3	B-MED
,	O
and	O
pfdn6	B-MED
are	O
promising	O
proteins	B-MED
that	O
might	O
serve	O
as	O
potential	O
biomarkers	B-MED
of	O
prognosis	B-MED
and	O
chemotherapy	B-MED
in	O
childhood	B-MED
all	B-MED
.	O
	
benthic	B-MED
injury	I-MED
dose-response	I-MED
models	I-MED
for	O
polychlorinated	B-MED
biphenyl	I-MED
-	O
contaminated	B-MED
sediment	B-MED
using	O
equilibrium	B-MED
partitioning	I-MED
the	O
study	B-MED
goal	O
was	O
to	O
develop	O
a	O
sediment	B-MED
polychlorinated	B-MED
biphenyl	I-MED
pcb	B-MED
dose-response	B-MED
model	I-MED
based	O
on	O
benthic	B-MED
invertebrate	I-MED
effects	O
to	O
pcbs	B-MED
.	O
	
the	O
authors	O
used	O
an	O
equilibrium	B-MED
partitioning	I-MED
eqp	I-MED
approach	I-MED
to	O
generate	O
predicted	O
pcb	B-MED
sediment	B-MED
effect	O
concentrations	B-MED
largely	O
aroclor	B-MED
1254	I-MED
associated	O
with	O
a	O
gradient	B-MED
of	O
toxic	B-MED
effects	I-MED
in	O
benthic	B-MED
organisms	I-MED
from	O
effects	O
observed	O
in	O
aquatic	B-MED
toxicity	B-MED
studies	B-MED
.	O
	
the	O
present	O
study	B-MED
differs	O
from	O
all	O
other	O
eqp	B-MED
collective	O
sediment	B-MED
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose-response	B-MED
gradient	B-MED
of	O
effects	O
for	O
pcbs	B-MED
rather	O
than	O
a	O
single	O
,	O
protective	O
value	O
.	O
	
the	O
authors	O
reviewed	O
the	O
chronic	B-MED
aquatic	B-MED
toxicity	B-MED
literature	B-MED
to	O
identify	O
measured	O
aqueous	B-MED
pcb	B-MED
concentrations	B-MED
and	O
associated	O
benthic	B-MED
invertebrate	I-MED
effects	O
.	O
	
the	O
authors	O
control-normalized	O
the	O
aquatic	B-MED
toxic	B-MED
effect	I-MED
data	B-MED
and	O
expressed	O
results	O
from	O
various	O
studies	B-MED
as	O
a	O
common	B-MED
metric	I-MED
,	O
percent	B-MED
injury	I-MED
.	O
	
then	O
,	O
they	O
calculated	O
organic	B-MED
carbon	I-MED
-normalized	O
sediment	B-MED
pcb	B-MED
concentrations	B-MED
mg/kg	O
organic	B-MED
carbon	I-MED
from	O
the	O
aqueous	B-MED
pcb	B-MED
toxicity	B-MED
data	B-MED
set	I-MED
using	O
eqp	B-MED
theory	O
based	O
on	O
the	O
us	B-MED
environmental	I-MED
protection	I-MED
agency's	I-MED
epiweb	B-MED
4.1	I-MED
derivation	O
of	O
the	O
water-organic	B-MED
carbon	I-MED
partition	I-MED
coefficient	I-MED
koc	B-MED
.	O
	
lastly	O
,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose-response	B-MED
numerical	I-MED
model	I-MED
for	O
these	O
synoptic	O
sediment	B-MED
pcb	B-MED
concentrations	B-MED
and	O
biological	B-MED
effects	I-MED
y	O
=	O
100/1	O
+	O
10	O
hill	O
slope	O
ec50	O
=	O
median	B-MED
effective	I-MED
concentration	I-MED
.	O
	
these	O
models	B-MED
were	O
used	O
to	O
generate	O
"""look-up"""	O
tables	B-MED
reporting	O
percent	B-MED
injury	I-MED
in	O
benthic	B-MED
biota	I-MED
for	O
a	O
range	O
of	O
aroclor	B-MED
-specific	O
sediment	B-MED
concentrations	B-MED
.	O
	
for	O
example	O
,	O
the	O
model	B-MED
using	O
the	O
epiweb	B-MED
koc	B-MED
estimate	O
predicts	O
mean	B-MED
benthic	I-MED
injury	I-MED
of	O
23.3	O
,	O
46.0	O
,	O
70.6	O
,	O
87.1	O
,	O
and	O
95%	O
for	O
hypothetical	O
sediment	B-MED
concentrations	B-MED
of	O
1	O
mg/kg	O
,	O
2	O
mg/kg	O
,	O
4	O
mg/kg	O
,	O
8	O
mg/kg	O
,	O
and	O
16	O
mg/kg	O
dry	O
weight	O
of	O
aroclor	B-MED
1254	I-MED
,	O
respectively	O
at	O
1%	O
organic	B-MED
carbon	I-MED
.	O
	
the	O
authors	O
recommend	O
the	O
model	B-MED
presented	O
for	O
screening	O
but	O
suggest	O
,	O
when	O
possible	O
,	O
determining	O
a	O
site-specific	B-MED
koc	B-MED
that	O
,	O
along	O
with	O
the	O
tables	B-MED
and	O
equations	B-MED
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose-response	B-MED
sediment	B-MED
concentration	B-MED
.	O
	
extract	B-MED
of	I-MED
caulis	I-MED
spatholobi	I-MED
,	O
a	O
novel	O
blocker	O
targeting	O
tumor	O
cell	O
induced	O
platelet	O
aggregation	O
,	O
inhibits	O
breast	O
cancer	O
metastasis	O
metastasis	O
of	O
breast	O
cancer	O
is	O
the	O
vital	O
step	O
for	O
malignant	O
progression	O
.	O
	
during	O
such	O
a	O
process	O
,	O
hematogenous	O
metastasis	O
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	O
cells	O
.	O
	
a	O
platelet	O
,	O
contributes	O
to	O
hypercoagulable	O
state	O
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	O
system	O
for	O
supporting	O
metastasis	O
.	O
	
therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	O
and	O
a	O
tumor	O
cell	O
plays	O
a	O
critical	O
role	O
in	O
tumor	O
cell	O
metastasis	O
.	O
	
consequently	O
,	O
inhibiting	O
tumor	O
cell	O
induced	O
platelet	O
aggregation	O
tcipa	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	O
of	O
tumor	O
metastasis	O
such	O
as	O
aspirin	O
asa	O
.	O
	
under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor	O
t	O
complex	O
,	O
80%	O
ethanol	O
extracts	O
of	O
caulis	B-MED
spatholobi	I-MED
set	O
successfully	O
alleviated	O
the	O
hypercoagulation	O
state	O
,	O
thereby	O
reducing	O
tumor	O
metastasis	O
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	O
cancer	O
cell	O
model	O
.	O
	
through	O
mtt	O
and	O
anti	O
assay	O
stimulated	O
by	O
adp	O
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
set	O
.	O
	
by	O
using	O
confocal	O
microscopy	O
,	O
we	O
observed	O
that	O
set	O
can	O
strongly	O
block	O
the	O
formation	O
of	O
t	O
complex	O
i	O
n	O
vitro	O
.	O
	
the	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
facs	O
analysis	O
.	O
	
the	O
fluorescent	O
value	O
of	O
t	O
complex	O
was	O
obviously	O
decreased	O
in	O
the	O
drug	O
groups	O
.	O
	
in	O
vivo	O
,	O
4t1	O
cells	O
were	O
injected	O
through	O
the	O
mouse	O
tail	O
vein	O
for	O
dynamic	O
visualization	O
by	O
small	O
animal	O
imaging	O
system	O
.	O
	
the	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	O
.	O
	
additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	O
and	O
eosin	O
h	O
staining	O
of	O
lung	O
tissue	O
was	O
performed	O
.	O
	
set	O
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	O
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	O
.	O
	
for	O
the	O
molecular	O
mechanism	O
study	O
of	O
anti	O
,	O
zymography	O
and	O
r	O
t	O
assay	O
preliminarily	O
revealed	O
the	O
molecular	O
mechanism	O
of	O
set	O
in	O
the	O
regulation	O
of	O
p	O
t	O
interaction	O
.	O
	
collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	O
metastasis	O
by	O
suppressing	O
tcipa	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	O
treatment	I-MED
generalized	B-MED
epilepsy	I-MED
and	O
myoclonic	B-MED
seizures	I-MED
in	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
prompted	O
by	O
the	O
observations	O
of	O
juvenile	B-MED
myoclonic	I-MED
epilepsy	I-MED
jme	B-MED
in	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
22q11ds	B-MED
and	O
recurrent	B-MED
copy	I-MED
number	I-MED
variants	I-MED
in	O
genetic	B-MED
generalized	B-MED
epilepsy	I-MED
gge	B-MED
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	B-MED
of	O
22q11ds	B-MED
with	O
gge	B-MED
and	O
with	O
myoclonic	B-MED
seizures	I-MED
.	O
	
through	O
routine	B-MED
diagnostics	I-MED
,	O
we	O
identified	O
3	O
novel	O
individuals	B-MED
with	O
the	O
seemingly	O
uncommon	B-MED
combination	B-MED
of	O
22q11ds	B-MED
and	O
jme	B-MED
.	O
	
we	O
subsequently	O
screened	B-MED
the	O
literature	B-MED
for	O
reports	B-MED
focussing	O
on	O
the	O
epilepsy	B-MED
phenotype	I-MED
in	O
22q11ds	B-MED
.	O
	
we	O
additionally	O
screened	B-MED
a	O
database	B-MED
of	O
173	O
22q11ds	B-MED
patients	B-MED
and	O
identified	O
a	O
fourth	O
individual	B-MED
with	O
jme	B-MED
as	O
well	O
as	O
2	O
additional	O
cases	B-MED
with	O
gge	B-MED
.	O
	
we	O
describe	O
6	O
novel	B-MED
and	O
22	O
published	B-MED
cases	B-MED
with	O
co-occurrence	B-MED
of	O
22q11ds	B-MED
and	O
gge	B-MED
.	O
	
in	O
many	O
patients	B-MED
,	O
gge	B-MED
was	O
associated	B-MED
with	I-MED
myoclonic	B-MED
seizures	I-MED
allowing	O
for	O
a	O
diagnosis	B-MED
of	O
jme	B-MED
in	O
at	O
least	O
6	O
individuals	B-MED
.	O
	
seventeen	O
of	O
the	O
173	O
22q11ds	B-MED
cases	B-MED
10%	O
had	O
a	O
diagnosis	B-MED
of	O
either	O
focal	B-MED
or	O
generalized	B-MED
epilepsy	I-MED
.	O
	
in	O
these	O
cases	B-MED
,	O
focal	B-MED
epilepsy	I-MED
could	O
often	O
be	O
attributed	O
to	O
syndrome-associated	B-MED
hypocalcaemia	I-MED
,	O
cerebral	B-MED
bleeds	I-MED
,	O
or	O
structural	B-MED
brain	I-MED
anomalies	I-MED
.	O
	
however	O
,	O
the	O
cause	O
of	O
gge	B-MED
remained	O
unclear	O
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	B-MED
with	O
22q11ds	B-MED
and	O
gge	B-MED
especially	O
jme	B-MED
,	O
showing	O
that	O
both	O
disorders	B-MED
frequently	B-MED
co-occur	I-MED
.	O
	
compared	O
to	O
the	O
reported	B-MED
prevalence	I-MED
of	O
15-21%	O
,	O
in	O
our	O
case	B-MED
series	I-MED
only	O
10%	O
of	O
22q11ds	B-MED
individuals	B-MED
were	O
found	O
to	O
have	O
epilepsy	B-MED
,	O
often	O
gge	B-MED
.	O
	
since	O
22q11.2	B-MED
does	O
not	O
contain	O
convincing	O
gge	B-MED
candidate	B-MED
genes	I-MED
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	B-MED
correlation	B-MED
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
gabab	B-MED
receptor	I-MED
.	O
	
normal	B-MED
levels	I-MED
of	O
urinary	B-MED
cc16	B-MED
protein	I-MED
.	O
	
comments	B-MED
on	I-MED
beamer	I-MED
et	I-MED
al	I-MED
.	O
	
association	I-MED
of	O
children's	B-MED
urinary	B-MED
cc16	B-MED
levels	B-MED
with	O
arsenic	B-MED
concentrations	I-MED
in	O
multiple	B-MED
environmental	I-MED
media	I-MED
.	O
	
int	O
.	O
	
j	O
.	O
	
environ	O
.	O
	
res	O
.	O
	
public	O
health	O
2016	O
,	O
13	O
,	O
521	O
in	O
1937	O
,	O
max	B-MED
clara	I-MED
described	O
a	O
new	O
type	O
of	O
cell	B-MED
in	O
the	O
human	B-MED
lung	B-MED
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	B-MED
secretory	I-MED
cell	I-MED
type	I-MED
containing	I-MED
granules	I-MED
composed	O
of	O
proteins	B-MED
diverse	O
colletotrichum	B-MED
species	I-MED
cause	O
anthracnose	B-MED
of	O
tea	B-MED
plants	I-MED
camellia	B-MED
sinensis	I-MED
l	I-MED
o	I-MED
.	O
	
kuntze	I-MED
in	O
china	B-MED
anthracnose	B-MED
caused	O
by	O
colletotrichum	B-MED
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-MED
that	O
can	O
afflict	O
camellia	B-MED
sinensis	I-MED
.	O
	
however	O
,	O
research	B-MED
on	O
the	O
diversity	B-MED
and	O
geographical	B-MED
distribution	I-MED
of	O
colletotrichum	B-MED
in	O
china	B-MED
remain	O
limited	O
.	O
	
in	O
this	O
study	B-MED
,	O
106	O
colletotrichum	B-MED
isolates	B-MED
were	O
collected	B-MED
from	O
diseased	B-MED
leaves	B-MED
of	O
ca	B-MED
.	O
	
sinensis	I-MED
cultivated	O
in	O
the	O
15	O
main	O
tea	B-MED
production	I-MED
provinces	B-MED
in	O
china	B-MED
.	O
	
multi-locus	B-MED
phylogenetic	I-MED
analysis	I-MED
coupled	O
with	O
morphological	B-MED
identification	I-MED
showed	O
that	O
the	O
collected	B-MED
isolates	B-MED
belonged	O
to	O
11	O
species	B-MED
,	O
including	O
6	O
known	O
species	B-MED
c	B-MED
.	O
	
camelliae	I-MED
,	O
c	B-MED
.	O
	
cliviae	I-MED
,	O
c	B-MED
.	O
	
fioriniae	I-MED
,	O
c	B-MED
.	O
	
fructicola	I-MED
,	O
c	B-MED
.	O
	
karstii	I-MED
,	O
and	O
c	B-MED
.	O
	
siamense	I-MED
,	O
3	O
new	O
record	B-MED
species	I-MED
c	B-MED
.	O
	
aenigma	I-MED
,	O
c	B-MED
.	O
	
endophytica	I-MED
,	O
and	O
c	B-MED
.	O
	
truncatum	I-MED
,	O
1	O
novel	O
species	B-MED
c	B-MED
.	O
	
wuxiense	I-MED
,	O
and	O
1	O
indistinguishable	O
strain	B-MED
,	O
herein	O
described	O
as	O
colletotrichum	B-MED
sp	I-MED
.	O
	
of	O
these	O
species	B-MED
,	O
c	B-MED
.	O
	
camelliae	I-MED
and	O
c	B-MED
.	O
	
fructicola	I-MED
were	O
the	O
dominant	O
species	B-MED
causing	O
anthracnose	B-MED
in	O
ca	B-MED
.	O
	
sinensis	I-MED
.	O
	
in	O
addition	O
,	O
our	O
study	B-MED
provided	O
further	O
evidence	B-MED
that	O
phylogenetic	B-MED
analysis	I-MED
using	O
a	O
combination	O
of	O
apmat	B-MED
and	I-MED
gs	I-MED
sequences	I-MED
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	B-MED
relationships	B-MED
within	O
the	O
c	B-MED
.	O
	
gloeosporioides	I-MED
species	B-MED
complex	I-MED
.	O
	
finally	O
,	O
pathogenicity	B-MED
tests	B-MED
suggested	O
that	O
c	B-MED
.	O
	
camelliae	I-MED
,	O
c	B-MED
.	O
	
aenigma	I-MED
,	O
and	O
c	B-MED
.	O
	
endophytica	I-MED
are	O
more	O
invasive	B-MED
than	O
other	O
species	B-MED
after	O
the	O
inoculation	B-MED
of	O
the	O
leaves	B-MED
of	O
ca	B-MED
.	O
	
sinensis	I-MED
.	O
	
atp	B-MED
release	B-MED
from	O
bladder	B-MED
urothelium	I-MED
and	O
serosa	B-MED
in	O
a	O
rat	O
model	B-MED
of	O
partial	B-MED
bladder	I-MED
outlet	I-MED
obstruction	I-MED
overactive	B-MED
bladder	I-MED
is	O
one	O
of	O
the	O
major	O
health	B-MED
problem	I-MED
especially	O
in	O
elderly	B-MED
people	I-MED
.	O
	
adenosine	B-MED
triphosphate	I-MED
atp	B-MED
is	O
released	B-MED
from	O
urinary	B-MED
bladder	I-MED
cells	I-MED
and	O
acts	O
as	O
a	O
smooth	B-MED
muscle	I-MED
contraction	I-MED
and	O
sensory	B-MED
signal	I-MED
in	O
micturition	B-MED
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
atp	B-MED
release	O
in	O
the	O
pathophysiology	B-MED
of	O
overactive	B-MED
bladder	I-MED
.	O
	
to	O
assess	O
the	O
relationship	O
between	O
atp	B-MED
and	O
overactive	B-MED
bladder	I-MED
,	O
we	O
used	O
a	O
partial	B-MED
bladder	I-MED
outlet	I-MED
obstruction	I-MED
pboo	B-MED
model	B-MED
in	O
rats	B-MED
.	O
	
the	O
bladder	B-MED
caused	O
several	O
changes	O
by	O
pboo	B-MED
an	O
increase	B-MED
in	O
bladder	B-MED
weight	B-MED
,	O
hypertrophy	B-MED
of	O
sub-urothelium	B-MED
and	O
sub-serosal	B-MED
area	I-MED
,	O
and	O
frequent	O
non	B-MED
-	O
voiding	B-MED
bladder	I-MED
contraction	I-MED
during	O
urine	B-MED
storage	O
.	O
	
basal	B-MED
atp	B-MED
release	O
from	O
urothelium	B-MED
and	O
serosa	B-MED
of	O
pboo	B-MED
rats	B-MED
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	B-MED
.	O
	
distention	B-MED
induced	O
atp	B-MED
release	B-MED
from	O
urothelium	B-MED
of	O
normal	O
and	O
pboo	B-MED
rats	B-MED
had	O
no	O
significant	O
change	O
.	O
	
however	O
,	O
distention	B-MED
-	O
induced	B-MED
atp	B-MED
release	B-MED
from	O
serosa	B-MED
of	O
pboo	B-MED
rats	B-MED
was	O
higher	O
than	O
that	O
of	O
normal	O
.	O
	
these	O
findings	O
may	O
identify	O
atp	B-MED
especially	O
released	B-MED
from	O
serosa	B-MED
as	O
one	O
of	O
causes	O
of	O
non	B-MED
-	O
voiding	B-MED
contractions	I-MED
and	O
overactive	B-MED
bladder	I-MED
symptoms	B-MED
.	O
	
determining	O
putative	B-MED
vectors	I-MED
of	O
the	O
bogia	B-MED
coconut	I-MED
syndrome	I-MED
phytoplasma	B-MED
using	O
loop-mediated	B-MED
isothermal	I-MED
amplification	I-MED
of	O
single-insect	B-MED
feeding	I-MED
media	I-MED
phytoplasmas	B-MED
are	O
insect	B-MED
vectored	I-MED
mollicutes	I-MED
responsible	O
for	O
disease	B-MED
in	O
many	O
economically	O
important	O
crops	B-MED
.	O
	
determining	O
which	O
insect	B-MED
species	I-MED
are	O
vectors	B-MED
of	O
a	O
given	O
phytoplasma	B-MED
is	O
important	O
for	O
managing	O
disease	B-MED
but	O
is	O
methodologically	O
challenging	O
because	O
disease-free	B-MED
plants	I-MED
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	B-MED
,	O
often	O
over	O
many	O
months	B-MED
.	O
	
a	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	B-MED
involves	O
molecular	B-MED
testing	I-MED
for	O
phytoplasma	B-MED
dna	B-MED
in	O
sucrose	B-MED
solution	B-MED
that	O
insects	B-MED
have	O
fed	B-MED
upon	O
.	O
	
in	O
this	O
study	B-MED
we	O
combined	O
this	O
feeding	B-MED
medium	I-MED
method	I-MED
with	O
a	O
loop-mediated	B-MED
isothermal	I-MED
amplification	I-MED
lamp	I-MED
assay	I-MED
to	O
study	O
627	O
insect	B-MED
specimens	B-MED
of	O
11	O
hemiptera	B-MED
taxa	I-MED
sampled	O
from	O
sites	O
in	O
papua	B-MED
new	I-MED
guinea	I-MED
affected	O
by	O
bogia	B-MED
coconut	I-MED
syndrome	I-MED
bcs	B-MED
.	O
	
the	O
lamp	B-MED
assay	I-MED
detected	O
phytoplasma	B-MED
dna	B-MED
from	O
the	O
feeding	B-MED
solution	I-MED
and	O
head	B-MED
tissue	B-MED
of	O
insects	B-MED
from	O
six	O
taxa	B-MED
belonging	O
to	O
four	O
families	O
derbidae	B-MED
,	O
lophopidae	B-MED
,	O
flatidae	B-MED
and	O
ricaniidae	B-MED
.	O
	
two	O
other	O
taxa	B-MED
yielded	O
positives	O
only	O
from	O
the	O
heads	B-MED
and	O
the	O
remainder	O
tested	O
negative	O
.	O
	
these	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single-insect	B-MED
feeding	I-MED
medium	I-MED
tests	I-MED
with	O
lamp	B-MED
assays	I-MED
to	O
identify	O
putative	B-MED
vectors	I-MED
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	B-MED
tests	B-MED
and	O
to	O
better	O
understand	O
phytoplasma	B-MED
pathosystems	B-MED
.	O
	
non-toxigenic	B-MED
environmental	B-MED
vibrio	B-MED
cholerae	I-MED
o1	I-MED
strain	B-MED
from	O
haiti	B-MED
provides	B-MED
evidence	B-MED
of	O
pre-pandemic	B-MED
cholera	B-MED
in	O
hispaniola	B-MED
vibrio	B-MED
cholerae	I-MED
is	O
ubiquitous	B-MED
in	O
aquatic	B-MED
environments	I-MED
,	O
with	O
environmental	B-MED
toxigenic	B-MED
v	B-MED
.	O
	
cholerae	I-MED
o1	I-MED
strains	B-MED
serving	B-MED
as	O
a	O
source	B-MED
for	O
recurrent	B-MED
cholera	B-MED
epidemics	I-MED
and	O
pandemic	B-MED
disease	B-MED
.	O
	
however	O
,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long-term	B-MED
survival	B-MED
and	O
evolution	O
of	O
v	B-MED
.	O
	
cholerae	I-MED
strains	B-MED
within	O
these	O
aquatic	B-MED
environmental	I-MED
reservoirs	B-MED
.	O
	
through	O
monitoring	B-MED
of	O
the	O
haitian	B-MED
aquatic	B-MED
environment	I-MED
following	O
the	O
2010	O
cholera	B-MED
epidemic	I-MED
,	O
we	O
isolated	B-MED
two	B-MED
novel	B-MED
non-toxigenic	B-MED
ctxa/b	B-MED
-	O
negative	B-MED
vibrio	B-MED
cholerae	I-MED
o1	I-MED
.	O
	
these	O
two	B-MED
isolates	B-MED
underwent	O
whole-genome	B-MED
sequencing	I-MED
and	O
were	O
investigated	B-MED
through	B-MED
comparative	B-MED
genomics	B-MED
and	O
bayesian	B-MED
coalescent	I-MED
analysis	I-MED
.	O
	
these	O
isolates	B-MED
cluster	O
in	O
the	O
evolutionary	O
tree	B-MED
with	O
strains	B-MED
responsible	O
for	O
clinical	B-MED
cholera	B-MED
,	O
possessing	B-MED
genomic	B-MED
components	I-MED
of	O
6	O
and	O
7	O
pandemic	B-MED
lineages	B-MED
,	O
and	O
diverge	B-MED
from	O
""""	O
modern	B-MED
""""	O
cholera	B-MED
strains	B-MED
around	O
1548	O
c.e	O
.	O
	
95%	O
hpd	O
1532-1555	O
.	O
	
vibrio	B-MED
pathogenicity	I-MED
island	I-MED
vpi	B-MED
was	O
present	B-MED
however	O
,	O
sxt/r391-family	B-MED
ice	I-MED
and	O
vpi-2	B-MED
were	O
absent	B-MED
.	O
	
rugose	B-MED
phenotype	I-MED
conversion	B-MED
and	O
vibriophage	B-MED
resistance	B-MED
evidenced	B-MED
adaption	O
for	O
persistence	B-MED
in	O
aquatic	B-MED
environments	I-MED
.	O
	
the	O
identification	B-MED
of	O
v	B-MED
.	O
	
cholerae	I-MED
o1	I-MED
strains	B-MED
in	O
the	O
haitian	B-MED
environment	B-MED
,	O
which	O
predate	O
the	O
first	O
reported	B-MED
cholera	B-MED
pandemic	B-MED
in	O
1817	O
,	O
broadens	O
our	O
understanding	B-MED
of	O
the	O
history	B-MED
of	O
pandemics	B-MED
.	O
	
it	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	B-MED
environmental	B-MED
strains	B-MED
could	O
acquire	B-MED
virulence	B-MED
genes	B-MED
from	O
the	O
2010	O
haitian	B-MED
epidemic	B-MED
clone	B-MED
,	O
including	O
the	O
cholera	B-MED
toxin	I-MED
producing	B-MED
ctxϕ	B-MED
.	O
	
the	O
pre-eclampsia	B-MED
ontology	B-MED
a	O
disease	B-MED
ontology	I-MED
representing	O
the	O
domain	O
knowledge	O
specific	O
to	O
pre-eclampsia	B-MED
pre-eclampsia	B-MED
pe	B-MED
is	O
a	O
clinical	B-MED
syndrome	I-MED
characterized	O
by	O
new-onset	B-MED
hypertension	I-MED
and	O
proteinuria	B-MED
at	O
20	B-MED
weeks	I-MED
of	I-MED
gestation	I-MED
,	O
and	O
is	O
a	O
leading	O
cause	B-MED
of	O
maternal	B-MED
and	O
perinatal	B-MED
morbidity	I-MED
and	O
mortality	B-MED
.	O
	
previous	O
studies	O
have	O
gathered	O
abundant	B-MED
data	B-MED
about	O
pe	B-MED
such	O
as	O
risk	B-MED
factors	I-MED
and	O
pathological	B-MED
findings	I-MED
.	O
	
however	O
,	O
most	O
of	O
these	O
data	B-MED
are	O
not	O
semantically	O
structured	O
.	O
	
clinical	B-MED
data	I-MED
on	O
pe	B-MED
patients	B-MED
are	O
often	O
generated	O
with	O
semantic	B-MED
heterogeneity	B-MED
such	O
as	O
using	O
disparate	B-MED
terminology	I-MED
to	O
describe	O
the	O
same	O
phenomena	B-MED
.	O
	
in	O
clinical	B-MED
studies	I-MED
,	O
interoperability	O
of	O
heterogenic	B-MED
clinical	B-MED
data	I-MED
is	O
required	O
in	O
various	O
situations	B-MED
.	O
	
in	O
such	O
a	O
situation	B-MED
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	B-MED
framework	B-MED
to	O
research	B-MED
the	O
pathology	B-MED
of	O
pe	B-MED
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	B-MED
clinical	B-MED
data	I-MED
of	O
pe	B-MED
patients	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
developed	O
an	O
ontology	B-MED
representing	O
clinical	B-MED
features	I-MED
,	O
treatments	B-MED
,	O
genetic	B-MED
factors	I-MED
,	O
environmental	B-MED
factors	I-MED
,	O
and	O
other	O
aspects	B-MED
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
pe	B-MED
.	O
	
we	O
call	O
this	O
pre-eclampsia	B-MED
ontology	B-MED
""""	O
peo	B-MED
""""	O
.	O
	
to	O
achieve	O
interoperability	O
with	O
other	O
ontologies	B-MED
,	O
the	O
core	O
structure	O
of	O
peo	B-MED
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
basic	B-MED
formal	I-MED
ontology	I-MED
bfo	B-MED
.	O
	
the	O
peo	B-MED
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	B-MED
and	O
terms	B-MED
of	O
pe	B-MED
from	O
clinical	B-MED
and	O
biomedical	B-MED
research	I-MED
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
pe	B-MED
therefore	O
,	O
peo	B-MED
is	O
expected	O
to	O
enhance	B-MED
pe	B-MED
-specific	O
information	B-MED
retrieval	I-MED
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	B-MED
and	O
biomedical	B-MED
research	I-MED
fields	B-MED
.	O
	
predictors	B-MED
and	O
moderators	B-MED
of	O
spontaneous	B-MED
pretend	B-MED
play	I-MED
in	O
children	B-MED
with	O
and	O
without	O
autism	B-MED
spectrum	I-MED
disorder	I-MED
although	O
pretend	B-MED
play	I-MED
has	O
long	O
been	O
linked	O
to	O
children's	B-MED
normative	B-MED
cognitive	B-MED
development	I-MED
,	O
inconsistent	B-MED
findings	B-MED
call	O
for	O
greater	O
rigor	O
in	O
examining	B-MED
this	O
relation	B-MED
lillard	O
et	O
al	O
,	O
2013	O
.	O
	
spontaneous	B-MED
pretend	B-MED
play	I-MED
is	O
often	O
impacted	O
in	O
atypical	B-MED
development	B-MED
,	O
notably	O
in	O
autism	B-MED
spectrum	I-MED
disorder	I-MED
asd	B-MED
.	O
	
since	O
asd	B-MED
traits	B-MED
exist	O
along	O
a	O
continuum	B-MED
in	O
the	O
general	B-MED
population	I-MED
,	O
investigating	B-MED
how	O
pretend	B-MED
play	I-MED
varies	O
across	O
the	O
range	O
of	O
asd	B-MED
symptoms	B-MED
by	O
indexing	O
variations	B-MED
in	O
asd	B-MED
traits	B-MED
in	O
both	O
typically	O
developing	O
and	O
asd	B-MED
populations	B-MED
may	O
provide	O
insight	O
into	O
how	O
asd	B-MED
symptoms	B-MED
may	O
influence	O
the	O
relation	B-MED
between	O
pretend	B-MED
play	I-MED
and	O
associated	O
processes	O
in	O
cognitive	B-MED
development	I-MED
.	O
	
this	O
study	B-MED
used	O
rigorous	B-MED
observational	I-MED
methods	I-MED
to	O
assess	O
spontaneous	B-MED
pretend	B-MED
play	I-MED
.	O
	
specifically	O
,	O
5-	O
min	B-MED
free-play	B-MED
sessions	I-MED
with	O
two	O
discrete	B-MED
toy	B-MED
sets	O
were	O
double-coded	O
by	O
blinded	B-MED
coders	I-MED
coder	O
assignment	O
counterbalanced	O
.	O
	
key	O
facets	O
of	O
pretense	B-MED
development	I-MED
attribution	B-MED
of	I-MED
pretend	I-MED
properties	I-MED
app	B-MED
,	O
object	B-MED
substitution	I-MED
os	B-MED
,	O
imaginary	B-MED
objects	I-MED
were	O
examined	B-MED
.	O
	
these	O
facets	O
of	O
pretend	B-MED
play	I-MED
production	B-MED
were	O
then	O
analyzed	B-MED
in	O
relation	B-MED
to	O
asd	B-MED
symptoms	B-MED
,	O
as	O
well	O
as	O
plausible	O
,	O
long-theorized	O
correlates	O
theory	B-MED
of	I-MED
mind	I-MED
tom	B-MED
,	O
verbal	B-MED
ability	I-MED
,	O
familiarity	B-MED
,	O
and	O
interest	B-MED
in	O
specific	B-MED
toys	B-MED
.	O
	
forty	O
children	B-MED
mage	O
=	O
6	O
,	O
sdage	O
=	O
1.45	O
29	O
males	B-MED
,	O
six	O
of	O
whom	O
met	O
the	O
threshold	B-MED
for	O
asd	B-MED
diagnosis	B-MED
via	O
parent	B-MED
-reported	O
asd	B-MED
symptoms	B-MED
,	O
participated	O
in	O
play	B-MED
sessions	I-MED
and	O
completed	O
measures	B-MED
of	O
verbal	B-MED
iq	I-MED
and	O
tom	B-MED
.	O
	
besides	O
the	O
measure	B-MED
of	O
child	B-MED
asd	B-MED
symptoms	B-MED
,	O
parents	B-MED
completed	O
a	O
survey	B-MED
of	O
their	O
child's	B-MED
interest	B-MED
in	O
and	O
familiarity	B-MED
with	O
the	O
play	B-MED
session	I-MED
toys	B-MED
.	O
	
overall	O
,	O
greater	O
tom	B-MED
predicted	B-MED
more	O
app	B-MED
,	O
and	O
more	O
interest	B-MED
in	O
the	O
toys	B-MED
presented	O
predicted	B-MED
more	O
os	B-MED
.	O
	
in	O
terms	O
of	O
overall	O
pretend	B-MED
play	I-MED
production	B-MED
,	O
two	O
results	O
were	O
counterintuitive	O
.	O
	
first	O
,	O
among	O
children	B-MED
with	O
more	O
asd	B-MED
symptoms	B-MED
,	O
verbal	B-MED
ability	I-MED
marginally	O
negatively	O
predicted	B-MED
pretend	B-MED
play	I-MED
production	B-MED
.	O
	
second	O
,	O
among	O
children	B-MED
with	O
fewer	O
asd	B-MED
symptoms	B-MED
,	O
tom	B-MED
negatively	O
predicted	B-MED
pretend	B-MED
play	I-MED
production	B-MED
.	O
	
further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
asd	B-MED
symptoms	B-MED
on	O
pretend	B-MED
play	I-MED
was	O
simultaneously	O
moderated	O
by	O
both	O
variables	O
low	O
tom	B-MED
and	O
high	O
verbal	B-MED
ability	I-MED
both	O
related	O
to	O
less	O
pretend	B-MED
play	I-MED
production	O
among	O
children	B-MED
with	O
more	O
asd	B-MED
symptoms	B-MED
.	O
	
implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-MED
for	O
pretend	B-MED
ability	I-MED
among	O
children	B-MED
with	O
varying	O
degrees	O
of	O
asd	B-MED
symptoms	B-MED
,	O
allelic	B-MED
diversity	B-MED
in	O
an	O
nlr	B-MED
gene	I-MED
bph9	B-MED
enables	O
rice	B-MED
to	O
combat	O
planthopper	B-MED
variation	B-MED
brown	B-MED
planthopper	I-MED
bph	B-MED
,	O
nilaparvata	B-MED
lugens	I-MED
stål	I-MED
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	B-MED
pests	B-MED
of	O
rice	B-MED
oryza	B-MED
sativa	I-MED
l	I-MED
.	O
	
currently	O
,	O
30	O
bph	B-MED
-	O
resistance	B-MED
genes	I-MED
have	O
been	O
genetically	O
defined	O
,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome	B-MED
regions	I-MED
.	O
	
here	O
,	O
we	O
describe	O
molecular	B-MED
cloning	I-MED
and	O
characterization	B-MED
of	O
a	O
bph	B-MED
-	O
resistance	B-MED
gene	I-MED
,	O
bph9	B-MED
,	O
mapped	O
on	O
the	O
long	B-MED
arm	I-MED
of	I-MED
rice	I-MED
chromosome	I-MED
12	I-MED
12l	O
.	O
	
bph9	B-MED
encodes	O
a	O
rare	O
type	O
of	O
nucleotide-binding	B-MED
and	O
leucine-rich	B-MED
repeat	I-MED
nlr	B-MED
protein	B-MED
that	O
localizes	O
to	O
the	O
endomembrane	B-MED
system	I-MED
and	O
causes	O
a	O
cell	B-MED
death	I-MED
phenotype	B-MED
.	O
	
bph9	B-MED
activates	O
salicylic	B-MED
acid	I-MED
-	O
and	O
jasmonic	B-MED
acid	I-MED
-	O
signaling	B-MED
pathways	I-MED
in	O
rice	B-MED
plants	B-MED
and	O
confers	O
both	O
antixenosis	B-MED
and	O
antibiosis	B-MED
to	O
bph	B-MED
.	O
	
we	O
further	O
demonstrated	O
that	O
the	O
eight	O
bph	B-MED
-	O
resistance	B-MED
genes	I-MED
that	O
are	O
clustered	O
on	O
chromosome	B-MED
12l	I-MED
,	O
including	O
the	O
widely	O
used	O
bph1	B-MED
,	O
are	O
allelic	O
with	O
each	O
other	O
.	O
	
to	O
honor	O
the	O
priority	O
in	O
the	O
literature	B-MED
,	O
we	O
thus	O
designated	O
this	O
locus	B-MED
as	O
bph1/9	B-MED
these	O
eight	O
genes	B-MED
can	O
be	O
classified	O
into	O
four	O
allelotypes	B-MED
,	O
bph1/9-1	B-MED
,	O
-2	B-MED
,	O
-7	B-MED
,	O
and	O
-9	B-MED
these	O
allelotypes	B-MED
confer	O
varying	O
levels	B-MED
of	O
resistance	B-MED
to	O
different	O
biotypes	B-MED
of	O
bph	B-MED
.	O
	
the	O
coding	B-MED
region	I-MED
of	O
bph1/9	B-MED
shows	O
a	O
high	O
level	O
of	O
diversity	B-MED
in	O
rice	B-MED
germplasm	I-MED
.	O
	
homologous	O
fragments	O
of	O
the	O
nucleotide-binding	B-MED
nb	B-MED
and	O
leucine-rich	B-MED
repeat	I-MED
lrr	B-MED
domains	B-MED
exist	O
,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	B-MED
for	O
generating	O
allele	B-MED
diversity	B-MED
.	O
	
our	O
findings	O
reveal	O
a	O
rice	B-MED
plant	B-MED
strategy	O
for	O
modifying	O
the	O
genetic	B-MED
information	I-MED
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	B-MED
herbivores	B-MED
.	O
	
further	O
exploration	O
of	O
natural	O
allelic	B-MED
variation	I-MED
and	O
artificial	B-MED
shuffling	I-MED
within	O
this	O
gene	B-MED
may	O
allow	O
breeding	B-MED
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	B-MED
of	O
nontoxic	B-MED
formulations	B-MED
of	O
scintillation	B-MED
nanocrystals	B-MED
for	O
use	O
as	O
x-ray	B-MED
computed	I-MED
tomography	I-MED
contrast	B-MED
agents	I-MED
x-ray	B-MED
computed	I-MED
tomography	I-MED
ct	B-MED
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	B-MED
,	O
clinical	B-MED
in	B-MED
vivo	I-MED
imaging	B-MED
techniques	I-MED
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
x-ray	B-MED
device	I-MED
and	O
contrast	B-MED
enhancement	B-MED
technologies	I-MED
.	O
	
the	O
present	O
study	B-MED
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	B-MED
tungstates	I-MED
such	O
as	O
cawo4	B-MED
are	O
promising	O
contrast	B-MED
agents	I-MED
for	O
x-ray	B-MED
,	O
radiation	B-MED
,	O
and	O
ct	B-MED
imaging	I-MED
,	O
because	O
of	O
the	O
high	O
x-ray	B-MED
mass	B-MED
attenuation	I-MED
of	O
tungsten	B-MED
w	B-MED
.	O
	
we	O
have	O
developed	O
a	O
method	O
of	O
formulation	B-MED
,	O
in	O
which	O
cawo4	B-MED
cwo	B-MED
nanoparticles	B-MED
nps	B-MED
are	O
encapsulated	B-MED
within	O
a	O
biocompatible	O
poly	B-MED
glycol-b-d	I-MED
acid	I-MED
peg-pla	I-MED
block	I-MED
copolymer	I-MED
bcp	I-MED
capsule	I-MED
.	O
	
we	O
show	O
that	O
these	O
peg-pla	B-MED
-	O
encapsulated	B-MED
cwo	B-MED
nps	I-MED
170	O
10	O
nm	O
hydrodynamic	O
diameter	O
produce	O
a	O
higher	O
ct	B-MED
contrast	B-MED
by	O
a	O
factor	O
of	O
about	O
2	O
than	O
commercial	O
iodine	B-MED
-based	O
radiocontrast	B-MED
agents	I-MED
e.g	O
,	O
iohexol	B-MED
at	O
identical	O
molar	O
concentrations	O
of	O
w	B-MED
or	O
i	B-MED
atoms	B-MED
.	O
	
peg-pla	B-MED
-	O
coated	B-MED
cwo	B-MED
nps	I-MED
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	B-MED
.	O
	
it	O
was	O
confirmed	O
that	O
the	O
maximum	B-MED
tolerated	I-MED
dose	I-MED
mtd	B-MED
of	O
this	O
material	B-MED
in	O
mice	B-MED
is	O
significantly	O
higher	O
250	O
50	O
mg	O
per	O
kg	O
body	B-MED
weight	I-MED
following	O
a	O
single	O
intravenous	B-MED
iv	I-MED
administration	I-MED
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B-MED
-	O
coated	B-MED
iron	B-MED
oxide	I-MED
nanoparticles	B-MED
that	O
are	O
currently	O
used	O
clinically	B-MED
as	O
mri	B-MED
contrast	B-MED
agents	I-MED
mtd	B-MED
in	O
mice	B-MED
168	O
mg/kg	O
per	O
dose	B-MED
iv	O
.	O
	
iv-	O
injected	B-MED
peg-pla	B-MED
/	O
cwo	B-MED
nps	I-MED
caused	O
no	B-MED
histopathologic	B-MED
damage	B-MED
in	O
major	O
excretory	B-MED
organs	I-MED
heart	B-MED
,	O
liver	B-MED
,	O
lungs	B-MED
,	O
spleen	B-MED
,	O
and	O
kidney	B-MED
.	O
	
when	O
an	O
iv	O
dose	B-MED
of	O
100	O
mg/kg	O
was	O
given	O
to	O
mice	B-MED
,	O
the	O
blood	B-MED
circulation	I-MED
half-life	B-MED
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90%	O
of	O
the	O
nps	B-MED
were	O
cleared	O
from	O
the	O
mice	B-MED
within	O
24	O
h	O
via	O
the	O
renal	B-MED
and	O
hepatobiliary	B-MED
systems	I-MED
.	O
	
when	O
intratumorally	B-MED
administered	I-MED
,	O
peg-pla	B-MED
-	O
coated	B-MED
cwo	B-MED
nps	I-MED
showed	O
complete	O
retention	O
in	O
a	O
tumor-bearing	B-MED
mouse	I-MED
model	I-MED
measurements	O
were	O
made	O
up	O
to	O
1	O
week	B-MED
.	O
	
these	O
results	O
suggest	O
that	O
peg-pla	B-MED
-	O
coated	B-MED
cwo	B-MED
nps	I-MED
are	O
promising	O
materials	B-MED
for	O
use	O
in	O
ct	B-MED
contrast	B-MED
.	O
	
albumin	B-MED
-bioinspired	O
gd	B-MED
cus	B-MED
nanotheranostic	B-MED
agent	I-MED
for	O
in	B-MED
vivo	I-MED
photoacoustic	B-MED
/	O
magnetic	O
resonance	O
imaging	O
-guided	O
tumor	O
-targeted	O
photothermal	O
therapy	O
photothermal	O
therapy	O
ptt	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	O
cancer	O
therapy	O
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O
	
however	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
ptt	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	O
,	O
monitoring	O
,	O
and	O
diagnosis	O
.	O
	
herein	O
,	O
a	O
biocompatible	O
gd	O
-integrated	O
cus	O
nanotheranostic	O
agent	O
gd	O
cus	O
bsa	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
bsa	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O
	
the	O
as-prepared	O
gd	O
cus	O
bsa	O
nanoparticles	O
nps	O
with	O
ultrasmall	O
sizes	O
ca	O
.	O
	
9	O
nm	O
exhibited	O
high	O
photothermal	O
conversion	O
efficiency	O
and	O
good	O
photostability	O
under	O
near-infrared	O
nir	O
laser	O
irradiation	O
.	O
	
with	O
doped	O
gd	O
species	O
and	O
strong	O
tunable	O
nir	O
absorbance	O
,	O
gd	O
cus	O
bsa	O
nps	O
demonstrate	O
prominent	O
tumor-contrasted	O
imaging	O
performance	O
both	O
on	O
the	O
photoacoustic	O
and	O
magnetic	O
resonance	O
imaging	O
modalities	O
.	O
	
the	O
subsequent	O
gd	O
cus	O
bsa	O
-mediated	O
ptt	O
result	O
shows	O
high	O
therapy	O
efficacy	O
as	O
a	O
result	O
of	O
their	O
potent	O
nir	O
absorption	O
and	O
high	O
photothermal	O
conversion	O
efficiency	O
.	O
	
the	O
immune	O
response	O
triggered	O
by	O
gd	O
cus	O
bsa	O
-mediated	O
ptt	O
is	O
preliminarily	O
explored	O
.	O
	
in	O
addition	O
,	O
toxicity	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
gd	O
cus	O
bsa	O
nps	O
qualify	O
as	O
biocompatible	O
agents	O
.	O
	
a	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
nps	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O
	
this	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
gd	O
cus	O
bsa	O
nps	O
possess	O
promising	O
imaging	O
guidance	O
and	O
effective	O
tumor	O
ablation	O
properties	O
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	I-MED
family	B-MED
and	O
healthcare	B-MED
professionals	I-MED
'	O
perceptions	B-MED
of	O
a	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
for	O
children	B-MED
a	O
qualitative	O
study	B-MED
parents	B-MED
commonly	O
report	O
a	O
significant	O
improvement	B-MED
in	O
quality	B-MED
of	I-MED
life	I-MED
following	O
the	O
provision	B-MED
of	O
hospice	B-MED
and	O
supportive	B-MED
care	I-MED
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-MED
in	O
the	O
home	B-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	B-MED
receiving	O
a	O
nurse	B-MED
led	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
and	O
the	O
experiences	B-MED
of	O
healthcare	B-MED
professionals	I-MED
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-MED
.	O
	
an	O
exploratory	O
,	O
qualitative	O
study	B-MED
was	O
conducted	O
,	O
including	O
telephone	B-MED
interviews	I-MED
with	O
parents	B-MED
and	O
focus	B-MED
groups	I-MED
and	O
individual	B-MED
interviews	B-MED
with	O
healthcare	B-MED
professionals	I-MED
.	O
	
all	O
parents	B-MED
of	O
families	B-MED
who	O
received	O
the	O
programme	B-MED
of	O
care	B-MED
between	O
june	O
2014	O
and	O
september	O
2015	O
and	O
healthcare	B-MED
professionals	I-MED
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-MED
were	O
invited	O
to	O
participate	O
.	O
	
seven	O
parents	B-MED
participated	O
in	O
telephone	B-MED
interviews	I-MED
.	O
	
four	O
focus	B-MED
groups	I-MED
took	O
place	O
,	O
two	O
with	O
external	B-MED
stakeholders	I-MED
18	O
participants	B-MED
in	O
total	O
,	O
one	O
with	O
in-patient	B-MED
hospice	B-MED
staff	I-MED
13	O
participants	B-MED
and	O
one	O
with	O
the	O
hospice	B-MED
at	O
home	O
team	O
8	O
participants	B-MED
.	O
	
two	O
additional	O
interviews	B-MED
took	O
place	O
with	O
individual	B-MED
stakeholders	B-MED
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus	B-MED
group	I-MED
.	O
	
themes	O
from	O
interviews	B-MED
with	O
parents	B-MED
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-MED
.	O
	
the	O
findings	O
from	O
healthcare	B-MED
professionals	I-MED
centred	O
on	O
communication	B-MED
within	O
and	O
across	O
services	B-MED
,	O
education	B-MED
and	I-MED
training	I-MED
and	O
lone	B-MED
working	I-MED
.	O
	
the	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	B-MED
.	O
	
the	O
programme	B-MED
may	O
be	O
improved	O
by	O
enhanced	O
clarification	B-MED
of	O
roles	O
,	O
enhanced	O
access	O
to	O
multi-disciplinary	O
services	B-MED
,	O
greater	O
communication	B-MED
across	O
services	B-MED
and	O
improved	O
information	O
provision	O
to	O
functional	B-MED
1	B-MED
scaffold	B-MED
design	B-MED
of	O
fluorescent	B-MED
probes	I-MED
for	O
kinesin	B-MED
spindle	I-MED
protein	I-MED
ksp	B-MED
1	B-MED
is	O
a	O
compact	O
fluorescent	B-MED
chromophore	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
triazapentalene	B-MED
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl-type	B-MED
inhibitors	B-MED
of	O
kinesin	B-MED
spindle	I-MED
protein	I-MED
ksp	B-MED
to	O
develop	O
fluorescent	B-MED
probes	I-MED
for	O
the	O
intracellular	B-MED
visualization	B-MED
of	O
this	O
protein	B-MED
.	O
	
microscopic	B-MED
studies	B-MED
demonstrated	O
that	O
these	O
novel	B-MED
triazapentalene	B-MED
-	O
labeled	B-MED
compounds	B-MED
exhibited	O
inhibitory	B-MED
activity	B-MED
towards	O
ksp	B-MED
in	O
cultured	B-MED
cells	I-MED
and	O
provided	O
important	O
information	B-MED
concerning	O
the	O
intracellular	B-MED
distribution	B-MED
.	O
	
c4b	B-MED
binding	I-MED
protein	I-MED
negatively	B-MED
regulates	I-MED
tlr1	B-MED
/	O
2	B-MED
response	B-MED
tlr2	B-MED
associates	B-MED
with	I-MED
tlr1	B-MED
and	O
recognizes	O
microbial	B-MED
lipoproteins	B-MED
.	O
	
pam3csk4	B-MED
,	O
a	O
triacylated	B-MED
lipoprotein	I-MED
,	O
is	O
anchored	B-MED
to	O
the	O
extracellular	B-MED
domain	I-MED
of	O
tlr1	B-MED
and	O
tlr2	B-MED
and	O
induces	B-MED
pro-inflammatory	B-MED
signals	B-MED
.	O
	
here	O
we	O
show	O
that	O
c4b	B-MED
binding	I-MED
protein	I-MED
c4bp	B-MED
,	O
which	O
is	O
a	O
complement	B-MED
pathway	I-MED
inhibitor	B-MED
,	O
is	O
a	O
tlr2	B-MED
-associated	O
molecule	O
.	O
	
immunoprecipitation	B-MED
assay	I-MED
using	O
anti-tlr2	B-MED
mab	I-MED
shows	O
that	O
c4bp	B-MED
binds	B-MED
to	I-MED
tlr2	B-MED
.	O
	
in	O
c4bp-deficient	B-MED
mice	B-MED
,	O
pam3csk4	B-MED
-	O
induced	B-MED
il-6	B-MED
levels	B-MED
were	O
increased	B-MED
compared	B-MED
with	O
wild	B-MED
type	I-MED
mice	I-MED
.	O
	
in	O
c4bp	B-MED
-	O
expressing	B-MED
cells	B-MED
,	O
pam3csk4	B-MED
-	O
induced	B-MED
il-8	B-MED
production	I-MED
was	O
reduced	B-MED
depending	O
on	O
the	O
c4bp	B-MED
expression	B-MED
levels	I-MED
.	O
	
these	O
results	O
reveal	B-MED
the	O
important	O
role	O
of	O
c4bp	B-MED
in	O
negative	B-MED
regulation	I-MED
of	O
tlr1	B-MED
/	O
2	B-MED
-	O
dependent	B-MED
pro-inflammatory	B-MED
cytokine	B-MED
production	I-MED
.	O
	
furthermore	O
,	O
using	O
a	O
fluorescent	B-MED
conjugated	I-MED
pam3csk4	B-MED
,	O
we	O
show	O
that	O
c4bp	B-MED
blocks	B-MED
the	O
binding	B-MED
of	I-MED
pam3csk4	B-MED
to	O
tlr1	B-MED
/	O
2	B-MED
.	O
	
finally	O
,	O
we	O
show	O
that	O
exogenous	B-MED
c4bp	B-MED
also	O
inhibits	B-MED
pam3csk4	B-MED
-	O
induced	B-MED
signaling	I-MED
leading	O
to	O
il-8	B-MED
production	I-MED
.	O
	
our	O
results	O
indicate	O
c4bp	B-MED
binding	B-MED
to	I-MED
tlr2	B-MED
and	O
consequent	B-MED
neutralization	B-MED
of	O
its	O
activity	B-MED
otherwise	O
inducing	O
pro-inflammatory	B-MED
cytokine	B-MED
production	I-MED
.	O
	
c4bp	B-MED
is	O
a	O
negative	B-MED
regulator	I-MED
of	O
tlr1	B-MED
/	O
2	B-MED
activity	B-MED
.	O
	
effect	B-MED
of	O
emodin	B-MED
on	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
of	O
gallbladder	B-MED
smooth	B-MED
muscle	I-MED
in	O
guinea	B-MED
pig	I-MED
with	O
cholelithiasis	B-MED
to	O
study	B-MED
the	O
effect	B-MED
of	O
emodin	B-MED
on	O
protein	B-MED
and	O
gene	B-MED
expressions	I-MED
of	O
the	O
massagers	B-MED
in	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
of	O
cholecyst	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
in	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
.	O
	
the	O
guinea	B-MED
pigs	I-MED
were	O
randomly	O
divided	O
into	O
4	O
groups	B-MED
,	O
such	O
as	O
control	B-MED
group	I-MED
,	O
gall-stone	B-MED
gs	B-MED
group	B-MED
,	O
emodin	B-MED
group	B-MED
and	O
ursodeoxycholic	B-MED
acid	I-MED
ua	B-MED
group	B-MED
.	O
	
cholesterol	B-MED
calculus	I-MED
models	B-MED
were	O
induced	O
in	O
guinea	B-MED
pigs	I-MED
of	O
gs	B-MED
,	O
emodin	B-MED
and	O
ua	B-MED
groups	B-MED
by	O
lithogenic	B-MED
diet	I-MED
,	O
while	O
emodin	B-MED
or	O
ua	B-MED
were	O
given	O
to	O
the	O
corresponding	O
group	B-MED
for	O
7	O
weeks	B-MED
.	O
	
the	O
histomorphological	B-MED
and	O
ultrastructure	B-MED
change	B-MED
of	O
gallbladder	B-MED
were	O
detected	B-MED
by	O
microscope	B-MED
and	O
electron	B-MED
microscope	I-MED
,	O
the	O
content	O
of	O
plasma	B-MED
cholecystokinin	B-MED
cck	B-MED
and	O
ca	B-MED
were	O
analyzed	B-MED
successively	O
by	O
radioimmunoassay	B-MED
and	O
flow	B-MED
cytometry	I-MED
.	O
	
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gsα	B-MED
,	O
giα	B-MED
and	O
cap	B-MED
in	O
cholecyst	B-MED
cells	B-MED
were	O
determined	B-MED
by	I-MED
western	B-MED
blotting	I-MED
and	O
real	B-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
rt-pcr	B-MED
.	O
	
emodin	B-MED
or	O
ua	B-MED
can	O
relieve	O
pathogenic	B-MED
changes	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
muscle	B-MED
cells	I-MED
in	O
gallbladder	B-MED
of	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
by	O
microscope	B-MED
and	O
transmission	B-MED
electron	I-MED
microscope	I-MED
.	O
	
in	O
the	O
cholecyst	B-MED
cells	B-MED
of	O
gs	B-MED
group	B-MED
,	O
cck	B-MED
levels	B-MED
in	O
plasma	B-MED
and	O
ca	B-MED
decreased	B-MED
,	O
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gs	B-MED
were	O
down-regulated	B-MED
,	O
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gi	B-MED
and	O
cap	B-MED
were	O
up-regulated	B-MED
.	O
	
emodin	B-MED
significantly	B-MED
decreased	B-MED
the	O
formative	B-MED
rate	B-MED
of	O
gallstone	B-MED
,	O
improved	O
the	O
pathogenic	B-MED
change	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
muscle	B-MED
cells	I-MED
,	O
increased	O
cck	B-MED
levels	B-MED
in	O
plasma	B-MED
and	O
ca	B-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
enhanced	O
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gs	B-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
reduced	B-MED
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gi	B-MED
and	O
cap	B-MED
in	O
cholecyst	B-MED
cells	B-MED
in	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
.	O
	
the	O
dysfunction	B-MED
of	O
gallbladder	B-MED
contraction	I-MED
gives	O
rise	O
to	O
the	O
disorders	B-MED
of	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
in	O
cholecyst	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
,	O
including	B-MED
low	O
content	O
of	O
plasma	B-MED
cck	B-MED
and	O
ca	B-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
abnormal	B-MED
protein	I-MED
and	O
mrna	B-MED
of	O
gs	B-MED
,	O
gi	B-MED
and	O
cap	B-MED
.	O
	
emodin	B-MED
can	O
enhance	B-MED
the	O
contractibility	B-MED
of	I-MED
gallbladder	I-MED
and	O
alleviate	B-MED
cholestasis	B-MED
by	O
regulating	B-MED
plasma	B-MED
cck	B-MED
levels	B-MED
,	O
ca	B-MED
in	O
cholecyst	B-MED
cells	B-MED
and	O
the	O
protein	B-MED
and	O
mrna	B-MED
of	O
gs	B-MED
,	O
gi	B-MED
and	O
quantification	B-MED
of	O
urinary	B-MED
mono-hydroxylated	B-MED
metabolites	I-MED
of	O
polycyclic	B-MED
aromatic	I-MED
hydrocarbons	I-MED
by	O
on-line	B-MED
solid	I-MED
phase	I-MED
extraction	I-MED
-	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography-tandem	I-MED
mass	I-MED
spectrometry	I-MED
human	B-MED
exposure	B-MED
to	I-MED
polycyclic	B-MED
aromatic	I-MED
hydrocarbons	I-MED
pahs	B-MED
can	O
be	O
assessed	B-MED
through	O
monitoring	B-MED
of	O
urinary	B-MED
mono-hydroxylated	B-MED
pahs	I-MED
oh-pahs	B-MED
.	O
	
gas	B-MED
chromatography	I-MED
gc	B-MED
has	O
been	O
widely	O
used	O
to	O
separate	B-MED
oh-pahs	B-MED
before	O
quantification	B-MED
by	O
mass	B-MED
spectrometry	I-MED
in	O
biomonitoring	B-MED
studies	B-MED
.	O
	
however	O
,	O
because	O
gc	B-MED
requires	O
derivatization	B-MED
,	O
it	O
can	O
be	O
time	B-MED
consuming	I-MED
.	O
	
we	O
developed	B-MED
an	O
on-line	B-MED
solid	I-MED
phase	I-MED
extraction	I-MED
coupled	B-MED
to	O
isotope	B-MED
dilution	B-MED
-	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography-tandem	I-MED
mass	I-MED
spectrometry	I-MED
on-line-spe	B-MED
-	O
hplc-ms	B-MED
/	O
ms	B-MED
method	B-MED
for	O
the	O
quantification	B-MED
in	O
urine	B-MED
of	O
1-oh-naphthalene	B-MED
,	O
2-oh-naphthalene	B-MED
,	O
2-oh-fluorene	B-MED
,	O
3-oh-fluorene	B-MED
,	O
1-oh-phenanthrene	B-MED
,	O
the	O
sum	O
of	O
2-oh	B-MED
and	O
3-oh-phenanthrene	B-MED
,	O
4-oh-phenanthrene	B-MED
,	O
and	O
1-oh-pyrene	B-MED
.	O
	
the	O
method	B-MED
,	O
which	O
employed	B-MED
a	O
96-	O
well	B-MED
plate	I-MED
platform	I-MED
and	O
on-line	B-MED
spe	I-MED
,	O
showed	O
good	B-MED
sensitivity	I-MED
i.e	O
,	O
limits	B-MED
of	O
detection	B-MED
ranged	B-MED
from	O
0.007	O
to	O
0.09	O
ng/ml	O
and	O
used	O
only	O
100	O
μl	O
of	O
urine	B-MED
.	O
	
accuracy	B-MED
,	O
calculated	B-MED
from	O
the	O
recovery	B-MED
percentage	B-MED
at	O
three	O
spiking	B-MED
levels	B-MED
,	O
varied	B-MED
from	O
94	O
to	O
113	O
%	O
,	O
depending	B-MED
on	O
the	O
analyte	B-MED
.	O
	
the	O
inter	B-MED
-	O
and	O
intra	B-MED
-	O
day	B-MED
precision	I-MED
,	O
calculated	B-MED
from	O
20	O
repeated	B-MED
measurements	B-MED
of	O
two	O
quality	B-MED
control	I-MED
materials	B-MED
,	O
varied	B-MED
from	O
5.2	O
to	O
16.7	O
%	O
.	O
	
adequate	B-MED
method	B-MED
performance	B-MED
was	O
also	O
confirmed	B-MED
by	I-MED
acceptable	B-MED
recovery	B-MED
83-102	O
%	O
of	O
two	O
nist	B-MED
standard	B-MED
reference	I-MED
materials	B-MED
3672	O
and	O
3673	O
.	O
	
this	O
high-throughput	B-MED
on-line-spe	B-MED
-	O
hplc-ms	B-MED
/	O
ms	B-MED
method	B-MED
can	O
be	O
applied	O
in	O
large	B-MED
-	O
scale	B-MED
epidemiological	B-MED
studies	I-MED
.	O
	
graphical	B-MED
abstract	I-MED
example	O
lc-ms	B-MED
chromatogram	I-MED
of	O
urinary	B-MED
mono-hydroxylated	B-MED
pah	I-MED
metabolites	B-MED
.	O
	
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
"""childhood"	B-MED
obesity	I-MED
risk	I-MED
"evaluation"""	I-MED
core	I-MED
in	O
predicting	O
obesity	B-MED
in	O
childhood	B-MED
and	O
adolescence	B-MED
in	O
greece	B-MED
from	O
early	B-MED
life	B-MED
the	O
""""	O
national	O
action	O
plan	O
for	O
public	O
health	O
""""	O
early	B-MED
identification	B-MED
of	O
infants	B-MED
being	O
at	O
high	B-MED
risk	I-MED
to	O
become	O
obese	B-MED
at	O
their	O
later	B-MED
childhood	B-MED
or	O
adolescence	B-MED
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-MED
prevention	B-MED
initiative	B-MED
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
"""childhood"	B-MED
obesity	I-MED
risk	I-MED
evaluation	I-MED
core	I-MED
index	I-MED
as	O
a	O
screening	B-MED
tool	B-MED
for	O
the	O
early	B-MED
prediction	B-MED
of	O
obesity	B-MED
in	O
childhood	B-MED
and	O
adolescence	B-MED
.	O
	
anthropometric	B-MED
,	O
socio-demographic	B-MED
data	I-MED
were	O
collected	B-MED
cross-sectionally	B-MED
and	O
retrospectively	B-MED
from	O
a	O
representative	O
sample	B-MED
of	O
5946	O
children	B-MED
,	O
and	O
adolescents	B-MED
and	O
were	O
combined	O
for	O
calculating	B-MED
the	O
core-index	B-MED
score	I-MED
.	O
	
logistic	B-MED
regression	I-MED
analyses	I-MED
were	O
performed	O
to	O
examine	O
the	O
associations	B-MED
of	O
the	O
core-index	B-MED
score	I-MED
with	O
obesity	B-MED
by	O
gender	B-MED
and	O
age	B-MED
group	I-MED
,	O
and	O
cut-off	B-MED
point	I-MED
analysis	I-MED
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	B-MED
value	B-MED
of	O
the	O
core-index	B-MED
score	I-MED
that	O
differentiates	B-MED
obese	B-MED
from	O
non-obese	B-MED
children	I-MED
.	O
	
mean	B-MED
core-index	I-MED
score	I-MED
in	O
the	O
total	B-MED
sample	B-MED
was	O
3.06	O
sd	B-MED
1.92	O
units	O
range	O
0-11	O
units	O
.	O
	
each	O
unit	O
increase	B-MED
in	O
the	O
core-index	B-MED
score	I-MED
was	O
found	O
to	O
be	O
associated	B-MED
with	I-MED
a	O
30	O
%	O
95	O
%	O
c.i	B-MED
.	O
	
1.24	O
increased	B-MED
likelihood	B-MED
for	O
obesity	B-MED
in	O
childhood	B-MED
or	O
adolescence	B-MED
,	O
while	O
the	O
optimal	B-MED
cut-off	B-MED
value	I-MED
of	O
the	O
core-index	B-MED
score	I-MED
that	O
predicted	B-MED
obesity	B-MED
with	O
the	O
highest	B-MED
possible	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
was	O
found	O
to	O
be	O
3.5	O
.	O
	
the	O
present	O
study	O
supports	O
the	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
core-index	B-MED
as	O
a	O
screening	B-MED
tool	B-MED
for	O
the	O
early	B-MED
identification	B-MED
of	O
infants	B-MED
that	O
are	O
potentially	O
at	O
a	O
higher	B-MED
risk	I-MED
for	O
becoming	O
obese	B-MED
at	O
their	O
childhood	B-MED
and	O
adolescence	B-MED
.	O
	
this	O
tool	B-MED
could	O
be	O
routinely	O
used	O
by	O
health	B-MED
professionals	I-MED
to	O
identify	O
infants	B-MED
at	O
high	B-MED
risk	I-MED
and	O
provide	O
appropriate	O
counselling	B-MED
to	O
their	O
parents	B-MED
and	O
caregivers	B-MED
so	O
as	O
to	O
maximize	O
the	O
effectiveness	B-MED
of	O
early	B-MED
obesity	B-MED
prevention	B-MED
initiatives	B-MED
.	O
	
what	O
is	O
known	O
childhood	B-MED
obesity	B-MED
has	O
reached	O
epidemic	B-MED
proportions	I-MED
worldwide	O
.	O
	
certain	O
perinatal	B-MED
and	O
socio-demographic	B-MED
indices	I-MED
that	O
were	O
previously	O
identified	B-MED
as	O
correlates	O
of	O
childhood	B-MED
obesity	B-MED
in	O
children	B-MED
were	O
combined	O
to	O
develop	O
the	O
core-index	B-MED
,	O
a	O
screening	B-MED
tool	B-MED
that	O
estimates	O
obesity	B-MED
risk	B-MED
in	O
9-13	O
year-old	B-MED
children	B-MED
.	O
	
what	O
is	O
new	O
the	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
core-index	B-MED
as	O
screening	B-MED
tool	B-MED
can	O
be	O
extended	O
to	O
the	O
age	B-MED
range	O
of	O
6-15	O
years	B-MED
.	O
	
the	O
core-index	B-MED
is	O
a	O
cost-effective	B-MED
screening	B-MED
tool	B-MED
that	O
can	O
assist	O
health	B-MED
professionals	I-MED
in	O
initiating	O
obesity	B-MED
preventive	B-MED
measures	I-MED
from	O
early	B-MED
life	B-MED
.	O
	
methodology	B-MED
development	B-MED
on	O
aquatic	B-MED
environmental	I-MED
assessment	B-MED
the	O
water	B-MED
framework	I-MED
directive	I-MED
aims	B-MED
at	O
reaching	O
the	O
good	O
ecological	B-MED
status	B-MED
of	O
the	O
surface	B-MED
and	O
ground	B-MED
water	I-MED
bodies	I-MED
lászló	O
et	O
al	O
.	O
	
microchem	O
j	O
85	O
,	O
2007	O
.	O
	
the	O
paper	O
deals	O
with	O
quality	B-MED
evaluation	B-MED
of	O
waters	B-MED
with	O
special	B-MED
focus	O
on	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
as	O
defined	O
in	O
the	O
water	B-MED
framework	I-MED
directive	I-MED
and	O
pertaining	O
legal	B-MED
regulations	I-MED
.	O
	
the	O
purpose	B-MED
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	B-MED
type	O
of	O
water	B-MED
quality	B-MED
assessment	B-MED
method	B-MED
which	O
could	O
provide	B-MED
rapid	B-MED
,	O
accurate	B-MED
,	O
and	O
reliable	B-MED
information	B-MED
on	O
the	O
quality	B-MED
of	O
the	O
surface	B-MED
waters	B-MED
by	O
using	O
water	B-MED
chemistry	B-MED
parameters	B-MED
.	O
	
quality	B-MED
classes	B-MED
have	O
been	O
defined	B-MED
for	O
every	O
water	B-MED
chemistry	B-MED
parameter	B-MED
in	O
light	O
of	O
the	O
legal	B-MED
limit	I-MED
values	I-MED
of	O
the	O
water	B-MED
parameters	B-MED
.	O
	
in	O
addition	O
to	O
this	O
,	O
weight	B-MED
indices	I-MED
were	O
calculated	B-MED
on	O
the	O
basis	O
of	O
the	O
outcome	B-MED
of	O
the	O
paired	B-MED
comparison	I-MED
of	O
water	B-MED
chemistry	B-MED
parameters	B-MED
and	O
normalized	B-MED
matrix	B-MED
.	O
	
this	O
was	O
followed	O
by	O
the	O
parametric	B-MED
level	I-MED
analysis	I-MED
of	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
,	O
and	O
finally	O
,	O
the	O
aquatic	B-MED
environment	I-MED
index	I-MED
aei	B-MED
was	O
calculated	B-MED
,	O
which	O
provided	B-MED
general	B-MED
information	I-MED
on	O
the	O
quality	B-MED
of	O
water	B-MED
regarding	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
.	O
	
the	O
method	B-MED
was	O
illustrated	O
on	O
lake	B-MED
balaton	B-MED
,	O
hungary	B-MED
in	O
which	O
case	O
water	B-MED
samples	B-MED
taken	O
from	O
balatonfüred	B-MED
city	I-MED
lake	B-MED
area	B-MED
were	O
analyzed	B-MED
and	O
evaluated	B-MED
with	O
the	O
method	B-MED
wdr26	B-MED
promotes	B-MED
mitophagy	B-MED
of	O
cardiomyocytes	B-MED
induced	B-MED
by	O
hypoxia	B-MED
through	O
parkin	B-MED
translocation	B-MED
myocardial	B-MED
ischemia	I-MED
is	O
a	O
heart	B-MED
condition	B-MED
caused	O
by	O
reduction	B-MED
of	O
blood	B-MED
flow	I-MED
to	O
the	O
heart	B-MED
,	O
preventing	O
heart	B-MED
from	O
receiving	B-MED
enough	O
oxygen	B-MED
.	O
	
myocardial	B-MED
ischemia	I-MED
is	O
the	O
most	O
common	O
cause	B-MED
of	I-MED
death	I-MED
globally	B-MED
.	O
	
heart	B-MED
ischemic	B-MED
preconditioning	I-MED
ipc	B-MED
has	O
a	O
protective	B-MED
effect	I-MED
against	O
myocardial	B-MED
cell	I-MED
death	B-MED
induced	B-MED
by	O
ischemia	B-MED
and	O
ischemia-reperfusion	B-MED
injury	I-MED
.	O
	
wdr26	B-MED
has	O
recently	O
been	O
identified	B-MED
as	O
a	O
protein	B-MED
that	O
is	O
increased	B-MED
following	O
rat	B-MED
cardiac	B-MED
ipc	B-MED
.	O
	
wdr26	B-MED
can	O
promote	B-MED
the	O
proliferation	B-MED
of	O
h9c2	B-MED
cells	I-MED
and	O
protect	O
cardiomyocytes	B-MED
against	O
oxidative	B-MED
stress	I-MED
through	O
inhibiting	B-MED
apoptosis	B-MED
.	O
	
however	O
,	O
its	O
role	B-MED
in	O
myocardial	B-MED
ischemia	I-MED
is	O
unclear	O
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
explore	O
the	O
role	O
of	O
wdr26	B-MED
in	O
myocardial	B-MED
ischemia	I-MED
and	O
h9c2	B-MED
cell	I-MED
hypoxia	B-MED
.	O
	
our	O
results	B-MED
showed	O
that	O
wdr26	B-MED
is	O
induced	B-MED
by	O
myocardial	B-MED
ischemia	I-MED
and	O
h9c2	B-MED
cell	I-MED
hypoxia	B-MED
.	O
	
wdr26	B-MED
protects	O
h9c2	B-MED
cells	I-MED
against	O
hypoxia	B-MED
injury	B-MED
through	O
inhibiting	B-MED
ldh	B-MED
release	O
and	O
increasing	O
cell	B-MED
viability	I-MED
.	O
	
wdr26	B-MED
promotes	B-MED
hypoxia	B-MED
-	O
induced	B-MED
autophagy	B-MED
in	O
hypoxia	B-MED
of	O
h9c2	B-MED
cells	I-MED
.	O
	
we	O
further	O
demonstrated	O
that	O
in	O
h9c2	B-MED
cell	I-MED
hypoxia	B-MED
,	O
wdr26	B-MED
increases	B-MED
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
,	O
thereby	O
increases	B-MED
parkin	B-MED
translocation	B-MED
of	O
mitochondria	B-MED
.	O
	
after	O
parkin	B-MED
is	O
translocated	B-MED
at	O
mitochondria	B-MED
,	O
wdr26	B-MED
can	O
increase	B-MED
mitochondria	B-MED
l	O
protein	B-MED
ubiquitination	I-MED
in	O
hypoxia	B-MED
of	O
h9c2	B-MED
cells	I-MED
.	O
	
wdr26	B-MED
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	B-MED
,	O
and	O
wdr26	B-MED
plays	O
an	O
important	O
role	O
in	O
hypoxia	B-MED
-mediated	O
autophagy	B-MED
and	O
mitophagy	B-MED
.	O
	
this	O
study	B-MED
provides	O
novel	B-MED
insights	O
into	O
the	O
protective	O
role	O
of	O
wdr26	B-MED
in	O
cardiomyocyte	B-MED
injury	B-MED
during	O
hypoxia	B-MED
.	O
	
wdr26	B-MED
may	O
serve	O
as	O
a	O
potential	O
target	B-MED
for	O
the	O
treatment	B-MED
of	O
myocardial	B-MED
ischemia	I-MED
.	O
	
impact	B-MED
of	O
antibiotic	B-MED
de-escalation	B-MED
on	O
clinical	B-MED
outcomes	I-MED
in	O
community-acquired	B-MED
pneumococcal	B-MED
pneumonia	I-MED
although	O
antibiotic	B-MED
de-escalation	B-MED
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	B-MED
selection	O
pressure	O
,	O
adverse	B-MED
drug	I-MED
effects	I-MED
and	O
costs	B-MED
,	O
evidence	B-MED
supporting	O
this	O
practice	O
in	O
community-acquired	B-MED
pneumococcal	I-MED
pneumonia	I-MED
capp	B-MED
is	O
lacking	B-MED
.	O
	
we	O
carried	O
out	O
a	O
retrospective	B-MED
analysis	B-MED
of	O
prospectively	O
collected	O
data	B-MED
of	O
a	O
cohort	B-MED
of	O
hospitalized	B-MED
adults	I-MED
with	O
capp	B-MED
.	O
	
pneumococcal	B-MED
aetiology	B-MED
was	O
established	B-MED
in	O
patients	B-MED
with	O
one	O
or	O
more	O
positive	B-MED
cultures	I-MED
for	O
streptococcus	B-MED
pneumoniae	I-MED
obtained	O
from	O
blood	B-MED
,	O
sterile	B-MED
fluids	I-MED
or	O
sputum	B-MED
,	O
and/or	O
a	O
positive	B-MED
urinary	B-MED
antigen	I-MED
test	I-MED
.	O
	
de-escalation	B-MED
therapy	I-MED
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B-MED
therapy	I-MED
was	O
narrowed	O
to	O
penicillin	B-MED
,	O
amoxicillin	B-MED
or	O
amoxicillin/clavulanate	B-MED
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-MED
.	O
	
the	O
primary	O
outcomes	B-MED
were	O
30	O
day	B-MED
mortality	B-MED
and	O
length	B-MED
of	I-MED
hospital	I-MED
stay	I-MED
los	B-MED
.	O
	
adjustment	B-MED
for	O
confounders	O
was	O
performed	B-MED
with	O
multivariate	B-MED
and	O
propensity	B-MED
score	I-MED
analyses	B-MED
.	O
	
of	O
1410	O
episodes	O
of	O
capp	B-MED
,	O
antibiotic	B-MED
de-escalation	B-MED
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-MED
was	O
performed	B-MED
in	O
166	O
cases	B-MED
.	O
	
after	O
adjustment	B-MED
,	O
antibiotic	B-MED
de-escalation	B-MED
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	O
risk	B-MED
of	O
mortality	B-MED
or	B-MED
=	O
0.83	O
,	O
95%	O
ci	B-MED
=	O
0.24	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	B-MED
factor	I-MED
for	O
prolonged	B-MED
los	B-MED
above	O
the	O
median	B-MED
or	B-MED
=	O
0.46	O
,	O
95%	O
ci	B-MED
=	O
0.30	O
.	O
	
similar	O
results	B-MED
were	O
found	O
in	O
patients	B-MED
classified	O
into	O
high-risk	B-MED
pneumonia	B-MED
severity	O
index	O
classes	O
iv-v	O
,	O
those	O
with	O
clinical	B-MED
instability	I-MED
and	O
those	O
with	O
bacteraemia	B-MED
.	O
	
no	B-MED
significant	I-MED
differences	I-MED
were	O
documented	B-MED
in	O
adverse	B-MED
drug	I-MED
reactions	I-MED
or	O
readmission	B-MED
<30	O
days	B-MED
.	O
	
antibiotic	B-MED
de-escalation	B-MED
seems	O
to	O
be	O
safe	O
and	O
effective	B-MED
in	O
reducing	B-MED
the	O
duration	B-MED
of	O
los	B-MED
,	O
and	O
did	O
not	O
adversely	B-MED
affect	I-MED
outcomes	B-MED
of	O
patients	B-MED
with	O
capp	B-MED
,	O
even	O
those	O
with	O
bacteraemia	B-MED
and	O
severe	B-MED
disease	I-MED
,	O
and	O
those	O
who	O
were	O
clinically	B-MED
unstable	I-MED
.	O
	
radiation	B-MED
-	O
induced	B-MED
parotid	B-MED
gland	I-MED
atrophy	I-MED
in	O
patients	B-MED
with	O
head	B-MED
and	I-MED
neck	I-MED
cancer	I-MED
after	O
carbon-ion	B-MED
radiotherapy	I-MED
this	O
study	B-MED
aimed	O
to	O
clarify	B-MED
the	O
relationship	B-MED
between	O
dosimetric	B-MED
factors	B-MED
and	O
parotid	B-MED
gland	I-MED
pg	I-MED
atrophy	I-MED
after	O
carbon	B-MED
ion	I-MED
radiotherapy	I-MED
c-ion	B-MED
rt	I-MED
.	O
	
fifty-four	O
patients	B-MED
with	O
head	B-MED
and	I-MED
neck	I-MED
tumours	I-MED
were	O
enrolled	O
and	O
93	O
irradiated	O
pgs	B-MED
were	O
analyzed	O
.	O
	
thirty	O
and	O
24	O
patients	B-MED
were	O
treated	B-MED
with	I-MED
total	B-MED
doses	I-MED
relative	B-MED
biological	I-MED
effectiveness	I-MED
rbe	B-MED
of	O
57.6	O
gy	O
and	O
64.0	O
gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O
	
pg	B-MED
volumes	B-MED
were	O
measured	B-MED
using	O
computed	B-MED
tomographic	I-MED
images	I-MED
obtained	O
before	O
c-ion	B-MED
rt	I-MED
and	O
every	O
3-6	O
months	B-MED
thereafter	O
.	O
	
the	O
median	B-MED
follow-up	B-MED
period	B-MED
was	O
46.4	O
months	B-MED
range	B-MED
=24	O
months	B-MED
.	O
	
univariate	B-MED
analysis	I-MED
showed	O
that	O
pg	B-MED
volumes	B-MED
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
gy	O
rbe	B-MED
v5	B-MED
,	O
v10	B-MED
,	O
v15	B-MED
and	O
v20	B-MED
,	O
respectively	O
,	O
mean	B-MED
dose	B-MED
,	O
and	O
maximum	B-MED
dose	B-MED
were	O
significantly	O
associated	B-MED
with	I-MED
pg	B-MED
atrophy	I-MED
.	O
	
multivariate	B-MED
analysis	I-MED
indicated	O
that	O
only	O
v5	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
atrophy	B-MED
.	O
	
increasing	B-MED
v5	B-MED
was	O
a	O
significant	O
risk	B-MED
factor	I-MED
for	O
pg	B-MED
atrophy	I-MED
after	O
c-ion	B-MED
rt	I-MED
.	O
	
il-27	B-MED
is	O
essential	O
for	O
suppression	B-MED
of	O
experimental	B-MED
allergic	B-MED
asthma	I-MED
by	O
the	O
tlr7	B-MED
/	O
8	B-MED
agonist	B-MED
r848	B-MED
resiquimod	B-MED
different	O
models	B-MED
of	I-MED
experimental	I-MED
allergic	B-MED
asthma	I-MED
have	O
shown	O
that	O
the	O
tlr7	B-MED
/	O
8	B-MED
agonist	B-MED
resiquimod	B-MED
r848	B-MED
is	O
a	O
potential	O
inhibitor	B-MED
of	O
type	B-MED
2	I-MED
helper	I-MED
cell	I-MED
-driven	O
inflammatory	B-MED
responses	I-MED
.	O
	
however	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	B-MED
effects	I-MED
are	O
not	O
fully	O
understood	O
.	O
	
using	O
a	O
model	B-MED
of	I-MED
experimental	I-MED
allergic	B-MED
asthma	I-MED
,	O
we	O
show	O
that	O
induction	B-MED
of	O
il-27	B-MED
by	O
r848	B-MED
is	O
critical	O
for	O
the	O
observed	O
ameliorative	B-MED
effects	O
.	O
	
r848	B-MED
significantly	O
inhibited	B-MED
all	O
hallmarks	B-MED
of	O
experimental	B-MED
allergic	B-MED
asthma	I-MED
,	O
including	O
airway	B-MED
hyperreactivity	I-MED
,	O
eosinophilic	B-MED
airway	B-MED
inflammation	B-MED
,	O
mucus	B-MED
hypersecretion	I-MED
,	O
and	O
ag	B-MED
-	O
specific	B-MED
ig	I-MED
production	B-MED
.	O
	
whereas	O
r848	B-MED
significantly	O
reduced	O
il-5	B-MED
,	O
il-13	B-MED
,	O
and	O
il-17	B-MED
,	O
it	O
induced	O
ifn-γ	B-MED
and	O
il-27	B-MED
.	O
	
neutralization	B-MED
of	O
il-27	B-MED
completely	O
reversed	O
the	O
therapeutic	B-MED
effect	I-MED
of	O
r848	B-MED
in	O
the	O
experimental	B-MED
asthma	B-MED
model	B-MED
,	O
demonstrating	O
dependence	O
of	O
r848	B-MED
-mediated	O
suppression	B-MED
on	O
il-27	B-MED
.	O
	
in	B-MED
vitro	I-MED
,	O
r848	B-MED
induced	B-MED
production	O
of	O
il-27	B-MED
by	O
murine	B-MED
alveolar	B-MED
macrophages	I-MED
and	O
dendritic	B-MED
cells	I-MED
and	O
enhanced	B-MED
expression	B-MED
of	O
programmed	B-MED
death-ligand	I-MED
1	I-MED
,	O
whose	O
expression	B-MED
on	O
monocytes	B-MED
and	O
dendritic	B-MED
cells	I-MED
has	O
been	O
shown	O
to	O
regulate	B-MED
peripheral	B-MED
tolerance	I-MED
in	O
both	O
murine	B-MED
and	O
human	B-MED
studies	O
.	O
	
moreover	O
,	O
in	B-MED
vitro	I-MED
il-27	B-MED
enhanced	B-MED
secretion	B-MED
of	O
ifn-γ	B-MED
whereas	O
it	O
inhibited	B-MED
il-5	B-MED
and	O
il-13	B-MED
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
th2	B-MED
responses	O
.	O
	
taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
r848	B-MED
-mediated	O
suppression	B-MED
of	O
experimental	B-MED
asthma	B-MED
is	O
dependent	O
on	O
il-27	B-MED
.	O
	
these	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
il-27	B-MED
for	O
the	O
control	O
of	O
th2	B-MED
-mediated	O
allergic	B-MED
diseases	I-MED
.	O
	
a	O
comparison	O
of	O
functional	B-MED
outcomes	O
in	O
patients	B-MED
undergoing	O
revision	B-MED
arthroscopic	I-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
with	O
and	O
without	B-MED
arthroscopic	B-MED
suprascapular	B-MED
nerve	I-MED
release	I-MED
this	O
study	O
was	O
designed	O
to	O
compare	O
functional	B-MED
outcomes	O
in	O
patients	B-MED
undergoing	O
revision	B-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
retracted	B-MED
medial	I-MED
to	O
the	O
glenoid	B-MED
with	O
goutallier	B-MED
grade	I-MED
4	I-MED
atrophy	I-MED
and	O
concomitant	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
to	O
a	O
similar	O
group	O
of	O
patients	B-MED
with	O
grade	B-MED
3	I-MED
atrophy	I-MED
undergoing	O
revision	B-MED
rotator	I-MED
cuff	I-MED
repair	I-MED
rtcr	B-MED
without	O
nerve	B-MED
release	I-MED
.	O
	
we	O
hypothesized	O
that	O
patients	B-MED
undergoing	O
nerve	B-MED
release	I-MED
would	O
have	O
more	O
favorable	O
functional	B-MED
outcomes	O
as	O
measured	O
by	O
the	O
modified	O
university	B-MED
of	I-MED
california	I-MED
at	O
los	B-MED
angeles	I-MED
shoulder	B-MED
rating	I-MED
scale	I-MED
ucla	B-MED
.	O
	
twenty-two	O
patients	B-MED
underwent	O
revision	B-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
with	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
at	O
the	O
suprascapular	B-MED
notch	I-MED
.	O
	
we	O
compared	O
total	O
preoperative	B-MED
,	O
postoperative	B-MED
,	O
and	O
change	O
in	O
ucla	B-MED
score	I-MED
in	O
these	O
patients	B-MED
to	O
a	O
similar	O
group	B-MED
of	O
22	O
patients	B-MED
undergoing	O
revision	B-MED
rtcr	I-MED
without	B-MED
suprascapular	B-MED
nerve	I-MED
release	I-MED
.	O
	
additionally	O
,	O
ucla	O
subscores	O
between	O
the	O
two	O
groups	B-MED
were	O
compared	O
preoperatively	B-MED
and	O
at	O
final	O
follow-up	B-MED
.	O
	
the	O
average	O
preoperative	B-MED
ucla	B-MED
score	I-MED
in	O
the	O
nerve-release	B-MED
group	I-MED
was	O
7.91	O
,	O
and	O
final	O
follow-up	B-MED
average	O
was	O
27.86	O
average	O
3.05	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
	
in	O
the	O
comparison	O
group	B-MED
,	O
average	O
preoperative	B-MED
ucla	B-MED
score	I-MED
was	O
11.77	O
,	O
and	O
final	O
follow-up	B-MED
average	O
was	O
29.09	O
average	O
1.32	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
	
the	O
average	O
preoperative	B-MED
ucla	B-MED
score	I-MED
was	O
significantly	O
worse	O
in	O
the	O
nerve-release	B-MED
group	I-MED
p=0	O
.	O
	
the	O
average	O
postoperative	B-MED
ucla	B-MED
score	I-MED
was	O
not	O
significantly	O
different	O
p=0	O
between	O
the	O
groups	B-MED
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve-release	B-MED
group	I-MED
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	B-MED
,	O
strength	B-MED
,	O
and	O
pain	B-MED
relief	I-MED
.	O
	
patients	B-MED
who	O
underwent	O
concomitant	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
during	O
revision	B-MED
rtcr	I-MED
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain	B-MED
relief	I-MED
,	O
active	B-MED
forward	I-MED
flexion	I-MED
,	O
and	O
strength	B-MED
,	O
than	O
a	O
comparable	O
group	B-MED
without	B-MED
nerve	B-MED
release	I-MED
.	O
	
fading	B-MED
with	B-MED
time	I-MED
of	O
pd-l1	B-MED
immunoreactivity	B-MED
in	O
non-small	B-MED
cells	I-MED
lung	I-MED
cancer	I-MED
tissues	B-MED
a	O
methodological	B-MED
study	I-MED
blockade	B-MED
of	O
inhibitory	B-MED
immune	I-MED
checkpoints	I-MED
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	B-MED
option	B-MED
for	O
tumor	B-MED
therapy	I-MED
.	O
	
inhibition	B-MED
of	O
programmed	B-MED
cell	I-MED
death	I-MED
protein	I-MED
1	I-MED
and/or	O
its	O
specific	O
ligand	B-MED
programmed	B-MED
death-ligand	I-MED
1	I-MED
pd-l1	B-MED
was	O
effective	O
in	O
clinical	B-MED
trials	I-MED
in	O
advanced	B-MED
melanoma	B-MED
,	O
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
nsclc	B-MED
bladder	B-MED
and	O
kidney	B-MED
cancer	I-MED
.	O
	
the	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-MED
ihc	B-MED
expression	B-MED
of	O
pd-l1	B-MED
is	O
highly	O
debated	O
.	O
	
different	O
reagents	B-MED
,	O
clones	B-MED
,	O
cutoffs	O
of	O
cell	B-MED
expression	B-MED
and	O
subjective	B-MED
interpretation	B-MED
of	O
pd-l1	B-MED
immunoreactivity	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
lymphocytes	B-MED
are	O
the	O
main	O
issue	B-MED
.	O
	
in	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
nsclc	B-MED
surgical	B-MED
specimens	I-MED
that	O
underwent	O
pathologic	B-MED
examination	I-MED
from	O
january	B-MED
2014	O
to	O
july	B-MED
2015	O
.	O
	
using	O
a	O
tissue	O
microarray	B-MED
approach	I-MED
we	O
evaluated	O
the	O
ihc	B-MED
expression	I-MED
of	O
pd-l1	B-MED
in	O
tumor-infiltrating	B-MED
lymphocytes	I-MED
and	O
tumor	B-MED
cells	I-MED
tcs	B-MED
and	O
compared	O
the	O
ich	B-MED
staining	I-MED
with	O
tumor	B-MED
histology	I-MED
,	O
grade	B-MED
and	O
the	O
age	O
of	O
the	O
tissue	B-MED
blocks	I-MED
.	O
	
the	O
main	O
new	O
finding	B-MED
was	O
the	O
fading	B-MED
of	O
pd-l1	B-MED
ihc	B-MED
expression	I-MED
in	O
tcs	B-MED
in	O
tissues	B-MED
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O
	
pd-l1	B-MED
expression	B-MED
in	O
tumor-infiltrating	B-MED
lymphocytes	I-MED
in	O
the	O
2	O
years	B-MED
was	O
similar	B-MED
.	O
	
we	O
also	O
found	O
a	O
significant	B-MED
higher	I-MED
immunoreactivity	B-MED
of	O
tcs	B-MED
in	O
high	B-MED
grade	I-MED
nsclc	B-MED
and	O
in	O
the	O
squamous	B-MED
carcinoma	I-MED
histotype	B-MED
compared	O
with	O
low	B-MED
grade	I-MED
tumors	B-MED
and	O
the	O
adenocarcinoma	B-MED
histology	B-MED
p=0	O
.	O
	
we	O
demonstrated	O
that	O
the	O
ihc	B-MED
evaluation	I-MED
of	O
pd-l1	B-MED
in	O
nsclc	B-MED
archival	B-MED
tissues	I-MED
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	B-MED
setting	I-MED
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	B-MED
blocks	I-MED
older	O
than	O
1	O
differential	B-MED
transcriptome	B-MED
expression	B-MED
in	O
human	B-MED
nucleus	B-MED
accumbens	I-MED
as	O
a	O
function	O
of	O
loneliness	B-MED
loneliness	B-MED
is	O
associated	B-MED
with	I-MED
impaired	B-MED
mental	B-MED
and	O
physical	B-MED
health	I-MED
.	O
	
studies	O
of	O
lonely	B-MED
individuals	I-MED
reported	O
differential	B-MED
expression	I-MED
of	O
inflammatory	B-MED
genes	B-MED
in	O
peripheral	B-MED
leukocytes	B-MED
and	O
diminished	B-MED
activation	B-MED
in	O
brain	B-MED
reward	B-MED
regions	I-MED
such	O
as	O
nucleus	B-MED
accumbens	I-MED
,	O
but	O
could	O
not	O
address	O
gene	B-MED
expression	I-MED
in	O
the	O
human	B-MED
brain	B-MED
.	O
	
here	O
,	O
we	O
examined	O
genome-wide	B-MED
rna	I-MED
expression	I-MED
in	O
post-mortem	B-MED
nucleus	B-MED
accumbens	I-MED
from	O
donors	B-MED
n=26	O
with	O
known	O
loneliness	B-MED
measures	B-MED
.	O
	
loneliness	B-MED
was	O
associated	B-MED
with	I-MED
1710	O
differentially	B-MED
expressed	I-MED
transcripts	I-MED
and	O
genes	B-MED
from	O
1599	O
genes	B-MED
degs	B-MED
false	B-MED
discovery	I-MED
rate	I-MED
p<0	O
,	O
fold	O
change	O
|2|	O
,	O
controlling	O
for	O
confounds	O
previously	O
associated	B-MED
with	I-MED
behavioral	B-MED
processes	I-MED
,	O
neurological	B-MED
disease	I-MED
,	O
psychological	B-MED
disorders	I-MED
,	O
cancer	B-MED
,	O
organismal	B-MED
injury	B-MED
and	O
skeletal	B-MED
and	O
muscular	B-MED
disorders	I-MED
,	O
as	O
well	O
as	O
networks	B-MED
of	O
upstream	B-MED
rna	B-MED
regulators	I-MED
.	O
	
furthermore	O
,	O
a	O
number	O
of	O
degs	B-MED
were	O
associated	B-MED
with	I-MED
alzheimer's	B-MED
disease	I-MED
ad	B-MED
genes	B-MED
that	O
was	O
correlated	B-MED
with	O
loneliness	B-MED
in	O
this	O
sample	B-MED
,	O
although	O
gene	B-MED
expression	I-MED
analyses	I-MED
controlled	O
for	O
ad	B-MED
diagnosis	B-MED
.	O
	
these	O
results	O
identify	O
novel	O
targets	B-MED
for	O
future	O
mechanistic	B-MED
studies	I-MED
of	O
gene	B-MED
networks	O
in	O
nucleus	B-MED
accumbens	I-MED
and	O
gene	B-MED
regulatory	I-MED
mechanisms	I-MED
across	O
a	O
variety	O
of	O
diseases	B-MED
exacerbated	O
by	O
loneliness	B-MED
.	O
	
molecular	B-MED
psychiatry	I-MED
advance	I-MED
online	I-MED
publication	I-MED
,	O
1	O
november	B-MED
overall	O
quality	B-MED
properties	I-MED
of	O
kiwifruit	B-MED
treated	B-MED
by	I-MED
cinnamaldehyde	B-MED
and	O
citral	B-MED
microbial	B-MED
,	O
antioxidant	B-MED
capacity	I-MED
during	O
cold	B-MED
storage	I-MED
this	O
work	O
was	O
undertaken	O
to	O
evaluate	B-MED
the	O
microbiological	B-MED
characteristics	B-MED
and	O
antioxidant	B-MED
and	O
physiological	B-MED
activities	I-MED
in	O
kiwifruits	B-MED
actinida	B-MED
deliciosa	I-MED
var	O
.	O
	
qinmei	O
with/without	O
cinnamaldehyde	B-MED
c1	O
and	O
citral	B-MED
c2	O
fumigation	B-MED
treatments	B-MED
5	O
μl/l	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	B-MED
at	O
4	O
c	O
.	O
	
essential	B-MED
oils	I-MED
eos	B-MED
treatment	B-MED
lowered	O
the	O
total	O
viable	B-MED
counts	I-MED
,	O
yeast	B-MED
,	O
and	O
mold	B-MED
to	O
1.54	O
,	O
2.36	O
,	O
and	O
2.05	O
log	O
cfu/g	O
,	O
respectively	O
.	O
	
moreover	O
,	O
eos	B-MED
improved	O
the	O
antioxidant	B-MED
activities	I-MED
of	O
kiwifruit	B-MED
.	O
	
they	O
enhanced	B-MED
phenolics	B-MED
and	O
flavonoids	B-MED
content	O
in	O
fruit	B-MED
tissue	B-MED
by	O
49.48	O
at	O
day	O
3	O
and	O
56.93	O
at	O
day	O
6	O
,	O
respectively	O
.	O
	
in	O
addition	O
,	O
ascorbic	B-MED
acid	I-MED
in	O
treated	B-MED
groups	B-MED
had	O
the	O
lower	O
losing	O
rate	B-MED
.	O
	
similarly	O
,	O
mda	B-MED
malondialdehyde	B-MED
,	O
h2	B-MED
o2	I-MED
hydrogen	B-MED
peroxide	I-MED
,	O
and	O
o2	B-MED
superoxide	B-MED
anion	I-MED
production	O
were	O
effectively	B-MED
decreased	B-MED
in	O
the	O
range	O
of	O
27.27	O
to	O
54.38	O
.	O
	
physicochemical	B-MED
characteristics	I-MED
showed	O
that	O
kiwifruits	B-MED
from	O
treated	B-MED
group	B-MED
maintained	O
higher	O
levels	O
of	O
flesh	B-MED
luminosity	I-MED
and	O
firmness	B-MED
.	O
	
eos	B-MED
also	O
decreased	B-MED
the	O
levels	O
of	O
reducing	B-MED
sugar	I-MED
by	O
45.97	O
at	O
day	O
3	O
,	O
and	O
increased	B-MED
the	O
content	O
of	O
soluble	B-MED
protein	I-MED
and	O
hydrolyzed	O
amino	B-MED
acid	I-MED
.	O
	
therefore	O
,	O
postharvest	O
eos	B-MED
treatment	B-MED
has	O
positive	B-MED
effects	I-MED
on	O
delaying	O
senescence	B-MED
and	O
enhancing	B-MED
antioxidant	B-MED
capacities	I-MED
in	O
anti-inflammatory	B-MED
effect	I-MED
of	O
yu-ping-feng-san	B-MED
via	O
tgf-β1	B-MED
signaling	B-MED
suppression	I-MED
in	O
rat	B-MED
model	B-MED
of	O
copd	B-MED
yu-ping-feng-san	B-MED
ypfs	B-MED
is	O
a	O
classical	O
traditional	O
chinese	B-MED
medicine	I-MED
that	O
is	O
widely	O
used	O
for	O
treatment	B-MED
of	O
the	O
diseases	B-MED
in	O
respiratory	B-MED
systems	I-MED
,	O
including	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
copd	B-MED
recognized	O
as	O
chronic	B-MED
inflammatory	I-MED
disease	I-MED
.	O
	
however	O
,	O
the	O
molecular	B-MED
mechanism	I-MED
remains	O
unclear	O
.	O
	
here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
1	I-MED
tgf-β1	B-MED
smad2	B-MED
signaling	B-MED
pathway	I-MED
and	O
inflammatory	B-MED
cytokines	I-MED
,	O
to	O
clarify	O
whether	O
ypfs	B-MED
could	O
attenuate	B-MED
inflammatory	B-MED
response	I-MED
dependent	O
on	O
tgf-β1	B-MED
/	O
smad2	B-MED
signaling	B-MED
in	O
copd	B-MED
rats	B-MED
or	O
cigarette	B-MED
smoke	I-MED
extract	I-MED
cse	B-MED
treated	B-MED
human	B-MED
bronchial	B-MED
epithelial	I-MED
beas-2b	I-MED
cells	I-MED
.	O
	
the	O
copd	B-MED
rat	B-MED
model	B-MED
was	O
established	O
by	O
exposure	B-MED
to	O
cigarette	B-MED
smoke	I-MED
and	O
intratracheal	B-MED
instillation	I-MED
of	O
lipopolysaccharide	B-MED
,	O
ypfs	B-MED
was	O
administered	O
to	O
the	O
animals	B-MED
.	O
	
the	O
efficacy	B-MED
of	O
ypfs	B-MED
was	O
evaluated	O
by	O
comparing	O
the	O
severity	B-MED
of	O
pulmonary	B-MED
pathological	I-MED
damage	I-MED
,	O
pro-inflammation	B-MED
cytokines	I-MED
,	O
collagen	B-MED
related	I-MED
genes	I-MED
and	O
the	O
activation	B-MED
of	O
tgf-β1	B-MED
/	O
smad2	B-MED
signaling	B-MED
pathway	I-MED
.	O
	
furthermore	O
,	O
cse	B-MED
-	O
treated	B-MED
cells	B-MED
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	B-MED
of	O
ypfs	B-MED
was	O
dependent	O
on	O
the	O
tgf-β1	B-MED
/	O
smad2	B-MED
signaling	B-MED
via	O
knockdown	B-MED
smad2	B-MED
si-rna	B-MED
,	O
or	O
pretreatment	B-MED
with	O
the	O
inhibitor	B-MED
of	O
tgf-β1	B-MED
.	O
	
administration	O
of	O
ypfs	B-MED
effectively	O
alleviated	O
injury	B-MED
of	I-MED
lung	I-MED
,	O
suppressed	B-MED
releasing	O
of	O
pro-inflammatory	B-MED
cytokines	I-MED
and	O
collagen	B-MED
deposition	I-MED
in	O
copd	B-MED
animals	B-MED
p<0	O
,	O
whereas	O
exogenous	B-MED
tgf-β1	I-MED
promoted	O
releasing	O
of	O
il-1β	B-MED
,	O
il-6	B-MED
,	O
tnfα	B-MED
p<0	O
.	O
	
administration	O
ypfs	B-MED
reduced	O
inflammatory	B-MED
response	I-MED
significantly	O
,	O
also	O
down-regulated	B-MED
tgf-β1	B-MED
/	O
smad2	B-MED
signaling	B-MED
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
.	O
	
unexpectedly	O
,	O
knockdown	B-MED
smad2	B-MED
or	O
inhibition	B-MED
of	O
tgf-β1	B-MED
abolished	O
anti-inflammatory	B-MED
effect	I-MED
of	O
ypfs	B-MED
in	O
cse	B-MED
-	O
treated	B-MED
cells	B-MED
.	O
	
ypfs	B-MED
accomplished	O
anti-inflammatory	B-MED
effects	I-MED
mainly	O
by	O
suppressing	B-MED
phosphorylation	B-MED
of	O
smad2	B-MED
,	O
tgf-β1	B-MED
/	O
smad2	B-MED
signaling	B-MED
pathway	I-MED
was	O
required	O
for	O
ypfs	B-MED
-mediated	O
anti-inflammation	B-MED
in	O
copd	B-MED
rats	B-MED
or	O
cse	B-MED
-	O
treated	B-MED
beas-2b	B-MED
cells	I-MED
.	O
	
the	O
association	B-MED
between	O
maternal	B-MED
hydronephrosis	B-MED
and	O
acute	B-MED
flank	B-MED
pain	I-MED
during	O
pregnancy	B-MED
a	O
prospective	B-MED
pilot-study	B-MED
maternal	B-MED
hydronephrosis	B-MED
may	O
cause	O
flank	B-MED
pain	I-MED
during	O
pregnancy	B-MED
.	O
	
we	O
aimed	B-MED
to	O
investigate	B-MED
the	O
association	O
between	O
maternal	B-MED
hydronephrosis	B-MED
and	O
flank	B-MED
pain	I-MED
intensity	B-MED
.	O
	
from	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	B-MED
women	B-MED
with	O
singleton	B-MED
pregnancies	I-MED
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	B-MED
flank	B-MED
pain	I-MED
,	O
were	O
prospectively	B-MED
evaluated	B-MED
by	O
renal	B-MED
ultrasonography	B-MED
and	O
pain	B-MED
questionnaires	B-MED
.	O
	
a	O
visual	B-MED
analogue	I-MED
scale	I-MED
was	O
used	O
to	O
assess	O
pain	B-MED
intensity	I-MED
.	O
	
the	O
study	B-MED
had	O
90%	O
power	O
to	O
detect	O
a	O
significant	B-MED
correlation	B-MED
between	O
hydronephrosis	B-MED
and	O
flank	B-MED
pain	I-MED
spearman's	B-MED
test	I-MED
.	O
	
a	O
total	O
of	O
51	O
consecutive	B-MED
women	B-MED
with	O
left-sided	B-MED
13.7	O
,	O
right-sided	B-MED
64.7	O
or	O
bilateral	B-MED
21.6	O
pain	B-MED
were	O
enrolled	O
.	O
	
the	O
mean	B-MED
gestational	B-MED
age	I-MED
of	O
these	O
women	B-MED
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-MED
,	O
was	O
27.5	O
6.8	O
weeks	B-MED
at	O
the	O
time	O
of	O
consultation	B-MED
.	O
	
the	O
mean	B-MED
vas	B-MED
score	I-MED
was	O
7.6	O
2.2	O
.	O
	
in	O
43/51	O
84.3	O
women	B-MED
,	O
hydronephrosis	B-MED
was	O
found	O
on	O
renal	B-MED
sonograms	O
.	O
	
no	O
correlation	B-MED
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-MED
and	O
pain	B-MED
intensity	I-MED
p	O
=	O
0.466	O
r=	O
-0	O
.	O
	
women	B-MED
delivered	O
at	O
a	O
mean	B-MED
gestational	B-MED
age	I-MED
of	O
38.1	O
2.4	O
weeks	B-MED
and	O
their	O
infants	B-MED
had	O
a	O
mean	B-MED
birthweight	B-MED
of	O
3138	O
677	O
g	O
.	O
	
hydronephrosis	B-MED
is	O
a	O
common	O
finding	B-MED
among	O
pregnant	B-MED
women	I-MED
with	O
acute	B-MED
flank	B-MED
pain	I-MED
.	O
	
the	O
grade	O
of	O
hydronephrosis	B-MED
does	O
not	O
affect	O
pain	B-MED
intensity	I-MED
.	O
	
this	O
study	B-MED
suggests	O
normal	B-MED
pregnancy	I-MED
outcomes	B-MED
in	O
these	O
simulating	B-MED
the	O
potential	B-MED
role	B-MED
of	O
media	B-MED
coverage	I-MED
and	O
infected	B-MED
bats	B-MED
in	O
the	O
2014	O
ebola	B-MED
outbreak	B-MED
multiple	O
epidemiological	B-MED
models	B-MED
have	O
been	O
developed	B-MED
to	O
model	O
the	O
transmission	B-MED
dynamics	I-MED
of	O
ebola	B-MED
virus	I-MED
ebov	I-MED
disease	I-MED
in	O
west	B-MED
africa	I-MED
in	O
2014	O
because	O
the	O
severity	B-MED
of	O
the	O
epidemic	B-MED
is	O
commonly	O
overestimated	O
.	O
	
a	O
compartmental	B-MED
model	I-MED
that	O
incorporates	O
the	O
media	B-MED
impact	I-MED
and	O
the	O
effect	B-MED
of	O
infected	B-MED
bats	B-MED
was	O
constructed	O
and	O
calibrated	B-MED
using	O
data	B-MED
reported	O
until	O
the	O
end	O
of	O
2014	O
.	O
	
the	O
final	O
cumulative	B-MED
number	B-MED
of	I-MED
deaths	I-MED
and	O
confirmed	B-MED
cases	B-MED
were	O
estimated	B-MED
to	O
be	O
1.0921	O
95%	O
ci	B-MED
9.7706	O
and	O
1.5193	O
95%	O
ci	B-MED
1.3593	O
,	O
respectively	O
.	O
	
the	O
epidemic	B-MED
was	O
estimated	B-MED
to	O
end	O
on	O
june	O
2015	O
,	O
which	O
was	O
similar	B-MED
to	O
the	O
data	B-MED
reported	B-MED
by	O
the	O
world	B-MED
health	I-MED
organization	I-MED
.	O
	
a	O
sensitivity	B-MED
analysis	I-MED
indicated	B-MED
that	O
an	O
increase	B-MED
of	O
either	O
the	O
media	B-MED
impact	I-MED
or	O
the	O
number	B-MED
of	O
infectious	B-MED
bats	B-MED
that	O
are	O
captured	O
daily	B-MED
can	O
increase	B-MED
the	O
cumulative	B-MED
number	B-MED
of	O
confirmed	B-MED
cases	B-MED
/	O
deaths	B-MED
.	O
	
of	O
the	O
considered	O
epidemiological	B-MED
parameters	I-MED
,	O
only	O
the	O
media	B-MED
coverage	I-MED
can	O
significantly	O
reduce	O
both	O
the	O
peak	B-MED
time	I-MED
and	O
the	O
value	B-MED
of	O
the	O
cumulative	B-MED
confirmed	B-MED
cases	B-MED
/	O
deaths	B-MED
.	O
	
thus	O
,	O
we	O
propose	O
'the	O
cumulative	B-MED
confirmed	B-MED
cases	B-MED
and	O
deaths	B-MED
'	O
as	O
another	O
media	B-MED
mechanism	B-MED
.	O
	
in	O
conclusion	O
,	O
the	O
media	B-MED
impact	I-MED
contributed	O
to	O
the	O
control	B-MED
of	O
the	O
2014	O
ebola	B-MED
outbreak	B-MED
,	O
and	O
infectious	B-MED
bats	B-MED
may	O
be	O
a	O
potential	B-MED
source	B-MED
of	O
the	O
body	B-MED
diffusion	B-MED
weighted	I-MED
imaging	I-MED
using	O
non-cpmg	B-MED
fast	I-MED
spin	I-MED
echo	I-MED
ss-fse	B-MED
is	O
a	O
fast	B-MED
technique	B-MED
that	O
does	O
not	O
suffer	O
from	O
off-resonance	B-MED
distortions	B-MED
to	O
the	O
degree	O
that	O
epi	B-MED
does	O
.	O
	
unlike	O
epi	B-MED
,	O
ss-fse	B-MED
is	O
ill-suited	O
to	O
diffusion	B-MED
weighted	I-MED
imaging	I-MED
dwi	B-MED
due	O
to	O
the	O
carr-purcell-meiboom-geill	B-MED
cpmg	I-MED
condition	I-MED
.	O
	
non-cpmg	B-MED
phase	B-MED
cycling	B-MED
does	O
accommodate	O
ss-fse	B-MED
and	O
dwi	B-MED
but	O
places	B-MED
constraints	B-MED
on	O
reconstruction	B-MED
,	O
which	O
are	O
resolved	B-MED
here	O
through	O
parallel	B-MED
imaging	I-MED
.	O
	
additionally	O
,	O
improved	B-MED
echo	B-MED
stability	I-MED
can	O
be	O
achieved	O
by	O
using	O
short	B-MED
duration	I-MED
and	O
highly	O
selective	O
diverse	B-MED
radiofrequency	B-MED
pulses	B-MED
.	O
	
here	O
,	O
signal-to-noise	B-MED
ratio	I-MED
snr	B-MED
comparisons	O
between	O
epi	B-MED
and	O
ncpmg	B-MED
ss-fse	B-MED
acquisitions	B-MED
and	O
reconstruction	B-MED
techniques	I-MED
give	O
similar	B-MED
values	B-MED
.	O
	
diffusion	B-MED
imaging	I-MED
with	O
ncpmg	B-MED
ss-fse	B-MED
gives	O
similar	B-MED
snr	B-MED
to	O
an	O
epi	B-MED
acquisition	B-MED
,	O
though	O
apparent	B-MED
diffusion	I-MED
coefficient	I-MED
values	B-MED
are	O
higher	B-MED
than	O
seen	O
with	O
epi	B-MED
.	O
	
in	B-MED
vivo	I-MED
images	B-MED
have	O
good	O
image	B-MED
quality	I-MED
with	O
little	O
distortion	B-MED
.	O
	
this	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	B-MED
-	O
free	B-MED
dwi	B-MED
images	B-MED
near	O
areas	B-MED
of	O
significant	B-MED
off-resonance	B-MED
as	O
well	O
as	O
preserve	O
adequate	O
snr	B-MED
.	O
	
parallel	B-MED
imaging	I-MED
and	O
diverse	B-MED
refocusing	O
rf	B-MED
pulses	B-MED
allow	O
shorter	B-MED
etl	I-MED
compared	O
to	O
previous	O
implementations	B-MED
and	O
thus	O
reduces	B-MED
phase	B-MED
encode	B-MED
direction	B-MED
blur	B-MED
and	O
sar	B-MED
accumulation	B-MED
.	O
	
modification	B-MED
of	O
mechanical	B-MED
properties	I-MED
,	O
polymerization	B-MED
temperature	B-MED
,	O
and	O
handling	B-MED
time	I-MED
of	O
polymethylmethacrylate	B-MED
cement	B-MED
for	O
enhancing	O
applicability	B-MED
in	O
vertebroplasty	B-MED
polymethylmethacrylate	B-MED
pmma	B-MED
bone	B-MED
cement	I-MED
is	O
a	O
popular	O
bone	B-MED
void	B-MED
filler	B-MED
for	O
vertebroplasty	B-MED
.	O
	
however	O
,	O
the	O
use	O
of	O
pmma	B-MED
has	O
some	O
drawbacks	O
,	O
including	O
the	O
material's	B-MED
excessive	O
stiffness	B-MED
,	O
exothermic	B-MED
polymerization	I-MED
,	O
and	O
short	B-MED
handling	B-MED
time	I-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
create	O
an	O
ideal	O
modified	B-MED
bone	B-MED
cement	I-MED
to	O
solve	O
the	O
above-mentioned	O
problems	B-MED
.	O
	
modified	B-MED
bone	B-MED
cements	I-MED
were	O
prepared	B-MED
by	O
combining	O
pmma	B-MED
with	O
three	O
different	O
volume	B-MED
fractions	I-MED
of	O
castor	B-MED
oil	I-MED
5%	O
,	O
10%	O
,	O
and	O
15%	O
.	O
	
the	O
peak	B-MED
polymerization	B-MED
temperatures	B-MED
,	O
times	O
to	O
achieve	O
the	O
peak	B-MED
polymerization	B-MED
temperature	B-MED
,	O
porosities	B-MED
,	O
densities	B-MED
,	O
modulus	B-MED
and	O
maximum	B-MED
compression	B-MED
strengths	I-MED
of	O
standard	B-MED
without	O
castor	B-MED
oil	I-MED
,	O
and	O
modified	B-MED
cements	B-MED
were	O
investigated	B-MED
following	O
storage	O
at	O
ambient	B-MED
temperature	I-MED
22	O
or	O
under	O
precooling	B-MED
conditions	B-MED
3	O
.	O
	
six	O
specimens	B-MED
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	B-MED
.	O
	
increasing	B-MED
castor	B-MED
oil	I-MED
content	O
and	O
precooling	B-MED
treatment	B-MED
effectively	O
decreased	B-MED
the	O
peak	B-MED
polymerization	B-MED
temperatures	B-MED
and	O
increased	B-MED
the	O
duration	B-MED
to	O
achieve	O
the	O
peak	B-MED
polymerization	B-MED
temperature	B-MED
p	O
<	O
0.05	O
.	O
	
furthermore	O
,	O
the	O
mechanical	B-MED
properties	I-MED
of	O
the	O
material	B-MED
,	O
including	O
density	B-MED
,	O
modulus	B-MED
,	O
and	O
maximum	B-MED
compression	B-MED
strength	I-MED
,	O
decreased	B-MED
with	O
increasing	B-MED
castor	B-MED
oil	I-MED
content	B-MED
.	O
	
however	O
,	O
preparation	B-MED
temperature	B-MED
room	B-MED
temperature	I-MED
versus	O
precooling	B-MED
had	O
no	O
significant	O
effect	O
p	O
>	O
0.05	O
on	O
these	O
mechanical	B-MED
properties	I-MED
.	O
	
in	O
conclusion	O
,	O
the	O
addition	O
of	O
castor	B-MED
oil	I-MED
to	O
pmma	B-MED
followed	O
by	O
precooling	B-MED
created	O
an	O
ideal	O
modified	B-MED
bone	B-MED
cement	I-MED
with	O
a	O
low	O
modulus	B-MED
,	O
low	O
polymerization	B-MED
temperature	B-MED
,	O
and	O
long	O
handling	B-MED
time	I-MED
,	O
enhancing	O
its	O
applicability	B-MED
and	O
safety	B-MED
for	O
a	O
case	B-MED
of	O
retrograde	B-MED
intussusception	I-MED
at	O
roux-en-y	B-MED
anastomosis	I-MED
10	O
years	O
after	O
total	B-MED
gastrectomy	I-MED
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
a	O
63-year-	O
old	B-MED
man	I-MED
,	O
who	O
had	O
undergone	O
total	B-MED
gastrectomy	I-MED
and	O
roux-en-y	B-MED
reconstruction	I-MED
for	O
gastric	B-MED
cancer	I-MED
10	O
years	O
previously	O
,	O
was	O
admitted	B-MED
to	O
our	O
hospital	B-MED
with	O
complaints	B-MED
of	O
abdominal	B-MED
pain	I-MED
,	O
palpable	B-MED
abdominal	B-MED
tumor	I-MED
,	O
and	O
hematemesis	B-MED
.	O
	
on	B-MED
admission	I-MED
,	O
the	O
abdominal	B-MED
tenderness	I-MED
was	O
improving	B-MED
and	O
no	O
abdominal	B-MED
tumor	I-MED
was	O
palpable	B-MED
.	O
	
mild	B-MED
inflammatory	I-MED
changes	O
and	O
anemia	B-MED
were	O
noted	O
on	O
blood	B-MED
examination	I-MED
.	O
	
abdominal	B-MED
computed	B-MED
tomography	I-MED
revealed	O
a	O
tumor	B-MED
with	O
a	O
layered	B-MED
structure	I-MED
in	O
the	O
left	B-MED
abdomen	I-MED
.	O
	
the	O
patient	B-MED
was	O
diagnosed	B-MED
with	O
intestinal	B-MED
obstruction	I-MED
secondary	O
to	O
intussusception	B-MED
,	O
and	O
surgery	B-MED
was	O
performed	B-MED
.	O
	
retrograde	B-MED
intussusception	I-MED
was	O
found	O
at	O
the	O
site	O
of	O
the	O
y	B-MED
anastomosis	I-MED
.	O
	
we	O
conducted	O
manual	B-MED
reduction	I-MED
using	O
the	O
hutchinson	B-MED
procedure	I-MED
.	O
	
the	O
intestinal	B-MED
color	B-MED
after	O
the	O
reduction	B-MED
was	O
good	O
,	O
and	O
no	O
intestinal	B-MED
resection	I-MED
was	O
required	B-MED
.	O
	
postoperative	B-MED
recovery	I-MED
was	O
uneventful	O
,	O
and	O
the	O
patient	B-MED
was	O
discharged	B-MED
12	O
days	O
after	O
surgery	B-MED
.	O
	
reports	B-MED
of	O
jejunal	B-MED
intussusception	B-MED
after	O
total	B-MED
gastrectomy	I-MED
with	O
roux-en-y	B-MED
reconstruction	I-MED
are	O
relatively	O
rare	O
.	O
	
here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-MED
intussusception	B-MED
after	O
total	B-MED
gastrectomy	I-MED
with	O
roux-en-y	B-MED
reconstruction	I-MED
.	O
	
brassinosteroid	B-MED
-	O
induced	B-MED
changes	B-MED
of	O
lipid	B-MED
composition	B-MED
in	O
leaves	B-MED
of	O
pisum	B-MED
sativum	I-MED
l	I-MED
.	O
	
during	O
senescence	B-MED
the	O
effect	B-MED
of	I-MED
steroid	B-MED
phytohormone	B-MED
24-epibrassinolide	B-MED
ebr	B-MED
on	O
the	O
composition	B-MED
of	O
some	O
lipid	B-MED
classes	B-MED
free	B-MED
fatty	I-MED
acids	I-MED
,	O
triacylglycerols	B-MED
and	O
galactolipids	B-MED
in	O
detached	B-MED
pea	B-MED
leaves	B-MED
was	O
studied	O
for	O
the	O
first	O
time	O
.	O
	
ebr	B-MED
0.1μm	O
promoted	O
senescence	B-MED
and	O
increased	B-MED
the	O
content	B-MED
of	O
14	O
,	O
16	O
and	O
18	O
free	B-MED
fatty	I-MED
acids	I-MED
as	O
well	O
as	O
18	O
and	O
18	O
bound	O
to	O
triacylglycerols	B-MED
in	O
the	O
detached	B-MED
leaves	B-MED
in	O
contrast	O
to	O
mock-treated	B-MED
leaves	I-MED
.	O
	
the	O
content	B-MED
of	O
all	O
identified	B-MED
fatty	B-MED
acids	I-MED
bound	O
to	O
galactolipids	B-MED
decreased	B-MED
in	O
the	O
detached	B-MED
leaves	B-MED
treated	B-MED
with	O
ebr	B-MED
compared	O
to	O
that	O
in	O
mock-treated	B-MED
leaves	I-MED
.	O
	
these	O
findings	B-MED
suggest	O
that	O
free	B-MED
fatty	I-MED
acids	I-MED
are	O
liberated	O
from	O
polar	B-MED
lipids	B-MED
and	O
then	O
undergo	O
esterification	B-MED
to	O
neutral	B-MED
lipids	I-MED
in	O
the	O
detached	B-MED
leaves	B-MED
upon	O
ebr	B-MED
treatment	B-MED
.	O
	
we	O
propose	O
that	O
steroid	B-MED
phytohormones	B-MED
may	O
be	O
involved	O
into	O
regulation	B-MED
of	O
leaf	B-MED
senescence	B-MED
via	O
alteration	B-MED
of	O
cell	B-MED
lipid	B-MED
composition	B-MED
.	O
	
posterior	B-MED
dislocation	I-MED
of	O
the	O
sternoclavicular	B-MED
joint	I-MED
report	B-MED
of	O
two	O
cases	B-MED
the	O
authors	O
report	B-MED
the	O
cases	B-MED
of	O
two	O
young	B-MED
patients	B-MED
who	O
had	O
suffered	O
a	O
sporting	B-MED
accident	I-MED
with	O
posterior	B-MED
traumatic	I-MED
dislocation	I-MED
of	O
sternoclavicular	B-MED
joint	I-MED
.	O
	
in	O
one	O
of	O
the	O
patients	B-MED
closed	B-MED
reduction	I-MED
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-MED
in	O
a	O
sling	B-MED
.	O
	
the	O
second	O
patient	B-MED
,	O
after	O
reduction	B-MED
was	O
done	O
,	O
presented	O
recurrence	B-MED
of	O
the	O
dislocation	B-MED
,	O
thus	O
requiring	O
surgical	B-MED
treatment	I-MED
.	O
	
it	O
is	O
important	O
to	O
observe	O
the	O
relevance	B-MED
of	O
computed	B-MED
tomography	I-MED
to	O
help	O
diagnosing	B-MED
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	B-MED
procedure	I-MED
.	O
	
the	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-MED
in	O
a	O
rare	B-MED
injury	B-MED
such	O
as	O
the	O
posterior	B-MED
dislocation	I-MED
of	O
sternoclavicular	B-MED
joint	I-MED
.	O
	
using	O
a	O
graphical	B-MED
risk	I-MED
tool	I-MED
to	O
examine	O
willingness	B-MED
to	I-MED
take	I-MED
migraine	B-MED
prophylactic	B-MED
medications	B-MED
many	O
migraine	B-MED
sufferers	B-MED
use	O
daily	B-MED
prophylactic	B-MED
therapy	I-MED
to	O
reduce	O
the	O
frequency	B-MED
of	O
their	O
headache	B-MED
attacks	O
.	O
	
the	O
food	B-MED
and	I-MED
drug	I-MED
administration	I-MED
has	O
approved	B-MED
several	B-MED
different	O
medications	B-MED
for	O
migraine	B-MED
prophylaxis	B-MED
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	B-MED
perceive	O
these	O
treatments	B-MED
to	O
provide	O
clinically	B-MED
significant	I-MED
benefits	B-MED
given	O
their	O
side	B-MED
effect	I-MED
profiles	B-MED
.	O
	
three	O
hundred	O
headache	B-MED
sufferers	B-MED
were	O
recruited	O
from	O
the	O
community	B-MED
and	O
local	B-MED
headache	B-MED
clinics	B-MED
using	O
print	B-MED
and	O
television	B-MED
advertising	B-MED
.	O
	
participants	B-MED
reported	O
experiencing	O
problematic	O
headache	B-MED
attacks	O
with	O
a	O
median	B-MED
iqr	O
frequency	B-MED
of	O
7.0	O
4-13	O
headache	B-MED
days	B-MED
per	I-MED
month	I-MED
.	O
	
these	O
sufferers	B-MED
participated	O
in	O
a	O
cross-sectional	B-MED
,	O
single-site	I-MED
,	O
study	I-MED
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O
	
participants	B-MED
were	O
instructed	O
on	O
the	O
probability	B-MED
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	B-MED
effects	I-MED
for	O
several	B-MED
blinded	B-MED
medication	B-MED
profiles	B-MED
divalproex	B-MED
sodium	I-MED
,	O
venlafaxine	B-MED
,	O
gabapentin	B-MED
,	O
propranolol	B-MED
,	O
and	O
topiramate	B-MED
.	O
	
after	O
learning	O
the	O
likelihood	B-MED
of	O
experiencing	O
side	B-MED
effect	I-MED
profiles	B-MED
of	O
each	O
medication	B-MED
,	O
participants	B-MED
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B-MED
to	I-MED
take	I-MED
the	O
medication	B-MED
for	O
a	O
given	O
headache	B-MED
reduction	B-MED
level	B-MED
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	B-MED
per	I-MED
month	I-MED
.	O
	
the	O
side	B-MED
effect	I-MED
profile	B-MED
for	O
divalproex	B-MED
sodium	I-MED
was	O
associated	B-MED
with	I-MED
the	O
smallest	B-MED
willingness	I-MED
to	I-MED
take	I-MED
,	O
with	O
gabapentin	B-MED
,	O
propranolol	B-MED
,	O
and	O
topiramate	B-MED
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O
	
however	O
,	O
<60%	O
of	O
participants	B-MED
reported	O
willingness	B-MED
to	I-MED
take	I-MED
any	O
of	O
these	O
medications	B-MED
even	O
if	O
they	O
provided	O
a	O
50%	O
reduction	B-MED
in	O
headache	B-MED
frequency	B-MED
.	O
	
several	B-MED
general	O
predictors	B-MED
of	O
willingness	B-MED
to	I-MED
take	I-MED
were	O
observed	O
including	O
high	B-MED
headache	B-MED
-related	O
disability	B-MED
,	O
depressive	B-MED
symptoms	I-MED
,	O
and	O
pain	B-MED
medication	I-MED
concerns	B-MED
including	O
fear	B-MED
of	O
tolerance	B-MED
.	O
	
these	O
findings	B-MED
suggest	O
that	O
if	O
properly	O
informed	B-MED
of	O
the	O
side	B-MED
effect	I-MED
profiles	B-MED
of	O
these	O
medications	B-MED
,	O
many	O
patients	B-MED
might	O
opt	O
for	O
other	O
genome-wide	B-MED
detection	I-MED
of	O
selective	B-MED
signatures	I-MED
in	O
chicken	B-MED
through	O
high	B-MED
density	I-MED
snps	I-MED
chicken	B-MED
is	O
recognized	O
as	O
an	O
excellent	O
model	B-MED
for	O
studies	O
of	O
genetic	B-MED
mechanism	B-MED
of	O
phenotypic	B-MED
and	O
genomic	B-MED
evolution	B-MED
,	O
with	O
large	O
effective	O
population	B-MED
size	I-MED
and	O
strong	O
human	B-MED
-driven	O
selection	B-MED
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
performed	O
extended	B-MED
haplotype	I-MED
homozygosity	I-MED
ehh	B-MED
tests	O
to	O
identify	O
significant	O
core	B-MED
regions	I-MED
employing	O
600k	O
snp	B-MED
chicken	B-MED
chip	B-MED
in	O
an	O
f2	B-MED
population	I-MED
of	O
1	O
hens	B-MED
,	O
which	O
was	O
derived	O
from	O
reciprocal	B-MED
crosses	I-MED
between	O
white	B-MED
leghorn	I-MED
and	O
dongxiang	B-MED
chicken	I-MED
.	O
	
results	O
indicated	O
that	O
a	O
total	O
of	O
49	O
core	B-MED
regions	I-MED
with	O
an	O
average	O
length	B-MED
of	O
9.79	O
kb	O
were	O
identified	B-MED
,	O
which	O
occupied	O
approximately	O
52.15	O
of	O
genome	B-MED
across	O
all	O
autosomes	B-MED
,	O
and	O
806	O
significant	O
core	B-MED
regions	I-MED
attracted	O
us	O
mostly	O
.	O
	
genes	B-MED
in	O
candidate	B-MED
regions	I-MED
may	O
experience	O
positive	B-MED
selection	I-MED
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	B-MED
traits	I-MED
.	O
	
a	O
panel	B-MED
of	O
genes	B-MED
including	O
aasdhppt	B-MED
,	O
gdpd5	B-MED
,	O
par3	B-MED
,	O
sox6	B-MED
,	O
gpc1	B-MED
and	O
a	O
signal	B-MED
pathway	I-MED
of	O
akt1	B-MED
were	O
detected	B-MED
with	O
the	O
most	O
extreme	O
p-values	B-MED
.	O
	
further	O
enrichment	B-MED
analyses	I-MED
indicated	O
that	O
these	O
genes	B-MED
were	O
associated	B-MED
with	I-MED
immune	B-MED
function	I-MED
,	O
sensory	B-MED
organ	I-MED
development	I-MED
and	O
neurogenesis	B-MED
,	O
and	O
may	O
have	O
experienced	O
positive	B-MED
selection	I-MED
in	O
chicken	B-MED
.	O
	
moreover	O
,	O
some	O
of	O
core	B-MED
regions	I-MED
exactly	O
overlapped	O
with	O
genes	B-MED
excavated	O
in	O
our	O
previous	O
gwas	B-MED
,	O
suggesting	O
that	O
these	O
genes	B-MED
have	O
undergone	O
positive	B-MED
selection	I-MED
may	O
affect	O
egg	B-MED
production	B-MED
.	O
	
findings	B-MED
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome-wide	B-MED
map	I-MED
of	O
selection	B-MED
signature	I-MED
in	O
the	O
chicken	B-MED
genome	B-MED
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	B-MED
mechanisms	B-MED
of	O
phenotypic	B-MED
diversity	B-MED
in	O
poultry	B-MED
breeding	B-MED
.	O
	
high-throughput	O
genotyping	B-MED
with	O
taqman	B-MED
allelic	I-MED
discrimination	I-MED
and	O
allele-specific	B-MED
genotyping	I-MED
assays	I-MED
real-time	B-MED
pcr	I-MED
-based	O
genotyping	B-MED
methods	I-MED
,	O
such	O
as	O
taqman	B-MED
allelic	I-MED
discrimination	I-MED
assays	I-MED
and	O
allele-specific	B-MED
genotyping	I-MED
,	O
are	O
particularly	O
useful	B-MED
when	O
screening	B-MED
a	O
handful	O
of	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
in	O
hundreds	O
of	O
samples	B-MED
either	O
derived	O
from	O
different	B-MED
individuals	B-MED
,	O
tissues	B-MED
,	O
or	O
pre	B-MED
-	O
amplified	B-MED
dna	I-MED
.	O
	
although	O
real-time	B-MED
pcr	I-MED
-	O
based	B-MED
methods	B-MED
such	O
as	O
taqman	B-MED
are	O
well-established	B-MED
,	O
alternative	B-MED
methods	B-MED
,	O
like	O
allele-specific	B-MED
genotyping	I-MED
,	O
are	O
powerful	O
alternatives	B-MED
,	O
especially	O
for	O
genotyping	B-MED
short	B-MED
tandem	I-MED
repeat	I-MED
str	B-MED
length	B-MED
polymorphisms	B-MED
.	O
	
here	O
,	O
we	O
describe	O
all	O
relevant	B-MED
aspects	B-MED
when	O
developing	B-MED
an	O
assay	B-MED
for	O
a	O
new	O
snp	B-MED
or	O
str	B-MED
using	O
either	O
taqman	B-MED
or	O
allele-specific	B-MED
genotyping	I-MED
,	O
respectively	O
,	O
such	O
as	O
primer	B-MED
and	O
probe	B-MED
design	O
,	O
optimization	B-MED
of	O
reaction	B-MED
conditions	B-MED
,	O
the	O
experimental	B-MED
procedure	I-MED
for	I-MED
typing	I-MED
hundreds	O
of	O
samples	B-MED
,	O
and	O
finally	O
the	O
data	B-MED
evaluation	B-MED
.	O
	
our	O
goal	B-MED
is	O
to	O
provide	B-MED
a	O
guideline	B-MED
for	O
developing	B-MED
genotyping	B-MED
assays	I-MED
using	O
these	O
two	O
approaches	B-MED
that	O
render	O
reliable	O
and	O
reproducible	B-MED
genotype	B-MED
calls	I-MED
involving	B-MED
minimal	B-MED
optimization	B-MED
.	O
	
the	O
role	O
of	O
p2x7	B-MED
receptors	I-MED
in	O
a	O
rodent	B-MED
pcp	B-MED
-	O
induced	B-MED
schizophrenia	B-MED
model	B-MED
p2x7	B-MED
receptors	I-MED
p2x7rs	B-MED
are	O
ligand-gated	B-MED
ion	I-MED
channels	I-MED
sensitive	B-MED
to	O
extracellular	B-MED
atp	B-MED
.	O
	
here	O
we	O
examined	B-MED
for	O
the	O
first	O
time	O
the	O
role	O
of	O
p2x7r	B-MED
in	O
an	O
animal	B-MED
model	I-MED
of	O
schizophrenia	B-MED
.	O
	
using	O
the	O
pcp	B-MED
induced	B-MED
schizophrenia	B-MED
model	B-MED
we	O
show	O
that	O
both	O
genetic	B-MED
deletion	I-MED
and	O
pharmacological	B-MED
inhibition	B-MED
of	O
p2x7rs	B-MED
alleviate	B-MED
schizophrenia-like	B-MED
behavioral	B-MED
alterations	B-MED
.	O
	
in	O
p2rx7+/+	B-MED
mice	B-MED
,	O
pcp	B-MED
induced	B-MED
hyperlocomotion	B-MED
,	O
stereotype	B-MED
behavior	I-MED
,	O
ataxia	B-MED
and	O
social	B-MED
withdrawal	I-MED
.	O
	
in	O
p2x7	B-MED
receptor	I-MED
deficient	B-MED
mice	B-MED
p2rx7-/-	B-MED
,	O
the	O
social	B-MED
interactions	I-MED
were	O
increased	B-MED
,	O
whereas	O
the	O
pcp	B-MED
induced	B-MED
hyperlocomotion	B-MED
and	O
stereotype	B-MED
behavior	I-MED
were	O
alleviated	B-MED
.	O
	
the	O
selective	O
p2x7	B-MED
receptor	I-MED
antagonist	I-MED
jnj-47965567	B-MED
partly	O
replicated	O
the	O
effect	B-MED
of	I-MED
gene	B-MED
deficiency	I-MED
on	O
pcp	B-MED
-	O
induced	B-MED
behavioral	B-MED
changes	I-MED
and	O
counteracted	O
pcp	B-MED
-	O
induced	B-MED
social	B-MED
withdrawal	I-MED
.	O
	
we	O
also	O
show	O
that	O
pcp	B-MED
treatment	B-MED
upregulates	B-MED
and	O
increases	B-MED
the	O
functional	B-MED
responsiveness	B-MED
of	O
p2x7rs	B-MED
in	O
the	O
prefrontal	B-MED
cortex	I-MED
of	O
young	B-MED
adult	I-MED
animals	B-MED
.	O
	
the	O
amplitude	B-MED
of	O
nmda	B-MED
evoked	B-MED
currents	B-MED
recorded	O
from	O
layer	B-MED
v	I-MED
pyramidal	I-MED
neurons	I-MED
of	O
cortical	B-MED
slices	O
were	O
slightly	O
decreased	B-MED
by	O
both	O
genetic	B-MED
deletion	I-MED
of	O
p2rx7	B-MED
and	O
by	O
jnj-47965567	B-MED
.	O
	
pcp	B-MED
induced	B-MED
alterations	B-MED
in	O
mrna	B-MED
expression	I-MED
encoding	O
schizophrenia-related	B-MED
genes	B-MED
,	O
such	O
as	O
nr2a	B-MED
,	O
nr2b	B-MED
,	O
neuregulin	B-MED
1	I-MED
,	O
nr1	B-MED
and	O
gaba	B-MED
α1	I-MED
subunit	O
were	O
absent	B-MED
in	O
the	O
pfc	O
of	O
young	B-MED
adult	I-MED
p2rx7-/-	B-MED
animals	B-MED
.	O
	
our	O
findings	B-MED
point	O
to	O
p2x7r	B-MED
as	O
a	O
potential	B-MED
therapeutic	B-MED
target	B-MED
in	O
the	O
flavor	B-MED
and	O
nutritional	B-MED
characteristic	B-MED
of	O
four	O
strawberry	B-MED
varieties	B-MED
cultured	B-MED
in	O
soilless	B-MED
system	I-MED
strawberry	B-MED
fruits	I-MED
cv	B-MED
.	O
	
benihoppe	I-MED
,	O
tochiotome	B-MED
,	O
sachinoka	B-MED
,	O
and	O
guimeiren	B-MED
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	B-MED
and	O
nutritional	B-MED
parameters	B-MED
.	O
	
by	O
principal	B-MED
component	I-MED
analysis	I-MED
and	O
hierarchical	B-MED
clustering	I-MED
analysis	I-MED
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	B-MED
compounds	I-MED
composition	B-MED
,	O
sugar	B-MED
and	O
acid	B-MED
concentration	B-MED
,	O
sweetness	B-MED
,	O
and	O
total	B-MED
soluble	I-MED
sugars	I-MED
/	O
total	B-MED
organic	I-MED
acids	I-MED
of	O
the	O
four	O
varieties	B-MED
.	O
	
a	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	B-MED
compounds	I-MED
were	O
identified	B-MED
and	O
determined	B-MED
in	O
cv	B-MED
.	O
	
benihoppe	I-MED
,	O
tochiotome	B-MED
,	O
sachinoka	B-MED
,	O
and	O
guimeiren	B-MED
strawberry	I-MED
fruits	I-MED
extracted	B-MED
by	O
head-space	B-MED
solid-phase	I-MED
microextraction	I-MED
hs-spme	B-MED
,	O
respectively	O
.	O
	
esters	B-MED
significantly	O
dominated	O
the	O
chemical	B-MED
composition	I-MED
of	O
the	O
four	O
varieties	B-MED
.	O
	
furaneol	B-MED
was	O
detected	O
in	O
cultivars	B-MED
of	O
sachinoka	B-MED
and	O
guimeiren	B-MED
,	O
but	O
mesifuran	B-MED
was	O
only	O
found	O
in	O
cv	B-MED
.	O
	
tochiotome	I-MED
.	O
	
tochiotome	B-MED
and	O
sachinoka	B-MED
showed	O
higher	O
content	B-MED
of	O
linalool	B-MED
and	O
e	B-MED
.	O
	
sachinoka	B-MED
showed	O
the	O
highest	B-MED
content	B-MED
of	O
total	B-MED
sugars	I-MED
and	O
total	B-MED
acids	I-MED
.	O
	
guimeiren	B-MED
showed	O
higher	O
sweetness	B-MED
index	B-MED
than	O
the	O
other	O
three	O
cultivars	B-MED
.	O
	
firmness	B-MED
of	O
tochiotome	B-MED
was	O
highest	B-MED
among	O
all	O
the	O
varieties	B-MED
.	O
	
the	O
highest	B-MED
total	B-MED
soluble	I-MED
solids	I-MED
tss	I-MED
value	I-MED
was	O
found	O
in	O
cv	B-MED
.	O
	
sachinoka	I-MED
,	O
followed	O
by	O
the	O
guimeiren	B-MED
and	O
tochiotome	B-MED
varieties	B-MED
.	O
	
sachinoka	B-MED
had	O
the	O
highest	B-MED
titratable	B-MED
acidity	I-MED
ta	I-MED
value	I-MED
.	O
	
the	O
content	B-MED
of	O
ascorbic	B-MED
acid	I-MED
asa	B-MED
of	O
cv	B-MED
.	O
	
tochiotome	I-MED
was	O
higher	B-MED
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	B-MED
significant	I-MED
difference	B-MED
in	O
cultivars	B-MED
of	O
benihoppe	B-MED
,	O
tochiotome	B-MED
,	O
and	O
sachinoka	B-MED
.	O
	
fructose	B-MED
and	O
glucose	B-MED
were	O
the	O
major	O
sugars	B-MED
in	O
all	O
cultivars	B-MED
.	O
	
citric	B-MED
acid	I-MED
was	O
the	O
major	O
organic	B-MED
acid	I-MED
in	O
cv	B-MED
.	O
	
tochiotome	I-MED
,	O
cv	B-MED
.	O
	
sachinoka	I-MED
,	O
and	O
cv	B-MED
.	O
	
guimeiren	I-MED
.	O
	
tochiotome	B-MED
had	O
higher	B-MED
ratios	B-MED
of	O
tss	B-MED
/	O
ta	B-MED
and	O
total	B-MED
sugars	I-MED
/	O
total	B-MED
organic	I-MED
acids	I-MED
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	B-MED
content	B-MED
.	O
	
the	O
order	O
of	O
the	O
comprehensive	B-MED
evaluation	I-MED
score	I-MED
was	O
sachinoka	B-MED
>	O
guimeiren	B-MED
>	O
tochiotome	B-MED
>	O
prognostic	B-MED
value	I-MED
of	O
glut-1	B-MED
expression	B-MED
in	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
a	O
prisma-compliant	B-MED
meta-analysis	I-MED
a	O
variety	O
of	O
studies	B-MED
have	O
evaluated	B-MED
the	O
correlation	B-MED
between	O
glucose	B-MED
transporter-1	I-MED
glut-1	B-MED
expression	B-MED
and	O
prognosis	B-MED
of	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
oscc	B-MED
however	O
,	O
the	O
results	B-MED
were	O
inconsistent	B-MED
and	O
inconclusive	B-MED
.	O
	
a	O
meta-analysis	B-MED
was	O
performed	O
to	O
assess	B-MED
the	O
prognostic	B-MED
significance	B-MED
of	O
glut-1	B-MED
in	O
oscc	B-MED
.	O
	
electronic	B-MED
databases	I-MED
of	O
pubmed	B-MED
,	O
embase	B-MED
,	O
and	O
web	B-MED
of	I-MED
science	I-MED
were	O
searched	O
for	O
relevant	B-MED
studies	I-MED
.	O
	
the	O
last	O
search	O
was	O
updated	O
on	O
july	B-MED
2016	O
.	O
	
odds	B-MED
ratio	I-MED
or	B-MED
and	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
were	O
pooled	O
to	O
evaluate	B-MED
the	O
relationship	B-MED
between	O
glut-1	B-MED
and	O
clinical	B-MED
features	I-MED
and	O
hazard	B-MED
ratio	I-MED
hr	B-MED
and	O
95%	O
ci	B-MED
were	O
combined	O
to	O
measure	B-MED
the	O
effect	B-MED
of	O
glut-1	B-MED
on	O
overall	B-MED
survival	I-MED
os	B-MED
.	O
	
p	O
value	O
<	O
0.05	O
was	O
considered	O
as	O
statistically	B-MED
significant	I-MED
.	O
	
a	O
total	O
of	O
13	O
studies	B-MED
with	O
1301	O
subjects	B-MED
were	O
included	O
for	O
meta-analysis	B-MED
.	O
	
the	O
pooled	B-MED
data	I-MED
showed	O
that	O
high	O
glut-1	B-MED
expression	B-MED
was	O
associated	B-MED
with	I-MED
advanced	B-MED
tumor	I-MED
stages	I-MED
n	O
=	O
7	O
,	O
or	B-MED
=	O
2.99	O
,	O
95%	O
ci	B-MED
2.01	O
,	O
p	O
<	O
0.001	O
,	O
higher	B-MED
tumor	I-MED
grade	I-MED
n	O
=	O
5	O
,	O
or	B-MED
=	O
3.34	O
,	O
95%	O
ci	B-MED
1.12	O
,	O
p	O
=	O
0.031	O
,	O
tumor	B-MED
size	I-MED
n	O
=	O
5	O
,	O
or	B-MED
=	O
3.36	O
,	O
95%	O
ci	B-MED
2.04	O
,	O
p	O
<	O
0.001	O
,	O
lymph	B-MED
node	I-MED
metastasis	I-MED
n	O
=	O
5	O
,	O
or	B-MED
=	O
3.15	O
,	O
95%	O
ci	B-MED
1.89	O
,	O
p	O
<	O
0.001	O
,	O
tobacco	B-MED
use	I-MED
n	O
=	O
3	O
,	O
or	B-MED
=	O
2.18	O
,	O
95%	O
ci	B-MED
1.18	O
,	O
p	O
=	O
0.013	O
,	O
and	O
distant	B-MED
metastasis	I-MED
n	O
=	O
2	O
,	O
or	B-MED
=	O
3.06	O
,	O
95%	O
ci	B-MED
1.19	O
,	O
p	O
=	O
0.02	O
.	O
	
furthermore	O
,	O
increased	B-MED
glut-1	B-MED
expression	B-MED
was	O
also	O
correlated	B-MED
with	O
shorter	B-MED
os	I-MED
n	O
=	O
8	O
,	O
hr	B-MED
=	O
1.88	O
,	O
95%	O
ci	B-MED
1.51	O
,	O
p	O
<	O
0.001	O
.	O
	
no	O
significant	B-MED
publication	I-MED
bias	I-MED
was	O
detected	B-MED
in	O
this	O
meta-analysis	B-MED
.	O
	
glut-1	B-MED
overexpression	B-MED
was	O
in	O
connection	O
with	O
aggressive	B-MED
clinical	I-MED
features	I-MED
and	O
worse	B-MED
os	I-MED
in	O
oscc	B-MED
.	O
	
however	O
,	O
further	O
studies	B-MED
are	O
still	O
needed	O
to	O
verify	O
whether	O
glut-1	B-MED
could	O
serve	O
as	O
a	O
prognostic	B-MED
biomarker	B-MED
for	O
biogeography	B-MED
and	O
character	O
evolution	B-MED
of	O
the	O
ciliate	B-MED
genus	B-MED
euplotes	B-MED
spirotrichea	B-MED
,	O
euplotia	B-MED
,	O
with	O
description	B-MED
of	O
euplotes	B-MED
curdsi	I-MED
sp	I-MED
.	O
	
nov	I-MED
ciliates	B-MED
comprise	O
a	O
diverse	B-MED
and	O
ecologically	B-MED
important	B-MED
phylum	B-MED
of	O
unicellular	B-MED
protists	I-MED
.	O
	
one	O
of	O
the	O
most	O
specious	O
and	O
best-defined	O
genera	B-MED
is	O
euplotes	B-MED
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	B-MED
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly	B-MED
tested	I-MED
.	O
	
the	O
increasing	O
number	O
of	O
described	O
euplotes	B-MED
taxa	B-MED
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	B-MED
of	O
new	O
ones	O
,	O
requiring	O
standardized	O
morphological	B-MED
observations	B-MED
,	O
sequencing	B-MED
of	O
molecular	B-MED
markers	I-MED
and	O
careful	O
comparison	B-MED
with	O
previous	O
literature	B-MED
.	O
	
here	O
we	O
describe	O
euplotes	B-MED
curdsi	I-MED
sp	I-MED
.	O
	
nov	I-MED
distinguishable	B-MED
by	O
the	O
combination	B-MED
of	O
the	O
following	O
features	B-MED
45-65	O
μm	O
length	B-MED
,	O
oval	B-MED
or	I-MED
elongated	I-MED
shape	I-MED
with	O
both	O
ends	O
rounded	O
,	O
narrow	B-MED
peristome	I-MED
with	O
25-34	O
adoral	B-MED
membranelles	I-MED
,	O
conspicuous	B-MED
paroral	I-MED
membrane	I-MED
,	O
double-eurystomus	B-MED
dorsal	I-MED
argyrome	I-MED
type	I-MED
,	O
6-7	O
dorsolateral	B-MED
kineties	I-MED
and	O
10	O
frontoventral	B-MED
cirri	I-MED
.	O
	
three	O
populations	B-MED
of	O
the	O
novel	O
species	B-MED
have	O
been	O
found	O
in	O
brackish	B-MED
and	O
marine	B-MED
samples	I-MED
in	O
the	O
mediterranean	B-MED
and	O
the	O
white	B-MED
sea	I-MED
.	O
	
we	O
provide	O
the	O
ssu	B-MED
rrna	I-MED
gene	I-MED
sequences	B-MED
of	O
these	O
populations	B-MED
,	O
and	O
an	O
updated	O
phylogeny	B-MED
of	O
the	O
genus	B-MED
euplotes	B-MED
.	O
	
using	O
the	O
molecular	B-MED
phylogenetic	B-MED
tree	I-MED
,	O
we	O
inferred	O
aspects	B-MED
of	O
the	O
biogeographical	B-MED
history	I-MED
of	O
the	O
genus	B-MED
and	O
the	O
evolution	B-MED
of	O
its	O
most	O
important	O
taxonomic	B-MED
characters	B-MED
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	B-MED
.	O
	
ultimately	O
,	O
these	O
data	B-MED
reveal	O
recurrent	B-MED
trends	B-MED
of	O
freshwater	B-MED
invasion	O
and	O
highlight	O
the	O
dynamic	O
,	O
yet	O
convergent	O
,	O
morphological	B-MED
evolution	B-MED
of	O
comparative	B-MED
effectiveness	I-MED
of	O
treatments	B-MED
for	O
chronic	B-MED
low	I-MED
back	I-MED
pain	I-MED
a	O
multiple	B-MED
treatment	I-MED
comparison	I-MED
analysis	I-MED
a	O
systematic	B-MED
review	I-MED
and	O
network	B-MED
meta-analysis	I-MED
.	O
	
to	O
determine	O
current	B-MED
treatment	I-MED
options	I-MED
of	O
chronic	B-MED
low	I-MED
back	I-MED
pain	I-MED
lbp	B-MED
as	O
defined	O
by	O
randomized	B-MED
controlled	I-MED
trials	I-MED
rcts	B-MED
and	O
to	O
compare	B-MED
effectiveness	B-MED
of	O
those	O
treatments	B-MED
using	O
a	O
mixed-treatment	B-MED
comparison	I-MED
mtc	B-MED
.	O
	
it	O
is	O
important	O
to	O
provide	O
an	O
evidence-based	B-MED
assessment	B-MED
of	O
the	O
treatment	B-MED
options	I-MED
that	O
exist	O
for	O
lbp	B-MED
.	O
	
a	O
systematic	B-MED
search	I-MED
of	O
rcts	B-MED
was	O
conducted	O
in	O
medline	B-MED
and	O
the	O
cochrane	B-MED
collaboration	I-MED
library	I-MED
from	O
1990	O
to	O
2014	O
.	O
	
from	O
the	O
selected	B-MED
studies	I-MED
,	O
we	O
extracted	O
preoperative	B-MED
and	O
postoperative	B-MED
odi	B-MED
and	O
vas	B-MED
back	I-MED
pain	I-MED
scores	I-MED
,	O
additional	B-MED
surgeries	I-MED
,	O
and	O
complications	B-MED
.	O
	
standard	B-MED
and	I-MED
network	I-MED
meta-analytic	I-MED
techniques	I-MED
were	O
used	O
.	O
	
twelve	O
rcts	B-MED
were	O
included	O
in	O
the	O
analysis	B-MED
5	O
total	B-MED
disk	I-MED
replacement	I-MED
tdr	B-MED
versus	O
fusion	B-MED
1	O
tdr	B-MED
versus	O
exercise	B-MED
and	O
cognitive	B-MED
behavioral	I-MED
therapy	I-MED
cbt	B-MED
5	O
fusion	B-MED
versus	O
exercise	B-MED
and	O
cbt	B-MED
and	O
1	O
fusion	B-MED
versus	O
physical	B-MED
therapy	I-MED
pt	B-MED
.	O
	
on	O
the	O
basis	O
of	O
mtc	B-MED
,	O
with	O
respect	O
to	O
odi	B-MED
change	I-MED
scores	I-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
fusion	B-MED
over	O
exercise	B-MED
and	O
cbt	B-MED
was	O
2.0	O
points	O
95%	O
ci	O
,	O
-1	O
to	O
4.8	O
.	O
	
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
tdr	B-MED
over	O
exercise	B-MED
and	O
cbt	B-MED
was	O
6.4	O
points	O
95%	O
ci	O
,	O
3.2	O
.	O
	
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
fusion	B-MED
over	O
pt	B-MED
was	O
8.8	O
points	O
95%	O
ci	O
,	O
4.1	O
.	O
	
the	O
pooled	B-MED
mean	I-MED
differences	I-MED
favoring	O
tdr	B-MED
over	O
fusion	B-MED
was	O
4.4	O
points	O
95%	O
ci	O
,	O
2.37	O
.	O
	
for	O
pt	B-MED
versus	O
structured	B-MED
exercise	I-MED
with	O
cbt	B-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
exercise	B-MED
with	O
cbt	B-MED
over	O
pt	B-MED
was	O
6.8	O
points	O
95%	O
ci	O
,	O
1.5	O
.	O
	
for	O
tdr	B-MED
versus	O
pt	B-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
tdr	B-MED
over	O
pt	B-MED
was	O
13.2	O
points	O
95%	O
ci	O
,	O
8.0	O
.	O
	
additional	O
surgery	B-MED
rates	I-MED
were	O
similar	O
between	O
treatment	B-MED
options	I-MED
.	O
	
all	O
4	O
treatments	B-MED
provided	O
some	O
benefit	B-MED
to	O
patients	B-MED
with	O
chronic	B-MED
lbp	I-MED
.	O
	
according	O
to	O
the	O
mtc	B-MED
analysis	I-MED
,	O
tdr	B-MED
may	O
be	O
the	O
most	B-MED
effective	I-MED
treatment	B-MED
and	O
pt	B-MED
the	O
least	B-MED
effective	I-MED
treatment	B-MED
for	O
chronic	B-MED
lbp	I-MED
.	O
	
this	O
review	B-MED
is	O
based	O
on	O
a	O
limited	B-MED
number	I-MED
of	O
rct	B-MED
studies	I-MED
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-MED
modality	B-MED
for	O
all	O
a	O
novel	O
selective	O
inhibitor	B-MED
of	O
delta-5	B-MED
desaturase	I-MED
lowers	O
insulin	B-MED
resistance	I-MED
and	O
reduces	B-MED
body	I-MED
weight	I-MED
in	O
diet	B-MED
-induced	O
obese	B-MED
c57bl/6j	B-MED
mice	I-MED
obesity	B-MED
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low-grade	O
inflammation	B-MED
and	O
is	O
called	O
as	O
metabolic	B-MED
inflammation	B-MED
.	O
	
delta-5	B-MED
desaturase	I-MED
d5d	B-MED
is	O
an	O
enzyme	B-MED
that	O
metabolizes	O
dihomo-γ-linolenic	B-MED
acid	I-MED
dgla	B-MED
to	O
arachidonic	B-MED
acid	I-MED
aa	B-MED
.	O
	
thus	O
,	O
d5d	B-MED
inhibition	B-MED
increases	O
dgla	B-MED
precursor	O
to	O
anti-inflammatory	B-MED
eicosanoids	B-MED
while	O
decreasing	O
aa	B-MED
precursor	O
to	O
pro-inflammatory	O
eicosanoids	B-MED
,	O
and	O
could	O
result	O
in	O
synergistic	B-MED
improvement	B-MED
in	O
the	O
low-grade	O
inflammatory	O
state	O
.	O
	
here	O
,	O
we	O
demonstrate	O
reduced	B-MED
insulin	B-MED
resistance	I-MED
and	O
the	O
anti-obesity	B-MED
effect	O
of	O
a	O
d5d	B-MED
selective	O
inhibitor	O
compound-326	B-MED
,	O
an	O
orally	B-MED
active	O
small-molecule	B-MED
,	O
in	O
a	O
high-fat	B-MED
diet	I-MED
-induced	O
obese	B-MED
dio	I-MED
mouse	I-MED
model	B-MED
.	O
	
in	O
vivo	O
d5d	B-MED
inhibition	B-MED
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	B-MED
aa	B-MED
/	O
dgla	B-MED
profiles	B-MED
.	O
	
in	O
dio	B-MED
mice	I-MED
,	O
chronic	O
treatment	O
with	O
compound-326	B-MED
lowered	O
insulin	B-MED
resistance	I-MED
and	O
caused	O
body	B-MED
weight	I-MED
loss	I-MED
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	B-MED
intake	I-MED
.	O
	
decreased	O
macrophage	B-MED
infiltration	I-MED
into	I-MED
adipose	I-MED
tissue	I-MED
was	O
expected	O
from	O
mrna	B-MED
analysis	I-MED
.	O
	
increased	O
daily	O
energy	B-MED
expenditure	I-MED
was	O
also	O
observed	O
following	O
administration	B-MED
of	O
compound-326	B-MED
,	O
in	O
line	O
with	O
sustained	O
body	B-MED
weight	I-MED
loss	I-MED
.	O
	
these	O
data	O
indicate	O
that	O
the	O
novel	O
d5d	B-MED
selective	O
inhibitor	B-MED
,	O
compound-326	B-MED
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-MED
and	O
diabetic	B-MED
patients	B-MED
.	O
	
blood	B-MED
collection	I-MED
tubes	I-MED
and	O
storage	B-MED
temperature	I-MED
should	O
be	O
evaluated	O
when	O
using	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
for	O
measuring	B-MED
25-hydroxyvitamin	I-MED
d	I-MED
a	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
for	O
measurement	B-MED
of	I-MED
25-hydroxyvitamin	I-MED
d	I-MED
25ohd	B-MED
with	O
vacuette	B-MED
tubes	I-MED
with	I-MED
serum	I-MED
clot	I-MED
activator	I-MED
and	I-MED
gel	I-MED
.	O
	
here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	B-MED
or	O
temperatures	B-MED
affected	O
25ohd	B-MED
results	I-MED
obtained	O
with	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
.	O
	
serum	B-MED
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	B-MED
blood	I-MED
collection	I-MED
tubes	I-MED
from	O
three	O
manufacturers	O
,	O
and	O
25ohd	B-MED
was	I-MED
analyzed	I-MED
using	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
and	O
liquid	B-MED
chromatography	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
lc-ms/ms	B-MED
immediately	O
or	O
after	O
storage	O
at	O
4	O
or	O
-80	O
for	O
48	O
h	O
.	O
	
significantly	B-MED
higher	I-MED
25ohd	B-MED
values	I-MED
were	O
found	O
when	O
using	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
with	O
vacuette	B-MED
tubes	I-MED
with	I-MED
serum	I-MED
clot	I-MED
activator	I-MED
and	I-MED
gel	I-MED
and	O
vacuette	B-MED
tubes	I-MED
with	I-MED
clot	I-MED
activator	I-MED
but	O
no	O
gel	O
compared	O
with	O
vacuette	B-MED
tubes	I-MED
with	O
no	O
additives	O
.	O
	
the	O
25ohd	B-MED
values	I-MED
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
lc-ms/ms	B-MED
.	O
	
moreover	O
,	O
after	O
storage	O
at	O
-80	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
improvevacuter	B-MED
tubes	I-MED
with	I-MED
serum	I-MED
clot	I-MED
activator	I-MED
and	I-MED
ge	I-MED
l	O
significantly	B-MED
increased	I-MED
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
.	O
	
vacuette	B-MED
tubes	I-MED
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25ohd	B-MED
results	I-MED
obtained	O
using	O
the	O
siemens	B-MED
advia	I-MED
centaur	I-MED
xp	I-MED
system	O
.	O
	
additionally	O
,	O
the	O
composition	O
of	O
serum	B-MED
collected	O
in	O
improvevacuter	B-MED
tubes	I-MED
was	O
affected	O
by	O
freezing	B-MED
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
siemens	O
25ohd	B-MED
assay	B-MED
platform	I-MED
.	O
	
evolution	B-MED
of	O
fitness	B-MED
cost-neutral	B-MED
mutant	B-MED
pfcrt	B-MED
conferring	O
p	B-MED
.	O
	
falciparum	I-MED
4-aminoquinoline	B-MED
drug	B-MED
resistance	I-MED
is	O
accompanied	O
by	O
altered	B-MED
parasite	B-MED
metabolism	B-MED
and	O
digestive	B-MED
vacuole	I-MED
physiology	B-MED
southeast	B-MED
asia	I-MED
is	O
an	O
epicenter	O
of	O
multidrug-resistant	B-MED
plasmodium	B-MED
falciparum	I-MED
strains	I-MED
.	O
	
selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	B-MED
variants	B-MED
of	O
parasite	B-MED
drug	B-MED
resistance	I-MED
genes	B-MED
,	O
including	O
the	O
p	B-MED
.	O
	
falciparum	I-MED
chloroquine	I-MED
resistance	I-MED
transporter	I-MED
pfcrt	B-MED
.	O
	
despite	O
significant	O
reductions	B-MED
in	O
the	O
deployment	B-MED
of	O
the	O
4-aminoquinoline	B-MED
drug	B-MED
chloroquine	B-MED
cq	B-MED
,	O
which	O
selected	O
for	O
the	O
mutant	B-MED
pfcrt	B-MED
alleles	B-MED
that	O
halted	O
cq	B-MED
efficacy	B-MED
decades	O
ago	O
,	O
the	O
parasite	B-MED
pfcrt	B-MED
locus	B-MED
is	O
continuously	O
evolving	O
.	O
	
this	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	B-MED
mutated	B-MED
allele	B-MED
,	O
cam734	B-MED
pfcrt	I-MED
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	B-MED
cq	B-MED
resistance	B-MED
without	O
an	O
associated	O
fitness	B-MED
cost	B-MED
.	O
	
here	O
,	O
we	O
used	O
pfcrt	B-MED
-specific	O
zinc-finger	B-MED
nucleases	I-MED
to	O
genetically	B-MED
dissect	I-MED
this	O
allele	B-MED
in	O
the	O
pathogenic	B-MED
setting	O
of	O
asexual	B-MED
blood-stage	I-MED
infection	I-MED
.	O
	
comparative	B-MED
analysis	I-MED
of	O
drug	B-MED
resistance	I-MED
and	O
growth	B-MED
profiles	O
of	O
recombinant	B-MED
parasites	I-MED
that	O
express	B-MED
cam734	B-MED
or	O
variants	B-MED
thereof	O
,	O
dd2	B-MED
the	O
most	O
common	O
southeast	B-MED
asian	I-MED
variant	B-MED
,	O
or	O
wild-type	B-MED
pfcrt	B-MED
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
pfcrt	B-MED
mutations	B-MED
in	O
modulating	O
parasite	B-MED
susceptibility	O
to	O
multiple	O
antimalarial	B-MED
agents	I-MED
.	O
	
these	O
results	O
were	O
generated	O
in	O
the	O
gc03	B-MED
strain	B-MED
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	B-MED
studies	B-MED
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	B-MED
.	O
	
results	O
presented	O
herein	O
show	O
that	O
cam734	B-MED
-mediated	O
cq	B-MED
resistance	B-MED
is	O
dependent	O
on	O
the	O
rare	O
a144f	B-MED
mutation	B-MED
that	O
has	O
not	O
been	O
observed	O
beyond	O
southeast	B-MED
asia	I-MED
,	O
and	O
reveal	O
distinct	O
impacts	B-MED
of	O
this	O
and	O
other	O
cam734	B-MED
-specific	O
mutations	B-MED
on	O
cq	B-MED
resistance	B-MED
and	O
parasite	B-MED
growth	B-MED
rates	I-MED
.	O
	
biochemical	B-MED
assays	I-MED
revealed	O
a	O
broad	O
impact	B-MED
of	O
mutant	B-MED
pfcrt	B-MED
isoforms	B-MED
on	O
parasite	B-MED
metabolism	B-MED
,	O
including	O
nucleoside	B-MED
triphosphate	I-MED
levels	B-MED
,	O
hemoglobin	B-MED
catabolism	I-MED
and	O
disposition	O
of	O
heme	B-MED
,	O
as	O
well	O
as	O
digestive	B-MED
vacuole	I-MED
volume	B-MED
and	O
ph	B-MED
.	O
	
results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	B-MED
molecular	I-MED
basis	I-MED
and	O
physiological	B-MED
impact	B-MED
of	O
pfcrt	B-MED
-mediated	O
antimalarial	B-MED
drug	B-MED
resistance	I-MED
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	B-MED
alleles	B-MED
that	O
can	O
undermine	O
the	O
efficacy	B-MED
of	O
first-line	O
antimalarial	B-MED
drug	I-MED
regimens	B-MED
.	O
	
effect	B-MED
of	O
nutritionally	B-MED
induced	I-MED
hyperlipidaemia	B-MED
on	O
in	B-MED
vitro	I-MED
bovine	B-MED
embryo	B-MED
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	B-MED
acid	I-MED
in	O
the	O
diet	B-MED
the	O
present	O
study	B-MED
examined	B-MED
whether	O
the	O
effects	B-MED
of	I-MED
dietary	B-MED
-induced	O
hyperlipidaemia	B-MED
on	O
preimplantation	B-MED
embryo	I-MED
development	I-MED
depend	O
on	O
the	O
predominant	O
fatty	B-MED
acid	I-MED
fa	B-MED
type	O
in	O
the	O
diet	B-MED
.	O
	
in	O
a	O
combined	O
in	B-MED
vivo	I-MED
-	O
in	B-MED
vitro	I-MED
bovine	B-MED
model	B-MED
,	O
two	O
groups	O
of	O
cows	B-MED
n=3	O
in	O
each	O
group	O
were	O
fed	B-MED
with	O
three	O
diets	B-MED
consecutively	O
4	O
weeks	O
feeding	B-MED
for	O
each	O
1	O
a	O
maintenance	B-MED
control	I-MED
diet	I-MED
cont	B-MED
2	O
a	O
high	B-MED
-	O
starch	B-MED
diet	B-MED
rich	O
in	O
saturated	B-MED
fat	I-MED
sat	B-MED
and	O
3	O
a	O
high	B-MED
-	O
starch	B-MED
diet	B-MED
rich	O
in	O
omega-3	B-MED
unsaturated	B-MED
fat	I-MED
unsat	B-MED
.	O
	
two	O
feeding	B-MED
sequences	B-MED
were	O
used	O
to	O
test	O
for	O
carry-over	O
effects	O
group	O
a	O
was	O
fed	B-MED
cont	B-MED
,	O
sat1	B-MED
and	O
then	O
unsat2	B-MED
,	O
whereas	O
group	O
b	O
was	O
fed	B-MED
cont	B-MED
,	O
unsat1	B-MED
and	O
then	O
sat2	B-MED
.	O
	
serum	B-MED
was	O
collected	O
after	O
each	O
dietary	B-MED
period	B-MED
,	O
analysed	B-MED
and	O
tested	B-MED
in	O
bovine	B-MED
in	B-MED
vitro	I-MED
embryo	B-MED
culture	I-MED
.	O
	
introducing	O
sat	B-MED
and	O
unsat	B-MED
diets	B-MED
induced	O
hyperlipidaemia	B-MED
specifically	O
hypercholesterolaemia	B-MED
and	O
elevated	O
free	B-MED
fas	I-MED
and	O
reduced	O
insulin	B-MED
sensitivity	I-MED
.	O
	
carry-over	O
effects	O
in	O
serum	B-MED
metabolites	B-MED
and	O
fa	B-MED
profile	I-MED
were	O
dependent	O
on	O
the	O
diet	B-MED
and	O
feeding	B-MED
sequence	B-MED
.	O
	
sat1	B-MED
and	O
sat2	B-MED
serum	B-MED
decreased	O
blastocyst	B-MED
rates	O
and	O
altered	O
blastocyst	B-MED
mrna	B-MED
expression	I-MED
related	O
to	O
apoptosis	B-MED
and	O
oxidative	B-MED
stress	I-MED
.	O
	
unsat1	B-MED
and	O
unsat2	B-MED
serum	B-MED
resulted	O
in	O
normal	O
embryo	B-MED
development	O
and	O
quality	B-MED
.	O
	
other	O
in	B-MED
vitro	I-MED
effects	O
depended	O
on	O
the	O
sequence	B-MED
of	O
feeding	B-MED
.	O
	
in	O
conclusion	O
,	O
substitution	B-MED
of	O
saturated	B-MED
fat	I-MED
with	O
omega-3	B-MED
fat	I-MED
in	O
a	O
high-caloric	B-MED
diet	I-MED
induced	O
hyperlipidaemia	B-MED
with	O
an	O
fa	B-MED
profile	I-MED
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-MED
compared	O
with	O
normolipidaemic	B-MED
controls	I-MED
.	O
	
draft	B-MED
genome	I-MED
sequence	I-MED
of	O
the	O
soil	B-MED
isolate	B-MED
lysinibacillus	B-MED
fusiformis	I-MED
m5	I-MED
,	O
a	O
potential	B-MED
hypoxanthine	B-MED
producer	O
lysinibacillus	B-MED
fusiformis	I-MED
strain	I-MED
m5	I-MED
is	O
a	O
potential	B-MED
hypoxanthine	B-MED
producer	O
that	O
was	O
isolated	B-MED
from	O
clay	B-MED
soil	B-MED
.	O
	
here	O
,	O
we	O
present	O
the	O
draft	B-MED
genome	I-MED
sequence	I-MED
that	O
was	O
annotated	B-MED
in	O
order	O
to	O
facilitate	O
future	O
studies	B-MED
of	O
l	B-MED
.	O
	
fusiformis	I-MED
m5	I-MED
.	O
	
impact	B-MED
of	O
clinical	B-MED
trial	I-MED
results	B-MED
on	O
the	O
temporal	B-MED
trends	B-MED
of	O
carotid	B-MED
endarterectomy	I-MED
and	O
stenting	B-MED
from	O
2002	O
to	O
2014	O
randomized	B-MED
trials	I-MED
provide	O
conflicting	B-MED
data	B-MED
for	O
the	O
efficacy	B-MED
of	O
carotid-artery	B-MED
stenting	I-MED
compared	O
with	O
endarterectomy	B-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	B-MED
of	O
conflicting	B-MED
clinical	B-MED
trial	I-MED
publications	I-MED
on	O
the	O
utilization	B-MED
rates	O
of	O
carotid	O
revascularization	O
procedures	O
.	O
	
we	O
conducted	O
a	O
population-level	O
time-series	O
analysis	O
of	O
all	O
individuals	O
who	O
underwent	O
carotid	O
endarterectomy	O
and	O
stenting	O
in	O
ontario	O
,	O
canada	O
2002-2014	O
.	O
	
the	O
primary	O
analysis	O
examined	O
temporal	O
changes	O
in	O
the	O
rates	O
of	O
carotid	O
revascularization	O
procedures	O
after	O
publications	O
of	O
major	O
randomized	O
trials	O
.	O
	
secondary	O
analyses	O
examined	O
changes	O
in	O
overall	O
and	O
age	O
,	O
sex	O
,	O
carotid-artery	O
symptom	O
,	O
and	O
operator	O
specialty-specific	O
procedure	O
rates	O
.	O
	
a	O
total	O
of	O
16	O
772	O
patients	O
were	O
studied	O
14	O
394	O
endarterectomy	O
86%	O
2378	O
stenting	O
14%	O
.	O
	
the	O
overall	O
rate	O
of	O
carotid	O
revascularization	O
decreased	O
from	O
6.0	O
procedures	O
per	O
100	O
000	O
individuals	O
40	O
years	O
old	O
in	O
april	O
2002	O
to	O
4.3	O
procedures	O
in	O
the	O
first	O
quarter	O
of	O
2014	O
29%	O
decrease	O
p<0	O
.	O
	
the	O
rate	O
of	O
endarterectomy	O
decreased	O
by	O
36%	O
p<0	O
,	O
whereas	O
the	O
rate	O
of	O
carotid-artery	O
stenting	O
increased	O
by	O
72%	O
p=0	O
.	O
	
we	O
observed	O
a	O
marked	O
increase	O
p=0	O
in	O
stenting	O
after	O
publication	O
of	O
the	O
sapphire	O
trial	O
stenting	O
and	O
angioplasty	O
with	O
protection	O
in	O
patients	O
at	O
high	O
risk	O
for	O
endarterectomy	O
in	O
2004	O
,	O
whereas	O
stenting	O
remained	O
relatively	O
unchanged	O
after	O
subsequent	O
randomized	O
trials	O
published	O
in	O
2006	O
p=0	O
and	O
2010	O
p=0	O
.	O
	
in	O
contrast	O
,	O
endarterectomy	O
decreased	O
after	O
trials	O
published	O
in	O
2006	O
p=0	O
and	O
2010	O
p=0	O
.	O
	
although	O
the	O
overall	O
rates	O
of	O
carotid	O
revascularization	O
and	O
endarterectomy	O
have	O
fallen	O
since	O
2002	O
,	O
the	O
rate	O
of	O
carotid-artery	O
stenting	O
has	O
risen	O
since	O
the	O
publication	O
of	O
stenting	O
-favorable	O
sapphire	O
trial	O
.	O
	
subsequent	O
conflicting	O
randomized	O
trials	O
were	O
associated	O
with	O
a	O
decreasing	O
rate	O
of	O
carotid	O
endarterectomy	I-MED
electronic	B-MED
tongues	I-MED
to	O
assess	O
wine	B-MED
sensory	B-MED
descriptors	B-MED
this	O
work	B-MED
reports	B-MED
the	O
application	B-MED
of	O
an	O
electronic	B-MED
tongue	I-MED
as	O
a	O
tool	B-MED
towards	O
the	O
analysis	B-MED
of	O
wine	B-MED
in	O
tasks	O
such	O
as	O
its	O
discrimination	B-MED
based	O
on	O
the	O
maturing	B-MED
in	O
barrels	B-MED
or	O
the	O
prediction	B-MED
of	O
the	O
global	B-MED
scores	B-MED
assigned	O
by	O
a	O
sensory	B-MED
panel	I-MED
.	O
	
to	O
this	O
aim	O
,	O
red	B-MED
wine	I-MED
samples	B-MED
were	O
first	O
analysed	B-MED
with	O
the	O
voltammetric	B-MED
sensor	I-MED
array	I-MED
,	O
without	O
performing	O
any	O
sample	B-MED
pretreatment	B-MED
.	O
	
afterwards	O
,	O
obtained	O
responses	B-MED
were	O
preprocessed	B-MED
employing	O
fast	B-MED
fourier	I-MED
transform	I-MED
fft	B-MED
for	O
the	O
compression	B-MED
and	O
reduction	B-MED
of	O
signal	B-MED
complexity	B-MED
,	O
and	O
obtained	O
coefficients	B-MED
were	O
then	O
used	O
as	O
inputs	B-MED
to	O
build	O
the	O
qualitative	B-MED
and	O
quantitative	B-MED
models	B-MED
employing	O
either	O
linear	B-MED
discriminant	I-MED
analysis	I-MED
lda	B-MED
or	O
partial	B-MED
least	I-MED
squares	I-MED
regression	I-MED
pls	B-MED
,	O
respectively	O
.	O
	
satisfactory	O
results	B-MED
were	O
obtained	O
overall	O
,	O
with	O
a	O
classification	B-MED
rate	B-MED
of	O
100%	O
in	O
the	O
discrimination	B-MED
of	O
the	O
type	O
of	O
barrel	B-MED
used	O
during	O
wine	B-MED
maturing	B-MED
,	O
a	O
normalized	B-MED
nrmse	I-MED
of	O
0.077	O
in	O
the	O
estimation	O
of	O
ageing	B-MED
time	B-MED
months	B-MED
or	O
0.11	O
in	O
the	O
prediction	B-MED
of	O
the	O
scores	B-MED
0-10	O
from	O
a	O
trained	B-MED
sensory	I-MED
panel	I-MED
all	O
for	O
the	O
external	O
test	B-MED
subset	B-MED
.	O
	
toward	O
optimizing	B-MED
dental	B-MED
implant	I-MED
performance	O
surface	B-MED
characterization	B-MED
of	O
ti	B-MED
and	O
tizr	B-MED
implant	B-MED
materials	I-MED
targeting	B-MED
understanding	O
enhanced	B-MED
osseointegration	B-MED
kinetics	B-MED
,	O
the	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
characterize	B-MED
the	O
surface	B-MED
morphology	B-MED
and	O
composition	B-MED
of	O
ti	B-MED
and	O
tizr	B-MED
dental	B-MED
implant	I-MED
substrates	B-MED
subjected	O
to	O
one	O
of	O
two	O
surface	B-MED
treatments	B-MED
developed	O
by	O
straumann	O
.	O
	
these	O
two	O
treatments	B-MED
are	O
typically	O
known	O
as	O
sla	B-MED
and	O
slactive	B-MED
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	B-MED
osseointegration	B-MED
.	O
	
a	O
range	O
of	O
techniques	B-MED
was	O
applied	B-MED
to	O
characterize	B-MED
four	O
different	B-MED
substrate	B-MED
/	O
surface	B-MED
treatment	B-MED
combinations	B-MED
tisla	B-MED
,	O
tislactive	B-MED
,	O
tizrsla	B-MED
,	O
and	O
tizrslactive	B-MED
.	O
	
contact	B-MED
angle	B-MED
measurements	B-MED
establish	O
establish	O
their	O
hydrophilic	B-MED
/	O
hydrophobic	B-MED
nature	O
.	O
	
surface	B-MED
morphology	B-MED
was	O
probed	O
with	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
.	O
	
x-ray	B-MED
diffraction	I-MED
,	O
raman	B-MED
μ-spectroscopy	I-MED
,	O
and	O
x-ray	B-MED
photoelectron	I-MED
spectroscopy	I-MED
were	O
used	O
to	O
elucidate	O
the	O
composition	B-MED
of	O
the	O
near-	O
surface	B-MED
region	O
.	O
	
consistent	B-MED
with	I-MED
previous	B-MED
work	O
,	O
surface	B-MED
morphology	B-MED
was	O
found	O
to	O
differ	B-MED
only	O
at	O
the	O
nanoscale	B-MED
,	O
with	O
both	O
slactive	B-MED
substrates	B-MED
displaying	B-MED
nano	B-MED
-	O
protrusions	B-MED
.	O
	
spectroscopic	B-MED
data	B-MED
indicate	O
that	O
all	O
substrates	B-MED
exhibit	O
surface	B-MED
films	B-MED
of	O
titanium	B-MED
oxide	I-MED
displaying	O
near	O
tio2	B-MED
stoichiometry	B-MED
.	O
	
raman	B-MED
μ-spectroscopy	I-MED
reveals	B-MED
that	O
amorphous	B-MED
tio2	B-MED
is	O
most	O
likely	O
the	O
only	O
phase	B-MED
present	B-MED
on	O
tisla	B-MED
,	O
whilst	O
rutile	B-MED
-	O
tio2	B-MED
is	O
also	O
evidenced	B-MED
on	O
tislactive	B-MED
,	O
tizrsla	B-MED
,	O
and	O
tizrslactive	B-MED
.	O
	
for	O
tizr	B-MED
alloy	B-MED
substrates	B-MED
,	O
there	O
is	O
no	O
evidence	B-MED
of	O
discrete	B-MED
phases	B-MED
of	O
oxidized	B-MED
zr	B-MED
.	O
	
x-ray	B-MED
photoelectron	I-MED
spectra	I-MED
demonstrate	O
that	O
all	O
samples	B-MED
are	O
terminated	B-MED
by	O
adventitious	B-MED
carbon	B-MED
,	O
with	O
it	O
being	O
somewhat	O
thicker	B-MED
1nm	O
on	O
tisla	B-MED
and	O
tizrsla	B-MED
.	O
	
given	O
previous	B-MED
in	B-MED
vivo	I-MED
studies	I-MED
,	O
acquired	B-MED
data	B-MED
suggest	O
that	O
both	O
nanoscale	B-MED
protrusions	B-MED
,	O
and	O
a	O
thinner	B-MED
layer	B-MED
of	O
adventitious	B-MED
carbon	B-MED
contribute	B-MED
to	O
the	O
more	O
rapid	B-MED
osseointegration	B-MED
of	O
slactive	B-MED
dental	B-MED
implants	I-MED
.	O
	
composition	B-MED
of	O
the	O
surface	B-MED
oxide	B-MED
layer	B-MED
is	O
apparently	O
less	B-MED
important	B-MED
in	O
determining	O
osseointegration	B-MED
kinetics	B-MED
.	O
	
cocaine	B-MED
use	B-MED
reverses	B-MED
striatal	B-MED
plasticity	I-MED
produced	B-MED
during	B-MED
cocaine	B-MED
seeking	O
relapse	B-MED
is	O
a	O
two	B-MED
-	O
component	B-MED
process	B-MED
consisting	O
of	O
a	O
highly	B-MED
motivated	B-MED
drug-seeking	O
phase	B-MED
that	O
,	O
if	O
successful	O
,	O
is	O
followed	B-MED
by	I-MED
a	O
drug-using	B-MED
phase	B-MED
resulting	B-MED
in	I-MED
temporary	B-MED
satiation	B-MED
.	O
	
in	O
rodents	B-MED
,	O
cue-induced	O
drug	O
seeking	O
requires	B-MED
transient	B-MED
synaptic	I-MED
potentiation	I-MED
t-sp	B-MED
of	O
cortical	B-MED
glutamatergic	I-MED
synapses	I-MED
on	O
nucleus	B-MED
accumbens	I-MED
core	B-MED
medium	B-MED
spiny	I-MED
neurons	I-MED
,	O
but	O
it	O
is	O
unknown	B-MED
how	O
achieving	O
drug	B-MED
use	I-MED
affects	B-MED
this	O
plasticity	B-MED
.	O
	
we	O
modeled	B-MED
the	O
two	O
phases	B-MED
of	O
relapse	B-MED
after	O
extinction	B-MED
from	O
cocaine	B-MED
self-administration	B-MED
to	O
assess	B-MED
how	O
cocaine	B-MED
use	O
affects	B-MED
t-sp	B-MED
associated	B-MED
with	I-MED
cue-induced	O
drug	O
seeking	O
.	O
	
rats	B-MED
were	O
trained	O
to	O
self-administer	B-MED
cocaine	B-MED
n	O
=	O
96	O
or	O
were	O
used	O
as	O
yoked	B-MED
-	O
saline	B-MED
control	B-MED
animals	I-MED
n	O
=	O
21	O
.	O
	
after	O
extinction	B-MED
,	O
reinstatement	B-MED
was	O
initiated	B-MED
by	O
10	O
minutes	B-MED
of	O
cue-induced	O
drug	O
seeking	O
,	O
followed	B-MED
by	I-MED
45	O
minutes	B-MED
with	O
contingent	B-MED
cocaine	B-MED
access	B-MED
,	O
after	O
which	O
cocaine	B-MED
was	O
discontinued	B-MED
and	O
unreinforced	B-MED
lever	I-MED
pressing	I-MED
ensued	I-MED
.	O
	
three	B-MED
measures	B-MED
of	O
t-sp	B-MED
were	O
assayed	B-MED
during	B-MED
reinstatement	B-MED
dendritic	B-MED
spine	I-MED
morphology	B-MED
,	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-MED
propionic	I-MED
acid	I-MED
ampa	B-MED
to	O
n-methyl-d-aspartate	B-MED
nmda	B-MED
ratios	B-MED
,	O
and	O
matrix	B-MED
metalloproteinase	I-MED
activity	B-MED
.	O
	
we	O
found	B-MED
that	O
cocaine	B-MED
use	O
for	O
10	O
minutes	B-MED
collapsed	B-MED
all	O
three	B-MED
measures	B-MED
of	O
cue-potentiated	O
t-sp	B-MED
back	O
to	O
baseline	B-MED
.	O
	
moreover	O
,	O
when	O
cocaine	B-MED
use	O
was	O
discontinued	B-MED
45	O
minutes	B-MED
later	O
,	O
dendritic	B-MED
spine	I-MED
morphology	B-MED
and	O
ampa	B-MED
to	O
nmda	B-MED
ratios	B-MED
were	O
restored	O
as	O
animals	B-MED
became	O
motivated	B-MED
to	O
engage	O
unrewarded	O
lever	B-MED
pressing	I-MED
.	O
	
nonreinforced	O
drug	O
seeking	O
was	O
positively	B-MED
correlated	B-MED
with	O
changes	B-MED
in	O
spine	B-MED
morphology	B-MED
,	O
and	O
cocaine	B-MED
access	B-MED
reversed	B-MED
this	O
relationship	B-MED
.	O
	
using	O
a	O
novel	B-MED
modification	B-MED
of	O
the	O
reinstatement	B-MED
paradigm	B-MED
,	O
we	O
show	O
that	O
achieving	O
cocaine	B-MED
use	O
reversed	B-MED
the	O
synaptic	B-MED
plasticity	I-MED
underpinning	O
the	O
motivation	B-MED
to	O
seek	O
the	O
delicaflavone	B-MED
induces	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
in	O
lung	B-MED
cancer	I-MED
via	O
akt	B-MED
/	O
mtor	B-MED
/	O
p70s6k	B-MED
signaling	B-MED
pathway	I-MED
searching	O
for	O
potential	B-MED
anticancer	B-MED
agents	I-MED
from	O
natural	B-MED
sources	I-MED
is	O
an	O
effective	B-MED
strategy	O
for	O
developing	O
novel	B-MED
chemotherapeutic	B-MED
agents	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
data	B-MED
supporting	O
the	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
anticancer	B-MED
effects	I-MED
of	O
delicaflavone	B-MED
,	O
a	O
rarely	O
occurring	O
biflavonoid	B-MED
from	O
selaginella	B-MED
doederleinii	I-MED
,	O
were	O
reported	O
.	O
	
delicaflavone	B-MED
exhibited	O
favorable	B-MED
anticancer	B-MED
properties	B-MED
,	O
as	O
shown	O
by	O
the	O
mtt	B-MED
assay	I-MED
and	O
xenograft	B-MED
model	I-MED
of	O
human	B-MED
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
in	O
male	B-MED
balb/c	B-MED
nude	I-MED
mice	I-MED
without	O
observable	O
adverse	B-MED
effect	I-MED
.	O
	
by	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
with	O
acridine	B-MED
orange	I-MED
and	O
cyto-id	B-MED
detection	O
dyes	B-MED
,	O
western	B-MED
blot	I-MED
analysis	B-MED
,	O
and	O
rt-pcr	B-MED
assay	I-MED
,	O
we	O
confirmed	O
that	O
delicaflavone	B-MED
induces	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
by	O
increasing	B-MED
the	O
ratio	O
of	O
lc3-ii	B-MED
to	O
lc3-i	B-MED
,	O
which	O
are	O
autophagy-related	B-MED
proteins	I-MED
,	O
and	O
promoting	B-MED
the	O
generation	B-MED
of	O
acidic	B-MED
vesicular	I-MED
organelles	I-MED
and	O
autolysosomes	B-MED
in	O
the	O
cytoplasm	B-MED
of	O
human	O
lung	B-MED
cancer	I-MED
a549	B-MED
and	O
pc-9	B-MED
cells	I-MED
in	O
a	O
time	B-MED
-	O
and	O
dose-dependent	B-MED
manner	O
.	O
	
delicaflavone	B-MED
downregulated	B-MED
the	O
expression	B-MED
of	I-MED
phospho-akt	I-MED
,	O
phospho-mtor	B-MED
,	O
and	O
phospho-p70s6k	B-MED
in	O
a	O
time	B-MED
-	O
and	O
dose-dependent	B-MED
manner	O
,	O
suggesting	B-MED
that	O
it	O
induced	B-MED
autophagy	B-MED
by	O
inhibiting	B-MED
the	O
akt	B-MED
/	O
mtor	B-MED
/	O
p70s6k	B-MED
pathway	B-MED
in	O
a549	B-MED
and	O
pc-9	B-MED
cells	I-MED
.	O
	
delicaflavone	B-MED
is	O
a	O
potential	B-MED
anticancer	B-MED
agent	I-MED
that	O
can	O
induce	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
in	O
human	B-MED
non-small	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
via	O
the	O
akt	B-MED
/	O
mtor	B-MED
/	O
p70s6k	B-MED
signaling	B-MED
pathway	I-MED
.	O
	
delicaflavone	B-MED
showed	O
anti-lung	B-MED
cancer	I-MED
effects	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
delicaflavone	B-MED
induced	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
via	O
akt	B-MED
/	O
mtor	B-MED
/	O
p70s6k	B-MED
signaling	B-MED
pathway	I-MED
.	O
	
delicaflavone	B-MED
did	O
not	O
show	O
observable	O
side	B-MED
effects	I-MED
in	O
a	O
xenograft	B-MED
mouse	I-MED
model	I-MED
.	O
	
delicaflavone	B-MED
may	O
represent	O
a	O
potential	B-MED
therapeutic	B-MED
agent	I-MED
for	O
lung	B-MED
cancer	I-MED
.	O
	
delicaflavone	B-MED
showed	O
anti-lung	B-MED
cancer	I-MED
effects	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
delicaflavone	B-MED
induced	O
autophagic	B-MED
cell	I-MED
death	I-MED
via	O
akt	B-MED
/	O
mtor	B-MED
/	O
p70s6k	B-MED
signaling	B-MED
pathway	I-MED
.	O
	
delicaflavone	B-MED
did	O
not	O
show	O
observable	O
side	B-MED
effects	I-MED
in	O
a	O
xenograft	B-MED
mouse	I-MED
model	I-MED
.	O
	
delicaflavone	B-MED
may	O
represent	O
a	O
potential	B-MED
therapeutic	B-MED
agent	I-MED
for	O
lung	B-MED
cancer	I-MED
.	O
	
determinants	B-MED
of	O
on-road	B-MED
driving	B-MED
in	O
multiple	B-MED
sclerosis	I-MED
to	O
investigate	B-MED
the	O
cognitive	B-MED
,	O
visual	B-MED
,	O
and	O
motor	B-MED
deficits	I-MED
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-MED
of	O
on-road	B-MED
driving	B-MED
in	O
individuals	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
ms	B-MED
.	O
	
prospective	O
cross-sectional	B-MED
study	I-MED
.	O
	
ms	B-MED
clinic	I-MED
and	O
driving	B-MED
simulator	B-MED
lab	B-MED
.	O
	
active	B-MED
drivers	I-MED
n=102	O
with	O
various	O
types	O
of	O
ms	B-MED
.	O
	
not	O
applicable	O
.	O
	
off-road	B-MED
cognitive	B-MED
,	O
visual	B-MED
,	O
and	O
motor	B-MED
functions	I-MED
,	O
as	O
well	O
as	O
13	O
specific	B-MED
driving	B-MED
skills	I-MED
.	O
	
these	O
skills	B-MED
were	O
categorized	B-MED
into	O
hierarchic	B-MED
clusters	I-MED
of	O
operational	B-MED
,	O
tactical	B-MED
,	O
visuo-integrative	B-MED
,	O
and	O
mixed	B-MED
driving	I-MED
.	O
	
stepwise	B-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
determine	O
the	O
off-road	B-MED
functions	O
influencing	O
performance	O
on	O
the	O
on-road	B-MED
test	B-MED
and	O
each	O
cluster	B-MED
.	O
	
visuospatial	B-MED
function	I-MED
p=	O
,	O
inhibition	B-MED
p=	O
,	O
binocular	B-MED
acuity	I-MED
p=	O
,	O
vertical	B-MED
visual	I-MED
field	I-MED
p=	O
,	O
and	O
stereopsis	B-MED
p=	O
best	O
determined	O
variance	B-MED
in	O
total	O
on-road	B-MED
score	B-MED
unadjusted	O
r	O
.	O
	
attentional	B-MED
shift	I-MED
p=	O
,	O
stereopsis	B-MED
p=	O
,	O
glare	B-MED
recovery	I-MED
p=	O
,	O
and	O
use	O
of	O
assistive	B-MED
devices	I-MED
p=	O
best	O
predicted	O
the	O
operational	B-MED
cluster	I-MED
unadjusted	O
r	O
.	O
	
visuospatial	B-MED
function	I-MED
p=	O
,	O
inhibition	B-MED
p=	O
,	O
reasoning	B-MED
p=	O
,	O
binocular	B-MED
acuity	I-MED
p=	O
,	O
and	O
stereopsis	B-MED
p=	O
best	O
determined	O
the	O
tactical	B-MED
cluster	I-MED
unadjusted	O
r	O
.	O
	
the	O
visuo-integrative	B-MED
mode	I-MED
l	O
unadjusted	O
r	O
comprised	O
binocular	B-MED
acuity	I-MED
p=	O
and	O
stereopsis	B-MED
p=	O
.	O
	
inhibition	B-MED
p=	O
and	O
binocular	B-MED
acuity	I-MED
p=	O
provided	O
the	O
best	O
model	B-MED
of	O
the	O
mixed	B-MED
cluster	I-MED
unadjusted	O
r	O
.	O
	
our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	B-MED
that	O
influence	O
different	O
dimensions	O
of	O
on-road	B-MED
driving	B-MED
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	B-MED
driving	B-MED
intervention	B-MED
programs	I-MED
in	O
netarsudil	B-MED
increases	B-MED
outflow	B-MED
facility	I-MED
in	O
human	B-MED
eyes	B-MED
through	O
multiple	B-MED
mechanisms	B-MED
netarsudil	B-MED
is	O
a	O
rho	B-MED
kinase/norepinephrine	I-MED
transporter	I-MED
inhibitor	I-MED
currently	O
in	O
phase	B-MED
3	I-MED
clinical	I-MED
development	I-MED
for	O
glaucoma	B-MED
treatment	B-MED
.	O
	
we	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B-MED
,	O
netarsudil-m1	B-MED
,	O
on	O
outflow	B-MED
facility	I-MED
c	B-MED
,	O
outflow	B-MED
hydrodynamics	B-MED
,	O
and	O
morphology	B-MED
of	O
the	O
conventional	B-MED
outflow	B-MED
pathway	I-MED
in	O
enucleated	B-MED
human	I-MED
eyes	I-MED
.	O
	
paired	B-MED
human	B-MED
eyes	B-MED
n	O
=	O
5	O
were	O
perfused	B-MED
with	O
either	O
0.3	O
μm	O
netarsudil-m1	B-MED
or	O
vehicle	B-MED
solution	I-MED
at	O
constant	B-MED
pressure	I-MED
15	O
mm	O
hg	O
.	O
	
after	O
3	O
hours	B-MED
,	O
fluorescent	B-MED
microspheres	I-MED
were	O
added	O
to	O
perfusion	B-MED
media	B-MED
to	O
trace	B-MED
the	O
outflow	B-MED
patterns	I-MED
before	O
perfusion	B-MED
-	O
fixation	B-MED
.	O
	
the	O
percentage	B-MED
effective	I-MED
filtration	I-MED
length	I-MED
pefl	B-MED
was	O
calculated	O
from	O
the	O
measured	B-MED
lengths	B-MED
of	O
tracer	B-MED
distribution	B-MED
in	O
the	O
trabecular	B-MED
meshwork	I-MED
tm	B-MED
,	O
episcleral	B-MED
veins	I-MED
esvs	B-MED
,	O
and	O
along	O
the	O
inner	B-MED
wall	I-MED
iw	B-MED
of	O
schlemm's	B-MED
canal	I-MED
after	O
global	B-MED
and	O
confocal	B-MED
imaging	I-MED
.	O
	
morphologic	B-MED
changes	I-MED
along	O
the	O
trabecular	B-MED
outflow	B-MED
pathway	I-MED
were	O
investigated	O
by	O
confocal	B-MED
,	O
light	B-MED
,	O
and	O
electron	B-MED
microscopy	I-MED
.	O
	
perfusion	B-MED
with	O
netarsudil-m1	B-MED
significantly	B-MED
increased	B-MED
c	B-MED
when	O
compared	O
to	O
baseline	O
51%	O
,	O
p	O
<	O
0.01	O
and	O
to	O
paired	B-MED
controls	O
102%	O
,	O
p	O
<	O
0.01	O
,	O
as	O
well	O
as	O
significantly	B-MED
increased	B-MED
pefl	B-MED
in	O
both	O
iw	B-MED
p	O
<	O
0.05	O
and	O
esvs	B-MED
p	O
<	O
0.01	O
.	O
	
in	O
treated	O
eyes	B-MED
,	O
pefl	B-MED
was	O
significantly	B-MED
higher	O
in	O
esvs	B-MED
than	O
in	O
the	O
iw	B-MED
p	O
<	O
0.01	O
and	O
was	O
associated	B-MED
with	I-MED
increased	B-MED
cross-sectional	B-MED
area	I-MED
of	O
esvs	B-MED
p	O
<	O
0.01	O
.	O
	
percentage	B-MED
effective	I-MED
filtration	I-MED
length	I-MED
in	O
esvs	B-MED
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
c	B-MED
r2	O
=	O
0.58	O
,	O
p	O
=	O
0.01	O
.	O
	
a	O
significant	B-MED
increase	B-MED
in	O
juxtacanalicular	B-MED
connective	I-MED
tissue	I-MED
jct	B-MED
thickness	B-MED
p	O
<	O
0.05	O
was	O
found	O
in	O
treated	O
eyes	B-MED
compared	O
to	O
controls	O
.	O
	
netarsudil	B-MED
acutely	B-MED
increased	B-MED
c	B-MED
by	O
expansion	O
of	O
the	O
jct	B-MED
and	O
dilating	O
the	O
esvs	B-MED
,	O
which	O
led	O
to	O
redistribution	B-MED
of	O
aqueous	O
outflow	B-MED
through	O
a	O
larger	B-MED
area	I-MED
of	O
the	O
iw	B-MED
and	O
geographical	B-MED
factors	B-MED
associated	B-MED
with	I-MED
health	B-MED
disparities	I-MED
in	O
prostate	B-MED
cancer	I-MED
treatment	B-MED
variation	B-MED
in	O
prostate	B-MED
cancer	I-MED
is	O
common	O
,	O
and	O
it	O
is	O
driven	O
by	O
clinical	B-MED
and	O
clinician	B-MED
factors	B-MED
,	O
patient	B-MED
preferences	I-MED
,	O
availability	B-MED
of	I-MED
resources	B-MED
,	O
and	O
access	B-MED
to	O
physicians	B-MED
and	O
treating	B-MED
facilities	I-MED
.	O
	
most	O
research	B-MED
on	O
treatment	B-MED
disparities	B-MED
in	O
men	B-MED
with	O
prostate	B-MED
cancer	I-MED
has	O
focused	O
on	O
race	B-MED
and	O
socioeconomic	B-MED
factors	I-MED
.	O
	
however	O
,	O
the	O
geography	B-MED
of	O
disparities	B-MED
-	O
capturing	O
racial	B-MED
and	O
socioeconomic	B-MED
differences	I-MED
based	O
on	O
where	O
patients	B-MED
live	B-MED
-	O
can	O
provide	O
insight	O
into	O
barriers	B-MED
to	O
care	B-MED
and	O
help	O
identify	O
outlier	O
areas	B-MED
in	O
which	O
access	B-MED
to	O
care	B-MED
,	O
health	B-MED
resources	I-MED
,	O
or	O
both	O
are	O
more	O
pronounced	O
.	O
	
research	B-MED
regarding	O
treatment	B-MED
patterns	B-MED
and	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
using	O
the	O
geographical	B-MED
information	I-MED
system	I-MED
gis	B-MED
was	O
searched	B-MED
.	O
	
studies	B-MED
were	O
limited	O
to	O
english-language	B-MED
articles	B-MED
and	O
research	B-MED
focused	O
on	O
us	B-MED
populations	B-MED
.	O
	
a	O
total	O
of	O
43	O
articles	B-MED
were	O
found	O
of	O
those	O
,	O
30	O
provided	O
information	B-MED
about	O
or	O
used	O
spatial	B-MED
or	O
geographical	B-MED
analyses	B-MED
to	O
assess	B-MED
and	O
describe	O
differences	B-MED
or	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
and	O
its	O
treatment	B-MED
.	O
	
two	O
additional	O
gis	B-MED
resources	O
were	O
included	O
.	O
	
the	O
research	B-MED
on	O
geographical	B-MED
and	O
spatial	B-MED
determinants	I-MED
of	O
prostate	B-MED
cancer	I-MED
disparities	B-MED
was	O
reviewed	B-MED
.	O
	
we	O
also	O
examined	O
geographical	B-MED
analyses	B-MED
at	O
the	O
state	B-MED
level	I-MED
,	O
focusing	O
on	O
florida	B-MED
.	O
	
overall	O
,	O
we	O
described	O
a	O
geographical	B-MED
framework	O
to	O
disparities	B-MED
that	O
affect	O
men	B-MED
with	O
prostate	B-MED
cancer	I-MED
and	O
reviewed	B-MED
existing	O
published	O
evidence	B-MED
supporting	O
the	O
interplay	O
of	O
geographical	B-MED
factors	B-MED
and	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
.	O
	
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
are	O
common	B-MED
and	O
persistent	B-MED
,	O
and	O
notable	O
differences	O
in	O
treatment	B-MED
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata	O
.	O
	
geographical	B-MED
analysis	B-MED
provides	O
additional	O
information	B-MED
about	O
where	O
disparate	B-MED
groups	B-MED
live	B-MED
and	O
also	O
helps	O
to	O
map	B-MED
access	B-MED
to	O
care	B-MED
.	O
	
this	O
information	B-MED
can	O
be	O
used	O
by	O
public	B-MED
health	I-MED
officials	I-MED
,	O
health-systems	B-MED
administrators	I-MED
,	O
clinicians	B-MED
,	O
and	O
policymakers	B-MED
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	B-MED
barriers	B-MED
that	O
contribute	O
to	O
disparities	B-MED
in	I-MED
care	I-MED
.	O
	
the	O
novel	O
mir-9600	B-MED
suppresses	B-MED
tumor	B-MED
progression	I-MED
and	O
promotes	O
paclitaxel	B-MED
sensitivity	B-MED
in	O
non-small-cell	B-MED
lung	I-MED
cancer	I-MED
through	O
altering	B-MED
stat3	B-MED
expression	B-MED
micrornas	B-MED
have	O
been	O
identified	B-MED
to	O
be	O
involved	O
in	O
center	B-MED
stage	I-MED
of	O
cancer	B-MED
biology	I-MED
.	O
	
they	O
accommodate	O
cell	B-MED
proliferation	I-MED
and	O
migration	B-MED
by	O
negatively	B-MED
regulate	B-MED
gene	I-MED
expression	I-MED
either	O
by	O
hampering	O
the	O
translation	B-MED
of	O
targeted	B-MED
mrnas	I-MED
or	O
by	O
promoting	O
their	O
degradation	B-MED
.	O
	
we	O
characterized	B-MED
and	O
identified	B-MED
the	O
novel	O
mir-9600	B-MED
and	O
its	O
target	B-MED
in	O
human	B-MED
non-small-cell	B-MED
lung	I-MED
cancer	I-MED
nsclc	B-MED
.	O
	
our	O
results	O
demonstrated	O
that	O
the	O
mir-9600	B-MED
were	O
downregulated	B-MED
in	O
nsclc	B-MED
tissues	B-MED
and	O
cells	B-MED
.	O
	
it	O
is	O
confirmed	O
that	O
signal	B-MED
transducer	I-MED
and	I-MED
activator	I-MED
of	I-MED
transcription	I-MED
3	I-MED
stat3	B-MED
,	O
a	O
putative	B-MED
target	I-MED
gene	I-MED
,	O
is	O
directly	O
inhibited	B-MED
by	O
mir-9600	B-MED
.	O
	
the	O
mir-9600	B-MED
markedly	O
suppressed	B-MED
the	O
protein	B-MED
expression	I-MED
of	O
stat3	B-MED
,	O
but	O
with	O
no	B-MED
significant	I-MED
influence	B-MED
in	O
corresponding	O
mrna	B-MED
levels	B-MED
,	O
and	O
the	O
direct	O
combination	O
of	O
mir-9600	B-MED
and	O
stat3	B-MED
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay	O
.	O
	
mir-9600	B-MED
inhibited	B-MED
cell	B-MED
growth	I-MED
,	O
hampered	O
expression	B-MED
of	O
cell	B-MED
cycle	I-MED
-related	O
proteins	B-MED
and	O
inhibited	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
in	O
human	B-MED
nsclc	B-MED
cell	B-MED
lines	I-MED
.	O
	
further	O
,	O
mir-9600	B-MED
significantly	O
suppressed	B-MED
tumor	B-MED
growth	I-MED
in	O
nude	B-MED
mice	I-MED
.	O
	
similarly	O
,	O
mir-9600	B-MED
impeded	O
tumorigenesis	B-MED
and	O
metastasis	B-MED
through	O
directly	O
targeting	B-MED
stat3	B-MED
.	O
	
furthermore	O
,	O
we	O
identified	B-MED
that	O
mir-9600	B-MED
augmented	O
paclitaxel	B-MED
and	O
cisplatin	B-MED
sensitivity	B-MED
by	O
downregulating	B-MED
stat3	B-MED
and	O
promoting	O
chemotherapy	B-MED
-	O
induced	B-MED
apoptosis	B-MED
.	O
	
these	O
data	O
demonstrate	O
that	O
mir-9600	B-MED
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	B-MED
target	B-MED
for	O
beneficial	B-MED
effects	I-MED
of	O
natural	B-MED
eggshell	I-MED
membrane	I-MED
nem	B-MED
on	O
multiple	O
indices	O
of	O
arthritis	B-MED
in	O
collagen-induced	B-MED
arthritic	I-MED
rats	B-MED
this	O
study	B-MED
was	O
performed	O
to	O
evaluate	B-MED
the	O
potential	B-MED
efficacy	I-MED
of	O
natural	B-MED
eggshell	I-MED
membrane	I-MED
nem	B-MED
in	O
collagen-induced	B-MED
arthritic	I-MED
rats	B-MED
,	O
a	O
well-established	O
rodent	B-MED
model	I-MED
of	I-MED
inflammation	I-MED
and	O
rheumatoid	B-MED
arthritis	I-MED
.	O
	
rats	B-MED
with	O
developing	O
type	B-MED
ii	I-MED
collagen-induced	I-MED
arthritis	I-MED
cia	B-MED
were	O
treated	O
once	O
daily	B-MED
by	O
oral	B-MED
gavage	I-MED
on	O
study	B-MED
days	I-MED
-14	O
to	O
17	O
with	O
vehicle	B-MED
or	O
nem	B-MED
52	O
mg/kg	O
body	B-MED
weight	I-MED
.	O
	
rats	B-MED
were	O
euthanized	B-MED
on	O
study	B-MED
day	I-MED
17	O
.	O
	
efficacy	B-MED
was	O
assessed	B-MED
by	O
daily	B-MED
ankle	B-MED
caliper	B-MED
measurements	B-MED
,	O
ankle	O
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
aucd0-17	O
,	O
and	O
histopathologic	O
evaluation	O
of	O
ankles	O
and	O
knees	O
.	O
	
serum	O
biomarkers	O
of	O
cartilage	O
function	O
and	O
inflammation	O
collagen	O
type	O
ii	O
c-telopeptide	O
ctxii	O
,	O
cartilage	O
oligomeric	O
matrix	O
protein	O
comp	O
,	O
and	O
alpha-2-macroglobulin	O
a2m	O
were	O
measured	O
by	O
elisa	O
.	O
	
treatment	O
with	O
nem	O
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	O
diameter	O
measurements	B-MED
and	O
ankle	B-MED
diameter	B-MED
auc	O
.	O
	
ankle	O
and	O
knee	O
histopathology	O
scores	O
were	O
significantly	O
reduced	O
36%	O
and	O
43%	O
reduction	O
of	O
summed	O
individual	O
histopathology	O
scores	O
for	O
ankle	O
and	O
knee	O
,	O
respectively	O
p	O
<	O
0.05	O
toward	O
normal	O
for	O
rats	O
given	O
nem	O
compared	O
to	O
vehicle	O
controls	O
.	O
	
the	O
percent	O
reduction	O
of	O
serum	O
ctxii	O
,	O
comp	O
,	O
and	O
a2m	O
in	O
nem	O
-	O
treated	O
rats	O
ranged	O
from	O
30%	O
to	O
72%	O
p	O
<	O
0.05	O
.	O
	
nem	O
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	O
arthritis	O
including	O
inflammation	O
,	O
pannus	O
,	O
cartilage	O
damage	O
,	O
bone	O
resorption	O
,	O
and	O
periosteal	O
bone	O
formation	O
.	O
	
this	O
study	O
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
ctxii	O
,	O
comp	O
,	O
and	O
a2m	O
as	O
relevant	O
biomarkers	O
that	O
were	O
responsive	O
to	O
nem	B-MED
mimicking	O
the	O
cell	B-MED
membrane	I-MED
bio-inspired	B-MED
simultaneous	B-MED
functions	O
with	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
and	O
antifouling	B-MED
properties	I-MED
of	O
anion	B-MED
exchange	O
membrane	B-MED
a	O
new	O
bio-inspired	B-MED
method	I-MED
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	B-MED
improve	O
the	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
and	O
antifouling	B-MED
properties	I-MED
of	O
anion	B-MED
exchange	O
membranes	B-MED
aems	O
.	O
	
three-layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-MED
pda	B-MED
and	O
electro-deposition	O
of	O
n-o-sulfonic	B-MED
acid	I-MED
benzyl	I-MED
chitosan	I-MED
nsbc	B-MED
.	O
	
the	O
innermost	B-MED
and	O
outermost	B-MED
layers	B-MED
were	O
pda	B-MED
with	O
different	O
deposition	O
time	O
.	O
	
the	O
middle	B-MED
layer	B-MED
was	O
prepared	O
by	O
nsbc	B-MED
.	O
	
fourier	B-MED
transform	I-MED
infrared	I-MED
spectroscopy	I-MED
and	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
confirmed	O
that	O
pda	B-MED
and	O
nsbc	B-MED
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
aems	O
.	O
	
the	O
contact	O
angle	O
of	O
the	O
membranes	B-MED
indicated	O
an	O
improved	O
hydrophilicity	B-MED
of	O
the	O
modified	O
membranes	B-MED
.	O
	
a	O
series	O
of	O
electrodialysis	B-MED
experiments	I-MED
in	O
which	O
cl	B-MED
/	O
so4	B-MED
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
of	O
the	O
samples	O
.	O
	
the	O
cl	B-MED
/	O
so4	B-MED
permselectivity	B-MED
of	O
the	O
modified	O
membranes	B-MED
can	O
reach	O
up	O
to	O
2.20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	B-MED
membrane	I-MED
only	O
0.78	O
during	O
90	O
minutes	O
in	O
electrodialysis	B-MED
ed	B-MED
.	O
	
the	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	B-MED
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	B-MED
properties	I-MED
.	O
	
sodium	B-MED
dodecyl	I-MED
benzene	I-MED
sulfonate	I-MED
sdbs	B-MED
was	O
used	O
as	O
the	O
fouling	B-MED
material	O
in	O
the	O
ed	B-MED
process	O
and	O
the	O
membrane	B-MED
area	O
resistance	O
of	O
modified	B-MED
membrane	I-MED
the	O
loop	B-MED
2	I-MED
region	I-MED
of	O
ribosomal	B-MED
protein	I-MED
us5	I-MED
influences	O
spectinomycin	B-MED
sensitivity	B-MED
,	O
translational	B-MED
fidelity	I-MED
,	O
and	O
ribosome	B-MED
biogenesis	I-MED
ribosomal	B-MED
protein	I-MED
us5	I-MED
is	O
an	O
essential	B-MED
component	I-MED
of	O
the	O
small	B-MED
ribosomal	I-MED
subunit	I-MED
that	O
is	O
involved	O
in	O
subunit	B-MED
assembly	I-MED
,	O
maintenance	B-MED
of	I-MED
translational	I-MED
fidelity	I-MED
,	O
and	O
the	O
ribosome's	B-MED
response	B-MED
to	O
the	O
antibiotic	B-MED
spectinomycin	I-MED
.	O
	
while	O
many	O
of	O
the	O
characterized	O
us5	B-MED
mutations	I-MED
that	O
affect	O
decoding	B-MED
map	O
to	O
its	O
interface	B-MED
with	O
us4	B-MED
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	B-MED
distant	O
from	O
the	O
us4-us5	B-MED
interface	I-MED
can	O
also	O
affect	O
the	O
decoding	B-MED
process	I-MED
.	O
	
we	O
targeted	O
one	O
such	O
interface-remote	B-MED
area	I-MED
,	O
the	O
loop	B-MED
2	I-MED
region	I-MED
residues	B-MED
20	O
to	O
31	O
,	O
for	O
mutagenesis	B-MED
in	O
escherichia	B-MED
.	O
	
coli	I-MED
and	O
generated	O
21	O
unique	B-MED
mutants	I-MED
.	O
	
a	O
majority	O
of	O
the	O
loop	B-MED
2	I-MED
alterations	O
confer	O
resistance	B-MED
to	O
spectinomycin	B-MED
and	O
affect	O
the	O
fidelity	B-MED
of	I-MED
translation	I-MED
.	O
	
however	O
,	O
only	O
a	O
minority	O
show	O
altered	O
rrna	B-MED
processing	O
or	O
ribosome	B-MED
biogenesis	I-MED
defects	B-MED
.	O
	
multiplex	B-MED
social	B-MED
ecological	B-MED
network	B-MED
analysis	I-MED
reveals	B-MED
how	O
social	B-MED
changes	I-MED
affect	B-MED
community	B-MED
robustness	B-MED
more	O
than	O
resource	B-MED
depletion	B-MED
network	B-MED
analysis	I-MED
provides	B-MED
a	O
powerful	O
tool	O
to	O
analyze	O
complex	B-MED
influences	B-MED
of	O
social	B-MED
and	O
ecological	B-MED
structures	I-MED
on	O
community	B-MED
and	O
household	B-MED
dynamics	O
.	O
	
most	O
network	B-MED
studies	I-MED
of	O
social	B-MED
-	O
ecological	B-MED
systems	I-MED
use	O
simple	B-MED
,	O
undirected	O
,	O
unweighted	B-MED
networks	I-MED
.	O
	
we	O
analyze	O
multiplex	B-MED
,	O
directed	B-MED
,	O
and	O
weighted	B-MED
networks	I-MED
of	O
subsistence	B-MED
food	B-MED
flows	O
collected	B-MED
in	O
three	O
small	O
indigenous	B-MED
communities	B-MED
in	O
arctic	B-MED
alaska	B-MED
potentially	O
facing	O
substantial	O
economic	B-MED
and	O
ecological	B-MED
changes	B-MED
.	O
	
our	O
analysis	O
of	O
plausible	O
future	B-MED
scenarios	B-MED
suggests	O
that	O
changes	B-MED
to	O
social	B-MED
relations	B-MED
and	O
key	O
households	B-MED
have	O
greater	O
effects	B-MED
on	O
community	B-MED
robustness	B-MED
than	O
changes	B-MED
to	O
specific	B-MED
wild	B-MED
food	I-MED
resources	I-MED
.	O
	
heavy	B-MED
resistance	I-MED
training	I-MED
in	O
hypoxia	B-MED
enhances	B-MED
1rm	B-MED
squat	B-MED
performance	B-MED
purpose	O
to	O
determine	O
if	O
heavy	B-MED
resistance	I-MED
training	I-MED
in	O
hypoxia	B-MED
ihrt	B-MED
is	O
more	O
effective	B-MED
at	O
improving	B-MED
strength	B-MED
,	O
power	B-MED
,	O
and	O
increasing	B-MED
lean	B-MED
mass	I-MED
than	O
the	O
same	O
training	B-MED
in	O
normoxia	O
.	O
	
methods	O
a	O
pair-matched	B-MED
,	O
placebo-controlled	B-MED
study	I-MED
design	B-MED
included	O
20	O
resistance-trained	B-MED
participants	B-MED
assigned	O
to	O
ihrt	B-MED
fio2	B-MED
0.143	O
or	O
placebo	B-MED
fio2	B-MED
0.20	O
,	O
n	O
=	O
10	O
per	O
group	B-MED
.	O
	
participants	B-MED
were	O
matched	B-MED
for	O
strength	B-MED
and	O
training	B-MED
.	O
	
both	B-MED
groups	B-MED
performed	B-MED
20	O
sessions	B-MED
over	O
7	O
weeks	B-MED
either	O
with	O
ihrt	B-MED
or	O
placebo	B-MED
.	O
	
all	O
participants	B-MED
were	O
tested	B-MED
for	O
1rm	B-MED
,	O
20-m	B-MED
sprint	B-MED
,	O
body	B-MED
composition	I-MED
,	O
and	O
countermovement	B-MED
jump	I-MED
pre	B-MED
-	O
,	O
mid	B-MED
-	O
,	O
and	O
post	B-MED
-	O
training	B-MED
and	O
compared	B-MED
via	O
magnitude	B-MED
-	O
based	B-MED
inferences	B-MED
.	O
	
presentation	O
of	O
results	O
groups	B-MED
were	O
not	B-MED
clearly	I-MED
different	B-MED
for	O
any	O
test	B-MED
at	O
baseline	B-MED
.	O
	
training	B-MED
improved	B-MED
both	B-MED
absolute	B-MED
ihrt	B-MED
13.1	O
3.9	O
,	O
effect	B-MED
size	I-MED
es	B-MED
0.60	O
,	O
placebo	B-MED
9.8	O
4.7	O
,	O
es	B-MED
0.31	O
and	O
relative	B-MED
1rm	B-MED
ihrt	B-MED
13.4	O
5.1	O
,	O
es	B-MED
0.76	O
,	O
placebo	B-MED
9.7	O
5.3	O
,	O
es	B-MED
0.48	O
at	O
mid	O
.	O
	
similarly	O
,	O
at	O
post	B-MED
both	B-MED
groups	B-MED
increased	B-MED
absolute	B-MED
ihrt	B-MED
20.7	O
7.6	O
,	O
es	B-MED
0.74	O
,	O
placebo	B-MED
14.1	O
6.0	O
,	O
es	B-MED
0.58	O
and	O
relative	B-MED
1rm	B-MED
ihrt	B-MED
21.6	O
8.5	O
,	O
es	B-MED
1.08	O
,	O
placebo	B-MED
13.2	O
6.4	O
,	O
es	B-MED
0.78	O
.	O
	
importantly	O
,	O
the	O
change	B-MED
in	O
ihrt	B-MED
was	O
greater	B-MED
than	O
placebo	B-MED
at	O
mid	O
for	O
both	B-MED
absolute	B-MED
4.4	O
greater	B-MED
change	B-MED
,	O
90%	O
confidence	B-MED
interval	I-MED
ci	B-MED
1.0	O
,	O
es	B-MED
0.21	O
,	O
and	O
relative	B-MED
strength	B-MED
5.6	O
greater	B-MED
change	B-MED
,	O
90%	O
ci	B-MED
1.0	O
,	O
es	B-MED
0.31	O
relative	B-MED
.	O
	
there	O
was	O
also	O
a	O
greater	B-MED
change	B-MED
for	O
ihrt	B-MED
at	O
post	O
for	O
both	B-MED
absolute	B-MED
7.0	O
greater	B-MED
change	B-MED
,	O
90%	O
ci	B-MED
1.3	O
,	O
es	B-MED
0.33	O
,	O
and	O
relative	B-MED
1rm	B-MED
9.2	O
greater	B-MED
change	B-MED
,	O
90%	O
ci	B-MED
1.6	O
,	O
es	B-MED
0.49	O
.	O
	
only	O
ihrt	B-MED
increased	B-MED
countermovement	B-MED
jump	I-MED
peak	B-MED
power	B-MED
at	O
post	B-MED
4.9	O
,	O
es	B-MED
0.35	O
,	O
however	O
the	O
difference	B-MED
between	O
ihrt	B-MED
and	O
placebo	B-MED
was	O
unclear	B-MED
2.7	O
,	O
90%	O
ci	B-MED
-2	O
,	O
es	B-MED
0.20	O
with	O
no	B-MED
clear	I-MED
differences	B-MED
in	O
speed	B-MED
or	O
body	B-MED
composition	I-MED
throughout	O
.	O
	
conclusion	O
heavy	B-MED
resistance	I-MED
training	I-MED
in	O
hypoxia	B-MED
is	O
more	O
effective	B-MED
than	O
placebo	B-MED
for	O
improving	B-MED
absolute	B-MED
and	O
relative	B-MED
strength	B-MED
.	O
	
ultrasonography	B-MED
and	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
evaluation	B-MED
of	O
pediatric	B-MED
spinal	B-MED
anomalies	I-MED
spinal	B-MED
dysraphisms	I-MED
are	O
congenital	B-MED
abnormalities	I-MED
of	O
the	O
spine	B-MED
due	O
to	O
imperfect	O
fusion	B-MED
of	O
midline	B-MED
mesenchymal	B-MED
,	O
bony	B-MED
and	O
neural	B-MED
structures	B-MED
.	O
	
imaging	B-MED
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-MED
as	O
significant	O
portion	O
of	O
patients	B-MED
may	O
present	O
with	O
concurrent	B-MED
anomalies	B-MED
that	O
need	O
to	O
be	O
corrected	B-MED
simultaneously	B-MED
to	O
avoid	O
repeat	B-MED
surgeries	I-MED
.	O
	
the	O
aims	O
of	O
the	O
study	B-MED
were	O
to	O
evaluate	B-MED
spinal	B-MED
dysraphisms	I-MED
using	O
usg	B-MED
and	O
mri	B-MED
and	O
to	O
correlate	B-MED
imaging	B-MED
findings	B-MED
with	O
operative	B-MED
findings	B-MED
in	O
patients	B-MED
undergoing	O
surgery	B-MED
.	O
	
hospital	B-MED
based	O
observational	B-MED
study	I-MED
conducted	O
over	O
a	O
period	B-MED
of	O
year	B-MED
.	O
	
38	O
cases	B-MED
of	O
both	O
sexes	B-MED
and	O
below	O
12	O
years	B-MED
of	O
age	B-MED
with	O
spinal	B-MED
dysraphism	I-MED
were	O
studied	O
.	O
	
usg	B-MED
was	O
performed	O
in	O
29	O
cases	B-MED
where	O
acoustic	B-MED
window	I-MED
was	O
available	O
for	O
proper	O
evaluation	B-MED
.	O
	
mri	B-MED
was	O
performed	O
in	O
all	O
cases	B-MED
.	O
	
usg	B-MED
findings	B-MED
were	O
compared	O
with	O
mri	B-MED
findings	B-MED
and	O
operative	B-MED
follow	B-MED
up	I-MED
was	O
taken	O
in	O
23	O
cases	B-MED
who	O
underwent	O
operative	B-MED
management	I-MED
.	O
	
results	O
were	O
analysed	B-MED
using	O
percentage	B-MED
and	O
arithmetic	B-MED
mean	I-MED
.	O
	
39.47	O
%	O
cases	B-MED
were	O
male	B-MED
and	O
60.53	O
%	O
cases	B-MED
were	O
female	B-MED
.	O
	
neonatal	B-MED
period	I-MED
was	O
the	O
most	O
common	O
presenting	O
age	B-MED
group	I-MED
.	O
	
closed	B-MED
spinal	B-MED
dysraphism	I-MED
63.16	O
was	O
more	O
common	O
than	O
open	B-MED
36.84	O
.	O
	
79.31	O
cases	B-MED
showed	O
full	O
agreement	O
between	O
spinal	B-MED
usg	B-MED
and	O
mri	B-MED
examinations	B-MED
and	O
6	O
out	O
of	O
20.69	O
showed	O
partial	O
agreement	O
.	O
	
on	O
operative	B-MED
correlation	B-MED
,	O
usg	B-MED
findings	B-MED
were	O
confirmatory	B-MED
in	O
91.30	O
cases	B-MED
and	O
mri	B-MED
findings	B-MED
were	O
confirmatory	B-MED
in	O
100%	O
cases	B-MED
.	O
	
usg	B-MED
can	O
be	O
used	O
as	O
the	O
initial	O
modality	B-MED
for	O
evaluation	B-MED
of	O
spinal	B-MED
dysraphism	I-MED
as	O
well	O
as	O
for	O
screening	B-MED
of	O
suspected	B-MED
cases	B-MED
.	O
	
mri	B-MED
is	O
indicated	O
to	O
confirm	O
abnormal	B-MED
usg	B-MED
findings	B-MED
,	O
which	O
shows	O
all	O
concurrent	B-MED
abnormalities	B-MED
and	O
also	O
provides	O
additional	O
anatomical	B-MED
details	B-MED
relevant	O
to	O
surgical	B-MED
planning	I-MED
.	O
	
bora	B-MED
-dependent	O
plk1	B-MED
regulation	B-MED
a	O
new	O
weapon	O
for	O
cancer	B-MED
therapy	I-MED
the	O
mitotic	B-MED
kinase	I-MED
polo	I-MED
like	I-MED
kinase	I-MED
1	I-MED
plk1	B-MED
is	O
overexpressed	B-MED
in	O
many	O
cancers	B-MED
and	I-MED
its	I-MED
inhibition	I-MED
slows	B-MED
down	I-MED
proliferation	I-MED
and	O
increases	B-MED
apoptosis	I-MED
in	O
cancer	B-MED
cell	I-MED
lines	I-MED
.	O
	
understanding	O
how	O
plk1	B-MED
is	I-MED
activated	I-MED
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
plk1	B-MED
inhibitors	I-MED
with	O
anticancer	B-MED
properties	I-MED
.	O
	
we	O
recently	O
identified	O
a	O
conserved	O
regulatory	B-MED
loop	I-MED
leading	O
to	O
plk1	B-MED
activation	I-MED
that	O
involves	O
cyclin-dependent	B-MED
kinase	I-MED
1	I-MED
cdk1	B-MED
.	O
	
activation	B-MED
of	I-MED
transcription	I-MED
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear	B-MED
bodies	I-MED
in	O
zebrafish	B-MED
embryos	B-MED
nuclear	B-MED
bodies	I-MED
are	O
cellular	B-MED
compartments	I-MED
that	O
lack	B-MED
lipid	B-MED
bilayers	I-MED
and	O
harbor	O
specific	B-MED
rnas	B-MED
and	O
proteins	B-MED
.	O
	
recent	O
proposals	O
that	O
nuclear	B-MED
bodies	I-MED
form	O
through	O
liquid-liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear	B-MED
bodies	I-MED
maintain	O
their	O
distinct	O
identities	O
unanswered	O
.	O
	
here	O
we	O
investigate	B-MED
cajal	B-MED
bodies	I-MED
cbs	B-MED
,	O
histone	B-MED
locus	I-MED
bodies	I-MED
hlbs	B-MED
and	O
nucleoli	B-MED
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing	B-MED
machinery	I-MED
,	O
histone	B-MED
mrna	I-MED
3'	I-MED
end	I-MED
processing	I-MED
,	O
and	O
rrna	B-MED
processing	I-MED
,	O
respectively	O
-	O
in	O
the	O
embryos	B-MED
of	O
the	O
zebrafish	B-MED
,	O
danio	B-MED
rerio	I-MED
.	O
	
we	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1-cell	O
embryo	B-MED
and	O
follow	O
nuclear	B-MED
body	I-MED
appearance	O
as	O
zygotic	B-MED
transcription	B-MED
becomes	O
activated	B-MED
.	O
	
cbs	B-MED
are	O
present	O
from	O
fertilization	B-MED
onwards	O
,	O
while	O
hlb	B-MED
and	O
nucleolar	B-MED
components	B-MED
formed	O
foci	B-MED
several	O
hours	O
later	O
when	O
histone	B-MED
genes	B-MED
and	O
rdna	B-MED
became	O
active	B-MED
.	O
	
hlb	B-MED
formation	O
was	O
blocked	B-MED
by	O
transcription	B-MED
inhibition	I-MED
,	O
suggesting	O
nascent	B-MED
histone	I-MED
transcripts	I-MED
recruit	O
hlb	B-MED
components	B-MED
like	O
u7	B-MED
snrnp	I-MED
.	O
	
surprisingly	O
,	O
we	O
found	O
that	O
u7	O
base-pairing	B-MED
with	O
nascent	B-MED
histone	I-MED
transcripts	I-MED
was	O
not	O
required	O
for	O
localization	B-MED
to	O
hlbs	B-MED
.	O
	
rather	O
,	O
the	O
type	O
of	O
sm	O
ring	O
assembled	O
on	O
u7	O
determined	O
its	O
targeting	O
to	O
hlbs	B-MED
or	O
cbs	B-MED
the	O
spliceosomal	O
sm	O
ring	O
targeted	O
snrnas	B-MED
to	O
cbs	B-MED
while	O
the	O
specialized	O
u7	O
sm-ring	O
localized	O
to	O
hlbs	B-MED
,	O
demonstrating	O
the	O
contribution	B-MED
of	O
protein	B-MED
constituents	B-MED
to	O
the	O
distinction	O
among	O
nuclear	B-MED
bodies	I-MED
.	O
	
thus	O
,	O
nucleolar	B-MED
,	O
hlb	B-MED
,	O
and	O
cb	B-MED
components	B-MED
can	O
mix	O
in	O
early	B-MED
embryogenesis	B-MED
when	O
transcription	B-MED
is	O
naturally	O
or	O
artificially	O
silenced	O
.	O
	
these	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	B-MED
of	O
specific	B-MED
gene	B-MED
loci	I-MED
nucleates	O
nuclear	B-MED
body	I-MED
components	B-MED
with	O
high	O
specificity	B-MED
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	B-MED
functions	B-MED
.	O
	
variation	B-MED
in	I-MED
the	I-MED
age	I-MED
of	O
first	B-MED
reproduction	I-MED
different	B-MED
strategies	I-MED
or	O
individual	B-MED
quality	I-MED
although	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
is	O
a	O
key	O
demographic	B-MED
parameter	I-MED
that	O
is	O
probably	O
under	O
high	B-MED
selective	I-MED
pressure	I-MED
,	O
it	O
is	O
highly	O
variable	B-MED
and	O
the	O
cause	O
of	O
this	O
variability	B-MED
is	O
not	O
well	O
understood	O
.	O
	
two	O
non-exclusive	O
hypotheses	B-MED
may	O
explain	O
such	O
variability	B-MED
.	O
	
it	O
could	O
be	O
the	O
expression	B-MED
of	O
different	O
individual	B-MED
strategies	I-MED
,	O
i.e	O
,	O
different	O
allocation	B-MED
strategies	I-MED
in	O
fitness	B-MED
components	I-MED
,	O
or	O
the	O
consequences	O
of	O
individual	B-MED
difference	I-MED
in	O
intrinsic	B-MED
quality	I-MED
,	O
i.e	O
,	O
some	O
individuals	B-MED
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness	B-MED
components	I-MED
.	O
	
we	O
tested	B-MED
these	O
hypotheses	B-MED
in	O
the	O
wandering	B-MED
albatross	I-MED
investigating	O
relationships	B-MED
between	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
and	O
subsequent	O
adult	B-MED
demographic	B-MED
traits	B-MED
.	O
	
using	O
finite	B-MED
mixture	I-MED
capture	I-MED
recapture	I-MED
modeling	I-MED
,	O
we	O
demonstrate	O
that	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
is	O
negatively	B-MED
related	O
to	O
both	O
reproductive	B-MED
performances	B-MED
and	O
adult	B-MED
survival	B-MED
,	O
suggesting	O
that	O
individual	B-MED
quality	I-MED
was	O
an	O
important	O
factor	O
explaining	O
variation	B-MED
in	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
.	O
	
our	O
results	O
suggest	O
that	O
age	B-MED
at	O
first	B-MED
breeding	I-MED
is	O
a	O
good	O
predictor	B-MED
of	O
quality	B-MED
in	O
this	O
long-lived	O
seabird	B-MED
species	I-MED
.	O
	
heterogeneity	B-MED
of	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
by	O
tumour	B-MED
characteristics	B-MED
large	O
prospective	B-MED
study	I-MED
of	O
uk	B-MED
women	B-MED
associations	B-MED
between	O
behavioural	B-MED
and	O
other	O
personal	B-MED
factors	B-MED
and	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-MED
characteristics	B-MED
,	O
but	O
evidence	O
is	O
inconsistent	O
.	O
	
in	O
a	O
large	O
uk	B-MED
-based	O
prospective	B-MED
study	I-MED
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk	B-MED
factors	I-MED
with	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
overall	O
,	O
and	O
across	O
three	O
anatomical	B-MED
sites	I-MED
and	O
four	O
morphological	B-MED
subtypes	B-MED
.	O
	
among	O
1.3	O
million	O
women	B-MED
,	O
18	O
incident	O
colorectal	B-MED
cancers	I-MED
were	O
identified	O
during	O
13.8	O
sd	O
3.4	O
years	O
follow-up	B-MED
via	O
record	O
linkage	O
to	O
national	B-MED
cancer	I-MED
registry	I-MED
data	B-MED
.	O
	
cox	B-MED
regression	I-MED
yielded	O
adjusted	O
relative	B-MED
risks	I-MED
.	O
	
statistical	B-MED
significance	I-MED
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing	O
.	O
	
overall	O
,	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
height	B-MED
,	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
,	O
smoking	B-MED
,	O
alcohol	B-MED
intake	I-MED
,	O
physical	B-MED
activity	I-MED
,	O
parity	B-MED
and	O
menopausal	B-MED
hormone	I-MED
therapy	I-MED
use	O
.	O
	
for	O
smoking	B-MED
there	O
was	O
substantial	O
heterogeneity	B-MED
across	O
morphological	B-MED
types	B-MED
relative	B-MED
risks	I-MED
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-MED
both	O
for	O
signet	B-MED
ring	I-MED
cell	I-MED
and	O
for	O
neuroendocrine	B-MED
tumours	I-MED
.	O
	
obese	B-MED
women	B-MED
were	O
also	O
at	B-MED
higher	I-MED
risk	I-MED
for	O
signet	B-MED
ring	I-MED
cell	I-MED
tumours	B-MED
.	O
	
for	O
adenocarcinomas	B-MED
,	O
the	O
large	O
majority	O
of	O
colorectal	B-MED
cancers	I-MED
in	O
the	O
cohort	B-MED
,	O
all	O
risk	B-MED
factor	I-MED
associations	B-MED
were	O
weak	O
.	O
	
there	O
was	O
little	O
or	O
no	O
heterogeneity	B-MED
in	O
risk	B-MED
between	O
tumours	B-MED
of	O
the	O
right	B-MED
colon	I-MED
,	O
left	B-MED
colon	I-MED
and	O
rectum	B-MED
for	O
any	O
of	O
the	O
14	O
factors	B-MED
examined	O
.	O
	
these	O
epidemiological	B-MED
findings	B-MED
complement	O
an	O
emerging	O
picture	O
from	O
molecular	B-MED
studies	I-MED
of	O
possible	O
different	O
developmental	B-MED
pathways	B-MED
for	O
different	O
tumour	B-MED
types	B-MED
.	O
	
impact	B-MED
of	O
alcohol	B-MED
use	I-MED
on	O
eeg	B-MED
dynamics	I-MED
of	O
response	B-MED
inhibition	I-MED
a	O
cotwin	B-MED
control	I-MED
analysis	I-MED
research	O
indicates	O
that	O
alcohol	B-MED
misuse	I-MED
is	O
associated	B-MED
with	I-MED
behavioral	B-MED
disinhibition	I-MED
,	O
but	O
the	O
neurophysiological	B-MED
mechanisms	I-MED
governing	O
this	O
relationship	B-MED
remain	O
largely	O
unknown	O
.	O
	
recent	O
work	O
suggests	O
that	O
successful	O
inhibition	B-MED
and	O
cognitive	B-MED
control	I-MED
involve	O
electrophysiological	B-MED
theta-band	I-MED
dynamics	I-MED
,	O
including	O
medial	B-MED
frontal	I-MED
cortex	I-MED
mfc	B-MED
power	B-MED
enhancement	I-MED
and	O
functional	B-MED
connectivity	I-MED
between	O
the	O
mfc	B-MED
and	O
dorsal	B-MED
prefrontal	I-MED
cortex	I-MED
dpfc	B-MED
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	B-MED
misuse	I-MED
.	O
	
in	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	B-MED
,	O
women	B-MED
are	O
at	O
heightened	O
risk	B-MED
of	O
experiencing	O
the	O
negative	O
physical	B-MED
and	O
neurocognitive	B-MED
correlates	I-MED
of	O
drinking	B-MED
.	O
	
the	O
present	O
study	B-MED
tested	O
the	O
hypothesis	O
that	O
alcohol	B-MED
misuse	I-MED
has	O
a	O
deleterious	B-MED
effect	I-MED
on	O
theta-band	B-MED
response	B-MED
inhibition	I-MED
eeg	B-MED
dynamics	I-MED
in	O
a	O
sample	B-MED
of	O
300	O
24-year-old	O
same-sex	O
twins	B-MED
.	O
	
a	O
cotwin	B-MED
control	I-MED
ctc	I-MED
design	I-MED
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	B-MED
for	O
alcohol	B-MED
use	I-MED
from	O
the	O
causal	B-MED
effects	I-MED
of	O
alcohol	B-MED
exposure	I-MED
.	O
	
drinking	B-MED
was	O
negatively	O
associated	B-MED
with	I-MED
theta-band	B-MED
mfc	B-MED
power	I-MED
and	O
mfc	B-MED
-	O
dpfc	B-MED
connectivity	B-MED
during	O
response	B-MED
inhibition	I-MED
,	O
and	O
this	O
effect	B-MED
was	O
stronger	O
among	O
women	B-MED
.	O
	
the	O
ctc	B-MED
analysis	I-MED
suggested	O
that	O
,	O
for	O
women	B-MED
,	O
reduced	O
nogo-related	O
theta-band	B-MED
mfc	B-MED
power	I-MED
and	O
mfc	B-MED
-	O
dpfc	B-MED
connectivity	B-MED
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	B-MED
causal	I-MED
effects	I-MED
of	O
alcohol	B-MED
exposure	I-MED
.	O
	
these	O
findings	O
suggest	O
that	O
diminished	B-MED
theta-band	B-MED
mfc	B-MED
power	I-MED
and	O
mfc	B-MED
-	O
dpfc	B-MED
connectivity	B-MED
may	O
be	O
neurophysiological	B-MED
mechanisms	I-MED
underlying	O
alcohol-related	B-MED
disinhibition	I-MED
.	O
	
although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	B-MED
levels	I-MED
of	O
alcohol	B-MED
use	I-MED
during	O
emerging	O
adulthood	B-MED
have	O
potential	O
sex-specific	O
causal	B-MED
effects	I-MED
on	O
response	B-MED
inhibition	I-MED
eeg	B-MED
dynamics	I-MED
,	O
neutrophil	B-MED
and	O
monocyte	B-MED
function	B-MED
in	O
patients	B-MED
with	O
chronic	B-MED
hepatitis	I-MED
c	I-MED
undergoing	O
antiviral	B-MED
therapy	I-MED
with	O
regimens	B-MED
containing	O
protease	B-MED
inhibitors	I-MED
with	O
and	O
without	O
interferon	B-MED
real-life	B-MED
data	I-MED
showed	O
an	O
increased	B-MED
incidence	B-MED
of	O
bacterial	B-MED
infections	I-MED
in	O
patients	B-MED
with	O
advanced	O
liver	B-MED
disease	I-MED
receiving	B-MED
a	O
protease	B-MED
inhibitor	I-MED
pi	B-MED
antiviral	B-MED
regimen	I-MED
against	O
hepatitis	B-MED
c	I-MED
hcv	B-MED
.	O
	
however	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O
	
we	O
hypothesized	O
that	O
pis	B-MED
might	O
impair	O
innate	B-MED
immune	I-MED
responses	I-MED
through	O
the	O
inhibition	B-MED
of	I-MED
proteases	I-MED
participating	O
in	O
the	O
anti-bacterial	B-MED
functions	I-MED
of	O
neutrophils	B-MED
and	O
monocytes	B-MED
.	O
	
the	O
aims	O
of	O
the	O
study	B-MED
were	O
to	O
assess	B-MED
phagocytic	B-MED
and	I-MED
oxidative	I-MED
burst	I-MED
capacity	B-MED
in	O
neutrophils	B-MED
and	O
monocytes	B-MED
obtained	O
from	O
patients	B-MED
receiving	B-MED
a	O
pi	B-MED
containing-	O
antiviral	B-MED
regimen	I-MED
,	O
and	O
to	O
determine	O
cytokine	B-MED
secretion	I-MED
after	O
neutrophil	B-MED
stimulation	B-MED
with	O
flagellin	B-MED
.	O
	
forty	O
patients	B-MED
with	O
chronic	B-MED
hcv	I-MED
80%	O
with	O
cirrhosis	B-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
,	O
28	O
received	B-MED
triple	B-MED
therapy	I-MED
group	B-MED
a	I-MED
with	O
pegylated-interferon	B-MED
and	O
ribavirin	B-MED
for	O
4	O
weeks	B-MED
followed	O
by	O
the	O
addition	O
of	O
a	O
pi	B-MED
telaprevir	B-MED
,	O
boceprevir	B-MED
or	O
simeprevir	B-MED
,	O
and	O
12	O
patients	B-MED
received	B-MED
an	O
interferon	B-MED
-free	O
regimen	O
group	O
b	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O
	
phagocytosis	O
and	O
oxidative	O
burst	O
capacity	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O
	
in	O
neutrophils	O
from	O
group	O
a	O
patients	O
,	O
oxidative	O
burst	O
rate	O
and	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
.	O
	
pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	O
.	O
	
no	O
differences	O
were	O
observed	O
after	O
the	O
introduction	O
of	O
the	O
pi	O
.	O
	
the	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
p	O
=	O
0.042	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
p	O
=	O
0.037	O
in	O
patients	O
from	O
group	O
a	O
.	O
	
none	O
of	O
these	O
findings	O
were	O
observed	O
in	O
group	O
b	O
patients	O
.	O
	
cytokine	O
secretion	O
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O
	
in	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	B-MED
rather	O
than	O
the	O
pi	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
hcv	O
-related	O
advanced	O
liver	O
fibrosis	I-MED
child	B-MED
death	I-MED
and	O
maternal	B-MED
psychosis-like	B-MED
experiences	I-MED
in	O
44	O
low-	B-MED
and	O
middle-income	B-MED
countries	B-MED
the	O
role	O
of	O
depression	B-MED
studies	O
on	O
the	O
effect	O
of	O
child	B-MED
death	I-MED
on	O
the	O
mental	B-MED
wellbeing	I-MED
of	O
women	B-MED
in	O
low-	B-MED
and	O
middle-income	B-MED
countries	B-MED
lmics	B-MED
are	O
scarce	O
despite	O
the	O
high	O
child	B-MED
mortality	I-MED
rates	O
.	O
	
thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	B-MED
between	O
child	B-MED
death	I-MED
and	O
psychosis-like	B-MED
experiences	I-MED
ples	B-MED
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-MED
in	O
this	O
association	B-MED
.	O
	
data	B-MED
from	O
44	O
lmics	B-MED
which	O
participated	O
in	O
the	O
world	B-MED
health	I-MED
survey	I-MED
whs	B-MED
were	O
analyzed	O
.	O
	
a	O
total	O
of	O
59	O
women	B-MED
who	O
ever	O
gave	O
birth	B-MED
,	O
aged	O
18-49	O
years	B-MED
,	O
without	O
a	O
self-reported	B-MED
lifetime	B-MED
psychosis	B-MED
diagnosis	I-MED
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
	
the	O
world	B-MED
mental	I-MED
health	I-MED
survey	I-MED
version	O
of	O
the	O
composite	B-MED
international	I-MED
diagnostic	I-MED
interview	I-MED
cidi	B-MED
was	O
used	O
to	O
establish	O
the	O
diagnosis	B-MED
of	O
past	O
12-	O
month	B-MED
dsm-iv	B-MED
depression	B-MED
,	O
and	O
assess	O
four	O
positive	B-MED
psychotic	I-MED
symptoms	I-MED
.	O
	
depression	B-MED
was	O
defined	O
as	O
self-reported	B-MED
lifetime	B-MED
depression	B-MED
diagnosis	I-MED
and/or	O
past	O
12-	O
month	B-MED
depression	B-MED
.	O
	
multivariable	O
logistic	B-MED
regression	I-MED
analyses	I-MED
were	O
performed	O
.	O
	
after	O
adjustment	O
for	O
potential	B-MED
confounders	I-MED
,	O
women	B-MED
who	O
experienced	O
child	B-MED
death	I-MED
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
ples	B-MED
when	O
unadjusted	O
for	O
depression	B-MED
or	B-MED
1.20	O
p<0	O
and	O
depression	B-MED
or	B-MED
=1	O
95%	O
ci	B-MED
=1	O
.	O
	
when	O
adjusted	O
for	O
depression	B-MED
,	O
only	O
delusion	B-MED
of	I-MED
control	I-MED
was	O
strongly	O
associated	B-MED
with	I-MED
child	B-MED
death	I-MED
or	B-MED
=1	O
95%	O
ci	B-MED
=1	O
.	O
	
child	B-MED
death	I-MED
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	B-MED
wellbeing	I-MED
among	O
women	B-MED
in	O
lmics	B-MED
.	O
	
given	O
the	O
known	O
adverse	B-MED
health	I-MED
outcomes	I-MED
associated	B-MED
with	I-MED
ples	B-MED
and	O
depression	B-MED
,	O
as	O
well	O
as	O
the	O
co-occurrence	O
of	O
these	O
symptoms	B-MED
,	O
mental	B-MED
health	I-MED
care	I-MED
may	O
be	O
particularly	O
important	O
for	O
mothers	B-MED
who	O
have	O
experienced	O
child	B-MED
loss	I-MED
in	O
prednisolone	B-MED
is	O
associated	B-MED
with	I-MED
a	O
worse	B-MED
lipid	I-MED
profile	I-MED
than	O
hydrocortisone	B-MED
in	O
patients	B-MED
with	O
adrenal	B-MED
insufficiency	I-MED
prednisolone	B-MED
is	O
used	O
as	O
glucocorticoid	B-MED
replacement	B-MED
therapy	I-MED
for	O
adrenal	B-MED
insufficiency	I-MED
ai	B-MED
.	O
	
recent	O
data	B-MED
indicate	O
that	O
its	O
use	O
in	O
ai	B-MED
is	O
associated	B-MED
with	I-MED
low	O
bone	B-MED
mineral	I-MED
density	I-MED
.	O
	
data	B-MED
on	O
risk	B-MED
factors	I-MED
for	O
cardiovascular	B-MED
disease	I-MED
in	O
patients	B-MED
with	O
ai	B-MED
treated	B-MED
with	O
prednisolone	B-MED
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-MED
of	O
excess	O
mortality	B-MED
.	O
	
we	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real-world	O
data	B-MED
from	O
the	O
european	B-MED
adrenal	I-MED
insufficiency	I-MED
registry	I-MED
eu-air	B-MED
.	O
	
eu-air	B-MED
,	O
comprising	O
of	O
19	O
centres	B-MED
across	O
germany	B-MED
,	O
the	O
netherlands	B-MED
,	O
sweden	B-MED
and	O
the	O
uk	B-MED
,	O
commenced	O
enrolling	O
patients	B-MED
with	O
ai	B-MED
in	O
august	O
2012	O
.	O
	
patients	B-MED
receiving	O
prednisolone	B-MED
3-6	O
mg/day	O
,	O
n	O
=	O
50	O
or	O
hydrocortisone	B-MED
15-30	O
mg/day	O
,	O
n	O
=	O
909	O
were	O
identified	B-MED
and	O
grouped	B-MED
at	O
a	O
ratio	O
of	O
1	O
prednisolone	B-MED
hydrocortisone	B-MED
by	O
matching	O
for	O
gender	B-MED
,	O
age	B-MED
,	O
duration	B-MED
and	O
type	B-MED
of	I-MED
disease	I-MED
.	O
	
data	B-MED
from	O
baseline	B-MED
and	O
follow-up	B-MED
visits	B-MED
were	O
analysed	O
.	O
	
data	B-MED
from	O
patients	B-MED
with	O
congenital	B-MED
adrenal	I-MED
hyperplasia	I-MED
were	O
excluded	B-MED
.	O
	
significantly	O
higher	O
mean	B-MED
s.d	I-MED
.	O
	
total	I-MED
6.3	O
1.6	O
vs	O
5.4	O
1.1	O
mmol/l	O
p	O
=	O
0.003	O
and	O
low-density	B-MED
lipoprotein	I-MED
ldl	I-MED
cholesterol	I-MED
levels	O
3.9	O
1.4	O
vs	O
3.2	O
1.0	O
mmol/l	O
p	O
=	O
0.013	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow-up	O
p	O
=	O
0.005	O
and	O
p	O
=	O
0.006	O
,	O
respectively	O
.	O
	
hba1c	O
,	O
high-density	O
lipoprotein	O
and	O
triglyceride	O
levels	O
,	O
body	O
mass	O
index	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
waist	O
circumference	O
were	O
not	O
significantly	O
different	O
.	O
	
this	O
is	O
the	O
first	O
matched	O
analysis	O
of	O
its	O
kind	O
.	O
	
significantly	O
higher	O
ldl	B-MED
levels	B-MED
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
the	O
former	O
group	B-MED
oxytocin	B-MED
reduces	B-MED
face	B-MED
processing	B-MED
time	B-MED
but	O
leaves	B-MED
recognition	B-MED
accuracy	B-MED
and	O
eye	B-MED
-	O
gaze	B-MED
unaffected	B-MED
previous	B-MED
studies	B-MED
have	O
found	O
that	O
oxytocin	B-MED
oxt	B-MED
can	O
improve	B-MED
the	O
recognition	B-MED
of	O
emotional	B-MED
facial	B-MED
expressions	I-MED
it	O
has	O
been	O
proposed	B-MED
that	O
this	O
effect	B-MED
is	O
mediated	B-MED
by	O
an	O
increase	B-MED
in	O
attention	B-MED
to	O
the	O
eye-region	B-MED
of	O
faces	B-MED
.	O
	
nevertheless	O
,	O
evidence	B-MED
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	B-MED
,	O
and	O
few	B-MED
studies	B-MED
have	O
directly	B-MED
tested	B-MED
the	O
effect	B-MED
of	O
oxytocin	B-MED
on	O
emotion	B-MED
recognition	B-MED
via	O
altered	B-MED
eye	B-MED
-	O
gaze	B-MED
methods	B-MED
in	O
a	O
double-blind	B-MED
,	O
within	B-MED
-	O
subjects	B-MED
,	O
randomized	B-MED
control	I-MED
experiment	I-MED
,	O
40	O
healthy	B-MED
male	B-MED
participants	I-MED
received	B-MED
24	O
iu	B-MED
intranasal	B-MED
oxt	B-MED
and	O
placebo	B-MED
in	O
two	O
identical	B-MED
experimental	B-MED
sessions	B-MED
separated	B-MED
by	O
a	O
2-	O
week	B-MED
interval	B-MED
.	O
	
visual	B-MED
attention	I-MED
to	O
the	O
eye-region	B-MED
was	O
assessed	B-MED
on	O
both	O
occasions	O
while	O
participants	B-MED
completed	B-MED
a	O
static	B-MED
facial	B-MED
emotion	B-MED
recognition	B-MED
task	B-MED
using	O
medium	B-MED
intensity	I-MED
facial	B-MED
expressions	I-MED
.	O
	
although	O
oxt	B-MED
had	O
no	B-MED
effect	I-MED
on	O
emotion	B-MED
recognition	B-MED
accuracy	B-MED
,	O
recognition	B-MED
performance	B-MED
was	O
improved	B-MED
because	O
face	B-MED
processing	B-MED
was	O
faster	B-MED
across	O
emotions	B-MED
under	O
the	O
influence	B-MED
of	O
oxt	B-MED
.	O
	
this	O
effect	B-MED
was	O
marginally	B-MED
significant	B-MED
p<	O
.	O
	
consistent	B-MED
with	I-MED
a	O
previous	B-MED
study	B-MED
using	O
dynamic	B-MED
stimuli	I-MED
,	O
oxt	B-MED
had	O
no	B-MED
effect	I-MED
on	O
eye	B-MED
-	O
gaze	B-MED
patterns	B-MED
when	O
viewing	B-MED
static	B-MED
emotional	B-MED
faces	B-MED
and	O
this	O
was	O
not	O
related	O
to	O
recognition	B-MED
accuracy	B-MED
or	O
face	B-MED
processing	B-MED
time	B-MED
.	O
	
these	O
findings	B-MED
suggest	B-MED
that	O
oxt	B-MED
-	O
induced	B-MED
enhanced	B-MED
facial	B-MED
emotion	B-MED
recognition	B-MED
is	O
not	O
necessarily	O
mediated	B-MED
by	O
an	O
increase	B-MED
in	O
attention	B-MED
to	O
the	O
eye-region	B-MED
of	O
faces	B-MED
,	O
as	O
previously	B-MED
assumed	B-MED
.	O
	
we	O
discuss	O
several	B-MED
methodological	B-MED
issues	B-MED
which	O
may	O
explain	O
discrepant	B-MED
findings	I-MED
and	O
suggest	B-MED
the	O
effect	B-MED
of	O
oxt	B-MED
on	O
visual	B-MED
attention	I-MED
may	O
differ	O
depending	O
on	O
task	B-MED
requirements	B-MED
.	O
	
new	O
directions	O
for	O
psychiatric	B-MED
rehabilitation	I-MED
in	O
the	O
usa	B-MED
american	B-MED
researchers	B-MED
have	O
led	O
the	O
world	B-MED
in	O
developing	B-MED
,	O
evaluating	B-MED
,	O
and	O
disseminating	B-MED
evidence	B-MED
-based	O
psychiatric	B-MED
rehabilitation	I-MED
practices	B-MED
for	O
people	B-MED
with	O
serious	B-MED
mental	B-MED
illness	I-MED
.	O
	
paradoxically	O
,	O
however	O
,	O
the	O
usa	B-MED
lags	O
behind	O
most	O
industrialized	B-MED
nations	I-MED
in	O
providing	O
access	B-MED
to	O
high-quality	B-MED
mental	B-MED
health	I-MED
and	O
psychiatric	B-MED
services	I-MED
.	O
	
this	O
essay	B-MED
examines	O
several	O
evidence-based	B-MED
practices	I-MED
developed	O
in	O
the	O
usa	B-MED
,	O
the	O
spread	O
of	O
these	O
practices	B-MED
,	O
the	O
barriers	B-MED
to	O
ensuring	O
availability	B-MED
to	O
people	B-MED
who	O
could	O
benefit	B-MED
from	O
these	O
services	B-MED
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	B-MED
the	O
barriers	B-MED
.	O
	
factors	B-MED
influencing	O
the	O
growth	O
and	O
sustainment	B-MED
of	O
effective	B-MED
client	B-MED
-centred	O
practices	B-MED
include	O
the	O
availability	B-MED
of	O
adequate	B-MED
and	I-MED
stable	I-MED
funding	I-MED
,	O
committed	B-MED
leadership	I-MED
,	O
and	O
the	O
influence	B-MED
of	O
vested	O
interests	O
.	O
	
two	O
strategies	O
for	O
promoting	B-MED
the	O
spread	B-MED
and	O
sustainment	B-MED
of	O
well-implemented	B-MED
evidence-based	I-MED
practices	I-MED
are	O
the	O
adoption	B-MED
of	O
fidelity	B-MED
scales	I-MED
and	O
learning	B-MED
communities	B-MED
.	O
	
modifiable	B-MED
healthy	B-MED
lifestyle	I-MED
behaviors	I-MED
10-year	O
health	B-MED
outcomes	I-MED
from	O
a	O
health	B-MED
promotion	I-MED
program	I-MED
previous	O
studies	O
have	O
examined	O
the	O
impact	B-MED
of	I-MED
healthy	B-MED
lifestyle	I-MED
choices	I-MED
on	O
health-related	B-MED
outcomes	I-MED
however	O
,	O
given	O
their	O
fragmented	B-MED
,	O
often	O
cross-sectional	B-MED
nature	I-MED
,	O
assessing	B-MED
the	I-MED
relative	I-MED
impact	I-MED
of	O
daily	O
modifiable	B-MED
behaviors	B-MED
on	O
overall	O
long-term	B-MED
outcomes	B-MED
,	O
particularly	O
for	O
a	O
diverse	O
working	B-MED
adult	I-MED
population	I-MED
,	O
remains	B-MED
challenging	I-MED
.	O
	
relationships	O
between	O
ten	O
self-reported	B-MED
healthy	B-MED
lifestyle	I-MED
behaviors	I-MED
and	O
health	B-MED
outcomes	I-MED
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	B-MED
of	O
10	O
participants	B-MED
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	B-MED
workplace	B-MED
wellness	B-MED
program	I-MED
were	O
assessed	O
.	O
	
cox	B-MED
proportional-hazards	I-MED
models	I-MED
computed	B-MED
hazard	I-MED
ratios	I-MED
hrs	B-MED
for	O
lifestyle	B-MED
characteristics	I-MED
associated	O
with	O
time	B-MED
to	O
one	O
of	O
seven	O
self-reported	B-MED
chronic	B-MED
diseases	I-MED
or	O
death	B-MED
.	O
	
data	B-MED
were	I-MED
collected	I-MED
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016	O
.	O
	
behaviors	B-MED
that	O
most	O
significantly	O
affected	O
future	B-MED
outcomes	I-MED
were	O
low-fat	B-MED
diet	I-MED
,	O
aerobic	B-MED
exercise	I-MED
,	O
nonsmoking	B-MED
,	O
and	O
adequate	B-MED
sleep	I-MED
.	O
	
a	O
dose-response	B-MED
effect	I-MED
was	O
seen	O
between	O
dietary	B-MED
fat	I-MED
intake	I-MED
and	O
hypertension	B-MED
,	O
obesity	B-MED
,	O
diabetes	B-MED
,	O
heart	B-MED
disease	I-MED
,	O
and	O
hypercholesterolemia	B-MED
.	O
	
after	O
dietary	B-MED
fat	I-MED
intake	I-MED
,	O
aerobic	B-MED
exercise	I-MED
was	O
the	O
next	O
most	O
significant	O
behavior	B-MED
associated	O
with	O
development	B-MED
of	I-MED
outcomes	I-MED
.	O
	
compared	O
with	O
sedentary	B-MED
participants	B-MED
,	O
those	O
who	O
exercised	B-MED
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new-onset	B-MED
diabetes	I-MED
hr	B-MED
=0	O
,	O
95%	O
ci	B-MED
=0	O
,	O
0.48	O
heart	B-MED
disease	I-MED
hr	B-MED
=0	O
,	O
95%	O
ci	B-MED
=0	O
,	O
0.80	O
and	O
hypercholesterolemia	B-MED
hr	B-MED
=0	O
,	O
95%	O
ci	B-MED
=0	O
,	O
0.74	O
.	O
	
low-fat	B-MED
diet	I-MED
and	O
adequate	B-MED
sleep	I-MED
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy	B-MED
behaviors	I-MED
,	O
such	O
as	O
eating	B-MED
a	I-MED
daily	I-MED
breakfast	I-MED
.	O
	
modifiable	B-MED
lifestyle	B-MED
behaviors	I-MED
targeted	O
in	O
health	B-MED
promotion	I-MED
programs	I-MED
should	O
be	O
prioritized	O
in	O
an	O
evidence-based	B-MED
manner	I-MED
.	O
	
top	O
priorities	O
for	O
workplace	B-MED
health	B-MED
promotion	I-MED
should	O
include	O
low-fat	B-MED
diet	I-MED
,	O
aerobic	B-MED
exercise	I-MED
,	O
nonsmoking	B-MED
,	O
and	O
adequate	B-MED
sleep	I-MED
.	O
	
diazoxide	B-MED
prevents	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
and	O
mitochondrial	B-MED
damage	I-MED
,	O
leading	O
to	O
anti-hypertrophic	B-MED
effects	I-MED
pathological	B-MED
cardiac	B-MED
hypertrophy	I-MED
is	O
characterized	B-MED
by	O
wall	B-MED
thickening	B-MED
or	O
chamber	B-MED
enlargement	B-MED
of	O
the	O
heart	B-MED
in	O
response	O
to	O
pressure	B-MED
or	O
volume	B-MED
overload	O
,	O
respectively	O
.	O
	
this	O
condition	B-MED
will	O
,	O
initially	O
,	O
improve	B-MED
the	O
organ	B-MED
contractile	B-MED
function	I-MED
,	O
but	O
if	O
sustained	B-MED
will	O
render	O
dysfunctional	B-MED
mitochondria	B-MED
and	O
oxidative	B-MED
stress	I-MED
.	O
	
mitochondrial	B-MED
atp-sensitive	I-MED
k	I-MED
channels	I-MED
mitokatp	B-MED
modulate	B-MED
the	O
redox	B-MED
status	I-MED
of	O
the	O
cell	B-MED
and	O
protect	B-MED
against	O
several	O
cardiac	B-MED
insults	B-MED
.	O
	
here	O
,	O
we	O
tested	O
the	O
hypothesis	B-MED
that	O
mitokatp	B-MED
opening	B-MED
using	O
diazoxide	B-MED
will	O
avoid	O
isoproterenol	B-MED
-	O
induced	B-MED
cardiac	B-MED
hypertrophy	I-MED
in	B-MED
vivo	I-MED
by	O
decreasing	O
reactive	B-MED
oxygen	I-MED
species	I-MED
ros	B-MED
production	O
and	O
mitochondrial	B-MED
ca	B-MED
-	O
induced	B-MED
swelling	B-MED
.	O
	
to	O
induce	B-MED
cardiac	B-MED
hypertrophy	I-MED
,	O
swiss	B-MED
mice	I-MED
were	O
treated	B-MED
intraperitoneally	B-MED
with	O
isoproterenol	B-MED
30	O
mg/kg/	O
day	B-MED
for	O
8	O
days	B-MED
.	O
	
diazoxide	B-MED
5	O
mg/kg/	O
day	B-MED
was	O
used	O
to	O
open	O
mitokatp	B-MED
and	O
5-hydroxydecanoate	B-MED
5	O
mg/kg/	O
day	B-MED
was	O
administrated	O
as	O
a	O
mitokatp	B-MED
blocker	B-MED
.	O
	
isoproterenol	B-MED
-	O
treated	B-MED
mice	B-MED
had	O
elevated	B-MED
heart	B-MED
weight	B-MED
/	O
tibia	B-MED
length	B-MED
ratios	B-MED
and	O
increased	B-MED
myocyte	B-MED
cross-sectional	B-MED
areas	I-MED
.	O
	
additionally	O
,	O
hypertrophic	B-MED
hearts	B-MED
produced	O
higher	B-MED
levels	B-MED
of	O
h2o2	B-MED
and	O
had	O
lower	O
glutathione	B-MED
peroxidase	I-MED
activity	I-MED
.	O
	
in	O
contrast	O
,	O
mitokatp	B-MED
opening	B-MED
with	O
diazoxide	B-MED
blocked	B-MED
all	O
isoproterenol	B-MED
effects	B-MED
in	O
a	O
manner	O
reversed	B-MED
by	O
5-hydroxydecanoate	B-MED
.	O
	
isolated	B-MED
mitochondria	B-MED
from	O
isoproterenol	B-MED
-	O
induced	B-MED
hypertrophic	B-MED
hearts	B-MED
had	O
increased	B-MED
susceptibility	B-MED
to	O
ca	B-MED
-	O
induced	B-MED
swelling	B-MED
secondary	O
to	O
mitochondrial	B-MED
permeability	I-MED
transition	I-MED
pore	I-MED
opening	B-MED
.	O
	
mitokatp	B-MED
opening	B-MED
was	O
accompanied	O
by	O
lower	O
ca	B-MED
-	O
induced	B-MED
mitochondrial	B-MED
swelling	I-MED
,	O
an	O
effect	B-MED
blocked	B-MED
by	O
5-hydroxydecanoate	B-MED
.	O
	
our	O
results	O
suggest	O
that	O
mitokatp	B-MED
opening	B-MED
negatively	B-MED
regulates	B-MED
cardiac	B-MED
hypertrophy	I-MED
by	O
avoiding	O
oxidative	B-MED
impairment	B-MED
and	O
mitochondrial	B-MED
damage	I-MED
.	O
	
anticholinergic	B-MED
premedication	B-MED
to	O
prevent	O
bradycardia	B-MED
in	O
combined	O
spinal	B-MED
anesthesia	I-MED
and	O
dexmedetomidine	B-MED
sedation	B-MED
a	O
randomized	B-MED
,	O
double-blind	B-MED
,	O
placebo-controlled	B-MED
study	I-MED
when	O
dexmedetomidine	B-MED
is	O
used	O
in	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
,	O
high	O
incidence	B-MED
of	O
bradycardia	B-MED
in	O
response	O
to	O
parasympathetic	B-MED
activation	B-MED
is	O
reported	O
.	O
	
therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	B-MED
of	O
atropine	B-MED
premedication	B-MED
for	O
preventing	B-MED
the	O
incidence	B-MED
of	O
bradycardia	B-MED
and	O
the	O
hemodynamic	B-MED
effect	I-MED
on	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
with	O
sedation	B-MED
by	O
dexmedetomidine	B-MED
.	O
	
randomized	B-MED
,	O
double-blind	B-MED
,	O
placebo-controlled	B-MED
study	I-MED
.	O
	
operating	B-MED
room	I-MED
.	O
	
one	O
hundred	O
fourteen	O
patients	B-MED
age	O
range	O
,	O
2-65	O
years	B-MED
american	B-MED
society	I-MED
of	I-MED
anesthesiology	I-MED
class	I-MED
i-ii	I-MED
participated	O
in	O
this	O
study	B-MED
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	B-MED
anesthesia	I-MED
.	O
	
the	O
patients	B-MED
were	O
divided	O
into	O
2	O
groups	B-MED
group	B-MED
a	I-MED
and	O
group	B-MED
c	I-MED
.	O
	
after	O
performing	O
spinal	B-MED
anesthesia	I-MED
,	O
dexmedetomidine	B-MED
was	O
infused	B-MED
at	O
a	O
loading	B-MED
dose	I-MED
of	O
0.6	O
μg/kg	O
for	O
10	O
minutes	B-MED
,	O
followed	O
by	O
an	O
infusion	B-MED
at	O
0.25	O
μg/	O
h	O
.	O
	
simultaneously	O
with	O
the	O
loading	B-MED
dose	I-MED
of	O
dexmedetomidine	B-MED
,	O
patients	B-MED
in	O
group	B-MED
a	I-MED
received	O
an	O
intravenous	B-MED
bolus	I-MED
of	O
0.5	O
mg	O
atropine	B-MED
,	O
whereas	O
patients	B-MED
in	O
group	B-MED
c	I-MED
received	O
an	O
intravenous	B-MED
normal	I-MED
saline	I-MED
bolus	B-MED
.	O
	
data	B-MED
on	O
administration	B-MED
of	O
atropine	B-MED
and	O
ephedrine	B-MED
were	O
collected	O
.	O
	
hemodynamic	B-MED
data	B-MED
including	O
heart	B-MED
rate	I-MED
,	O
systolic	B-MED
blood	I-MED
pressure	I-MED
,	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
dbp	B-MED
,	O
and	O
mean	B-MED
blood	I-MED
pressure	I-MED
mbp	B-MED
were	O
also	O
recorded	O
.	O
	
the	O
incidence	B-MED
of	O
bradycardia	B-MED
requiring	O
atropine	B-MED
treatment	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
group	B-MED
c	I-MED
than	O
group	B-MED
a	I-MED
p=	O
.	O
	
however	O
,	O
the	O
incidence	B-MED
of	O
hypotension	B-MED
needing	O
ephedrine	B-MED
treatment	B-MED
showed	O
no	B-MED
significant	I-MED
difference	I-MED
between	O
the	O
2	O
groups	B-MED
p=	O
.	O
	
systolic	B-MED
blood	I-MED
pressure	I-MED
and	O
heart	B-MED
rate	I-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
between	O
the	O
2	O
groups	B-MED
p=	O
and	O
464	O
,	O
respectively	O
.	O
	
however	O
,	O
group	B-MED
a	I-MED
showed	O
significant	O
increases	B-MED
in	O
dbp	B-MED
and	O
mbp	B-MED
,	O
and	O
group	B-MED
c	I-MED
did	O
not	O
p=	O
and	O
008	O
,	O
respectively	O
.	O
	
prophylactic	B-MED
atropine	B-MED
reduces	O
the	O
incidence	B-MED
of	O
bradycardia	B-MED
in	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
with	O
dexmedetomidine	B-MED
sedation	B-MED
.	O
	
however	O
,	O
dbp	B-MED
and	O
mbp	B-MED
showed	O
significant	O
increases	B-MED
in	O
patients	B-MED
when	O
prophylactic	B-MED
atropine	B-MED
was	O
administrated	B-MED
.	O
	
therefore	O
,	O
atropine	B-MED
premedication	B-MED
should	O
be	O
administered	B-MED
downregulation	B-MED
of	O
endothelial	B-MED
transient	I-MED
receptor	I-MED
potential	I-MED
vanilloid	I-MED
type	I-MED
4	I-MED
channel	I-MED
and	O
small-conductance	B-MED
of	I-MED
ca2+-activated	I-MED
k+	I-MED
channels	I-MED
underpins	O
impaired	B-MED
endothelium-dependent	B-MED
hyperpolarization	I-MED
in	O
hypertension	B-MED
endothelium-dependent	B-MED
hyperpolarization	I-MED
edh	B-MED
responses	B-MED
are	O
impaired	B-MED
in	O
hypertension	B-MED
,	O
but	O
the	O
underlying	O
mechanisms	B-MED
have	O
not	O
yet	O
been	O
determined	O
.	O
	
the	O
activation	B-MED
of	O
small-	B-MED
and	O
intermediate-conductance	B-MED
of	I-MED
ca	I-MED
k	I-MED
channels	I-MED
skca	B-MED
and	O
ikca	B-MED
underpins	O
edh	B-MED
-mediated	O
responses	B-MED
.	O
	
it	O
was	O
recently	O
reported	B-MED
that	O
ca	B-MED
influx	I-MED
through	O
endothelial	B-MED
transient	I-MED
receptor	I-MED
potential	I-MED
vanilloid	I-MED
type	I-MED
4	I-MED
channel	I-MED
trpv4	B-MED
is	O
a	O
prerequisite	B-MED
for	O
the	O
activation	B-MED
of	O
skca	B-MED
/	O
ikca	B-MED
in	O
endothelial	B-MED
cells	I-MED
in	O
specific	O
beds	O
.	O
	
here	O
,	O
we	O
attempted	B-MED
to	O
determine	O
whether	O
the	O
impairment	B-MED
of	O
edh	B-MED
in	O
hypertension	B-MED
is	O
attributable	O
to	O
the	O
dysfunction	B-MED
of	O
trpv4	B-MED
and	O
s	B-MED
/	O
ikca	B-MED
,	O
using	O
isolated	O
superior	B-MED
mesenteric	I-MED
arteries	I-MED
of	O
20-week-old	O
stroke-prone	B-MED
spontaneously	I-MED
hypertensive	I-MED
rats	I-MED
shrsp	B-MED
and	O
age-matched	O
wistar-kyoto	B-MED
wky	I-MED
rats	I-MED
.	O
	
in	O
the	O
wky	B-MED
arteries	B-MED
,	O
edh	B-MED
-mediated	O
responses	B-MED
were	O
reduced	B-MED
by	O
a	O
combination	B-MED
of	O
skca	B-MED
/	O
ikca	B-MED
blockers	B-MED
apamin	B-MED
plus	O
tram-34	B-MED
1-	B-MED
and	O
by	O
the	O
blockade	B-MED
of	O
trpv4	B-MED
with	O
the	O
selective	O
antagonist	B-MED
rn-1734	B-MED
or	O
hc-067047	B-MED
.	O
	
in	O
the	O
shrsp	B-MED
arteries	B-MED
,	O
edh-mediated	B-MED
hyperpolarization	I-MED
and	O
relaxation	B-MED
were	O
significantly	B-MED
impaired	B-MED
when	O
compared	O
with	O
wky	B-MED
.	O
	
gsk1016790a	B-MED
,	O
a	O
selective	O
trpv4	B-MED
activator	B-MED
,	O
evoked	O
robust	O
hyperpolarization	B-MED
and	O
relaxation	B-MED
in	O
wky	B-MED
arteries	B-MED
.	O
	
in	O
contrast	O
,	O
in	O
shrsp	B-MED
arteries	B-MED
,	O
the	O
gsk1016790a	B-MED
-evoked	O
hyperpolarization	B-MED
was	O
small	O
and	O
relaxation	B-MED
was	O
absent	B-MED
.	O
	
hyperpolarization	B-MED
and	O
relaxation	B-MED
to	O
cyclohexyl-	B-MED
,	O
a	O
selective	O
skca	B-MED
activator	B-MED
,	O
were	O
marginally	B-MED
decreased	B-MED
in	O
shrsp	B-MED
arteries	B-MED
compared	O
with	O
wky	B-MED
arteries	B-MED
.	O
	
the	O
expression	B-MED
of	O
endothelial	B-MED
trpv4	I-MED
and	O
skca	B-MED
protein	O
was	O
significantly	B-MED
decreased	I-MED
in	O
the	O
shrsp	B-MED
mesenteric	B-MED
arteries	I-MED
compared	O
with	O
those	O
of	O
wky	B-MED
,	O
whereas	O
function	B-MED
and	O
expression	B-MED
of	O
ikca	B-MED
were	O
preserved	O
in	O
shrsp	B-MED
arteries	B-MED
.	O
	
these	O
findings	B-MED
suggest	O
that	O
edh	B-MED
-mediated	O
responses	B-MED
are	O
impaired	B-MED
in	O
superior	B-MED
mesenteric	I-MED
arteries	I-MED
of	O
shrsp	B-MED
because	O
of	O
a	O
reduction	B-MED
in	O
both	O
trpv4	B-MED
and	O
skca	B-MED
input	B-MED
to	O
bioavailability	B-MED
and	O
health	B-MED
risk	I-MED
assessment	I-MED
of	O
potentially	B-MED
toxic	B-MED
elements	I-MED
in	O
thriasio	B-MED
plain	I-MED
,	O
near	I-MED
athens	I-MED
,	O
greece	B-MED
elevated	O
concentrations	B-MED
of	O
potentially	B-MED
toxic	B-MED
elements	I-MED
ptes	B-MED
are	O
usually	O
found	O
in	O
areas	B-MED
of	I-MED
intense	I-MED
industrial	I-MED
activity	I-MED
.	O
	
thriasio	B-MED
plain	I-MED
is	O
a	O
plain	B-MED
near	I-MED
athens	I-MED
,	O
greece	B-MED
,	O
where	O
most	O
of	O
the	O
heavy	B-MED
industry	I-MED
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades	O
,	O
but	O
it	O
also	O
is	O
a	O
residential	B-MED
and	O
horticultural	B-MED
area	B-MED
.	O
	
we	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
ptes	B-MED
in	O
soils	B-MED
and	O
indigenous	O
plant	O
species	O
and	O
assessing	O
the	O
health	O
risk	O
associated	O
with	O
direct	O
soil	O
ingestion	O
.	O
	
samples	O
of	O
soils	B-MED
at	O
roadsides	O
and	O
growing	O
plants	O
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	O
.	O
	
concentrations	O
of	O
al	O
,	O
as	O
,	O
cd	O
,	O
co	O
,	O
cr	O
,	O
cu	O
,	O
fe	O
,	O
mn	O
,	O
mo	O
,	O
ni	O
,	O
pb	O
,	O
v	O
and	O
zn	O
were	O
measured	O
in	O
both	O
soils	O
as	O
pseudo-total	O
and	O
aerial	O
plant	O
tissues	O
.	O
	
we	O
found	O
that	O
as	O
,	O
cd	O
,	O
cr	O
,	O
cu	O
,	O
ni	O
,	O
pb	O
and	O
zn	O
were	O
higher	O
than	O
maximum	O
regulatory	O
limits	O
.	O
	
element	O
concentrations	O
in	O
plants	O
were	O
rather	O
lower	O
than	O
expected	O
,	O
probably	O
because	O
indigenous	B-MED
plants	O
have	O
developed	O
excluder	O
behaviour	O
over	O
time	O
.	O
	
copper	O
and	O
zn	O
soil	O
-to-	O
plant	B-MED
coefficients	O
were	O
highest	O
among	O
the	O
other	O
elements	O
for	O
cu	O
this	O
was	O
unexpected	O
,	O
and	O
probably	O
associated	O
with	O
recent	O
cu	O
-	O
releasing	O
industrial	O
activity	O
.	O
	
risk	O
assessment	O
analysis	O
indicated	O
that	O
as	O
was	O
the	O
element	O
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	O
risk	O
related	O
to	O
direct	O
soil	O
ingestion	O
,	O
followed	O
by	O
cr	O
,	O
pb	O
,	O
and	O
,	O
surprisingly	O
,	O
mn	O
.	O
	
we	O
concluded	O
that	O
in	O
a	O
multi	O
-	O
element	O
contamination	O
situation	O
,	O
elevated	O
risk	O
of	O
ptes	O
such	O
as	O
as	O
,	O
cr	O
and	O
pb	O
may	O
reduce	O
the	O
tolerance	O
limits	O
of	O
exposure	O
to	O
less-	O
toxic	O
elements	O
here	O
,	O
mn	B-MED
nutrients	B-MED
influence	O
the	O
thermal	B-MED
ecophysiology	I-MED
of	O
an	O
intertidal	B-MED
macroalga	B-MED
multiple	B-MED
stressors	I-MED
or	O
multiple	B-MED
drivers	I-MED
urbanization	B-MED
of	O
coastlines	B-MED
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	B-MED
from	O
the	O
terrestrial	B-MED
environment	I-MED
to	O
nearshore	B-MED
habitats	I-MED
.	O
	
while	O
such	O
nutrient	B-MED
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	B-MED
marine	B-MED
organisms	I-MED
due	O
to	O
increased	O
eutrophication	B-MED
and	O
subsequent	O
reduced	B-MED
oxygen	B-MED
,	O
they	O
could	O
also	O
have	O
positive	B-MED
effects	I-MED
i.e	O
,	O
increased	O
food	B-MED
availability	B-MED
on	O
species	B-MED
that	O
are	O
nitrogen-limited	B-MED
such	O
as	O
macroalgae	B-MED
.	O
	
nutrient	B-MED
enrichment	B-MED
in	O
this	O
environment	B-MED
thus	O
has	O
the	O
potential	B-MED
to	O
counteract	O
some	O
of	O
the	O
negative	B-MED
impacts	I-MED
of	O
increasing	B-MED
temperatures	B-MED
,	O
at	O
least	O
for	O
some	O
species	B-MED
.	O
	
characterizing	O
the	O
physiological	B-MED
response	I-MED
of	O
organisms	B-MED
to	O
simultaneous	B-MED
changes	B-MED
in	O
multiple	B-MED
drivers	I-MED
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	B-MED
climate	B-MED
change	I-MED
may	O
lead	O
to	O
ecological	B-MED
responses	B-MED
at	O
more	O
local	B-MED
levels	I-MED
.	O
	
we	O
evaluated	O
how	O
nutrient	B-MED
enrichment	B-MED
i.e	O
,	O
nitrogen	B-MED
availability	B-MED
affected	O
the	O
growth	B-MED
of	O
fucus	B-MED
vesiculosus	I-MED
,	O
a	O
foundational	O
macroalgal	B-MED
species	B-MED
in	O
the	O
north	B-MED
atlantic	I-MED
rocky	I-MED
intertidal	I-MED
zone	I-MED
,	O
and	O
found	O
that	O
nutrient	B-MED
-enriched	O
algal	B-MED
blades	I-MED
showed	O
a	O
significant	O
increase	O
in	O
tissue	B-MED
growth	I-MED
compared	O
to	O
individuals	B-MED
grown	O
under	O
ambient	B-MED
conditions	O
.	O
	
we	O
further	O
quantified	O
net	O
photosynthesis	B-MED
by	O
ambient	O
and	O
nutrient	B-MED
-enriched	O
tissues	B-MED
at	O
saturating	B-MED
irradiance	I-MED
over	O
a	O
range	O
of	O
temperature	B-MED
conditions	O
6-30	O
.	O
	
respiration	B-MED
was	O
unaffected	O
by	O
nutrient	B-MED
treatment	B-MED
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	B-MED
oxygen	B-MED
production	O
for	O
nutrient	B-MED
-enriched	O
tissue	B-MED
compared	O
to	O
ambient	B-MED
,	O
but	O
only	O
at	O
elevated	B-MED
18	O
temperatures	B-MED
.	O
	
this	O
study	B-MED
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	B-MED
showing	O
the	O
complexity	O
of	O
responses	B-MED
to	I-MED
changes	I-MED
in	O
multiple	B-MED
drivers	I-MED
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	B-MED
the	O
impacts	B-MED
of	O
global	B-MED
climate	B-MED
change	I-MED
within	O
the	O
context	O
of	O
more	O
local	O
environmental	B-MED
conditions	B-MED
.	O
	
a	O
trial	B-MED
to	O
determine	O
whether	O
septic	B-MED
shock	I-MED
-	O
reversal	B-MED
is	O
quicker	B-MED
in	O
pediatric	B-MED
patients	B-MED
randomized	B-MED
to	O
an	O
early	B-MED
goal-directed	B-MED
fluid-sparing	I-MED
strategy	I-MED
versus	O
usual	B-MED
care	I-MED
squeeze	B-MED
study	B-MED
protocol	I-MED
for	O
a	O
pilot	B-MED
randomized	I-MED
controlled	I-MED
trial	I-MED
current	B-MED
pediatric	B-MED
septic	B-MED
shock	I-MED
resuscitation	B-MED
guidelines	B-MED
from	O
the	O
american	B-MED
college	I-MED
of	I-MED
critical	I-MED
care	I-MED
medicine	I-MED
focus	O
on	O
the	O
early	B-MED
and	O
goal-directed	B-MED
administration	I-MED
of	O
intravascular	B-MED
fluid	B-MED
followed	O
by	O
vasoactive	B-MED
medication	B-MED
infusions	B-MED
for	O
persistent	B-MED
and	O
fluid-refractory	B-MED
shock	I-MED
.	O
	
however	O
,	O
accumulating	B-MED
adult	B-MED
and	O
pediatric	B-MED
data	B-MED
suggest	O
that	O
excessive	B-MED
fluid	B-MED
administration	I-MED
is	O
associated	O
with	O
worse	B-MED
patient	B-MED
outcomes	B-MED
and	O
even	O
increased	B-MED
risk	I-MED
of	I-MED
death	I-MED
.	O
	
the	O
optimal	B-MED
amount	I-MED
of	O
intravascular	B-MED
fluid	B-MED
required	O
in	O
early	B-MED
pediatric	B-MED
septic	B-MED
shock	I-MED
resuscitation	B-MED
prior	O
to	O
the	O
initiation	B-MED
of	O
vasoactive	B-MED
support	I-MED
remains	O
unanswered	O
.	O
	
the	O
squeeze	B-MED
pilot	I-MED
trial	I-MED
is	O
a	O
pragmatic	B-MED
,	O
two-arm	B-MED
,	O
parallel-group	B-MED
,	O
open-label	B-MED
,	O
prospective	B-MED
pilot	I-MED
randomized	I-MED
controlled	I-MED
trial	I-MED
.	O
	
participants	B-MED
are	O
children	B-MED
aged	B-MED
29	O
days	B-MED
to	O
under	O
18	O
years	B-MED
with	O
suspected	B-MED
or	O
confirmed	B-MED
septic	B-MED
shock	I-MED
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-MED
.	O
	
eligible	O
participants	B-MED
are	O
enrolled	B-MED
under	O
an	O
exception	B-MED
to	O
consent	B-MED
process	B-MED
and	O
randomly	B-MED
assigned	B-MED
via	O
concealed	B-MED
allocation	B-MED
to	O
either	O
the	O
usual	B-MED
care	I-MED
control	B-MED
or	O
fluid	B-MED
sparing	I-MED
intervention	I-MED
resuscitation	I-MED
strategy	I-MED
.	O
	
the	O
primary	B-MED
objective	B-MED
of	O
this	O
pilot	B-MED
trial	I-MED
is	O
to	O
determine	O
feasibility	B-MED
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-MED
participants	B-MED
and	O
to	O
adhere	O
to	O
the	O
study	B-MED
protocol	I-MED
.	O
	
the	O
primary	B-MED
outcome	I-MED
measure	I-MED
by	O
which	O
success	B-MED
will	O
be	O
determined	O
is	O
participant	B-MED
enrollment	B-MED
rate	B-MED
"""pass"""	O
defined	O
as	O
at	O
least	O
two	O
participants	B-MED
/	O
site	B-MED
/	O
month	B-MED
,	O
recognizing	O
that	O
enrollment	B-MED
may	O
be	O
slower	O
during	O
the	O
run-in	O
phase	O
.	O
	
secondary	O
objectives	B-MED
include	O
assessing	O
1	O
appropriateness	B-MED
of	O
eligibility	B-MED
criteria	I-MED
,	O
and	O
2	O
completeness	B-MED
of	O
clinical	B-MED
outcomes	I-MED
to	O
inform	O
the	O
endpoints	B-MED
for	O
the	O
planned	B-MED
multisite	B-MED
trial	I-MED
.	O
	
to	O
support	O
the	O
nested	B-MED
translational	I-MED
study	I-MED
,	O
squeeze-d	B-MED
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	B-MED
of	O
describing	O
cell-free	B-MED
dna	I-MED
a	O
procoagulant	B-MED
molecule	I-MED
with	O
prognostic	B-MED
utility	I-MED
in	O
blood	B-MED
samples	I-MED
obtained	O
from	O
children	B-MED
enrolled	B-MED
into	O
the	O
squeeze	B-MED
pilot	I-MED
trial	I-MED
at	O
baseline	B-MED
and	O
at	O
24	O
h	O
.	O
	
the	O
optimal	O
degree	B-MED
of	O
fluid	B-MED
resuscitation	B-MED
and	O
the	O
timing	B-MED
of	O
initiation	B-MED
of	O
vasoactive	B-MED
support	I-MED
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	B-MED
targets	B-MED
in	O
children	B-MED
with	O
septic	B-MED
shock	I-MED
remains	O
unanswered	O
.	O
	
no	O
prospective	B-MED
study	I-MED
to	O
date	B-MED
has	O
examined	O
this	O
important	O
question	B-MED
for	O
children	B-MED
in	O
developed	B-MED
countries	I-MED
including	O
canada	B-MED
.	O
	
recruitment	B-MED
for	O
the	O
squeeze	B-MED
pilot	I-MED
trial	I-MED
opened	B-MED
on	O
6	O
january	O
2014	O
.	O
	
findings	B-MED
will	O
inform	O
the	O
feasibility	B-MED
of	O
the	O
planned	B-MED
multicenter	B-MED
trial	I-MED
to	O
answer	O
our	O
overall	B-MED
research	B-MED
question	I-MED
.	O
	
entropy-driven	B-MED
reactions	I-MED
in	O
living	B-MED
cells	B-MED
for	O
assay	B-MED
let-7a	B-MED
microrna	I-MED
imaging	B-MED
of	O
microrna	B-MED
mirna	B-MED
in	O
living	B-MED
cells	B-MED
could	O
facilitate	O
the	O
monitoring	B-MED
of	O
the	O
expression	B-MED
and	O
distribution	B-MED
of	O
mirna	B-MED
and	O
research	B-MED
on	O
mirna	B-MED
-related	O
diseases	B-MED
.	O
	
given	O
the	O
low	O
expression	B-MED
levels	I-MED
and	O
even	O
down-regulation	B-MED
of	O
cellular	B-MED
mirna	B-MED
that	O
is	O
associated	B-MED
with	I-MED
some	O
diseases	B-MED
,	O
enzyme	B-MED
-	O
free	B-MED
amplification	B-MED
strategies	I-MED
are	O
imperative	O
for	O
intracellular	B-MED
mirna	B-MED
assay	B-MED
.	O
	
in	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy-driven	B-MED
reaction	I-MED
for	O
amplification	B-MED
assay	B-MED
mirna	B-MED
with	O
a	O
detection	B-MED
limit	I-MED
of	O
0.27	O
pm	O
.	O
	
the	O
resulting	O
signal	B-MED
amplification	B-MED
provides	O
excellent	O
recognition	O
and	O
signal	B-MED
enhancement	B-MED
of	O
specific	B-MED
mirna	B-MED
s	O
in	O
living	B-MED
cells	B-MED
.	O
	
this	O
method	O
supplies	O
accurate	B-MED
information	B-MED
regarding	O
cellular	B-MED
mirna	B-MED
-related	O
biological	B-MED
events	I-MED
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	B-MED
sensitive	I-MED
and	O
simultaneous	B-MED
imaging	B-MED
of	O
multiple	B-MED
low-level	O
biomarkers	B-MED
,	O
thereby	O
improving	O
the	O
accuracy	B-MED
of	O
early	B-MED
disease	I-MED
diagnosis	I-MED
.	O
	
iterative	B-MED
development	B-MED
and	O
evaluation	B-MED
of	O
a	O
pharmacogenomic	B-MED
-guided	O
clinical	B-MED
decision	I-MED
support	I-MED
system	I-MED
for	O
warfarin	B-MED
dosing	I-MED
pharmacogenomic	B-MED
-guided	O
dosing	B-MED
has	O
the	O
potential	O
to	O
improve	O
patient	B-MED
outcomes	O
but	O
its	O
implementation	B-MED
has	O
been	O
met	O
with	O
clinical	B-MED
challenges	B-MED
.	O
	
our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-MED
a	O
clinical	B-MED
decision	I-MED
support	I-MED
system	I-MED
cdss	B-MED
for	O
pharmacogenomic	B-MED
-guided	O
warfarin	B-MED
dosing	I-MED
designed	B-MED
for	O
physicians	B-MED
and	O
pharmacists	B-MED
.	O
	
twelve	O
physicians	B-MED
and	O
pharmacists	B-MED
completed	O
6	O
prescribing	B-MED
tasks	B-MED
using	O
simulated	B-MED
patient	I-MED
scenarios	B-MED
in	O
two	O
iterations	B-MED
development	B-MED
and	O
validation	B-MED
phases	B-MED
of	O
a	O
newly	O
developed	O
pharmacogenomic	B-MED
-driven	O
cdss	B-MED
prototype	B-MED
.	O
	
for	O
each	O
scenario	B-MED
,	O
usability	B-MED
was	O
measured	B-MED
via	O
efficiency	B-MED
,	O
recorded	B-MED
as	O
time	B-MED
to	I-MED
task	I-MED
completion	I-MED
,	O
and	O
participants	B-MED
'	O
perceived	B-MED
satisfaction	B-MED
which	O
were	O
compared	O
using	O
kruskal-wallis	B-MED
and	I-MED
mann	I-MED
whitney	I-MED
u	I-MED
tests	I-MED
,	O
respectively	O
.	O
	
debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-MED
analyzed	I-MED
.	O
	
usability	B-MED
findings	O
from	O
the	O
first	O
i.e	O
.	O
	
development	B-MED
iteration	B-MED
were	O
incorporated	O
into	O
the	O
cdss	B-MED
design	B-MED
for	O
the	O
second	B-MED
i.e	O
.	O
	
validation	B-MED
iteration	B-MED
.	O
	
during	O
the	O
cdss	B-MED
validation	B-MED
iteration	B-MED
,	O
participants	B-MED
took	O
more	O
time	B-MED
to	I-MED
complete	I-MED
tasks	I-MED
with	O
a	O
median	B-MED
iqr	O
of	O
183	O
124-247	O
seconds	B-MED
versus	O
101	O
73.5	O
seconds	B-MED
in	O
the	O
development	B-MED
iteration	B-MED
p=0	O
.	O
	
this	O
increase	B-MED
in	O
time	B-MED
on	I-MED
task	I-MED
was	O
due	O
to	O
the	O
increase	B-MED
in	O
time	B-MED
spent	O
in	O
the	O
cdss	B-MED
corresponding	O
to	O
several	O
design	B-MED
changes	O
.	O
	
efficiency	B-MED
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B-MED
and	O
physicians	B-MED
in	O
the	O
development	B-MED
iteration	B-MED
were	O
eliminated	O
in	O
the	O
validation	B-MED
iteration	B-MED
.	O
	
the	O
increased	B-MED
use	O
of	O
the	O
cdss	B-MED
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
cdss	B-MED
recommended	O
doses	B-MED
in	O
the	O
validation	B-MED
iteration	B-MED
4%	O
in	O
the	O
first	O
iteration	B-MED
vs	O
.	O
	
37.5	O
in	O
the	O
second	B-MED
iteration	B-MED
,	O
p<0	O
.	O
	
overall	O
satisfaction	B-MED
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-MED
but	O
the	O
qualitative	B-MED
analysis	I-MED
revealed	O
greater	O
trust	O
in	O
the	O
second	B-MED
prototype	B-MED
.	O
	
a	O
pharmacogenomic	B-MED
-guided	O
cdss	B-MED
has	O
been	O
developed	O
using	O
warfarin	B-MED
as	O
the	O
test	O
drug	B-MED
.	O
	
the	O
final	O
cdss	B-MED
prototype	B-MED
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	B-MED
the	O
time	B-MED
using	O
the	O
tool	B-MED
and	O
acceptance	O
of	O
the	O
recommended	O
doses	B-MED
.	O
	
this	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B-MED
into	O
cdss	B-MED
design	B-MED
for	O
clinical	B-MED
testing	I-MED
.	O
	
pedicle	B-MED
screw	I-MED
combined	B-MED
with	O
lateral	B-MED
mass	I-MED
screw	I-MED
fixation	B-MED
in	O
the	O
treatment	B-MED
of	O
basilar	B-MED
invagination	I-MED
and	O
congenital	B-MED
c2-c3	I-MED
fusion	I-MED
clinical	B-MED
evaluation	I-MED
of	O
a	O
surgical	B-MED
fixation	B-MED
technique	B-MED
featuring	O
combined	B-MED
use	O
of	O
pedicle	B-MED
screw	I-MED
and	O
lateral	B-MED
mass	I-MED
screw	I-MED
lms	B-MED
.	O
	
introduction	O
of	O
a	O
novel	O
technique	B-MED
for	O
the	O
treatment	B-MED
of	O
congenital	B-MED
c2-c3	I-MED
fusion	I-MED
and	O
basilar	B-MED
invagination	I-MED
bi	B-MED
.	O
	
posterior	B-MED
occipitocervical	B-MED
fixation	B-MED
using	O
c2	B-MED
pedicle	I-MED
screw	I-MED
was	O
widely	O
used	O
for	O
bi	B-MED
.	O
	
however	O
,	O
in	O
cases	B-MED
where	O
bi	B-MED
is	O
concurrent	B-MED
with	O
congenital	B-MED
c2-c3	I-MED
fusion	I-MED
,	O
the	O
c2	B-MED
pedicles	I-MED
tend	O
to	O
be	O
thinner	B-MED
than	O
that	O
in	O
normal	B-MED
population	B-MED
and	O
hence	O
more	O
likely	O
to	O
fail	B-MED
.	O
	
we	O
prompted	O
to	O
tackle	O
the	O
issue	B-MED
by	O
combining	B-MED
the	O
pedicle	B-MED
screw	I-MED
with	O
the	O
additional	O
use	O
of	O
lms	B-MED
in	O
attempt	O
to	O
strengthen	B-MED
the	O
fixation	B-MED
.	O
	
twenty-five	O
patients	B-MED
who	O
underwent	O
combined	B-MED
pedicle	B-MED
screw	I-MED
with	O
lms	B-MED
fixation	B-MED
were	O
retrospectively	B-MED
studied	I-MED
.	O
	
the	O
instrument	B-MED
position	B-MED
,	O
fusion	B-MED
status	B-MED
,	O
and	O
complications	B-MED
were	O
analyzed	B-MED
.	O
	
none	O
had	O
spinal	B-MED
cord	I-MED
or	O
vertebral	B-MED
artery	I-MED
injury	I-MED
.	O
	
the	O
average	O
follow-up	B-MED
time	B-MED
was	O
20	O
months	B-MED
.	O
	
solid	O
fusion	B-MED
was	O
achieved	O
in	O
23	O
patients	B-MED
92%	O
as	O
detected	O
radiologically	B-MED
.	O
	
two	O
cases	B-MED
suffered	O
from	O
recurred	B-MED
bi	B-MED
and	O
instrument	B-MED
failure	B-MED
but	O
eventually	O
achieved	O
solid	O
fusion	B-MED
between	O
the	O
occiput	B-MED
and	O
c2	B-MED
was	O
after	O
revision	B-MED
.	O
	
among	O
all	O
25	O
patients	B-MED
,	O
4	O
suffered	O
from	O
complications	B-MED
including	O
instrument	B-MED
s	O
failure	B-MED
,	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
,	O
and	O
intracranial	B-MED
infection	B-MED
.	O
	
the	O
clinical	B-MED
outcome	B-MED
indicates	O
that	O
the	O
technique	B-MED
is	O
reliable	O
for	O
the	O
treatment	B-MED
of	O
bi	B-MED
with	O
congenital	B-MED
c2-c3	I-MED
fusion	I-MED
.	O
	
co-occurrence	B-MED
and	O
clustering	B-MED
of	O
health	B-MED
conditions	B-MED
at	O
age	B-MED
11	O
cross-sectional	B-MED
findings	B-MED
from	O
the	O
millennium	B-MED
cohort	I-MED
study	I-MED
to	O
identify	O
patterns	O
of	O
co-occurrence	B-MED
and	O
clustering	B-MED
of	O
6	O
common	O
adverse	B-MED
health	B-MED
conditions	B-MED
in	O
11-	O
year	B-MED
-old	O
children	B-MED
and	O
explore	O
differences	B-MED
by	O
sociodemographic	B-MED
factors	I-MED
.	O
	
nationally	O
representative	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
	
children	B-MED
born	O
in	O
the	O
uk	B-MED
between	O
2000	O
and	O
2002	O
.	O
	
11	O
399	O
11-	O
year	B-MED
-old	O
singleton	B-MED
children	B-MED
for	O
whom	O
data	B-MED
on	O
all	O
6	O
health	B-MED
conditions	B-MED
and	O
sociodemographic	B-MED
information	I-MED
were	O
available	O
complete	B-MED
cases	B-MED
.	O
	
prevalence	B-MED
,	O
co-occurrence	B-MED
and	O
clustering	B-MED
of	O
6	O
common	O
health	B-MED
conditions	B-MED
wheeze	B-MED
eczema	B-MED
long-standing	B-MED
illness	I-MED
excluding	O
wheeze	B-MED
and	O
eczema	B-MED
injury	B-MED
socioemotional	B-MED
difficulties	I-MED
measured	O
using	O
strengths	B-MED
and	I-MED
difficulties	I-MED
questionnaire	I-MED
and	O
unfavourable	B-MED
weight	I-MED
thin	B-MED
/	O
overweight	B-MED
/	O
obese	B-MED
vs	O
normal	B-MED
.	O
	
42.4	O
of	O
children	B-MED
had	O
2	O
or	O
more	O
adverse	B-MED
health	B-MED
conditions	B-MED
co-occurrence	B-MED
.	O
	
co-occurrence	B-MED
was	O
more	O
common	O
in	O
boys	B-MED
and	O
children	B-MED
from	O
lower	O
income	B-MED
households	B-MED
.	O
	
latent	B-MED
class	I-MED
analysis	I-MED
identified	O
6	O
classes	B-MED
'	O
normative	B-MED
'	O
57.4	O
'	O
atopic	B-MED
burdened	B-MED
'	O
14.0	O
'	O
socioemotional	B-MED
burdened	I-MED
'	O
11.0	O
'	O
unfavourable	B-MED
weight	I-MED
/	O
injury	B-MED
'	O
7.7	O
'	O
eczema	B-MED
/	O
injury	B-MED
'	O
6.0	O
and	O
'	O
eczema	B-MED
/	O
unfavourable	B-MED
weight	I-MED
'	O
3.9	O
.	O
	
as	O
with	O
co-occurrence	B-MED
,	O
class	B-MED
membership	B-MED
differed	O
by	O
sociodemographic	B-MED
factors	I-MED
boys	B-MED
,	O
children	B-MED
of	O
mothers	B-MED
with	O
lower	O
educational	B-MED
attainment	I-MED
and	O
children	B-MED
from	O
lower	O
income	B-MED
households	B-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional	B-MED
burdened	I-MED
'	O
class	B-MED
.	O
	
children	B-MED
of	O
mothers	B-MED
with	O
higher	O
educational	B-MED
attainment	I-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	B-MED
'	O
and	O
'	O
eczema	B-MED
/	O
unfavourable	B-MED
weight	I-MED
'	O
classes	B-MED
.	O
	
co-occurrence	B-MED
of	O
adverse	B-MED
health	B-MED
conditions	B-MED
at	O
age	B-MED
11	O
is	O
common	O
and	O
is	O
associated	B-MED
with	I-MED
adverse	B-MED
socioeconomic	B-MED
circumstances	B-MED
.	O
	
holistic	B-MED
,	O
child	B-MED
focused	O
care	B-MED
,	O
particularly	O
in	O
boys	B-MED
and	O
those	O
in	O
lower	O
income	B-MED
groups	B-MED
,	O
may	O
help	O
to	O
prevent	B-MED
and	O
reduce	B-MED
co-occurrence	B-MED
in	O
later	B-MED
childhood	B-MED
and	O
genomic	B-MED
characterization	B-MED
of	O
a	O
wild-bird	B-MED
-	O
origin	B-MED
pigeon	B-MED
paramyxovirus	B-MED
type	I-MED
1	I-MED
ppmv-1	B-MED
first	O
isolated	B-MED
in	O
the	O
northwest	B-MED
region	I-MED
of	I-MED
china	I-MED
pigeon	B-MED
paramyxovirus	B-MED
type-1	I-MED
ppmv-1	B-MED
is	O
an	O
enzootic	B-MED
in	O
pigeon	B-MED
flocks	B-MED
and	O
causes	O
severe	B-MED
economic	B-MED
losses	I-MED
in	O
the	O
poultry	B-MED
industry	B-MED
in	O
many	O
countries	B-MED
.	O
	
a	O
ppmv-1	B-MED
isolate	B-MED
,	O
abbreviated	O
as	O
ppmv-1/ql-01/ch/15	B-MED
,	O
was	O
isolated	B-MED
from	O
a	O
great	O
spotted	O
woodpecker	B-MED
in	O
the	O
northwest	B-MED
region	I-MED
of	I-MED
china	I-MED
in	O
2015	O
.	O
	
the	O
complete	O
genome	B-MED
was	O
sequenced	B-MED
,	O
and	O
the	O
results	B-MED
showed	O
that	O
the	O
virus	B-MED
genome	B-MED
was	O
15	O
nt	O
in	O
length	B-MED
,	O
in	O
the	O
gene	B-MED
arrangement	I-MED
3'-np-p-m-f-hn-l-5'	I-MED
.	O
	
several	O
amino	B-MED
acid	I-MED
mutations	B-MED
were	O
identified	B-MED
in	O
the	O
functional	B-MED
domains	I-MED
of	O
the	O
f	B-MED
and	O
hn	B-MED
proteins	I-MED
.	O
	
the	O
pathogenicity	B-MED
index	I-MED
of	O
the	O
isolate	B-MED
was	O
evaluated	B-MED
,	O
and	O
the	O
mean	B-MED
death	I-MED
time	I-MED
mdt	B-MED
was	O
72	O
h	O
and	O
the	O
intracerebral	B-MED
pathogenicity	I-MED
index	I-MED
icpi	B-MED
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	B-MED
was	O
mesogenic	B-MED
.	O
	
sequencing	B-MED
results	B-MED
showed	O
that	O
it	O
had	O
a	O
virulent	B-MED
newcastle	B-MED
disease	I-MED
virus	I-MED
cleavage	B-MED
motif	I-MED
112	I-MED
at	O
the	O
fusion	B-MED
protein	I-MED
cleavage	B-MED
site	I-MED
.	O
	
morbidity	B-MED
and	O
mortality	B-MED
were	O
70%	O
and	O
50%	O
,	O
after	O
inoculation	B-MED
of	O
pigeons	B-MED
,	O
whereas	O
this	O
virus	B-MED
was	O
nonpathogenic	B-MED
in	O
chickens	B-MED
.	O
	
different	O
immune	B-MED
responses	I-MED
of	O
pigeons	B-MED
and	O
chickens	B-MED
were	O
induced	B-MED
in	B-MED
vivo	I-MED
,	O
which	O
led	O
to	O
different	O
hi	B-MED
serum	I-MED
antibody	I-MED
titers	I-MED
.	O
	
the	O
results	B-MED
of	O
phylogenetic	B-MED
and	O
evolutionary	B-MED
distance	I-MED
analysis	I-MED
showed	O
that	O
this	O
ppmv-1	B-MED
strain	B-MED
belonged	O
to	O
sub-genotype	B-MED
via	I-MED
in	O
class	B-MED
ii	I-MED
.	O
	
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-MED
and	O
analysis	B-MED
of	O
ppmv-1	B-MED
co-circulation	B-MED
among	O
wild	B-MED
birds	I-MED
and	O
domestic	B-MED
pigeon	I-MED
flocks	B-MED
in	O
china	B-MED
.	O
	
the	O
data	B-MED
from	O
this	O
study	B-MED
highlight	O
the	O
important	O
role	O
of	O
wild	B-MED
birds	I-MED
in	O
the	O
dissemination	B-MED
of	O
ppmv-1	B-MED
and	O
provide	O
useful	O
references	B-MED
for	O
improving	B-MED
our	O
understanding	O
of	O
the	O
distribution	B-MED
and	O
evolution	B-MED
of	O
ppmv-1	B-MED
in	O
memory	B-MED
consolidation	I-MED
effects	B-MED
on	O
memory	B-MED
stabilization	I-MED
and	O
item	B-MED
integration	I-MED
in	O
older	B-MED
adults	I-MED
this	O
study	B-MED
examined	O
the	O
differential	B-MED
effects	I-MED
of	O
aging	B-MED
on	O
consolidation	B-MED
processes	I-MED
that	O
strengthen	O
newly	O
acquired	O
memory	B-MED
traces	I-MED
in	O
veridical	O
form	O
memory	B-MED
stabilization	I-MED
versus	O
consolidation	B-MED
processes	I-MED
that	O
are	O
responsible	O
for	O
integrating	B-MED
these	O
memory	B-MED
traces	I-MED
into	O
an	O
existing	O
body	O
of	O
knowledge	B-MED
item	B-MED
integration	I-MED
.	O
	
older	B-MED
adults	I-MED
learned	B-MED
13	O
nonwords	B-MED
and	O
were	O
tested	O
on	O
their	O
memory	B-MED
for	O
the	O
nonwords	B-MED
,	O
and	O
on	O
whether	O
these	O
nonwords	B-MED
impacted	O
upon	O
processing	O
of	O
similar-sounding	O
english	B-MED
words	B-MED
immediately	O
and	O
24	O
hours	B-MED
later	O
.	O
	
participants	B-MED
accurately	O
recognized	O
the	O
nonwords	B-MED
immediately	O
,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	B-MED
and	O
recall	B-MED
.	O
	
in	O
comparison	O
,	O
the	O
nonwords	B-MED
impacted	O
upon	O
processing	B-MED
of	O
similar-sounding	B-MED
words	I-MED
only	O
in	O
the	O
delayed	B-MED
test	I-MED
.	O
	
together	O
,	O
these	O
findings	O
suggest	O
that	O
memory	B-MED
consolidation	I-MED
processes	I-MED
may	O
be	O
more	O
evident	O
in	O
item	B-MED
integration	I-MED
than	O
memory	B-MED
stabilization	I-MED
processes	I-MED
for	O
new	O
declarative	O
memories	B-MED
in	O
older	B-MED
adults	I-MED
.	O
	
mucosa	B-MED
-	O
associated	B-MED
biohydrogenating	B-MED
microbes	I-MED
protect	O
the	O
simulated	O
colon	B-MED
microbiome	B-MED
from	O
stress	B-MED
associated	B-MED
with	I-MED
high	B-MED
concentrations	I-MED
of	O
poly-unsaturated	B-MED
fat	I-MED
polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
pufas	B-MED
may	O
affect	O
colon	B-MED
microbiome	B-MED
homeostasis	B-MED
by	O
exerting	B-MED
specific	B-MED
antimicrobial	B-MED
effects	B-MED
and/or	O
interfering	O
with	O
mucosal	B-MED
biofilm	B-MED
formation	B-MED
at	O
the	O
gut	B-MED
mucosal	I-MED
interface	I-MED
.	O
	
we	O
used	O
standardized	B-MED
batch	I-MED
incubations	I-MED
and	O
the	O
mucosal-simulator	B-MED
of	I-MED
the	I-MED
human	I-MED
microbial	I-MED
intestinal	I-MED
ecosystem	I-MED
m-shime	B-MED
to	O
show	O
the	O
in	B-MED
vitro	I-MED
luminal	B-MED
and	O
mucosal	B-MED
effects	B-MED
of	I-MED
the	O
main	O
pufa	B-MED
in	O
the	O
western	B-MED
diet	I-MED
,	O
linoleic	B-MED
acid	I-MED
la	B-MED
.	O
	
high	B-MED
concentrations	I-MED
of	O
la	B-MED
were	O
found	O
to	O
decrease	B-MED
butyrate	B-MED
production	B-MED
and	O
faecalibacterium	B-MED
prausnitzii	I-MED
numbers	O
dependent	O
on	O
la	B-MED
biohydrogenation	B-MED
to	O
vaccenic	B-MED
acid	I-MED
va	B-MED
and	O
stearic	B-MED
acid	I-MED
sa	B-MED
.	O
	
in	O
faecal	B-MED
batch	B-MED
incubations	I-MED
,	O
la	B-MED
biohydrogenation	B-MED
and	O
butyrate	B-MED
production	B-MED
were	O
positively	B-MED
correlated	I-MED
and	O
sa	B-MED
did	O
not	O
inhibit	B-MED
butyrate	B-MED
production	B-MED
.	O
	
in	O
the	O
m-shime	B-MED
,	O
addition	O
of	O
a	O
mucosal	B-MED
environment	B-MED
stimulated	B-MED
biohydrogenation	B-MED
to	O
sa	B-MED
and	O
protected	O
f	B-MED
.	O
	
prausnitzii	I-MED
from	O
inhibition	B-MED
by	O
la	B-MED
.	O
	
this	O
was	O
probably	O
due	O
to	O
the	O
preference	B-MED
of	O
two	O
biohydrogenating	B-MED
genera	B-MED
roseburia	B-MED
and	O
pseudobutyrivibrio	B-MED
for	O
the	O
mucosal	B-MED
niche	O
.	O
	
co-culture	B-MED
batch	B-MED
incubations	I-MED
using	O
roseburia	B-MED
hominis	I-MED
and	O
f	B-MED
.	O
	
prausnitzii	I-MED
validated	B-MED
these	O
observations	B-MED
.	O
	
correlations	B-MED
networks	B-MED
further	O
uncovered	O
the	O
central	O
role	O
of	O
roseburia	B-MED
and	O
pseudobutyrivibrio	B-MED
in	O
protecting	O
luminal	B-MED
and	O
mucosal	B-MED
shime	I-MED
microbiota	I-MED
from	O
la	B-MED
-	O
induced	B-MED
stress	I-MED
.	O
	
our	O
results	B-MED
confirm	O
how	O
cross-shielding	B-MED
interactions	I-MED
provide	O
resilience	O
to	O
the	O
microbiome	B-MED
and	O
demonstrate	O
the	O
importance	B-MED
of	O
biohydrogenating	B-MED
,	O
mucosal	B-MED
bacteria	B-MED
for	O
recovery	B-MED
from	O
la	B-MED
stress	B-MED
.	O
	
genetic	B-MED
parameters	B-MED
for	O
tick	B-MED
count	I-MED
and	O
udder	B-MED
health	B-MED
in	O
commercial	B-MED
and	O
indigenous	B-MED
ewes	B-MED
in	O
south	B-MED
africa	I-MED
the	O
genetics	B-MED
of	O
tick	B-MED
infestation	I-MED
in	O
sheep	B-MED
need	O
study	O
,	O
as	O
host	B-MED
resistance	I-MED
often	O
forms	O
part	O
of	O
integrated	O
pest	B-MED
control	I-MED
programs	I-MED
.	O
	
repeated	O
udder	B-MED
health	B-MED
scores	I-MED
,	O
site-specific	B-MED
tick	B-MED
count	I-MED
,	O
mating	B-MED
weight	B-MED
and	O
reproduction	B-MED
records	B-MED
n=879-1204	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	B-MED
of	O
the	O
indigenous	B-MED
namaqua	B-MED
afrikaner	I-MED
na	B-MED
fat-tailed	B-MED
breed	I-MED
,	O
as	O
well	O
as	O
the	O
commercial	B-MED
dorper	B-MED
and	O
sa	B-MED
mutton	I-MED
merino	I-MED
samm	I-MED
breeds	I-MED
.	O
	
udder	B-MED
s	O
were	O
scored	B-MED
subjectively	O
on	O
a	O
1-5	O
scale	O
1	O
-	O
udder	B-MED
intact	B-MED
and	O
5	O
-	O
udder	B-MED
damaged	B-MED
severely	I-MED
and	O
ticks	B-MED
were	O
counted	B-MED
on	O
three	B-MED
locations	I-MED
.	O
	
the	O
body	B-MED
sites	I-MED
counted	B-MED
were	O
the	O
head	B-MED
and	I-MED
thoracic	I-MED
limb	I-MED
htltc	B-MED
,	O
udder-pelvic	B-MED
limb	I-MED
upltc	B-MED
and	O
perineum-breech-tail	B-MED
pbttc	B-MED
.	O
	
these	O
counts	B-MED
were	O
also	O
totaled	O
for	O
a	O
total	B-MED
tick	I-MED
count	I-MED
ttc	B-MED
.	O
	
reproduction	B-MED
traits	B-MED
were	O
number	O
of	O
lambs	B-MED
weaned	B-MED
per	O
ewe	B-MED
lambed	I-MED
and	O
total	O
weight	O
of	O
lamb	B-MED
weaned	I-MED
per	O
ewe	B-MED
lambed	I-MED
.	O
	
udder	B-MED
health	B-MED
scores	I-MED
of	O
na	B-MED
ewes	B-MED
were	O
lower	O
than	O
those	O
of	O
dorpers	B-MED
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
samm	B-MED
ewes	B-MED
.	O
	
na	B-MED
ewes	B-MED
had	O
lower	O
values	O
for	O
htltc	B-MED
,	O
upltc	B-MED
and	O
ttc	B-MED
than	O
the	O
commercial	B-MED
breeds	B-MED
,	O
but	O
higher	O
values	O
for	O
pbttc	B-MED
than	O
dorpers	B-MED
.	O
	
heritability	B-MED
estimates	B-MED
amounted	O
to	O
0.26	O
for	O
htltc	B-MED
,	O
0.53	O
for	O
upltc	B-MED
,	O
0.07	O
for	O
pbttc	B-MED
,	O
0.44	O
for	O
ttc	B-MED
and	O
0.61	O
for	O
udder	B-MED
health	B-MED
score	I-MED
.	O
	
animal	B-MED
permanent	I-MED
environment	I-MED
also	O
affected	O
pbttc	B-MED
0.14	O
.	O
	
significant	B-MED
genetic	I-MED
correlations	I-MED
were	O
found	O
between	O
the	O
htltc	B-MED
and	O
upltc	B-MED
0.47	O
,	O
upltc	B-MED
and	O
udder	B-MED
health	B-MED
score	I-MED
0.52	O
,	O
htltc	B-MED
and	O
upltc	B-MED
0.24	O
as	O
well	O
as	O
upltc	B-MED
and	O
pbttc	B-MED
-0	O
.	O
	
heavier	O
ewes	B-MED
had	O
higher	O
upltc	B-MED
0.38	O
,	O
ttc	B-MED
0.33	O
and	O
impaired	B-MED
udder	B-MED
health	B-MED
0.21	O
.	O
	
udder	B-MED
health	B-MED
score	I-MED
s	O
and	O
tick	B-MED
counts	I-MED
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	B-MED
traits	B-MED
.	O
	
the	O
indigenous	B-MED
na	B-MED
breed	B-MED
outperformed	O
the	O
commercial	B-MED
breeds	B-MED
with	O
lower	O
values	O
for	O
htltc	B-MED
,	O
upltc	B-MED
,	O
ttc	B-MED
and	O
a	O
better	O
udder	B-MED
health	B-MED
score	I-MED
.	O
	
mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
na	B-MED
breed	B-MED
under	O
pastoral	B-MED
conditions	I-MED
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-MED
tolerance	B-MED
within	O
breeds	B-MED
starvation	B-MED
-	O
and	O
antibiotics	B-MED
-induced	O
formation	B-MED
of	O
persister	B-MED
cells	I-MED
in	O
pseudomonas	B-MED
aeruginosa	I-MED
planktonic	B-MED
stationary	B-MED
and	I-MED
exponential	I-MED
cultures	I-MED
of	O
pseudomonas	B-MED
aeruginosa	I-MED
are	O
highly	B-MED
resistant	I-MED
to	O
killing	B-MED
by	O
bactericidal	B-MED
antimicrobials	I-MED
because	O
of	O
the	O
presence	O
of	O
persisters	B-MED
,	O
cells	B-MED
that	O
are	O
multidrug	B-MED
tolerant	I-MED
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	B-MED
of	O
biofilm	B-MED
infections	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
formation	B-MED
of	O
persister	B-MED
cells	I-MED
in	O
p	B-MED
.	O
	
aeruginosa	I-MED
stationary	B-MED
vs	O
.	O
	
exponential	B-MED
cultures	I-MED
using	O
different	B-MED
class	B-MED
antimicrobials	B-MED
.	O
	
the	O
susceptibilities	B-MED
of	O
p	B-MED
.	O
	
aeruginosa	I-MED
pao1	I-MED
wild-type	I-MED
and	O
mutant	B-MED
strains	I-MED
to	O
antimicrobials	B-MED
were	O
determined	O
by	O
standard	B-MED
microtiter	I-MED
broth	I-MED
dilution	I-MED
method	I-MED
.	O
	
in	O
order	O
to	O
determine	O
persister	B-MED
formation	B-MED
,	O
dose	B-MED
-	O
and	O
time	B-MED
-dependent	O
killing	B-MED
experiments	I-MED
were	O
performed	B-MED
with	O
antibiotics	B-MED
.	O
	
ceftazidime	B-MED
cephalosporin	B-MED
showed	O
little	O
efficacy	B-MED
against	O
either	O
culture	B-MED
.	O
	
stationary-phase	B-MED
cells	I-MED
were	O
more	O
tolerant	B-MED
to	O
imipenem	B-MED
carbapenem	B-MED
than	O
exponential	B-MED
cells	I-MED
,	O
leaving	O
a	O
small	O
fraction	B-MED
of	I-MED
persisters	B-MED
at	O
high	B-MED
imipenem	B-MED
concentration	B-MED
in	O
both	O
populations	B-MED
.	O
	
polymyxin	B-MED
b	I-MED
polymyxin	B-MED
appeared	O
to	O
be	O
ineffective	O
at	O
low	B-MED
concentrations	I-MED
against	O
both	O
cell	B-MED
populations	I-MED
.	O
	
very	O
high	O
polymyxin	B-MED
b	I-MED
concentration	B-MED
completely	O
eradicated	O
exponential	B-MED
cells	I-MED
and	O
regrowth	B-MED
was	O
seen	O
in	O
a	O
stationary	B-MED
population	I-MED
.	O
	
stationary	B-MED
cells	I-MED
were	O
more	O
tolerant	B-MED
to	O
tobramycin	B-MED
aminoglycoside	B-MED
than	O
exponential	B-MED
cells	I-MED
but	O
a	O
higher	B-MED
concentration	I-MED
of	O
tobramycin	B-MED
completely	O
eliminated	B-MED
survivors	B-MED
.	O
	
ciprofloxacin	B-MED
fluoroquinolone	B-MED
at	O
a	O
low	B-MED
concentration	I-MED
resulted	O
in	O
killing	B-MED
of	O
both	O
cultures	B-MED
of	O
p	B-MED
.	O
	
aeruginosa	I-MED
,	O
producing	O
persisters	B-MED
that	O
were	O
invulnerable	O
to	O
killing	B-MED
.	O
	
stationary	B-MED
cells	I-MED
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-MED
than	O
exponential	B-MED
cells	I-MED
in	O
all	O
of	O
these	O
assays	B-MED
.	O
	
we	O
also	O
showed	O
that	O
nutrient	B-MED
deprivation	B-MED
serine	B-MED
starvation	B-MED
regulated	O
by	O
stringent	B-MED
and	I-MED
general	I-MED
stress	I-MED
response	I-MED
,	O
contribute	O
to	O
the	O
increased	B-MED
tolerance	I-MED
of	O
p	B-MED
.	O
	
aeruginosa	I-MED
exponential	B-MED
and	I-MED
stationary	I-MED
planktonic	I-MED
cells	I-MED
via	O
production	B-MED
of	O
chaetomium	B-MED
thermophilum	I-MED
formate	B-MED
dehydrogenase	I-MED
has	O
high	O
activity	O
in	O
the	O
reduction	B-MED
of	O
hydrogen	B-MED
carbonate	I-MED
hco3	B-MED
-	I-MED
to	O
formate	B-MED
while	O
formate	B-MED
dehydrogenases	I-MED
fdhs	B-MED
have	O
been	O
used	O
for	O
cofactor	B-MED
recycling	B-MED
in	O
chemoenzymatic	B-MED
synthesis	I-MED
,	O
the	O
ability	O
of	O
fdh	B-MED
to	O
reduce	O
co2	B-MED
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	B-MED
of	O
co2	B-MED
to	O
useful	O
products	B-MED
via	O
formate	B-MED
hcoo	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
investigated	B-MED
the	O
reduction	B-MED
of	O
co2	B-MED
in	O
the	O
form	O
of	O
hydrogen	B-MED
carbonate	I-MED
hco3	B-MED
to	O
formate	B-MED
by	O
fdhs	B-MED
from	O
candida	B-MED
methylica	I-MED
cmfdh	B-MED
and	O
chaetomium	B-MED
thermophilum	I-MED
ctfdh	B-MED
in	O
a	O
nadh	B-MED
-dependent	O
reaction	B-MED
.	O
	
the	O
catalytic	B-MED
performance	I-MED
with	O
hco3	B-MED
as	O
a	O
substrate	B-MED
was	O
evaluated	O
by	O
measuring	B-MED
the	O
kinetic	B-MED
rates	I-MED
and	O
conducting	O
productivity	B-MED
assays	I-MED
.	O
	
ctfdh	B-MED
showed	O
a	O
higher	O
efficiency	B-MED
in	O
converting	B-MED
hco3	B-MED
to	O
formate	B-MED
than	O
cmfdh	B-MED
,	O
whereas	O
cmfdh	B-MED
was	O
better	O
in	O
the	O
oxidation	B-MED
of	O
formate	B-MED
.	O
	
the	O
ph	B-MED
optimum	O
of	O
the	O
reduction	B-MED
was	O
at	O
ph	B-MED
7-8	O
.	O
	
however	O
,	O
the	O
high	B-MED
concentrations	I-MED
of	O
hco3	B-MED
reduced	O
the	O
reaction	B-MED
rate	I-MED
.	O
	
ctfdh	B-MED
was	O
modeled	O
in	O
the	O
presence	O
of	O
hco3	B-MED
showing	O
that	O
it	O
fits	O
to	O
the	O
active	B-MED
site	I-MED
.	O
	
the	O
active	B-MED
site	I-MED
setting	O
for	O
hydride	B-MED
transfer	I-MED
in	O
co2	B-MED
reduction	B-MED
was	O
modeled	O
.	O
	
the	O
hydride	B-MED
donated	I-MED
by	O
nadh	B-MED
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	B-MED
atom	I-MED
of	O
hco3	B-MED
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	B-MED
within	O
the	O
molecule	B-MED
.	O
	
this	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	B-MED
carbonate	I-MED
and	O
the	O
hydride	B-MED
to	O
break	O
into	O
formate	B-MED
and	O
hydroxide	B-MED
ions	I-MED
.	O
	
evaluation	B-MED
of	O
an	O
international	B-MED
educational	B-MED
programme	I-MED
for	O
health	B-MED
care	I-MED
professionals	I-MED
on	O
best	O
practice	O
in	O
the	O
management	B-MED
of	O
a	O
perinatal	B-MED
death	B-MED
improving	B-MED
perinatal	I-MED
mortality	I-MED
review	I-MED
and	I-MED
outcomes	I-MED
via	I-MED
education	I-MED
improve	B-MED
stillbirths	B-MED
and	O
neonatal	B-MED
deaths	I-MED
are	O
devastating	B-MED
events	I-MED
for	O
both	O
parents	B-MED
and	O
clinicians	B-MED
and	O
are	O
global	B-MED
public	I-MED
health	I-MED
concerns	B-MED
.	O
	
careful	O
clinical	B-MED
management	I-MED
after	O
these	O
deaths	B-MED
is	O
required	O
,	O
including	O
appropriate	O
investigation	B-MED
and	O
assessment	B-MED
to	O
determine	O
cause	O
s	O
to	O
prevent	O
future	O
losses	O
,	O
and	O
to	O
improve	O
bereavement	B-MED
care	I-MED
for	O
families	B-MED
.	O
	
an	O
educational	B-MED
programme	I-MED
for	O
health	B-MED
care	I-MED
professionals	I-MED
working	O
in	O
maternal	B-MED
and	O
child	B-MED
health	I-MED
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
perinatal	B-MED
society	I-MED
of	I-MED
australia	I-MED
and	I-MED
new	I-MED
zealand	I-MED
guideline	I-MED
for	I-MED
perinatal	I-MED
mortality	I-MED
improving	B-MED
perinatal	I-MED
mortality	I-MED
review	I-MED
and	I-MED
outcomes	I-MED
via	I-MED
education	I-MED
improve	B-MED
.	O
	
the	O
programme	B-MED
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-MED
and	O
is	O
delivered	O
as	O
six	O
interactive	B-MED
skills	I-MED
-based	O
stations	B-MED
.	O
	
we	O
aimed	O
to	O
determine	O
participants	B-MED
'	O
pre-	B-MED
and	O
post-programme	B-MED
knowledge	B-MED
of	O
and	O
confidence	B-MED
in	O
the	O
management	B-MED
of	O
perinatal	B-MED
deaths	B-MED
,	O
along	O
with	O
satisfaction	B-MED
with	O
the	O
programme	B-MED
.	O
	
we	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	B-MED
use	O
.	O
	
the	O
improve	B-MED
programme	I-MED
was	O
delivered	O
to	O
health	B-MED
professionals	I-MED
in	O
maternity	B-MED
hospitals	I-MED
in	O
all	O
seven	O
australian	B-MED
states	B-MED
and	O
territories	B-MED
and	O
modified	O
for	O
use	O
internationally	B-MED
with	O
piloting	O
in	O
vietnam	B-MED
,	O
fiji	B-MED
,	O
and	O
the	O
netherlands	B-MED
with	O
the	O
assistance	B-MED
of	O
the	O
international	B-MED
stillbirth	I-MED
alliance	I-MED
,	O
isa	B-MED
.	O
	
modifications	O
were	O
made	O
to	O
programme	B-MED
materials	I-MED
in	O
consultation	B-MED
with	O
local	O
teams	O
and	O
included	O
translation	B-MED
for	O
the	O
vietnam	B-MED
programme	I-MED
.	O
	
participants	B-MED
completed	O
pre-	B-MED
and	O
post-programme	B-MED
evaluation	B-MED
questionnaires	B-MED
on	O
knowledge	B-MED
and	O
confidence	B-MED
on	O
six	O
key	O
components	O
of	O
perinatal	B-MED
death	B-MED
management	B-MED
as	O
well	O
as	O
a	O
satisfaction	B-MED
questionnaire	I-MED
.	O
	
over	O
the	O
period	O
may	O
2012	O
to	O
may	O
2015	O
,	O
30	O
improve	B-MED
workshops	B-MED
were	O
conducted	O
,	O
including	O
26	O
with	O
758	O
participants	B-MED
in	O
australia	B-MED
and	O
four	O
with	O
136	O
participants	B-MED
internationally	B-MED
.	O
	
evaluations	B-MED
showed	O
a	O
significant	B-MED
improvement	B-MED
between	O
pre-	B-MED
and	O
post-programme	B-MED
knowledge	B-MED
and	O
confidence	B-MED
in	O
all	O
six	O
stations	B-MED
and	O
overall	O
,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	B-MED
in	O
all	O
settings	B-MED
.	O
	
the	O
improve	B-MED
programme	I-MED
has	O
been	O
well	O
received	O
in	O
australia	B-MED
and	O
in	O
three	O
different	O
international	B-MED
settings	B-MED
and	O
is	O
now	O
being	O
made	O
available	O
through	O
isa	B-MED
.	O
	
future	O
research	B-MED
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	B-MED
in	O
knowledge	B-MED
are	O
sustained	B-MED
with	O
less	O
causes	O
of	O
death	B-MED
being	O
classified	O
as	O
unknown	O
,	O
changes	B-MED
in	I-MED
clinical	I-MED
practice	I-MED
and	O
improvement	B-MED
in	O
parents'	B-MED
experiences	O
with	O
care	B-MED
.	O
	
the	O
suitability	O
for	O
this	O
programme	B-MED
in	O
low-income	B-MED
countries	B-MED
experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	B-MED
recovery	B-MED
goals	B-MED
a	O
collaborative	B-MED
,	O
qualitative	B-MED
study	I-MED
recovery	B-MED
can	O
be	O
understood	O
as	O
a	O
subjective	B-MED
process	I-MED
guided	O
by	O
personal	B-MED
expectations	B-MED
,	O
goals	B-MED
and	O
hopes	B-MED
.	O
	
the	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
explore	O
how	O
persons	B-MED
using	O
a	O
community	B-MED
mental	I-MED
health	I-MED
centre	I-MED
cmhc	B-MED
experienced	O
that	O
their	O
expectations	B-MED
for	O
treatment	B-MED
,	O
and	O
goals	B-MED
and	O
hopes	B-MED
for	O
recovery	B-MED
were	O
supported	O
by	O
the	O
health	B-MED
professionals	I-MED
during	O
treatment	B-MED
.	O
	
employing	O
a	O
hermeneutic	B-MED
-phenomenological	O
approach	O
,	O
eight	O
service	B-MED
users	I-MED
were	O
interviewed	O
about	O
their	O
expectations	B-MED
for	O
treatment	B-MED
and	O
their	O
goals	B-MED
and	O
hopes	B-MED
for	O
recovery	B-MED
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health	B-MED
professionals	I-MED
at	O
a	O
cmhc	B-MED
.	O
	
two	O
years	B-MED
later	O
,	O
they	O
were	O
re-interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-MED
and	O
support	O
from	O
the	O
health	B-MED
professionals	I-MED
in	O
their	O
work	O
towards	O
these	O
goals	B-MED
and	O
hopes	B-MED
.	O
	
a	O
collaborative	B-MED
approach	I-MED
was	O
adopted	O
.	O
	
a	O
co-researcher	B-MED
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	B-MED
.	O
	
data	B-MED
were	O
analysed	O
by	O
means	O
of	O
a	O
data	B-MED
-driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic	B-MED
analysis	I-MED
.	O
	
five	O
themes	O
reflecting	O
how	O
participants	B-MED
experienced	O
support	O
from	O
health	B-MED
professionals	I-MED
at	O
the	O
cmhc	B-MED
in	O
their	O
work	O
towards	O
their	O
recovery	B-MED
goals	B-MED
were	O
elicited	O
,	O
as	O
follows	O
developing	B-MED
an	I-MED
understanding	I-MED
of	I-MED
oneself	I-MED
and	O
one's	O
mental	B-MED
health	I-MED
problems	I-MED
learning	O
how	O
to	O
change	O
feelings	B-MED
and	O
behaviours	B-MED
being	B-MED
'pushed'	I-MED
into	I-MED
social	I-MED
arenas	I-MED
finding	B-MED
helpful	I-MED
medication	I-MED
and	O
counselling	B-MED
in	O
family	B-MED
,	O
practical	B-MED
and	O
financial	B-MED
issues	I-MED
.	O
	
the	O
participants	B-MED
'	O
expectations	B-MED
about	O
counselling	B-MED
with	O
regard	O
to	O
longer-term	O
family	B-MED
,	O
practical	B-MED
,	O
and	O
financial	B-MED
challenges	I-MED
were	O
insufficiently	O
met	O
by	O
the	O
cmhc	B-MED
.	O
	
in	O
the	O
experience	O
of	O
the	O
service	B-MED
users	I-MED
,	O
recovery	B-MED
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday	B-MED
life	I-MED
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	B-MED
helpers	B-MED
.	O
	
to	O
facilitate	O
recovery	B-MED
,	O
health	B-MED
professionals	I-MED
should	O
acknowledge	O
the	O
service	B-MED
user's	I-MED
personal	B-MED
goals	B-MED
and	O
hopes	B-MED
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer-term	O
approach	O
to	O
his	O
or	O
her	O
needs	B-MED
and	O
desires	B-MED
.	O
	
acknowledging	O
and	O
facilitating	O
recovery	B-MED
goals	B-MED
by	O
offering	O
counselling	B-MED
with	O
regard	O
to	O
family	B-MED
,	O
practical	B-MED
and	O
financial	B-MED
issues	I-MED
pathogenesis	B-MED
of	O
copd	B-MED
and	O
asthma	B-MED
asthma	B-MED
and	O
copd	B-MED
remain	O
two	O
diseases	B-MED
of	I-MED
the	I-MED
respiratory	I-MED
tract	I-MED
with	O
unmet	B-MED
medical	B-MED
needs	B-MED
.	O
	
this	O
review	B-MED
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	B-MED
of	O
these	O
two	O
chronic	B-MED
inflammatory	I-MED
diseases	I-MED
of	O
the	O
lung	B-MED
.	O
	
the	O
review	B-MED
highlights	O
why	O
they	O
are	O
different	O
conditions	B-MED
requiring	O
different	O
approaches	O
to	O
treatment	B-MED
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	B-MED
and	O
treatment	B-MED
of	O
asthma	B-MED
and	O
antigen	B-MED
specificity	I-MED
determines	O
anti-red	B-MED
blood	I-MED
cell	I-MED
igg-fc	I-MED
alloantibody	I-MED
glycosylation	B-MED
and	O
thereby	O
severity	B-MED
of	O
haemolytic	B-MED
disease	I-MED
of	I-MED
the	I-MED
fetus	I-MED
and	I-MED
newborn	I-MED
haemolytic	B-MED
disease	I-MED
of	I-MED
the	I-MED
fetus	I-MED
and	I-MED
newborn	I-MED
hdfn	B-MED
is	O
a	O
severe	O
disease	B-MED
in	O
which	O
fetal	B-MED
red	B-MED
blood	I-MED
cells	I-MED
rbc	B-MED
are	O
destroyed	B-MED
by	O
maternal	B-MED
anti-rbc	I-MED
igg	I-MED
alloantibodies	I-MED
.	O
	
hdfn	B-MED
is	O
most	O
often	O
caused	O
by	O
anti-d	B-MED
but	O
may	O
also	O
occur	O
due	B-MED
to	I-MED
anti-k	B-MED
,	O
-c	B-MED
-	O
or	O
-e	B-MED
.	O
	
we	O
recently	O
found	O
n-linked	B-MED
glycosylation	I-MED
of	O
anti-d	B-MED
to	O
be	O
skewed	O
towards	O
low	B-MED
fucosylation	B-MED
,	O
thereby	O
increasing	B-MED
the	O
affinity	B-MED
to	O
igg-fc	B-MED
receptor	I-MED
iiia	I-MED
and	O
iiib	B-MED
,	O
which	O
correlated	B-MED
with	O
hdfn	B-MED
disease	B-MED
severity	B-MED
.	O
	
here	O
,	O
we	O
analysed	O
230	O
pregnant	B-MED
women	I-MED
with	O
anti-c	B-MED
,	O
-e	B-MED
or	O
-k	B-MED
alloantibodies	B-MED
from	O
a	O
prospective	O
screening	B-MED
cohort	I-MED
and	O
investigated	B-MED
the	O
type	O
of	O
fc-tail	B-MED
glycosylation	I-MED
of	O
these	O
antibodies	B-MED
in	O
relation	O
to	O
the	O
trigger	B-MED
of	O
immunisation	B-MED
and	O
pregnancy	B-MED
outcome	I-MED
.	O
	
anti-c	B-MED
,	O
-e	B-MED
and	O
-k	B-MED
show	O
-	O
independent	B-MED
of	I-MED
the	O
event	B-MED
that	O
had	O
led	O
to	O
immunisation	B-MED
-	O
a	O
different	B-MED
kind	O
of	O
fc-glycosylation	B-MED
compared	O
to	O
that	O
of	O
the	O
total	O
igg	B-MED
fraction	O
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti-d	O
.	O
	
high	O
fc-galactosylation	O
and	O
sialylation	O
of	O
anti-c	O
correlated	O
with	O
hdfn	O
disease	O
severity	O
,	O
while	O
low	O
anti-k	O
fc-fucosylation	O
correlated	O
with	O
severe	O
fetal	O
anaemia	O
.	O
	
igg-fc	O
glycosylation	O
of	O
anti-rbc	O
antibodies	O
is	O
shaped	O
depending	O
on	O
the	O
antigen	O
.	O
	
these	O
features	O
influence	O
their	O
clinical	O
potency	O
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	O
severity	O
and	O
identify	O
those	O
needing	O
treatment	B-MED
shout	O
louder	O
about	O
poor	B-MED
pay	I-MED
it	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
nhs	B-MED
pay	B-MED
campaign	B-MED
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
nhs	B-MED
or	O
with	O
the	O
sars	B-MED
-	O
cov	B-MED
fusion	O
peptides	B-MED
induce	O
membrane	B-MED
surface	B-MED
ordering	B-MED
and	O
curvature	B-MED
viral	B-MED
membrane	I-MED
fusion	I-MED
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane-anchored	B-MED
viral	B-MED
fusion	I-MED
glycoproteins	I-MED
.	O
	
the	O
s2	B-MED
subunit	B-MED
of	O
the	O
spike	B-MED
glycoprotein	I-MED
from	O
severe	B-MED
acute	I-MED
respiratory	I-MED
syndrome	I-MED
sars	B-MED
coronavirus	B-MED
cov	B-MED
contains	O
internal	B-MED
domains	I-MED
called	O
fusion	B-MED
peptides	I-MED
fp	B-MED
that	O
play	O
essential	O
roles	O
in	O
virus	B-MED
entry	I-MED
.	O
	
although	O
membrane	B-MED
fusion	I-MED
has	O
been	O
broadly	O
studied	B-MED
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	B-MED
details	O
of	O
lipid	B-MED
rearrangements	B-MED
in	O
the	O
bilayer	B-MED
during	O
fusion	B-MED
peptide	I-MED
-	O
membrane	B-MED
interactions	B-MED
.	O
	
here	O
we	O
employed	O
differential	B-MED
scanning	I-MED
calorimetry	I-MED
dsc	B-MED
and	O
electron	B-MED
spin	I-MED
resonance	I-MED
esr	B-MED
to	O
gather	O
information	O
on	O
the	O
membrane	B-MED
fusion	I-MED
mechanism	B-MED
promoted	B-MED
by	O
two	O
putative	O
sars	B-MED
fps	B-MED
.	O
	
dsc	B-MED
data	B-MED
showed	O
the	O
peptides	B-MED
strongly	O
perturb	O
the	O
structural	B-MED
integrity	B-MED
of	O
anionic	B-MED
vesicles	I-MED
and	O
support	O
the	O
hypothesis	B-MED
that	O
the	O
peptides	B-MED
generate	O
opposing	O
curvature	B-MED
stresses	O
on	O
phosphatidylethanolamine	B-MED
membranes	B-MED
.	O
	
esr	B-MED
showed	O
that	O
both	O
fps	B-MED
increase	O
lipid	B-MED
packing	B-MED
and	O
head	O
group	O
ordering	B-MED
as	O
well	O
as	O
reduce	O
the	O
intramembrane	B-MED
water	B-MED
content	I-MED
for	O
anionic	B-MED
membranes	I-MED
.	O
	
therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	B-MED
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	B-MED
.	O
	
the	O
significance	B-MED
of	O
the	O
ordering	B-MED
effect	I-MED
,	O
membrane	B-MED
dehydration	B-MED
,	O
changes	O
in	O
the	O
curvature	B-MED
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-MED
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
sars	B-MED
-	O
cov	B-MED
-mediated	O
membrane	B-MED
fusion	I-MED
elucidating	O
a	O
chemical	O
defense	B-MED
mechanism	I-MED
of	O
antarctic	B-MED
sponges	B-MED
a	O
computational	B-MED
study	I-MED
in	O
2000	O
,	O
a	O
novel	O
secondary	B-MED
metabolite	I-MED
erebusinone	B-MED
,	O
ereb	B-MED
was	O
isolated	O
from	O
the	O
antarctic	B-MED
sea	B-MED
sponge	I-MED
,	O
isodictya	B-MED
erinacea	I-MED
.	O
	
the	O
bioactivity	B-MED
of	O
ereb	B-MED
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	B-MED
molting	B-MED
when	O
fed	O
to	O
the	O
arthropod	B-MED
species	I-MED
orchomene	B-MED
plebs	I-MED
.	O
	
xanthurenic	B-MED
acid	I-MED
xa	B-MED
is	O
a	O
known	O
endogenous	B-MED
molt	B-MED
regulator	I-MED
present	O
in	O
arthropods	B-MED
.	O
	
experimental	O
studies	O
have	O
confirmed	O
that	O
xa	B-MED
inhibits	B-MED
molting	B-MED
by	O
binding	B-MED
to	O
either	O
or	O
both	O
of	O
two	O
p450	B-MED
enzymes	I-MED
cyp315a1	B-MED
or	O
cyp314a1	B-MED
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	B-MED
in	O
the	O
production	O
of	O
the	O
molt-inducing	B-MED
hormone	I-MED
,	O
20-hydroxyecdysone	B-MED
20e	B-MED
.	O
	
the	O
lack	O
of	O
crystal	B-MED
structures	I-MED
and	O
biochemical	B-MED
assays	I-MED
for	O
cyp315a1	B-MED
or	O
cyp314a1	B-MED
,	O
has	O
prevented	O
further	O
experimental	O
exploration	B-MED
of	O
xa	B-MED
and	O
ereb's	B-MED
molt	B-MED
inhibition	B-MED
mechanisms	B-MED
.	O
	
herein	O
,	O
a	O
wide	O
array	O
of	O
computational	B-MED
techniques	I-MED
-	O
homology	B-MED
modeling	I-MED
,	O
molecular	B-MED
dynamics	I-MED
simulations	I-MED
,	O
binding	B-MED
site	I-MED
bioinformatics	B-MED
,	O
flexible	B-MED
receptor-flexible	I-MED
ligand	I-MED
docking	I-MED
,	O
and	O
molecular	O
mechanics-generalized	O
born	B-MED
surface	I-MED
area	I-MED
calculations	I-MED
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure-function	B-MED
relationships	I-MED
between	O
the	O
aforementioned	O
p450s	B-MED
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	B-MED
ereb	B-MED
and	O
xa	B-MED
.	O
	
results	O
indicate	O
that	O
ereb	B-MED
likely	O
targets	O
cyp315a1	B-MED
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	B-MED
residues	I-MED
in	O
the	O
binding	B-MED
site	I-MED
,	O
while	O
xa	B-MED
may	O
inhibit	O
both	O
cyp315a1	B-MED
and	O
cyp314a1	B-MED
because	O
of	O
its	O
aromatic	B-MED
,	O
as	O
well	O
as	O
charged	B-MED
nature	I-MED
.	O
	
the	O
anatomical	B-MED
mummies	I-MED
of	O
mombello	B-MED
detection	B-MED
of	O
cocaine	B-MED
,	O
nicotine	B-MED
,	O
and	O
caffeine	B-MED
in	O
the	O
hair	B-MED
of	O
psychiatric	B-MED
patients	I-MED
of	O
the	O
early	O
20th	O
century	O
the	O
mombello	B-MED
psychiatric	I-MED
hospital	I-MED
in	O
limbiate	B-MED
,	O
near	O
milan	B-MED
,	O
replaced	O
the	O
old	O
senavra	B-MED
hospital	I-MED
as	O
the	O
psychiatric	B-MED
hospital	I-MED
for	O
the	O
province	B-MED
of	I-MED
milan	I-MED
in	O
the	O
19th	O
century	O
.	O
	
during	O
the	O
early	O
20th	O
century	O
,	O
bodies	B-MED
of	O
several	O
mombello	B-MED
patients	I-MED
were	O
dissected	B-MED
and	O
preserved	B-MED
by	O
giuseppe	B-MED
paravicini	I-MED
,	O
an	O
anatomist	B-MED
who	O
operated	O
within	O
the	O
asylum	B-MED
.	O
	
the	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	B-MED
.	O
	
to	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	B-MED
the	O
head	B-MED
hair	I-MED
of	O
six	O
such	O
preparations	B-MED
for	O
toxicological	B-MED
analysis	B-MED
.	O
	
by	O
means	O
of	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
,	O
cocaine	B-MED
and	O
its	O
main	O
metabolite	B-MED
,	O
benzoylecgonine	B-MED
,	O
were	O
detected	B-MED
in	O
two	O
out	O
of	O
six	O
hair	B-MED
samples	I-MED
.	O
	
the	O
concentrations	B-MED
for	O
cocaine	B-MED
were	O
0.151	O
and	O
0.09ng	O
and	O
for	O
benzoylecgonine	B-MED
0.103	O
and	O
0.147ng	O
,	O
respectively	O
.	O
	
given	O
that	O
cocaine	B-MED
was	O
a	O
commonly	O
used	O
medicine	B-MED
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	B-MED
may	O
have	O
ingested	B-MED
this	O
drug	B-MED
.	O
	
in	O
addition	O
to	O
the	O
detection	B-MED
of	O
cocaine	B-MED
,	O
these	O
analyses	B-MED
also	O
provided	O
evidence	O
of	O
nicotine	B-MED
and	O
caffeine	B-MED
intake	B-MED
.	O
	
terahertz	B-MED
identification	I-MED
and	O
quantification	B-MED
of	O
neurotransmitter	B-MED
and	O
neurotrophy	B-MED
mixture	I-MED
terahertz	B-MED
spectroscopy	I-MED
has	O
been	O
widely	O
used	O
for	O
investigating	B-MED
the	O
fingerprint	B-MED
spectrum	I-MED
of	O
different	O
substances	B-MED
.	O
	
for	O
cancerous	B-MED
tissues	B-MED
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	B-MED
peaks	O
of	O
various	O
substances	B-MED
contained	O
in	O
tissues	B-MED
overlap	B-MED
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	B-MED
analyze	B-MED
.	O
	
as	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	B-MED
cell	I-MED
and	O
then	O
to	O
diagnose	B-MED
accurately	B-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	B-MED
γ-aminobutyric	B-MED
acid	I-MED
,	O
l-glutamic	B-MED
acid	I-MED
,	O
dopamine	B-MED
hydrochloride	I-MED
and	O
two	O
typical	O
metabolites	B-MED
inositol	B-MED
and	O
creatine	B-MED
in	O
neurons	B-MED
to	O
measure	O
their	O
terahertz	B-MED
spectra	I-MED
with	O
different	O
mixture	B-MED
ratios	I-MED
.	O
	
by	O
choosing	O
characteristic	B-MED
absorption	B-MED
peaks	O
,	O
removing	O
baseline	B-MED
and	O
using	O
the	O
least	B-MED
square	I-MED
method	I-MED
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	B-MED
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	B-MED
of	I-MED
fit	I-MED
to	O
practical	O
situation	O
is	O
up	O
to	O
94%	O
.	O
	
these	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	B-MED
substances	I-MED
and	O
obtaining	O
exact	O
quantitative	B-MED
analysis	B-MED
.	O
	
comparing	O
the	O
bulking	O
effect	O
of	O
calcium	B-MED
hydroxyapatite	I-MED
and	O
deflux	B-MED
injection	B-MED
into	O
the	O
bladder	B-MED
neck	I-MED
for	O
improvement	B-MED
of	O
urinary	B-MED
incontinence	I-MED
in	O
bladder	B-MED
exstrophy-epispadias	I-MED
complex	I-MED
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
efficacy	B-MED
of	O
the	O
endoscopic	B-MED
injection	I-MED
of	O
calcium	B-MED
hydroxyapatite	I-MED
caha	B-MED
into	O
the	O
bladder	B-MED
neck	I-MED
bn	B-MED
region	O
of	O
patients	B-MED
with	O
urinary	B-MED
incontinence	I-MED
and	O
bladder	B-MED
exstrophy-epispadias	I-MED
complex	I-MED
beec	B-MED
.	O
	
we	O
designed	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
in	O
which	O
we	O
retrospectively	B-MED
studied	I-MED
medical	B-MED
charts	I-MED
of	O
female	B-MED
and	O
male	B-MED
patients	B-MED
of	O
beec	B-MED
who	O
had	O
undergone	O
caha	B-MED
or	O
deflux	B-MED
injection	B-MED
for	O
continence	B-MED
improvement	I-MED
between	O
2009	O
and	O
2014	O
.	O
	
sixteen	O
incontinent	B-MED
patients	B-MED
with	O
a	O
mean	O
sd	O
age	O
of	O
8.09	O
3.5	O
years	O
received	O
an	O
endoscopic	B-MED
submucosal	I-MED
injection	I-MED
of	O
5.4	O
ml	O
of	O
pure	O
caha	B-MED
powder	O
with	O
autologous	B-MED
plasma	B-MED
group	O
a	O
.	O
	
patients	B-MED
in	O
group	O
b	O
n	O
=	O
21	O
,	O
control	B-MED
group	I-MED
,	O
with	O
a	O
mean	O
sd	O
age	O
of	O
7.51	O
2.8	O
years	O
received	O
deflux	B-MED
injection	B-MED
5.1	O
ml	O
.	O
	
the	O
mean	O
follow-up	B-MED
after	O
injection	B-MED
was	O
38	O
5.2	O
and	O
33	O
4.1	O
months	O
in	O
groups	O
a	O
and	O
b	O
,	O
respectively	O
.	O
	
no	O
post-injection	B-MED
complication	I-MED
was	O
detected	B-MED
in	O
none	O
of	O
the	O
patients	B-MED
during	O
the	O
follow-up	B-MED
.	O
	
eleven	O
patients	B-MED
68.75	O
in	O
group	O
a	O
became	O
socially	O
dry	B-MED
following	O
1-2	O
injections	B-MED
,	O
the	O
degree	O
of	O
incontinence	B-MED
was	O
improved	O
in	O
4	O
patients	B-MED
25%	O
,	O
and	O
there	O
was	O
no	B-MED
change	I-MED
in	O
one	O
patient	B-MED
6.25	O
.	O
	
however	O
,	O
deflux	B-MED
injection	B-MED
resulted	O
in	O
complete	B-MED
dryness	I-MED
in	O
14	O
66.66	O
,	O
improvement	B-MED
in	O
the	O
degree	O
of	O
incontinence	B-MED
in	O
5	O
23.81	O
and	O
no	B-MED
change	I-MED
in	O
2	O
patients	B-MED
9.52	O
,	O
leading	O
to	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
continence	B-MED
achievement	I-MED
between	O
caha	B-MED
and	O
deflux	B-MED
groups	O
p	O
=	O
0.9	O
.	O
	
the	O
statistical	B-MED
analysis	I-MED
was	O
not	B-MED
significantly	I-MED
different	I-MED
in	O
terms	O
of	O
bladder	B-MED
capacity	I-MED
p	O
=	O
0.7	O
or	O
q	O
max	O
p	O
=	O
0.8	O
.	O
	
the	O
preliminary	B-MED
results	I-MED
of	O
this	O
study	B-MED
revealed	B-MED
that	O
caha	B-MED
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking	B-MED
agent	I-MED
in	O
treatment	B-MED
of	O
urinary	B-MED
incontinence	I-MED
in	O
opportunities	B-MED
for	O
genomic	B-MED
prediction	B-MED
for	O
fertility	B-MED
using	O
endocrine	B-MED
and	O
classical	B-MED
fertility	B-MED
traits	B-MED
in	O
dairy	B-MED
cattle	I-MED
endocrine	B-MED
fertility	B-MED
traits	B-MED
,	O
defined	O
from	O
progesterone	B-MED
concentration	B-MED
levels	B-MED
in	O
milk	B-MED
,	O
have	O
been	O
suggested	O
as	O
alternative	B-MED
indicators	B-MED
for	O
fertility	B-MED
in	O
dairy	B-MED
cows	I-MED
because	O
they	O
are	O
less	O
biased	O
by	O
farm	B-MED
management	B-MED
decisions	B-MED
and	O
more	O
directly	O
reflect	O
a	O
cow	B-MED
's	O
reproductive	B-MED
physiology	B-MED
than	O
classical	B-MED
traits	B-MED
derived	O
from	O
insemination	B-MED
and	O
calving	O
data	B-MED
.	O
	
to	O
determine	O
the	O
potential	O
use	B-MED
of	I-MED
endocrine	B-MED
fertility	B-MED
traits	B-MED
in	O
genomic	B-MED
evaluations	B-MED
,	O
the	O
improvement	B-MED
in	O
accuracy	B-MED
from	O
using	O
endocrine	B-MED
fertility	B-MED
traits	B-MED
concurrent	B-MED
with	O
classical	B-MED
traits	B-MED
in	O
the	O
genomic	B-MED
prediction	B-MED
of	O
fertility	B-MED
was	O
quantified	B-MED
.	O
	
the	O
impact	B-MED
of	O
recording	O
all	O
traits	B-MED
on	O
all	O
training	O
animals	B-MED
was	O
also	O
investigated	B-MED
.	O
	
endocrine	B-MED
and	O
classical	B-MED
fertility	B-MED
records	O
were	O
available	O
on	O
5	O
lactations	B-MED
from	O
2	O
holstein	B-MED
cows	I-MED
in	O
ireland	B-MED
,	O
the	O
netherlands	B-MED
,	O
sweden	B-MED
,	O
and	O
the	O
united	B-MED
kingdom	I-MED
.	O
	
the	O
endocrine	B-MED
traits	B-MED
were	O
commencement	B-MED
of	I-MED
luteal	I-MED
activity	I-MED
c-la	B-MED
and	O
proportion	B-MED
of	O
samples	B-MED
with	O
luteal	B-MED
activity	I-MED
pla	B-MED
the	O
classical	B-MED
trait	B-MED
was	O
the	O
interval	B-MED
from	O
calving	O
to	O
first	O
service	O
cfs	O
.	O
	
the	O
interval	B-MED
from	O
c-la	B-MED
to	O
first	O
service	O
c-lafs	O
,	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	B-MED
trait	B-MED
and	O
a	O
classical	B-MED
trait	B-MED
,	O
was	O
also	O
investigated	B-MED
.	O
	
the	O
target	B-MED
breeding	B-MED
goal	I-MED
trait	B-MED
for	O
fertility	B-MED
was	O
cfs	O
or	O
c-lafs	O
,	O
whereas	O
c-la	B-MED
and	O
pla	B-MED
served	O
as	O
predictor	B-MED
traits	B-MED
.	O
	
genomic	B-MED
ebv	I-MED
gebv	B-MED
for	O
fertility	B-MED
were	O
derived	O
using	O
genomic	B-MED
blup	I-MED
in	O
bivariate	B-MED
models	I-MED
with	O
85	O
snp	B-MED
.	O
	
genomic	O
ebv	O
for	O
the	O
separate	O
fertility	B-MED
traits	B-MED
were	O
also	O
computed	O
,	O
in	O
univariate	B-MED
models	I-MED
.	O
	
the	O
accuracy	B-MED
of	O
gebv	B-MED
was	O
evaluated	O
by	O
5-fold	O
cross-validation	B-MED
.	O
	
the	O
highest	O
accuracy	B-MED
of	O
gebv	B-MED
was	O
achieved	O
using	O
bivariate	B-MED
predictions	B-MED
,	O
where	O
both	O
an	O
endocrine	B-MED
fertility	B-MED
trait	B-MED
and	O
the	O
classical	B-MED
fertility	B-MED
trait	B-MED
were	O
used	O
.	O
	
accuracy	B-MED
of	O
gebv	B-MED
for	O
predicting	B-MED
adjusted	O
phenotypes	B-MED
for	O
cfs	O
in	O
the	O
univariate	B-MED
model	I-MED
was	O
0.04	O
,	O
but	O
when	O
predicting	B-MED
cfs	O
using	O
a	O
bivariate	B-MED
model	I-MED
with	O
c-la	B-MED
,	O
the	O
accuracy	B-MED
increased	B-MED
to	O
0.14	O
when	O
all	O
training	B-MED
animals	I-MED
were	O
phenotyped	B-MED
for	O
c-la	B-MED
and	O
or	O
not	O
for	O
cfs	O
.	O
	
on	O
phenotyping	B-MED
all	O
training	B-MED
animals	I-MED
for	O
both	O
c-la	B-MED
and	O
cfs	O
,	O
accuracy	B-MED
for	O
cfs	O
increased	B-MED
to	O
0.18	O
however	O
,	O
when	O
validation	B-MED
animals	B-MED
were	O
also	O
phenotyped	B-MED
for	O
c-la	B-MED
,	O
there	O
was	O
no	B-MED
substantial	B-MED
increase	I-MED
in	O
accuracy	B-MED
.	O
	
when	O
predicting	B-MED
cfs	O
in	O
bivariate	B-MED
analysis	I-MED
with	O
pla	B-MED
,	O
accuracy	B-MED
ranged	O
from	O
0.07	O
to	O
0.14	O
.	O
	
this	O
first	O
study	B-MED
on	O
genomic	B-MED
predictions	B-MED
for	O
fertility	B-MED
using	O
endocrine	B-MED
traits	B-MED
suggests	O
some	O
improvement	B-MED
in	O
the	O
accuracy	B-MED
of	O
prediction	B-MED
over	O
using	O
only	O
the	O
classical	B-MED
traits	B-MED
.	O
	
further	O
studies	B-MED
with	O
larger	B-MED
training	B-MED
populations	I-MED
may	O
show	O
greater	B-MED
improvements	B-MED
.	O
	
a	O
microfluidic	B-MED
platform	O
to	O
design	B-MED
crosslinked	B-MED
hyaluronic	I-MED
acid	I-MED
nanoparticles	I-MED
chanps	B-MED
for	O
enhanced	B-MED
mri	I-MED
recent	B-MED
advancements	B-MED
in	O
imaging	B-MED
diagnostics	I-MED
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	B-MED
that	O
entrap	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
mri	B-MED
contrast	B-MED
agents	I-MED
cas	B-MED
,	O
without	O
the	O
need	O
to	O
chemically	B-MED
modify	B-MED
the	O
clinically	B-MED
approved	B-MED
compounds	B-MED
.	O
	
nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	B-MED
platforms	I-MED
for	O
their	O
controlled	B-MED
and	O
continuous	B-MED
production	B-MED
is	O
still	O
missing	O
.	O
	
here	O
,	O
a	O
microfluidic	B-MED
platform	I-MED
is	O
used	O
to	O
synthesize	B-MED
crosslinked	B-MED
hyaluronic	I-MED
acid	I-MED
nanoparticles	I-MED
chanps	B-MED
in	O
which	O
a	O
clinically	B-MED
relevant	B-MED
mri	B-MED
-	O
cas	B-MED
,	O
gadolinium	B-MED
diethylenetriamine	I-MED
penta-acetic	I-MED
acid	I-MED
gd-dtpa	B-MED
,	O
is	O
entrapped	O
.	O
	
this	O
microfluidic	B-MED
process	B-MED
facilitates	O
a	O
high	O
degree	B-MED
of	O
control	B-MED
over	O
particle	B-MED
synthesis	B-MED
,	O
enabling	O
the	O
production	B-MED
of	O
monodisperse	B-MED
particles	I-MED
as	O
small	O
as	O
35	O
nm	O
.	O
	
furthermore	O
,	O
the	O
interference	B-MED
of	O
gd-dtpa	B-MED
during	O
polymer	B-MED
precipitation	B-MED
is	O
overcome	O
by	O
finely	O
tuning	O
process	B-MED
parameters	B-MED
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic-lipophilic	B-MED
balance	I-MED
hlb	B-MED
of	O
surfactants	B-MED
and	O
ph	B-MED
conditions	B-MED
.	O
	
for	O
both	O
production	B-MED
strategies	O
proposed	O
to	O
design	B-MED
gd	B-MED
-loaded	O
chanps	B-MED
,	O
a	O
boosting	O
of	O
the	O
relaxation	B-MED
rate	I-MED
t1	I-MED
is	O
observed	O
since	O
a	O
t1	B-MED
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μm	O
of	O
gd	B-MED
-loaded	O
chanps	B-MED
while	O
a	O
similar	O
value	B-MED
is	O
reached	O
with	O
100	O
μm	O
of	O
the	O
relevant	B-MED
clinical	B-MED
gd-dtpa	B-MED
in	O
solution	B-MED
.	O
	
the	O
advanced	O
microfluidic	B-MED
platform	O
to	O
synthesize	O
intravascularly	B-MED
-	O
injectable	B-MED
and	O
completely	O
biocompatible	B-MED
hydrogel	I-MED
nanoparticles	B-MED
entrapping	O
clinically	B-MED
approved	B-MED
cas	B-MED
enables	O
the	O
implementation	B-MED
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	B-MED
and	O
therapy	B-MED
applications	B-MED
.	O
	
arthrobacter	B-MED
ginkgonis	I-MED
sp	I-MED
.	O
	
nov	I-MED
,	O
an	O
actinomycete	B-MED
isolated	B-MED
from	O
rhizosphere	B-MED
of	O
ginkgo	B-MED
biloba	I-MED
l	I-MED
a	O
gram-stain-positive	B-MED
,	O
aerobic	B-MED
actinobacterial	B-MED
strain	I-MED
designated	O
syp-a7299t	B-MED
,	O
which	O
displayed	O
a	O
rod-coccus	B-MED
growth	I-MED
lifecycle	I-MED
,	O
was	O
isolated	B-MED
from	O
the	O
rhizosphere	B-MED
of	O
ginkgo	B-MED
biloba	I-MED
l	I-MED
.	O
	
phylogenetic	B-MED
analyses	I-MED
based	O
on	O
16s	B-MED
rrna	I-MED
gene	I-MED
sequences	I-MED
indicated	O
that	O
strain	B-MED
syp-a7299t	I-MED
belongs	O
to	O
the	O
genus	B-MED
arthrobacter	B-MED
and	O
is	O
most	O
closely	O
related	O
to	O
arthrobacter	B-MED
halodurans	I-MED
jsm	I-MED
078085t	I-MED
97.4	O
%	O
16s	B-MED
rrna	I-MED
gene	I-MED
sequence	I-MED
similarity	B-MED
.	O
	
the	O
dna	B-MED
-	O
dna	B-MED
relatedness	B-MED
value	I-MED
between	O
strain	B-MED
syp-a7299t	I-MED
and	O
a	B-MED
.	O
	
halodurans	I-MED
jsm	I-MED
078085t	I-MED
was	O
37	O
%	O
2.9	O
.	O
	
the	O
cell-wall	B-MED
peptidoglycan	B-MED
was	O
a4α	B-MED
,	O
and	O
glucose	B-MED
and	O
galactose	B-MED
were	O
whole-cell	B-MED
sugars	I-MED
.	O
	
the	O
polar	B-MED
lipids	I-MED
consisted	O
of	O
diphosphatidylglycerol	B-MED
,	O
phosphatidylglycerol	B-MED
,	O
phosphatidylinositol	B-MED
,	O
two	O
glycolipids	B-MED
and	O
an	O
unknown	O
polar	B-MED
lipid	I-MED
.	O
	
the	O
major	O
menaquinone	B-MED
were	O
mk-8	B-MED
72	O
%	O
and	O
mk-9	B-MED
28	O
%	O
,	O
and	O
the	O
predominant	O
cellular	B-MED
fatty	I-MED
acids	I-MED
were	O
anteiso-c15	B-MED
0	I-MED
,	O
iso-c15	B-MED
0	I-MED
and	O
anteiso-c17	B-MED
0	I-MED
.	O
	
the	O
dna	B-MED
g+c	B-MED
content	I-MED
was	O
68.9	O
mol%	O
.	O
	
based	O
on	O
the	O
morphological	B-MED
,	O
physiological	B-MED
,	O
biochemical	B-MED
and	O
chemotaxonomic	B-MED
characters	I-MED
presented	O
in	O
this	O
study	O
,	O
strain	B-MED
syp-a7299t	I-MED
represents	O
a	O
novel	O
species	B-MED
of	O
the	O
genus	B-MED
arthrobacter	B-MED
,	O
for	O
which	O
the	O
name	O
arthrobacter	B-MED
ginkgonis	I-MED
sp	I-MED
.	O
	
nov	I-MED
.	O
	
is	O
proposed	O
.	O
	
the	O
type	B-MED
strain	I-MED
is	O
syp-a7299t	B-MED
=dsm	B-MED
100491t=kctc	I-MED
39	I-MED
592t	I-MED
.	O
	
decoding	B-MED
the	O
interactions	B-MED
regulating	B-MED
the	O
active	B-MED
state	I-MED
mechanics	B-MED
of	O
eukaryotic	B-MED
protein	B-MED
kinases	I-MED
eukaryotic	B-MED
protein	B-MED
kinases	I-MED
regulate	B-MED
most	O
cellular	B-MED
functions	I-MED
by	O
phosphorylating	B-MED
targeted	B-MED
protein	B-MED
substrates	B-MED
through	B-MED
a	O
highly	B-MED
conserved	B-MED
catalytic	B-MED
core	I-MED
.	O
	
in	O
the	O
active	B-MED
state	I-MED
,	O
the	O
catalytic	B-MED
core	I-MED
oscillates	B-MED
between	O
open	B-MED
,	O
intermediate	B-MED
,	O
and	O
closed	B-MED
conformations	B-MED
.	O
	
currently	B-MED
,	O
the	O
intramolecular	B-MED
interactions	I-MED
that	O
regulate	B-MED
the	O
active	B-MED
state	I-MED
mechanics	B-MED
are	O
not	B-MED
well	I-MED
understood	I-MED
.	O
	
here	O
,	O
using	O
camp-dependent	B-MED
protein	I-MED
kinase	I-MED
as	O
a	O
representative	B-MED
model	B-MED
coupled	B-MED
with	O
biochemical	B-MED
,	O
biophysical	B-MED
,	O
and	O
computational	B-MED
techniques	I-MED
,	O
we	O
define	O
a	O
set	O
of	O
highly	B-MED
conserved	B-MED
electrostatic	B-MED
and	O
hydrophobic	B-MED
interactions	I-MED
working	O
harmoniously	B-MED
to	O
regulate	B-MED
these	O
mechanics	B-MED
.	O
	
these	O
include	B-MED
the	O
previously	B-MED
identified	B-MED
salt	B-MED
bridge	I-MED
between	O
a	O
lysine	B-MED
from	O
the	O
β3-strand	B-MED
and	O
a	O
glutamate	B-MED
from	O
the	O
αc-helix	B-MED
as	O
well	O
as	O
an	O
electrostatic	B-MED
interaction	I-MED
between	O
the	O
phosphorylated	B-MED
activation	B-MED
loop	B-MED
and	O
αc-helix	B-MED
and	O
an	O
ensemble	B-MED
of	O
hydrophobic	B-MED
residues	B-MED
of	O
the	O
regulatory	O
spine	O
and	O
shell	O
.	O
	
moreover	O
,	O
for	O
over	O
three	O
decades	B-MED
it	O
was	O
thought	O
that	O
the	O
highly	B-MED
conserved	B-MED
β3	B-MED
-lysine	O
was	O
essential	O
for	O
phosphoryl	O
transfer	O
,	O
but	O
our	O
findings	O
show	O
that	O
the	O
β3	B-MED
-lysine	I-MED
is	O
not	O
required	O
for	O
phosphoryl	O
transfer	O
but	O
is	O
essential	B-MED
for	O
the	O
active	O
state	O
mechanics	B-MED
acute	B-MED
clinical	B-MED
adverse	B-MED
radiation	I-MED
effects	I-MED
after	O
gamma	B-MED
knife	I-MED
surgery	I-MED
for	O
vestibular	B-MED
schwannomas	I-MED
objective	O
vestibular	B-MED
schwannomas	I-MED
vss	B-MED
represent	O
a	O
common	O
indication	O
of	O
gamma	B-MED
knife	I-MED
surgery	I-MED
gks	B-MED
.	O
	
while	O
most	O
studies	B-MED
focus	O
on	O
the	O
long-term	B-MED
morbidity	B-MED
and	O
adverse	B-MED
radiation	I-MED
effects	I-MED
ares	B-MED
,	O
none	O
describe	O
the	O
acute	B-MED
clinical	B-MED
ares	B-MED
that	O
might	O
appear	O
on	O
a	O
short-term	B-MED
basis	O
.	O
	
these	O
types	O
of	O
events	O
are	O
investigated	B-MED
,	O
and	O
their	O
incidence	B-MED
,	O
type	B-MED
,	O
and	O
outcomes	B-MED
are	O
reported	B-MED
in	O
the	O
present	O
paper	O
.	O
	
methods	O
the	O
included	O
patients	B-MED
were	O
treated	B-MED
between	O
july	O
2010	O
and	O
march	O
2016	O
,	O
underwent	O
at	O
least	O
6	O
months	B-MED
of	O
follow-up	B-MED
,	O
and	O
presented	O
with	O
a	O
disabling	B-MED
symptom	B-MED
during	O
the	O
first	O
6	O
months	B-MED
after	O
gks	B-MED
that	O
affected	B-MED
their	O
quality	B-MED
of	I-MED
life	I-MED
.	O
	
the	O
timing	O
of	O
appearance	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-MED
and	O
outcome	B-MED
,	O
were	O
noted	O
.	O
	
the	O
prescribed	B-MED
dose	B-MED
was	O
12	O
gy	O
at	O
the	O
margin	O
.	O
	
results	O
thirty-five	O
22%	O
of	O
159	O
patients	B-MED
who	O
fulfilled	O
the	O
inclusion	B-MED
criteria	O
had	O
acute	B-MED
clinical	B-MED
ares	B-MED
.	O
	
the	O
mean	B-MED
followup	B-MED
period	O
was	O
30	O
months	B-MED
range	B-MED
6-49	O
months	B-MED
.	O
	
the	O
mean	B-MED
time	O
of	O
appearance	O
was	O
37.9	O
days	B-MED
median	B-MED
31	O
days	B-MED
range	B-MED
3-110	O
days	B-MED
.	O
	
in	O
patients	B-MED
with	O
de	B-MED
novo	I-MED
symptoms	B-MED
,	O
the	O
more	O
frequent	O
symptoms	B-MED
were	O
vertigo	B-MED
n	O
=	O
4	O
11.4	O
and	O
gait	B-MED
disturbance	I-MED
n	O
=	O
3	O
8.6	O
.	O
	
the	O
exacerbation	B-MED
of	O
a	O
preexisting	O
symptom	B-MED
was	O
more	O
frequently	O
related	O
to	O
hearing	B-MED
loss	I-MED
n	O
=	O
10	O
28.6	O
,	O
followed	O
by	O
gait	B-MED
disturbance	I-MED
n	O
=	O
7	O
20%	O
and	O
vertigo	B-MED
n	O
=	O
3	O
,	O
8.6	O
.	O
	
in	O
the	O
univariate	B-MED
logistic	B-MED
regression	I-MED
analysis	I-MED
,	O
the	O
following	O
factors	B-MED
were	O
statistically	B-MED
significant	I-MED
age	B-MED
p	O
=	O
0.002	O
odds	B-MED
ratio	I-MED
or	B-MED
0.96	O
,	O
hearing	O
at	O
baseline	B-MED
by	O
gardner-robertson	B-MED
gr	B-MED
class	O
p	O
=	O
0.006	O
or	B-MED
0.21	O
,	O
pure	B-MED
tone	I-MED
average	I-MED
at	O
baseline	B-MED
p	O
=	O
0.006	O
or	B-MED
0.97	O
,	O
and	O
koos	B-MED
grade	I-MED
at	O
baseline	B-MED
with	O
koos	B-MED
grade	I-MED
i	I-MED
used	O
as	O
a	O
reference	O
for	O
koos	B-MED
grade	I-MED
ii	I-MED
,	O
or	B-MED
0.17	O
and	O
p	O
=	O
0.002	O
for	O
koos	B-MED
grade	I-MED
iii	I-MED
,	O
or	B-MED
0.42	O
and	O
p	O
=	O
0.05	O
.	O
	
the	O
following	O
were	O
not	O
statistically	B-MED
significant	I-MED
but	O
showed	O
a	O
tendency	O
toward	O
significance	O
the	O
number	O
of	O
isocenters	B-MED
p	O
=	O
0.06	O
or	B-MED
0.94	O
and	O
the	O
maximal	B-MED
dose	B-MED
received	O
by	O
the	O
cochlea	B-MED
p	O
=	O
0.07	O
or	B-MED
0.74	O
.	O
	
fractional	B-MED
polynomial	I-MED
regression	I-MED
analysis	I-MED
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	B-MED
and	O
the	O
radiation	B-MED
dose	I-MED
rate	I-MED
minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2.5	O
gy/minute	O
and	O
the	O
maximal	B-MED
vestibular	B-MED
dose	B-MED
maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
gy	O
,	O
but	O
the	O
small	O
sample	B-MED
size	I-MED
precludes	B-MED
a	O
detailed	O
analysis	B-MED
of	O
the	O
former	O
.	O
	
the	O
clinical	B-MED
acute	B-MED
ares	B-MED
disappeared	O
in	O
32	O
91.4	O
patients	B-MED
during	O
the	O
first	O
6	O
months	B-MED
after	O
appearance	O
.	O
	
permanent	O
and	O
somewhat	O
disabling	B-MED
morbidity	B-MED
was	O
found	O
in	O
3	O
cases	B-MED
1.9	O
from	O
the	O
whole	O
series	O
1	O
each	O
with	O
complete	B-MED
hearing	I-MED
loss	I-MED
gr	B-MED
class	I-MED
i	I-MED
before	O
and	O
v	B-MED
after	O
,	O
hemifacial	B-MED
spasm	I-MED
persistent	B-MED
but	O
alleviated	O
,	O
and	O
dysgeusia	B-MED
.	O
	
conclusions	O
acute	B-MED
effects	B-MED
after	O
radiosurgery	B-MED
for	O
vs	B-MED
are	O
not	O
rare	O
.	O
	
they	O
concern	O
predominantly	O
de	B-MED
novo	I-MED
vertigo	B-MED
and	O
gait	B-MED
disturbance	I-MED
and	O
the	O
exacerbation	B-MED
of	O
preexistent	O
hearing	B-MED
loss	I-MED
.	O
	
in	O
de	B-MED
novo	I-MED
vestibular	B-MED
symptom	B-MED
s	O
,	O
a	O
vestibular	B-MED
dose	B-MED
of	O
more	O
than	O
8	O
gy	O
is	O
thought	O
to	O
play	O
a	O
role	O
.	O
	
in	O
most	O
cases	B-MED
,	O
none	O
of	O
these	O
effects	B-MED
are	O
permanent	O
,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid	B-MED
therapy	I-MED
.	O
	
permanent	O
ares	B-MED
remain	O
very	O
long-chain	B-MED
n-3	I-MED
pufa	I-MED
supplied	B-MED
by	O
the	O
usual	B-MED
diet	B-MED
decrease	B-MED
plasma	B-MED
stearoyl-coa	I-MED
desaturase	I-MED
index	B-MED
in	O
non-hypertriglyceridemic	B-MED
older	B-MED
adults	I-MED
at	O
high	O
vascular	B-MED
risk	B-MED
the	O
activity	B-MED
of	O
stearoyl-coa	B-MED
desaturase-1	I-MED
scd1	B-MED
,	O
the	O
central	B-MED
enzyme	I-MED
in	O
the	O
synthesis	B-MED
of	O
monounsaturated	B-MED
fatty	I-MED
acids	I-MED
mufa	B-MED
,	O
has	O
been	O
associated	B-MED
with	I-MED
de	B-MED
novo	I-MED
lipogenesis	B-MED
.	O
	
in	O
experimental	B-MED
models	I-MED
scd1	B-MED
is	O
down-regulated	B-MED
by	O
polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
pufa	B-MED
,	O
but	O
clinical	B-MED
studies	I-MED
are	O
scarce	O
.	O
	
the	O
effect	B-MED
of	O
long-chain	B-MED
n-3	I-MED
pufa	I-MED
lcn-3pufa	B-MED
supplied	B-MED
by	O
the	O
regular	B-MED
diet	I-MED
,	O
in	O
the	O
absence	B-MED
of	O
fatty	B-MED
fish	I-MED
or	O
fish	B-MED
oil	I-MED
supplementation	B-MED
,	O
remains	O
to	O
be	O
explored	O
.	O
	
we	O
related	B-MED
1-y	O
changes	B-MED
in	O
plasma	B-MED
scd1	I-MED
index	B-MED
,	O
as	O
assessed	B-MED
by	O
the	O
c16	B-MED
/	O
c16	B-MED
ratio	B-MED
,	O
to	O
both	O
adiposity	B-MED
traits	B-MED
and	O
nutrient	B-MED
intake	I-MED
changes	B-MED
in	O
a	O
sub-cohort	B-MED
n	O
=	O
243	O
of	O
non-hypertriglyceridemic	B-MED
subjects	B-MED
of	O
the	O
predimed	B-MED
prevención	I-MED
con	I-MED
dieta	I-MED
mediterranea	I-MED
trial	I-MED
.	O
	
after	O
adjustment	O
for	O
confounders	O
,	O
including	O
changes	B-MED
in	O
fasting	B-MED
triglycerides	B-MED
,	O
plasma	B-MED
scd1	I-MED
index	B-MED
increased	B-MED
in	O
parallel	O
with	O
body	B-MED
weight	I-MED
0.221	O
95%	O
confidence	B-MED
interval	I-MED
,	O
0.021	O
to	O
0.422	O
,	O
p	O
=	O
0.031	O
and	O
bmi	B-MED
0.115	O
0.027	O
to	O
0.202	O
,	O
p	O
=	O
0.011	O
.	O
	
additionally	O
,	O
dietary	B-MED
lcn-3pufa	B-MED
but	O
not	O
mufa	B-MED
or	O
plant-derived	B-MED
pufa	I-MED
were	O
associated	B-MED
with	I-MED
decreased	B-MED
plasma	B-MED
scd1	I-MED
index	B-MED
-0	O
-1	O
to	O
-0	O
,	O
p	O
=	O
0.033	O
,	O
for	O
each	O
1	O
g/d-	O
increase	B-MED
in	O
lcn-3pufa	B-MED
.	O
	
no	O
associations	B-MED
were	O
found	O
for	O
other	O
food	B-MED
groups	B-MED
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty	B-MED
fish	I-MED
intake	B-MED
-0	O
-0	O
to	O
0.012	O
,	O
p	O
=	O
0.085	O
,	O
for	O
each	O
10	O
g/d-	O
increase	B-MED
.	O
	
our	O
data	B-MED
add	O
clinical	B-MED
evidence	B-MED
on	O
the	O
down-regulation	B-MED
of	O
plasma	B-MED
scd1	I-MED
index	B-MED
by	O
lcn-3pufa	B-MED
in	O
the	O
context	B-MED
of	O
realistic	O
changes	B-MED
in	O
fish	B-MED
consumption	B-MED
in	O
the	O
customary	B-MED
,	O
non-supplemented	B-MED
diet	B-MED
.	O
	
distinct	B-MED
cortical	I-MED
and	I-MED
sub-cortical	I-MED
neurogenic	I-MED
domains	I-MED
for	O
gabaergic	B-MED
interneuron	B-MED
precursor	B-MED
transcription	B-MED
factors	I-MED
nkx2.1	B-MED
,	O
olig2	B-MED
and	O
coup-tfii	B-MED
in	O
early	O
fetal	B-MED
human	B-MED
telencephalon	B-MED
the	O
extent	O
of	O
similarities	B-MED
and	O
differences	B-MED
between	O
cortical	B-MED
gabaergic	I-MED
interneuron	I-MED
generation	I-MED
in	O
rodent	B-MED
and	O
primate	B-MED
telencephalon	B-MED
remains	O
contentious	O
.	O
	
we	O
examined	O
expression	B-MED
of	O
three	O
interneuron	B-MED
precursor	B-MED
transcription	B-MED
factors	I-MED
,	O
alongside	O
other	O
markers	B-MED
,	O
using	O
immunohistochemistry	B-MED
on	O
8-12	O
post-conceptional	B-MED
weeks	I-MED
pcw	B-MED
human	B-MED
telencephalon	B-MED
sections	O
.	O
	
nkx2.1	B-MED
,	O
olig2	B-MED
,	O
and	O
coup-tfii	B-MED
expression	B-MED
occupied	O
distinct	O
although	O
overlapping	O
neurogenic	B-MED
domains	I-MED
which	O
extended	O
into	O
the	O
cortex	B-MED
and	O
revealed	O
three	O
cge	B-MED
compartments	I-MED
lateral	B-MED
,	O
medial	B-MED
,	O
and	O
ventral	B-MED
.	O
	
nkx2.1	B-MED
expression	B-MED
was	O
very	O
largely	O
confined	O
to	O
the	O
mge	B-MED
,	O
medial	B-MED
cge	B-MED
,	O
and	O
ventral	B-MED
septum	B-MED
confirming	O
that	O
,	O
at	O
this	O
developmental	B-MED
stage	I-MED
,	O
interneuron	B-MED
generation	O
from	O
nkx2.1	B-MED
+	O
precursor	B-MED
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	B-MED
.	O
	
olig2	B-MED
immunoreactivity	B-MED
was	O
observed	O
in	O
gabaergic	B-MED
cells	I-MED
of	O
the	O
proliferative	B-MED
zones	B-MED
of	O
the	O
mge	B-MED
and	O
septum	B-MED
,	O
but	O
not	O
necessarily	O
co-expressed	O
with	O
nkx2.1	B-MED
,	O
and	O
olig2	B-MED
expression	B-MED
was	O
also	O
extensively	O
seen	O
in	O
the	O
lge	B-MED
,	O
cge	B-MED
,	O
and	O
cortex	B-MED
.	O
	
at	O
8	O
pcw	B-MED
,	O
olig2	B-MED
+	O
cells	B-MED
were	O
only	O
present	O
in	O
the	O
medial	B-MED
and	O
anterior	B-MED
cortical	B-MED
wall	I-MED
suggesting	O
a	O
migratory	B-MED
pathway	B-MED
for	O
interneuron	B-MED
precursor	B-MED
s	O
via	O
the	O
septum	B-MED
into	O
the	O
medial	B-MED
cortex	B-MED
.	O
	
by	O
12	O
pcw	B-MED
,	O
olig2	B-MED
+	O
cells	B-MED
were	O
present	O
throughout	O
the	O
cortex	B-MED
and	O
many	O
were	O
actively	O
dividing	B-MED
but	O
without	O
co-expressing	O
cortical	B-MED
progenitor	B-MED
markers	B-MED
.	O
	
dividing	O
coup-tfii	B-MED
+	O
progenitor	B-MED
cells	I-MED
were	O
localized	B-MED
to	O
ventral	B-MED
cge	B-MED
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	B-MED
cortex	B-MED
in	O
both	O
the	O
cases	O
,	O
coup-tfii	B-MED
was	O
co-expressed	O
with	O
pax6	B-MED
in	O
proliferative	B-MED
zones	B-MED
and	O
tbr1	B-MED
or	O
calretinin	B-MED
in	O
post-	O
mitotic	B-MED
cortical	B-MED
neurons	I-MED
.	O
	
thus	O
coup-tfii	B-MED
+	O
progenitors	B-MED
gave	O
rise	O
to	O
pyramidal	B-MED
cells	I-MED
,	O
but	O
also	O
interneurons	B-MED
which	O
not	O
only	O
migrated	B-MED
posteriorly	O
into	O
the	O
cortex	B-MED
from	O
ventral	B-MED
cge	B-MED
but	O
also	O
anteriorly	B-MED
via	O
the	O
primary	B-MED
neuroendocrine	I-MED
carcinoma	I-MED
of	O
the	O
breast	B-MED
a	O
single	B-MED
center	I-MED
experience	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
neuroendocrine	B-MED
carcinoma	I-MED
of	O
the	O
breast	B-MED
is	O
an	O
extremely	B-MED
rare	B-MED
tumor	B-MED
.	O
	
a	O
standard	B-MED
treatment	B-MED
has	O
yet	O
to	O
be	O
established	B-MED
because	O
only	O
a	O
few	O
cases	B-MED
have	O
been	O
reported	O
in	O
literature	B-MED
.	O
	
the	O
authors	B-MED
report	O
five	O
cases	B-MED
observed	O
from	O
january	B-MED
2007	O
to	O
december	B-MED
2014	O
and	O
a	O
review	B-MED
of	I-MED
literature	I-MED
.	O
	
four	O
patients	B-MED
underwent	O
quadrantectomy	B-MED
and	O
in	O
two	O
cases	B-MED
axillary	B-MED
nodal	I-MED
dissection	I-MED
and	O
only	O
one	O
to	O
mastectomy	B-MED
with	O
axillary	B-MED
nodal	I-MED
dissection	I-MED
.	O
	
tumor	B-MED
size	I-MED
was	O
from	O
t1	B-MED
to	O
t2	B-MED
with	O
n0	B-MED
to	O
n1	B-MED
,	O
according	O
tnm	B-MED
classification	I-MED
.	O
	
pathological	B-MED
specimens	I-MED
were	O
stained	B-MED
with	O
hematoxylin	B-MED
and	O
eosin	B-MED
and	O
an	O
immunohistochemical	B-MED
panel	B-MED
of	O
antibodies	B-MED
neuron-specific	B-MED
enolase	I-MED
,	O
chromogranin	B-MED
,	O
synaptophysin	B-MED
,	O
estrogen	B-MED
and	O
progesterone	B-MED
receptors	I-MED
,	O
c-erb	B-MED
and	O
ki-67	B-MED
.	O
	
all	O
cases	B-MED
showed	O
markers	B-MED
positivity	O
to	O
neuron-specific	B-MED
enolase	I-MED
,	O
chromogranin	B-MED
,	O
synaptophysin	B-MED
and	O
estrogen	B-MED
and	O
progesterone	B-MED
receptors	I-MED
were	O
found	O
.	O
	
ki-67	B-MED
was	O
higher	O
than	O
40%	O
in	O
four	O
patients	B-MED
.	O
	
adjuvant	B-MED
chemotherapy	I-MED
was	O
administrated	B-MED
in	O
patients	B-MED
with	O
ki-67	B-MED
>10%	O
every	O
patients	B-MED
were	O
treated	B-MED
with	O
radiotherapy	B-MED
and	O
with	O
hormonal	B-MED
therapy	I-MED
too	O
.	O
	
although	O
neuroendocrine	B-MED
breast	I-MED
tumor	I-MED
is	O
considered	O
a	O
distinct	O
entity	B-MED
,	O
the	O
best	O
treatment	B-MED
seems	O
to	O
be	O
correlate	B-MED
to	O
the	O
size	B-MED
of	I-MED
tumor	I-MED
and	O
to	O
the	O
lymph	B-MED
node	I-MED
status	B-MED
and	O
to	O
ki-67	B-MED
index	B-MED
like	O
the	O
common	O
breast	B-MED
cancer	I-MED
.	O
	
diagnosis	B-MED
,	O
neuroendocrine	B-MED
breast	I-MED
carcinoma	I-MED
.	O
	
a	O
new	O
parametric	B-MED
model	I-MED
to	O
assess	B-MED
delay	B-MED
and	O
compression	B-MED
of	O
mortality	B-MED
a	O
decrease	B-MED
in	O
mortality	B-MED
across	O
all	O
ages	B-MED
causes	O
a	O
shift	O
of	O
the	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
,	O
or	O
mortality	B-MED
delay	B-MED
,	O
while	O
differences	B-MED
in	O
the	O
rate	B-MED
of	O
decrease	B-MED
across	O
ages	B-MED
cause	O
a	O
change	O
in	O
the	O
shape	B-MED
of	O
the	O
age-at-death	B-MED
distribution	B-MED
,	O
mortality	B-MED
compression	B-MED
or	O
expansion	B-MED
.	O
	
evidence	B-MED
exists	O
for	O
both	O
compression	B-MED
and	O
delay	B-MED
of	O
mortality	B-MED
.	O
	
existing	O
parametric	B-MED
models	I-MED
to	O
describe	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
are	O
not	O
able	O
to	O
capture	O
mortality	B-MED
delay	B-MED
versus	O
mortality	B-MED
compression	B-MED
.	O
	
more	O
recent	O
models	B-MED
that	O
assess	O
delay	B-MED
versus	O
compression	B-MED
mostly	O
focused	O
on	O
the	O
adult	B-MED
or	O
old	B-MED
ages	I-MED
alone	O
and	O
did	O
not	O
distinguish	O
mortality	B-MED
compression	B-MED
below	O
and	O
above	O
the	O
modal	B-MED
age	I-MED
at	O
death	B-MED
,	O
although	O
they	O
represent	O
different	B-MED
mechanisms	B-MED
.	O
	
this	O
paper	B-MED
presents	O
a	O
new	O
parametric	B-MED
model	I-MED
that	O
describes	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
and	O
assesses	O
compression	B-MED
-	O
at	O
different	B-MED
stages	B-MED
of	I-MED
life	I-MED
-	O
and	O
delay	B-MED
of	O
mortality	B-MED
the	O
code	B-MED
model	I-MED
.	O
	
the	O
model	B-MED
includes	O
10	O
parameters	B-MED
,	O
of	O
which	O
five	O
are	O
constant	B-MED
over	O
time	B-MED
.	O
	
the	O
five	O
time	B-MED
-varying	O
parameters	B-MED
reflect	O
delay	B-MED
of	O
mortality	B-MED
and	O
compression	B-MED
of	O
mortality	B-MED
in	O
infancy	B-MED
,	O
adolescence	B-MED
,	O
young	B-MED
adulthood	I-MED
,	O
late	B-MED
adulthood	I-MED
,	O
and	O
old	B-MED
age	I-MED
.	O
	
the	O
model	B-MED
describes	O
infant	B-MED
and	O
background	O
mortality	B-MED
by	O
two	O
simple	O
functions	B-MED
,	O
uses	O
a	O
mixed	B-MED
logistic	I-MED
model	I-MED
with	O
different	B-MED
slopes	B-MED
in	O
adult	B-MED
,	O
middle	B-MED
,	O
and	O
old	B-MED
age	I-MED
,	O
and	O
includes	O
the	O
modal	B-MED
age	I-MED
at	O
death	B-MED
as	O
a	O
parameter	B-MED
to	O
account	O
for	O
the	O
delay	B-MED
in	O
mortality	B-MED
.	O
	
applying	O
the	O
code	B-MED
model	I-MED
to	O
age	B-MED
-	O
specific	B-MED
probabilities	B-MED
of	O
death	B-MED
for	O
japanese	B-MED
,	O
french	B-MED
,	O
american	B-MED
,	O
and	O
danish	B-MED
men	B-MED
and	O
women	B-MED
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
.	O
	
delay	B-MED
of	O
mortality	B-MED
explained	O
about	O
two-thirds	O
of	O
the	O
increase	B-MED
in	O
life	B-MED
expectancy	I-MED
at	O
birth	B-MED
,	O
whereas	O
compression	B-MED
of	O
mortality	B-MED
due	O
to	O
mortality	B-MED
declines	I-MED
in	O
young	B-MED
age	I-MED
explained	O
about	O
one-third	O
.	O
	
no	O
strong	O
compression	B-MED
of	O
mortality	B-MED
in	O
late	B-MED
adulthood	I-MED
age	I-MED
was	O
observed	O
.	O
	
mortality	B-MED
compression	B-MED
in	O
old	B-MED
age	I-MED
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life	B-MED
expectancy	I-MED
.	O
	
the	O
code	B-MED
model	I-MED
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	B-MED
delay	B-MED
and	O
compression	B-MED
-	O
at	O
different	B-MED
stages	B-MED
of	I-MED
life	I-MED
-	O
on	O
the	O
increase	B-MED
in	O
life	B-MED
expectancy	I-MED
.	O
	
prevalence	B-MED
of	O
hypothyroidism	B-MED
in	O
andalusia	B-MED
,	O
spain	I-MED
,	O
determined	O
by	O
thyroid	B-MED
hormone	I-MED
comsumption	B-MED
hypothyroidism	B-MED
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone	B-MED
deficiency	I-MED
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	B-MED
are	O
scarce	O
in	O
spain	B-MED
.	O
	
for	O
that	O
reason	O
,	O
we	O
have	O
estimated	O
its	O
prevalence	B-MED
through	O
the	O
registration	B-MED
of	O
patients	B-MED
who	O
had	O
used	O
thyroid	B-MED
hormones	I-MED
in	O
andalusia	B-MED
south	I-MED
spain	I-MED
.	O
	
data	O
of	O
patients	B-MED
who	O
had	O
withdrawn	O
levothyroxine	B-MED
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
andalusian	B-MED
health	I-MED
service	I-MED
were	O
considered	O
.	O
	
prevalence	B-MED
were	O
calculated	O
with	O
confidence	B-MED
intervals	I-MED
of	O
95%	O
for	O
each	O
management	B-MED
area	I-MED
,	O
stratified	O
by	O
sex	B-MED
and	O
age	B-MED
groups	I-MED
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-MED
.	O
	
321	O
people	B-MED
98%	O
older	O
than	O
18	O
years	O
and	O
83%	O
female	B-MED
were	O
identified	O
as	O
levothyroxine	B-MED
users	O
and	O
a	O
prevalence	B-MED
of	O
hypothyroidism	B-MED
of	O
3.95	O
95%	O
ci	B-MED
3.94	O
was	O
estimated	O
for	O
the	O
general	O
population	B-MED
.	O
	
the	O
condition	O
was	O
more	O
common	O
in	O
females	B-MED
,	O
in	O
the	O
older	O
18	O
years	O
7.81	O
95%	O
ci	B-MED
7.80	O
to	O
7.82	O
compared	O
to	O
males	B-MED
1.75	O
95%	O
ci	B-MED
1.73	O
with	O
a	O
ratio	O
of	O
4.5	B-MED
.	O
	
it	O
increases	O
in	O
the	O
population	B-MED
of	O
women	B-MED
older	O
than	O
45	O
years	O
,	O
10.32	O
95%	O
ci	B-MED
10.30	O
and	O
in	O
the	O
over	O
60	O
years	O
11.37	O
95%	O
ci	B-MED
11.35	O
.	O
	
the	O
prevalence	B-MED
in	O
adult	B-MED
women	B-MED
in	O
the	O
western	B-MED
provinces	I-MED
is	O
7.38	O
95%	O
ci	B-MED
7.36	O
,	O
in	O
the	O
eastern	B-MED
provinces	I-MED
8.59	O
95%	O
ci	B-MED
8.57	O
and	O
in	O
coastal	B-MED
areas	I-MED
6.70	O
95%	O
ci	B-MED
6.68	O
compared	O
to	O
the	O
mountainous	B-MED
ones	I-MED
,	O
which	O
is	O
8.91	O
95%	O
ci	B-MED
8.88	O
.	O
	
the	O
results	O
denote	O
a	O
high	B-MED
prevalence	I-MED
of	O
hypothyroidism	B-MED
in	O
the	O
adult	B-MED
population	B-MED
of	O
andalusia	B-MED
compared	O
to	O
the	O
nearby	O
countries	B-MED
,	O
with	O
a	O
clear	O
increased	O
associated	B-MED
with	I-MED
females	B-MED
and	O
age	B-MED
.	O
	
furthermore	O
,	O
the	O
prevalence	B-MED
of	O
the	O
illness	B-MED
presents	O
also	O
a	O
geographically-related	B-MED
variability	B-MED
.	O
	
disease	B-MED
activity	I-MED
and	O
increased	B-MED
risk	I-MED
of	I-MED
cardiovascular	B-MED
death	I-MED
among	O
patients	B-MED
with	O
psoriatic	B-MED
arthritis	I-MED
recent	O
studies	O
indicate	O
increased	O
cardiovascular	B-MED
cv	I-MED
morbidity	I-MED
and	O
mortality	B-MED
in	O
patients	B-MED
with	O
psoriatic	B-MED
arthritis	I-MED
psa	B-MED
,	O
but	O
results	O
are	O
inconsistent	O
.	O
	
this	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	B-MED
rate	I-MED
,	O
cause	B-MED
of	I-MED
death	I-MED
,	O
and	O
incidence	O
of	O
acute	O
cv	B-MED
events	I-MED
in	O
patients	B-MED
from	O
northern	B-MED
sweden	B-MED
with	O
psa	B-MED
.	O
	
patients	B-MED
with	O
established	O
psa	B-MED
464	O
were	O
included	O
.	O
	
to	O
calculate	O
standardized	B-MED
mortality	I-MED
ratio	I-MED
smr	B-MED
and	O
standardized	B-MED
incidence	I-MED
ratio	I-MED
sir	B-MED
for	O
cv	B-MED
events	I-MED
,	O
data	O
were	O
extracted	O
from	O
the	O
national	B-MED
causes	I-MED
of	I-MED
death	I-MED
register	I-MED
and	O
the	O
national	B-MED
inpatient	I-MED
care	I-MED
register	I-MED
in	O
sweden	B-MED
,	O
and	O
compared	O
with	O
the	O
general	B-MED
population	I-MED
.	O
	
the	O
study	O
period	O
was	O
1995-2011	O
.	O
	
to	O
study	O
the	O
effect	O
of	O
inflammatory	B-MED
activity	O
,	O
a	O
composite	O
disease	B-MED
activity	I-MED
index	I-MED
dai	B-MED
was	O
used	O
.	O
	
the	O
smr	B-MED
95%	O
ci	O
for	O
overall	B-MED
mortality	I-MED
and	O
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
international	B-MED
classification	I-MED
of	I-MED
diseases	I-MED
,	O
10th	O
edition	O
i00-i99	O
was	O
1.22	O
0.89	O
and	O
1.64	O
1.02	O
,	O
respectively	O
.	O
	
in	O
regression	B-MED
analysis	I-MED
,	O
dai	B-MED
was	O
significantly	O
associated	O
with	O
death	B-MED
or	O
1.99	O
,	O
95%	O
ci	O
1.41	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
p	O
<	O
0.001	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	B-MED
patients	B-MED
into	O
the	O
2	O
major	O
causes	B-MED
of	I-MED
death	I-MED
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
and	O
malignant	B-MED
neoplasms	I-MED
.	O
	
peripheral	B-MED
and	O
axial	B-MED
disease	I-MED
was	O
associated	O
with	O
death	B-MED
or	O
4.02	O
,	O
95%	O
ci	O
1.84	O
,	O
p	O
<	O
0.001	O
compared	O
with	O
peripheral	B-MED
disease	I-MED
only	O
.	O
	
the	O
sir	B-MED
95%	O
ci	O
for	O
a	O
cv	B-MED
event	I-MED
myocardial	B-MED
infarction	I-MED
or	O
stroke	B-MED
was	O
0.597	O
0.40	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	B-MED
.	O
	
patients	B-MED
with	O
psa	B-MED
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
smr	B-MED
for	O
death	B-MED
due	O
to	O
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
compared	O
with	O
the	O
general	B-MED
population	I-MED
.	O
	
among	O
patients	B-MED
,	O
death	B-MED
was	O
associated	O
with	O
dai	B-MED
,	O
as	O
well	O
as	O
axial	B-MED
involvement	I-MED
in	O
combination	O
with	O
peripheral	B-MED
disease	I-MED
,	O
indicating	O
more	O
aggressive	O
disease	B-MED
phenotypes	I-MED
.	O
	
histomorphometric	B-MED
and	O
transcriptome	B-MED
evaluation	B-MED
of	O
early	O
healing	B-MED
bone	I-MED
treated	B-MED
with	I-MED
a	O
novel	B-MED
human	B-MED
particulate	I-MED
dentin	I-MED
powder	B-MED
human	B-MED
particulate	I-MED
dentin	I-MED
hpd	B-MED
shows	O
potential	B-MED
as	O
an	O
alternative	B-MED
bone	B-MED
grafting	I-MED
material	B-MED
.	O
	
however	O
,	O
the	O
mechanism	B-MED
of	O
bone	B-MED
healing	I-MED
at	O
the	O
molecular	B-MED
level	B-MED
after	O
grafting	B-MED
with	O
hpd	B-MED
is	O
unclear	O
.	O
	
this	O
study	B-MED
assessed	B-MED
the	O
histological	B-MED
and	O
global	B-MED
gene	B-MED
expression	I-MED
of	O
bone	B-MED
tissues	I-MED
grafted	B-MED
with	O
hpd	B-MED
.	O
	
the	O
hpd	B-MED
was	O
prepared	B-MED
to	O
250-500	O
µm	O
in	O
size	O
.	O
	
x-ray	B-MED
diffraction	I-MED
xrd	B-MED
and	O
energy	B-MED
dispersive	I-MED
x-ray	I-MED
spectroscopy	I-MED
edx	B-MED
were	O
performed	B-MED
to	O
confirm	B-MED
the	O
crystal	B-MED
structure	I-MED
,	O
organic	B-MED
compound	I-MED
residues	B-MED
,	O
and	O
surface	B-MED
morphology	I-MED
,	O
respectively	O
.	O
	
bony	B-MED
defects	B-MED
were	O
created	B-MED
on	O
the	O
heads	B-MED
of	O
24	O
new	B-MED
zealand	I-MED
white	I-MED
rabbits	I-MED
.	O
	
sterilized	B-MED
hpd	B-MED
was	O
used	O
as	O
the	O
grafting	B-MED
material	I-MED
.	O
	
the	O
quality	B-MED
and	O
quantity	B-MED
of	O
new	B-MED
bone	I-MED
formation	I-MED
was	O
evaluated	B-MED
using	O
micro-ct	B-MED
and	O
histologic	B-MED
analyses	B-MED
during	B-MED
the	O
8	O
week	O
experimental	B-MED
periods	B-MED
.	O
	
for	O
microarray	B-MED
assay	I-MED
,	O
bone	B-MED
tissue	I-MED
and	O
blood	B-MED
samples	I-MED
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post-implantation	B-MED
.	O
	
the	O
results	B-MED
of	O
xrd	B-MED
and	O
edx	B-MED
showed	O
that	O
hpd	B-MED
exhibited	O
physical	B-MED
and	O
chemical	B-MED
properties	I-MED
similar	B-MED
to	O
natural	B-MED
hydroxyapatite	B-MED
.	O
	
new	B-MED
bone	I-MED
formation	I-MED
was	O
observed	B-MED
after	O
hpd	B-MED
implantation	B-MED
compared	B-MED
to	O
the	O
controls	B-MED
,	O
as	O
shown	O
on	O
hematoxylin	B-MED
and	I-MED
eosin	I-MED
staining	I-MED
and	O
micro-ct	B-MED
.	O
	
the	O
bone	B-MED
volume	I-MED
of	O
hpd	B-MED
treated	B-MED
animals	B-MED
was	O
higher	B-MED
than	O
that	O
of	O
the	O
control	B-MED
group	I-MED
at	O
all	O
observation	B-MED
times	B-MED
.	O
	
microarray	B-MED
analysis	I-MED
showed	O
that	O
vascular	B-MED
development	I-MED
coupled	O
with	O
immune	B-MED
and	O
inflammatory	B-MED
related	O
genes	B-MED
were	O
expressed	B-MED
in	O
the	O
early	B-MED
healing	B-MED
stage	B-MED
.	O
	
the	O
gene	B-MED
coding	I-MED
for	O
the	O
il-1	B-MED
antagonist	I-MED
,	O
il1rn	B-MED
,	O
was	O
expressed	B-MED
to	O
inhibit	B-MED
the	O
inflammatory	B-MED
response	I-MED
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
ccl2	B-MED
gene	I-MED
was	O
activated	B-MED
to	O
2.3	O
times	O
the	O
normal	B-MED
level	B-MED
.	O
	
bmp2	B-MED
,	O
runx2	B-MED
,	O
col1a	B-MED
,	O
and	O
opn	B-MED
expression	B-MED
were	O
also	O
up-regulated	B-MED
.	O
	
ccl2	B-MED
predominated	B-MED
in	O
osteoblastogenesis	B-MED
of	O
the	O
hpd	B-MED
-	O
treated	B-MED
bony	B-MED
defect	B-MED
in	O
the	O
early	B-MED
stage	I-MED
of	O
healing	B-MED
.	O
	
hpd	B-MED
accelerated	B-MED
bone	B-MED
regeneration	I-MED
and	O
augmentation	B-MED
.	O
	
these	O
results	B-MED
suggested	B-MED
that	O
hpd	B-MED
provided	B-MED
potential	B-MED
as	O
a	O
bone	B-MED
graft	I-MED
resource	B-MED
during	B-MED
the	O
bone	B-MED
healing	B-MED
process	I-MED
.	O
	
'you	O
can't	O
be	O
a	O
person	B-MED
and	O
a	O
docto	B-MED
r'	O
the	O
work-life	B-MED
balance	I-MED
of	O
doctors	B-MED
in	O
training	B-MED
-a	O
qualitative	B-MED
study	I-MED
investigate	B-MED
the	O
work-life	B-MED
balance	I-MED
of	O
doctors	B-MED
in	O
training	B-MED
in	O
the	O
uk	B-MED
from	O
the	O
perspectives	O
of	O
trainers	B-MED
and	O
trainees	O
.	O
	
qualitative	B-MED
semistructured	O
focus	O
groups	O
and	O
interviews	B-MED
with	O
trainees	O
and	O
trainers	B-MED
.	O
	
postgraduate	B-MED
medical	I-MED
training	I-MED
in	O
london	B-MED
,	O
yorkshire	B-MED
and	O
humber	B-MED
,	O
kent	B-MED
,	O
surrey	B-MED
and	O
sussex	B-MED
,	O
and	O
wales	B-MED
during	O
the	O
junior	B-MED
doctor	I-MED
contract	B-MED
dispute	B-MED
at	O
the	O
end	O
of	O
2015	O
.	O
	
part	O
of	O
a	O
larger	O
general	B-MED
medical	I-MED
council	I-MED
study	B-MED
about	O
the	O
fairness	O
of	O
postgraduate	B-MED
medical	I-MED
training	I-MED
.	O
	
96	O
trainees	O
and	O
41	O
trainers	B-MED
.	O
	
trainees	O
comprised	O
uk	B-MED
graduates	B-MED
and	O
international	B-MED
medical	I-MED
graduates	I-MED
,	O
across	O
all	O
stages	O
of	O
training	B-MED
in	O
6	O
specialties	B-MED
general	B-MED
practice	I-MED
,	O
medicine	B-MED
,	O
obstetrics	B-MED
and	I-MED
gynaecology	I-MED
,	O
psychiatry	B-MED
,	O
radiology	B-MED
,	O
surgery	B-MED
and	O
foundation	B-MED
.	O
	
postgraduate	B-MED
training	I-MED
was	O
characterised	O
by	O
work-life	B-MED
imbalance	I-MED
.	O
	
long	B-MED
hours	B-MED
at	O
work	B-MED
were	O
typically	O
supplemented	O
with	O
revision	B-MED
and	O
completion	B-MED
of	O
the	O
e-portfolio	B-MED
.	O
	
trainees	O
regularly	O
moved	O
workplaces	B-MED
which	O
could	O
disrupt	B-MED
their	O
personal	B-MED
lives	I-MED
and	O
sometimes	O
led	O
to	O
separation	B-MED
from	O
friends	B-MED
and	O
family	B-MED
.	O
	
this	O
made	O
it	O
challenging	O
to	O
cope	B-MED
with	O
personal	O
pressures	O
,	O
the	O
stresses	B-MED
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	B-MED
and	O
training	B-MED
,	O
while	O
also	O
leaving	B-MED
trainees	O
with	O
a	O
lack	B-MED
of	O
social	B-MED
support	I-MED
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-MED
of	O
training	B-MED
.	O
	
low	B-MED
morale	B-MED
and	O
harm	B-MED
to	O
well-being	B-MED
resulted	O
in	O
some	O
trainees	O
feeling	B-MED
dehumanised	B-MED
.	O
	
work-life	B-MED
imbalance	I-MED
was	O
particularly	O
severe	B-MED
for	O
those	O
with	O
children	B-MED
and	O
especially	O
women	B-MED
who	O
faced	O
a	O
lack	B-MED
of	O
less-than	B-MED
-	O
full-time	B-MED
positions	I-MED
and	O
discriminatory	B-MED
attitudes	B-MED
.	O
	
female	B-MED
trainees	O
frequently	O
talked	B-MED
about	O
having	O
to	O
choose	B-MED
a	O
specialty	B-MED
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work-life	B-MED
balance	I-MED
such	O
as	O
general	B-MED
practice	I-MED
.	O
	
the	O
proposed	O
junior	B-MED
doctor	I-MED
contract	B-MED
was	O
felt	O
to	O
exacerbate	B-MED
existing	B-MED
problems	B-MED
.	O
	
a	O
lack	B-MED
of	O
work-life	B-MED
balance	I-MED
in	O
postgraduate	B-MED
medical	I-MED
training	I-MED
negatively	B-MED
impacted	B-MED
on	O
trainees	O
'	O
learning	B-MED
and	O
well-being	B-MED
.	O
	
women	B-MED
with	O
children	B-MED
were	O
particularly	O
affected	B-MED
,	O
suggesting	O
this	O
group	B-MED
would	O
benefit	B-MED
the	O
greatest	B-MED
from	O
changes	B-MED
to	O
improve	B-MED
the	O
work-life	B-MED
balance	I-MED
reappraisal	B-MED
modulates	O
attentional	B-MED
bias	I-MED
to	O
angry	B-MED
faces	O
heightened	O
attentional	O
bias	O
to	O
emotional	O
information	O
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	O
related	O
to	O
emotion	O
dysregulation	O
such	O
as	O
anxiety	O
,	O
depression	O
,	O
and	O
substance	O
abuse	O
.	O
	
although	O
reappraisal	O
,	O
an	O
emotion	O
regulation	O
strategy	O
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective	O
experience	O
of	O
emotions	O
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	O
can	O
alter	O
attentional	O
biases	O
to	O
emotional	O
information	O
.	O
	
in	O
the	O
current	O
research	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
instruction-induced	O
state	O
reappraisal	O
study	O
1	O
and	O
trait	O
reappraisal	O
study	O
2	O
on	O
attentional	O
biases	O
to	O
happy	O
and	O
angry	O
faces	O
.	O
	
in	O
study	O
1	O
,	O
healthy	O
young	O
women	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	O
up	O
-	O
,	O
down	O
-	O
,	O
and	O
no-regulation	O
.	O
	
participants	O
were	O
instructed	O
to	O
reappraise	O
their	O
emotions	O
to	O
increase	O
and	O
decrease	O
emotional	O
experience	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
.	O
	
attentional	O
bias	O
was	O
assessed	O
with	O
a	O
dot-probe	O
task	O
with	O
pictures	O
of	O
angry	O
and	O
happy	O
facial	O
expressions	O
.	O
	
in	O
study	O
2	O
,	O
a	O
separate	O
group	O
of	O
healthy	O
young	O
men	O
and	O
women	O
participated	O
.	O
	
participants	O
'	O
trait	O
reappraisal	O
and	O
suppression	O
as	O
well	O
as	O
state	O
and	O
trait	O
anxiety	O
were	O
assessed	O
.	O
	
a	O
dot-probe	O
task	O
was	O
completed	O
by	O
all	O
participants	O
.	O
	
statistical	O
tests	O
in	O
study	O
1	O
revealed	O
that	O
participants	O
who	O
reappraised	O
to	O
decrease	O
negative	O
emotions	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
had	O
reduced	O
attentional	O
bias	O
to	O
subsequently	O
presented	O
angry	O
faces	O
compared	O
to	O
participants	O
who	O
reappraised	O
to	O
increase	O
negative	O
emotions	O
.	O
	
multiple	O
regression	O
analyses	O
in	O
study	O
2	O
revealed	O
that	O
trait	O
reappraisal	O
predicted	O
slower	O
orienting	O
toward	O
angry	O
faces	O
,	O
whereas	O
state	O
anxiety	O
predicted	O
slower	O
disengagement	O
from	O
angry	O
faces	O
.	O
	
interestingly	O
,	O
trait	O
suppression	O
predicted	O
slower	O
disengagement	O
from	O
happy	O
faces	O
.	O
	
taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
both	O
instruction-induced	O
state	O
reappraisal	O
and	O
trait	O
reappraisal	O
are	O
linked	O
to	O
reduced	O
attentional	O
bias	O
to	O
negative	O
information	O
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion	O
regulation	O
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	O
information	B-MED
graded	B-MED
structure	I-MED
in	O
sexual	B-MED
definitions	B-MED
categorizations	B-MED
of	O
having	O
""""	O
had	B-MED
sex	I-MED
""""	O
and	O
virginity	B-MED
loss	B-MED
among	O
homosexual	B-MED
and	O
heterosexual	B-MED
men	B-MED
and	O
women	B-MED
definitions	B-MED
of	O
sexual	B-MED
behavior	I-MED
display	O
a	O
robust	O
hierarchy	B-MED
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	B-MED
should	O
be	O
classed	O
as	O
,	O
for	O
example	O
,	O
sex	B-MED
or	O
virginity	B-MED
loss	B-MED
.	O
	
the	O
current	O
research	B-MED
offers	O
a	O
theoretical	B-MED
explanation	B-MED
for	O
this	O
hierarchy	B-MED
,	O
proposing	O
that	O
sexual	B-MED
definitions	B-MED
display	O
graded	B-MED
categorical	I-MED
structure	I-MED
,	O
arising	O
from	O
goodness	O
of	O
membership	B-MED
judgments	B-MED
.	O
	
moderation	B-MED
of	O
this	O
graded	B-MED
structure	I-MED
is	O
also	O
predicted	O
,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual	B-MED
orientation	I-MED
identity	B-MED
affects	O
sexual	B-MED
definitions	B-MED
.	O
	
a	O
total	O
of	O
300	O
18-	O
to	O
30-	O
year	B-MED
-old	O
participants	B-MED
completed	O
an	O
online	B-MED
survey	I-MED
,	O
rating	B-MED
18	O
behaviors	B-MED
for	O
how	O
far	O
each	O
constitutes	O
having	O
""""	O
had	B-MED
sex	I-MED
""""	O
and	O
virginity	B-MED
loss	B-MED
.	O
	
participants	B-MED
fell	O
into	O
one	O
of	O
four	O
groups	B-MED
heterosexual	B-MED
male	B-MED
or	O
female	B-MED
,	O
gay	B-MED
male	I-MED
or	O
lesbian	B-MED
.	O
	
the	O
predicted	O
ratings	B-MED
hierarchy	B-MED
emerged	O
,	O
in	O
which	O
bidirectional	B-MED
genital	I-MED
acts	I-MED
were	O
rated	B-MED
significantly	O
higher	B-MED
than	O
unidirectional	B-MED
or	O
nonpenetrative	B-MED
contact	I-MED
,	O
which	O
was	O
in	O
turn	O
rated	B-MED
significantly	O
higher	B-MED
than	O
acts	B-MED
involving	O
no	B-MED
genital	I-MED
contact	I-MED
.	O
	
moderation	B-MED
of	O
graded	B-MED
structure	I-MED
was	O
also	O
in	O
line	O
with	O
predictions	B-MED
.	O
	
compared	O
to	O
the	O
other	O
groups	B-MED
,	O
the	O
lesbian	B-MED
group	I-MED
significantly	O
upgraded	O
ratings	B-MED
of	O
genital	B-MED
contact	I-MED
that	O
was	O
either	O
unidirectional	B-MED
or	O
nonpenetrative	B-MED
.	O
	
there	O
was	O
also	O
evidence	B-MED
of	O
upgrading	O
by	O
the	O
gay	B-MED
male	I-MED
sample	O
of	O
anal	B-MED
intercourse	I-MED
ratings	B-MED
.	O
	
these	O
effects	B-MED
are	O
theorized	O
to	O
reflect	O
group	B-MED
-level	O
variation	B-MED
in	O
experience	B-MED
,	O
contextual	B-MED
perspective	I-MED
,	O
and	O
identity	B-MED
-management	O
.	O
	
the	O
implications	B-MED
of	O
the	O
findings	B-MED
in	O
relation	O
to	O
previous	O
research	B-MED
are	O
discussed	O
.	O
	
it	O
is	O
suggested	O
that	O
a	O
graded	B-MED
structure	I-MED
approach	O
can	O
greatly	O
benefit	B-MED
future	O
research	B-MED
into	O
sexual	B-MED
definitions	B-MED
,	O
by	O
permitting	O
variable	O
definitions	B-MED
effects	O
of	O
soybean	B-MED
isoflavone	I-MED
on	O
intestinal	B-MED
antioxidant	B-MED
capacity	I-MED
and	O
cytokines	B-MED
in	O
young	O
piglets	B-MED
fed	B-MED
oxidized	B-MED
fish	B-MED
oil	I-MED
to	O
investigate	O
the	O
effect	O
of	O
glycitein	B-MED
,	O
a	O
synthetic	B-MED
soybean	B-MED
isoflavone	I-MED
isf	B-MED
,	O
on	O
the	O
intestinal	B-MED
antioxidant	B-MED
capacity	I-MED
,	O
morphology	B-MED
,	O
and	O
cytokine	B-MED
content	O
in	O
young	O
piglets	B-MED
fed	B-MED
oxidized	B-MED
fish	B-MED
oil	I-MED
,	O
72	O
4-d-old	O
male	O
piglets	B-MED
were	O
assigned	O
to	O
three	O
treatments	B-MED
.	O
	
the	O
control	B-MED
group	I-MED
was	O
fed	B-MED
a	O
basal	B-MED
diet	I-MED
containing	O
fresh	B-MED
fish	B-MED
oil	I-MED
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	B-MED
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
alone	O
or	O
with	O
isf	B-MED
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
isf	B-MED
.	O
	
after	O
21	O
d	O
of	O
feeding	B-MED
,	O
supplementation	B-MED
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
increased	O
the	O
levels	O
of	O
malondialdehyde	B-MED
mda	B-MED
,	O
oxidized	B-MED
glutathione	I-MED
gssg	B-MED
,	O
interleukin-1β	B-MED
il-1β	B-MED
,	O
tumor	B-MED
necrosis	I-MED
factor-α	I-MED
tnf-α	B-MED
,	O
interleukin-2	B-MED
il-2	B-MED
,	O
nuclear	B-MED
factor	I-MED
κ	I-MED
b	I-MED
nf-κb	B-MED
,	O
inducible	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
inos	B-MED
,	O
no	B-MED
,	O
and	O
caspase-3	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
,	O
and	O
decreased	O
the	O
villous	B-MED
height	B-MED
in	O
duodenum	B-MED
and	O
the	O
levels	O
of	O
secretory	B-MED
immunoglobulin	I-MED
a	I-MED
siga	B-MED
and	O
il-4	B-MED
in	O
the	O
jejunal	B-MED
mucosa	I-MED
compared	O
with	O
supplementation	B-MED
with	O
fresh	B-MED
oil	B-MED
.	O
	
the	O
addition	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
isf	B-MED
partially	O
alleviated	O
this	O
negative	O
effect	O
.	O
	
the	O
addition	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
isf	B-MED
increased	O
the	O
villous	B-MED
height	B-MED
and	O
levels	O
of	O
siga	B-MED
and	O
il-4	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
,	O
but	O
decreased	O
the	O
levels	O
of	O
il-1β	B-MED
and	O
il-2	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
p<0	O
compared	O
with	O
oxidized	B-MED
fish	B-MED
oil	I-MED
.	O
	
collectively	O
,	O
these	O
results	O
show	O
that	O
dietary	B-MED
supplementation	I-MED
of	O
isf	B-MED
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
by	O
improving	O
the	O
intestinal	B-MED
morphology	I-MED
as	O
well	O
as	O
the	O
antioxidant	B-MED
capacity	I-MED
and	O
immune	B-MED
function	I-MED
in	O
young	O
piglets	B-MED
.	O
	
evolution	B-MED
enhanced	B-MED
footing	B-MED
for	O
snake	B-MED
limb	B-MED
development	I-MED
two	O
groups	O
have	O
studied	O
the	O
loss	B-MED
of	O
limbs	B-MED
in	O
snake	B-MED
evolution	B-MED
by	O
focusing	O
on	O
a	O
long-distance	B-MED
cis-acting	B-MED
enhancer	I-MED
of	O
sonic	B-MED
hedgehog	I-MED
.	O
	
they	O
find	O
a	O
progressive	B-MED
degeneration	B-MED
of	O
binding	B-MED
sites	I-MED
for	O
key	O
transcription	B-MED
factors	I-MED
,	O
mirroring	O
the	O
progressive	B-MED
limblessness	B-MED
occurring	B-MED
in	O
these	O
dynamin-related	B-MED
protein	I-MED
1	I-MED
mediates	B-MED
low	B-MED
glucose	I-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
in	O
human	B-MED
arterioles	B-MED
intensive	O
glycemic	B-MED
regulation	I-MED
has	O
resulted	O
in	O
an	O
increased	B-MED
incidence	B-MED
of	O
hypoglycemia	B-MED
.	O
	
hypoglycemic	B-MED
burden	B-MED
correlates	O
with	O
adverse	B-MED
cardiovascular	B-MED
complications	I-MED
and	O
contributes	O
acutely	B-MED
and	O
chronically	B-MED
to	O
endothelial	B-MED
dysfunction	I-MED
.	O
	
prior	O
data	B-MED
indicate	O
that	O
mitochondrial	B-MED
dysfunction	I-MED
contributes	O
to	O
hypoglycemia	B-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
,	O
but	O
the	O
mechanisms	B-MED
behind	O
this	O
linkage	B-MED
remain	O
unknown	B-MED
.	O
	
we	O
attempt	O
to	O
determine	O
whether	O
clinically	B-MED
relevant	B-MED
low-glucose	B-MED
lg	B-MED
exposures	B-MED
acutely	B-MED
induce	B-MED
endothelial	B-MED
dysfunction	I-MED
through	O
activation	B-MED
of	O
the	O
mitochondrial	B-MED
fission	I-MED
process	I-MED
.	O
	
characterization	B-MED
of	O
mitochondrial	B-MED
morphology	I-MED
was	O
carried	O
out	O
in	O
cultured	B-MED
endothelial	B-MED
cells	I-MED
by	O
using	O
confocal	B-MED
microscopy	I-MED
.	O
	
isolated	B-MED
human	B-MED
arterioles	B-MED
were	O
used	O
to	O
explore	O
the	O
effect	B-MED
lg	B-MED
-	O
induced	B-MED
mitochondrial	B-MED
fission	I-MED
has	O
on	O
the	O
formation	B-MED
of	O
detrimental	B-MED
reactive	I-MED
oxygen	I-MED
species	I-MED
ros	B-MED
,	O
bioavailability	B-MED
of	O
nitric	B-MED
oxide	I-MED
no	B-MED
,	O
and	O
endothelial-dependent	B-MED
vascular	I-MED
relaxation	I-MED
.	O
	
fluorescence	B-MED
microscopy	I-MED
was	O
employed	O
to	O
visualize	O
changes	B-MED
in	O
mitochondrial	B-MED
ros	B-MED
and	O
no	B-MED
levels	B-MED
and	O
videomicroscopy	B-MED
applied	O
to	O
measure	B-MED
vasodilation	B-MED
response	B-MED
.	O
	
pharmacological	B-MED
disruption	B-MED
of	O
the	O
profission	B-MED
protein	I-MED
drp1	B-MED
with	O
mdivi-1	B-MED
during	O
lg	B-MED
exposure	B-MED
reduced	B-MED
mitochondrial	B-MED
fragmentation	I-MED
among	O
vascular	B-MED
endothelial	I-MED
cells	I-MED
lg	B-MED
0.469	O
lg	B-MED
+	O
mdivi-1	B-MED
0.276	O
p	O
=	O
0.003	O
,	O
prevented	B-MED
formation	B-MED
of	O
vascular	B-MED
ros	B-MED
lg	B-MED
2.036	O
lg	B-MED
+	O
mdivi-1	B-MED
1.774	O
p	O
=	O
0.005	O
,	O
increased	B-MED
the	O
presence	B-MED
of	O
no	B-MED
lg	B-MED
1.352	O
lg	B-MED
+	O
mdivi-1	B-MED
1.502	O
p	O
=	O
0.048	O
,	O
and	O
improved	B-MED
vascular	B-MED
dilation	I-MED
response	B-MED
to	O
acetylcholine	B-MED
lg	B-MED
31.6	O
lg	B-MED
+	O
mdivi-1	B-MED
78.5	O
at	O
maximum	B-MED
dose	B-MED
p	O
<	O
0.001	O
.	O
	
additionally	O
,	O
decreased	B-MED
expression	B-MED
of	O
drp1	B-MED
via	O
sirna	B-MED
knockdown	B-MED
during	O
lg	B-MED
conditions	B-MED
also	O
improved	B-MED
vascular	B-MED
relaxation	I-MED
.	O
	
exposure	B-MED
to	I-MED
lg	B-MED
imparts	O
endothelial	B-MED
dysfunction	I-MED
coupled	B-MED
with	O
altered	B-MED
mitochondrial	B-MED
phenotypes	B-MED
among	O
isolated	B-MED
human	B-MED
arterioles	B-MED
.	O
	
disruption	B-MED
of	O
drp1	B-MED
and	O
subsequent	B-MED
mitochondrial	B-MED
fragmentation	I-MED
events	O
prevents	B-MED
impaired	B-MED
vascular	B-MED
dilation	I-MED
,	O
restores	B-MED
mitochondrial	B-MED
phenotype	B-MED
,	O
and	O
implicates	O
mitochondrial	B-MED
fission	I-MED
as	O
a	O
primary	B-MED
mediator	B-MED
of	O
lg	B-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
new	O
noteworthy	O
acute	B-MED
low-glucose	B-MED
exposure	B-MED
induces	B-MED
mitochondrial	B-MED
fragmentation	I-MED
in	O
endothelial	B-MED
cells	I-MED
via	O
drp1	B-MED
and	O
is	O
associated	B-MED
with	I-MED
impaired	B-MED
endothelial	B-MED
function	B-MED
in	O
human	B-MED
arterioles	B-MED
.	O
	
targeting	B-MED
of	O
drp1	B-MED
prevents	B-MED
fragmentation	B-MED
,	O
improves	O
vasofunction	B-MED
,	O
and	O
may	O
provide	O
a	O
therapeutic	B-MED
target	B-MED
for	O
improving	O
cardiovascular	B-MED
complications	I-MED
among	O
diabetics	B-MED
listen	O
to	O
this	O
article's	O
corresponding	O
podcast	O
a	O
16	O
yin	B-MED
yang	I-MED
gene	B-MED
expression	I-MED
ratio	B-MED
signature	B-MED
for	O
er+	B-MED
/	O
node-	B-MED
breast	I-MED
cancer	I-MED
breast	B-MED
cancer	I-MED
is	O
one	O
of	O
the	O
leading	O
causes	B-MED
of	O
cancer	B-MED
death	B-MED
in	O
women	B-MED
.	O
	
it	O
is	O
a	O
complex	B-MED
and	O
heterogeneous	B-MED
disease	B-MED
with	O
different	O
clinical	B-MED
outcomes	B-MED
.	O
	
stratifying	B-MED
patients	B-MED
into	O
subgroups	B-MED
with	O
different	O
outcomes	B-MED
could	O
help	O
guide	O
clinical	B-MED
decision	I-MED
making	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
used	O
two	O
opposing	O
groups	B-MED
of	O
genes	B-MED
,	O
yin	B-MED
and	I-MED
yang	I-MED
,	O
to	O
develop	O
a	O
prognostic	B-MED
expression	B-MED
ratio	B-MED
signature	B-MED
.	O
	
using	O
the	O
metabric	B-MED
cohort	B-MED
we	O
identified	O
a16-	O
gene	B-MED
signature	I-MED
capable	O
of	O
stratifying	B-MED
breast	B-MED
cancer	I-MED
patients	B-MED
into	O
four	O
risk	B-MED
levels	I-MED
with	O
intention	O
that	O
low-risk	B-MED
patients	B-MED
would	O
not	O
undergo	O
adjuvant	B-MED
systemic	B-MED
therapy	I-MED
,	O
intermediate	B-MED
-	O
low-risk	B-MED
patients	B-MED
will	O
be	O
treated	B-MED
with	I-MED
hormonal	B-MED
therapy	I-MED
only	O
,	O
and	O
intermediate	B-MED
-high-	O
and	O
high-risk	B-MED
groups	I-MED
will	O
be	O
treated	B-MED
by	O
chemotherapy	B-MED
in	O
addition	O
to	O
the	O
hormonal	B-MED
therapy	I-MED
.	O
	
the	O
16-	O
gene	B-MED
signature	I-MED
for	O
four	O
risk	B-MED
level	I-MED
stratifications	B-MED
of	O
breast	B-MED
cancer	I-MED
patients	B-MED
has	O
been	O
validated	B-MED
using	O
14	O
independent	O
datasets	B-MED
.	O
	
notably	O
,	O
the	O
low-risk	B-MED
group	B-MED
n	O
=	O
51	O
of	O
205	O
estrogen	B-MED
receptor-positive	I-MED
and	O
node	B-MED
negative	I-MED
er+	B-MED
/	O
node-	B-MED
patients	B-MED
from	O
three	O
different	O
datasets	B-MED
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B-MED
therapy	I-MED
had	O
100%	O
15-	O
year	B-MED
disease-specific	B-MED
survival	I-MED
rate	I-MED
.	O
	
the	O
concordance	B-MED
index	I-MED
of	O
ymr	B-MED
for	O
er+	B-MED
/	O
node	B-MED
negative	I-MED
patients	B-MED
is	O
close	O
to	O
the	O
commercially	B-MED
available	O
signatures	B-MED
.	O
	
however	O
,	O
ymr	B-MED
showed	O
more	O
significance	B-MED
hr	B-MED
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
in	O
stratifying	B-MED
er+	B-MED
/	O
node-	B-MED
subgroup	B-MED
than	O
oncotypedx	B-MED
hr	B-MED
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
,	O
mammaprint	B-MED
hr	B-MED
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
,	O
rors	B-MED
hr	B-MED
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
,	O
and	O
npi	B-MED
hr	B-MED
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
.	O
	
ymr	B-MED
signature	B-MED
may	O
be	O
developed	O
as	O
a	O
clinical	B-MED
tool	B-MED
to	O
select	O
a	O
subgroup	B-MED
of	O
low-risk	B-MED
er+	B-MED
/	O
node-	B-MED
patients	B-MED
who	O
do	O
not	O
require	O
any	O
adjuvant	B-MED
hormonal	B-MED
therapy	I-MED
aht	B-MED
.	O
	
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
repeated	B-MED
hiv	B-MED
testing	I-MED
among	O
internet	B-MED
-using	O
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
msm	B-MED
represent	B-MED
a	O
disproportionately	B-MED
impacted	B-MED
risk	B-MED
group	I-MED
for	O
hiv	B-MED
incidence	B-MED
among	O
at-risk	B-MED
u.s	B-MED
.	O
	
few	O
studies	B-MED
have	O
identified	B-MED
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
hiv	B-MED
testing	I-MED
frequency	B-MED
both	O
within	B-MED
and	O
outside	B-MED
of	O
traditional	O
health	B-MED
care	I-MED
settings	I-MED
.	O
	
msm	B-MED
enrolled	O
in	O
a	O
prospective	B-MED
cohort	I-MED
were	O
mailed	B-MED
at-home	B-MED
specimen	I-MED
collection	I-MED
kits	I-MED
and	O
followed	B-MED
for	O
a	O
year	B-MED
.	O
	
incidence	B-MED
density	I-MED
rate	I-MED
ratios	I-MED
idrr	B-MED
of	O
testing	B-MED
were	O
calculated	B-MED
,	O
and	O
generalized	B-MED
estimating	B-MED
equations	B-MED
were	O
used	O
to	O
analyze	O
the	O
association	B-MED
between	O
hiv	B-MED
testing	I-MED
and	O
behavioral	B-MED
factors	B-MED
.	O
	
the	O
incidence	B-MED
rate	I-MED
of	O
testing	B-MED
was	O
higher	B-MED
among	O
black	B-MED
msm	B-MED
than	O
white	B-MED
msm	B-MED
idrr	B-MED
1.3	O
,	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
1.1	O
,	O
1.5	O
and	O
higher	B-MED
among	O
msm	B-MED
who	O
reported	O
3+	O
condomless	B-MED
anal	O
intercourse	O
partners	O
cai	O
than	O
msm	O
who	O
reported	O
no	O
cai	O
idrr	O
1.6	O
,	O
95%	O
ci	O
1.3	O
,	O
2.0	O
.	O
	
increasing	O
availability	O
of	O
hiv	O
testing	O
outside	O
traditional	O
health	O
care	O
settings	O
,	O
including	O
at-home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	O
treatment	O
preventions	O
is	O
nursingstandard.com	B-MED
1	O
nurse	B-MED
donna	O
wood	O
has	O
been	O
suspended	B-MED
for	O
2	O
months	B-MED
by	O
the	O
nursing	B-MED
and	I-MED
midwifery	I-MED
council	I-MED
nmc	B-MED
for	O
concealing	B-MED
the	O
high	B-MED
temperature	I-MED
of	O
colleague	B-MED
pauline	O
cafferkey	O
,	O
who	O
later	O
developed	O
ebola	B-MED
.	O
	
read	O
more	O
theory	B-MED
of	I-MED
mind	I-MED
in	O
adolescents	B-MED
with	O
bipolar	B-MED
disorder	I-MED
in	O
euthymic	B-MED
phase	I-MED
using	O
the	O
strange	B-MED
stories	I-MED
test	I-MED
objective	O
this	O
study	O
evaluated	B-MED
the	O
theory	B-MED
of	I-MED
mind	I-MED
tom	B-MED
in	O
adolescents	B-MED
diagnosed	B-MED
with	O
bipolar	B-MED
disorder	I-MED
bd	B-MED
during	O
their	O
euthymic	B-MED
period	I-MED
compared	O
to	O
a	O
typically	B-MED
developing	I-MED
td	I-MED
group	I-MED
method	O
the	O
bd	B-MED
group	B-MED
consisted	O
of	O
thirty	O
11-18	O
year	O
old	O
inpatients	B-MED
in	O
euthymic	B-MED
phase	I-MED
.	O
	
the	O
td	B-MED
group	I-MED
included	O
30	O
age	B-MED
,	O
gender	B-MED
,	O
and	O
iq	B-MED
matched	O
volunteer	O
students	B-MED
.	O
	
to	O
assess	O
the	O
diagnosis	B-MED
and	O
comorbid	B-MED
disorders	I-MED
,	O
we	O
performed	O
the	O
semi-structured	B-MED
interview	I-MED
of	O
the	O
kiddie	B-MED
schedule	I-MED
for	I-MED
affective	I-MED
disorders	I-MED
and	I-MED
schizophrenia-present	I-MED
and	I-MED
lifetime	I-MED
version	I-MED
k-sads-pl	B-MED
for	O
the	O
bd	B-MED
adolescents	B-MED
.	O
	
to	O
evaluate	B-MED
the	O
severity	O
of	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
adhd	B-MED
and	O
mania	B-MED
,	O
conner's	B-MED
parent	I-MED
rating	I-MED
scale-revised	I-MED
version	I-MED
cprs-r	I-MED
,	O
and	O
young	B-MED
mania	I-MED
rating	I-MED
scale	I-MED
ymrs	B-MED
were	O
used	O
,	O
respectively	O
.	O
	
ravens	B-MED
progressive	I-MED
matrices	I-MED
was	O
conducted	O
to	O
evaluate	B-MED
intellectual	B-MED
ability	I-MED
in	O
the	O
both	O
groups	B-MED
.	O
	
happe	B-MED
strange	I-MED
stories	I-MED
test	I-MED
was	O
performed	O
to	O
assess	O
tom	B-MED
in	O
the	O
participants	B-MED
.	O
	
data	B-MED
were	O
analyzed	O
using	O
the	O
independent	O
t-test	B-MED
,	O
analysis	B-MED
of	I-MED
covariance	I-MED
,	O
and	O
pearson	B-MED
correlation	I-MED
analysis	I-MED
results	O
the	O
two	O
groups	B-MED
did	O
not	O
show	O
any	O
differences	O
in	O
comprehending	O
the	O
stories	O
however	O
,	O
the	O
bd	B-MED
group's	B-MED
mentalizing	B-MED
scores	I-MED
were	O
significantly	O
weaker	O
than	O
the	O
td	B-MED
group	I-MED
p<0	O
conclusion	O
the	O
tom	B-MED
impairments	B-MED
in	O
adolescents	B-MED
with	O
bd	B-MED
may	O
be	O
explained	O
as	O
a	O
trait	B-MED
marker	I-MED
which	O
may	O
lead	O
to	O
continuation	O
of	O
social	B-MED
problems	I-MED
even	O
during	O
remission	B-MED
structural	O
and	O
functional	O
characterization	O
of	O
the	O
tyw3	B-MED
/	O
taw3	B-MED
class	O
of	O
sam-dependent	B-MED
methyltransferases	I-MED
s-adenosylmethionine	B-MED
sam	I-MED
methyltransferases	I-MED
regulate	B-MED
a	O
wide	O
range	O
of	O
biological	B-MED
processes	I-MED
through	O
the	O
modification	B-MED
of	O
proteins	B-MED
,	O
nucleic	B-MED
acids	I-MED
,	O
polysaccharides	B-MED
,	O
as	O
well	O
as	O
various	O
metabolites	B-MED
.	O
	
tyw3	B-MED
/	O
taw3	B-MED
is	O
a	O
sam-dependent	B-MED
methyltransferase	I-MED
responsible	O
for	O
the	O
formation	O
of	O
a	O
trna	B-MED
modification	I-MED
known	O
as	O
wybutosine	B-MED
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	B-MED
in	O
protein	B-MED
synthesis	I-MED
.	O
	
here	O
,	O
we	O
report	O
the	O
crystal	B-MED
structure	I-MED
of	O
taw3	B-MED
,	O
a	O
homolog	O
of	O
tyw3	B-MED
from	O
sulfolobus	B-MED
solfataricus	I-MED
,	O
which	O
revealed	O
a	O
novel	O
α/β	B-MED
fold	I-MED
.	O
	
the	O
sequence	O
motif	O
s/t	B-MED
and	O
invariant	O
aspartate	B-MED
and	O
histidine	B-MED
,	O
conserved	O
in	O
tyw3	B-MED
/	O
taw3	B-MED
,	O
cluster	B-MED
to	O
form	O
the	O
catalytic	B-MED
center	O
.	O
	
these	O
structural	B-MED
and	O
sequence	B-MED
features	O
indicate	O
that	O
tyw3	B-MED
/	O
taw3	B-MED
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
sam-dependent	B-MED
methyltransferases	I-MED
.	O
	
using	O
site-directed	B-MED
mutagenesis	I-MED
along	O
with	O
in	B-MED
vivo	I-MED
complementation	I-MED
assays	I-MED
combined	O
with	O
mass	B-MED
spectrometry	I-MED
as	O
well	O
as	O
ligand	B-MED
docking	I-MED
and	O
cofactor	B-MED
binding	I-MED
assays	B-MED
,	O
we	O
have	O
identified	O
the	O
active	B-MED
site	I-MED
of	O
tyw3	B-MED
and	O
residues	O
essential	O
for	O
cofactor	B-MED
binding	I-MED
and	O
methyltransferase	B-MED
activity	I-MED
.	O
	
developmental	B-MED
profile	B-MED
and	O
diagnoses	B-MED
in	O
children	B-MED
presenting	O
with	O
motor	B-MED
stereotypies	I-MED
motor	B-MED
stereotypies	I-MED
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	B-MED
in	O
distinguishing	O
non-clinical	B-MED
behaviors	I-MED
physiological	B-MED
and	O
transient	B-MED
from	O
symptoms	B-MED
or	O
among	O
different	O
disorders	B-MED
""""	O
primary	B-MED
stereotypies	I-MED
""""	O
associated	B-MED
with	I-MED
autistic	B-MED
spectrum	I-MED
disorder	I-MED
asd	B-MED
,	O
intellectual	B-MED
disabilities	I-MED
,	O
genetic	B-MED
syndromes	I-MED
,	O
and	O
sensory	B-MED
impairment	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
obtain	B-MED
an	O
accurate	O
assessment	B-MED
on	O
the	O
relationship	B-MED
between	O
stereotypies	B-MED
and	O
neurodevelopmental	B-MED
disorders	I-MED
.	O
	
we	O
studied	B-MED
23	O
children	B-MED
3	O
girls	B-MED
,	O
aged	B-MED
36-95	O
months	B-MED
,	O
who	O
requested	O
a	O
consultation	B-MED
due	O
to	O
the	O
persistence	B-MED
or	O
increased	B-MED
severity	B-MED
of	O
motor	B-MED
stereotypies	I-MED
.	O
	
none	O
of	O
the	O
patients	B-MED
had	O
a	O
previous	O
diagnosis	B-MED
of	O
asd	B-MED
.	O
	
the	O
assessment	B-MED
included	O
the	O
motor	B-MED
severity	I-MED
stereotypy	I-MED
scale	I-MED
msss	B-MED
,	O
the	O
repetitive	B-MED
behavior	I-MED
scale-revised	I-MED
rbs-r	B-MED
,	O
the	O
raven's	B-MED
colored	I-MED
progressive	I-MED
matrices	I-MED
,	O
the	O
child	B-MED
behavior	I-MED
checklist	I-MED
for	O
ages	B-MED
1½-5	O
or	O
4-18	O
cbcl	B-MED
,	O
the	O
social	B-MED
responsiveness	I-MED
scale	I-MED
srs	B-MED
,	O
and	O
the	O
autism	B-MED
diagnostic	I-MED
observation	I-MED
schedule-second	I-MED
edition	I-MED
ados	B-MED
2	I-MED
.	O
	
all	O
patients	B-MED
were	O
showing	O
motor	B-MED
stereotypies	I-MED
for	O
periods	B-MED
of	I-MED
time	I-MED
varying	O
from	O
6	O
to	O
77	O
months	B-MED
.	O
	
the	O
msss	B-MED
showed	O
that	O
each	O
child	B-MED
had	O
a	O
limited	B-MED
number	B-MED
of	O
stereotypies	B-MED
their	O
frequency	B-MED
and	O
intensity	B-MED
were	O
mild	B-MED
.	O
	
the	O
interference	B-MED
of	O
stereotypies	B-MED
was	O
variable	B-MED
the	O
impairment	B-MED
in	O
daily	O
life	B-MED
was	O
mild	B-MED
.	O
	
the	O
rbs-r	B-MED
scores	B-MED
were	O
positive	O
for	O
the	O
subscale	O
of	O
""""	O
stereotypic	B-MED
behaviors	I-MED
""""	O
in	O
all	O
children	B-MED
.	O
	
moreover	O
,	O
several	O
children	B-MED
presented	O
other	O
repetitive	B-MED
behaviors	I-MED
,	O
mainly	O
""""	O
ritualistic	B-MED
behavior	I-MED
""""	O
and	O
""""	O
sameness	B-MED
behavior	I-MED
""""	O
all	O
patients	B-MED
showed	O
a	O
normal	B-MED
cognitive	I-MED
level	I-MED
.	O
	
the	O
cbcl	B-MED
evidenced	B-MED
behavioral	B-MED
problems	I-MED
in	O
22%	O
of	O
the	O
children	B-MED
internalizing	B-MED
problems	I-MED
,	O
attention	B-MED
,	O
and	O
withdrawn	B-MED
were	O
the	O
main	O
complaints	O
.	O
	
on	O
the	O
srs	B-MED
,	O
all	O
but	O
one	O
of	O
the	O
tested	B-MED
patients	B-MED
obtained	B-MED
clinical	B-MED
scores	I-MED
in	O
the	O
clinical	B-MED
range	B-MED
for	O
at	O
least	O
one	O
area	O
.	O
	
on	O
the	O
ados	B-MED
2	I-MED
,	O
4	O
patients	B-MED
obtained	B-MED
scores	B-MED
indicating	O
a	O
moderate	B-MED
level	B-MED
of	O
asd	B-MED
symptoms	B-MED
,	O
4	O
had	O
a	O
mild	B-MED
level	B-MED
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-MED
of	O
asd	B-MED
.	O
	
motor	B-MED
stereotypies	I-MED
in	O
children	B-MED
with	O
normal	B-MED
cognitive	I-MED
level	I-MED
represent	O
a	O
challenging	O
diagnostic	B-MED
issue	B-MED
for	O
which	O
a	O
finely	O
tailored	B-MED
assessment	B-MED
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	B-MED
profile	B-MED
.	O
	
thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	B-MED
tests	I-MED
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-MED
.	O
	
furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	B-MED
stereotypies	I-MED
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	B-MED
disorder	I-MED
.	O
	
left	B-MED
ventricular	I-MED
rotational	B-MED
mechanics	B-MED
in	O
infants	B-MED
with	O
hypoxic	B-MED
ischemic	I-MED
encephalopathy	I-MED
and	O
preterm	B-MED
infants	I-MED
at	O
36	O
weeks	B-MED
postmenstrual	B-MED
age	I-MED
a	O
comparison	B-MED
with	O
healthy	B-MED
term	B-MED
controls	I-MED
there	O
is	O
a	O
paucity	O
of	O
data	B-MED
on	O
left	B-MED
ventricle	I-MED
lv	B-MED
rotational	B-MED
physiology	I-MED
in	O
neonates	B-MED
.	O
	
we	O
aimed	O
to	O
assess	O
rotational	B-MED
mechanics	B-MED
in	O
infants	B-MED
with	O
hypoxic	B-MED
ischemic	I-MED
encephalopathy	I-MED
hie	B-MED
and	O
premature	B-MED
infants	I-MED
<32	O
weeks	B-MED
at	O
36	O
weeks	B-MED
postmenstrual	B-MED
age	I-MED
pma	B-MED
preterm	B-MED
group	I-MED
and	O
compare	B-MED
them	O
with	O
healthy	B-MED
term	B-MED
controls	I-MED
term	B-MED
controls	I-MED
.	O
	
we	O
also	O
compared	B-MED
the	O
parameters	B-MED
in	O
preterm	B-MED
infants	I-MED
with	O
and	O
without	O
chronic	B-MED
lung	I-MED
disease	I-MED
cld	B-MED
.	O
	
echocardiography	B-MED
was	O
performed	O
within	O
48	O
hours	B-MED
of	O
birth	B-MED
or	O
at	O
36	O
weeks	B-MED
pma	B-MED
.	O
	
lv	B-MED
basal	B-MED
and	O
apical	O
rotation	B-MED
,	O
twist	B-MED
and	O
torsion	O
=	O
twist	B-MED
/	O
lv	B-MED
length	I-MED
,	O
twist	B-MED
rate	I-MED
lvtr	B-MED
,	O
and	O
untwist	B-MED
rate	I-MED
lvutr	B-MED
were	O
measured	O
.	O
	
one-way	B-MED
anova	I-MED
was	O
used	O
to	O
compare	B-MED
values	B-MED
.	O
	
there	O
was	O
no	O
difference	O
in	O
gestation	B-MED
40.0	O
39.1	O
vs	O
39.9	O
39.0	O
,	O
p>	O
or	O
birthweight	B-MED
3.7	O
3.4	O
vs	O
3.5	O
3.2	O
,	O
p>	O
between	O
the	O
hie	B-MED
group	B-MED
n=16	O
and	O
term	B-MED
controls	I-MED
n=30	O
.	O
	
the	O
preterm	B-MED
group	I-MED
n=35	O
had	O
a	O
gestation	B-MED
and	O
weight	B-MED
of	O
36.0	O
34.6	O
weeks	B-MED
and	O
2.3	O
2.0	O
kg	O
.	O
	
the	O
hie	B-MED
group	O
had	O
lower	O
twist	B-MED
,	O
torsion	O
,	O
lvtr	B-MED
,	O
and	O
lvutr	B-MED
than	O
the	O
other	O
two	O
groups	O
.	O
	
the	O
preterm	B-MED
group	I-MED
had	O
a	O
more	O
negative	O
clockwise	B-MED
basal	B-MED
rotation	B-MED
while	O
the	O
term	B-MED
group	I-MED
had	O
a	O
more	O
positive	O
counterclockwise	B-MED
apical	B-MED
rotation	B-MED
.	O
	
preterm	B-MED
infants	I-MED
with	O
cld	B-MED
had	O
higher	O
apical	B-MED
rotation	B-MED
,	O
twist	B-MED
,	O
and	O
torsion	O
when	O
compared	B-MED
to	O
infants	B-MED
without	O
cld	B-MED
.	O
	
infants	B-MED
with	O
hie	B-MED
have	O
reduced	O
rotational	B-MED
mechanics	B-MED
.	O
	
preterm	B-MED
infants	I-MED
at	O
36	O
weeks	B-MED
pma	B-MED
have	O
comparable	B-MED
measurements	B-MED
of	O
twist	B-MED
to	O
term	B-MED
infants	I-MED
.	O
	
this	O
is	O
achieved	O
by	O
predominant	O
basal	B-MED
rather	O
than	O
apical	O
rotation	O
.	O
	
infants	O
with	O
cld	O
have	O
increased	O
apical	O
rotation	B-MED
comparing	B-MED
the	O
effects	B-MED
of	I-MED
different	B-MED
dynamic	B-MED
sitting	I-MED
strategies	I-MED
in	O
wheelchair	B-MED
seating	I-MED
on	O
lumbar-pelvic	B-MED
angle	I-MED
prolonged	B-MED
static	B-MED
sitting	I-MED
in	O
a	O
wheelchair	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
lower	B-MED
back	I-MED
pain	I-MED
.	O
	
the	O
wheelchair	B-MED
seating	I-MED
system	I-MED
is	O
a	O
key	B-MED
factor	I-MED
of	O
this	O
risk	B-MED
because	O
it	O
affects	O
spinal	B-MED
loading	B-MED
in	O
the	O
sitting	B-MED
position	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
7	O
dynamic	B-MED
sitting	I-MED
strategies	I-MED
dsss	B-MED
are	O
examined	B-MED
lumbar	B-MED
prominent	I-MED
dynamic	I-MED
sitting	I-MED
lpds	B-MED
,	O
back	B-MED
reclined	I-MED
dynamic	I-MED
sitting	I-MED
brds	B-MED
,	O
femur	B-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
fuds	B-MED
,	O
lumbar	B-MED
prominent	I-MED
with	I-MED
back	I-MED
reclined	I-MED
dynamic	I-MED
sitting	I-MED
lbds	B-MED
,	O
lumbar	B-MED
prominent	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
lfds	B-MED
,	O
back	B-MED
reclined	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
bfds	B-MED
,	O
and	O
lumbar	B-MED
prominent	I-MED
with	I-MED
back	I-MED
reclined	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
lbfds	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
analyze	B-MED
the	O
biomechanical	B-MED
effects	B-MED
of	I-MED
these	O
sitting	B-MED
strategies	I-MED
on	O
lumbar-pelvic	B-MED
angles	I-MED
.	O
	
twenty	O
able-bodied	B-MED
participants	B-MED
were	O
recruited	B-MED
for	O
the	O
study	B-MED
.	O
	
all	O
participants	B-MED
performed	B-MED
lpds	B-MED
,	O
brds	B-MED
,	O
fuds	B-MED
,	O
lbds	B-MED
,	O
lfds	B-MED
,	O
bfds	B-MED
,	O
and	O
lbfds	B-MED
in	O
a	O
random	B-MED
order	B-MED
.	O
	
all	O
lumbar-pelvic	B-MED
angle	I-MED
parameters	B-MED
,	O
including	O
the	O
static	B-MED
lumbar	B-MED
angle	I-MED
,	O
static	B-MED
pelvic	B-MED
angle	I-MED
,	O
lumbar	B-MED
range	I-MED
of	I-MED
motion	I-MED
,	O
and	O
pelvic	B-MED
range	I-MED
of	I-MED
motion	I-MED
were	O
measured	B-MED
and	O
compared	B-MED
.	O
	
results	B-MED
show	O
that	O
lbds	B-MED
and	O
lbfds	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
lumbar	B-MED
movements	I-MED
,	O
although	O
the	O
difference	B-MED
between	O
the	O
2	O
strategies	B-MED
was	O
nonsignificant	B-MED
.	O
	
brds	B-MED
and	O
bfds	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
pelvic	B-MED
movements	I-MED
,	O
although	O
the	O
difference	B-MED
between	O
the	O
2	O
strategies	B-MED
was	O
nonsignificant	B-MED
.	O
	
among	O
all	O
the	O
upright	O
dsss	B-MED
,	O
lpds	B-MED
and	O
lfds	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
lumbar	B-MED
and	O
pelvic	B-MED
movements	I-MED
,	O
although	O
no	B-MED
significant	I-MED
difference	B-MED
was	O
observed	B-MED
between	O
these	O
2	O
strategies	B-MED
.	O
	
we	O
identified	B-MED
the	O
effects	B-MED
and	O
differences	B-MED
among	O
7	O
dsss	B-MED
on	O
lumbar-pelvic	B-MED
angles	I-MED
.	O
	
wheelchair	B-MED
users	I-MED
can	O
choose	B-MED
the	O
most	O
suitable	B-MED
dss	B-MED
that	O
meets	B-MED
their	O
needs	B-MED
.	O
	
these	O
findings	B-MED
may	O
serve	O
as	O
a	O
reference	B-MED
for	O
practicing	B-MED
physicians	I-MED
or	O
wheelchair	B-MED
users	I-MED
to	O
choose	B-MED
an	O
appropriate	B-MED
dynamic	O
wheelchair	B-MED
seating	I-MED
source	O
apportionment	O
and	O
heavy	B-MED
metal	I-MED
health	B-MED
risk	I-MED
hmhr	B-MED
quantification	B-MED
from	O
sources	B-MED
in	O
a	O
southern	B-MED
city	B-MED
in	O
china	B-MED
,	O
using	O
an	O
me2	B-MED
-	O
hmhr	B-MED
model	B-MED
heavy	B-MED
metals	I-MED
cr	B-MED
,	O
co	B-MED
,	O
ni	B-MED
,	O
as	B-MED
,	O
cd	B-MED
,	O
and	O
pb	B-MED
can	O
be	O
bound	O
to	O
pm	B-MED
adversely	B-MED
affecting	I-MED
human	B-MED
health	B-MED
.	O
	
quantifying	O
the	O
source	B-MED
impacts	O
on	O
heavy	B-MED
metals	I-MED
can	O
provide	O
source	B-MED
-	O
specific	B-MED
estimates	O
of	O
the	O
heavy	B-MED
metal	I-MED
health	B-MED
risk	I-MED
hmhr	B-MED
to	O
guide	O
effective	B-MED
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	B-MED
from	O
exposure	B-MED
to	I-MED
heavy	B-MED
metals	I-MED
in	O
pm2.5	B-MED
particulate	B-MED
matter	I-MED
pm	B-MED
with	O
aerodynamic	B-MED
diameter	I-MED
less	O
than	O
or	O
equal	O
to	O
2.5	O
μm	O
.	O
	
in	O
this	O
study	O
,	O
a	O
method	O
combining	O
multilinear	B-MED
engine	I-MED
2	I-MED
me2	B-MED
and	O
a	O
risk	B-MED
assessment	I-MED
model	B-MED
is	O
developed	O
to	O
more	O
effectively	O
quantify	B-MED
source	B-MED
contributions	B-MED
to	O
hmhr	B-MED
,	O
including	O
heavy	B-MED
metal	I-MED
non-cancer	B-MED
risk	I-MED
non-hmcr	B-MED
and	O
cancer	B-MED
risk	I-MED
hmcr	B-MED
.	O
	
the	O
combined	O
model	B-MED
called	O
me2-hmhr	B-MED
has	O
two	O
steps	O
step1	O
,	O
source	B-MED
contributions	B-MED
to	O
heavy	B-MED
metals	I-MED
are	O
estimated	O
by	O
employing	O
the	O
me2	B-MED
model	B-MED
step2	O
,	O
the	O
source	B-MED
contributions	B-MED
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk	B-MED
assessment	I-MED
model	B-MED
to	O
calculate	O
the	O
source	B-MED
contributions	B-MED
to	O
hmhr	B-MED
.	O
	
the	O
approach	O
was	O
applied	O
to	O
huzou	B-MED
,	O
china	B-MED
and	O
five	O
significant	O
sources	B-MED
were	O
identified	O
.	O
	
soil	B-MED
dust	B-MED
is	O
the	O
largest	O
source	B-MED
of	O
non-hmcr	B-MED
.	O
	
for	O
hmcr	B-MED
,	O
the	O
source	B-MED
contributions	B-MED
of	O
soil	B-MED
dust	B-MED
,	O
coal	B-MED
combustion	B-MED
,	O
cement	B-MED
dust	I-MED
,	O
vehicle	O
,	O
and	O
secondary	O
sources	O
are	O
1.0	O
10	O
,	O
3.7	O
10	O
,	O
2.7	O
10	O
,	O
1.6	O
10	O
and	O
1.9	O
10	O
,	O
respectively	O
.	O
	
the	O
soil	O
dust	B-MED
is	O
the	O
largest	O
contributor	O
to	O
hmcr	O
,	O
being	O
driven	O
by	O
the	O
high	O
impact	O
of	O
soil	O
dust	O
on	O
pm2.5	O
and	O
the	O
abundance	O
of	O
heavy	O
metals	O
in	O
soil	O
dust	B-MED
aspirin	B-MED
suppresses	B-MED
growth	B-MED
in	O
pi3k	B-MED
-	O
mutant	B-MED
breast	B-MED
cancer	I-MED
by	O
activating	B-MED
ampk	B-MED
and	O
inhibiting	B-MED
mtorc1	B-MED
signaling	O
despite	O
the	O
high	O
incidence	B-MED
of	O
oncogenic	B-MED
mutations	B-MED
in	O
pik3ca	B-MED
,	O
the	O
gene	B-MED
encoding	I-MED
the	O
catalytic	B-MED
subunit	I-MED
of	O
pi3k	B-MED
,	O
pi3k	B-MED
inhibitors	B-MED
have	O
yielded	O
little	O
clinical	B-MED
benefit	I-MED
for	O
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
	
recent	B-MED
epidemiologic	B-MED
studies	I-MED
have	O
suggested	B-MED
a	O
therapeutic	B-MED
benefit	B-MED
from	O
aspirin	B-MED
intake	O
in	O
cancers	B-MED
harboring	O
oncogenic	B-MED
pik3ca	I-MED
here	O
,	O
we	O
show	O
that	O
mutant	B-MED
pik3ca	B-MED
-	O
expressing	B-MED
breast	B-MED
cancer	I-MED
cells	I-MED
have	O
greater	O
sensitivity	B-MED
to	O
aspirin	B-MED
-mediated	O
growth	B-MED
suppression	B-MED
than	O
their	O
wild-type	B-MED
counterparts	O
.	O
	
aspirin	B-MED
decreased	B-MED
viability	B-MED
and	O
anchorage-independent	B-MED
growth	I-MED
of	O
mutant	B-MED
pik3ca	B-MED
breast	B-MED
cancer	I-MED
cells	I-MED
independently	B-MED
of	O
its	O
effects	B-MED
on	O
cox-2	B-MED
and	O
nf-κb	B-MED
.	O
	
we	O
ascribed	O
the	O
effects	B-MED
of	I-MED
aspirin	B-MED
to	O
amp-activated	B-MED
protein	I-MED
kinase	I-MED
ampk	B-MED
activation	B-MED
,	O
mtorc1	B-MED
inhibition	B-MED
,	O
and	O
autophagy	B-MED
induction	O
.	O
	
in	O
vivo	O
,	O
oncogenic	B-MED
pik3ca	B-MED
-driven	O
mouse	B-MED
mammary	B-MED
tumors	I-MED
treated	B-MED
daily	O
with	O
aspirin	B-MED
resulted	O
in	O
decreased	B-MED
tumor	B-MED
growth	I-MED
kinetics	B-MED
,	O
whereas	O
combination	B-MED
therapy	B-MED
of	O
aspirin	B-MED
and	O
a	O
pi3k	B-MED
inhibitor	B-MED
further	O
attenuated	B-MED
tumor	B-MED
growth	I-MED
.	O
	
our	O
study	O
supports	O
the	O
evaluation	B-MED
of	O
aspirin	B-MED
and	O
pi3k	B-MED
pathway	O
inhibitors	B-MED
as	O
a	O
combination	B-MED
therapy	B-MED
for	O
targeting	B-MED
breast	B-MED
cancer	I-MED
.	O
	
prevalence	B-MED
of	O
psychiatric	B-MED
disorders	I-MED
among	O
female	B-MED
juvenile	B-MED
offenders	I-MED
inmates	B-MED
of	O
juvenile	B-MED
developmental	I-MED
centers	I-MED
are	O
the	O
special	B-MED
group	B-MED
of	O
youth	B-MED
population	B-MED
who	O
are	O
in	O
conflict	B-MED
with	O
law	B-MED
.	O
	
they	O
are	O
vulnerable	B-MED
to	O
psychiatric	B-MED
illness	I-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
see	O
the	O
prevalence	B-MED
and	O
type	B-MED
of	O
psychiatric	B-MED
disorders	I-MED
in	O
institutionalized	B-MED
female	B-MED
juvenile	B-MED
offenders	I-MED
and	O
non-offenders	B-MED
of	O
same	B-MED
age	B-MED
,	O
sex	B-MED
and	O
socioeconomic	B-MED
group	I-MED
in	O
the	O
community	B-MED
.	O
	
the	O
association	B-MED
of	O
mental	B-MED
disorders	I-MED
was	O
examined	B-MED
in	O
43	O
female	B-MED
inmates	B-MED
of	O
juvenile	B-MED
development	I-MED
centers	I-MED
and	O
43	O
randomly	B-MED
selected	B-MED
comparison	B-MED
subjects	B-MED
in	O
community	B-MED
.	O
	
one	B-MED
stage-structured	I-MED
assessment	I-MED
of	O
psychopathology	B-MED
was	O
carried	O
out	O
by	O
using	O
a	O
structured	B-MED
and	O
valid	B-MED
bangla	B-MED
version	B-MED
of	O
the	O
development	B-MED
and	I-MED
well-being	I-MED
assessment	I-MED
dawba	B-MED
.	O
	
development	B-MED
and	I-MED
well-being	I-MED
assessment	I-MED
generated	O
psychiatric	B-MED
diagnosis	B-MED
was	O
assigned	O
based	O
on	O
icd-10	B-MED
diagnostic	B-MED
criteria	I-MED
for	O
research	B-MED
.	O
	
the	O
result	B-MED
revealed	B-MED
that	O
,	O
of	O
those	O
who	O
were	O
in	O
conflict	B-MED
with	O
law	B-MED
,	O
93%	O
had	O
mental	B-MED
disorder	I-MED
,	O
whereas	O
14%	O
of	O
non-offenders	B-MED
had	O
psychiatric	B-MED
disorder	I-MED
.	O
	
among	O
the	O
offenders	B-MED
with	O
psychiatric	B-MED
disorders	I-MED
,	O
most	O
of	O
them	O
32.6	O
suffered	O
from	O
major	B-MED
depressive	I-MED
disorder	I-MED
mdd	B-MED
,	O
followed	O
by	O
combined	B-MED
mdd	B-MED
post	B-MED
traumatic	I-MED
stress	I-MED
disorder	I-MED
ptsd	B-MED
.	O
	
on	O
the	O
other	O
hand	O
,	O
among	O
the	O
non-offenders	B-MED
with	O
psychiatric	B-MED
disorder	I-MED
9.3	O
suffered	O
from	O
mdd	B-MED
.	O
	
it	O
can	O
be	O
concluded	B-MED
that	O
considerable	B-MED
psychiatric	B-MED
disorders	I-MED
are	O
prevalent	B-MED
among	O
the	O
female	B-MED
juvenile	B-MED
offenders	I-MED
with	O
comparison	B-MED
to	O
non-offenders	B-MED
.	O
	
broad	B-MED
-based	O
replication	B-MED
study	I-MED
could	O
confirm	B-MED
these	O
association	B-MED
between	O
neutrophil	B-MED
-to-	O
lymphocyte	B-MED
ratio	B-MED
and	O
differentiated	B-MED
thyroid	I-MED
cancer	I-MED
a	O
meta-analysis	B-MED
the	O
association	B-MED
between	O
neutrophil	B-MED
-to-	O
lymphocyte	B-MED
ratio	B-MED
nlr	B-MED
and	O
differentiated	B-MED
thyroid	I-MED
cancer	I-MED
dtc	B-MED
is	O
undecided	O
.	O
	
to	O
rectify	O
this	O
question	O
,	O
we	O
conducted	B-MED
a	O
systematic	B-MED
meta-analysis	B-MED
based	O
on	O
7	O
prospective	B-MED
cohort	I-MED
studies	I-MED
published	B-MED
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	B-MED
.	O
	
six	O
of	O
these	O
cohorts	B-MED
included	O
pretreatment	B-MED
baseline	B-MED
nlr	B-MED
data	B-MED
for	O
patients	B-MED
with	O
thyroid	B-MED
nodules	I-MED
.	O
	
the	O
meta-analysis	B-MED
of	O
these	O
6	O
cohorts	B-MED
showed	O
that	O
the	O
nlr	B-MED
of	O
patients	B-MED
with	O
dtc	B-MED
4617	O
cases	B-MED
was	O
statistically	B-MED
similar	O
to	O
patients	B-MED
with	O
benign	B-MED
nodules	I-MED
only	O
1666	O
cases	B-MED
,	O
with	O
a	O
mean	O
difference	O
md	O
of	O
0.19	O
95%	O
ci	B-MED
-0	O
to	O
0.46	O
i	O
=	O
93%	O
p	B-MED
<	O
0.001	O
.	O
	
no	O
significant	O
difference	O
in	O
nlr	B-MED
was	O
found	O
between	O
patients	B-MED
with	O
dtc	B-MED
and	O
patients	B-MED
with	O
benign	B-MED
nodules	I-MED
.	O
	
two	O
studies	B-MED
addressed	O
an	O
association	B-MED
between	O
nlr	B-MED
and	O
papillary	B-MED
thyroid	I-MED
carcinoma	I-MED
in	O
patients	B-MED
stratified	B-MED
by	O
age	B-MED
<45	O
and	O
45	O
years	B-MED
496	O
and	O
891	O
cases	B-MED
,	O
respectively	O
the	O
pooled	O
md	O
was	O
0.09	O
95%	O
ci	B-MED
-0	O
to	O
0.55	O
i	O
=	O
92.2	O
,	O
p	B-MED
<	O
0.001	O
.	O
	
an	O
elevated	B-MED
nlr	B-MED
seems	O
not	O
a	O
reliable	B-MED
indicator	B-MED
of	O
progressing	B-MED
dtc	B-MED
in	O
patients	B-MED
with	O
goiters	B-MED
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
nlr	B-MED
between	O
patients	B-MED
aged	B-MED
<45	O
years	B-MED
and	O
those	O
aged	B-MED
45	O
years	B-MED
.	O
	
well-designed	O
and	O
large-scale	O
investigations	B-MED
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
nlr	B-MED
in	O
the	O
prognosis	B-MED
of	O
transcriptomic	B-MED
insights	O
into	O
the	O
allelopathic	B-MED
effects	B-MED
of	I-MED
the	O
garlic	B-MED
allelochemical	B-MED
diallyl	B-MED
disulfide	I-MED
on	O
tomato	B-MED
roots	B-MED
garlic	B-MED
is	O
an	O
allelopathic	B-MED
crop	B-MED
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	B-MED
cropping	B-MED
of	O
vegetable	B-MED
crops	I-MED
.	O
	
diallyl	B-MED
disulfide	I-MED
dads	B-MED
,	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	B-MED
in	O
garlic	B-MED
,	O
promotes	B-MED
tomato	B-MED
root	B-MED
growth	I-MED
.	O
	
therefore	O
,	O
the	O
global	B-MED
transcriptome	B-MED
profiles	B-MED
of	O
dads	B-MED
-	O
treated	B-MED
tomato	B-MED
roots	B-MED
over	O
time	O
were	O
investigated	B-MED
to	O
reveal	O
the	O
potential	B-MED
growth-promoting	B-MED
mechanisms	I-MED
.	O
	
we	O
detected	B-MED
1828	O
,	O
1296	O
and	O
1190	O
differentially	B-MED
expressed	I-MED
genes	B-MED
degs	B-MED
in	O
the	O
4	O
,	O
24	O
and	O
48	O
h	O
samples	O
,	O
respectively	O
.	O
	
most	O
degs	B-MED
involved	O
in	O
assimilatory	B-MED
sulfate	I-MED
reduction	I-MED
and	O
glutathione	B-MED
metabolism	I-MED
were	O
up-regulated	B-MED
after	O
short-term	B-MED
4	O
h	O
dads	B-MED
treatment	B-MED
.	O
	
in	O
addition	O
,	O
increased	B-MED
activity	I-MED
of	I-MED
defensive	I-MED
enzymes	I-MED
and	O
up-regulation	B-MED
of	O
six	O
peroxidase	B-MED
genes	I-MED
were	O
observed	B-MED
,	O
suggesting	O
that	O
dads	B-MED
could	O
induce	B-MED
tomato	B-MED
resistance	B-MED
.	O
	
in	O
plant-pathogen	B-MED
interactions	I-MED
,	O
degs	B-MED
related	O
to	O
calcium	B-MED
signaling	I-MED
were	O
primarily	O
inhibited	B-MED
,	O
while	O
those	O
encoding	B-MED
pathogenesis-related	B-MED
proteins	I-MED
were	O
primarily	O
up-regulated	B-MED
.	O
	
although	O
plant	B-MED
hormone	B-MED
synthesis	I-MED
and	O
signal	B-MED
transduction	I-MED
were	O
both	O
significantly	B-MED
affected	I-MED
by	O
dads	B-MED
,	O
the	O
expression	B-MED
trends	B-MED
of	O
the	O
genes	B-MED
in	O
these	O
two	O
pathways	B-MED
were	O
conflicting	O
.	O
	
this	O
research	B-MED
provides	O
comprehensive	B-MED
information	B-MED
concerning	O
the	O
changes	B-MED
in	O
the	O
tomato	B-MED
root	B-MED
transcriptome	B-MED
affected	B-MED
by	O
dads	B-MED
and	O
may	O
help	O
direct	O
further	O
studies	B-MED
on	O
dads	B-MED
-	O
responsive	B-MED
genes	B-MED
to	O
enhance	B-MED
the	O
current	B-MED
understanding	O
of	O
the	O
mechanisms	B-MED
by	O
which	O
dads	B-MED
alleviates	O
the	O
obstacles	O
to	O
continuous	B-MED
cropping	B-MED
.	O
	
mitotic	B-MED
phosphotyrosine	B-MED
network	B-MED
analysis	I-MED
reveals	O
that	O
tyrosine	B-MED
phosphorylation	I-MED
regulates	O
polo-like	B-MED
kinase	I-MED
1	I-MED
plk1	B-MED
tyrosine	B-MED
phosphorylation	I-MED
is	O
closely	O
associated	B-MED
with	I-MED
cell	B-MED
proliferation	I-MED
.	O
	
during	O
the	O
cell	B-MED
cycle	I-MED
,	O
serine	B-MED
and	I-MED
threonine	I-MED
phosphorylation	I-MED
plays	O
the	O
leading	O
role	O
,	O
and	O
such	O
phosphorylation	B-MED
events	O
are	O
most	O
dynamic	B-MED
during	O
the	O
mitotic	B-MED
phase	I-MED
of	O
the	O
cell	B-MED
cycle	I-MED
.	O
	
however	O
,	O
mitotic	B-MED
phosphotyrosine	B-MED
is	O
not	O
well	O
characterized	O
.	O
	
although	O
a	O
few	O
functionally	B-MED
-	O
relevant	B-MED
mitotic	B-MED
phosphotyrosine	B-MED
sites	B-MED
have	O
been	O
characterized	B-MED
,	O
evidence	O
suggests	O
that	O
this	O
modification	B-MED
may	O
be	O
more	O
prevalent	B-MED
than	O
previously	O
appreciated	O
.	O
	
here	O
,	O
we	O
examined	B-MED
tyrosine	B-MED
phosphorylation	I-MED
in	O
mitotic	B-MED
human	I-MED
cells	I-MED
including	O
those	O
on	O
spindle-associated	B-MED
proteins	I-MED
database	B-MED
mining	I-MED
confirmed	O
2000	O
mitotic	B-MED
phosphotyrosine	B-MED
sites	B-MED
,	O
and	O
network	B-MED
analysis	I-MED
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine-phosphorylated	B-MED
proteins	I-MED
,	O
including	O
components	O
of	O
the	O
kinetochore	B-MED
or	O
spindle	B-MED
and	O
src	B-MED
family	I-MED
kinases	I-MED
.	O
	
we	O
identified	O
polo-like	B-MED
kinase	I-MED
1	I-MED
plk1	B-MED
,	O
a	O
major	O
signaling	B-MED
hub	O
in	O
the	O
spindle	B-MED
subnetwork	B-MED
,	O
as	O
phosphorylated	B-MED
at	O
the	O
conserved	O
tyr	B-MED
in	O
the	O
kinase	B-MED
domain	I-MED
.	O
	
substitution	B-MED
of	O
tyr	B-MED
with	O
a	O
phosphomimetic	B-MED
residue	I-MED
eliminated	O
plk1	B-MED
activity	B-MED
in	B-MED
vitro	I-MED
and	O
in	O
cells	B-MED
.	O
	
further	O
analysis	B-MED
showed	O
that	O
tyr	B-MED
phosphorylation	B-MED
reduced	O
the	O
phosphorylation	B-MED
of	I-MED
thr	I-MED
in	O
the	O
activation	B-MED
loop	I-MED
,	O
a	O
phosphorylation	B-MED
event	O
necessary	O
for	O
plk1	B-MED
activity	B-MED
.	O
	
our	O
data	O
indicate	O
that	O
mitotic	B-MED
tyrosine	B-MED
phosphorylation	I-MED
regulated	O
a	O
key	O
serine/threonine	B-MED
kinase	I-MED
hub	O
in	O
mitotic	B-MED
cells	I-MED
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine	B-MED
phosphorylation	I-MED
events	O
can	O
reveal	O
previously	O
unrecognized	B-MED
regulatory	B-MED
events	I-MED
and	O
complexes	B-MED
associated	O
with	O
specific	O
structures	B-MED
of	O
the	O
cell	B-MED
cycle	I-MED
.	O
	
divided	B-MED
and	O
sliding	B-MED
superficial	B-MED
temporal	I-MED
artery	I-MED
flap	B-MED
for	O
primary	B-MED
donor-site	B-MED
closure	B-MED
superficial	B-MED
temporal	I-MED
artery	I-MED
sta	B-MED
flaps	B-MED
are	O
often	O
used	O
for	O
reconstruction	B-MED
of	O
hair-bearing	B-MED
areas	I-MED
.	O
	
however	O
,	O
primary	B-MED
closure	I-MED
of	O
the	O
donor	B-MED
site	I-MED
is	O
not	O
easy	O
when	O
the	O
size	B-MED
of	O
the	O
necessary	O
skin	B-MED
island	I-MED
is	O
relatively	O
large	B-MED
.	O
	
in	O
such	O
cases	O
,	O
skin	B-MED
grafts	I-MED
are	O
needed	O
at	O
the	O
donor	B-MED
site	I-MED
,	O
resulting	O
in	O
baldness	B-MED
.	O
	
we	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	B-MED
and	O
sliding	B-MED
flap	B-MED
technique	B-MED
,	O
which	O
was	O
first	O
reported	O
for	O
primary	B-MED
donor-site	I-MED
closure	I-MED
of	O
a	O
latissimus	B-MED
dorsi	I-MED
musculocutaneous	I-MED
flap	B-MED
.	O
	
we	O
applied	O
this	O
technique	B-MED
to	O
the	O
hair-bearing	B-MED
sta	I-MED
flap	B-MED
,	O
where	O
primary	B-MED
donor-site	I-MED
closure	I-MED
is	O
extremely	O
beneficial	O
for	O
preventing	B-MED
baldness	B-MED
consequent	O
to	O
skin	B-MED
grafting	I-MED
.	O
	
the	O
sta	B-MED
flap	B-MED
was	O
divided	B-MED
into	O
3	O
,	O
and	O
creation	B-MED
of	O
large	O
flap	B-MED
was	O
possible	O
.	O
	
therefore	O
,	O
we	O
concluded	O
that	O
the	O
divided	B-MED
and	O
sliding	B-MED
sta	B-MED
flap	B-MED
could	O
at	O
least	O
partially	O
solve	O
the	O
donor-site	B-MED
problem	B-MED
.	O
	
although	O
further	O
investigation	B-MED
is	O
necessary	O
to	O
validate	B-MED
the	O
maximum	B-MED
possible	B-MED
flap	B-MED
size	B-MED
,	O
this	O
technique	B-MED
may	O
be	O
applicable	O
to	O
at	O
least	O
small	B-MED
defects	B-MED
that	O
are	O
common	O
after	O
skin	B-MED
cancer	I-MED
ablation	B-MED
or	O
influence	B-MED
of	O
surface	B-MED
properties	I-MED
on	O
adhesion	B-MED
forces	I-MED
and	O
attachment	B-MED
of	O
streptococcus	B-MED
mutans	I-MED
to	O
zirconia	B-MED
in	B-MED
vitro	I-MED
zirconia	B-MED
is	O
becoming	O
a	O
prevalent	B-MED
material	I-MED
in	O
dentistry	B-MED
.	O
	
however	O
,	O
any	O
foreign	B-MED
bodies	I-MED
inserted	B-MED
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-MED
in	O
oral	B-MED
cavity	I-MED
.	O
	
the	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	B-MED
of	O
surface	B-MED
properties	I-MED
including	O
surface	B-MED
roughness	I-MED
and	O
hydrophobicity	B-MED
on	O
the	O
adhesion	B-MED
and	O
biofilm	B-MED
formation	I-MED
of	O
streptococcus	B-MED
mutans	I-MED
s	B-MED
.	O
	
mutans	I-MED
to	O
zirconia	B-MED
.	O
	
atomic	B-MED
force	I-MED
microscopy	I-MED
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-MED
surface	B-MED
morphology	B-MED
and	O
the	O
adhesion	B-MED
forces	I-MED
between	O
the	O
s	B-MED
.	O
	
mutans	I-MED
and	O
zirconia	B-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
the	O
surface	B-MED
roughness	I-MED
was	O
nanoscale	B-MED
and	O
significantly	O
different	B-MED
among	O
tested	B-MED
groups	I-MED
p	O
<	O
0.05	O
coarse	B-MED
23.94	O
2.52	O
nm	O
>	O
medium	B-MED
17.00	O
3.81	O
nm	O
>	O
fine	B-MED
11.89	O
1.68	O
nm	O
.	O
	
the	O
contact	B-MED
angles	I-MED
of	O
the	O
coarse	B-MED
group	I-MED
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
medium	B-MED
and	O
the	O
fine	B-MED
groups	I-MED
.	O
	
increasing	O
the	O
surface	B-MED
roughness	I-MED
and	O
hydrophobicity	B-MED
resulted	O
in	O
an	O
increase	O
of	O
adhesion	B-MED
forces	I-MED
and	O
early	O
attachment	B-MED
2	O
h	O
and	O
4	O
h	O
of	O
s	B-MED
.	O
	
mutans	I-MED
on	O
the	O
zirconia	B-MED
but	O
no	O
influence	B-MED
on	O
the	O
further	O
development	B-MED
of	O
biofilm	B-MED
6	O
h	O
h	O
.	O
	
our	O
findings	O
suggest	O
that	O
the	O
surface	B-MED
roughness	I-MED
in	O
nanoscale	B-MED
and	O
hydrophobicity	B-MED
of	O
zirconia	B-MED
had	O
influence	B-MED
on	O
the	O
s	B-MED
.	O
	
mutans	I-MED
initial	O
adhesion	B-MED
force	I-MED
and	O
early	O
attachment	B-MED
instead	O
of	O
whole	O
stages	O
of	O
biofilm	B-MED
formation	I-MED
.	O
	
the	O
relationship	O
between	O
thiamine	B-MED
and	O
two	O
symbioses	B-MED
root	B-MED
nodule	I-MED
symbiosis	B-MED
and	O
arbuscular	B-MED
mycorrhiza	I-MED
lotus	B-MED
japonicus	I-MED
thic	B-MED
is	O
expressed	B-MED
in	O
all	O
organs	B-MED
,	O
and	O
the	O
encoded	B-MED
protein	I-MED
catalyzes	B-MED
thiamine	B-MED
biosynthesis	I-MED
.	O
	
loss	B-MED
of	I-MED
function	I-MED
produces	O
chlorosis	B-MED
,	O
a	O
typical	O
thiamine	B-MED
-deficiency	O
phenotype	B-MED
,	O
and	O
mortality	B-MED
.	O
	
to	O
investigate	O
thiamine's	B-MED
role	O
in	O
symbiosis	B-MED
,	O
we	O
focused	O
on	O
thi1	B-MED
,	O
a	O
thiamine-biosynthesis	B-MED
gene	I-MED
expressed	B-MED
in	O
roots	B-MED
,	O
nodules	B-MED
,	O
and	O
seeds	B-MED
.	O
	
the	O
thi1	B-MED
mutant	I-MED
had	O
green	B-MED
leaves	I-MED
,	O
but	O
formed	O
small	B-MED
nodules	B-MED
and	O
immature	B-MED
seeds	B-MED
.	O
	
these	O
phenotypes	B-MED
were	O
rescued	O
by	O
thi1	B-MED
complementation	B-MED
and	O
by	O
exogenous	B-MED
thiamine	B-MED
.	O
	
thus	O
,	O
thi1	B-MED
is	O
required	O
for	O
nodule	B-MED
enlargement	B-MED
and	O
seed	B-MED
maturation	I-MED
.	O
	
on	O
the	O
other	O
hand	O
,	O
colonization	B-MED
by	O
arbuscular	B-MED
mycorrhiza	I-MED
am	B-MED
fungus	B-MED
rhizophagus	B-MED
irregularis	I-MED
was	O
not	O
affected	O
in	O
the	O
thi1	B-MED
mutant	I-MED
or	O
by	O
exogenous	B-MED
thiamine	B-MED
.	O
	
however	O
,	O
spores	B-MED
of	O
r	B-MED
.	O
	
irregularis	I-MED
stored	O
more	O
thiamine	B-MED
than	O
the	O
source	O
host	B-MED
plants	I-MED
,	O
despite	O
lacking	O
thiamine	B-MED
biosynthesis	I-MED
genes	I-MED
.	O
	
therefore	O
,	O
disturbance	O
of	O
the	O
thiamine	B-MED
supply	O
would	O
affect	O
progeny	B-MED
phenotypes	B-MED
such	O
as	O
spore	B-MED
formation	I-MED
and	O
hyphal	B-MED
growth	I-MED
.	O
	
further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine's	B-MED
effect	O
on	O
bilateral	B-MED
sternal	B-MED
infusion	B-MED
of	O
ropivacaine	B-MED
and	O
length	B-MED
of	I-MED
stay	I-MED
in	O
icu	B-MED
after	O
cardiac	B-MED
surgery	I-MED
with	O
increased	B-MED
respiratory	B-MED
risk	I-MED
a	O
randomised	B-MED
controlled	I-MED
trial	I-MED
the	O
continuous	O
bilateral	B-MED
infusion	B-MED
of	O
a	O
local	B-MED
anaesthetic	I-MED
solution	B-MED
around	O
the	O
sternotomy	B-MED
wound	B-MED
bilateral	B-MED
sternal	B-MED
is	O
an	O
innovative	O
technique	B-MED
for	O
reducing	B-MED
pain	B-MED
after	O
sternotomy	B-MED
.	O
	
to	O
assess	O
the	O
effects	B-MED
of	O
the	O
technique	B-MED
on	O
the	O
need	O
for	O
intensive	B-MED
care	I-MED
in	O
cardiac	B-MED
patients	I-MED
at	O
increased	B-MED
risk	B-MED
of	O
respiratory	B-MED
complications	I-MED
.	O
	
randomised	B-MED
,	O
observer-blind	I-MED
controlled	I-MED
trial	I-MED
.	O
	
single	O
centre	O
,	O
french	B-MED
university	I-MED
hospital	I-MED
.	O
	
in	O
total	O
,	O
120	O
adults	B-MED
scheduled	O
for	O
open-heart	B-MED
surgery	I-MED
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
age	B-MED
more	O
than	O
75	O
years	B-MED
,	O
bmi	B-MED
>30	O
kg	O
m	O
,	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
,	O
active	B-MED
smoking	I-MED
habit	I-MED
.	O
	
either	O
a	O
bilateral	B-MED
sternal	B-MED
infusion	B-MED
of	O
0.2	O
ropivacaine	B-MED
3	O
ml	O
h	O
through	O
each	O
catheter	B-MED
'intervention'	B-MED
group	I-MED
,	O
or	O
standardised	B-MED
care	I-MED
only	O
'control'	B-MED
group	I-MED
.	O
	
analgesia	B-MED
was	O
provided	O
with	O
paracetamol	B-MED
and	O
self-administered	B-MED
intravenous	B-MED
morphine	B-MED
.	O
	
the	O
length	B-MED
of	I-MED
time	I-MED
to	O
readiness	B-MED
for	O
discharge	B-MED
from	O
icu	B-MED
,	O
blindly	O
assessed	B-MED
by	O
a	O
committee	B-MED
of	O
experts	B-MED
.	O
	
no	B-MED
effect	I-MED
was	O
found	O
between	O
groups	B-MED
for	O
the	O
primary	B-MED
outcome	I-MED
p	O
=	O
0.680	O
,	O
intention	B-MED
to	I-MED
treat	I-MED
the	O
median	B-MED
values	I-MED
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	B-MED
and	O
intervention	B-MED
groups	I-MED
p	O
=	O
0.873	O
.	O
	
similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-MED
delays	B-MED
.	O
	
significant	O
effects	B-MED
favouring	O
the	O
intervention	B-MED
were	O
noted	O
for	O
dynamic	B-MED
pain	I-MED
,	O
patient	B-MED
satisfaction	I-MED
,	O
occurrence	B-MED
of	I-MED
nausea	I-MED
and	O
vomiting	B-MED
,	O
occurrence	B-MED
of	O
delirium	B-MED
or	O
mental	B-MED
confusion	I-MED
and	O
occurrence	B-MED
of	O
pulmonary	B-MED
complications	I-MED
.	O
	
in	O
12	O
patients	B-MED
,	O
although	O
no	O
symptoms	B-MED
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B-MED
symptoms	I-MED
have	O
been	O
observed	O
in	O
healthy	B-MED
volunteers	I-MED
.	O
	
because	O
of	O
a	O
small	B-MED
size	I-MED
effect	I-MED
,	O
and	O
despite	O
significant	O
analgesic	B-MED
effects	I-MED
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	B-MED
spent	O
in	O
icu	B-MED
.	O
	
eudract	B-MED
n	O
2012-005225-69	O
clinicaltrials.gov	B-MED
pupil	B-MED
sizes	I-MED
scale	B-MED
with	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
in	O
a	O
multiple	B-MED
object	B-MED
tracking	B-MED
task	B-MED
previous	O
studies	O
have	O
related	O
changes	B-MED
in	O
attentional	B-MED
load	I-MED
to	O
pupil	B-MED
size	I-MED
modulations	B-MED
.	O
	
however	O
,	O
studies	O
relating	O
changes	B-MED
in	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
on	O
a	O
finer	O
scale	B-MED
to	O
pupil	B-MED
size	I-MED
modulations	B-MED
are	O
scarce	O
.	O
	
here	O
,	O
we	O
investigated	B-MED
how	O
these	O
changes	B-MED
affect	B-MED
pupil	B-MED
sizes	I-MED
.	O
	
to	O
manipulate	B-MED
attentional	B-MED
load	I-MED
,	O
participants	B-MED
covertly	O
tracked	B-MED
between	O
zero	B-MED
and	O
five	B-MED
objects	B-MED
among	O
several	O
randomly	B-MED
moving	O
objects	B-MED
on	O
a	O
computer	B-MED
screen	B-MED
.	O
	
to	O
investigate	B-MED
effects	B-MED
of	I-MED
task	B-MED
experience	B-MED
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	B-MED
consecutive	B-MED
days	B-MED
.	O
	
we	O
found	O
that	O
pupil	B-MED
sizes	I-MED
increased	O
with	O
each	O
increment	B-MED
in	O
attentional	B-MED
load	I-MED
.	O
	
across	O
days	B-MED
,	O
we	O
found	O
systematic	B-MED
pupil	B-MED
size	I-MED
reductions	B-MED
.	O
	
we	O
compared	O
the	O
model	B-MED
fit	I-MED
for	O
predicting	O
pupil	B-MED
size	I-MED
modulations	B-MED
using	O
attentional	B-MED
load	I-MED
,	O
task	B-MED
experience	B-MED
,	O
and	O
task	B-MED
performance	I-MED
as	O
predictors	B-MED
.	O
	
we	O
found	O
that	O
a	O
model	B-MED
which	O
included	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
as	O
predictors	B-MED
had	O
the	O
best	O
model	B-MED
fit	I-MED
while	O
adding	O
performance	B-MED
as	O
a	O
predictor	B-MED
to	O
this	O
model	B-MED
reduced	O
the	O
overall	O
model	B-MED
fit	I-MED
.	O
	
overall	O
,	O
results	B-MED
suggest	O
that	O
pupillometry	B-MED
provides	O
a	O
viable	B-MED
metric	B-MED
for	O
precisely	O
assessing	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
in	O
visuospatial	B-MED
tasks	B-MED
.	O
	
back	O
to	O
the	O
roots	O
deep	O
view	O
into	O
the	O
evolutionary	B-MED
history	B-MED
of	O
adp-ribosylation	B-MED
opened	O
by	O
the	O
dna	B-MED
-	O
targeting	B-MED
toxin	B-MED
-	O
antitoxin	B-MED
module	B-MED
dartg	I-MED
in	O
this	O
issue	O
of	O
molecular	B-MED
cell	I-MED
,	O
jankevicius	O
et	O
al	O
.	O
	
2016	O
characterize	O
the	O
dartg	B-MED
toxin	B-MED
-	O
antitoxin	B-MED
module	B-MED
in	O
which	O
the	O
dart	B-MED
toxin	B-MED
adp-ribosylates	B-MED
single-stranded	B-MED
dna	I-MED
and	O
the	O
darg	B-MED
antitoxin	B-MED
counteracts	B-MED
dart	B-MED
by	O
direct	O
binding	B-MED
and	O
by	O
enzymatic	B-MED
remova	B-MED
l	O
of	O
the	O
growth	B-MED
differentiation	I-MED
factor	I-MED
15	I-MED
is	O
a	O
myomitokine	B-MED
governing	B-MED
systemic	I-MED
energy	I-MED
homeostasis	I-MED
reduced	B-MED
mitochondrial	B-MED
electron	I-MED
transport	I-MED
chain	I-MED
activity	B-MED
promotes	B-MED
longevity	B-MED
and	O
improves	B-MED
energy	B-MED
homeostasis	I-MED
via	O
cell-autonomous	B-MED
and	O
-	O
non-autonomous	B-MED
factors	I-MED
in	O
multiple	B-MED
model	I-MED
systems	I-MED
.	O
	
this	O
mitohormetic	B-MED
effect	B-MED
is	O
thought	O
to	O
involve	O
the	O
mitochondrial	B-MED
unfolded	I-MED
protein	I-MED
response	I-MED
upr	B-MED
,	O
an	O
adaptive	B-MED
stress-response	I-MED
pathway	B-MED
activated	B-MED
by	O
mitochondrial	B-MED
proteotoxic	B-MED
stress	I-MED
.	O
	
using	O
mice	B-MED
with	O
skeletal	B-MED
muscle-specific	I-MED
deficiency	B-MED
of	O
crif1	B-MED
muscle-specific	B-MED
knockout	B-MED
mko	B-MED
,	O
an	O
integral	B-MED
protein	I-MED
of	O
the	O
large	B-MED
mitoribosomal	I-MED
subunit	I-MED
39s	B-MED
,	O
we	O
identified	O
growth	B-MED
differentiation	I-MED
factor	I-MED
15	I-MED
gdf15	B-MED
as	O
a	O
upr	B-MED
-associated	O
cell-non-autonomous	B-MED
myomitokine	B-MED
that	O
regulates	B-MED
systemic	I-MED
energy	I-MED
homeostasis	I-MED
.	O
	
mko	B-MED
mice	I-MED
were	O
protected	B-MED
against	O
obesity	B-MED
and	O
sensitized	B-MED
to	O
insulin	B-MED
,	O
an	O
effect	O
associated	B-MED
with	I-MED
elevated	B-MED
gdf15	B-MED
secretion	B-MED
after	O
upr	B-MED
activation	B-MED
.	O
	
in	O
ob/ob	B-MED
mice	I-MED
,	O
administration	O
of	O
recombinant	B-MED
gdf15	B-MED
decreased	B-MED
body	B-MED
weight	I-MED
and	O
improved	B-MED
insulin	B-MED
sensitivity	I-MED
,	O
which	O
was	O
attributed	O
to	O
elevated	B-MED
oxidative	B-MED
metabolism	I-MED
and	O
lipid	B-MED
mobilization	I-MED
in	O
the	O
liver	B-MED
,	O
muscle	B-MED
,	O
and	O
adipose	B-MED
tissue	I-MED
.	O
	
thus	O
,	O
gdf15	B-MED
is	O
a	O
potent	B-MED
mitohormetic	B-MED
signal	B-MED
that	O
safeguards	O
against	O
the	O
onset	B-MED
of	I-MED
obesity	I-MED
and	O
insulin	B-MED
resistance	I-MED
.	O
	
synthesis	B-MED
and	O
characterization	B-MED
of	O
acetylated	B-MED
amylose	I-MED
and	O
development	B-MED
of	O
inclusion	B-MED
complexes	I-MED
with	O
rifampicin	B-MED
amylose	B-MED
am	B-MED
tends	O
to	O
form	O
single	O
helical	O
inclusion	B-MED
complexes	I-MED
with	O
suitable	O
agents	B-MED
.	O
	
these	O
complexes	B-MED
are	O
considered	B-MED
promising	O
biomaterial	B-MED
carrier	O
since	O
the	O
guest	B-MED
molecules	I-MED
can	O
be	O
released	B-MED
later	B-MED
,	O
leading	O
to	O
many	O
applications	B-MED
,	O
especially	O
in	O
the	O
pharmaceutical	B-MED
industry	I-MED
.	O
	
rifampicin	B-MED
rif	B-MED
has	O
long	O
been	O
recognized	O
as	O
an	O
active	B-MED
drug	B-MED
against	O
mycobacterium	B-MED
tuberculosis	I-MED
,	O
however	O
,	O
the	O
administration	B-MED
of	O
rif	B-MED
in	O
high	O
dosages	B-MED
can	O
originate	O
unwanted	O
side-effects	B-MED
.	O
	
due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	B-MED
amylose	B-MED
am	B-MED
in	O
the	O
formation	B-MED
of	O
complexes	B-MED
is	O
limited	O
by	O
their	O
low	O
water	B-MED
solubility	I-MED
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	B-MED
of	O
substitution	B-MED
ds	B-MED
,	O
allowing	O
solubilizing	B-MED
0.5gl	O
acetylated	B-MED
amylose	I-MED
ama	B-MED
in	O
water	B-MED
at	O
neutral	B-MED
ph	I-MED
,	O
in	O
opposition	O
to	O
that	O
observed	B-MED
with	O
native	B-MED
amylose	B-MED
trace	B-MED
solubility	B-MED
.	O
	
the	O
resulting	O
acetylated	B-MED
amylose	I-MED
was	O
characterized	B-MED
by	O
means	O
of	O
fourier	B-MED
transform	I-MED
infrared	I-MED
ft-ir	I-MED
spectroscopy	I-MED
and	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
sem	B-MED
.	O
	
ft-ir	B-MED
results	B-MED
indicated	B-MED
that	O
the	O
acetylation	B-MED
of	O
anhydroglucose	B-MED
units	B-MED
of	O
amylose	B-MED
corresponds	O
to	O
a	O
low	B-MED
ds	B-MED
,	O
whereas	O
sem	B-MED
results	B-MED
suggested	O
that	O
the	O
smooth	B-MED
surfaces	I-MED
of	O
amylose	B-MED
granules	B-MED
were	O
changed	B-MED
into	O
rougher	O
surfaces	B-MED
after	O
acetylation	B-MED
.	O
	
ultraviolet	B-MED
absorption	I-MED
spectroscopy	I-MED
uv-vis	B-MED
analysis	B-MED
confirmed	B-MED
the	O
formation	B-MED
and	O
allowed	O
the	O
quantification	B-MED
of	O
both	O
native	B-MED
am	B-MED
-	O
rif	B-MED
and	O
acetylated	O
ama	B-MED
-	O
rif	B-MED
amylose	B-MED
inclusion	B-MED
complexes	I-MED
.	O
	
their	O
characterization	B-MED
in	O
solution	B-MED
was	O
performed	B-MED
by	O
dynamic	B-MED
light	I-MED
scattering	I-MED
dls	B-MED
and	O
zeta	B-MED
potential	I-MED
zp	B-MED
measurements	B-MED
.	O
	
the	O
average	B-MED
size	I-MED
of	O
inclusion	B-MED
complexes	I-MED
as	O
determined	B-MED
by	I-MED
dls	B-MED
,	O
ranged	B-MED
between	O
70	O
and	O
100nm	O
.	O
	
besides	O
,	O
zp	B-MED
analysis	B-MED
showed	O
that	O
both	O
complexes	B-MED
are	O
more	O
stable	B-MED
in	O
the	O
presence	B-MED
of	O
rif	B-MED
.	O
	
this	O
study	O
may	O
lead	O
to	O
the	O
development	B-MED
of	O
an	O
effective	B-MED
method	O
for	O
the	O
preparation	B-MED
of	O
amylose	B-MED
inclusion	B-MED
complexes	I-MED
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B-MED
application	B-MED
in	O
drug	B-MED
delivery	I-MED
systems	I-MED
.	O
	
selective	B-MED
reaching	B-MED
in	O
macaques	B-MED
evidence	B-MED
for	O
action	B-MED
-centred	O
attention	B-MED
when	O
a	O
monkey	B-MED
selects	B-MED
a	O
piece	O
of	O
food	B-MED
lying	O
on	O
the	O
ground	O
from	O
among	O
other	B-MED
viable	B-MED
objects	B-MED
in	O
the	O
near	B-MED
vicinity	B-MED
,	O
only	O
the	O
desired	B-MED
item	B-MED
governs	B-MED
the	O
particular	O
pattern	B-MED
and	O
direction	B-MED
of	O
the	O
animal's	B-MED
reaching	B-MED
action	B-MED
.	O
	
it	O
would	O
seem	O
then	O
that	O
selection	B-MED
is	O
an	O
important	B-MED
component	B-MED
controlling	B-MED
the	O
animal's	B-MED
action	B-MED
.	O
	
but	O
,	O
we	O
may	O
ask	O
,	O
is	O
the	O
selection	B-MED
process	B-MED
in	O
such	O
cases	B-MED
impervious	O
to	O
the	O
presence	B-MED
of	O
other	B-MED
objects	B-MED
that	O
could	O
constitute	B-MED
potential	B-MED
obstacles	B-MED
to	O
or	O
constraints	B-MED
on	O
movement	B-MED
execution	B-MED
and	O
if	O
it	O
is	O
,	O
in	O
fact	O
,	O
pervious	B-MED
to	O
other	B-MED
objects	B-MED
,	O
do	O
they	O
have	O
a	O
direct	B-MED
influence	B-MED
on	O
the	O
organization	B-MED
of	O
the	O
response	B-MED
the	O
kinematics	B-MED
of	O
macaques	B-MED
'	O
reaching	B-MED
movements	B-MED
were	O
examined	B-MED
by	O
the	O
current	B-MED
study	B-MED
that	O
analysed	B-MED
some	O
exemplars	O
as	O
they	O
selectively	B-MED
reached	B-MED
to	O
grasp	B-MED
a	O
food	B-MED
item	I-MED
in	O
the	O
absence	B-MED
as	O
well	O
as	O
in	O
the	O
presence	B-MED
of	O
potential	B-MED
obstacles	B-MED
i.e	O
,	O
stones	B-MED
that	O
could	O
affect	B-MED
the	O
arm	B-MED
trajectory	B-MED
.	O
	
changes	B-MED
in	O
movement	B-MED
parameterization	B-MED
were	O
noted	B-MED
in	O
temporal	B-MED
measures	B-MED
,	O
such	O
as	O
movement	B-MED
time	B-MED
,	O
as	O
well	O
as	O
in	O
spatial	B-MED
ones	I-MED
,	O
such	O
as	O
paths	O
of	O
trajectory	B-MED
.	O
	
generally	O
speaking	O
,	O
the	O
presence	B-MED
of	O
stones	B-MED
in	O
the	O
vicinity	B-MED
of	O
the	O
acting	B-MED
hand	B-MED
stalled	B-MED
the	O
reaching	B-MED
movement	B-MED
and	O
affected	B-MED
the	O
arm	B-MED
trajectory	B-MED
as	O
the	O
hand	B-MED
veered	B-MED
away	I-MED
from	O
the	O
stone	B-MED
even	O
when	O
it	O
was	O
not	B-MED
a	O
physical	B-MED
obstacle	B-MED
.	O
	
we	O
concluded	O
that	O
nearby	B-MED
objects	B-MED
evoke	O
a	O
motor	B-MED
response	I-MED
in	O
macaques	B-MED
,	O
and	O
the	O
attentional	B-MED
mechanisms	B-MED
that	O
allow	O
for	O
a	O
successful	B-MED
action	B-MED
selection	B-MED
are	O
revealed	B-MED
in	O
the	O
reaching	B-MED
path	B-MED
.	O
	
the	O
data	B-MED
outlined	O
here	O
concur	O
with	O
human	B-MED
studies	B-MED
indicating	B-MED
that	O
potential	B-MED
obstacles	B-MED
are	O
internally	B-MED
represented	B-MED
,	O
a	O
finding	B-MED
implying	O
basic	B-MED
cognitive	B-MED
operations	B-MED
allowing	O
for	O
action	B-MED
selection	B-MED
in	O
a	O
novel	B-MED
method	B-MED
for	O
interactive	B-MED
multi-objective	B-MED
dose-guided	B-MED
patient	I-MED
positioning	I-MED
in	O
intensity-modulated	B-MED
radiation	I-MED
therapy	I-MED
imrt	B-MED
,	O
3d	O
in-room	O
imaging	B-MED
data	B-MED
is	O
typically	O
utilized	O
for	O
accurate	B-MED
patient	B-MED
alignment	I-MED
on	O
the	O
basis	O
of	O
anatomical	B-MED
landmarks	I-MED
.	O
	
in	O
the	O
presence	O
of	O
non-rigid	O
anatomical	B-MED
changes	I-MED
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	B-MED
position	I-MED
is	O
most	O
suitable	O
.	O
	
thus	O
,	O
dose	B-MED
-guided	O
patient	B-MED
alignment	I-MED
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in-room	O
imaging	B-MED
data	B-MED
for	O
up-to-date	O
dose	B-MED
calculation	B-MED
,	O
aimed	O
at	O
finding	B-MED
the	O
position	O
that	O
yields	O
the	O
optimal	B-MED
dose	B-MED
distribution	B-MED
.	O
	
this	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	B-MED
-guided	O
patient	B-MED
alignment	I-MED
as	O
multi-criteria	O
optimization	O
problem	O
.	O
	
user-defined	O
clinical	B-MED
objectives	B-MED
are	O
employed	O
for	O
setting	O
up	O
a	O
multi-objective	B-MED
problem	O
.	O
	
using	O
pre-calculated	O
dose	B-MED
distributions	B-MED
at	O
a	O
limited	O
number	O
of	O
patient	B-MED
shifts	I-MED
and	O
dose	B-MED
interpolation	B-MED
,	O
a	O
continuous	O
space	O
of	O
pareto-efficient	B-MED
patient	I-MED
shifts	I-MED
becomes	O
accessible	O
.	O
	
pareto	O
sliders	O
facilitate	O
interactive	B-MED
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real-time	O
dose	B-MED
display	O
to	O
the	O
user	O
.	O
	
dose	B-MED
interpolation	B-MED
accuracy	B-MED
is	O
validated	O
and	O
the	O
potential	O
of	O
multi-objective	B-MED
dose-guided	B-MED
positioning	I-MED
demonstrated	O
for	O
three	O
head	B-MED
and	I-MED
neck	I-MED
h	B-MED
and	O
three	O
prostate	B-MED
cancer	I-MED
patients	B-MED
.	O
	
dose-guided	B-MED
positioning	I-MED
is	O
compared	B-MED
to	O
replanning	O
for	O
all	O
cases	O
.	O
	
a	O
delineated	O
replanning	O
ct	B-MED
served	O
as	O
surrogate	O
for	O
in-room	O
imaging	B-MED
data	B-MED
.	O
	
dose	B-MED
interpolation	B-MED
accuracy	B-MED
was	O
high	B-MED
.	O
	
using	O
a	O
formula	O
see	O
text	O
dose	B-MED
difference	O
criterion	O
,	O
a	O
median	O
pass-rate	O
of	O
95.7	O
for	O
h	B-MED
and	O
99.6	O
for	O
prostate	B-MED
cases	I-MED
was	O
determined	O
in	O
a	O
comparison	B-MED
to	O
exact	O
dose	B-MED
calculations	B-MED
.	O
	
for	O
all	O
patients	B-MED
,	O
dose-guided	B-MED
positioning	I-MED
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	B-MED
distribution	B-MED
compared	B-MED
to	O
bony	B-MED
anatomy	I-MED
based	I-MED
alignment	I-MED
.	O
	
for	O
all	O
h	B-MED
cases	O
,	O
mean	O
dose	B-MED
to	O
the	O
spared	O
parotid	B-MED
glands	I-MED
was	O
below	O
formula	O
see	O
text	O
up	O
to	O
formula	O
see	O
text	O
with	O
bony	B-MED
alignment	I-MED
and	O
clinical	B-MED
target	I-MED
volume	I-MED
ctv	B-MED
formula	O
see	O
text	O
above	O
99.1	O
compared	B-MED
to	O
95.1	O
.	O
	
for	O
all	O
prostate	B-MED
patients	B-MED
,	O
ctv	B-MED
formula	O
see	O
text	O
was	O
above	O
98.9	O
compared	B-MED
to	O
88.5	O
and	O
formula	O
see	O
text	O
to	O
the	O
rectum	O
below	O
formula	O
see	O
text	O
compared	B-MED
to	O
56.1	O
.	O
	
replanning	O
yielded	O
improved	O
results	O
for	O
the	O
h	B-MED
cases	O
.	O
	
for	O
the	O
prostate	B-MED
cases	I-MED
,	O
differences	O
to	O
dose-guided	B-MED
positioning	I-MED
clinical	B-MED
and	O
radiological	B-MED
outcome	B-MED
following	O
pneumothorax	B-MED
after	O
endoscopic	B-MED
lung	I-MED
volume	I-MED
reduction	I-MED
with	O
valves	B-MED
valve	B-MED
implantation	B-MED
has	O
evolved	O
as	O
a	O
therapy	B-MED
for	O
patients	B-MED
with	O
advanced	B-MED
emphysema	B-MED
.	O
	
although	O
it	O
is	O
a	O
minimally	B-MED
invasive	I-MED
treatmen	I-MED
t	O
,	O
it	O
is	O
associated	B-MED
with	I-MED
complications	B-MED
,	O
the	O
most	O
common	B-MED
being	O
pneumothorax	B-MED
.	O
	
pneumothorax	B-MED
occurs	O
due	O
to	O
the	O
rapid	B-MED
target	B-MED
lobe	B-MED
volume	B-MED
reduction	I-MED
and	O
may	O
be	O
a	O
predictor	B-MED
of	O
clinical	B-MED
benefit	B-MED
despite	O
this	O
complication	B-MED
.	O
	
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
conduct	O
an	O
exploratory	B-MED
data	I-MED
analysis	I-MED
of	O
patients	B-MED
who	O
developed	O
a	O
pneumothorax	B-MED
following	O
endoscopic	B-MED
valve	I-MED
therapy	I-MED
for	O
emphysema	B-MED
.	O
	
this	O
study	B-MED
performed	B-MED
a	O
retrospective	B-MED
evaluation	I-MED
of	O
pneumothorax	B-MED
management	B-MED
and	O
the	O
impact	B-MED
of	O
pneumothorax	B-MED
on	O
clinical	B-MED
outcomes	I-MED
in	O
70	O
patients	B-MED
following	O
valve	B-MED
therapy	I-MED
in	O
381	O
consecutive	B-MED
patients	B-MED
.	O
	
pneumothorax	B-MED
rate	B-MED
following	O
valve	B-MED
therapy	I-MED
was	O
18%	O
.	O
	
pneumothorax	B-MED
management	B-MED
consisted	O
of	O
chest	B-MED
tube	I-MED
insertion	I-MED
,	O
valve	B-MED
removal	B-MED
,	O
and	O
surgical	B-MED
intervention	I-MED
in	O
87%	O
61/70	O
,	O
44%	O
31/70	O
,	O
and	O
19%	O
13/70	O
of	O
the	O
patients	B-MED
,	O
respectively	O
.	O
	
despite	O
pneumothorax	B-MED
,	O
patients	B-MED
experienced	O
modest	B-MED
but	O
significant	B-MED
improvements	B-MED
in	O
lung	B-MED
function	I-MED
parameters	B-MED
forced	B-MED
expiratory	I-MED
volume	I-MED
in	O
1	O
second	O
55	O
ml	O
,	O
residual	B-MED
volume	I-MED
-390	O
ml	O
,	O
total	B-MED
lung	I-MED
capacity	I-MED
-348	O
all	O
p<0	O
.	O
	
persistent	B-MED
lobar	B-MED
atelectasis	I-MED
3	O
months	O
after	O
recovering	B-MED
from	O
pneumothorax	B-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
relevant	B-MED
clinical	B-MED
improvement	B-MED
,	O
was	O
observed	B-MED
in	O
only	O
21%	O
15/70	O
of	O
the	O
patients	B-MED
.	O
	
pneumothorax	B-MED
is	O
a	O
frequent	B-MED
severe	B-MED
complication	B-MED
following	O
valve	B-MED
therapy	I-MED
that	O
requires	O
further	O
intervention	B-MED
.	O
	
nevertheless	O
,	O
the	O
pneumothorax	B-MED
does	O
not	O
impair	B-MED
the	O
clinical	B-MED
status	I-MED
in	O
the	O
majority	O
of	O
patients	B-MED
.	O
	
patients	B-MED
with	O
lobar	B-MED
atelectasis	I-MED
benefit	B-MED
after	O
recovering	B-MED
from	O
pneumothorax	B-MED
in	O
terms	O
of	O
lung	B-MED
function	I-MED
parameters	B-MED
.	O
	
3mo	B-MED
a	O
model	B-MED
for	O
music	B-MED
-	O
based	B-MED
biofeedback	B-MED
in	O
the	O
domain	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
,	O
it	O
is	O
of	O
major	B-MED
importance	B-MED
to	O
regulate	B-MED
and	O
control	B-MED
physiological	B-MED
processes	I-MED
and	O
physical	B-MED
motion	I-MED
in	O
most	B-MED
optimal	B-MED
ways	O
.	O
	
for	O
that	O
purpose	B-MED
,	O
real-time	B-MED
auditory	B-MED
feedback	I-MED
of	O
physiological	B-MED
and	O
physical	B-MED
information	B-MED
based	B-MED
on	O
sound	B-MED
signals	I-MED
,	O
often	O
termed	O
""""	O
sonification	B-MED
""""	O
has	O
been	O
proven	B-MED
particularly	O
useful	B-MED
.	O
	
however	O
,	O
the	O
use	B-MED
of	O
music	B-MED
in	O
biofeedback	B-MED
systems	B-MED
has	O
been	O
much	O
less	B-MED
explored	B-MED
.	O
	
in	O
the	O
current	B-MED
article	B-MED
,	O
we	O
assert	O
that	O
the	O
use	B-MED
of	O
music	B-MED
,	O
and	O
musical	B-MED
principles	B-MED
,	O
can	O
have	O
a	O
major	B-MED
added	O
value	B-MED
,	O
on	O
top	O
of	O
mere	B-MED
sound	B-MED
signals	I-MED
,	O
to	O
the	O
benefit	B-MED
of	O
psychological	B-MED
and	O
physical	B-MED
optimization	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
tasks	B-MED
.	O
	
in	O
this	O
article	B-MED
,	O
we	O
present	B-MED
the	O
3mo	B-MED
model	I-MED
to	O
describe	O
three	O
main	B-MED
functions	B-MED
of	O
music	B-MED
that	O
contribute	B-MED
to	O
these	O
benefits	B-MED
.	O
	
these	O
functions	B-MED
relate	O
the	O
power	B-MED
of	O
music	B-MED
to	O
motivate	B-MED
,	O
and	O
to	O
monitor	B-MED
and	O
modify	B-MED
physiological	B-MED
and	O
physical	B-MED
processes	B-MED
.	O
	
the	O
model	B-MED
brings	O
together	O
concepts	B-MED
and	O
theories	B-MED
related	O
to	O
human	B-MED
sensorimotor	B-MED
interaction	I-MED
with	O
music	B-MED
,	O
and	O
specifies	B-MED
the	O
underlying	O
psychological	B-MED
and	O
physiological	B-MED
principles	B-MED
.	O
	
this	O
3mo	B-MED
model	I-MED
is	O
intended	B-MED
to	O
provide	B-MED
a	O
conceptual	B-MED
framework	I-MED
that	O
guides	B-MED
future	B-MED
research	B-MED
on	O
musical	B-MED
biofeedback	B-MED
systems	B-MED
in	O
the	O
domain	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
.	O
	
analysis	B-MED
of	O
tilianin	B-MED
and	O
acacetin	B-MED
in	O
agastache	B-MED
rugosa	I-MED
by	O
high-performance	B-MED
liquid	I-MED
chromatography	I-MED
with	O
ionic	B-MED
liquids	I-MED
-	O
ultrasound	B-MED
based	O
extraction	B-MED
ionic	B-MED
liquid	I-MED
1-butyl-3-methylimidazolium	B-MED
bromide	I-MED
-	O
methanol	B-MED
-based	O
ultrasonic	B-MED
-assisted	O
extraction	B-MED
iluae	B-MED
was	O
used	O
to	O
extract	B-MED
tilianin	B-MED
and	O
acacetin	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
agastache	B-MED
rugose	I-MED
a	B-MED
.	O
	
rugose	I-MED
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-MED
phase	I-MED
high	I-MED
performance	I-MED
liquid	I-MED
chromatographic	I-MED
rp-hplc	B-MED
method	O
with	O
ultraviolet	B-MED
detection	I-MED
rp-hplc-uv	B-MED
.	O
	
an	O
inertsustain	B-MED
rp-c18	I-MED
column	I-MED
was	O
used	O
with	O
the	O
mobile	B-MED
phase	I-MED
consisting	O
of	O
methanol	B-MED
and	O
0.2	O
acetic	B-MED
acid	I-MED
as	O
gradient	B-MED
elution	B-MED
at	O
the	O
detection	B-MED
wavelength	I-MED
of	O
332	O
nm	O
.	O
	
the	O
flow	B-MED
rate	I-MED
was	O
0.8	O
ml/min	O
,	O
and	O
the	O
column	B-MED
temperature	B-MED
was	O
30	O
c	O
.	O
	
under	O
the	O
optimized	B-MED
conditions	B-MED
,	O
tilianin	B-MED
and	O
acacetin	B-MED
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595	O
and	O
0.0585	O
μg/ml	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
,	O
respectively	O
.	O
	
the	O
method	B-MED
of	O
iluae	B-MED
was	O
compared	O
with	O
the	O
traditional	B-MED
methods	I-MED
,	O
it	O
exhibited	O
higher	B-MED
efficiency	B-MED
,	O
higher	B-MED
reproducibility	B-MED
and	O
environmental	B-MED
friendly	I-MED
in	O
analyzing	O
the	O
active	B-MED
compounds	B-MED
in	O
traditional	B-MED
chinese	I-MED
medicines	I-MED
tcms	B-MED
.	O
	
evaluation	B-MED
of	O
mif	B-MED
-173	I-MED
g/c	I-MED
polymorphism	B-MED
in	O
turkish	B-MED
patients	B-MED
with	O
ankylosing	B-MED
spondylitis	I-MED
ankylosing	B-MED
spondylitis	I-MED
as	B-MED
is	O
a	O
chronic	B-MED
inflammatory	I-MED
disease	I-MED
mainly	O
affecting	O
the	O
spine	B-MED
and	O
sacroiliac	B-MED
joints	I-MED
.	O
	
macrophage	B-MED
migration	I-MED
inhibitory	I-MED
mif	I-MED
factor	I-MED
is	O
a	O
regulatory	B-MED
cytokine	B-MED
that	O
inhibits	B-MED
random	O
immune	B-MED
cell	I-MED
migration	I-MED
.	O
	
mif	B-MED
gene	I-MED
promoter	B-MED
polymorphisms	B-MED
play	O
a	O
role	O
in	O
the	O
progression	B-MED
of	O
several	O
inflammatory	B-MED
disorders	I-MED
.	O
	
to	O
investigate	B-MED
the	O
relationship	O
between	O
the	O
mif	B-MED
gene	I-MED
-173	I-MED
g/c	I-MED
single-nucleotide	B-MED
polymorphism	I-MED
snp	B-MED
and	O
as	B-MED
.	O
	
cross-sectional	B-MED
study	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
a	O
total	O
of	O
161	O
as	B-MED
and	O
194	O
normal	B-MED
controls	B-MED
were	O
recruited	O
.	O
	
the	O
mif	B-MED
gene	I-MED
-173	I-MED
g/c	I-MED
snp	B-MED
was	O
analyzed	B-MED
by	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
using	O
the	O
restriction	B-MED
fragment	I-MED
length	I-MED
polymorphism	I-MED
method	I-MED
.	O
	
there	O
was	O
no	O
significant	B-MED
difference	O
between	O
groups	B-MED
in	O
terms	O
of	O
genotype	B-MED
distribution	O
p>0	O
.	O
	
when	O
wild-type	B-MED
g/g	B-MED
and	O
g/c+c/c	B-MED
genotypes	I-MED
are	O
compared	O
in	O
terms	O
of	O
clinical	B-MED
characteristics	I-MED
,	O
there	O
is	O
a	O
significant	B-MED
difference	O
between	O
the	O
average	O
age	B-MED
and	O
the	O
duration	B-MED
of	I-MED
disease	I-MED
in	O
as	B-MED
patients	B-MED
p<0	O
.	O
	
no	O
significant	B-MED
relationship	O
between	O
as	B-MED
disease	B-MED
and	O
mif	B-MED
-173	I-MED
g/c	I-MED
polymorphism	B-MED
was	O
found	O
.	O
	
mif	B-MED
-173	I-MED
g/c	I-MED
polymorphism	B-MED
c	B-MED
allele	I-MED
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	B-MED
of	I-MED
disease	I-MED
in	O
as	B-MED
patients	B-MED
.	O
	
mechanisms	O
of	O
global	B-MED
cerebral	B-MED
edema	I-MED
formation	O
in	O
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
a	O
growing	O
body	O
of	O
clinical	B-MED
literature	B-MED
emphasizes	O
the	O
impact	O
of	O
cerebral	B-MED
edema	I-MED
in	O
early	B-MED
brain	I-MED
injury	I-MED
following	O
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
asah	B-MED
.	O
	
aneurysm	B-MED
rupture	I-MED
itself	O
initiates	O
global	B-MED
cerebral	B-MED
edema	I-MED
in	O
up	O
to	O
two	O
thirds	O
of	O
cases	O
.	O
	
although	O
cerebral	B-MED
edema	I-MED
is	O
not	O
a	O
universal	O
feature	O
of	O
asah	B-MED
,	O
it	O
portends	O
a	O
poor	O
clinical	B-MED
course	I-MED
,	O
with	O
quantitative	B-MED
analysis	I-MED
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	B-MED
edema	I-MED
and	O
poor	B-MED
outcome	I-MED
,	O
including	O
mortality	O
and	O
cognitive	O
deficits	O
.	O
	
mechanistically	O
,	O
global	B-MED
cerebral	B-MED
edema	I-MED
has	O
been	O
linked	O
to	O
global	B-MED
ischemia	B-MED
at	O
the	O
time	O
of	O
aneurysm	B-MED
rupture	I-MED
,	O
dysfunction	B-MED
of	O
autoregulation	B-MED
,	O
blood	B-MED
breakdown	I-MED
products	B-MED
,	O
neuroinflammation	B-MED
,	O
and	O
hyponatremia	B-MED
/	O
endocrine	B-MED
abnormalities	I-MED
.	O
	
at	O
a	O
molecular	B-MED
level	B-MED
,	O
several	O
culprits	O
have	O
been	O
identified	O
,	O
including	O
aquaporin-4	B-MED
,	O
matrix	B-MED
metalloproteinase-9	I-MED
,	O
sur1	B-MED
-	O
trpm4	B-MED
cation	I-MED
channels	I-MED
,	O
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
,	O
bradykinin	B-MED
,	O
and	O
others	O
.	O
	
here	O
,	O
we	O
review	O
these	O
cellular	B-MED
and	O
molecular	B-MED
mechanisms	O
of	O
global	B-MED
cerebral	B-MED
edema	I-MED
formation	O
in	O
asah	B-MED
.	O
	
given	O
the	O
importance	O
of	O
edema	B-MED
to	O
the	O
outcome	O
of	O
patients	B-MED
with	O
asah	B-MED
and	O
its	O
status	B-MED
as	O
a	O
highly	O
modifiable	O
pathological	B-MED
process	I-MED
,	O
a	O
better	O
understanding	O
of	O
cerebral	B-MED
edema	I-MED
in	O
asah	B-MED
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	B-MED
therapies	I-MED
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	B-MED
disease	B-MED
.	O
	
biliary	B-MED
phospholipids	B-MED
sustain	B-MED
enterocyte	B-MED
proliferation	B-MED
and	O
intestinal	B-MED
tumor	I-MED
progression	B-MED
via	O
nuclear	B-MED
receptor	I-MED
lrh1	B-MED
in	O
mice	B-MED
the	O
proliferative-	O
crypt	B-MED
compartment	I-MED
of	O
the	O
intestinal	B-MED
epithelium	I-MED
is	O
enriched	O
in	O
phospholipids	B-MED
and	O
accumulation	B-MED
of	O
phospholipids	B-MED
has	O
been	O
described	O
in	O
colorectal	B-MED
tumors	I-MED
.	O
	
here	O
we	O
hypothesize	O
that	O
biliary	B-MED
phospholipid	B-MED
flow	B-MED
could	O
directly	O
contribute	O
to	O
the	O
proliferative	B-MED
power	I-MED
of	O
normal	B-MED
and	O
dysplastic	B-MED
enterocytes	I-MED
.	O
	
we	O
used	O
abcb4	B-MED
-/-	O
mice	B-MED
which	O
lack	O
biliary	B-MED
phospholipid	B-MED
secretion	B-MED
.	O
	
we	O
first	O
show	O
that	O
abcb4	B-MED
-/-	O
mice	B-MED
are	O
protected	B-MED
against	O
intestinal	B-MED
tumorigenesis	B-MED
.	O
	
at	O
the	O
molecular	B-MED
level	B-MED
,	O
the	O
transcriptional	B-MED
activity	I-MED
of	O
the	O
nuclear	B-MED
receptor	I-MED
liver	B-MED
receptor	I-MED
homolog-1	I-MED
lrh1	B-MED
is	O
reduced	B-MED
in	O
abcb4	B-MED
-/-	O
mice	B-MED
and	O
its	O
re-activation	B-MED
re-establishes	O
a	O
tumor	B-MED
burden	B-MED
comparable	O
to	O
control	B-MED
mice	B-MED
.	O
	
feeding	B-MED
abcb4	B-MED
-/-	O
mice	B-MED
a	O
diet	B-MED
supplemented	I-MED
with	O
phospholipids	B-MED
completely	O
overcomes	B-MED
the	O
intestinal	B-MED
tumor	I-MED
protective	O
phenotype	B-MED
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	B-MED
of	O
biliary	B-MED
phospholipids	B-MED
and	O
not	O
lack	O
of	O
abcb4	B-MED
gene	I-MED
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	B-MED
.	O
	
in	O
turn	O
,	O
phospholipids	B-MED
cannot	O
re-establish	O
intestinal	B-MED
tumorigenesis	B-MED
in	O
abcb4	B-MED
-/-	O
mice	B-MED
crossed	O
with	O
mice	B-MED
with	O
intestinal	B-MED
specific	B-MED
ablation	B-MED
of	O
lrh1	B-MED
,	O
a	O
nuclear	B-MED
hormone	I-MED
receptor	I-MED
that	O
is	O
activates	B-MED
by	O
phospholipids	B-MED
.	O
	
our	O
data	B-MED
identify	O
the	O
key	O
role	O
of	O
biliary	B-MED
phospholipids	B-MED
in	O
sustaining	O
intestinal	B-MED
mucosa	I-MED
proliferation	B-MED
and	O
tumor	B-MED
progression	I-MED
through	O
the	O
activation	B-MED
of	O
nuclear	B-MED
receptor	I-MED
lrh1	B-MED
.	O
	
metalloproteinase	B-MED
meprin	B-MED
α	I-MED
regulates	O
migration	B-MED
and	O
invasion	B-MED
of	O
human	B-MED
hepatocarcinoma	B-MED
cells	B-MED
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	B-MED
reptin	B-MED
hepatocellular	B-MED
carcinoma	I-MED
is	O
associated	B-MED
with	I-MED
a	O
high	B-MED
rate	B-MED
of	O
intra-hepatic	B-MED
invasion	B-MED
that	O
carries	O
a	O
poor	B-MED
prognosis	I-MED
.	O
	
meprin	B-MED
alpha	I-MED
mep1a	B-MED
is	O
a	O
secreted	B-MED
metalloproteinase	B-MED
with	O
many	O
substrates	O
relevant	O
to	O
cancer	B-MED
invasion	I-MED
.	O
	
we	O
found	O
that	O
mep1a	B-MED
was	O
a	O
target	B-MED
of	O
reptin	B-MED
,	O
a	O
protein	B-MED
that	I-MED
is	I-MED
oncogenic	I-MED
in	O
hcc	B-MED
.	O
	
we	O
studied	O
mep1a	B-MED
regulation	B-MED
by	O
reptin	B-MED
,	O
its	O
role	O
in	O
hcc	B-MED
,	O
and	O
whether	O
it	O
mediates	O
reptin	B-MED
oncogenic	B-MED
effects	B-MED
.	O
	
mepa	B-MED
and	O
reptin	B-MED
expression	B-MED
was	O
measured	O
in	O
human	B-MED
hcc	B-MED
by	O
qrt-pcr	B-MED
and	O
in	O
cultured	B-MED
cells	I-MED
by	O
pcr	B-MED
,	O
western	B-MED
blot	I-MED
and	O
enzymatic	B-MED
activity	I-MED
measurements	I-MED
.	O
	
cell	B-MED
growth	I-MED
was	O
assessed	B-MED
by	O
counting	B-MED
and	O
mts	B-MED
assay	I-MED
.	O
	
cell	B-MED
migration	I-MED
was	O
measured	O
in	O
boyden	B-MED
chambers	I-MED
and	O
wound	B-MED
healing	I-MED
assays	B-MED
,	O
and	O
cell	B-MED
invasion	I-MED
in	O
boyden	B-MED
chambers	I-MED
.	O
	
silencing	B-MED
reptin	B-MED
decreased	B-MED
mep1a	B-MED
expression	B-MED
and	O
activity	B-MED
,	O
without	O
affecting	O
meprin	B-MED
β	I-MED
.	O
	
mep1a	B-MED
,	O
but	O
not	O
meprin	B-MED
β	I-MED
,	O
was	O
overexpressed	B-MED
in	O
a	O
series	O
of	O
242	O
human	B-MED
hcc	B-MED
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
,	O
and	O
a	O
high	B-MED
expression	B-MED
correlated	B-MED
with	O
a	O
poor	B-MED
prognosis	I-MED
.	O
	
mep1a	B-MED
and	O
reptin	B-MED
expressions	B-MED
were	O
positively	O
correlated	B-MED
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
.	O
	
silencing	B-MED
mep1a	B-MED
had	O
little	O
effect	O
on	O
cell	B-MED
proliferation	I-MED
,	O
but	O
decreased	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
of	O
huh7	B-MED
and	O
hep3b	B-MED
cells	I-MED
.	O
	
conversely	O
,	O
overexpression	B-MED
of	O
mep1a	B-MED
or	O
addition	O
of	O
recombinant	B-MED
mep1a	B-MED
increased	B-MED
migration	B-MED
and	O
invasion	B-MED
.	O
	
finally	O
,	O
overexpression	B-MED
of	O
mep1a	B-MED
restored	O
a	O
normal	B-MED
cell	B-MED
migration	I-MED
in	O
cells	B-MED
where	O
reptin	B-MED
was	O
depleted	B-MED
.	O
	
mep1a	B-MED
is	O
overexpressed	B-MED
in	O
most	O
hcc	B-MED
and	O
induces	B-MED
hcc	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
.	O
	
mep1a	B-MED
expression	B-MED
is	O
regulated	O
by	O
reptin	B-MED
,	O
and	O
mep1a	B-MED
mediates	O
reptin	B-MED
-	O
induced	B-MED
migration	B-MED
.	O
	
overall	O
,	O
we	O
suggest	O
that	O
mep1a	B-MED
may	O
be	O
a	O
useful	O
target	B-MED
in	O
psychosocial	B-MED
impact	I-MED
on	O
families	B-MED
with	O
an	O
infant	B-MED
with	O
a	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
during	B-MED
and	I-MED
after	I-MED
the	I-MED
interstage	I-MED
monitoring	I-MED
period	I-MED
-	O
a	O
prospective	B-MED
mixed-method	I-MED
study	I-MED
to	O
investigate	O
parents'	B-MED
experiences	I-MED
,	O
coping	B-MED
ability	I-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
while	O
monitoring	B-MED
their	O
sick	B-MED
child	I-MED
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
at	O
home	B-MED
.	O
	
interstage	B-MED
home	I-MED
monitoring	I-MED
for	O
children	B-MED
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
reduces	O
interstage	O
mortality	B-MED
between	O
norwood	B-MED
stages	I-MED
i	I-MED
and	I-MED
ii	I-MED
.	O
	
little	O
is	O
known	O
about	O
the	O
psychosocial	B-MED
impact	I-MED
of	O
interstage	B-MED
home	I-MED
monitoring	I-MED
.	O
	
prospective	B-MED
mixed-method	I-MED
study	I-MED
.	O
	
this	O
study	O
assessed	O
the	O
psychosocial	B-MED
impact	I-MED
on	O
parents	B-MED
during	O
interstage	B-MED
home	I-MED
monitoring	I-MED
.	O
	
this	O
contains	O
for	O
quantitative	B-MED
assessment	I-MED
the	O
short	B-MED
form	I-MED
health	I-MED
survey	I-MED
questionnaire	I-MED
and	O
the	O
impact	O
of	O
family	B-MED
scale	I-MED
administered	I-MED
one	O
and	O
five	O
weeks	O
following	O
discharge	B-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
ii	I-MED
.	O
	
for	O
qualitative	B-MED
assessment	I-MED
,	O
semi-structured	B-MED
interviews	I-MED
focussing	O
on	O
the	O
postdischarge	B-MED
coping	B-MED
strategies	I-MED
were	O
conducted	O
twice	O
,	O
five	O
weeks	O
after	B-MED
hospital	I-MED
discharge	I-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
ii	I-MED
.	O
	
ten	O
infants	B-MED
eight	O
males	B-MED
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
n	O
=	O
7	O
or	O
other	O
types	O
of	O
univentricular	B-MED
heart	I-MED
malformations	I-MED
n	O
=	O
3	O
,	O
and	O
their	O
parents	B-MED
nine	O
mother/father	B-MED
two-	O
parent	B-MED
households	B-MED
,	O
one	O
single	B-MED
mother	I-MED
were	O
included	O
.	O
	
there	O
were	O
no	B-MED
interstage	I-MED
deaths	I-MED
.	O
	
mental	B-MED
health	I-MED
composite	B-MED
summary	I-MED
scores	I-MED
were	O
low	O
in	O
both	O
parents	B-MED
mothers	B-MED
40	O
9	O
fathers	B-MED
40	O
9	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-MED
'	O
mothers	B-MED
37	O
19	O
fathers	B-MED
43	O
25	O
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
ii	I-MED
.	O
	
impact	O
of	O
family	B-MED
scale	I-MED
values	I-MED
showed	O
higher	O
daily	O
and	O
social	B-MED
burdens	I-MED
for	O
mothers	B-MED
.	O
	
'becoming	O
a	O
family'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping	B-MED
strategy	I-MED
to	O
equilibrate	O
the	O
fragile	B-MED
emotional	I-MED
balance	I-MED
.	O
	
the	O
parents	B-MED
judged	O
interstage	B-MED
home	I-MED
monitoring	I-MED
as	O
a	O
protective	B-MED
intervention	I-MED
.	O
	
although	O
psychosocial	B-MED
burden	I-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
ii	I-MED
remains	O
high	O
,	O
becoming	O
a	O
family	B-MED
is	O
an	O
essential	O
experience	O
for	O
parents	B-MED
and	O
confirms	O
their	O
parenthood	B-MED
.	O
	
healthcare	B-MED
professionals	I-MED
must	O
be	O
aware	O
of	O
parents	B-MED
'	O
needs	O
during	O
this	O
vulnerable	B-MED
interstage	I-MED
period	I-MED
and	O
to	O
provide	O
psychosocial	B-MED
and	O
nursing	B-MED
support	I-MED
.	O
	
rates	B-MED
and	O
predictors	B-MED
of	O
injury	B-MED
in	O
a	O
population	B-MED
-	O
based	B-MED
cohort	B-MED
of	O
people	B-MED
living	B-MED
with	O
hiv	B-MED
injuries	B-MED
are	O
responsible	O
for	O
10%	O
of	O
the	O
global	B-MED
burden	B-MED
of	O
disease	B-MED
however	O
,	O
the	O
epidemiology	B-MED
of	O
injury	B-MED
among	O
people	B-MED
living	I-MED
with	I-MED
hiv	I-MED
plhiv	B-MED
has	O
not	B-MED
been	I-MED
well	I-MED
elucidated	B-MED
.	O
	
this	O
study	B-MED
seeks	O
to	O
characterize	B-MED
rates	B-MED
and	O
predictors	B-MED
of	O
injury	B-MED
among	O
plhiv	B-MED
compared	B-MED
to	O
the	O
general	B-MED
population	I-MED
in	O
british	B-MED
columbia	I-MED
bc	B-MED
,	O
canada	B-MED
.	O
	
a	O
population	B-MED
-	O
based	B-MED
dataset	B-MED
was	O
created	B-MED
via	O
linkage	B-MED
between	B-MED
the	O
bc	B-MED
centre	I-MED
for	I-MED
excellence	I-MED
in	I-MED
hiv/aids	I-MED
and	O
populationdatabc	B-MED
.	O
	
plhiv	B-MED
aged	B-MED
20	B-MED
years	I-MED
and	O
older	B-MED
were	O
compared	B-MED
to	O
a	O
random	B-MED
10%	O
sample	B-MED
of	O
the	O
adult	B-MED
general	B-MED
population	I-MED
.	O
	
the	O
international	B-MED
classification	B-MED
of	O
diseases	B-MED
9	O
and	O
10	O
codes	O
were	O
used	B-MED
to	O
classify	B-MED
unintentional	B-MED
and	O
intentional	B-MED
injuries	I-MED
based	B-MED
on	O
the	O
external	B-MED
cause	I-MED
of	O
the	O
injury	B-MED
from	O
1996	O
to	O
2013	O
.	O
	
generalized	B-MED
estimating	I-MED
equation	I-MED
gee	B-MED
poisson	B-MED
regression	I-MED
models	I-MED
were	O
fit	O
to	O
estimate	B-MED
the	O
effect	B-MED
of	O
hiv	B-MED
status	B-MED
on	O
rates	B-MED
of	O
unintentional	B-MED
and	O
intentional	B-MED
injury	I-MED
,	O
and	O
to	O
identify	B-MED
correlates	B-MED
of	O
injury	B-MED
among	O
plhiv	B-MED
.	O
	
the	O
crude	O
incidence	B-MED
rate	I-MED
of	O
unintentional	B-MED
injury	I-MED
was	O
18.56	O
person	B-MED
-	O
years	B-MED
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
17.77	O
among	O
plhiv	B-MED
and	O
8.51	O
person	B-MED
-	O
years	B-MED
95%	O
ci	B-MED
8.42	O
in	O
the	O
general	B-MED
population	I-MED
.	O
	
among	O
plhiv	B-MED
,	O
13.45	O
of	O
deaths	B-MED
were	O
due	B-MED
to	I-MED
injury	B-MED
,	O
compared	B-MED
to	O
5.52	O
of	O
deaths	B-MED
in	O
the	O
general	B-MED
population	I-MED
.	O
	
in	O
adjusted	O
models	B-MED
,	O
plhiv	B-MED
were	O
more	O
likely	O
to	O
report	B-MED
unintentional	B-MED
incidence	B-MED
rate	I-MED
ratio	B-MED
1.42	O
,	O
95%	O
ci	B-MED
1.32	O
and	O
intentional	B-MED
injury	I-MED
incidence	B-MED
rate	I-MED
ratio	B-MED
1.93	O
,	O
95%	O
ci	B-MED
1.70	O
compared	B-MED
to	O
the	O
general	B-MED
population	I-MED
.	O
	
we	O
identified	B-MED
elevated	B-MED
rates	B-MED
of	O
intentional	B-MED
and	O
unintentional	B-MED
injury	I-MED
among	O
plhiv	B-MED
.	O
	
injuries	B-MED
are	O
largely	B-MED
preventable	B-MED
as	O
such	O
,	O
targeted	B-MED
efforts	O
are	O
needed	B-MED
to	O
decrease	B-MED
the	O
burden	B-MED
of	O
injury	B-MED
-	O
related	B-MED
disability	B-MED
and	O
death	B-MED
among	O
trek-1	B-MED
k2p2.1	I-MED
k	I-MED
channels	I-MED
are	O
suppressed	B-MED
in	O
patients	B-MED
with	O
atrial	B-MED
fibrillation	I-MED
and	O
heart	B-MED
failure	I-MED
and	O
provide	B-MED
therapeutic	B-MED
targets	I-MED
for	O
rhythm	B-MED
control	I-MED
atrial	B-MED
fibrillation	I-MED
af	B-MED
is	O
the	O
most	O
common	O
cardiac	B-MED
arrhythmia	I-MED
.	O
	
concomitant	B-MED
heart	I-MED
failure	I-MED
hf	B-MED
poses	O
a	O
particular	O
therapeutic	B-MED
challenge	B-MED
and	O
is	O
associated	O
with	O
prolonged	B-MED
atrial	B-MED
electrical	I-MED
refractoriness	I-MED
compared	O
with	O
non-failing	B-MED
hearts	I-MED
.	O
	
we	O
hypothesized	O
that	O
downregulation	B-MED
of	O
atrial	B-MED
repolarizing	I-MED
trek-1	B-MED
k2p2.1	I-MED
k	I-MED
channels	I-MED
contributes	B-MED
to	O
electrical	B-MED
remodeling	I-MED
during	O
af	B-MED
with	O
hf	B-MED
,	O
and	O
that	O
trek-1	B-MED
gene	I-MED
transfer	I-MED
would	O
provide	O
rhythm	B-MED
control	I-MED
via	O
normalization	B-MED
of	O
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
in	O
this	O
af	B-MED
subset	B-MED
.	O
	
in	O
patients	B-MED
with	O
chronic	B-MED
af	I-MED
and	O
hf	B-MED
,	O
atrial	B-MED
trek-1	I-MED
mrna	B-MED
levels	B-MED
were	O
reduced	O
by	O
82%	O
left	B-MED
atrium	I-MED
and	O
81%	O
right	B-MED
atrium	I-MED
compared	O
with	O
sinus	B-MED
rhythm	I-MED
sr	B-MED
subjects	B-MED
.	O
	
human	B-MED
findings	B-MED
were	O
recapitulated	O
in	O
a	O
porcine	B-MED
model	I-MED
of	O
atrial	B-MED
tachypacing-induced	I-MED
af	I-MED
and	O
reduced	B-MED
left	B-MED
ventricular	I-MED
function	I-MED
.	O
	
trek-1	B-MED
mrna	B-MED
-66%	O
and	O
protein	B-MED
-61%	O
was	O
suppressed	B-MED
in	O
af	B-MED
animals	B-MED
at	O
14-day	O
follow-up	O
compared	B-MED
with	O
sr	B-MED
controls	O
.	O
	
downregulation	B-MED
of	O
repolarizing	B-MED
trek-1	B-MED
channels	I-MED
was	O
associated	O
with	O
prolongation	B-MED
of	O
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
versus	O
baseline	B-MED
conditions	O
,	O
consistent	B-MED
with	I-MED
prior	B-MED
observations	B-MED
in	O
humans	B-MED
with	O
hf	B-MED
.	O
	
in	O
a	O
preclinical	B-MED
therapeutic	B-MED
approach	I-MED
,	O
pigs	B-MED
were	O
randomized	B-MED
to	O
either	O
atrial	B-MED
ad-trek-1	I-MED
gene	I-MED
therapy	I-MED
or	O
sham	B-MED
treatment	I-MED
.	O
	
gene	B-MED
transfer	I-MED
effectively	B-MED
increased	B-MED
trek-1	B-MED
protein	I-MED
levels	B-MED
and	O
attenuated	B-MED
atrial	B-MED
effective	I-MED
refractory	I-MED
period	I-MED
prolongation	B-MED
in	O
the	O
porcine	B-MED
af	I-MED
model	I-MED
.	O
	
ad-trek-1	B-MED
increased	O
the	O
sr	B-MED
prevalence	B-MED
to	O
62%	O
during	O
follow-up	O
in	O
af	B-MED
animals	B-MED
,	O
compared	B-MED
to	O
35%	O
in	O
the	O
untreated	O
af	B-MED
group	O
.	O
	
in	O
conclusion	B-MED
,	O
trek-1	B-MED
downregulation	B-MED
and	O
rhythm	B-MED
control	I-MED
by	O
ad-trek-1	B-MED
transfer	I-MED
suggest	B-MED
mechanistic	B-MED
and	I-MED
potential	I-MED
therapeutic	I-MED
significance	B-MED
of	O
trek-1	B-MED
channels	I-MED
in	O
a	O
subgroup	B-MED
of	O
af	B-MED
patients	B-MED
with	O
hf	B-MED
and	O
prolonged	B-MED
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
.	O
	
functional	B-MED
correction	I-MED
of	O
ionic	O
remodeling	O
through	O
trek-1	B-MED
gene	I-MED
therapy	I-MED
represents	O
a	O
novel	B-MED
paradigm	B-MED
to	O
optimize	O
and	O
specify	O
af	B-MED
a	O
rasch	B-MED
rating	I-MED
scale	I-MED
analysis	B-MED
of	O
the	O
presence	B-MED
of	O
nursing	B-MED
scale	B-MED
-	O
rn	B-MED
the	O
phenomenon	B-MED
of	O
nursing	B-MED
presence	B-MED
encompasses	O
the	O
emotional	B-MED
connection	B-MED
between	O
nurse	B-MED
and	O
patient	B-MED
,	O
and	O
technical	B-MED
skills	I-MED
performed	B-MED
by	O
the	O
nurse	B-MED
.	O
	
the	O
presence	B-MED
of	O
nursing	B-MED
scale	B-MED
-	O
rn	B-MED
version	B-MED
pons	B-MED
-	O
rn	B-MED
was	O
developed	B-MED
to	O
measure	B-MED
nurses'	B-MED
perceptions	B-MED
of	O
their	O
ability	B-MED
to	O
be	O
present	B-MED
to	O
their	O
patients	B-MED
.	O
	
this	O
study	B-MED
summarizes	B-MED
the	O
process	B-MED
of	O
re-evaluation	B-MED
of	O
the	O
psychometric	B-MED
properties	I-MED
of	O
the	O
pons	B-MED
-	O
rn	B-MED
instrument	O
.	O
	
a	O
sample	B-MED
of	O
76	O
registered	B-MED
nurses	I-MED
providing	B-MED
direct	B-MED
patient	B-MED
care	I-MED
responded	B-MED
to	O
the	O
31-	O
item	B-MED
questionnaire	B-MED
.	O
	
the	O
rasch	B-MED
rating	I-MED
scale	I-MED
model	I-MED
was	O
used	O
for	O
assessing	B-MED
construct	B-MED
validity	I-MED
of	O
pons	B-MED
-	O
rn	B-MED
data	B-MED
.	O
	
a	O
principal	B-MED
component	I-MED
analysis	I-MED
pca	B-MED
of	O
residuals	B-MED
supported	B-MED
appropriateness	B-MED
of	O
the	O
subscales	B-MED
defined	O
by	O
a	O
2-dimensional	B-MED
structure	B-MED
.	O
	
the	O
results	B-MED
of	O
item	B-MED
and	O
person	B-MED
fit	B-MED
analysis	B-MED
,	O
rating	B-MED
scale	I-MED
functioning	B-MED
analysis	B-MED
and	O
reliability	B-MED
analysis	I-MED
have	O
demonstrated	B-MED
that	O
the	O
thirty-one	O
item	B-MED
presence	B-MED
of	O
nursing	B-MED
scale	B-MED
-	O
rn	B-MED
instrument	O
yielded	O
measures	B-MED
with	O
high	B-MED
validity	B-MED
and	I-MED
reliability	I-MED
as	O
two	O
sub-scales	B-MED
.	O
	
jou	O
elastin	B-MED
is	O
differentially	B-MED
regulated	I-MED
by	O
pressure	B-MED
therapy	I-MED
in	O
a	O
porcine	B-MED
model	B-MED
of	O
hypertrophic	B-MED
scar	I-MED
beneficial	B-MED
effects	I-MED
of	O
pressure	B-MED
therapy	I-MED
for	O
hypertrophic	B-MED
scars	I-MED
have	O
been	O
reported	O
,	O
but	O
the	O
mechanisms	B-MED
of	O
action	O
are	O
not	O
fully	O
understood	O
.	O
	
this	O
study	B-MED
evaluated	O
elastin	B-MED
and	O
its	O
contribution	O
to	O
scar	B-MED
pliability	B-MED
.	O
	
the	O
relationship	B-MED
between	O
changes	O
in	O
vancouver	B-MED
scar	I-MED
scale	I-MED
vss	B-MED
scores	B-MED
of	O
pressure-treated	B-MED
scars	B-MED
and	O
differential	O
regulation	O
of	O
elastin	B-MED
was	O
assessed	O
.	O
	
hypertrophic	B-MED
scars	I-MED
were	O
created	O
and	O
assessed	O
weekly	B-MED
using	O
vss	B-MED
and	O
biopsy	B-MED
procurement	B-MED
.	O
	
pressure	B-MED
treatment	I-MED
began	O
on	O
day	B-MED
70	O
postinjury	B-MED
.	O
	
treated	B-MED
scars	B-MED
were	O
compared	B-MED
with	O
untreated	O
shams	B-MED
.	O
	
treatment	B-MED
lasted	O
2	O
weeks	B-MED
,	O
through	O
day	B-MED
84	O
,	O
and	O
scars	B-MED
were	O
assessed	O
weekly	B-MED
through	O
day	B-MED
126	O
.	O
	
transcript	B-MED
and	O
protein	B-MED
levels	I-MED
of	O
elastin	B-MED
were	O
quantified	B-MED
.	O
	
pressure	B-MED
treatment	I-MED
resulted	O
in	O
lower	O
vss	B-MED
scores	B-MED
compared	B-MED
with	O
sham-treated	B-MED
scars	B-MED
.	O
	
pliability	B-MED
vssp	B-MED
was	O
a	O
key	O
contributor	O
to	O
this	O
difference	O
.	O
	
at	O
day	B-MED
70	O
pretreatment	B-MED
,	O
vssp	B-MED
=	O
2	O
.	O
	
without	B-MED
treatment	I-MED
,	O
sham-treated	B-MED
scars	B-MED
became	O
less	O
pliable	B-MED
,	O
while	O
pressure-treated	B-MED
scars	B-MED
became	O
more	O
pliable	B-MED
.	O
	
the	O
percentage	O
of	O
elastin	B-MED
in	O
scars	B-MED
at	O
day	B-MED
70	O
was	O
higher	O
than	O
in	O
uninjured	B-MED
skin	I-MED
.	O
	
following	O
treatment	B-MED
,	O
the	O
percentage	O
of	O
elastin	B-MED
increased	B-MED
and	O
continued	O
to	O
increase	B-MED
through	O
day	B-MED
126	O
.	O
	
untreated	O
sham	B-MED
scars	B-MED
did	O
not	O
show	O
a	O
similar	O
increase	B-MED
.	O
	
quantification	B-MED
of	O
verhoeff-van	B-MED
gieson	I-MED
staining	I-MED
corroborated	O
the	O
findings	B-MED
and	O
immunofluorescence	B-MED
revealed	O
the	O
alignment	B-MED
of	O
elastin	B-MED
fibers	I-MED
.	O
	
pressure	B-MED
treatment	I-MED
results	O
in	O
increased	B-MED
protein	B-MED
level	I-MED
expression	I-MED
of	O
elastin	B-MED
compared	B-MED
with	O
sham	B-MED
-untreated	O
scars	B-MED
.	O
	
these	O
findings	B-MED
further	O
characterize	O
the	O
extracellular	B-MED
matrix's	I-MED
response	O
to	O
the	O
application	O
of	O
pressure	B-MED
as	O
a	O
scar	B-MED
treatment	B-MED
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	B-MED
practices	O
and	O
ultimately	O
improvements	B-MED
in	O
functional	B-MED
and	O
psychosocial	B-MED
outcomes	B-MED
for	O
epigenome-wide	B-MED
analysis	I-MED
links	O
smad3	B-MED
methylation	B-MED
at	O
birth	B-MED
to	O
asthma	B-MED
in	I-MED
children	I-MED
of	O
asthmatic	B-MED
mothers	B-MED
the	O
timing	O
and	O
mechanisms	B-MED
of	O
asthma	B-MED
inception	B-MED
remain	O
imprecisely	O
defined	O
.	O
	
although	O
epigenetic	B-MED
mechanisms	B-MED
likely	O
contribute	O
to	O
asthma	B-MED
pathogenesis	B-MED
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-MED
inception	B-MED
.	O
	
we	O
sought	O
to	O
assess	B-MED
whether	O
the	O
trajectory	O
to	O
asthma	B-MED
begins	O
already	O
at	O
birth	B-MED
and	O
whether	O
epigenetic	B-MED
mechanisms	B-MED
,	O
specifically	O
dna	B-MED
methylation	I-MED
,	O
contribute	O
to	O
asthma	B-MED
inception	B-MED
.	O
	
we	O
used	O
the	O
methylated	B-MED
cpg	I-MED
island	I-MED
recovery	I-MED
assay	I-MED
chip	I-MED
to	O
survey	B-MED
dna	B-MED
methylation	I-MED
in	O
cord	B-MED
blood	I-MED
mononuclear	B-MED
cells	I-MED
from	O
36	O
children	B-MED
18	O
nonasthmatic	B-MED
and	O
18	O
asthmatic	B-MED
subjects	B-MED
by	O
age	B-MED
9	O
years	B-MED
from	O
the	O
infant	B-MED
immune	B-MED
study	B-MED
iis	B-MED
,	O
an	O
unselected	O
birth	B-MED
cohort	B-MED
closely	O
monitored	O
for	O
asthma	B-MED
for	O
a	O
decade	O
.	O
	
smad3	B-MED
methylation	B-MED
in	O
iis	B-MED
n	O
=	O
60	O
and	O
in	O
2	O
replication	B-MED
cohorts	B-MED
the	O
manchester	B-MED
asthma	B-MED
and	O
allergy	B-MED
study	I-MED
n	O
=	O
30	O
and	O
the	O
childhood	B-MED
origins	I-MED
of	I-MED
asthma	I-MED
study	B-MED
n	O
=	O
28	O
was	O
analyzed	B-MED
by	O
using	O
bisulfite	B-MED
sequencing	I-MED
or	O
illumina	B-MED
450k	I-MED
arrays	I-MED
.	O
	
cord	B-MED
blood	I-MED
mononuclear	B-MED
cell	I-MED
-derived	O
il-1β	B-MED
levels	B-MED
were	O
measured	B-MED
by	O
means	O
of	O
elisa	B-MED
.	O
	
neonatal	B-MED
immune	B-MED
cells	B-MED
harbored	O
589	O
differentially	O
methylated	B-MED
regions	I-MED
that	O
distinguished	O
iis	B-MED
children	B-MED
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-MED
by	O
age	B-MED
9	O
years	B-MED
.	O
	
in	O
all	O
3	O
cohorts	B-MED
methylation	B-MED
in	O
smad3	B-MED
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-MED
-	O
associated	B-MED
,	O
differentially	O
methylated	B-MED
regions	I-MED
,	O
was	O
selectively	O
increased	B-MED
in	O
asthmatic	B-MED
children	B-MED
of	O
asthmatic	B-MED
mothers	B-MED
and	O
was	O
associated	B-MED
with	I-MED
childhood	B-MED
asthma	I-MED
risk	B-MED
.	O
	
moreover	O
,	O
smad3	B-MED
methylation	B-MED
in	O
iis	B-MED
neonates	B-MED
with	O
maternal	B-MED
asthma	B-MED
was	O
strongly	O
and	O
positively	O
associated	B-MED
with	I-MED
neonatal	B-MED
production	O
of	O
il-1β	B-MED
,	O
an	O
innate	B-MED
inflammatory	I-MED
mediator	I-MED
.	O
	
the	O
trajectory	O
to	O
childhood	B-MED
asthma	I-MED
begins	O
at	O
birth	B-MED
and	O
involves	O
epigenetic	B-MED
modifications	B-MED
in	O
immunoregulatory	B-MED
and	O
proinflammatory	B-MED
pathways	B-MED
.	O
	
maternal	B-MED
asthma	B-MED
influences	O
epigenetic	B-MED
mechanisms	B-MED
that	O
contribute	O
to	O
the	O
inception	B-MED
clinical	B-MED
correlates	B-MED
of	O
faecal	B-MED
incontinence	I-MED
in	O
systemic	B-MED
sclerosis	I-MED
identifying	O
therapeutic	B-MED
avenues	I-MED
the	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	B-MED
and	O
severity	B-MED
of	O
faecal	B-MED
incontinence	I-MED
fi	B-MED
in	O
ssc	B-MED
,	O
its	O
association	B-MED
with	O
other	O
intestinal	B-MED
manifestations	B-MED
and	O
potential	B-MED
predictors	B-MED
of	O
fi	B-MED
,	O
and	O
its	O
impact	B-MED
on	O
quality	B-MED
of	I-MED
life	I-MED
.	O
	
a	O
multicentre	O
,	O
cross-sectional	B-MED
study	I-MED
of	O
298	O
ssc	B-MED
subjects	B-MED
followed	O
in	O
the	O
canadian	B-MED
scleroderma	I-MED
research	I-MED
group	I-MED
cohort	B-MED
was	O
performed	O
using	O
validated	O
questionnaires	B-MED
jorge-wexner	B-MED
score	I-MED
an	O
fi	B-MED
severity	B-MED
scale	I-MED
,	O
bristol	B-MED
stool	I-MED
scale	I-MED
a	O
visual	O
scale	O
of	O
stool	B-MED
consistency	I-MED
and	O
fi	B-MED
quality-of-life	B-MED
scale	I-MED
.	O
	
constipation	B-MED
was	O
defined	O
by	O
the	O
rome	B-MED
iii	I-MED
criteria	I-MED
.	O
	
associations	B-MED
between	O
the	O
jorge-wexner	B-MED
score	I-MED
and	O
other	O
clinical	B-MED
variables	I-MED
were	O
determined	O
using	O
multivariate	B-MED
regression	I-MED
analyses	I-MED
.	O
	
eighty-one	O
27.2	O
subjects	B-MED
had	O
fi	B-MED
,	O
which	O
was	O
mild	B-MED
in	O
37	O
12.4	O
and	O
moderate	B-MED
to	I-MED
severe	I-MED
in	O
44	O
14.8	O
.	O
	
most	O
patients	B-MED
had	O
well-formed	O
stools	B-MED
,	O
111	O
38.8	O
reported	O
constipation	B-MED
and	O
38	O
13.4	O
had	O
been	O
previously	B-MED
treated	B-MED
for	O
small	B-MED
intestinal	I-MED
bacterial	I-MED
overgrowth	I-MED
sibo	B-MED
.	O
	
variables	B-MED
independently	B-MED
associated	B-MED
with	I-MED
fi	B-MED
were	O
loose	B-MED
vs	O
well-formed	O
stools	B-MED
odds	B-MED
ratio	I-MED
or	B-MED
=	O
7.01	O
,	O
95%	O
ci	B-MED
2.09	O
,	O
23.51	O
,	O
constipation	B-MED
or	B-MED
=	O
3.64	O
,	O
95%	O
ci	B-MED
1.61	O
,	O
8.27	O
,	O
p	B-MED
=	O
0.002	O
,	O
history	B-MED
of	O
sibo	B-MED
or	B-MED
=	O
2.97	O
,	O
95%	O
ci	B-MED
1.06	O
,	O
8.27	O
and	O
urinary	B-MED
incontinence	I-MED
or	B-MED
=	O
2.45	O
,	O
95%	O
ci	B-MED
1.14	O
,	O
5.27	O
.	O
	
quality	B-MED
of	I-MED
life	I-MED
measured	B-MED
with	O
the	O
fi	B-MED
quality-of-life	B-MED
scale	I-MED
was	O
inversely	B-MED
correlated	B-MED
with	O
fi	B-MED
severity	B-MED
correlation	B-MED
coefficients	B-MED
between	O
-0	O
and	O
-0	O
,	O
p	B-MED
<	O
0.001	O
.	O
	
fi	B-MED
was	O
common	B-MED
and	O
often	O
severe	B-MED
in	O
ssc	B-MED
.	O
	
loose	B-MED
stools	I-MED
,	O
sibo	B-MED
,	O
constipation	B-MED
and	O
urinary	B-MED
incontinence	I-MED
were	O
strongly	B-MED
associated	B-MED
with	I-MED
fi	B-MED
.	O
	
other	O
than	O
targeting	B-MED
anorectal	B-MED
dysfunction	B-MED
,	O
concomitant	B-MED
treatment	B-MED
of	O
clinical	B-MED
correlates	B-MED
could	O
lead	O
to	O
improvement	B-MED
in	O
fi	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
in	O
from	O
training	B-MED
to	O
practice	B-MED
the	O
impact	B-MED
of	O
engage	B-MED
,	O
ireland's	B-MED
national	B-MED
men's	I-MED
health	I-MED
training	I-MED
programme	I-MED
ireland's	B-MED
national	B-MED
men's	I-MED
health	I-MED
policy	I-MED
recommended	B-MED
developing	O
training	B-MED
programmes	I-MED
tailored	B-MED
to	O
the	O
needs	B-MED
of	O
those	O
working	B-MED
in	O
health	B-MED
and	O
allied	B-MED
health	I-MED
professionals	I-MED
and	O
engage	B-MED
was	O
developed	O
to	O
meet	O
that	O
recommendation	B-MED
.	O
	
this	O
study	B-MED
evaluated	B-MED
the	O
impact	B-MED
of	O
engage	B-MED
on	O
frontline	B-MED
service	I-MED
providers'	I-MED
self-reported	B-MED
knowledge	I-MED
,	O
skills	B-MED
,	O
capacity	B-MED
and	O
practice	B-MED
up	O
to	O
5-months	O
post	B-MED
training	B-MED
.	O
	
between	O
2012	O
and	O
2015	O
,	O
engage	B-MED
trainers	B-MED
n	O
=	O
57	O
delivered	O
62	O
1-day	O
training	B-MED
programmes	I-MED
to	O
810	O
participants	B-MED
.	O
	
this	O
study	B-MED
was	O
conducted	O
on	O
a	O
subset	B-MED
of	O
those	O
training	B-MED
days	O
n	O
=	O
26	O
and	O
participants	B-MED
.	O
	
quantitative	B-MED
methodologies	B-MED
were	O
used	O
to	O
collect	O
pre	O
n	O
=	O
295	O
,	O
post	B-MED
n	O
=	O
295	O
and	O
5-month	O
post	B-MED
n	O
=	O
128	O
training	B-MED
questionnaire	B-MED
data	O
.	O
	
overall	B-MED
,	O
participants	B-MED
were	O
highly	O
satisfied	B-MED
with	O
the	O
training	B-MED
immediately	B-MED
post	B-MED
training	B-MED
8.60	O
1.60	O
out	O
of	O
10	O
and	O
at	O
5-month	O
follow	B-MED
up	I-MED
8.06	O
1.43	O
out	O
of	O
10	O
.	O
	
participants'	B-MED
self-reported	B-MED
level	I-MED
of	I-MED
knowledge	I-MED
,	O
skill	B-MED
and	O
capacity	B-MED
in	O
identifying	O
priorities	B-MED
,	O
engaging	O
men	B-MED
and	O
influencing	B-MED
practice	B-MED
beyond	O
their	O
own	O
organisation	B-MED
increased	B-MED
immediately	B-MED
following	O
training	B-MED
p	O
<	O
0.001	O
and	O
,	O
with	O
the	O
exception	B-MED
of	O
improving	B-MED
capacity	B-MED
to	O
engage	O
men	B-MED
and	O
influencing	B-MED
practice	B-MED
beyond	O
their	O
organisation	B-MED
,	O
these	O
improvements	B-MED
were	O
sustained	B-MED
at	O
5-month	O
post	B-MED
training	B-MED
p	O
<	O
0.001	O
.	O
	
the	O
vast	O
majority	B-MED
of	O
service	B-MED
providers	I-MED
93.4	O
reported	B-MED
that	O
engage	B-MED
had	O
impacted	B-MED
their	O
work	B-MED
practice	B-MED
up	O
to	O
5-month	O
post	B-MED
training	B-MED
.	O
	
the	O
findings	B-MED
suggest	B-MED
that	O
engage	B-MED
has	O
succeeded	B-MED
in	O
improving	B-MED
service	B-MED
providers'	I-MED
capacity	B-MED
to	O
engage	O
and	O
work	B-MED
with	O
men	B-MED
improving	B-MED
gender	B-MED
competency	B-MED
in	O
the	O
delivery	O
of	O
health	B-MED
and	O
health	B-MED
related	I-MED
services	I-MED
may	O
increase	B-MED
the	O
utilisation	B-MED
of	O
such	O
services	B-MED
by	O
men	B-MED
and	O
thereby	O
improve	B-MED
health	B-MED
outcomes	I-MED
for	O
double	B-MED
strand	I-MED
break	I-MED
induction	B-MED
and	O
kinetics	B-MED
indicate	O
preserved	O
hypersensitivity	B-MED
in	O
keratinocytes	B-MED
to	O
subtherapeutic	B-MED
doses	B-MED
for	O
7	O
weeks	B-MED
of	O
radiotherapy	B-MED
previously	O
we	O
reported	O
that	O
hyper-radiosensitivity	B-MED
hrs	B-MED
was	O
evidenced	O
by	O
quantifying	B-MED
dna	B-MED
double	I-MED
strand	I-MED
break	I-MED
dsb	I-MED
foci	I-MED
in	O
epidermis	B-MED
biopsies	B-MED
collected	O
after	O
delivering	O
radiotherapeutic	B-MED
one	O
and	O
five	O
dose	B-MED
fractions	I-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
whether	O
hrs	B-MED
was	O
preserved	O
throughout	O
a	O
7-	O
week	B-MED
radiotherapy	B-MED
treatment	B-MED
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B-MED
decline	O
and	O
foci	B-MED
persistence	O
between	O
dose	B-MED
fractions	I-MED
.	O
	
42	O
patients	B-MED
with	O
prostate	B-MED
cancer	I-MED
received	O
7-	O
week	B-MED
fractionated	O
radiotherapy	B-MED
treatment	I-MED
rt	B-MED
with	O
daily	O
dose	B-MED
fractions	I-MED
of	O
0.05	O
to	O
the	O
skin	B-MED
.	O
	
before	O
rt	B-MED
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-MED
,	O
skin	B-MED
biopsies	I-MED
n=452	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	B-MED
fractions	I-MED
.	O
	
dsb-foci	B-MED
markers	B-MED
,	O
γh2ax	B-MED
and	O
53bp1	B-MED
,	O
were	O
labelled	O
in	O
epidermal	B-MED
keratinocytes	B-MED
with	O
immunofluorescence	B-MED
and	O
immunohistochemical	B-MED
staining	I-MED
.	O
	
foci	O
were	O
counted	O
both	O
with	O
digital	B-MED
image	I-MED
analysis	I-MED
and	O
manually	O
.	O
	
hrs	B-MED
in	O
keratinocytes	B-MED
was	O
evidenced	O
by	O
the	O
dose-response	B-MED
relationships	I-MED
of	O
dsb	B-MED
foci	I-MED
,	O
observed	O
throughout	O
the	O
treatment	B-MED
course	I-MED
,	O
independent	B-MED
of	I-MED
sampling	B-MED
time	B-MED
and	O
quantification	B-MED
method	B-MED
.	O
	
foci	B-MED
observed	O
at	O
24h	O
after	O
dose	B-MED
fractions	I-MED
indicated	O
considerable	O
dsb	B-MED
persistence	O
.	O
	
accordingly	O
,	O
foci	B-MED
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	B-MED
fractions	I-MED
.	O
	
for	O
doses	B-MED
below	O
0.3gy	O
,	O
persistent	O
foci	B-MED
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B-MED
induction	B-MED
.	O
	
a	O
comparison	B-MED
of	O
γh2ax	B-MED
and	O
53bp1	B-MED
quantifications	B-MED
in	O
double-staine	B-MED
d	O
biopsies	B-MED
showed	O
similar	O
hrs	B-MED
dose-response	B-MED
relationships	I-MED
.	O
	
these	O
results	O
represented	O
the	O
first	O
evidence	B-MED
of	O
preserved	O
hrs	B-MED
,	O
assessed	B-MED
by	O
γh2ax	B-MED
-	O
and	O
53bp1	B-MED
-labelled	O
dsb	B-MED
foci	I-MED
,	O
throughout	O
a	O
7-	O
week	B-MED
treatment	B-MED
course	I-MED
with	O
daily	B-MED
repeated	O
subtherapeutic	B-MED
dose	B-MED
fractions	I-MED
.	O
	
ct	B-MED
angiography	I-MED
for	O
planning	B-MED
transcatheter	B-MED
aortic	I-MED
valve	I-MED
replacement	I-MED
using	O
automated	B-MED
tube	I-MED
voltage	I-MED
selection	I-MED
image	B-MED
quality	I-MED
and	O
radiation	B-MED
exposure	B-MED
to	O
assess	B-MED
image	B-MED
quality	I-MED
and	O
accuracy	B-MED
of	O
ct	B-MED
angiography	I-MED
cta	B-MED
for	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
replacement	I-MED
tavr	B-MED
planning	B-MED
performed	O
with	O
3rd	B-MED
generation	I-MED
dual-source	I-MED
ct	I-MED
dsct	B-MED
.	O
	
we	O
evaluated	O
125	O
patients	B-MED
who	O
underwent	O
tavr	B-MED
-	O
planning	B-MED
cta	B-MED
on	O
3rd	B-MED
generation	I-MED
dsct	I-MED
.	O
	
a	O
two-part	B-MED
protocol	I-MED
was	O
performed	O
including	O
retrospectively	B-MED
ecg-gated	B-MED
coronary	I-MED
cta	I-MED
ccta	B-MED
and	O
prospectively	B-MED
ecg-triggered	B-MED
aortoiliac	I-MED
cta	I-MED
using	O
60ml	O
of	O
contrast	B-MED
medium	I-MED
.	O
	
automated	B-MED
tube	I-MED
voltage	I-MED
selection	I-MED
and	O
advanced	B-MED
iterative	I-MED
reconstruction	I-MED
were	O
applied	O
.	O
	
effective	B-MED
dose	I-MED
ed	B-MED
,	O
signal-to-noise	B-MED
snr	B-MED
and	O
contrast-to-noise	B-MED
ratios	I-MED
cnr	B-MED
were	O
calculated	O
.	O
	
five-point	B-MED
scales	I-MED
were	O
used	O
for	O
subjective	B-MED
image	B-MED
quality	I-MED
analysis	I-MED
.	O
	
in	O
patients	B-MED
who	O
underwent	O
tavr	B-MED
,	O
sizing	B-MED
parameters	I-MED
were	O
obtained	O
.	O
	
image	B-MED
quality	I-MED
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
of	O
ccta	B-MED
and	O
100%	O
of	O
aortoiliac	B-MED
ctas	I-MED
.	O
	
cta	B-MED
studies	B-MED
at	O
>100kv	O
showed	O
decreased	B-MED
objective	B-MED
image	B-MED
quality	I-MED
compared	O
to	O
70-100kv	O
snr	B-MED
,	O
all	O
p	O
cnr	B-MED
,	O
all	O
p	O
.	O
	
mean	B-MED
ed	B-MED
increased	B-MED
continuously	O
from	O
70	O
to	O
>100kv	O
ccta	B-MED
4.5	O
,	O
all	O
p	O
aortoiliac	B-MED
cta	I-MED
2.4	O
,	O
all	O
p	O
.	O
	
in	O
39	O
patients	B-MED
tavr	B-MED
was	O
performed	O
and	O
annulus	B-MED
diameter	B-MED
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	B-MED
.	O
	
no	B-MED
severe	B-MED
cardiac	B-MED
or	O
vascular	B-MED
complications	I-MED
were	O
noted	O
.	O
	
3rd	B-MED
generation	I-MED
dsct	I-MED
provides	O
diagnostic	B-MED
image	B-MED
quality	I-MED
in	O
tavr	B-MED
-	O
planning	B-MED
cta	B-MED
and	O
facilitates	O
reliable	O
assessment	B-MED
of	O
tavr	B-MED
device	B-MED
and	O
delivery	B-MED
option	O
while	O
reducing	B-MED
radiation	B-MED
dose	I-MED
.	O
	
a	O
giant	B-MED
aneurysmal	B-MED
bone	I-MED
cyst	I-MED
in	O
the	O
mandibular	B-MED
condyle	I-MED
aneurysmal	B-MED
bone	I-MED
cyst	I-MED
abc	B-MED
is	O
a	O
rare	B-MED
,	O
rapidly	B-MED
expanding	B-MED
,	O
locally	B-MED
destructive	B-MED
,	O
and	O
easily	B-MED
misdiagnosed	B-MED
lesion	B-MED
.	O
	
an	O
abc	B-MED
of	O
the	O
condyle	B-MED
is	O
rare	B-MED
.	O
	
this	O
report	O
presents	O
a	O
25-	O
year	B-MED
-	O
old	B-MED
female	B-MED
with	O
a	O
giant	B-MED
abc	B-MED
in	O
the	O
left	B-MED
mandibular	I-MED
condyle	I-MED
.	O
	
this	O
patient	O
was	O
treated	O
with	O
surgical	O
resection	O
of	O
the	O
affected	O
bone	O
and	O
immediate	O
mandibular	B-MED
reconstruction	O
using	O
autologous	O
bone	O
.	O
	
follow-up	O
to	O
date	O
showed	O
no	O
signs	O
of	O
recurrence	O
.	O
	
the	O
clinical	O
feature	O
,	O
imaging	O
finding	O
,	O
pathogenesis	O
,	O
and	O
treatment	O
methods	O
of	O
abcs	O
are	O
association	B-MED
between	O
postpartum	B-MED
depression	I-MED
and	O
the	O
practice	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
in	O
the	O
first	O
three	O
months	B-MED
of	O
life	B-MED
to	O
investigate	B-MED
the	O
association	B-MED
between	O
postpartum	B-MED
depression	I-MED
and	O
the	O
occurrence	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
.	O
	
this	O
is	O
a	O
cross-sectional	B-MED
study	I-MED
conducted	O
in	O
the	O
states	B-MED
of	O
the	O
northeast	B-MED
region	I-MED
,	O
during	O
the	O
vaccination	B-MED
campaign	I-MED
in	O
2010	O
.	O
	
the	O
sample	O
consisted	O
of	O
2583	O
mother	B-MED
-	O
child	B-MED
pairs	B-MED
,	O
with	O
children	B-MED
aged	B-MED
from	O
15	O
days	B-MED
to	O
3	O
months	B-MED
.	O
	
the	O
edinburgh	B-MED
postnatal	I-MED
depression	I-MED
scale	I-MED
was	O
used	O
to	O
screen	B-MED
for	O
postpartum	B-MED
depression	I-MED
.	O
	
the	O
outcome	B-MED
was	O
lack	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
,	O
defined	O
as	O
the	O
occurrence	B-MED
of	O
this	O
practice	B-MED
in	O
the	O
24h	O
preceding	B-MED
the	O
interview	B-MED
.	O
	
postpartum	B-MED
depression	I-MED
was	O
the	O
explanatory	B-MED
variable	I-MED
of	O
interest	O
and	O
the	O
covariates	B-MED
were	O
socioeconomic	B-MED
and	O
demographic	B-MED
conditions	I-MED
maternal	B-MED
health	I-MED
care	I-MED
prenatal	B-MED
,	O
delivery	B-MED
,	O
and	O
postnatal	B-MED
care	I-MED
and	O
the	O
child's	B-MED
biological	I-MED
factors	I-MED
.	O
	
multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding	B-MED
factors	I-MED
.	O
	
exclusive	B-MED
breastfeeding	I-MED
was	O
observed	B-MED
in	O
50.8	O
of	O
the	O
infants	B-MED
and	O
11.8	O
of	O
women	B-MED
had	O
symptoms	B-MED
of	O
postpartum	B-MED
depression	I-MED
.	O
	
in	O
the	O
multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
,	O
a	O
higher	O
chance	O
of	O
exclusive	B-MED
breastfeeding	I-MED
absence	B-MED
was	O
found	O
among	O
mothers	B-MED
with	O
symptoms	B-MED
of	O
postpartum	B-MED
depression	I-MED
or=1	O
p<0	O
,	O
among	O
younger	B-MED
subjects	I-MED
or=1	O
p<0	O
,	O
those	O
who	O
reported	O
receiving	O
benefits	B-MED
from	O
the	O
bolsa	B-MED
família	I-MED
program	I-MED
or=1	O
p=0	O
,	O
and	O
those	O
started	O
antenatal	B-MED
care	I-MED
later	O
during	O
pregnancy	B-MED
or=2	O
p=0	O
.	O
	
postpartum	B-MED
depression	I-MED
contributed	O
to	O
reducing	B-MED
the	O
practice	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
.	O
	
therefore	O
,	O
this	O
disorder	B-MED
should	O
be	O
included	O
in	O
the	O
prenatal	B-MED
and	O
early	B-MED
postpartum	I-MED
support	B-MED
guidelines	I-MED
for	O
breastfeeding	B-MED
,	O
especially	O
in	O
low	B-MED
socioeconomic	I-MED
status	I-MED
women	B-MED
.	O
	
evidence	B-MED
of	I-MED
toothpick	B-MED
groove	B-MED
formation	B-MED
in	O
neandertal	B-MED
anterior	B-MED
and	O
posterior	B-MED
teeth	B-MED
during	O
the	O
microscopic	B-MED
examination	I-MED
of	O
the	O
neandertal	B-MED
dentitions	B-MED
from	O
el	B-MED
sidrón	I-MED
spain	B-MED
and	O
hortus	B-MED
france	B-MED
,	O
we	O
found	O
unusual	B-MED
fine	O
parallel	O
microstriations	B-MED
on	O
the	O
mesial	B-MED
and	O
distal	B-MED
sides	I-MED
of	O
all	O
tooth	B-MED
types	O
,	O
near	O
the	O
cervix	B-MED
.	O
	
as	O
its	O
appearance	O
was	O
similar	B-MED
to	O
toothpick	B-MED
grooves	B-MED
described	O
in	O
other	O
homo	B-MED
species	I-MED
,	O
it	O
could	O
correspond	O
to	O
early	B-MED
stages	I-MED
on	O
its	O
formation	B-MED
.	O
	
to	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	B-MED
replication	I-MED
of	O
a	O
groove	B-MED
using	O
grass	B-MED
stalks	B-MED
.	O
	
comparisons	B-MED
between	O
204	O
isolated	B-MED
neandertal	B-MED
teeth	B-MED
and	O
the	O
two	O
experimental	B-MED
dental	B-MED
specimens	B-MED
corroborate	O
that	O
the	O
marks	B-MED
correspond	O
to	O
initial	B-MED
stages	I-MED
of	O
toothpick	B-MED
groove	B-MED
formation	B-MED
,	O
and	O
we	O
propose	O
a	O
five-grade	B-MED
recording	I-MED
scale	I-MED
that	O
summarized	O
the	O
groove	B-MED
formation	B-MED
process	I-MED
.	O
	
using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
hortus	B-MED
individuals	B-MED
have	O
higher	O
incidence	B-MED
of	O
this	O
trait	O
eight	O
individuals	B-MED
out	O
of	O
nine	O
than	O
the	O
el	B-MED
sidrón	I-MED
individuals	B-MED
nine	O
out	O
of	O
11	O
.	O
	
toothpick	B-MED
grooves	B-MED
from	O
el	B-MED
sidrón	I-MED
show	O
the	O
earliest	B-MED
stages	I-MED
of	O
development	B-MED
,	O
whereas	O
the	O
grooves	B-MED
found	O
on	O
hortus	B-MED
neandertals	B-MED
were	O
well-developed	B-MED
.	O
	
toothpick	B-MED
grooves	B-MED
were	O
also	O
found	O
in	O
21	O
incisors	B-MED
and	O
canines	B-MED
.	O
	
these	O
differences	B-MED
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	B-MED
dental	B-MED
wear	I-MED
in	O
hortus	B-MED
individuals	B-MED
,	O
maybe	O
age	B-MED
-related	O
and	O
with	O
a	O
more	O
meat	B-MED
-based	O
diet	B-MED
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	B-MED
debris	B-MED
and	O
thus	O
probing	B-MED
as	O
the	O
cleaning	B-MED
methodology	I-MED
.	O
	
our	O
results	O
allow	O
the	O
identification	B-MED
and	O
characterization	B-MED
of	O
incipient	B-MED
toothpick	B-MED
grooves	B-MED
on	O
the	O
human	B-MED
fossil	B-MED
record	B-MED
and	O
contribute	B-MED
to	O
increase	B-MED
our	O
knowledge	B-MED
on	O
neandertals	B-MED
behavioral	B-MED
and	O
oral	B-MED
care	I-MED
habits	I-MED
.	O
	
thsd7a	B-MED
expression	B-MED
in	O
human	B-MED
cancer	B-MED
we	O
recently	O
described	O
a	O
case	O
of	O
a	O
thrombospondin	B-MED
type-1	I-MED
domain	I-MED
containing	I-MED
7a	I-MED
thsd7a	B-MED
associated	O
membranous	B-MED
nephropathy	I-MED
in	O
a	O
female	B-MED
patient	I-MED
who	O
was	O
synchronously	B-MED
suffering	B-MED
from	O
a	O
thsd7a	B-MED
-	O
positive	B-MED
malignancy	B-MED
.	O
	
we	O
here	O
investigated	O
the	O
role	O
of	O
thsd7a	B-MED
as	O
a	O
new	O
potential	O
tumor	B-MED
antigen	I-MED
by	O
evaluating	O
over	O
20	O
000	O
tissue	B-MED
spots	I-MED
in	O
more	O
than	O
70	O
different	O
tumor	B-MED
entities	I-MED
by	O
immunohistochemistry	B-MED
using	O
tissue	B-MED
microarrays	I-MED
.	O
	
thsd7a	B-MED
expression	B-MED
was	O
highly	O
variable	O
in	O
different	B-MED
neoplasias	I-MED
with	O
differing	O
staining	B-MED
patterns	I-MED
.	O
	
both	O
gain	B-MED
and	I-MED
loss	I-MED
of	O
thsd7a	B-MED
expression	B-MED
compared	O
to	O
expression	B-MED
status	I-MED
in	O
non-tumor	B-MED
tissue	I-MED
were	O
linked	O
to	O
tumor-specific	B-MED
markers	I-MED
in	O
the	O
different	O
tumor	B-MED
entities	I-MED
and	O
were	O
of	O
prognostic	B-MED
value	I-MED
.	O
	
the	O
potential	O
role	O
of	O
thsd7a	B-MED
in	O
tumor	B-MED
development	I-MED
and	O
therapy	B-MED
civil	B-MED
society	I-MED
-driven	O
drug	B-MED
policy	I-MED
reform	I-MED
for	O
health	B-MED
and	O
human	B-MED
welfare	I-MED
-	O
india	B-MED
the	O
lack	B-MED
of	O
adequate	B-MED
access	O
to	O
opioids	B-MED
in	O
india	B-MED
as	O
analgesics	B-MED
and	O
for	O
agonist	B-MED
therapies	B-MED
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	B-MED
unalleviated	B-MED
pain	I-MED
,	O
or	O
languish	B-MED
with	O
suffering	B-MED
associated	O
with	O
drug	B-MED
dependence	I-MED
.	O
	
although	O
india	B-MED
is	O
a	O
major	O
opium	B-MED
exporter	B-MED
,	O
the	O
excessively	O
prohibitive	B-MED
1985	O
narcotics	B-MED
law	I-MED
formulated	O
to	O
control	B-MED
harmful	B-MED
use	I-MED
of	I-MED
drugs	I-MED
,	O
impeded	O
the	O
availability	B-MED
and	O
access	B-MED
to	O
opioids	B-MED
for	O
medical	B-MED
and	O
scientific	B-MED
purposes	B-MED
.	O
	
amendment	B-MED
of	O
this	O
law	B-MED
in	O
2014	O
established	O
a	O
new	O
national	B-MED
regulatory	I-MED
framework	I-MED
for	O
improved	O
access	B-MED
to	O
essential	B-MED
opioid	B-MED
analgesics	I-MED
.	O
	
this	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	B-MED
.	O
	
unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy	B-MED
reforms	I-MED
for	O
law	B-MED
enforcement	I-MED
,	O
realizing	O
the	O
2014	O
drug	B-MED
policy	I-MED
change	O
primarily	O
to	O
mitigate	B-MED
human	B-MED
suffering	I-MED
,	O
was	O
a	O
22-year-long	O
process	O
.	O
	
the	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered	B-MED
complexities	I-MED
of	O
the	O
prior	O
policy	B-MED
framework	I-MED
and	O
understanding	O
their	O
adverse	B-MED
impact	B-MED
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	B-MED
.	O
	
the	O
evolution	O
of	O
an	O
informal	O
civil	B-MED
society	I-MED
movement	I-MED
involving	O
health	B-MED
care	I-MED
professionals	I-MED
,	O
lawyers	B-MED
,	O
media	B-MED
,	O
policy	B-MED
analysts	I-MED
,	O
government	B-MED
officials	I-MED
,	O
and	O
the	O
public	B-MED
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-MED
and	O
garnering	O
momentum	O
for	O
reform	B-MED
.	O
	
the	O
success	B-MED
of	O
the	O
effort	O
for	O
improving	O
access	B-MED
to	O
opioid	B-MED
medications	B-MED
was	O
underpinned	O
by	O
a	O
three-pronged	O
strategy	O
of	O
1	O
persuading	O
the	O
executive	B-MED
arm	I-MED
of	I-MED
the	I-MED
government	I-MED
to	O
take	O
interim	B-MED
enabling	O
measures	B-MED
2	O
leveraging	O
judicial	B-MED
intervention	I-MED
through	O
public	B-MED
interest	B-MED
litigation	B-MED
and	O
3	O
crafting	B-MED
a	I-MED
viable	I-MED
policy	I-MED
document	I-MED
for	O
legislative	B-MED
approval	I-MED
and	O
implementation	B-MED
.	O
	
we	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug	B-MED
policy	I-MED
reforms	I-MED
,	O
given	O
the	O
current	O
transformed	O
global	B-MED
policy	B-MED
mandates	B-MED
emphasizing	O
humanitarian	B-MED
,	O
healthcare	B-MED
,	O
and	O
quality-of-life	B-MED
considerations	B-MED
.	O
	
efficacy	B-MED
of	O
synbiotics	B-MED
for	O
treatment	B-MED
of	O
bacillary	B-MED
dysentery	I-MED
in	O
children	B-MED
a	O
double-blind	B-MED
,	O
randomized	B-MED
,	O
placebo-controlled	B-MED
study	I-MED
bacillary	B-MED
dysentery	I-MED
is	O
a	O
major	O
cause	O
of	O
children's	B-MED
admission	B-MED
to	I-MED
hospitals	I-MED
.	O
	
to	O
assess	B-MED
the	O
probiotic	B-MED
and	O
prebiotic	B-MED
synbiotics	B-MED
effects	B-MED
in	O
children	B-MED
with	O
dysentery	B-MED
in	O
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
,	O
200	O
children	B-MED
with	O
dysentery	B-MED
were	O
studied	O
in	O
2	O
groups	B-MED
the	O
synbiotic	B-MED
group	B-MED
received	O
1	O
tablet	B-MED
/day	B-MED
of	O
synbiotic	B-MED
for	O
3-5	O
days	B-MED
and	O
the	O
placebo	B-MED
group	B-MED
received	O
placebo	B-MED
tablets	B-MED
identical	O
tablet	B-MED
form	O
like	O
probiotics	B-MED
.	O
	
the	O
standard	B-MED
treatment	B-MED
was	O
administered	B-MED
for	O
all	O
patients	B-MED
.	O
	
duration	B-MED
of	O
hospitalization	B-MED
,	O
dysentery	B-MED
,	O
fever	B-MED
,	O
and	O
the	O
weight	B-MED
loss	I-MED
were	O
assessed	B-MED
in	O
each	O
group	B-MED
.	O
	
it	O
was	O
concluded	O
that	O
there	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
both	O
groups	B-MED
in	O
the	O
baseline	B-MED
characteristics	B-MED
.	O
	
the	O
mean	B-MED
duration	I-MED
of	O
dysentery	B-MED
reduced	B-MED
p	O
<	O
0.05	O
.	O
	
the	O
mean	B-MED
duration	I-MED
of	O
fever	B-MED
has	O
been	O
significantly	O
reduced	B-MED
in	O
the	O
synbiotic	B-MED
group	B-MED
1.64	O
0.87	O
days	B-MED
in	O
comparison	B-MED
to	O
the	O
placebo	B-MED
group	B-MED
2.13	O
0.94	O
days	B-MED
p	O
<	O
0.001	O
.	O
	
average	B-MED
amount	I-MED
of	O
weight	B-MED
loss	I-MED
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	B-MED
group	B-MED
in	O
comparison	B-MED
to	O
that	O
in	O
the	O
placebo	B-MED
group	B-MED
129.5	O
23.388	O
grams	O
and	O
278	O
28.385	O
grams	O
,	O
resp	O
p	O
<	O
0.001	O
.	O
	
there	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
the	O
mean	B-MED
duration	I-MED
of	O
hospitalization	B-MED
in	O
both	O
groups	B-MED
p	O
>	O
0.05	O
.	O
	
the	O
use	O
of	O
synbiotics	B-MED
as	O
an	O
adjuvant	B-MED
therapy	I-MED
to	O
the	O
standard	B-MED
treatment	B-MED
of	O
dysentery	B-MED
significantly	O
reduces	B-MED
the	O
duration	B-MED
of	O
dysentery	B-MED
,	O
fever	B-MED
,	O
and	O
rate	B-MED
of	I-MED
weight	I-MED
losses	I-MED
.	O
	
the	O
trial	B-MED
is	O
registered	B-MED
effect	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
on	O
the	O
pharmacokinetics	B-MED
and	O
transplacental	B-MED
transfer	I-MED
of	O
nifedipine	B-MED
in	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
diabetes	B-MED
mellitus	I-MED
can	O
inhibit	B-MED
cytochrome	B-MED
p450	I-MED
3a4	I-MED
,	O
an	O
enzyme	B-MED
responsible	O
for	O
the	O
metabolism	B-MED
of	O
nifedipine	B-MED
,	O
used	O
for	O
the	O
treatment	B-MED
of	O
hypertension	B-MED
in	O
pregnant	B-MED
women	I-MED
.	O
	
we	O
aimed	B-MED
to	O
assess	B-MED
the	O
effect	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
t2dm	B-MED
on	O
the	O
pharmacokinetics	B-MED
,	O
placental	B-MED
transfer	I-MED
and	O
distribution	O
of	O
nifedipine	B-MED
in	O
amniotic	B-MED
fluid	I-MED
in	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
.	O
	
the	O
study	B-MED
was	O
conducted	O
in	O
12	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
control	B-MED
group	I-MED
cg	B-MED
and	O
10	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
with	O
t2dm	B-MED
taking	O
slow-release	O
nifedipine	B-MED
20	O
mg	O
,	O
12/12	O
h	O
.	O
	
on	O
the	O
34th	O
week	B-MED
of	O
gestation	B-MED
,	O
serial	O
blood	B-MED
samples	I-MED
were	O
collected	O
0-12	O
h	O
after	O
administration	B-MED
of	O
the	O
medication	B-MED
.	O
	
at	B-MED
delivery	I-MED
,	O
samples	B-MED
of	O
maternal	B-MED
and	O
fetal	B-MED
blood	I-MED
and	O
amniotic	B-MED
fluid	I-MED
were	O
collected	O
for	O
determination	B-MED
of	O
nifedipine	B-MED
distribution	O
in	O
these	O
compartments	O
.	O
	
the	O
median	B-MED
pharmacokinetic	B-MED
parameters	B-MED
of	O
cg	B-MED
were	O
peak	B-MED
plasma	I-MED
concentration	I-MED
cmax	B-MED
26.41	O
ng	O
ml	O
,	O
time	B-MED
to	I-MED
reach	I-MED
cmax	I-MED
tmax	B-MED
1.79	O
h	O
,	O
area	B-MED
under	I-MED
the	I-MED
plasma	I-MED
concentration	I-MED
vs	O
.	O
	
time	B-MED
curve	I-MED
from	O
0-12	O
h	O
auc	B-MED
0-12	O
235.99	O
ng.h	O
ml	O
,	O
half-life	B-MED
t½	O
4.34	O
h	O
,	O
volume	B-MED
of	I-MED
distribution	I-MED
divided	O
by	O
bioavailability	B-MED
vd	B-MED
/	O
f	B-MED
560.96	O
l	O
,	O
and	O
clt	B-MED
/	O
f	B-MED
84.77	O
l	O
h	O
.	O
	
the	O
parameters	B-MED
for	O
t2dm	B-MED
group	B-MED
were	O
cmax	B-MED
23.52	O
ng	O
ml	O
,	O
tmax	B-MED
1.48	O
h	O
,	O
auc	B-MED
0-12	O
202.23	O
ng.h	O
ml	O
,	O
t½	O
5.00	O
h	O
,	O
vd	B-MED
/	O
f	B-MED
609.40	O
l	O
,	O
and	O
apparent	O
total	B-MED
clearance	I-MED
clt	B-MED
/	O
f	B-MED
98.94	O
l	O
h	O
.	O
	
the	O
ratios	B-MED
of	O
plasma	B-MED
concentrations	I-MED
of	O
nifedipine	B-MED
in	O
the	O
umbilical	B-MED
vein	I-MED
,	O
intervillous	B-MED
space	I-MED
and	O
amniotic	B-MED
fluid	I-MED
to	O
those	O
in	O
the	O
maternal	B-MED
vein	O
for	O
cg	B-MED
and	O
t2dm	B-MED
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	B-MED
fluid	I-MED
/	O
maternal	B-MED
plasma	B-MED
ratio	B-MED
of	O
0.05	O
for	O
both	O
groups	B-MED
.	O
	
the	O
ratios	B-MED
of	O
plasma	B-MED
concentrations	I-MED
in	O
the	O
umbilical	B-MED
artery	I-MED
to	O
those	O
in	O
the	O
umbilical	B-MED
vein	I-MED
were	O
0.82	O
for	O
cg	B-MED
and	O
0.88	O
for	O
t2dm	B-MED
.	O
	
there	O
was	O
no	O
influence	B-MED
of	O
t2dm	B-MED
on	O
the	O
pharmacokinetics	B-MED
or	O
placental	B-MED
transfer	I-MED
of	O
nifedipine	B-MED
in	O
hypertensive	B-MED
women	B-MED
with	O
controlled	B-MED
diabetes	B-MED
.	O
	
results	B-MED
of	O
an	O
international	B-MED
postmarketing	I-MED
surveillance	I-MED
study	I-MED
of	O
pl-vegf165	B-MED
safety	B-MED
and	O
efficacy	B-MED
in	O
210	O
patients	B-MED
with	O
peripheral	B-MED
arterial	I-MED
disease	I-MED
the	O
effective	O
treatment	B-MED
of	O
chronic	B-MED
lower	B-MED
limb	I-MED
ischemia	B-MED
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	B-MED
surgeons	I-MED
.	O
	
current	O
pharmacological	B-MED
therapies	B-MED
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	B-MED
progression	I-MED
,	O
and	O
new	O
treatment	B-MED
methods	I-MED
are	O
needed	O
.	O
	
pl-vegf165	B-MED
,	O
a	O
gene	B-MED
therapy	I-MED
drug	B-MED
,	O
was	O
approved	O
in	O
russia	B-MED
for	O
the	O
treatment	B-MED
of	O
atherosclerotic	B-MED
peripheral	B-MED
arterial	I-MED
disease	I-MED
pad	B-MED
after	O
clinical	B-MED
studies	I-MED
in	O
2011	O
.	O
	
the	O
study	B-MED
drug	B-MED
is	O
an	O
original	O
gene	B-MED
construction	I-MED
in	O
which	O
pl-vegf165	B-MED
1.2	O
mg	O
is	O
the	O
active	B-MED
substance	I-MED
.	O
	
this	O
postmarketing	B-MED
surveillance	I-MED
study	I-MED
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	B-MED
identification	O
of	O
uncommon	O
side	B-MED
effects	I-MED
and	O
efficacy	B-MED
of	O
gene	B-MED
therapy	I-MED
in	O
patients	B-MED
in	O
routine	O
clinical	B-MED
practice	I-MED
.	O
	
in	O
total	O
,	O
210	O
patients	B-MED
with	O
stage	B-MED
ii-iii	I-MED
chronic	B-MED
limb	B-MED
ischemia	B-MED
according	O
to	O
the	O
fontaine	B-MED
classification	I-MED
modified	O
by	O
av	O
pokrovsky	O
in	O
33	O
healthcare	B-MED
facilities	I-MED
in	O
russia	B-MED
and	O
the	O
ukraine	B-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
.	O
	
the	O
control	B-MED
group	I-MED
n	O
=	O
60	O
received	O
conservative	B-MED
therapy	I-MED
without	O
prostaglandins	B-MED
and	O
prostacyclins	B-MED
,	O
and	O
the	O
treatment	B-MED
group	I-MED
n	O
=	O
150	O
received	O
treatment	B-MED
with	O
pl-vegf165	B-MED
as	O
two	O
intramuscular	B-MED
injections	I-MED
for	O
a	O
total	O
dose	B-MED
of	O
2.4	O
mg	O
.	O
	
pain-free	B-MED
walking	I-MED
distance	I-MED
pwd	B-MED
the	O
primary	O
efficacy	B-MED
criterion	O
for	O
fontaine	B-MED
stages	B-MED
ii-iii	I-MED
,	O
blood	B-MED
flow	I-MED
linear	I-MED
velocity	I-MED
bflv	B-MED
,	O
and	O
ankle-brachial	B-MED
index	I-MED
abi	B-MED
were	O
monitored	O
for	O
6	O
months	B-MED
.	O
	
the	O
safety	B-MED
of	O
pl-vegf165	B-MED
gene	B-MED
transfer	I-MED
in	O
terms	O
of	O
the	O
trial	B-MED
protocol	I-MED
was	O
initially	O
evaluated	O
6	O
months	B-MED
after	O
the	O
start	O
of	O
the	O
study	O
adverse	B-MED
events	I-MED
aes	B-MED
and	O
serious	B-MED
adverse	I-MED
events	I-MED
saes	B-MED
were	O
recorded	O
during	O
both	O
routine	O
visits	B-MED
and	O
unscheduled	O
requests	O
for	O
medical	B-MED
care	I-MED
.	O
	
overall	O
,	O
pwd	B-MED
increased	O
by	O
177%	O
,	O
from	O
100.3	O
6.9	O
to	O
277.1	O
16.2	O
m	O
p	O
=	O
0.0001	O
,	O
in	O
the	O
treatment	B-MED
group	I-MED
,	O
whereas	O
the	O
mean	B-MED
value	O
was	O
unchanged	O
in	O
the	O
control	B-MED
group	I-MED
p	O
=	O
0.218	O
.	O
	
both	O
bflv	B-MED
and	O
abi	B-MED
values	I-MED
increased	O
by	O
24%	O
p	O
=	O
0.0001	O
in	O
the	O
treatment	B-MED
group	I-MED
but	O
decreased	O
in	O
the	O
control	B-MED
group	I-MED
.	O
	
the	O
greatest	O
therapeutic	B-MED
effect	I-MED
was	O
observed	O
for	O
stage	B-MED
iii	I-MED
disease	B-MED
pwd	B-MED
increased	O
by	O
683%	O
p	O
=	O
0.0001	O
.	O
	
no	B-MED
angiogenic	B-MED
therapy	I-MED
-related	O
aes	B-MED
or	O
side	B-MED
effects	I-MED
were	O
recorded	O
,	O
and	O
target	O
limb	B-MED
salvage	I-MED
was	O
96	O
and	O
97%	O
in	O
the	O
treatment	B-MED
and	O
control	B-MED
groups	I-MED
,	O
respectively	O
.	O
	
the	O
results	B-MED
obtained	O
in	O
this	O
study	B-MED
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	B-MED
iib	I-MED
/	O
iii	B-MED
registration	O
clinical	B-MED
study	I-MED
completed	O
in	O
2011	O
.	O
	
pl-vegf165	B-MED
intramuscular	B-MED
gene	B-MED
transfer	I-MED
is	O
an	O
effective	O
treatment	B-MED
for	O
moderate	O
to	O
severe	O
claudication	B-MED
due	O
to	O
chronic	B-MED
lower	B-MED
limb	I-MED
ischemia	B-MED
in	O
routine	O
clinical	B-MED
practice	I-MED
.	O
	
psychological	B-MED
factors	I-MED
associated	B-MED
with	I-MED
nafld	B-MED
/	O
nash	B-MED
a	O
systematic	B-MED
review	I-MED
nonalcoholic	B-MED
fatty	I-MED
liver	I-MED
disease	I-MED
nafld	B-MED
represents	O
one	O
of	O
the	O
most	O
common	O
chronic	B-MED
liver	I-MED
diseases	I-MED
worldwide	O
.	O
	
so	O
far	O
,	O
the	O
pathogenesis	B-MED
of	O
nafld	B-MED
and	O
its	O
more	O
severe	B-MED
variant	O
nonalcoholic	B-MED
steatohepatitis	I-MED
nash	B-MED
is	O
yet	O
unclear	O
,	O
with	O
many	O
mechanisms	B-MED
being	O
proposed	O
as	O
possible	O
causes	O
.	O
	
this	O
article	O
aims	O
to	O
review	B-MED
the	O
psychological	B-MED
factors	I-MED
associated	B-MED
with	I-MED
nafld	B-MED
/	O
nash	B-MED
.	O
	
three	O
main	O
categories	O
of	O
factors	B-MED
have	O
been	O
investigated	B-MED
emotional	B-MED
,	O
cognitive	B-MED
and	O
behavioral	B-MED
.	O
	
five	O
electronic	B-MED
databases	I-MED
were	O
searched	O
,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
english	B-MED
language	I-MED
,	O
during	O
the	O
period	B-MED
2005-2015	O
pubmed	B-MED
,	O
thomson	B-MED
isi	I-MED
-	I-MED
web	I-MED
of	I-MED
science	I-MED
,	O
scopus	B-MED
,	O
proquest	B-MED
,	O
and	O
sciencedirect	B-MED
.	O
	
results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-MED
factors	B-MED
to	O
be	O
depression	B-MED
and	O
anxiety	B-MED
.	O
	
the	O
areas	O
of	O
investigation	B-MED
for	O
cognitive	B-MED
functioning	I-MED
concern	O
those	O
contents	B-MED
and	O
processes	B-MED
related	O
to	O
the	O
ability	O
to	O
initiate	B-MED
and	O
maintain	O
lifestyle	B-MED
changes	I-MED
.	O
	
the	O
most	O
important	O
behavioral	B-MED
factors	B-MED
identified	O
are	O
physical	B-MED
activity	I-MED
,	O
nutrition	B-MED
/	O
food	B-MED
intake	I-MED
and	O
substance	B-MED
consumption	B-MED
coffee	B-MED
,	O
alcohol	B-MED
,	O
cigarettes	B-MED
.	O
	
some	O
of	O
the	O
factors	B-MED
identified	O
act	O
as	O
protective	B-MED
factors	I-MED
,	O
other	O
as	O
vulnerability	B-MED
factors	I-MED
.	O
	
nafld	B-MED
/	O
nash	B-MED
may	O
be	O
considered	O
a	O
cognitive-behavioral	B-MED
disease	I-MED
,	O
the	O
most	O
effective	O
management	B-MED
being	O
lifestyle	B-MED
changes	I-MED
,	O
with	O
emphasis	O
on	O
diet	B-MED
and	O
an	O
approach	O
to	O
functionally	O
relevant	O
clustering	B-MED
of	O
the	O
protein	B-MED
universe	I-MED
active	B-MED
site	I-MED
profile-based	I-MED
clustering	I-MED
of	O
protein	B-MED
structures	I-MED
and	O
sequences	B-MED
protein	B-MED
function	I-MED
identification	O
remains	O
a	O
significant	O
problem	O
.	O
	
solving	O
this	O
problem	O
at	O
the	O
molecular	B-MED
functional	I-MED
level	I-MED
would	O
allow	O
mechanistic	O
determinant	O
identification-	O
amino	B-MED
acids	I-MED
that	O
distinguish	O
details	O
between	O
functional	B-MED
families	I-MED
within	O
a	O
superfamily	B-MED
.	O
	
active	B-MED
site	I-MED
profiling	I-MED
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants	O
.	O
	
dasp	B-MED
and	O
dasp2	B-MED
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence	B-MED
databases	I-MED
using	O
active	B-MED
site	I-MED
profiling	I-MED
.	O
	
here	O
,	O
tulip	B-MED
two-level	B-MED
iterative	I-MED
clustering	I-MED
process	I-MED
is	O
introduced	O
as	O
an	O
iterative	O
,	O
divisive	O
clustering	B-MED
process	I-MED
that	O
utilizes	O
active	B-MED
site	I-MED
profiling	I-MED
to	O
separate	O
structurally	O
characterized	O
superfamily	B-MED
members	O
into	O
functionally	O
relevant	O
clusters	B-MED
.	O
	
underlying	O
tulip	B-MED
is	O
the	O
observation	O
that	O
functionally	B-MED
relevant	I-MED
families	I-MED
curated	O
by	O
structure-function	B-MED
linkage	I-MED
database	I-MED
,	O
sfld	B-MED
self-identify	O
in	O
dasp2	B-MED
searches	O
clusters	B-MED
containing	O
multiple	B-MED
functional	I-MED
families	I-MED
do	O
not	O
.	O
	
each	O
tulip	B-MED
iteration	O
produces	O
candidate	O
clusters	B-MED
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self-identifies	O
using	O
dasp2	B-MED
.	O
	
if	O
so	O
,	O
it	O
is	O
deemed	O
a	O
functionally	B-MED
relevant	I-MED
group	I-MED
.	O
	
divisive	O
clustering	B-MED
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally	B-MED
relevant	I-MED
group	I-MED
member	O
or	O
a	O
singlet	O
.	O
	
tulip	B-MED
is	O
validated	O
on	O
enolase	B-MED
and	O
glutathione	B-MED
transferase	I-MED
structures	B-MED
,	O
superfamilies	B-MED
well-curated	O
by	O
sfld	B-MED
.	O
	
correlation	B-MED
is	O
strong	O
small	O
numbers	O
of	O
structures	B-MED
prevent	O
statistically	B-MED
significant	I-MED
analysis	I-MED
.	O
	
tulip	B-MED
-identified	O
enolase	B-MED
clusters	B-MED
are	O
used	O
in	O
dasp2	B-MED
genbank	I-MED
searches	O
to	O
identify	O
sequences	B-MED
sharing	O
functional	O
site	O
features	O
.	O
	
analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96%	O
,	O
false	O
negative	O
rate	O
of	O
4%	O
,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4%	O
.	O
	
f-measure	B-MED
and	O
performance	B-MED
analysis	I-MED
on	O
the	O
enolase	B-MED
search	O
results	O
and	O
comparison	O
to	O
gemma	B-MED
and	O
sci-phy	B-MED
demonstrate	O
that	O
tulip	B-MED
avoids	O
the	O
over-division	O
problem	O
of	O
these	O
methods	O
.	O
	
mechanistic	O
determinants	O
for	O
enolase	B-MED
families	I-MED
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	B-MED
early	B-MED
high	B-MED
school	I-MED
engagement	I-MED
in	O
students	B-MED
with	O
attention/deficit	B-MED
hyperactivity	I-MED
disorder	I-MED
students	B-MED
with	O
attention/deficit	B-MED
hyperactivity	I-MED
disorder	I-MED
adhd	B-MED
continue	O
to	O
languish	O
behind	O
their	O
peers	B-MED
with	O
regard	O
to	O
academic	B-MED
achievement	I-MED
and	O
education	B-MED
attainment	I-MED
.	O
	
school	B-MED
engagement	I-MED
is	O
potentially	O
modifiable	O
,	O
and	O
targeting	O
engagement	B-MED
may	O
be	O
a	O
means	O
to	O
improve	O
education	B-MED
outcomes	B-MED
.	O
	
to	O
investigate	O
school	B-MED
engagement	I-MED
for	O
students	B-MED
with	O
adhd	B-MED
during	O
the	O
crucial	O
high	B-MED
school	I-MED
transition	I-MED
period	B-MED
and	O
to	O
identify	O
factors	O
associated	O
with	O
low	B-MED
school	I-MED
engagement	I-MED
.	O
	
participants	B-MED
are	O
adolescents	B-MED
12-15	O
years	B-MED
in	O
the	O
first	O
and	O
third	O
year	B-MED
of	O
high	B-MED
school	I-MED
with	O
diagnosed	B-MED
adhd	B-MED
n	O
=	O
130	O
.	O
	
participants	B-MED
were	O
recruited	O
from	O
21	O
paediatric	B-MED
practices	B-MED
.	O
	
cross-sectional	B-MED
study	I-MED
assessing	O
school	B-MED
engagement	I-MED
.	O
	
data	B-MED
were	O
collected	O
through	O
direct	O
assessment	B-MED
and	O
child	B-MED
,	O
parent	B-MED
,	O
and	O
teacher	B-MED
surveys	B-MED
.	O
	
school	B-MED
engagement	I-MED
is	O
measured	O
as	O
student	B-MED
attitudes	I-MED
to	O
school	B-MED
cognitive	B-MED
and	O
emotional	B-MED
and	O
suspension	B-MED
rates	B-MED
behavioural	B-MED
.	O
	
multivariable	B-MED
regression	I-MED
analyses	I-MED
examined	O
student	B-MED
,	O
family	B-MED
,	O
and	O
school	B-MED
factors	I-MED
affecting	O
engagement	B-MED
.	O
	
in	O
comparison	O
with	O
state	O
data	O
,	O
students	B-MED
with	O
adhd	B-MED
in	O
the	O
first	O
year	B-MED
of	O
high	B-MED
school	I-MED
were	O
less	O
motivated	O
p	O
<	O
01	O
and	O
less	O
connected	O
to	O
peers	B-MED
p	O
<	O
01	O
.	O
	
overall	O
,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	B-MED
attitudes	B-MED
.	O
	
there	O
were	O
high	B-MED
rates	I-MED
of	I-MED
suspension	I-MED
in	O
both	O
years	B-MED
in	O
comparison	O
to	O
state-wide	O
suspensions	B-MED
21%	O
vs	O
.	O
	
6%	O
,	O
p	O
<	O
01	O
.	O
	
explanatory	O
factors	O
for	O
poor	O
attitudes	B-MED
include	O
adolescent	B-MED
depression	B-MED
,	O
poor	O
adolescent	B-MED
supervision	B-MED
,	O
and	O
devaluing	B-MED
education	B-MED
.	O
	
conduct	B-MED
problems	I-MED
and	O
increased	O
hyperactivity	B-MED
were	O
related	O
to	O
increased	B-MED
likelihood	I-MED
of	I-MED
being	I-MED
suspended	I-MED
,	O
whilst	O
higher	O
cognitive	B-MED
ability	I-MED
,	O
family	B-MED
socio-economic	B-MED
status	I-MED
,	O
and	O
independent	O
schools	B-MED
reduced	O
risk	B-MED
.	O
	
potentially	O
modifiable	O
individual	B-MED
and	O
family	B-MED
factors	B-MED
including	O
adolescent	B-MED
depression	B-MED
,	O
behavioural	B-MED
problems	I-MED
,	O
education	B-MED
values	B-MED
,	O
and	O
family	B-MED
supervision	B-MED
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high	B-MED
school	I-MED
transition	I-MED
for	O
students	B-MED
with	O
proliferation	B-MED
-related	O
activity	O
in	O
endothelial	B-MED
cells	I-MED
is	O
enhanced	B-MED
by	O
micropower	O
plasma	B-MED
nonthermal	B-MED
plasma	I-MED
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical	B-MED
treatment	I-MED
technique	I-MED
in	O
recent	O
years	O
.	O
	
it	O
can	O
easily	O
create	O
various	O
reactive	B-MED
chemical	I-MED
species	I-MED
ros	B-MED
and	O
is	O
harmless	O
to	O
living	B-MED
body	I-MED
.	O
	
although	O
plasma	B-MED
at	O
gas	O
-	O
liquid	O
interface	O
has	O
a	O
potential	O
for	O
a	O
biomedical	O
application	O
,	O
the	O
interactions	O
between	O
the	O
gas	O
-	O
liquid	O
plasma	B-MED
and	O
living	O
cells	O
remain	O
unclear	O
.	O
	
here	O
,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	O
with	O
0.018	O
w	O
of	O
the	O
power	O
input	O
,	O
generated	O
at	O
gas	B-MED
-	O
liquid	B-MED
interface	B-MED
.	O
	
we	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	O
-induced	O
enhancement	O
in	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
	
the	O
plasma	O
produced	O
h2o2	O
,	O
hno2	O
,	O
and	O
hno3	O
in	O
phosphate	O
buffered	O
saline	O
containing	O
mg	O
and	O
ca	O
pbs	O
+	O
,	O
and	O
their	O
concentration	O
increased	O
linearly	O
during	O
600-second	O
discharge	O
.	O
	
the	O
value	O
of	O
ph	O
in	O
pbs	O
+	O
against	O
the	O
plasma	O
discharge	O
time	O
was	O
stable	O
at	O
about	O
7.0	O
.	O
	
temperature	O
in	O
pbs	O
+	O
rose	O
monotonically	O
,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0.8	O
at	O
the	O
bottom	O
of	O
a	O
cell-cultured	O
dish	O
by	O
the	O
plasma	O
discharge	O
for	O
600	O
s	O
.	O
	
short-time	O
treatment	O
of	O
the	O
plasma	O
enhanced	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
	
in	O
contrast	O
,	O
the	O
treatment	O
of	O
h2o2	O
does	O
not	O
enhance	O
the	O
cell	O
proliferation	O
.	O
	
thus	O
,	O
the	O
ros	O
production	O
and	O
the	O
nuclear	O
factor-kappa	O
b	O
nf-κb	O
activation	O
due	O
to	O
the	O
plasma	O
treatment	O
might	O
be	O
related	O
to	O
enhancement	O
of	O
the	O
cell	O
proliferation	O
.	O
	
our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical	B-MED
applications	O
using	O
the	O
gas	O
-	O
liquid	O
plasma	B-MED
ph	B-MED
-dependent	O
transmembrane	B-MED
activity	I-MED
of	O
peptide	B-MED
-functionalized	O
gold	B-MED
nanostars	I-MED
for	O
computed	B-MED
tomography	I-MED
/	O
photoacoustic	B-MED
imaging	I-MED
and	O
photothermal	B-MED
therapy	I-MED
progress	B-MED
in	O
multifunctional	B-MED
nanomaterials	I-MED
for	O
tumor	B-MED
therapy	I-MED
mostly	O
depends	O
on	O
the	O
development	B-MED
of	O
tumor	B-MED
-	O
targeting	B-MED
delivery	B-MED
strategies	I-MED
.	O
	
one	O
approach	B-MED
is	O
to	O
explore	O
a	O
ph	B-MED
-responsive	O
strategy	B-MED
to	O
target	B-MED
the	O
slightly	O
acidic	B-MED
solid	I-MED
tumor	I-MED
microenvironment	I-MED
.	O
	
a	O
novel	O
class	O
of	O
ph	B-MED
low	I-MED
insertion	I-MED
peptides	I-MED
phlips	B-MED
with	O
ph	B-MED
-dependent	O
transmembrane	B-MED
activity	I-MED
can	O
fold	B-MED
and	O
rapidly	O
insert	B-MED
into	O
the	O
lipid	B-MED
bilayer	I-MED
of	O
tumor	B-MED
cells	I-MED
triggered	O
by	O
acidity	B-MED
,	O
facilitating	O
the	O
cellular	B-MED
internalization	I-MED
of	O
nanomaterials	B-MED
synchronously	B-MED
.	O
	
here	O
,	O
we	O
innovatively	O
decorated	O
gold	B-MED
nanostars	I-MED
gnss	B-MED
with	O
phlips	B-MED
gns	B-MED
-	O
phlip	B-MED
to	O
improve	O
their	O
targeting	B-MED
ability	O
and	O
photothermal	B-MED
therapeutic	I-MED
ptt	B-MED
efficiency	B-MED
.	O
	
the	O
obtained	O
gns	B-MED
-	O
phlip	B-MED
exhibited	O
the	O
excellent	O
characteristics	B-MED
of	O
uniform	O
size	B-MED
and	O
good	O
biocompatibility	B-MED
.	O
	
as	O
compared	O
to	O
gns	B-MED
-	O
mpeg	B-MED
,	O
the	O
cellular	B-MED
internalization	I-MED
of	O
gns	B-MED
-	O
phlip	B-MED
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	B-MED
in	O
media	B-MED
at	O
ph	B-MED
6.4	O
than	O
at	O
ph	B-MED
7.4	O
.	O
	
moreover	O
,	O
the	O
tumor	B-MED
accumulation	B-MED
of	O
the	O
gns	B-MED
-	O
phlip	B-MED
was	O
3-fold	O
higher	O
than	O
that	O
of	O
gns	B-MED
-	O
mpeg	B-MED
after	O
intravenous	B-MED
injection	I-MED
into	O
mcf-7	B-MED
breast	B-MED
tumor	I-MED
animal	B-MED
models	I-MED
for	O
24	O
h	O
.	O
	
furthermore	O
,	O
gns	B-MED
-	O
phlip	B-MED
exhibited	O
stronger	O
signals	B-MED
than	O
the	O
gns	B-MED
-	O
mpeg	B-MED
through	O
computed	B-MED
tomography	I-MED
ct	B-MED
and	O
photoacoustic	B-MED
pa	I-MED
imaging	I-MED
.	O
	
simultaneously	O
,	O
the	O
desirable	O
targeting	B-MED
efficiency	B-MED
significantly	O
improved	O
the	O
ptt	B-MED
efficacy	B-MED
to	O
tumors	B-MED
,	O
with	O
low	O
side	B-MED
effects	I-MED
on	O
normal	O
tissues	B-MED
.	O
	
the	O
results	O
clearly	O
demonstrate	O
that	O
the	O
gns	B-MED
-	O
phlip	B-MED
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-MED
-	O
targeting	B-MED
ability	O
of	O
phlips	B-MED
and	O
the	O
good	O
characteristics	B-MED
of	O
gns	B-MED
s	O
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	O
imaging	O
and	O
therapy	B-MED
stepwise	O
cyclopropanation	B-MED
on	O
the	O
polycyclopropanated	B-MED
polyketide	I-MED
formation	O
in	O
jawsamycin	B-MED
biosynthesis	B-MED
jawsamycin	B-MED
is	O
a	O
polyketide	B-MED
-	O
nucleoside	B-MED
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-MED
moiety	O
on	O
a	O
single	O
polyketide	B-MED
chain	I-MED
.	O
	
the	O
unexpected	O
isolation	O
of	O
cyclopropane	B-MED
deficient	O
jawsamycin	B-MED
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	B-MED
mechanism	B-MED
for	O
the	O
enzymatic	B-MED
synthesis	B-MED
of	O
this	O
polyketide	B-MED
.	O
	
the	O
concise	O
timing	O
of	O
the	O
cyclopropanation	B-MED
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction	B-MED
rates	I-MED
of	O
the	O
condensation	B-MED
and	O
cyclopropanation	B-MED
reactions	I-MED
.	O
	
initial	O
experience	O
with	O
laparoscopic	B-MED
radical	I-MED
antegrade	I-MED
modular	I-MED
pancreatosplenectomy	I-MED
for	O
left-sided	B-MED
pancreatic	I-MED
cancer	I-MED
in	O
a	O
single	O
institution	B-MED
technical	O
aspects	O
and	O
oncological	B-MED
outcomes	I-MED
laparoscopic	B-MED
surgery	I-MED
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	B-MED
cancer	I-MED
due	O
to	O
technical	B-MED
difficulties	I-MED
and	O
concerns	O
about	O
oncological	B-MED
safety	B-MED
.	O
	
radical	B-MED
antegrade	I-MED
modular	I-MED
pancreatosplenectomy	I-MED
ramps	B-MED
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	B-MED
margin	I-MED
during	O
radical	B-MED
lymph	I-MED
node	I-MED
dissection	I-MED
.	O
	
we	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	B-MED
as	O
a	O
laparoscopic	B-MED
application	I-MED
due	O
to	O
unique	O
features	O
.	O
	
fifteen	O
laparoscopic	B-MED
ramps	B-MED
for	O
well-selected	O
patients	B-MED
with	O
left-sided	B-MED
pancreatic	I-MED
cancer	I-MED
were	O
performed	O
from	O
july	O
2011	O
to	O
april	O
2016	O
.	O
	
five	O
trocars	B-MED
were	O
usually	O
used	O
,	O
and	O
the	O
operative	B-MED
procedures	I-MED
and	O
range	B-MED
of	I-MED
dissection	I-MED
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
ramps	B-MED
described	O
by	O
strasberg	B-MED
.	O
	
all	O
medical	O
records	O
and	O
follow-up	B-MED
data	I-MED
were	O
reviewed	O
and	O
analyzed	O
.	O
	
all	O
patients	B-MED
had	O
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
.	O
	
mean	O
operative	B-MED
time	I-MED
was	O
219.3	O
53.8	O
min	O
,	O
and	O
estimated	B-MED
blood	I-MED
loss	I-MED
was	O
250	O
70	O
ml	O
.	O
	
the	O
length	B-MED
of	I-MED
postoperative	I-MED
hospital	I-MED
stay	I-MED
was	O
6.1	O
1.2	O
days	O
,	O
and	O
postoperative	B-MED
morbidities	B-MED
developed	O
in	O
two	O
patients	B-MED
13.3	O
with	O
urinary	B-MED
retention	I-MED
.	O
	
the	O
median	O
number	O
of	O
retrieved	O
lymph	B-MED
nodes	I-MED
was	O
18.1	O
6.2	O
and	O
all	O
had	O
negative	B-MED
margins	I-MED
.	O
	
median	O
follow-up	B-MED
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3-year	O
disease	B-MED
free	I-MED
survival	I-MED
and	O
overall	B-MED
survival	I-MED
rates	I-MED
were	O
56.3	O
and	O
74.1	O
,	O
respectively	O
.	O
	
our	O
early	O
experience	O
with	O
laparoscopic	B-MED
ramps	B-MED
achieved	O
feasible	O
perioperative	B-MED
results	O
accompanied	O
by	O
acceptable	O
survival	B-MED
outcomes	I-MED
.	O
	
laparoscopic	B-MED
ramps	B-MED
could	O
be	O
a	O
safe	O
and	O
oncologically	B-MED
feasible	B-MED
procedure	I-MED
in	O
well-selected	O
patients	B-MED
with	O
left-sided	B-MED
pancreatic	I-MED
cancer	I-MED
.	O
	
individual	B-MED
classification	B-MED
of	O
strong	B-MED
risk	B-MED
attitudes	B-MED
an	O
application	O
across	O
lottery	B-MED
types	B-MED
and	O
age	B-MED
groups	I-MED
empirical	B-MED
evaluations	B-MED
of	O
risk	B-MED
attitudes	B-MED
often	O
rely	O
on	O
a	O
weak	B-MED
definition	B-MED
of	O
risk	B-MED
that	O
concerns	O
preferences	O
towards	O
risky	B-MED
and	O
riskless	B-MED
options	I-MED
e.g	O
,	O
a	O
lottery	B-MED
vs	O
.	O
	
a	O
sure	O
outcome	B-MED
.	O
	
a	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	B-MED
tend	O
to	O
be	O
weak	B-MED
risk	B-MED
averse	O
in	O
choice	B-MED
contexts	B-MED
involving	O
risky	B-MED
and	O
riskless	B-MED
gains	I-MED
but	O
weak	B-MED
risk	B-MED
seeking	O
in	O
contexts	B-MED
involving	O
losses	B-MED
,	O
a	O
phenomenon	B-MED
known	O
as	O
the	O
reflection	B-MED
effect	I-MED
.	O
	
recent	O
attempts	O
to	O
evaluate	O
age	B-MED
differences	I-MED
in	O
risk	B-MED
attitudes	B-MED
have	O
relied	O
on	O
this	O
weak	B-MED
definition	B-MED
,	O
testing	O
whether	O
the	O
reflection	B-MED
effect	I-MED
increases	B-MED
or	O
diminishes	B-MED
as	O
we	O
grow	O
older	B-MED
.	O
	
the	O
present	O
work	O
argues	O
that	O
weak	B-MED
risk	B-MED
attitudes	B-MED
have	O
limited	O
generalizability	B-MED
and	O
proposes	O
the	O
use	B-MED
of	I-MED
a	O
strong	B-MED
definition	O
of	O
risk	O
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	O
with	O
the	O
same	O
expected	O
value	O
but	O
different	O
degrees	O
of	O
risk	O
i.e	O
,	O
outcome	O
variance	O
.	O
	
a	O
reanalysis	O
of	O
previously-published	O
data	O
and	O
the	O
results	O
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	O
manifests	O
the	O
reflection	O
effect	O
under	O
a	O
strong	B-MED
definition	B-MED
of	O
risk	B-MED
,	O
and	O
that	O
,	O
when	O
facing	O
certain	O
lottery	O
-	O
pair	O
types	O
,	O
older	O
adults	O
appear	O
to	O
be	O
more	O
risk	O
seeking	O
than	O
younger	O
adults	I-MED
treating	B-MED
the	O
binge	B-MED
or	O
the	O
fat	B-MED
body	I-MED
representations	B-MED
of	O
fatness	B-MED
in	O
a	O
gold	B-MED
standard	I-MED
psychological	B-MED
treatment	B-MED
manual	I-MED
for	O
binge	B-MED
eating	I-MED
disorder	I-MED
this	O
article	O
reports	B-MED
the	O
results	B-MED
of	O
a	O
foucauldian	B-MED
-informed	O
discourse	B-MED
analysis	I-MED
exploring	O
representations	B-MED
of	O
fatness	B-MED
embedded	O
within	O
an	O
empirically	B-MED
based	O
psychological	B-MED
treatment	B-MED
manual	I-MED
for	O
binge	B-MED
eating	I-MED
disorder	I-MED
,	O
a	O
condition	B-MED
characterized	B-MED
by	O
overvaluation	O
of	O
weight	B-MED
and	O
shape	B-MED
.	O
	
analyses	B-MED
indicate	B-MED
that	O
the	O
manual	B-MED
prioritizes	O
weight	B-MED
loss	I-MED
with	O
relatively	B-MED
less	O
emphasis	O
placed	O
on	O
treating	B-MED
the	O
diagnostic	B-MED
symptoms	B-MED
and	O
underlying	O
mechanisms	B-MED
of	O
binge	B-MED
eating	I-MED
disorder	I-MED
.	O
	
we	O
raise	O
critical	B-MED
concerns	I-MED
about	O
these	O
observations	B-MED
and	O
link	O
our	O
findings	B-MED
to	O
mainstream	O
psychology's	B-MED
adoption	O
of	O
the	O
medical	B-MED
framing	I-MED
of	O
fatness	B-MED
as	O
obesity	B-MED
within	O
the	O
""""	O
gold	B-MED
standard	I-MED
""""	O
approach	O
to	O
intervention	B-MED
.	O
	
we	O
recommend	O
that	O
psychology	B-MED
as	O
a	O
discipline	B-MED
abandons	O
the	O
weight	B-MED
loss	I-MED
imperative	O
associated	B-MED
with	I-MED
binge	B-MED
eating	I-MED
disorder	I-MED
and	O
fat	B-MED
bodies	I-MED
.	O
	
we	O
recommend	O
that	O
practitioners	B-MED
locate	O
the	O
problem	B-MED
of	O
fat	B-MED
shame	I-MED
in	O
society	B-MED
as	O
opposed	O
to	O
the	O
individual	B-MED
person's	O
body	B-MED
and	O
provide	B-MED
individuals	B-MED
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat	B-MED
stigma	I-MED
and	O
oppression	B-MED
,	O
rather	O
than	O
provide	B-MED
them	O
with	O
tools	O
to	O
reshape	O
their	O
high	O
diversity	B-MED
of	O
planctomycetes	B-MED
in	O
soils	B-MED
of	O
two	O
lichen	B-MED
-dominated	O
sub-arctic	B-MED
ecosystems	B-MED
of	O
northwestern	B-MED
siberia	B-MED
a	O
wide	O
variety	O
of	O
terrestrial	B-MED
ecosystems	B-MED
in	O
tundra	B-MED
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	B-MED
genera	B-MED
cladonia	B-MED
and	O
cetraria	B-MED
.	O
	
the	O
microbial	B-MED
communities	O
of	O
two	O
lichen	B-MED
-dominated	O
ecosystems	B-MED
typical	O
of	O
the	O
sub-arctic	B-MED
zone	I-MED
of	O
northwestern	B-MED
siberia	B-MED
,	O
that	O
is	O
a	O
forested	B-MED
tundra	B-MED
soil	B-MED
and	O
a	O
shallow	B-MED
acidic	I-MED
peatland	I-MED
,	O
were	O
examined	O
in	O
our	O
study	B-MED
.	O
	
as	O
revealed	O
by	O
molecular	O
analyses	O
,	O
soil	B-MED
and	O
peat	B-MED
layers	O
just	O
beneath	O
the	O
lichen	B-MED
cover	O
were	O
abundantly	O
colonized	B-MED
by	O
bacteria	B-MED
from	O
the	O
phylum	B-MED
planctomycetes	B-MED
.	O
	
highest	O
abundance	O
of	O
planctomycetes	B-MED
detected	O
by	O
fluorescence	B-MED
in	B-MED
situ	I-MED
hybridization	I-MED
was	O
in	O
the	O
range	O
2.2	O
10	O
cells	B-MED
per	I-MED
gram	I-MED
of	I-MED
wet	I-MED
weight	I-MED
.	O
	
16s	B-MED
rrna	I-MED
gene	B-MED
fragments	I-MED
from	O
the	O
planctomycetes	B-MED
comprised	O
8-13%	O
of	O
total	O
16s	B-MED
rrna	I-MED
gene	B-MED
reads	O
retrieved	O
using	O
illumina	B-MED
pair-end	I-MED
sequencing	I-MED
from	O
the	O
soil	B-MED
and	O
peat	B-MED
samples	I-MED
.	O
	
lichen	B-MED
-associated	O
assemblages	O
of	O
planctomycetes	B-MED
displayed	O
unexpectedly	O
high	O
diversity	B-MED
,	O
with	O
a	O
total	O
of	O
89	O
reads	O
representing	O
1723	O
operational	B-MED
taxonomic	I-MED
units	I-MED
determined	O
at	O
97%	O
sequence	B-MED
identity	I-MED
.	O
	
the	O
soil	B-MED
of	O
forested	O
tundra	B-MED
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	B-MED
planctomycetaceae	B-MED
53-71%	O
of	O
total	O
planctomycetes	B-MED
-like	O
reads	O
,	O
while	O
sequences	B-MED
affiliated	O
with	O
the	O
phycisphaera-related	B-MED
group	I-MED
wd2101	I-MED
recently	O
assigned	O
to	O
the	O
order	B-MED
tepidisphaerales	B-MED
were	O
most	O
abundant	O
in	O
peat	B-MED
28-51%	O
of	O
total	O
reads	O
.	O
	
representatives	O
of	O
the	O
isosphaera	B-MED
-	O
singulisphaera	B-MED
group	I-MED
14-28%	O
of	O
total	O
reads	O
and	O
the	O
lineages	B-MED
defined	O
by	O
the	O
genera	B-MED
gemmata	B-MED
1-4%	O
and	O
planctopirus	B-MED
-	O
rubinisphaera	B-MED
1-3%	O
were	O
present	O
in	O
both	O
habitats	B-MED
.	O
	
two	O
strains	O
of	O
singulisphaera-like	B-MED
bacteria	I-MED
were	O
isolated	O
from	O
studied	O
soil	B-MED
and	O
peat	B-MED
samples	I-MED
.	O
	
these	O
planctomycetes	B-MED
displayed	O
good	O
tolerance	O
of	O
low	B-MED
temperatures	I-MED
4-15	O
and	O
were	O
capable	O
of	O
growth	B-MED
on	O
a	O
number	O
of	O
polysaccharides	B-MED
,	O
including	O
lichenan	B-MED
,	O
a	O
characteristic	O
component	O
of	O
lichen	B-MED
-derived	O
relationship	B-MED
between	O
polycythemia	B-MED
and	O
in-hospital	B-MED
mortality	I-MED
in	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
patients	B-MED
with	O
low-risk	B-MED
pulmonary	B-MED
embolism	I-MED
pulmonary	B-MED
embolism	I-MED
pe	B-MED
is	O
frequent	B-MED
in	O
subjects	B-MED
with	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
copd	B-MED
and	O
associated	B-MED
with	I-MED
high	O
mortality	B-MED
.	O
	
this	O
multi-center	B-MED
retrospective	I-MED
study	I-MED
was	O
performed	O
to	O
investigate	B-MED
if	O
secondary	O
polycythemia	B-MED
is	O
associated	B-MED
with	I-MED
in-hospital	B-MED
mortality	I-MED
in	O
copd	B-MED
patients	B-MED
with	O
low-risk	B-MED
pe	B-MED
.	O
	
we	O
identified	O
copd	B-MED
patients	B-MED
with	O
proven	O
pe	B-MED
between	O
october	O
,	O
2005	O
and	O
october	O
,	O
2015	O
.	O
	
patients	B-MED
in	O
risk	O
classes	O
iii-v	O
on	O
the	O
basis	O
of	O
the	O
pesi	B-MED
score	I-MED
were	O
excluded	O
.	O
	
we	O
extracted	O
demographic	B-MED
,	O
clinical	B-MED
and	O
laboratory	B-MED
information	I-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
from	O
medical	B-MED
records	I-MED
.	O
	
all	O
subjects	B-MED
were	O
followed	O
until	O
hospital	B-MED
discharge	I-MED
to	O
identify	O
all-cause	O
mortality	B-MED
.	O
	
we	O
enrolled	O
629	O
consecutive	O
patients	B-MED
with	O
copd	B-MED
and	O
pe	B-MED
at	O
low	B-MED
risk	I-MED
132	O
of	O
them	O
21.0	O
with	O
and	O
497	O
79.0	O
without	O
secondary	O
polycythemia	B-MED
.	O
	
compared	O
with	O
those	O
without	O
polycythemia	B-MED
,	O
the	O
polycythemia	B-MED
group	O
had	O
significantly	B-MED
lower	I-MED
forced	B-MED
expiratory	I-MED
volume	I-MED
in	I-MED
one	I-MED
second	I-MED
fev1	I-MED
level	I-MED
0.9	O
vs	O
.	O
	
1.4	O
,	O
p=0	O
,	O
lower	B-MED
pao2	I-MED
and	O
spo2	B-MED
as	O
well	O
as	O
higher	B-MED
paco2	I-MED
p=0	O
,	O
p=0	O
and	O
p=0	O
,	O
respectively	O
.	O
	
copd	B-MED
patients	B-MED
with	O
polycythemia	B-MED
had	O
a	O
higher	B-MED
proportion	B-MED
of	O
arrhythmia	B-MED
in	O
electrocardiogram	B-MED
ecg	B-MED
49.5	O
vs	O
.	O
	
35.7	O
,	O
p=0	O
,	O
a	O
longer	O
hospital	B-MED
duration	I-MED
time	I-MED
15.3	O
vs	O
.	O
	
9.7	O
,	O
p=0	O
,	O
a	O
higher	B-MED
mechanical	B-MED
ventilation	I-MED
rate	I-MED
noninvasive	B-MED
and	O
invasive	B-MED
,	O
51.7	O
vs	O
.	O
	
30.3	O
,	O
p=0	O
and	O
31.0	O
vs	O
.	O
	
7.9	O
,	O
p=0	O
,	O
respectively	O
,	O
and	O
a	O
higher	B-MED
in-hospital	B-MED
mortality	I-MED
12.1	O
vs	O
.	O
	
6.6	O
,	O
p=0	O
.	O
	
multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
revealed	O
that	O
polycythemia	B-MED
was	O
associated	B-MED
with	I-MED
mortality	B-MED
in	O
copd	B-MED
patients	B-MED
with	O
low-risk	B-MED
pe	B-MED
adjusted	O
or	O
1.11	O
95%	O
ci	O
,	O
1.04	O
.	O
	
polycythemia	B-MED
is	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
all-cause	O
in-hospital	B-MED
mortality	I-MED
in	O
copd	B-MED
patients	B-MED
with	O
pe	B-MED
at	O
low	B-MED
risk	I-MED
.	O
	
masitinib	B-MED
for	O
treatment	B-MED
of	O
severely	B-MED
symptomatic	B-MED
indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
a	O
randomised	B-MED
,	O
placebo-controlled	B-MED
,	O
phase	B-MED
3	I-MED
study	I-MED
indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
including	O
the	O
subvariant	B-MED
of	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
is	O
a	O
lifelong	B-MED
condition	O
associated	B-MED
with	I-MED
reduced	B-MED
quality	I-MED
of	I-MED
life	I-MED
.	O
	
masitinib	B-MED
inhibits	B-MED
kit	B-MED
and	O
lyn	B-MED
kinases	I-MED
that	O
are	O
involved	O
in	O
indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
pathogenesis	B-MED
.	O
	
we	O
aimed	O
to	O
assess	O
safety	B-MED
and	O
efficacy	B-MED
of	O
masitinib	B-MED
versus	O
placebo	B-MED
in	O
severely	B-MED
symptomatic	I-MED
patients	B-MED
who	O
were	O
unresponsive	B-MED
to	O
optimal	B-MED
symptomatic	B-MED
treatments	B-MED
.	O
	
in	O
this	O
randomised	B-MED
,	O
double-blind	B-MED
,	O
placebo-controlled	B-MED
,	O
phase	B-MED
3	I-MED
study	I-MED
,	O
we	O
enrolled	O
adults	B-MED
aged	B-MED
18-75	O
years	O
with	O
indolent	B-MED
or	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
according	O
to	O
who	B-MED
classification	B-MED
or	O
documented	B-MED
mastocytosis	B-MED
based	O
on	O
histological	B-MED
criteria	I-MED
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B-MED
.	O
	
we	O
excluded	O
patients	B-MED
with	O
cutaneous	B-MED
or	O
non-severe	O
systemic	B-MED
mastocytosis	I-MED
after	O
a	O
protocol	B-MED
amendment	I-MED
.	O
	
patients	B-MED
were	O
centrally	O
randomised	B-MED
1	O
to	O
receive	O
either	O
oral	B-MED
masitinib	B-MED
6	O
mg/kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
or	O
matched	O
placebo	B-MED
with	O
minimisation	O
according	O
to	O
severe	B-MED
symptoms	I-MED
.	O
	
the	O
primary	B-MED
endpoint	I-MED
was	O
cumulative	O
response	B-MED
75%	O
improvement	B-MED
from	O
baseline	B-MED
within	O
weeks	O
8-24	O
in	O
at	O
least	O
one	O
severe	B-MED
baseline	I-MED
symptom	I-MED
from	O
the	O
following	O
pruritus	B-MED
score	B-MED
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
hamilton	B-MED
rating	I-MED
scale	I-MED
for	I-MED
depression	I-MED
of	O
19	O
or	O
more	O
,	O
or	O
fatigue	B-MED
impact	I-MED
scale	I-MED
of	O
75	O
or	O
more	O
.	O
	
we	O
assessed	O
treatment	B-MED
effect	I-MED
using	O
repeated	O
measures	O
methodology	B-MED
for	O
rare	B-MED
diseases	I-MED
via	O
the	O
generalised	B-MED
estimating	I-MED
equation	I-MED
model	I-MED
in	O
a	O
modified	O
intention-to-treat	B-MED
population	B-MED
,	O
including	O
all	O
participants	B-MED
assigned	O
to	O
treatment	B-MED
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment-related	B-MED
cause	I-MED
.	O
	
we	O
assessed	O
safety	B-MED
in	O
all	O
patients	B-MED
who	O
received	O
at	O
least	O
one	O
dose	B-MED
of	O
study	B-MED
drug	I-MED
.	O
	
this	O
trial	B-MED
is	O
registered	O
with	O
clinicaltrials.gov	B-MED
,	O
number	I-MED
nct00814073	I-MED
.	O
	
between	O
feb	B-MED
19	O
,	O
2009	O
,	O
and	O
july	B-MED
15	O
,	O
2015	O
,	O
135	O
patients	B-MED
were	O
randomly	B-MED
assigned	I-MED
to	O
masitinib	B-MED
n=71	O
or	O
placebo	B-MED
n=64	O
.	O
	
by	O
24	O
weeks	B-MED
,	O
masitinib	B-MED
was	O
associated	B-MED
with	I-MED
a	O
cumulative	O
response	B-MED
of	O
18	O
in	O
the	O
primary	B-MED
endpoint	I-MED
122	O
responses	B-MED
of	O
656	O
possible	O
responses	B-MED
weighted	B-MED
generalised	I-MED
estimating	I-MED
equation	I-MED
compared	O
with	O
7	O
for	O
placebo	B-MED
48	O
of	O
656	O
difference	O
11	O
odds	B-MED
ratio	I-MED
3	O
95%	O
ci	O
1	O
p=0	O
.	O
	
frequent	B-MED
severe	B-MED
adverse	I-MED
events	I-MED
>4%	O
difference	O
from	O
placebo	B-MED
were	O
diarrhoea	B-MED
eight	O
11%	O
of	O
70	O
in	O
the	O
masitinib	B-MED
group	B-MED
vs	O
one	O
2%	O
of	O
63	O
in	O
the	O
placebo	B-MED
group	B-MED
,	O
rash	O
four	O
6%	O
vs	O
none	O
,	O
and	O
asthenia	B-MED
four	O
6%	O
vs	O
one	O
2%	O
.	O
	
the	O
most	O
frequent	B-MED
serious	B-MED
adverse	I-MED
events	I-MED
were	O
diarrhoea	B-MED
three	O
patients	B-MED
4%	O
vs	O
one	O
2%	O
and	O
urticaria	B-MED
two	O
3%	O
vs	O
none	O
,	O
and	O
no	O
life-threatening	B-MED
toxicities	B-MED
occurred	O
.	O
	
one	O
patient	B-MED
in	O
the	O
placebo	B-MED
group	B-MED
died	B-MED
unrelated	B-MED
to	O
study	B-MED
treatment	I-MED
.	O
	
these	O
study	B-MED
findings	I-MED
indicate	O
that	O
masitinib	B-MED
is	O
an	O
effective	B-MED
and	O
well	O
tolerated	B-MED
agent	I-MED
for	O
the	O
treatment	B-MED
of	O
severely	B-MED
symptomatic	I-MED
indolent	B-MED
or	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
.	O
	
attributable	B-MED
risk	I-MED
of	O
ambient	B-MED
pm10	B-MED
on	O
daily	O
mortality	B-MED
and	O
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
in	O
chengdu	B-MED
,	O
china	B-MED
attributable	B-MED
risk	I-MED
is	O
an	O
important	O
indicator	O
for	O
planning	B-MED
and	O
evaluating	B-MED
public	I-MED
health	I-MED
interventions	I-MED
.	O
	
however	O
,	O
most	O
current	O
measures	O
of	O
the	O
attributable	B-MED
risk	I-MED
of	O
air	B-MED
pollutants	I-MED
have	O
not	O
considered	O
temporal	B-MED
relationships	I-MED
between	O
exposure	B-MED
and	O
risk	B-MED
.	O
	
more	O
importantly	O
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable	B-MED
risk	I-MED
due	O
to	O
ambient	B-MED
air	B-MED
pollutants	I-MED
in	O
basin	B-MED
regions	I-MED
like	O
the	O
sichuan	B-MED
basin	I-MED
,	O
china	B-MED
.	O
	
to	O
quantify	O
the	O
association	O
between	O
pm10	B-MED
and	O
deaths	B-MED
in	O
the	O
basin	B-MED
region	I-MED
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed	B-MED
lag	I-MED
non-linear	I-MED
model	I-MED
to	O
estimate	O
the	O
attributable	B-MED
risk	I-MED
in	O
chengdu	B-MED
,	O
china	B-MED
.	O
	
meanwhile	O
,	O
we	O
examined	O
the	O
association	B-MED
between	O
pm10	B-MED
and	O
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
yll	B-MED
.	O
	
our	O
analysis	B-MED
showed	O
that	O
population-attributable	B-MED
fractions	I-MED
for	O
non-accidental	B-MED
,	O
respiratory	B-MED
,	O
and	O
cardiovascular	B-MED
mortality	I-MED
were	O
0.569	O
95%	O
ci	O
-3	O
,	O
4.374	O
,	O
0.695	O
95%	O
ci	O
-5	O
,	O
6.457	O
,	O
and	O
0.631	O
95%	O
ci	O
-6	O
,	O
7.390	O
,	O
respectively	O
.	O
	
on	O
average	O
,	O
a	O
1μg/m	O
increase	O
in	O
pm10	B-MED
was	O
associated	O
with	O
cumulative	B-MED
increases	I-MED
of	O
0.26893	O
,	O
0.30437	O
,	O
and	O
0.21924	O
yll	B-MED
for	O
non-accidental	B-MED
,	O
respiratory	B-MED
,	O
and	O
cardiovascular	B-MED
mortality	I-MED
,	O
respectively	O
,	O
referring	O
to	O
20μg/m	O
.	O
	
in	O
addition	O
,	O
we	O
found	O
an	O
inverse	B-MED
u-shaped	I-MED
pattern	I-MED
for	O
the	O
cumulative	B-MED
risk	I-MED
with	O
350μg/m	O
as	O
the	O
reverse	O
point	O
.	O
	
with	O
a	O
1μg/m	O
increase	O
in	O
pm10	B-MED
,	O
yll	B-MED
changed	O
more	O
significantly	O
than	O
mortality	B-MED
.	O
	
moreover	O
,	O
pm10	B-MED
demonstrated	O
remarkable	O
effects	B-MED
on	O
yll	B-MED
among	O
men	B-MED
and	O
the	O
far-infrared	B-MED
protects	B-MED
vascular	B-MED
endothelial	I-MED
cells	I-MED
from	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
-	O
induced	B-MED
injury	B-MED
via	O
plzf	B-MED
-mediated	O
autophagy	B-MED
in	O
diabetic	B-MED
mice	I-MED
the	O
accumulation	O
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
ages	B-MED
in	O
diabetic	B-MED
patients	B-MED
induces	B-MED
vascular	B-MED
endothelial	I-MED
injury	B-MED
.	O
	
promyelocytic	B-MED
leukemia	I-MED
zinc	I-MED
finger	I-MED
protein	I-MED
plzf	B-MED
is	O
a	O
transcription	B-MED
factor	I-MED
that	O
can	O
be	O
activated	B-MED
by	O
low-temperature	B-MED
far-infrared	B-MED
fir	B-MED
irradiation	B-MED
to	O
exert	B-MED
beneficial	I-MED
effects	I-MED
on	O
the	O
vascular	B-MED
endothelium	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
influence	B-MED
of	O
fir	B-MED
-	O
induced	B-MED
plzf	B-MED
activation	B-MED
on	O
age	B-MED
-	O
induced	B-MED
endothelial	B-MED
injury	B-MED
both	B-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
fir	B-MED
irradiation	B-MED
inhibited	B-MED
age	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
human	B-MED
umbilical	I-MED
vein	I-MED
endothelial	I-MED
cells	I-MED
huvecs	B-MED
.	O
	
plzf	B-MED
activation	B-MED
increased	B-MED
the	O
expression	B-MED
of	O
phosphatidylinositol-3	B-MED
kinases	I-MED
pi3k	B-MED
,	O
which	O
are	O
important	B-MED
kinases	B-MED
in	O
the	O
autophagic	B-MED
signaling	B-MED
pathway	I-MED
.	O
	
fir	B-MED
-	O
induced	B-MED
plzf	B-MED
activation	B-MED
led	O
to	O
autophagy	B-MED
in	O
huvec	B-MED
,	O
which	O
was	O
mediated	O
through	B-MED
the	O
upregulation	B-MED
of	O
pi3k	B-MED
.	O
	
immunofluorescence	B-MED
staining	B-MED
showed	O
that	O
ages	B-MED
were	O
engulfed	O
by	O
huvecs	B-MED
and	O
localized	B-MED
to	O
lysosomes	B-MED
.	O
	
fir	B-MED
-	O
induced	B-MED
autophagy	B-MED
promoted	B-MED
ages	B-MED
degradation	B-MED
in	O
huvecs	B-MED
.	O
	
in	O
nicotinamide	B-MED
/	O
streptozotocin	B-MED
-	O
induced	B-MED
diabetic	B-MED
mice	I-MED
,	O
fir	B-MED
therapy	B-MED
reduced	B-MED
serum	B-MED
ages	I-MED
and	O
ages	B-MED
deposition	B-MED
at	O
the	O
vascular	B-MED
endothelium	I-MED
.	O
	
fir	B-MED
therapy	B-MED
also	O
reduced	B-MED
diabetes	B-MED
-	O
induced	B-MED
inflammatory	B-MED
markers	I-MED
in	O
the	O
vascular	B-MED
endothelium	I-MED
and	O
improved	B-MED
vascular	B-MED
endothelial	I-MED
function	B-MED
.	O
	
these	O
protective	B-MED
effects	I-MED
of	O
fir	B-MED
therapy	B-MED
were	O
not	B-MED
found	I-MED
in	O
plzf	B-MED
-	O
knockout	B-MED
mice	I-MED
.	O
	
our	O
data	B-MED
suggest	B-MED
that	O
fir	B-MED
-	O
induced	B-MED
plzf	B-MED
activation	B-MED
in	O
vascular	B-MED
endothelial	I-MED
cells	I-MED
protects	O
the	O
vascular	B-MED
endothelium	I-MED
in	O
diabetic	B-MED
mice	I-MED
from	O
age	B-MED
-	O
induced	B-MED
injury	B-MED
.	O
	
ultrasonic	B-MED
computed	I-MED
tomography	I-MED
imaging	I-MED
of	O
iron	B-MED
oxide	I-MED
nanoparticles	I-MED
iron	B-MED
oxide	I-MED
nanoparticles	I-MED
ionps	B-MED
are	O
becoming	O
increasingly	B-MED
used	O
and	O
intensively	B-MED
investigated	I-MED
in	O
the	O
field	B-MED
of	O
medical	B-MED
imaging	I-MED
.	O
	
they	O
are	O
currently	B-MED
fda	B-MED
approved	B-MED
for	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
mri	B-MED
,	O
and	O
it	O
would	O
be	O
highly	B-MED
desirable	O
to	O
visualize	B-MED
them	O
by	O
ultrasound	B-MED
as	O
well	O
.	O
	
previous	B-MED
reports	B-MED
using	O
the	O
conventional	B-MED
ultrasound	B-MED
b-scan	I-MED
pulse-echo	I-MED
imaging	I-MED
technique	I-MED
have	O
shown	O
very	O
limited	B-MED
detectability	B-MED
of	O
these	O
particles	B-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
is	O
to	O
explore	O
the	O
feasibility	B-MED
of	O
imaging	B-MED
ionps	B-MED
using	O
the	O
through-transmission	B-MED
ultrasound	I-MED
methodology	I-MED
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-MED
computed	I-MED
tomography	I-MED
uct	B-MED
.	O
	
commercially	O
available	O
ionps	B-MED
were	O
acoustically	B-MED
analysed	B-MED
to	O
quantify	B-MED
their	O
effect	B-MED
on	O
the	O
speed	B-MED
of	O
sound	B-MED
sos	B-MED
and	O
acoustic	B-MED
attenuation	B-MED
as	O
a	O
function	B-MED
of	O
concentration	B-MED
.	O
	
next	O
,	O
through-transmission	B-MED
projection	I-MED
and	O
uct	B-MED
imaging	I-MED
were	O
performed	B-MED
on	O
a	O
breast	B-MED
mimicking	O
phantom	O
and	O
on	O
an	O
ex	O
vivo	O
tissue	O
model	O
,	O
to	O
which	O
ionps	O
were	O
injected	O
.	O
	
finally	O
,	O
an	O
mri	O
scan	O
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	O
examined	O
in	O
the	O
ultrasound	O
experiment	O
can	O
be	O
imaged	O
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O
	
the	O
results	O
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
1.86	O
formula	O
see	O
text	O
rise	O
per	O
100	O
µg	O
ml	O
ionps	O
.	O
	
imaging	O
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast-to-noise	O
ratio	O
improvement	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
.	O
	
the	O
sos	O
-related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	O
contrast	O
and	O
allowed	O
the	O
detection	O
of	O
the	O
particles	O
existence	O
and	O
location	O
,	O
in	O
both	O
raster-scan	O
projection	O
and	O
uct	O
imaging	O
.	O
	
conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O
	
based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
ionps	O
can	O
be	O
used	O
as	O
an	O
effective	O
sos	O
-	O
based	O
contrast	O
agent	O
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	B-MED
imaging	O
.	O
	
furthermore	O
,	O
the	O
particle	O
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	O
mri	O
-	O
ultrasound	O
imaging	O
capabilities	B-MED
genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	I-MED
for	O
studying	O
long-term	B-MED
calcium	B-MED
dynamics	B-MED
during	O
apoptosis	B-MED
intracellular	B-MED
calcium	I-MED
release	I-MED
is	O
essential	B-MED
for	O
regulating	B-MED
almost	O
all	O
cellular	B-MED
functions	I-MED
.	O
	
specific	B-MED
spatio-temporal	B-MED
patterns	B-MED
of	O
cytosolic	B-MED
calcium	B-MED
elevations	B-MED
are	O
critical	B-MED
determinants	B-MED
of	O
cell	B-MED
fate	I-MED
in	O
response	O
to	O
pro-apoptotic	B-MED
cellular	B-MED
stressors	B-MED
.	O
	
as	O
the	O
apoptotic	B-MED
program	I-MED
can	O
take	O
hours	B-MED
or	O
days	B-MED
,	O
measurement	B-MED
of	O
long-term	B-MED
calcium	B-MED
dynamics	B-MED
are	O
essential	B-MED
for	O
understanding	B-MED
the	O
mechanistic	B-MED
role	B-MED
of	O
calcium	B-MED
in	O
apoptotic	B-MED
cell	I-MED
death	I-MED
.	O
	
due	O
to	O
the	O
technical	B-MED
limitations	B-MED
of	O
using	O
calcium	B-MED
-	O
sensitive	B-MED
dyes	B-MED
to	O
measure	B-MED
cytosolic	B-MED
calcium	B-MED
little	O
is	O
known	O
about	O
long-term	B-MED
calcium	B-MED
dynamics	B-MED
in	O
living	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
apoptosis	B-MED
-	O
inducing	B-MED
drugs	B-MED
.	O
	
genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	I-MED
could	O
potentially	O
overcome	B-MED
some	O
of	O
the	O
limitations	B-MED
of	O
calcium	B-MED
-	O
sensitive	B-MED
dyes	B-MED
.	O
	
here	O
,	O
we	O
compared	O
the	O
performance	B-MED
of	O
the	O
genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	B-MED
gcamp6s	B-MED
and	O
gcamp6f	B-MED
with	O
the	O
ratiometric	B-MED
dye	I-MED
fura-2	B-MED
.	O
	
gcamp6s	B-MED
performed	O
as	O
well	O
or	O
better	O
than	O
fura-2	B-MED
in	O
detecting	O
agonist	B-MED
-	O
induced	B-MED
calcium	B-MED
transients	B-MED
.	O
	
we	O
then	O
examined	O
the	O
utility	B-MED
of	O
gcamp6s	B-MED
for	O
continuously	B-MED
measuring	B-MED
apoptotic	B-MED
calcium	B-MED
release	I-MED
over	O
the	O
course	B-MED
of	O
ten	O
hours	B-MED
after	O
treatment	B-MED
with	O
staurosporine	B-MED
.	O
	
we	O
found	O
that	O
gcamp6s	B-MED
was	O
suitable	O
for	O
measuring	B-MED
apoptotic	B-MED
calcium	B-MED
release	I-MED
over	O
long	O
time	O
courses	B-MED
and	O
revealed	O
significant	B-MED
heterogeneity	B-MED
in	O
calcium	B-MED
release	I-MED
dynamics	B-MED
in	O
individual	O
cells	B-MED
challenged	O
with	O
staurosporine	B-MED
.	O
	
our	O
results	O
suggest	O
gcamp6s	B-MED
is	O
an	O
excellent	B-MED
indicator	B-MED
for	O
monitoring	B-MED
long-term	B-MED
changes	B-MED
cytosolic	B-MED
calcium	B-MED
during	O
staphylococcus	B-MED
pseudintermedius	I-MED
human	B-MED
infection	B-MED
cases	B-MED
in	O
spain	B-MED
dog	B-MED
-to-	O
human	B-MED
transmission	B-MED
staphylococcus	B-MED
pseudintermedius	I-MED
is	O
an	O
opportunistic	B-MED
pathogen	I-MED
that	O
has	O
been	O
identified	B-MED
as	O
infectious	B-MED
agent	I-MED
or	O
colonizer	B-MED
mainly	O
in	O
dogs	B-MED
.	O
	
s	B-MED
.	O
	
pseudintermedius	I-MED
has	O
been	O
also	O
detected	B-MED
in	O
humans	B-MED
and	O
more	O
specifically	O
in	O
people	B-MED
in	O
contact	B-MED
with	I-MED
dogs	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
the	O
possible	B-MED
s	B-MED
.	O
	
pseudintermedius	I-MED
pet	B-MED
-to-	O
human	B-MED
transmission	B-MED
was	O
analyzed	B-MED
in	O
four	O
clinical	B-MED
human	B-MED
cases	B-MED
.	O
	
two	O
patients	B-MED
were	O
dog	B-MED
owners	B-MED
and	O
s	B-MED
.	O
	
pseudintermedius	I-MED
was	O
also	O
detected	B-MED
as	O
colonizer	B-MED
in	O
these	O
healthy	B-MED
animals	B-MED
.	O
	
s	B-MED
.	O
	
pseudintermedius	I-MED
isolates	B-MED
from	O
patients	B-MED
and	O
dogs	B-MED
of	O
the	O
same	O
household	B-MED
showed	O
identical	B-MED
pulsed-field	B-MED
gel	I-MED
electrophoresis	I-MED
patterns	B-MED
,	O
sequence	B-MED
types	I-MED
sts	B-MED
,	O
and	O
antimicrobial	B-MED
resistance	I-MED
phenotypes	B-MED
and	I-MED
genotypes	I-MED
,	O
and	O
were	O
methicillin	B-MED
susceptible	I-MED
.	O
	
resistance	B-MED
to	O
erythromycin	B-MED
,	O
clindamycin	B-MED
,	O
tetracycline	B-MED
,	O
trimetoprim-sulfamethoxazole	B-MED
,	O
and/or	O
ciprofloxacin	B-MED
was	O
identified	B-MED
among	O
s	B-MED
.	O
	
pseudintermedius	I-MED
strains	B-MED
.	O
	
the	O
lineages	B-MED
st241	B-MED
and	O
the	O
new	O
st521	B-MED
were	O
detected	B-MED
in	O
the	O
strains	B-MED
of	O
the	O
two	O
dog	B-MED
-	O
owner	B-MED
patients	B-MED
,	O
respectively	O
.	O
	
the	O
strains	B-MED
from	O
the	O
other	B-MED
two	O
patients	B-MED
presented	B-MED
two	O
new	O
sts	B-MED
,	O
st719	B-MED
and	O
st720	B-MED
.	O
	
to	O
our	O
knowledge	B-MED
,	O
this	O
is	O
the	O
first	O
description	B-MED
of	O
human	B-MED
infections	B-MED
caused	O
by	O
s	B-MED
.	O
	
pseudintermedius	I-MED
in	O
tango	B-MED
-	O
a	O
screening	B-MED
tool	I-MED
to	O
identify	O
comorbidities	B-MED
on	O
the	O
causal	B-MED
pathway	I-MED
of	O
nocturia	B-MED
to	O
develop	O
a	O
robust	B-MED
screening	I-MED
metric	I-MED
for	O
use	O
in	O
identifying	O
non-lower	O
urinary	B-MED
tract	I-MED
comorbidities	B-MED
pertinent	O
to	O
the	O
multidisciplinary	B-MED
assessment	I-MED
of	O
patients	B-MED
with	O
nocturia	B-MED
.	O
	
variables	B-MED
having	O
a	O
significant	O
risk	O
association	B-MED
with	I-MED
nocturia	B-MED
of	O
greater	O
than	O
once	O
per	O
night	B-MED
were	O
identified	O
.	O
	
discriminating	B-MED
items	O
from	O
validated	O
and	O
reliable	O
tools	B-MED
measuring	O
these	O
comorbidities	B-MED
were	O
identified	O
.	O
	
a	O
self-completed	O
57-item	O
questionnaire	B-MED
was	O
developed	O
and	O
a	O
medical	B-MED
checklist	B-MED
and	O
pertinent	O
clinical	B-MED
measures	I-MED
added	O
.	O
	
pre-determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
short-form	B-MED
sf	B-MED
screening	B-MED
tool	I-MED
.	O
	
the	O
tool	B-MED
was	O
administered	O
to	O
252	O
individuals	B-MED
with	O
nocturia	B-MED
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
sleep	B-MED
,	O
continence	B-MED
,	O
falls	B-MED
or	O
rehabilitation	B-MED
service	I-MED
for	O
routine	B-MED
care	I-MED
.	O
	
data	B-MED
collected	I-MED
were	O
subjected	O
to	O
descriptive	B-MED
analysis	I-MED
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O
	
using	O
pre-determined	O
domains	O
,	O
a	O
nocturia	B-MED
screening	B-MED
metric	I-MED
,	O
entitled	O
tango	B-MED
,	O
was	O
generated	O
.	O
	
the	O
acronym	O
tango	B-MED
stands	O
for	O
targeting	B-MED
the	O
individual's	B-MED
aetiology	I-MED
of	O
nocturia	B-MED
to	O
guide	O
outcomes	O
.	O
	
the	O
demographic	B-MED
characteristics	I-MED
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O
	
the	O
statistical	B-MED
and	O
structural	B-MED
framework	I-MED
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
tango	B-MED
long-form	O
to	O
the	O
sf	B-MED
is	O
presented	O
.	O
	
the	O
resultant	O
tango	B-MED
-	O
sf	B-MED
patient	B-MED
-completed	O
nocturia	B-MED
screening	B-MED
tool	I-MED
is	O
reported	O
.	O
	
a	O
novel	O
all-cause	O
diagnostic	B-MED
metric	O
for	O
identifying	O
co-existing	O
morbidities	B-MED
of	O
clinical	B-MED
relevance	I-MED
to	O
nocturia	B-MED
in	O
patients	B-MED
who	O
present	O
across	O
disciplines	B-MED
and	O
medical	B-MED
specialties	I-MED
has	O
been	O
developed	O
.	O
	
tango	B-MED
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	B-MED
inequalities	I-MED
associated	B-MED
with	I-MED
a	O
siloed	O
approach	O
to	O
assessment	B-MED
and	O
subsequent	O
care	B-MED
of	O
patients	B-MED
with	O
probabilistic	B-MED
acute	B-MED
risk	B-MED
assessment	I-MED
of	O
cumulative	B-MED
exposure	I-MED
to	O
organophosphorus	B-MED
and	O
carbamate	B-MED
pesticides	I-MED
from	O
dietary	B-MED
vegetables	I-MED
and	O
fruits	B-MED
in	O
shanghai	B-MED
populations	B-MED
organophosphorus	B-MED
pesticides	I-MED
ops	B-MED
and	O
carbamate	B-MED
pesticides	I-MED
cps	B-MED
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	B-MED
in	O
china	B-MED
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	B-MED
agricultural	B-MED
commodities	I-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
determined	B-MED
the	O
cumulative	B-MED
acute	I-MED
exposure	I-MED
to	O
ops	B-MED
and	O
cps	B-MED
of	O
shanghai	B-MED
residents	B-MED
from	O
vegetables	B-MED
and	O
fruits	B-MED
vfs	B-MED
.	O
	
the	O
food	B-MED
consumption	I-MED
data	B-MED
were	O
obtained	B-MED
from	O
the	O
shanghai	B-MED
food	I-MED
consumption	I-MED
survey	I-MED
shfcs	B-MED
of	O
2012-14	O
including	O
a	O
total	O
of	O
1973	O
participants	B-MED
aged	B-MED
2-90	O
years	B-MED
.	O
	
the	O
pesticide	B-MED
residue	I-MED
data	B-MED
were	O
obtained	B-MED
from	O
the	O
shanghai	B-MED
monitoring	B-MED
programme	B-MED
during	O
2008-11	O
with	O
34	O
organophosphates	B-MED
and	O
11	O
carbamates	B-MED
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	B-MED
of	O
vfs	B-MED
.	O
	
a	O
probabilistic	B-MED
approach	O
was	O
performed	B-MED
as	O
recommended	B-MED
by	O
the	O
efsa	B-MED
,	O
using	O
the	O
optimistic	B-MED
model	I-MED
with	O
non-detects	O
set	O
as	O
zero	B-MED
and	O
with	O
processing	B-MED
factors	B-MED
pfs	B-MED
being	O
used	O
and	O
the	O
pessimistic	B-MED
model	I-MED
with	O
non-detects	O
replaced	B-MED
by	I-MED
limit	B-MED
of	I-MED
detection	I-MED
lod	B-MED
and	O
without	B-MED
pfs	B-MED
.	O
	
we	O
used	O
the	O
relative	B-MED
potency	I-MED
factor	I-MED
rpf	I-MED
method	I-MED
to	O
normalise	O
the	O
various	O
pesticides	B-MED
to	O
the	O
index	B-MED
compound	I-MED
ic	B-MED
of	O
methamidophos	B-MED
and	O
chlorpyrifos	B-MED
separately	B-MED
.	O
	
only	O
in	O
the	O
pessimistic	B-MED
model	I-MED
using	O
methamidophos	B-MED
as	O
the	O
ic	B-MED
was	O
there	O
was	O
small	O
risk	B-MED
of	O
exposure	B-MED
exceeding	O
the	O
arfd	B-MED
3	O
µg	O
kg	O
bw	O
day	B-MED
-	O
in	O
the	O
populations	B-MED
of	O
preschool	B-MED
children	I-MED
0.029	O
,	O
school-age	B-MED
children	I-MED
0.022	O
and	O
adults	B-MED
0.002	O
.	O
	
there	O
were	O
no	B-MED
risk	I-MED
of	O
exposure	B-MED
exceeding	O
the	O
arfd	B-MED
of	O
methamidophos	B-MED
in	O
the	O
optimistic	B-MED
model	I-MED
and	O
of	O
chlorpyrifos	B-MED
100	O
µg	O
kg	O
bw	O
day	B-MED
-	O
in	O
both	O
optimistic	B-MED
and	O
pessimistic	B-MED
models	I-MED
in	O
all	O
three	O
populations	B-MED
.	O
	
considering	O
the	O
chinese	B-MED
habits	I-MED
of	O
overwhelmingly	O
eating	B-MED
processed	B-MED
food	I-MED
vegetables	B-MED
being	O
cooked	B-MED
,	O
and	O
fruits	B-MED
being	O
washed	B-MED
or	O
peeled	B-MED
,	O
we	O
conclude	O
that	O
little	O
acute	B-MED
risk	B-MED
was	O
found	O
for	O
the	O
exposure	B-MED
to	I-MED
vf	B-MED
-	O
sourced	B-MED
ops	B-MED
and	O
cps	B-MED
in	O
modem	B-MED
a	O
comprehensive	B-MED
approach	B-MED
to	O
modelling	B-MED
outcome	B-MED
and	O
costs	B-MED
impacts	B-MED
of	O
interventions	B-MED
for	O
dementia	B-MED
.	O
	
protocol	B-MED
paper	B-MED
the	O
modem	B-MED
project	I-MED
a	O
comprehensive	B-MED
approach	B-MED
to	O
modelling	B-MED
outcome	B-MED
and	O
costs	B-MED
impacts	B-MED
of	O
interventions	B-MED
for	O
dementia	B-MED
explores	O
how	O
changes	B-MED
in	O
arrangements	O
for	O
the	O
future	B-MED
treatment	B-MED
and	O
care	B-MED
of	O
people	B-MED
living	O
with	O
dementia	B-MED
,	O
and	O
support	B-MED
for	O
family	B-MED
and	O
other	O
unpaid	B-MED
carers	B-MED
,	O
could	O
result	B-MED
in	O
better	O
outcomes	B-MED
and	O
more	O
efficient	B-MED
use	B-MED
of	I-MED
resources	B-MED
.	O
	
modem	B-MED
starts	O
with	O
a	O
systematic	B-MED
mapping	B-MED
of	O
the	O
literature	B-MED
on	O
effective	B-MED
and	O
potentially	O
cost	B-MED
-	O
effective	B-MED
interventions	B-MED
in	O
dementia	B-MED
care	B-MED
.	O
	
those	O
findings	B-MED
,	O
as	O
well	O
as	O
data	B-MED
from	O
a	O
cohort	B-MED
,	O
will	O
then	O
be	O
used	O
to	O
model	B-MED
the	O
quality	B-MED
of	I-MED
life	I-MED
and	O
cost	B-MED
impacts	B-MED
of	O
making	O
these	O
evidence	B-MED
-based	O
interventions	B-MED
more	O
widely	O
available	B-MED
in	O
england	B-MED
over	O
the	O
period	B-MED
from	O
now	O
to	O
2040	O
.	O
	
modelling	B-MED
will	O
use	O
a	O
suite	O
of	O
models	B-MED
,	O
combining	B-MED
microsimulation	B-MED
and	O
macrosimulation	B-MED
methods	I-MED
,	O
modelling	B-MED
the	O
costs	B-MED
and	O
outcomes	B-MED
of	O
care	B-MED
,	O
both	O
for	O
an	O
individual	B-MED
over	O
the	O
life-course	B-MED
from	O
the	O
point	O
of	O
dementia	B-MED
diagnosis	I-MED
,	O
and	O
for	O
individuals	B-MED
and	O
england	B-MED
as	O
a	O
whole	B-MED
in	O
a	O
particular	O
year	O
.	O
	
project	B-MED
outputs	O
will	O
include	O
an	O
online	B-MED
dementia	B-MED
evidence	I-MED
toolkit	I-MED
,	O
making	O
evidence	B-MED
summaries	B-MED
and	O
a	O
literature	B-MED
database	B-MED
available	B-MED
free	O
to	O
anyone	O
,	O
papers	B-MED
in	O
academic	B-MED
journals	I-MED
and	O
other	O
written	O
outputs	O
,	O
and	O
a	O
modem	B-MED
legacy	I-MED
model	I-MED
,	O
which	O
will	O
enable	O
local	B-MED
commissioners	I-MED
of	O
services	B-MED
to	O
apply	O
the	O
model	B-MED
to	O
their	O
own	O
populations	B-MED
.	O
	
modelling	B-MED
the	O
effects	B-MED
of	I-MED
evidence	B-MED
-based	O
cost	B-MED
-	O
effective	B-MED
interventions	B-MED
and	O
making	O
this	O
information	B-MED
widely	O
available	B-MED
has	O
the	O
potential	B-MED
to	O
improve	B-MED
the	O
health	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
both	O
of	O
people	B-MED
with	O
dementia	B-MED
and	O
their	O
carers	B-MED
,	O
while	O
ensuring	O
that	O
resources	B-MED
assessment	B-MED
of	O
neuroanatomical	B-MED
and	O
behavioural	B-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
methylmercury	B-MED
exposure	B-MED
in	O
zebra	B-MED
finches	I-MED
taeniopygia	B-MED
guttata	I-MED
methylmercury	B-MED
mehg	B-MED
readily	O
crosses	B-MED
the	O
blood	B-MED
brain	I-MED
barrier	I-MED
and	O
is	O
a	O
known	B-MED
neuro	B-MED
-	O
toxicant	B-MED
.	O
	
mehg	B-MED
accumulation	B-MED
in	O
the	O
brain	B-MED
causes	B-MED
histopathological	B-MED
alterations	B-MED
,	O
neurobehavioral	B-MED
changes	B-MED
,	O
and	O
impairments	B-MED
to	O
cognitive	B-MED
motor	B-MED
functions	I-MED
in	O
mammalian	B-MED
models	B-MED
.	O
	
however	O
,	O
in	O
birds	B-MED
the	O
neurotoxic	B-MED
effects	I-MED
of	O
mehg	B-MED
on	O
the	O
developing	O
pre	B-MED
-	O
hatching	B-MED
brain	B-MED
and	O
consequent	B-MED
behavioral	B-MED
alterations	I-MED
in	O
adult	B-MED
birds	B-MED
have	O
not	B-MED
received	B-MED
much	O
attention	B-MED
.	O
	
moreover	O
,	O
passerine	B-MED
birds	I-MED
are	O
poorly	B-MED
represented	B-MED
in	O
mehg	B-MED
neurotoxicology	B-MED
studies	B-MED
in	O
comparison	B-MED
to	O
other	O
avian	B-MED
orders	B-MED
.	O
	
hence	O
in	O
this	O
study	B-MED
,	O
we	O
used	B-MED
the	O
egg	B-MED
injection	B-MED
method	I-MED
to	O
investigate	B-MED
the	O
long	B-MED
term	I-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
mehg	B-MED
exposure	B-MED
on	O
brain	B-MED
histopathology	B-MED
and	O
courtship	B-MED
behavior	I-MED
in	O
a	O
model	B-MED
songbird	B-MED
species	B-MED
,	O
the	O
zebra	B-MED
finch	I-MED
taeniopygia	B-MED
guttata	I-MED
.	O
	
egg	B-MED
treatment	B-MED
groups	B-MED
included	B-MED
a	O
low	B-MED
mehg	B-MED
dose	B-MED
of	O
0.2μg	O
hg	B-MED
g	O
egg	B-MED
,	O
a	O
high	B-MED
mehg	B-MED
dose	B-MED
of	O
3.2μg	O
hg	B-MED
g	O
egg	B-MED
,	O
and	O
a	O
vehicle	B-MED
control	I-MED
water	B-MED
.	O
	
no	B-MED
adverse	I-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
mehg	B-MED
treatment	B-MED
were	O
detected	B-MED
on	O
courtship	B-MED
song	O
quality	O
or	O
on	O
mating	O
behavior	O
in	O
experimental	O
males	O
at	O
sexually	O
maturity	O
which	O
would	O
suggest	O
that	O
observable	O
neurobehavioral	O
effects	O
of	O
mehg	O
exposure	O
may	O
depend	O
on	O
the	O
timing	O
of	O
exposure	O
during	O
offspring	O
development	O
.	O
	
however	O
,	O
neuroanatomical	O
analysis	O
indicated	O
an	O
increase	O
in	O
telencephalon	O
volume	O
with	O
increased	O
mehg	O
concentrations	O
which	O
may	O
suggest	O
a	O
prolonged	O
inflammatory	O
response	O
in	O
this	O
region	O
of	O
the	O
brain	I-MED
evaluation	B-MED
of	O
the	O
condom	B-MED
barriers	I-MED
scale	I-MED
for	O
young	B-MED
black	B-MED
men	I-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
reliability	B-MED
and	I-MED
validity	I-MED
of	O
3	O
subscales	B-MED
reliable	B-MED
and	O
valid	B-MED
scale	B-MED
measures	B-MED
of	O
barriers	B-MED
to	O
condom	B-MED
use	I-MED
are	O
not	O
available	O
for	O
young	B-MED
black	B-MED
men	I-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
ybmsm	B-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
condom	B-MED
barriers	I-MED
scales	I-MED
for	O
application	O
with	O
ybmsm	B-MED
.	O
	
a	O
clinic-based	B-MED
sample	B-MED
of	O
600	O
ybmsm	B-MED
completed	O
a	O
computer-assisted	B-MED
self-interview	B-MED
.	O
	
the	O
primary	O
measure	B-MED
was	O
a	O
14-item	O
abbreviated	B-MED
version	I-MED
of	O
the	O
condom	B-MED
barriers	I-MED
scale	I-MED
.	O
	
reliability	B-MED
and	O
criterion	B-MED
validity	I-MED
were	O
assessed	O
.	O
	
all	O
3	O
subscales	B-MED
were	O
reliable	B-MED
partner	B-MED
-related	O
barriers	B-MED
cronbach	B-MED
α	I-MED
=0	O
,	O
sensation	B-MED
-related	O
barriers	B-MED
α=0	O
,	O
and	O
motivation	B-MED
-related	O
barriers	B-MED
α	O
=0	O
.	O
	
a	O
complete	B-MED
absence	I-MED
of	I-MED
barriers	I-MED
was	O
common	O
47.0	O
partner	B-MED
-related	O
,	O
30.7	O
sensation	B-MED
-related	O
,	O
and	O
46.5	O
motivation	B-MED
-related	O
.	O
	
dichotomized	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
reporting	O
any	O
condomless	B-MED
insertive	B-MED
anal	B-MED
sex	I-MED
all	O
ps	B-MED
<	O
0.001	O
and	O
any	O
condomless	B-MED
receptive	B-MED
anal	B-MED
sex	I-MED
all	O
ps	B-MED
<	O
0.001	O
.	O
	
the	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
these	O
measures	B-MED
of	O
condomless	B-MED
sex	B-MED
preserved	O
at	O
a	O
continuous	B-MED
level	B-MED
all	O
ps	B-MED
<0	O
,	O
except	O
for	O
sensation	B-MED
barriers	B-MED
associated	B-MED
with	I-MED
condomless	B-MED
receptive	O
anal	B-MED
sex	I-MED
=	O
0.03	O
.	O
	
further	O
,	O
the	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
reporting	O
any	O
condom	B-MED
use	I-MED
problems	B-MED
all	O
ps	B-MED
<0	O
and	O
a	O
measure	B-MED
of	O
condomless	B-MED
oral	B-MED
sex	I-MED
all	O
ps	B-MED
<0	O
,	O
except	O
for	O
partner	B-MED
-related	O
barriers	B-MED
=0	O
.	O
	
finally	O
,	O
the	O
sensation	B-MED
-related	O
barriers	B-MED
subscale	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
testing	O
positive	B-MED
for	O
chlamydia	B-MED
and/or	O
gonorrhea	B-MED
p=0	O
.	O
	
the	O
3	O
identified	O
subscales	B-MED
yielded	O
adequate	O
reliability	B-MED
and	O
strong	O
evidence	O
of	O
validity	B-MED
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	B-MED
for	O
use	O
in	O
observational	B-MED
and	O
experimental	B-MED
research	I-MED
with	O
variation	B-MED
in	O
the	O
intensity	B-MED
of	O
selection	B-MED
on	O
codon	B-MED
bias	B-MED
over	O
time	B-MED
causes	O
contrasting	B-MED
patterns	I-MED
of	O
base	B-MED
composition	I-MED
evolution	B-MED
in	O
drosophila	B-MED
four-fold	O
degenerate	B-MED
coding	B-MED
sites	I-MED
form	O
a	O
major	O
component	O
of	O
the	O
genome	B-MED
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	B-MED
and	O
demography	B-MED
,	O
so	O
that	O
understanding	O
their	O
evolution	B-MED
is	O
important	O
.	O
	
despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	B-MED
composition	I-MED
changes	B-MED
at	O
these	O
sites	B-MED
in	O
drosophila	B-MED
remain	O
unanswered	O
.	O
	
to	O
shed	O
further	O
light	O
on	O
this	O
issue	B-MED
,	O
we	O
obtained	O
a	O
new	O
whole-genome	B-MED
polymorphism	I-MED
data	I-MED
set	I-MED
from	O
d	B-MED
.	O
	
simulans	I-MED
.	O
	
we	O
analyzed	B-MED
samples	B-MED
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
d	B-MED
.	O
	
simulans	I-MED
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	B-MED
data	I-MED
set	I-MED
from	O
an	O
african	O
population	O
of	O
d	B-MED
.	O
	
melanogaster	I-MED
.	O
	
by	O
using	O
d	B-MED
.	O
	
yakuba	I-MED
as	O
an	O
outgroup	B-MED
,	O
we	O
found	O
clear	O
evidence	B-MED
for	O
selection	B-MED
on	O
4-fold	O
sites	B-MED
along	O
both	O
lineages	B-MED
over	O
a	O
substantial	B-MED
period	I-MED
,	O
with	O
the	O
intensity	B-MED
of	O
selection	B-MED
increasing	O
with	O
gc	B-MED
content	I-MED
.	O
	
based	O
on	O
an	O
explicit	O
model	B-MED
of	O
base	B-MED
composition	I-MED
evolution	B-MED
,	O
we	O
suggest	O
that	O
the	O
observed	B-MED
at-	O
biased	B-MED
substitution	B-MED
pattern	I-MED
in	O
both	O
lineages	B-MED
is	O
probably	O
due	O
to	O
an	O
ancestral	B-MED
reduction	I-MED
in	O
selection	B-MED
intensity	B-MED
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	B-MED
of	O
an	O
increase	B-MED
in	O
mutational	B-MED
bias	B-MED
towards	O
at	O
alone	O
.	O
	
by	O
using	O
two	O
polymorphism-based	B-MED
methods	I-MED
for	O
estimating	B-MED
selection	B-MED
coefficients	B-MED
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	B-MED
intensity	B-MED
on	O
codon	B-MED
usage	O
has	O
been	O
rather	O
stable	B-MED
in	O
d	B-MED
.	O
	
simulans	I-MED
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long-term	B-MED
estimates	B-MED
in	O
d	B-MED
.	O
	
melanogaster	I-MED
are	O
much	O
higher	B-MED
than	O
the	O
short-term	B-MED
ones	O
,	O
indicating	O
a	O
continuing	B-MED
decline	B-MED
in	O
selection	B-MED
intensity	B-MED
,	O
to	O
such	O
an	O
extent	B-MED
that	O
the	O
short-term	B-MED
estimates	B-MED
suggest	O
that	O
selection	B-MED
is	O
only	O
active	B-MED
in	O
the	O
most	O
gc	B-MED
-rich	O
parts	O
of	O
the	O
genome	B-MED
.	O
	
finally	O
,	O
we	O
provide	O
evidence	B-MED
for	O
complex	B-MED
evolutionary	B-MED
patterns	I-MED
in	O
the	O
putatively	O
neutral	B-MED
short	I-MED
introns	I-MED
,	O
which	O
cannot	O
be	O
explained	O
by	O
the	O
standard	B-MED
gc	B-MED
-	O
biased	B-MED
gene	B-MED
conversion	I-MED
model	B-MED
.	O
	
these	O
results	B-MED
reveal	O
a	O
dynamic	B-MED
picture	O
of	O
base	B-MED
composition	I-MED
evolution	B-MED
.	O
	
a	O
case	B-MED
of	O
koch's	B-MED
spine	I-MED
treated	B-MED
with	O
modified	B-MED
transpedicular	B-MED
vertebral	I-MED
curettage	I-MED
and	O
posterior	B-MED
fixation	B-MED
a	O
novel	O
technique	B-MED
tuberculosis	B-MED
tb	B-MED
is	O
a	O
chronic	B-MED
granulomatous	B-MED
infection	I-MED
caused	O
by	O
acid-fast	B-MED
mycobacterium	I-MED
tuberculosis	I-MED
bacilli	I-MED
.	O
	
spinal	B-MED
involvement	I-MED
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
tb	B-MED
.	O
	
spinal	B-MED
tb	I-MED
pott's	B-MED
disease	I-MED
accounts	O
for	O
50%	O
of	O
skeletal	B-MED
tb	I-MED
.	O
	
though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	B-MED
junction	I-MED
,	O
it	O
can	O
occur	O
at	O
any	O
level	B-MED
of	O
the	O
spine	B-MED
.	O
	
early	O
diagnosis	B-MED
and	O
treatment	B-MED
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	B-MED
complications	I-MED
and	O
spinal	B-MED
deformity	I-MED
.	O
	
we	O
report	B-MED
a	O
case	B-MED
of	O
a	O
young	B-MED
female	B-MED
with	O
tuberculosis	B-MED
of	O
d12-l1	B-MED
who	O
was	O
treated	B-MED
with	O
posterior	B-MED
decompression	B-MED
using	O
a	O
modified	B-MED
transpedicular	B-MED
approach	I-MED
and	O
posterior	B-MED
instrumentation	B-MED
with	O
a	O
successful	O
a	O
comparison	B-MED
of	O
two	O
comorbidity	B-MED
indices	I-MED
for	O
predicting	B-MED
inpatient	B-MED
rehabilitation	B-MED
outcomes	B-MED
comorbid	B-MED
conditions	I-MED
are	O
important	O
in	O
health	B-MED
care	I-MED
.	O
	
the	O
best	O
comorbidity	B-MED
index	I-MED
for	O
predicting	B-MED
the	O
impact	B-MED
of	O
comorbidities	B-MED
on	O
rehabilitation	B-MED
outcomes	B-MED
has	O
not	O
been	O
determined	B-MED
.	O
	
compare	B-MED
the	O
associations	B-MED
of	O
comorbidity	B-MED
measured	B-MED
using	O
the	O
charlson	B-MED
comorbidity	I-MED
index	I-MED
cci	B-MED
and	O
the	O
cumulative	B-MED
index	I-MED
rating	I-MED
scale	I-MED
cirs	B-MED
with	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
	
aim	O
was	O
to	O
determine	B-MED
whether	O
either	O
of	O
these	O
comorbidity	B-MED
indices	I-MED
helped	O
explain	O
the	O
variation	B-MED
in	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
	
prospective	B-MED
open-cohort	I-MED
study	I-MED
.	O
	
inpatient	B-MED
rehabilitation	B-MED
ward	B-MED
,	O
melbourne	B-MED
,	O
australia	B-MED
.	O
	
adults	B-MED
admitted	B-MED
for	O
inpatient	B-MED
rehabilitation	B-MED
n=280	O
.	O
	
the	O
main	O
outcomes	B-MED
were	O
demographic	B-MED
e.g	O
.	O
	
age	B-MED
,	O
gender	B-MED
,	O
discharge	B-MED
destination	B-MED
and	O
clinical	B-MED
outcomes	B-MED
reason	B-MED
for	O
rehabilitation	B-MED
,	O
length	B-MED
of	I-MED
stay	I-MED
,	O
functional	B-MED
independence	I-MED
measure	I-MED
,	O
cci	B-MED
and	O
cirs	B-MED
.	O
	
a	O
series	O
of	O
regression	B-MED
analyses	I-MED
were	O
performed	B-MED
to	O
determine	B-MED
the	O
influence	B-MED
of	O
comorbidity	B-MED
on	O
three	O
dependent	B-MED
variables	I-MED
los	B-MED
in	O
rehabilitation	B-MED
2	O
the	O
change	B-MED
in	O
functional	B-MED
independence	I-MED
measure-motor	I-MED
score	B-MED
between	O
rehabilitation	B-MED
discharge	B-MED
and	O
admission	B-MED
and	O
3	O
the	O
discharge	B-MED
destination	B-MED
home	B-MED
vs	O
other	O
.	O
	
the	O
mean	B-MED
age	B-MED
was	O
57.7	O
years	B-MED
,	O
there	O
were	O
slightly	O
more	O
females	B-MED
51%	O
,	O
most	O
95%	O
patients	B-MED
previously	B-MED
lived	B-MED
at	I-MED
home	I-MED
with	O
family	B-MED
or	O
other	O
relatives	B-MED
63%	O
.	O
	
the	O
most	O
common	O
reason	B-MED
for	O
rehabilitation	B-MED
was	O
orthopaedic	B-MED
or	O
other	O
conditions	B-MED
52%	O
and	O
most	O
80%	O
people	B-MED
were	O
discharged	B-MED
home	B-MED
.	O
	
the	O
median	O
los	B-MED
was	O
27	O
days	B-MED
.	O
	
there	O
were	O
100	O
35.7	O
patients	B-MED
who	O
had	O
no	O
comorbidity	B-MED
recorded	B-MED
using	O
the	O
cci	B-MED
,	O
112	O
40.0	O
and	O
26	O
9.3	O
who	O
three	O
or	O
more	O
.	O
	
all	O
patients	B-MED
had	O
at	O
least	O
one	O
comorbidity	B-MED
recorded	B-MED
with	O
the	O
cirs	B-MED
,	O
and	O
264	O
94.3	O
had	O
3	O
or	O
more	O
comorbidities	B-MED
.	O
	
there	O
was	O
little	O
or	O
no	O
difference	B-MED
between	O
the	O
cci	B-MED
or	O
cirs	B-MED
in	O
terms	O
of	O
their	O
ability	B-MED
to	O
explain	O
the	O
variance	B-MED
in	O
los	B-MED
adjusted	O
r2	B-MED
=0	O
with	O
and	O
without	O
comorbidities	B-MED
,	O
change	B-MED
in	O
disability	B-MED
during	O
rehabilitation	B-MED
adjusted	O
r2	B-MED
=0	O
-	O
0.33	O
with	O
and	O
without	O
comorbidities	B-MED
or	O
the	O
discharge	B-MED
destination	B-MED
auc=0	O
without	O
comorbidities	B-MED
0.73	O
-	O
0.74	O
with	O
comorbidities	B-MED
beyond	O
that	O
accounted	O
for	O
by	O
demographic	B-MED
and	O
clinical	B-MED
information	I-MED
.	O
	
neither	O
the	O
cirs	B-MED
nor	O
the	O
cci	B-MED
in	O
our	O
patient	B-MED
sample	B-MED
provide	B-MED
additional	O
information	B-MED
that	O
explains	O
the	O
impact	B-MED
of	O
comorbidities	B-MED
on	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
	
further	O
research	B-MED
is	O
needed	O
to	O
determine	B-MED
the	O
most	O
appropriate	B-MED
measure	B-MED
of	O
comorbidity	B-MED
of	O
relevance	B-MED
to	O
inpatient	B-MED
rehabilitation	B-MED
outcomes	B-MED
.	O
	
internet	B-MED
gaming	I-MED
disorder	B-MED
explains	O
unique	B-MED
variance	I-MED
in	O
psychological	B-MED
distress	I-MED
and	O
disability	B-MED
after	O
controlling	O
for	O
comorbid	B-MED
depression	B-MED
,	O
ocd	B-MED
,	O
adhd	B-MED
,	O
and	O
anxiety	B-MED
this	O
study	B-MED
extends	O
knowledge	B-MED
about	O
the	O
relationship	B-MED
of	O
internet	B-MED
gaming	I-MED
disorder	I-MED
igd	B-MED
to	O
other	O
established	O
mental	B-MED
disorders	I-MED
by	O
exploring	O
comorbidities	B-MED
with	O
anxiety	B-MED
,	O
depression	B-MED
,	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
adhd	B-MED
,	O
and	O
obsessive	B-MED
compulsive	I-MED
disorder	I-MED
ocd	B-MED
,	O
and	O
assessing	B-MED
whether	O
igd	B-MED
accounts	O
for	O
unique	B-MED
variance	I-MED
in	O
distress	B-MED
and	O
disability	B-MED
.	O
	
an	O
online	B-MED
survey	I-MED
was	O
completed	O
by	O
a	O
convenience	B-MED
sample	I-MED
that	O
engages	O
in	O
internet	B-MED
gaming	I-MED
n	O
=	O
404	O
.	O
	
participants	B-MED
meeting	B-MED
criteria	I-MED
for	O
igd	B-MED
based	O
on	O
the	O
personal	B-MED
internet	I-MED
gaming	I-MED
disorder	I-MED
evaluation-9	I-MED
pie-9	B-MED
reported	O
higher	B-MED
comorbidity	I-MED
with	O
depression	B-MED
,	O
ocd	B-MED
,	O
adhd	B-MED
,	O
and	O
anxiety	B-MED
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
igd	B-MED
criteria	B-MED
.	O
	
igd	B-MED
explained	O
a	O
small	O
proportion	B-MED
of	O
unique	B-MED
variance	I-MED
in	O
distress	B-MED
1%	O
and	O
disability	B-MED
3%	O
.	O
	
igd	B-MED
accounted	O
for	O
a	O
larger	B-MED
proportion	I-MED
of	O
unique	B-MED
variance	I-MED
in	O
disability	B-MED
than	O
anxiety	B-MED
and	O
adhd	B-MED
,	O
and	O
a	O
similar	O
proportion	B-MED
to	O
depression	B-MED
.	O
	
replications	B-MED
with	O
clinical	B-MED
samples	I-MED
using	O
longitudinal	B-MED
designs	I-MED
and	O
structured	B-MED
diagnostic	I-MED
interviews	I-MED
what	O
is	O
the	O
real	B-MED
impact	B-MED
of	O
urinary	B-MED
incontinence	I-MED
on	O
female	B-MED
sexual	I-MED
dysfunction	I-MED
a	O
case	B-MED
control	I-MED
study	I-MED
urinary	B-MED
incontinence	I-MED
ui	B-MED
has	O
been	O
associated	B-MED
with	I-MED
negative	B-MED
effects	B-MED
on	O
women's	B-MED
sexuality	B-MED
.	O
	
women's	B-MED
sexuality	B-MED
and	O
sexual	B-MED
function	I-MED
are	O
a	O
complex	B-MED
issue	B-MED
,	O
and	O
the	O
role	B-MED
of	O
ui	B-MED
is	O
not	B-MED
completely	I-MED
clear	O
.	O
	
to	O
assess	B-MED
the	O
impact	B-MED
of	O
ui	B-MED
on	O
female	B-MED
sexual	I-MED
function	I-MED
by	O
comparing	B-MED
this	O
population	B-MED
with	O
a	O
control	B-MED
group	I-MED
of	O
continent	B-MED
women	B-MED
.	O
	
we	O
performed	O
a	O
case-control	B-MED
study	I-MED
from	O
august	O
2012	O
to	O
september	O
2013	O
.	O
	
we	O
evaluated	B-MED
continent	B-MED
and	O
incontinent	B-MED
women	B-MED
age	B-MED
range	B-MED
=	O
30-70	O
years	O
for	O
their	O
sexuality	B-MED
.	O
	
all	O
patients	B-MED
were	O
evaluated	B-MED
by	O
anamnesis	B-MED
,	O
physical	B-MED
examination	I-MED
,	O
and	O
self-report	B-MED
quality-of-life	B-MED
questionnaires	I-MED
.	O
	
in	O
addition	O
,	O
incontinent	B-MED
women	B-MED
underwent	O
a	O
1-hour	O
pad	B-MED
test	I-MED
.	O
	
patients	B-MED
without	O
sexual	B-MED
activity	I-MED
were	O
evaluated	B-MED
for	O
the	O
role	B-MED
of	O
ui	B-MED
in	O
their	O
sexual	B-MED
abstinence	I-MED
.	O
	
sexual	B-MED
abstinence	I-MED
was	O
defined	O
as	O
the	O
absence	B-MED
of	I-MED
sexual	I-MED
activity	I-MED
for	O
more	O
than	O
6	O
months	O
.	O
	
all	O
sexually	B-MED
active	I-MED
women	B-MED
completed	O
the	O
self-report	B-MED
sexuality	B-MED
quotient	B-MED
-	O
female	B-MED
version	B-MED
sq-f	O
questionnaire	B-MED
.	O
	
a	O
total	O
of	O
356	O
women	B-MED
were	O
included	O
in	O
the	O
study	B-MED
incontinent	B-MED
,	O
n	O
=	O
243	O
continent	B-MED
,	O
n	O
=	O
113	O
.	O
	
sexual	B-MED
abstinence	I-MED
was	O
found	O
in	O
162	O
women	B-MED
45%	O
.	O
	
incontinent	B-MED
women	B-MED
presented	O
a	O
higher	B-MED
prevalence	I-MED
p	O
<	O
001	O
of	O
sexual	B-MED
abstinence	I-MED
than	O
their	O
counterparts	B-MED
129	O
53%	O
and	O
33	O
29.2	O
,	O
respectively	O
.	O
	
age	B-MED
,	O
marital	B-MED
status	I-MED
,	O
and	O
ui	B-MED
were	O
found	O
to	O
be	O
isolated	B-MED
predictive	B-MED
factors	I-MED
for	O
more	O
sexual	B-MED
abstinence	I-MED
in	O
incontinent	B-MED
women	B-MED
.	O
	
sexually	B-MED
active	I-MED
women	B-MED
incontinent	B-MED
,	O
n	O
=	O
114	O
continent	B-MED
,	O
n	O
=	O
80	O
presented	O
similar	O
demographic	B-MED
data	B-MED
.	O
	
despite	O
a	O
similar	O
frequency	B-MED
of	O
sexual	B-MED
activity	I-MED
,	O
incontinent	B-MED
women	B-MED
had	O
less	O
sexual	B-MED
desire	I-MED
,	O
foreplay	B-MED
,	O
harmony	B-MED
with	O
a	O
partner	B-MED
,	O
sexual	B-MED
comfort	I-MED
,	O
and	O
sexual	B-MED
satisfaction	I-MED
than	O
their	O
counterparts	O
.	O
	
women	B-MED
with	O
greater	B-MED
urinary	B-MED
leakage	I-MED
during	O
the	O
1-hour	O
pad	B-MED
test	I-MED
weight	B-MED
>	O
11	O
g	O
had	O
the	O
worst	O
sexual	B-MED
function	I-MED
sq-f	O
score	B-MED
.	O
	
women	B-MED
with	O
ui	B-MED
were	O
more	O
likely	O
to	O
be	O
sexual	B-MED
abstinent	I-MED
than	O
continent	B-MED
women	B-MED
.	O
	
furthermore	O
,	O
women	B-MED
with	O
ui	B-MED
showed	O
less	O
sexual	B-MED
desire	I-MED
,	O
sexual	B-MED
comfort	I-MED
,	O
and	O
sexual	B-MED
satisfaction	I-MED
than	O
their	O
counterparts	B-MED
despite	O
having	O
a	O
similar	O
frequency	B-MED
of	O
sexual	B-MED
activity	I-MED
.	O
	
salvianolic	B-MED
acids	I-MED
for	O
injection	B-MED
safi	B-MED
suppresses	B-MED
inflammatory	B-MED
responses	I-MED
in	O
activated	B-MED
microglia	B-MED
to	O
attenuate	B-MED
brain	B-MED
damage	I-MED
in	O
focal	B-MED
cerebral	I-MED
ischemia	I-MED
inflammatory	B-MED
reactions	I-MED
induced	O
by	O
microglia	B-MED
in	O
the	O
brain	B-MED
play	O
crucial	O
roles	B-MED
in	O
ischemia	B-MED
/	O
reperfusion	B-MED
i/r	I-MED
cerebral	I-MED
injuries	I-MED
.	O
	
microglia	B-MED
activation	B-MED
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
tlr4	B-MED
/	O
nf-κb	B-MED
signal	I-MED
pathways	I-MED
.	O
	
salvianolic	B-MED
acids	I-MED
for	O
injection	B-MED
safi	B-MED
have	O
been	O
used	O
in	O
clinical	B-MED
practice	I-MED
to	O
treat	B-MED
ischemic	B-MED
stroke	I-MED
with	O
reported	B-MED
neuroprotective	B-MED
effects	I-MED
however	O
,	O
the	O
underlying	O
mechanisms	B-MED
are	O
still	O
uncertain	O
.	O
	
first	O
,	O
we	O
studied	B-MED
the	O
effect	B-MED
of	O
safi	B-MED
on	O
inflammatory	B-MED
responses	I-MED
in	O
lps	B-MED
-	O
stimulated	B-MED
bv-2	B-MED
microglia	B-MED
.	O
	
then	O
,	O
to	O
discover	B-MED
whether	O
the	O
beneficial	B-MED
in	B-MED
vitro	I-MED
effects	B-MED
of	O
safi	B-MED
lead	O
to	O
in	B-MED
vivo	I-MED
therapeutic	B-MED
effect	I-MED
s	O
,	O
an	O
mcao	B-MED
middle	B-MED
cerebral	I-MED
artery	I-MED
occlusion	I-MED
rat	B-MED
model	B-MED
was	O
further	O
employed	B-MED
to	O
elucidate	O
the	O
probable	O
mechanism	B-MED
of	O
safi	B-MED
in	O
treating	B-MED
ischemic	B-MED
stroke	I-MED
.	O
	
rats	B-MED
in	O
the	O
safi	B-MED
group	B-MED
were	O
given	O
safi	B-MED
23	O
or	O
46mg/kg	O
before	O
i	B-MED
/	O
r	B-MED
injury	I-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
safi	B-MED
treatment	B-MED
significantly	B-MED
decreased	I-MED
neuroinflammation	B-MED
and	O
the	O
infarction	B-MED
volume	B-MED
compared	O
with	O
the	O
vehicle	B-MED
group	B-MED
.	O
	
activation	B-MED
of	O
microglia	B-MED
cells	I-MED
was	O
reduced	B-MED
,	O
and	O
tlr4	B-MED
/	O
nf-κb	B-MED
signals	I-MED
,	O
which	O
were	O
markedly	O
inhibited	B-MED
by	O
safi	B-MED
treatment	B-MED
in	O
ischemic	B-MED
hemisphere	B-MED
,	O
were	O
accompanied	O
by	O
reduced	B-MED
expression	B-MED
and	O
release	B-MED
of	O
cytokines	B-MED
il-1β	B-MED
and	O
il-6	B-MED
.	O
	
this	O
study	B-MED
provides	O
evidence	B-MED
that	O
safi	B-MED
effectively	B-MED
protects	O
the	O
brain	B-MED
after	O
cerebral	B-MED
ischemia	I-MED
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	B-MED
inflammation	B-MED
in	O
dynamics	B-MED
of	O
bacterial	B-MED
class	B-MED
bacilli	I-MED
in	O
the	O
deepest	B-MED
valley	I-MED
lake	I-MED
of	O
kashmir	B-MED
-the	O
manasbal	B-MED
lake	I-MED
in	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-MED
as	O
ecological	B-MED
indicators	I-MED
of	O
the	O
aquatic	B-MED
systems	I-MED
a	O
comprehensive	B-MED
and	I-MED
systematic	I-MED
analysis	I-MED
was	O
carried	O
out	O
on	O
manasbal	B-MED
lake	I-MED
,	O
the	O
deepest	B-MED
spring	I-MED
fed	I-MED
valley	I-MED
lake	I-MED
of	O
kashmir	B-MED
.	O
	
the	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	B-MED
bacterial	B-MED
community	I-MED
composition	I-MED
bcc	B-MED
and	O
for	O
this	O
purpose	O
systematic	B-MED
and	O
regular	B-MED
sampling	I-MED
of	I-MED
waters	I-MED
from	O
ten	O
different	O
sampling	O
stations	O
,	O
predetermined	O
in	O
the	O
lake	O
according	O
to	O
differences	O
in	O
degree	O
of	O
human	O
interference	O
and	O
also	O
as	O
zones	O
of	O
special	O
ecological	O
interests	O
were	O
selected	O
.	O
	
the	O
isolated	O
species	O
were	O
identified	O
according	O
to	O
bergey's	O
manual	O
specification	O
by	O
examining	O
their	O
micro	O
and	O
macro	O
morphological	O
characteristics	O
and	O
biochemical	O
characteristics	O
on	O
different	O
culture	O
media	O
.	O
	
further	O
confirmation	O
was	O
done	O
by	O
sequencing	O
the	O
16s	O
rrna	O
gene	O
by	O
using	O
universal	O
bacterial	O
primers	O
27f	O
and	O
1429r	O
.	O
	
from	O
all	O
the	O
sampling	O
stations	O
the	O
class	O
bacilli	O
showed	O
a	O
maximum	O
relative	O
abundance	O
with	O
a	O
contribution	O
of	O
16	O
bacterial	O
species	O
.	O
	
the	O
whole	O
process	O
resulted	O
in	O
the	O
identification	O
of	O
bacillus	O
aerius	O
,	O
bacillus	O
altitudinis	O
,	O
bacillus	O
anthracis	O
,	O
bacillus	O
cereus	O
,	O
bacillus	O
ginsengisoli	O
,	O
bacillus	O
pumilus	O
,	O
bacillus	O
safensis	O
,	O
bacillus	O
stratosphericus	O
,	O
bacillus	O
subtilis	O
,	O
bacillus	O
tequilensis	O
,	O
bacillus	O
thermocopriae	O
,	O
bacillus	O
thuringiensis	O
,	O
brevibacillus	O
agri	O
strain	O
,	O
lysinibacillus	O
boronitolerans	O
,	O
lysinibacillus	O
pakistanensis	O
and	O
lysinibacillus	O
sphaericus	I-MED
a	O
new	O
angle	B-MED
and	O
its	O
relationship	O
with	O
early	O
fixation	B-MED
failure	I-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
the	O
pauwels	O
angle	B-MED
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	O
is	O
difficult	O
because	O
of	O
deformity	B-MED
of	O
the	O
affected	B-MED
lower	B-MED
extremity	I-MED
.	O
	
therefore	O
we	O
designed	O
a	O
new	O
measurement	B-MED
of	O
the	O
orientation	B-MED
of	O
femoral	B-MED
neck	I-MED
fracture	I-MED
and	O
applied	O
this	O
in	O
a	O
retrospective	B-MED
study	I-MED
to	O
assess	O
1	O
its	O
reproducibility	B-MED
,	O
2	O
its	O
advantages	O
compared	O
with	O
the	O
pauwels	O
angle	O
,	O
3	O
its	O
relationship	O
with	O
the	O
short-term	B-MED
prognosis	I-MED
treated	B-MED
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
.	O
	
this	O
new	O
measurement	B-MED
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
.	O
	
two	O
hundred	O
and	O
twenty-eight	O
patients	B-MED
with	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
were	O
retrospectively	B-MED
analyzed	I-MED
.	O
	
the	O
vn	O
angle	B-MED
,	O
which	O
was	O
the	O
angle	O
between	O
the	O
fracture	B-MED
line	I-MED
and	O
the	O
vertical	B-MED
of	O
the	O
neck	B-MED
axis	I-MED
,	O
and	O
the	O
pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O
	
the	O
method	O
of	O
icc	B-MED
was	O
performed	O
to	O
assess	O
the	O
reproducibility	B-MED
of	O
the	O
two	O
angles	B-MED
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre-operative	B-MED
and	O
post-operative	B-MED
radiographs	B-MED
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	B-MED
.	O
	
these	O
fractures	B-MED
were	O
divided	O
into	O
four	O
groups	B-MED
according	O
to	O
vn	O
angle	O
vn<0	O
n=92	O
,	O
0	O
n=82	O
,	O
10	O
n=26	O
,	O
vn	O
n=28	O
,	O
and	O
the	O
short-term	O
within	O
6	O
months	B-MED
fixation	B-MED
results	O
of	O
radiographs	B-MED
in	O
these	O
fractures	B-MED
were	O
evaluated	O
.	O
	
the	O
icc	B-MED
of	O
the	O
vn	O
angle	O
and	O
the	O
pauwels	O
angle	O
in	O
pre-operative	B-MED
radiographs	B-MED
were	O
0.937	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
0.922	O
and	O
0.942	O
respectively	O
95%	O
ci	B-MED
0.914	O
,	O
indicating	O
both	O
angles	B-MED
had	O
a	O
good	O
inter-rater	B-MED
reproducibility	I-MED
.	O
	
however	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
pauwels	O
angle	O
in	O
pre-operative	B-MED
and	O
post-operative	B-MED
radiographs	B-MED
p=0	O
,	O
the	O
absolute	O
difference	O
was	O
10.66	O
range	O
1.72	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
vn	O
angle	O
p=0	O
and	O
the	O
absolute	O
difference	O
was	O
2.20	O
range	O
0.05	O
.	O
	
the	O
overall	O
fixation	B-MED
failure	I-MED
rate	B-MED
which	O
was	O
defined	O
as	O
screw	B-MED
loosening	I-MED
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	B-MED
displacement	I-MED
or	O
femoral	B-MED
neck	I-MED
shortening	O
was	O
11.84	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
vn	O
angles	O
were	O
respectively	O
0%	O
,	O
3.24	O
95%	O
ci	B-MED
1.64	O
,	O
22.69	O
95%	O
ci	B-MED
16.43	O
,	O
65.45	O
95%	O
ci	B-MED
59.36	O
.	O
	
the	O
mean	O
failure	B-MED
rates	I-MED
of	O
fractures	B-MED
according	O
to	O
post-operative	B-MED
pauwels	O
angle	O
<30	O
,	O
30-50	O
,	O
>50	O
were	O
respectively	O
0%	O
,	O
1.46	O
95%	O
ci	B-MED
1.42	O
and	O
36.24	O
95%	O
ci	B-MED
34.93	O
.	O
	
the	O
vn	O
angle	O
has	O
a	O
good	O
inter-rater	B-MED
reproducibility	I-MED
,	O
a	O
higher	O
reliability	O
than	O
the	O
pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short-term	B-MED
prognosis	I-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
cannulated	B-MED
compression	I-MED
screws	I-MED
.	O
	
retirement	B-MED
crisis	B-MED
warnings	B-MED
becoming	O
a	O
reality	B-MED
the	O
figures	B-MED
are	O
startling	B-MED
the	O
number	O
of	O
nhs	B-MED
staff	B-MED
applying	O
to	O
retire	B-MED
has	O
surged	B-MED
by	O
a	O
quarter	O
since	O
2012	O
.	O
	
the	O
potential	O
consequences	B-MED
are	O
alarming	B-MED
a	O
serious	O
shortage	B-MED
of	O
nurses	B-MED
and	O
other	O
healthcare	B-MED
professionals	I-MED
now	O
seems	O
the	O
burden	B-MED
of	O
mental	B-MED
disorders	I-MED
in	O
the	O
eastern	B-MED
mediterranean	I-MED
region	I-MED
,	O
1990-2013	O
the	O
eastern	B-MED
mediterranean	I-MED
region	I-MED
emr	B-MED
is	O
witnessing	O
an	O
increase	B-MED
in	O
chronic	B-MED
disorders	I-MED
,	O
including	O
mental	B-MED
illness	I-MED
.	O
	
with	O
ongoing	O
unrest	O
,	O
this	O
is	O
expected	O
to	O
rise	O
.	O
	
this	O
is	O
the	O
first	O
study	B-MED
to	O
quantify	O
the	O
burden	B-MED
of	O
mental	B-MED
disorders	I-MED
in	O
the	O
emr	B-MED
.	O
	
we	O
used	O
data	B-MED
from	O
the	O
global	B-MED
burden	I-MED
of	I-MED
disease	I-MED
study	I-MED
gbd	B-MED
2013	O
.	O
	
dalys	B-MED
disability-adjusted	B-MED
life	I-MED
years	I-MED
allow	O
assessment	B-MED
of	O
both	O
premature	B-MED
mortality	I-MED
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
-	O
ylls	B-MED
and	O
nonfatal	O
outcomes	O
years	B-MED
lived	I-MED
with	I-MED
disability	I-MED
-	O
ylds	B-MED
.	O
	
dalys	B-MED
are	O
computed	O
by	O
adding	O
ylls	B-MED
and	O
ylds	B-MED
for	O
each	O
age-sex-country	O
group	O
.	O
	
in	O
2013	O
,	O
mental	B-MED
disorders	I-MED
contributed	O
to	O
5.6	O
of	O
the	O
total	B-MED
disease	I-MED
burden	I-MED
in	O
the	O
emr	B-MED
1894	O
dalys	B-MED
/100	O
population	B-MED
2519	O
dalys	B-MED
/100	O
2590/100	O
males	B-MED
,	O
2426/100	O
females	B-MED
in	O
high-income	B-MED
countries	O
,	O
1884	O
dalys	O
/100	O
1618/100	O
males	O
,	O
2157/100	O
females	O
in	O
middle-income	O
countries	O
,	O
1607	O
dalys	O
/100	O
1500/100	O
males	O
,	O
1717/100	O
females	O
in	O
low-income	O
countries	O
.	O
	
females	O
had	O
a	O
greater	O
proportion	O
of	O
burden	O
due	O
to	O
mental	O
disorders	O
than	O
did	O
males	O
of	O
equivalent	O
ages	O
,	O
except	O
for	O
those	O
under	O
15	O
years	O
of	O
age	O
.	O
	
the	O
highest	O
proportion	O
of	O
dalys	O
occurred	O
in	O
the	O
25-49	O
age	O
group	O
,	O
with	O
a	O
peak	O
in	O
the	O
35-39	O
years	O
age	O
group	O
5344	O
dalys	O
/100	O
.	O
	
the	O
burden	O
of	O
mental	O
disorders	O
in	O
emr	O
increased	O
from	O
1726	O
dalys	O
/100	O
in	O
1990	O
to	O
1912	O
dalys	O
/100	O
in	O
2013	O
10.8	O
increase	O
.	O
	
within	O
the	O
mental	O
disorders	O
group	O
in	O
emr	O
,	O
depressive	O
disorders	O
accounted	O
for	O
most	O
dalys	O
,	O
followed	O
by	O
anxiety	O
disorders	O
.	O
	
among	O
emr	O
countries	O
,	O
palestine	O
had	O
the	O
largest	O
burden	O
of	O
mental	O
disorders	O
.	O
	
nearly	O
all	O
emr	O
countries	O
had	O
a	O
higher	O
mental	O
disorder	O
burden	O
compared	O
to	O
the	O
global	O
level	O
.	O
	
our	O
findings	O
call	O
for	O
emr	O
ministries	O
of	O
health	O
to	O
increase	O
provision	O
of	O
mental	O
health	O
services	O
and	O
to	O
address	O
the	O
stigma	O
of	O
mental	O
illness	O
.	O
	
moreover	O
,	O
our	O
results	O
showing	O
the	O
accelerating	O
burden	O
of	O
mental	O
health	O
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	O
.	O
	
indeed	O
,	O
mental	O
health	O
problems	O
,	O
if	O
not	O
properly	O
addressed	O
,	O
will	O
lead	O
to	O
an	O
increased	O
burden	O
of	O
diseases	O
in	O
the	O
region	B-MED
like	O
father	B-MED
,	O
like	O
daughter	B-MED
-	O
inherited	B-MED
cutis	B-MED
aplasia	I-MED
occurring	O
in	O
a	O
family	B-MED
with	O
marfan	B-MED
syndrome	I-MED
a	O
case	B-MED
report	I-MED
we	O
present	O
the	O
case	B-MED
of	O
a	O
newborn	B-MED
with	O
co-occurrence	B-MED
of	O
marfan	B-MED
syndrome	I-MED
and	O
aplasia	B-MED
cutis	I-MED
congenita	I-MED
acc	B-MED
and	O
a	O
family	B-MED
history	I-MED
significant	B-MED
for	O
marfan	B-MED
syndrome	I-MED
and	O
acc	B-MED
in	O
the	O
father	B-MED
.	O
	
this	O
case	B-MED
details	B-MED
a	O
previously	O
unreported	O
mutation	B-MED
in	O
marfan	B-MED
syndrome	I-MED
and	O
describes	O
a	O
novel	O
coinheritance	B-MED
of	O
marfan	B-MED
syndrome	I-MED
and	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
prevalence	B-MED
,	O
characteristics	B-MED
and	O
association	B-MED
with	I-MED
body	B-MED
mass	I-MED
index	I-MED
hyperandrogenemia	B-MED
is	O
one	O
of	O
the	O
major	O
diagnostic	B-MED
features	O
for	O
the	O
diagnosis	B-MED
of	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
pcos	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	B-MED
the	O
prevalence	B-MED
and	O
the	O
characteristics	B-MED
of	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
pcos	B-MED
and	O
to	O
investigate	B-MED
the	O
association	O
of	O
clinical	B-MED
and	O
biochemical	B-MED
characteristics	B-MED
with	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
according	O
to	O
the	O
presence	B-MED
of	O
hyperandrogenemia	B-MED
.	O
	
we	O
studied	O
266	O
women	B-MED
diagnosed	B-MED
with	O
pcos	B-MED
.	O
	
hyperandrogenemia	B-MED
was	O
defined	O
by	O
testosterone	B-MED
t	B-MED
and/or	O
free	B-MED
testosterone	I-MED
ft	B-MED
and/or	O
4	B-MED
androstenedione	I-MED
δ4-a	B-MED
higher	O
than	O
75%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	B-MED
.	O
	
patients	B-MED
were	O
stratified	B-MED
in	O
two	O
groups	B-MED
according	O
to	O
a	O
bmi	B-MED
threshold	B-MED
of	O
25	O
kg/m2	O
.	O
	
hyperandrogenemia	B-MED
was	O
present	B-MED
in	O
78.2	O
of	O
the	O
patients	B-MED
.	O
	
elevated	B-MED
levels	O
of	O
t	B-MED
were	O
found	O
in	O
58.4	O
,	O
while	O
elevated	B-MED
levels	O
of	O
ft	B-MED
and	O
δ4-a	B-MED
were	O
found	O
in	O
42.5	O
and	O
34.1	O
of	O
patients	B-MED
.	O
	
in	O
normal	B-MED
weight	I-MED
women	B-MED
bmi	B-MED
25	O
kg/m2	O
with	O
hyperandrogenemia	B-MED
lower	O
values	O
of	O
hip	B-MED
circumference	I-MED
and	O
homa-ir	B-MED
and	O
increased	B-MED
levels	O
of	O
t	B-MED
,	O
ft	B-MED
,	O
δ4-a	B-MED
,	O
17-hydroxyprogesterone	B-MED
17-ohp	B-MED
,	O
dehydroepiandrosterone	B-MED
sulfate	I-MED
dheas	B-MED
,	O
white	B-MED
blood	I-MED
cells	I-MED
wbc	B-MED
and	O
neutrophils	B-MED
were	O
observed	O
compared	O
to	O
women	B-MED
without	O
hyperandrogenemia	B-MED
.	O
	
also	O
,	O
in	O
overweight	B-MED
women	B-MED
higher	O
levels	O
of	O
t	B-MED
,	O
ft	B-MED
,	O
δ4-a	B-MED
,	O
17-ohp	B-MED
,	O
dheas	B-MED
and	O
cortisol	B-MED
were	O
measured	B-MED
,	O
while	O
lower	O
thyroid-stimulating	B-MED
hormone	I-MED
tsh	I-MED
levels	I-MED
were	O
comparable	O
to	O
women	B-MED
without	O
hyperandrogenemia	B-MED
.	O
	
this	O
study	O
showed	O
high	O
prevalence	B-MED
of	O
hyperandrogenemia	B-MED
in	O
pcos	B-MED
women	B-MED
.	O
	
women	B-MED
with	O
bmi	B-MED
25	O
kg/m2	O
have	O
significant	B-MED
differences	O
in	O
androgens	B-MED
,	O
wbc	B-MED
,	O
neutrophils	B-MED
and	O
homa-ir	B-MED
and	O
women	B-MED
with	O
bmi	B-MED
25	O
kg/m2	O
in	O
androgens	B-MED
,	O
tsh	B-MED
and	O
cortisol	B-MED
according	O
to	O
the	O
presence	B-MED
or	O
not	O
of	O
a	O
course	B-MED
-based	O
approach	B-MED
to	O
the	O
doctor	B-MED
of	O
nursing	B-MED
practice	I-MED
project	I-MED
supporting	O
student	B-MED
growth	O
from	O
concept	B-MED
to	O
completion	B-MED
we	O
describe	O
a	O
course	B-MED
-based	O
approach	B-MED
to	O
the	O
doctor	B-MED
of	O
nursing	B-MED
practice	I-MED
project	I-MED
in	O
which	O
students	B-MED
work	B-MED
in	O
groups	B-MED
of	O
8	O
to	O
12	O
with	O
a	O
faculty	B-MED
member	I-MED
to	O
complete	B-MED
individual	O
final	O
projects	B-MED
that	O
require	O
a	O
minimum	B-MED
of	O
360	O
practicum	B-MED
hours	B-MED
in	O
3-	O
semester	B-MED
-long	O
courses	B-MED
.	O
	
project	B-MED
teams	I-MED
include	O
agency	B-MED
or	O
community	B-MED
-based	O
mentors	B-MED
.	O
	
project	B-MED
findings	I-MED
are	O
disseminated	B-MED
through	O
written	B-MED
and	O
oral	B-MED
reports	I-MED
.	O
	
this	O
approach	B-MED
preserves	O
faculty	B-MED
resources	B-MED
and	O
provides	O
students	B-MED
with	O
mentoring	B-MED
,	O
opportunities	B-MED
for	O
reflection	B-MED
,	O
and	O
time	B-MED
for	O
project	B-MED
development	I-MED
.	O
	
clinical	B-MED
and	O
angiographic	B-MED
correlation	B-MED
of	O
high-sensitivity	B-MED
c-reactive	I-MED
protein	I-MED
with	O
acute	B-MED
st	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
vascular	B-MED
inflammation	I-MED
and	O
associated	O
ongoing	O
inflammatory	B-MED
responses	I-MED
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	B-MED
of	O
acute	B-MED
atherothrombotic	B-MED
events	B-MED
such	O
as	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
acs	B-MED
and	O
myocardial	B-MED
infarction	I-MED
mi	B-MED
.	O
	
st	B-MED
segment	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
stemi	B-MED
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	B-MED
forms	B-MED
of	O
acs	B-MED
.	O
	
moreover	O
,	O
c-reactive	B-MED
protein	I-MED
crp	B-MED
is	O
an	O
important	O
acute	B-MED
phase	I-MED
prsotein	I-MED
,	O
which	O
may	O
be	O
estimated	O
using	O
high-sensitivity	B-MED
methods	I-MED
hs-crp	B-MED
,	O
and	O
its	O
elevated	B-MED
level	B-MED
in	O
body	B-MED
fluids	I-MED
reflects	O
chronic	B-MED
inflammatory	I-MED
status	B-MED
.	O
	
the	O
circulating	O
hs-crp	B-MED
level	B-MED
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	B-MED
marker	B-MED
of	O
coronary	B-MED
artery	I-MED
disease	I-MED
cad	B-MED
.	O
	
the	O
present	O
study	B-MED
investigated	B-MED
the	O
correlation	B-MED
of	O
hs-crp	B-MED
level	B-MED
with	O
clinical	B-MED
and	O
angiographic	B-MED
features	B-MED
of	O
stemi	B-MED
,	O
various	O
other	O
traditional	O
risk	B-MED
factors	I-MED
,	O
complications	B-MED
of	O
myocardial	B-MED
infarction	I-MED
and	O
angiographically	B-MED
significant	I-MED
cad	B-MED
.	O
	
out	O
of	O
190	O
patients	B-MED
with	O
stemi	B-MED
that	O
were	O
analyzed	B-MED
,	O
the	O
interval	B-MED
between	O
symptom	B-MED
onset	I-MED
and	O
reperfusion	B-MED
therapy	I-MED
window	B-MED
period	I-MED
varied	O
from	O
0.5	O
to	O
24	O
h	B-MED
.	O
	
the	O
hs-crp	B-MED
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non-diabetic	B-MED
patients	I-MED
0.61	O
mg/dl	O
compared	B-MED
with	O
diabetic	B-MED
patients	B-MED
0.87	O
mg/dl	O
.	O
	
moreover	O
,	O
a	O
significant	O
correlation	B-MED
between	O
hs-crp	B-MED
and	O
hs-troponin	B-MED
t	I-MED
was	O
also	O
recorded	O
p<0	O
.	O
	
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs-crp	B-MED
values	B-MED
in	O
patients	B-MED
with	O
or	O
without	O
mortality	B-MED
.	O
	
it	O
is	O
considered	O
that	O
the	O
present	O
study	B-MED
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-MED
in	O
general	O
and	O
may	O
also	O
have	O
clinical	B-MED
applications	I-MED
in	O
the	O
targeting	O
of	O
therapy	B-MED
for	O
this	O
harmful	O
bioelectrochemical	B-MED
anaerobic	B-MED
sewage	B-MED
treatment	I-MED
technology	B-MED
for	O
arctic	B-MED
communities	B-MED
this	O
study	B-MED
describes	O
a	O
novel	O
wastewater	B-MED
treatment	B-MED
technology	B-MED
suitable	O
for	O
small	O
remote	B-MED
northern	B-MED
communities	B-MED
.	O
	
the	O
technology	B-MED
is	O
based	B-MED
on	O
an	O
enhanced	B-MED
biodegradation	B-MED
of	O
organic	B-MED
carbon	I-MED
through	O
a	O
combination	O
of	O
anaerobic	B-MED
methanogenic	B-MED
and	O
microbial	B-MED
electrochemical	B-MED
bioelectrochemical	B-MED
degradation	B-MED
processes	I-MED
leading	O
to	O
biomethane	B-MED
production	B-MED
.	O
	
the	O
microbial	B-MED
electrochemical	B-MED
degradation	B-MED
is	O
achieved	O
in	O
a	O
membraneless	B-MED
flow	I-MED
-through	O
bioanode	B-MED
-	O
biocathode	B-MED
setup	O
operating	B-MED
at	O
an	O
applied	B-MED
voltage	B-MED
below	O
the	O
water	B-MED
electrolysis	B-MED
threshold	B-MED
.	O
	
laboratory	B-MED
wastewater	B-MED
treatment	B-MED
tests	B-MED
conducted	O
through	O
a	O
broad	B-MED
range	I-MED
of	O
mesophilic	B-MED
and	O
psychrophilic	B-MED
temperatures	I-MED
5-23	O
c	O
using	O
synthetic	B-MED
wastewater	B-MED
showed	O
a	O
biochemical	B-MED
oxygen	I-MED
demand	I-MED
bod5	B-MED
removal	B-MED
efficiency	B-MED
of	O
90-97%	O
and	O
an	O
effluent	B-MED
bod5	B-MED
concentration	B-MED
as	O
low	O
as	O
7	O
mg	O
l	O
.	O
	
an	O
electricity	B-MED
consumption	B-MED
of	O
0.6	O
kwh	O
kg	O
of	O
chemical	B-MED
oxygen	I-MED
demand	I-MED
cod	B-MED
removed	B-MED
was	O
observed	B-MED
.	O
	
low	B-MED
energy	B-MED
consumption	B-MED
coupled	O
with	O
enhanced	B-MED
methane	B-MED
production	B-MED
led	O
to	O
a	O
net	O
positive	B-MED
energy	B-MED
balance	B-MED
in	O
the	O
bioelectrochemical	B-MED
treatment	B-MED
system	B-MED
.	O
	
impact	B-MED
of	O
femoral	B-MED
artery	I-MED
puncture	B-MED
using	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
and	O
road	B-MED
mapping	I-MED
on	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
the	O
use	O
of	O
large	B-MED
-	O
diameter	B-MED
sheaths	O
carries	O
the	O
risk	B-MED
of	O
significant	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
tavi	B-MED
.	O
	
in	O
this	O
analysis	B-MED
,	O
we	O
sought	O
to	O
assess	B-MED
the	O
impact	B-MED
of	O
a	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
dsa	B-MED
and	O
road	B-MED
mapping	I-MED
during	O
transfemoral	O
tavi	B-MED
on	O
periprocedural	B-MED
vascular	B-MED
and	O
bleeding	B-MED
events	O
.	O
	
this	O
is	O
a	O
retrospective	O
analysis	B-MED
of	O
transfemoral	O
tavi	B-MED
patients	B-MED
included	O
in	O
a	O
prospective	B-MED
institutional	I-MED
database	I-MED
.	O
	
the	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
dsa	B-MED
-derived	O
road	B-MED
mapping	I-MED
guidance	O
was	O
introduced	O
in	O
october	O
2012	O
.	O
	
before	O
the	O
introduction	O
of	O
this	O
technique	B-MED
,	O
vascular	B-MED
puncture	B-MED
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-MED
data	B-MED
,	O
the	O
bony	B-MED
iliofemoral	B-MED
landmarks	B-MED
and	O
a	O
radiopaque	B-MED
object	I-MED
.	O
	
consecutive	O
patients	B-MED
who	O
underwent	O
tavi	B-MED
with	O
the	O
road	B-MED
mapping	I-MED
technique	B-MED
rm	B-MED
group	I-MED
,	O
n=160	O
were	O
compared	O
with	O
consecutive	O
patients	B-MED
who	O
underwent	O
tavi	B-MED
without	O
road	B-MED
mapping	I-MED
control	B-MED
group	I-MED
,	O
n=160	O
prior	O
to	O
its	O
introduction	O
.	O
	
a	O
standardised	O
strategy	O
of	O
periprocedural	B-MED
anticoagulation	I-MED
was	O
adopted	O
in	O
both	O
groups	B-MED
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	B-MED
suture-based	I-MED
closure	I-MED
device	I-MED
.	O
	
all	O
endpoints	B-MED
were	O
defined	O
according	O
to	O
the	O
varc-2	B-MED
criteria	I-MED
for	O
event	O
definition	O
.	O
	
the	O
mean	O
age	O
in	O
the	O
rm	B-MED
group	I-MED
was	O
80	O
years	B-MED
compared	O
to	O
81	O
years	B-MED
in	O
the	O
control	B-MED
group	I-MED
p=0	O
,	O
and	O
females	B-MED
were	O
equally	O
distributed	O
between	O
both	O
groups	B-MED
63.1	O
vs	O
.	O
	
58.1	O
,	O
p=0	O
.	O
	
the	O
baseline	B-MED
logistic	I-MED
euroscore	I-MED
was	O
20.7	O
vs	O
.	O
	
24.9	O
in	O
the	O
rm	B-MED
and	O
control	B-MED
group	I-MED
,	O
respectively	O
p=0	O
.	O
	
notably	O
,	O
sheath	B-MED
size	I-MED
was	O
significantly	O
larger	O
in	O
the	O
rm	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
fr	O
sheath	O
23.8	O
vs	O
.	O
	
1.8	O
,	O
p<0	O
,	O
respectively	O
associated	B-MED
with	I-MED
the	O
more	O
frequent	O
implantation	B-MED
of	O
the	O
29	O
mm	O
edwards	O
sapien	O
xt	O
valve	O
in	O
the	O
rm	B-MED
group	I-MED
43.8	O
vs	O
.	O
	
7%	O
,	O
respectively	O
,	O
p<0	O
.	O
	
despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	B-MED
complications	I-MED
and	O
major	O
bleeding	B-MED
at	O
30	O
days	B-MED
were	O
significantly	O
lower	B-MED
in	O
the	O
rm	B-MED
group	I-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
4.3	O
vs	O
.	O
	
11.8	O
,	O
p=0	O
,	O
and	O
14.4	O
vs	O
.	O
	
25.6	O
,	O
p=0	O
.	O
	
an	O
analysis	B-MED
limited	O
to	O
access	O
site-related	O
complications	B-MED
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	B-MED
map	I-MED
group	I-MED
but	O
did	O
not	O
reach	O
statistical	B-MED
significance	I-MED
8.1	O
vs	O
.	O
	
13.8	O
,	O
p=0	O
.	O
	
other	O
forms	O
of	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
as	O
well	O
as	O
all-cause	B-MED
mortality	I-MED
were	O
comparable	O
in	O
both	O
groups	B-MED
.	O
	
a	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
dsa	B-MED
and	O
road	B-MED
mapping	I-MED
was	O
associated	B-MED
with	I-MED
a	O
reduction	O
in	O
major	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
tavi	B-MED
,	O
and	O
provides	O
a	O
simple	B-MED
and	O
effective	B-MED
strategy	O
for	O
potentially	O
improving	O
patient	B-MED
outcomes	I-MED
.	O
	
differential	B-MED
roles	B-MED
of	O
axin1	B-MED
and	O
axin2	B-MED
in	O
tankyrase	B-MED
inhibitor-induced	B-MED
formation	B-MED
of	O
degradasomes	B-MED
and	O
β-catenin	B-MED
degradation	B-MED
inhibition	B-MED
of	O
the	O
tankyrase	B-MED
enzymes	I-MED
tnks1	B-MED
and	O
tnks2	B-MED
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	B-MED
dynamic	B-MED
assemblies	B-MED
of	O
β-catenin	B-MED
destruction	B-MED
complex	I-MED
components	B-MED
known	O
as	O
degradasomes	B-MED
,	O
which	O
promote	B-MED
degradation	B-MED
of	O
β-catenin	B-MED
and	O
reduced	B-MED
wnt	B-MED
signaling	I-MED
activity	B-MED
in	O
colorectal	B-MED
cancer	I-MED
cells	B-MED
.	O
	
axin1	B-MED
and	O
axin2	B-MED
/	O
conductin	B-MED
,	O
the	O
rate-limiting	B-MED
factors	B-MED
for	O
the	O
stability	B-MED
and	O
function	B-MED
of	O
endogenous	B-MED
destruction	B-MED
complexes	I-MED
,	O
are	O
stabilized	B-MED
upon	O
tnks	B-MED
inhibition	B-MED
due	O
to	O
abrogated	O
degradation	B-MED
of	O
axin	B-MED
by	O
the	O
proteasome	B-MED
.	O
	
since	O
the	O
role	B-MED
of	O
axin1	B-MED
versus	O
axin2	B-MED
as	O
scaffolding	B-MED
proteins	I-MED
in	O
the	O
wnt	B-MED
signaling	I-MED
pathway	I-MED
still	O
remains	B-MED
incompletely	B-MED
understood	B-MED
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	B-MED
contribution	B-MED
in	O
the	O
formation	B-MED
of	O
degradasomes	B-MED
,	O
as	O
these	O
protein	B-MED
assemblies	B-MED
most	O
likely	O
represent	O
the	O
morphological	B-MED
and	O
functional	B-MED
correlates	B-MED
of	O
endogenous	B-MED
β-catenin	B-MED
destruction	B-MED
complexes	I-MED
.	O
	
in	O
sw480	B-MED
colorectal	B-MED
cancer	I-MED
cells	B-MED
treated	B-MED
with	O
the	O
tankyrase	B-MED
inhibitor	I-MED
tnksi	B-MED
g007-lk	B-MED
we	O
found	B-MED
that	O
axin1	B-MED
was	O
not	O
required	O
for	O
degradasome	B-MED
formation	B-MED
.	O
	
in	O
contrast	O
,	O
the	O
formation	B-MED
of	O
degradasomes	B-MED
as	O
well	O
as	O
their	O
capacity	B-MED
to	O
degrade	B-MED
β-catenin	B-MED
were	O
considerably	B-MED
impaired	B-MED
in	O
g007-lk-treated	B-MED
cells	B-MED
depleted	O
of	O
axin2	B-MED
.	O
	
these	O
findings	B-MED
give	O
novel	B-MED
insights	B-MED
into	O
differential	B-MED
functional	B-MED
roles	I-MED
of	O
axin1	B-MED
versus	O
axin2	B-MED
in	O
the	O
β-catenin	B-MED
destruction	B-MED
complex	I-MED
.	O
	
mri	B-MED
-based	O
prostate	B-MED
cancer	I-MED
detection	B-MED
with	O
high-level	B-MED
representation	I-MED
and	O
hierarchical	B-MED
classification	B-MED
extracting	O
the	O
high-level	B-MED
feature	I-MED
representation	I-MED
by	O
using	O
deep	B-MED
neural	I-MED
networks	I-MED
for	O
detection	B-MED
of	O
prostate	B-MED
cancer	I-MED
,	O
and	O
then	O
based	O
on	O
high-level	B-MED
feature	I-MED
representation	I-MED
constructing	O
hierarchical	B-MED
classification	B-MED
to	O
refine	O
the	O
detection	B-MED
results	B-MED
.	O
	
high-level	B-MED
feature	I-MED
representation	I-MED
is	O
first	O
learned	O
by	O
a	O
deep	B-MED
learning	I-MED
network	I-MED
,	O
where	O
multiparametric	B-MED
mr	I-MED
images	B-MED
are	O
used	O
as	O
the	O
input	O
data	B-MED
.	O
	
then	O
,	O
based	O
on	O
the	O
learned	O
high-level	B-MED
features	I-MED
,	O
a	O
hierarchical	B-MED
classification	B-MED
method	B-MED
is	O
developed	O
,	O
where	O
multiple	B-MED
random	I-MED
forest	I-MED
classifiers	I-MED
are	O
iteratively	B-MED
constructed	I-MED
to	O
refine	O
the	O
detection	B-MED
results	B-MED
of	O
prostate	B-MED
cancer	I-MED
.	O
	
the	O
experiments	B-MED
were	O
carried	O
on	O
21	O
real	O
patient	B-MED
subjects	O
,	O
and	O
the	O
proposed	O
method	B-MED
achieves	O
an	O
averaged	O
section-based	B-MED
evaluation	I-MED
sbe	B-MED
of	O
89.90	O
,	O
an	O
averaged	O
sensitivity	B-MED
of	O
91.51	O
,	O
and	O
an	O
averaged	O
specificity	B-MED
of	O
88.47	O
.	O
	
the	O
high-level	B-MED
features	I-MED
learned	O
from	O
our	O
proposed	O
method	B-MED
can	O
achieve	O
better	O
performance	B-MED
than	O
the	O
conventional	B-MED
handcrafted	B-MED
features	I-MED
e.g	O
,	O
lbp	B-MED
and	O
haar-like	B-MED
features	I-MED
in	O
detecting	B-MED
prostate	B-MED
cancer	I-MED
regions	B-MED
,	O
also	O
the	O
context	B-MED
features	B-MED
obtained	O
from	O
the	O
proposed	O
hierarchical	B-MED
classification	B-MED
approach	O
are	O
effective	B-MED
in	O
refining	O
cancer	B-MED
detection	B-MED
result	B-MED
.	O
	
quantitative	B-MED
susceptibility	I-MED
mapping	I-MED
using	O
structural	B-MED
feature	I-MED
based	I-MED
collaborative	I-MED
reconstruction	I-MED
sfcr	B-MED
in	O
the	O
human	B-MED
brain	B-MED
the	O
reconstruction	B-MED
of	O
mr	B-MED
quantitative	B-MED
susceptibility	I-MED
mapping	I-MED
qsm	B-MED
from	O
local	B-MED
phase	I-MED
measurements	B-MED
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	B-MED
strategies	I-MED
incorporating	O
a	O
priori	B-MED
information	B-MED
extracted	O
from	O
magnitude	B-MED
and	O
phase	B-MED
images	I-MED
have	O
been	O
proposed	B-MED
.	O
	
however	O
,	O
the	O
anatomy	B-MED
observed	O
in	O
magnitude	B-MED
and	O
phase	B-MED
images	I-MED
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	B-MED
maps	I-MED
,	O
which	O
could	O
give	O
erroneous	B-MED
estimation	B-MED
in	O
the	O
reconstructed	B-MED
susceptibility	I-MED
map	I-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	B-MED
feature	I-MED
based	I-MED
collaborative	I-MED
reconstruction	I-MED
sfcr	B-MED
method	O
for	O
qsm	B-MED
including	O
both	O
magnitude	B-MED
and	O
susceptibility	B-MED
based	O
information	B-MED
.	O
	
the	O
sfcr	B-MED
algorithm	B-MED
is	O
composed	O
of	O
two	O
consecutive	B-MED
steps	I-MED
corresponding	O
to	O
complementary	O
reconstruction	B-MED
models	I-MED
,	O
each	O
with	O
a	O
structural	B-MED
feature	I-MED
based	O
l1	O
norm	B-MED
constraint	I-MED
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	B-MED
constraint	I-MED
,	O
which	O
allows	O
both	O
the	O
structure	B-MED
edges	O
and	O
tiny	O
features	B-MED
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	B-MED
and	O
artifacts	B-MED
could	O
be	O
reduced	O
.	O
	
in	O
the	O
m-step	B-MED
,	O
the	O
initial	O
susceptibility	B-MED
map	I-MED
is	O
reconstructed	B-MED
by	O
employing	O
a	O
k-space	O
based	O
compressed	B-MED
sensing	I-MED
model	I-MED
incorporating	O
magnitude	B-MED
prior	O
.	O
	
in	O
the	O
s-step	B-MED
,	O
the	O
susceptibility	B-MED
map	I-MED
is	O
fitted	O
in	O
spatial	B-MED
domain	I-MED
using	O
weighted	O
constraints	B-MED
derived	O
from	O
the	O
initial	O
susceptibility	B-MED
map	I-MED
from	O
the	O
m-step	B-MED
.	O
	
simulations	B-MED
and	O
in	B-MED
vivo	I-MED
human	B-MED
experiments	B-MED
at	O
7t	O
mri	B-MED
show	O
that	O
the	O
sfcr	B-MED
method	O
provides	O
high	O
quality	B-MED
susceptibility	B-MED
maps	I-MED
with	O
improved	O
rmse	B-MED
and	O
mssim	B-MED
.	O
	
finally	O
,	O
the	O
susceptibility	B-MED
values	O
of	O
deep	O
gray	B-MED
matter	I-MED
are	O
analyzed	O
in	O
multiple	B-MED
head	I-MED
positions	I-MED
,	O
with	O
the	O
supine	B-MED
position	I-MED
most	O
approximate	O
to	O
the	O
gold	O
standard	O
cosmos	B-MED
result	B-MED
.	O
	
high	B-MED
hba1c	B-MED
at	O
onset	B-MED
cannot	O
be	O
used	O
as	O
a	O
predictor	B-MED
for	O
future	O
metabolic	B-MED
control	I-MED
for	O
the	O
individual	B-MED
child	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
to	O
study	O
how	O
metabolic	B-MED
control	I-MED
at	O
onset	B-MED
of	O
type	B-MED
1	I-MED
diabetes	I-MED
correlates	O
to	O
metabolic	B-MED
control	I-MED
and	O
clinical	B-MED
parameters	B-MED
during	O
childhood	B-MED
until	O
transition	B-MED
from	O
pediatric	B-MED
care	I-MED
to	O
adult	B-MED
diabetes	B-MED
care	I-MED
.	O
	
data	B-MED
at	O
onset	B-MED
,	O
three	O
months	B-MED
,	O
one	O
,	O
three	O
,	O
and	O
five	O
years	B-MED
after	O
diagnosis	B-MED
and	O
at	O
transition	B-MED
,	O
on	O
hba1c	B-MED
and	O
clinical	B-MED
parameters	B-MED
,	O
on	O
8084	O
patients	B-MED
in	O
the	O
swedish	B-MED
pediatric	I-MED
quality	I-MED
registry	I-MED
,	O
swediabkids	I-MED
,	O
were	O
used	O
.	O
	
of	O
these	O
patients	B-MED
,	O
26%	O
had	O
been	O
referred	O
to	O
adult	B-MED
diabetes	B-MED
care	I-MED
by	O
2014	O
.	O
	
children	B-MED
with	O
hba1c	B-MED
<	O
72	O
mmol/mol	O
8.7	O
20%	O
of	O
patients	B-MED
,	O
low	B-MED
group	B-MED
at	O
diagnosis	B-MED
continued	O
to	O
have	O
good	O
metabolic	B-MED
control	I-MED
during	O
childhood	B-MED
,	O
in	O
contrast	O
to	O
children	B-MED
with	O
hba1c	B-MED
>	O
114	O
mmol/mol	O
12.6	O
20%	O
of	O
patients	B-MED
,	O
high	B-MED
group	B-MED
at	O
diagnosis	B-MED
,	O
who	O
continued	O
to	O
have	O
high	B-MED
hba1c	B-MED
at	O
follow-up	B-MED
.	O
	
for	O
the	O
individual	B-MED
,	O
there	O
was	O
no	B-MED
significant	I-MED
correlation	B-MED
between	O
high	B-MED
hba1c	B-MED
at	O
onset	B-MED
and	O
during	O
follow-up	B-MED
.	O
	
during	O
follow-up	B-MED
,	O
children	B-MED
in	O
the	O
high	B-MED
group	B-MED
were	O
more	O
often	O
smokers	B-MED
,	O
less	O
physically	B-MED
active	I-MED
,	O
and	O
more	O
often	O
had	O
retinopathy	B-MED
than	O
children	B-MED
in	O
the	O
low	B-MED
group	B-MED
p	O
<	O
01	O
,	O
01	O
,	O
03	O
respectively	O
.	O
	
high	B-MED
hba1c	B-MED
at	O
onset	B-MED
was	O
associated	B-MED
with	I-MED
high	B-MED
hba1c	B-MED
during	O
follow-up	B-MED
on	O
a	O
group	B-MED
level	O
,	O
but	O
it	O
cannot	O
be	O
used	O
as	O
a	O
predictor	B-MED
of	O
future	O
metabolic	B-MED
control	I-MED
on	O
an	O
individual	B-MED
level	O
.	O
	
these	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-MED
team	B-MED
in	O
the	O
first	O
years	O
after	O
diagnosis	B-MED
.	O
	
it	O
is	O
important	O
to	O
continuously	O
set	O
high	B-MED
goals	B-MED
for	O
the	O
achievement	B-MED
of	O
tight	O
metabolic	B-MED
control	I-MED
,	O
in	O
order	O
to	O
decrease	B-MED
the	O
risk	B-MED
of	O
microvascular	B-MED
complications	I-MED
.	O
	
photosensitizer	B-MED
decorated	B-MED
red	B-MED
blood	I-MED
cells	I-MED
as	O
an	O
ultra-sensitive	B-MED
light-responsive	I-MED
drug	I-MED
delivery	I-MED
system	I-MED
red	B-MED
blood	I-MED
cells	I-MED
rbcs	B-MED
,	O
the	O
most	O
abundant	B-MED
type	O
of	O
cells	B-MED
in	O
our	O
blood	B-MED
,	O
have	O
shown	O
promises	O
as	O
a	O
natural	B-MED
drug	I-MED
delivery	I-MED
system	I-MED
dds	B-MED
with	O
inherent	O
biocompatibility	B-MED
.	O
	
herein	O
,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-MED
,	O
chlorin	B-MED
e6	I-MED
ce6	B-MED
,	O
could	O
be	O
decorated	B-MED
into	O
the	O
membrane	B-MED
of	O
rbcs	B-MED
upon	O
simple	O
mixing	B-MED
,	O
without	O
affecting	O
the	O
membrane	B-MED
integrity	B-MED
and	O
stability	B-MED
in	O
dark	O
.	O
	
upon	O
light	B-MED
irradiation	B-MED
with	O
a	O
rather	O
low	O
power	O
density	B-MED
,	O
the	O
generated	B-MED
singlet	B-MED
oxygen	I-MED
by	O
ce6	B-MED
as	O
the	O
result	B-MED
of	I-MED
photodynamic	I-MED
effect	I-MED
would	O
lead	O
to	O
rather	O
efficient	O
disruption	B-MED
of	O
rbc	B-MED
membrane	B-MED
.	O
	
with	O
doxorubicin	B-MED
dox	B-MED
,	O
a	O
typical	O
chemotherapy	O
drug	O
,	O
as	O
the	O
model	O
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light-responsive	O
rbc-based	O
dds	O
by	O
decorating	O
ce6	O
on	O
the	O
cell	O
membrane	O
and	O
loading	O
dox	B-MED
inside	O
cells	O
.	O
	
the	O
light	O
triggered	O
cell	O
membrane	O
break	O
down	O
would	O
thus	O
trigger	O
instant	O
release	O
of	O
dox	O
,	O
enabling	O
light-controlled	O
chemotherapy	B-MED
with	O
great	O
specificity	O
.	O
	
beyond	O
that	O
,	O
our	O
rbc	O
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	O
such	O
as	O
enzymes	O
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	O
function	O
is	O
also	O
controlled	O
by	O
light	O
.	O
	
our	O
work	O
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible	O
cell-based	O
dds	O
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	O
,	O
promising	O
not	O
only	O
for	O
cancer	O
therapy	O
but	O
also	O
for	O
other	O
potential	O
applications	O
in	O
biotechnologies	B-MED
validation	B-MED
of	O
the	O
neogen	B-MED
fentanyl	I-MED
elisa	B-MED
kit	O
for	O
blood	B-MED
and	O
urine	B-MED
the	O
neogen	B-MED
fentanyl	I-MED
ready-to-use	O
enzyme-linked	B-MED
immunosorbent	I-MED
assay	I-MED
kit	O
was	O
validated	O
following	O
the	O
scientific	B-MED
working	I-MED
group	I-MED
for	O
forensic	B-MED
toxicology	I-MED
standard	B-MED
practices	I-MED
for	O
method	O
validation	B-MED
in	O
forensic	B-MED
toxicology	I-MED
laboratory	B-MED
guidelines	I-MED
.	O
	
two	O
decision	O
points	O
,	O
0.5	O
and	O
1	O
ng/ml	O
,	O
were	O
successfully	O
validated	O
for	O
whole	B-MED
blood	I-MED
.	O
	
for	O
urine	B-MED
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng/ml	O
,	O
were	O
also	O
successfully	O
validated	O
.	O
	
the	O
validation	B-MED
included	O
the	O
evaluation	B-MED
of	O
sensitivity	B-MED
,	O
precision	B-MED
,	O
specificity	B-MED
,	O
carryover	B-MED
,	O
plate	B-MED
drift	I-MED
,	O
ruggedness/robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-MED
.	O
	
the	O
empirically	O
determined	O
limit	B-MED
of	I-MED
detection	I-MED
was	O
0.25	O
ng/ml	O
for	O
blood	B-MED
and	O
0.5	O
ng/ml	O
for	O
urine	B-MED
.	O
	
precision	B-MED
was	O
determined	O
at	O
five	O
different	O
concentrations	B-MED
ranging	O
from	O
0.25	O
to	O
1.5	O
ng/ml	O
with	O
15	O
replicates	B-MED
at	O
each	O
level	O
for	O
whole	B-MED
blood	I-MED
and	O
demonstrated	O
a	O
<2	O
coefficient	B-MED
of	I-MED
variation	I-MED
cv	B-MED
.	O
	
in	O
urine	B-MED
,	O
the	O
cv	B-MED
was	O
<5	O
at	O
six	O
different	O
concentrations	B-MED
from	O
0.5	O
to	O
7.5	O
ng/ml	O
with	O
15	O
replicates	B-MED
at	O
each	O
level	O
.	O
	
cross-reactivity	B-MED
was	O
evaluated	B-MED
for	O
norfentanyl	B-MED
,	O
acetyl	B-MED
fentanyl	I-MED
,	O
4-anilino-n-phenethylpiperidine	B-MED
,	O
beta-hydroxythiofentanyl	B-MED
,	O
butyryl	B-MED
fentanyl	I-MED
and	O
furanyl	B-MED
fentanyl	I-MED
.	O
	
everolimus	B-MED
for	O
treatment	B-MED
of	O
pseudomyogenic	B-MED
hemangioendothelioma	I-MED
pseudomyogenic	B-MED
hemangioendothelioma	I-MED
pmh	B-MED
is	O
a	O
recently	O
described	O
vascular	B-MED
neoplasm	I-MED
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	B-MED
tissue	I-MED
of	O
the	O
distal	O
extremities	O
of	O
young	B-MED
adults	I-MED
.	O
	
metastatic	B-MED
pmh	B-MED
can	O
be	O
fatal	B-MED
and	O
there	O
are	O
no	O
effective	B-MED
medications	B-MED
.	O
	
we	O
describe	O
a	O
case	B-MED
of	O
a	O
15-year-old	O
boy	B-MED
with	O
metastatic	B-MED
pmh	B-MED
,	O
who	O
responded	B-MED
to	I-MED
treatment	I-MED
with	O
everolimus	B-MED
,	O
a	O
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
inhibitor	I-MED
.	O
	
immunohistochemistry	B-MED
showed	O
that	O
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
was	O
expressed	B-MED
in	O
pmh	B-MED
biopsy	B-MED
specimens	I-MED
,	O
which	O
may	O
explain	O
the	O
reduction	B-MED
in	O
pmh	B-MED
tumor	B-MED
size	I-MED
following	O
opposing	O
roles	B-MED
of	O
acetylation	B-MED
and	O
phosphorylation	B-MED
in	O
lifr	B-MED
-	O
dependent	B-MED
self-renewal	B-MED
growth	B-MED
signaling	B-MED
in	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
lif	B-MED
promotes	O
self-renewal	B-MED
of	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
mescs	B-MED
,	O
and	O
in	O
its	O
absence	B-MED
,	O
the	O
cells	B-MED
differentiate	B-MED
.	O
	
lif	B-MED
binds	O
to	O
the	O
lif	B-MED
receptor	I-MED
lifr	B-MED
and	O
activates	B-MED
the	O
jak-stat3	B-MED
pathway	I-MED
,	O
but	O
it	O
remains	B-MED
unknown	I-MED
how	O
the	O
receptor	B-MED
complex	I-MED
triggers	B-MED
differentiation	B-MED
or	O
self-renewal	B-MED
.	O
	
here	O
,	O
we	O
report	O
that	O
the	O
lifr	B-MED
cytoplasmic	B-MED
domain	I-MED
contains	O
a	O
self-renewal	B-MED
domain	B-MED
within	O
the	O
juxtamembrane	B-MED
region	I-MED
and	O
a	O
differentiation	B-MED
domain	B-MED
within	O
the	O
c-terminal	B-MED
region	I-MED
.	O
	
the	O
differentiation	B-MED
domain	B-MED
contains	O
four	O
spxx	B-MED
repeats	I-MED
that	O
are	O
phosphorylated	B-MED
by	O
mapk	B-MED
to	O
restrict	B-MED
stat3	B-MED
activation	I-MED
the	O
self-renewal	B-MED
domain	B-MED
is	O
characterized	O
by	O
a	O
3k	B-MED
motif	I-MED
that	O
is	O
acetylated	B-MED
by	O
p300	O
.	O
	
in	O
mescs	B-MED
,	O
acetyl-	O
lifr	B-MED
undergoes	O
homodimerization	B-MED
,	O
leading	O
to	O
stat3	B-MED
hypo-	B-MED
or	I-MED
hyper-activation	I-MED
depending	B-MED
on	O
the	O
presence	B-MED
or	O
absence	B-MED
of	O
gp130	B-MED
.	O
	
lifr	B-MED
-	O
activated	B-MED
stat3	B-MED
restricts	B-MED
differentiation	B-MED
via	O
cytokine	B-MED
induction	B-MED
.	O
	
thus	O
,	O
lifr	B-MED
acetylation	B-MED
and	O
serine	B-MED
phosphorylation	I-MED
differentially	B-MED
promote	O
stem	B-MED
cell	I-MED
self-renewal	B-MED
and	O
interprofessional	B-MED
primary	B-MED
care	I-MED
team	B-MED
meetings	I-MED
a	O
qualitative	B-MED
approach	B-MED
comparing	O
observations	B-MED
with	O
personal	B-MED
opinions	B-MED
the	O
number	O
of	O
people	B-MED
with	O
multiple	B-MED
chronic	I-MED
conditions	I-MED
requiring	O
primary	B-MED
care	I-MED
services	I-MED
increases	B-MED
.	O
	
professionals	B-MED
from	O
different	O
disciplines	B-MED
collaborate	B-MED
and	O
coordinate	B-MED
care	B-MED
to	O
deal	O
with	O
the	O
complex	O
health	B-MED
care	I-MED
needs	I-MED
.	O
	
there	O
is	O
lack	B-MED
of	O
information	B-MED
on	O
current	O
practices	O
regarding	O
interprofessional	B-MED
team	B-MED
ipt	I-MED
meetings	I-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	B-MED
collaboration	B-MED
in	O
primary	B-MED
care	I-MED
team	B-MED
meetings	I-MED
in	O
the	O
netherlands	B-MED
by	O
observing	O
the	O
current	B-MED
practice	I-MED
and	O
exploring	O
personal	B-MED
opinions	B-MED
.	O
	
qualitative	B-MED
study	I-MED
involving	O
observations	B-MED
of	O
team	B-MED
meeting	I-MED
s	O
and	O
interviews	B-MED
with	O
participants	B-MED
.	O
	
eight	O
different	O
ipt	B-MED
meetings	I-MED
n	O
=	O
8	O
in	O
different	O
primary	B-MED
care	I-MED
practices	I-MED
were	O
observed	O
by	O
means	O
of	O
video	B-MED
recordings	I-MED
.	O
	
experiences	B-MED
were	O
explored	O
by	O
conducting	O
individual	O
semi-structured	B-MED
interviews	I-MED
n	O
=	O
60	O
with	O
participants	B-MED
i.e	O
.	O
	
health	B-MED
care	I-MED
professionals	I-MED
from	O
different	O
disciplines	B-MED
of	O
the	O
observed	O
team	B-MED
meetings	I-MED
.	O
	
the	O
data	B-MED
were	O
analysed	B-MED
by	O
means	O
of	O
content	B-MED
analysis	I-MED
.	O
	
most	O
participants	B-MED
expressed	O
favourable	O
opinions	B-MED
about	O
their	O
team	B-MED
meetings	I-MED
.	O
	
however	O
,	O
observations	B-MED
showed	O
that	O
team	B-MED
meetings	I-MED
were	O
more	O
or	O
less	O
hectic	O
,	O
and	O
lacked	B-MED
a	O
clear	O
structure	O
and	O
team	B-MED
coordinator	I-MED
or	O
leader	B-MED
.	O
	
there	O
appears	O
to	O
be	O
a	O
discrepancy	B-MED
between	O
findings	B-MED
from	O
observations	B-MED
and	O
interviews	B-MED
.	O
	
from	O
the	O
interviews	B-MED
,	O
four	O
main	O
themes	O
were	O
extracted	O
1	O
team	B-MED
structure	I-MED
and	I-MED
composition	I-MED
,	O
2	O
patient-centredness	B-MED
,	O
3	O
interaction	B-MED
and	O
4	O
attitude	B-MED
and	O
motivation	B-MED
.	O
	
ipt	B-MED
meetings	I-MED
could	O
benefit	O
from	O
improvements	B-MED
in	O
structure	O
,	O
patient-centredness	B-MED
and	O
leadership	B-MED
by	O
the	O
chairpersons	B-MED
.	O
	
given	O
the	O
discrepancy	B-MED
between	O
observations	B-MED
and	O
interviews	B-MED
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	B-MED
team	B-MED
members	I-MED
'	O
awareness	B-MED
of	O
aspects	B-MED
that	O
could	O
be	O
improved	B-MED
before	O
training	B-MED
them	O
in	O
dealing	O
with	O
specific	O
urachal	B-MED
carcinoma	I-MED
report	B-MED
of	O
two	O
cases	B-MED
and	O
review	B-MED
of	I-MED
the	O
literature	B-MED
urachal	B-MED
carcinoma	I-MED
is	O
a	O
rare	B-MED
tumor	B-MED
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-MED
and	O
less	B-MED
often	I-MED
in	O
the	O
adnexal	B-MED
region	B-MED
and	O
urinary	B-MED
system	I-MED
.	O
	
we	O
herein	O
present	B-MED
two	O
cases	B-MED
of	O
urachal	B-MED
carcinoma	I-MED
one	O
case	B-MED
was	O
a	O
32-year-old	O
male	B-MED
patient	B-MED
who	O
presented	B-MED
with	O
painless	B-MED
hematuria	I-MED
with	O
blood	B-MED
clots	I-MED
for	O
1	O
month	B-MED
,	O
whereas	O
the	O
other	O
case	B-MED
was	O
a	O
50-year-old	O
woman	B-MED
who	O
presented	B-MED
with	O
gross	B-MED
hematuria	I-MED
with	O
mild	B-MED
dysuria	B-MED
,	O
urgency	B-MED
and	I-MED
frequent	I-MED
urination	I-MED
for	O
1	O
year	B-MED
.	O
	
following	O
surgical	B-MED
resection	I-MED
,	O
the	O
two	O
patients	B-MED
were	O
diagnosed	B-MED
with	O
urachal	B-MED
adenocarcinoma	I-MED
mixed	B-MED
type	B-MED
and	O
urachal	B-MED
mucinous	I-MED
adenocarcinoma	I-MED
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	B-MED
examination	B-MED
.	O
	
a	O
review	B-MED
of	I-MED
previously	O
published	B-MED
cases	B-MED
and	O
relevant	B-MED
literature	B-MED
is	O
also	O
presented	B-MED
.	O
	
the	O
aim	B-MED
of	O
the	O
present	B-MED
study	B-MED
was	O
to	O
help	O
understand	B-MED
this	O
disease	B-MED
better	B-MED
,	O
in	O
order	O
to	O
reduce	B-MED
the	O
rate	B-MED
of	O
clinical	B-MED
and	O
pathological	B-MED
misdiagnosis	B-MED
.	O
	
a	O
recombinant	B-MED
human	B-MED
anti-platelet	B-MED
scfv	I-MED
antibody	I-MED
produced	O
in	O
pichia	O
pastoris	O
for	O
atheroma	O
targeting	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	O
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
cerebrovascular	O
disease	O
and	O
peripheral	O
arterial	O
disease	O
.	O
	
here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single-chain	O
variable	O
fragment	O
scfv	B-MED
derived	O
from	O
a	O
human	O
anti-αiibβ3	O
antibody	O
huab	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O
	
indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O
	
the	O
dna	O
sequence	O
that	O
encodes	O
the	O
anti-αiibβ3	O
teg4	O
scfv	O
previously	O
obtained	O
from	O
a	O
phage-display	O
selection	O
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
ppiczαa	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	O
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	O
.	O
	
the	O
recombinant	O
protein	O
was	O
expressed	O
at	O
high	O
yields	O
in	O
pichia	B-MED
pastoris	I-MED
30	O
mg/l	O
culture	O
.	O
	
the	O
advantage	O
of	O
p	O
.	O
	
pastoris	O
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	O
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scfv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
.	O
	
the	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	O
scfv	O
fragments	O
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	O
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	O
of	O
instability	B-MED
identification	B-MED
of	O
mir-21-5p	B-MED
as	O
a	O
functional	B-MED
regulator	I-MED
of	O
mesothelin	B-MED
expression	B-MED
using	O
microrna	B-MED
capture	O
affinity	B-MED
coupled	B-MED
with	O
next	B-MED
generation	I-MED
sequencing	I-MED
micrornas	B-MED
mirnas	B-MED
are	O
small	B-MED
non-coding	I-MED
rnas	I-MED
that	O
regulate	B-MED
mrna	B-MED
expression	I-MED
mainly	O
by	O
silencing	B-MED
target	B-MED
transcripts	B-MED
via	O
binding	B-MED
to	O
mirna	B-MED
recognition	I-MED
elements	I-MED
mres	I-MED
in	O
the	O
3'untranslated	B-MED
region	I-MED
3'utr	B-MED
.	O
	
the	O
identification	B-MED
of	O
bona	B-MED
fide	I-MED
targets	B-MED
is	O
challenging	O
for	O
researchers	B-MED
working	I-MED
on	O
the	O
functional	B-MED
aspect	I-MED
of	O
mirnas	B-MED
.	O
	
recently	O
,	O
we	O
developed	O
a	O
method	B-MED
mir-catch	I-MED
based	O
on	O
biotinylated	B-MED
dna	B-MED
antisense	B-MED
oligonucleotides	I-MED
that	O
capture	O
the	O
mrna	B-MED
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
mirnas	B-MED
interactions	I-MED
in	O
a	O
physiological	B-MED
cellular	I-MED
context	O
.	O
	
here	O
,	O
the	O
mir-catch	B-MED
technique	I-MED
was	O
applied	O
to	O
the	O
mesothelin	B-MED
msln	I-MED
gene	I-MED
and	O
coupled	B-MED
with	O
next	B-MED
generation	I-MED
sequencing	I-MED
ngs	B-MED
,	O
to	O
identify	O
mirnas	B-MED
that	O
regulate	B-MED
msln	B-MED
mrna	I-MED
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	B-MED
levels	I-MED
found	O
in	O
malignant	B-MED
pleural	I-MED
mesothelioma	I-MED
mpm	B-MED
.	O
	
biotinylated	B-MED
msln	B-MED
oligos	I-MED
were	O
employed	O
to	O
isolate	O
mirna	B-MED
mrna	I-MED
complexes	I-MED
from	O
a	O
normal	O
cell	B-MED
line	I-MED
met-5a	I-MED
which	O
expresses	B-MED
low	O
levels	O
of	O
msln	B-MED
.	O
	
mirnas	B-MED
targeting	B-MED
the	O
msln	B-MED
mrna	I-MED
were	O
identified	O
by	O
ngs	B-MED
and	O
mir-21-5p	B-MED
and	O
mir-100-5p	B-MED
were	O
selected	O
for	O
further	O
validation	B-MED
analyses	I-MED
.	O
	
mir-21-5p	B-MED
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	B-MED
msln	B-MED
expression	B-MED
in	O
mirna	B-MED
mimic	B-MED
experiments	B-MED
in	O
a	O
panel	O
of	O
malignant	B-MED
and	O
non-malignant	O
cell	B-MED
lines	I-MED
.	O
	
further	O
mirna	B-MED
inhibitor	B-MED
experiments	B-MED
and	O
luciferase	B-MED
assays	B-MED
in	O
mero-14	B-MED
cells	I-MED
validated	O
mir-21-5p	B-MED
as	O
a	O
true	O
regulator	B-MED
of	O
msln	B-MED
.	O
	
moreover	O
,	O
in	B-MED
vitro	I-MED
experiments	I-MED
showed	O
that	O
treatment	B-MED
with	O
mir-21-5p	B-MED
mimic	B-MED
reduced	O
proliferation	B-MED
of	O
mpm	B-MED
cell	B-MED
lines	I-MED
.	O
	
altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
mir-catch	B-MED
technique	I-MED
,	O
coupled	B-MED
with	O
ngs	B-MED
and	O
in	B-MED
vitro	I-MED
validation	B-MED
,	O
represents	O
a	O
reliable	O
method	B-MED
to	O
identify	O
native	O
mirna	B-MED
interactions	I-MED
.	O
	
mir-21-5p	B-MED
is	O
suggested	O
as	O
novel	O
regulator	B-MED
of	O
msln	B-MED
with	O
a	O
possible	O
functional	B-MED
role	I-MED
in	O
cellular	B-MED
growth	I-MED
.	O
	
zoonotic	B-MED
and	O
non-zoonotic	B-MED
parasites	B-MED
of	O
wild	B-MED
rodents	B-MED
in	O
turkman	B-MED
sahra	I-MED
,	O
northeastern	I-MED
iran	I-MED
this	O
study	B-MED
was	O
conducted	O
to	O
collect	B-MED
informative	I-MED
data	I-MED
on	O
the	O
parasitic	B-MED
infection	I-MED
of	O
wild	B-MED
rodents	B-MED
,	O
emphasizing	O
on	O
finding	B-MED
parasites	B-MED
,	O
which	O
have	O
medical	B-MED
importance	B-MED
to	O
human	B-MED
.	O
	
during	O
2012-2014	O
,	O
a	O
total	B-MED
number	I-MED
of	O
91	O
wild	B-MED
rodents	B-MED
were	O
captured	B-MED
from	O
rural	B-MED
areas	I-MED
of	O
turkmen	B-MED
sahra	I-MED
,	O
golestan	I-MED
province	I-MED
,	O
using	O
handmade	B-MED
traps	I-MED
.	O
	
animals	B-MED
were	O
anesthetized	B-MED
,	O
surveyed	B-MED
for	O
any	O
ectoparasite	B-MED
and	O
then	O
their	O
carcasses	B-MED
were	O
carefully	O
dissected	B-MED
for	O
examination	B-MED
of	O
endoparsites	B-MED
.	O
	
four	O
species	B-MED
of	O
rodents	B-MED
including	B-MED
mus	B-MED
musculus	I-MED
52.75	O
,	O
rattus	B-MED
norvegicus	I-MED
38.46	O
,	O
rhombomys	B-MED
opimus	I-MED
4.40	O
and	O
meriones	B-MED
libycus	I-MED
4.40	O
were	O
captured	B-MED
.	O
	
parasitic	B-MED
infestation	I-MED
was	O
detected	B-MED
in	O
38.5	O
of	O
sampled	B-MED
rodents	B-MED
.	O
	
parasite	B-MED
infestation	I-MED
rates	B-MED
of	O
sampled	B-MED
rodents	B-MED
was	O
hymenolepis	B-MED
diminuta	I-MED
=	O
7.7	O
,	O
cryptosporidium	B-MED
spp	I-MED
=	O
6.6	O
,	O
trichuris	B-MED
spp	I-MED
=	O
5.5	O
,	O
cysticercus	B-MED
fasciolaris	I-MED
=	O
2.20	O
,	O
angiostrongylus	B-MED
spp	I-MED
=	O
2.20	O
,	O
capillaria	B-MED
sp	I-MED
=	O
1.09	O
,	O
rhipicephalus	B-MED
spp	I-MED
.	O
	
=	O
8.70	O
,	O
nosopsyllus	B-MED
fasciatus	I-MED
=	O
1.09	O
,	O
and	O
laelaps	B-MED
nuttalli	I-MED
=	O
3.29	O
.	O
	
among	O
10	O
genera	B-MED
/	O
species	B-MED
of	O
identified	B-MED
parasites	B-MED
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	B-MED
with	O
public	B-MED
health	I-MED
importance	B-MED
.	O
	
l	B-MED
.	O
	
nuttalli	I-MED
and	O
n	B-MED
.	O
	
fasciatus	I-MED
were	O
the	O
only	O
two	O
non-zoonotic	B-MED
detected	B-MED
parasites	B-MED
in	O
this	O
survey	B-MED
.	O
	
harboring	B-MED
a	O
wide	B-MED
variety	O
of	O
zoonotic	B-MED
parasites	B-MED
in	O
sampled	B-MED
wild	B-MED
rodents	B-MED
particularly	B-MED
when	O
they	O
live	O
nearby	B-MED
villages	B-MED
,	O
represents	O
a	O
potential	B-MED
risk	B-MED
to	O
native	B-MED
inhabitants	I-MED
.	O
	
hence	O
,	O
controlling	B-MED
rodents	B-MED
'	O
population	B-MED
in	O
residential	B-MED
regions	I-MED
and	O
improving	B-MED
awareness	B-MED
of	O
local	B-MED
people	B-MED
about	O
the	O
risk	B-MED
of	O
disease	B-MED
transmission	I-MED
through	O
rodents	B-MED
seems	O
to	O
be	O
entirely	O
creative	O
approach	O
for	O
successful	B-MED
aging	B-MED
a	O
pilot	B-MED
study	I-MED
of	O
an	O
intergenerational	B-MED
health	B-MED
promotion	I-MED
program	I-MED
to	O
develop	O
and	O
evaluate	B-MED
the	O
effectiveness	B-MED
of	O
an	O
intergenerational	B-MED
health	B-MED
promotion	I-MED
program	I-MED
.	O
	
this	O
was	O
an	O
action	O
research	B-MED
project	I-MED
.	O
	
a	O
total	B-MED
of	O
34	O
participants	B-MED
attended	O
the	O
12-	O
week	B-MED
program	B-MED
and	O
completed	B-MED
the	O
pre-test	B-MED
and	I-MED
post-test	I-MED
.	O
	
there	O
were	O
16	O
middle-aged	B-MED
and	O
nine	O
older	B-MED
adults	I-MED
recruited	B-MED
from	O
a	O
district	O
of	O
taipei	B-MED
,	O
and	O
nine	O
young	B-MED
adults	I-MED
recruited	B-MED
from	O
the	O
principal	B-MED
investigator's	I-MED
university	B-MED
.	O
	
the	O
""""	O
attitudes	B-MED
toward	I-MED
aging	I-MED
scale	I-MED
""""	O
and	O
the	O
""""	O
spiritual	B-MED
health	I-MED
scale	I-MED
""""	O
were	O
two	O
assessment	B-MED
instruments	B-MED
used	O
in	O
the	O
study	B-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
there	O
were	O
significant	B-MED
improvements	B-MED
in	O
the	O
attitudes	B-MED
toward	I-MED
aging	I-MED
scale	I-MED
for	O
the	O
young	B-MED
adult	I-MED
group	B-MED
aged	O
18-29	O
years	B-MED
and	O
in	O
the	O
spiritual	B-MED
health	I-MED
scale	I-MED
for	O
the	O
older	B-MED
adult	I-MED
group	B-MED
aged	B-MED
65-80	O
years	B-MED
.	O
	
the	O
evaluation	B-MED
showed	O
that	O
participants	B-MED
were	O
satisfied	B-MED
with	O
the	O
program	B-MED
.	O
	
the	O
results	B-MED
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	B-MED
aging	B-MED
and	O
intergenerational	B-MED
learning	B-MED
.	O
	
signs	B-MED
of	O
dysarthria	B-MED
in	O
adults	B-MED
with	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
the	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
investigate	O
how	O
adults	B-MED
with	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
22q11ds	B-MED
performed	O
on	O
dysarthria	B-MED
and	O
intelligibility	B-MED
tests	B-MED
compared	B-MED
with	O
a	O
control	B-MED
group	I-MED
.	O
	
ten	O
participants	B-MED
with	O
confirmed	O
22q11.2	B-MED
deletion	I-MED
,	O
five	O
males	B-MED
and	O
five	O
females	B-MED
with	O
a	O
mean	O
age	B-MED
of	O
31	O
years	B-MED
range	O
19-49	O
,	O
were	O
compared	B-MED
with	O
a	O
control	B-MED
group	I-MED
matched	O
for	O
gender	B-MED
and	O
age	B-MED
five	O
males	B-MED
and	O
five	O
females	B-MED
,	O
mean	O
age	B-MED
32	O
years	B-MED
,	O
range	O
19-49	O
.	O
	
assessment	B-MED
of	O
non-verbal	B-MED
and	I-MED
verbal	I-MED
tasks	I-MED
reflecting	O
respiration	B-MED
,	O
phonation	B-MED
,	O
oral	B-MED
motor	I-MED
function	I-MED
,	O
velopharyngeal	B-MED
function	I-MED
,	O
articulation	B-MED
,	O
and	O
prosody	B-MED
was	O
performed	O
as	O
well	O
as	O
the	O
swedish	B-MED
test	I-MED
of	I-MED
intelligibility	I-MED
sti	B-MED
.	O
	
all	O
assessments	B-MED
were	O
made	O
by	O
two	O
raters	O
inter-rater	B-MED
and	O
intra-rater	B-MED
reliability	I-MED
was	O
acceptable	O
.	O
	
the	O
participants	B-MED
with	O
22q11ds	B-MED
had	O
significantly	O
more	O
problems	B-MED
than	O
the	O
control	B-MED
group	I-MED
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
sti	B-MED
.	O
	
overall	O
,	O
the	O
severity	O
of	O
their	O
speech	B-MED
deviation	I-MED
was	O
rated	B-MED
as	O
mild	O
to	O
moderate	O
.	O
	
the	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	B-MED
respiration	B-MED
,	O
phonation	B-MED
,	O
oral	B-MED
motor	I-MED
function	I-MED
,	O
and	O
velopharyngeal	B-MED
function	I-MED
.	O
	
the	O
results	O
of	O
the	O
present	O
study	B-MED
suggest	O
that	O
a	O
neurological	B-MED
etiology	I-MED
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	B-MED
etiology	I-MED
explaining	O
the	O
speech	B-MED
difficulties	I-MED
found	O
in	O
22q11ds	B-MED
.	O
	
signs	B-MED
of	O
difficulties	O
in	O
both	O
speech	B-MED
motor	I-MED
planning	I-MED
and	O
speech	B-MED
motor	I-MED
programming	I-MED
were	O
found	O
.	O
	
further	O
studies	B-MED
are	O
needed	O
to	O
confirm	O
the	O
results	B-MED
,	O
as	O
are	O
studies	B-MED
of	O
the	O
association	O
between	O
structural	B-MED
brain	I-MED
abnormalities	I-MED
and	O
neurological	B-MED
speech	I-MED
symptoms	I-MED
.	O
	
for	O
clinical	B-MED
purposes	I-MED
,	O
it	O
is	O
important	O
that	O
clinicians	B-MED
have	O
knowledge	O
about	O
the	O
variable	O
speech	B-MED
symptoms	I-MED
that	O
may	O
occur	O
in	O
individuals	B-MED
with	O
22q11ds	B-MED
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	B-MED
of	O
such	O
speech	B-MED
symptoms	I-MED
.	O
	
sulfur	B-MED
and	O
zinc	B-MED
availability	B-MED
from	O
co-granulated	B-MED
zn	B-MED
-enriched	O
elemental	B-MED
sulfur	I-MED
fertilizers	B-MED
acidification	B-MED
by	O
oxidation	B-MED
of	O
elemental	B-MED
sulfur	I-MED
es	B-MED
can	O
solubilize	O
zno	B-MED
,	O
providing	O
slow	B-MED
release	B-MED
of	O
both	O
sulfur	B-MED
s	B-MED
and	O
zinc	B-MED
zn	B-MED
in	O
soil	O
.	O
	
for	O
this	O
study	O
,	O
a	O
new	O
granular	B-MED
fertilizer	B-MED
with	O
es	B-MED
and	O
zno	B-MED
was	O
produced	O
and	O
evaluated	B-MED
.	O
	
the	O
effect	B-MED
of	O
incorporating	O
microorganisms	B-MED
or	O
a	O
carbon	B-MED
source	B-MED
in	O
the	O
granule	B-MED
was	O
also	O
evaluated	B-MED
.	O
	
four	O
granulated	B-MED
es-zn	B-MED
fertilizers	I-MED
with	O
and	O
without	B-MED
s-oxidizing	B-MED
microorganisms	I-MED
,	O
a	O
commercial	O
es	O
pastille	O
,	O
znso4	B-MED
,	O
and	O
zno	B-MED
were	O
applied	O
to	O
the	O
center	B-MED
of	O
petri	B-MED
dishes	I-MED
containing	O
two	O
contrasting	B-MED
ph	B-MED
soils	B-MED
.	O
	
soil	B-MED
ph	B-MED
,	O
cacl2	B-MED
-extractable	O
s	B-MED
and	O
zn	B-MED
,	O
and	O
remaining	O
es	B-MED
were	O
evaluated	B-MED
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	B-MED
sections	I-MED
0-5	O
and	O
5-9	O
mm	O
from	O
the	O
fertilizer	B-MED
application	B-MED
site	I-MED
.	O
	
a	O
visualization	B-MED
test	I-MED
was	O
performed	O
to	O
evaluate	O
zn	B-MED
diffusion	B-MED
over	O
time	O
.	O
	
a	O
significant	B-MED
ph	B-MED
decrease	I-MED
was	O
observed	B-MED
in	O
the	O
acidic	B-MED
soil	B-MED
for	O
all	O
es-zn	B-MED
fertilizer	I-MED
treatments	B-MED
and	O
in	O
the	O
alkaline	B-MED
soil	B-MED
for	O
the	O
acidithiobacillus	B-MED
thiooxidans	I-MED
-	O
inoculated	B-MED
treatment	I-MED
only	O
.	O
	
in	O
agreement	O
with	O
zn	B-MED
visualization	B-MED
tests	I-MED
,	O
extractable-	O
zn	B-MED
concentrations	B-MED
were	O
higher	B-MED
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	B-MED
62.9	O
mg	O
dm	O
compared	O
to	O
the	O
alkaline	B-MED
soil	B-MED
5.5	O
mg	O
dm	O
.	O
	
elemental	B-MED
s	I-MED
oxidation	I-MED
was	O
greater	B-MED
in	O
the	O
acidic	B-MED
soil	B-MED
20.9	O
than	O
slightly	O
alkaline	B-MED
soil	B-MED
12%	O
.	O
	
the	O
es-zn	B-MED
granular	I-MED
fertilizers	I-MED
increased	B-MED
s	B-MED
and	O
zn	B-MED
concentrations	B-MED
in	O
soil	B-MED
and	O
can	O
provide	O
a	O
strategically	O
slow	B-MED
release	B-MED
of	O
nutrients	B-MED
to	O
the	O
impact	B-MED
of	O
blood	B-MED
transfusions	I-MED
on	O
survival	B-MED
of	O
locally	B-MED
advanced	B-MED
cervical	B-MED
cancer	I-MED
patients	B-MED
undergoing	O
neoadjuvant	B-MED
chemotherapy	I-MED
plus	O
radical	B-MED
surgery	I-MED
transfusions	B-MED
represent	O
one	O
of	O
the	O
main	O
progresses	B-MED
of	O
modern	B-MED
medicine	I-MED
.	O
	
however	O
,	O
accumulating	O
evidence	B-MED
supports	O
that	O
transfusions	B-MED
correlate	O
with	O
worse	O
survival	B-MED
outcomes	B-MED
in	O
patients	B-MED
affected	B-MED
by	O
solid	B-MED
cancers	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
we	O
aimed	B-MED
to	O
investigate	B-MED
the	O
effects	O
of	O
perioperative	B-MED
blood	B-MED
transfusion	I-MED
in	O
locally	B-MED
advanced	B-MED
cervical	B-MED
cancer	I-MED
.	O
	
data	O
of	O
consecutive	O
patients	B-MED
affected	B-MED
by	O
locally	B-MED
advanced	B-MED
cervical	B-MED
cancer	I-MED
scheduled	O
to	O
undergo	O
neoadjuvant	B-MED
chemotherapy	I-MED
plus	O
radical	B-MED
surgery	I-MED
were	O
retrospectively	B-MED
searched	B-MED
to	O
test	B-MED
the	O
impact	B-MED
of	O
perioperative	B-MED
transfusions	B-MED
on	O
survival	B-MED
outcomes	B-MED
.	O
	
five-	O
year	B-MED
survival	B-MED
outcomes	B-MED
were	O
evaluated	O
using	O
kaplan-meier	B-MED
and	O
cox	B-MED
models	I-MED
.	O
	
the	O
study	B-MED
included	O
275	O
patients	B-MED
.	O
	
overall	O
,	O
170	O
62%	O
patients	B-MED
had	O
blood	B-MED
transfusion	I-MED
.	O
	
via	O
univariate	B-MED
analysis	I-MED
,	O
we	O
observed	B-MED
that	O
transfusion	B-MED
correlated	O
with	O
an	O
increased	O
risk	B-MED
of	O
developing	B-MED
recurrence	B-MED
hazard	B-MED
ratio	I-MED
hr	B-MED
,	O
2.2	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
,	O
1.09	O
p	B-MED
=	O
0.02	O
.	O
	
other	O
factors	O
associated	O
with	O
5-	O
year	B-MED
disease-free	B-MED
survival	I-MED
were	O
noncomplete	B-MED
clinical	B-MED
response	I-MED
after	O
neoadjuvant	B-MED
chemotherapy	I-MED
hr	B-MED
,	O
2.99	O
95%	O
ci	B-MED
,	O
0.92	O
p	B-MED
=	O
0.06	O
and	O
pathological	B-MED
p	B-MED
=	O
0.03	O
response	B-MED
at	O
neoadjuvant	B-MED
chemotherapy	I-MED
as	O
well	O
as	O
parametrial	B-MED
p	B-MED
=	O
0.004	O
,	O
vaginal	B-MED
p	B-MED
<	O
0.001	O
,	O
and	O
lymph	B-MED
node	I-MED
p	B-MED
=	O
0.002	O
involvements	O
.	O
	
however	O
,	O
via	O
multivariate	B-MED
analysis	I-MED
,	O
only	O
vaginal	B-MED
hr	B-MED
,	O
3.07	O
95%	O
ci	B-MED
,	O
1.20	O
p	B-MED
=	O
0.01	O
and	O
lymph	B-MED
node	I-MED
involvements	O
hr	B-MED
,	O
2.4	O
95%	O
ci	B-MED
,	O
1.00	O
p	B-MED
=	O
0.05	O
correlate	O
with	O
worse	O
disease-free	O
survival	O
.	O
	
no	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	O
transfusion	O
hr	O
,	O
2.71	O
95%	O
ci	O
,	O
0.91	O
p	B-MED
=	O
0.07	O
.	O
	
looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	O
node	O
status	O
p	O
=	O
0.01	O
and	O
vaginal	O
involvement	O
p	O
=	O
0.06	O
were	O
independently	O
associated	O
with	O
survival	O
.	O
	
the	O
role	O
of	O
blood	O
transfusions	O
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
laac	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	O
remains	O
unclear	O
further	O
prospective	O
studies	O
are	O
tissue	B-MED
reservoirs	O
of	O
antiviral	B-MED
t	B-MED
cell	I-MED
immunity	I-MED
in	O
persistent	O
human	B-MED
cmv	B-MED
infection	I-MED
t	B-MED
cell	I-MED
responses	B-MED
to	O
viruses	B-MED
are	O
initiated	O
and	O
maintained	O
in	O
tissue	B-MED
sites	O
however	O
,	O
knowledge	O
of	O
human	B-MED
antiviral	B-MED
t	B-MED
cells	I-MED
is	O
largely	O
derived	O
from	O
blood	B-MED
.	O
	
cytomegalovirus	B-MED
cmv	B-MED
persists	O
in	O
most	O
humans	B-MED
,	O
requires	O
t	B-MED
cell	I-MED
immunity	I-MED
to	O
control	O
,	O
yet	O
tissue	B-MED
immune	B-MED
responses	I-MED
remain	O
undefined	O
.	O
	
here	O
,	O
we	O
investigated	O
human	B-MED
cmv	B-MED
-specific	O
t	O
cells	O
,	O
virus	O
persistence	O
and	O
cmv	B-MED
-associated	O
t	B-MED
cell	O
homeostasis	O
in	O
blood	O
,	O
lymphoid	O
,	O
mucosa	O
l	O
and	O
secretory	O
tissues	O
of	O
44	O
cmv	O
seropositive	O
and	O
28	O
seronegative	O
donors	O
.	O
	
cmv	O
-specific	O
t	O
cells	I-MED
were	O
maintained	O
in	O
distinct	O
distribution	O
patterns	O
,	O
highest	O
in	O
blood	O
,	O
bone	O
marrow	O
bm	O
,	O
or	O
lymph	O
nodes	O
ln	O
,	O
with	O
the	O
frequency	O
and	O
function	O
in	O
blood	O
distinct	O
from	O
tissues	O
.	O
	
cmv	O
genomes	O
were	O
detected	O
predominantly	O
in	O
lung	O
and	O
also	O
in	O
spleen	O
,	O
bm	O
,	O
blood	O
and	O
ln	O
.	O
	
high	O
frequencies	O
of	O
activated	O
cmv	O
-specific	O
t	O
cells	O
were	O
found	O
in	O
blood	O
and	O
bm	O
samples	O
with	O
low	O
virus	B-MED
detection	O
,	O
whereas	O
in	O
lung	O
,	O
cmv	O
-specific	O
t	O
cells	O
were	O
present	O
along	O
with	O
detectable	O
virus	O
.	O
	
in	O
lns	O
,	O
cmv	O
-specific	O
t	O
cells	O
exhibited	O
quiescent	O
phenotypes	O
independent	O
of	O
virus	O
.	O
	
overall	O
,	O
t	O
cell	O
differentiation	O
was	O
enhanced	O
in	O
sites	O
of	O
viral	O
persistence	B-MED
with	O
age	O
.	O
	
together	O
,	O
our	O
results	O
suggest	O
tissue	O
t	O
cell	O
reservoirs	O
for	O
cmv	B-MED
control	O
shaped	O
by	O
both	O
viral	O
and	O
tissue	O
-	O
intrinsic	O
factors	O
,	O
with	O
global	O
effects	O
on	O
homeostasis	O
of	O
tissue	O
t	B-MED
cells	O
over	O
the	O
lifespan	B-MED
lipid	B-MED
levels	I-MED
and	O
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
results	B-MED
from	O
the	O
mega	B-MED
follow-up	I-MED
study	I-MED
essentials	O
the	O
role	O
of	O
lipid	B-MED
levels	I-MED
in	O
the	O
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
is	O
unclear	B-MED
.	O
	
lipids	B-MED
were	O
assessed	B-MED
in	O
patients	B-MED
with	O
a	O
first	O
venous	B-MED
thrombosis	I-MED
n	O
=	O
2106	O
followed	B-MED
for	O
6.9	O
years	B-MED
.	O
	
lipids	B-MED
were	O
not	O
associated	B-MED
with	I-MED
recurrence	B-MED
,	O
overall	O
or	O
in	O
patients	B-MED
with	O
unprovoked	O
first	O
events	B-MED
.	O
	
testing	B-MED
lipid	I-MED
levels	I-MED
is	O
not	O
useful	B-MED
to	O
identify	B-MED
patients	B-MED
at	O
an	O
increased	B-MED
risk	B-MED
of	O
recurrence	B-MED
.	O
	
background	O
knowledge	O
of	O
risk	B-MED
factors	I-MED
for	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
may	O
guide	O
decisions	O
on	O
duration	B-MED
of	O
anticoagulation	B-MED
.	O
	
the	O
association	B-MED
between	O
lipid	B-MED
levels	I-MED
and	O
first	O
venous	B-MED
thrombosis	I-MED
has	O
been	O
studied	O
extensively	O
.	O
	
however	O
,	O
data	B-MED
on	O
the	O
role	O
of	O
lipids	B-MED
in	O
the	O
risk	B-MED
of	O
recurrence	B-MED
are	O
scarce	O
.	O
	
objective	O
to	O
assess	B-MED
the	O
association	B-MED
between	O
lipid	B-MED
levels	I-MED
and	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
.	O
	
patients	B-MED
/methods	O
patients	B-MED
with	O
a	O
first	O
venous	B-MED
thrombosis	I-MED
from	O
the	O
mega	B-MED
study	I-MED
were	O
included	B-MED
.	O
	
follow-up	B-MED
started	B-MED
at	O
the	O
date	B-MED
of	O
end	B-MED
of	O
anticoagulant	B-MED
treatment	I-MED
.	O
	
percentile	B-MED
categories	B-MED
of	O
total	B-MED
/	O
low-density	B-MED
lipoprotein	I-MED
/	O
high-density	B-MED
lipoprotein	I-MED
cholesterol	I-MED
,	O
triglycerides	B-MED
and	O
apolipoproteins	B-MED
b	I-MED
and	O
a1	B-MED
were	O
established	B-MED
<	O
10th	O
,	O
10th-25th	O
,	O
25th-75th	O
reference	B-MED
,	O
75th-90th	O
,	O
>	O
90th	O
percentile	B-MED
.	O
	
lipids	B-MED
were	O
measured	B-MED
at	O
least	O
3	O
months	B-MED
after	O
discontinuing	B-MED
anticoagulation	B-MED
.	O
	
results	B-MED
of	O
2106	O
patients	B-MED
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	B-MED
,	O
326	O
developed	O
recurrence	B-MED
incidence	B-MED
rate	I-MED
,	O
2.7	O
patient	B-MED
-	O
years	B-MED
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
,	O
2.5	O
.	O
	
with	O
hazard	B-MED
ratios	I-MED
ranging	B-MED
from	O
0.88	O
95%	O
ci	B-MED
,	O
0.55	O
to	O
1.33	O
95%	O
ci	B-MED
,	O
0.86	O
in	O
the	O
highest	O
percentile	B-MED
category	B-MED
vs	O
.	O
	
the	O
reference	B-MED
,	O
we	O
found	O
no	O
association	B-MED
across	O
percentile	B-MED
categories	B-MED
between	O
recurrence	B-MED
and	O
lipid	B-MED
levels	I-MED
in	O
age-	B-MED
and	O
sex	B-MED
-adjusted	O
models	B-MED
,	O
nor	O
after	O
further	B-MED
adjustments	B-MED
for	O
body	B-MED
mass	I-MED
index	I-MED
,	O
diabetes	B-MED
,	O
estrogen	B-MED
and	O
statin	B-MED
use	B-MED
,	O
and	O
duration	B-MED
of	O
anticoagulation	B-MED
.	O
	
subgroup	B-MED
analyses	B-MED
stratified	B-MED
by	O
unprovoked	O
or	O
provoked	B-MED
first	O
events	B-MED
,	O
location	B-MED
deep	B-MED
vein	I-MED
thrombosis	I-MED
or	O
pulmonary	B-MED
embolism	I-MED
and	O
sex	B-MED
also	O
did	O
not	O
reveal	B-MED
an	O
association	B-MED
with	O
any	O
of	O
the	O
lipid	B-MED
levels	I-MED
studied	O
.	O
	
conclusions	O
testing	B-MED
lipid	I-MED
levels	I-MED
did	O
not	O
identify	B-MED
patients	B-MED
at	O
an	O
increased	B-MED
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
in	O
this	O
study	B-MED
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	B-MED
,	O
and	O
these	O
should	O
not	O
influence	B-MED
decisions	O
on	O
duration	B-MED
of	O
insecticidal	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
in	O
laboratory	B-MED
and	O
field	B-MED
populations	B-MED
of	O
culicoides	B-MED
species	I-MED
how	O
effective	O
are	O
host	B-MED
-	O
contact	B-MED
reduction	B-MED
methods	B-MED
in	O
india	B-MED
bluetongue	B-MED
virus	I-MED
btv	B-MED
is	O
transmitted	B-MED
by	O
culicoides	B-MED
biting	B-MED
midges	I-MED
and	O
causes	O
bluetongue	B-MED
bt	B-MED
,	O
a	O
clinical	B-MED
disease	I-MED
observed	O
primarily	O
in	O
sheep	B-MED
.	O
	
bt	B-MED
has	O
a	O
detrimental	B-MED
effect	I-MED
on	O
subsistence	O
farmers	B-MED
in	O
india	B-MED
,	O
where	O
hyperendemic	B-MED
outbreaks	I-MED
impact	O
on	O
smallholdings	O
in	O
the	O
southern	B-MED
states	I-MED
of	O
the	O
country	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	B-MED
for	O
testing	O
the	O
toxic	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
on	O
culicoides	B-MED
and	O
then	O
compare	O
deltamethrin	B-MED
with	O
traditional	B-MED
control	I-MED
methods	I-MED
used	O
by	O
farmers	B-MED
in	O
india	B-MED
.	O
	
effects	O
of	O
deltamethrin	B-MED
were	O
initially	O
tested	O
using	O
a	O
colonised	B-MED
strain	I-MED
of	O
culicoides	B-MED
nubeculosus	I-MED
meigen	I-MED
and	O
a	O
modified	O
world	B-MED
health	I-MED
organisation	I-MED
exposure	B-MED
assay	I-MED
.	O
	
this	O
method	B-MED
was	O
then	O
applied	O
to	O
field	B-MED
populations	B-MED
of	O
culicoides	B-MED
spp	I-MED
.	O
	
in	O
india	B-MED
.	O
	
the	O
field	B-MED
population	B-MED
of	O
c	B-MED
.	O
	
oxystoma	I-MED
in	O
india	B-MED
had	O
a	O
greater	O
lc50	O
0.012	O
0.009	O
for	O
deltamethrin	B-MED
than	O
laboratory-reared	B-MED
c.nubeculosus	B-MED
0.0013	O
0.0002	O
.	O
	
exposure	O
of	O
c	B-MED
.	O
	
nubeculosus	I-MED
to	O
deltamethrin	B-MED
at	O
higher	O
ambient	B-MED
temperatures	I-MED
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	B-MED
rate	I-MED
at	O
24	O
h	O
post-exposure	O
.	O
	
behavioural	B-MED
assays	I-MED
with	O
c	B-MED
.	O
	
nubeculosus	I-MED
in	O
who	B-MED
tubes	B-MED
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-MED
.	O
	
the	O
field	B-MED
experiments	B-MED
in	O
india	B-MED
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	B-MED
or	O
toxic	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
.	O
	
traditional	B-MED
methods	I-MED
such	O
as	O
the	O
application	B-MED
of	O
neem	B-MED
oil	I-MED
and	O
burning	B-MED
of	O
neem	B-MED
leaves	B-MED
also	O
provided	O
no	B-MED
protection	B-MED
.	O
	
our	O
study	O
demonstrates	O
that	O
field	B-MED
-collected	O
culicoides	B-MED
in	O
india	B-MED
are	O
less	O
susceptible	O
to	O
deltamethrin	B-MED
exposure	O
than	O
laboratory-bred	B-MED
c	B-MED
.	O
	
nubeculosus	I-MED
and	O
traditional	B-MED
methods	I-MED
of	O
insect	B-MED
control	I-MED
do	O
not	O
provide	O
protection	B-MED
to	O
sheep	B-MED
.	O
	
these	O
low	O
levels	O
of	O
susceptibility	B-MED
to	O
deltamethrin	B-MED
have	O
not	O
been	O
recorded	O
before	O
in	O
field	B-MED
populations	B-MED
of	O
culicoides	B-MED
and	O
suggest	O
resistance	B-MED
to	O
synthetic	B-MED
pyrethrioids	I-MED
.	O
	
alternative	O
insect	B-MED
control	I-MED
methods	B-MED
,	O
in	O
addition	O
to	O
vaccination	B-MED
,	O
may	O
be	O
needed	O
to	O
protect	O
indian	B-MED
livestock	B-MED
from	O
btv	B-MED
transmission	B-MED
.	O
	
correlation	B-MED
of	O
the	O
lipid	B-MED
profile	B-MED
,	O
bmi	B-MED
and	O
bone	B-MED
mineral	I-MED
density	I-MED
in	O
postmenopausal	B-MED
women	B-MED
to	O
the	O
reduction	B-MED
of	O
bone	B-MED
density	I-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
contribute	O
elevated	B-MED
lipid	B-MED
parameters	B-MED
and	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
.	O
	
the	O
goal	O
of	O
our	O
study	B-MED
was	O
to	O
determine	O
the	O
correlation	B-MED
between	O
lipid	B-MED
parameters	B-MED
,	O
bmi	B-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
.	O
	
the	O
study	B-MED
was	O
carried	O
out	O
by	O
matched	B-MED
type	B-MED
between	O
experimental	B-MED
group	B-MED
and	O
controls	B-MED
.	O
	
the	O
experimental	B-MED
group	B-MED
consisted	O
of	O
100	O
females	B-MED
at	O
postmenopausal	B-MED
age	B-MED
,	O
in	O
which	O
by	O
the	O
dexa	B-MED
method	I-MED
was	O
diagnosed	B-MED
osteoporosis	B-MED
at	O
the	O
department	O
of	O
endocrinology	O
,	O
diabetes	O
and	O
metabolic	O
diseases	O
,	O
university	B-MED
medical	I-MED
center	I-MED
of	I-MED
rs	I-MED
during	O
2015-2016	O
,	O
while	O
the	O
control	B-MED
group	I-MED
consisted	O
of	O
100	O
females	B-MED
in	O
a	O
postmenopausal	B-MED
age	B-MED
but	O
without	O
diagnosed	B-MED
osteoporosis	B-MED
.	O
	
the	O
groups	B-MED
were	O
matched	B-MED
by	O
age	B-MED
2	O
years	B-MED
.	O
	
to	O
all	O
participants	B-MED
of	O
the	O
study	B-MED
were	O
carried	O
out	O
biochemical	B-MED
analysis	I-MED
of	I-MED
blood	I-MED
,	O
or	O
the	O
analysis	B-MED
of	O
the	O
lipid	B-MED
profile	B-MED
that	O
included	O
total	B-MED
cholesterol	I-MED
,	O
ldl	B-MED
cholesterol	I-MED
,	O
triglycerides	B-MED
tg	B-MED
and	O
hdl	B-MED
cholesterol	I-MED
,	O
and	O
was	O
determined	O
the	O
values	B-MED
of	O
bmi	B-MED
and	O
waist	B-MED
circumference	I-MED
wc	B-MED
.	O
	
analysis	B-MED
of	O
the	O
data	B-MED
of	O
our	O
research	B-MED
shows	O
that	O
by	O
the	O
univariate	B-MED
logistic	I-MED
regression	I-MED
the	O
values	B-MED
of	O
lipid	B-MED
parameters	B-MED
total	B-MED
cholesterol	I-MED
p=0	O
,	O
ldl	B-MED
p=0	O
and	O
tg	B-MED
p=0	O
were	O
significantly	B-MED
associated	B-MED
with	I-MED
osteoporosis	B-MED
,	O
while	O
in	O
multivariate	B-MED
logistic	I-MED
model	I-MED
only	O
total	B-MED
cholesterol	I-MED
p=	O
0.018	O
was	O
found	O
as	O
an	O
independent	B-MED
risk	B-MED
factor	I-MED
for	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
.	O
	
bmi	B-MED
values	B-MED
were	O
not	B-MED
statistically	B-MED
significantly	I-MED
associated	B-MED
with	I-MED
osteoporosis	B-MED
p=0	O
.	O
	
on	O
the	O
decrease	B-MED
in	O
bone	B-MED
mineral	I-MED
density	I-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
influence	O
many	O
risk	B-MED
factors	I-MED
whose	O
identification	B-MED
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	B-MED
prevention	B-MED
of	O
this	O
disease	B-MED
in	O
the	O
heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
recombinant	B-MED
human	I-MED
bone	I-MED
morphogenetic	I-MED
protein-7	I-MED
to	O
present	O
the	O
incidence	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
recombinant	B-MED
human	I-MED
bone	I-MED
morphogenetic	I-MED
protein-7	I-MED
rhbmp-7	B-MED
for	O
the	O
treatment	B-MED
of	O
nonunions	B-MED
.	O
	
bone	B-MED
morphogenetic	I-MED
proteins	I-MED
bmps	B-MED
promote	O
bone	B-MED
formation	I-MED
by	O
auto-induction	B-MED
.	O
	
recombinant	B-MED
human	I-MED
bmp-7	I-MED
in	O
combination	O
with	O
bone	B-MED
grafts	I-MED
was	O
used	O
in	O
84	O
patients	B-MED
for	O
the	O
treatment	B-MED
of	O
long	B-MED
bone	I-MED
nonunions	I-MED
.	O
	
all	O
patients	B-MED
were	O
evaluated	B-MED
radiographicaly	B-MED
for	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
during	O
the	O
standard	B-MED
assessment	B-MED
for	O
the	O
nonunion	B-MED
healing	B-MED
.	O
	
in	O
all	O
patients	B-MED
80.9	O
with	O
radiographic	B-MED
signs	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
,	O
a	O
ct	B-MED
scan	I-MED
was	O
performed	O
.	O
	
nonunion	B-MED
site	B-MED
palpation	B-MED
and	O
rom	B-MED
evaluation	I-MED
of	O
the	O
adjacent	B-MED
joints	B-MED
were	O
also	O
carried	O
out	O
.	O
	
factors	B-MED
related	O
to	O
the	O
patient	B-MED
age	B-MED
,	O
gender	B-MED
,	O
the	O
nonunion	B-MED
location	B-MED
,	O
size	B-MED
,	O
chronicity	B-MED
,	O
number	B-MED
of	I-MED
previous	I-MED
procedures	I-MED
,	O
infection	B-MED
,	O
surrounding	B-MED
tissues	B-MED
condition	B-MED
and	O
the	O
surgical	B-MED
procedure	I-MED
graft	B-MED
and	O
fixation	B-MED
type	B-MED
,	O
amount	B-MED
of	O
rhbmp-7	B-MED
were	O
correlated	B-MED
with	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
and	O
statistical	B-MED
analysis	I-MED
with	O
pearsons	B-MED
χ	I-MED
2	I-MED
test	I-MED
was	O
performed	O
.	O
	
eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-MED
treated	B-MED
with	O
rhbmp-7	B-MED
,	O
healed	B-MED
with	O
no	O
need	O
for	O
further	O
procedures	B-MED
.	O
	
heterotopic	B-MED
bone	I-MED
formation	I-MED
occurred	O
in	O
15	O
of	O
84	O
patients	B-MED
17.8	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	B-MED
evaluation	I-MED
of	O
the	O
nonunion	B-MED
site	O
,	O
in	O
a	O
mean	B-MED
time	I-MED
of	O
5.5	O
mo	O
after	O
the	O
rhbmp-7	B-MED
application	B-MED
range	O
3-12	O
.	O
	
the	O
heterotopic	B-MED
ossification	I-MED
was	O
located	O
at	O
the	O
femur	B-MED
in	O
8	O
cases	B-MED
,	O
at	O
the	O
tibia	B-MED
in	O
6	O
,	O
and	O
at	O
the	O
humerus	B-MED
in	O
οne	O
patient	B-MED
.	O
	
in	O
4	O
patients	B-MED
a	O
palpable	B-MED
mass	I-MED
was	O
present	O
and	O
only	O
in	O
one	O
patient	B-MED
,	O
with	O
a	O
para-articular	B-MED
knee	I-MED
nonunion	I-MED
treated	B-MED
with	O
rhbmp-7	B-MED
,	O
the	O
size	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
affected	O
the	O
knee	B-MED
range	I-MED
of	I-MED
motion	I-MED
.	O
	
all	O
the	O
patients	B-MED
with	O
heterotopic	B-MED
ossification	I-MED
were	O
male	B-MED
.	O
	
statistical	B-MED
analysis	I-MED
proved	O
that	O
patient's	B-MED
gender	B-MED
was	O
the	O
only	O
important	O
factor	B-MED
for	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
p	O
=	O
0.007	O
.	O
	
heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
rhbmp-7	B-MED
in	O
nonunions	B-MED
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	B-MED
outcome	I-MED
in	O
most	O
cases	B-MED
,	O
and	O
affected	O
only	O
male	B-MED
patients	B-MED
.	O
	
hypocretin/orexin	B-MED
peptides	I-MED
excite	B-MED
rat	B-MED
neuroendocrine	B-MED
dopamine	B-MED
neurons	I-MED
through	O
orexin	B-MED
2	I-MED
receptor	I-MED
-mediated	O
activation	B-MED
of	O
a	O
mixed	B-MED
cation	B-MED
current	B-MED
hypocretin/orexin	B-MED
h/o	B-MED
neurons	B-MED
of	O
the	O
lateral	B-MED
hypothalamus	I-MED
are	O
compelling	B-MED
modulator	B-MED
candidates	I-MED
for	O
the	O
chronobiology	B-MED
of	O
neuroendocrine	B-MED
output	B-MED
and	O
,	O
as	O
a	O
consequence	B-MED
,	O
hormone	B-MED
release	I-MED
from	O
the	O
anterior	B-MED
pituitary	I-MED
.	O
	
here	O
we	O
investigate	O
the	O
effects	B-MED
of	O
h/o	B-MED
peptides	I-MED
upon	O
tuberoinfundibular	B-MED
dopamine	I-MED
tida	I-MED
neurons	I-MED
-	O
cells	B-MED
which	O
control	B-MED
,	O
via	O
inhibition	B-MED
,	O
the	O
pituitary	B-MED
secretion	B-MED
of	I-MED
prolactin	I-MED
.	O
	
in	O
whole	B-MED
cell	I-MED
recordings	I-MED
performed	B-MED
in	O
male	B-MED
rat	B-MED
hypothalamic	B-MED
slices	I-MED
,	O
application	O
of	O
h/o-a	B-MED
,	O
as	O
well	O
as	O
h/o-b	B-MED
,	O
excited	B-MED
oscillating	O
tida	B-MED
neurons	I-MED
,	O
inducing	B-MED
a	O
reversible	B-MED
depolarising	B-MED
switch	O
from	O
phasic	B-MED
to	I-MED
tonic	I-MED
discharge	I-MED
.	O
	
the	O
h/o	B-MED
-	O
induced	B-MED
inward	B-MED
current	B-MED
underpinning	B-MED
this	O
effect	B-MED
was	O
post-synaptic	B-MED
as	O
it	O
endured	O
in	O
the	O
presence	B-MED
of	O
tetrodotoxin	B-MED
,	O
appeared	B-MED
to	O
be	O
carried	O
by	O
a	O
na	B-MED
-	O
dependent	B-MED
transient	B-MED
receptor	I-MED
potential-like	I-MED
channel	I-MED
as	O
it	O
was	O
blocked	B-MED
by	O
2-apb	B-MED
and	O
was	O
diminished	B-MED
by	O
removal	B-MED
of	O
extracellular	B-MED
na	B-MED
,	O
and	O
was	O
a	O
consequence	B-MED
of	I-MED
ox2r	B-MED
receptor	I-MED
activation	B-MED
as	O
it	O
was	O
blocked	B-MED
by	O
the	O
ox2r	B-MED
receptor	I-MED
antagonist	B-MED
tcs	B-MED
ox2	I-MED
29	I-MED
,	O
but	O
not	O
the	O
ox1r	B-MED
receptor	I-MED
antagonist	B-MED
sb	B-MED
334867	I-MED
.	O
	
application	B-MED
of	O
the	O
hormone	B-MED
,	O
melatonin	B-MED
,	O
failed	B-MED
to	O
alter	B-MED
tida	B-MED
membrane	B-MED
potential	I-MED
or	O
oscillatory	B-MED
activity	I-MED
.	O
	
this	O
first	O
description	B-MED
of	O
the	O
electrophysiological	B-MED
effects	I-MED
of	O
h/os	B-MED
upon	O
the	O
tida	B-MED
network	I-MED
identifies	B-MED
cellular	B-MED
mechanisms	I-MED
that	O
may	O
contribute	B-MED
to	O
the	O
circadian	B-MED
rhythmicity	I-MED
of	O
prolactin	B-MED
secretion	I-MED
.	O
	
improving	B-MED
exchange	O
with	O
consumers	B-MED
within	O
mental	B-MED
health	I-MED
organizations	I-MED
recognizing	O
mental	B-MED
ill	I-MED
health	I-MED
experience	O
as	O
a	O
'sneaky	O
,	O
special	O
degree'	O
stigmatizing	B-MED
views	O
towards	O
consumers	B-MED
may	O
be	O
held	O
even	O
by	O
those	O
working	B-MED
within	O
mental	B-MED
health	I-MED
organizations	I-MED
.	O
	
contemporary	O
mental	B-MED
health	I-MED
policies	I-MED
require	O
organizations	B-MED
to	O
work	B-MED
collaboratively	B-MED
with	O
consumers	B-MED
in	O
producing	B-MED
and	O
delivering	B-MED
services	B-MED
.	O
	
using	O
social	B-MED
exchange	I-MED
theory	I-MED
,	O
which	O
emphasises	O
mutual	B-MED
exchange	B-MED
to	O
maximise	B-MED
benefits	B-MED
in	O
partnership	B-MED
,	O
the	O
current	B-MED
study	B-MED
explores	O
the	O
perspectives	B-MED
of	O
those	O
working	B-MED
within	O
organizations	B-MED
that	O
have	O
some	O
level	B-MED
of	O
consumer	B-MED
leadership	B-MED
.	O
	
interviews	B-MED
were	O
conducted	O
with	O
14	O
participants	B-MED
from	O
a	O
range	B-MED
of	O
mental	B-MED
health	I-MED
organizations	I-MED
.	O
	
data	B-MED
were	O
transcribed	O
,	O
and	O
analyzed	B-MED
using	O
thematic	B-MED
analytic	I-MED
and	O
discursive	B-MED
psychological	B-MED
techniques	I-MED
.	O
	
findings	B-MED
suggest	O
stigma	B-MED
is	O
still	O
prevalent	O
even	O
in	O
organizations	B-MED
that	O
have	O
consumers	B-MED
in	O
leadership	B-MED
positions	I-MED
,	O
and	O
consumers	B-MED
are	O
often	O
perceived	B-MED
as	O
less	O
able	O
to	O
work	B-MED
in	O
mental	B-MED
health	I-MED
organizations	I-MED
than	O
non-consumers	O
.	O
	
several	O
discourses	B-MED
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	B-MED
bring	O
value	O
to	O
mental	B-MED
health	I-MED
organizations	I-MED
through	O
their	O
expertise	O
in	O
the	O
mental	B-MED
health	I-MED
system	I-MED
,	O
and	O
their	O
ability	B-MED
to	O
provide	O
safety	B-MED
and	O
support	B-MED
to	O
other	O
consumers	B-MED
.	O
	
through	O
a	O
social	B-MED
exchange	I-MED
theory	I-MED
lens	O
,	O
the	O
authors	B-MED
call	O
for	O
organizations	B-MED
to	O
challenge	O
stigma	B-MED
and	O
promote	B-MED
the	O
value	O
that	O
consumers	B-MED
can	O
bring	O
to	O
maximize	B-MED
mutual	B-MED
benefits	B-MED
.	O
	
does	O
sex	B-MED
really	O
matter	O
explaining	O
intraspecies	B-MED
variation	B-MED
in	O
ocean	B-MED
acidification	B-MED
responses	B-MED
ocean	B-MED
acidification	B-MED
oa	B-MED
poses	O
a	O
major	B-MED
threat	I-MED
to	O
marine	O
ecosystems	B-MED
globally	B-MED
,	O
having	O
significant	B-MED
ecological	B-MED
and	O
economic	B-MED
importance	B-MED
.	O
	
the	O
number	B-MED
and	O
complexity	B-MED
of	O
experiments	B-MED
examining	B-MED
the	O
effects	B-MED
of	I-MED
oa	B-MED
has	O
substantially	B-MED
increased	B-MED
over	O
the	O
past	B-MED
decade	B-MED
,	O
in	O
an	O
attempt	B-MED
to	O
address	B-MED
multi-stressor	B-MED
interactions	B-MED
and	O
long-term	B-MED
responses	B-MED
in	O
an	O
increasing	B-MED
range	B-MED
of	O
aquatic	B-MED
organisms	I-MED
.	O
	
however	O
,	O
differences	B-MED
in	O
the	O
response	B-MED
of	O
males	B-MED
and	O
females	B-MED
to	O
elevated	B-MED
pco2	I-MED
have	O
been	O
investigated	B-MED
in	O
fewer	B-MED
than	O
4%	O
of	O
studies	O
to	O
date	B-MED
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	B-MED
of	O
determining	O
sex	B-MED
non-destructively	B-MED
,	O
particularly	O
in	O
early	B-MED
life	I-MED
stages	I-MED
.	O
	
here	O
we	O
highlight	O
that	O
sex	B-MED
can	O
significantly	B-MED
impact	B-MED
organism	B-MED
responses	B-MED
to	O
oa	B-MED
,	O
differentially	O
affecting	B-MED
physiology	B-MED
,	O
reproduction	B-MED
,	O
biochemistry	B-MED
and	O
ultimately	B-MED
survival	I-MED
.	O
	
what	O
is	O
more	O
,	O
these	O
impacts	B-MED
do	O
not	O
always	O
conform	O
to	O
ecological	B-MED
theory	I-MED
based	O
on	O
differential	B-MED
resource	B-MED
allocation	I-MED
towards	O
reproduction	B-MED
,	O
which	O
would	O
predict	B-MED
females	B-MED
to	O
be	O
more	O
sensitive	B-MED
to	O
oa	B-MED
owing	O
to	O
the	O
higher	O
production	B-MED
cost	I-MED
of	O
eggs	B-MED
compared	B-MED
with	O
sperm	B-MED
.	O
	
therefore	O
,	O
non-	O
sex	B-MED
-	O
specific	B-MED
studies	I-MED
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	B-MED
differences	B-MED
in	O
the	O
responses	B-MED
of	O
males	B-MED
and	O
females	B-MED
to	O
oa	B-MED
,	O
with	O
consequences	B-MED
for	O
forecasting	B-MED
the	O
fate	O
of	O
natural	B-MED
populations	B-MED
in	O
a	O
near-future	B-MED
ocean	B-MED
.	O
	
computational	B-MED
analysis	I-MED
of	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
in	O
the	O
mitochondrial	B-MED
genomic	I-MED
sequences	I-MED
of	O
dermatophytes	B-MED
dermatophyte	B-MED
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	B-MED
that	O
have	O
the	O
capacity	O
to	O
invade	B-MED
keratinized	B-MED
tissue	B-MED
of	O
humans	B-MED
and	O
other	O
animals	B-MED
.	O
	
the	O
infection	B-MED
known	O
as	O
dermatophytosis	B-MED
,	O
caused	O
by	O
members	O
of	O
the	O
genera	B-MED
microsporum	B-MED
,	O
trichophyton	B-MED
,	O
and	O
epidermophyton	B-MED
includes	O
infection	B-MED
to	O
the	O
groin	B-MED
tinea	B-MED
cruris	I-MED
,	O
beard	B-MED
tinea	B-MED
barbae	I-MED
,	O
scalp	B-MED
tinea	B-MED
capitis	I-MED
,	O
feet	B-MED
tinea	B-MED
pedis	I-MED
,	O
glabrous	B-MED
skin	I-MED
tinea	B-MED
corporis	I-MED
,	O
nail	B-MED
tinea	B-MED
unguium	I-MED
,	O
and	O
hand	B-MED
tinea	B-MED
manuum	I-MED
.	O
	
the	O
identification	O
of	O
evolutionary	B-MED
relationship	B-MED
between	O
these	O
three	B-MED
genera	I-MED
of	O
dermatophyte	B-MED
is	O
epidemiologically	B-MED
important	I-MED
to	O
understand	O
their	O
pathogenicity	B-MED
.	O
	
mitochondrial	B-MED
dna	I-MED
evolves	B-MED
more	B-MED
rapidly	I-MED
than	O
a	O
nuclear	B-MED
dna	I-MED
due	O
to	O
higher	O
rate	B-MED
of	I-MED
mutation	I-MED
but	O
is	O
very	O
less	B-MED
affected	I-MED
by	O
genetic	B-MED
recombination	I-MED
,	O
making	O
it	O
an	O
important	B-MED
tool	I-MED
for	O
phylogenetic	B-MED
studies	I-MED
.	O
	
thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
of	O
trichophyton	B-MED
rubrum	I-MED
,	O
trichophyton	B-MED
mentagrophytes	I-MED
,	O
epidermophyton	B-MED
floccosum	I-MED
and	O
microsporum	B-MED
canis	I-MED
.	O
	
protein	B-MED
coding	I-MED
sequences	I-MED
of	O
the	O
mitochondrial	B-MED
genome	I-MED
were	O
aligned	O
for	O
their	O
similar	B-MED
sequences	I-MED
and	O
homology	B-MED
modelling	I-MED
was	O
performed	O
for	O
structure	B-MED
and	O
pocket	B-MED
identification	B-MED
.	O
	
the	O
results	O
obtained	O
from	O
comparative	B-MED
analysis	I-MED
of	O
the	O
protein	B-MED
sequences	I-MED
revealed	O
the	O
presence	O
of	O
functionally	O
active	B-MED
sites	I-MED
in	O
all	O
the	O
species	O
of	O
the	O
genera	B-MED
trichophyton	B-MED
and	O
microsporum	B-MED
.	O
	
however	O
in	O
epidermophyton	B-MED
floccosum	I-MED
it	O
was	O
observed	O
in	O
three	O
protein	B-MED
sequences	I-MED
of	O
the	O
five	O
studied	O
.	O
	
the	O
absence	O
of	O
these	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
in	O
e	B-MED
.	O
	
floccusum	I-MED
may	O
be	O
correlated	O
with	O
lesser	B-MED
infectivity	I-MED
of	O
this	O
organism	B-MED
.	O
	
the	O
functional	B-MED
residues	I-MED
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-MED
and	O
thus	O
can	O
act	O
as	O
putative	B-MED
target	I-MED
sites	I-MED
for	O
drug	B-MED
designing	I-MED
.	O
	
non-intubated	B-MED
subxiphoid	B-MED
uniportal	B-MED
video-assisted	I-MED
thoracoscopic	I-MED
thymectomy	I-MED
using	O
glasses-free	O
3d	O
vision	O
trans-sternal	O
thymectomy	B-MED
has	O
long	O
been	O
accepted	O
as	O
the	O
standard	O
surgical	O
procedure	O
for	O
thymic	O
masses	O
.	O
	
recently	O
,	O
minimally	O
invasive	O
methods	O
,	O
such	O
as	O
video-assisted	O
thoracoscopic	O
surgery	O
vats	O
and	O
,	O
even	O
more	O
recently	O
,	O
non-intubated	O
anesthesia	O
,	O
have	O
emerged	O
.	O
	
these	O
methods	O
provide	O
advantages	O
including	O
reductions	O
in	O
surgical	O
trauma	O
,	O
postoperative	O
associated	O
pain	O
,	O
and	O
in	O
regards	O
to	O
vats	O
,	O
provide	O
certain	O
cosmetic	O
benefits	O
.	O
	
considering	O
these	O
advantages	O
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	O
uniportal	O
vats	O
for	O
thymic	O
mass	O
using	O
a	O
glasses-free	B-MED
3d	B-MED
thoracoscopic	O
display	O
system	I-MED
trends	B-MED
in	O
dietary	B-MED
intake	I-MED
among	O
adults	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
nhanes	B-MED
1988-2012	O
dietary	B-MED
recommendations	B-MED
for	O
adults	B-MED
with	O
diabetes	B-MED
are	O
to	O
follow	O
a	O
healthy	B-MED
diet	I-MED
in	O
appropriate	O
portion	B-MED
sizes	I-MED
.	O
	
we	O
determined	O
recent	O
trends	B-MED
in	O
energy	B-MED
and	O
nutrient	B-MED
intakes	I-MED
among	O
a	O
nationally	O
representative	O
sample	O
of	O
us	B-MED
adults	B-MED
with	O
and	O
without	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
	
participants	B-MED
were	O
adults	B-MED
aged	B-MED
20	O
years	B-MED
from	O
the	O
cross-sectional	B-MED
national	I-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
surveys	I-MED
,	O
1988-2012	O
n	O
=	O
49	O
770	O
.	O
	
diabetes	B-MED
was	O
determined	O
by	O
self-report	B-MED
of	O
a	O
physician's	B-MED
diagnosis	B-MED
n	O
=	O
4885	O
.	O
	
intake	B-MED
of	I-MED
energy	I-MED
and	O
nutrients	B-MED
were	O
determined	O
from	O
a	O
24-	O
h	B-MED
recall	O
by	O
participants	B-MED
of	O
all	O
food	B-MED
consumed	O
.	O
	
linear	B-MED
regression	I-MED
was	O
used	O
to	O
test	B-MED
for	O
trends	B-MED
in	O
mean	O
intake	B-MED
over	O
time	B-MED
for	O
all	O
participants	B-MED
and	O
by	O
demographic	B-MED
characteristics	I-MED
.	O
	
among	O
adults	B-MED
with	O
diabetes	B-MED
,	O
overall	O
total	O
energy	B-MED
intake	I-MED
increased	B-MED
between	O
1988-1994	O
and	O
2011-2012	O
1689	B-MED
kcal	I-MED
versus	O
1895	B-MED
kcal	I-MED
ptrend	O
<	O
0.001	O
with	O
evidence	O
of	O
a	O
plateau	B-MED
between	O
2003-2006	O
and	O
2011-2012	O
.	O
	
in	O
2007-2012	O
,	O
energy	B-MED
intake	I-MED
was	O
greater	O
for	O
younger	B-MED
than	O
older	B-MED
adults	I-MED
,	O
for	O
men	B-MED
than	O
women	B-MED
,	O
and	O
for	O
non-hispanic	B-MED
whites	I-MED
versus	O
non-hispanic	B-MED
blacks	I-MED
.	O
	
there	O
was	O
no	O
change	O
in	O
the	O
percentage	B-MED
of	O
calories	B-MED
from	O
carbohydrate	B-MED
,	O
total	B-MED
fat	I-MED
or	O
protein	B-MED
.	O
	
percentage	B-MED
of	O
calories	B-MED
from	O
saturated	B-MED
fat	I-MED
was	O
similar	O
across	O
study	B-MED
periods	B-MED
but	O
remained	O
above	O
recommendations	B-MED
11.2	O
in	O
2011-2012	O
.	O
	
fibre	B-MED
intake	I-MED
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	B-MED
ptrend	O
=	O
0.002	O
.	O
	
sodium	B-MED
,	O
cholesterol	B-MED
and	O
calcium	B-MED
intakes	B-MED
increased	B-MED
.	O
	
there	O
was	O
no	O
change	O
in	O
energy	B-MED
intake	I-MED
among	O
adults	B-MED
without	O
diabetes	B-MED
and	O
dietary	B-MED
trends	B-MED
were	O
similar	O
to	O
those	O
with	O
diabetes	B-MED
.	O
	
future	O
data	B-MED
are	O
needed	O
to	O
confirm	O
a	O
plateau	B-MED
in	O
energy	B-MED
intake	I-MED
among	O
adults	B-MED
with	O
diabetes	B-MED
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	B-MED
fibre	B-MED
and	O
reduce	B-MED
saturated	B-MED
fat	I-MED
.	O
	
clonal	B-MED
and	O
serotype	B-MED
dynamics	B-MED
of	O
serogroup	B-MED
6	I-MED
isolates	B-MED
causing	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
portugal	B-MED
1999-2012	O
although	O
serogroup	B-MED
6	I-MED
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
streptococcus	B-MED
pneumoniae	I-MED
,	O
several	O
new	O
serotypes	B-MED
were	O
identified	B-MED
since	O
the	O
introduction	B-MED
of	O
pneumococcal	B-MED
conjugate	I-MED
vaccines	I-MED
pcvs	B-MED
.	O
	
a	O
decrease	B-MED
of	O
the	O
6b-2	B-MED
variant	I-MED
among	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
ipd	B-MED
,	O
but	O
not	O
6b-1	B-MED
,	O
was	O
noted	O
post	B-MED
conjugate	B-MED
vaccine	I-MED
introduction	B-MED
,	O
underpinned	O
by	O
a	O
decrease	B-MED
of	O
cc273	B-MED
isolates	I-MED
.	O
	
serotype	B-MED
6c	I-MED
was	O
associated	B-MED
with	I-MED
adult	B-MED
ipd	B-MED
and	O
increased	B-MED
in	O
this	O
age	B-MED
group	I-MED
representing	O
two	O
lineages	B-MED
cc315	B-MED
and	O
cc395	B-MED
,	O
while	O
the	O
same	O
lineages	B-MED
expressed	B-MED
other	O
serogroup	B-MED
6	I-MED
serotypes	B-MED
in	O
children	B-MED
.	O
	
taken	O
together	O
,	O
these	O
findings	B-MED
suggest	O
a	O
potential	O
cross-protection	B-MED
of	O
pcvs	B-MED
against	O
serotype	B-MED
6c	I-MED
ipd	B-MED
among	O
vaccinated	B-MED
children	B-MED
but	O
not	O
among	O
adults	B-MED
.	O
	
serotype	B-MED
6a	I-MED
became	O
the	O
most	O
important	O
serogroup	B-MED
6	I-MED
serotype	B-MED
in	O
children	B-MED
but	O
it	O
decreased	B-MED
in	O
adult	B-MED
ipd	B-MED
.	O
	
no	O
other	O
serogroup	B-MED
6	I-MED
serotypes	B-MED
were	O
detected	B-MED
,	O
so	O
available	O
phenotypic	B-MED
or	O
simple	O
genotypic	B-MED
assays	B-MED
remain	O
adequate	B-MED
for	O
distinguishing	O
serotypes	B-MED
within	O
serogroup	B-MED
6	I-MED
isolates	B-MED
.	O
	
minimally	B-MED
invasive	I-MED
percutaneous	B-MED
nephrolithotomy	I-MED
improves	O
stone-free	O
rates	O
for	O
impacted	B-MED
proximal	B-MED
ureteral	B-MED
stones	I-MED
a	O
systematic	B-MED
review	I-MED
and	O
meta-analysis	B-MED
urinary	B-MED
stones	I-MED
are	O
common	O
medical	B-MED
disorders	B-MED
and	O
the	O
treatment	B-MED
of	O
impacted	B-MED
proximal	I-MED
ureteral	I-MED
stones	I-MED
ipus	O
is	O
still	O
a	O
challenge	O
for	O
urologists	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
minimally	O
invasive	O
percutaneous	O
nephrolithotomy	O
mi	O
-	O
pcnl	O
and	O
ureteroscopic	O
lithotripsy	O
url	O
in	O
the	O
treatment	O
of	O
ipus	O
via	O
a	O
meta-analysis	O
.	O
	
we	O
collected	O
studies	O
using	O
pubmed	O
,	O
embase	O
,	O
and	O
cochrane	O
library	O
from	O
1978	O
to	O
november	O
2016	O
and	O
analyzed	O
them	O
using	O
stata	O
12.0	O
and	O
revman	O
5.3	O
.	O
	
odds	O
ratios	O
or	O
s	O
and	O
standard	O
mean	O
difference	O
smd	O
were	O
calculated	O
for	O
binary	O
and	O
continuous	O
variables	O
respectively	O
,	O
accompanied	O
with	O
95%	O
confidence	O
intervals	O
cis	O
.	O
	
all	O
study	O
procedures	O
followed	O
the	O
prisma	O
guidelines	O
.	O
	
five	O
prospective	O
studies	O
were	O
included	O
in	O
our	O
meta-analysis	O
,	O
with	O
242	O
mi	O
-	O
pcnl	O
and	O
256	O
url	O
cases	O
.	O
	
mi	O
-	O
pcnl	O
was	O
associated	O
with	O
a	O
longer	O
postoperative	O
hospital	O
stay	O
than	O
url	O
smd	O
,	O
3.14	O
95%	O
ci	O
,	O
1.27	O
to	O
5.55	O
.	O
	
however	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
operative	O
time	O
smd	O
,	O
-0	O
95%	O
ci	O
,	O
-3	O
to	O
2.38	O
.	O
	
in	O
addition	O
,	O
mi	O
-	O
pcnl	O
had	O
higher	O
initial	O
or	O
,	O
11.12	O
95%	O
ci	O
,	O
5.56	O
to	O
22.24	O
and	O
overall	O
stone-free	O
rates	O
or	O
,	O
8.70	O
95%	O
ci	O
,	O
3.23	O
to	O
23.45	O
than	O
url	O
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical	O
conversion	O
or	O
,	O
0.11	O
95%	O
ci	O
,	O
0.03	O
to	O
0.49	O
and	O
postoperative	O
shock	O
wave	O
lithotripsy	O
or	O
,	O
0.06	O
95%	O
ci	O
,	O
0.02	O
to	O
0.18	O
.	O
	
regarding	O
complications	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
mi	O
-	O
pcnl	O
and	O
url	O
or	O
,	O
1.39	O
95%	O
ci	O
,	O
0.93	O
to	O
2.10	O
,	O
except	O
for	O
hematuria	O
or	O
,	O
4.80	O
95%	O
ci	O
,	O
1.45	O
to	O
15.94	O
.	O
	
mi	O
-	O
pcnl	O
is	O
optimal	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
treatment	O
method	O
for	O
ipus	O
,	O
as	O
it	O
has	O
better	O
efficacy	O
and	O
a	O
safety	O
profile	O
similar	O
to	O
that	O
of	O
url	O
.	O
	
however	O
,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	O
in	O
future	B-MED
predictive	B-MED
factors	I-MED
for	O
long-term	B-MED
outcome	B-MED
of	O
subthalamic	B-MED
nucleus	I-MED
deep	B-MED
brain	I-MED
stimulation	I-MED
for	O
parkinson's	B-MED
disease	I-MED
despite	O
the	O
recognition	O
of	O
the	O
usefulness	B-MED
of	O
subthalamic	B-MED
nucleus	I-MED
deep	B-MED
brain	I-MED
stimulation	I-MED
stn	B-MED
-	O
dbs	B-MED
for	O
the	O
treatment	B-MED
of	O
parkinson's	B-MED
disease	I-MED
pd	B-MED
,	O
preoperative	B-MED
predictive	B-MED
factors	I-MED
for	O
the	O
long-term	B-MED
outcome	B-MED
of	O
stn	B-MED
-	O
dbs	B-MED
are	O
not	B-MED
sufficiently	B-MED
established	B-MED
.	O
	
we	O
performed	O
this	O
study	B-MED
to	O
determine	O
such	O
predictive	B-MED
factors	I-MED
.	O
	
the	O
subjects	B-MED
were	O
66	O
patients	B-MED
who	O
were	O
classified	B-MED
into	O
two	B-MED
groups	B-MED
on	O
the	O
basis	B-MED
of	O
their	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
adl	B-MED
evaluated	O
five	B-MED
years	I-MED
after	B-MED
the	O
stn	B-MED
-	O
dbs	B-MED
surgery	B-MED
33	O
patients	B-MED
were	O
assigned	B-MED
to	O
the	O
independent	B-MED
adl	B-MED
group	B-MED
group	B-MED
i	I-MED
and	O
the	O
remaining	O
33	O
patients	B-MED
to	O
the	O
dependent	B-MED
adl	B-MED
group	B-MED
group	B-MED
d	I-MED
.	O
	
group	B-MED
i	I-MED
patients	B-MED
showed	O
a	O
schwab	B-MED
and	I-MED
england	I-MED
s	I-MED
scale	I-MED
score	O
of	O
more	O
than	O
70	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
maintain	O
their	O
independent	O
adl	O
all	O
the	O
time	O
.	O
	
group	O
d	O
patients	O
showed	O
a	O
score	O
of	O
70	O
or	O
lower	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
cannot	O
maintain	O
their	O
independent	O
adl	O
for	O
an	O
entire	O
day	O
.	O
	
we	O
studied	O
the	O
differences	O
in	O
the	O
preoperative	O
state	O
between	O
these	O
two	O
groups	O
.	O
	
statistically	O
significant	O
differences	O
were	O
noted	O
in	O
pd	O
onset	O
age	O
,	O
age	O
at	O
surgery	O
,	O
preoperative	O
unified	O
parkinson's	O
disease	O
rating	O
scale	O
updrs	O
part	O
i	O
score	O
,	O
part	O
ii	O
score	O
,	O
total	O
subscore	O
for	O
axial	O
symptoms	O
in	O
part	O
iii	O
,	O
mini-mental	O
state	O
examination	O
mmse	O
score	O
and	O
s	B-MED
score	B-MED
.	O
	
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
significant	O
independent	O
variables	O
related	O
to	O
long-term	O
independent	O
adl	O
were	O
the	O
age	O
at	O
surgery	O
,	O
mmse	O
score	O
and	O
preoperative	O
s	O
scale	O
score	O
during	B-MED
the	O
off-period	B-MED
.	O
	
the	O
pd	O
onset	O
age	O
,	O
age	O
at	O
surgery	O
,	O
preoperative	O
high	O
-	O
level	O
adl	O
,	O
cognitive	O
function	O
,	O
and	O
axial	O
symptoms	O
are	O
important	O
predictive	O
factors	O
for	O
the	O
long-term	O
outcome	O
of	O
stn	O
-	O
dbs	B-MED
who	O
persuades	B-MED
who	O
an	O
analysis	B-MED
of	O
persuasion	B-MED
choices	B-MED
related	O
to	O
antibiotic	B-MED
-	O
free	B-MED
food	B-MED
personal	B-MED
communication	I-MED
,	O
in	O
which	O
one	O
person	B-MED
persuades	B-MED
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	B-MED
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	B-MED
spread	B-MED
.	O
	
to	O
better	O
understand	B-MED
how	O
personal	B-MED
communication	I-MED
spreads	B-MED
behavior	B-MED
,	O
we	O
investigated	B-MED
adults'	B-MED
n	O
=	O
228	O
likelihood	B-MED
of	O
persuading	B-MED
others	O
in	O
a	O
fictitious	O
social	B-MED
network	I-MED
to	O
buy	B-MED
antibiotic	B-MED
-	O
free	B-MED
food	B-MED
,	O
and	O
who	O
they	O
attempted	B-MED
to	O
persuade	B-MED
,	O
based	O
on	O
behavioral	B-MED
determinants	B-MED
,	O
homophily	B-MED
,	O
and	O
superdiffuser	B-MED
traits	B-MED
.	O
	
for	O
potential	B-MED
consumers	B-MED
,	O
the	O
findings	B-MED
showed	O
that	O
behavioral	B-MED
determinants	B-MED
,	O
behavioral	B-MED
intentions	B-MED
,	O
and	O
mavenism	B-MED
predicted	B-MED
intentions	B-MED
to	O
persuade	B-MED
others	O
.	O
	
homophily	B-MED
,	O
mavenism	B-MED
,	O
and	O
connectivity	B-MED
predicted	B-MED
patterns	B-MED
of	O
interpersonal	B-MED
persuasion	B-MED
.	O
	
for	O
vegetarians	B-MED
without	O
homophily	B-MED
in	O
action	B-MED
,	O
behavioral	B-MED
determinants	B-MED
and	O
mavenism	B-MED
predicted	B-MED
persuasion	B-MED
intentions	B-MED
.	O
	
persuasiveness	B-MED
was	O
associated	B-MED
with	I-MED
targeting	B-MED
more	O
network	B-MED
members	B-MED
mavenism	B-MED
was	O
associated	B-MED
with	I-MED
selecting	O
structurally	B-MED
central	B-MED
members	B-MED
.	O
	
modeling	B-MED
the	O
flux	B-MED
of	O
metabolites	B-MED
in	O
the	O
juvenile	B-MED
hormone	I-MED
biosynthesis	B-MED
pathway	B-MED
using	O
generalized	B-MED
additive	I-MED
models	I-MED
and	O
ordinary	B-MED
differential	I-MED
equations	I-MED
juvenile	B-MED
hormone	I-MED
jh	B-MED
regulates	O
development	B-MED
and	O
reproductive	B-MED
maturation	I-MED
in	O
insects	B-MED
.	O
	
the	O
corpora	B-MED
allata	I-MED
ca	B-MED
from	O
female	B-MED
adult	B-MED
mosquitoes	I-MED
synthesize	O
fluctuating	B-MED
levels	B-MED
of	O
jh	B-MED
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian	B-MED
development	I-MED
and	O
are	O
influenced	O
by	O
nutritional	B-MED
signals	B-MED
.	O
	
the	O
rate	B-MED
of	O
jh	B-MED
biosynthesis	B-MED
is	O
controlled	O
by	O
the	O
rate	B-MED
of	O
flux	B-MED
of	O
isoprenoids	B-MED
in	O
the	O
pathway	B-MED
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	B-MED
in	O
precursor	B-MED
pools	O
and	O
enzyme	B-MED
levels	B-MED
.	O
	
a	O
comprehensive	B-MED
study	B-MED
of	O
the	O
changes	B-MED
in	O
enzymatic	B-MED
activities	I-MED
and	O
precursor	B-MED
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	B-MED
aedes	B-MED
aegypti	I-MED
jh	B-MED
biosynthesis	B-MED
pathway	B-MED
.	O
	
in	O
the	O
present	O
studies	B-MED
,	O
we	O
used	O
two	O
different	O
quantitative	B-MED
approaches	I-MED
to	O
describe	O
and	O
predict	O
how	O
changes	B-MED
in	O
the	O
individual	O
metabolic	B-MED
reactions	B-MED
in	O
the	O
pathway	B-MED
affect	O
jh	B-MED
synthesis	B-MED
.	O
	
first	O
,	O
we	O
constructed	O
generalized	B-MED
additive	I-MED
models	I-MED
gams	B-MED
that	O
described	O
the	O
association	O
between	O
changes	B-MED
in	O
specific	O
metabolite	B-MED
concentrations	B-MED
with	O
changes	B-MED
in	O
enzymatic	B-MED
activities	I-MED
and	O
substrate	B-MED
concentrations	B-MED
.	O
	
changes	B-MED
in	O
substrate	B-MED
concentrations	B-MED
explained	O
50%	O
or	O
more	O
of	O
the	O
model	B-MED
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	B-MED
steps	B-MED
analyzed	B-MED
.	O
	
addition	O
of	O
information	O
on	O
enzymatic	B-MED
activities	I-MED
almost	O
always	O
improved	O
the	O
fitness	B-MED
of	O
gams	B-MED
built	O
solely	O
based	O
on	O
substrate	B-MED
concentrations	B-MED
.	O
	
gams	B-MED
were	O
validated	O
using	O
experimental	B-MED
data	B-MED
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built	O
.	O
	
in	O
addition	O
,	O
a	O
system	O
of	O
ordinary	B-MED
differential	I-MED
equations	I-MED
ode	B-MED
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	B-MED
in	O
metabolites	B-MED
as	O
a	O
function	B-MED
of	O
the	O
levels	B-MED
of	O
enzymatic	B-MED
catalytic	I-MED
activities	I-MED
.	O
	
the	O
results	B-MED
demonstrated	O
the	O
ability	O
of	O
the	O
models	B-MED
to	O
predict	O
changes	B-MED
in	O
the	O
flux	B-MED
of	O
metabolites	B-MED
in	O
the	O
jh	B-MED
pathway	B-MED
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	B-MED
and	O
validate	B-MED
experimental	B-MED
manipulations	B-MED
of	O
jh	B-MED
synthesis	B-MED
.	O
	
associations	B-MED
between	O
human	B-MED
breast	I-MED
milk	I-MED
hormones	B-MED
and	O
adipocytokines	B-MED
and	O
infant	B-MED
growth	I-MED
and	O
body	B-MED
composition	I-MED
in	O
the	O
first	B-MED
6	I-MED
months	I-MED
of	I-MED
life	I-MED
much	O
is	O
to	O
be	O
learnt	O
about	O
human	B-MED
breast	I-MED
milk	I-MED
hbm	B-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
hbm	B-MED
by	O
investigating	O
the	O
role	O
of	O
maternal	B-MED
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
,	O
sex	B-MED
and	O
stage	B-MED
of	I-MED
lactation	I-MED
month	O
1	O
vs	O
.	O
	
6	O
on	O
hbm	B-MED
insulin	B-MED
,	O
glucose	B-MED
,	O
leptin	B-MED
,	O
il-6	B-MED
and	O
tnf-α	B-MED
and	O
their	O
associations	B-MED
with	O
infant	B-MED
body	B-MED
composition	I-MED
.	O
	
thirty-seven	O
exclusively	O
breastfeeding	B-MED
infants	I-MED
n	O
=	O
37	O
16	O
,	O
21	O
,	O
and	O
their	O
mothers	B-MED
19-47	O
kg	O
m	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	B-MED
.	O
	
infants	B-MED
had	O
body	B-MED
composition	I-MED
measured	I-MED
using	O
dual-energy	B-MED
x-ray	I-MED
absorptiometry	I-MED
and	O
hbm	B-MED
collected	O
.	O
	
a	O
significant	O
interaction	B-MED
between	O
maternal	B-MED
bmi	B-MED
and	O
infant	B-MED
sex	I-MED
on	O
insulin	B-MED
levels	I-MED
p	O
=	O
0.0322	O
was	O
observed	O
such	O
that	O
insulin	B-MED
was	I-MED
229%	I-MED
higher	I-MED
in	O
obese	B-MED
mothers	B-MED
nursing	O
female	B-MED
infants	I-MED
than	O
in	O
normal	B-MED
weight	I-MED
mothers	B-MED
nursing	B-MED
female	O
infants	O
and	O
179%	O
higher	O
than	O
obese	O
mothers	O
nursing	B-MED
male	O
infants	O
.	O
	
for	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
bmi	O
category	O
was	O
observed	O
p	O
<	O
0.0001	O
such	O
that	O
overweight	O
and	O
obese	O
mothers	O
had	O
96.5	O
and	O
315.1	O
higher	O
leptin	O
levels	O
than	O
normal	O
weight	O
mothers	O
,	O
respectively	O
.	O
	
leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
p	O
=	O
0.0004	O
33.7	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
bmi	O
category	O
and	O
sex	O
.	O
	
a	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	O
length	O
p	O
=	O
0.0257	O
,	O
percent	O
fat	O
p	O
=	O
0.0223	O
,	O
total	O
fat	O
mass	O
p	O
=	O
0.0226	O
and	O
trunk	O
fat	O
mass	O
p	O
=	O
0.0111	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O
	
no	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	O
,	O
tnf-α	O
or	O
il-6	O
.	O
	
these	O
data	O
demonstrate	O
that	O
maternal	O
bmi	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	O
and	O
leptin	B-MED
aryl	B-MED
hydrocarbon	I-MED
receptor	I-MED
ahr	I-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
association	O
with	O
infertile	B-MED
oligoasthenoteratozoospermic	B-MED
men	B-MED
and	O
seminal	B-MED
oxidative	B-MED
stress	I-MED
this	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	B-MED
hydrocarbon	I-MED
receptor	I-MED
ahr	I-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
with	O
infertile	B-MED
oligoasthenoteratozoospermic	B-MED
oat	B-MED
men	B-MED
and	O
seminal	B-MED
oxidative	B-MED
stress	I-MED
os	B-MED
.	O
	
a	O
total	O
of	O
170	O
egyptian	B-MED
men	I-MED
were	O
allocated	O
according	O
to	O
their	O
semen	B-MED
analysis	I-MED
into	O
fertile	B-MED
normozoospermic	B-MED
controls	I-MED
n	O
=	O
50	O
and	O
infertile	B-MED
oat	B-MED
men	B-MED
n	O
=	O
120	O
.	O
	
they	O
were	O
subjected	O
to	O
history	B-MED
taking	I-MED
,	O
clinical	B-MED
examination	I-MED
,	O
semen	B-MED
analysis	I-MED
,	O
estimation	B-MED
of	O
seminal	B-MED
glutathione	B-MED
peroxidase	I-MED
gpx	B-MED
,	O
and	O
malondialdehyde	B-MED
mda	B-MED
.	O
	
ahr	B-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
was	O
identified	O
in	O
the	O
blood	B-MED
by	O
pcr	B-MED
-	O
rflp	B-MED
.	O
	
comparing	O
infertile	B-MED
oat	B-MED
men	B-MED
with	O
fertile	B-MED
controls	B-MED
,	O
ahr	B-MED
rs2066853	I-MED
genotypes	B-MED
showed	O
decreased	B-MED
prevalence	B-MED
for	O
wild	B-MED
homozygous	B-MED
genotype	I-MED
gg	I-MED
35.8	O
vs	O
56%	O
and	O
for	O
heterozygous	B-MED
genotype	I-MED
ga	I-MED
17.5	O
vs	O
30%	O
and	O
an	O
increased	B-MED
prevalence	B-MED
for	O
homozygous	B-MED
genotype	I-MED
aa	I-MED
46.7	O
vs	O
14%	O
.	O
	
distribution	O
of	O
alleles	B-MED
of	O
ahr	B-MED
rs2066853	I-MED
among	O
oat	B-MED
men	B-MED
compared	O
with	O
fertile	B-MED
men	B-MED
showed	O
decreased	B-MED
prevalence	B-MED
of	O
g	B-MED
allele	I-MED
44.6	O
vs	O
71%	O
and	O
an	O
increased	B-MED
prevalence	B-MED
of	O
a	B-MED
allele	I-MED
55.4	O
vs	O
29%	O
.	O
	
seminal	B-MED
mda	B-MED
demonstrated	O
significant	O
increase	B-MED
whereas	O
seminal	B-MED
gpx	B-MED
demonstrated	O
significant	O
decrease	B-MED
in	O
cases	O
with	O
aa	B-MED
and	O
ga	B-MED
/	O
aa	B-MED
genotypes	I-MED
compared	O
to	O
cases	O
with	O
gg	B-MED
genotype	I-MED
.	O
	
it	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
ahr	B-MED
rs2066853	I-MED
genotype	B-MED
polymorphism	B-MED
with	O
decreased	B-MED
sperm	B-MED
parameters	O
as	O
well	O
as	O
increased	B-MED
seminal	B-MED
oxidative	B-MED
stress	I-MED
in	O
infertile	B-MED
oat	B-MED
men	B-MED
.	O
	
associations	B-MED
of	O
gender	B-MED
and	O
a	O
proxy	B-MED
of	O
female	B-MED
menopausal	B-MED
status	I-MED
with	O
histological	B-MED
features	B-MED
of	O
drug-induced	B-MED
liver	I-MED
injury	I-MED
gender	B-MED
and	O
menopause	B-MED
may	O
contribute	O
to	O
type	B-MED
and	O
severity	B-MED
of	O
drug-induced	B-MED
liver	I-MED
injury	I-MED
dili	B-MED
by	O
influencing	B-MED
host	B-MED
responses	B-MED
to	O
injury	B-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
the	O
associations	B-MED
of	O
gender	B-MED
and	O
female	B-MED
age	B-MED
50	O
a	O
proxy	B-MED
of	O
menopause	B-MED
with	O
histological	B-MED
features	B-MED
of	O
liver	B-MED
injury	I-MED
in	O
212	O
adults	B-MED
enrolled	O
in	O
the	O
drug-induced	B-MED
liver	I-MED
injury	I-MED
network	B-MED
dilin	B-MED
registry	B-MED
.	O
	
all	O
participants	B-MED
had	O
a	O
causality	B-MED
score	B-MED
of	O
at	O
least	O
'	O
probable	B-MED
'	O
,	O
a	O
liver	B-MED
biopsy	I-MED
within	O
30	O
days	O
of	O
dili	B-MED
onset	O
,	O
and	O
no	O
prior	O
chronic	B-MED
liver	I-MED
disease	I-MED
.	O
	
biochemical	B-MED
and	O
histological	B-MED
injury	B-MED
types	B-MED
were	O
classified	O
as	O
hepatocellular	B-MED
or	O
cholestatic/mixed	B-MED
injury	I-MED
.	O
	
the	O
cohort	B-MED
was	O
divided	B-MED
into	O
three	O
gender	B-MED
/	O
age	B-MED
categories	B-MED
men	B-MED
41.0	O
,	O
women	B-MED
<50	O
years	O
27.4	O
and	O
women	B-MED
50	O
years	O
of	O
age	B-MED
31.6	O
.	O
	
interaction	B-MED
of	O
gender	B-MED
and	O
age	B-MED
category	B-MED
50	O
or	O
not	O
was	O
assessed	B-MED
.	O
	
hepatocellular	B-MED
injury	I-MED
was	O
more	O
prevalent	O
in	O
women	B-MED
<50	O
years	O
vs	O
.	O
	
others	O
p=	O
.	O
	
after	O
adjusting	O
for	O
biochemical	B-MED
injury	B-MED
types	B-MED
,	O
black	B-MED
race	I-MED
and	O
possible	B-MED
ageing	B-MED
effects	B-MED
,	O
more	O
severe	B-MED
interface	O
hepatitis	B-MED
was	O
noted	O
in	O
biopsies	B-MED
of	O
women	B-MED
<50	O
years	O
compared	B-MED
to	O
those	O
of	O
men	B-MED
and	O
women	B-MED
50	O
years	O
p=	O
and	O
p=	O
respectively	O
.	O
	
compared	B-MED
to	O
those	O
of	O
men	B-MED
,	O
biopsies	B-MED
of	O
women	B-MED
showed	O
greater	B-MED
plasma	B-MED
cell	I-MED
infiltration	I-MED
,	O
hepatocyte	B-MED
apoptosis	I-MED
,	O
hepatocyte	B-MED
rosettes	B-MED
and	O
lobular	B-MED
disarray	O
but	O
less	O
iron	B-MED
-	O
positive	B-MED
hepatocytes	B-MED
and	O
histological	B-MED
cholestasis	B-MED
p<	O
.	O
	
these	O
associations	B-MED
persisted	O
after	O
excluding	O
cases	B-MED
of	O
amoxicillin/clavulanic	B-MED
acid	I-MED
,	O
anabolic	B-MED
steroids	I-MED
or	O
nitrofurantoin	B-MED
dili	B-MED
which	O
showed	O
gender	B-MED
-specific	O
distributions	B-MED
.	O
	
gender	B-MED
and	O
a	O
proxy	B-MED
of	O
menopause	B-MED
were	O
associated	B-MED
with	I-MED
various	O
features	B-MED
of	O
inflammation	B-MED
and	O
injury	B-MED
in	O
a	O
novel	O
potent	O
anticancer	B-MED
compound	I-MED
optimized	O
from	O
a	O
natural	B-MED
oridonin	B-MED
scaffold	O
induces	O
apoptosis	B-MED
and	O
cell	B-MED
cycle	I-MED
arrest	I-MED
through	O
the	O
mitochondrial	B-MED
pathway	I-MED
the	O
cytotoxicity	B-MED
of	O
the	O
natural	B-MED
ent-kaurene	B-MED
diterpenoid	I-MED
,	O
oridonin	B-MED
,	O
has	O
been	O
extensively	O
studied	O
.	O
	
however	O
,	O
the	O
application	O
of	O
oridonin	B-MED
for	O
cancer	B-MED
therapy	I-MED
was	O
hampered	O
primarily	O
by	O
its	O
moderate	B-MED
potency	I-MED
.	O
	
in	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B-MED
a-ring	B-MED
modified	I-MED
analogues	I-MED
,	O
and	I-MED
their	I-MED
derivatives	I-MED
bearing	O
various	O
substituents	B-MED
on	I-MED
14-oh	I-MED
position	I-MED
,	O
were	O
designed	O
,	O
synthesized	B-MED
,	O
and	O
evaluated	B-MED
for	O
anticancer	B-MED
efficacy	B-MED
.	O
	
some	O
of	O
the	O
derivatives	B-MED
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-MED
against	O
both	O
drug	B-MED
-	O
sensitive	B-MED
and	O
drug-resistant	B-MED
cancer	B-MED
cells	I-MED
.	O
	
the	O
most	O
potent	O
compound	B-MED
,	O
13p	I-MED
,	O
was	O
200-fold	B-MED
more	O
efficacious	B-MED
than	O
oridonin	B-MED
in	O
mcf-7	B-MED
cancer	I-MED
cells	I-MED
.	O
	
furthermore	O
,	O
13p	B-MED
induced	O
apoptosis	B-MED
and	O
cell	B-MED
cycle	I-MED
arrest	I-MED
at	O
the	O
g2/m	B-MED
phase	I-MED
.	O
	
a	O
decrease	O
in	O
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
and	O
an	O
increase	O
in	O
bax/bcl-2	B-MED
ratio	O
,	O
accompanied	O
by	O
activated	B-MED
caspase-3	I-MED
cleavage	B-MED
,	O
were	O
observed	O
in	O
mcf-7	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
13p	B-MED
,	O
suggesting	O
that	O
the	O
mitochondrial	B-MED
pathway	I-MED
was	O
involved	O
in	O
the	O
13p	B-MED
-mediated	O
apoptosis	B-MED
.	O
	
moreover	O
,	O
13p	B-MED
significantly	O
inhibited	O
tumor	B-MED
growth	I-MED
in	O
mouse	B-MED
xenograft	B-MED
models	I-MED
and	O
had	O
no	B-MED
observable	I-MED
toxic	I-MED
effect	I-MED
.	O
	
stromal	B-MED
alterations	I-MED
in	O
ovarian	B-MED
cancers	I-MED
via	O
wavelength	B-MED
dependent	B-MED
second	B-MED
harmonic	I-MED
generation	I-MED
microscopy	I-MED
and	O
optical	B-MED
scattering	I-MED
ovarian	B-MED
cancer	I-MED
remains	O
the	O
most	O
deadly	O
gynecological	B-MED
cancer	B-MED
with	O
a	O
poor	O
aggregate	O
survival	B-MED
rate	I-MED
however	O
,	O
the	O
specific	B-MED
rates	I-MED
are	O
highly	O
dependent	B-MED
on	O
the	O
stage	O
of	O
the	O
disease	B-MED
upon	O
diagnosis	B-MED
.	O
	
current	O
screening	B-MED
and	O
imaging	B-MED
tools	I-MED
are	O
insufficient	O
to	O
detect	O
early	B-MED
lesions	I-MED
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	B-MED
of	O
ovarian	B-MED
cancer	I-MED
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-MED
.	O
	
as	O
an	O
alternative	O
to	O
current	O
screening	B-MED
and	O
imaging	B-MED
tools	I-MED
,	O
we	O
utilized	O
wavelength	B-MED
dependent	B-MED
collagen	B-MED
-specific	O
second	B-MED
harmonic	I-MED
generation	I-MED
shg	I-MED
imaging	I-MED
microscopy	I-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
to	O
probe	O
the	O
structural	B-MED
differences	B-MED
in	O
the	O
extracellular	B-MED
matrix	I-MED
ecm	B-MED
of	O
normal	O
stroma	B-MED
,	O
benign	B-MED
tumors	I-MED
,	O
endometrioid	B-MED
tumors	I-MED
,	O
and	O
low	B-MED
and	O
high-grade	B-MED
serous	I-MED
tumors	I-MED
.	O
	
the	O
shg	B-MED
signatures	B-MED
of	O
the	O
emission	O
directionality	O
and	O
conversion	B-MED
efficiency	B-MED
as	O
well	O
as	O
the	O
optical	B-MED
scattering	I-MED
are	O
related	O
to	O
the	O
organization	B-MED
of	O
collagen	B-MED
on	O
the	O
sub-micron	B-MED
size	B-MED
scale	I-MED
and	O
encode	O
structural	B-MED
information	B-MED
.	O
	
the	O
wavelength	B-MED
dependence	B-MED
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	B-MED
and	O
distribution	B-MED
of	O
collagen	B-MED
fibrils	I-MED
/	O
fibers	B-MED
relative	O
to	O
the	O
interrogating	O
wavelengths	B-MED
.	O
	
we	O
found	O
a	O
strong	O
wavelength	B-MED
dependence	B-MED
of	O
these	O
metrics	B-MED
that	O
are	O
related	O
to	O
significant	O
structural	B-MED
differences	B-MED
in	O
the	O
collagen	B-MED
organization	B-MED
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	B-MED
of	O
type	B-MED
i	I-MED
and	I-MED
ii	I-MED
serous	I-MED
tumors	I-MED
.	O
	
moreover	O
,	O
type	B-MED
i	I-MED
endometrioid	I-MED
tumors	I-MED
have	O
strongly	O
differing	O
ecm	B-MED
architecture	O
than	O
the	O
serous	B-MED
malignancies	I-MED
.	O
	
the	O
shg	B-MED
metrics	B-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
were	O
used	O
to	O
form	O
a	O
linear	B-MED
discriminant	I-MED
model	I-MED
to	O
classify	O
the	O
tissues	B-MED
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
>90%	O
between	O
high-grade	B-MED
serous	I-MED
tumors	I-MED
from	O
the	O
other	O
tissue	B-MED
types	I-MED
.	O
	
high-grade	B-MED
serous	I-MED
tumors	I-MED
account	O
for	O
70%	O
of	O
ovarian	B-MED
cancers	I-MED
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	B-MED
analysis	I-MED
,	O
understanding	O
the	O
etiology	B-MED
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	B-MED
vivo	I-MED
screening	B-MED
tool	I-MED
.	O
	
shg	B-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
provide	O
sub-resolution	O
information	B-MED
and	O
when	O
combined	O
provide	O
superior	B-MED
diagnostic	I-MED
power	I-MED
over	O
clinical	B-MED
imaging	I-MED
modalities	B-MED
.	O
	
additionally	O
the	O
measurements	B-MED
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	B-MED
of	O
ovarian	B-MED
cancer	I-MED
and	O
may	O
potentially	O
assist	O
in	O
treatment	B-MED
protocols	I-MED
.	O
	
understanding	O
the	O
altered	B-MED
collagen	B-MED
assembly	O
can	O
supplement	O
histological	B-MED
analysis	I-MED
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	B-MED
.	O
	
these	O
methods	O
could	O
become	O
an	O
in	B-MED
vivo	I-MED
screening	B-MED
tool	I-MED
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	B-MED
malignancies	I-MED
can	O
metastasize	B-MED
while	O
undetectable	O
by	O
current	O
clinical	B-MED
imaging	I-MED
the	O
role	O
of	O
metal-on-metal	B-MED
bearings	I-MED
in	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
and	O
hip	B-MED
resurfacing	I-MED
review	B-MED
article	I-MED
the	O
current	O
role	O
of	O
metal-on-metal	B-MED
mom	I-MED
bearings	I-MED
in	O
hip	B-MED
arthroplasty	I-MED
remains	O
controversial	O
.	O
	
the	O
low	O
wear	O
offered	O
by	O
mom	B-MED
bearings	I-MED
compared	O
to	O
metal-on-polyethylene	B-MED
and	O
the	O
possibility	O
of	O
a	O
lower	B-MED
risk	I-MED
of	I-MED
dislocation	B-MED
with	O
larger	B-MED
head	I-MED
sizes	I-MED
,	O
encouraged	O
a	O
trend	B-MED
towards	O
the	O
re-introduction	B-MED
of	O
the	O
mom	B-MED
bearing	I-MED
couple	O
.	O
	
however	O
,	O
recent	O
evidence	B-MED
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
mom	B-MED
bearing	I-MED
have	O
been	O
successful	B-MED
.	O
	
the	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
mom	B-MED
bearings	I-MED
and	O
address	O
the	O
following	O
issues	O
1	O
the	O
reintroduction	B-MED
of	O
metal-on-metal	B-MED
bearings	I-MED
in	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
,	O
2	O
the	O
failure	O
of	O
metal-on-metal	B-MED
bearings	I-MED
in	O
stemmed	B-MED
total	I-MED
hip	I-MED
arthroplasty	I-MED
,	O
3	O
the	O
role	O
of	O
metal-on-metal	B-MED
hip	I-MED
resurfacing	I-MED
in	O
modern	O
orthopaedics	B-MED
and	O
4	O
metal-on-metal	B-MED
hip	I-MED
resurfacing	I-MED
versus	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
.	O
	
a	O
literature	B-MED
search	O
strategy	B-MED
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
medline	B-MED
and	O
embase	B-MED
.	O
	
the	O
highest	O
quality	B-MED
articles	I-MED
that	O
met	O
the	O
inclusion	B-MED
criteria	I-MED
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	B-MED
were	O
selected	O
.	O
	
key	O
search	O
terms	O
included	O
'	O
metal-on-metal	B-MED
'	O
,	O
'	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
'	O
and	O
'	O
hip	B-MED
resurfacing	I-MED
'	O
.	O
	
the	O
initial	O
search	O
retrieved	O
1240	O
articles	B-MED
.	O
	
twenty-two	O
articles	B-MED
were	O
selected	O
and	O
used	O
in	O
the	O
review	B-MED
.	O
	
metal-on-metal	B-MED
hip	I-MED
resurfacing	I-MED
is	O
still	O
a	O
suitable	O
treatment	B-MED
option	O
in	O
specific	B-MED
patient	B-MED
populations	I-MED
with	O
the	O
appropriate	B-MED
implant	B-MED
design	I-MED
and	O
surgical	O
skill	O
,	O
while	O
stemmed	O
metal-on-metal	B-MED
total	I-MED
hip	I-MED
arthroplasty	I-MED
should	O
be	O
avoided	O
in	O
all	B-MED
patient	I-MED
populations	I-MED
.	O
	
continued	O
follow-up	B-MED
of	O
patients	B-MED
undergoing	O
metal-on-metal	B-MED
hip	I-MED
resurfacing	I-MED
is	O
critical	B-MED
in	O
order	O
to	O
further	O
understand	O
the	O
long-term	B-MED
outcomes	B-MED
of	O
these	O
patients	B-MED
and	O
why	O
certain	O
complications	B-MED
morphogenetic	B-MED
alterations	B-MED
of	O
alternaria	B-MED
alternata	I-MED
exposed	B-MED
to	I-MED
dicarboximide	B-MED
fungicide	I-MED
,	O
iprodione	B-MED
fungicide-resistant	B-MED
alternaria	B-MED
alternata	I-MED
impede	O
the	O
practical	O
control	B-MED
of	O
the	O
alternaria	B-MED
diseases	I-MED
in	O
crop	B-MED
fields	B-MED
.	O
	
this	O
study	O
aimed	O
to	O
investigate	B-MED
cytological	B-MED
fungicide	B-MED
resistance	B-MED
mechanisms	B-MED
of	O
a	B-MED
.	O
	
alternata	I-MED
against	O
dicarboximide	B-MED
fungicide	I-MED
iprodione	B-MED
.	O
	
a	B-MED
.	O
	
alternata	I-MED
isolated	B-MED
from	O
cactus	B-MED
brown	B-MED
spot	I-MED
was	O
cultured	B-MED
on	O
potato-dextrose	B-MED
agar	I-MED
pda	B-MED
with	O
or	O
without	B-MED
iprodione	B-MED
,	O
and	O
the	O
fungal	B-MED
cultures	I-MED
with	O
different	B-MED
growth	B-MED
characteristics	B-MED
from	O
no	B-MED
,	O
initial	B-MED
and	O
full	B-MED
growth	B-MED
were	O
observed	B-MED
by	O
light	B-MED
and	O
electron	B-MED
microscopy	I-MED
.	O
	
mycelia	B-MED
began	O
to	O
grow	B-MED
from	O
one	B-MED
day	I-MED
after	I-MED
incubation	I-MED
dai	B-MED
and	O
continued	B-MED
to	O
be	O
in	O
full	B-MED
growth	B-MED
control-growth	B-MED
,	O
con-g	B-MED
on	O
pda	B-MED
without	O
fungicide	B-MED
,	O
while	O
on	O
pda	B-MED
with	O
iprodione	B-MED
,	O
no	B-MED
fungal	I-MED
growth	I-MED
iprodione-no	B-MED
growth	I-MED
,	O
ipr-n	B-MED
occurred	O
for	O
the	O
first	O
3	O
dai	B-MED
,	O
but	O
once	O
the	O
initial	B-MED
growth	B-MED
iprodione-initial	B-MED
growth	I-MED
,	O
ipr-i	B-MED
began	O
at	O
4-5	O
dai	B-MED
,	O
the	O
colonies	B-MED
grew	O
and	O
expanded	B-MED
continuously	B-MED
to	O
be	O
in	O
full	B-MED
growth	B-MED
iprodione-growth	B-MED
,	O
ipr-g	B-MED
,	O
suggesting	O
ipr-i	B-MED
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	B-MED
changes	B-MED
resisting	B-MED
fungicidal	B-MED
toxicity	B-MED
.	O
	
con-g	B-MED
formed	O
multicellular	B-MED
conidia	I-MED
with	O
cell	B-MED
walls	I-MED
and	O
septa	B-MED
and	O
intact	B-MED
dense	B-MED
cytoplasm	B-MED
.	O
	
in	O
ipr-n	B-MED
,	O
fungal	B-MED
sporulation	B-MED
was	O
inhibited	B-MED
by	O
forming	O
mostly	O
undeveloped	B-MED
unicellular	B-MED
conidia	I-MED
with	O
degraded	B-MED
and	O
necrotic	B-MED
cytoplasm	B-MED
.	O
	
however	O
,	O
in	O
ipr-i	B-MED
,	O
conspicuous	B-MED
cellular	I-MED
changes	I-MED
occurred	O
during	O
sporulation	B-MED
by	O
forming	O
multicellular	B-MED
conidia	I-MED
with	O
double	B-MED
layered	I-MED
thickened	B-MED
cell	B-MED
walls	I-MED
and	O
accumulation	B-MED
of	O
proliferated	B-MED
lipid	B-MED
bodies	I-MED
in	O
the	O
conidial	B-MED
cytoplasm	B-MED
,	O
which	O
may	O
inhibit	B-MED
the	O
penetration	B-MED
of	O
the	O
fungicide	B-MED
into	O
conidial	B-MED
cells	B-MED
,	O
reducing	O
fungicide	B-MED
-	O
associated	B-MED
toxicity	B-MED
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	B-MED
and	O
nutritional	B-MED
sources	B-MED
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	B-MED
growth	B-MED
to	O
form	O
mature	B-MED
colonies	B-MED
as	O
in	O
ipr-g	B-MED
that	O
formed	O
multicellular	B-MED
conidia	I-MED
with	O
cell	B-MED
walls	I-MED
and	O
intact	B-MED
cytoplasm	B-MED
with	O
lipid	B-MED
bodies	I-MED
as	O
in	O
limits	O
of	O
the	O
possible	O
diagnostic	B-MED
image	I-MED
quality	B-MED
in	O
coronary	B-MED
angiography	I-MED
with	O
third-generation	B-MED
dual-source	I-MED
ct	I-MED
the	O
usage	B-MED
of	O
coronary	B-MED
ct	I-MED
angiography	I-MED
cta	B-MED
is	O
appropriate	O
in	O
patients	B-MED
with	O
acute	B-MED
or	O
chronic	B-MED
chest	I-MED
pain	I-MED
however	O
the	O
diagnostic	B-MED
accuracy	I-MED
may	O
be	O
challenged	O
with	O
increased	O
agatston	B-MED
score	I-MED
as	B-MED
,	O
increased	O
heart	B-MED
rate	I-MED
,	O
arrhythmia	B-MED
and	O
severe	B-MED
obesity	I-MED
.	O
	
thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third-generation	B-MED
dual-source	I-MED
ct	I-MED
dsct	B-MED
for	O
cta	B-MED
in	O
a	O
'real-life'	O
clinical	B-MED
setting	I-MED
.	O
	
two	O
hundred	O
and	O
sixty-eight	O
consecutive	O
patients	B-MED
age	O
67	O
10	O
years	O
bmi	B-MED
27	O
5	O
kg/m²	O
61%	O
male	B-MED
undergoing	O
clinically	O
indicated	O
cta	B-MED
with	O
dsct	B-MED
were	O
included	O
in	O
the	O
retrospective	B-MED
single-center	I-MED
analysis	I-MED
.	O
	
a	O
contrast-enhanced	B-MED
volume	I-MED
dataset	I-MED
was	O
acquired	O
in	O
sequential	B-MED
ssm	B-MED
n	O
=	O
151	O
or	O
helical	B-MED
scan	I-MED
mode	I-MED
hsm	B-MED
n	O
=	O
117	O
.	O
	
coronary	B-MED
segments	I-MED
were	O
classified	O
in	O
diagnostic	B-MED
or	O
non-diagnostic	B-MED
image	I-MED
quality	I-MED
.	O
	
a	O
subset	O
underwent	O
invasive	B-MED
angiography	I-MED
to	O
determine	O
the	O
diagnostic	B-MED
accuracy	I-MED
of	O
cta	B-MED
.	O
	
ssm	B-MED
96.8	O
6%	O
and	O
hsm	B-MED
97.5	O
8%	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	B-MED
image	I-MED
quality	B-MED
.	O
	
however	O
,	O
as	B-MED
had	O
significant	O
influence	B-MED
on	O
diagnostic	B-MED
image	I-MED
quality	B-MED
exclusively	O
in	O
ssm	B-MED
b	O
=	O
0.003	O
p	O
=	O
0.0001	O
,	O
but	O
not	O
in	O
hsm	B-MED
.	O
	
diagnostic	B-MED
image	I-MED
quality	B-MED
significantly	O
decreased	O
in	O
ssm	B-MED
in	O
patients	B-MED
with	O
as	B-MED
2	O
p	O
=	O
0.03	O
.	O
	
ssm	B-MED
sensitivity	B-MED
93.9	O
specificity	B-MED
96.7	O
ppv	B-MED
88.6	O
npv	B-MED
98.3	O
and	O
hsm	B-MED
sensitivity	B-MED
97.4	O
specificity	B-MED
94.3	O
ppv	B-MED
86.0	O
npv	B-MED
99.0	O
provided	O
comparable	O
diagnostic	B-MED
accuracy	I-MED
p	O
=	O
n.s	O
.	O
	
ssm	B-MED
yielded	O
significantly	O
lower	O
radiation	B-MED
doses	I-MED
as	O
compared	O
to	O
hsm	B-MED
2.1	O
2.0	O
vs	O
.	O
	
5.1	O
3.3	O
msv	O
p	O
=	O
0.0001	O
in	O
age	B-MED
and	O
bmi	B-MED
-matched	O
cohorts	B-MED
.	O
	
ssm	B-MED
in	O
third-generation	B-MED
dsct	I-MED
enables	O
significant	O
dose	B-MED
savings	O
and	O
provides	O
robust	O
diagnostic	B-MED
image	I-MED
quality	B-MED
in	O
patients	B-MED
with	O
as	B-MED
2000	O
independent	O
of	O
heart	B-MED
rate	I-MED
,	O
heart	B-MED
rhythm	I-MED
or	O
antagonistic	B-MED
self-organizing	B-MED
patterning	I-MED
systems	O
control	B-MED
maintenance	B-MED
and	O
regeneration	B-MED
of	O
the	O
anteroposterior	B-MED
axis	B-MED
in	O
planarians	B-MED
planarian	B-MED
flatworms	B-MED
maintain	B-MED
their	O
body	B-MED
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	B-MED
from	O
arbitrary	B-MED
tissue	B-MED
fragments	B-MED
.	O
	
both	O
phenomena	B-MED
require	O
self-maintaining	B-MED
and	O
self-organizing	B-MED
patterning	I-MED
mechanisms	B-MED
,	O
the	O
molecular	B-MED
mechanisms	B-MED
of	O
which	O
remain	O
poorly	O
understood	O
.	O
	
we	O
show	O
that	O
a	O
morphogenic	B-MED
gradient	B-MED
of	O
canonical	B-MED
wnt	I-MED
signaling	I-MED
patterns	O
gene	B-MED
expression	I-MED
along	O
the	O
planarian	B-MED
anteroposterior	B-MED
a/p	B-MED
axis	B-MED
.	O
	
our	O
results	B-MED
demonstrate	O
that	O
gradient	B-MED
formation	B-MED
likely	O
occurs	O
autonomously	B-MED
in	O
the	O
tail	B-MED
and	O
that	O
an	O
autoregulatory	B-MED
module	O
of	O
wnt	B-MED
-mediated	O
wnt	B-MED
expression	B-MED
both	O
shapes	O
the	O
gradient	B-MED
at	O
steady	B-MED
state	I-MED
and	O
governs	O
its	O
re-establishment	O
during	O
regeneration	B-MED
.	O
	
functional	B-MED
antagonism	B-MED
between	O
the	O
tail	B-MED
wnt	B-MED
gradient	B-MED
and	O
an	O
unknown	B-MED
head	B-MED
patterning	B-MED
system	O
further	O
determines	O
the	O
spatial	B-MED
proportions	B-MED
of	O
the	O
planarian	B-MED
a/p	B-MED
axis	B-MED
and	O
mediates	O
mutually	B-MED
exclusive	B-MED
molecular	B-MED
fate	I-MED
choices	O
during	B-MED
regeneration	B-MED
.	O
	
overall	O
,	O
our	O
results	B-MED
suggest	O
that	O
the	O
planarian	B-MED
a/p	B-MED
axis	B-MED
is	O
patterned	O
by	O
self-organizing	B-MED
patterning	I-MED
systems	O
deployed	B-MED
from	O
either	O
end	O
that	O
are	O
functionally	B-MED
coupled	B-MED
by	O
mutual	B-MED
antagonism	B-MED
.	O
	
characterization	B-MED
and	O
ectopic	B-MED
expression	I-MED
of	O
cowri1	B-MED
,	O
an	O
ap2/erebp	B-MED
domain-containing	O
transcription	B-MED
factor	I-MED
from	O
coconut	B-MED
cocos	B-MED
nucifera	I-MED
l	I-MED
endosperm	B-MED
,	O
changes	O
the	O
seeds	B-MED
oil	B-MED
content	O
in	O
transgenic	B-MED
arabidopsis	B-MED
thaliana	I-MED
and	O
rice	B-MED
oryza	B-MED
sativa	I-MED
l	I-MED
coconut	B-MED
cocos	B-MED
nucifera	I-MED
l	I-MED
is	O
a	O
key	O
tropical	B-MED
crop	B-MED
and	O
a	O
member	O
of	O
the	O
monocotyledonous	B-MED
family	I-MED
arecaceae	B-MED
palmaceae	B-MED
.	O
	
few	O
genes	B-MED
and	O
related	O
metabolic	B-MED
processes	I-MED
involved	O
in	O
coconut	B-MED
endosperm	B-MED
development	O
have	O
been	O
investigated	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
a	O
new	O
member	O
of	O
the	O
wri1	B-MED
gene	B-MED
family	I-MED
was	O
isolated	O
from	O
coconut	B-MED
endosperm	B-MED
and	O
was	O
named	O
cowri1	B-MED
.	O
	
its	O
transcriptional	B-MED
activities	B-MED
and	O
interactions	B-MED
with	O
the	O
acetyl-coa	B-MED
carboxylase	I-MED
bccp2	B-MED
promoter	B-MED
of	O
cowri1	B-MED
were	O
confirmed	O
by	O
the	O
yeast	B-MED
two-hybrid	I-MED
and	O
yeast	B-MED
one-hybrid	I-MED
approaches	O
,	O
respectively	O
.	O
	
functional	O
characterization	B-MED
was	O
carried	O
out	O
through	O
seed	B-MED
-specific	O
expression	B-MED
in	O
arabidopsis	B-MED
and	O
endosperm	B-MED
-specific	O
expression	B-MED
in	O
rice	B-MED
.	O
	
in	O
transgenic	B-MED
arabidopsis	B-MED
,	O
high	O
over-expressions	B-MED
of	O
cowri1	B-MED
in	O
seven	O
independent	O
t2	B-MED
lines	B-MED
were	O
detected	O
by	O
quantitative	B-MED
real-time	I-MED
pcr	I-MED
.	O
	
the	O
relative	O
mrna	B-MED
accumulation	O
of	O
genes	B-MED
encoding	B-MED
enzymes	B-MED
involved	O
in	O
either	O
fatty	B-MED
acid	I-MED
biosynthesis	I-MED
or	O
triacylglycerols	B-MED
assembly	O
bccp2	B-MED
,	O
kasi	B-MED
,	O
mat	B-MED
,	O
enr	B-MED
,	O
fata	B-MED
,	O
and	O
gpdh	B-MED
were	O
also	O
assayed	B-MED
in	O
mature	O
seeds	B-MED
.	O
	
furthermore	O
,	O
lipid	B-MED
and	O
fatty	B-MED
acids	I-MED
c16	B-MED
and	O
c18	B-MED
significantly	O
increased	O
.	O
	
in	O
two	O
homozygous	B-MED
t2	B-MED
transgenic	B-MED
rice	B-MED
lines	I-MED
g5	B-MED
and	O
g2	B-MED
,	O
different	O
cowri1	B-MED
expression	B-MED
levels	O
were	O
detected	O
,	O
but	O
no	O
cowri1	B-MED
transcripts	B-MED
were	O
detected	O
in	O
the	O
wild	B-MED
type	I-MED
.	O
	
analyses	B-MED
of	O
the	O
seed	B-MED
oil	B-MED
content	O
,	O
starch	B-MED
content	O
,	O
and	O
total	O
protein	B-MED
content	O
indicated	O
that	O
the	O
two	O
t2	B-MED
transgenic	B-MED
lines	I-MED
showed	O
a	O
significant	O
increase	O
p	O
<	O
0.05	O
in	O
seed	B-MED
oil	B-MED
content	O
.	O
	
the	O
transgenic	B-MED
lines	I-MED
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-MED
content	O
,	O
whereas	O
total	O
protein	B-MED
content	O
decreased	O
significantly	O
.	O
	
further	O
analysis	B-MED
of	O
the	O
fatty	B-MED
acid	I-MED
composition	O
revealed	O
that	O
palmitic	B-MED
acid	I-MED
c16	B-MED
and	O
linolenic	B-MED
acid	I-MED
c18	B-MED
increased	O
significantly	O
in	O
the	O
seeds	B-MED
of	O
the	O
transgenic	B-MED
rice	B-MED
lines	I-MED
,	O
but	O
oleic	B-MED
acid	I-MED
c18	B-MED
tooth	B-MED
discoloration	I-MED
resulting	B-MED
from	O
a	O
nano	B-MED
zinc	B-MED
oxide-eugenol	I-MED
sealer	B-MED
a	O
desirable	O
quality	B-MED
of	O
any	O
endodontic	B-MED
sealer	I-MED
is	O
its	O
ability	O
to	O
be	O
tooth	B-MED
color	I-MED
friendly	B-MED
.	O
	
therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
evaluate	O
the	O
tooth	B-MED
discoloration	I-MED
potential	B-MED
of	O
a	O
nano	B-MED
zinc	B-MED
oxide-eugenol	I-MED
nzoe	B-MED
sealer	B-MED
.	O
	
in	O
order	O
to	O
evaluate	O
tooth	B-MED
discoloration	I-MED
,	O
the	O
pulp	B-MED
chamber	I-MED
of	O
60	O
human	B-MED
maxillary	B-MED
central	I-MED
and	O
lateral	B-MED
incisors	I-MED
were	O
filled	B-MED
with	O
one	O
of	O
the	O
sealers	B-MED
,	O
naming	O
ah-26	B-MED
resin-based	B-MED
sealer	I-MED
,	O
pulpdent	B-MED
sealer	B-MED
zoe	B-MED
-based	O
and	O
a	O
nzoe	B-MED
experimental	O
sealer	B-MED
.	O
	
color	B-MED
measurements	B-MED
was	O
assessed	O
at	O
the	O
baseline	B-MED
before	B-MED
placement	I-MED
of	O
sealers	B-MED
t0	O
,	O
24	O
h	B-MED
t1	O
and	O
72	O
h	B-MED
t2	O
h	B-MED
,	O
1-	O
week	B-MED
t3	O
,	O
and	O
1-	O
month	B-MED
t4	O
after	O
the	O
placement	O
of	O
sealers	B-MED
using	O
the	O
easy	B-MED
shade	I-MED
spectrophotometer	I-MED
.	O
	
data	B-MED
were	O
analyzed	B-MED
in	O
spss	B-MED
software	I-MED
using	O
one-way	B-MED
anova	I-MED
,	O
and	O
repeated	O
measured	O
anova	B-MED
.	O
	
no	O
significant	O
differences	O
were	O
observed	B-MED
when	O
the	O
paired	B-MED
comparison	I-MED
test	I-MED
was	O
performed	O
p>0	O
.	O
	
the	O
tested	O
nzoe	B-MED
sealer	B-MED
had	O
similar	O
tooth	B-MED
discoloration	I-MED
potential	B-MED
in	O
comparison	B-MED
with	O
ah-26	B-MED
and	O
zoe	B-MED
sealer	B-MED
.	O
	
on	O
the	O
identity	B-MED
of	O
the	O
palearctic	B-MED
species	B-MED
of	O
the	O
wolf	B-MED
spider	I-MED
genus	B-MED
<i>	O
trebacosa	B-MED
</i>	O
lycosidae	O
in	O
this	O
paper	O
we	O
propose	O
trebacosa	O
brunhesi	O
villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
trebacosa	O
europaea	O
szinetár	O
kan-csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	O
from	O
where	O
those	O
species	O
are	O
known	O
.	O
	
illustration	O
of	O
the	O
type	O
species	O
of	O
the	O
genus	O
,	O
trebacosa	O
marxi	O
stone	O
,	O
1890	O
and	O
specimens	O
from	O
all	O
known	O
localities	O
of	O
t	O
.	O
	
europaea	O
are	O
given	O
to	O
show	O
both	O
the	O
inter-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	O
.	O
	
scanning	O
electron	O
micrographs	O
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	O
of	O
the	O
female's	O
genitalia	I-MED
a	O
numerical	B-MED
study	B-MED
on	O
the	O
application	O
of	O
the	O
functionally	B-MED
graded	I-MED
materials	I-MED
in	O
the	O
stent	B-MED
design	B-MED
undesirable	B-MED
deformation	B-MED
of	O
the	O
stent	B-MED
can	O
induce	O
a	O
significant	B-MED
amount	O
of	O
injure	B-MED
not	O
only	O
to	O
the	O
blood	B-MED
vessel	I-MED
but	O
also	O
to	O
the	O
plaque	B-MED
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce/minimize	B-MED
these	O
undesirable	B-MED
deformations	B-MED
by	O
the	O
application	O
of	O
functionally	B-MED
graded	I-MED
materials	I-MED
fgm	B-MED
.	O
	
to	O
do	O
this	O
,	O
finite	B-MED
element	I-MED
fe	I-MED
method	I-MED
was	O
employed	B-MED
to	O
simulate	B-MED
the	O
expansion	B-MED
of	O
a	O
stent	B-MED
and	O
the	O
corresponding	O
displacement	B-MED
of	O
the	O
stenosis	B-MED
plaque	B-MED
.	O
	
three	O
hyperelastic	B-MED
plaque	B-MED
types	O
as	O
well	O
as	O
five	O
elastoplastic	B-MED
stents	I-MED
were	O
simulated	O
.	O
	
dogboning	B-MED
,	O
foreshortening	B-MED
,	O
maximum	B-MED
stress	B-MED
in	O
the	O
plaque	B-MED
,	O
and	O
the	O
pressure	B-MED
which	O
is	O
needed	O
to	O
fully	O
expand	B-MED
the	O
stent	B-MED
for	O
different	O
stent	B-MED
materials	B-MED
,	O
were	O
acquired	O
.	O
	
while	O
all	O
fgms	B-MED
had	O
lower	B-MED
dogboning	B-MED
in	O
comparison	O
to	O
the	O
stents	B-MED
made	O
of	O
the	O
uniform	B-MED
materials	B-MED
,	O
the	O
stent	B-MED
with	O
the	O
lowest	B-MED
heterogeneous	B-MED
index	I-MED
displayed	O
the	O
lowest	B-MED
amount	O
of	O
dogboning	B-MED
.	O
	
steel	B-MED
stent	B-MED
showed	O
the	O
lowest	B-MED
foreshortening	B-MED
and	O
fully	O
expansion	B-MED
pressure	I-MED
but	O
the	O
difference	B-MED
was	O
much	O
lower	B-MED
than	O
that	O
the	O
one	O
for	O
dogboning	B-MED
.	O
	
therefore	O
,	O
the	O
fgm	B-MED
with	O
the	O
heterogeneous	B-MED
index	I-MED
of	O
0.5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	B-MED
results	B-MED
.	O
	
in	O
addition	O
,	O
the	O
results	B-MED
revealed	O
that	O
the	O
material	B-MED
parameters	B-MED
has	O
crucial	B-MED
effects	B-MED
on	O
the	O
deformation	B-MED
of	O
the	O
stent	B-MED
and	O
,	O
as	O
a	O
result	B-MED
,	O
as	O
a	O
design	B-MED
point	O
of	O
view	O
the	O
fgm	B-MED
parameters	B-MED
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	B-MED
optimization	B-MED
.	O
	
women's	B-MED
perspectives	O
on	O
human	B-MED
papillomavirus	I-MED
self-sampling	B-MED
in	O
the	O
context	O
of	O
the	O
uk	B-MED
cervical	B-MED
screening	B-MED
programme	I-MED
testing	B-MED
for	O
human	B-MED
papillomavirus	I-MED
hpv	B-MED
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-MED
screening	B-MED
programme	I-MED
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
hpv	B-MED
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
hpv	B-MED
self-sampling	B-MED
.	O
	
in	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	B-MED
and	O
practice	B-MED
by	O
identifying	O
potential	B-MED
barriers	B-MED
to	O
hpv	B-MED
self-sampling	B-MED
.	O
	
a	O
cross-sectional	B-MED
survey	I-MED
of	O
194	O
women	B-MED
aged	O
20-64	O
years	O
was	O
conducted	O
.	O
	
logistic	B-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
identify	O
determinants	B-MED
of	O
self-sampling	B-MED
intentions	O
.	O
	
a	O
purposive	O
subsample	O
of	O
19	O
women	B-MED
who	O
reported	O
low	O
self-sampling	B-MED
intentions	O
were	O
interviewed	O
.	O
	
interviews	B-MED
were	O
framework-analysed	O
.	O
	
most	O
survey	B-MED
participants	B-MED
n=133	O
,	O
69.3	O
intended	O
to	O
hpv	B-MED
self-sample	O
.	O
	
lower	B-MED
intention	B-MED
was	O
associated	B-MED
with	I-MED
lower	B-MED
self-efficacy	O
or=24	O
,	O
p	O
,	O
lower	B-MED
education	B-MED
or=6	O
,	O
p	O
and	O
lower	B-MED
perceived	B-MED
importance	O
of	O
hpv	B-MED
as	O
a	O
cause	O
of	O
cervical	B-MED
cancer	I-MED
or=2	O
,	O
p	O
.	O
	
interviews	B-MED
revealed	O
personal	B-MED
and	O
system-related	O
barriers	B-MED
.	O
	
personal	B-MED
barriers	B-MED
included	O
a	O
lack	O
of	O
knowledge	B-MED
about	O
hpv	B-MED
self-sampling	B-MED
,	O
women's	B-MED
low	B-MED
confidence	I-MED
in	O
their	O
ability	O
to	O
self-sample	O
correctly	O
and	O
low	B-MED
confidence	I-MED
in	O
the	O
subsequent	O
results	O
.	O
	
system-related	O
factors	O
included	O
a	O
lack	B-MED
of	I-MED
confidence	I-MED
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-MED
screening	B-MED
programme	I-MED
,	O
and	O
concerns	O
about	O
sample	B-MED
contamination	B-MED
and	O
identity	B-MED
theft	I-MED
.	O
	
insights	O
gained	O
from	O
this	O
research	B-MED
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
hpv	B-MED
self-sampling	B-MED
and	O
to	O
help	O
inform	O
future	O
policy	B-MED
and	O
practice	B-MED
.	O
	
personal	B-MED
and	O
system-related	B-MED
barriers	I-MED
including	O
low	B-MED
confidence	I-MED
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-MED
screening	B-MED
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
hpv	B-MED
self-sampling	B-MED
be	O
incorporated	O
into	O
the	O
cervical	B-MED
screening	B-MED
programme	I-MED
.	O
	
n-terminal	B-MED
hypothesis	B-MED
for	O
alzheimer's	B-MED
disease	I-MED
although	O
the	O
amyloid	B-MED
abeta	B-MED
peptide	I-MED
,	O
aβ	B-MED
hypothesis	B-MED
is	O
25	O
years	B-MED
old	O
,	O
is	O
the	O
dominant	B-MED
model	B-MED
of	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
pathogenesis	B-MED
,	O
and	O
guides	O
the	O
development	B-MED
of	O
potential	O
treatments	B-MED
,	O
it	O
is	O
still	O
controversial	B-MED
.	O
	
one	O
possible	O
reason	O
is	O
a	O
lack	B-MED
of	O
a	O
mechanistic	B-MED
path	I-MED
from	O
the	O
cleavage	B-MED
products	I-MED
of	O
the	O
amyloid	B-MED
precursor	I-MED
protein	I-MED
app	B-MED
such	O
as	O
soluble	B-MED
aβ	B-MED
monomer	I-MED
and	O
soluble	O
molecular	B-MED
fragments	B-MED
to	O
the	O
deleterious	B-MED
effects	I-MED
on	O
synaptic	B-MED
form	I-MED
and	O
function	B-MED
.	O
	
from	O
a	O
review	B-MED
of	I-MED
the	O
recent	O
literature	B-MED
and	O
our	O
own	O
published	B-MED
work	I-MED
including	O
aggregation	B-MED
kinetics	I-MED
and	O
structural	B-MED
morphology	B-MED
,	O
aβ	B-MED
clearance	B-MED
,	O
molecular	B-MED
simulations	B-MED
,	O
long-term	B-MED
potentiation	I-MED
measurements	B-MED
with	O
inhibition	B-MED
binding	I-MED
,	O
and	O
the	O
binding	B-MED
of	O
a	O
commercial	O
monoclonal	B-MED
antibody	I-MED
,	O
aducanumab	B-MED
,	O
we	O
hypothesize	B-MED
that	O
the	O
n-terminal	B-MED
domains	I-MED
of	O
neurotoxic	B-MED
aβ	B-MED
oligomers	I-MED
are	O
implicated	O
in	O
causing	B-MED
the	O
generation	B-MED
of	O
high-quality	B-MED
swath	B-MED
acquisition	B-MED
data	B-MED
for	O
label-free	B-MED
quantitative	B-MED
proteomics	B-MED
studies	I-MED
using	O
tripletof	B-MED
mass	I-MED
spectrometers	I-MED
data	B-MED
-	O
independent	B-MED
acquisition	B-MED
is	O
a	O
powerful	O
mass	B-MED
spectrometry	I-MED
technique	I-MED
that	O
enables	O
comprehensive	O
ms	B-MED
and	O
ms/ms	B-MED
analysis	B-MED
of	O
all	O
detectable	B-MED
species	B-MED
,	O
providing	O
an	O
information	B-MED
rich	O
data	B-MED
file	O
that	O
can	O
be	O
mined	B-MED
deeply	O
.	O
	
here	O
,	O
we	O
describe	O
how	O
to	O
acquire	B-MED
high-quality	B-MED
swath	B-MED
acquisition	B-MED
data	B-MED
to	O
be	O
used	O
for	O
large	B-MED
quantitative	B-MED
proteomic	B-MED
studies	I-MED
.	O
	
we	O
specifically	O
focus	O
on	O
using	O
variable	B-MED
sized	B-MED
q1	B-MED
windows	I-MED
for	O
acquisition	B-MED
of	O
ms/ms	B-MED
data	B-MED
for	O
generating	B-MED
higher	O
specificity	B-MED
quantitative	B-MED
data	B-MED
.	O
	
a	O
new	O
light	O
on	O
alkaptonuria	B-MED
a	O
fourier-transform	B-MED
infrared	I-MED
microscopy	I-MED
ftirm	B-MED
and	O
low	B-MED
energy	I-MED
x-ray	I-MED
fluorescence	I-MED
microscopy	I-MED
lexrf	B-MED
correlative	B-MED
study	I-MED
on	O
a	O
rare	B-MED
disease	I-MED
alkaptonuria	B-MED
aku	B-MED
is	O
an	O
ultra-rare	B-MED
disease	I-MED
associated	B-MED
to	O
the	O
lack	B-MED
of	O
an	O
enzyme	B-MED
involved	O
in	O
tyrosine	B-MED
catabolism	I-MED
.	O
	
this	O
deficiency	B-MED
results	O
in	O
the	O
accumulation	B-MED
of	O
homogentisic	B-MED
acid	I-MED
hga	B-MED
in	O
the	O
form	O
of	O
ochronotic	B-MED
pigment	I-MED
in	O
joint	B-MED
cartilage	B-MED
,	O
leading	O
to	O
a	O
severe	B-MED
arthropathy	B-MED
.	O
	
secondary	B-MED
amyloidosis	I-MED
has	O
been	O
also	O
unequivocally	B-MED
assessed	B-MED
as	O
a	O
comorbidity	B-MED
of	O
aku	B-MED
arthropathy	B-MED
.	O
	
composition	O
of	O
ochronotic	B-MED
pigment	I-MED
and	O
how	O
it	O
is	O
structurally	B-MED
related	O
to	O
amyloid	B-MED
is	O
still	O
unknown	O
.	O
	
we	O
exploited	O
synchrotron	B-MED
radiation	I-MED
infrared	B-MED
and	O
x-ray	B-MED
fluorescence	I-MED
microscopies	I-MED
in	O
combination	O
with	O
conventional	O
bio-assays	B-MED
and	O
analytical	B-MED
tools	O
to	O
characterize	O
chemical	B-MED
composition	I-MED
and	O
morphology	B-MED
of	O
aku	B-MED
cartilage	B-MED
.	O
	
we	O
evinced	B-MED
that	O
aku	B-MED
cartilage	B-MED
is	O
characterized	O
by	O
proteoglycans	B-MED
depletion	B-MED
,	O
increased	B-MED
sodium	I-MED
levels	I-MED
,	O
accumulation	B-MED
of	O
lipids	B-MED
in	O
the	O
peri-lacunar	B-MED
regions	I-MED
and	O
amyloid	B-MED
formation	B-MED
.	O
	
we	O
also	O
highlighted	O
an	O
increase	B-MED
of	O
aromatic	B-MED
compounds	I-MED
and	O
oxygen-containing	B-MED
species	I-MED
,	O
depletion	B-MED
in	O
overall	O
magnesium	B-MED
content	B-MED
although	O
localized	B-MED
in	O
the	O
peri-lacunar	B-MED
region	I-MED
and	O
the	O
presence	B-MED
of	O
calcium	B-MED
carbonate	I-MED
fragments	O
in	O
proximity	B-MED
of	O
cartilage	B-MED
lacunae	I-MED
.	O
	
we	O
highlighted	O
common	B-MED
features	O
between	O
aku	B-MED
and	O
arthropathy	B-MED
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-MED
,	O
like	O
presence	B-MED
of	O
amyloids	B-MED
and	O
peculiar	B-MED
calcifications	B-MED
.	O
	
our	O
analyses	B-MED
provide	O
a	O
unified	O
picture	O
of	O
aku	B-MED
cartilage	B-MED
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-MED
and	O
opening	O
new	B-MED
perspectives	O
.	O
	
ochronotic	B-MED
pigment	I-MED
is	O
a	O
hallmark	O
of	O
aku	B-MED
and	O
responsible	O
of	O
tissue	B-MED
degeneration	I-MED
.	O
	
conventional	O
bio-assays	B-MED
have	O
not	O
yet	O
clarified	O
its	O
composition	B-MED
and	O
its	O
structural	B-MED
relationship	B-MED
with	O
amyloids	B-MED
.	O
	
the	O
present	B-MED
work	B-MED
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	B-MED
of	O
new	O
analytical	B-MED
approaches	O
with	O
standardized	B-MED
analyses	B-MED
.	O
	
unbiased	B-MED
estimates	I-MED
of	O
cerebrospinal	B-MED
fluid	I-MED
β-amyloid	B-MED
1-42	I-MED
cutoffs	B-MED
in	O
a	O
large	O
memory	B-MED
clinic	I-MED
population	B-MED
we	O
sought	O
to	O
define	O
a	O
cutoff	B-MED
for	O
β-amyloid	B-MED
1-42	I-MED
in	O
cerebrospinal	B-MED
fluid	I-MED
csf	B-MED
,	O
a	O
key	O
marker	B-MED
for	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
,	O
with	O
data-driven	B-MED
gaussian	B-MED
mixture	I-MED
modeling	I-MED
in	O
a	O
memory	B-MED
clinic	I-MED
population	B-MED
.	O
	
we	O
performed	O
a	O
combined	O
cross-sectional	B-MED
and	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
	
we	O
selected	O
2462	O
subjects	B-MED
with	O
subjective	B-MED
cognitive	I-MED
decline	I-MED
,	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
,	O
ad	B-MED
-type	O
dementia	B-MED
,	O
and	O
dementia	B-MED
other	O
than	O
ad	B-MED
from	O
the	O
amsterdam	B-MED
dementia	B-MED
cohort	B-MED
.	O
	
we	O
defined	O
csf	B-MED
β-amyloid	B-MED
1-42	I-MED
cutoffs	B-MED
by	O
data-driven	B-MED
gaussian	B-MED
mixture	I-MED
modeling	I-MED
in	O
the	O
total	B-MED
population	I-MED
and	O
in	O
subgroups	B-MED
based	O
on	O
clinical	B-MED
diagnosis	I-MED
,	O
age	B-MED
,	O
and	O
apolipoprotein	B-MED
e	I-MED
apoe	I-MED
genotype	I-MED
.	O
	
we	O
investigated	B-MED
whether	O
abnormal	B-MED
β-amyloid	B-MED
1-42	I-MED
as	O
defined	O
by	O
the	O
data-driven	B-MED
cutoff	B-MED
could	O
better	O
predict	B-MED
progression	B-MED
to	O
ad	B-MED
-type	O
dementia	B-MED
than	O
abnormal	B-MED
β-amyloid	B-MED
1-42	I-MED
defined	O
by	O
a	O
clinical	B-MED
diagnosis	I-MED
-based	O
cutoff	B-MED
using	O
cox	B-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
.	O
	
in	O
the	O
total	O
group	B-MED
of	O
patients	B-MED
,	O
we	O
found	O
a	O
cutoff	B-MED
for	O
abnormal	B-MED
csf	B-MED
β-amyloid	B-MED
1-42	I-MED
of	O
680	O
pg/ml	O
95%	O
ci	B-MED
660-705	O
pg/ml	O
.	O
	
similar	O
cutoffs	B-MED
were	O
found	O
within	O
diagnostic	B-MED
and	O
apoe	B-MED
genotype	I-MED
subgroups	B-MED
.	O
	
the	O
cutoff	B-MED
was	O
higher	B-MED
in	O
elderly	B-MED
subjects	B-MED
than	O
in	O
younger	O
subjects	B-MED
.	O
	
the	O
data-driven	B-MED
cutoff	B-MED
was	O
higher	B-MED
than	O
our	O
clinical	B-MED
diagnosis	I-MED
-based	O
cutoff	B-MED
and	O
had	O
a	O
better	O
predictive	B-MED
accuracy	B-MED
for	O
progression	B-MED
to	O
ad	B-MED
-type	O
dementia	B-MED
in	O
nondemented	O
subjects	B-MED
hr	B-MED
7.6	O
versus	O
5.2	O
,	O
p	B-MED
<	O
0.01	O
.	O
	
mixture	B-MED
modeling	I-MED
is	O
a	O
robust	B-MED
method	B-MED
to	O
determine	O
cutoffs	B-MED
for	O
csf	B-MED
β-amyloid	B-MED
1-42	I-MED
.	O
	
it	O
might	O
better	O
capture	O
biological	B-MED
changes	B-MED
that	O
are	O
related	O
to	O
ad	B-MED
than	O
cutoffs	B-MED
based	O
on	O
clinical	B-MED
diagnosis	I-MED
.	O
	
identification	B-MED
of	O
the	O
anti-mycobacterial	B-MED
functional	B-MED
properties	B-MED
of	O
piperidinol	B-MED
derivatives	I-MED
tuberculosis	B-MED
tb	B-MED
remains	O
a	O
major	O
global	B-MED
health	B-MED
threat	B-MED
and	O
is	O
now	O
the	O
leading	O
cause	B-MED
of	I-MED
death	I-MED
from	O
a	O
single	O
infectious	B-MED
agent	I-MED
worldwide	B-MED
.	O
	
the	O
current	O
tb	B-MED
drug	B-MED
regimen	B-MED
is	O
inadequate	B-MED
,	O
and	O
new	O
anti-tubercular	B-MED
agents	I-MED
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	B-MED
of	O
drug-resistant	B-MED
tb	I-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
a	O
piperidinol	B-MED
compound	I-MED
derivative	I-MED
that	O
is	O
highly	O
active	B-MED
against	O
the	O
mycobacterium	B-MED
tuberculosis	I-MED
bacillus	B-MED
.	O
	
the	O
antibacterial	B-MED
properties	B-MED
of	O
the	O
piperidinol	B-MED
compound	I-MED
and	O
its	O
corresponding	O
bis-mannich	B-MED
base	I-MED
analogue	B-MED
were	O
evaluated	B-MED
against	O
m	B-MED
.	O
	
smegmatis	I-MED
and	O
gram-negative	B-MED
organisms	I-MED
.	O
	
cytotoxicity	B-MED
studies	B-MED
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity	B-MED
index	I-MED
for	O
these	O
compounds	B-MED
.	O
	
spontaneous	O
resistant	B-MED
mutants	B-MED
of	O
m	B-MED
.	O
	
smegmatis	I-MED
were	O
generated	O
against	O
the	O
piperidinol	B-MED
and	O
corresponding	O
bis-mannich	B-MED
base	I-MED
lead	I-MED
derivatives	I-MED
and	O
whole	O
genome	B-MED
sequencing	I-MED
employed	O
to	O
determine	O
the	O
genetic	B-MED
modifications	I-MED
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-MED
.	O
	
the	O
piperidinol	B-MED
and	O
the	O
bis-mannich	B-MED
base	I-MED
analogue	I-MED
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-MED
and	O
rapidly	O
kill	O
this	O
organism	B-MED
with	O
a	O
cytotoxicity	B-MED
selectivity	B-MED
index	I-MED
for	O
mycobacteria	B-MED
of	O
>30-fold	O
.	O
	
whole	O
genome	B-MED
sequencing	I-MED
of	O
m	B-MED
.	O
	
smegmatis	I-MED
strains	B-MED
resistant	B-MED
to	O
the	O
lead	B-MED
compounds	I-MED
led	O
to	O
the	O
identification	B-MED
of	O
a	O
number	O
of	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
indicating	O
multiple	O
targets	O
.	O
	
our	O
results	B-MED
indicate	O
that	O
the	O
piperidinol	B-MED
moiety	I-MED
represents	O
an	O
attractive	O
compound	B-MED
class	I-MED
in	O
the	O
pursuit	O
of	O
novel	O
anti-tubercular	B-MED
agents	I-MED
.	O
	
metatranscriptomics	B-MED
reveals	O
the	O
active	O
bacterial	B-MED
and	O
eukaryotic	B-MED
fibrolytic	I-MED
communities	I-MED
in	O
the	O
rumen	B-MED
of	O
dairy	B-MED
cow	I-MED
fed	O
a	O
mixed	B-MED
diet	B-MED
ruminants	B-MED
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	B-MED
from	O
the	O
degradation	B-MED
of	O
plant	B-MED
polysaccharides	B-MED
through	O
the	O
activity	B-MED
of	O
the	O
rumen	B-MED
microbiota	B-MED
.	O
	
although	O
this	O
process	B-MED
is	O
well	O
studied	O
in	B-MED
vitro	I-MED
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota	B-MED
members	I-MED
and	O
enzymes	B-MED
in	B-MED
vivo	I-MED
.	O
	
the	O
present	O
study	O
used	O
rna-sequencing	B-MED
to	O
reveal	O
both	O
the	O
expression	B-MED
of	O
genes	B-MED
encoding	O
carbohydrate-active	B-MED
enzymes	I-MED
cazymes	B-MED
by	O
the	O
rumen	B-MED
microbiota	B-MED
of	O
a	O
lactating	B-MED
dairy	I-MED
cow	I-MED
and	O
the	O
microorganisms	B-MED
forming	O
the	O
fiber	B-MED
-degrading	O
community	B-MED
.	O
	
functional	B-MED
analysis	I-MED
identified	O
12	O
cazymes	B-MED
,	O
accounting	O
for	O
1%	O
of	O
the	O
transcripts	B-MED
.	O
	
the	O
cazyme	B-MED
profile	O
was	O
dominated	O
by	O
families	O
gh94	B-MED
cellobiose-phosphorylase	B-MED
,	O
gh13	B-MED
amylase	B-MED
,	O
gh43	B-MED
and	O
gh10	B-MED
hemicellulases	B-MED
,	O
gh9	B-MED
and	O
gh48	B-MED
cellulases	B-MED
,	O
pl11	B-MED
pectinase	B-MED
as	O
well	O
as	O
gh2	B-MED
and	O
gh3	B-MED
oligosaccharidases	B-MED
.	O
	
our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic	B-MED
bacteria	I-MED
prevotella	B-MED
,	O
ruminocccus	B-MED
and	O
fibrobacter	B-MED
,	O
and	O
highlight	O
a	O
substantial	O
,	O
although	O
most	O
probably	O
underestimated	O
,	O
contribution	B-MED
of	O
fungi	B-MED
and	O
ciliate	B-MED
protozoa	I-MED
to	O
polysaccharide	B-MED
degradation	B-MED
.	O
	
particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	B-MED
in	O
the	O
rumen	B-MED
.	O
	
moreover	O
,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic	B-MED
bacterial	I-MED
community	I-MED
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
cazyme	B-MED
transcripts	B-MED
originated	O
from	O
distantly	O
related	O
strains	B-MED
.	O
	
these	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-MED
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-MED
microbial	B-MED
community	I-MED
fine	B-MED
mapping	I-MED
of	O
carbon	B-MED
assimilation	I-MED
rate	I-MED
8	I-MED
,	O
a	O
quantitative	B-MED
trait	I-MED
locus	I-MED
for	O
flag	B-MED
leaf	I-MED
nitrogen	B-MED
content	B-MED
,	O
stomatal	B-MED
conductance	B-MED
and	O
photosynthesis	B-MED
in	O
rice	B-MED
increasing	B-MED
the	O
rate	B-MED
of	O
leaf	B-MED
photosynthesis	I-MED
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain	B-MED
yield	I-MED
in	O
rice	B-MED
oryza	B-MED
sativa	I-MED
.	O
	
exploiting	O
the	O
natural	O
variation	B-MED
in	O
co2	B-MED
assimilation	I-MED
rate	I-MED
a	O
between	O
rice	B-MED
cultivars	I-MED
using	O
quantitative	B-MED
genetics	I-MED
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	B-MED
contributing	O
to	O
higher	O
photosynthesis	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
determined	O
precise	O
location	B-MED
of	O
carbon	B-MED
assimilation	I-MED
rate	I-MED
8	I-MED
car8	B-MED
by	O
crossing	B-MED
a	O
high-yielding	O
indica	B-MED
cultivar	I-MED
with	O
a	O
japanese	B-MED
commercial	B-MED
cultivar	B-MED
.	O
	
fine	B-MED
mapping	I-MED
suggested	O
that	O
car8	B-MED
encodes	B-MED
a	O
putative	B-MED
heme	I-MED
activator	I-MED
protein	I-MED
3	I-MED
oshap3	B-MED
subunit	O
of	O
a	O
ccaat-box-binding	B-MED
transcription	I-MED
factor	I-MED
called	O
oshap3h	B-MED
.	O
	
sequencing	B-MED
analysis	I-MED
revealed	O
that	O
the	O
indica	B-MED
allele	B-MED
of	O
car8	B-MED
has	O
a	O
1-bp	B-MED
deletion	I-MED
at	O
322	O
bp	B-MED
from	O
the	O
start	B-MED
codon	I-MED
,	O
resulting	O
in	O
a	O
truncated	B-MED
protein	I-MED
of	O
125	O
amino	B-MED
acids	I-MED
.	O
	
in	O
addition	O
,	O
car8	B-MED
is	O
identical	B-MED
to	O
dth8	B-MED
/	O
ghd8	B-MED
/	O
lhd1	B-MED
,	O
which	O
was	O
reported	O
to	O
control	O
rice	B-MED
flowering	B-MED
date	B-MED
.	O
	
the	O
increase	B-MED
of	O
a	B-MED
is	O
largely	O
due	O
to	O
an	O
increase	B-MED
of	O
rubp	B-MED
regeneration	I-MED
rate	I-MED
via	O
increased	B-MED
leaf	B-MED
nitrogen	B-MED
content	B-MED
,	O
and	O
partially	O
explained	O
by	O
reduced	B-MED
stomatal	B-MED
limitation	B-MED
via	O
increased	B-MED
stomatal	B-MED
conductance	B-MED
relative	O
to	O
a	B-MED
.	O
	
this	O
allele	B-MED
also	O
increases	O
hydraulic	B-MED
conductivity	I-MED
,	O
which	O
would	O
promote	B-MED
higher	O
stomatal	B-MED
conductance	B-MED
.	O
	
this	O
indicates	O
that	O
car8	B-MED
affects	O
multiple	O
physiological	B-MED
aspects	I-MED
relating	O
to	O
photosynthesis	B-MED
.	O
	
the	O
detailed	O
analysis	B-MED
of	O
molecular	B-MED
functions	I-MED
of	O
car8	B-MED
would	O
help	O
to	O
understand	O
the	O
association	B-MED
between	O
photosynthesis	B-MED
and	O
flowering	B-MED
and	O
demonstrate	O
specific	O
genetic	B-MED
mechanisms	B-MED
that	O
can	O
be	O
exploited	O
to	O
improve	B-MED
photosynthesis	B-MED
in	O
rice	B-MED
and	O
potentially	O
other	O
allogeneic	B-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
for	O
adult	B-MED
patients	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
who	O
had	O
central	B-MED
nervous	I-MED
system	I-MED
involvement	I-MED
a	O
study	B-MED
from	O
the	O
adult	B-MED
all	B-MED
working	B-MED
group	I-MED
of	O
the	O
japan	B-MED
society	B-MED
for	O
hematopoietic	B-MED
cell	I-MED
transplantation	I-MED
the	O
prognosis	B-MED
for	O
adult	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
all	B-MED
patients	B-MED
with	O
central	B-MED
nervous	I-MED
system	I-MED
cns	I-MED
involvement	I-MED
cns+	B-MED
who	O
received	O
allogeneic	B-MED
hematopoietic	I-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
allo-sct	B-MED
remains	O
unclear	O
.	O
	
we	O
retrospectively	B-MED
compared	O
the	O
outcomes	B-MED
of	O
allo-sct	B-MED
for	O
patients	B-MED
with	O
cns	B-MED
involvement	I-MED
and	O
for	O
patients	B-MED
without	B-MED
cns	B-MED
involvement	I-MED
cns-	B-MED
using	O
a	O
database	B-MED
in	O
japan	B-MED
.	O
	
the	O
eligibility	O
criteria	B-MED
for	O
this	O
study	B-MED
were	O
as	O
follows	O
diagnosis	B-MED
of	O
all	B-MED
,	O
aged	O
more	O
than	O
16	O
years	B-MED
,	O
allo-sct	B-MED
between	O
2005	O
and	O
2012	O
,	O
and	O
first	B-MED
sct	B-MED
.	O
	
data	B-MED
for	O
2582	O
patients	B-MED
including	O
136	O
cns+	B-MED
patients	I-MED
and	O
2446	O
cns-	B-MED
patients	I-MED
were	O
used	O
for	O
analyses	B-MED
.	O
	
as	O
compared	O
with	O
cns-	B-MED
patients	I-MED
,	O
cns+	B-MED
patients	I-MED
were	O
younger	B-MED
,	O
had	O
worse	B-MED
disease	B-MED
status	B-MED
at	O
sct	B-MED
and	O
had	O
poorer	O
performance	B-MED
status	I-MED
ps	B-MED
at	O
sct	B-MED
p	O
<	O
0.01	O
.	O
	
incidence	B-MED
of	O
relapse	B-MED
was	O
higher	O
in	O
cns+	B-MED
patients	I-MED
p	O
=	O
0.02	O
,	O
and	O
incidence	B-MED
of	O
cns	B-MED
relapse	B-MED
was	O
also	O
higher	O
p	O
<	O
0.01	O
.	O
	
the	O
probability	B-MED
of	O
3-	O
year	B-MED
overall	B-MED
survival	I-MED
os	B-MED
was	O
better	O
in	O
cns-	B-MED
patients	I-MED
p	O
<	O
0.01	O
by	O
univariate	B-MED
analysis	I-MED
.	O
	
however	O
,	O
in	O
patients	B-MED
who	O
received	B-MED
sct	B-MED
in	O
cr	B-MED
,	O
there	O
was	O
no	B-MED
difference	I-MED
in	O
the	O
probability	B-MED
of	O
os	B-MED
between	O
cns+	B-MED
and	O
cns-	B-MED
patients	B-MED
p	O
=	O
0.38	O
and	O
cns	B-MED
involvement	I-MED
did	O
not	O
have	O
an	O
unfavorable	B-MED
effect	B-MED
on	O
os	B-MED
by	O
multivariate	B-MED
analysis	I-MED
.	O
	
cns+	B-MED
patients	I-MED
who	O
achieved	O
cr	B-MED
showed	O
os	B-MED
comparable	O
to	O
that	O
of	O
cns-	B-MED
patients	I-MED
.	O
	
silent	B-MED
strain	I-MED
of	I-MED
caregiving	I-MED
exploring	O
the	O
best	B-MED
predictors	I-MED
of	O
distress	B-MED
in	O
family	B-MED
carers	I-MED
of	O
geriatric	B-MED
patients	I-MED
the	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	B-MED
predictors	I-MED
of	O
distress	B-MED
suffered	I-MED
by	O
family	B-MED
carers	I-MED
fcs	B-MED
of	O
geriatric	B-MED
patients	I-MED
.	O
	
a	O
cross-sectional	B-MED
study	I-MED
of	O
100	O
fc	B-MED
-	O
geriatric	B-MED
patient	I-MED
dyads	B-MED
was	O
conducted	O
.	O
	
the	O
negative	B-MED
impact	I-MED
of	I-MED
care	I-MED
nioc	B-MED
subscale	B-MED
of	O
the	O
cope	B-MED
index	I-MED
was	O
dichotomized	O
to	O
identify	O
lower	B-MED
stress	I-MED
score	O
of	O
15	O
on	O
the	O
scale	O
and	O
higher	B-MED
stress	I-MED
score	O
of	O
16	O
on	O
the	O
scale	O
exerted	O
on	O
fcs	B-MED
by	O
the	O
process	B-MED
of	I-MED
providing	I-MED
care	I-MED
.	O
	
the	O
set	O
of	O
explanatory	B-MED
variables	B-MED
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	B-MED
and	O
care-related	B-MED
attributes	I-MED
,	O
including	O
patient-related	B-MED
results	I-MED
from	O
comprehensive	O
geriatric	B-MED
assessments	I-MED
and	O
disease	B-MED
profiles	B-MED
.	O
	
the	O
best	O
combination	O
of	O
explanatory	B-MED
variables	B-MED
that	O
provided	O
the	O
highest	B-MED
predictive	I-MED
powe	I-MED
r	O
for	O
distress	B-MED
among	O
fcs	B-MED
in	O
the	O
multiple	B-MED
logistic	I-MED
regression	I-MED
lr	I-MED
model	I-MED
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O
	
the	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross-validation	O
method	O
.	O
	
the	O
mean	O
age	O
of	O
fcs	O
was	O
57.2	O
10.6	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
6.4	O
years	O
.	O
	
despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	O
,	O
only	O
five	O
predictors	O
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O
	
a	O
higher	O
level	O
of	O
distress	O
was	O
independently	O
predicted	O
by	O
lower	O
self-evaluation	O
of	O
health	O
worse	O
self-appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
lower	O
sense	O
of	O
general	O
support	O
more	O
hours	O
of	O
care	O
per	O
week	O
and	O
the	O
motor	O
retardation	O
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
timed	O
up	O
and	O
go	O
tug	O
test	O
.	O
	
worse	O
performance	O
on	O
the	O
tug	O
test	O
was	O
only	O
the	O
patient	O
-related	O
predictor	O
of	O
distress	O
among	O
the	O
variables	O
examined	O
as	O
contributors	O
to	O
the	O
higher	O
nioc	O
.	O
	
enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	O
methods	O
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
fcs	B-MED
microbiological	B-MED
and	O
clinical	B-MED
characteristics	I-MED
of	O
hypermucoviscous	B-MED
klebsiella	I-MED
pneumoniae	I-MED
isolates	B-MED
associated	B-MED
with	I-MED
invasive	B-MED
infections	I-MED
in	O
china	B-MED
a	O
distinctive	B-MED
syndrome	I-MED
caused	B-MED
by	I-MED
hypermucoviscous	B-MED
klebsiella	I-MED
pneumoniae	I-MED
hmkp	B-MED
including	O
pyogenic	B-MED
liver	I-MED
abscess	I-MED
pla	B-MED
is	O
now	O
becoming	O
a	O
globally	B-MED
emerging	I-MED
disease	I-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
22.8	O
84/369	O
of	O
k	B-MED
.	O
	
pneumoniae	I-MED
clinical	O
isolates	B-MED
associated	B-MED
with	I-MED
various	B-MED
types	I-MED
of	O
invasive	B-MED
infections	I-MED
were	O
identified	O
as	O
hmkp	B-MED
,	O
with	O
45.2	O
associated	B-MED
with	I-MED
pla	B-MED
.	O
	
multivariate	B-MED
regression	I-MED
analysis	I-MED
showed	O
that	O
male	B-MED
patients	I-MED
with	O
41-50	O
years	B-MED
,	O
pla	B-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
hypertension	B-MED
were	O
independent	B-MED
risk	B-MED
factors	I-MED
for	O
hmkp	B-MED
infections	I-MED
.	O
	
k2	B-MED
42.9	O
,	O
36/84	O
was	O
the	O
most	O
common	O
capsular	B-MED
serotype	B-MED
among	O
hmkp	B-MED
isolates	B-MED
,	O
followed	O
by	O
k1	B-MED
23.8	O
,	O
20/84	O
.	O
	
seventy-five	B-MED
percentage	I-MED
of	O
k1	B-MED
hmkp	B-MED
isolates	B-MED
were	O
associated	B-MED
with	I-MED
pla	B-MED
,	O
while	O
k2	B-MED
hmkp	B-MED
isolates	B-MED
accounted	B-MED
for	O
more	B-MED
types	I-MED
of	O
invasive	B-MED
infections	I-MED
.	O
	
the	O
positive	B-MED
rates	B-MED
of	O
iuta	B-MED
,	O
mrkd	B-MED
,	O
aerobactin	B-MED
,	O
iron	B-MED
,	O
and	O
rmpa	B-MED
among	O
hmkp	B-MED
isolates	B-MED
were	O
significantly	B-MED
higher	I-MED
than	O
those	O
among	O
non-hmkp	B-MED
isolates	B-MED
p	O
<	O
0.05	O
.	O
	
there	O
was	O
a	O
correlation	B-MED
between	O
maga	B-MED
,	O
ybts	B-MED
,	O
alls	B-MED
,	O
and	O
wcag	B-MED
and	O
k1	B-MED
isolates	B-MED
.	O
	
interestingly	O
,	O
mrkd	B-MED
was	O
exclusively	B-MED
detected	I-MED
among	O
hmkp	B-MED
32.1	O
,	O
27/84	O
and	O
k2	B-MED
isolates	B-MED
65.9	O
,	O
27/41	O
.	O
	
all	O
k1	B-MED
and	O
k2	B-MED
hmkp	B-MED
and	O
non-hmkp	B-MED
isolates	B-MED
were	O
positive	B-MED
for	O
rmpa	B-MED
.	O
	
aerobactin	B-MED
was	O
found	B-MED
among	O
95.0	O
and	O
97.5	O
of	O
k1	B-MED
and	O
k2	B-MED
isolates	B-MED
.	O
	
st23	B-MED
was	O
found	B-MED
to	O
be	O
the	O
most	B-MED
prevalent	I-MED
st	B-MED
among	O
69	O
hmkp	B-MED
isolates	B-MED
with	O
k1	B-MED
,	O
k2	B-MED
,	O
k5	B-MED
,	O
k20	B-MED
,	O
and	O
k57	B-MED
27.5	O
,	O
19/69	O
and	O
was	O
only	O
found	B-MED
among	O
k1	B-MED
isolates	B-MED
.	O
	
st65	B-MED
was	O
the	O
second	O
most	B-MED
prevalent	I-MED
st	B-MED
26.1	O
,	O
18/69	O
and	O
was	O
also	O
only	O
found	B-MED
among	O
k2	B-MED
isolates	B-MED
.	O
	
st23-k1	B-MED
hmkp	B-MED
isolates	B-MED
84.2	O
,	O
16/19	O
were	O
associated	B-MED
with	I-MED
pla	B-MED
,	O
while	O
st65-k2	B-MED
isolates	B-MED
were	O
correlated	B-MED
with	O
more	O
types	B-MED
of	I-MED
infections	I-MED
relative	O
to	O
st23-k1	B-MED
isolates	B-MED
.	O
	
pfge	B-MED
results	B-MED
showed	O
that	O
the	O
homology	B-MED
of	O
84	O
hmkp	B-MED
isolates	B-MED
was	O
diverse	B-MED
.	O
	
only	O
five	B-MED
pfge	B-MED
clusters	B-MED
with	O
more	O
than	O
75%	O
similarity	B-MED
accounted	B-MED
for	O
more	O
than	O
three	B-MED
isolates	B-MED
.	O
	
these	O
five	B-MED
pfge	B-MED
clusters	B-MED
only	O
accounted	B-MED
for	O
35	O
41.7	O
,	O
35/84	O
isolates	B-MED
.	O
	
in	O
conclusion	O
,	O
our	O
study	B-MED
first	O
found	B-MED
that	O
hypertension	B-MED
and	O
male	B-MED
patients	I-MED
with	O
41-50	O
years	B-MED
old	B-MED
were	O
independent	B-MED
risk	B-MED
factors	I-MED
.	O
	
the	O
composition	B-MED
of	O
st	B-MED
types	I-MED
and	O
pfge	B-MED
clusters	B-MED
among	O
k	B-MED
.	O
	
pneumoniae	I-MED
k2	B-MED
isolates	B-MED
was	O
more	O
diverse	B-MED
than	O
k1	B-MED
isolates	B-MED
.	O
	
k1	B-MED
and	O
k2	B-MED
hmkp	B-MED
isolates	B-MED
had	O
respective	O
specific	B-MED
profiles	I-MED
of	O
virulence	B-MED
-	O
associated	B-MED
genes	B-MED
.	O
	
haemoglobinopathies	B-MED
and	O
β-thalassaemia	B-MED
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
,	O
india	B-MED
prevalence	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β-thalassaemia	B-MED
are	O
very	B-MED
high	I-MED
in	O
india	B-MED
but	O
information	B-MED
about	O
its	O
status	O
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
is	O
very	B-MED
less	I-MED
.	O
	
the	O
present	O
study	B-MED
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β-thalassaemia	B-MED
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
.	O
	
a	O
total	O
1204	O
samples	O
from	O
the	O
tribals	B-MED
working	B-MED
in	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
were	O
analysed	B-MED
for	O
both	O
complete	B-MED
blood	I-MED
count	I-MED
cbc	B-MED
and	O
high	B-MED
pressure	I-MED
liquid	I-MED
chromatography	I-MED
hplc	B-MED
for	O
detection	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β-thalassaemia	B-MED
.	O
	
this	O
study	B-MED
showed	O
that	O
the	O
prevalence	B-MED
of	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
and	O
β-thalassaemia	B-MED
were	O
very	B-MED
high	I-MED
among	O
this	O
population	B-MED
.	O
	
our	O
results	B-MED
indicated	B-MED
a	O
higher	O
prevalence	B-MED
of	O
β-thalassaemia	B-MED
3.07	O
among	O
the	O
munda	B-MED
ethnic	I-MED
group	I-MED
and	O
higher	O
prevalence	B-MED
of	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
4.73	O
among	O
the	O
lohar	B-MED
ethnic	I-MED
group	I-MED
.	O
	
this	O
was	O
the	O
first	O
study	B-MED
to	O
report	O
the	O
presence	B-MED
of	O
hbe	B-MED
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
.	O
	
based	O
on	O
the	O
present	O
findings	B-MED
,	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
and	O
β-thalassaemia	B-MED
were	O
major	O
health	B-MED
problem	B-MED
for	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
assam	B-MED
.	O
	
proper	O
diagnostic	B-MED
facilities	I-MED
for	O
haemoglobinopathy	B-MED
and	O
thalassaemia	B-MED
should	O
be	O
established	B-MED
in	O
these	O
areas	B-MED
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-MED
and	O
thalassaemia	B-MED
database	B-MED
collection	B-MED
,	O
haematological	B-MED
analysis	I-MED
laboratories	I-MED
,	O
genetic	B-MED
counselling	I-MED
clinics	I-MED
,	O
prenatal	B-MED
diagnosis	I-MED
centres	I-MED
and	O
neonatal	B-MED
screening	I-MED
centres	I-MED
.	O
	
long	B-MED
term	I-MED
outcome	B-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
stenting	I-MED
for	O
cancer	B-MED
esophagus	I-MED
-	O
our	O
experience	O
at	O
a	O
rural	B-MED
hospital	I-MED
of	O
punjab	B-MED
,	O
india	B-MED
cancer	B-MED
of	I-MED
the	I-MED
esophagus	I-MED
is	O
among	O
the	O
leading	O
cause	B-MED
of	O
cancer	B-MED
deaths	I-MED
in	O
punjab	B-MED
,	O
india	B-MED
.	O
	
patients	B-MED
generally	O
present	B-MED
with	O
dysphagia	B-MED
as	O
their	O
first	O
symptom	B-MED
and	O
more	O
often	O
they	O
have	O
advanced	B-MED
disease	I-MED
at	O
the	O
time	B-MED
of	O
presentation	B-MED
to	O
a	O
tertiary	B-MED
care	I-MED
centre	I-MED
.	O
	
palliative	B-MED
procedures	I-MED
have	O
important	B-MED
roles	O
in	O
this	O
setting	O
.	O
	
stenting	B-MED
is	O
the	O
best	O
option	B-MED
to	O
palliate	B-MED
the	O
symptoms	B-MED
of	O
dysphagia	B-MED
,	O
from	O
which	O
patient	B-MED
is	O
suffering	B-MED
the	I-MED
most	I-MED
.	O
	
to	O
know	O
the	O
success	B-MED
rate	B-MED
,	O
early	B-MED
and	O
long	B-MED
term	I-MED
complications	B-MED
and	O
mortality	B-MED
in	O
esophageal	B-MED
stenting	I-MED
,	O
when	O
it	O
was	O
done	O
in	O
malignant	B-MED
esophageal	I-MED
stricture	I-MED
patients	B-MED
.	O
	
one	B-MED
hundred	I-MED
patients	B-MED
,	O
who	O
had	O
undergone	O
esophageal	B-MED
stenting	I-MED
from	O
january	B-MED
2012	O
to	O
january	B-MED
2015	O
,	O
were	O
included	B-MED
in	O
the	O
study	B-MED
.	O
	
we	O
retrospectively	B-MED
analysed	I-MED
the	O
data	B-MED
for	O
patient	B-MED
characteristics	B-MED
,	O
causes	B-MED
of	O
non-operability	B-MED
,	O
early	B-MED
and	O
long	B-MED
term	I-MED
complications	B-MED
,	O
re-interventions	B-MED
,	O
efficacy	B-MED
and	O
mortality	B-MED
.	O
	
out	O
of	O
100	O
patients	B-MED
,	O
indications	B-MED
for	O
stenting	B-MED
were	O
locally	O
advanced	B-MED
disease	I-MED
not	O
amenable	B-MED
to	O
surgery	B-MED
52%	O
,	O
metastatic	B-MED
disease	I-MED
35%	O
,	O
cva	B-MED
1%	O
,	O
cardiac	B-MED
and	O
respiratory	B-MED
problem	I-MED
8%	O
,	O
un-willing	O
for	O
surgery	B-MED
in	O
5%	O
of	O
patients	B-MED
.	O
	
majority	O
of	O
patients	B-MED
94%	O
had	O
squamous	B-MED
cell	I-MED
carcinoma	I-MED
,	O
while	O
only	O
6%	O
had	O
adenocarcinoma	B-MED
.	O
	
84%	O
of	O
patients	B-MED
presented	B-MED
with	O
dysphagia	B-MED
with	O
or	O
without	O
chest	B-MED
pain	I-MED
and	O
recurrent	B-MED
cough	I-MED
while	O
16%	O
had	O
recurrent	B-MED
vomiting	I-MED
.	O
	
58%	O
had	O
dysphagia	B-MED
to	O
liquids	B-MED
and	O
solids	B-MED
and	O
17%	O
had	O
complete	B-MED
dysphagia	I-MED
.	O
	
after	O
stenting	B-MED
93%	O
had	O
significant	B-MED
improvement	B-MED
in	O
dysphagia	B-MED
score	B-MED
from	O
median	O
of	O
3	O
to	O
1	O
.	O
	
post	B-MED
procedure	I-MED
stay	B-MED
was	O
3.61	O
days	B-MED
.	O
	
one	O
patient	B-MED
had	O
procedure	B-MED
related	O
major	O
complication	B-MED
in	O
the	O
form	O
of	O
post	B-MED
procedural	I-MED
bleed	I-MED
after	O
16	O
days	B-MED
of	O
stenting	B-MED
leading	O
to	O
death	B-MED
of	O
that	O
patient	B-MED
.	O
	
minor	B-MED
complications	B-MED
were	O
present	B-MED
in	O
52	O
patients	B-MED
treated	B-MED
conservatively	O
not	O
affecting	B-MED
the	O
efficacy	B-MED
of	O
procedure	B-MED
.	O
	
these	O
include	B-MED
pain	B-MED
after	O
stenting	B-MED
38%	O
,	O
stent	B-MED
obstruction	I-MED
23%	O
and	O
stent	B-MED
migration	I-MED
6%	O
.	O
	
all	O
the	O
minor	B-MED
complications	B-MED
were	O
treated	B-MED
conservatively	O
except	B-MED
in	O
six	O
patients	B-MED
in	O
whom	O
re-stenting	B-MED
was	O
done	O
.	O
	
esophageal	B-MED
stenting	I-MED
is	O
relatively	O
safe	O
procedure	B-MED
with	O
short	O
stay	B-MED
of	O
the	O
patient	B-MED
in	O
the	O
hospital	B-MED
.	O
	
although	O
,	O
it	O
helps	O
in	O
alleviating	O
patients	B-MED
'	O
morbidity	B-MED
very	O
effectively	B-MED
and	O
reliably	O
,	O
there	O
are	O
many	O
technical	B-MED
glitches	I-MED
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	B-MED
should	O
be	O
properly	O
counseled	B-MED
before	O
the	O
procedure	B-MED
to	O
prevent	B-MED
and	O
manage	B-MED
post	B-MED
procedure	I-MED
complications	B-MED
treatment	B-MED
of	O
carcinoma	B-MED
in	I-MED
situ	I-MED
of	I-MED
the	I-MED
glans	I-MED
penis	I-MED
with	O
topical	B-MED
imiquimod	I-MED
followed	O
by	O
carbon	B-MED
dioxide	I-MED
laser	I-MED
excision	B-MED
different	B-MED
approaches	B-MED
have	O
been	O
described	B-MED
in	O
published	O
studies	O
for	O
carcinoma	B-MED
in	I-MED
situ	I-MED
cis	I-MED
of	I-MED
the	I-MED
glans	I-MED
penis	I-MED
erythroplasia	B-MED
of	I-MED
queyrat	I-MED
,	O
including	B-MED
topical	B-MED
chemotherapy	I-MED
or	O
immunotherapy	B-MED
and	O
laser	B-MED
or	O
surgical	B-MED
excision	I-MED
.	O
	
we	O
evaluated	B-MED
the	O
efficacy	B-MED
of	O
topical	B-MED
imiquimod	I-MED
iq	B-MED
followed	O
by	O
carbon	B-MED
dioxide	I-MED
laser	I-MED
ablation	B-MED
of	O
the	O
lesion	B-MED
.	O
	
from	O
2010	O
to	O
2015	O
,	O
10	O
patients	B-MED
affected	I-MED
by	O
cis	B-MED
of	O
the	O
glans	B-MED
were	O
treated	B-MED
by	O
iq	B-MED
,	O
followed	O
by	O
carbon	B-MED
dioxide	I-MED
laser	I-MED
ablation	B-MED
.	O
	
for	O
every	O
patient	B-MED
,	O
we	O
performed	B-MED
histologic	B-MED
examination	I-MED
before	B-MED
and	O
after	B-MED
iq	B-MED
.	O
	
local	O
toxicity	B-MED
and	O
adverse	B-MED
effects	I-MED
were	O
recorded	O
.	O
	
after	B-MED
treatment	I-MED
,	O
histologic	B-MED
examination	I-MED
showed	O
no	B-MED
residual	I-MED
tumor	I-MED
in	O
6	O
patients	B-MED
complete	B-MED
response	I-MED
cr	B-MED
,	O
stable	B-MED
disease	I-MED
in	O
2	O
patients	B-MED
,	O
and	O
progressive	B-MED
disease	I-MED
in	O
2	O
patients	B-MED
.	O
	
those	O
with	O
a	O
cr	B-MED
had	O
human	B-MED
papillomavirus	I-MED
-	O
related	B-MED
lesions	B-MED
,	O
and	O
they	O
had	O
no	B-MED
experienced	O
relapses	B-MED
after	B-MED
a	O
mean	O
follow-up	B-MED
of	O
26	O
months	B-MED
.	O
	
the	O
2	O
patients	B-MED
with	O
progressive	B-MED
disease	I-MED
underwent	O
total	O
penectomy	B-MED
.	O
	
all	O
patients	B-MED
were	O
alive	B-MED
at	O
the	O
last	O
follow-up	B-MED
examination	I-MED
.	O
	
all	O
patients	B-MED
experienced	O
a	O
mild	B-MED
local	O
toxicity	B-MED
burning	B-MED
erythema	I-MED
but	O
no	B-MED
major	B-MED
adverse	B-MED
effects	I-MED
.	O
	
local	O
treatment	B-MED
with	O
iq	B-MED
for	O
glans	B-MED
cis	B-MED
is	O
effective	B-MED
mainly	O
for	O
human	B-MED
papillomavirus	I-MED
-	O
related	B-MED
lesions	B-MED
.	O
	
the	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-MED
examination	I-MED
findings	O
before	B-MED
and	O
after	B-MED
iq	B-MED
treatment	B-MED
.	O
	
the	O
small	O
number	O
of	O
patients	B-MED
,	O
owing	O
to	O
the	O
rarity	B-MED
of	O
this	O
disease	B-MED
,	O
was	O
the	O
main	O
limitation	B-MED
of	O
the	O
present	O
study	O
.	O
	
iq	B-MED
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow-up	B-MED
protocol	B-MED
is	O
mandatory	B-MED
because	O
of	O
the	O
lack	B-MED
of	O
long-term	B-MED
efficacy	B-MED
progressive	B-MED
subcortical	B-MED
calcifications	B-MED
secondary	O
to	O
venous	B-MED
hypertension	I-MED
in	O
an	O
intracranial	B-MED
dural	B-MED
arteriovenous	I-MED
fistula	I-MED
intracranial	B-MED
dural	B-MED
arteriovenous	I-MED
fistulas	I-MED
davf	B-MED
are	O
acquired	B-MED
lesions	I-MED
,	O
with	O
the	O
most	O
commonly	O
reported	B-MED
findings	B-MED
on	O
ct	B-MED
haemorrhage	B-MED
or	O
focal	B-MED
oedema	I-MED
.	O
	
we	O
describe	O
a	O
case	O
of	O
progressive	B-MED
subcortical	B-MED
calcification	B-MED
on	O
ct	B-MED
secondary	O
to	O
venous	B-MED
hypertension	I-MED
from	O
a	O
high	O
grade	O
effects	O
of	O
static	B-MED
cold	I-MED
storage	I-MED
and	O
hypothermic	B-MED
machine	I-MED
perfusion	I-MED
on	O
oxidative	B-MED
stress	I-MED
factors	I-MED
,	O
adhesion	B-MED
molecules	I-MED
,	O
and	O
zinc	B-MED
finger	I-MED
transcription	I-MED
factor	I-MED
proteins	I-MED
before	O
and	O
after	O
liver	B-MED
transplantation	I-MED
background	O
this	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-MED
cold	I-MED
storage	I-MED
scs	B-MED
and	O
hypothermic	B-MED
machine	I-MED
perfusion	I-MED
hmp	B-MED
on	O
the	O
oxidative	B-MED
stress	I-MED
factors	I-MED
osf	B-MED
,	O
adhesion	B-MED
molecules	I-MED
am	B-MED
,	O
and	O
zinc	B-MED
finger	I-MED
transcription	I-MED
factor	I-MED
snail	B-MED
before	O
and	O
after	O
liver	B-MED
transplantation	I-MED
.	O
	
material	O
and	O
methods	O
experimental	O
dogs	B-MED
were	O
randomly	O
divided	O
into	O
donor	B-MED
group	B-MED
a	O
,	O
scs	B-MED
group	B-MED
b	O
,	O
and	O
hmp	B-MED
group	B-MED
c	O
n=30	O
groups	B-MED
.	O
	
livers	B-MED
retrieved	I-MED
from	O
group	B-MED
a	O
were	O
transplanted	B-MED
into	O
group	B-MED
b	O
after	O
scs	B-MED
,	O
and	O
the	O
livers	B-MED
sampled	O
from	O
group	B-MED
b	O
were	O
transplanted	B-MED
into	O
group	B-MED
c	O
after	O
hmp	B-MED
.	O
	
the	O
dogs	O
in	O
group	B-MED
a	O
were	O
euthanized	B-MED
and	O
discarded	O
,	O
and	O
the	O
livers	B-MED
sampled	O
from	O
group	B-MED
c	O
were	O
used	O
for	O
other	O
experiments	O
.	O
	
twenty	O
dogs	B-MED
with	O
successful	O
liver	B-MED
transplants	I-MED
were	O
randomly	O
selected	O
from	O
groups	B-MED
b	O
and	O
c	O
for	O
analysis	O
.	O
	
results	O
during	O
the	O
liver	B-MED
sampling	B-MED
process	I-MED
,	O
the	O
levels	O
of	O
osf	B-MED
,	O
am	B-MED
,	O
and	O
snail	O
between	O
the	O
2	O
groups	B-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
p>0	O
before	O
the	O
transplantation	B-MED
,	O
the	O
levels	O
of	O
chemokine	B-MED
cxcl14	I-MED
and	O
snail	B-MED
between	O
the	O
2	O
groups	B-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
p>0	O
,	O
and	O
compared	O
with	O
group	B-MED
b	O
,	O
hif-1α	O
and	O
p-selectin	B-MED
in	O
group	B-MED
c	O
were	O
lower	O
p<0	O
60	O
min	O
after	O
the	O
transplantation	B-MED
,	O
hif-1α	B-MED
,	O
chemokine	B-MED
cxcl14	I-MED
,	O
p-selectin	B-MED
,	O
and	O
snail	B-MED
in	O
group	B-MED
c	O
were	O
lower	O
than	O
that	O
in	O
group	B-MED
b	O
p<0	O
.	O
	
conclusions	O
hmp	B-MED
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
osf	B-MED
and	O
inflammatory	B-MED
factors	I-MED
,	O
which	O
is	O
conducive	B-MED
for	O
liver	B-MED
transplantation	I-MED
.	O
	
physiology	B-MED
of	O
respiratory	B-MED
disturbances	I-MED
in	O
muscular	B-MED
dystrophies	I-MED
muscular	B-MED
dystrophy	I-MED
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-MED
characterised	O
by	O
progressive	B-MED
skeletal	B-MED
muscle	I-MED
wasting	I-MED
,	O
including	O
of	O
the	O
respiratory	B-MED
muscles	I-MED
.	O
	
respiratory	B-MED
failure	I-MED
,	O
i.e	O
.	O
	
when	O
the	O
respiratory	B-MED
system	I-MED
fails	B-MED
in	O
its	O
gas	B-MED
exchange	I-MED
functions	I-MED
,	O
is	O
a	O
common	O
feature	B-MED
in	O
muscular	B-MED
dystrophy	I-MED
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-MED
,	O
and	O
it	O
is	O
a	O
consequence	B-MED
of	I-MED
lung	B-MED
failure	B-MED
,	O
pump	B-MED
failure	I-MED
or	O
a	O
combination	O
of	O
the	O
two	O
.	O
	
the	O
former	O
is	O
due	O
to	O
recurrent	B-MED
aspiration	B-MED
,	O
the	O
latter	O
to	O
progressive	B-MED
weakness	B-MED
of	I-MED
respiratory	I-MED
muscles	I-MED
and	O
an	O
increase	B-MED
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	B-MED
.	O
	
in	O
fact	O
,	O
both	O
the	O
resistive	B-MED
and	I-MED
elastic	I-MED
components	I-MED
of	O
the	O
work	O
of	O
breathing	B-MED
increase	B-MED
due	O
to	O
airway	B-MED
obstruction	I-MED
and	O
chest	B-MED
wall	I-MED
and	O
lung	B-MED
stiffening	B-MED
,	O
respectively	O
.	O
	
the	O
respiratory	B-MED
disturbances	I-MED
in	O
muscular	B-MED
dystrophy	I-MED
are	O
restrictive	B-MED
pulmonary	I-MED
function	I-MED
,	O
hypoventilation	B-MED
,	O
altered	O
thoracoabdominal	B-MED
pattern	O
,	O
hypercapnia	B-MED
,	O
dyspnoea	B-MED
,	O
impaired	B-MED
regulation	I-MED
of	I-MED
breathing	I-MED
,	O
inefficient	B-MED
cough	I-MED
and	O
sleep	B-MED
disordered	I-MED
breathing	I-MED
.	O
	
they	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular	B-MED
dystrophy	I-MED
and	O
its	O
progression	B-MED
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-MED
,	O
prognosis	B-MED
and	O
degree	B-MED
of	I-MED
respiratory	I-MED
involvement	I-MED
.	O
	
a	O
common	O
feature	B-MED
of	O
muscular	B-MED
dystrophy	I-MED
is	O
respiratory	B-MED
failure	I-MED
,	O
i.e	O
.	O
	
the	O
inability	O
of	O
the	O
respiratory	B-MED
system	I-MED
to	O
provide	O
proper	O
oxygenation	B-MED
and	O
carbon	B-MED
dioxide	I-MED
elimination	I-MED
in	O
the	O
lung	B-MED
,	O
respiratory	B-MED
failure	I-MED
is	O
caused	O
by	O
recurrent	B-MED
aspiration	B-MED
,	O
and	O
leads	O
to	O
hypoxaemia	B-MED
and	O
hypercarbia	B-MED
.	O
	
ventilatory	B-MED
failure	I-MED
in	O
muscular	B-MED
dystrophy	I-MED
is	O
caused	O
by	O
increased	B-MED
respiratory	B-MED
load	I-MED
and	O
respiratory	B-MED
muscles	I-MED
weakness	I-MED
.	O
	
respiratory	B-MED
load	I-MED
increases	B-MED
in	O
muscular	B-MED
dystrophy	I-MED
because	O
scoliosis	B-MED
makes	O
chest	B-MED
wall	I-MED
compliance	I-MED
decrease	B-MED
,	O
atelectasis	B-MED
and	O
fibrosis	B-MED
make	O
lung	B-MED
compliance	I-MED
decrease	B-MED
,	O
and	O
airway	B-MED
obstruction	I-MED
makes	O
airway	B-MED
resistance	I-MED
increase	B-MED
the	O
consequences	B-MED
of	I-MED
respiratory	B-MED
pump	I-MED
failure	I-MED
are	O
restrictive	B-MED
pulmonary	I-MED
function	I-MED
,	O
hypoventilation	B-MED
,	O
altered	O
thoracoabdominal	B-MED
pattern	O
,	O
hypercapnia	B-MED
,	O
dyspnoea	B-MED
,	O
impaired	B-MED
regulation	I-MED
of	I-MED
breathing	I-MED
,	O
inefficient	B-MED
cough	I-MED
and	O
sleep	B-MED
disordered	I-MED
breathing	I-MED
.	O
	
to	O
understand	O
the	O
mechanisms	B-MED
leading	O
to	O
respiratory	B-MED
disturbances	I-MED
in	O
patients	B-MED
with	O
muscular	B-MED
dystrophy	I-MED
to	O
understand	O
the	O
impact	O
of	O
respiratory	B-MED
disturbances	I-MED
in	O
patients	B-MED
with	O
muscular	B-MED
dystrophy	I-MED
to	O
provide	O
a	O
brief	O
description	B-MED
of	O
the	O
main	O
forms	O
of	O
muscular	B-MED
dystrophy	I-MED
with	O
their	O
respiratory	B-MED
implications	I-MED
.	O
	
significance	B-MED
of	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
in	O
early-stage	B-MED
cervical	B-MED
cancer	I-MED
to	O
examine	O
characteristics	B-MED
and	O
survival	B-MED
outcomes	B-MED
of	O
women	B-MED
with	O
surgically-treated	B-MED
cervical	B-MED
cancer	I-MED
exhibiting	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
.	O
	
we	O
utilized	O
the	O
surveillance	B-MED
,	O
epidemiology	I-MED
,	O
and	I-MED
end	I-MED
results	I-MED
program	I-MED
to	O
identify	O
cervical	B-MED
cancer	I-MED
patients	B-MED
who	O
underwent	O
hysterectomy	B-MED
between	O
1973	O
and	O
2003	O
.	O
	
logistic	B-MED
regression	I-MED
models	I-MED
were	O
used	O
to	O
identify	O
risk	B-MED
factors	I-MED
for	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
on	O
multivariable	B-MED
analysis	I-MED
.	O
	
association	B-MED
of	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
and	O
cause-specific	B-MED
survival	I-MED
css	B-MED
from	O
cervical	B-MED
cancer	I-MED
was	O
examined	O
with	O
cox	B-MED
proportional	I-MED
hazard	I-MED
regression	I-MED
models	I-MED
on	O
multivariable	B-MED
analysis	I-MED
.	O
	
we	O
identified	O
837	O
4.9	O
cases	O
of	O
uterine	B-MED
corpus	I-MED
invasion	B-MED
and	O
16	O
95.1	O
cases	O
of	O
non-invasion	B-MED
.	O
	
median	B-MED
follow-up	B-MED
time	B-MED
was	O
14.0	O
years	O
.	O
	
there	O
were	O
1642	O
deaths	B-MED
due	O
to	O
cervical	B-MED
cancer	I-MED
.	O
	
uterine	B-MED
corpus	I-MED
invasion	B-MED
was	O
independently	B-MED
associated	B-MED
with	I-MED
older	B-MED
age	I-MED
,	O
non-squamous	B-MED
histology	I-MED
,	O
high-grade	B-MED
tumors	I-MED
,	O
large	B-MED
tumor	I-MED
size	I-MED
,	O
and	O
nodal	B-MED
metastasis	B-MED
on	O
multivariable	B-MED
analysis	I-MED
all	O
,	O
p	O
<	O
0.001	O
.	O
	
on	O
univariable	B-MED
analysis	I-MED
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
decreased	B-MED
css	B-MED
compared	O
to	O
the	O
non-invasion	B-MED
5-year	O
rates	O
,	O
79.0	O
versus	O
94.5	O
,	O
p	O
<	O
0.001	O
.	O
	
after	O
controlling	B-MED
for	O
other	O
significant	B-MED
prognostic	B-MED
factors	I-MED
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
remained	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
css	B-MED
adjusted-hazard	B-MED
ratio	I-MED
1.45	O
,	O
95%	O
confidence	B-MED
interval	I-MED
1.21	O
.	O
	
among	O
stage	B-MED
t1b	I-MED
cases	O
n	O
=	O
6730	O
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
remained	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
css	B-MED
adjusted-hazard	B-MED
ratio	I-MED
1.95	O
,	O
95%ci	O
1.47	O
.	O
	
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
decreased	B-MED
css	B-MED
in	O
stage	B-MED
t1b1	I-MED
disease	B-MED
74.5	O
versus	O
90.7	O
,	O
p	O
<	O
0.001	O
and	O
in	O
stage	B-MED
t1b2	I-MED
disease	B-MED
67.0	O
versus	O
79.5	O
,	O
p	O
=	O
0.01	O
.	O
	
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
is	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
survival	B-MED
of	O
women	B-MED
with	O
early-stage	B-MED
cervical	B-MED
cancer	I-MED
.	O
	
efficient	O
gene	B-MED
targeting	I-MED
in	O
non-homologous	B-MED
end-joining	I-MED
-deficient	O
lipomyces	B-MED
starkeyi	I-MED
strains	B-MED
microbial	B-MED
lipids	B-MED
are	O
sustainable	O
feedstock	O
for	O
the	O
production	B-MED
of	O
oleochemicals	B-MED
and	O
biodiesel	B-MED
.	O
	
oleaginous	B-MED
yeasts	I-MED
have	O
recently	O
been	O
proposed	O
as	O
alternative	B-MED
lipid	B-MED
producers	B-MED
to	O
plants	B-MED
and	O
animals	B-MED
to	O
promote	O
sustainability	O
in	O
the	O
chemical	B-MED
and	O
fuel	B-MED
industries	I-MED
.	O
	
the	O
oleaginous	B-MED
yeast	I-MED
lipomyces	B-MED
starkeyi	I-MED
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	B-MED
producer	B-MED
.	O
	
however	O
,	O
improvement	O
of	O
its	O
lipid	B-MED
productivity	B-MED
is	O
essential	O
for	O
the	O
cost-effective	B-MED
production	I-MED
of	O
oleochemicals	B-MED
and	O
fuels	B-MED
.	O
	
genetic	B-MED
and	O
metabolic	B-MED
engineering	I-MED
of	O
l	B-MED
.	O
	
starkeyi	I-MED
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	B-MED
production	B-MED
and	O
our	O
understanding	O
of	O
the	O
mechanisms	B-MED
behind	O
lipid	B-MED
biosynthesis	B-MED
pathways	I-MED
.	O
	
we	O
previously	O
described	O
an	O
integrative	B-MED
transformation	I-MED
system	I-MED
using	O
a	O
drug	B-MED
-resistant	O
marker	B-MED
for	O
l	B-MED
.	O
	
starkeyi	I-MED
.	O
	
however	O
,	O
gene-targeting	B-MED
frequencies	B-MED
were	O
very	O
low	O
because	O
non-homologous	B-MED
recombination	I-MED
is	O
probably	O
predominant	O
in	O
l	B-MED
.	O
	
starkeyi	I-MED
.	O
	
genetic	B-MED
engineering	I-MED
tools	I-MED
for	O
l	B-MED
.	O
	
starkeyi	I-MED
have	O
not	O
been	O
sufficiently	O
developed	O
.	O
	
in	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
genetic	B-MED
tool	I-MED
and	O
its	O
application	B-MED
in	O
l	B-MED
.	O
	
starkeyi	I-MED
.	O
	
to	O
develop	O
a	O
highly	O
efficient	O
gene-targeting	B-MED
system	I-MED
for	O
l	B-MED
.	O
	
starkeyi	I-MED
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	B-MED
by	O
disrupting	B-MED
genes	B-MED
for	O
lsku70p	B-MED
,	O
lsku80p	B-MED
,	O
and/or	O
lslig4p	B-MED
,	O
which	O
share	O
homology	B-MED
with	O
other	O
yeasts	B-MED
ku70p	B-MED
,	O
ku80p	B-MED
,	O
and	O
lig4p	B-MED
,	O
respectively	O
,	O
being	O
involved	O
in	O
non-homologous	B-MED
end-joining	I-MED
pathway	I-MED
.	O
	
deletion	B-MED
of	O
the	O
lslig4	B-MED
gene	I-MED
dramatically	O
improved	O
the	O
homologous	B-MED
recombination	I-MED
efficiency	B-MED
80.0	O
at	O
the	O
lsura3	B-MED
locus	B-MED
compared	O
with	O
that	O
in	O
the	O
wild-type	B-MED
strain	B-MED
1.4	O
,	O
when	O
2000-bp	B-MED
homologous	I-MED
flanking	I-MED
regions	I-MED
were	O
used	O
.	O
	
the	O
homologous	B-MED
recombination	I-MED
efficiencies	B-MED
of	O
the	O
double	O
mutant	B-MED
l	B-MED
sku70	I-MED
and	O
the	O
triple	O
mutant	B-MED
lsku70	B-MED
were	O
also	O
markedly	O
enhanced	O
.	O
	
therefore	O
,	O
the	O
l	B-MED
.	O
	
starkeyi	I-MED
lslig4	B-MED
background	O
strains	B-MED
have	O
promise	O
as	O
efficient	O
recipient	B-MED
strains	I-MED
for	O
genetic	B-MED
and	O
metabolic	B-MED
engineering	I-MED
approaches	B-MED
in	O
this	O
evaluating	O
clinical	B-MED
,	O
dietary	B-MED
and	O
psychological	B-MED
risk	B-MED
factors	I-MED
for	O
relapse	B-MED
of	O
ulcerative	B-MED
colitis	I-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
the	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	B-MED
in	O
patients	B-MED
with	O
ulcerative	B-MED
colitis	I-MED
uc	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
on	O
long	O
term	O
follow	B-MED
up	I-MED
is	O
scarce	O
.	O
	
to	O
determine	O
the	O
relapse	B-MED
rate	O
in	O
patients	B-MED
with	O
uc	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	B-MED
of	O
relapse	B-MED
.	O
	
patients	B-MED
with	O
uc	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
were	O
enrolled	O
between	O
january-july	O
2010	O
and	O
followed	B-MED
up	I-MED
for	O
1	O
year	B-MED
to	O
determine	O
the	O
effect	O
of	O
clinical	B-MED
,	O
dietary	B-MED
and	O
psychological	B-MED
factors	B-MED
on	O
relapse	B-MED
.	O
	
information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	B-MED
such	O
as	O
infection	B-MED
,	O
antibiotic	B-MED
or	O
nsaids	B-MED
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	B-MED
felt	O
important	O
,	O
and	O
compliance	B-MED
with	O
medications	B-MED
was	O
obtained	O
.	O
	
97	O
patients	B-MED
59	O
males	B-MED
,	O
mean	O
age	B-MED
39	O
+	O
11.9	O
years	B-MED
were	O
followed	B-MED
up	I-MED
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2.3	O
months	B-MED
.	O
	
18	O
relapsed	B-MED
with	O
the	O
median	O
time	O
to	O
relapse	B-MED
being	O
3.5	O
months	B-MED
.	O
	
on	O
univariate	B-MED
analysis	I-MED
more	O
relapsers	O
had	O
significantly	O
higher	O
nsaids	B-MED
use	O
within	O
15	O
days	B-MED
of	O
relapse	B-MED
,	O
respiratory	B-MED
tract	I-MED
infection	I-MED
within	O
4	O
weeks	B-MED
,	O
use	O
of	O
steroids	B-MED
more	O
than	O
once	O
in	O
past	O
,	O
higher	O
consumption	B-MED
of	O
calcium	B-MED
,	O
riboflavin	B-MED
,	O
vitamin	B-MED
a	I-MED
and	O
lower	O
consumption	B-MED
of	O
sugars	B-MED
.	O
	
on	O
multivariate	B-MED
analysis	I-MED
,	O
nsaids	B-MED
use	O
hr	O
intake	B-MED
of	O
vitamin	B-MED
a	I-MED
hr	O
were	O
statistically	O
significant	O
predictors	B-MED
of	O
relapse	B-MED
.	O
	
with	O
a	O
relapse	B-MED
rate	O
of	O
18.6	O
over	O
a	O
follow	B-MED
up	I-MED
of	O
9	O
months	B-MED
in	O
patients	B-MED
with	O
uc	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
,	O
independent	O
predictors	B-MED
of	O
relapse	B-MED
were	O
history	O
of	O
nsaids	B-MED
use	O
within	O
15	O
days	B-MED
of	O
relapse	B-MED
and	O
higher	O
intake	O
of	O
vitamin	B-MED
a	I-MED
.	O
	
high	O
performance	O
reduction	B-MED
of	O
h2o2	B-MED
with	O
an	O
electron	B-MED
transport	I-MED
decaheme	B-MED
cytochrome	I-MED
on	O
a	O
porous	O
ito	B-MED
electrode	B-MED
the	O
decaheme	B-MED
cytochrome	I-MED
mtrc	I-MED
from	O
shewanella	B-MED
oneidensis	I-MED
mr-1	I-MED
immobilized	B-MED
on	O
an	O
ito	B-MED
electrode	B-MED
displays	O
unprecedented	O
h2o2	B-MED
reduction	B-MED
activity	O
.	O
	
although	O
mtrc	B-MED
showed	O
lower	O
peroxidase	B-MED
activity	I-MED
in	O
solution	O
compared	O
to	O
horseradish	B-MED
peroxidase	I-MED
,	O
the	O
ten	O
heme	B-MED
cofactors	B-MED
enable	O
excellent	O
electronic	B-MED
communication	I-MED
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	B-MED
surface	O
.	O
	
a	O
hierarchical	O
ito	B-MED
electrode	B-MED
enabled	O
optimal	O
immobilization	B-MED
of	O
mtrc	B-MED
and	O
a	O
high	O
current	B-MED
density	I-MED
of	O
1	O
ma	O
cm	O
at	O
0.4	O
v	O
vs	O
she	B-MED
could	O
be	O
obtained	O
at	O
ph	O
6.5	O
eonset	O
=	O
0.72	O
v	O
.	O
	
uv-visible	B-MED
and	O
resonance	B-MED
raman	I-MED
spectroelectrochemical	I-MED
studies	I-MED
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron-oxo	O
species	O
as	O
the	O
catalytic	B-MED
intermediate	O
.	O
	
our	O
findings	O
demonstrate	O
the	O
potential	B-MED
of	O
multiheme	B-MED
cytochromes	I-MED
to	O
catalyze	B-MED
technologically	B-MED
relevant	O
reactions	O
and	O
establish	O
mtrc	B-MED
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	B-MED
h2o2	B-MED
reduction	B-MED
with	O
scope	O
for	O
applications	O
in	O
fuel	B-MED
cells	I-MED
and	O
ophthalmic	B-MED
manifestations	I-MED
of	O
facial	B-MED
dog	B-MED
bites	I-MED
in	O
children	B-MED
to	O
characterize	O
ophthalmic	B-MED
manifestations	I-MED
and	O
periocular	B-MED
injuries	I-MED
of	O
pediatric	B-MED
facial	B-MED
dog	B-MED
bites	I-MED
.	O
	
a	O
retrospective	B-MED
review	B-MED
of	O
all	O
children	B-MED
younger	B-MED
than	O
18	O
years	B-MED
who	O
sought	O
medical	B-MED
attention	B-MED
after	O
a	O
dog	B-MED
bite	I-MED
to	O
the	O
face	B-MED
between	O
january	B-MED
1	O
,	O
2003	O
and	O
may	B-MED
22	O
,	O
2014	O
was	O
performed	B-MED
at	O
a	O
large	B-MED
tertiary	I-MED
pediatric	B-MED
hospital	I-MED
.	O
	
data	B-MED
on	O
type	B-MED
and	O
location	B-MED
of	I-MED
injury	I-MED
,	O
surgical	B-MED
intervention	I-MED
,	O
and	O
complications	B-MED
were	O
collected	B-MED
.	O
	
a	O
total	B-MED
of	O
1	O
children	B-MED
aged	B-MED
0.19	O
to	O
17	O
years	B-MED
were	O
identified	B-MED
with	O
dog	B-MED
bite	I-MED
s	O
.	O
	
dog	O
bite	O
s	O
to	O
the	O
face	O
occurred	O
in	O
most	O
patients	O
n	O
=	O
1	O
,	O
414	O
71%	O
.	O
	
of	O
those	O
children	O
with	O
facial	O
dog	B-MED
bite	I-MED
injuries	O
,	O
230	O
16%	O
suffered	O
ophthalmic	O
manifestations	O
.	O
	
the	O
average	O
age	O
was	O
4.3	O
years	O
.	O
	
eyelid	O
injuries	O
occurred	O
in	O
227	O
99%	O
of	O
children	O
,	O
47	O
20%	O
sustained	O
canalicular	O
system	O
injuries	O
,	O
3	O
1.3	O
suffered	O
corneal	O
abrasions	O
,	O
and	O
2	O
patients	O
sustained	O
facial	O
nerve	O
injury	O
resulting	O
in	O
lagophthalmos	O
.	O
	
no	O
patients	O
suffered	O
vision	O
loss	O
.	O
	
complications	O
occurred	O
in	O
32	O
patients	O
14%	O
,	O
with	O
the	O
most	O
common	O
being	O
epiphora	O
in	O
9	O
patients	O
28%	O
,	O
upper	O
eyelid	O
ptosis	O
in	O
8	O
25%	O
,	O
and	O
prominent	O
scar	O
formation	O
in	O
4	O
patients	O
13%	O
.	O
	
thirteen	O
children	O
5.7	O
needed	O
one	O
or	O
more	O
secondary	O
procedure	O
to	O
correct	O
complications	O
.	O
	
the	O
authors	O
report	O
the	O
clinical	O
features	O
and	O
management	O
on	O
the	O
largest	O
series	O
of	O
ophthalmic	O
and	O
periocular	O
injuries	O
associated	O
with	O
pediatric	O
facial	O
dog	O
bite	O
s	I-MED
.	O
	
these	O
injuries	O
occur	O
in	O
about	O
1	O
in	O
6	O
dog	O
bite	O
s	O
to	O
the	O
face	O
and	O
primarily	O
involve	O
the	O
ocular	O
adnexa	O
.	O
	
despite	O
early	O
and	O
appropriate	O
surgical	O
management	O
,	O
complications	O
and	O
the	O
need	O
for	O
revision	O
surgery	O
are	O
relatively	O
common	B-MED
blastocystis	B-MED
subtyping	I-MED
and	O
its	O
association	O
with	O
intestinal	B-MED
parasites	I-MED
in	O
children	B-MED
from	O
different	O
geographical	B-MED
regions	I-MED
of	I-MED
colombia	I-MED
blastocystis	B-MED
is	O
a	O
common	O
enteric	B-MED
protist	I-MED
colonizing	I-MED
probably	O
more	O
than	O
1	O
billion	O
people	B-MED
with	O
a	O
large	O
variety	O
of	O
non-human	B-MED
hosts	I-MED
.	O
	
remarkable	O
genetic	B-MED
diversity	I-MED
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	B-MED
of	I-MED
the	I-MED
genus	I-MED
into	O
multiple	B-MED
subtypes	I-MED
st	B-MED
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non-human	B-MED
hosts	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
blastocystis	B-MED
sts	I-MED
/	O
18s	B-MED
alleles	I-MED
in	O
symptomatic	B-MED
abdominal	B-MED
pain	I-MED
,	O
anal	B-MED
pruritus	I-MED
,	O
diarrhea	B-MED
,	O
headache	B-MED
,	O
nauseas	B-MED
and/or	O
vomit	B-MED
and	O
asymptomatic	B-MED
children	B-MED
from	O
nine	O
geographical	B-MED
regions	I-MED
of	I-MED
colombia	I-MED
.	O
	
a	O
total	O
of	O
2026	O
fecal	B-MED
samples	I-MED
were	O
collected	O
as	O
part	O
of	O
a	O
national	B-MED
survey	I-MED
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	B-MED
parasites	I-MED
in	O
children	B-MED
.	O
	
a	O
set	O
of	O
256	O
samples	O
that	O
were	O
blastocystis	B-MED
positive	I-MED
was	O
finally	O
selected	O
.	O
	
the	O
samples	O
were	O
submitted	O
to	O
dna	B-MED
extraction	I-MED
,	O
real	B-MED
time	I-MED
pcr	I-MED
and	O
sequencing	B-MED
using	O
blastocystis	B-MED
-specific	O
primers	B-MED
targeting	O
the	O
small	B-MED
subunit	I-MED
rrna	B-MED
gene	I-MED
for	O
st	B-MED
identification	I-MED
.	O
	
dna	B-MED
of	O
ascaris	B-MED
lumbricoides	I-MED
16.4	O
,	O
trichuris	B-MED
trichiura	I-MED
8.2	O
,	O
hookworms	B-MED
necator	B-MED
americanus	I-MED
/	O
ancylostoma	B-MED
duodenale	I-MED
7.3	O
,	O
giardia	B-MED
duodenalis	I-MED
23.1	O
,	O
entamoeba	B-MED
complex	I-MED
82%	O
,	O
entamoeba	B-MED
coli	I-MED
55%	O
,	O
hymenolepis	B-MED
nana	I-MED
0.8	O
,	O
endolimax	B-MED
nana	I-MED
33.2	O
and	O
neobalantidium	B-MED
coli	I-MED
2.7	O
was	O
detected	O
in	O
the	O
blastocystis	B-MED
-	O
positive	B-MED
samples	I-MED
.	O
	
we	O
detected	O
st1	B-MED
21.4	O
,	O
st2	B-MED
19.5	O
,	O
st3	B-MED
55.5	O
,	O
st4	B-MED
0.8	O
,	O
st6	B-MED
2%	O
and	O
st7	B-MED
0.8	O
alleles	B-MED
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
st1	B-MED
alleles	B-MED
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
st2	B-MED
alleles	B-MED
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
st3	B-MED
allele	B-MED
42	O
for	O
st4	B-MED
allele	B-MED
122	O
for	O
st6	B-MED
,	O
and	O
allele	B-MED
142	O
for	O
st7	B-MED
.	O
	
further	O
studies	O
implementing	O
high-resolution	B-MED
molecular	B-MED
markers	I-MED
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
blastocystis	B-MED
transmission	B-MED
and	O
the	O
role	O
of	O
this	O
stramenopila	B-MED
in	O
health	B-MED
and	I-MED
disease	I-MED
.	O
	
did	O
municipal	B-MED
solid	I-MED
waste	I-MED
landfill	B-MED
have	O
obvious	O
influence	B-MED
on	O
polychlorinated	B-MED
dibenzo-p-dioxins	I-MED
and	O
polychlorinated	B-MED
dibenzofurans	I-MED
pcdd	B-MED
/	O
fs	B-MED
in	O
ambient	B-MED
air	I-MED
a	O
case	B-MED
study	I-MED
in	O
east	B-MED
china	I-MED
municipal	B-MED
solid	I-MED
waste	I-MED
msw	B-MED
landfill	B-MED
was	O
a	O
main	O
way	O
to	O
disposal	B-MED
of	O
msw	B-MED
and	O
almost	O
95%	O
of	O
msw	B-MED
was	O
disposed	B-MED
by	O
landfills	B-MED
in	O
the	O
world	B-MED
.	O
	
in	O
order	O
to	O
understand	O
the	O
influence	B-MED
of	O
msw	B-MED
landfill	B-MED
on	O
polychlorinated	B-MED
dibenzo-p-dioxins	I-MED
and	O
polychlorinated	B-MED
dibenzofurans	I-MED
pcdd	B-MED
/	O
fs	B-MED
in	O
surrounding	B-MED
atmosphere	I-MED
,	O
42	O
ambient	B-MED
air	I-MED
samples	O
were	O
collected	O
and	O
analyzed	B-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
of	O
a	O
msw	B-MED
landfill	B-MED
in	O
east	B-MED
china	I-MED
.	O
	
the	O
results	O
of	O
present	O
study	B-MED
were	O
summarized	O
as	O
follows	O
.	O
	
1	O
the	O
total	O
concentrations	B-MED
of	O
pcdd	B-MED
/	O
fs	B-MED
pcdd	B-MED
/	O
fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
2.215	O
,	O
2.058	O
,	O
2.617	O
and	O
1.822	O
,	O
respectively	O
.	O
	
2	O
the	O
toxic	B-MED
equivalent	I-MED
concentrations	I-MED
teq	B-MED
of	O
pcdd	B-MED
/	O
fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
0.103	O
,	O
0.096	O
,	O
0.120	O
and	O
0.108	O
i-teqnm	O
,	O
respectively	O
.	O
	
3	O
the	O
congener	B-MED
profiles	I-MED
,	O
pcdd	B-MED
/	O
fs	B-MED
and	O
teq	B-MED
between	O
background	B-MED
atmosphere	I-MED
and	O
surrounding	B-MED
atmosphere	I-MED
of	O
landfill	B-MED
did	O
not	O
show	O
statistically	B-MED
significant	I-MED
difference	O
.	O
	
4	O
the	O
pcdd	B-MED
/	O
fs	B-MED
and	O
teq	B-MED
in	O
ambient	B-MED
air	I-MED
of	O
downwind	B-MED
site	I-MED
were	O
not	O
higher	O
than	O
that	O
of	O
upwind	B-MED
site	I-MED
,	O
suggesting	O
that	O
studied	O
landfill	B-MED
did	O
not	O
have	O
obvious	O
influence	B-MED
on	O
pcdd	B-MED
/	O
fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
downwind	B-MED
site	I-MED
.	O
	
5	O
the	O
95th	O
percentile	B-MED
carcinogenic	B-MED
risk	I-MED
cr	B-MED
of	O
pcdd	B-MED
/	O
fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
s	O
urrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
8.03	O
,	O
7.57	O
,	O
9.69	O
and	O
8.15	O
,	O
respectively	O
,	O
which	O
were	O
much	B-MED
lower	I-MED
than	I-MED
the	I-MED
threshold	I-MED
value	I-MED
of	O
cr	B-MED
10	O
,	O
suggesting	O
that	O
studied	O
landfill	B-MED
did	O
not	O
influence	B-MED
the	O
cr	B-MED
of	O
pcdd	B-MED
/	O
fs	B-MED
in	O
surrounding	B-MED
atmosphere	I-MED
and	O
negligible	O
cancer	B-MED
risk	I-MED
occurred	O
.	O
	
6	O
the	O
non-carcinogenic	B-MED
risk	I-MED
non-cr	B-MED
analysis	B-MED
indicated	O
that	O
landfill	B-MED
did	O
not	O
have	O
influence	B-MED
on	O
the	O
non-cr	B-MED
of	O
pcdd	B-MED
/	O
fs	B-MED
in	O
surrounding	B-MED
atmosphere	I-MED
and	O
no	O
obvious	O
non-carcinogenic	B-MED
effects	I-MED
methodological	B-MED
considerations	I-MED
for	O
designing	O
a	O
community	B-MED
water	B-MED
fluoridation	I-MED
cessation	B-MED
study	B-MED
high-quality	B-MED
,	O
up-to-date	O
research	B-MED
on	O
community	B-MED
water	B-MED
fluoridation	I-MED
cwf	B-MED
,	O
and	O
especially	O
on	O
the	O
implications	O
of	O
cwf	B-MED
cessation	B-MED
for	O
dental	B-MED
health	I-MED
,	O
is	O
limited	O
.	O
	
although	O
cwf	B-MED
cessation	B-MED
studies	B-MED
have	O
been	O
conducted	O
,	O
they	O
are	O
few	O
in	O
number	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological	B-MED
complexity	I-MED
of	O
conducting	O
such	O
a	O
study	B-MED
.	O
	
this	O
article	O
draws	O
on	O
a	O
systematic	B-MED
review	I-MED
of	O
existing	O
cessation	B-MED
studies	B-MED
n=15	O
to	O
explore	O
methodological	B-MED
considerations	I-MED
of	O
conducting	O
cwf	B-MED
cessation	B-MED
studies	B-MED
in	O
future	B-MED
.	O
	
we	O
review	O
nine	O
important	O
methodological	B-MED
aspects	I-MED
study	B-MED
design	I-MED
,	O
comparison	B-MED
community	I-MED
,	O
target	B-MED
population	I-MED
,	O
time	B-MED
frame	I-MED
,	O
sampling	B-MED
strategy	I-MED
,	O
clinical	B-MED
indicators	I-MED
,	O
assessment	B-MED
criteria	I-MED
,	O
covariates	O
and	O
biomarkers	B-MED
and	O
provide	O
recommendations	B-MED
for	O
planning	B-MED
future	B-MED
cwf	B-MED
cessation	B-MED
studies	B-MED
that	O
examine	O
effects	O
on	O
dental	B-MED
caries	I-MED
.	O
	
there	O
is	O
no	O
one	O
ideal	O
study	B-MED
design	I-MED
to	O
answer	O
a	O
research	B-MED
question	I-MED
.	O
	
however	O
,	O
recommendations	B-MED
proposed	O
regarding	O
methodological	B-MED
aspects	I-MED
to	O
conduct	O
an	O
epidemiological	B-MED
study	I-MED
to	O
observe	O
the	O
effects	O
of	O
cwf	B-MED
cessation	B-MED
on	O
dental	B-MED
caries	I-MED
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps	O
,	O
will	O
be	O
useful	O
for	O
researchers	B-MED
who	O
are	O
looking	O
to	O
optimize	B-MED
resources	B-MED
to	O
conduct	O
such	O
a	O
study	B-MED
central	B-MED
myxoma	I-MED
/	O
myxofibroma	B-MED
of	O
the	O
jaws	B-MED
a	O
clinico	B-MED
-	O
epidemiologic	B-MED
review	B-MED
myxomas	B-MED
are	O
a	O
group	O
of	O
benign	B-MED
rare	B-MED
tumors	I-MED
of	O
connective-tissue	B-MED
origin	B-MED
that	O
occur	O
in	O
both	O
hard	B-MED
central	I-MED
and	O
soft	B-MED
tissues	I-MED
of	O
the	O
body	B-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central	B-MED
myxoma	I-MED
of	I-MED
the	I-MED
jaw	I-MED
,	O
with	O
emphasis	O
on	O
its	O
clinic	B-MED
-	O
epidemiologic	B-MED
features	O
as	O
seen	O
in	O
our	O
environment	B-MED
.	O
	
all	O
patients	B-MED
who	O
were	O
managed	O
for	O
central	B-MED
myxoma	I-MED
of	I-MED
the	I-MED
jaw	I-MED
at	O
the	O
oral	B-MED
and	I-MED
maxillofacial	I-MED
surgery	I-MED
department	I-MED
of	O
a	O
regional	B-MED
university	I-MED
teaching	I-MED
hospital	I-MED
between	O
september	O
1997	O
and	O
october	O
2015	O
were	O
retrospectively	B-MED
studied	I-MED
.	O
	
details	O
sourced	O
included	O
age	B-MED
,	O
sex	B-MED
,	O
site	B-MED
of	I-MED
tumor	I-MED
,	O
duration	B-MED
,	O
signs/symptoms	B-MED
,	O
treatment	B-MED
given	I-MED
,	O
and	O
complications	B-MED
.	O
	
data	B-MED
were	O
analyzed	B-MED
using	O
statistical	B-MED
package	I-MED
for	I-MED
social	I-MED
sciences	I-MED
spss	I-MED
version	I-MED
16	I-MED
spss	B-MED
inc	I-MED
chicago	B-MED
,	O
il	B-MED
,	O
usa	B-MED
and	O
microsoft	B-MED
excel	I-MED
2007	I-MED
microsoft	B-MED
,	O
redmond	B-MED
,	O
wa	B-MED
,	O
usa	B-MED
.	O
	
results	B-MED
from	O
descriptive	B-MED
statistics	I-MED
were	O
represented	O
in	O
the	O
form	O
of	O
tables	B-MED
and	O
charts	B-MED
,	O
with	O
a	O
test	B-MED
for	I-MED
significance	I-MED
ρ	O
using	O
pearson	B-MED
chi-square	I-MED
χ	O
set	O
at	O
0.05	O
.	O
	
a	O
total	O
of	O
16	O
patients	B-MED
were	O
managed	O
within	O
the	O
period	B-MED
reviewed	B-MED
,	O
consisting	O
of	O
10	O
62.5	O
females	B-MED
and	O
six	O
37.5	O
males	B-MED
,	O
giving	O
a	O
male-to-female	B-MED
ratio	I-MED
of	O
1	O
.	O
	
the	O
ages	B-MED
of	O
patients	B-MED
ranged	B-MED
from	O
5	O
to	O
70	O
years	B-MED
,	O
with	O
a	O
mean	O
of	O
27.06	O
years	B-MED
.	O
	
the	O
mandible	B-MED
accounted	O
for	O
nine	O
56.3	O
cases	B-MED
and	O
the	O
maxilla	B-MED
for	O
six	O
37.5	O
cases	B-MED
,	O
while	O
a	O
combination	B-MED
of	O
the	O
maxilla	B-MED
and	O
the	O
zygoma	B-MED
were	O
involved	O
in	O
one	O
6.3	O
case	B-MED
.	O
	
bucco-lingual	B-MED
or	O
bucco-palatal	B-MED
expansion	B-MED
were	O
the	O
most	O
common	O
presentation	O
six	O
46.2	O
cases	B-MED
each	O
.	O
	
histological	B-MED
assessment	B-MED
of	O
tissue	B-MED
specimens	I-MED
showed	O
that	O
fibromyxoma	B-MED
accounted	B-MED
for	O
seven	O
43.8	O
cases	B-MED
,	O
while	O
the	O
remaining	O
nine	O
56.3	O
cases	B-MED
were	O
diagnosed	B-MED
as	O
myxoma	B-MED
.	O
	
all	O
patients	B-MED
had	O
jaw	B-MED
resections	I-MED
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-MED
in	O
nine	O
60.0	O
patients	B-MED
and	O
maxillectomies	B-MED
in	O
six	O
40.0	O
patients	B-MED
.	O
	
the	O
duration	B-MED
of	I-MED
hospital	I-MED
stay	I-MED
ranged	B-MED
from	O
5	O
to	O
29	O
days	B-MED
,	O
with	O
a	O
mean	O
of	O
17.86	O
days	B-MED
.	O
	
complications	B-MED
were	O
noted	O
in	O
three	O
patients	B-MED
,	O
and	O
all	O
were	O
surgical	B-MED
wound	I-MED
infections	I-MED
.	O
	
most	O
patients	B-MED
in	O
our	O
environment	B-MED
present	O
late	O
with	O
large	B-MED
tumors	I-MED
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow-up	B-MED
review	B-MED
.	O
	
thus	O
,	O
a	O
radical	B-MED
approach	O
is	O
favored	O
in	O
most	O
pediatric	B-MED
hypovitaminosis	B-MED
d	I-MED
molecular	O
perspectives	B-MED
and	O
clinical	B-MED
implications	B-MED
vitamin	B-MED
d	I-MED
,	O
a	O
secosteroid	B-MED
,	O
is	O
essential	B-MED
for	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
healthy	B-MED
bone	B-MED
in	O
both	O
the	O
adult	B-MED
and	O
pediatric	B-MED
populations	B-MED
.	O
	
low	B-MED
level	I-MED
of	O
25-hydroxy	B-MED
vitamin	I-MED
d	I-MED
25-	B-MED
is	O
highly	O
prevalent	O
in	O
children	B-MED
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	B-MED
health	B-MED
outcomes	I-MED
including	O
rickets	B-MED
,	O
osteomalacia	B-MED
,	O
osteomalacic	B-MED
myopathy	I-MED
,	O
sarcopenia	B-MED
,	O
and	O
weakness	B-MED
,	O
growth	B-MED
retardation	I-MED
,	O
hypocalcemia	B-MED
,	O
seizure	B-MED
and	O
tetany	B-MED
,	O
autism	B-MED
,	O
cardiovascular	B-MED
diseases	I-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
cancers	B-MED
prostate	B-MED
,	O
colon	B-MED
,	O
breast	B-MED
,	O
infectious	B-MED
diseases	I-MED
viral	B-MED
,	O
tuberculosis	B-MED
,	O
and	O
autoimmune	B-MED
diseases	I-MED
,	O
such	O
as	O
multiple	B-MED
sclerosis	I-MED
and	O
hashimoto's	B-MED
thyroiditis	I-MED
.	O
	
risk	B-MED
factors	I-MED
for	O
hypovitaminosis	B-MED
d	I-MED
are	O
people	B-MED
with	O
darker	B-MED
skin	I-MED
pigmentation	I-MED
,	O
use	B-MED
of	O
sunscreen	B-MED
,	O
insufficient	B-MED
ultraviolet	B-MED
b	I-MED
exposure	B-MED
,	O
prematurity	B-MED
,	O
living	B-MED
in	I-MED
northern	I-MED
latitudes	I-MED
,	O
malnutrition	B-MED
,	O
obesity	B-MED
,	O
exclusive	B-MED
breastfeeding	I-MED
,	O
low	B-MED
maternal	I-MED
vitamin	I-MED
d	I-MED
level	I-MED
,	O
certain	O
medications	B-MED
,	O
drinking	B-MED
unfortified	B-MED
cow's	I-MED
milk	I-MED
,	O
liver	B-MED
failure	I-MED
,	O
chronic	B-MED
renal	I-MED
insufficiency	I-MED
,	O
cystic	B-MED
fibrosis	I-MED
,	O
asthma	B-MED
,	O
and	O
sickle	B-MED
cell	I-MED
hemoglobinopathy	I-MED
.	O
	
this	O
review	B-MED
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin	B-MED
d	I-MED
deficiency	I-MED
and	O
its	O
potential	O
adverse	B-MED
health	B-MED
outcomes	I-MED
in	O
pediatric	B-MED
age	B-MED
groups	I-MED
.	O
	
the	O
recommended	B-MED
treatment	I-MED
regimen	I-MED
is	O
beyond	O
the	O
scope	O
of	O
this	O
causes	O
of	O
ecological	B-MED
gradients	B-MED
in	O
leaf	B-MED
margin	B-MED
entirety	B-MED
evaluating	B-MED
the	O
roles	B-MED
of	O
biomechanics	B-MED
,	O
hydraulics	B-MED
,	O
vein	B-MED
geometry	I-MED
,	O
and	O
bud	B-MED
packing	B-MED
a	O
recent	B-MED
commentary	B-MED
by	O
edwards	O
et	O
al	O
.	O
	
am	O
.	O
	
j	O
.	O
	
bot	O
.	O
	
103	O
975-978	O
proposed	B-MED
that	O
constraints	B-MED
imposed	O
by	O
the	O
packing	B-MED
of	O
young	B-MED
leaves	B-MED
in	O
buds	B-MED
could	O
explain	O
the	O
positive	B-MED
association	B-MED
between	O
non-entire	B-MED
leaf	B-MED
margins	B-MED
and	O
latitude	B-MED
but	O
did	O
not	O
thoroughly	O
consider	B-MED
alternative	B-MED
explanations	B-MED
.	O
	
we	O
review	B-MED
the	O
logic	B-MED
and	O
evidence	B-MED
underlying	O
six	O
major	B-MED
hypotheses	B-MED
for	O
the	O
functional	B-MED
significance	B-MED
of	O
marginal	B-MED
teeth	B-MED
,	O
involving	O
putative	B-MED
effects	B-MED
on	O
1	O
leaf	B-MED
cooling	B-MED
,	O
2	O
optimal	B-MED
support	O
and	O
supply	O
of	O
the	O
areas	B-MED
served	O
by	O
major	B-MED
veins	B-MED
,	O
3	O
enhanced	B-MED
leaf	B-MED
-	O
margin	B-MED
photosynthesis	B-MED
,	O
4	O
hydathodal	B-MED
function	I-MED
,	O
5	O
defense	B-MED
against	B-MED
herbivores	B-MED
,	O
and	O
6	O
bud	B-MED
packing	B-MED
.	O
	
theoretical	B-MED
and	O
empirical	B-MED
problems	B-MED
undermine	O
all	O
hypotheses	B-MED
except	B-MED
the	O
support-supply	B-MED
hypothesis	I-MED
,	O
which	O
implies	O
that	O
thinner	B-MED
leaves	B-MED
should	O
have	O
non-entire	B-MED
margins	B-MED
.	O
	
phylogenetically	B-MED
structured	B-MED
analyses	I-MED
across	O
angiosperms	B-MED
,	O
the	O
el	B-MED
yunque	I-MED
flora	B-MED
,	O
and	O
the	O
genus	B-MED
viburnum	B-MED
all	O
demonstrate	O
that	O
non-entire	B-MED
margins	B-MED
are	O
indeed	B-MED
more	O
common	B-MED
in	O
thinner	B-MED
leaves	B-MED
.	O
	
across	O
angiosperms	B-MED
,	O
the	O
association	B-MED
of	O
leaf	B-MED
thickness	B-MED
with	O
non-entire	B-MED
leaf	B-MED
margins	B-MED
is	O
stronger	B-MED
than	O
that	O
of	O
latitude	B-MED
.	O
	
we	O
outline	B-MED
a	O
synthetic	B-MED
model	I-MED
showing	O
how	O
biomechanics	B-MED
,	O
hydraulics	B-MED
,	O
vein	B-MED
geometry	B-MED
,	O
rates	B-MED
of	O
leaf	B-MED
expansion	B-MED
,	O
and	O
length	O
of	O
development	B-MED
within	O
resting	B-MED
buds	B-MED
,	O
all	O
tied	O
to	O
leaf	B-MED
thickness	B-MED
,	O
drive	B-MED
patterns	B-MED
in	O
the	O
distribution	B-MED
of	O
entire	B-MED
vs	O
.	O
	
non-entire	B-MED
leaf	B-MED
margins	B-MED
.	O
	
our	O
model	B-MED
accounts	O
for	O
dominance	B-MED
of	O
entire	B-MED
margins	B-MED
in	O
the	O
tropics	B-MED
,	O
mediterranean	B-MED
scrub	I-MED
,	O
and	O
tundra	B-MED
,	O
non-entire	B-MED
margins	B-MED
in	O
cold	B-MED
temperate	I-MED
deciduous	B-MED
forests	I-MED
and	O
tropical	B-MED
vines	B-MED
and	O
early-successional	B-MED
trees	I-MED
,	O
and	O
entire	B-MED
leaf	B-MED
margins	B-MED
in	O
monocots	B-MED
.	O
	
spinose-toothed	B-MED
leaves	I-MED
should	O
be	O
favored	O
in	O
short-statured	B-MED
evergreen	B-MED
trees	I-MED
and	O
shrubs	B-MED
,	O
primarily	O
in	O
mediterranean	B-MED
scrub	I-MED
and	O
related	O
semiarid	B-MED
habitats	I-MED
.	O
	
viral	B-MED
vector	I-MED
biosafety	B-MED
in	O
laboratory	B-MED
animal	I-MED
research	I-MED
viral	B-MED
vector	I-MED
research	B-MED
presents	B-MED
unique	B-MED
occupational	B-MED
health	I-MED
and	O
safety	B-MED
challenges	B-MED
to	O
institutions	B-MED
due	O
to	O
the	O
rapid	B-MED
development	B-MED
ofboth	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
gene-editing	B-MED
technologies	I-MED
.	O
	
risks	B-MED
to	O
human	B-MED
and	O
animal	B-MED
health	B-MED
make	O
it	O
incumbent	B-MED
on	O
institutions	B-MED
to	O
appropriately	B-MED
evaluate	B-MED
viral	B-MED
vector	I-MED
usage	B-MED
in	O
research	B-MED
on	O
the	O
basis	B-MED
of	O
available	B-MED
information	B-MED
and	O
governmental	B-MED
regulations	I-MED
and	O
guidelines	B-MED
here	O
we	O
review	B-MED
the	O
factors	B-MED
related	O
to	O
risk	B-MED
assessment	I-MED
regarding	O
viral	B-MED
vector	I-MED
usage	B-MED
in	O
animals	B-MED
and	O
the	O
relevant	B-MED
regulatory	B-MED
documents	I-MED
associated	B-MED
with	I-MED
this	O
research	B-MED
,	O
and	O
we	O
highlight	O
the	O
most	B-MED
commonly	B-MED
used	O
viral	B-MED
vectors	I-MED
in	O
research	B-MED
today	O
.	O
	
this	O
review	B-MED
is	O
particularly	B-MED
focused	B-MED
on	O
the	O
background	B-MED
,	O
use	O
in	O
research	B-MED
and	O
associated	B-MED
health	B-MED
and	O
environmental	B-MED
risks	I-MED
related	B-MED
to	O
adenoviral	B-MED
,	O
adeno-associated	B-MED
viral	I-MED
,	O
lentiviral	B-MED
,	O
and	O
herpesviral	B-MED
vectors	B-MED
.	O
	
liver	B-MED
inflammation	I-MED
relates	O
to	O
decreased	B-MED
canalicular	B-MED
bile	B-MED
transporter	I-MED
expression	B-MED
in	O
pediatric	B-MED
onset	B-MED
intestinal	B-MED
failure	I-MED
although	O
liver	B-MED
disease	I-MED
is	O
a	O
major	O
complication	B-MED
of	O
parenteral	B-MED
nutrition	I-MED
pn	B-MED
for	O
intestinal	B-MED
failure	I-MED
if	B-MED
,	O
its	O
pathogenesis	B-MED
remains	O
unclear	O
.	O
	
we	O
investigated	B-MED
potential	O
molecular	B-MED
mechanisms	B-MED
of	O
liver	B-MED
injury	I-MED
in	O
pediatric	B-MED
onset	B-MED
if	B-MED
.	O
	
liver	B-MED
expression	B-MED
of	O
canalicular	B-MED
phospholipid	B-MED
abcb4	B-MED
,	O
bile	B-MED
acid	I-MED
abcb11	B-MED
,	O
and	O
sterol	B-MED
abcg5/8	B-MED
transporters	B-MED
,	O
their	O
upstream	B-MED
regulators	I-MED
lxr	B-MED
and	O
fxr	B-MED
as	O
well	O
as	O
pro-inflammatory	B-MED
cytokines	I-MED
interleukin-6	B-MED
il6	B-MED
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
tnf	B-MED
were	O
investigated	B-MED
among	O
patients	B-MED
with	O
if	B-MED
age	B-MED
median	O
3.8	O
iqr	B-MED
1.2	O
to	O
11	O
in	O
relation	O
to	O
biochemical	B-MED
and	O
histologic	B-MED
liver	B-MED
injury	I-MED
,	O
pn	B-MED
,	O
serum	B-MED
plant	B-MED
sterols	I-MED
,	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
19	I-MED
,	O
and	O
α-tocopherol	B-MED
.	O
	
patients	B-MED
receiving	O
pn	B-MED
currently	O
n	O
=	O
18	O
showed	O
more	O
advanced	O
liver	B-MED
injury	I-MED
than	O
patients	B-MED
after	O
weaning	B-MED
off	O
pn	B-MED
n	O
=	O
30	O
.	O
	
histologic	B-MED
portal	B-MED
inflammation	I-MED
strongly	O
segregated	O
pn	B-MED
-	O
dependent	B-MED
44%	O
from	O
weaned	B-MED
off	O
patients	B-MED
3%	O
,	O
p	O
=	O
0.001	O
and	O
coupled	O
with	O
progression	B-MED
of	O
cholestasis	B-MED
and	O
liver	B-MED
fibrosis	I-MED
.	O
	
patients	B-MED
with	O
portal	B-MED
inflammation	I-MED
demonstrated	O
markedly	O
induced	O
liver	B-MED
rna	B-MED
expression	I-MED
of	O
il6	B-MED
and	O
tnf	B-MED
,	O
repression	B-MED
of	O
fxr	B-MED
and	O
its	O
canalicular	B-MED
bile	B-MED
transporter	I-MED
target	O
gene	B-MED
rna	B-MED
expression	I-MED
,	O
including	O
abcb4	B-MED
and	O
abcb11	B-MED
as	O
well	O
as	O
decreased	B-MED
protein	B-MED
expression	I-MED
of	O
abcb11	B-MED
and	O
abcb4	B-MED
.	O
	
furthermore	O
,	O
upregulation	B-MED
of	O
lxr	B-MED
and	O
abcg5/8	B-MED
rna	B-MED
expression	I-MED
was	O
suppressed	B-MED
in	O
patients	B-MED
with	O
portal	B-MED
inflammation	I-MED
.	O
	
current	O
pn	B-MED
,	O
increased	B-MED
serum	B-MED
levels	B-MED
of	O
plant	B-MED
sterols	I-MED
stigmasterol	B-MED
,	O
avenasterol	B-MED
,	O
and	O
sitosterol	B-MED
along	O
with	O
serum	B-MED
citrulline	B-MED
,	O
a	O
marker	B-MED
of	O
enterocyte	B-MED
mass	I-MED
,	O
predicted	O
portal	B-MED
inflammation	I-MED
.	O
	
in	O
pediatric	B-MED
onset	B-MED
if	B-MED
,	O
current	O
pn	B-MED
delivery	O
synergistically	O
with	O
intestinal	B-MED
compromise	B-MED
promote	O
liver	B-MED
inflammation	I-MED
,	O
which	O
associates	B-MED
with	O
progression	B-MED
of	O
biochemical	B-MED
and	O
histologic	B-MED
liver	B-MED
injury	I-MED
,	O
while	O
reducing	B-MED
expression	B-MED
of	O
canalicular	B-MED
bile	B-MED
transporters	I-MED
.	O
	
impaired	B-MED
mobility	I-MED
,	O
depressed	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
are	O
independently	O
associated	O
with	O
disability	B-MED
in	O
older	O
cancer	B-MED
outpatients	B-MED
the	O
prospective	O
physical	B-MED
frailty	I-MED
in	O
elderly	B-MED
cancer	B-MED
patients	I-MED
pf	B-MED
-	O
ec	B-MED
cohort	B-MED
study	I-MED
to	O
assess	O
the	O
prevalence	O
of	O
disability	B-MED
and	O
the	O
oncologic	B-MED
factors	I-MED
associated	O
with	O
disability	B-MED
in	O
older	O
outpatients	B-MED
with	O
cancer	B-MED
.	O
	
the	O
physical	B-MED
frailty	I-MED
in	O
elderly	B-MED
cancer	B-MED
patients	I-MED
pf	B-MED
-	O
ec	B-MED
study	O
france	B-MED
is	O
a	O
prospective	B-MED
bicentric	I-MED
observational	I-MED
cohort	I-MED
study	I-MED
.	O
	
two	O
hundred	O
and	O
ninety	O
outpatients	B-MED
with	O
cancer	B-MED
were	O
included	O
.	O
	
a	O
cross-sectional	B-MED
analysis	I-MED
of	O
oncologic	B-MED
factors	I-MED
and	O
geriatric	B-MED
variables	B-MED
associated	O
with	O
disability	B-MED
that	O
were	O
collected	O
using	O
a	O
comprehensive	B-MED
geriatric	B-MED
assessment	I-MED
cga	B-MED
was	O
conducted	O
.	O
	
disability	B-MED
was	O
defined	O
as	O
impairment	B-MED
in	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
adl	B-MED
and/or	O
instrumental	B-MED
activities	I-MED
of	I-MED
daily	I-MED
living	I-MED
iadl	B-MED
,	O
simplified	O
to	O
four	O
items	O
.	O
	
univariate	B-MED
and	O
multivariate	B-MED
logistic	B-MED
models	I-MED
of	O
disabled	B-MED
patients	I-MED
were	O
performed	O
.	O
	
the	O
three	O
final	O
multivariate	B-MED
models	B-MED
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
curve	I-MED
auc	B-MED
/	O
roc	B-MED
of	O
the	O
logistic	B-MED
model	I-MED
.	O
	
the	O
mean	O
age	O
was	O
80.6years	O
,	O
and	O
51%	O
of	O
the	O
patients	O
were	O
women	B-MED
with	O
various	O
types	O
of	O
cancer	B-MED
.	O
	
the	O
prevalence	O
of	O
disability	B-MED
was	O
67.6	O
.	O
	
no	O
oncologic	B-MED
factors	I-MED
cancer	B-MED
site	I-MED
,	O
cancer	B-MED
extension	I-MED
were	O
associated	O
with	O
disability	B-MED
.	O
	
impaired	B-MED
mobility	I-MED
,	O
poor	B-MED
functional	I-MED
status	I-MED
,	O
depressive	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
were	O
independently	O
associated	O
with	O
disability	B-MED
p<0	O
.	O
	
the	O
auc/roc	O
of	O
the	O
final	O
models	O
was	O
similar	O
.	O
	
disability	B-MED
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-MED
outpatients	B-MED
before	O
cancer	B-MED
treatment	I-MED
but	O
was	O
not	O
associated	O
with	O
oncologic	B-MED
factors	I-MED
.	O
	
impaired	B-MED
mobility	I-MED
,	O
depressed	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-MED
.	O
	
identifying	O
these	O
factors	O
prior	O
to	O
cancer	B-MED
treatment	I-MED
could	O
enable	O
the	O
implementation	O
of	O
corrective	B-MED
actions	I-MED
to	O
improve	O
patient	B-MED
autonomy	B-MED
before	O
treatment	B-MED
and	O
during	O
synthesis	B-MED
,	O
sar	B-MED
and	O
molecular	B-MED
docking	I-MED
study	B-MED
of	O
novel	O
non-β-lactam	B-MED
inhibitors	I-MED
of	O
tem	B-MED
type	I-MED
β-lactamase	I-MED
the	O
novel	O
classes	O
of	O
acylated	B-MED
phenoxyanilide	I-MED
and	O
thiourea	B-MED
compounds	I-MED
were	O
investigated	B-MED
for	O
their	O
ability	O
to	O
inhibit	B-MED
tem	B-MED
type	I-MED
β-lactamase	I-MED
enzyme	I-MED
.	O
	
two	O
compounds	B-MED
4g	I-MED
and	O
5c	B-MED
reveal	O
the	O
inhibition	B-MED
potency	B-MED
in	O
micromolar	B-MED
range	O
and	O
show	O
their	O
action	B-MED
by	O
non-covalent	B-MED
binding	I-MED
in	O
the	O
vicinity	O
of	O
the	O
tem-171	B-MED
active	B-MED
site	I-MED
.	O
	
the	O
structure	B-MED
activity	I-MED
relationship	I-MED
around	O
carbon	B-MED
chain	I-MED
length	I-MED
and	O
different	O
substituents	B-MED
in	I-MED
ortho-	I-MED
and	I-MED
para-positions	I-MED
of	O
acylated	B-MED
phenoxyanilide	I-MED
as	O
well	O
as	O
molecular	B-MED
modelling	I-MED
study	B-MED
metabolic	B-MED
responses	I-MED
of	O
the	O
growing	O
daphnia	B-MED
similis	I-MED
to	O
chronic	B-MED
agnps	B-MED
exposure	O
as	O
revealed	O
by	O
gc-q-tof/ms	B-MED
and	O
lc-q-tof/ms	B-MED
silver	B-MED
nanoparticles	B-MED
agnps	B-MED
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	B-MED
.	O
	
their	O
fast-growing	B-MED
utilization	O
has	O
increased	B-MED
the	O
occurrence	O
of	O
agnps	B-MED
in	O
the	O
environment	B-MED
,	O
posing	O
potential	O
health	B-MED
and	I-MED
ecological	I-MED
risks	I-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-MED
toxicity	I-MED
tests	I-MED
and	O
investigated	O
the	O
metabolic	B-MED
changes	B-MED
of	O
the	O
growing	O
daphna	B-MED
similis	I-MED
with	O
exposure	B-MED
to	I-MED
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
agnps	B-MED
,	O
using	O
non-targeted	B-MED
mass	I-MED
spectrometry	I-MED
-based	O
metabolomics	B-MED
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	B-MED
metabolite	B-MED
change	B-MED
of	O
a	O
common	O
aquatic	B-MED
organism	I-MED
daphnia	B-MED
crustacean	I-MED
through	O
its	O
life-cycle	B-MED
.	O
	
the	O
results	O
show	O
a	O
dynamic	B-MED
kinetic	I-MED
pattern	I-MED
of	O
the	O
growing	O
daphnia's	B-MED
metabolome	B-MED
underwent	O
a	O
cycle	B-MED
from	O
day	B-MED
0	O
to	O
day	B-MED
21	O
,	O
with	O
the	O
level	B-MED
of	O
metabolites	B-MED
gradually	O
increasing	B-MED
from	O
day	B-MED
0	O
to	O
day	B-MED
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	B-MED
level	B-MED
of	O
day	B-MED
0	O
on	O
day	B-MED
21	O
.	O
	
as	O
for	O
the	O
samples	B-MED
exposed	B-MED
to	I-MED
environmental	B-MED
concentrations	I-MED
of	O
agnps	B-MED
,	O
although	O
without	O
morphological	B-MED
or	I-MED
structural	I-MED
changes	I-MED
,	O
numerous	O
metabolite	B-MED
changes	B-MED
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	B-MED
,	O
and	O
these	O
changes	B-MED
reached	O
steady	B-MED
state	I-MED
by	O
day	B-MED
13	O
.	O
	
the	O
significant	O
changes	B-MED
in	O
certain	O
metabolites	B-MED
,	O
such	O
as	O
amino	B-MED
acids	I-MED
serine	B-MED
,	O
threonine	B-MED
and	O
tyrosine	B-MED
,	O
sugars	B-MED
d-allose	B-MED
and	O
fatty	B-MED
acids	I-MED
arachidonic	B-MED
acid	I-MED
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	B-MED
in	O
daphnia	B-MED
respond	O
to	O
chronic	B-MED
agnps	B-MED
stress	B-MED
.	O
	
these	O
findings	B-MED
highlight	O
the	O
capability	B-MED
of	O
metabolomics	B-MED
to	O
discover	O
early	O
metabolic	B-MED
responses	I-MED
to	O
environmental	B-MED
silver	B-MED
nanoparticles	B-MED
.	O
	
evaluating	O
the	O
relative	B-MED
effectiveness	I-MED
of	O
high-intensity	B-MED
and	O
low-intensity	B-MED
models	I-MED
of	O
behaviour	B-MED
change	I-MED
communication	B-MED
interventions	I-MED
for	O
abortion	B-MED
care-seeking	B-MED
in	O
bihar	B-MED
and	O
jharkhand	B-MED
,	O
india	B-MED
a	O
cross-sectional	B-MED
study	I-MED
this	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	B-MED
of	O
a	O
high-intensity	B-MED
model	I-MED
him	B-MED
and	O
a	O
low-intensity	B-MED
model	I-MED
lim	B-MED
of	O
behaviour	B-MED
change	I-MED
communication	B-MED
interventions	I-MED
in	O
bihar	B-MED
and	O
jharkhand	B-MED
states	O
of	O
india	B-MED
designed	O
to	O
improve	O
women's	B-MED
knowledge	B-MED
and	O
usage	O
of	O
safe	B-MED
abortion	I-MED
services	O
,	O
as	O
well	O
as	O
the	O
dose	B-MED
effect	I-MED
of	O
intervention	B-MED
exposure	O
.	O
	
we	O
conducted	O
two	O
cross-sectional	B-MED
household	I-MED
surveys	I-MED
among	O
married	B-MED
women	B-MED
aged	B-MED
15-49	O
years	O
in	O
intervention	B-MED
and	O
comparison	O
districts	B-MED
.	O
	
difference-in-difference	B-MED
models	I-MED
were	O
used	O
to	O
assess	O
the	O
efficacy	B-MED
of	O
the	O
intervention	B-MED
,	O
adjusting	O
for	O
sociodemographic	B-MED
characteristics	I-MED
.	O
	
although	O
both	O
intervention	B-MED
types	O
improved	O
abortion	B-MED
knowledge	B-MED
,	O
the	O
him	B-MED
intervention	B-MED
was	O
more	O
effective	O
in	O
improving	O
comprehensive	B-MED
knowledge	I-MED
about	O
abortion	B-MED
.	O
	
in	O
particular	O
,	O
there	O
were	O
improvements	O
in	O
knowledge	B-MED
on	O
legality	B-MED
of	I-MED
abortion	I-MED
aor=2	O
95%	O
ci	O
1.6	O
to	O
2.9	O
and	O
nearby	O
sources	O
of	O
safe	B-MED
abortion	I-MED
care	I-MED
aor=1	O
95%	O
ci	O
1.2	O
to	O
1.3	O
.	O
	
higher	O
level	O
of	O
exposure	O
to	O
abortion-related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	B-MED
about	O
abortion	B-MED
within	O
both	O
intervention	B-MED
groups	O
.	O
	
evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-MED
care-seeking	B-MED
behaviour	B-MED
.	O
	
more	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	B-MED
seek	O
safe	B-MED
abortion	I-MED
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion	B-MED
complications	I-MED
.	O
	
tissue	B-MED
microrna	B-MED
profiles	O
as	O
diagnostic	B-MED
and	O
prognostic	B-MED
biomarkers	I-MED
in	O
patients	B-MED
with	O
resectable	B-MED
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
and	O
periampullary	B-MED
cancers	I-MED
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
validate	O
previously	O
described	O
diagnostic	B-MED
and	O
prognostic	B-MED
microrna	B-MED
expression	B-MED
profiles	I-MED
in	O
tissue	B-MED
samples	O
from	O
patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
and	O
other	O
periampullary	B-MED
cancers	I-MED
.	O
	
expression	B-MED
of	O
46	O
selected	O
micrornas	B-MED
was	O
studied	O
in	O
formalin	B-MED
-fixed	O
paraffin-embedded	B-MED
tissue	I-MED
from	O
patients	B-MED
with	O
resected	B-MED
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
n	O
=	O
165	O
,	O
ampullary	B-MED
cancer	I-MED
n=59	O
,	O
duodenal	B-MED
cancer	I-MED
n	O
=	O
6	O
,	O
distal	B-MED
common	B-MED
bile	I-MED
duct	I-MED
cancer	I-MED
n	O
=	O
21	O
,	O
and	O
gastric	B-MED
cancer	I-MED
n	O
=	O
20	O
chronic	B-MED
pancreatitis	I-MED
n	O
=	O
39	O
and	O
normal	B-MED
pancreas	I-MED
n	O
=	O
35	O
.	O
	
the	O
micrornas	B-MED
were	O
analyzed	O
by	O
pcr	B-MED
using	O
the	O
fluidigm	B-MED
platform	I-MED
.	O
	
twenty-two	O
micrornas	B-MED
were	O
significantly	O
differently	O
expressed	B-MED
in	O
patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
when	O
compared	O
to	O
healthy	B-MED
controls	I-MED
and	O
chronic	B-MED
pancreatitis	I-MED
patients	B-MED
17	O
mirnas	B-MED
were	O
upregulated	B-MED
mir-21-5p	B-MED
,	O
-	O
23a-3p	B-MED
,	O
-	O
31-5p	B-MED
,	O
-	O
34c-5p	B-MED
,	O
-	O
93-3p	B-MED
,	O
-	O
135b-3p	B-MED
,	O
-	O
155-5p	B-MED
,	O
-	O
186-5p	B-MED
,	O
-	O
196b-5p	B-MED
,	O
-	O
203	B-MED
,	O
-	O
205-5p	B-MED
,	O
-	O
210	B-MED
,	O
-	O
222-3p	B-MED
,	O
-	O
451	B-MED
,	O
-	O
492	B-MED
,	O
-	O
614	B-MED
,	O
and	O
mir-622	B-MED
and	O
5	O
were	O
downregulated	B-MED
mir-122-5p	B-MED
,	O
-	O
130b-3p	B-MED
,	O
-	O
216b	B-MED
,	O
-	O
217	B-MED
,	O
and	O
mir-375	B-MED
.	O
	
micrornas	B-MED
were	O
grouped	O
into	O
diagnostic	B-MED
indices	O
of	O
varying	O
complexity	B-MED
.	O
	
ten	O
micrornas	B-MED
associated	B-MED
with	I-MED
prognosis	B-MED
were	O
identified	O
let-7	B-MED
g	I-MED
,	O
mir-29a-5p	B-MED
,	O
-	O
34a-5p	B-MED
,	O
-	O
125a-3p	B-MED
,	O
-	O
146a-5p	B-MED
,	O
-	O
187	B-MED
,	O
-	O
205-5p	B-MED
,	O
-	O
212-3p	B-MED
,	O
-	O
222-5p	B-MED
,	O
and	O
mir-450b-5p	B-MED
.	O
	
prognostic	B-MED
indices	I-MED
based	O
on	O
differences	O
in	O
expression	B-MED
of	O
2	O
different	O
micrornas	B-MED
were	O
constructed	O
for	O
pancreatic	B-MED
and	O
ampullary	B-MED
cancer	I-MED
combined	O
and	O
separately	O
30	O
,	O
5	O
,	O
and	O
21	O
indices	O
.	O
	
the	O
study	B-MED
confirms	O
that	O
pancreatic	B-MED
cancer	I-MED
tissue	B-MED
has	O
a	O
microrna	B-MED
expression	B-MED
profile	I-MED
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary	B-MED
cancers	I-MED
,	O
chronic	B-MED
pancreatitis	I-MED
,	O
and	O
normal	B-MED
pancreas	I-MED
.	O
	
we	O
identified	O
prognostic	B-MED
micrornas	B-MED
and	O
microrna	B-MED
indices	O
that	O
were	O
associated	B-MED
with	I-MED
shorter	O
overall	B-MED
survival	I-MED
in	O
patients	B-MED
with	O
radically	O
resected	B-MED
pancreatic	B-MED
cancer	I-MED
.	O
	
effectiveness	B-MED
of	O
workers	B-MED
'	O
general	B-MED
health	I-MED
examination	I-MED
in	O
korea	B-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
retrospective	B-MED
cohort	I-MED
study	I-MED
using	O
nationwide	O
data	O
our	O
study	O
evaluated	B-MED
the	O
effectiveness	B-MED
of	O
the	O
workers	B-MED
'	O
general	B-MED
health	I-MED
examination	I-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
.	O
	
a	O
retrospective	B-MED
cohort	I-MED
of	O
the	O
health	B-MED
examination	I-MED
participants	B-MED
in	O
2006	O
baseline	O
year	O
n	O
was	O
used	O
.	O
	
we	O
identified	O
newly	O
occurring	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
over	O
7	O
years	O
from	O
2007	O
to	O
2013	O
.	O
	
after	O
stratification	B-MED
by	O
age	B-MED
,	O
sex	B-MED
,	O
and	O
national	B-MED
health	I-MED
insurance	I-MED
type	I-MED
,	O
we	O
identified	O
7	O
years'	O
cumulative	B-MED
incidence	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
by	O
health	B-MED
examination	I-MED
compliance	B-MED
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
.	O
	
the	O
compliant	B-MED
group	I-MED
presented	O
a	O
lower	O
cumulative	B-MED
incidence	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
than	O
the	O
non-compliant	B-MED
group	I-MED
this	O
result	O
was	O
consistent	O
across	O
sex	B-MED
,	O
working	B-MED
age	B-MED
40s	O
and	O
50s	O
,	O
and	O
workplace	B-MED
policyholder	B-MED
.	O
	
relative	O
risk	O
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
1	O
and	O
2	O
years	O
showed	O
statistically	B-MED
significant	I-MED
results	O
in	O
ischemic	B-MED
heart	I-MED
disease	I-MED
for	O
male	O
participants	B-MED
.	O
	
of	O
men	B-MED
in	O
their	O
40s	O
,	O
office	B-MED
workers	I-MED
over	O
a	O
2-year	O
period	O
presented	O
statistically	O
higher	B-MED
relative	I-MED
risk	I-MED
of	I-MED
ischemic	B-MED
heart	I-MED
disease	I-MED
than	O
non-office	B-MED
workers	I-MED
over	O
a	O
1-year	O
period	O
1.03	O
95%	O
confidence	B-MED
interval	I-MED
,	O
1.02	O
.	O
	
however	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	B-MED
cerebrovascular	B-MED
disease	I-MED
and	O
hemorrhagic	B-MED
cerebrovascular	B-MED
disease	I-MED
for	O
men	B-MED
or	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
for	O
women	B-MED
.	O
	
a	O
1-year	O
period	O
of	O
workers	B-MED
'	O
general	B-MED
health	I-MED
examinations	I-MED
in	O
non-office	B-MED
workers	I-MED
had	O
a	O
more	O
significant	O
prevention	B-MED
effect	O
on	O
ischemic	B-MED
heart	I-MED
disease	I-MED
than	O
a	O
2-year	O
period	O
in	O
office	B-MED
workers	I-MED
among	O
working	O
age	B-MED
40s-50s	O
men	B-MED
.	O
	
it	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	B-MED
characteristics	I-MED
rather	O
than	O
by	O
health	B-MED
examination	I-MED
period	I-MED
.	O
	
calibration	B-MED
of	O
self-report	B-MED
measures	B-MED
of	O
physical	B-MED
activity	I-MED
and	O
sedentary	B-MED
behavior	I-MED
calibration	B-MED
equations	B-MED
offer	O
potential	B-MED
to	O
improve	B-MED
the	O
accuracy	B-MED
and	O
utility	O
of	O
self-report	B-MED
measures	B-MED
of	O
physical	B-MED
activity	I-MED
pa	B-MED
and	O
sedentary	B-MED
behavior	I-MED
sb	B-MED
by	O
re-scaling	B-MED
potentially	B-MED
biased	O
estimates	B-MED
.	O
	
the	O
present	O
study	O
evaluates	O
calibration	B-MED
models	B-MED
designed	O
to	O
estimate	B-MED
pa	B-MED
and	O
sb	B-MED
in	O
a	O
representative	B-MED
sample	O
of	O
adults	B-MED
from	O
the	O
physical	B-MED
activity	I-MED
measurement	B-MED
survey	I-MED
pams	B-MED
.	O
	
participants	B-MED
in	O
the	O
pams	B-MED
project	O
completed	O
replicate	O
single	O
day	O
trials	B-MED
that	O
involved	O
wearing	O
a	O
sensewear	B-MED
armband	I-MED
swa	I-MED
monitor	B-MED
for	O
24	B-MED
hours	I-MED
followed	O
by	O
a	O
telephone	B-MED
administered	B-MED
24-hour	O
physical	B-MED
activity	I-MED
recall	I-MED
par	B-MED
.	O
	
comprehensive	O
statistical	B-MED
model	I-MED
selection	O
and	O
validation	B-MED
procedures	B-MED
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	B-MED
models	B-MED
designed	O
to	O
predict	B-MED
objectively	B-MED
-	O
measured	B-MED
sb	B-MED
and	O
moderate	B-MED
to	I-MED
vigorous	I-MED
pa	I-MED
mvpa	B-MED
from	O
self-reported	B-MED
par	B-MED
data	O
.	O
	
equivalence	B-MED
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	B-MED
of	O
the	O
model-	O
predicted	B-MED
values	O
with	O
the	O
objective	B-MED
measures	B-MED
in	O
a	O
separate	O
holdout	O
sample	O
.	O
	
the	O
final	O
prediction	O
model	O
for	O
both	O
sb	B-MED
and	O
mvpa	B-MED
included	O
reported	O
time	O
spent	O
in	O
sb	B-MED
and	O
mvpa	B-MED
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	B-MED
,	O
age	B-MED
,	O
education	B-MED
,	O
and	O
bmi	B-MED
.	O
	
cross-validation	B-MED
analyses	B-MED
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
sb	B-MED
r	O
=	O
0.72	O
and	O
mvpa	B-MED
r	O
=	O
0.75	O
.	O
	
equivalence	B-MED
testing	O
demonstrated	O
that	O
the	O
model-	O
predicted	B-MED
values	O
were	O
statistically	B-MED
equivalent	O
to	O
the	O
corresponding	O
objective	B-MED
values	O
for	O
both	O
sb	B-MED
and	O
mvpa	B-MED
.	O
	
the	O
results	O
demonstrate	O
that	O
simple	O
regression	B-MED
models	B-MED
can	O
be	O
used	O
to	O
statistically	B-MED
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self-report	B-MED
measures	B-MED
among	O
different	O
segments	O
of	O
the	O
population	B-MED
.	O
	
the	O
models	B-MED
produced	O
group	O
estimates	B-MED
from	O
the	O
par	B-MED
that	O
were	O
statistically	B-MED
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
sb	B-MED
and	O
mvpa	B-MED
obtained	O
from	O
the	O
objective	O
swa	B-MED
monitor	B-MED
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	B-MED
of	O
individual	B-MED
behavior	I-MED
.	O
	
human	B-MED
amnion	B-MED
epithelial	B-MED
cells	I-MED
rescue	O
cell	B-MED
death	I-MED
via	O
immunomodulation	B-MED
of	O
microglia	B-MED
in	O
a	O
mouse	B-MED
model	I-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
human	B-MED
amnion	B-MED
epithelial	B-MED
cells	I-MED
haecs	B-MED
are	O
clonogenic	B-MED
and	O
have	O
been	O
proposed	O
to	O
reduce	B-MED
inflammatory	B-MED
-	O
induced	B-MED
tissue	B-MED
injury	I-MED
.	O
	
perturbation	B-MED
of	O
the	O
immune	B-MED
response	I-MED
is	O
implicated	O
in	O
the	O
pathogenesis	B-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
modulating	B-MED
this	O
response	B-MED
could	O
thus	O
be	O
a	O
novel	B-MED
therapy	B-MED
for	O
treating	B-MED
or	O
preventing	O
such	O
injury	B-MED
.	O
	
the	O
immunomodulatory	B-MED
properties	O
of	O
haecs	B-MED
have	O
been	O
shown	O
in	O
other	O
animal	B-MED
models	I-MED
,	O
but	O
a	O
detailed	O
investigation	B-MED
of	O
the	O
effects	B-MED
on	O
brain	B-MED
immune	B-MED
cells	B-MED
following	O
injury	B-MED
has	O
not	O
been	O
undertaken	O
.	O
	
here	O
,	O
we	O
investigate	B-MED
the	O
effects	B-MED
of	O
haecs	B-MED
on	O
microglia	B-MED
,	O
the	O
first	O
immune	B-MED
responders	I-MED
to	O
injury	B-MED
within	O
the	O
brain	B-MED
.	O
	
we	O
generated	O
a	O
mouse	B-MED
model	I-MED
combining	O
neonatal	B-MED
inflammation	B-MED
and	O
perinatal	B-MED
hyperoxia	B-MED
,	O
both	O
of	O
which	O
are	O
risk	B-MED
factors	I-MED
associated	O
with	O
perinatal	B-MED
brain	I-MED
injury	I-MED
.	O
	
on	O
embryonic	B-MED
day	B-MED
16	O
we	O
administered	B-MED
lipopolysaccharide	B-MED
lps	B-MED
,	O
or	O
saline	B-MED
control	B-MED
,	O
intra-amniotically	B-MED
to	O
c57bl/6	B-MED
j	I-MED
mouse	I-MED
pups	I-MED
.	O
	
on	O
postnatal	B-MED
day	B-MED
p	O
,	O
lps	B-MED
pups	B-MED
were	O
placed	O
in	O
hyperoxia	B-MED
65%	O
oxygen	B-MED
and	O
control	B-MED
pups	I-MED
in	O
normoxia	B-MED
for	O
14	O
days	B-MED
.	O
	
pups	B-MED
were	O
given	O
either	O
haecs	B-MED
or	O
saline	B-MED
intravenously	B-MED
on	O
p4	O
.	O
	
at	O
p14	O
,	O
relative	O
to	O
controls	B-MED
,	O
lps	B-MED
and	O
hyperoxia	B-MED
pups	B-MED
had	O
reduced	B-MED
body	B-MED
weight	I-MED
,	O
increased	B-MED
density	B-MED
of	O
apoptotic	B-MED
cells	B-MED
tunel	B-MED
in	O
the	O
cortex	B-MED
,	O
striatum	B-MED
and	O
white	B-MED
matter	I-MED
,	O
astrocytes	B-MED
gfap	B-MED
in	O
the	O
white	B-MED
matter	I-MED
and	O
activated	B-MED
microglia	B-MED
cd68	B-MED
in	O
the	O
cortex	B-MED
and	O
striatum	B-MED
,	O
but	O
no	O
change	O
in	O
total	O
microglia	B-MED
density	B-MED
iba1	B-MED
.	O
	
haec	B-MED
administration	B-MED
rescued	O
the	O
decreased	B-MED
body	B-MED
weight	I-MED
and	O
reduced	B-MED
apoptosis	B-MED
and	O
astrocyte	B-MED
areal	B-MED
coverage	I-MED
in	O
the	O
white	B-MED
matter	I-MED
,	O
but	O
increased	B-MED
the	O
density	B-MED
of	O
total	O
and	O
activated	B-MED
microglia	B-MED
.	O
	
we	O
then	O
stimulated	O
primary	B-MED
microglia	B-MED
cd45	B-MED
low	O
cd11b	B-MED
+	O
with	O
lps	B-MED
for	O
24	O
h	O
,	O
followed	O
by	O
co-culture	B-MED
with	O
haec	B-MED
conditioned	B-MED
medium	I-MED
for	O
48	O
h	O
.	O
	
haec	B-MED
conditioned	B-MED
medium	I-MED
increased	B-MED
microglial	B-MED
phagocytic	B-MED
activity	I-MED
,	O
decreased	B-MED
microglia	B-MED
apoptosis	B-MED
and	O
decreased	B-MED
m1	B-MED
activation	I-MED
markers	I-MED
cd86	B-MED
.	O
	
stimulating	O
haecs	B-MED
for	O
24	O
h	O
with	O
lps	B-MED
did	O
not	O
alter	O
release	B-MED
of	O
cytokines	B-MED
known	O
to	O
modulate	B-MED
microglia	B-MED
activity	B-MED
.	O
	
these	O
data	B-MED
demonstrate	O
that	O
haecs	B-MED
can	O
directly	O
immunomodulate	B-MED
brain	B-MED
microglia	B-MED
,	O
probably	O
via	O
release	B-MED
of	O
trophic	B-MED
factors	I-MED
.	O
	
this	O
observation	B-MED
offers	O
promise	O
that	O
haecs	B-MED
may	O
afford	O
therapeutic	B-MED
utility	I-MED
in	O
the	O
management	B-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
.	O
	
identification	B-MED
of	O
predictive	O
dna	B-MED
methylation	I-MED
biomarkers	B-MED
for	O
chemotherapy	B-MED
response	B-MED
in	O
colorectal	B-MED
cancer	I-MED
resistance	B-MED
to	O
5-fluorouracil	B-MED
5-fu	B-MED
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	B-MED
of	O
colorectal	B-MED
cancer	I-MED
crc	B-MED
and	O
posed	O
an	O
increased	O
risk	B-MED
of	I-MED
recurrence	I-MED
.	O
	
dna	B-MED
methylation	I-MED
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	B-MED
for	O
recurrent	B-MED
disease	I-MED
and	O
its	O
contribution	B-MED
to	O
the	O
development	O
of	O
drug	B-MED
resistance	I-MED
remains	O
to	O
be	O
clarified	B-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
determine	O
the	O
methylation	B-MED
phenotype	B-MED
in	O
crc	B-MED
for	O
identification	B-MED
of	O
predictive	O
markers	B-MED
for	O
chemotherapy	B-MED
response	B-MED
.	O
	
we	O
performed	O
dna	B-MED
methylation	I-MED
profiling	B-MED
on	O
43	O
non-recurrent	B-MED
and	O
five	O
recurrent	B-MED
crc	B-MED
patients	B-MED
using	O
the	O
illumina	B-MED
infinium	I-MED
humanmethylation450	I-MED
beadchip	I-MED
assay	I-MED
.	O
	
in	O
addition	O
,	O
crc	B-MED
cells	B-MED
with	O
different	O
genetic	B-MED
backgrounds	I-MED
,	O
response	B-MED
to	O
5-fu	B-MED
and	O
global	B-MED
methylation	I-MED
levels	B-MED
ht29	B-MED
and	O
sw48	B-MED
were	O
treated	B-MED
with	O
5-fu	B-MED
and	O
dna	B-MED
methylation	I-MED
inhibitor	B-MED
5-aza-2'-deoxycytidine	B-MED
5-azadc	B-MED
.	O
	
the	O
singular	O
and	O
combined	O
effects	B-MED
of	O
these	O
two	O
drug	B-MED
classes	B-MED
on	O
cell	B-MED
viability	I-MED
and	O
global	B-MED
methylation	I-MED
profiles	B-MED
were	O
investigated	O
.	O
	
our	O
genome-wide	B-MED
methylation	I-MED
study	I-MED
on	O
the	O
clinical	B-MED
specimens	B-MED
showed	O
that	O
recurrent	B-MED
crcs	B-MED
exhibited	O
higher	O
methylation	B-MED
levels	B-MED
compared	O
to	O
non-recurrent	B-MED
crcs	B-MED
.	O
	
we	O
identified	B-MED
4787	O
significantly	O
differentially	O
methylated	B-MED
genes	I-MED
p	O
<	O
0.05	O
3112	O
genes	B-MED
were	O
hyper	B-MED
-	O
while	O
1675	O
genes	B-MED
were	O
hypomethylated	B-MED
in	O
the	O
recurrent	B-MED
group	B-MED
compared	O
to	O
the	O
non-recurrent	B-MED
.	O
	
fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	B-MED
and	I-MED
hypomethylated	I-MED
genes	I-MED
have	O
an	O
absolute	O
recurrent	B-MED
/	O
non-recurrent	B-MED
methylation	B-MED
difference	O
of	O
20%	O
.	O
	
most	O
of	O
the	O
hypermethylated	B-MED
genes	I-MED
were	O
involved	O
in	O
the	O
mapk	B-MED
signaling	I-MED
pathway	I-MED
which	O
is	O
a	O
key	O
regulator	B-MED
for	O
apoptosis	B-MED
while	O
the	O
hypomethylated	B-MED
genes	I-MED
were	O
involved	O
in	O
the	O
pi3k-akt	B-MED
signaling	I-MED
pathway	I-MED
and	O
proliferation	B-MED
process	I-MED
.	O
	
we	O
also	O
demonstrate	O
that	O
5-azadc	B-MED
treatment	B-MED
enhanced	O
response	B-MED
to	O
5-fu	B-MED
which	O
resulted	O
in	O
significant	O
growth	B-MED
inhibition	I-MED
compared	O
to	O
5-fu	B-MED
alone	O
in	O
hypermethylated	B-MED
cell	I-MED
lines	I-MED
sw48	I-MED
.	O
	
in	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B-MED
in	O
recurrent	B-MED
crcs	B-MED
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-MED
targets	B-MED
for	O
patients	B-MED
with	O
chemoresistance	B-MED
.	O
	
we	O
postulate	O
that	O
aberrant	B-MED
methylation	B-MED
of	O
ccnei	B-MED
,	O
ccndbp1	B-MED
,	O
pon3	B-MED
,	O
ddx43	B-MED
,	O
and	O
chl1	B-MED
in	O
crc	B-MED
might	O
be	O
associated	B-MED
with	I-MED
the	O
recurrence	B-MED
of	O
crc	B-MED
and	O
5-azadc	B-MED
-mediated	O
restoration	O
of	O
5-fu	B-MED
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
mapk	B-MED
signaling	I-MED
pathway	I-MED
.	O
	
effect	B-MED
of	O
successive	B-MED
administration	I-MED
of	O
vancomycin	B-MED
and	O
amikacin	B-MED
on	O
auditory	B-MED
function	I-MED
of	O
immature	B-MED
animals	I-MED
effect	B-MED
of	O
successive	B-MED
administration	I-MED
vancomycin	B-MED
and	O
amikacin	B-MED
in	O
therapeutic	B-MED
doses	B-MED
on	O
immature	B-MED
auditory	B-MED
organ	I-MED
was	O
compared	B-MED
to	O
single	B-MED
administration	B-MED
of	O
the	O
same	B-MED
drugs	B-MED
in	O
chronic	B-MED
experiments	B-MED
on	O
immature	B-MED
rabbits	B-MED
by	O
recording	B-MED
of	O
short-latency	B-MED
auditory	B-MED
brainstem	I-MED
response	I-MED
abr	B-MED
and	O
distortion	B-MED
product	I-MED
otoacoustic	I-MED
emission	I-MED
dpoae	B-MED
.	O
	
drug	B-MED
administration	I-MED
always	O
increased	B-MED
significantly	O
the	O
abr	B-MED
peak	O
i	O
threshold	B-MED
.	O
	
ototoxic	B-MED
antibiotics	B-MED
did	O
not	O
change	O
dpoae	B-MED
,	O
but	O
selectively	O
affected	B-MED
activity	B-MED
of	O
outer	B-MED
hair	I-MED
cells	I-MED
.	O
	
no	B-MED
enhancement	B-MED
of	O
the	O
ototoxic	B-MED
effects	I-MED
was	O
observed	B-MED
after	O
successive	B-MED
administration	I-MED
of	O
the	O
two	O
water	B-MED
safety	B-MED
in	O
healthcare	B-MED
facilities	I-MED
.	O
	
the	O
vieste	B-MED
charter	I-MED
the	O
study	B-MED
group	I-MED
on	O
hospital	B-MED
hygiene	B-MED
of	O
the	O
italian	B-MED
society	I-MED
of	I-MED
hygiene	I-MED
,	O
preventive	I-MED
medicine	I-MED
and	I-MED
public	I-MED
health	I-MED
gisio-siti	B-MED
and	O
the	O
local	B-MED
health	I-MED
authority	I-MED
of	O
foggia	B-MED
,	O
apulia	B-MED
,	O
italy	B-MED
,	O
after	O
the	O
national	B-MED
convention	I-MED
"""safe"	O
water	B-MED
in	O
healthcare	B-MED
facilities	I-MED
""""	O
held	O
in	O
vieste-pugnochiuso	B-MED
on	O
27-28	O
may	O
2016	O
,	O
present	O
the	O
""""	O
vieste	B-MED
charter	I-MED
""""	O
,	O
drawn	O
up	O
in	O
collaboration	B-MED
with	O
experts	B-MED
from	O
the	O
national	B-MED
institute	I-MED
of	I-MED
health	I-MED
and	O
the	B-MED
ministry	I-MED
of	I-MED
health	I-MED
.	O
	
this	O
paper	O
considers	O
the	O
risk	B-MED
factors	I-MED
that	O
may	O
affect	B-MED
the	O
water	B-MED
safety	B-MED
in	O
healthcare	B-MED
facilities	I-MED
and	O
reports	O
the	O
current	O
regulatory	B-MED
frameworks	I-MED
governing	O
the	O
management	B-MED
of	I-MED
installations	I-MED
and	O
the	O
quality	B-MED
of	O
the	O
water	B-MED
.	O
	
the	O
authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	B-MED
that	O
characterize	O
the	O
health	B-MED
facilities	I-MED
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas	O
,	O
including	O
water	B-MED
safety	I-MED
plans	I-MED
approval	O
of	O
treatments	B-MED
healthcare	B-MED
facilities	I-MED
responsibility	B-MED
,	O
installation	O
and	O
maintenance	B-MED
of	O
facilities	B-MED
multidisciplinary	B-MED
approach	I-MED
education	B-MED
and	O
research	B-MED
regional	B-MED
and	I-MED
national	I-MED
coordination	I-MED
communication	B-MED
.	O
	
in	B-MED
vivo	I-MED
three-dimensional	B-MED
patellar	B-MED
mechanics	B-MED
normal	B-MED
knees	B-MED
compared	B-MED
with	O
domed	B-MED
and	O
anatomic	B-MED
patellar	B-MED
components	B-MED
patellofemoral	B-MED
complications	B-MED
are	O
a	O
major	O
cause	O
of	O
revision	B-MED
surgery	I-MED
following	B-MED
total	B-MED
knee	I-MED
arthroplasty	I-MED
tka	B-MED
.	O
	
high	B-MED
forces	B-MED
occurring	O
at	O
the	O
patellofemoral	B-MED
articulation	I-MED
coupled	B-MED
with	O
a	O
small	B-MED
patellofemoral	B-MED
contact	B-MED
area	I-MED
pose	O
substantial	O
design	B-MED
challenges	O
.	O
	
in	O
this	O
study	B-MED
,	O
the	O
three-dimensional	B-MED
3d	B-MED
in	B-MED
vivo	I-MED
mechanics	B-MED
of	O
domed	B-MED
and	O
anatomically	B-MED
shaped	B-MED
patellar	B-MED
components	B-MED
were	O
compared	B-MED
with	O
those	O
of	O
native	B-MED
patellae	B-MED
.	O
	
ten	O
normal	B-MED
knees	B-MED
,	O
10	O
treated	B-MED
with	I-MED
an	O
lcs-ps	B-MED
low	I-MED
contact	I-MED
stress-posterior	I-MED
stabilized	I-MED
tka	I-MED
anatomically	B-MED
shaped	B-MED
patellar	B-MED
component	B-MED
,	O
and	O
10	O
treated	B-MED
with	I-MED
a	O
pfc	B-MED
sigma	I-MED
rp-ps	I-MED
press-fit	I-MED
condylar	I-MED
sigma	I-MED
rotating	I-MED
platform-posterior	I-MED
stabilized	I-MED
tka	I-MED
domed	B-MED
patellar	B-MED
component	B-MED
were	O
analyzed	B-MED
under	O
fluoroscopic	B-MED
surveillance	B-MED
while	O
the	O
patient	B-MED
performed	B-MED
a	O
weight-bearing	B-MED
deep	B-MED
knee	B-MED
bend	I-MED
from	O
full	B-MED
knee	B-MED
extension	I-MED
to	O
maximum	B-MED
knee	B-MED
flexion	I-MED
.	O
	
relevant	O
bone	O
geometries	O
were	O
segmented	B-MED
out	O
from	O
computed	B-MED
tomography	I-MED
ct	B-MED
scans	B-MED
,	O
and	O
computer-assisted-design	B-MED
cad	B-MED
models	B-MED
of	O
the	O
implanted	B-MED
components	B-MED
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O
	
three-dimensional	B-MED
patellofemoral	B-MED
kinematics	B-MED
were	O
obtained	O
using	O
a	O
3d	B-MED
-to-	O
2d	B-MED
registration	O
process	O
.	O
	
contact	B-MED
mechanics	I-MED
were	O
calculated	B-MED
using	O
a	O
distance	B-MED
map	I-MED
between	O
the	O
articulating	B-MED
patellar	I-MED
and	O
femoral	B-MED
surfaces	I-MED
.	O
	
both	O
patellar	B-MED
component	B-MED
designs	O
exhibited	O
good	B-MED
rotational	B-MED
kinematics	I-MED
and	O
tracked	O
well	O
within	O
the	O
femoral	B-MED
trochlea	I-MED
when	O
compared	B-MED
with	O
the	O
normal	B-MED
patella	B-MED
.	O
	
the	O
contact	B-MED
areas	I-MED
in	O
the	O
tka	B-MED
groups	B-MED
peaked	O
at	O
60	O
of	O
knee	B-MED
flexion	I-MED
mean	B-MED
and	O
standard	B-MED
deviation	I-MED
,	O
201	O
63.4	O
mm	O
for	O
the	O
lcs-ps	B-MED
group	I-MED
and	O
218	O
95.4	O
mm	O
for	O
the	O
sigma	B-MED
rp-ps	I-MED
group	I-MED
,	O
and	O
the	O
areas	B-MED
were	O
substantially	O
smaller	B-MED
than	O
those	O
previously	O
reported	B-MED
for	O
the	O
normal	B-MED
patella	B-MED
.	O
	
contact	B-MED
points	I-MED
in	O
the	O
tka	B-MED
groups	B-MED
stayed	O
close	O
to	O
the	O
center	B-MED
of	O
the	O
patellar	B-MED
components	B-MED
.	O
	
both	O
designs	B-MED
performed	B-MED
satisfactorily	B-MED
,	O
although	O
patellofemoral	B-MED
contact	B-MED
areas	I-MED
were	O
reduced	B-MED
in	O
comparison	B-MED
with	O
those	O
in	O
the	O
native	B-MED
patella	B-MED
.	O
	
assessment	B-MED
of	O
the	O
extravascular	B-MED
implantable	I-MED
defibrillator	I-MED
feasibility	B-MED
of	O
substernal	B-MED
ventricular	I-MED
pacing	I-MED
the	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
feasibility	B-MED
of	O
ventricular	B-MED
pacing	I-MED
and	O
thresholds	B-MED
from	O
within	B-MED
the	O
substernal	B-MED
space	I-MED
to	O
examine	O
a	O
new	B-MED
extravascular	B-MED
icd	I-MED
configuration	B-MED
with	O
pacing	B-MED
capabilities	B-MED
.	O
	
in	O
patients	B-MED
undergoing	O
midline	B-MED
sternotomy	I-MED
,	O
a	O
duodecapolar	B-MED
diagnostic	I-MED
pacing	I-MED
catheter	I-MED
was	O
positioned	B-MED
in	O
the	O
substernal	B-MED
space	I-MED
anterior	B-MED
to	O
the	O
pericardium	B-MED
,	O
and	O
a	O
cutaneous	B-MED
patch	I-MED
in	O
left	B-MED
lateral	I-MED
position	I-MED
.	O
	
different	B-MED
unipolar	B-MED
and	O
bipolar	B-MED
pacing	B-MED
configurations	B-MED
were	O
assessed	B-MED
.	O
	
strength-duration	B-MED
curves	I-MED
were	O
performed	B-MED
to	O
identify	O
the	O
optimal	B-MED
output	B-MED
,	O
starting	O
at	O
25	O
ma	B-MED
with	O
a	O
pulse	B-MED
width	I-MED
of	O
10	O
milliseconds	B-MED
.	O
	
eight	O
patients	B-MED
with	O
mean	B-MED
age	B-MED
69	O
9	O
years	B-MED
were	O
included	B-MED
.	O
	
in	O
5	O
,	O
ventricular	B-MED
capture	O
was	O
achieved	O
in	O
1	O
configuration	B-MED
.	O
	
the	O
mean	B-MED
bipolar	B-MED
pacing	B-MED
thresholds	B-MED
at	O
pw	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	B-MED
were	O
12.4	O
3.7	O
ma	B-MED
5	O
patients	B-MED
,	O
13.3	O
5.8	O
ma	B-MED
3	O
patients	B-MED
,	O
18.3	O
5.7	O
ma	B-MED
3	O
patients	B-MED
,	O
and	O
25	O
0	O
ma	B-MED
2	O
patients	B-MED
,	O
respectively	O
.	O
	
the	O
60-mm	O
electrode	B-MED
spacing	B-MED
was	O
the	O
most	O
successful	B-MED
bipolar	B-MED
configuration	B-MED
.	O
	
unipolar	B-MED
pacing	B-MED
was	O
successful	B-MED
in	O
3	O
out	O
of	O
4	O
patients	B-MED
with	O
mean	B-MED
thresholds	B-MED
of	O
10	O
0	O
ma	B-MED
at	O
10	O
milliseconds	B-MED
3	O
patients	B-MED
,	O
15	O
0	O
ma	B-MED
at	O
5	O
milliseconds	B-MED
3	O
patients	B-MED
,	O
16.7	O
2.9	O
ma	B-MED
at	O
3	O
milliseconds	B-MED
3	O
patients	B-MED
,	O
and	O
20	O
7.1	O
ma	B-MED
at	O
1	O
milliseconds	B-MED
2	O
patients	B-MED
.	O
	
ventricular	B-MED
pacing	I-MED
from	O
the	O
substernal	O
space	O
in	O
patients	O
with	O
midline	O
sternotomy	O
is	O
feasible	O
.	O
	
closed	O
sternum	O
studies	O
are	O
needed	O
to	O
determine	O
pacing	B-MED
thresholds	O
more	O
accurately	B-MED
effects	B-MED
of	O
a	O
specific	B-MED
blend	I-MED
of	O
essential	B-MED
oils	I-MED
on	O
apparent	B-MED
nutrient	B-MED
digestion	B-MED
,	O
rumen	B-MED
fermentation	B-MED
and	O
rumen	B-MED
microbial	B-MED
populations	I-MED
in	O
sheep	B-MED
fed	O
a	O
50	O
alfalfa	B-MED
hay	I-MED
concentrate	B-MED
diet	I-MED
an	O
experiment	B-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	O
a	O
specific	O
mixture	B-MED
of	O
essential	B-MED
oils	I-MED
meo	B-MED
,	O
containing	O
thyme	B-MED
,	O
clove	B-MED
and	O
cinnamon	B-MED
eo	I-MED
,	O
on	O
rumen	B-MED
microbial	B-MED
fermentation	I-MED
,	O
nutrient	B-MED
apparent	B-MED
digestibility	B-MED
and	O
blood	B-MED
metabolites	B-MED
in	O
fistulated	B-MED
sheep	I-MED
.	O
	
six	O
sheep	B-MED
fitted	O
with	O
ruminal	B-MED
fistulas	I-MED
were	O
used	O
in	O
a	O
repeated	B-MED
measurement	I-MED
design	I-MED
with	O
two	O
24-d	O
periods	B-MED
to	O
investigate	O
the	O
effect	B-MED
of	O
adding	O
meo	B-MED
at	O
0	O
control	O
,	O
0.8	O
,	O
and	O
1.6	O
ml/d	O
on	O
apparent	B-MED
nutrient	B-MED
digestibility	B-MED
,	O
rumen	B-MED
fermentation	B-MED
characteristics	B-MED
,	O
rumen	B-MED
microbial	B-MED
population	I-MED
and	O
blood	B-MED
chemical	B-MED
metabolites	I-MED
.	O
	
animals	B-MED
were	O
fed	O
with	O
a	O
50	O
alfalfa	B-MED
hay	I-MED
concentrate	B-MED
diet	I-MED
.	O
	
ruminal	B-MED
ph	I-MED
,	O
total	O
volatile	B-MED
fatty	I-MED
acids	I-MED
vfa	B-MED
concentration	B-MED
,	O
molar	B-MED
proportion	I-MED
of	I-MED
individual	I-MED
vfa	B-MED
,	O
acetate	B-MED
propionate	I-MED
ratio	I-MED
and	O
methane	B-MED
production	I-MED
were	O
not	O
affected	O
with	O
meo	B-MED
.	O
	
relative	O
to	O
the	O
control	B-MED
,	O
small	B-MED
peptides	I-MED
plus	O
amino	O
acid	O
nitrogen	O
and	O
large	O
peptides	O
nitrogen	O
concentration	O
in	O
rumen	O
fluid	O
were	O
not	O
affected	O
with	O
meo	O
supplementation	O
while	O
,	O
rumen	O
fluid	O
ammonia	O
nitrogen	O
concentration	O
at	O
0	O
and	O
6	O
h	O
after	O
morning	O
feeding	O
in	O
sheep	O
fed	O
with	O
1.6	O
ml/d	O
of	O
meo	O
was	O
lower	O
p<0	O
compared	O
to	O
the	O
control	O
and	O
0.8	O
ml/d	O
of	O
meo	O
.	O
	
at	O
0	O
h	O
after	O
morning	O
feeding	O
,	O
ammonia	O
nitrogen	O
concentration	O
was	O
higher	O
p<0	O
in	O
sheep	O
fed	O
0.8	O
ml/d	O
of	O
meo	O
relative	O
to	O
1.6	O
ml/d	O
and	O
control	O
diet	O
.	O
	
ruminal	O
protozoa	O
and	O
hyper	O
ammonia	O
producing	O
hap	O
bacteria	O
counts	O
were	O
not	O
affected	O
by	O
addition	O
of	O
meo	O
in	O
the	O
diet	O
.	O
	
relative	O
to	O
the	O
control	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	O
and	O
white	O
blood	O
cells	O
,	O
hemoglobin	O
,	O
hematocrit	O
,	O
glucose	O
,	O
beta-hydroxybutyric	O
acid	O
,	O
cholesterol	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
blood	O
urea	O
nitrogen	O
and	O
aspartate	O
aminotransferase	O
and	O
alanine	O
aminotransferase	O
concentration	O
.	O
	
apparent	O
total	O
tract	O
digestibility	O
of	O
dry	O
matter	O
,	O
crude	O
proten	O
,	O
organic	O
matter	O
,	O
and	O
neutral	O
detergent	O
fiber	O
were	O
not	O
influenced	O
by	O
meo	O
supplementation	O
.	O
	
the	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	O
of	O
meo	O
may	O
have	O
limited	O
effects	O
on	O
apparent	O
nutrient	O
digestibility	O
,	O
ruminal	O
fermentation	O
and	O
protozoa	O
and	O
hap	O
bacteria	O
count	O
,	O
blood	O
cells	O
and	O
metabolites	B-MED
high	B-MED
throughput	I-MED
selection	B-MED
of	O
antibiotic-resistant	B-MED
transgenic	B-MED
arabidopsis	B-MED
plants	I-MED
kanamycin	B-MED
resistance	B-MED
is	O
the	O
most	B-MED
frequently	B-MED
used	O
antibiotic-resistance	B-MED
marker	B-MED
for	O
arabidopsis	B-MED
transformations	B-MED
,	O
however	O
,	O
this	O
method	B-MED
frequently	B-MED
causes	O
escape	B-MED
of	O
untransformed	B-MED
plants	I-MED
,	O
particularly	O
at	O
the	O
high	B-MED
seedling	B-MED
density	B-MED
during	O
the	O
selection	B-MED
.	O
	
here	O
we	O
developed	B-MED
a	O
robust	B-MED
high	B-MED
-	O
density	B-MED
selection	B-MED
method	B-MED
using	O
top	B-MED
agar	B-MED
for	O
arabidopsis	B-MED
thaliana	I-MED
.	O
	
top	B-MED
agar	B-MED
effectively	B-MED
suppressed	B-MED
growth	B-MED
of	O
untransformed	B-MED
wild-type	I-MED
plants	I-MED
on	O
selection	B-MED
media	B-MED
at	O
high	B-MED
density	B-MED
.	O
	
survival	B-MED
of	O
the	O
transformed	B-MED
plants	B-MED
during	O
the	O
selection	B-MED
were	O
confirmed	B-MED
by	O
production	O
of	O
green	B-MED
true	B-MED
leaves	B-MED
and	O
expression	B-MED
of	O
a	O
firefly	B-MED
luciferase	I-MED
reporter	B-MED
gene	I-MED
.	O
	
top	B-MED
agar	B-MED
method	B-MED
allowed	O
selection	B-MED
using	O
a	O
large	B-MED
amount	B-MED
of	O
seeds	B-MED
in	O
arabidopsis	B-MED
transformation	B-MED
.	O
	
limb	B-MED
remote	B-MED
ischaemic	I-MED
postconditioning	I-MED
-	O
induced	B-MED
elevation	B-MED
of	O
fibulin-5	B-MED
confers	O
neuroprotection	B-MED
to	O
rats	B-MED
with	O
cerebral	B-MED
ischaemia	I-MED
/	O
reperfusion	B-MED
injury	I-MED
activation	B-MED
of	O
the	O
akt	B-MED
pathway	I-MED
limb	B-MED
remote	B-MED
ischaemic	I-MED
postconditioning	I-MED
ripostc	B-MED
is	O
an	O
effective	O
and	O
well-acknowledged	O
treatment	B-MED
for	O
brain	B-MED
ischaemia	I-MED
injury	I-MED
.	O
	
the	O
present	O
study	B-MED
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin-5	B-MED
in	O
the	O
neuroprotection	B-MED
of	O
ripostc	B-MED
against	O
cerebral	B-MED
ischaemia	I-MED
/	O
reperfusion	B-MED
i/r	I-MED
injury	I-MED
in	O
rats	B-MED
.	O
	
the	O
middle	B-MED
cerebral	I-MED
artery	I-MED
occlusion	I-MED
mcao	B-MED
model	B-MED
was	O
established	O
in	O
rats	B-MED
and	O
then	O
ripostc	B-MED
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	B-MED
occlusion	B-MED
/10	O
minutes	B-MED
release	O
of	O
the	O
bilateral	B-MED
femoral	B-MED
artery	I-MED
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-MED
.	O
	
to	O
downregulate	B-MED
the	O
fibulin-5	B-MED
level	B-MED
,	O
fibulin-5	B-MED
sirna	I-MED
was	O
injected	B-MED
into	O
the	O
lateral	B-MED
ventricle	I-MED
24	O
hours	B-MED
before	O
mcao	B-MED
.	O
	
according	O
to	O
our	O
present	O
study	B-MED
,	O
ripostc	B-MED
attenuated	B-MED
cerebral	B-MED
i	I-MED
/	O
r	B-MED
injury	I-MED
by	O
decreasing	B-MED
infarct	B-MED
volume	B-MED
,	O
improving	O
neurobehavioral	B-MED
score	I-MED
and	O
suppressing	B-MED
blood	B-MED
brain	I-MED
barrier	I-MED
bbb	B-MED
leakage	B-MED
.	O
	
moreover	O
,	O
the	O
mrna	B-MED
and	O
protein	B-MED
levels	I-MED
of	O
fibulin-5	B-MED
were	O
upregulated	B-MED
by	O
ripostc	B-MED
at	O
24	O
hours	B-MED
and	O
72	O
hours	B-MED
after	O
reperfusion	B-MED
.	O
	
downregulation	B-MED
of	O
fibulin-5	B-MED
attenuated	B-MED
the	O
neuroprotection	B-MED
of	O
ripostc	B-MED
.	O
	
finally	O
,	O
the	O
result	O
showed	O
that	O
fibulin-5	B-MED
was	O
upregulated	B-MED
by	O
ripostc	B-MED
via	O
activation	B-MED
of	O
the	O
pi3k/akt	B-MED
pathway	I-MED
.	O
	
taken	O
together	O
,	O
these	O
results	B-MED
provide	O
evidence	B-MED
that	O
upregulation	B-MED
of	O
fibulin-5	B-MED
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
ripostc	B-MED
against	O
cerebral	B-MED
i	I-MED
/	O
r	B-MED
injury	I-MED
.	O
	
optomechanical	B-MED
control	I-MED
of	O
quantum	B-MED
yield	I-MED
in	O
trans-cis	B-MED
ultrafast	I-MED
photoisomerization	I-MED
of	O
a	O
retinal	B-MED
chromophore	B-MED
model	B-MED
the	O
quantum	B-MED
yield	I-MED
of	O
a	O
photochemical	B-MED
reaction	I-MED
is	O
one	O
of	O
the	O
most	O
fundamental	B-MED
quantities	I-MED
in	O
photochemistry	B-MED
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction	B-MED
of	I-MED
light	I-MED
energy	I-MED
into	I-MED
chemical	I-MED
energy	I-MED
.	O
	
nature	B-MED
has	O
evolved	O
photoreceptors	B-MED
in	O
which	O
the	O
reactivity	B-MED
of	O
a	O
chromophore	B-MED
is	O
enhanced	O
by	O
its	O
molecular	B-MED
environment	I-MED
to	O
achieve	O
high	O
quantum	B-MED
yields	I-MED
.	O
	
the	O
retinal	B-MED
chromophore	B-MED
sterically	O
constrained	O
inside	O
rhodopsin	B-MED
proteins	I-MED
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control	O
.	O
	
in	O
a	O
more	O
general	O
framework	O
,	O
mechanical	B-MED
forces	I-MED
acting	O
on	O
a	O
molecular	B-MED
system	I-MED
can	O
strongly	O
modify	O
its	O
reactivity	B-MED
.	O
	
herein	O
,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile	B-MED
forces	I-MED
on	O
a	O
simplified	O
retinal	B-MED
chromophore	B-MED
model	B-MED
provokes	O
a	O
substantial	B-MED
and	I-MED
regular	I-MED
increase	I-MED
in	O
the	O
trans-to-cis	B-MED
photoisomerization	I-MED
quantum	B-MED
yield	I-MED
in	O
a	O
counterintuitive	O
way	O
,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis	B-MED
photoisomer	I-MED
.	O
	
a	O
rationale	B-MED
for	O
the	O
mechanochemical	B-MED
effect	I-MED
on	O
this	O
photoisomerization	B-MED
mechanism	I-MED
quality	B-MED
of	O
nursing	B-MED
intensity	I-MED
data	I-MED
inter-rater	B-MED
reliability	I-MED
of	O
the	O
patient	B-MED
classification	B-MED
after	O
two	B-MED
decades	I-MED
in	O
clinical	B-MED
use	B-MED
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
measure	B-MED
the	O
inter-rater	B-MED
reliability	I-MED
of	O
the	O
oulu	B-MED
patient	I-MED
classification	I-MED
and	O
to	O
discuss	O
existing	O
methods	B-MED
of	O
reliability	B-MED
testing	I-MED
.	O
	
the	O
oulu	B-MED
patient	I-MED
classification	I-MED
,	O
part	O
of	O
the	O
rafaela	B-MED
system	I-MED
,	O
has	O
been	O
developed	O
to	O
assist	B-MED
nursing	B-MED
managers	I-MED
with	O
the	O
proper	O
allocation	B-MED
of	O
nursing	B-MED
resources	B-MED
.	O
	
due	O
to	O
the	O
increased	B-MED
intensity	B-MED
of	O
inpatient	B-MED
care	I-MED
during	O
recent	O
years	B-MED
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability	B-MED
testing	I-MED
of	O
the	O
classification	B-MED
,	O
which	O
has	O
been	O
in	O
clinical	B-MED
use	B-MED
for	O
20	O
years	B-MED
.	O
	
retrospective	B-MED
statistical	B-MED
study	I-MED
.	O
	
to	O
test	B-MED
inter-rater	B-MED
reliability	I-MED
,	O
a	O
pair	O
of	O
nurses	B-MED
classified	B-MED
the	O
same	O
patients	B-MED
,	O
without	O
knowledge	O
of	O
each	O
other's	O
ratings	B-MED
,	O
as	O
a	O
part	O
of	O
annually	B-MED
conducted	O
standardization	B-MED
.	O
	
data	B-MED
on	O
the	O
parallel	B-MED
classifications	I-MED
n	O
=	O
19	O
was	O
obtained	B-MED
from	O
inpatient	B-MED
units	O
n	O
=	O
32	O
with	O
different	B-MED
specialties	B-MED
at	O
a	O
university	B-MED
hospital	I-MED
in	O
finland	B-MED
during	O
2010-2015	O
.	O
	
parallel	B-MED
classification	I-MED
practices	B-MED
were	O
also	O
analysed	O
.	O
	
the	O
reliability	B-MED
of	O
the	O
overall	O
classification	B-MED
and	O
its	O
subareas	O
were	O
calculated	B-MED
using	O
suitable	O
statistical	B-MED
coefficients	I-MED
.	O
	
inter-rater	B-MED
reliability	I-MED
coefficients	B-MED
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-MED
intensity	B-MED
category	B-MED
and	O
various	O
practices	B-MED
,	O
but	O
there	O
were	O
detectable	B-MED
differences	B-MED
between	O
subareas	O
.	O
	
the	O
lowest	O
agreement	B-MED
levels	B-MED
occurred	B-MED
in	O
the	O
subareas	O
'	O
planning	B-MED
and	I-MED
coordination	I-MED
of	I-MED
nursing	I-MED
care	I-MED
'	O
and	O
'	O
guiding	B-MED
of	I-MED
care	I-MED
/	O
continued	B-MED
care	I-MED
and	O
emotional	B-MED
support	I-MED
'	O
.	O
	
there	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	B-MED
of	O
subareas	O
and	O
to	O
clarify	B-MED
the	O
related	O
concepts	B-MED
.	O
	
precise	O
nursing	B-MED
documentation	I-MED
can	O
promote	B-MED
a	O
high	O
level	B-MED
of	O
agreement	B-MED
and	O
reliable	O
results	B-MED
.	O
	
the	O
traditional	O
overall	O
proportion	O
of	O
agreement	B-MED
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa	B-MED
coefficients	I-MED
water	B-MED
pipe	I-MED
shisha	O
,	O
hookah	O
,	O
arghile	O
smoking	B-MED
and	O
secondhand	B-MED
tobacco	I-MED
smoke	I-MED
effects	B-MED
on	O
cyp1a2	B-MED
and	O
cyp2a6	B-MED
phenotypes	B-MED
as	O
measured	O
by	O
caffeine	B-MED
urine	I-MED
test	I-MED
public	B-MED
policies	I-MED
to	O
stop	O
or	O
reduce	O
cigarette	B-MED
smoking	I-MED
and	O
exposure	B-MED
to	O
secondhand	B-MED
smoke	I-MED
and	O
associated	B-MED
diseases	I-MED
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O
	
yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	B-MED
consumption	I-MED
,	O
water	B-MED
pipe	I-MED
smoking	B-MED
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	B-MED
pipe	I-MED
smoking	B-MED
on	O
cytochrome	B-MED
p450	I-MED
cyp450	I-MED
activities	I-MED
and	O
drug	B-MED
interaction	I-MED
potential	B-MED
in	O
humans	B-MED
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	B-MED
smoke	I-MED
on	O
drug	B-MED
metabolism	I-MED
.	O
	
in	O
a	O
sample	O
of	O
99	O
healthy	B-MED
volunteers	I-MED
28	O
water	B-MED
pipe	I-MED
smokers	I-MED
,	O
30	O
secondhand	B-MED
tobacco	I-MED
smoke	I-MED
exposed	O
persons	B-MED
,	O
and	O
41	O
controls	B-MED
,	O
we	O
systematically	B-MED
compared	I-MED
cyp1a2	B-MED
and	O
cyp2a6	B-MED
enzyme	B-MED
activities	I-MED
in	B-MED
vivo	I-MED
using	O
caffeine	B-MED
urine	I-MED
test	I-MED
.	O
	
the	O
median	O
self-reported	B-MED
duration	B-MED
of	O
water	B-MED
pipe	I-MED
smoking	B-MED
was	O
7.5	O
h	B-MED
/	O
week	B-MED
and	O
3	O
years	B-MED
of	O
exposure	B-MED
in	O
total	O
.	O
	
the	O
secondhand	B-MED
smoke	I-MED
group	B-MED
had	O
a	O
median	O
of	O
14	O
h	B-MED
of	O
self-reported	B-MED
weekly	B-MED
exposure	B-MED
to	O
tobacco	B-MED
smoke	I-MED
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	B-MED
were	O
smoked	B-MED
/	O
hour	B-MED
for	O
a	O
total	O
of	O
3.5	O
years	B-MED
median	O
.	O
	
analysis	B-MED
of	O
variance	B-MED
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
cyp1a2	B-MED
and	O
cyp2a6	B-MED
activities	B-MED
among	O
the	O
three	O
study	B-MED
groups	B-MED
p	O
>	O
0.05	O
.	O
	
nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	B-MED
pipe	I-MED
or	O
secondhand	B-MED
smoke	I-MED
exposure	B-MED
and	O
the	O
cyp1a2	B-MED
and	O
cyp2a6	B-MED
activities	B-MED
p	O
>	O
0.05	O
.	O
	
further	O
analysis	B-MED
in	O
a	O
subsample	O
with	O
smoke	O
exposure	B-MED
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	B-MED
.	O
	
although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	B-MED
pipe	I-MED
smoke	O
and	O
secondhand	B-MED
smoke	I-MED
on	O
in	B-MED
vivo	I-MED
activities	B-MED
of	O
these	O
two	O
drug	B-MED
metabolism	I-MED
pathways	B-MED
,	O
variability	O
in	O
smoke	O
constituents	B-MED
from	O
different	O
tobacco	B-MED
consumption	I-MED
methods	O
e.g	O
,	O
water	B-MED
pipe	I-MED
might	O
affect	O
drug	B-MED
metabolism	I-MED
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	B-MED
smoke	I-MED
.	O
	
further	O
studies	B-MED
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	B-MED
pipe	I-MED
and	O
secondhand	B-MED
tobacco	I-MED
smoke	I-MED
effects	O
on	O
cyp450	B-MED
function	O
,	O
particularly	O
at	O
higher	O
smoke	B-MED
exposure	B-MED
how	O
do	O
wettability	B-MED
,	O
zeta	B-MED
potential	I-MED
and	O
hydroxylation	B-MED
degree	O
affect	O
the	O
biological	O
response	O
of	O
biomaterials	O
it	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	O
surfaces	O
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	O
fluids	O
and	O
tissues	O
,	O
but	O
systematic	O
studies	O
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	O
literature	O
.	O
	
the	O
aim	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-MED
degree	I-MED
and	O
the	O
biological	B-MED
response	I-MED
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
cell	O
and	O
bacterial	O
adhesion	O
to	O
some	O
model	O
biomaterials	B-MED
.	O
	
the	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	O
for	O
implantable	O
biomaterials	O
.	O
	
roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
smooth	O
surfaces	O
prepared	O
by	O
a	O
controlled	O
protocol	O
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O
	
three	O
oxides	O
zro2	O
,	O
al2o3	O
,	O
sio2	O
,	O
three	O
metals	O
316lss	O
steel	O
,	O
ti	O
,	O
nb	O
and	O
two	O
polymers	O
corona	O
treated	O
polystyrene	O
for	O
cell	O
culture	O
and	O
untreated	O
polystyrene	O
for	O
bacteria	O
culture	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O
	
the	O
surfaces	O
were	O
characterized	O
by	O
contact	O
profilometry	O
,	O
sem	O
-	O
eds	O
,	O
xps	O
,	O
ftir	O
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O
	
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
bacterial	O
and	O
cell	O
adhesion	O
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	O
responses	O
.	O
	
from	O
a	O
methodological	O
standpoint	O
,	O
xps	O
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	O
degree	O
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O
	
moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	O
appeared	O
a	O
specific	O
and	O
crucial	O
test	O
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	O
.	O
	
hydroxylation	O
degree	O
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	O
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O
	
wetting	O
tests	O
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look-alike	O
materials	O
.	O
	
a	O
dependence	O
of	O
protein	O
absorption	O
on	O
hydroxylation	O
degree	O
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	O
with	O
low	O
wettability	O
in	O
both	O
water	O
based	O
and	O
protein	O
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O
	
as	O
far	O
as	O
bacterial	O
adhesion	O
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	O
adsorption	O
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O
	
finally	O
,	O
the	O
combination	O
of	O
hydroxylation	O
degree	O
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
polar	O
component	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	O
adhesion	O
and	O
viability	B-MED
persistent	B-MED
effects	B-MED
of	O
pre-columbian	B-MED
plant	B-MED
domestication	B-MED
on	O
amazonian	B-MED
forest	I-MED
composition	B-MED
the	O
extent	O
to	O
which	O
pre-columbian	B-MED
societies	B-MED
altered	O
amazonian	B-MED
landscapes	B-MED
is	O
hotly	O
debated	O
.	O
	
we	O
performed	O
a	O
basin-wide	B-MED
analysis	I-MED
of	O
pre-columbian	B-MED
impacts	B-MED
on	O
amazonian	B-MED
forests	I-MED
by	O
overlaying	O
known	O
archaeological	B-MED
sites	I-MED
in	O
amazonia	B-MED
with	O
the	O
distributions	O
and	O
abundances	B-MED
of	O
85	O
woody	B-MED
species	B-MED
domesticated	B-MED
by	O
pre-columbian	B-MED
peoples	B-MED
.	O
	
domesticated	B-MED
species	B-MED
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated	B-MED
species	I-MED
to	O
be	O
hyperdominant	B-MED
.	O
	
across	O
the	O
basin	O
,	O
the	O
relative	O
abundance	B-MED
and	O
richness	B-MED
of	O
domesticated	B-MED
species	B-MED
increase	O
in	O
forests	B-MED
on	O
and	O
around	O
archaeological	B-MED
sites	I-MED
.	O
	
in	O
southwestern	B-MED
and	I-MED
eastern	I-MED
amazonia	I-MED
,	O
distance	O
to	O
archaeological	B-MED
sites	I-MED
strongly	O
influences	O
the	O
relative	O
abundance	B-MED
and	O
richness	O
of	O
domesticated	B-MED
species	B-MED
.	O
	
our	O
analyses	B-MED
indicate	O
that	O
modern	O
tree	B-MED
communities	B-MED
in	O
amazonia	B-MED
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	B-MED
of	O
plant	B-MED
domestication	B-MED
by	O
amazonian	B-MED
peoples	B-MED
.	O
	
halogenated	B-MED
phenolic	I-MED
compounds	I-MED
in	O
wild	B-MED
fish	I-MED
from	O
canadian	B-MED
areas	I-MED
of	O
concern	B-MED
concentrations	O
of	O
halogenated	B-MED
phenolic	I-MED
compounds	I-MED
were	O
measured	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
ameiurus	B-MED
nebulosus	I-MED
from	O
4	O
canadian	B-MED
areas	I-MED
of	O
concern	B-MED
aocs	B-MED
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-MED
-	O
disrupting	B-MED
chemicals	I-MED
.	O
	
hydroxylated	B-MED
polychlorinated	I-MED
biphenyls	I-MED
oh-pcbs	B-MED
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
aocs	B-MED
the	O
detection	B-MED
frequency	B-MED
was	O
lower	O
in	O
samples	O
from	O
the	O
detroit	B-MED
river	I-MED
aoc	B-MED
.	O
	
the	O
oh-pcbs	B-MED
most	O
frequently	O
detected	O
were	O
pentachloro	B-MED
,	O
hexachloro	I-MED
,	O
and	I-MED
heptachloro	I-MED
congeners	I-MED
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	B-MED
hormones	I-MED
.	O
	
pentachlorophenol	B-MED
pcp	B-MED
was	O
detected	O
at	O
highest	O
concentrations	O
1.8	O
ng/g	O
in	O
fish	B-MED
from	O
prince	B-MED
edward	I-MED
bay	I-MED
,	O
the	O
bay	B-MED
of	I-MED
quinte	I-MED
lake	I-MED
reference	I-MED
site	I-MED
,	O
and	O
hillman	B-MED
marsh	I-MED
the	B-MED
wheatley	I-MED
harbour	I-MED
reference	I-MED
site	I-MED
,	O
suggesting	O
local	O
sources	B-MED
of	I-MED
contamination	I-MED
.	O
	
elevated	B-MED
pcp	I-MED
concentrations	I-MED
were	O
also	O
detected	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
from	O
exposed	O
sites	O
in	O
the	O
toronto	B-MED
and	I-MED
region	I-MED
aoc	I-MED
0.4	O
ng/g	O
.	O
	
triclosan	B-MED
was	O
consistently	O
detected	O
in	O
the	O
toronto	B-MED
and	I-MED
region	I-MED
aoc	I-MED
0.05	O
ng/g	O
,	O
consistent	O
with	O
wastewater	B-MED
emission	O
.	O
	
greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
from	O
the	O
bay	B-MED
of	I-MED
quinte	I-MED
aoc	B-MED
.	O
	
concentrations	O
of	O
polybrominated	B-MED
diphenyl	I-MED
ethers	I-MED
were	O
highest	O
in	O
the	O
toronto	B-MED
and	I-MED
region	I-MED
aoc	I-MED
,	O
and	O
at	O
2	O
of	O
the	O
bay	B-MED
of	I-MED
quinte	I-MED
aoc	B-MED
exposed	O
sites	O
near	O
trenton	B-MED
and	I-MED
belleville	I-MED
.	O
	
distribution	B-MED
patterns	I-MED
reflected	O
the	O
properties	B-MED
and	O
usage	B-MED
of	O
the	O
compounds	O
under	O
investigation	B-MED
and	O
the	O
characteristics	B-MED
of	O
each	O
aoc	B-MED
.	O
	
the	O
genetic	B-MED
basis	O
for	O
variation	B-MED
in	O
resistance	B-MED
to	O
infection	B-MED
in	O
the	O
drosophila	B-MED
melanogaster	I-MED
genetic	I-MED
reference	I-MED
panel	I-MED
individuals	B-MED
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-MED
but	O
the	O
genetic	B-MED
basis	O
of	O
this	O
variation	B-MED
is	O
not	O
fully	O
understood	O
.	O
	
we	O
found	O
substantial	O
individual	B-MED
variation	B-MED
in	O
resistance	B-MED
and	O
tolerance	B-MED
to	O
the	O
fungal	B-MED
pathogen	I-MED
metarhizium	I-MED
anisopliae	I-MED
ma549	I-MED
using	O
the	O
drosophila	B-MED
melanogaster	I-MED
genetic	I-MED
reference	I-MED
panel	I-MED
dgrp	B-MED
.	O
	
in	O
addition	O
,	O
we	O
found	O
that	O
host	B-MED
defense	I-MED
to	O
ma549	B-MED
was	O
correlated	O
with	O
defense	B-MED
to	O
the	O
bacterium	B-MED
pseudomonas	B-MED
aeruginosa	I-MED
pa14	I-MED
,	O
and	O
several	O
previously	O
published	O
dgrp	B-MED
phenotypes	B-MED
including	O
oxidative	B-MED
stress	I-MED
sensitivity	B-MED
,	O
starvation	B-MED
stress	B-MED
resistance	I-MED
,	O
hemolymph	B-MED
glucose	B-MED
levels	I-MED
,	O
and	O
sleep	B-MED
indices	B-MED
.	O
	
we	O
identified	O
polymorphisms	B-MED
associated	B-MED
with	I-MED
differences	B-MED
between	O
lines	O
in	O
both	O
their	O
mean	B-MED
survival	I-MED
times	I-MED
and	O
microenvironmental	B-MED
plasticity	B-MED
,	O
suggesting	O
that	O
lines	O
differ	B-MED
in	O
their	O
ability	B-MED
to	O
adapt	B-MED
to	O
variable	B-MED
pathogen	B-MED
exposures	B-MED
.	O
	
the	O
majority	O
of	O
polymorphisms	B-MED
increasing	B-MED
resistance	B-MED
to	O
ma549	B-MED
were	O
sex	B-MED
biased	I-MED
,	O
located	O
in	O
non-coding	B-MED
regions	I-MED
,	O
had	O
moderately	O
large	O
effect	B-MED
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	B-MED
.	O
	
nevertheless	O
,	O
host	B-MED
defense	I-MED
was	O
not	O
negatively	O
correlated	B-MED
with	O
overall	O
longevity	B-MED
and	O
fecundity	B-MED
.	O
	
in	O
contrast	O
to	O
ma549	B-MED
,	O
minor	B-MED
alleles	I-MED
were	O
concentrated	O
in	O
the	O
most	O
pa14	B-MED
-	O
susceptible	B-MED
as	O
well	O
as	O
the	O
most	O
pa14	B-MED
-	O
resistant	B-MED
lines	O
.	O
	
a	O
pathway	B-MED
based	O
analysis	B-MED
revealed	O
a	O
network	O
of	O
pa14	B-MED
and	O
ma549	B-MED
-	O
resistance	B-MED
genes	B-MED
that	O
are	O
functionally	B-MED
connected	O
through	O
processes	B-MED
that	O
encompass	O
phagocytosis	B-MED
and	O
engulfment	B-MED
,	O
cell	B-MED
mobility	I-MED
,	O
intermediary	B-MED
metabolism	I-MED
,	O
protein	B-MED
phosphorylation	I-MED
,	O
axon	B-MED
guidance	I-MED
,	O
response	B-MED
to	I-MED
dna	I-MED
damage	I-MED
,	O
and	O
drug	B-MED
metabolism	I-MED
.	O
	
functional	B-MED
testing	B-MED
with	O
insertional	B-MED
mutagenesis	I-MED
lines	O
indicates	O
that	O
12/13	O
candidate	B-MED
genes	I-MED
tested	B-MED
influence	B-MED
susceptibility	B-MED
to	O
ma549	B-MED
.	O
	
many	O
candidate	B-MED
genes	I-MED
have	O
homologs	B-MED
identified	O
in	O
studies	B-MED
of	O
human	B-MED
disease	B-MED
,	O
suggesting	O
that	O
genes	B-MED
affecting	O
variation	B-MED
in	O
susceptibility	B-MED
are	O
conserved	O
across	O
surrogate	B-MED
inaccuracy	B-MED
in	O
predicting	O
older	B-MED
adults'	I-MED
desire	B-MED
for	O
life-sustaining	B-MED
interventions	I-MED
in	O
the	O
event	O
of	O
decisional	B-MED
incapacity	B-MED
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	B-MED
quality-of-life	B-MED
assessments	I-MED
family	B-MED
members	I-MED
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	B-MED
for	O
an	O
incapacitated	O
relative	B-MED
.	O
	
yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one's	O
desire	B-MED
to	O
receive	O
treatments	B-MED
in	O
hypothetical	O
situations	O
.	O
	
we	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality-of-life	B-MED
assessments	I-MED
.	O
	
the	O
data	B-MED
come	O
from	O
235	O
community-dwelling	B-MED
adults	B-MED
aged	O
70	O
years	B-MED
and	O
over	O
who	O
rated	O
their	O
quality	B-MED
of	I-MED
life	I-MED
and	O
desire	B-MED
for	O
specified	O
interventions	B-MED
in	O
four	O
health	B-MED
states	I-MED
current	B-MED
state	I-MED
,	O
mild	B-MED
to	O
moderate	B-MED
stroke	B-MED
,	O
incurable	O
brain	B-MED
cancer	I-MED
,	O
and	O
severe	B-MED
dementia	B-MED
.	O
	
all	O
ratings	B-MED
were	O
made	O
on	O
likert-type	B-MED
scales	I-MED
.	O
	
using	O
identical	O
rating	B-MED
scales	I-MED
,	O
a	O
surrogate	B-MED
chosen	O
by	O
the	O
older	B-MED
adult	I-MED
was	O
asked	O
to	O
predict	O
the	O
latter's	O
responses	O
.	O
	
linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality-of-life	B-MED
ratings	B-MED
between	O
the	O
older	B-MED
adult	I-MED
and	O
surrogate	B-MED
were	O
associated	O
with	O
surrogates'	B-MED
inaccuracy	B-MED
in	O
predicting	O
desire	B-MED
for	O
treatment	B-MED
.	O
	
the	O
difference	O
in	O
quality-of-life	B-MED
ratings	B-MED
was	O
a	O
significant	O
predictor	B-MED
of	O
prediction	O
inaccuracy	B-MED
for	O
the	O
three	O
hypothetical	O
health	B-MED
states	I-MED
p	O
<	O
0.01	O
and	O
nearly	O
significant	O
for	O
the	O
current	B-MED
health	I-MED
state	I-MED
p	O
=	O
0.077	O
.	O
	
all	O
regression	B-MED
coefficients	I-MED
were	O
negative	B-MED
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	B-MED
overestimated	O
quality	B-MED
of	I-MED
life	I-MED
compared	O
to	O
the	O
older	B-MED
adult	I-MED
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	B-MED
adult	I-MED
's	O
desire	B-MED
to	O
be	O
treated	O
.	O
	
discrepant	O
quality-of-life	B-MED
ratings	B-MED
are	O
associated	O
with	O
surrogates'	B-MED
difficulty	O
in	O
predicting	O
desire	B-MED
for	O
life-sustaining	B-MED
interventions	I-MED
in	O
hypothetical	O
situations	O
.	O
	
this	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	B-MED
of	I-MED
life	I-MED
in	O
states	O
of	O
cognitive	B-MED
decline	I-MED
,	O
to	O
better	O
prepare	O
family	B-MED
members	I-MED
for	O
making	O
difficult	O
decisions	B-MED
gain-of-function	B-MED
mutation	I-MED
in	O
scn5a	B-MED
causes	O
ventricular	B-MED
arrhythmias	I-MED
and	O
early	B-MED
onset	I-MED
atrial	B-MED
fibrillation	I-MED
mutations	B-MED
in	O
scn5a	B-MED
,	O
the	O
gene	B-MED
encoding	B-MED
the	O
α-subunit	O
of	O
the	O
cardiac	B-MED
sodium	B-MED
channel	I-MED
nav1.5	I-MED
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	B-MED
of	O
inherited	B-MED
cardiac	B-MED
arrhythmia	I-MED
disorders	I-MED
.	O
	
the	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
identify	O
the	O
genetic	B-MED
and	O
functional	B-MED
determinants	I-MED
underlying	O
a	O
dutch	B-MED
family	B-MED
that	O
presented	O
with	O
a	O
combined	O
phenotype	B-MED
of	O
ventricular	B-MED
arrhythmias	I-MED
with	O
a	O
likely	O
adrenergic	B-MED
component	B-MED
,	O
either	O
in	O
isolation	B-MED
or	O
in	O
combination	B-MED
with	O
a	O
mildly	O
decreased	O
heart	B-MED
function	I-MED
and	O
early	B-MED
onset	I-MED
<55	O
years	B-MED
atrial	B-MED
fibrillation	I-MED
.	O
	
we	O
performed	O
next	O
generation	B-MED
sequencing	B-MED
in	O
the	O
proband	B-MED
of	O
a	O
two-	O
generation	B-MED
dutch	B-MED
family	B-MED
and	O
demonstrated	O
a	O
novel	O
missense	B-MED
mutation	I-MED
in	O
scn5a-	B-MED
which	O
co-segregated	O
with	O
the	O
clinical	B-MED
phenotype	B-MED
in	O
the	O
family	B-MED
.	O
	
we	O
functionally	B-MED
evaluated	O
the	O
putative	O
genetic	B-MED
defect	B-MED
by	O
patch	B-MED
clamp	I-MED
electrophysiological	B-MED
studies	I-MED
in	O
human	B-MED
embryonic	I-MED
kidney	B-MED
cells	I-MED
transfected	B-MED
with	O
mutant	B-MED
or	O
wild-type	B-MED
nav1.5	I-MED
.	O
	
the	O
current	B-MED
inactivation	B-MED
was	O
slower	O
and	O
recovery	O
from	O
inactivation	B-MED
was	O
faster	O
in	O
scn5a-m1851v	B-MED
channels	I-MED
.	O
	
the	O
voltage	B-MED
dependence	B-MED
of	O
inactivation	B-MED
was	O
shifted	O
towards	O
more	O
positive	B-MED
potentials	B-MED
and	O
consequently	O
,	O
a	O
larger	O
ttx	B-MED
-	O
sensitive	B-MED
window	B-MED
current	I-MED
was	O
observed	O
in	O
scn5a-m1851v	B-MED
channels	I-MED
.	O
	
furthermore	O
,	O
a	O
higher	O
upstroke	B-MED
velocity	I-MED
was	O
observed	O
for	O
the	O
scn5a-m1851v	B-MED
channels	I-MED
,	O
while	O
the	O
depolarization	B-MED
voltage	I-MED
was	O
more	O
negative	B-MED
,	O
both	O
indicating	O
increased	O
excitability	O
.	O
	
this	O
mutation	B-MED
leads	O
to	O
a	O
gain-of-function	B-MED
mechanism	I-MED
based	O
on	O
increased	O
channel	B-MED
availability	O
and	O
increased	O
window	B-MED
current	I-MED
,	O
fitting	O
the	O
observed	O
clinical	B-MED
phenotype	B-MED
of	O
likely	O
adrenergic-induced	O
ventricular	B-MED
arrhythmias	I-MED
and	O
atrial	B-MED
fibrillation	I-MED
.	O
	
these	O
findings	B-MED
further	O
expand	O
the	O
range	O
of	O
cardiac	B-MED
arrhythmias	I-MED
associated	O
with	O
mutations	B-MED
in	O
the	O
cancer	B-MED
warburg	B-MED
effect	I-MED
may	O
be	O
a	O
testable	B-MED
example	B-MED
of	O
the	O
minimum	B-MED
entropy	B-MED
production	B-MED
rate	I-MED
principle	B-MED
cancer	B-MED
cells	I-MED
consume	B-MED
more	O
glucose	B-MED
by	O
glycolytic	B-MED
fermentation	I-MED
to	O
lactate	B-MED
than	O
by	O
respiration	B-MED
,	O
a	O
characteristic	B-MED
known	O
as	O
the	O
warburg	B-MED
effect	I-MED
.	O
	
in	O
contrast	O
with	O
the	O
34	O
moles	B-MED
of	O
atp	B-MED
produced	O
by	O
respiration	B-MED
,	O
fermentation	B-MED
produces	O
two	O
moles	B-MED
of	O
atp	B-MED
per	O
mole	B-MED
of	O
glucose	B-MED
consumed	B-MED
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	B-MED
of	O
the	O
warburg	B-MED
effect	I-MED
.	O
	
productions	B-MED
of	O
free	B-MED
energy	I-MED
δg	B-MED
,	O
enthalpy	B-MED
δh	B-MED
and	O
entropy	B-MED
δs	B-MED
per	O
mole	B-MED
linearly	B-MED
vary	O
with	O
the	O
fraction	B-MED
x	I-MED
of	I-MED
glucose	B-MED
consumed	B-MED
by	O
fermentation	B-MED
that	O
is	O
frequently	B-MED
estimated	B-MED
around	O
0.9	O
.	O
	
hence	O
,	O
calculation	B-MED
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	B-MED
respiration	B-MED
,	O
the	O
predominant	O
fermentative	B-MED
metabolism	B-MED
decreases	B-MED
around	O
10%	O
the	O
production	B-MED
of	O
entropy	B-MED
per	O
mole	B-MED
of	O
glucose	B-MED
consumed	B-MED
in	O
cancer	B-MED
cells	I-MED
.	O
	
we	O
hypothesize	B-MED
that	O
increased	B-MED
fermentation	B-MED
could	O
allow	O
cancer	B-MED
cells	I-MED
to	O
accomplish	B-MED
the	O
prigogine	B-MED
theorem	I-MED
of	O
the	O
trend	B-MED
to	O
minimize	B-MED
the	O
rate	B-MED
of	O
production	B-MED
of	O
entropy	B-MED
.	O
	
according	O
the	O
theorem	B-MED
,	O
open	B-MED
cellular	I-MED
systems	I-MED
near	O
the	O
steady	B-MED
state	I-MED
could	O
evolve	B-MED
to	O
minimize	B-MED
the	O
rates	B-MED
of	O
entropy	B-MED
production	B-MED
that	O
may	O
be	O
reached	O
by	O
modified	B-MED
replicating	B-MED
cells	B-MED
producing	O
entropy	B-MED
at	O
low	O
rate	B-MED
.	O
	
remarkably	O
,	O
at	O
co2	B-MED
concentrations	B-MED
above	O
930	O
ppm	B-MED
,	O
glucose	B-MED
respiration	B-MED
produces	O
less	O
entropy	B-MED
than	O
fermentation	B-MED
,	O
which	O
suggests	O
experimental	B-MED
tests	B-MED
to	O
validate	B-MED
the	O
hypothesis	B-MED
of	O
minimization	B-MED
of	O
the	O
rate	B-MED
of	O
entropy	B-MED
production	B-MED
through	O
the	O
warburg	B-MED
effect	I-MED
.	O
	
potential	B-MED
drug-drug	B-MED
interactions	I-MED
among	O
prescriptions	B-MED
for	O
elderly	B-MED
patients	B-MED
in	O
primary	B-MED
health	I-MED
care	I-MED
elderly	B-MED
patients	B-MED
are	O
at	O
high	B-MED
risk	I-MED
from	O
drug-drug	B-MED
interactions	I-MED
ddis	B-MED
.	O
	
this	O
study	B-MED
evaluates	B-MED
the	O
potential	B-MED
ddis	B-MED
in	O
turkish	O
elderly	B-MED
patients	B-MED
at	O
a	O
primary	B-MED
health	I-MED
care	I-MED
outpatient	B-MED
clinic	I-MED
.	O
	
online	B-MED
database	I-MED
systems	I-MED
were	O
used	O
to	O
examine	O
ddis	B-MED
on	O
the	O
prescriptions	B-MED
of	O
patients	B-MED
n	O
=	O
1206	O
.	O
	
the	O
clinical	B-MED
severity	I-MED
of	O
ddis	B-MED
was	O
classified	O
by	O
the	O
lexi-interact	B-MED
online	I-MED
database	I-MED
.	O
	
of	O
the	O
5059	O
prescriptions	B-MED
,	O
33%	O
were	O
found	O
to	O
have	O
ddis	B-MED
.	O
	
we	O
detected	B-MED
29	O
0.9	O
a	O
,	O
380	O
11.8	O
b	O
,	O
2494	O
77.7	O
c	O
,	O
289	O
9%	O
d	O
,	O
and	O
18	O
0.6	O
x	O
risk	O
rating	O
category	O
ddis	B-MED
among	O
the	O
prescriptions	B-MED
.	O
	
prescriptions	B-MED
of	O
female	O
patients	B-MED
and	O
patients	B-MED
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly	B-MED
higher	I-MED
number	O
of	O
ddis	B-MED
.	O
	
the	O
frequency	B-MED
of	O
ddis	B-MED
increased	B-MED
both	O
with	O
the	O
number	O
of	O
drugs	B-MED
and	O
combined	O
preparations	O
per	O
prescription	B-MED
.	O
	
acetylsalicylic	B-MED
acid	I-MED
and	O
salbutamol	B-MED
were	O
the	O
most	O
frequently	B-MED
prescribed	B-MED
drugs	B-MED
contributing	O
to	O
clinically	B-MED
important	I-MED
ddis	B-MED
.	O
	
additionally	O
,	O
acetylsalicylic	B-MED
acid	I-MED
and	O
escitalopram	B-MED
,	O
which	O
interact	B-MED
with	O
each	O
other	O
,	O
were	O
found	O
on	O
the	O
list	O
of	O
beers	B-MED
criteria	I-MED
.	O
	
the	O
most	O
predicted	B-MED
clinical	I-MED
outcomes	I-MED
of	O
ddis	B-MED
were	O
increase	O
in	O
therapeutic	B-MED
efficacy	I-MED
and	O
adverse	B-MED
/	O
toxic	B-MED
reactions	I-MED
.	O
	
conclusions	O
prediction	B-MED
of	O
ddis	B-MED
in	O
elderly	B-MED
patients	B-MED
will	O
provide	O
better	O
prescribing	B-MED
and	O
drug	B-MED
safety	I-MED
.	O
	
use	O
of	O
nonsteroidal	B-MED
anti-inflammatory	I-MED
agents	I-MED
,	O
selective	B-MED
serotonin	I-MED
reuptake	I-MED
inhibitors	I-MED
,	O
and	O
beta-2	B-MED
adrenergic	I-MED
receptor	I-MED
agonists	I-MED
discontinued	B-MED
splenogonadal	B-MED
fusion	I-MED
and	O
bilateral	B-MED
empty	I-MED
scrotum	I-MED
in	O
an	O
18-	O
month	B-MED
-old	O
boy	B-MED
splenogonadal	B-MED
fusion	I-MED
is	O
a	O
rare	B-MED
benign	O
congenital	B-MED
anomaly	I-MED
defined	O
as	O
the	O
presence	O
of	O
splenic	B-MED
tissue	I-MED
adherent	B-MED
to	O
gonads	B-MED
.	O
	
it	O
was	O
first	O
described	O
in	O
1883	O
by	O
bostroem	B-MED
,	O
a	O
german	B-MED
pathologist	B-MED
.	O
	
we	O
present	O
a	O
case	B-MED
of	O
an	O
18-	O
month	B-MED
-old	O
boy	B-MED
who	O
was	O
referred	O
as	O
a	O
case	B-MED
of	O
bilateral	B-MED
empty	I-MED
scrotum	I-MED
since	O
birth	O
.	O
	
during	O
routine	B-MED
laparoscopic	B-MED
exploration	B-MED
,	O
right	B-MED
vas	I-MED
deferens	I-MED
and	O
testicular	B-MED
vessels	I-MED
were	O
entering	O
the	O
right	B-MED
internal	I-MED
inguinal	I-MED
ring	I-MED
so	O
right	B-MED
inguinal	I-MED
exploration	B-MED
was	O
done	O
,	O
which	O
revealed	O
blind	B-MED
ending	I-MED
vas	B-MED
deferens	I-MED
and	O
testicular	B-MED
vessels	I-MED
and	O
the	O
left	B-MED
testis	I-MED
was	O
found	O
intra-abdominally	B-MED
near	O
the	O
left	O
internal	B-MED
ring	I-MED
with	O
a	O
mass	B-MED
on	O
its	O
upper	B-MED
pole	I-MED
.	O
	
wedge	B-MED
biopsy	I-MED
was	O
taken	O
from	O
the	O
upper	B-MED
pole	I-MED
of	I-MED
the	I-MED
testicle	I-MED
site	B-MED
of	O
the	O
mass	B-MED
for	O
tissue	B-MED
diagnosis	I-MED
followed	O
by	O
orchidopexy	B-MED
.	O
	
histology	B-MED
showed	O
splenic	B-MED
tissue	I-MED
.	O
	
although	O
splenogonadal	B-MED
fusion	I-MED
is	O
a	O
rare	B-MED
condition	B-MED
,	O
surgeons	B-MED
should	O
be	O
aware	O
of	O
this	O
rare	B-MED
disease	I-MED
entity	O
to	O
avoid	O
unnecessary	B-MED
aggressive	O
interventions	B-MED
such	O
as	O
real-world	B-MED
impact	I-MED
of	O
non-breast	B-MED
cancer-specific	I-MED
death	I-MED
on	O
overall	B-MED
survival	I-MED
in	O
resectable	B-MED
breast	B-MED
cancer	I-MED
the	O
real-world	O
occurrence	B-MED
rate	I-MED
of	O
non-breast	B-MED
cancer-specific	I-MED
death	I-MED
non-bcsd	B-MED
and	O
its	O
impact	B-MED
on	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
are	O
poorly	O
recognized	O
.	O
	
women	B-MED
with	O
resectable	B-MED
breast	B-MED
cancer	I-MED
from	O
1990	O
to	O
2007	O
in	O
the	O
surveillance	B-MED
,	O
epidemiology	I-MED
,	O
and	I-MED
end	I-MED
results	I-MED
database	I-MED
n	O
=	O
199	O
were	O
analyzed	B-MED
.	O
	
the	O
outcome	B-MED
events	B-MED
of	O
breast	B-MED
cancer	I-MED
were	O
classified	O
as	O
breast	B-MED
cancer-specific	I-MED
death	I-MED
bcsd	B-MED
,	O
non-bcsd	B-MED
,	O
or	O
survival	B-MED
.	O
	
binary	B-MED
logistics	I-MED
was	O
used	O
to	O
estimate	B-MED
the	O
occurrence	B-MED
rates	I-MED
of	O
non-bcsd	B-MED
and	O
bcsd	B-MED
with	O
different	O
clinicopathological	B-MED
factors	I-MED
.	O
	
the	O
gray	B-MED
method	I-MED
was	O
used	O
to	O
measure	B-MED
the	O
cumulative	B-MED
incidence	I-MED
of	O
non-bcsd	B-MED
and	O
bcsd	B-MED
.	O
	
the	O
ratio	B-MED
of	O
non-bcsds	B-MED
to	O
all	O
causes	B-MED
of	I-MED
death	I-MED
and	O
stacked	B-MED
cumulative	B-MED
incidence	I-MED
function	B-MED
plots	I-MED
were	O
used	O
to	O
present	O
the	O
impact	B-MED
of	O
non-bcsd	B-MED
on	O
overall	B-MED
survival	I-MED
os	B-MED
.	O
	
models	B-MED
of	I-MED
cox	I-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
and	O
competing	B-MED
risk	I-MED
regression	I-MED
were	O
compared	O
to	O
highlight	O
the	O
suitable	B-MED
model	I-MED
.	O
	
there	O
were	O
12	O
non-bcsds	B-MED
6.44	O
and	O
28	O
bcsds	B-MED
14.39	O
.	O
	
the	O
oldest	B-MED
age	I-MED
group	I-MED
>62	O
years	O
,	O
black	B-MED
race	I-MED
,	O
and	O
a	O
single	B-MED
or	I-MED
divorced	I-MED
marital	I-MED
status	I-MED
were	O
associated	B-MED
with	I-MED
more	O
non-bcsds	B-MED
.	O
	
with	O
adjustments	O
for	O
age	B-MED
,	O
a	O
hormone	B-MED
receptor-positive	I-MED
hor+	I-MED
status	I-MED
was	O
no	O
longer	O
related	O
to	O
increased	B-MED
non-bcsd	B-MED
s	O
.	O
	
in	O
patients	B-MED
with	O
grade	B-MED
1	I-MED
,	O
stage	I-MED
i	I-MED
disease	I-MED
and	O
an	O
hor+	B-MED
status	I-MED
as	O
well	O
as	O
the	O
oldest	O
subgroup	O
,	O
a	O
great	O
dilution	O
of	O
non-bcsd	B-MED
on	O
all	O
causes	B-MED
of	I-MED
death	I-MED
could	O
be	O
observed	O
,	O
and	O
this	O
led	O
to	O
incorrect	B-MED
interpretations	I-MED
.	O
	
the	O
inaccuracy	B-MED
,	O
caused	O
by	O
the	O
commonly	O
used	O
cox	B-MED
proportional	I-MED
hazards	I-MED
model	I-MED
,	O
could	O
be	O
corrected	O
by	O
a	O
competing	B-MED
risk	I-MED
model	I-MED
.	O
	
os	B-MED
was	O
largely	O
impaired	B-MED
by	O
non-bcsd	B-MED
during	O
early	O
breast	B-MED
cancer	I-MED
.	O
	
for	O
some	O
future	O
clinical	B-MED
trial	I-MED
planning	B-MED
,	O
especially	O
for	O
the	O
oldest	B-MED
patients	B-MED
and	O
those	O
with	O
hor+	B-MED
breast	B-MED
cancer	I-MED
,	O
non-bcsd	B-MED
should	O
be	O
considered	O
a	O
competing	B-MED
risk	I-MED
event	I-MED
.	O
	
cancer	O
2017	O
.	O
	
2017	O
american	B-MED
cancer	I-MED
society	I-MED
.	O
	
hip	B-MED
segmentation	B-MED
from	O
mri	B-MED
volumes	O
in	O
infants	B-MED
for	O
ddh	B-MED
diagnosis	B-MED
and	O
treatment	B-MED
planning	I-MED
diagnosis	B-MED
and	O
surgical	B-MED
management	I-MED
of	O
developmental	B-MED
dysplasia	I-MED
of	I-MED
the	I-MED
hip	I-MED
ddh	B-MED
relies	O
on	O
physical	B-MED
examination	I-MED
and	O
2d	O
ultrasound	B-MED
scanning	I-MED
.	O
	
magnetic	B-MED
resonance	I-MED
imaging	I-MED
mri	B-MED
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	B-MED
and	O
could	O
be	O
advantageous	O
in	O
treatment	B-MED
planning	I-MED
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O
	
in	O
this	O
paper	O
we	O
propose	O
a	O
semi-automatic	B-MED
method	B-MED
to	O
segment	B-MED
surface	I-MED
models	I-MED
of	O
the	O
acetabulum	B-MED
from	O
mri	B-MED
images	B-MED
.	O
	
the	O
method	B-MED
incorporates	O
clinical	B-MED
knowledge	B-MED
in	O
the	O
form	O
of	O
intensity	B-MED
priors	I-MED
which	O
are	O
integrated	O
into	O
a	O
random	B-MED
walker	I-MED
rw	I-MED
formulation	I-MED
.	O
	
we	O
use	O
a	O
modified	B-MED
rw	B-MED
framework	O
which	O
compensates	B-MED
for	O
incomplete	B-MED
or	O
blurred	B-MED
boundaries	B-MED
in	O
the	O
image	B-MED
by	O
using	O
information	B-MED
from	O
neighboring	B-MED
slices	I-MED
in	O
the	O
sequence	B-MED
incorporated	O
as	O
node	B-MED
weights	I-MED
.	O
	
we	O
conducted	O
a	O
pilot	B-MED
study	I-MED
to	O
evaluate	B-MED
the	O
segmentation	B-MED
on	O
a	O
set	O
of	O
10	O
infant	B-MED
hip	B-MED
mri	B-MED
sequences	B-MED
using	O
a	O
1.5	O
tesla	O
mr	B-MED
scanner	I-MED
.	O
	
contours	B-MED
obtained	O
from	O
the	O
semi-automated	B-MED
segmentation	B-MED
were	O
compared	B-MED
against	O
manually	B-MED
segmented	B-MED
hip	B-MED
contours	B-MED
using	O
dice	B-MED
ratio	I-MED
dr	B-MED
,	O
hausdorff	B-MED
distance	I-MED
hd	B-MED
and	O
root	B-MED
mean	I-MED
square	I-MED
rms	B-MED
distance	O
.	O
	
the	O
proposed	O
method	B-MED
gave	O
values	O
of	O
dr	B-MED
=	O
0.84	O
0.5	O
,	O
hd	B-MED
=3	O
0.7	O
,	O
rms	B-MED
=1	O
0.3	O
and	O
dr	B-MED
=0	O
0.2	O
,	O
hd	B-MED
=3	O
0.1	O
,	O
rms	B-MED
=	O
2.0	O
0.6	O
for	O
right	B-MED
and	O
left	B-MED
acetabular	I-MED
contours	I-MED
respectively	O
which	O
was	O
higher	B-MED
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	B-MED
rw	B-MED
segmentation	B-MED
.	O
	
the	O
execution	B-MED
time	B-MED
of	O
the	O
segmentation	B-MED
algorithm	B-MED
was	O
less	O
than	O
4	O
seconds	B-MED
on	O
a	O
3.5	O
ghz	O
automated	O
basal	B-MED
cell	I-MED
carcinoma	I-MED
detection	O
in	O
high-definition	B-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
basal	B-MED
cell	I-MED
carcinoma	I-MED
bcc	B-MED
is	O
the	O
most	O
common	O
non-melanoma	B-MED
skin	I-MED
cancer	I-MED
.	O
	
conventional	O
diagnosis	O
of	O
bcc	B-MED
requires	O
invasive	B-MED
biopsies	B-MED
.	O
	
recently	O
,	O
a	O
high-definition	B-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
hd-oct	B-MED
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non-invasive	B-MED
in	B-MED
vivo	I-MED
imaging	I-MED
method	I-MED
of	O
skin	B-MED
.	O
	
good	O
agreements	O
of	O
bcc	B-MED
features	O
between	O
hd-oct	B-MED
images	B-MED
and	O
histopathological	B-MED
architecture	I-MED
have	O
been	O
found	O
.	O
	
therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
bcc	B-MED
using	O
hd-oct	B-MED
.	O
	
this	O
paper	O
presents	O
a	O
novel	O
bcc	B-MED
detection	B-MED
method	I-MED
that	O
consists	O
of	O
four	O
steps	O
graph	O
based	O
skin	B-MED
surface	I-MED
segmentation	B-MED
,	O
surface	B-MED
flattening	I-MED
,	O
deep	O
feature	O
extraction	O
and	O
the	O
bcc	B-MED
classification	O
.	O
	
the	O
effectiveness	B-MED
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5	O
images	O
.	O
	
it	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
fall	B-MED
risk	B-MED
factors	I-MED
analysis	B-MED
based	O
on	O
sample	B-MED
entropy	I-MED
of	O
plantar	B-MED
kinematic	B-MED
signal	B-MED
during	O
stance	B-MED
phase	I-MED
falls	B-MED
are	O
a	O
multi-causal	B-MED
phenomenon	I-MED
with	O
a	O
complex	B-MED
interaction	B-MED
.	O
	
the	O
aim	O
of	O
our	O
research	B-MED
is	O
to	O
study	B-MED
the	O
effect	B-MED
of	O
multiple	B-MED
variables	B-MED
for	O
potential	B-MED
risk	B-MED
of	I-MED
falls	I-MED
and	O
construct	B-MED
an	O
elderly	B-MED
fall	I-MED
risk	I-MED
assessment	I-MED
model	I-MED
based	O
on	O
demographics	B-MED
data	B-MED
and	O
gait	B-MED
characteristics	I-MED
.	O
	
a	O
total	O
of	O
101	O
subjects	B-MED
,	O
whom	O
belong	O
to	O
malianwa	B-MED
street	I-MED
,	O
aged	B-MED
above	O
50	O
years	B-MED
old	I-MED
and	O
participated	B-MED
in	O
questionnaire	B-MED
survey	B-MED
.	O
	
participants	B-MED
were	O
classified	O
into	O
three	O
groups	B-MED
high	B-MED
,	O
medium	B-MED
and	O
low	B-MED
risk	I-MED
group	B-MED
according	O
to	O
the	O
score	B-MED
of	O
elderly	B-MED
fall	I-MED
risk	I-MED
assessment	I-MED
scale	I-MED
.	O
	
in	O
addition	O
,	O
the	O
data	B-MED
of	O
ground	B-MED
reaction	I-MED
force	I-MED
grf	B-MED
and	O
ground	B-MED
reaction	I-MED
moment	I-MED
grm	B-MED
was	O
record	B-MED
when	O
they	O
performed	B-MED
walking	B-MED
at	O
comfortable	B-MED
state	I-MED
.	O
	
the	O
demographic	B-MED
variables	B-MED
,	O
sample	B-MED
entropy	I-MED
of	O
grf	B-MED
and	O
grm	B-MED
,	O
and	O
impulse	B-MED
difference	I-MED
of	O
bilateral	B-MED
foot	I-MED
were	O
considered	O
as	O
potential	B-MED
explanatory	B-MED
variables	B-MED
of	O
risk	B-MED
assessment	I-MED
model	B-MED
.	O
	
firstly	O
,	O
we	O
investigated	B-MED
whether	O
different	O
groups	B-MED
could	O
present	O
difference	B-MED
in	O
every	O
variable	B-MED
.	O
	
statistical	B-MED
differences	I-MED
were	O
found	B-MED
for	O
the	O
following	O
variables	B-MED
age	B-MED
p=2	O
impulse	B-MED
difference	I-MED
p=0	O
sample	B-MED
entropy	I-MED
of	O
grf	B-MED
in	O
vertical	B-MED
direction	B-MED
p=0	O
sample	B-MED
entropy	I-MED
of	O
grm	B-MED
in	O
anterior-posterior	B-MED
direction	B-MED
p=0	O
.	O
	
finally	O
,	O
the	O
multiple	B-MED
regression	B-MED
analysis	I-MED
results	B-MED
indicated	B-MED
that	O
age	B-MED
,	O
impulse	B-MED
difference	I-MED
and	O
sample	B-MED
entropy	I-MED
of	O
resultant	O
grm	B-MED
could	O
identify	O
individuals	B-MED
who	O
had	O
different	O
levels	B-MED
of	I-MED
fall	I-MED
risk	I-MED
.	O
	
therefore	O
,	O
those	O
results	B-MED
could	O
potentially	B-MED
be	O
useful	B-MED
in	O
the	O
fall	B-MED
risk	I-MED
assessment	I-MED
and	O
monitor	B-MED
the	O
state	B-MED
of	O
physical	B-MED
function	I-MED
in	O
elderly	B-MED
population	I-MED
.	O
	
endurance	B-MED
based	O
personalized	B-MED
fitness	I-MED
planner	I-MED
endurance	B-MED
is	O
an	O
important	B-MED
factor	B-MED
of	O
cardiovascular	B-MED
fitness	I-MED
indicating	O
the	O
capacity	B-MED
of	O
an	O
individual	B-MED
to	O
perform	B-MED
exercise	B-MED
for	O
a	O
longer	B-MED
duration	I-MED
with	O
increased	B-MED
intensity	B-MED
.	O
	
various	O
subject	B-MED
specific	I-MED
and	O
exercise	B-MED
related	O
parameters	B-MED
affect	O
endurance	B-MED
of	O
an	O
individual	B-MED
.	O
	
in	O
this	O
work	O
,	O
we	O
propose	O
a	O
statistical	B-MED
technique	I-MED
to	O
model	B-MED
endurance	B-MED
as	O
a	O
function	O
of	O
these	O
factors	B-MED
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	B-MED
generated	O
by	O
individuals	B-MED
over	B-MED
time	I-MED
.	O
	
the	O
proposed	B-MED
model	B-MED
provides	O
a	O
device	B-MED
to	O
predict	O
future	O
endurance	B-MED
of	O
a	O
test	O
subject	B-MED
following	O
particular	O
exercise	B-MED
regime	I-MED
.	O
	
this	O
facilitates	O
a	O
test	B-MED
user	I-MED
with	O
a	O
fitness	B-MED
planner	I-MED
with	O
the	O
provision	O
to	O
fix	O
exercise	B-MED
regimes	I-MED
to	O
reach	O
a	O
set	O
fitness	B-MED
goal	B-MED
.	O
	
heart	B-MED
rate	I-MED
variability	B-MED
as	O
a	O
biomarker	B-MED
for	O
sedation	B-MED
depth	I-MED
estimation	B-MED
in	O
icu	B-MED
patients	B-MED
an	O
automated	B-MED
patient-specific	I-MED
system	I-MED
to	O
classify	O
the	O
level	B-MED
of	I-MED
sedation	I-MED
in	O
icu	B-MED
patients	B-MED
using	O
heart	B-MED
rate	I-MED
variability	B-MED
signal	B-MED
is	O
presented	B-MED
in	O
this	O
paper	B-MED
.	O
	
ecg	B-MED
from	O
70	O
mechanically	B-MED
ventilated	I-MED
adult	B-MED
patients	B-MED
with	O
administered	B-MED
sedatives	B-MED
in	O
an	O
icu	B-MED
setting	I-MED
were	O
used	O
to	O
develop	O
a	O
support	B-MED
vector	I-MED
machine	I-MED
based	O
system	O
for	O
sedation	B-MED
depth	I-MED
monitoring	B-MED
using	O
several	O
heart	B-MED
rate	I-MED
variability	B-MED
measures	B-MED
.	O
	
a	O
leave-one-subject-out	B-MED
cross	I-MED
validation	I-MED
was	O
used	O
for	O
classifier	B-MED
training	B-MED
and	O
performance	B-MED
evaluations	B-MED
.	O
	
the	O
proposed	O
patient-specific	B-MED
system	I-MED
provided	B-MED
a	O
sensitivity	B-MED
,	O
specificity	B-MED
and	O
an	O
auc	B-MED
of	O
64%	O
,	O
84.8	O
and	O
0.72	O
,	O
respectively	O
.	O
	
it	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	B-MED
signals	B-MED
the	O
proposed	O
patient	B-MED
-	O
specific	B-MED
sedation	B-MED
level	I-MED
prediction	B-MED
system	B-MED
could	O
lead	O
to	O
a	O
fully	O
automated	B-MED
multimodal	I-MED
system	I-MED
to	O
assist	O
clinical	B-MED
staff	B-MED
in	O
icus	B-MED
to	O
interpret	B-MED
the	O
sedation	B-MED
level	I-MED
of	O
the	O
reliability	B-MED
and	I-MED
validity	I-MED
of	O
the	O
diabetes	B-MED
eating	I-MED
problem	I-MED
survey-revised	I-MED
on	O
turkish	B-MED
children	B-MED
and	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
examine	B-MED
the	O
reliability	B-MED
and	I-MED
validity	I-MED
of	O
turkish	B-MED
version	B-MED
of	O
diabetes	B-MED
eating	I-MED
problem	I-MED
survey-revised	I-MED
deps-r	B-MED
for	O
children	B-MED
and	O
adolescent	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
.	O
	
a	O
total	O
of	O
200	O
children	B-MED
and	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
,	O
ages	B-MED
9-18	O
years	B-MED
,	O
completed	O
the	O
deps-r	B-MED
turkish	B-MED
version	B-MED
.	O
	
in	O
addition	O
to	O
tests	B-MED
of	O
validity	B-MED
,	O
confirmatory	B-MED
factor	I-MED
analysis	I-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
factor	B-MED
structure	I-MED
of	O
the	O
16-item	O
turkish	B-MED
version	B-MED
of	O
deps-r	B-MED
.	O
	
the	O
turkish	B-MED
version	B-MED
of	O
deps-r	B-MED
demonstrated	O
satisfactory	B-MED
cronbach's	B-MED
0.847	O
and	O
was	O
significantly	O
correlated	B-MED
with	O
ag	B-MED
e	O
r=0	O
p<0	O
,	O
hemoglobin	B-MED
a1c	I-MED
levels	I-MED
r=0	O
p<0	O
and	O
bmi	B-MED
-	O
sds	B-MED
r=0	O
p<0	O
indicating	O
criterion	B-MED
validity	I-MED
.	O
	
median	O
deps-r	B-MED
scores	B-MED
of	O
turkish	B-MED
version	B-MED
for	O
the	O
total	O
samples	B-MED
,	O
females	B-MED
and	O
males	B-MED
were	O
as	O
follows	O
11.0	O
,	O
11.5	O
and	O
10.5	O
respectively	O
.	O
	
disturbed	B-MED
eating	I-MED
behaviors	I-MED
and	O
insulin	B-MED
restriction	B-MED
were	O
associated	O
with	O
poor	O
metabolic	B-MED
control	I-MED
.	O
	
a	O
short	O
,	O
self-administered	B-MED
diabetes	B-MED
specific	O
screening	B-MED
tool	O
for	O
disordered	B-MED
eating	I-MED
behavior	I-MED
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	B-MED
care	B-MED
of	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
.	O
	
the	O
turkish	B-MED
version	B-MED
of	O
deps-r	B-MED
is	O
a	O
valid	O
screening	B-MED
tool	O
for	O
disordered	B-MED
eating	I-MED
behaviors	I-MED
in	O
type	B-MED
1	I-MED
diabetes	I-MED
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered	B-MED
eating	I-MED
behaviors	I-MED
.	O
	
a	O
comparison	B-MED
of	O
the	O
localization	B-MED
of	O
rectal	B-MED
carcinomas	I-MED
according	O
to	O
the	O
general	B-MED
rules	B-MED
of	O
the	O
japanese	B-MED
classification	I-MED
of	I-MED
colorectal	I-MED
carcinoma	I-MED
jccrc	B-MED
and	O
western	B-MED
guidelines	B-MED
the	O
aim	B-MED
of	O
this	O
study	O
was	O
to	O
compare	B-MED
the	O
localization	B-MED
of	O
rectal	B-MED
cancers	I-MED
as	O
classified	B-MED
according	O
to	O
the	O
general	B-MED
rules	B-MED
of	O
the	O
japanese	B-MED
classification	I-MED
of	I-MED
colorectal	I-MED
carcinoma	I-MED
jccrc	B-MED
and	O
also	O
according	O
to	O
the	O
european	B-MED
society	I-MED
for	I-MED
medical	I-MED
oncology	I-MED
esmo	B-MED
and	O
the	O
national	B-MED
comprehensive	I-MED
cancer	I-MED
network	I-MED
nccn	B-MED
guidelines	B-MED
,	O
which	O
are	O
based	O
on	O
rigid	B-MED
endoscopic	I-MED
measurements	B-MED
.	O
	
the	O
medical	B-MED
records	I-MED
of	O
patients	B-MED
scheduled	B-MED
to	O
receive	B-MED
curative	B-MED
surgery	I-MED
for	O
histologically	B-MED
proven	O
rectal	B-MED
adenocarcinoma	I-MED
during	B-MED
2009-2015	O
were	O
investigated	B-MED
n	O
=	O
230	O
.	O
	
rigid	B-MED
proctoscopy	I-MED
was	O
performed	B-MED
in	O
patients	B-MED
with	O
rectal	B-MED
cancer	I-MED
located	B-MED
in	I-MED
the	O
upper	B-MED
ra	B-MED
or	O
lower	B-MED
rb	B-MED
division	B-MED
using	O
double-contrast	B-MED
barium	I-MED
enema	I-MED
.	O
	
the	O
median	B-MED
values	O
of	O
height	B-MED
from	O
the	O
anal	B-MED
verge	I-MED
were	O
7.5	O
cm	O
range	B-MED
2-12	O
and	O
3	O
cm	O
0-9	O
on	O
rigid	B-MED
proctoscopy	I-MED
for	O
cancers	B-MED
assigned	B-MED
as	O
ra	B-MED
and	O
rb	B-MED
,	O
respectively	O
.	O
	
all	O
159	O
cancers	B-MED
at	O
ra	B-MED
or	O
rb	B-MED
were	O
located	B-MED
within	B-MED
12	O
cm	O
from	O
the	O
anal	B-MED
verge	I-MED
by	O
rigid	B-MED
proctoscopy	I-MED
,	O
while	O
only	O
79.7	O
of	O
ra	B-MED
or	O
82.1	O
of	O
rb	B-MED
cancers	B-MED
were	O
located	B-MED
in	I-MED
the	O
mid	B-MED
5.1	O
cm	O
or	O
low	B-MED
5	O
cm	O
rectum	B-MED
,	O
respectively	O
.	O
	
ra	B-MED
and	O
rb	B-MED
cancers	B-MED
are	O
deemed	O
to	O
be	O
rectal	B-MED
cancers	I-MED
according	O
to	O
nccn	B-MED
guidelines	B-MED
,	O
but	O
these	O
classifications	B-MED
are	O
not	O
interchangeable	O
with	O
mid-	B-MED
and	O
low	B-MED
-	O
rectal	B-MED
cancers	I-MED
,	O
respectively	O
,	O
according	O
to	O
the	O
esmo	B-MED
guidelines	B-MED
.	O
	
natural	B-MED
orifice	I-MED
transluminal	I-MED
endoscopic	I-MED
surgery	I-MED
with	O
a	O
snake-mechanism	B-MED
using	O
a	O
movable	B-MED
pulley	I-MED
natural	B-MED
orifice	I-MED
transluminal	I-MED
endoscopic	I-MED
surgery	I-MED
is	O
an	O
emerging	O
technique	B-MED
.	O
	
we	O
aimed	O
to	O
develop	B-MED
an	O
advanced	B-MED
surgical	B-MED
robot	I-MED
mechanism	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
	
we	O
propose	O
the	O
active-controlled	B-MED
overtube-type	I-MED
platform	I-MED
with	O
multiple	O
channels	B-MED
for	O
an	O
endoscopic	B-MED
camera	I-MED
and	O
surgical	B-MED
tools	B-MED
.	O
	
to	O
make	O
such	O
a	O
platform	B-MED
,	O
we	O
suggest	B-MED
an	O
advanced	B-MED
snake	B-MED
mechanism	I-MED
comprising	O
movable	B-MED
pulleys	I-MED
to	O
make	O
a	O
snake	B-MED
mechanism	I-MED
with	O
multiple	O
degrees	B-MED
of	I-MED
freedom	I-MED
and	O
high	O
operating	O
force	O
.	O
	
the	O
stiffness	B-MED
and	O
maneuverability	B-MED
of	O
the	O
active-controlled	B-MED
platform	I-MED
appeared	O
satisfactory	B-MED
.	O
	
using	O
prototypes	B-MED
and	O
ex	B-MED
vivo	I-MED
experiments	B-MED
,	O
we	O
confirmed	O
that	O
the	O
mechanism	B-MED
was	O
suitable	O
for	O
a	O
snake-like	B-MED
robotic	I-MED
platform	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
	
the	O
suggested	B-MED
snake	B-MED
mechanism	I-MED
using	O
movable	B-MED
pulleys	I-MED
has	O
the	O
advantages	O
of	O
stiffness	B-MED
and	O
maneuverability	B-MED
.	O
	
this	O
new	O
mechanism	B-MED
can	O
be	O
an	O
alternative	B-MED
platform	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
	
real	O
role	O
of	O
β-blockers	B-MED
in	O
regression	B-MED
of	O
left	B-MED
ventricular	I-MED
mass	I-MED
in	O
hypertension	B-MED
patients	B-MED
bayesian	B-MED
network	I-MED
meta-analysis	B-MED
left	B-MED
ventricular	I-MED
hypertrophy	I-MED
lvh	B-MED
is	O
commonly	O
present	O
in	O
patients	B-MED
with	O
hypertension	B-MED
ht	B-MED
.	O
	
according	O
to	O
the	O
expert	B-MED
consensus	I-MED
document	I-MED
from	O
american	B-MED
,	O
angiotensin-converting	B-MED
enzyme	I-MED
inhibitor	I-MED
acei	B-MED
and	O
angiotensin	B-MED
receptor	I-MED
blockers	I-MED
arbs	B-MED
were	O
recommended	O
as	O
1st-line	O
therapeutic	B-MED
drugs	I-MED
.	O
	
however	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	B-MED
between	O
fat-soluble	B-MED
and	I-MED
selective	I-MED
β1-receptor	I-MED
blockers	I-MED
fs-β-b	B-MED
and	O
other	O
β-blockers	B-MED
on	O
regression	B-MED
of	O
lvh	B-MED
before	O
.	O
	
the	O
aim	O
of	O
this	O
analysis	B-MED
was	O
to	O
compare	B-MED
the	O
efficacy	B-MED
of	O
fs-β-b	B-MED
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B-MED
drugs	I-MED
acei	B-MED
,	O
arbs	B-MED
,	O
calcium	B-MED
channel	I-MED
blockers	I-MED
ccbs	B-MED
,	O
and	O
diuretics	B-MED
on	O
regression	B-MED
of	O
lvh	B-MED
.	O
	
relative	B-MED
trials	B-MED
were	O
identified	O
in	O
the	O
pubmed	B-MED
,	O
web	B-MED
of	I-MED
science	I-MED
,	O
ovid	B-MED
ebm	I-MED
reviews	I-MED
and	O
cochrane	B-MED
databases	I-MED
,	O
and	O
the	O
relevant	O
papers	B-MED
were	O
examined	B-MED
.	O
	
we	O
performed	O
both	O
traditional	O
and	O
bayesian	B-MED
meta-analysis	B-MED
of	O
randomized	B-MED
controlled	I-MED
trials	I-MED
rcts	B-MED
about	O
the	O
regression	B-MED
of	O
lvh	B-MED
.	O
	
sensitivity	B-MED
analysis	I-MED
and	O
regression	B-MED
analysis	I-MED
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	B-MED
.	O
	
inconsistency	B-MED
analysis	I-MED
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B-MED
of	O
the	O
trials	B-MED
in	O
the	O
network	B-MED
was	O
indeed	O
consistent	B-MED
.	O
	
a	O
total	O
of	O
41	O
rcts	B-MED
involving	O
2566	O
patients	B-MED
with	O
ht	B-MED
and	O
lvh	B-MED
were	O
included	O
in	O
this	O
analysis	B-MED
.	O
	
bayesian	B-MED
network	I-MED
meta-analysis	B-MED
indicated	O
no	O
statistically	B-MED
significant	I-MED
differences	O
between	O
these	O
groups	B-MED
fs-β-b	B-MED
and	O
acei	B-MED
md	O
,	O
-7	O
95%	O
ci	B-MED
,	O
-14	O
,	O
1.27	O
fs-β-b	B-MED
and	O
arb	B-MED
md	O
,	O
-2	O
95%	O
cl	B-MED
,	O
-12	O
,	O
6.31	O
.	O
	
although	O
fs-β-b	B-MED
showed	O
greater	O
efficacy	B-MED
when	O
compared	B-MED
with	O
diuretic	B-MED
md	O
,	O
13.04	O
95%	O
ci	B-MED
,	O
3.38	O
,	O
22.59	O
or	O
ccb	B-MED
md	O
,	O
10.90	O
95%	O
ci	B-MED
,	O
1.98	O
,	O
19.49	O
.	O
	
the	O
probabilities	B-MED
of	O
being	O
among	O
the	O
most	O
efficacious	B-MED
treatments	B-MED
were	O
fs-β-b	B-MED
72%	O
,	O
arb	B-MED
27%	O
,	O
acei	B-MED
0.01	O
,	O
ccb	B-MED
0.00	O
,	O
and	O
diuretic	B-MED
0.00	O
.	O
	
evidence	O
from	O
our	O
analysis	B-MED
reveals	O
that	O
fs-β-b	B-MED
have	O
potential	O
to	O
become	O
1st-line	O
therapeutic	B-MED
drugs	I-MED
in	O
ht	B-MED
and	O
lvh	B-MED
patients	B-MED
.	O
	
however	O
,	O
the	O
real	O
efficacy	B-MED
of	O
fs-β-b	B-MED
on	O
regression	B-MED
of	O
lvh	B-MED
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	B-MED
trials	B-MED
improved	B-MED
risk	B-MED
stratification	B-MED
for	O
patients	B-MED
with	O
high-grade	O
urothelial	B-MED
carcinoma	I-MED
following	O
application	O
of	O
the	O
paris	B-MED
system	B-MED
for	O
reporting	B-MED
urinary	B-MED
cytology	I-MED
the	O
paris	B-MED
system	B-MED
for	O
reporting	B-MED
urinary	B-MED
cytology	I-MED
tps	B-MED
requires	O
4	O
cytomorphologic	B-MED
criteria	B-MED
for	O
a	O
definitive	O
diagnosis	B-MED
of	O
high-grade	B-MED
urothelial	I-MED
carcinoma	I-MED
hguc	B-MED
in	O
urinary	B-MED
tract	I-MED
cytology	I-MED
utc	B-MED
specimens	B-MED
an	O
elevated	B-MED
nuclear-to-cytoplasmic	B-MED
n/c	I-MED
ratio	I-MED
at	O
or	O
above	O
0.7	O
,	O
markedly	O
atypical	B-MED
nuclear	B-MED
borders	B-MED
,	O
moderate	B-MED
to	O
severe	B-MED
hyperchromasia	B-MED
,	O
and	O
coarse	B-MED
chromatin	I-MED
.	O
	
however	O
,	O
malignant	B-MED
utc	B-MED
specimens	B-MED
often	O
contain	O
degenerative	B-MED
changes	B-MED
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	B-MED
cells	I-MED
meeting	O
all	O
4	O
tps	B-MED
cytomorphologic	B-MED
criteria	B-MED
.	O
	
one	O
hundred	O
twelve	O
utc	B-MED
specimens	B-MED
from	O
patients	B-MED
with	O
a	O
subsequent	O
diagnosis	B-MED
of	O
hguc	B-MED
were	O
reviewed	B-MED
and	O
reclassified	B-MED
according	O
to	O
tps	B-MED
criteria	B-MED
.	O
	
the	O
presence	B-MED
of	O
tps	B-MED
cytomorphologic	B-MED
criteria	B-MED
for	O
hguc	B-MED
in	O
each	O
specimen	B-MED
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	B-MED
cells	B-MED
meeting	O
all	O
4	O
criteria	B-MED
.	O
	
the	O
number	O
of	O
specimens	B-MED
definitively	O
diagnosed	B-MED
as	O
hguc	B-MED
did	O
not	O
significantly	B-MED
change	B-MED
upon	O
reclassification	B-MED
.	O
	
however	O
,	O
approximately	B-MED
40%	O
of	O
indeterminate	B-MED
specimens	B-MED
21	O
of	O
51	O
were	O
reclassified	B-MED
into	O
a	O
higher	O
risk	B-MED
category	B-MED
.	O
	
the	O
most	O
restrictive	O
cytomorphologic	B-MED
criterion	O
was	O
an	O
n/c	B-MED
ratio	I-MED
of	O
0.7	O
or	O
higher	O
seen	O
in	O
78%	O
of	O
specimens	B-MED
,	O
and	O
approximately	B-MED
half	O
of	O
specimens	B-MED
containing	O
all	O
4	O
cytomorphologic	O
criteria	O
did	O
not	O
meet	O
tps	O
's	O
numerical	O
criterion	O
for	O
hguc	O
at	O
least	O
5	O
malignant	O
cells	O
.	O
	
in	O
the	O
majority	O
of	O
specimens	B-MED
qualifying	O
for	O
hguc	O
by	O
tps	O
standards	O
,	O
only	O
a	O
small	O
fraction	O
of	O
atypical	O
cells	O
10%-20%	O
met	O
all	O
the	O
criteria	O
.	O
	
when	O
applied	O
to	O
malignant	O
utc	O
specimens	O
,	O
tps	O
criteria	O
improved	O
specimen	O
risk	O
stratification	O
by	O
upgrading	O
approximately	O
40%	O
of	O
indeterminate	O
specimens	O
into	O
higher	O
risk	O
categories	O
while	O
not	O
significantly	O
changing	O
the	O
frequency	O
of	O
hguc	O
diagnoses	O
.	O
	
cancer	O
cytopathol	O
2017	O
.	O
	
2017	O
american	O
cancer	O
society	I-MED
questionable	O
diagnostic	B-MED
benefit	B-MED
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B-MED
venom	I-MED
components	B-MED
for	O
many	O
years	B-MED
,	O
only	O
the	O
major	O
allergen	B-MED
rapi	B-MED
m	I-MED
1	I-MED
has	O
been	O
available	O
on	O
the	O
immunocap	B-MED
system	I-MED
for	O
routine	O
diagnosis	B-MED
of	O
bee	B-MED
venom	I-MED
bv	I-MED
allergy	I-MED
.	O
	
now	O
,	O
there	O
are	O
five	O
components	B-MED
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
rapi	B-MED
m	I-MED
1	I-MED
,	O
2	B-MED
,	O
3	B-MED
,	O
5	B-MED
,	O
and	O
10	B-MED
in	O
bv-allergic	B-MED
patients	B-MED
.	O
	
we	O
further	O
evaluated	O
the	O
sensitivity	B-MED
of	O
rapi	B-MED
m	I-MED
1	I-MED
and	O
2	B-MED
of	O
an	O
alternative	O
platform	O
and	O
investigated	B-MED
possible	O
differences	O
in	O
the	O
sensitization	B-MED
profile	O
between	O
monosensitization	B-MED
and	O
clinically	O
relevant	O
double	B-MED
sensitization	I-MED
.	O
	
analysis	B-MED
of	O
the	O
whole	O
panel	O
of	O
bv	B-MED
allergens	B-MED
of	O
the	O
cap	B-MED
system	I-MED
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	B-MED
than	O
analysis	B-MED
of	O
the	O
combination	O
of	O
rapi	B-MED
m	I-MED
1	I-MED
and	O
2	B-MED
of	O
the	O
immulite	B-MED
71.6	O
vs	O
85.8	O
.	O
	
sensitization	B-MED
rate	B-MED
of	O
rapi	B-MED
m	I-MED
5	I-MED
was	O
more	O
than	O
doubled	O
in	O
double-sensitized	B-MED
patients	B-MED
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rapi	B-MED
m	I-MED
2	I-MED
.	O
	
the	O
benefit	B-MED
of	O
the	O
commercially	O
available	O
panel	O
of	O
bv	B-MED
components	B-MED
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	B-MED
sensitivity	B-MED
and	O
still	O
unavailable	O
important	O
cross-reacting	B-MED
allergens	B-MED
.	O
	
orai1	B-MED
-mediated	O
antimicrobial	B-MED
secretion	B-MED
from	O
pancreatic	B-MED
acini	I-MED
shapes	O
the	O
gut	B-MED
microbiome	I-MED
and	O
regulates	B-MED
gut	B-MED
innate	B-MED
immunity	I-MED
the	O
gut	B-MED
microbiome	I-MED
participates	O
in	O
numerous	O
physiologic	B-MED
functions	I-MED
and	O
communicates	B-MED
intimately	O
with	O
the	O
host	B-MED
immune	B-MED
system	I-MED
.	O
	
antimicrobial	B-MED
peptides	I-MED
are	O
critica	B-MED
l	O
components	B-MED
of	O
intestinal	B-MED
innate	B-MED
immunity	I-MED
.	O
	
we	O
report	O
a	O
prominent	B-MED
role	O
for	O
antimicrobials	B-MED
secreted	I-MED
by	O
pancreatic	B-MED
acini	I-MED
in	O
shaping	O
the	O
gut	B-MED
microbiome	I-MED
that	O
is	O
essential	O
for	O
intestinal	B-MED
innate	B-MED
immunity	I-MED
,	O
barrier	B-MED
function	I-MED
,	O
and	O
survival	B-MED
.	O
	
deletion	B-MED
of	O
the	O
ca	B-MED
channel	I-MED
orai1	I-MED
in	O
pancreatic	B-MED
acini	I-MED
of	O
adult	O
mice	B-MED
resulted	O
in	O
60%-70%	O
mortality	B-MED
within	O
3	O
weeks	O
.	O
	
despite	O
robust	O
activation	B-MED
of	I-MED
the	I-MED
intestinal	I-MED
innate	I-MED
immune	I-MED
response	I-MED
,	O
mice	B-MED
lacking	O
acinar	B-MED
orai1	B-MED
exhibited	O
intestinal	B-MED
bacterial	B-MED
outgrowth	B-MED
and	O
dysbiosis	B-MED
,	O
ultimately	O
causing	O
systemic	B-MED
translocation	B-MED
,	O
inflammation	B-MED
,	O
and	O
death	B-MED
.	O
	
while	O
digestive	B-MED
enzyme	I-MED
supplementation	B-MED
was	O
ineffective	B-MED
,	O
treatments	B-MED
constraining	O
bacterial	B-MED
outgrowth	B-MED
purified	B-MED
liquid	B-MED
diet	I-MED
,	O
broad-spectrum	B-MED
antibiotics	I-MED
rescued	O
survival	B-MED
,	O
feeding	B-MED
,	O
and	O
weight	B-MED
gain	I-MED
.	O
	
pancreatic	B-MED
levels	I-MED
of	O
cathelicidin	B-MED
-related	O
antimicrobial	B-MED
peptide	I-MED
cramp	B-MED
were	O
reduced	B-MED
,	O
and	O
supplement	B-MED
of	O
synthetic	O
cramp	B-MED
prevented	O
intestinal	B-MED
disease	I-MED
.	O
	
these	O
findings	B-MED
reveal	O
a	O
critical	B-MED
role	O
for	O
antimicrobial	B-MED
pancreatic	B-MED
secretion	I-MED
in	O
gut	B-MED
innate	B-MED
immunity	I-MED
.	O
	
palliative	B-MED
care	I-MED
with	O
attachment	B-MED
hybrid	B-MED
removable	I-MED
prosthesis	I-MED
abutment	B-MED
injury	B-MED
,	O
unsatisfactory	B-MED
aesthetics	B-MED
and	O
lesser	O
retention	B-MED
exist	O
with	O
the	O
cast	B-MED
partial	I-MED
denture	I-MED
.	O
	
though	O
these	O
constraints	O
exist	O
in	O
the	O
removable	B-MED
partial	I-MED
denture	I-MED
rpd	B-MED
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-MED
,	O
fabrication	B-MED
,	O
economics	B-MED
and	O
patient	B-MED
comfort	I-MED
.	O
	
this	O
clinical	B-MED
report	I-MED
describes	O
a	O
hybrid	O
rpd	B-MED
technique	B-MED
which	O
uses	O
extra	O
coronal	B-MED
attachment	B-MED
that	O
reduces	B-MED
the	O
limitations	O
and	O
provides	O
better	O
comfort	B-MED
for	O
the	O
cxcl5	B-MED
plays	O
a	O
promoting	O
role	O
in	O
osteosarcoma	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
in	O
autocrine	B-MED
-	O
and	O
paracrine	B-MED
-dependent	O
manners	O
cxcl5	B-MED
,	O
a	O
cxc-type	B-MED
chemokine	I-MED
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic	B-MED
immune	I-MED
cells	I-MED
by	O
binding	B-MED
to	I-MED
its	I-MED
receptor	I-MED
cxcr2	I-MED
.	O
	
recently	O
,	O
cxcl5	B-MED
/	O
cxcr2	B-MED
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	B-MED
role	O
in	O
many	O
human	B-MED
cancers	B-MED
.	O
	
however	O
,	O
the	O
exact	O
role	O
of	O
cxcl5	B-MED
in	O
osteosarcoma	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
has	O
not	O
been	O
revealed	O
.	O
	
here	O
we	O
found	O
that	O
the	O
protein	B-MED
expression	I-MED
of	O
cxcl5	B-MED
was	O
significantly	O
increased	B-MED
in	O
osteosarcoma	B-MED
tissues	B-MED
compared	O
with	O
that	O
in	O
matched	B-MED
adjacent	I-MED
nontumor	I-MED
tissues	I-MED
.	O
	
moreover	O
,	O
the	O
expression	B-MED
of	O
cxcl5	B-MED
was	O
significantly	O
associated	O
with	O
advanced	B-MED
clinical	I-MED
stage	I-MED
and	O
metastasis	B-MED
.	O
	
further	O
investigation	O
showed	O
that	O
the	O
cxcl5	B-MED
expression	B-MED
levels	I-MED
were	O
also	O
significantly	O
increased	B-MED
in	O
osteosarcoma	B-MED
cell	B-MED
lines	I-MED
,	O
including	O
saos-2	B-MED
,	O
mg63	B-MED
,	O
u2os	B-MED
,	O
and	O
sw1353	B-MED
,	O
when	O
compared	O
with	O
those	O
in	O
normal	B-MED
osteoblast	I-MED
hfob1.19	B-MED
cells	I-MED
.	O
	
u2os	B-MED
cells	I-MED
were	O
further	O
transfected	B-MED
with	O
cxcl5	B-MED
-	O
specific	B-MED
sirna	I-MED
or	O
overexpression	B-MED
plasmid	B-MED
.	O
	
knockdown	B-MED
of	O
cxcl5	B-MED
significantly	O
suppressed	B-MED
u2os	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
.	O
	
on	O
the	O
contrary	O
,	O
overexpression	B-MED
of	O
cxlc5	B-MED
remarkably	O
promoted	O
the	O
migration	B-MED
and	I-MED
invasion	I-MED
of	O
u2os	B-MED
cells	I-MED
.	O
	
interestingly	O
,	O
both	O
exogenous	B-MED
cxcl5	B-MED
treatment	B-MED
and	O
the	O
conditioned	O
medium	O
of	O
cxcl5	B-MED
-	O
overexpressing	B-MED
hfob1.19	B-MED
cells	I-MED
could	O
also	O
enhance	O
the	O
migration	B-MED
and	I-MED
invasion	I-MED
of	O
u2os	B-MED
cells	I-MED
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
cxcl5	B-MED
in	O
u2os	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
is	O
also	O
in	O
a	O
paracrine	B-MED
-dependent	O
manner	O
.	O
	
according	O
to	O
these	O
data	O
,	O
our	O
study	O
demonstrates	O
that	O
cxcl5	B-MED
is	O
upregulated	O
in	O
osteosarcoma	B-MED
and	O
may	O
play	O
an	O
oncogenic	B-MED
role	O
in	O
osteosarcoma	B-MED
metastasis	B-MED
.	O
	
therefore	O
,	O
cxcl5	B-MED
may	O
become	O
a	O
potential	B-MED
therapeutic	B-MED
target	I-MED
for	O
osteosarcoma	B-MED
treatment	B-MED
.	O
	
integrating	B-MED
molecular	B-MED
qtl	B-MED
data	B-MED
into	O
genome-wide	B-MED
genetic	I-MED
association	I-MED
analysis	I-MED
probabilistic	B-MED
assessment	B-MED
of	O
enrichment	B-MED
and	O
colocalization	B-MED
we	O
propose	O
a	O
novel	O
statistical	B-MED
framework	I-MED
for	O
integrating	B-MED
the	O
result	B-MED
from	O
molecular	B-MED
quantitative	B-MED
trait	I-MED
loci	I-MED
qtl	B-MED
mapping	B-MED
into	O
genome-wide	B-MED
genetic	I-MED
association	I-MED
analysis	I-MED
of	O
complex	B-MED
traits	B-MED
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	B-MED
assessing	B-MED
the	O
enrichment	B-MED
of	O
the	O
molecular	B-MED
qtls	B-MED
in	O
complex	B-MED
trait	B-MED
-	O
associated	B-MED
genetic	B-MED
variants	I-MED
and	O
the	O
colocalizations	B-MED
of	O
the	O
two	O
types	B-MED
of	O
association	B-MED
signals	B-MED
.	O
	
we	O
introduce	O
a	O
natural	B-MED
bayesian	I-MED
hierarchical	I-MED
model	I-MED
that	O
treats	O
the	O
latent	O
association	B-MED
status	O
of	O
molecular	B-MED
qtls	B-MED
as	O
snp	B-MED
-	O
level	B-MED
annotations	O
for	O
candidate	O
snps	B-MED
of	O
complex	B-MED
traits	B-MED
.	O
	
we	O
detail	O
a	O
computational	B-MED
procedure	B-MED
to	O
seamlessly	O
perform	O
enrichment	B-MED
,	O
fine-mapping	B-MED
and	O
colocalization	B-MED
analyses	B-MED
,	O
which	O
is	O
a	O
distinct	B-MED
feature	I-MED
compared	B-MED
to	O
the	O
existing	O
colocalization	B-MED
analysis	B-MED
procedures	B-MED
in	O
the	O
literature	B-MED
.	O
	
the	O
proposed	O
approach	B-MED
is	O
computationally	B-MED
efficient	B-MED
and	O
requires	O
only	O
summary	B-MED
-	O
level	B-MED
statistics	B-MED
.	O
	
we	O
evaluate	B-MED
and	O
demonstrate	O
the	O
proposed	O
computational	B-MED
approach	B-MED
through	O
extensive	B-MED
simulation	B-MED
studies	B-MED
and	O
analyses	B-MED
of	O
blood	B-MED
lipid	I-MED
data	B-MED
and	O
the	O
whole	B-MED
blood	I-MED
eqtl	B-MED
data	B-MED
from	O
the	O
gtex	B-MED
project	I-MED
.	O
	
in	O
addition	O
,	O
a	O
useful	O
utility	B-MED
from	O
our	O
proposed	O
method	B-MED
enables	O
the	O
computation	B-MED
of	O
expected	O
colocalization	B-MED
signals	B-MED
using	O
simple	O
characteristics	B-MED
of	O
the	O
association	B-MED
data	B-MED
.	O
	
using	O
this	O
utility	B-MED
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	B-MED
analysis	B-MED
on	O
the	O
ability	O
to	O
discover	O
colocalized	B-MED
signals	B-MED
and	O
the	O
potential	B-MED
limitations	B-MED
of	O
currently	O
available	O
molecular	B-MED
qtl	B-MED
data	B-MED
.	O
	
the	O
software	B-MED
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	B-MED
procedures	B-MED
,	O
enloc	B-MED
,	O
is	O
freely	O
available	O
at	O
engineering	B-MED
the	O
ribosomal	B-MED
dna	I-MED
in	O
a	O
megabase	B-MED
synthetic	I-MED
chromosome	I-MED
we	O
designed	O
and	O
synthesized	O
a	O
976	B-MED
pair	I-MED
linear	I-MED
chromosome	I-MED
,	O
synxii	B-MED
,	O
based	O
on	O
native	O
chromosome	B-MED
xii	I-MED
in	O
saccharomyces	B-MED
cerevisiae	I-MED
synxii	B-MED
was	O
assembled	O
using	O
a	O
two-step	B-MED
method	I-MED
,	O
specified	O
by	O
successive	O
megachunk	B-MED
integration	I-MED
and	O
meiotic	B-MED
recombination-mediated	I-MED
assembly	I-MED
,	O
producing	O
a	O
functional	B-MED
chromosome	B-MED
in	O
s	B-MED
.	O
	
cerevisiae	I-MED
.	O
	
minor	B-MED
growth	I-MED
defect	I-MED
""""	O
bugs	B-MED
""""	O
detected	B-MED
in	O
synxii	B-MED
,	O
caused	O
by	O
deletion	B-MED
of	O
trna	B-MED
genes	B-MED
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic	B-MED
copy	I-MED
of	O
a	O
single	B-MED
trna	I-MED
gene	B-MED
.	O
	
the	O
ribosomal	B-MED
gene	I-MED
cluster	I-MED
rdna	B-MED
on	O
synxii	B-MED
was	O
left	O
intact	O
during	O
the	O
assembly	B-MED
process	I-MED
and	O
subsequently	O
replaced	O
by	O
a	O
modified	B-MED
rdna	B-MED
unit	O
used	O
to	O
regenerate	B-MED
rdna	B-MED
at	O
three	O
distinct	O
chromosomal	B-MED
locations	I-MED
.	O
	
the	O
signature	O
sequences	B-MED
within	O
rdna	B-MED
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	B-MED
identity	B-MED
,	O
were	O
swapped	O
to	O
generate	O
a	O
saccharomyces	B-MED
synxii	B-MED
strain	B-MED
that	O
would	O
be	O
identified	B-MED
as	O
saccharomyces	B-MED
bayanus	I-MED
by	O
standard	B-MED
reversible	O
humidity	B-MED
sensitive	B-MED
clothing	B-MED
for	O
personal	B-MED
thermoregulation	I-MED
two	O
kinds	O
of	O
humidity	B-MED
-	O
induced	B-MED
,	O
bendable	O
smart	B-MED
clothing	I-MED
have	O
been	O
designed	B-MED
to	I-MED
reversibly	I-MED
adapt	I-MED
their	O
thermal	B-MED
insulation	I-MED
functionality	I-MED
.	O
	
the	O
first	O
design	O
mimics	O
the	O
pores	B-MED
in	O
human	B-MED
skin	I-MED
,	O
in	O
which	O
pre-cut	O
flaps	O
open	O
to	O
produce	O
pores	B-MED
in	O
nafion	B-MED
sheets	B-MED
when	O
humidity	B-MED
increases	O
,	O
as	O
might	O
occur	O
during	O
human	B-MED
sweating	I-MED
thus	O
permitting	O
air	B-MED
flow	I-MED
and	O
reducing	O
both	O
the	O
humidity	B-MED
level	O
and	O
the	O
apparent	B-MED
temperature	I-MED
.	O
	
like	O
the	O
smart	O
human	B-MED
sweating	I-MED
pores	I-MED
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-MED
to	O
keep	O
the	O
wearer	B-MED
warm	I-MED
.	O
	
the	O
second	O
design	O
involves	O
thickness	B-MED
adjustable	B-MED
clothes	I-MED
by	O
inserting	O
the	O
bent	B-MED
polymer	I-MED
sheets	I-MED
between	O
two	O
fabrics	B-MED
.	O
	
as	O
the	O
humidity	B-MED
increases	O
,	O
the	O
sheets	B-MED
become	O
thinner	O
,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	B-MED
to	O
reduce	O
the	O
thermal	B-MED
insulation	I-MED
.	O
	
the	O
insulation	B-MED
layer	I-MED
can	O
recover	O
its	O
original	O
thickness	B-MED
upon	O
humidity	B-MED
reduction	O
to	O
restore	O
its	O
warmth-preservation	B-MED
function	O
.	O
	
such	O
humidity	B-MED
sensitive	B-MED
smart	O
polymer	B-MED
materials	I-MED
can	O
be	O
utilized	O
to	O
adjust	O
personal	B-MED
comfort	I-MED
,	O
and	O
be	O
effective	O
in	O
reducing	B-MED
energy	I-MED
consumption	I-MED
for	O
building	O
heating	B-MED
or	I-MED
cooling	I-MED
with	O
numerous	O
smart	B-MED
design	I-MED
.	O
	
development	B-MED
of	O
an	O
automaton	B-MED
model	I-MED
of	O
rotational	B-MED
activity	I-MED
driving	O
atrial	B-MED
fibrillation	I-MED
atrial	B-MED
fibrillation	I-MED
af	B-MED
is	O
difficult	O
to	O
treat	B-MED
effectively	B-MED
,	O
owing	O
to	O
uncertainty	B-MED
in	O
where	O
to	O
best	O
ablate	B-MED
to	O
eliminate	B-MED
arrhythmogenic	B-MED
substrate	B-MED
.	O
	
a	O
model	B-MED
providing	O
insight	O
into	O
the	O
electrical	B-MED
activation	B-MED
events	B-MED
would	O
be	O
useful	O
to	O
guide	O
catheter	B-MED
ablation	I-MED
strategy	I-MED
.	O
	
method	O
a	O
two-dimensional	B-MED
,	O
576	B-MED
node	I-MED
automaton	I-MED
was	O
developed	O
to	O
simulate	B-MED
atrial	B-MED
electrical	O
activity	O
.	O
	
the	O
substrate	O
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	O
refractory	O
period	O
at	O
varying	O
locations	O
.	O
	
fibrosis	O
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	O
block	O
.	O
	
larger	O
areas	O
of	O
block	O
were	O
used	O
to	O
simulate	O
ablation	O
lesions	O
.	O
	
anisotropy	O
was	O
imposed	O
in	O
a	O
2	O
ratio	O
.	O
	
a	O
premature	O
electrical	O
impulse	O
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	O
activation	O
.	O
	
rotational	O
activity	O
was	O
uninducible	O
when	O
refractory	O
patch	O
dimensions	O
were	O
less	O
than	O
20	O
.	O
	
for	O
larger	O
refractory	O
regions	O
,	O
a	O
single	O
premature	O
stimulus	O
was	O
capable	O
of	O
inducing	O
an	O
average	O
of	O
1.19	O
rotors	O
,	O
which	O
often	O
formed	O
near	O
the	O
patch	O
edges	O
.	O
	
a	O
maximum	O
of	O
5	O
rotors	O
formed	O
when	O
refractory	O
patch	O
dimensions	O
approached	O
the	O
size	O
of	O
the	O
entire	O
left	O
atrial	B-MED
virtual	O
field	O
.	O
	
rotors	O
formed	O
along	O
a	O
refractory	O
patch	O
edge	O
,	O
after	O
wavefront	O
arrival	O
was	O
delayed	O
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	O
cluster	O
of	O
sufficient	O
size	O
.	O
	
however	O
,	O
rotational	O
activity	O
could	O
also	O
occur	O
around	O
a	O
large	O
fiber	O
cluster	O
without	O
the	O
need	O
of	O
spatially	O
variable	O
refractoriness	O
.	O
	
when	O
obstacles	O
to	O
conduction	O
were	O
lacking	O
in	O
size	O
,	O
nascent	O
rotors	O
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	O
upon	O
anchoring	O
at	O
a	O
sufficiently	O
large	O
fiber	O
cluster	O
elsewhere	O
in	O
the	O
field	O
.	O
	
transient	O
rotors	O
terminated	O
when	O
traversing	O
a	O
region	O
with	O
differing	O
refractory	O
periods	O
,	O
if	O
no	O
obstacle	O
to	O
conduction	O
was	O
present	O
to	O
sufficiently	O
delay	O
wavefront	O
arrival	O
beyond	O
the	O
longest	O
refractory	O
period	O
.	O
	
other	O
rotors	O
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	O
with	O
faster	O
spin	O
rate	O
gradually	O
interrupted	O
the	O
activation	O
pathway	O
.	O
	
elimination	O
of	O
anchors	O
by	O
removal	O
,	O
or	O
by	O
simulated	O
ablation	O
over	O
a	O
sufficient	O
region	O
,	O
prevented	O
rotor	O
onset	O
at	O
a	O
particular	O
location	O
where	O
it	O
would	O
otherwise	O
form	O
.	O
	
the	O
presence	O
of	O
obstacles	O
to	O
conduction	O
and	O
spatial	O
differences	O
in	O
refractory	O
period	O
are	O
important	O
parameters	O
for	O
initiating	O
and	O
maintaining	O
rotational	O
activity	O
in	O
this	O
simulation	O
of	O
an	O
atrial	O
substrate	B-MED
multimodal	B-MED
brain	I-MED
imaging	I-MED
with	O
magnetoencephalography	B-MED
a	O
method	B-MED
for	O
measuring	B-MED
blood	B-MED
pressure	I-MED
and	O
cardiorespiratory	B-MED
oscillations	I-MED
studies	B-MED
with	O
magnetoencephalography	B-MED
meg	B-MED
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-MED
that	O
can	O
provide	O
a	O
metabolic	B-MED
dimension	I-MED
to	O
meg	B-MED
investigation	B-MED
s	O
.	O
	
in	O
addition	O
,	O
continuous	O
blood	B-MED
pressure	I-MED
measurements	I-MED
which	O
comply	O
with	O
meg	B-MED
compatibility	O
requirements	O
are	O
lacking	O
.	O
	
for	O
instance	O
,	O
by	O
combining	O
methods	B-MED
reflecting	O
neurovascular	B-MED
status	I-MED
one	O
could	O
obtain	O
more	O
information	O
on	O
low	B-MED
frequency	I-MED
fluctuations	B-MED
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	B-MED
connectivity	I-MED
within	O
brain	B-MED
networks	I-MED
.	O
	
this	O
paper	O
presents	O
a	O
multimodal	B-MED
brain	I-MED
imaging	I-MED
setup	O
,	O
capable	O
to	O
non-invasively	B-MED
and	O
continuously	O
measure	O
cerebral	B-MED
hemodynamic	B-MED
,	O
cardiorespiratory	B-MED
and	O
blood	B-MED
pressure	I-MED
oscillations	B-MED
simultaneously	O
with	O
meg	B-MED
.	O
	
in	O
the	O
setup	O
,	O
all	O
methods	B-MED
apart	O
from	O
meg	B-MED
rely	O
on	O
the	O
use	O
of	O
fibre	B-MED
optics	I-MED
.	O
	
in	O
particular	O
,	O
we	O
present	O
a	O
method	B-MED
for	O
measuring	B-MED
of	O
blood	B-MED
pressure	I-MED
and	O
cardiorespiratory	B-MED
oscillations	I-MED
continuously	O
with	O
meg	B-MED
.	O
	
the	O
potential	B-MED
of	O
this	O
type	O
of	O
multimodal	B-MED
setup	O
for	O
brain	B-MED
research	I-MED
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	B-MED
,	O
showing	O
effects	B-MED
of	I-MED
mild	B-MED
hypercapnia	I-MED
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
effect	B-MED
of	I-MED
peritoneal	B-MED
lavage	I-MED
solution	B-MED
temperature	B-MED
on	O
body	B-MED
temperature	I-MED
in	O
anaesthetised	B-MED
cats	B-MED
and	O
small	O
dogs	B-MED
a	O
prospective	B-MED
,	O
randomised	B-MED
,	O
non-blinded	B-MED
,	O
clinical	B-MED
study	I-MED
to	O
assess	O
the	O
effect	B-MED
of	I-MED
peritoneal	B-MED
lavage	I-MED
using	O
warmed	B-MED
fluid	B-MED
on	O
body	B-MED
temperature	I-MED
in	O
anesthetised	B-MED
cats	B-MED
and	O
dogs	B-MED
of	O
less	O
than	O
10	O
kg	O
body	B-MED
mass	I-MED
undergoing	O
coeliotomy	B-MED
.	O
	
a	O
standardised	B-MED
anaesthetic	I-MED
protocol	I-MED
was	O
used	O
.	O
	
oesophageal	B-MED
and	O
rectal	B-MED
temperatures	I-MED
were	O
measured	B-MED
at	O
various	B-MED
time	I-MED
points	I-MED
.	O
	
at	O
the	O
end	O
of	O
surgery	B-MED
,	O
group	B-MED
1	I-MED
patients	I-MED
n=10	O
were	O
lavaged	B-MED
with	O
200	O
ml/kg	O
sterile	B-MED
isotonic	B-MED
saline	I-MED
at	O
34	O
and	O
group	B-MED
2	O
n=10	O
at	O
40	O
.	O
	
groups	B-MED
were	O
similar	O
with	O
respect	O
to	O
age	B-MED
,	O
mass	B-MED
,	O
body	B-MED
condition	I-MED
and	O
surgical	B-MED
incision	I-MED
length	O
.	O
	
duration	B-MED
of	O
anaesthesia	B-MED
,	O
surgical	B-MED
procedures	I-MED
and	O
peritoneal	B-MED
lavage	I-MED
was	O
similar	O
between	O
groups	B-MED
.	O
	
linear	B-MED
regression	I-MED
showed	O
no	B-MED
significant	I-MED
change	I-MED
in	O
oesophageal	B-MED
temperature	I-MED
during	O
the	O
lavage	B-MED
period	B-MED
for	O
group	B-MED
1	O
p=0	O
,	O
but	O
a	O
significant	O
increase	O
for	O
group	B-MED
2	I-MED
patients	I-MED
p<0	O
,	O
with	O
mean	B-MED
temperature	B-MED
changes	I-MED
of	O
-0	O
from	O
36.3	O
to	O
35.9	O
and	O
+0	O
from	O
35.4	O
to	O
36.3	O
,	O
respectively	O
.	O
	
similar	O
results	B-MED
were	O
found	O
for	O
rectal	B-MED
temperature	I-MED
,	O
with	O
mean	B-MED
changes	O
of	O
-0	O
and	O
+0	O
p=0	O
and	O
0.045	O
,	O
respectively	O
.	O
	
the	O
use	O
of	O
isotonic	B-MED
crystalloid	B-MED
solution	I-MED
for	O
peritoneal	B-MED
lavage	I-MED
at	O
a	O
temperature	B-MED
of	O
40	O
significantly	O
warms	B-MED
small	B-MED
animal	I-MED
patients	I-MED
,	O
when	O
applied	O
in	O
a	O
clinical	B-MED
setting	I-MED
,	O
compared	O
with	O
lavage	B-MED
bioengineered	B-MED
3d	B-MED
models	B-MED
for	O
studying	B-MED
human	B-MED
cell	B-MED
-	O
tuberculosis	B-MED
interactions	B-MED
in	B-MED
vivo	I-MED
animal	B-MED
models	I-MED
have	O
intrinsic	O
limitations	O
for	O
studying	B-MED
relationships	B-MED
between	O
tuberculosis	B-MED
and	O
its	O
host	B-MED
and	O
there	O
is	O
a	O
need	O
for	O
alternative	O
,	O
in	B-MED
vitro	I-MED
cellular	B-MED
models	I-MED
.	O
	
a	O
microsphere	B-MED
-based	O
3d	B-MED
in	B-MED
vitro	I-MED
culture	B-MED
system	I-MED
of	O
mycobacterium	B-MED
tuberculosis	I-MED
-infected	O
human	B-MED
blood	B-MED
mononuclear	B-MED
cells	I-MED
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	B-MED
-	O
pathogen	B-MED
interactions	B-MED
.	O
	
perspectives	B-MED
on	O
cardiovascular	B-MED
effects	B-MED
of	I-MED
incretin	B-MED
-based	O
drugs	B-MED
from	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
recently	O
,	O
cardiovascular	B-MED
outcome	B-MED
trials	B-MED
with	O
glucose	B-MED
-lowering	O
drugs	B-MED
used	O
in	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
,	O
namely	O
glucagon-like	B-MED
peptide-1	I-MED
receptor	I-MED
agonists	B-MED
glp-1ra	B-MED
,	O
liraglutide	B-MED
and	O
semaglutide	B-MED
,	O
showed	O
a	O
reduction	B-MED
in	O
cardiovascular	B-MED
events	I-MED
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B-MED
with	O
other	O
incretin	B-MED
-based	O
drugs	B-MED
,	O
such	O
as	O
lixisenatide	B-MED
or	O
with	O
dipeptidyl	B-MED
peptidase-4	I-MED
inhibitors	I-MED
dpp4i	B-MED
.	O
	
mechanisms	B-MED
underlying	O
the	O
observed	O
cardiovascular	B-MED
differences	B-MED
between	O
dpp4i	B-MED
and	O
glp1-ra	B-MED
,	O
and	O
across	O
individual	O
glp1-ra	B-MED
are	O
poorly	O
understood	O
.	O
	
this	O
review	B-MED
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	B-MED
from	O
experimental	B-MED
and	O
mechanistic	B-MED
studies	I-MED
on	O
the	O
action	B-MED
of	O
glp1-ra	B-MED
and	O
dpp4i	B-MED
on	O
the	O
cardiovascular	B-MED
system	I-MED
,	O
both	O
deriving	O
from	O
clinical	B-MED
and	O
pre-clinical	B-MED
sources	I-MED
.	O
	
the	O
results	B-MED
of	O
cardiovascular	B-MED
outcome	B-MED
trials	B-MED
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B-MED
preclinical	B-MED
data	I-MED
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B-MED
failure	I-MED
results	B-MED
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	B-MED
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	B-MED
of	O
cardioprotection	B-MED
of	O
incretin	B-MED
-based	O
drugs	B-MED
.	O
	
in	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-MED
cardiovascular	B-MED
effects	B-MED
of	I-MED
a	O
direct	O
cardiac	B-MED
action	B-MED
of	O
glp-1	B-MED
metabolites	B-MED
through	O
glp-1	B-MED
receptor	I-MED
-independent	O
pathways	B-MED
,	O
and	O
of	O
dpp4	B-MED
substrates	B-MED
other	O
than	O
role	O
of	O
breast	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
in	O
predicting	B-MED
residual	B-MED
lobular	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
after	O
initial	B-MED
excision	B-MED
breast	B-MED
magnetic	I-MED
resonance	I-MED
mr	I-MED
imaging	I-MED
is	O
a	O
useful	O
screening	B-MED
modality	B-MED
in	O
detecting	B-MED
suspicious	B-MED
lesions	B-MED
in	O
patients	B-MED
with	O
a	O
history	B-MED
of	O
lobular	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
lcis	B-MED
.	O
	
this	O
study	B-MED
aimed	B-MED
to	O
evaluate	B-MED
the	O
effectiveness	B-MED
of	O
breast	B-MED
mr	I-MED
imaging	I-MED
in	O
detecting	B-MED
remnant	B-MED
lcis	B-MED
lesions	B-MED
after	B-MED
initial	B-MED
excision	B-MED
.	O
	
between	O
2011	O
and	O
2015	O
,	O
29	O
patients	B-MED
with	O
lcis	B-MED
who	O
underwent	B-MED
initial	B-MED
excision	B-MED
were	O
enrolled	O
.	O
	
breast	B-MED
ultrasonography	I-MED
and	O
breast	B-MED
mr	I-MED
imaging	I-MED
was	O
conducted	O
after	B-MED
initial	B-MED
excision	B-MED
.	O
	
imaging	B-MED
findings	I-MED
were	O
compared	B-MED
with	O
pathologic	B-MED
results	B-MED
.	O
	
there	O
were	O
nine	O
31.0	O
cases	B-MED
with	O
positive	B-MED
margins	I-MED
after	B-MED
initial	B-MED
excision	B-MED
they	O
were	O
lcis	B-MED
n=8	O
and	O
atypical	B-MED
lobular	I-MED
hyperplasia	I-MED
n=1	O
.	O
	
residual	B-MED
lesions	B-MED
were	O
identified	B-MED
in	O
12	O
cases	B-MED
they	O
were	O
invasive	B-MED
lobular	I-MED
carcinoma	I-MED
n=1	O
3.4	O
,	O
lcis	B-MED
n=9	O
31.0	O
,	O
atypical	B-MED
lobular	I-MED
hyperplasia	I-MED
n=1	O
3.4	O
,	O
and	O
papillary	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
n=1	O
3.4	O
.	O
	
prior	B-MED
to	O
the	O
second	B-MED
operation	B-MED
,	O
these	O
lesions	B-MED
could	O
be	O
detected	O
in	O
seven	O
cases	B-MED
using	O
ultrasonography	B-MED
sensitivity	B-MED
,	O
53.3	O
specificity	B-MED
,	O
100%	O
and	O
in	O
10	O
cases	B-MED
using	O
breast	B-MED
mr	I-MED
imaging	I-MED
sensitivity	B-MED
,	O
83.3	O
specificity	B-MED
,	O
100%	O
.	O
	
breast	B-MED
mr	I-MED
imaging	I-MED
showed	O
higher	B-MED
sensitivity	B-MED
than	O
breast	B-MED
ultrasonography	I-MED
in	O
detecting	B-MED
remnant	B-MED
lcis	B-MED
lesions	B-MED
.	O
	
if	O
a	O
suspicious	B-MED
lesion	B-MED
was	O
found	O
using	O
breast	B-MED
mr	I-MED
imaging	I-MED
,	O
a	O
second	B-MED
operation	B-MED
should	O
be	O
considered	B-MED
because	O
of	O
the	O
possibility	B-MED
of	O
multifocality	B-MED
,	O
even	O
if	O
lcis	B-MED
was	O
confirmed	B-MED
at	O
the	O
initial	B-MED
operation	B-MED
.	O
	
construction	B-MED
of	O
fused	B-MED
polyheterocycles	I-MED
through	O
sequential	B-MED
4	B-MED
+	I-MED
2	I-MED
and	I-MED
3	I-MED
+	I-MED
2	I-MED
cycloadditions	I-MED
a	O
method	O
for	O
pd	B-MED
-	O
catalyzed	B-MED
aerobic	B-MED
oxidative	B-MED
reaction	I-MED
of	O
quinazolinones	B-MED
and	O
alkynes	B-MED
has	O
been	O
developed	O
for	O
sequential	B-MED
4	B-MED
+	I-MED
2	I-MED
and	I-MED
3	I-MED
+	I-MED
2	I-MED
cycloadditions	I-MED
to	O
assemble	B-MED
a	O
novel	B-MED
fused-polycyclic	B-MED
system	I-MED
containing	O
tetrahydropyridine	B-MED
and	O
dihydrofuran	B-MED
rings	I-MED
.	O
	
the	O
reaction	B-MED
process	I-MED
involves	O
c-h	B-MED
and	I-MED
n-h	I-MED
bond	I-MED
functionalization	O
for	O
the	O
formation	B-MED
of	O
tetrahydropyridine	B-MED
and	O
an	O
oxygen	B-MED
radical	I-MED
cyclization	B-MED
for	O
the	O
dihydrofuran	B-MED
ring	I-MED
.	O
	
this	O
atom	B-MED
-	O
and	O
step-	O
economical	B-MED
synthesis	I-MED
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	B-MED
tolerance	B-MED
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	B-MED
of	O
polycyclic	B-MED
molecules	I-MED
with	O
potential	O
pharmaceutical	B-MED
interest	I-MED
.	O
	
biological	B-MED
basis	B-MED
of	O
radiation	B-MED
protection	I-MED
needs	O
rejuvenation	B-MED
human	B-MED
beings	I-MED
encounter	O
radiation	B-MED
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	B-MED
to	O
radioactive	B-MED
waste	I-MED
sites	B-MED
to	O
participation	B-MED
in	O
medical	B-MED
procedures	I-MED
using	O
x-rays	B-MED
etc	O
.	O
	
limits	O
for	O
radiation	B-MED
exposures	I-MED
are	O
legally	B-MED
regulated	I-MED
however	O
,	O
current	O
radiation	B-MED
protection	I-MED
policy	B-MED
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	B-MED
,	O
cellular	B-MED
and	O
molecular	B-MED
effects	B-MED
of	I-MED
low	B-MED
doses	I-MED
and	O
low	O
dose	B-MED
rates	I-MED
of	O
radiation	B-MED
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	B-MED
dose	I-MED
radiation	B-MED
exposures	I-MED
.	O
	
recent	O
technical	B-MED
developments	I-MED
in	O
biology	B-MED
and	O
medicine	B-MED
,	O
from	O
single	B-MED
cell	I-MED
techniques	I-MED
to	O
big	B-MED
data	I-MED
computational	I-MED
research	I-MED
,	O
have	O
enabled	O
new	O
approaches	B-MED
for	O
study	B-MED
of	O
biology	B-MED
of	O
low	B-MED
doses	I-MED
of	O
radiation	B-MED
.	O
	
results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	B-MED
the	O
idea	B-MED
that	O
low	B-MED
doses	I-MED
of	O
radiation	B-MED
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	B-MED
with	I-MED
high	B-MED
dose	I-MED
exposures	B-MED
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	B-MED
for	O
the	O
development	B-MED
of	O
a	O
new	O
theoretical	B-MED
framework	I-MED
needed	O
for	O
the	O
understanding	O
of	O
low	B-MED
dose	I-MED
radiation	B-MED
exposures	I-MED
.	O
	
mechanistic	O
understanding	O
of	O
radiation	B-MED
effects	I-MED
at	O
low	B-MED
doses	I-MED
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-MED
protection	I-MED
policy	B-MED
.	O
	
gleason	B-MED
grade	I-MED
grouping	I-MED
of	O
prostate	B-MED
cancer	I-MED
is	O
of	O
prognostic	B-MED
value	I-MED
in	O
asian	B-MED
men	B-MED
the	O
international	B-MED
society	I-MED
of	I-MED
urological	I-MED
pathology	I-MED
made	O
recommendations	O
for	O
the	O
use	O
of	O
grade	B-MED
groups	I-MED
gg	B-MED
originally	O
described	O
by	O
epstein	B-MED
and	O
colleagues	B-MED
over	O
gleason	B-MED
score	I-MED
gs	B-MED
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B-MED
by	O
the	O
who	B-MED
classification	I-MED
in	O
2016	O
.	O
	
the	O
majority	O
of	O
studies	B-MED
validating	O
this	O
revision	B-MED
have	O
been	O
in	O
caucasian	B-MED
populations	I-MED
.	O
	
we	O
therefore	O
asked	O
whether	O
the	O
new	O
gg	B-MED
system	I-MED
was	O
retrospectively	O
associated	O
with	O
biochemical	B-MED
disease-free	I-MED
survival	I-MED
in	O
a	O
mixed-ethnicity	B-MED
cohort	B-MED
of	O
asian	B-MED
men	B-MED
.	O
	
a	O
total	O
of	O
680	O
radical	B-MED
prostatectomies	I-MED
rps	B-MED
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O
	
gs	B-MED
from	O
initial	O
biopsy	B-MED
and	O
rp	B-MED
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	B-MED
to	O
gg	B-MED
,	O
defined	O
as	O
1	O
gs	B-MED
6	O
2	O
gs	B-MED
3+4=7	O
3	O
gs	B-MED
4+3=7	O
4	O
gs	B-MED
4+4=8/5+3=8/3+5=8	O
and	O
5	O
gs	B-MED
9-10	O
.	O
	
biochemical	B-MED
recurrence	I-MED
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
rp	B-MED
prostate-specific	B-MED
antigen	I-MED
psa	B-MED
levels	O
of	O
>0	O
ng/ml	O
after	O
post-	O
rp	B-MED
psa	B-MED
reaching	O
the	O
nadir	B-MED
of	O
<0	O
ng/ml	O
.	O
	
our	O
data	B-MED
showed	O
that	O
kaplan-meier	B-MED
analysis	I-MED
revealed	O
significant	O
differences	O
in	O
biochemical	B-MED
recurrence	I-MED
within	O
gleason	B-MED
gg	I-MED
based	O
on	O
either	O
biopsy	B-MED
or	O
prostatectomy	B-MED
scoring	B-MED
.	O
	
multivariate	B-MED
analysis	I-MED
further	O
confirmed	O
that	O
a	O
higher	O
gg	B-MED
was	O
significantly	O
associated	O
with	O
risk	B-MED
of	O
biochemical	B-MED
recurrence	I-MED
.	O
	
this	O
gg	B-MED
system	I-MED
had	O
a	O
higher	O
prognostic	B-MED
discrimination	B-MED
for	O
both	O
initial	O
biopsy	B-MED
and	O
rp	B-MED
than	O
gs	B-MED
.	O
	
our	O
study	B-MED
validates	B-MED
the	O
use	O
of	O
the	O
revised	B-MED
and	O
updated	B-MED
gg	B-MED
system	I-MED
in	O
a	O
mixed-ethnicity	B-MED
population	I-MED
of	O
asian	B-MED
men	B-MED
.	O
	
higher	O
gg	B-MED
was	O
significantly	O
associated	O
with	O
increased	O
risk	B-MED
of	O
biochemical	B-MED
recurrence	I-MED
.	O
	
we	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B-MED
management	I-MED
for	O
patients	B-MED
with	O
prostate	B-MED
cancer	I-MED
.	O
	
membrane	B-MED
nanoclusters	B-MED
of	O
fcγri	B-MED
segregate	O
from	O
inhibitory	B-MED
sirpα	B-MED
upon	O
activation	B-MED
of	I-MED
human	I-MED
macrophages	I-MED
signal	B-MED
integration	I-MED
between	O
activating	B-MED
fc	B-MED
receptors	I-MED
and	O
inhibitory	B-MED
signal	B-MED
regulatory	I-MED
protein	I-MED
α	I-MED
sirpα	B-MED
controls	O
macrophage	B-MED
phagocytosis	B-MED
.	O
	
here	O
,	O
using	O
dual-color	B-MED
direct	I-MED
stochastic	I-MED
optical	I-MED
reconstruction	I-MED
microscopy	I-MED
,	O
we	O
report	O
that	O
fcγ	B-MED
receptor	I-MED
i	I-MED
fcγri	B-MED
,	O
fcγrii	B-MED
,	O
and	O
sirpα	B-MED
are	O
not	O
homogeneously	B-MED
distributed	O
at	O
macrophage	B-MED
surfaces	B-MED
but	O
are	O
organized	O
in	O
discrete	B-MED
nanoclusters	B-MED
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
11	O
nm	O
,	O
60	O
6	O
nm	O
,	O
and	O
48	O
3	O
nm	O
,	O
respectively	O
.	O
	
nanoclusters	B-MED
of	O
fcγri	B-MED
,	O
but	O
not	O
fcγrii	B-MED
,	O
are	O
constitutively	O
associated	B-MED
with	I-MED
nanoclusters	B-MED
of	O
sirpα	B-MED
,	O
within	O
62	O
5	O
nm	O
,	O
mediated	O
by	O
the	O
actin	B-MED
cytoskeleton	I-MED
.	O
	
upon	O
fc	B-MED
receptor	I-MED
activation	B-MED
,	O
src-family	B-MED
kinase	I-MED
signaling	B-MED
leads	O
to	O
segregation	O
of	O
fcγri	B-MED
and	O
sirpα	B-MED
nanoclusters	B-MED
to	O
be	O
197	O
3	O
nm	O
apart	O
.	O
	
co-ligation	B-MED
of	O
sirpα	B-MED
with	O
cd47	B-MED
abrogates	O
nanocluster	B-MED
segregation	O
.	O
	
if	O
the	O
balance	O
of	O
signals	B-MED
favors	O
activation	B-MED
,	O
fcγri	B-MED
nanoclusters	B-MED
reorganize	B-MED
into	O
periodically	B-MED
spaced	O
concentric	B-MED
rings	I-MED
.	O
	
thus	O
,	O
a	O
nanometer	B-MED
-	O
and	O
micron-scale	B-MED
reorganization	B-MED
of	O
activating	B-MED
and	O
inhibitory	B-MED
receptors	B-MED
occurs	O
at	O
the	O
surface	O
of	O
human	B-MED
macrophages	I-MED
concurrent	B-MED
with	O
signal	B-MED
integration	I-MED
.	O
	
firecracker	B-MED
eye	B-MED
exposure	I-MED
experimental	B-MED
study	I-MED
and	O
simulation	B-MED
understanding	O
the	O
mechanisms	B-MED
of	O
traumatic	B-MED
ocular	B-MED
injury	I-MED
is	O
helpful	O
to	O
make	O
accurate	B-MED
diagnoses	B-MED
before	O
the	O
symptoms	B-MED
emerge	O
and	O
to	O
develop	O
specific	O
eye	B-MED
protection	I-MED
.	O
	
the	O
comprehension	B-MED
of	O
the	O
dynamics	B-MED
of	O
primary	B-MED
blast	B-MED
injury	I-MED
mechanisms	B-MED
is	O
a	O
challenging	O
issue	B-MED
.	O
	
the	O
question	O
is	O
whether	O
the	O
pressure	B-MED
wave	B-MED
propagation	B-MED
and	O
reflection	B-MED
alone	O
could	O
cause	B-MED
ocular	B-MED
damage	I-MED
.	O
	
to	O
date	O
,	O
there	O
are	O
dissenting	B-MED
opinions	B-MED
and	O
no	O
conclusive	B-MED
evidence	B-MED
thereupon	O
.	O
	
a	O
previous	O
numerical	B-MED
investigation	I-MED
of	O
blast	B-MED
trauma	B-MED
highlighted	O
the	O
dynamic	B-MED
effect	B-MED
of	O
pressure	B-MED
propagation	B-MED
and	O
its	O
amplification	B-MED
by	O
the	O
geometry	B-MED
of	O
the	O
bony	B-MED
orbit	I-MED
,	O
inducing	B-MED
a	O
resonance	B-MED
cavity	B-MED
effect	B-MED
and	O
a	O
standing	B-MED
wave	I-MED
hazardous	B-MED
for	O
eye	B-MED
tissues	B-MED
.	O
	
the	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	B-MED
evidence	B-MED
of	O
the	O
numerically	B-MED
identified	B-MED
phenomenon	B-MED
.	O
	
therefore	O
,	O
tests	B-MED
aimed	O
at	O
evaluating	B-MED
the	O
response	B-MED
of	O
porcine	B-MED
eyes	B-MED
to	O
blast	B-MED
overpressure	B-MED
generated	O
by	O
firecrackers	B-MED
explosion	B-MED
were	O
performed	B-MED
.	O
	
the	O
orbital	B-MED
cavity	I-MED
effect	B-MED
was	O
considered	O
mounting	O
the	O
enucleated	B-MED
eyes	I-MED
inside	O
a	O
dummy	O
orbit	B-MED
.	O
	
the	O
experimental	B-MED
measurements	B-MED
obtained	B-MED
during	O
the	O
explosion	B-MED
tests	B-MED
presented	O
in	O
this	O
paper	B-MED
corroborate	B-MED
the	O
numerical	B-MED
evidence	I-MED
of	O
a	O
high-frequency	B-MED
pressure	B-MED
amplification	B-MED
,	O
enhancing	B-MED
the	O
loading	O
on	O
the	O
ocular	B-MED
tissues	B-MED
,	O
attributable	B-MED
to	O
the	O
orbital	B-MED
bony	I-MED
walls	I-MED
surrounding	O
the	O
the	O
platelet-activating	B-MED
receptor	I-MED
c-type	B-MED
lectin	I-MED
receptor-2	I-MED
plays	O
an	O
essential	O
role	B-MED
in	O
liver	B-MED
regeneration	I-MED
after	O
partial	B-MED
hepatectomy	I-MED
in	O
mice	B-MED
essentials	O
regeneration	B-MED
role	B-MED
of	O
c-type	B-MED
lectin	I-MED
receptor-2	I-MED
clec-2	B-MED
after	O
70%	B-MED
hepatectomy	I-MED
hpx	B-MED
was	O
investigated	O
.	O
	
wild-type	B-MED
or	O
clec-2	B-MED
deleted	B-MED
from	O
platelets	B-MED
of	O
chimeric	B-MED
mice	I-MED
flko	B-MED
underwent	O
hpx	B-MED
.	O
	
the	O
liver/body	B-MED
weight	I-MED
ratio	I-MED
was	O
significantly	O
lower	O
in	O
the	O
flko	B-MED
than	O
in	O
the	O
wild-type	B-MED
.	O
	
clec-2	B-MED
plays	O
an	O
essential	O
role	B-MED
in	O
liver	B-MED
regeneration	I-MED
after	O
hpx	B-MED
.	O
	
background	O
and	O
aim	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	B-MED
of	O
c-type	B-MED
lectin	I-MED
receptor	I-MED
clec	I-MED
in	O
liver	B-MED
regeneration	I-MED
following	O
partial	B-MED
liver	I-MED
resection	I-MED
in	O
mice	B-MED
.	O
	
materials	O
and	O
methods	O
irradiated	O
chimeric	B-MED
mice	I-MED
transplanted	B-MED
with	O
fetal	B-MED
liver	B-MED
cells	I-MED
from	O
wild-type	B-MED
wt	I-MED
mice	I-MED
,	O
clec-2	B-MED
-	O
deleted	B-MED
ko	O
mice	B-MED
or	O
mice	B-MED
with	O
clec-2	B-MED
deleted	B-MED
specifically	O
from	O
platelets	B-MED
flko	O
were	O
generated	B-MED
.	O
	
mice	B-MED
underwent	O
70%	B-MED
partial	I-MED
hepatectomy	I-MED
ph	B-MED
.	O
	
immunohistochemical	B-MED
staining	I-MED
was	O
performed	O
to	O
investigate	O
the	O
expression	B-MED
of	O
the	O
endogenous	B-MED
ligand	B-MED
for	O
clec-2	B-MED
,	O
podoplanin	B-MED
.	O
	
the	O
accumulation	B-MED
of	O
platelets	B-MED
in	O
the	O
liver	B-MED
was	O
also	O
quantified	B-MED
.	O
	
the	O
hepatic	B-MED
expression	B-MED
of	O
the	O
il-6	B-MED
/	O
gp130	B-MED
and	O
stat3	B-MED
,	O
akt	B-MED
and	O
erk1/2	B-MED
was	O
also	O
examined	O
.	O
	
results	O
the	O
liver/body	B-MED
weight	I-MED
ratio	I-MED
and	O
expression	B-MED
of	O
all	O
cell	B-MED
proliferation	I-MED
markers	B-MED
were	O
significantly	O
lower	O
in	O
the	O
flko	B-MED
group	I-MED
than	O
in	O
the	O
wt	B-MED
group	I-MED
.	O
	
the	O
expression	B-MED
of	O
phosphorylated	B-MED
p	I-MED
akt	I-MED
and	O
perk1	B-MED
/2	O
was	O
similar	O
in	O
the	O
wt	B-MED
and	O
flko	B-MED
groups	I-MED
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
expression	B-MED
of	O
pstat3	B-MED
and	O
il-6	B-MED
was	O
significantly	O
stronger	O
in	O
the	O
wt	B-MED
group	I-MED
than	O
in	O
the	O
flko	B-MED
group	I-MED
.	O
	
the	O
expression	B-MED
of	O
podoplanin	B-MED
was	O
detected	O
in	O
the	O
hepatic	B-MED
sinusoids	I-MED
of	O
both	O
groups	B-MED
.	O
	
however	O
,	O
the	O
extent	O
to	O
which	O
platelets	B-MED
accumulated	O
in	O
hepatic	B-MED
sinusoids	I-MED
was	O
significantly	O
less	O
in	O
the	O
flko	B-MED
group	I-MED
than	O
in	O
the	O
wt	B-MED
group	I-MED
.	O
	
conclusion	O
clec-2	B-MED
was	O
involved	O
in	O
hepatic	B-MED
regeneration	I-MED
after	O
liver	B-MED
resection	I-MED
and	O
clec-2	B-MED
-related	O
liver	B-MED
regeneration	I-MED
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	B-MED
and	O
sinusoidal	B-MED
endothelial	B-MED
cells	I-MED
.	O
	
temporal	B-MED
stability	B-MED
of	O
heavy	B-MED
drinking	I-MED
days	O
and	O
drinking	B-MED
reductions	B-MED
among	O
heavy	B-MED
drinkers	I-MED
in	O
the	O
combine	B-MED
study	I-MED
recently	O
,	O
the	O
food	B-MED
and	I-MED
drug	I-MED
administration	I-MED
fda	B-MED
proposed	O
to	O
expand	B-MED
the	O
options	O
for	O
primary	B-MED
end	B-MED
points	I-MED
in	O
the	O
development	B-MED
of	O
medications	B-MED
for	O
alcohol	B-MED
use	I-MED
disorder	I-MED
to	O
include	O
either	O
abstinence	B-MED
from	O
alcohol	B-MED
or	O
a	O
nonabstinent	B-MED
outcome	B-MED
no	O
heavy	B-MED
drinking	I-MED
days	O
with	O
a	O
heavy	B-MED
drinking	I-MED
day	O
defined	B-MED
as	O
more	O
than	O
3	O
drinks	B-MED
per	O
day	O
for	O
women	B-MED
and	O
more	O
than	O
4	O
drinks	B-MED
per	O
day	O
for	O
men	B-MED
>3/>4	O
cutoff	B-MED
.	O
	
the	O
fda	B-MED
also	O
suggested	B-MED
that	O
6	O
months	B-MED
would	O
be	O
the	O
most	O
appropriate	B-MED
length	B-MED
for	I-MED
a	I-MED
clinical	I-MED
trial	I-MED
to	O
demonstrate	O
the	O
stability	B-MED
of	O
this	O
nonabstinent	B-MED
drinking	B-MED
outcome	B-MED
.	O
	
however	O
,	O
few	O
alcohol	O
clinical	B-MED
trials	I-MED
have	O
examined	B-MED
the	O
stability	B-MED
of	O
nonheavy	B-MED
drinking	I-MED
during	B-MED
and	O
after	B-MED
treatment	I-MED
.	O
	
in	O
a	O
secondary	B-MED
analysis	I-MED
of	O
the	O
combine	B-MED
study	I-MED
data	B-MED
n	O
=	O
1	O
,	O
we	O
examined	B-MED
transitions	B-MED
in	O
heavy	B-MED
drinking	I-MED
days	O
during	B-MED
the	I-MED
course	I-MED
of	I-MED
treatment	I-MED
months	B-MED
1	O
through	O
4	O
,	O
during	B-MED
the	O
transition	B-MED
out	O
of	O
treatment	B-MED
months	B-MED
4	O
through	O
7	O
,	O
and	O
up	O
to	O
12	O
months	B-MED
afterward	O
months	B-MED
13	O
through	O
16	O
using	O
latent	B-MED
variable	I-MED
mixture	I-MED
models	I-MED
.	O
	
heavy	B-MED
drinking	I-MED
and	O
nonheavy	B-MED
drinking	I-MED
were	O
relatively	O
stable	B-MED
in	O
consecutive	B-MED
months	B-MED
minimum	B-MED
agreement	O
kappa	O
=	O
0.64	O
for	O
months	B-MED
1	O
to	O
2	O
.	O
	
most	O
individuals	B-MED
were	O
stable	B-MED
low-risk	B-MED
drinkers	B-MED
/	O
abstainers	B-MED
or	O
heavy	B-MED
drinkers	I-MED
by	O
the	O
end	O
of	O
treatment	B-MED
,	O
as	O
characterized	B-MED
by	O
a	O
10%	O
probability	B-MED
or	O
less	O
of	O
transitioning	B-MED
out	O
of	O
either	O
a	O
no	O
heavy	B-MED
drinking	I-MED
state	B-MED
or	O
a	O
heavy	B-MED
drinking	I-MED
state	B-MED
.	O
	
more	O
than	O
two-thirds	O
of	O
the	O
heavy	B-MED
drinkers	I-MED
who	O
exceeded	O
the	O
heavy	B-MED
drinking	I-MED
threshold	B-MED
during	B-MED
treatment	I-MED
reported	B-MED
,	O
on	O
average	B-MED
,	O
a	O
64%	O
reduction	B-MED
in	O
drinking	B-MED
frequency	I-MED
and	O
a	O
38%	O
reduction	B-MED
in	O
drinking	B-MED
intensity	O
from	O
pretreatment	B-MED
drinking	B-MED
levels	B-MED
.	O
	
the	O
results	B-MED
show	O
stability	B-MED
of	O
no	O
heavy	B-MED
drinking	I-MED
as	O
an	O
outcome	B-MED
within	O
the	O
first	O
4	O
months	B-MED
of	O
treatment	B-MED
and	O
that	O
the	O
>3/>4	O
drink	B-MED
cutoff	B-MED
may	O
mask	O
substantial	O
reductions	B-MED
in	O
alcohol	B-MED
consumption	I-MED
among	O
some	O
patients	B-MED
.	O
	
future	O
studies	B-MED
should	O
explore	O
the	O
clinical	B-MED
utility	O
of	O
reduction	B-MED
end	B-MED
points	I-MED
.	O
	
oral	B-MED
health	I-MED
in	O
transition	B-MED
the	O
hadza	B-MED
foragers	I-MED
of	O
tanzania	B-MED
conventional	B-MED
wisdom	O
holds	O
that	O
a	O
decline	B-MED
in	O
oral	B-MED
health	I-MED
accompanies	O
the	O
transition	B-MED
from	O
hunting	B-MED
and	O
gathering	B-MED
to	O
agriculture	B-MED
,	O
given	O
increased	B-MED
consumption	B-MED
of	O
carbohydrates	B-MED
.	O
	
this	O
widely	O
touted	O
example	B-MED
of	O
the	O
mismatch	B-MED
between	O
our	O
biology	B-MED
and	O
modern	B-MED
lifestyle	I-MED
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological	B-MED
record	I-MED
of	O
the	O
neolithic	B-MED
revolution	I-MED
in	O
the	O
new	B-MED
world	I-MED
.	O
	
recent	O
studies	B-MED
of	O
other	O
populations	B-MED
have	O
,	O
however	O
,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	B-MED
.	O
	
here	O
,	O
we	O
present	O
the	O
first	O
comprehensive	B-MED
study	B-MED
of	O
oral	B-MED
health	I-MED
among	O
a	O
living	B-MED
population	I-MED
in	O
transition	B-MED
from	O
the	O
bush	B-MED
to	O
village	B-MED
life	I-MED
,	O
the	O
hadza	B-MED
hunter	B-MED
-	O
gatherers	B-MED
of	O
tanzania	B-MED
,	O
to	O
test	O
the	O
hypothesis	B-MED
that	O
the	O
shift	B-MED
from	O
foraging	B-MED
to	O
farming	B-MED
,	O
or	O
agricultural	B-MED
intensification	I-MED
,	O
inevitably	O
leads	O
to	O
increased	B-MED
periodontal	B-MED
disease	I-MED
,	O
caries	B-MED
,	O
and	O
orthodontic	B-MED
disorders	B-MED
.	O
	
our	O
results	B-MED
showed	O
that	O
women	B-MED
living	B-MED
in	O
villages	B-MED
consuming	B-MED
a	O
mostly	O
agricultural	B-MED
diet	B-MED
exhibited	O
more	O
caries	B-MED
and	O
periodontal	B-MED
disease	I-MED
than	O
those	O
living	B-MED
in	O
the	O
bush	B-MED
consuming	B-MED
a	O
mostly	O
wild-food	B-MED
diet	I-MED
.	O
	
furthermore	O
,	O
men	B-MED
living	B-MED
in	O
the	O
bush	B-MED
consuming	B-MED
mostly	O
a	O
wild-food	B-MED
diet	I-MED
had	O
more	O
than	O
those	O
living	B-MED
in	O
the	O
village	B-MED
consuming	B-MED
a	O
mostly	O
agricultural	B-MED
diet	B-MED
.	O
	
these	O
findings	B-MED
are	O
explained	O
by	O
the	O
high	B-MED
incidence	B-MED
of	O
maize	B-MED
consumption	B-MED
in	O
village	B-MED
settings	O
,	O
along	O
with	O
previously	O
recognized	O
variation	B-MED
in	O
rate	B-MED
of	O
caries	B-MED
between	O
men	B-MED
and	O
women	B-MED
.	O
	
the	O
unexpected	O
discovery	O
of	O
high	B-MED
caries	B-MED
incidences	B-MED
for	O
men	B-MED
in	O
the	O
bush	B-MED
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	B-MED
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	B-MED
and	O
marijuana	B-MED
.	O
	
these	O
data	B-MED
support	O
the	O
notions	O
that	O
mechanisms	B-MED
of	O
cariogenesis	B-MED
are	O
multifactorial	B-MED
and	O
that	O
the	O
relationships	B-MED
between	O
oral	B-MED
health	I-MED
and	O
the	O
shift	B-MED
from	O
a	O
predominantly	O
wild-food	B-MED
diet	I-MED
to	O
one	O
dominated	O
by	O
cultigens	B-MED
the	O
r2r3myb	B-MED
vvmybpa1	B-MED
from	O
grape	B-MED
reprograms	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
in	O
tobacco	B-MED
flowers	B-MED
this	O
work	O
shows	O
that	O
,	O
in	O
tobacco	B-MED
,	O
the	O
ectopic	B-MED
expression	I-MED
of	O
vvmybpa1	B-MED
,	O
a	O
grape	B-MED
regulator	B-MED
of	O
proanthocyanidin	B-MED
biosynthesis	O
,	O
up-	B-MED
or	I-MED
down-regulates	I-MED
different	O
branches	O
of	O
the	O
phenylproanoid	B-MED
pathway	I-MED
,	O
in	O
a	O
structure-specific	O
fashion	O
.	O
	
proanthocyanidins	B-MED
are	O
flavonoids	B-MED
of	O
paramount	O
importance	O
for	O
animal	B-MED
and	O
human	B-MED
diet	I-MED
.	O
	
research	B-MED
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	B-MED
enriched	O
with	O
these	O
health	B-MED
-promoting	O
compounds	B-MED
.	O
	
flavonoids	B-MED
synthesis	B-MED
is	O
regulated	O
by	O
the	O
mbw	B-MED
transcriptional	B-MED
complex	I-MED
,	O
made	O
of	O
r2r3myb	B-MED
,	O
bhlh	B-MED
and	O
wd40	B-MED
proteins	I-MED
,	O
with	O
the	O
myb	B-MED
components	O
liable	O
for	O
channeling	B-MED
the	O
complex	B-MED
towards	O
specific	O
branches	O
of	O
the	O
pathway	B-MED
.	O
	
hence	O
,	O
using	O
tobacco	B-MED
as	O
a	O
model	B-MED
,	O
here	O
,	O
we	O
tested	B-MED
if	O
the	O
ectopic	B-MED
expression	I-MED
of	O
the	O
proanthocyanidin	B-MED
regulator	B-MED
vvmybpa1	B-MED
from	O
grape	B-MED
induces	B-MED
the	O
biosynthesis	B-MED
of	O
these	O
compounds	B-MED
in	O
not-naturally	O
committed	B-MED
cells	I-MED
.	O
	
here	O
,	O
we	O
show	O
,	O
via	O
targeted	O
transcriptomic	B-MED
and	O
metabolic	B-MED
analyses	B-MED
of	O
primary	O
transgenic	B-MED
lines	I-MED
and	O
their	O
progeny	B-MED
,	O
that	O
vvmybpa1	B-MED
alters	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
in	O
tobacco	B-MED
floral	B-MED
organs	I-MED
,	O
in	O
a	O
structure-specific	O
fashion	O
.	O
	
we	O
also	O
report	O
that	O
a	O
modest	O
vvmybpa1	B-MED
expression	B-MED
is	O
sufficient	O
to	O
induce	O
the	O
expression	B-MED
of	O
both	O
proanthocyanidin	B-MED
-specific	O
and	O
early	B-MED
genes	I-MED
of	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
.	O
	
consequently	O
,	O
proanthocyanidins	B-MED
and	O
chlorogenic	B-MED
acids	I-MED
are	O
induced	O
or	O
de	B-MED
novo	I-MED
synthetised	O
in	O
floral	B-MED
limbs	I-MED
,	O
tubes	I-MED
and	O
stamens	B-MED
.	O
	
other	O
phenylpropanoid	B-MED
branches	I-MED
are	O
conversely	O
induced	O
or	O
depleted	B-MED
according	O
to	O
the	O
floral	B-MED
structure	I-MED
.	O
	
our	O
study	O
documents	O
a	O
novel	B-MED
and	O
distinct	O
function	O
of	O
vvmybpa1	B-MED
with	O
respect	O
to	O
other	O
mybs	B-MED
regulating	O
proanthocyanidins	B-MED
.	O
	
present	O
findings	B-MED
may	O
have	O
major	O
implications	O
in	O
designing	B-MED
strategies	I-MED
for	O
enriching	O
crops	B-MED
with	O
health	B-MED
-promoting	O
genome-wide	B-MED
association	I-MED
mapping	I-MED
in	O
winter	B-MED
barley	I-MED
for	O
grain	B-MED
yield	B-MED
and	O
culm	B-MED
cell	B-MED
wall	I-MED
polymer	B-MED
content	B-MED
using	O
the	O
high-throughput	O
compp	B-MED
technique	I-MED
a	O
collection	B-MED
of	O
112	O
winter	B-MED
barley	I-MED
varieties	I-MED
hordeum	B-MED
vulgare	I-MED
l	I-MED
was	O
grown	B-MED
in	O
the	O
field	B-MED
for	O
two	O
years	B-MED
2008/09	O
and	O
2009/10	O
in	O
northern	B-MED
italy	B-MED
and	O
grain	B-MED
and	O
straw	B-MED
yields	B-MED
recorded	O
.	O
	
in	O
the	O
first	O
year	B-MED
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	B-MED
yellow	I-MED
mosaic	I-MED
virus	I-MED
baymv	B-MED
strongly	O
influenced	B-MED
final	O
performances	B-MED
with	O
an	O
average	B-MED
reduction	B-MED
of	O
50%	O
for	O
grain	B-MED
and	O
straw	B-MED
harvested	B-MED
in	O
comparison	B-MED
to	O
the	O
second	B-MED
year	B-MED
.	O
	
the	O
genetic	B-MED
determination	I-MED
gd	B-MED
for	O
grain	B-MED
yield	B-MED
was	O
0.49	O
and	O
0.70	O
,	O
for	O
the	O
two	O
years	B-MED
respectively	O
,	O
and	O
for	O
straw	B-MED
yield	B-MED
gd	B-MED
was	O
low	O
in	O
2009	O
0.09	O
and	O
higher	O
in	O
2010	O
0.29	O
.	O
	
cell	B-MED
wall	I-MED
polymers	B-MED
in	O
culms	B-MED
were	O
quantified	O
by	O
means	O
of	O
the	O
monoclonal	O
antibodies	O
lm6	O
,	O
lm11	O
,	O
jim13	O
and	O
bs-400-3	O
and	O
the	O
carbohydrate-binding	O
module	O
cbm3a	O
using	O
the	O
high-throughput	O
compp	O
technique	O
.	O
	
of	O
these	O
,	O
lm6	O
,	O
which	O
detects	O
arabinan	O
components	O
,	O
showed	O
a	O
relatively	O
high	O
gd	O
in	O
both	O
years	O
and	O
a	O
significantly	O
negative	O
correlation	O
with	O
grain	O
yield	O
gyld	O
.	O
	
overall	O
,	O
heritability	O
h2	O
was	O
calculated	O
for	O
gyld	O
,	O
lm6	O
and	O
jim	O
and	O
resulted	O
to	O
be	O
0.42	O
,	O
0.32	O
and	O
0.20	O
,	O
respectively	O
.	O
	
a	O
total	O
of	O
4	O
snps	O
from	O
the	O
9k	O
iselect	O
array	O
were	O
used	O
in	O
the	O
study	O
for	O
the	O
analysis	O
of	O
population	O
structure	O
,	O
linkage	O
disequilibrium	O
ld	O
and	O
genome-wide	O
association	O
study	O
gwas	O
.	O
	
marker-trait	O
associations	O
mta	O
were	O
analyzed	O
for	O
grain	O
yield	O
and	O
cell	O
wall	O
determination	O
by	O
lm6	O
and	O
jim13	O
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	O
correlations	O
between	O
the	O
years	O
.	O
	
a	O
single	O
qtl	O
for	O
gyld	O
containing	O
three	O
mtas	O
was	O
found	O
on	O
chromosome	O
3h	O
located	O
close	O
to	O
the	O
hv-eif4e	O
gene	O
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	O
to	O
baymv	O
.	O
	
subsequently	O
the	O
qtl	O
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	O
,	O
a	O
locus	O
for	O
resistance	O
to	O
the	O
virus	O
.	O
	
gwas	O
on	O
arabinans	O
quantified	O
by	O
lm6	O
resulted	O
in	O
the	O
identification	O
of	O
major	O
qtls	O
closely	O
located	O
on	O
3h	O
and	O
hypotheses	O
regarding	O
putative	O
candidate	O
genes	O
were	O
formulated	O
through	O
the	O
study	O
of	O
gene	O
expression	O
levels	O
based	O
on	O
bioinformatics	O
the	O
prevalence	B-MED
and	O
clinical	B-MED
relevance	B-MED
of	O
asa	B-MED
nonresponse	B-MED
after	O
cardiac	B-MED
surgery	I-MED
we	O
aimed	O
to	O
identify	O
the	O
prevalence	B-MED
of	O
acetylsalicylic	B-MED
acid	I-MED
asa	B-MED
nonresponse	B-MED
in	O
patients	B-MED
after	O
coronary	B-MED
artery	I-MED
bypass	I-MED
graft	I-MED
cabg	I-MED
surgery	I-MED
and	O
the	O
possible	O
consequences	B-MED
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B-MED
events	I-MED
.	O
	
this	O
prospective	B-MED
,	O
observational	B-MED
,	O
bicentric	B-MED
cohort	I-MED
study	I-MED
was	O
conducted	O
in	O
two	O
german	B-MED
university	I-MED
hospitals	I-MED
.	O
	
a	O
total	O
of	O
400	O
patients	B-MED
200	O
in	O
each	O
study	O
center	O
undergoing	O
elective	B-MED
cabg	B-MED
surgery	I-MED
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O
	
platelet	B-MED
function	I-MED
was	O
analyzed	O
on	O
day	O
3	O
d3	O
and	O
day	O
5	O
d5	O
postoperatively	B-MED
following	O
stimulation	O
with	O
arachidonic	B-MED
acid	I-MED
aspitest	B-MED
and	O
with	O
thrombin	B-MED
receptor-activating	I-MED
peptide	I-MED
6	I-MED
traptest	B-MED
using	O
multiple	B-MED
electrode	I-MED
aggregometry	I-MED
multiplate	B-MED
.	O
	
individuals	O
with	O
an	O
aspitest	B-MED
40	O
au	O
were	O
categorized	O
as	O
asa	B-MED
nonresponders	B-MED
.	O
	
a	O
1-year	O
follow-up	B-MED
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B-MED
events	I-MED
,	O
hospital	B-MED
admissions	I-MED
,	O
or	O
deaths	B-MED
related	O
to	O
cardiovascular	B-MED
disease	I-MED
.	O
	
the	O
prevalence	B-MED
of	O
asa	B-MED
nonresponse	B-MED
was	O
51.5	O
on	O
d3	O
,	O
and	O
it	O
significantly	B-MED
increased	B-MED
to	O
71.3	O
on	O
d5	O
p	O
=	O
0049	O
.	O
	
the	O
area	O
under	O
the	O
aggregation	B-MED
curve	I-MED
in	O
the	O
traptest	B-MED
p	O
<	O
0001	O
,	O
the	O
platelet	B-MED
count	I-MED
on	O
d5	O
p	O
=	O
009	O
,	O
and	O
the	O
cardiopulmonary	B-MED
bypass	I-MED
time	I-MED
p	O
=	O
01	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
asa	B-MED
nonresponse	B-MED
.	O
	
a	O
1-year	O
follow-up	B-MED
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	B-MED
point	I-MED
with	O
no	O
difference	O
between	O
asa	B-MED
responders	B-MED
and	O
nonresponders	B-MED
.	O
	
this	O
study	B-MED
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	B-MED
asa	B-MED
nonresponse	B-MED
in	O
patients	B-MED
following	O
cabg	B-MED
.	O
	
no	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B-MED
events	I-MED
was	O
recorded	O
in	O
the	O
1-year	O
follow-up	B-MED
.	O
	
therefore	O
,	O
a	O
randomized	B-MED
dosage	I-MED
adjustment	I-MED
trial	I-MED
should	O
elucidate	O
whether	O
a	O
tailored	O
asa	B-MED
treatment	B-MED
after	O
cabg	B-MED
surgery	I-MED
genome	B-MED
sequences	I-MED
of	O
mycobacteriophages	B-MED
jane	I-MED
and	I-MED
sneeze	I-MED
,	O
new	O
members	O
of	O
cluster	O
g	O
jane	O
and	O
sneeze	O
are	O
newly	O
isolated	B-MED
phages	B-MED
of	O
mycobacterium	B-MED
smegmatis	I-MED
mc	I-MED
from	O
hillsborough	B-MED
,	O
nj	B-MED
,	O
and	O
palo	B-MED
verde	I-MED
,	O
costa	B-MED
rica	I-MED
,	O
respectively	O
.	O
	
both	O
are	O
cluster	O
g	O
,	O
subcluster	O
g1	O
mycobacteriophages	B-MED
.	O
	
notable	O
nucleotide	B-MED
differences	B-MED
exist	O
between	O
genomes	B-MED
in	O
the	O
right	O
half	O
,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-MED
mobile	B-MED
element	I-MED
1	I-MED
effect	B-MED
of	O
punica	B-MED
granatum	I-MED
fruit	B-MED
peel	I-MED
on	O
glucose-6-phosphate	B-MED
dehydrogenase	I-MED
and	O
malate	B-MED
dehydrogenase	I-MED
in	O
amphistome	B-MED
gastrothylax	B-MED
indicus	I-MED
increasing	B-MED
anthelmintic	B-MED
resistance	B-MED
and	O
the	O
impact	B-MED
of	O
conventional	O
anthelmintics	B-MED
on	O
the	O
environment	B-MED
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth	B-MED
parasite	I-MED
in	O
sheep	B-MED
.	O
	
important	O
lipogenic	B-MED
enzymes	I-MED
like	O
glucose-6-phosphate	B-MED
dehydrogenase	I-MED
g-6-pdh	B-MED
and	O
malate	B-MED
dehydrogenase	I-MED
mdh	B-MED
show	O
subcellular	B-MED
distribution	B-MED
pattern	I-MED
.	O
	
activity	B-MED
of	O
g-6-pdh	B-MED
was	O
largely	O
restricted	O
to	O
cytosolic	B-MED
fraction	I-MED
while	O
mdh	B-MED
was	O
found	O
in	O
both	O
cytosolic	B-MED
and	O
mitochondrial	B-MED
fraction	I-MED
in	O
gastrothylax	B-MED
indicus	I-MED
.	O
	
following	O
in	B-MED
vitro	I-MED
treatment	B-MED
with	O
ethanolic	B-MED
and	O
aqueous	B-MED
extracts	I-MED
of	O
punica	B-MED
granatum	I-MED
fruit	B-MED
peel	I-MED
and	O
commercial	O
anthelmintic	B-MED
,	O
albendazole	B-MED
g-6-pdh	B-MED
activity	B-MED
was	O
decreased	B-MED
by	O
19-32	O
%	O
,	O
whereas	O
mdh	B-MED
was	O
suppressed	B-MED
by	O
24-41	O
%	O
,	O
compared	O
to	O
the	O
respective	O
control	B-MED
.	O
	
albendazole	B-MED
was	O
quite	O
effective	B-MED
when	O
compared	O
with	O
negative	B-MED
control	I-MED
and	O
both	O
the	O
extracts	B-MED
.	O
	
the	O
results	B-MED
indicate	O
that	O
phytochemicals	B-MED
of	O
plant	B-MED
may	O
act	O
as	O
potential	B-MED
vermifuge	B-MED
or	O
remitting	B-MED
seronegative	I-MED
symmetrical	I-MED
synovitis	I-MED
with	I-MED
pitting	I-MED
edema	I-MED
appearance	O
on	O
fdg	B-MED
pet/ct	I-MED
remitting	B-MED
seronegative	I-MED
symmetrical	I-MED
synovitis	I-MED
with	I-MED
pitting	I-MED
edema	I-MED
rs3pe	B-MED
is	O
a	O
rare	B-MED
condition	I-MED
in	O
the	O
elderly	B-MED
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	B-MED
of	O
rheumatic	B-MED
and	O
malignant	B-MED
diseases	I-MED
.	O
	
we	O
presented	O
a	O
62-	O
year	B-MED
-old	O
man	B-MED
with	O
the	O
diagnosis	B-MED
of	O
rs3pe	B-MED
based	O
on	O
the	O
clinical	B-MED
sign	I-MED
and	O
laboratory	B-MED
data	I-MED
.	O
	
because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-MED
in	O
rs3pe	B-MED
,	O
fdg	B-MED
pet/ct	I-MED
was	O
performed	O
to	O
exclude	O
occult	B-MED
tumors	I-MED
.	O
	
the	O
images	B-MED
showed	O
multiple	B-MED
,	O
symmetrically	B-MED
,	O
diffusely	B-MED
increased	B-MED
f-fdg	B-MED
uptake	B-MED
in	O
the	O
soft	B-MED
tissue	I-MED
around	O
joints	B-MED
and	O
bones	B-MED
in	O
the	O
shoulders	B-MED
,	O
hips	B-MED
,	O
knees	B-MED
,	O
and	O
parks	B-MED
as	O
social	B-MED
and	O
cultural	B-MED
spaces	B-MED
among	O
u.s	B-MED
-	O
and	O
foreign	B-MED
-	O
born	B-MED
latinas	B-MED
parks	B-MED
provide	O
opportunities	B-MED
for	O
people	B-MED
to	O
engage	O
in	O
activities	B-MED
that	O
can	O
promote	B-MED
physical	B-MED
and	O
emotional	B-MED
well-being	B-MED
.	O
	
using	O
focus	B-MED
groups	I-MED
and	O
personal	B-MED
interviews	B-MED
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
northeastern	B-MED
city	B-MED
with	O
a	O
high	B-MED
rate	B-MED
of	O
obesity	B-MED
,	O
we	O
examined	B-MED
perceptions	B-MED
of	O
barriers	B-MED
and	O
facilitators	B-MED
regarding	O
the	O
use	B-MED
of	I-MED
parks	B-MED
and	O
park	B-MED
features	B-MED
that	O
would	O
promote	B-MED
physical	B-MED
activity	I-MED
among	O
latina	B-MED
women	B-MED
n	O
=	O
39	O
.	O
	
foreign	B-MED
-	O
born	B-MED
latinas	B-MED
emphasized	O
the	O
environmental	B-MED
characteristics	B-MED
of	O
parks	B-MED
and	O
the	O
types	B-MED
of	O
amenities	B-MED
that	O
can	O
support	O
preferred	O
cultural	B-MED
and	O
social	B-MED
activities	I-MED
,	O
while	O
u.s	B-MED
.	O
	
-	O
born	B-MED
latinas	B-MED
emphasized	O
the	O
use	O
of	O
parks	B-MED
for	O
physical	B-MED
activity	I-MED
and	O
weight	B-MED
management	B-MED
.	O
	
most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	B-MED
-	O
born	B-MED
participants	B-MED
conceptualized	B-MED
parks	B-MED
as	O
sociocultural	B-MED
family	I-MED
centers	I-MED
,	O
extending	O
more	O
common	B-MED
conceptualizations	B-MED
centered	O
on	O
exercise	B-MED
or	O
individual	B-MED
health	B-MED
gain	B-MED
.	O
	
these	O
findings	B-MED
suggest	O
the	O
need	O
for	O
new	B-MED
policies	B-MED
that	O
incorporate	O
culturally	B-MED
specific	B-MED
park	B-MED
programming	B-MED
to	O
promote	B-MED
national	O
goals	B-MED
of	O
increasing	B-MED
levels	B-MED
of	O
physical	B-MED
activity	I-MED
for	O
the	O
impact	B-MED
of	O
childhood	B-MED
maltreatment	I-MED
on	O
the	O
differential	B-MED
efficacy	B-MED
of	O
cbasp	B-MED
versus	O
escitalopram	B-MED
in	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
a	O
secondary	B-MED
analysis	I-MED
childhood	B-MED
maltreatment	I-MED
cm	B-MED
has	O
been	O
indicated	B-MED
as	O
a	O
predictor	B-MED
of	O
a	O
differential	B-MED
response	B-MED
to	O
antidepressant	B-MED
treatment	I-MED
with	O
psychotherapy	B-MED
compared	B-MED
to	O
medication	B-MED
.	O
	
in	O
this	O
secondary	B-MED
analysis	I-MED
,	O
we	O
investigated	B-MED
whether	O
the	O
presence	B-MED
of	O
cm	B-MED
results	B-MED
in	O
a	O
differential	B-MED
indication	B-MED
for	O
the	O
cognitive	B-MED
behavioral	I-MED
analysis	I-MED
system	I-MED
of	I-MED
psychotherapy	I-MED
cbasp	B-MED
or	O
escitalopram	B-MED
plus	O
clinical	B-MED
management	I-MED
esc	B-MED
.	O
	
sixty	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
were	O
randomized	B-MED
to	O
either	O
22	O
sessions	B-MED
of	O
cbasp	B-MED
or	O
esc	B-MED
over	O
the	O
course	B-MED
of	O
8	B-MED
weeks	I-MED
of	O
acute	B-MED
and	O
20	B-MED
weeks	I-MED
of	O
extended	B-MED
treatment	B-MED
at	O
2	O
german	B-MED
treatment	B-MED
sites	I-MED
.	O
	
cm	B-MED
was	O
assessed	B-MED
using	O
the	O
childhood	B-MED
trauma	B-MED
questionnaire	B-MED
and	O
the	O
clinician	B-MED
rated	B-MED
early	B-MED
trauma	I-MED
inventory	I-MED
.	O
	
intention-to-treat	B-MED
analyses	I-MED
were	O
used	O
to	O
examine	O
the	O
impact	B-MED
of	O
cm	B-MED
on	O
depression	B-MED
,	O
global	B-MED
functioning	I-MED
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
.	O
	
the	O
presence	B-MED
of	O
cm	B-MED
did	O
not	O
result	B-MED
in	O
significant	B-MED
differences	B-MED
in	O
treatment	B-MED
response	I-MED
to	O
cbasp	B-MED
or	O
esc	B-MED
on	O
any	O
outcome	B-MED
measure	I-MED
after	O
28	B-MED
weeks	I-MED
of	O
treatment	B-MED
independent	B-MED
of	I-MED
the	O
type	O
of	O
cm	B-MED
assessment	B-MED
.	O
	
after	O
8	B-MED
weeks	I-MED
,	O
a	O
significant	B-MED
cm	B-MED
treatment	B-MED
interaction	B-MED
was	O
found	B-MED
for	O
scores	B-MED
on	O
the	O
montgomery-asberg	B-MED
depression	I-MED
rating	I-MED
scale	I-MED
.	O
	
patients	B-MED
with	O
a	O
history	B-MED
of	O
cm	B-MED
receiving	B-MED
cbasp	B-MED
had	O
a	O
significantly	B-MED
lower	I-MED
response	B-MED
rate	I-MED
compared	B-MED
to	O
patients	B-MED
without	O
cm	B-MED
and	O
to	O
those	O
receiving	B-MED
esc	B-MED
after	O
8	B-MED
weeks	I-MED
.	O
	
conclusively	B-MED
,	O
cbasp	B-MED
and	O
esc	B-MED
are	O
equally	O
effective	B-MED
treatment	B-MED
options	O
for	O
the	O
difficult	B-MED
to	O
treat	B-MED
subgroup	B-MED
of	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
and	O
a	O
history	B-MED
of	O
cm	B-MED
.	O
	
cm	B-MED
may	O
be	O
a	O
predictor	B-MED
of	O
a	O
longer	B-MED
latency	B-MED
of	O
treatment	B-MED
response	I-MED
in	O
the	O
case	B-MED
of	O
psychotherapy	B-MED
.	O
	
cbasp	B-MED
and	O
escitalopram	B-MED
are	O
equally	O
effective	B-MED
treatment	B-MED
options	O
for	O
chronic	B-MED
depression	I-MED
.	O
	
both	O
treatments	B-MED
are	O
also	O
equally	O
effective	B-MED
for	O
the	O
difficult	B-MED
to	O
treat	B-MED
subgroup	B-MED
of	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
and	O
a	O
history	B-MED
of	O
childhood	B-MED
maltreatment	I-MED
.	O
	
childhood	B-MED
maltreatment	I-MED
may	O
result	B-MED
in	O
a	O
longer	B-MED
latency	B-MED
of	O
treatment	B-MED
response	I-MED
in	O
the	O
case	B-MED
of	O
a	O
role	O
for	O
the	O
locus	B-MED
coeruleus	I-MED
in	O
the	O
analgesic	B-MED
efficacy	I-MED
of	O
n-acetylaspartylglutamate	B-MED
peptidase	I-MED
gcpii	B-MED
inhibitors	B-MED
zj43	B-MED
and	O
2-pmpa	B-MED
n-acetylaspartylglutamate	B-MED
naag	B-MED
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B-MED
in	O
the	O
mammalian	B-MED
nervous	B-MED
system	I-MED
.	O
	
naag	B-MED
activates	B-MED
a	O
group	B-MED
ii	I-MED
metabotropic	I-MED
glutamate	I-MED
receptor	I-MED
mglur3	B-MED
and	O
is	O
inactivated	O
by	O
an	O
extracellular	B-MED
enzyme	I-MED
,	O
glutamate	I-MED
carboxypeptidase	I-MED
ii	I-MED
gcpii	B-MED
in	B-MED
vivo	I-MED
.	O
	
inhibitors	B-MED
of	I-MED
this	I-MED
enzyme	I-MED
are	O
analgesic	B-MED
in	O
animal	B-MED
models	I-MED
of	O
inflammatory	B-MED
,	O
neuropathic	B-MED
and	O
bone	B-MED
cancer	I-MED
pain	B-MED
.	O
	
naag	B-MED
and	O
gcpii	B-MED
are	O
present	O
in	O
the	O
locus	B-MED
coeruleus	I-MED
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	B-MED
inhibitory	B-MED
pain	O
system	O
.	O
	
in	O
the	O
formalin	B-MED
footpad	B-MED
model	B-MED
,	O
systemic	B-MED
treatment	B-MED
with	O
gcpii	B-MED
inhibitors	I-MED
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-MED
pain	I-MED
response	B-MED
and	O
increases	O
release	O
of	O
spinal	B-MED
noradrenaline	B-MED
.	O
	
this	O
analgesic	B-MED
efficacy	I-MED
is	O
blocked	B-MED
by	O
systemic	B-MED
injection	B-MED
of	O
a	O
group	B-MED
ii	I-MED
mglur	I-MED
antagonist	B-MED
,	O
by	O
intrathecal	B-MED
spinal	I-MED
injection	I-MED
of	O
an	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptor	I-MED
antagonist	I-MED
and	O
by	O
microinjection	B-MED
of	O
an	O
α-amino-3-hydroxy-5-methylisoxazole-4-propionic	B-MED
acid	I-MED
ampa	I-MED
receptor	I-MED
antagonist	I-MED
directly	O
into	O
the	O
contralateral	B-MED
locus	B-MED
coeruleus	I-MED
.	O
	
footpad	B-MED
inflammation	B-MED
increases	O
release	O
of	O
glutamate	B-MED
in	O
the	O
contralateral	B-MED
locus	B-MED
coeruleu	I-MED
s	O
and	O
systemic	B-MED
treatment	B-MED
with	O
a	O
gcpii	B-MED
inhibitor	I-MED
blocks	B-MED
this	O
increase	O
.	O
	
direct	B-MED
injection	B-MED
of	O
gcpii	B-MED
inhibitors	I-MED
into	O
the	O
contralateral	B-MED
or	O
ipsilatera	B-MED
l	O
locus	B-MED
coeruleus	I-MED
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-MED
pain	I-MED
response	B-MED
in	O
a	O
dose-dependent	B-MED
manner	O
and	O
the	O
contralateral	B-MED
effect	B-MED
also	O
is	O
blocked	B-MED
by	O
intrathecal	B-MED
injection	I-MED
of	O
an	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptor	I-MED
antagonist	I-MED
.	O
	
these	O
data	O
support	O
the	O
hypothesis	B-MED
that	O
the	O
analgesic	B-MED
efficacy	I-MED
of	O
systemically	O
administered	O
gcpii	B-MED
inhibitors	I-MED
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	B-MED
l	O
locus	B-MED
coeruleus	I-MED
via	O
group	B-MED
ii	I-MED
mglur	I-MED
,	O
ampa	B-MED
and	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptors	I-MED
.	O
	
association	B-MED
of	O
physical	B-MED
activity	I-MED
on	O
body	B-MED
composition	I-MED
,	O
cardiometabolic	B-MED
risk	I-MED
factors	I-MED
,	O
and	O
prevalence	B-MED
of	O
cardiovascular	B-MED
disease	I-MED
in	O
the	O
korean	B-MED
population	I-MED
from	O
the	O
fifth	O
korea	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
,	O
2008-2011	O
data	B-MED
regarding	O
associations	B-MED
among	O
physical	B-MED
activity	I-MED
pa	B-MED
level	B-MED
,	O
body	B-MED
composition	I-MED
,	O
and	O
prevalence	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
in	O
asian	B-MED
populations	I-MED
are	O
rare	B-MED
.	O
	
the	O
international	B-MED
physical	I-MED
activity	I-MED
questionnaire	I-MED
ipaq	B-MED
was	O
utilized	O
to	O
estimate	B-MED
pa	B-MED
levels	B-MED
and	O
analyze	B-MED
the	O
association	B-MED
of	O
pa	B-MED
level	B-MED
with	O
various	O
body	B-MED
composition	I-MED
parameters	B-MED
and	O
the	O
prevalence	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
by	O
using	O
data	B-MED
from	O
the	O
korean	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
from	O
2008	O
to	O
2011	O
.	O
	
moderate	B-MED
and	O
high	B-MED
pa	B-MED
levels	B-MED
were	O
associated	B-MED
with	O
lower	B-MED
prevalence	I-MED
of	O
hypertension	B-MED
and	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
lower	B-MED
concentrations	B-MED
of	O
serum	B-MED
ferritin	I-MED
,	O
parathyroid	B-MED
hormone	I-MED
,	O
and	O
alkaline	B-MED
phosphatase	I-MED
.	O
	
sarcopenia	B-MED
low	B-MED
vs	O
.	O
	
moderate	B-MED
vs	O
.	O
	
high	B-MED
pa	B-MED
group	B-MED
14.3	O
vs	O
.	O
	
10.5	O
vs	O
.	O
	
7.3	O
,	O
p	B-MED
=	O
0.001	O
,	O
underweight	B-MED
5.7	O
vs	O
.	O
	
4.9	O
vs	O
.	O
	
3.5	O
,	O
p	O
=	O
0.001	O
,	O
and	O
central	B-MED
obesity	I-MED
7.8	O
vs	O
.	O
	
6.9	O
vs	O
.	O
	
6.3	O
,	O
p	O
=	O
0.002	O
were	O
more	O
often	O
observed	B-MED
in	O
the	O
low	B-MED
pa	B-MED
group	B-MED
.	O
	
the	O
prevalence	B-MED
rates	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
were	O
lower	B-MED
in	O
the	O
moderate	B-MED
odds	B-MED
ratio	I-MED
or	B-MED
,	O
0.822	O
95%	O
confidence	B-MED
interval	I-MED
ci	B-MED
,	O
0.737	O
p	B-MED
=	O
0.001	O
and	O
high	B-MED
activity	B-MED
groups	B-MED
or	B-MED
,	O
0.663	O
95%	O
ci	B-MED
,	O
0.589	O
p	B-MED
=	O
0.001	O
than	O
in	O
the	O
low	B-MED
activity	B-MED
group	B-MED
,	O
even	O
after	O
adjusting	O
for	O
age	B-MED
,	O
sex	B-MED
,	O
smoking	B-MED
,	O
underlying	B-MED
disease	I-MED
,	O
and	O
general	B-MED
or	O
abdominal	B-MED
obesity	I-MED
and	O
muscle	B-MED
mass	I-MED
.	O
	
regular	B-MED
physical	I-MED
activity	I-MED
was	O
associated	B-MED
with	O
a	O
low	B-MED
prevalence	I-MED
of	O
cardiovascular	B-MED
diseases	I-MED
stroke	B-MED
,	O
myocardial	B-MED
infarction	I-MED
,	O
stable	B-MED
angina	I-MED
,	O
and	O
chronic	B-MED
renal	I-MED
disease	I-MED
,	O
which	O
was	O
independent	B-MED
of	I-MED
body	B-MED
composition	I-MED
and	O
conventional	O
risk	B-MED
factors	I-MED
in	O
the	O
korean	B-MED
population	I-MED
,	O
with	O
a	O
positive	B-MED
dose-response	B-MED
relationship	I-MED
.	O
	
treated	B-MED
prevalence	B-MED
of	O
attention-deficit/hyperactivity	B-MED
disorder	I-MED
increased	B-MED
from	O
2009	O
to	O
2015	O
among	O
school-aged	B-MED
children	I-MED
and	O
adolescents	B-MED
in	O
the	O
united	B-MED
states	I-MED
the	O
purpose	B-MED
of	O
this	O
brief	O
is	O
to	O
describe	B-MED
changes	B-MED
in	O
the	O
treated	B-MED
prevalence	B-MED
of	O
medically	B-MED
managed	B-MED
attention-deficit/hyperactivity	B-MED
disorder	I-MED
adhd	B-MED
among	O
insured	B-MED
school-aged	B-MED
children	I-MED
and	O
adolescents	B-MED
in	O
the	O
united	B-MED
states	I-MED
from	O
2009	O
to	O
2015	O
.	O
	
we	O
examine	B-MED
the	O
differences	B-MED
between	O
those	O
with	O
employer-sponsored	B-MED
insurance	I-MED
esi	B-MED
and	O
with	O
medicaid	B-MED
insurance	I-MED
.	O
	
we	O
utilized	O
two	O
large	O
longitudinal	B-MED
administrative	B-MED
datasets	I-MED
containing	O
medical	B-MED
and	O
drug	B-MED
claims	B-MED
data	B-MED
on	O
individuals	B-MED
with	O
esi	B-MED
and	O
medicaid	B-MED
insurance	I-MED
from	O
truven	B-MED
health	I-MED
marketscan	I-MED
administrative	I-MED
claims	I-MED
databases	I-MED
.	O
	
treated	B-MED
prevalence	B-MED
was	O
measured	B-MED
as	O
the	O
percentage	B-MED
of	O
school-aged	B-MED
children	I-MED
and	O
adolescents	B-MED
enrolled	O
in	O
a	O
calendar	B-MED
year	I-MED
who	O
met	O
the	O
criteria	B-MED
for	O
medically	B-MED
managed	B-MED
adhd	B-MED
in	O
the	O
same	O
calendar	B-MED
year	I-MED
.	O
	
subjects	B-MED
were	O
eligible	B-MED
for	O
inclusion	B-MED
if	O
they	O
were	O
aged	B-MED
6-17	O
years	B-MED
and	O
were	O
continuously	B-MED
enrolled	O
during	O
a	O
calendar	B-MED
year	I-MED
.	O
	
the	O
annual	B-MED
prevalence	B-MED
of	O
treated	B-MED
adhd	B-MED
among	O
school-aged	B-MED
children	I-MED
and	O
adolescents	B-MED
with	O
esi	B-MED
increased	B-MED
from	O
4.5	O
in	O
2009	O
to	O
6.7	O
in	O
2015	O
.	O
	
among	O
those	O
with	O
medicaid	B-MED
it	O
increased	B-MED
from	O
11.3	O
in	O
2009	O
to	O
13.3	O
in	O
2012	O
,	O
and	O
fell	O
after	O
2012	O
,	O
remaining	O
steady	B-MED
from	O
2013	O
through	O
2015	O
.	O
	
treated	B-MED
prevalence	B-MED
of	O
adhd	B-MED
increased	B-MED
continuously	B-MED
over	O
time	B-MED
among	O
school-aged	B-MED
children	I-MED
and	O
adolescents	B-MED
with	O
esi	B-MED
,	O
but	O
declined	B-MED
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
medicaid	B-MED
sample	I-MED
.	O
	
acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
after	O
pancreas	B-MED
transplantation	I-MED
with	O
accelerated	B-MED
progression	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
the	O
effect	O
of	O
pancreas	B-MED
transplantation	I-MED
on	O
diabetic	B-MED
retinopathy	I-MED
remains	O
inconclusive	B-MED
.	O
	
herein	O
,	O
we	O
report	O
six	O
patients	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
dm	B-MED
who	O
underwent	O
pancreas	B-MED
transplantation	I-MED
and	O
developed	O
acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
with	O
rapid	B-MED
progression	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
.	O
	
in	O
this	O
retrospective	B-MED
observational	I-MED
study	I-MED
,	O
diabetic	B-MED
patients	B-MED
who	O
underwent	O
pancreas	B-MED
transplantation	I-MED
in	O
a	O
single	B-MED
medical	B-MED
center	I-MED
and	O
developed	O
symptomatic	B-MED
acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
within	B-MED
3	B-MED
months	I-MED
after	B-MED
the	O
operation	B-MED
were	O
enrolled	O
.	O
	
the	O
complete	B-MED
ophthalmic	B-MED
course	I-MED
and	O
medical	B-MED
records	I-MED
of	O
the	O
patients	B-MED
were	O
retrospectively	B-MED
reviewed	B-MED
.	O
	
diabetic	B-MED
retinopathy	I-MED
and	O
progression	B-MED
following	B-MED
treatment	B-MED
after	O
pancreas	B-MED
transplantation	I-MED
were	O
measured	B-MED
.	O
	
six	O
chinese	B-MED
women	B-MED
with	O
type	B-MED
1	I-MED
dm	I-MED
were	O
enrolled	O
in	O
this	O
study	B-MED
.	O
	
mean	O
hemoglobin	B-MED
hb	I-MED
a1c	I-MED
was	O
13.4	O
prior	O
to	O
transplantation	B-MED
and	O
decreased	B-MED
rapidly	B-MED
to	O
6.5	O
within	B-MED
2	B-MED
months	I-MED
postsurgery	B-MED
.	O
	
the	O
patients	B-MED
had	O
no	B-MED
or	O
mild	B-MED
pretransplant	B-MED
diabetic	B-MED
retinopathy	I-MED
and	O
developed	O
acute	B-MED
symptomatic	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
in	O
both	B-MED
eyes	I-MED
after	O
pancreas	B-MED
transplantation	I-MED
.	O
	
all	O
macular	B-MED
edema	I-MED
resolved	B-MED
either	O
with	O
or	O
without	B-MED
treatment	B-MED
.	O
	
five	O
cases	B-MED
progressed	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
and	O
received	B-MED
panretinal	B-MED
photocoagulation	I-MED
.	O
	
diabetic	B-MED
retinopathy	I-MED
remained	O
stable	B-MED
in	O
all	B-MED
eyes	B-MED
after	B-MED
treatment	B-MED
,	O
and	O
the	O
visual	B-MED
prognosis	B-MED
was	I-MED
good	I-MED
,	O
except	B-MED
in	O
one	B-MED
eye	B-MED
that	O
had	O
macular	B-MED
branch	B-MED
retinal	I-MED
artery	I-MED
occlusion	I-MED
with	O
foveal	B-MED
involvement	B-MED
.	O
	
acute	B-MED
macular	B-MED
edema	I-MED
after	O
pancreas	B-MED
transplantation	I-MED
has	O
a	O
favorable	B-MED
treatment	B-MED
outcome	I-MED
despite	O
rapid	O
progression	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
.	O
	
high	B-MED
pretransplant	B-MED
hba1c	B-MED
and	O
abrupt	B-MED
blood	B-MED
sugar	I-MED
normalization	B-MED
may	O
be	O
related	O
to	O
the	O
disease	B-MED
course	I-MED
.	O
	
anger	B-MED
and	O
aggression	B-MED
in	O
borderline	B-MED
personality	I-MED
disorder	I-MED
and	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
-	O
does	O
stress	B-MED
matter	O
the	O
impact	B-MED
of	O
stress	B-MED
on	O
anger	B-MED
and	O
aggression	B-MED
in	O
borderline	B-MED
personality	I-MED
disorder	I-MED
bpd	B-MED
and	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
adhd	B-MED
has	O
not	O
been	O
thoroughly	O
investigated	B-MED
.	O
	
the	O
goal	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
different	O
aspects	O
of	O
anger	B-MED
and	O
aggression	B-MED
in	O
patients	B-MED
with	O
these	O
disorders	B-MED
.	O
	
twenty-nine	O
unmedicated	B-MED
female	B-MED
bpd	B-MED
patients	B-MED
,	O
28	O
adhd	B-MED
patients	B-MED
and	O
30	O
healthy	B-MED
controls	I-MED
hc	B-MED
completed	O
self-reports	B-MED
measuring	B-MED
trait	B-MED
anger	B-MED
,	O
aggression	B-MED
and	O
emotion	B-MED
regulation	I-MED
capacities	O
.	O
	
a	O
modified	O
version	O
of	O
the	O
point	B-MED
subtraction	I-MED
aggression	I-MED
paradigm	I-MED
and	O
a	O
state	B-MED
anger	I-MED
measurement	I-MED
were	O
applied	O
under	O
resting	B-MED
and	O
stress	B-MED
conditions	I-MED
.	O
	
stress	B-MED
was	O
induced	B-MED
by	O
the	O
mannheim	B-MED
multicomponent	I-MED
stress	I-MED
test	I-MED
mmst	B-MED
.	O
	
both	O
patient	B-MED
groups	O
scored	B-MED
significantly	O
higher	O
on	O
all	O
self-report	B-MED
measures	B-MED
compared	B-MED
to	O
hcs	B-MED
.	O
	
compared	B-MED
to	O
adhd	B-MED
patients	B-MED
,	O
bpd	B-MED
patients	B-MED
reported	O
higher	O
trait	B-MED
aggression	B-MED
and	O
hostility	B-MED
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	B-MED
when	O
provoked	O
and	O
to	O
direct	O
anger	B-MED
inwardly	O
.	O
	
furthermore	O
,	O
bpd	B-MED
patients	B-MED
exhibited	O
higher	O
state	O
anger	B-MED
than	O
hcs	B-MED
and	O
adhd	B-MED
patients	B-MED
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	B-MED
anger	B-MED
increase	O
.	O
	
at	O
the	O
behavioral	B-MED
level	I-MED
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O
	
in	O
bpd	B-MED
patients	B-MED
,	O
aggression	B-MED
and	O
anger	B-MED
were	O
positively	O
correlated	O
with	O
emotion	B-MED
regulation	I-MED
deficits	B-MED
.	O
	
our	O
findings	B-MED
suggest	O
a	O
significant	O
impact	B-MED
of	O
stress	B-MED
on	O
self-perceived	O
state	O
anger	B-MED
in	O
bpd	B-MED
patients	B-MED
but	O
not	O
on	O
aggressive	B-MED
behavior	I-MED
towards	O
others	O
in	O
females	B-MED
with	O
bpd	B-MED
or	O
adhd	B-MED
.	O
	
however	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	B-MED
which	O
is	O
of	O
clinical	B-MED
importance	B-MED
in	O
bpd	B-MED
patients	B-MED
.	O
	
interferon	B-MED
gamma	I-MED
and	O
interleukin	B-MED
10	I-MED
polymorphisms	B-MED
in	O
chinese	B-MED
children	B-MED
with	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
the	O
aim	O
of	O
the	O
study	B-MED
is	O
to	O
investigate	B-MED
the	O
association	O
of	O
interferon	B-MED
gamma	I-MED
ifn-γ	B-MED
and	O
interleukin-10	B-MED
il-10	B-MED
gene	B-MED
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
with	O
the	O
susceptibility	B-MED
of	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
hlh	B-MED
in	O
chinese	B-MED
children	B-MED
without	B-MED
known	I-MED
family	I-MED
history	I-MED
of	I-MED
hlh	B-MED
.	O
	
forty	O
children	B-MED
with	O
hlh	B-MED
and	O
160	O
age	B-MED
-	O
and	O
gender	B-MED
-matched	O
healthy	B-MED
controls	I-MED
from	O
xuzhou	B-MED
children's	I-MED
hospital	I-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
.	O
	
serum	B-MED
ifn-γ	B-MED
and	O
il-10	B-MED
levels	O
were	O
measured	B-MED
by	O
enzyme	B-MED
linked-immunosorbent	I-MED
assay	I-MED
.	O
	
polymorphisms	B-MED
of	O
the	O
ifn-γ	B-MED
gene	I-MED
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
il-10	B-MED
at	O
position	O
-1082	O
were	O
analyzed	B-MED
by	O
allele	B-MED
-	O
specific	B-MED
pcr	B-MED
.	O
	
median	B-MED
serum	I-MED
concentrations	B-MED
of	O
ifn	B-MED
-γ	I-MED
and	O
il-10	B-MED
were	O
significantly	B-MED
higher	I-MED
in	O
children	B-MED
with	O
hlh	B-MED
compared	B-MED
to	O
healthy	B-MED
controls	I-MED
.	O
	
the	O
frequencies	B-MED
of	O
ifn-γ	B-MED
+874	O
t/a	B-MED
and	I-MED
t/t	I-MED
genotypes	I-MED
,	O
as	O
well	O
as	O
t	B-MED
allele	I-MED
,	O
were	O
significantly	B-MED
higher	I-MED
in	O
the	O
hlh	B-MED
group	O
compared	B-MED
with	O
those	O
in	O
the	O
control	B-MED
group	I-MED
.	O
	
the	O
frequencies	B-MED
of	O
il-10	B-MED
-1082	O
g/a	B-MED
genotype	I-MED
and	O
g	B-MED
allele	I-MED
were	O
significantly	B-MED
increased	I-MED
in	O
hlh	B-MED
patients	B-MED
compared	B-MED
with	O
healthy	B-MED
controls	I-MED
.	O
	
no	B-MED
significant	I-MED
difference	B-MED
was	O
found	O
in	O
the	O
distribution	B-MED
of	O
ifn-γ	B-MED
+2109	O
g/a	B-MED
genotypes	I-MED
between	O
children	B-MED
with	O
hlh	B-MED
and	O
controls	B-MED
.	O
	
this	O
study	B-MED
presents	B-MED
preliminary	B-MED
evidence	B-MED
for	O
the	O
association	O
between	O
ifn	B-MED
+874	O
t/a	B-MED
,	O
t/t	I-MED
,	O
il-10	B-MED
-1082	O
a/g	B-MED
genotypes	I-MED
,	O
and	O
hlh	B-MED
susceptibility	B-MED
in	O
chinese	B-MED
children	B-MED
with	O
data	B-MED
-driven	O
implementation	B-MED
of	O
alarm	B-MED
reduction	B-MED
interventions	B-MED
in	O
a	O
cardiovascular	B-MED
surgical	I-MED
icu	I-MED
alarm	B-MED
fatigue	I-MED
in	O
the	O
icu	B-MED
setting	B-MED
has	O
been	O
well	O
documented	B-MED
in	O
the	O
literature	B-MED
.	O
	
the	O
icu's	B-MED
high-intensity	B-MED
environment	B-MED
requires	O
staff's	B-MED
vigilant	B-MED
attention	B-MED
,	O
and	O
distraction	B-MED
from	O
false	B-MED
and	O
non-actionable	O
alarms	B-MED
pulls	O
staff	B-MED
away	O
from	O
important	O
tasks	B-MED
,	O
creates	O
dissatisfaction	B-MED
,	O
and	O
is	O
a	O
potential	O
patient	B-MED
safety	I-MED
risk	B-MED
if	O
alarms	B-MED
are	O
missed	B-MED
or	O
ignored	B-MED
.	O
	
this	O
project	O
was	O
intended	O
to	O
improve	O
patient	B-MED
safety	I-MED
by	O
optimizing	O
alarm	B-MED
systems	B-MED
in	O
a	O
cardiovascular	B-MED
surgical	I-MED
intensive	I-MED
care	I-MED
unit	I-MED
cvsicu	B-MED
.	O
	
specific	O
aims	O
were	O
to	O
examine	B-MED
nurses	B-MED
'	O
attitudes	B-MED
toward	O
clinical	B-MED
alarm	B-MED
signals	B-MED
,	O
assess	O
nurses	B-MED
'	O
ability	O
to	O
discriminate	O
audible	B-MED
alarm	I-MED
signals	B-MED
,	O
and	O
implement	B-MED
a	O
bundled	O
set	O
of	O
best	B-MED
practices	I-MED
for	O
monitor	B-MED
alarm	I-MED
reduction	B-MED
without	O
undermining	O
patient	B-MED
safety	I-MED
.	O
	
cvsicu	B-MED
nurses	B-MED
completed	O
an	O
alarm	B-MED
perception	B-MED
survey	I-MED
and	O
participated	O
in	O
alarm	B-MED
discriminability	B-MED
testing	I-MED
.	O
	
nurse	B-MED
survey	I-MED
data	I-MED
and	O
baseline	B-MED
monitor	O
alarm	B-MED
data	B-MED
were	O
used	O
to	O
select	O
targeted	B-MED
alarm	B-MED
reduction	B-MED
interventions	B-MED
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O
	
monitor	O
alarm	B-MED
data	B-MED
and	O
cardiorespiratory	B-MED
event	I-MED
data	B-MED
were	O
trended	O
over	O
one	O
year	B-MED
.	O
	
five	O
of	O
the	O
most	O
frequent	O
cvsicu	B-MED
monitor	B-MED
alarm	I-MED
types-	O
pulse	B-MED
oximetry	I-MED
,	O
heart	B-MED
rate	I-MED
,	O
systolic	B-MED
and	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
,	O
pulse	B-MED
oximetry	I-MED
sensor	B-MED
,	O
and	O
ventricular	B-MED
tachycardia	I-MED
>	O
2-were	O
targeted	B-MED
.	O
	
after	O
implementation	B-MED
,	O
there	O
was	O
a	O
61%	O
reduction	B-MED
in	O
average	O
alarms	B-MED
per	O
monitored	O
bed	B-MED
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	B-MED
events	I-MED
.	O
	
to	O
reduce	B-MED
alarm	B-MED
fatigue	I-MED
it	O
is	O
important	O
to	O
decrease	B-MED
alarm	B-MED
burden	B-MED
through	O
targeted	B-MED
interventions	B-MED
.	O
	
methods	O
to	O
reduce	O
non-actionable	O
alarms	B-MED
include	O
adding	O
short	O
delays	B-MED
to	O
allow	O
alarm	B-MED
self-correction	B-MED
,	O
adjusting	O
default	O
alarm	B-MED
threshold	B-MED
limits	B-MED
,	O
providing	O
alarm	B-MED
notification	B-MED
through	O
a	O
secondary	B-MED
device	I-MED
,	O
and	O
teaching	B-MED
staff	B-MED
to	O
optimize	O
alarm	B-MED
settings	O
for	O
individual	B-MED
patients	B-MED
.	O
	
the	O
ncam1	B-MED
gene	I-MED
set	I-MED
is	O
linked	O
to	O
depressive	B-MED
symptoms	I-MED
and	O
their	O
brain	B-MED
structural	I-MED
correlates	B-MED
in	O
healthy	B-MED
individuals	I-MED
depressive	B-MED
symptoms	I-MED
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	B-MED
disorders	I-MED
.	O
	
utilizing	O
the	O
continuous	B-MED
spectrum	I-MED
of	O
depressive	B-MED
symptoms	I-MED
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	B-MED
underpinnings	I-MED
of	O
depression	B-MED
.	O
	
gene	B-MED
set	I-MED
enrichment	I-MED
analysis	I-MED
gsea	B-MED
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	B-MED
groups	I-MED
linked	O
to	O
complex	B-MED
traits	I-MED
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome-wide	B-MED
association	I-MED
study	I-MED
gwas	B-MED
data	B-MED
of	I-MED
depression	I-MED
scores	I-MED
and	O
their	O
brain-level	B-MED
structural	I-MED
correlates	B-MED
in	O
healthy	B-MED
young	I-MED
individuals	I-MED
.	O
	
on	O
symptom	B-MED
level	I-MED
i.e	O
.	O
	
depression	B-MED
scores	I-MED
,	O
robust	B-MED
enrichment	O
was	O
identified	O
for	O
two	O
gene	B-MED
sets	I-MED
ncam1	B-MED
interactions	B-MED
and	O
collagen	B-MED
formation	I-MED
.	O
	
depression	B-MED
scores	I-MED
were	O
also	O
associated	B-MED
with	I-MED
decreased	B-MED
fractional	B-MED
anisotropy	I-MED
fa	B-MED
-	O
a	O
brain	B-MED
white	I-MED
matter	I-MED
property	I-MED
-	O
within	B-MED
the	I-MED
forceps	I-MED
minor	I-MED
and	O
the	O
left	B-MED
superior	I-MED
temporal	I-MED
longitudinal	I-MED
fasciculus	I-MED
.	O
	
within	O
each	O
of	O
these	O
tracts	O
,	O
mean	B-MED
fa	I-MED
value	O
of	O
depression	B-MED
score	I-MED
-	O
associated	B-MED
voxels	I-MED
was	O
used	O
as	O
a	O
phenotype	B-MED
in	O
a	O
subsequent	O
gsea	B-MED
.	O
	
the	O
ncam1	B-MED
interactions	B-MED
gene	B-MED
set	I-MED
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O
	
by	O
linking	O
the	O
ncam1	B-MED
interactions	B-MED
gene	B-MED
set	I-MED
to	O
depression	B-MED
scores	I-MED
and	O
their	O
structural	B-MED
brain	I-MED
correlates	B-MED
in	O
healthy	B-MED
participants	I-MED
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	B-MED
underpinnings	I-MED
of	O
depressive	B-MED
symptomatology	I-MED
.	O
	
the	O
burden	O
of	O
hpv	B-MED
-related	O
diseases	B-MED
in	O
italy	B-MED
,	O
2001-12	O
human	B-MED
papillomavirus	I-MED
hpv	I-MED
infection	I-MED
is	O
the	O
main	O
cause	O
of	O
cervical	B-MED
cancer	I-MED
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	B-MED
of	O
genital	B-MED
warts	I-MED
and	O
of	O
the	O
cancer	B-MED
of	O
penis	B-MED
and	O
anus	B-MED
,	O
head	B-MED
/	O
neck	B-MED
,	O
oropharynx	B-MED
and	O
genitourinary	B-MED
system	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
is	O
the	O
evaluation	B-MED
of	O
hospitalizations	B-MED
due	O
to	O
hpv-related	B-MED
pathologies	I-MED
in	O
2001-12	O
in	O
italy	B-MED
.	O
	
the	O
national	B-MED
hospital	I-MED
discharge	I-MED
forms	B-MED
were	O
provided	O
by	O
the	O
ministry	B-MED
of	I-MED
health	I-MED
.	O
	
the	O
hpv	B-MED
-related	O
hospitalizations	B-MED
were	O
identified	O
using	O
specific	O
diagnostic	B-MED
codes	B-MED
,	O
accordingly	O
to	O
the	O
icd-9-cm	B-MED
coding	B-MED
system	I-MED
.	O
	
the	O
proportion	O
of	O
hospitalizations	B-MED
of	O
potentially	O
hpv-related	B-MED
pathologies	I-MED
,	O
obtained	O
from	O
the	O
literature	B-MED
,	O
was	O
evaluated	B-MED
as	O
well	O
as	O
the	O
hospitalization	B-MED
rates	I-MED
hr	B-MED
and	O
their	O
trend	B-MED
over	O
time	B-MED
.	O
	
uterine	B-MED
cervical	I-MED
cancer	I-MED
and	O
cin	B-MED
iii	I-MED
accounted	O
for	O
40%	O
of	O
hospitalizations	B-MED
hr	B-MED
15.6	O
000	O
and	O
17.6	O
000	O
,	O
respectively	O
.	O
	
head	B-MED
/	O
neck	B-MED
and	O
oropharynx	B-MED
pathologies	B-MED
accounted	O
for	O
24.5	O
of	O
cases	B-MED
hr	B-MED
16/100	O
000	O
and	O
3.9	O
000	O
,	O
in	O
males	B-MED
and	O
females	B-MED
,	O
respectively	O
,	O
followed	O
by	O
genital	B-MED
warts	I-MED
17.3	O
of	O
hospitalizations	B-MED
hr	B-MED
7.5	O
000	O
in	O
males	B-MED
and	O
8.52	O
000	O
in	O
females	B-MED
,	O
anal	B-MED
8.1	O
of	O
hospitalizations	B-MED
,	O
genitourinary	B-MED
7.7	O
and	O
penis	B-MED
cancers	I-MED
2.2	O
.	O
	
the	O
study	B-MED
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	B-MED
of	O
hospitalizations	B-MED
,	O
points	O
out	O
how	O
hpv-related	B-MED
pathologies	I-MED
continue	O
to	O
be	O
a	O
relevant	O
public	B-MED
health	I-MED
issue	B-MED
in	O
italy	B-MED
with	O
a	O
high	O
impact	B-MED
on	O
the	O
discovery	B-MED
of	O
potent	B-MED
and	O
selective	B-MED
kynurenine	B-MED
3-monooxygenase	I-MED
inhibitors	B-MED
for	O
the	O
treatment	B-MED
of	O
acute	B-MED
pancreatitis	I-MED
a	O
series	B-MED
of	O
potent	B-MED
,	O
competitive	B-MED
and	O
highly	B-MED
selective	B-MED
kynurenine	B-MED
monooxygenase	I-MED
inhibitors	B-MED
have	O
been	O
discovered	B-MED
via	O
a	O
substrate	B-MED
-based	O
approach	B-MED
for	O
the	O
treatment	B-MED
of	O
acute	B-MED
pancreatitis	I-MED
.	O
	
the	O
lead	B-MED
compound	B-MED
demonstrated	O
good	B-MED
cellular	B-MED
potency	B-MED
and	O
clear	O
pharmacodynamic	B-MED
activity	B-MED
in	B-MED
vivo	I-MED
.	O
	
draft	B-MED
genome	I-MED
sequence	B-MED
of	O
providencia	B-MED
stuartii	I-MED
ps71	I-MED
,	O
a	O
multidrug-resistant	B-MED
strain	B-MED
associated	B-MED
with	I-MED
nosocomial	B-MED
infections	I-MED
in	O
greece	B-MED
providencia	B-MED
stuartii	I-MED
is	O
frequently	B-MED
associated	B-MED
with	I-MED
nosocomial	B-MED
outbreaks	I-MED
and	O
displays	O
intrinsic	B-MED
resistance	B-MED
to	O
many	O
commonly	B-MED
used	O
antimicrobials	B-MED
.	O
	
we	O
report	O
here	O
the	O
draft	B-MED
genome	I-MED
sequence	B-MED
of	O
a	O
p	B-MED
.	O
	
stuartii	I-MED
strain	I-MED
carrying	O
acquired	B-MED
resistance	B-MED
genes	I-MED
conferring	O
panresistance	B-MED
to	O
cephalosporins	B-MED
blashv-5	B-MED
and	O
blaveb-1	B-MED
,	O
carbapenems	B-MED
blavim-1	B-MED
,	O
and	O
aminoglycosides	B-MED
rmtb	B-MED
involved	O
in	O
an	O
outbreak	B-MED
in	O
greek	B-MED
hospitals	B-MED
.	O
	
impact	B-MED
of	O
diabetic	B-MED
ketoacidosis	I-MED
management	B-MED
in	O
the	O
medical	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
after	O
order	B-MED
set	I-MED
implementation	B-MED
to	O
determine	O
the	O
rate	B-MED
of	O
compliance	B-MED
to	O
the	O
2006	O
and	O
2009	O
ada	B-MED
dka	I-MED
guidelines	I-MED
in	O
the	O
medical	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
micu	B-MED
at	O
a	O
large	O
academic	B-MED
medical	I-MED
centre	I-MED
after	O
the	O
implementation	B-MED
of	O
a	O
computerised	B-MED
dka	I-MED
order	I-MED
set	I-MED
and	O
protocol	B-MED
.	O
	
retrospective	B-MED
chart	B-MED
review	I-MED
of	O
adult	B-MED
patients	I-MED
with	O
dka	B-MED
admitted	B-MED
to	O
the	O
micu	B-MED
.	O
	
results	O
of	O
pre-order	B-MED
set	I-MED
pre	B-MED
were	O
compared	O
to	O
those	O
of	O
data	O
post-order	B-MED
set	I-MED
post	B-MED
.	O
	
the	O
primary	B-MED
outcome	I-MED
was	O
a	O
composite	O
administration	B-MED
of	O
intravenous	B-MED
fluid	I-MED
resuscitation	I-MED
in	O
the	O
first	O
24	O
h	O
,	O
insulin	B-MED
bolus	B-MED
and	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
.	O
	
twelve	O
of	O
60	O
patients	B-MED
20%	O
in	O
the	O
pre	B-MED
group	I-MED
received	O
treatment	B-MED
compliant	B-MED
with	O
the	O
2006	O
guidelines	B-MED
versus	O
14	O
of	O
55	O
patients	B-MED
25.5	O
in	O
the	O
post	B-MED
group	I-MED
or	B-MED
1.22	O
95%	O
ci	B-MED
0.44	O
to	O
3.4	O
,	O
p	O
=	O
0.51	O
.	O
	
compliance	B-MED
to	O
the	O
2009	O
guidelines	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
the	O
post	B-MED
group	I-MED
31.7	O
versus	O
65.5	O
,	O
or	B-MED
4.44	O
95%	O
ci	B-MED
1.8	O
to	O
10.92	O
,	O
p	O
=	O
0.0004	O
.	O
	
compliance	B-MED
for	O
individual	O
components	O
was	O
26.7	O
versus	O
70.9	O
for	O
fluid	B-MED
resuscitation	I-MED
p	O
=	O
0.0001	O
,	O
55%	O
versus	O
49.1	O
for	O
insulin	B-MED
bolus	B-MED
p	O
=	O
0.58	O
and	O
60%	O
versus	O
81.3	O
for	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
p	O
=	O
0.014	O
,	O
respectively	O
.	O
	
time	B-MED
to	O
dka	B-MED
resolution	B-MED
was	O
decreased	B-MED
p	O
=	O
0.04	O
,	O
and	O
hypoglycaemia	B-MED
was	O
increased	B-MED
p	O
=	O
0.0022	O
.	O
	
implementation	B-MED
of	O
a	O
computerised	B-MED
dka	I-MED
order	I-MED
set	I-MED
and	O
protocol	B-MED
was	O
associated	B-MED
with	I-MED
improved	B-MED
compliance	B-MED
to	O
the	O
2009	O
ada	B-MED
dka	I-MED
guidelines	I-MED
,	O
24-h	O
fluid	B-MED
resuscitation	I-MED
,	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
,	O
time	B-MED
to	O
dka	B-MED
resolution	B-MED
and	O
appropriate	O
transition	B-MED
to	O
subcutaneous	B-MED
insulin	B-MED
.	O
	
however	O
,	O
patients	B-MED
in	O
the	O
post	B-MED
implementation	I-MED
group	I-MED
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-MED
.	O
	
construction	O
of	O
an	O
acetylcholinesterase	B-MED
sensor	B-MED
based	O
on	O
synthesized	B-MED
paramagnetic	I-MED
nanoparticles	I-MED
,	O
a	O
simple	O
tool	O
for	O
neurotoxic	B-MED
compounds	I-MED
assay	B-MED
magnetic	B-MED
particles	I-MED
mps	B-MED
have	O
been	O
widely	O
used	O
in	O
biological	B-MED
applications	I-MED
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	B-MED
.	O
	
their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	B-MED
molecules	B-MED
including	O
enzymes	B-MED
.	O
	
acetylcholinesterase	B-MED
ache	B-MED
is	O
an	O
enzyme	B-MED
playing	O
crucial	O
role	O
in	O
neurotransmission	B-MED
and	O
the	O
enzyme	B-MED
is	O
targeted	B-MED
by	O
various	O
molecules	B-MED
like	O
alzheimer's	B-MED
drugs	B-MED
,	O
pesticides	B-MED
and	O
warfare	B-MED
agents	I-MED
.	O
	
in	O
this	O
work	O
,	O
an	O
electrochemical	B-MED
biosensor	I-MED
having	O
ache	B-MED
immobilized	B-MED
onto	O
mps	B-MED
and	O
stabilized	B-MED
through	O
glutaraldehyde	B-MED
ga	I-MED
molecule	I-MED
was	O
proposed	O
for	O
assay	B-MED
of	O
the	O
neurotoxic	B-MED
compounds	I-MED
.	O
	
the	O
prepared	B-MED
nanoparticles	I-MED
were	O
modified	B-MED
by	I-MED
pure	B-MED
ache	I-MED
and	O
they	O
were	O
used	O
for	O
the	O
measurement	B-MED
anti-alzheimer's	B-MED
drug	B-MED
galantamine	B-MED
and	O
carbamate	B-MED
pesticide	I-MED
carbofuran	B-MED
with	O
limit	B-MED
of	O
detection	B-MED
1.5	O
µm	O
and	O
20	O
nm	O
,	O
respectively	O
.	O
	
all	O
measurements	B-MED
were	O
carried	O
out	O
using	O
screen-printed	B-MED
sensor	I-MED
with	O
carbon	B-MED
working	B-MED
,	O
silver	B-MED
reference	B-MED
,	O
and	O
carbon	B-MED
auxiliary	B-MED
electrode	I-MED
.	O
	
standard	B-MED
ellman's	I-MED
assay	I-MED
was	O
used	O
for	O
validation	B-MED
measurement	B-MED
of	O
both	O
inhibitors	B-MED
.	O
	
part	O
of	O
this	O
work	O
was	O
the	O
elimination	B-MED
of	O
reversible	B-MED
inhibitors	B-MED
represented	O
by	O
galantamine	B-MED
from	O
the	O
active	B-MED
site	I-MED
of	O
ache	B-MED
.	O
	
for	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	B-MED
ph	B-MED
to	O
get	O
the	O
original	B-MED
activity	B-MED
of	O
ache	B-MED
after	O
inhibition	B-MED
by	O
galantamine	B-MED
.	O
	
we	O
also	O
observed	B-MED
decarbamylation	B-MED
of	O
the	O
ache	B-MED
-	O
carbofuran	B-MED
adduct	B-MED
.	O
	
influence	O
of	O
organic	B-MED
solvents	I-MED
to	O
ache	B-MED
as	O
well	O
as	O
repeatability	O
of	O
measurement	B-MED
with	O
mps	B-MED
with	O
ache	B-MED
alanine	B-MED
aminotransferase	I-MED
is	O
a	O
marker	B-MED
of	O
lipotoxicity	B-MED
consequences	B-MED
and	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
several	O
studies	B-MED
have	O
reported	O
higher	O
levels	O
of	O
alanine	B-MED
aminotransferase	I-MED
alt	B-MED
in	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
pcos	B-MED
compared	O
with	O
control	B-MED
subjects	I-MED
.	O
	
plasma	B-MED
alt	I-MED
levels	I-MED
are	O
considered	O
a	O
marker	B-MED
of	O
hepatic	B-MED
lipotoxicity	B-MED
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B-MED
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B-MED
steatosis	I-MED
and	O
hepatic	B-MED
insulin	B-MED
resistance	I-MED
.	O
	
retrospective	B-MED
chart	I-MED
review	O
aiming	O
to	O
assess	O
,	O
in	O
pcos	B-MED
women	B-MED
,	O
the	O
relationship	O
between	O
alt	B-MED
levels	I-MED
and	O
measures	O
of	O
lipotoxicity	B-MED
consequences	B-MED
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-MED
and	O
using	O
the	O
oral	B-MED
glucose	I-MED
tolerance	I-MED
test	I-MED
.	O
	
women	B-MED
n	O
=	O
132	O
with	O
pcos	B-MED
,	O
were	O
in	O
average	O
27.9	O
years	B-MED
of	O
age	B-MED
,	O
with	O
a	O
mean	O
body	B-MED
mass	I-MED
index	I-MED
of	O
34.1	O
kg/m	O
and	O
49%	O
had	O
a	O
metabolic	B-MED
syndrome	I-MED
mets	B-MED
.	O
	
alt	B-MED
levels	I-MED
were	O
significantly	O
correlated	O
with	O
homeostatic	B-MED
model	I-MED
assessment	I-MED
for	I-MED
insulin	I-MED
resistance	I-MED
r	O
=	O
0.42	O
,	O
p	O
<	O
0.001	O
,	O
hdl-c	B-MED
r	O
=	O
-0	O
,	O
p	O
<	O
0.001	O
,	O
matsuda	B-MED
index	I-MED
-0	O
,	O
p	O
<	O
0.001	O
,	O
insulin	B-MED
secretion-sensitivity	I-MED
index-2	I-MED
-0	O
,	O
p	O
=	O
0.043	O
,	O
and	O
free	B-MED
testosterone	I-MED
0.38	O
,	O
p	O
<	O
0.001	O
,	O
but	O
not	O
with	O
fasting	B-MED
glucose	I-MED
and	O
triglyceride	B-MED
levels	I-MED
.	O
	
alt	B-MED
cutoff	O
24	O
iu/l	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	B-MED
glucose	I-MED
p	O
=	O
0.021	O
and	O
triglyceride	B-MED
levels	I-MED
p	O
=	O
0.041	O
,	O
and	O
detected	O
more	O
women	B-MED
with	O
the	O
mets	B-MED
59.2	O
vs	O
.	O
	
36.1	O
,	O
p	O
=	O
0.008	O
and	O
whole-body	B-MED
insulin	I-MED
resistance	I-MED
matsuda	B-MED
index	I-MED
<12	O
l	O
,	O
85.3	O
vs	O
.	O
	
51.9	O
,	O
p	O
=	O
0.004	O
.	O
	
plasma	B-MED
alt	I-MED
levels	I-MED
seem	O
to	O
be	O
a	O
strong	O
predictor	B-MED
not	O
only	O
of	O
liver	B-MED
lipotoxicity	B-MED
but	O
also	O
of	O
systemic	B-MED
lipotoxic	I-MED
consequences	B-MED
and	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
pcos	B-MED
.	O
	
although	O
it	O
requires	O
validation	B-MED
in	O
another	O
study	B-MED
,	O
an	O
alt	B-MED
cutoff	O
of	O
24	O
iu/l	O
may	O
help	O
clinicians	B-MED
identify	O
women	B-MED
with	O
increased	O
metabolic	B-MED
risks	I-MED
.	O
	
opioid	B-MED
use	O
in	O
chronic	B-MED
pain	I-MED
patients	B-MED
with	O
chronic	B-MED
kidney	I-MED
disease	I-MED
a	O
systematic	B-MED
review	I-MED
to	O
investigate	O
the	O
prevalence	B-MED
of	O
chronic	B-MED
pain	I-MED
and	O
opioid	B-MED
management	B-MED
among	O
patients	B-MED
with	O
chronic	B-MED
kidney	I-MED
disease	I-MED
ckd	B-MED
.	O
	
systematic	B-MED
review	I-MED
.	O
	
a	O
systematic	O
search	O
was	O
performed	O
,	O
including	O
citations	O
from	O
1960	O
to	O
may	O
2015	O
.	O
	
the	O
review	O
highlights	O
methodological	B-MED
quality	I-MED
assessment	I-MED
of	O
the	O
selected	O
studies	B-MED
prevalence	B-MED
of	O
pain	B-MED
type	B-MED
,	O
dose	B-MED
,	O
and	O
reason	O
for	O
opioid	B-MED
use	O
effectiveness	B-MED
of	O
pain	B-MED
control	I-MED
and	O
associated	O
adverse	B-MED
effects	I-MED
of	O
opioids	B-MED
in	O
ckd	B-MED
patients	B-MED
.	O
	
twelve	O
of	O
131	O
articles	O
met	O
inclusion	B-MED
criteria	I-MED
.	O
	
there	O
were	O
no	O
randomized	B-MED
controlled	I-MED
trials	I-MED
rct	B-MED
evaluable	O
,	O
and	O
12	O
were	O
observational	B-MED
studies	I-MED
.	O
	
out	O
of	O
12	O
studies	B-MED
,	O
four	O
were	O
of	O
high	B-MED
quality	B-MED
,	O
six	O
were	O
of	O
moderate	B-MED
quality	B-MED
,	O
and	O
the	O
remaining	O
two	O
were	O
low	B-MED
-	O
quality	B-MED
studies	B-MED
.	O
	
the	O
studies	B-MED
were	O
from	O
different	O
countries	B-MED
with	O
sample	B-MED
size	I-MED
ranging	O
from	O
10	O
to	O
12	O
.	O
	
several	O
studies	B-MED
showed	O
a	O
high	O
prevalence	B-MED
of	O
chronic	B-MED
uncontrolled	B-MED
pain	I-MED
.	O
	
the	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-MED
,	O
dose	B-MED
,	O
duration	B-MED
,	O
and	O
commonly	O
prescribed	B-MED
opioids	B-MED
varied	O
across	O
studies	B-MED
.	O
	
based	O
on	O
a	O
systematic	B-MED
review	I-MED
of	O
the	O
current	O
literature	O
,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	B-MED
of	O
chronic	B-MED
pain	I-MED
among	O
patients	B-MED
with	O
ckd	B-MED
,	O
which	O
is	O
not	O
being	O
effectively	O
managed	O
,	O
probably	O
due	O
to	O
underprescription	B-MED
of	O
analgesics	B-MED
or	O
opioids	B-MED
in	O
the	O
ckd	B-MED
population	B-MED
.	O
	
clinicians	B-MED
are	O
in	O
need	O
of	O
additional	O
and	O
well-designed	O
randomized	B-MED
control	I-MED
trials	I-MED
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-MED
therapy	B-MED
,	O
appropriate	O
opioid	B-MED
doses	B-MED
and	O
dosing	B-MED
intervals	B-MED
,	O
outcomes	O
with	O
adequacy	B-MED
of	O
symptom	B-MED
control	I-MED
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse	B-MED
side	I-MED
effects	I-MED
.	O
	
cognitive	B-MED
impairment	I-MED
in	O
first-episode	B-MED
drug-naïve	B-MED
patients	I-MED
with	O
schizophrenia	B-MED
relationships	B-MED
with	O
serum	B-MED
concentrations	I-MED
of	O
brain-derived	B-MED
neurotrophic	I-MED
factor	I-MED
and	O
glial	B-MED
cell	I-MED
line-derived	I-MED
neurotrophic	I-MED
factor	I-MED
evidence	O
suggests	O
that	O
brain-derived	B-MED
neurotrophic	I-MED
factor	I-MED
bdnf	B-MED
and	O
glial	B-MED
cell	I-MED
line	I-MED
-derived	I-MED
neurotrophic	I-MED
factor	I-MED
gdnf	B-MED
are	O
important	O
in	O
the	O
regulation	B-MED
of	I-MED
synaptic	I-MED
plasticity	I-MED
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	B-MED
processes	I-MED
in	O
psychiatric	B-MED
disorders	I-MED
.	O
	
our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	B-MED
between	O
serum	B-MED
bdnf	B-MED
and	O
gdnf	B-MED
levels	O
and	O
cognitive	B-MED
functions	I-MED
in	O
first-episode	B-MED
drug-naïve	I-MED
fedn	I-MED
patients	I-MED
with	O
schizophrenia	B-MED
.	O
	
the	O
bdnf	B-MED
and	O
gdnf	B-MED
levels	O
of	O
58	O
fedn	B-MED
patients	I-MED
and	O
55	O
age	B-MED
-	O
and	O
sex	B-MED
-matched	O
healthy	B-MED
controls	I-MED
were	O
measured	O
and	O
test	B-MED
subjects	I-MED
were	O
examined	O
using	O
several	O
neurocognitive	B-MED
tests	I-MED
including	O
the	O
verbal	B-MED
fluency	I-MED
test	I-MED
vft	B-MED
,	O
the	O
trail	B-MED
making	I-MED
test	I-MED
tmt	B-MED
,	O
the	O
digit	B-MED
span	I-MED
test	I-MED
dst	B-MED
,	O
and	O
the	O
stroop	B-MED
test	I-MED
.	O
	
patients	B-MED
performed	O
significantly	O
worse	O
than	O
controls	B-MED
in	O
nearly	O
all	O
neurocognitive	B-MED
performances	I-MED
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
dst	B-MED
.	O
	
bdnf	B-MED
levels	B-MED
were	O
inversely	O
correlated	O
to	O
tmt-part	B-MED
b	I-MED
scores	I-MED
and	O
positively	O
correlated	O
to	O
vft-action	B-MED
in	O
the	O
fedn	O
group	O
.	O
	
gdnf	B-MED
levels	B-MED
showed	O
a	O
positive	O
correlation	O
with	O
vft-action	B-MED
scores	I-MED
and	O
a	O
negative	O
correlation	O
with	O
tmt-part	B-MED
b	I-MED
scores	I-MED
of	O
these	O
patients	B-MED
.	O
	
current	O
data	O
suggests	O
that	O
cognitive	B-MED
dysfunction	I-MED
widely	O
exists	O
in	O
the	O
early	B-MED
stages	I-MED
of	O
schizophrenia	B-MED
.	O
	
bdnf	B-MED
and	O
gdnf	B-MED
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	B-MED
mechanisms	B-MED
involved	O
in	O
cognitive	B-MED
impairment	I-MED
in	O
fedn	B-MED
patients	I-MED
with	O
comprehensive	B-MED
functional	B-MED
analysis	I-MED
of	O
large	O
lists	O
of	O
genes	B-MED
and	O
proteins	B-MED
the	O
interpretation	B-MED
of	O
high	B-MED
dimensional	I-MED
datasets	I-MED
resulting	O
from	O
genomic	B-MED
and	O
proteomic	B-MED
experiments	I-MED
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging	O
.	O
	
cluego	B-MED
software	I-MED
is	O
a	O
cytoscape	B-MED
app	I-MED
that	O
extracts	O
representative	O
functional	O
biological	B-MED
information	B-MED
for	O
large	O
lists	O
of	O
genes	B-MED
or	O
proteins	B-MED
.	O
	
the	O
functional	B-MED
enrichment	I-MED
analysis	I-MED
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	B-MED
from	O
multiple	O
annotation	B-MED
and	O
ontology	B-MED
resources	B-MED
that	O
can	O
be	O
automatically	B-MED
accessed	B-MED
through	O
cluego	B-MED
.	O
	
predefined	B-MED
settings	I-MED
for	O
the	O
selection	B-MED
of	O
the	O
terms	B-MED
are	O
provided	O
to	O
facilitate	O
the	O
analysis	B-MED
.	O
	
results	B-MED
are	O
visualized	O
as	O
networks	B-MED
in	O
which	O
gene	B-MED
ontology	I-MED
go	B-MED
terms	O
and	O
pathways	B-MED
are	O
grouped	O
based	O
on	O
their	O
biological	O
role	O
.	O
	
many	O
species	B-MED
are	O
now	O
supported	O
by	O
cluego	B-MED
and	O
additional	O
organisms	B-MED
are	O
added	O
on	O
demand	O
.	O
	
cluego	B-MED
can	O
be	O
used	O
together	O
with	O
the	O
cluepedia	B-MED
app	I-MED
to	O
enable	O
the	O
visualization	O
of	O
protein-protein	B-MED
interactions	I-MED
within	O
or	O
between	O
management	B-MED
of	O
precipitated	B-MED
opiate	I-MED
withdrawal	I-MED
syndrome	I-MED
induced	B-MED
by	O
nalmefene	B-MED
mistakenly	O
prescribed	B-MED
in	O
opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
a	O
review	B-MED
for	O
clinicians	B-MED
nalmefene	B-MED
,	O
a	O
long-acting	B-MED
µ-opioid	I-MED
antagonist	I-MED
approved	B-MED
to	O
treat	B-MED
alcohol	B-MED
use	I-MED
disorder	I-MED
,	O
is	O
occasionally	B-MED
mistakenly	O
prescribed	B-MED
to	O
opiate	B-MED
-	O
dependent	B-MED
or	O
opioid	B-MED
-	O
treated	B-MED
patients	B-MED
.	O
	
we	O
review	B-MED
recent	O
literature	B-MED
on	O
drug-drug	B-MED
interactions	I-MED
between	O
nalmefene	B-MED
and	O
opioids	B-MED
that	O
lead	O
to	O
precipitated	B-MED
opioid	I-MED
withdrawal	I-MED
,	O
and	O
focus	O
on	O
its	O
management	B-MED
and	O
planning	B-MED
for	O
care	B-MED
at	O
discharge	B-MED
.	O
	
areas	O
covered	O
this	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	B-MED
review	I-MED
of	O
management	O
of	O
precipitated	B-MED
opioid	I-MED
withdrawal	I-MED
syndrome	I-MED
when	O
nalmefene	B-MED
is	O
associated	B-MED
with	I-MED
an	O
opioid	B-MED
,	O
whether	O
misused	B-MED
or	O
legally	B-MED
prescribed	B-MED
.	O
	
expert	B-MED
opinion	I-MED
when	O
treating	B-MED
an	O
opiate	B-MED
-	O
dependent	B-MED
patient	I-MED
with	O
co-occurring	O
alcohol	B-MED
use	I-MED
disorder	I-MED
,	O
both	O
conditions	B-MED
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	B-MED
attention	I-MED
.	O
	
new	B-MED
drugs	B-MED
for	O
alcohol	B-MED
use	I-MED
disorder	I-MED
have	O
been	O
approved	B-MED
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	B-MED
drug-drug	B-MED
interactions	I-MED
with	O
opioid	B-MED
medications	B-MED
.	O
	
opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
should	O
be	O
intensively	O
monitored	O
for	O
risk	B-MED
factors	I-MED
of	O
alcohol	B-MED
use	I-MED
disorder	I-MED
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	B-MED
maintenance	I-MED
.	O
	
when	O
nalmefene	B-MED
is	O
administered	B-MED
to	O
opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
,	O
acute	B-MED
opioid	B-MED
withdrawal	I-MED
syndrome	I-MED
may	O
occur	B-MED
.	O
	
management	B-MED
of	O
precipitated	O
acute	B-MED
opioid	B-MED
withdrawal	I-MED
may	O
include	B-MED
short	O
or	O
long-acting	B-MED
µ-opioid	I-MED
agonists	I-MED
during	O
hospitalization	B-MED
,	O
in	O
addition	O
to	O
supportive	B-MED
treatment	I-MED
.	O
	
the	O
best	O
management	B-MED
of	O
polydrug	B-MED
abusers	I-MED
is	O
based	O
on	O
a	O
multidisciplinary	B-MED
approach	I-MED
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-MED
through	B-MED
continuing	B-MED
medical	I-MED
education	I-MED
.	O
	
discovering	O
key	O
residues	B-MED
of	O
dengue	B-MED
virus	I-MED
ns2b-ns3-protease	B-MED
new	O
binding	B-MED
sites	I-MED
for	O
antiviral	B-MED
inhibitors	I-MED
design	O
the	O
ns2b-ns3	B-MED
protease	I-MED
is	O
essential	O
for	O
the	O
dengue	B-MED
virus	I-MED
denv	B-MED
replication	B-MED
process	I-MED
.	O
	
this	O
complex	B-MED
constitutes	O
a	O
target	B-MED
for	O
efficient	O
antiviral	B-MED
discovery	B-MED
because	O
a	O
drug	B-MED
could	O
inhibit	O
the	O
viral	B-MED
polyprotein	I-MED
processing	I-MED
.	O
	
furthermore	O
,	O
since	O
the	O
protease	B-MED
is	O
highly	O
conserved	B-MED
between	O
the	O
four	O
dengue	B-MED
virus	I-MED
serotypes	B-MED
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-MED
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them	O
.	O
	
in	O
this	O
article	O
,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	B-MED
residues	B-MED
on	O
the	O
function	O
of	O
the	O
dengue	B-MED
ns2b-ns3	B-MED
protease	I-MED
.	O
	
moreover	O
,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	B-MED
for	O
the	O
search	O
of	O
alternative	O
influential	B-MED
residues	B-MED
,	O
and	O
for	O
non-competitive	B-MED
inhibitor	I-MED
development	B-MED
.	O
	
first	O
,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	B-MED
alanine	B-MED
scanning	B-MED
mutagenesis	I-MED
,	O
sequence	B-MED
,	O
structure	B-MED
conservation	I-MED
,	O
and	O
other	O
structure	B-MED
-based	O
characteristics	B-MED
.	O
	
second	O
,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer	B-MED
perceptron	I-MED
model	I-MED
to	O
identify	O
defined	O
groups	B-MED
clusters	O
of	O
key	O
residues	B-MED
as	O
possible	O
candidate	O
pockets	O
for	O
binding	B-MED
sites	I-MED
of	O
new	O
leads	O
on	O
the	O
denv	B-MED
protease	B-MED
.	O
	
the	O
identified	O
residues	B-MED
included	O
i	O
amino	B-MED
acids	I-MED
close	O
to	O
the	O
beta	B-MED
sheet	I-MED
-loop-	O
beta	B-MED
sheet	I-MED
known	O
to	O
be	O
important	O
in	O
its	O
closed	B-MED
conformation	I-MED
for	O
ns2b	B-MED
ii	O
residues	B-MED
close	O
to	O
the	O
active	B-MED
site	I-MED
,	O
iii	O
several	O
residues	B-MED
evenly	O
spread	O
on	O
the	O
ns2b-ns3	B-MED
contact	O
surface	O
,	O
and	O
iv	O
some	O
inner	O
residues	B-MED
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	B-MED
of	O
the	O
protease	B-MED
.	O
	
in	O
addition	O
,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	B-MED
with	O
previously	O
identified	O
amino	B-MED
acids	I-MED
part	O
of	O
a	O
highly	O
conserved	O
peptide	B-MED
studied	O
for	O
vaccine	B-MED
development	I-MED
.	O
	
association	B-MED
of	O
toll-like	B-MED
receptor	I-MED
4	I-MED
on	O
human	B-MED
monocyte	B-MED
subsets	B-MED
and	O
vulnerability	B-MED
characteristics	B-MED
of	O
coronary	B-MED
plaque	B-MED
as	O
assessed	B-MED
by	O
64-slice	B-MED
multidetector	I-MED
computed	I-MED
tomography	I-MED
although	O
toll-like	B-MED
receptor	I-MED
4	I-MED
tlr-4	B-MED
is	O
involved	O
in	O
monocyte	B-MED
activation	I-MED
in	O
patients	B-MED
with	O
accelerated	B-MED
forms	O
of	O
atherosclerosis	B-MED
,	O
the	O
relationship	B-MED
between	O
the	O
expression	B-MED
of	O
tlr-4	B-MED
on	O
circulating	B-MED
monocyte	B-MED
s	O
and	O
coronary	B-MED
plaque	B-MED
vulnerability	B-MED
has	O
not	O
previously	O
been	O
evaluated	B-MED
.	O
	
we	O
investigated	O
this	O
relationship	B-MED
using	O
64-slice	B-MED
multidetector	I-MED
computed	I-MED
tomography	I-MED
mdct	B-MED
in	O
patients	B-MED
with	O
stable	B-MED
angina	I-MED
pectoris	I-MED
sap	B-MED
and	O
results	O
enrolled	O
65	O
patients	B-MED
with	O
sap	B-MED
who	O
underwent	O
mdct	B-MED
.	O
	
three	O
monocyte	B-MED
subsets	B-MED
cd14	B-MED
,	O
cd14	B-MED
,	O
and	O
cd14	B-MED
and	O
expression	B-MED
of	O
tlr-4	B-MED
were	O
measured	O
by	O
flow	B-MED
cytometry	I-MED
.	O
	
intracoronary	B-MED
plaques	B-MED
were	O
assessed	B-MED
by	O
64-slice	B-MED
mdct	I-MED
.	O
	
we	O
defined	O
vulnerability	B-MED
of	O
intracoronary	B-MED
plaques	B-MED
according	O
to	O
the	O
presence	O
of	O
positive	B-MED
remodeling	I-MED
remodeling	B-MED
index	I-MED
>1	O
and/or	O
low	O
ct	B-MED
attenuation	B-MED
<35	O
hu	O
.	O
	
the	O
circulating	B-MED
cd14	B-MED
more	O
frequently	O
expressed	B-MED
tlr-4	B-MED
than	O
cd14	B-MED
and	O
cd14	B-MED
p<0	O
.	O
	
the	O
relative	O
proportion	O
of	O
the	O
expression	B-MED
of	O
tlr-4	B-MED
on	O
cd14	B-MED
was	O
significantly	O
greater	O
in	O
patients	B-MED
with	O
vulnerable	B-MED
plaque	I-MED
compared	O
with	O
those	O
without	O
10.4	O
4.1	O
%	O
vs	O
.	O
	
4.5	O
2.8	O
%	O
,	O
p=0	O
.	O
	
in	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
tlr-4	B-MED
expression	B-MED
on	O
cd14	B-MED
positively	O
correlated	B-MED
with	O
the	O
remodeling	B-MED
index	I-MED
r=0	O
,	O
p=0	O
and	O
negatively	O
correlated	B-MED
with	O
ct	B-MED
attenuation	B-MED
value	I-MED
r=-0	O
,	O
p=0	O
.	O
	
upregulation	B-MED
of	O
tlr-4	B-MED
on	O
cd14	B-MED
might	O
be	O
associated	B-MED
with	I-MED
coronary	B-MED
plaque	B-MED
vulnerability	B-MED
in	O
patients	B-MED
with	O
delta-frequency	B-MED
stimulation	B-MED
of	O
cerebellar	B-MED
projections	B-MED
can	O
compensate	B-MED
for	O
schizophrenia	B-MED
-related	O
medial	B-MED
frontal	I-MED
dysfunction	I-MED
schizophrenia	B-MED
involves	O
abnormalities	B-MED
in	O
the	O
medial	B-MED
frontal	I-MED
cortex	I-MED
that	O
lead	O
to	O
cognitive	B-MED
deficits	I-MED
.	O
	
here	O
we	O
investigate	B-MED
a	O
novel	B-MED
strategy	B-MED
to	O
normalize	B-MED
medial	B-MED
frontal	I-MED
brain	I-MED
activity	B-MED
by	O
stimulating	B-MED
cerebellar	B-MED
projections	B-MED
.	O
	
we	O
used	O
an	O
interval	B-MED
timing	I-MED
task	O
to	O
study	B-MED
elementary	O
cognitive	B-MED
processing	I-MED
that	O
requires	O
both	O
frontal	B-MED
and	O
cerebellar	B-MED
networks	I-MED
that	O
are	O
disrupted	B-MED
in	O
patients	B-MED
with	O
schizophrenia	B-MED
.	O
	
we	O
report	O
three	O
novel	B-MED
findings	B-MED
.	O
	
first	O
,	O
patients	B-MED
with	O
schizophrenia	B-MED
had	O
dysfunctional	O
delta	B-MED
rhythms	I-MED
between	O
1-4	O
hz	O
in	O
the	O
medial	B-MED
frontal	I-MED
cortex	I-MED
.	O
	
we	O
explored	O
cerebellar	B-MED
-	O
frontal	B-MED
interactions	B-MED
in	O
animal	B-MED
models	I-MED
and	O
found	O
that	O
both	O
frontal	B-MED
and	O
cerebellar	B-MED
neurons	I-MED
were	O
modulated	B-MED
during	O
interval	B-MED
timing	I-MED
and	O
had	O
delta-frequency	B-MED
interactions	B-MED
.	O
	
finally	O
,	O
delta-frequency	B-MED
optogenetic	B-MED
stimulation	B-MED
of	O
thalamic	B-MED
synaptic	B-MED
terminals	I-MED
of	O
lateral	B-MED
cerebellar	B-MED
projection	B-MED
neurons	B-MED
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial	B-MED
frontal	I-MED
activity	B-MED
in	O
a	O
rodent	B-MED
model	I-MED
of	O
schizophrenia-related	B-MED
frontal	B-MED
dysfunction	I-MED
.	O
	
these	O
data	B-MED
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-MED
influences	B-MED
medial	B-MED
frontal	I-MED
networks	I-MED
and	O
the	O
role	O
of	O
the	O
cerebellum	B-MED
in	O
cognitive	B-MED
processing	I-MED
.	O
	
variables	B-MED
associated	B-MED
with	I-MED
unplanned	B-MED
general	B-MED
adult	I-MED
icu	B-MED
admission	I-MED
in	O
hospitalised	B-MED
patients	I-MED
protocol	B-MED
for	O
a	O
systematic	B-MED
review	B-MED
failure	B-MED
to	O
promptly	O
identify	B-MED
deterioration	B-MED
in	O
hospitalised	B-MED
patients	I-MED
is	O
associated	B-MED
with	I-MED
delayed	B-MED
admission	B-MED
to	I-MED
intensive	I-MED
care	I-MED
units	I-MED
icus	B-MED
and	O
poor	B-MED
outcomes	B-MED
.	O
	
existing	B-MED
vital	B-MED
sign	I-MED
-based	O
early	B-MED
warning	I-MED
score	I-MED
ews	B-MED
algorithms	B-MED
do	O
not	O
have	O
a	O
sufficiently	B-MED
high	B-MED
positive	B-MED
predictive	B-MED
value	I-MED
to	O
be	O
used	O
for	O
automated	B-MED
activation	B-MED
of	O
an	O
icu	B-MED
outreach	B-MED
team	I-MED
.	O
	
incorporating	B-MED
additional	O
patient	B-MED
data	I-MED
might	O
improve	B-MED
the	O
predictive	B-MED
power	B-MED
of	O
ews	B-MED
algorithms	B-MED
however	O
,	O
it	O
is	O
currently	B-MED
not	O
known	O
which	O
patient	B-MED
data	I-MED
or	O
variables	B-MED
are	O
most	O
predictive	B-MED
of	O
icu	B-MED
admission	I-MED
.	O
	
we	O
describe	O
the	O
protocol	B-MED
for	O
a	O
systematic	B-MED
review	B-MED
of	O
variables	B-MED
associated	B-MED
with	I-MED
icu	B-MED
admission	I-MED
.	O
	
medline	B-MED
,	O
embase	B-MED
,	O
cinahl	B-MED
and	O
the	O
cochrane	B-MED
library	I-MED
,	O
including	B-MED
cochrane	B-MED
database	I-MED
of	I-MED
systematic	I-MED
reviews	I-MED
and	O
the	O
cochrane	B-MED
central	I-MED
register	I-MED
of	I-MED
controlled	I-MED
trials	I-MED
central	B-MED
will	O
be	O
searched	B-MED
for	O
studies	B-MED
that	O
assess	B-MED
the	O
association	B-MED
of	O
routinely	B-MED
recorded	B-MED
variables	B-MED
associated	B-MED
with	I-MED
subsequent	B-MED
unplanned	B-MED
icu	B-MED
admission	I-MED
.	O
	
only	O
studies	B-MED
involving	B-MED
adult	B-MED
patients	B-MED
admitted	B-MED
to	I-MED
general	B-MED
icus	B-MED
will	O
be	O
included	B-MED
.	O
	
we	O
will	O
extract	B-MED
data	B-MED
relating	B-MED
to	I-MED
the	O
statistical	B-MED
association	I-MED
between	O
icu	B-MED
admission	I-MED
and	O
predictor	B-MED
variables	B-MED
,	O
the	O
quality	B-MED
of	O
the	O
studies	B-MED
and	O
the	O
generalisability	B-MED
of	O
the	O
findings	B-MED
.	O
	
the	O
results	B-MED
of	O
this	O
review	B-MED
will	O
aid	B-MED
the	O
development	B-MED
of	O
future	O
models	B-MED
which	O
predict	B-MED
the	O
risk	B-MED
of	O
unplanned	B-MED
icu	B-MED
admission	I-MED
.	O
	
diagnosis	B-MED
of	O
retinal	B-MED
health	B-MED
in	O
digital	B-MED
fundus	I-MED
images	I-MED
using	O
continuous	B-MED
wavelet	I-MED
transform	I-MED
cwt	B-MED
and	O
entropies	B-MED
vision	B-MED
is	O
paramount	O
to	O
humans	B-MED
to	O
lead	O
an	O
active	O
personal	B-MED
and	O
professional	B-MED
life	I-MED
.	O
	
the	O
prevalence	B-MED
of	O
ocular	B-MED
diseases	I-MED
is	O
rising	O
,	O
and	O
diseases	B-MED
such	O
as	O
glaucoma	B-MED
,	O
diabetic	B-MED
retinopathy	I-MED
dr	B-MED
and	O
age-related	B-MED
macular	I-MED
degeneration	I-MED
amd	B-MED
are	O
the	O
leading	B-MED
causes	B-MED
of	O
blindness	B-MED
in	O
developed	B-MED
countries	I-MED
.	O
	
identifying	O
these	O
diseases	B-MED
in	O
mass	B-MED
screening	I-MED
programmes	I-MED
is	O
time-consuming	B-MED
,	O
labor	B-MED
-intensive	O
and	O
the	O
diagnosis	B-MED
can	O
be	O
subjective	B-MED
.	O
	
the	O
use	O
of	O
an	O
automated	B-MED
computer	I-MED
aided	I-MED
diagnosis	I-MED
system	I-MED
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	B-MED
and	O
will	O
also	O
reduce	O
the	O
inter-observer	B-MED
subjective	I-MED
variabilities	I-MED
in	O
image	B-MED
interpretation	I-MED
.	O
	
in	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	B-MED
classification	B-MED
of	O
normal	B-MED
from	O
abnormal	B-MED
dr	B-MED
,	O
amd	B-MED
,	O
glaucoma	B-MED
images	B-MED
.	O
	
we	O
had	O
a	O
total	O
of	O
404	O
normal	B-MED
and	O
1082	O
abnormal	B-MED
fundus	B-MED
images	I-MED
in	O
our	O
database	B-MED
.	O
	
as	O
the	O
first	O
step	O
,	O
2d-continuous	B-MED
wavelet	I-MED
transform	I-MED
cwt	B-MED
decomposition	O
on	O
the	O
fundus	B-MED
images	I-MED
of	O
two	O
classes	O
was	O
performed	O
.	O
	
subsequently	O
,	O
energy	B-MED
features	O
and	O
various	O
entropies	B-MED
namely	O
yager	O
,	O
renyi	O
,	O
kapoor	O
,	O
shannon	O
,	O
and	O
fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	B-MED
.	O
	
then	O
,	O
adaptive	O
synthetic	O
sampling	B-MED
approach	I-MED
was	O
applied	O
to	O
balance	O
the	O
normal	B-MED
and	O
abnormal	B-MED
datasets	B-MED
.	O
	
next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
particle	B-MED
swarm	I-MED
optimization	I-MED
pso	B-MED
.	O
	
thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	B-MED
10-fold	O
cross	B-MED
validation	I-MED
.	O
	
overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	B-MED
rate	I-MED
of	O
92.48	O
,	O
and	O
a	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
89.37	O
and	O
95.58	O
respectively	O
using	O
15	O
features	O
.	O
	
this	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-MED
fundus	B-MED
images	I-MED
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-MED
health	B-MED
screening	B-MED
tool	I-MED
that	O
could	O
be	O
employed	O
in	O
polyclinics	B-MED
,	O
and	O
thereby	O
reduce	O
the	O
workload	B-MED
of	O
specialists	B-MED
at	O
the	O
epigenetic	B-MED
landscape	I-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
the	O
geroscience	B-MED
perspective	B-MED
in	O
this	O
review	B-MED
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	B-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
,	O
focusing	O
on	O
those	O
studies	B-MED
that	O
have	O
described	O
dna	B-MED
methylation	I-MED
landscape	I-MED
in	O
cardio-vascular	B-MED
diseases	I-MED
,	O
musculoskeletal	B-MED
function	I-MED
and	O
frailty	B-MED
.	O
	
we	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual	B-MED
framework	I-MED
of	O
""""	O
geroscience	B-MED
""""	O
,	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	B-MED
age	B-MED
is	O
the	O
major	O
risk	B-MED
factor	I-MED
for	O
several	O
of	O
these	O
pathologies	B-MED
and	O
aims	B-MED
at	O
identifying	O
the	O
mechanistic	B-MED
links	I-MED
between	O
aging	B-MED
and	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
.	O
	
dna	B-MED
methylation	I-MED
undergoes	O
a	O
profound	O
remodeling	B-MED
during	O
aging	B-MED
,	O
which	O
includes	O
global	B-MED
hypomethylation	I-MED
of	O
the	O
genome	B-MED
,	O
hypermethylation	B-MED
at	O
specific	B-MED
loci	B-MED
and	O
an	O
increase	B-MED
in	O
inter-individual	B-MED
variation	I-MED
and	O
in	O
stochastic	B-MED
changes	B-MED
of	O
dna	B-MED
methylation	I-MED
values	B-MED
.	O
	
these	O
epigenetic	B-MED
modifications	B-MED
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	B-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	B-MED
relationship	B-MED
between	O
the	O
epigenetic	B-MED
signatures	I-MED
of	O
aging	B-MED
and	O
age	B-MED
-	O
related	B-MED
disease	B-MED
is	O
still	O
poor	O
.	O
	
the	O
most	O
relevant	B-MED
results	B-MED
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
""""	O
epigenetics	B-MED
clocks	I-MED
""""	O
in	O
cohorts	B-MED
of	O
subjects	B-MED
affected	B-MED
by	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
.	O
	
we	O
report	O
these	O
studies	B-MED
in	O
final	O
section	O
of	O
this	O
beneficial	B-MED
effects	I-MED
of	O
phyllanthus	B-MED
amarus	I-MED
against	O
high	B-MED
fructose	I-MED
diet	I-MED
induced	O
insulin	B-MED
resistance	I-MED
and	O
hepatic	B-MED
oxidative	I-MED
stress	I-MED
in	O
male	B-MED
wistar	B-MED
rats	I-MED
insulin	B-MED
resistance	I-MED
ir	B-MED
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-MED
,	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
,	O
and	O
cardiovascular	B-MED
diseases	I-MED
.	O
	
emerging	O
evidence	O
suggests	O
that	O
the	O
high-fructose	B-MED
consumption	B-MED
is	O
a	O
potential	B-MED
and	O
important	O
factor	B-MED
responsible	O
for	O
the	O
rising	B-MED
incidence	I-MED
of	O
ir	B-MED
.	O
	
the	O
present	O
study	B-MED
investigates	B-MED
the	O
beneficial	B-MED
effects	I-MED
of	O
aqueous	B-MED
extract	I-MED
of	O
phyllanthus	B-MED
amaru	I-MED
s	O
paae	B-MED
on	O
ir	B-MED
and	O
oxidative	B-MED
stress	I-MED
in	O
high-fructose	B-MED
hf	B-MED
fed	O
male	B-MED
wistar	B-MED
rats	I-MED
.	O
	
hf	B-MED
diet	I-MED
66%	O
of	O
fructose	O
and	O
paae	B-MED
200	O
mg/kg	O
body	O
weight/day	O
were	O
given	O
concurrently	B-MED
to	O
the	O
rats	B-MED
for	O
a	O
period	O
of	O
60	O
days	O
.	O
	
fructose-fed	B-MED
rats	B-MED
showed	O
weight	B-MED
gain	I-MED
,	O
hyperglycemia	B-MED
,	O
hyperinsulinemia	B-MED
,	O
impaired	B-MED
glucose	I-MED
tolerance	I-MED
,	O
impaired	B-MED
insulin	I-MED
sensitivity	I-MED
,	O
dyslipidemia	B-MED
,	O
hyperleptinemia	B-MED
,	O
and	O
hypoadiponectinemia	B-MED
p	O
<	O
0.05	O
after	O
60	O
days	O
.	O
	
co-administration	B-MED
of	O
paae	B-MED
along	O
with	O
hf	B-MED
diet	I-MED
significantly	O
ameliorated	O
all	O
these	O
alterations	B-MED
.	O
	
regarding	O
hepatic	B-MED
antioxidant	B-MED
status	I-MED
,	O
higher	O
lipid	B-MED
peroxidation	I-MED
and	O
protein	B-MED
oxidation	I-MED
,	O
lower	O
reduced	B-MED
glutathione	I-MED
levels	O
and	O
lower	B-MED
activities	I-MED
of	O
enzymatic	B-MED
antioxidants	I-MED
,	O
and	O
the	O
histopathological	B-MED
changes	I-MED
like	O
mild	O
to	O
severe	O
distortion	B-MED
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver	B-MED
sinusoids	I-MED
observed	O
in	O
the	O
hf	B-MED
diet	I-MED
-fed	O
rats	B-MED
were	O
significantly	O
prevented	O
by	O
paae	B-MED
treatment	B-MED
.	O
	
these	O
findings	O
indicate	O
that	O
paae	B-MED
is	O
beneficial	O
in	O
improving	O
insulin	B-MED
sensitivity	I-MED
and	O
attenuating	O
metabolic	B-MED
syndrome	I-MED
and	O
hepatic	B-MED
oxidative	I-MED
stress	I-MED
in	O
fructose-fed	B-MED
rats	B-MED
.	O
	
environmental	B-MED
factors	I-MED
and	O
hypertension	B-MED
environmental	B-MED
factors	I-MED
are	O
a	O
major	O
cause	O
of	O
poor	B-MED
health	I-MED
worldwide	B-MED
.	O
	
the	O
most	O
solid	O
evidence	B-MED
is	O
for	O
air	B-MED
pollution	I-MED
,	O
leading	O
to	O
increased	O
disability-adjusted	B-MED
life	I-MED
years	I-MED
.	O
	
outdoor	B-MED
temperature	B-MED
and	O
other	O
seasonal	B-MED
climate	B-MED
changes	I-MED
may	O
also	O
influence	O
cardiovascular	B-MED
health	B-MED
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air	B-MED
pollution	I-MED
.	O
	
moreover	O
,	O
an	O
increasing	O
body	O
of	O
evidence	B-MED
associates	O
environmental	B-MED
exposure	I-MED
to	O
noise	B-MED
with	O
poor	B-MED
cardiovascular	I-MED
outcome	I-MED
,	O
and	O
in	O
particular	O
with	O
hypertension	B-MED
.	O
	
this	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	B-MED
about	O
the	O
role	O
of	O
these	O
environmental	B-MED
factors	I-MED
in	O
cardiovascular	B-MED
disease	I-MED
and	O
specifically	O
hypertension	B-MED
.	O
	
in	O
particular	O
,	O
the	O
impact	B-MED
of	O
air	B-MED
pollution	I-MED
,	O
with	O
its	O
short-term	B-MED
and	O
long-term	B-MED
effects	I-MED
,	O
the	O
outdoor	B-MED
temperature	B-MED
and	O
noise	B-MED
pollution	I-MED
will	O
be	O
investigated	O
.	O
	
people	B-MED
belonging	O
to	O
low	B-MED
social	B-MED
classes	I-MED
,	O
as	O
well	O
as	O
children	B-MED
,	O
women	B-MED
,	O
older	B-MED
people	I-MED
and	O
those	O
with	O
established	O
cardiovascular	B-MED
diseases	I-MED
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	B-MED
to	O
the	O
effects	B-MED
of	O
environmental	B-MED
stressors	I-MED
,	O
recalling	O
the	O
concept	B-MED
of	O
""""	O
environmental	B-MED
justice	I-MED
""""	O
.	O
	
the	O
accumulating	O
strong	O
scientific	O
evidence	B-MED
may	O
thus	O
support	O
public	B-MED
health	I-MED
policies	I-MED
aimed	O
at	O
reducing	O
social	B-MED
inequalities	I-MED
in	O
cardiovascular	B-MED
health	B-MED
.	O
	
the	O
effects	B-MED
of	I-MED
probiotic	B-MED
and	O
synbiotic	B-MED
supplementation	B-MED
on	O
metabolic	B-MED
syndrome	I-MED
indices	B-MED
in	O
adults	B-MED
at	O
risk	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
study	B-MED
protocol	I-MED
for	O
a	O
randomized	B-MED
controlled	I-MED
trial	I-MED
the	O
incidence	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
,	O
cardiovascular	B-MED
diseases	I-MED
,	O
and	O
obesity	B-MED
has	O
been	O
rising	B-MED
dramatically	O
however	O
,	O
their	O
pathogenesis	B-MED
is	O
particularly	O
intriguing	B-MED
.	O
	
recently	O
,	O
dysbiosis	B-MED
of	O
the	O
intestinal	B-MED
microbiota	I-MED
has	O
emerged	O
as	O
a	O
new	B-MED
candidate	B-MED
that	O
may	O
be	O
linked	O
to	O
metabolic	B-MED
diseases	I-MED
.	O
	
we	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	B-MED
microbiota	I-MED
by	O
probiotic	B-MED
or	O
synbiotic	B-MED
supplementation	B-MED
may	B-MED
improve	I-MED
metabolic	B-MED
dysfunction	I-MED
and	O
prevent	B-MED
diabetes	B-MED
in	O
prediabetics	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
a	O
synthesis	B-MED
and	O
study	B-MED
of	O
synbiotics	B-MED
will	O
be	O
carried	B-MED
out	O
for	O
the	O
first	O
time	O
in	O
iran	B-MED
.	O
	
in	O
a	O
randomized	B-MED
triple-blind	I-MED
controlled	I-MED
clinical	I-MED
trial	I-MED
,	O
120	O
adults	B-MED
with	O
impaired	B-MED
glucose	I-MED
tolerance	I-MED
based	O
on	O
the	O
inclusion	B-MED
criteria	I-MED
will	O
be	O
selected	B-MED
by	O
a	O
simple	O
random	B-MED
sampling	B-MED
method	I-MED
and	O
will	O
be	O
randomly	B-MED
allocated	B-MED
to	O
6	O
months	B-MED
of	O
6	O
g/d	O
probiotic	B-MED
,	O
synbiotic	B-MED
or	O
placebo	B-MED
.	O
	
the	O
fecal	B-MED
abundance	B-MED
of	O
bacteria	B-MED
,	O
blood	B-MED
pressure	I-MED
,	O
height	B-MED
,	O
weight	B-MED
,	O
and	O
waist	B-MED
and	O
hip	B-MED
circumferences	I-MED
will	O
be	O
measured	B-MED
at	O
baseline	B-MED
and	O
following	B-MED
treatment	B-MED
.	O
	
also	O
,	O
plasma	B-MED
lipid	I-MED
profiles	I-MED
,	O
hba1c	B-MED
,	O
fasting	B-MED
plasma	I-MED
glucose	I-MED
,	O
and	O
insulin	B-MED
levels	B-MED
,	O
will	O
be	O
measured	B-MED
and	O
insulin	B-MED
resistance	I-MED
homa-ir	B-MED
and	O
beta-cell	B-MED
function	I-MED
homa-b	B-MED
will	O
be	O
calculated	B-MED
at	O
baseline	B-MED
and	O
will	O
be	O
repeated	B-MED
at	O
months	B-MED
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O
	
the	O
data	B-MED
will	O
be	O
compared	B-MED
within	O
and	O
between	O
groups	B-MED
using	B-MED
statistical	B-MED
methods	I-MED
.	O
	
the	O
results	B-MED
of	O
this	O
trial	B-MED
could	O
contribute	B-MED
to	O
the	O
evidence-based	B-MED
clinical	I-MED
guidelines	I-MED
that	O
address	O
gut	B-MED
microbiota	I-MED
manipulation	B-MED
to	O
maximize	B-MED
health	B-MED
benefits	I-MED
in	O
prevention	B-MED
and	O
management	B-MED
of	O
metabolic	B-MED
syndrome	I-MED
in	O
prediabetes	B-MED
.	O
	
iranian	B-MED
registry	I-MED
of	O
clinical	B-MED
trials	I-MED
irct201511032321n2	B-MED
.	O
	
evaluation	B-MED
of	O
the	O
relationship	B-MED
between	O
the	O
static	B-MED
measurement	B-MED
of	O
transverse	B-MED
arch	I-MED
flexibility	B-MED
of	O
the	O
forefoot	B-MED
and	O
gait	B-MED
parameters	B-MED
in	O
healthy	B-MED
subjects	I-MED
purpose	B-MED
to	O
investigate	B-MED
the	O
relationship	B-MED
between	O
the	O
static	B-MED
measurement	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
,	O
using	O
a	O
3-dimensional	B-MED
3d	B-MED
foot	B-MED
scanner	I-MED
,	O
and	O
kinetics	B-MED
and	O
kinematics	B-MED
of	O
gait	B-MED
parameters	B-MED
in	O
the	O
sagittal	B-MED
plane	I-MED
.	O
	
subjects	B-MED
and	O
methods	B-MED
twenty	O
healthy	B-MED
subjects	I-MED
participated	O
in	O
this	O
study	B-MED
.	O
	
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
measured	B-MED
under	O
three	O
conditions	B-MED
as	O
follows	O
condition	B-MED
1	O
,	O
sitting	B-MED
condition	B-MED
2	O
,	O
standing	B-MED
and	O
condition	B-MED
3	O
,	O
foot	B-MED
forward	B-MED
and	O
lower	B-MED
leg	I-MED
tilting	B-MED
anteriorly	B-MED
to	O
the	O
maximum	B-MED
position	B-MED
with	O
heel	B-MED
contact	B-MED
.	O
	
gait	B-MED
parameters	B-MED
were	O
recorded	B-MED
using	O
a	O
3d	B-MED
motion	I-MED
analysis	I-MED
system	I-MED
and	O
force	B-MED
plate	I-MED
.	O
	
correlation	B-MED
coefficients	B-MED
between	O
taf	B-MED
for	O
each	O
comparison	B-MED
of	O
conditions	B-MED
and	O
gait	B-MED
parameters	B-MED
were	O
calculated	B-MED
using	O
the	O
spearman	B-MED
correlation	I-MED
analysis	I-MED
.	O
	
results	B-MED
rates	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
width	B-MED
and	O
height	B-MED
between	O
condition	B-MED
2	O
and	O
condition	B-MED
3	O
were	O
significantly	B-MED
correlated	I-MED
with	O
the	O
anterior	B-MED
and	O
posterior	B-MED
component	B-MED
of	O
ground	B-MED
reaction	I-MED
forces	I-MED
,	O
the	O
hip	B-MED
joint	I-MED
extension	B-MED
angle	B-MED
,	O
and	O
the	O
ankle	B-MED
plantar	B-MED
flexion	I-MED
moment	I-MED
.	O
	
conclusion	B-MED
our	O
study's	B-MED
findings	B-MED
indicated	B-MED
that	O
increased	B-MED
stiffness	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
related	B-MED
to	O
the	O
increase	B-MED
in	O
ankle	B-MED
plantar	B-MED
moment	I-MED
,	O
and	O
decreased	B-MED
stiffness	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
related	B-MED
to	O
the	O
increase	B-MED
in	O
hip	B-MED
joint	I-MED
extension	B-MED
angle	B-MED
during	O
management	B-MED
and	O
case	B-MED
outcome	I-MED
of	O
gastric	B-MED
impaction	I-MED
in	O
four	O
raptors	B-MED
a	O
case	B-MED
series	I-MED
four	O
captive	O
raptors	B-MED
,	O
an	O
american	B-MED
kestrel	I-MED
falco	B-MED
sparverius	I-MED
,	O
peregrine	B-MED
falcon	I-MED
falco	B-MED
peregrinus	I-MED
,	O
golden	B-MED
eagle	I-MED
aquila	B-MED
chrysaetos	I-MED
,	O
and	O
barn	B-MED
owl	I-MED
tyto	B-MED
alba	I-MED
,	O
were	O
diagnosed	B-MED
with	O
ventricular	B-MED
and/or	O
proventricular	B-MED
foreign	B-MED
material	I-MED
impactions	B-MED
consisting	O
of	O
artificial	B-MED
turf	I-MED
substrate	I-MED
,	O
paper	B-MED
and	O
plastic	B-MED
substrate	I-MED
,	O
grass	B-MED
,	O
and	O
newspaper	B-MED
.	O
	
partial	B-MED
or	I-MED
total	I-MED
anorexia	I-MED
was	O
reported	O
in	O
all	O
birds	B-MED
and	O
decreased	B-MED
casting	B-MED
in	O
2	O
birds	B-MED
.	O
	
survey	B-MED
radiographs	B-MED
confirmed	O
presence	O
of	O
gastric	B-MED
enlargement	B-MED
in	O
all	O
4	O
birds	B-MED
.	O
	
the	O
kestrel	B-MED
and	O
eagle	B-MED
were	O
treated	B-MED
unsuccessfully	O
with	O
gastroscopy	B-MED
and	O
gastric	B-MED
lavage	I-MED
,	O
respectively	O
,	O
followed	O
by	O
surgical	B-MED
intervention	I-MED
to	O
remove	O
the	O
ventricular	B-MED
impactions	B-MED
.	O
	
both	O
birds	B-MED
died	B-MED
of	I-MED
undetermined	I-MED
causes	I-MED
after	B-MED
surgery	I-MED
.	O
	
the	O
peregrine	B-MED
falcon	I-MED
died	B-MED
before	B-MED
medical	I-MED
or	O
surgical	B-MED
intervention	I-MED
was	O
started	O
,	O
and	O
the	O
owl	B-MED
was	O
managed	O
successfully	O
with	O
oral	B-MED
mineral	I-MED
oil	I-MED
and	O
liquid	B-MED
diet	I-MED
to	O
facilitate	B-MED
egestion	I-MED
of	I-MED
the	I-MED
foreign	I-MED
material	I-MED
as	O
a	O
pellet	B-MED
.	O
	
lead	B-MED
poisoning	I-MED
was	O
suspected	O
as	O
the	O
predisposing	B-MED
cause	I-MED
for	O
foreign	B-MED
body	I-MED
ingestion	I-MED
in	O
the	O
eagle	B-MED
,	O
but	O
underlying	B-MED
causes	I-MED
for	O
pica	B-MED
in	O
the	O
other	O
birds	B-MED
were	O
not	B-MED
determined	I-MED
.	O
	
radiographs	B-MED
can	O
provide	O
useful	O
diagnostic	B-MED
information	I-MED
in	O
sick	B-MED
raptors	B-MED
that	O
exhibit	B-MED
vomiting	I-MED
or	O
changes	B-MED
in	I-MED
appetite	I-MED
or	O
casting	B-MED
frequency	I-MED
,	O
and	O
may	O
help	O
guide	O
treatment	B-MED
decisions	I-MED
of	O
impacted	B-MED
birds	B-MED
.	O
	
careful	O
consideration	B-MED
of	O
substrate	B-MED
,	O
enrichment	B-MED
items	I-MED
,	O
and	O
access	O
to	O
potential	B-MED
foreign	B-MED
material	I-MED
that	I-MED
could	I-MED
be	I-MED
ingested	I-MED
may	O
be	O
the	O
best	O
pre-emptive	O
management	B-MED
strategy	I-MED
in	O
captive	O
anti-inflammatory	B-MED
activity	B-MED
of	O
elaeagnus	B-MED
angustifolia	I-MED
fruit	B-MED
extract	I-MED
on	O
rat	B-MED
paw	B-MED
edema	B-MED
the	O
elaeagnus	B-MED
angustifolia	I-MED
fruit	B-MED
has	O
been	O
traditionally	O
used	O
in	O
iranian	B-MED
herbal	B-MED
medicine	I-MED
to	O
treat	B-MED
diarrhea	B-MED
and	O
rheumatoid	B-MED
arthritis	I-MED
.	O
	
in	O
the	O
present	O
study	O
,	O
the	O
effects	B-MED
of	O
e	B-MED
.	O
	
angustifolia	I-MED
fruit	B-MED
extract	I-MED
on	O
the	O
acute	B-MED
and	O
chronic	B-MED
phases	I-MED
of	O
formalin	B-MED
-	O
induced	B-MED
rat	B-MED
paw	B-MED
edema	B-MED
were	O
examined	B-MED
.	O
	
the	O
acute	B-MED
and	O
chronic	B-MED
anti-inflammatory	B-MED
effects	I-MED
of	O
e	B-MED
.	O
	
angustifolia	I-MED
fruit	B-MED
extract	I-MED
were	O
investigated	B-MED
through	O
the	O
subcutaneous	B-MED
injection	I-MED
of	O
100	O
μl	O
of	O
formalin	B-MED
2.5	O
into	O
a	O
rat's	B-MED
hind	O
paw	B-MED
.	O
	
thirty	B-MED
minutes	I-MED
before	O
the	O
procedure	B-MED
,	O
the	O
experimental	B-MED
groups	B-MED
were	O
treated	B-MED
intraperitoneally	B-MED
with	O
hydroalcoholic	B-MED
fruit	I-MED
extracts	I-MED
of	O
e	B-MED
.	O
	
angustifolia	I-MED
concentrations	B-MED
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg/kg	O
sodium	B-MED
salicylate	I-MED
ss	B-MED
,	O
400	O
mg/kg	O
and	O
distilled	B-MED
water	I-MED
were	O
used	O
as	O
positive	B-MED
and	O
negative	B-MED
control	B-MED
groups	I-MED
,	O
respectively	O
.	O
	
treatment	B-MED
with	O
ss	B-MED
and	O
the	O
fruit	B-MED
extracts	I-MED
were	O
performed	B-MED
daily	B-MED
for	O
8	O
days	B-MED
,	O
and	O
the	O
degree	B-MED
of	O
edema	B-MED
was	O
measured	B-MED
by	O
using	O
mercury	B-MED
plethysmometer	I-MED
and	O
digital	B-MED
caliper	I-MED
.	O
	
in	O
the	O
acute	B-MED
anti-inflammatory	B-MED
study	B-MED
,	O
the	O
extract	B-MED
showed	O
a	O
significant	O
anti-inflammatory	B-MED
effect	I-MED
in	O
a	O
dose-dependent	B-MED
manner	O
.	O
	
the	O
results	B-MED
of	O
1000	O
mg/kg	O
of	O
the	O
extract	B-MED
was	O
significantly	O
different	B-MED
compared	B-MED
with	I-MED
the	O
negative	B-MED
control	B-MED
group	I-MED
p<0	O
and	O
was	O
comparable	O
to	O
sodium	B-MED
salicylate	I-MED
p<0	O
.	O
	
results	B-MED
from	O
the	O
chronic	B-MED
study	B-MED
suggested	B-MED
that	O
e	B-MED
.	O
	
angustifolia	I-MED
extract	B-MED
significantly	O
reduced	B-MED
paw	B-MED
edema	B-MED
and	O
inflammation	B-MED
in	O
a	O
dose-dependent	B-MED
manner	O
.	O
	
the	O
results	B-MED
also	O
showed	O
that	O
the	O
measurement	B-MED
by	O
digital	B-MED
caliper	I-MED
and	O
mercury	B-MED
plethysmometer	I-MED
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
p<0	O
.	O
	
phytochemical	B-MED
tests	I-MED
indicated	O
that	O
the	O
hydroalcoholic	B-MED
fruit	I-MED
extract	I-MED
of	O
e	B-MED
.	O
	
angustifolia	I-MED
was	O
positive	B-MED
for	O
cardiac	B-MED
glycosides	I-MED
,	O
flavonoids	B-MED
,	O
terpenoids	B-MED
,	O
and	O
saponins	B-MED
.	O
	
based	O
on	O
our	O
findings	B-MED
,	O
the	O
e	B-MED
.	O
	
angustifolia	I-MED
fruit	B-MED
extract	I-MED
probably	O
has	O
acute	B-MED
and	O
chronic	B-MED
anti-inflammatory	B-MED
activities	B-MED
to	O
support	O
its	O
applications	O
in	O
folk	B-MED
medicine	I-MED
.	O
	
increased	B-MED
cerebral	B-MED
blood	I-MED
volume	I-MED
pulsatility	B-MED
during	O
head-down	B-MED
tilt	I-MED
with	O
elevated	B-MED
carbon	I-MED
dioxide	I-MED
the	O
spacecot	O
study	O
astronauts	O
aboard	O
the	O
international	O
space	O
station	O
iss	O
have	O
exhibited	O
hyperopic	O
shifts	O
,	O
posterior	O
eye	O
globe	O
flattening	O
,	O
dilated	O
optic	O
nerve	O
sheaths	O
,	O
and	O
even	O
optic	O
disc	O
swelling	O
from	O
spaceflight	O
.	O
	
elevated	O
intracranial	O
pressure	O
icp	O
consequent	O
to	O
cephalad	O
fluid	O
shifts	O
is	O
commonly	O
hypothesized	O
as	O
contributing	O
to	O
these	O
ocular	O
changes	O
.	O
	
head-down	O
tilt	O
hdt	O
is	O
frequently	O
utilized	O
as	O
an	O
earth	O
-based	O
analog	O
to	O
study	O
similar	O
fluid	O
shifts	O
.	O
	
sealed	O
environments	O
like	O
the	O
iss	O
also	O
exhibit	O
elevated	B-MED
carbon	I-MED
dioxide	I-MED
co2	O
,	O
a	O
potent	O
arteriolar	O
vasodilator	O
that	O
could	O
further	O
affect	O
cerebral	O
blood	O
volume	O
and	O
flow	O
,	O
intracranial	O
compliance	O
,	O
and	O
icp	O
.	O
	
a	O
collaborative	O
pilot	O
study	O
between	O
the	O
national	O
space	O
biomedical	O
research	O
institute	O
and	O
the	O
german	O
aerospace	O
center	O
tested	O
the	O
hypotheses	O
that	O
1	O
hdt	O
and	O
elevated	O
co2	O
physiologically	O
interact	O
,	O
and	O
2	O
cerebrovascular	O
pulsatility	O
is	O
related	O
to	O
hdt	O
and/or	O
elevated	O
co2	O
in	O
a	O
double-blind	O
crossover	O
study	O
n=6	O
,	O
we	O
measured	O
cerebral	O
blood	O
volume	O
cbv	O
pulsatility	O
via	O
near-infrared	O
spectroscopy	O
,	O
alongside	O
non-invasive	O
icp	O
and	O
intraocular	O
pressure	O
iop	O
during	O
28-hr	O
-12	O
hdt	O
at	O
both	O
nominal	O
0.04	O
and	O
elevated	O
0.5	O
ambient	O
co2	O
in	O
our	O
cohort	O
,	O
cbv	O
pulsatility	O
increased	O
significantly	O
over	O
time	O
at	O
cardiac	O
frequencies	O
0.031	O
μm/hr	O
increase	O
in	O
hbt	O
pulsatility	O
amplitude	O
and	O
mayer	O
wave	O
frequencies	O
0.019	O
μm/hr	O
increase	O
.	O
	
the	O
hdt	O
-	O
co2	O
interaction	O
on	O
pulsatility	O
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	O
.	O
	
significant	O
differences	O
between	O
atmospheres	O
were	O
not	O
detected	O
in	O
icp	O
or	O
iop	O
.	O
	
further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	O
,	O
to	O
determine	O
whether	O
a	O
"""water"	O
"hammer"""	O
effect	O
in	O
cerebral	O
pulsatility	O
is	O
also	O
present	O
during	O
spaceflight	O
,	O
and	O
whether	O
it	O
is	O
associated	O
with	O
ocular	O
changes	O
in	O
astronauts	B-MED
shift	B-MED
work	I-MED
is	O
associated	B-MED
with	I-MED
metabolic	B-MED
syndrome	I-MED
in	O
young	B-MED
female	B-MED
korean	B-MED
workers	B-MED
shift	B-MED
work	I-MED
is	O
associated	B-MED
with	I-MED
health	B-MED
problems	I-MED
,	O
including	O
metabolic	B-MED
syndrome	I-MED
.	O
	
this	O
study	B-MED
investigated	O
the	O
association	B-MED
between	O
shift	B-MED
work	I-MED
and	O
metabolic	B-MED
syndrome	I-MED
in	O
young	B-MED
workers	B-MED
.	O
	
a	O
total	O
of	O
3	O
subjects	B-MED
aged	O
20-40	O
years	O
enrolled	O
in	O
the	O
2011-2012	O
korean	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
were	O
divided	O
into	O
shift	B-MED
and	O
day	B-MED
workers	I-MED
.	O
	
we	O
conducted	O
a	O
cross-sectional	B-MED
study	I-MED
and	O
calculated	B-MED
odds	B-MED
ratios	I-MED
using	O
multivariate	B-MED
logistic	B-MED
regression	I-MED
analysis	I-MED
in	O
order	O
to	O
examine	B-MED
the	O
association	B-MED
between	O
shift	B-MED
work	I-MED
and	O
metabolic	B-MED
syndrome	I-MED
.	O
	
the	O
prevalence	B-MED
of	O
metabolic	B-MED
syndrome	I-MED
was	O
14.3	O
and	O
7.1	O
among	O
male	B-MED
and	O
female	B-MED
shift	B-MED
workers	I-MED
,	O
respectively	O
.	O
	
after	O
adjusting	O
for	O
confounding	B-MED
factors	I-MED
,	O
shift	B-MED
work	I-MED
was	O
associated	B-MED
with	I-MED
metabolic	B-MED
syndrome	I-MED
in	O
female	B-MED
workers	B-MED
odds	B-MED
ratio	I-MED
,	O
2.53	O
95%	O
confidence	B-MED
interval	I-MED
,	O
1.12	O
to	O
5.70	O
.	O
	
shift	B-MED
work	I-MED
was	O
associated	B-MED
with	I-MED
metabolic	B-MED
syndrome	I-MED
in	O
young	B-MED
women	B-MED
.	O
	
timely	O
efforts	O
are	O
necessary	O
to	O
manage	B-MED
metabolic	B-MED
syndrome	I-MED
in	O
the	O
in	B-MED
vitro	I-MED
differentiation	B-MED
of	O
human	B-MED
pluripotent	B-MED
stem	I-MED
cells	I-MED
into	O
trophoblastic	B-MED
cells	I-MED
the	O
placenta	B-MED
is	O
the	O
first	O
organ	B-MED
to	O
develop	O
during	O
embryogenesis	B-MED
and	O
is	O
required	O
for	O
the	O
survival	B-MED
of	O
the	O
developing	O
embryo	B-MED
.	O
	
the	O
placenta	B-MED
is	O
comprised	O
of	O
various	O
trophoblastic	B-MED
cells	I-MED
that	O
differentiate	B-MED
from	O
the	O
extra-embryonic	B-MED
trophectoderm	I-MED
cells	I-MED
of	O
the	O
preimplantation	B-MED
blastocyst	B-MED
.	O
	
as	O
such	O
,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation	B-MED
events	I-MED
of	O
the	O
human	B-MED
placenta	B-MED
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-MED
and	O
manipulation	B-MED
of	O
human	B-MED
embryogenesis	B-MED
.	O
	
human	B-MED
pluripotent	I-MED
stem	I-MED
cells	I-MED
hpscs	B-MED
are	O
a	O
robust	O
model	B-MED
system	I-MED
for	O
investigating	O
human	B-MED
development	I-MED
and	O
can	O
also	O
be	O
differentiated	B-MED
in	B-MED
vitro	I-MED
into	O
trophoblastic	B-MED
cells	I-MED
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	B-MED
cell	B-MED
types	I-MED
.	O
	
here	O
,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	B-MED
hpscs	B-MED
into	O
trophoblastic	B-MED
cells	I-MED
using	O
bone	B-MED
morphogenic	I-MED
protein	I-MED
4	I-MED
and	O
inhibitors	B-MED
of	O
the	O
activin	B-MED
/	O
nodal	B-MED
signaling	I-MED
pathways	I-MED
.	O
	
this	O
protocol	O
generates	O
various	O
trophoblast	B-MED
cell	B-MED
types	I-MED
that	O
can	O
be	O
transfected	B-MED
with	O
sirnas	B-MED
for	O
investigating	O
loss-of-function	O
phenotypes	B-MED
or	O
can	O
be	O
infected	B-MED
with	O
pathogens	B-MED
.	O
	
additionally	O
,	O
hpscs	B-MED
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	B-MED
into	O
trophoblast	B-MED
progenitors	B-MED
for	O
gain-of-function	O
analyses	O
.	O
	
this	O
in	B-MED
vitro	I-MED
differentiation	B-MED
method	I-MED
for	O
generating	O
human	B-MED
trophoblasts	B-MED
starting	O
from	O
hpscs	B-MED
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	B-MED
of	O
working	O
with	O
early	O
human	B-MED
embryos	B-MED
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
drug	B-MED
discovery	I-MED
and	O
stem	B-MED
cell	I-MED
research	I-MED
.	O
	
metabolomics	B-MED
analysis	B-MED
of	O
anaphylactoid	B-MED
reaction	I-MED
reveals	B-MED
its	O
mechanism	B-MED
in	O
a	O
rat	B-MED
model	B-MED
anaphylactoid	B-MED
reactions	I-MED
,	O
accounting	O
for	O
more	O
than	O
77%	O
of	O
all	O
immune-mediated	B-MED
immediate	I-MED
hypersensitivity	I-MED
reactions	I-MED
,	O
have	O
become	O
a	O
serious	B-MED
threat	B-MED
to	O
public	B-MED
health	I-MED
,	O
but	O
their	O
effect	B-MED
mechanism	B-MED
is	O
not	B-MED
clear	I-MED
and	O
diagnostic	B-MED
tests	I-MED
are	O
limited	B-MED
.	O
	
comprehensive	B-MED
metabolite	B-MED
analysis	B-MED
may	O
reveal	B-MED
the	O
anaphylactoid	B-MED
effect	B-MED
mechanism	B-MED
systematically	B-MED
and	O
provide	B-MED
reference	B-MED
for	O
future	B-MED
diagnostic	B-MED
purposes	B-MED
.	O
	
plasma	B-MED
from	O
brown	B-MED
norway	I-MED
rats	I-MED
given	O
intravenous	B-MED
injection	I-MED
of	O
saline	B-MED
,	O
compound	B-MED
48/80	I-MED
2.5	O
ml/kg	O
or	O
ovalbumin	B-MED
20	O
ml/kg	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	B-MED
to	O
study	B-MED
the	O
effect	B-MED
mechanism	B-MED
of	O
anaphylactoid	B-MED
reactions	I-MED
through	O
metabolomics	B-MED
uplc-qtof-ms/ms	B-MED
.	O
	
metabolomics	B-MED
integrated	O
with	O
proteomics	B-MED
data	I-MED
were	O
used	B-MED
to	O
analyze	B-MED
the	O
anaphylactoid	B-MED
pathways	B-MED
by	O
metaboanalyst	B-MED
followed	B-MED
by	I-MED
integrated	O
pathway	B-MED
analysis	I-MED
.	O
	
thirty	O
metabolites	B-MED
were	O
identified	B-MED
through	O
the	O
metlin	B-MED
database	I-MED
by	O
ms/ms	B-MED
and	O
18	O
of	O
them	O
were	O
confirmed	B-MED
by	I-MED
authentic	B-MED
standards	I-MED
.	O
	
the	O
results	B-MED
showed	O
that	O
adenosine	B-MED
,	O
histamine	B-MED
,	O
n-acetylhistamine	B-MED
,	O
n	B-MED
,	O
malate	B-MED
and	O
xanthine	B-MED
are	O
important	B-MED
indices	O
for	O
anaphylactoid	B-MED
reactions	I-MED
.	O
	
it	O
could	O
be	O
concluded	O
that	O
the	O
effect	B-MED
mechanism	B-MED
is	O
mainly	O
composed	O
of	O
histidine	B-MED
metabolism	I-MED
,	O
arachidonic	B-MED
acid	I-MED
metabolism	I-MED
,	O
energy	B-MED
metabolism	I-MED
,	O
purine	B-MED
metabolism	I-MED
and	O
other	B-MED
small	B-MED
molecules	B-MED
through	B-MED
30	O
metabolites	B-MED
.	O
	
multiple	B-MED
linear	I-MED
regression	I-MED
analysis	I-MED
indicated	B-MED
that	O
not	B-MED
only	B-MED
histamine	B-MED
but	O
also	O
n	B-MED
and	O
arachidonic	B-MED
acid	I-MED
could	O
be	O
used	B-MED
to	O
evaluate	O
anaphylactoid	B-MED
symptoms	B-MED
of	O
animals	B-MED
.	O
	
furthermore	O
,	O
the	O
citrate	B-MED
cycle	I-MED
,	O
histidine	B-MED
metabolism	I-MED
and	O
arachidonic	B-MED
acid	I-MED
metabolism	I-MED
could	O
be	O
the	O
main	B-MED
pathways	B-MED
of	O
anaphylactoid	B-MED
reactions	I-MED
as	O
determined	B-MED
by	I-MED
metaboanalyst	B-MED
.	O
	
the	O
results	B-MED
may	O
provide	B-MED
a	O
reference	B-MED
to	O
improve	B-MED
diagnostic	B-MED
accuracy	I-MED
and	O
predict	B-MED
and	O
monitor	O
treatment	B-MED
efficacy	I-MED
in	O
anaphylactoid	B-MED
reactions	I-MED
in	O
the	O
clinical	B-MED
setting	I-MED
.	O
	
the	O
prevalence	B-MED
of	O
sleep	B-MED
apnea	I-MED
in	O
type	B-MED
b	I-MED
aortic	I-MED
dissection	I-MED
implications	O
for	O
false	B-MED
lumen	B-MED
thrombosis	B-MED
obstructive	B-MED
sleep	I-MED
apnea	I-MED
osa	B-MED
has	O
been	O
implicated	O
in	O
aortic	B-MED
dissection	I-MED
.	O
	
thrombosis	B-MED
of	O
the	O
false	B-MED
lumen	B-MED
is	O
associated	B-MED
with	I-MED
a	O
prognosis	B-MED
of	O
type	B-MED
b	I-MED
aortic	I-MED
dissection	I-MED
aod	B-MED
,	O
and	O
partial	B-MED
thrombosis	I-MED
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	B-MED
of	O
mortality	B-MED
.	O
	
this	O
study	B-MED
sought	O
to	O
explore	O
whether	O
the	O
severity	B-MED
of	O
osa	B-MED
is	O
associated	B-MED
with	I-MED
false	B-MED
lumen	B-MED
thrombosis	B-MED
.	O
	
in	O
this	O
observational	B-MED
study	I-MED
,	O
151	O
type	B-MED
b	I-MED
aod	I-MED
patients	B-MED
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O
	
the	O
status	O
of	O
the	O
false	B-MED
lumen	B-MED
was	O
classified	O
as	O
patent	O
,	O
partially	B-MED
thrombosed	B-MED
,	O
or	O
completely	O
thrombosed	B-MED
based	O
on	O
a	O
computer	B-MED
tomography	I-MED
angiography	I-MED
image	B-MED
.	O
	
patients	B-MED
were	O
divided	O
into	O
non-osa	B-MED
group	I-MED
apnea-hypopnea	B-MED
index	I-MED
ahi	B-MED
<	O
5	O
,	O
and	O
mild	B-MED
5	O
ahi	B-MED
15	O
,	O
moderate	B-MED
15	O
<	O
ahi	B-MED
30	O
,	O
and	O
severe	B-MED
osa	I-MED
groups	I-MED
ahi	B-MED
>	O
30	O
using	O
the	O
ahi	B-MED
.	O
	
the	O
prevalence	B-MED
of	O
osa	B-MED
in	O
type	B-MED
b	I-MED
dissection	I-MED
was	O
66.2	O
.	O
	
among	O
151	O
cases	B-MED
,	O
51	O
patients	B-MED
33.8	O
were	O
in	O
the	O
non-osa	B-MED
group	I-MED
,	O
56	O
37.1	O
were	O
in	O
the	O
mild	B-MED
group	I-MED
,	O
21	O
13.9	O
were	O
in	O
the	O
moderate	B-MED
group	I-MED
,	O
and	O
23	O
15.2	O
were	O
in	O
the	O
severe	B-MED
group	I-MED
.	O
	
additionally	O
,	O
a	O
partially	B-MED
thrombosed	B-MED
false	B-MED
lumen	B-MED
was	O
observed	O
in	O
88	O
patients	B-MED
58.3	O
.	O
	
multivariable	B-MED
analysis	I-MED
revealed	O
that	O
osa	B-MED
severity	B-MED
was	O
positively	B-MED
associated	B-MED
with	I-MED
partial	B-MED
thrombosis	B-MED
odds	B-MED
ratio	I-MED
,	O
1.784	O
,	O
95%	O
confidence	B-MED
interval	I-MED
1.182	O
,	O
p	O
=	O
006	O
after	O
adjusting	O
for	O
other	O
confounding	B-MED
factors	I-MED
.	O
	
osa	B-MED
was	O
present	O
in	O
two-thirds	O
of	O
patients	B-MED
with	O
type	B-MED
b	I-MED
aod	I-MED
.	O
	
the	O
severity	B-MED
of	O
osa	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
partial	B-MED
false	B-MED
lumen	B-MED
thrombosis	B-MED
.	O
	
osa	B-MED
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	B-MED
and	O
prognosis	B-MED
of	O
contextual	B-MED
factors	I-MED
for	O
stunting	B-MED
among	O
children	B-MED
of	O
age	B-MED
6	O
to	O
24	O
months	B-MED
in	O
an	O
under-privileged	B-MED
community	I-MED
of	O
dhaka	B-MED
,	O
bangladesh	B-MED
to	O
determine	O
factors	B-MED
associated	B-MED
with	I-MED
stunting	B-MED
among	O
children	B-MED
aged	B-MED
6	O
to	O
24	O
months	B-MED
in	O
a	O
slum	B-MED
of	O
dhaka	B-MED
,	O
bangladesh	B-MED
.	O
	
we	O
conducted	O
this	O
case	B-MED
control	I-MED
study	I-MED
during	O
november	O
2009	O
to	O
december	O
2012	O
.	O
	
children	B-MED
were	O
classified	O
as	O
case	O
if	O
length-for-age	B-MED
z-score	I-MED
laz	B-MED
was	O
<-2	O
and	O
as	O
control	B-MED
if	O
laz	B-MED
was	O
>-1	O
sd	O
.	O
	
the	O
logistic	B-MED
regression	I-MED
model	I-MED
was	O
used	O
to	O
find	O
the	O
factors	B-MED
associated	B-MED
with	I-MED
stunting	B-MED
.	O
	
the	O
significant	O
risk	B-MED
factors	I-MED
for	O
stunting	B-MED
were	O
child's	B-MED
age	B-MED
>12	O
months	B-MED
,	O
maternal	B-MED
undernutrition	B-MED
,	O
mother's	B-MED
education	I-MED
<5	O
years	B-MED
,	O
consumption	B-MED
of	O
untreated	B-MED
drinking	I-MED
water	I-MED
and	O
monthly	B-MED
family	B-MED
income	B-MED
<100	O
usd	B-MED
.	O
	
the	O
findings	B-MED
of	O
this	O
study	B-MED
reiterated	O
the	O
role	O
of	O
maternal	B-MED
undernutrition	B-MED
and	O
less	B-MED
education	I-MED
,	O
consumption	B-MED
of	O
untreated	B-MED
drinking	I-MED
water	I-MED
and	O
poor	O
family	B-MED
income	B-MED
as	O
important	O
associated	B-MED
factors	B-MED
of	O
childhood	B-MED
stunting	B-MED
most	O
americans	B-MED
have	O
good	B-MED
health	I-MED
,	O
little	O
unmet	B-MED
need	I-MED
,	O
and	O
few	O
health	B-MED
care	I-MED
expenses	I-MED
the	O
distribution	O
of	O
health	B-MED
care	I-MED
expenditures	I-MED
remains	O
highly	O
concentrated	B-MED
,	O
but	O
most	O
americans	B-MED
use	O
few	O
health	B-MED
care	I-MED
resources	I-MED
and	O
have	O
low	O
out-of-pocket	B-MED
spending	I-MED
.	O
	
more	O
than	O
93	O
percent	O
of	O
""""	O
low	B-MED
spenders	I-MED
""""	O
those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	B-MED
believe	O
they	O
have	O
received	B-MED
all	O
needed	O
care	B-MED
in	O
a	O
timely	B-MED
manner	O
.	O
	
the	O
low	O
spending	B-MED
by	O
the	O
majority	O
of	O
the	O
population	B-MED
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty-seven-	O
year	B-MED
period	B-MED
examined	B-MED
.	O
	
penile	B-MED
erosion	I-MED
in	O
a	O
paraplegic	B-MED
man	B-MED
with	O
indwelling	B-MED
urinary	I-MED
catheter	I-MED
and	O
scrotal	B-MED
edema	I-MED
the	O
chronic	B-MED
use	B-MED
of	I-MED
urinary	B-MED
indwelling	I-MED
catheters	I-MED
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long-term	B-MED
patient	B-MED
care	I-MED
and	O
is	O
associated	O
with	O
numerous	O
complications	B-MED
.	O
	
more	O
awareness	B-MED
about	O
urogenital	B-MED
trauma	B-MED
from	O
urinary	B-MED
catheterization	I-MED
is	O
needed	O
,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	B-MED
urinary	B-MED
tract	I-MED
infections	I-MED
.	O
	
there	O
are	O
a	O
number	O
of	O
preventable	B-MED
measures	I-MED
that	O
can	O
be	O
taken	O
to	O
decrease	B-MED
the	O
risk	B-MED
of	O
mechanical	B-MED
trauma	I-MED
to	O
the	O
urethra	B-MED
and	O
glans	B-MED
penis	I-MED
caused	O
by	O
chronic	B-MED
catheterization	B-MED
.	O
	
we	O
present	O
a	O
case	O
of	O
a	O
27-	O
year	B-MED
old	B-MED
paraplegic	B-MED
male	B-MED
needing	O
a	O
chronic	B-MED
indwelling	B-MED
catheter	I-MED
that	O
acquired	B-MED
ventral	B-MED
penile	B-MED
erosion	I-MED
while	O
being	O
cared	B-MED
for	O
in	O
the	O
icu	B-MED
setting	I-MED
.	O
	
modified	B-MED
anastomotic	B-MED
technique	I-MED
for	O
thoracolaparoscopic	B-MED
ivor-lewis	I-MED
esophagectomy	I-MED
early	B-MED
outcomes	B-MED
and	O
technical	B-MED
details	I-MED
thoracoscopic	B-MED
intrathoracic	I-MED
esophagogastrostomy	I-MED
is	O
a	O
technically	O
demanding	O
operation	O
these	O
technical	B-MED
requirements	I-MED
restrict	O
the	O
extensive	O
application	B-MED
of	I-MED
minimally	B-MED
invasive	B-MED
ivor-lewis	B-MED
esophagectomy	I-MED
.	O
	
in	O
an	O
attempt	O
to	O
reduce	B-MED
the	O
difficulty	O
of	O
this	O
surgical	B-MED
procedure	I-MED
,	O
this	O
study	O
developed	O
a	O
modified	B-MED
anastomotic	B-MED
technique	I-MED
for	O
thoracolaparoscopic	B-MED
ivor-lewis	I-MED
esophagectomy	I-MED
.	O
	
during	O
the	O
entirety	O
of	O
this	O
modified	B-MED
approach	B-MED
,	O
neither	O
technically	O
challenging	O
operations	B-MED
such	O
as	O
intrathoracic	B-MED
suturing	I-MED
or	O
knotting	B-MED
,	O
nor	O
special	O
instruments	B-MED
such	O
as	O
an	O
orvil	B-MED
system	I-MED
or	O
a	O
reverse-puncture	B-MED
head	I-MED
are	O
required	O
.	O
	
between	O
october	O
2015	O
and	O
january	O
2016	O
,	O
15	O
consecutive	B-MED
patients	B-MED
with	O
cancer	B-MED
in	O
the	O
distal	B-MED
third	I-MED
of	I-MED
the	I-MED
esophagus	I-MED
or	O
the	O
gastric	B-MED
cardia	I-MED
underwent	O
this	O
modified	B-MED
surgical	B-MED
procedure	I-MED
.	O
	
the	O
good	O
short-term	B-MED
outcomes	B-MED
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	B-MED
anastomotic	B-MED
technique	I-MED
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic	B-MED
ivor-lewis	I-MED
esophagectomy	I-MED
.	O
	
quantitative	B-MED
analysis	I-MED
of	O
cell	B-MED
proliferation	I-MED
by	O
a	O
dye	B-MED
dilution	I-MED
assay	I-MED
application	B-MED
to	O
cell	B-MED
lines	I-MED
and	O
cocultures	B-MED
cell	B-MED
proliferation	I-MED
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	B-MED
in	I-MED
biological	I-MED
systems	I-MED
,	O
thus	O
the	O
quantitative	B-MED
analysis	I-MED
of	O
cell	B-MED
proliferation	I-MED
is	O
important	O
in	O
many	O
biological	B-MED
applications	B-MED
such	O
as	O
drug	B-MED
screening	I-MED
,	O
production	O
of	O
biologics	B-MED
,	O
and	O
assessment	B-MED
of	O
cytotoxicity	B-MED
.	O
	
conventional	B-MED
proliferation	B-MED
assays	I-MED
mainly	O
quantify	O
cell	B-MED
number	I-MED
based	O
on	O
a	O
calibration	B-MED
curve	I-MED
of	O
a	O
homogeneous	B-MED
cell	B-MED
population	I-MED
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	B-MED
of	O
cocultured	B-MED
cells	I-MED
.	O
	
moreover	O
,	O
these	O
assays	B-MED
measure	B-MED
cell	B-MED
proliferation	I-MED
indirectly	O
,	O
based	O
on	O
cellular	B-MED
metabolic	I-MED
activity	I-MED
or	O
dna	B-MED
content	I-MED
.	O
	
to	O
overcome	B-MED
these	O
shortcomings	O
,	O
a	O
dye	B-MED
dilution	I-MED
assay	I-MED
employing	O
fluorescent	B-MED
cell	I-MED
tracking	I-MED
dyes	I-MED
that	O
are	O
retained	B-MED
within	O
cells	B-MED
was	O
applied	O
and	O
was	O
diluted	B-MED
proportionally	B-MED
by	O
subsequent	O
cell	B-MED
divisions	I-MED
.	O
	
here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-MED
could	O
be	O
implemented	O
to	O
quantitatively	B-MED
analyze	I-MED
the	O
cell	B-MED
proliferation	I-MED
of	O
different	O
types	O
of	O
cell	B-MED
lines	I-MED
,	O
and	O
to	O
concurrently	B-MED
analyze	B-MED
the	O
proliferation	B-MED
of	O
two	O
types	O
of	O
cell	B-MED
lines	I-MED
in	O
coculture	B-MED
by	O
utilizing	O
cell	B-MED
tracking	I-MED
dyes	B-MED
with	O
different	O
spectral	B-MED
characteristics	B-MED
.	O
	
the	O
mean	B-MED
division	I-MED
time	I-MED
estimated	B-MED
by	O
the	O
dye	B-MED
dilution	I-MED
assay	I-MED
is	O
compared	O
with	O
the	O
population	B-MED
doubling	I-MED
time	I-MED
obtained	O
from	O
conventional	B-MED
methods	B-MED
and	O
values	B-MED
from	O
literature	B-MED
.	O
	
additionally	O
,	O
dye	B-MED
transfer	O
between	O
cocultured	B-MED
cells	I-MED
was	O
investigated	B-MED
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	B-MED
of	O
the	O
cells	B-MED
rather	O
than	O
a	O
characteristic	B-MED
of	O
the	O
dye	B-MED
.	O
	
it	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-MED
cytometric	I-MED
analyses	I-MED
of	O
cellular	B-MED
properties	B-MED
,	O
providing	O
valuable	B-MED
information	B-MED
on	O
cell	B-MED
status	I-MED
under	O
diverse	B-MED
conditions	B-MED
.	O
	
engineering	B-MED
and	O
in	B-MED
vivo	I-MED
applications	B-MED
of	O
riboswitches	B-MED
riboswitches	B-MED
are	O
common	B-MED
gene	B-MED
regulatory	I-MED
units	I-MED
mostly	O
found	O
in	O
bacteria	B-MED
that	O
are	O
capable	B-MED
of	O
altering	B-MED
gene	B-MED
expression	I-MED
in	O
response	B-MED
to	O
a	O
small	B-MED
molecule	I-MED
.	O
	
these	O
structured	B-MED
rna	I-MED
elements	I-MED
consist	O
of	O
two	O
modular	B-MED
subunits	B-MED
an	O
aptamer	B-MED
domain	I-MED
that	O
binds	B-MED
with	O
high	B-MED
specificity	B-MED
and	O
affinity	B-MED
to	O
a	O
target	B-MED
ligand	B-MED
and	O
an	O
expression	B-MED
platform	O
that	O
transduces	B-MED
ligand	B-MED
binding	I-MED
to	O
a	O
gene	B-MED
expression	I-MED
output	O
.	O
	
significant	B-MED
progress	B-MED
has	O
been	O
made	O
in	O
engineering	B-MED
novel	B-MED
aptamer	B-MED
domains	I-MED
for	O
new	B-MED
small	B-MED
molecule	I-MED
inducers	B-MED
of	O
gene	B-MED
expression	I-MED
.	O
	
modified	B-MED
expression	B-MED
platforms	O
have	O
also	O
been	O
optimized	B-MED
to	O
function	B-MED
when	O
fused	B-MED
with	O
both	O
natural	B-MED
and	O
synthetic	B-MED
aptamer	B-MED
domains	I-MED
.	O
	
as	O
this	O
field	B-MED
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	B-MED
scaffolds	B-MED
has	O
permitted	O
the	O
development	B-MED
of	O
tools	B-MED
such	O
as	O
rna	B-MED
-based	O
fluorescent	B-MED
biosensors	B-MED
.	O
	
in	O
this	O
review	B-MED
,	O
we	O
summarize	B-MED
the	O
methods	B-MED
that	O
have	O
been	O
developed	O
to	O
engineer	B-MED
new	O
riboswitches	B-MED
and	O
highlight	O
applications	B-MED
of	O
natural	B-MED
and	O
synthetic	B-MED
riboswitches	B-MED
in	O
enzyme	B-MED
and	O
strain	B-MED
engineering	I-MED
,	O
in	O
controlling	O
gene	B-MED
expression	I-MED
and	O
cellular	B-MED
physiology	I-MED
,	O
and	O
in	O
real-time	B-MED
imaging	I-MED
of	O
cellular	B-MED
metabolites	I-MED
and	O
signals	B-MED
.	O
	
a	O
novel	B-MED
assay	B-MED
to	O
measure	B-MED
tertiary	B-MED
and	O
quaternary	B-MED
amines	I-MED
in	O
wastewater	B-MED
an	O
indicator	B-MED
for	O
ndma	B-MED
wastewater	B-MED
precursors	B-MED
this	O
study	B-MED
examined	B-MED
the	O
potential	B-MED
of	O
using	O
a	O
novel	B-MED
bulk	B-MED
amine	I-MED
assay	I-MED
as	O
an	O
approximation	B-MED
for	O
the	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
load	O
in	O
wastewaters	B-MED
and	O
surface	B-MED
water	B-MED
samples	I-MED
,	O
and	O
this	O
approximation	B-MED
was	O
compared	B-MED
to	O
n-nitrosodimethylamine	B-MED
ndma	B-MED
formation	B-MED
potential	B-MED
using	O
chloramines	B-MED
.	O
	
an	O
existing	O
colorimetric	B-MED
method	I-MED
was	O
examined	B-MED
and	O
optimized	O
for	O
the	O
detection	B-MED
of	O
amines	B-MED
in	O
environmental	B-MED
water	B-MED
samples	I-MED
.	O
	
the	O
method	B-MED
consists	O
of	O
liquid-liquid	B-MED
extraction	I-MED
followed	O
by	O
a	O
catalyzed	B-MED
reaction	B-MED
to	O
form	O
a	O
yet-	O
undefined	B-MED
product	B-MED
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	B-MED
chromophore	B-MED
and	O
fluorophore	B-MED
.	O
	
previous	O
work	O
verified	O
that	O
this	O
reaction	B-MED
was	O
effectively	O
catalyzed	B-MED
by	O
a	O
number	B-MED
of	O
compounds	B-MED
containing	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
moieties	B-MED
.	O
	
many	O
tertiary	B-MED
and	O
quaternary	B-MED
compounds	I-MED
are	O
also	O
efficient	B-MED
producers	B-MED
of	O
ndma	B-MED
under	O
chloramination	B-MED
conditions	B-MED
,	O
and	O
a	O
linear	B-MED
correlation	I-MED
was	O
consequently	B-MED
derived	O
from	O
the	O
bulk	B-MED
amine	I-MED
signals	I-MED
vs	O
.	O
	
ndma	B-MED
formation	B-MED
potential	B-MED
in	O
various	O
wastewater	B-MED
samples	B-MED
r	O
=	O
0.74	O
n	O
=	O
24	O
p-value	O
<	O
0.05	O
.	O
	
the	O
results	O
provide	O
evidence	B-MED
that	O
approximately	B-MED
2%	O
of	O
the	O
tertiary	B-MED
and	O
quaternary	O
amines	O
measured	B-MED
can	O
form	O
ndma	B-MED
and	O
an	O
estimated	B-MED
0.01	O
of	O
nitrogen	B-MED
in	O
dissolved	B-MED
organic	I-MED
nitrogen	I-MED
originates	I-MED
from	O
these	O
bulk	B-MED
amines	I-MED
.	O
	
the	O
normalization	B-MED
of	O
ndma	B-MED
concentration	B-MED
by	O
the	O
amine	B-MED
measurement	B-MED
revealed	O
that	O
ozone	B-MED
effectively	B-MED
destroyed	B-MED
those	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
structures	B-MED
more	O
likely	O
to	O
form	O
ndma	B-MED
in	O
treated	B-MED
wastewater	B-MED
samples	B-MED
.	O
	
this	O
bulk	B-MED
amine	I-MED
assay	I-MED
illustrates	O
that	O
proxy	O
measurements	B-MED
of	O
tertiary	B-MED
and	O
quaternary	B-MED
amines	I-MED
can	O
be	O
linked	O
to	O
the	O
ndma	B-MED
formation	B-MED
potential	B-MED
of	O
a	O
given	O
sample	B-MED
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	B-MED
as	O
a	O
characterizing	B-MED
tool	B-MED
for	O
ndma	B-MED
precursors	B-MED
in	O
chlamydia	B-MED
pneumoniae	I-MED
infection	B-MED
promotes	B-MED
vascular	B-MED
endothelial	I-MED
cell	I-MED
angiogenesis	B-MED
through	O
an	O
iqgap1	B-MED
-related	O
signaling	B-MED
pathway	I-MED
chlamydia	B-MED
pneumoniae	I-MED
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
plays	O
a	O
potential	B-MED
role	I-MED
in	O
angiogenesis	B-MED
.	O
	
however	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
c	B-MED
.	O
	
pneumoniae	I-MED
is	O
involved	B-MED
in	O
this	O
process	B-MED
.	O
	
therefore	O
,	O
we	O
investigated	B-MED
the	O
effect	B-MED
of	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
on	O
angiogenesis	B-MED
,	O
and	O
then	O
explored	O
the	O
roles	B-MED
of	O
iqgap1	B-MED
-related	O
signaling	B-MED
in	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
-	O
induced	B-MED
angiogenesis	B-MED
.	O
	
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
significantly	B-MED
enhanced	I-MED
angiogenesis	B-MED
as	O
assessed	B-MED
by	O
the	O
tube	B-MED
formation	I-MED
assay	I-MED
possibly	B-MED
by	O
inducing	B-MED
vascular	B-MED
endothelial	I-MED
cell	I-MED
vec	B-MED
migration	B-MED
in	O
the	O
wound	B-MED
healing	I-MED
and	O
transwell	B-MED
migration	I-MED
assays	I-MED
.	O
	
subsequently	B-MED
,	O
immunoprecipitation	B-MED
,	O
western	B-MED
blot	I-MED
and	O
tube	B-MED
formation	I-MED
assay	I-MED
results	B-MED
showed	O
that	O
the	O
phosphorylation	B-MED
of	O
both	O
iqgap1	B-MED
and	O
n-wasp	B-MED
was	O
required	B-MED
for	O
the	O
angiogenesis	B-MED
induced	B-MED
by	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
.	O
	
our	O
co-immunoprecipitation	B-MED
study	B-MED
revealed	B-MED
that	O
iqgap1	B-MED
physically	O
associated	B-MED
with	I-MED
n-wasp	B-MED
after	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
of	O
vecs	B-MED
.	O
	
actin	B-MED
polymerization	I-MED
assay	B-MED
further	O
showed	O
that	O
in	O
c	B-MED
.	O
	
pneumoniae	I-MED
-	O
infected	B-MED
vecs	B-MED
,	O
both	O
iqgap1	B-MED
and	O
n-wasp	B-MED
were	O
recruited	O
to	O
filamentous	B-MED
actin	I-MED
,	O
and	O
shared	O
some	O
common	B-MED
compartments	O
localized	B-MED
at	O
the	O
leading	B-MED
edge	I-MED
of	O
lamellipodia	B-MED
,	O
which	O
was	O
impaired	B-MED
after	O
the	O
depletion	B-MED
of	O
iqgap1	B-MED
by	O
using	O
the	O
small	B-MED
interference	I-MED
rna	I-MED
.	O
	
moreover	O
,	O
the	O
knockdown	B-MED
of	O
iqgap1	B-MED
also	O
significantly	B-MED
decreased	I-MED
n-wasp	B-MED
phosphorylation	B-MED
at	O
tyr256	B-MED
induced	B-MED
by	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
.	O
	
we	O
conclude	B-MED
that	O
c	B-MED
.	O
	
pneumoniae	I-MED
infection	B-MED
promotes	B-MED
vec	B-MED
migration	B-MED
and	O
angiogenesis	B-MED
presumably	O
through	O
the	O
iqgap1	B-MED
-related	O
signaling	B-MED
pathway	I-MED
.	O
	
four-dimensional	B-MED
graded	B-MED
consciousness	B-MED
both	O
the	O
multidimensional	B-MED
phenomenon	B-MED
and	O
the	O
polysemous	B-MED
notion	I-MED
of	O
consciousness	B-MED
continue	O
to	O
prove	O
resistant	B-MED
to	O
consistent	B-MED
measurement	B-MED
and	O
unambiguous	B-MED
definition	I-MED
.	O
	
this	O
is	O
hardly	O
surprising	O
,	O
given	O
that	O
there	O
is	O
no	B-MED
agreement	I-MED
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-MED
they	O
involve	O
.	O
	
one	O
of	O
the	O
basic	O
disagreements	B-MED
present	O
in	O
the	O
continuing	O
debate	B-MED
about	O
consciousness	B-MED
pertains	O
to	O
its	O
gradational	B-MED
nature	B-MED
.	O
	
the	O
general	O
aim	O
of	O
this	O
article	B-MED
is	O
to	O
show	O
how	O
consciousness	B-MED
might	O
be	O
graded	B-MED
and	O
multidimensional	B-MED
at	O
the	O
same	O
time	B-MED
.	O
	
we	O
therefore	O
focus	O
on	O
the	O
question	B-MED
of	O
what	O
it	O
is	O
,	O
exactly	O
,	O
that	O
is	O
or	O
could	O
be	O
graded	B-MED
in	O
cases	B-MED
of	O
consciousness	B-MED
,	O
and	O
how	O
we	O
can	O
measure	B-MED
it	O
.	O
	
ultimately	O
,	O
four	O
different	O
gradable	B-MED
aspects	B-MED
of	O
consciousness	B-MED
will	O
be	O
described	O
quality	B-MED
,	O
abstractness	B-MED
,	O
complexity	B-MED
and	O
usefulness	B-MED
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	B-MED
,	O
these	O
being	O
understood	O
,	O
respectively	O
,	O
as	O
phenomenal	B-MED
,	O
semantic	B-MED
,	O
physiological	B-MED
,	O
and	O
functional	B-MED
.	O
	
consequently	O
,	O
consciousness	B-MED
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	B-MED
quality	B-MED
,	O
semantic	B-MED
abstraction	B-MED
,	O
physiological	B-MED
complexity	B-MED
,	O
and	O
functional	B-MED
usefulness	B-MED
.	O
	
it	O
is	O
hoped	O
that	O
such	O
a	O
four-dimensional	B-MED
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical	B-MED
nature	I-MED
of	O
consciousness	B-MED
.	O
	
the	O
approach	B-MED
also	O
proves	O
explanatorily	O
advantageous	B-MED
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	B-MED
to	O
certain	O
new	O
and	O
important	B-MED
differences	B-MED
in	O
respect	O
of	O
subjective	B-MED
measures	B-MED
of	O
awareness	B-MED
and	O
to	O
justify	O
how	O
a	O
given	O
creature	B-MED
may	O
be	O
ranked	B-MED
higher	B-MED
in	O
one	O
dimension	O
of	O
consciousness	B-MED
and	O
lower	O
in	O
terms	O
of	O
another	O
,	O
but	O
also	O
allows	O
for	O
innovative	B-MED
explanations	I-MED
of	O
a	O
variety	O
of	O
well-known	O
phenomena	B-MED
amongst	O
these	O
,	O
the	O
interpretations	B-MED
of	O
blindsight	B-MED
and	O
locked-in	B-MED
syndrome	I-MED
will	O
be	O
briefly	O
outlined	O
here	O
.	O
	
moreover	O
,	O
a	O
4d	B-MED
framework	O
makes	O
possible	O
many	O
predictions	B-MED
and	O
hypotheses	B-MED
that	O
may	O
be	O
experimentally	B-MED
tested	B-MED
we	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional	B-MED
dependencies	I-MED
.	O
	
synthesis	B-MED
of	O
some	O
unique	O
carbamate	B-MED
derivatives	B-MED
bearing	O
2-furoyl-1-piperazine	B-MED
as	O
a	O
valuable	O
therapeutic	B-MED
agents	I-MED
the	O
aim	B-MED
of	O
the	O
research	B-MED
work	I-MED
was	O
to	O
synthesize	O
different	O
biologically	B-MED
active	I-MED
carbamate	B-MED
derivatives	B-MED
bearing	O
2-furoyl-1-piperazine	B-MED
and	O
having	O
modest	O
toxicity	B-MED
.	O
	
the	O
synthesis	B-MED
was	O
completed	O
as	O
a	O
multiple	B-MED
sequence	I-MED
.	O
	
the	O
structural	B-MED
confirmation	B-MED
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
ei-ms	B-MED
,	O
ir	B-MED
and	O
1h-nmr	B-MED
spectral	O
data	O
.	O
	
the	O
enzyme	B-MED
inhibition	I-MED
and	O
antibacterial	B-MED
potential	I-MED
of	O
the	O
synthesized	B-MED
compounds	I-MED
was	O
evaluated	B-MED
.	O
	
to	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	B-MED
as	O
possible	O
therapeutic	B-MED
agents	I-MED
their	O
cytotoxicity	B-MED
was	O
also	O
checked	O
.	O
	
all	O
the	O
compounds	B-MED
were	O
active	B-MED
against	O
acetylcholinesterase	B-MED
enzyme	I-MED
,	O
especially	O
12	B-MED
and	O
14	B-MED
showed	O
very	O
good	B-MED
inhibitory	B-MED
potential	I-MED
relative	O
to	O
eserine	B-MED
,	O
a	O
reference	B-MED
standard	I-MED
.	O
	
almost	O
all	O
the	O
compounds	B-MED
showed	O
good	O
activities	O
against	O
both	O
gram-positive	B-MED
and	O
gram-negative	B-MED
bacterial	I-MED
strains	I-MED
.	O
	
epidemiology	B-MED
and	O
outcomes	B-MED
of	O
injuries	B-MED
in	O
kenya	B-MED
a	O
multisite	B-MED
surveillance	I-MED
study	I-MED
injury	B-MED
is	O
a	O
leading	O
cause	O
of	O
disability	B-MED
and	O
death	B-MED
worldwide	O
,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-MED
each	O
year	B-MED
.	O
	
the	O
injury	B-MED
burden	B-MED
is	O
higher	O
in	O
low-	B-MED
and	I-MED
middle-income	I-MED
countries	I-MED
where	O
more	O
than	O
90%	O
of	O
injury	B-MED
-related	O
deaths	O
occur	O
.	O
	
despite	O
this	O
burden	O
,	O
the	O
use	O
of	O
prospective	O
trauma	O
registries	O
to	O
describe	O
injury	B-MED
epidemiology	O
and	O
outcomes	O
is	O
limited	O
in	O
low-	O
and	O
middle-income	O
countries	O
.	O
	
kenya	O
lacks	O
robust	O
data	O
to	O
describe	O
injury	O
epidemiology	O
and	O
care	O
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
epidemiology	O
and	O
outcomes	O
of	O
injuries	O
at	O
4	O
referral	O
hospitals	O
in	O
kenya	O
using	O
hospital	O
-based	O
trauma	O
registries	O
.	O
	
from	O
january	O
2014	O
to	O
may	O
2015	O
,	O
all	O
injured	O
patients	O
presenting	O
to	O
the	O
casualty	O
departments	O
of	O
kenyatta	O
national	O
,	O
thika	O
level	O
5	O
,	O
machakos	O
level	O
5	O
,	O
and	O
meru	O
level	O
5	O
hospitals	O
were	O
enrolled	O
prospectively	O
.	O
	
data	O
collected	O
included	O
demographic	O
characteristics	O
,	O
type	O
of	O
prehospital	O
care	O
received	O
,	O
prehospital	O
time	O
,	O
injury	O
pattern	O
,	O
and	O
outcomes	O
.	O
	
a	O
total	O
of	O
14	O
patients	O
were	O
enrolled	O
in	O
our	O
study	O
.	O
	
patients	O
were	O
predominantly	O
male	O
76.1	O
and	O
young	O
mean	O
age	O
28	O
years	O
.	O
	
the	O
most	O
common	O
mechanisms	O
of	O
injury	O
were	O
road	O
traffic	O
injuries	O
36.8	O
,	O
falls	O
26.4	O
,	O
and	O
being	O
struck/hit	O
by	O
a	O
person	O
or	O
object	O
20.1	O
.	O
	
burn	O
was	O
the	O
most	O
common	O
mechanism	O
of	O
injury	O
in	O
the	O
age	O
category	O
under	O
5	O
years	O
.	O
	
body	O
regions	O
commonly	O
injured	O
were	O
lower	O
extremity	O
35.1	O
,	O
upper	O
extremity	O
33.4	O
,	O
and	O
head	O
26.0	O
.	O
	
the	O
overall	O
mortality	O
rate	O
was	O
2.4	O
.	O
	
significant	O
predictors	O
of	O
mortality	O
from	O
multivariate	O
analysis	O
were	O
glasgow	O
coma	O
scale	O
12	O
,	O
estimated	O
injury	O
severity	O
score	O
9	O
,	O
burns	O
,	O
and	O
gunshot	O
injuries	O
.	O
	
hospital	O
-based	O
trauma	O
registries	O
can	O
be	O
important	O
sources	O
of	O
data	O
to	O
study	O
the	O
epidemiology	O
of	O
injuries	O
in	O
low-	O
and	O
middle-income	O
countries	O
.	O
	
data	O
from	O
such	O
trauma	O
registries	O
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	O
health	O
interventions	O
and	O
quality-of-care	O
improvement	O
programs	I-MED
a	O
child	B-MED
with	O
phenylketonuria	B-MED
and	O
focal	B-MED
segmental	I-MED
glomerulosclerosis	I-MED
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-MED
phenylketonuria	B-MED
pku	B-MED
is	O
the	O
most	O
common	B-MED
inborn	B-MED
error	I-MED
of	I-MED
amino	I-MED
acid	I-MED
metabolism	I-MED
.	O
	
phenylalanine	B-MED
hydroxylase	I-MED
is	O
the	O
underlying	O
deficient	B-MED
enzyme	B-MED
.	O
	
if	O
left	O
untreated	B-MED
,	O
growth	B-MED
failure	I-MED
,	O
microcephaly	B-MED
,	O
global	B-MED
developmental	I-MED
delay	I-MED
,	O
seizures	B-MED
and	O
severe	B-MED
intellectual	I-MED
impairment	I-MED
would	O
characterize	B-MED
the	O
clinical	B-MED
picture	I-MED
of	O
pku	B-MED
.	O
	
on	O
the	O
other	O
side	O
of	O
protein	B-MED
homeostasis	B-MED
lies	O
nephrotic	B-MED
syndrome	I-MED
.	O
	
it	O
is	O
a	O
well-known	O
quantitative	B-MED
defect	B-MED
due	O
to	O
significant	B-MED
proteinuria	B-MED
.	O
	
focal	B-MED
segmental	I-MED
glomerulosclerosis	I-MED
fsgs	B-MED
is	O
a	O
special	B-MED
congenital	B-MED
variant	B-MED
affecting	B-MED
children	B-MED
and	O
adults	B-MED
.	O
	
hereby	O
,	O
we	O
describe	O
a	O
three-	O
year	O
old	O
male	B-MED
child	B-MED
who	O
presented	B-MED
with	O
generalized	B-MED
edema	I-MED
and	O
global	B-MED
developmental	I-MED
delay	I-MED
.	O
	
investigations	B-MED
revealed	B-MED
pku	B-MED
along	O
with	O
fsgs	B-MED
.	O
	
we	O
assume	O
that	O
congenital	B-MED
nephrosis	I-MED
ameliorated	B-MED
the	O
picture	O
of	O
pku	B-MED
,	O
and	O
had	O
a	O
salutary	B-MED
effect	I-MED
on	O
the	O
growth	B-MED
and	I-MED
development	I-MED
.	O
	
such	O
coexistence	O
between	O
pku	B-MED
and	O
fsgs	B-MED
gastrointestinal	B-MED
disorders	I-MED
in	O
curry-jones	B-MED
syndrome	I-MED
clinical	B-MED
and	O
molecular	B-MED
insights	B-MED
from	O
an	O
affected	B-MED
newborn	B-MED
curry-jones	B-MED
syndrome	I-MED
cjs	B-MED
is	O
a	O
pattern	B-MED
of	O
malformation	B-MED
that	O
includes	O
craniosynostosis	B-MED
,	O
pre-axial	B-MED
polysyndactyly	I-MED
,	O
agenesis	B-MED
of	I-MED
the	I-MED
corpus	I-MED
callosum	I-MED
,	O
cutaneous	B-MED
and	O
gastrointestinal	B-MED
abnormalities	O
.	O
	
a	O
recurrent	O
,	O
mosaic	O
mutation	O
of	O
smo	O
c.1234	O
c>t	O
p.leu412phe	O
causes	O
cjs	O
.	O
	
this	O
report	O
describes	O
the	O
gastrointestinal	B-MED
and	O
surgical	O
findings	O
in	O
a	O
baby	O
with	O
cjs	O
who	O
presented	O
with	O
abdominal	O
obstruction	O
and	O
reviews	O
the	O
spectrum	O
of	O
gastrointestinal	O
malformations	O
in	O
this	O
rare	O
disorder	O
.	O
	
a	O
41-	O
week	O
,	O
4	O
g	O
,	O
female	O
presented	O
with	O
craniosynostosis	O
,	O
pre-axial	O
polysyndactyly	O
,	O
and	O
cutaneous	O
findings	O
consistent	O
with	O
a	O
clinical	O
diagnosis	O
of	O
cjs	O
.	O
	
the	O
infant	O
developed	O
abdominal	O
distension	O
beginning	O
on	O
the	O
second	O
day	O
of	O
life	O
.	O
	
surgical	O
exploration	O
revealed	O
an	O
intestinal	O
malrotation	O
for	O
which	O
she	O
underwent	O
a	O
ladd	O
procedure	O
.	O
	
multiple	O
small	O
nodules	O
were	O
found	O
on	O
the	O
surface	O
of	O
the	O
small	O
and	O
large	O
bowel	O
in	O
addition	O
to	O
an	O
apparent	O
intestinal	O
duplication	O
that	O
seemed	O
to	O
originate	O
posterior	O
to	O
the	O
pancreas	O
.	O
	
histopathology	O
of	O
serosal	O
nodules	O
revealed	O
bundles	O
of	O
smooth	O
muscle	O
with	O
associated	O
ganglion	O
cells	O
.	O
	
molecular	O
analysis	O
demonstrated	O
the	O
smo	O
c.1234	O
c>t	O
mutation	O
in	O
varying	O
amounts	O
in	O
affected	O
skin	O
up	O
to	O
35%	O
and	O
intestinal	O
hamartoma	O
26%	O
.	O
	
gastrointestinal	O
features	O
including	O
structural	O
malformations	O
,	O
motility	O
disorders	O
,	O
and	O
upper	O
gi	O
bleeding	O
are	O
major	O
causes	O
of	O
morbidity	O
in	O
cjs	O
.	O
	
smooth	O
muscle	O
hamartomas	O
are	O
a	O
recognized	O
feature	O
of	O
children	O
with	O
cjs	O
typically	O
presenting	O
with	O
abdominal	O
obstruction	O
requiring	O
surgical	O
intervention	O
.	O
	
a	O
somatic	O
mutation	O
in	O
smo	O
likely	O
accounts	O
for	O
the	O
structural	O
malformations	O
and	O
predisposition	O
to	O
form	O
bowel	O
hamartomas	O
and	O
myofibromas	O
.	O
	
the	O
mutation	O
burden	O
in	O
the	O
involved	O
tissues	O
likely	O
accounts	O
for	O
the	O
variable	O
manifestations	I-MED
sella	B-MED
turcica	I-MED
bridging	I-MED
and	O
dental	B-MED
anomalies	I-MED
is	O
there	O
an	O
association	B-MED
sella	B-MED
turcica	I-MED
bridging	I-MED
stb	B-MED
,	O
or	O
calcification	B-MED
of	O
the	O
interclinoid	B-MED
ligament	I-MED
of	O
sella	B-MED
turcica	I-MED
,	O
has	O
been	O
reported	O
to	O
be	O
associated	B-MED
with	I-MED
some	O
dental	B-MED
anomalies	I-MED
palatal	B-MED
canine	I-MED
impaction	B-MED
and	O
transposition	B-MED
.	O
	
the	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
find	O
any	O
association	B-MED
between	O
canine	B-MED
impaction	B-MED
,	O
hyperdontia	B-MED
or	O
hypodontia	B-MED
and	O
sellar	B-MED
dimensions	B-MED
or	O
bridging	B-MED
.	O
	
lateral	B-MED
cephalometric	B-MED
radiographs	B-MED
from	O
78	O
patients	B-MED
with	O
impacted	B-MED
canines	B-MED
,	O
68	O
with	O
dental	B-MED
agenesis	I-MED
and	O
17	O
with	O
hyperdontia	B-MED
were	O
collected	O
.	O
	
linear	B-MED
dimensions	B-MED
of	O
sella	B-MED
turcica	I-MED
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	B-MED
group	I-MED
47	O
individuals	B-MED
.	O
	
a	O
standardize	B-MED
scoring	I-MED
scale	I-MED
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
stb	B-MED
from	O
each	O
radiographs	B-MED
.	O
	
the	O
frequency	B-MED
of	O
partial	B-MED
and	O
complete	B-MED
calcifications	B-MED
of	O
sella	B-MED
in	O
patients	B-MED
with	O
dental	B-MED
anomalies	I-MED
is	O
increased	B-MED
when	O
compared	O
to	O
controls	B-MED
.	O
	
stb	B-MED
can	O
influence	O
the	O
interclinoid	B-MED
distance	I-MED
but	O
does	O
not	O
affect	O
other	O
linear	B-MED
dimensions	B-MED
of	O
sella	B-MED
.	O
	
no	O
statistically	B-MED
significant	I-MED
difference	O
has	O
been	O
found	O
in	O
sellar	B-MED
dimensions	B-MED
and	O
stb	B-MED
expression	O
when	O
evaluating	O
radiographs	B-MED
at	O
different	O
ages	B-MED
.	O
	
stb	B-MED
is	O
frequently	O
found	O
in	O
patients	B-MED
with	O
dental	B-MED
abnormalities	I-MED
.	O
	
coxiella	B-MED
burnetii	I-MED
isolates	B-MED
originating	O
from	O
infected	B-MED
cattle	I-MED
induce	B-MED
a	O
more	O
pronounced	O
proinflammatory	B-MED
cytokine	I-MED
response	I-MED
compared	O
to	O
isolates	B-MED
from	O
infected	B-MED
goats	I-MED
and	O
sheep	B-MED
coxiella	B-MED
burnetii	I-MED
is	O
the	O
causative	B-MED
agent	I-MED
of	O
q	B-MED
fever	I-MED
.	O
	
although	O
the	O
prevalence	B-MED
of	O
c	B-MED
.	O
	
burnetii	I-MED
in	O
cattle	B-MED
is	O
much	O
higher	O
than	O
in	O
goats	B-MED
and	O
sheep	B-MED
,	O
infected	B-MED
cattle	I-MED
are	O
rarely	O
associated	B-MED
with	I-MED
human	B-MED
outbreaks	B-MED
.	O
	
we	O
investigated	B-MED
whether	O
the	O
immune	B-MED
response	I-MED
of	O
humans	B-MED
differs	O
after	O
contact	O
with	O
c	B-MED
.	O
	
burnetii	I-MED
isolates	B-MED
from	O
different	O
host	B-MED
origins	I-MED
or	O
with	O
different	O
multilocus	B-MED
variable	I-MED
number	I-MED
of	I-MED
tandem	I-MED
repeat	I-MED
analysis	I-MED
mlva	B-MED
genotypes	B-MED
.	O
	
cytokine	B-MED
responses	I-MED
were	O
measured	O
in	O
human	B-MED
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
pbmcs	B-MED
stimulated	B-MED
with	O
16	O
c	B-MED
.	O
	
burnetii	I-MED
isolates	B-MED
with	O
known	O
mlva	B-MED
genotype	B-MED
from	O
goats	B-MED
,	O
sheep	B-MED
,	O
cattle	B-MED
,	O
acute	B-MED
and	O
chronic	B-MED
q	I-MED
fever	I-MED
patients	B-MED
.	O
	
coxiella	B-MED
burnetii	I-MED
isolates	B-MED
originating	O
from	O
cattle	B-MED
induce	B-MED
significantly	O
more	O
il-1β	B-MED
,	O
tnf-α	B-MED
and	O
il-22	B-MED
than	O
the	O
isolates	B-MED
from	O
goats	B-MED
,	O
sheep	B-MED
or	O
chronic	B-MED
q	I-MED
fever	I-MED
patients	B-MED
.	O
	
comparing	O
the	O
cytokine	B-MED
induction	B-MED
of	O
the	O
isolates	B-MED
based	O
on	O
their	O
mvla	B-MED
genotype	B-MED
did	O
not	O
reveal	O
differences	O
in	O
response	B-MED
between	O
the	O
mlva	B-MED
genotypes	B-MED
.	O
	
the	O
proinflammatory	B-MED
cytokine	I-MED
response	I-MED
induced	B-MED
in	O
human	B-MED
pbmcs	B-MED
by	O
c	B-MED
.	O
	
burnetii	I-MED
isolates	B-MED
from	O
cattle	B-MED
may	O
explain	O
the	O
low	O
incidence	B-MED
of	O
human	B-MED
q	B-MED
fever	I-MED
outbreaks	B-MED
caused	O
by	O
cattle	B-MED
.	O
	
the	O
cytokine	B-MED
profile	O
of	O
pbmcs	O
stimulated	O
with	O
c	O
.	O
	
burnetii	O
isolates	O
from	O
chronic	O
q	O
fever	O
patients	O
resembles	O
isolates	O
from	O
goats	O
.	O
	
furthermore	O
,	O
cytokine	B-MED
responses	O
seem	O
to	O
be	O
depending	O
on	O
host	O
origin	O
than	O
on	O
mlva	O
genotype	B-MED
a	O
novel	O
brca1-associated	B-MED
protein-1	I-MED
isoform	B-MED
affects	B-MED
response	B-MED
of	O
mesothelioma	B-MED
cells	I-MED
to	O
drugs	B-MED
impairing	B-MED
brca1	B-MED
-mediated	O
dna	B-MED
repair	I-MED
brca1	B-MED
associated	I-MED
protein1	I-MED
bap1	B-MED
is	O
a	O
tumor	B-MED
suppressor	I-MED
involved	O
in	O
multiple	B-MED
cellular	B-MED
processes	I-MED
such	O
as	O
transcriptional	B-MED
regulation	I-MED
,	O
chromatin	B-MED
modification	I-MED
by	O
deubiquitinating	B-MED
histone	B-MED
2a	I-MED
,	O
and	O
dna	B-MED
repair	I-MED
.	O
	
bap1	B-MED
mutations	B-MED
are	O
frequent	B-MED
in	O
malignant	B-MED
pleural	I-MED
mesothelioma	I-MED
mpm	B-MED
.	O
	
our	O
aim	B-MED
was	O
to	O
functionally	B-MED
characterize	B-MED
a	O
newly	O
identified	B-MED
isoform	B-MED
of	B-MED
bap1	I-MED
and	O
investigate	B-MED
the	O
effects	B-MED
of	O
its	O
expression	B-MED
on	O
drug	B-MED
sensitivity	I-MED
in	O
mpm	B-MED
.	O
	
expression	B-MED
of	O
bap1	B-MED
isoforms	O
was	O
detected	B-MED
by	O
quantitative	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
in	O
mpm	B-MED
and	O
normal	B-MED
mesothelium	B-MED
cell	B-MED
lines	I-MED
and	O
tumor	B-MED
and	O
nontumor	B-MED
samples	I-MED
.	O
	
histone	B-MED
h2a	I-MED
ubiquitination	B-MED
levels	B-MED
were	O
analyzed	B-MED
by	O
western	B-MED
blot	I-MED
after	O
acidic	B-MED
extraction	I-MED
of	O
core	B-MED
histones	I-MED
.	O
	
subcellular	B-MED
localization	B-MED
of	O
bap1	B-MED
isoforms	B-MED
was	O
examined	B-MED
by	O
immunofluorescence	B-MED
.	O
	
mpm	B-MED
cell	B-MED
survival	I-MED
in	O
response	B-MED
to	O
poly	B-MED
diphosphate-ribose	I-MED
polymerase	I-MED
parp	B-MED
and	O
dual	O
phosphoinositide	B-MED
3-kinase	I-MED
pi3k	B-MED
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
mtor	B-MED
inhibitors	B-MED
was	O
analyzed	B-MED
by	O
in	B-MED
vitro	I-MED
assays	I-MED
.	O
	
we	O
have	O
identified	B-MED
a	O
novel	O
alternative	B-MED
splice	I-MED
isoform	I-MED
of	O
bap1	B-MED
bap1δ	B-MED
that	O
misses	O
part	O
of	O
the	O
catalytic	B-MED
domain	I-MED
.	O
	
cells	B-MED
transfected	B-MED
with	O
bap1δ	B-MED
showed	O
reduced	B-MED
deubiquitinating	B-MED
activity	I-MED
compared	B-MED
with	O
full-length	O
bap1	B-MED
.	O
	
the	O
expression	B-MED
of	O
bap1δ	B-MED
transcript	B-MED
is	O
more	O
abundant	B-MED
in	O
nontumor	B-MED
than	O
in	O
tumor	O
samples	O
.	O
	
mpm	B-MED
cell	B-MED
lines	I-MED
expressing	B-MED
more	O
than	O
20%	O
of	O
bap1δ	B-MED
are	O
more	O
sensitive	B-MED
to	O
olaparib	B-MED
a	O
parp1	B-MED
inhibitor	B-MED
cytotoxicity	B-MED
,	O
and	O
this	O
sensitivity	B-MED
is	O
enhanced	B-MED
when	O
olaparib	B-MED
treatment	B-MED
is	O
combined	B-MED
with	O
gdc0980	B-MED
a	O
dual	O
pi3k	B-MED
-	O
mtor	B-MED
inhibitor	B-MED
,	O
which	O
induces	B-MED
downregulation	B-MED
of	O
brca1	B-MED
.	O
	
these	O
observations	B-MED
suggest	O
that	O
bap1δ	B-MED
does	O
regulate	B-MED
dna	I-MED
damage	I-MED
response	I-MED
and	O
influences	B-MED
drug	B-MED
sensitivity	I-MED
.	O
	
it	O
might	O
therefore	O
be	O
relevant	B-MED
to	O
investigate	B-MED
whether	O
patients	B-MED
with	O
high	B-MED
expression	B-MED
of	O
bap1δ	B-MED
may	O
be	O
responsive	B-MED
to	O
parp	B-MED
/	O
pi3k	B-MED
-	O
mtor	B-MED
inhibitors	B-MED
.	O
	
cucurbitacin	B-MED
b	I-MED
protects	O
against	O
pressure	B-MED
overload	B-MED
induced	O
cardiac	B-MED
hypertrophy	I-MED
lack	O
of	O
effective	O
anti-cardiac	B-MED
hypertrophy	I-MED
drugs	I-MED
creates	O
a	O
major	O
cause	B-MED
for	O
the	O
increasing	O
prevalence	B-MED
of	O
heart	B-MED
failure	I-MED
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
anti-hypertrophy	B-MED
and	O
anti-fibrosis	B-MED
potential	B-MED
of	O
a	O
natural	B-MED
plant	I-MED
triterpenoid	B-MED
,	O
cucurbitacin	B-MED
b	I-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
aortic	B-MED
banding	I-MED
ab	B-MED
was	O
performed	O
to	O
induce	O
cardiac	B-MED
hypertrophy	I-MED
.	O
	
after	O
1	O
week	O
of	O
surgery	B-MED
,	O
mice	B-MED
were	O
receive	O
cucurbitacin	B-MED
b	I-MED
treatment	B-MED
gavage	B-MED
,	O
0.2	O
mg/kg	O
body	B-MED
weight	I-MED
/2	O
day	O
.	O
	
after	O
4	O
weeks	O
of	O
ab	B-MED
,	O
cucurbitacin	B-MED
b	I-MED
demonstrated	O
a	O
strong	O
anti-hypertrophy	B-MED
and	O
-fibrosis	B-MED
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-MED
weight	B-MED
,	O
myocardial	B-MED
cell	I-MED
cross-sectional	B-MED
area	I-MED
and	O
interstitial	B-MED
fibrosis	I-MED
,	O
ameliorated	O
of	O
systolic	B-MED
and	O
diastolic	B-MED
abnormalities	B-MED
,	O
normalized	O
in	O
gene	B-MED
expression	I-MED
of	O
hypertrophic	B-MED
and	O
fibrotic	B-MED
markers	B-MED
,	O
reserved	O
microvascular	B-MED
density	I-MED
in	O
pressure	B-MED
overload	B-MED
induced	O
hypertrophic	B-MED
mice	B-MED
.	O
	
cucurbitacin	B-MED
b	I-MED
also	O
showed	O
significant	O
hypertrophy	B-MED
inhibitory	B-MED
effect	I-MED
in	O
phenylephrine	B-MED
stimulated	B-MED
cardiomyocytes	B-MED
.	O
	
the	O
cucurbitacin	B-MED
b	I-MED
-mediated	O
mitigated	B-MED
cardiac	B-MED
hypertrophy	I-MED
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	B-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
the	O
blockade	B-MED
of	O
akt	B-MED
/	O
mtor	B-MED
/	O
foxo3a	B-MED
signal	B-MED
pathway	I-MED
,	O
validated	O
by	O
sc79	B-MED
,	O
mk2206	B-MED
,	O
and	O
3-ma	B-MED
,	O
the	O
akt	B-MED
agonist	B-MED
,	O
inhibitor	B-MED
and	O
autophagy	B-MED
inhibitor	B-MED
in	B-MED
vitro	I-MED
.	O
	
the	O
overexpression	B-MED
of	O
constitutively	O
active	O
akt	B-MED
completely	O
abolished	O
the	O
cucurbitacin	B-MED
b	I-MED
-mediated	O
protection	O
of	O
cardiac	B-MED
hypertrophy	I-MED
in	O
human	B-MED
cardiomyocytes	B-MED
ac16	I-MED
.	O
	
collectively	O
,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin	B-MED
b	I-MED
protects	O
against	O
cardiac	B-MED
hypertrophy	I-MED
through	O
increasing	O
the	O
autophagy	B-MED
level	O
in	O
cardiomyocytes	B-MED
,	O
which	O
is	O
associated	B-MED
with	I-MED
the	O
inhibition	B-MED
of	O
akt	B-MED
/	O
mtor	B-MED
/	O
foxo3a	B-MED
signal	B-MED
axis	I-MED
.	O
	
inflammatory	B-MED
and	O
oxidative	B-MED
stress	I-MED
markers	B-MED
in	O
experimental	B-MED
allergic	B-MED
asthma	I-MED
ovalbumin	B-MED
-	O
induced	B-MED
allergic	B-MED
lung	I-MED
inflammation	I-MED
ali	B-MED
is	O
a	O
condition	B-MED
believed	O
to	O
be	O
mediated	O
by	O
cytokines	B-MED
,	O
extracellular	B-MED
matrix	I-MED
remodeling	B-MED
,	O
and	O
redox	B-MED
imbalance	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
evaluated	B-MED
pulmonary	B-MED
function	I-MED
together	O
with	O
inflammatory	B-MED
markers	B-MED
as	O
interleukin-4	B-MED
il-4	B-MED
,	O
myeloperoxidase	B-MED
mpo	B-MED
,	O
eosinophil	B-MED
cells	I-MED
,	O
and	O
redox	B-MED
markers	B-MED
in	O
the	O
lungs	B-MED
of	O
balb/c	B-MED
mice	I-MED
after	O
ovalbumin	B-MED
ova	B-MED
sensitization	B-MED
and	O
challenge	B-MED
.	O
	
our	O
results	B-MED
showed	O
an	O
increase	B-MED
in	O
bronchial	B-MED
hyperresponsiveness	I-MED
stimulated	B-MED
by	O
methacholine	B-MED
mch	B-MED
,	O
inflammatory	B-MED
cell	B-MED
influx	I-MED
,	O
especially	O
eosinophils	B-MED
together	O
with	O
an	O
increase	B-MED
of	O
high	B-MED
mobility	I-MED
group	I-MED
box	I-MED
1	I-MED
hmgb1	B-MED
and	O
altered	O
lipid	B-MED
peroxidation	I-MED
lp	B-MED
and	O
antioxidant	B-MED
defenses	B-MED
in	O
the	O
ova	B-MED
group	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
p	O
0.5	O
.	O
	
thus	O
,	O
we	O
demonstrated	O
that	O
ova	B-MED
-	O
induced	B-MED
ali	B-MED
altered	O
redox	B-MED
status	O
concomitantly	B-MED
with	O
impaired	B-MED
lung	B-MED
function	I-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
hmgb1	B-MED
expression	B-MED
and	O
proteolytic	B-MED
remodeling	B-MED
.	O
	
taken	O
together	O
all	O
results	B-MED
found	O
here	O
,	O
we	O
may	O
suggest	O
hmgb1	B-MED
is	O
an	O
important	B-MED
therapeutic	B-MED
target	B-MED
for	O
asthma	B-MED
,	O
once	O
orchestrates	B-MED
the	O
redox	B-MED
signaling	B-MED
,	O
inflammation	B-MED
,	O
and	O
remodeling	B-MED
that	O
contribute	O
to	O
the	O
disease	B-MED
development	B-MED
.	O
	
association	B-MED
among	O
prematurity	B-MED
<30	B-MED
weeks'	I-MED
gestational	I-MED
age	I-MED
,	O
blood	B-MED
pressure	I-MED
,	O
urinary	B-MED
albumin	B-MED
,	O
calcium	B-MED
,	O
and	O
phosphate	B-MED
in	O
early	B-MED
childhood	I-MED
there	O
is	O
a	O
paucity	O
of	O
data	B-MED
on	O
blood	B-MED
pressures	I-MED
bp	B-MED
,	O
urinary	B-MED
albumin	B-MED
,	O
and	O
mineral	B-MED
excretion	B-MED
in	O
early	B-MED
childhood	I-MED
in	O
contemporary	B-MED
cohorts	B-MED
of	O
extremely	B-MED
low	B-MED
gestational	B-MED
age	I-MED
ga	B-MED
neonates	B-MED
.	O
	
our	O
aim	O
was	O
to	O
compare	B-MED
bps	B-MED
and	O
the	O
urinary	B-MED
excretion	B-MED
of	O
albumin	B-MED
,	O
calcium	B-MED
,	O
and	O
phosphate	B-MED
in	O
preterm	B-MED
and	O
term-born	B-MED
cohorts	B-MED
in	O
early	B-MED
childhood	I-MED
.	O
	
this	O
was	O
a	O
prospective	B-MED
observational	I-MED
study	I-MED
conducted	O
at	O
a	O
single	B-MED
center	B-MED
,	O
involving	B-MED
children	B-MED
<5	B-MED
years	I-MED
age	I-MED
,	O
born	B-MED
preterm	I-MED
ga	B-MED
<30	I-MED
weeks	I-MED
or	O
at	B-MED
term	I-MED
37	B-MED
weeks'	I-MED
ga	I-MED
.	O
	
urinary	B-MED
albumin	I-MED
mg/l	O
,	O
calcium	B-MED
and	O
phosphate	B-MED
levels	I-MED
indexed	B-MED
to	O
creatinine	B-MED
mg/dl	O
,	O
and	O
bp	B-MED
were	O
measured	B-MED
.	O
	
the	O
median	B-MED
iqr	B-MED
follow-up	B-MED
age	B-MED
of	O
our	O
cohort	B-MED
n	O
=	O
106	O
was	O
30	O
16-48	O
months	B-MED
.	O
	
preterm-born	B-MED
children	I-MED
n	O
=	O
55	O
had	O
a	O
significantly	B-MED
lower	I-MED
mean	B-MED
ga	B-MED
and	O
birth	B-MED
weight	I-MED
and	O
higher	B-MED
mean	B-MED
systolic	B-MED
,	O
diastolic	B-MED
,	O
and	O
mean	B-MED
bps	I-MED
,	O
compared	B-MED
with	O
term	B-MED
n	O
=	O
51	O
controls	B-MED
.	O
	
a	O
significantly	B-MED
higher	I-MED
proportion	B-MED
of	O
preterm-born	B-MED
children	I-MED
weighed	B-MED
<10th	B-MED
centile	I-MED
and	O
had	O
systolic	B-MED
bp	I-MED
>95th	B-MED
centile	I-MED
at	O
follow-up	B-MED
.	O
	
albumin	B-MED
and	O
calcium	B-MED
excretion	B-MED
did	O
not	B-MED
differ	I-MED
between	O
the	O
groups	B-MED
median	B-MED
urine-phosphate	B-MED
creatinine	I-MED
ratios	I-MED
were	O
higher	B-MED
in	O
the	O
preterm	B-MED
group	I-MED
.	O
	
on	O
logistic	B-MED
regression	I-MED
,	O
lower	B-MED
ga	B-MED
and	O
younger	B-MED
age	B-MED
at	O
follow-up	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
systolic	B-MED
and	O
diastolic	B-MED
bp	I-MED
above	O
the	O
95th	B-MED
centile	I-MED
male	B-MED
gender	I-MED
was	O
associated	B-MED
with	I-MED
decreased	B-MED
risk	B-MED
of	O
diastolic	B-MED
hypertension	I-MED
.	O
	
even	O
in	O
early	B-MED
childhood	I-MED
,	O
children	B-MED
born	I-MED
preterm	I-MED
had	O
significantly	B-MED
elevated	B-MED
bp	B-MED
,	O
compared	B-MED
with	O
their	O
term-born	B-MED
counterparts	B-MED
.	O
	
closer	O
monitoring	B-MED
of	O
bps	B-MED
in	O
this	O
population	B-MED
recombinant	B-MED
protein	B-MED
transduction	I-MED
domain	I-MED
-	O
cu/zn	B-MED
superoxide	I-MED
dismutase	I-MED
alleviates	B-MED
bone	B-MED
cancer	I-MED
pain	B-MED
via	O
peroxiredoxin	B-MED
4	I-MED
modulation	B-MED
and	O
antioxidation	B-MED
bone	B-MED
cancer	I-MED
pain	B-MED
bcp	B-MED
is	O
a	O
serious	B-MED
chronic	B-MED
clinical	B-MED
condition	I-MED
and	O
reactive	B-MED
oxygen	I-MED
species	I-MED
ros	B-MED
were	O
considered	B-MED
to	O
be	O
involved	B-MED
in	O
its	O
development	B-MED
and	O
persistency	B-MED
.	O
	
normally	B-MED
,	O
superoxide	B-MED
dismutase	I-MED
sod	B-MED
converts	O
superoxide	B-MED
anions	I-MED
to	O
hydrogen	B-MED
peroxide	I-MED
h2o2	B-MED
and	O
h2o2	B-MED
is	O
then	O
naturalized	O
to	O
be	O
water	B-MED
by	O
peroxiredoxin	B-MED
4	I-MED
.	O
	
we	O
reported	B-MED
previously	O
that	O
recombinant	B-MED
protein	B-MED
transduction	I-MED
domain	I-MED
ptd	B-MED
cu/zn	B-MED
sod	I-MED
effectively	B-MED
scavenged	B-MED
excessive	B-MED
ros	B-MED
and	O
prevented	B-MED
cardiomyocytes	B-MED
from	O
hypoxia-reoxygenation	B-MED
damage	B-MED
.	O
	
however	O
,	O
whether	O
ptd	B-MED
-	O
cu/zn	B-MED
sod	I-MED
would	O
prevent	B-MED
bcp	B-MED
development	B-MED
is	O
unknown	B-MED
.	O
	
in	O
the	O
current	B-MED
study	B-MED
,	O
we	O
found	B-MED
that	O
an	O
implanted	B-MED
carcinoma	B-MED
in	O
the	O
rat	B-MED
tibia	B-MED
induced	B-MED
remarkable	O
hyperalgesia	B-MED
,	O
increased	B-MED
h2o2	B-MED
levels	B-MED
and	O
decreased	B-MED
sod	B-MED
and	O
peroxiredoxin	B-MED
4	I-MED
levels	B-MED
.	O
	
after	O
administration	B-MED
of	O
recombinant	B-MED
ptd	B-MED
-	O
cu/zn	B-MED
sod	I-MED
to	O
these	O
tumor-burden	B-MED
rats	B-MED
,	O
their	O
hyperalgesia	B-MED
was	O
significantly	B-MED
attenuated	B-MED
and	O
peroxiredoxin	B-MED
4	I-MED
expression	B-MED
was	O
significantly	B-MED
increased	I-MED
.	O
	
in	B-MED
addition	I-MED
,	O
an	O
increased	B-MED
expression	B-MED
of	O
n-methyl-d-aspartic	B-MED
acid	I-MED
nmda	I-MED
receptors	I-MED
and	O
a	O
decreased	B-MED
expression	B-MED
of	O
γ-aminobutyric	B-MED
acid	I-MED
gaba	I-MED
receptors	I-MED
in	O
this	O
cancer	B-MED
pain	I-MED
were	O
prevented	B-MED
by	O
ptd	B-MED
-	O
cu/zn	B-MED
sod	I-MED
administration	B-MED
or	O
peroxiredoxin	B-MED
4	I-MED
overexpression	B-MED
.	O
	
our	O
data	B-MED
suggested	B-MED
that	O
reactive	B-MED
oxygen	I-MED
species	I-MED
,	O
at	O
least	O
in	O
part	O
,	O
play	O
a	O
role	B-MED
in	O
cancer	B-MED
metastatic	I-MED
pain	B-MED
development	B-MED
and	O
persistency	B-MED
which	O
can	O
be	O
attenuated	B-MED
by	I-MED
the	O
adminstration	B-MED
of	O
recombinant	B-MED
ptd	I-MED
-	O
cu/zn	B-MED
sod	I-MED
via	O
the	O
peroxiredoxin	B-MED
4	I-MED
modulation	B-MED
from	O
oxidative	B-MED
stress	I-MED
.	O
	
immune	B-MED
dysregulation	I-MED
in	O
offspring	B-MED
of	O
a	O
bipolar	B-MED
parent	B-MED
.	O
	
altered	O
serum	B-MED
levels	B-MED
of	O
immune	B-MED
growth	B-MED
factors	I-MED
at	O
adolescent	B-MED
age	I-MED
immune	B-MED
dysregulation	I-MED
plays	O
a	O
role	O
in	O
the	O
vulnerability	B-MED
for	O
mood	B-MED
disorders	I-MED
.	O
	
immune	B-MED
growth	B-MED
factors	I-MED
,	O
such	O
as	O
stem	B-MED
cell	I-MED
factor	I-MED
scf	B-MED
,	O
insulin-like	B-MED
growth	I-MED
factor-binding	I-MED
protein-2	I-MED
igf-bp2	B-MED
,	O
epidermal	B-MED
growth	I-MED
factor	I-MED
egf	B-MED
,	O
il-7	B-MED
and	O
scd25	B-MED
have	O
repeatedly	O
been	O
reported	O
altered	B-MED
in	O
patients	B-MED
with	O
mood	B-MED
disorders	I-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
levels	B-MED
of	O
these	O
factors	B-MED
in	O
serum	B-MED
of	O
adolescent	B-MED
bipolar	B-MED
offspring	B-MED
,	O
who	O
have	O
a	O
heightened	B-MED
risk	B-MED
for	O
mood	B-MED
disorder	I-MED
development	B-MED
and	O
to	O
also	O
analyze	B-MED
the	O
data	B-MED
combined	O
with	O
previously	O
published	B-MED
data	I-MED
.	O
	
growth	B-MED
factors	I-MED
were	O
assessed	B-MED
by	O
cba	B-MED
/	O
elisa	B-MED
in	O
adolescent	B-MED
bipolar	B-MED
offspring	B-MED
n=96	O
,	O
mean	B-MED
age	B-MED
=16	O
years	B-MED
and	O
in	O
age	B-MED
-	O
and	O
gender	B-MED
-	O
matched	B-MED
healthy	B-MED
controls	B-MED
n=50	O
.	O
	
egf	B-MED
belonged	O
to	O
a	O
mutually	O
correlating	B-MED
cluster	B-MED
of	O
mainly	O
neurotrophic	B-MED
compounds	I-MED
including	O
s100b	B-MED
and	O
bdnf	B-MED
,	O
which	O
were	O
in	O
general	O
decreased	B-MED
in	O
serum	B-MED
.	O
	
il-7	B-MED
,	O
scf	B-MED
,	O
igf-bp2	B-MED
and	O
scd25	B-MED
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	B-MED
cluster	B-MED
of	O
immune	B-MED
growth	B-MED
factors	I-MED
,	O
which	O
were	O
in	O
general	O
increased	B-MED
igf-bp2	B-MED
significantly	B-MED
in	O
serum	B-MED
of	O
offspring	B-MED
without	O
a	O
mood	B-MED
disorder	I-MED
,	O
il-7	B-MED
and	O
scf	B-MED
in	O
serum	B-MED
of	O
offspring	B-MED
who	O
had	O
expirienced	B-MED
a	O
mood	B-MED
episode	I-MED
.	O
	
this	O
pattern	B-MED
of	O
de	B-MED
-	O
and	O
increases	B-MED
was	O
not	O
different	O
between	O
bipolar	B-MED
offspring	B-MED
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood	B-MED
disorder	I-MED
over	O
time	B-MED
,	O
apart	O
from	O
the	O
igf-bp2	B-MED
level	B-MED
,	O
which	O
was	O
near	O
significantly	B-MED
higher	O
in	O
offspring	B-MED
later	O
developing	O
a	O
mood	B-MED
disorder	I-MED
.	O
	
correlations	B-MED
with	O
the	O
previously	O
published	B-MED
immune-cellular	B-MED
abnormalities	I-MED
were	O
not	O
found	O
.	O
	
in	O
conclusion	B-MED
non-affected	O
adolescents	B-MED
at	O
familial	B-MED
mood	B-MED
disorder	I-MED
development	B-MED
risk	B-MED
were	O
characterized	B-MED
by	O
a	O
distinct	O
pattern	B-MED
of	O
a	O
series	O
of	O
compounds	B-MED
operating	O
in	O
a	O
network	B-MED
of	O
hematopoiesis	B-MED
,	O
neurogenesis	B-MED
and	O
enos	B-MED
s-nitrosylates	B-MED
β-actin	B-MED
on	O
cys374	B-MED
and	O
regulates	B-MED
pkc-θ	B-MED
at	O
the	O
immune	B-MED
synapse	I-MED
by	O
impairing	B-MED
actin	B-MED
binding	I-MED
to	O
profilin-1	B-MED
the	O
actin	B-MED
cytoskeleton	I-MED
coordinates	I-MED
the	I-MED
organization	I-MED
of	O
signaling	B-MED
microclusters	I-MED
at	O
the	O
immune	B-MED
synapse	I-MED
is	B-MED
however	O
,	O
the	O
mechanisms	B-MED
involved	O
remain	O
poorly	O
understood	O
.	O
	
we	O
show	O
here	O
that	O
nitric	B-MED
oxide	I-MED
no	B-MED
generated	O
by	O
endothelial	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
enos	B-MED
controls	O
the	O
coalescence	O
of	O
protein	B-MED
kinase	I-MED
c-θ	I-MED
pkc-θ	B-MED
at	O
the	O
central	B-MED
supramolecular	I-MED
activation	I-MED
cluster	I-MED
c-smac	B-MED
of	O
the	O
is	B-MED
.	O
	
enos	B-MED
translocated	B-MED
with	O
the	O
golgi	B-MED
to	O
the	O
is	B-MED
and	O
partially	O
colocalized	B-MED
with	O
f-actin	B-MED
around	O
the	O
c-smac	B-MED
.	O
	
this	O
resulted	O
in	O
reduced	O
actin	B-MED
polymerization	I-MED
and	O
centripetal	O
retrograde	B-MED
flow	I-MED
of	O
β-actin	B-MED
and	O
pkc-θ	B-MED
from	O
the	O
lamellipodium-like	B-MED
distal	B-MED
d	B-MED
,	O
promoting	B-MED
pkc-θ	B-MED
activation	B-MED
.	O
	
furthermore	O
,	O
enos	B-MED
-derived	O
no	B-MED
s-nitrosylated	B-MED
β-actin	B-MED
on	O
cys374	B-MED
and	O
impaired	B-MED
actin	B-MED
binding	I-MED
to	O
profilin-1	B-MED
pfn1	B-MED
,	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	B-MED
agent	O
s-nitroso-l-cysteine	B-MED
cys-no	B-MED
.	O
	
the	O
importance	O
of	O
no	B-MED
and	O
the	O
formation	O
of	O
pfn1-actin	B-MED
complexes	I-MED
on	O
the	O
regulation	B-MED
of	O
pkc-θ	B-MED
was	O
corroborated	O
by	O
overexpression	B-MED
of	O
pfn1	B-MED
-	O
and	O
actin-binding	B-MED
defective	O
mutants	B-MED
of	O
β-actin	B-MED
c374s	I-MED
and	O
pfn1	B-MED
h119e	I-MED
,	O
respectively	O
,	O
which	O
reduced	O
the	O
coalescence	O
of	O
pkc-θ	B-MED
at	O
the	O
c-smac	B-MED
.	O
	
these	O
findings	O
unveil	O
a	O
novel	O
no	B-MED
-dependent	O
mechanism	B-MED
by	O
which	O
the	O
actin	B-MED
cytoskeleton	I-MED
controls	I-MED
the	I-MED
organization	I-MED
and	O
activation	B-MED
of	O
signaling	B-MED
microclusters	I-MED
at	O
the	O
dobutamine	B-MED
stress	I-MED
echocardiography	I-MED
impact	B-MED
of	O
abnormal	B-MED
blood	B-MED
potassium	I-MED
levels	I-MED
on	O
cardiac	B-MED
arrhythmias	I-MED
guidelines	B-MED
suggest	O
that	O
an	O
abnormal	B-MED
blood	B-MED
potassium	I-MED
level	I-MED
is	O
a	O
relative	O
contraindication	B-MED
to	O
performing	B-MED
dobutamine	B-MED
stress	I-MED
echocardiography	I-MED
dse	B-MED
.	O
	
however	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O
	
we	O
reviewed	B-MED
a	O
consecutive	B-MED
series	I-MED
of	I-MED
patients	I-MED
who	O
had	O
potassium	B-MED
testing	B-MED
within	O
48	O
hours	B-MED
of	O
undergoing	O
dse	B-MED
for	O
the	O
evaluation	B-MED
of	O
myocardial	B-MED
ischemia	I-MED
over	O
a	O
10-	O
year	B-MED
period	B-MED
n	O
=	O
13	O
.	O
	
normal	O
potassium	B-MED
range	B-MED
in	O
our	O
laboratory	B-MED
is	O
3.6	O
mmol/l	O
.	O
	
hemolyzed	B-MED
samples	I-MED
were	O
not	O
included	O
.	O
	
the	O
association	B-MED
of	O
potassium	B-MED
levels	I-MED
with	O
the	O
development	B-MED
of	O
supraventricular	B-MED
and	O
ventricular	B-MED
arrhythmias	I-MED
was	O
assessed	B-MED
.	O
	
the	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-MED
was	O
very	O
low	B-MED
supraventricular	B-MED
tachycardia	I-MED
/	O
atrial	B-MED
fibrillation	I-MED
,	O
4.9	O
nonsustained	B-MED
ventricular	I-MED
tachycardia	I-MED
,	O
2.9	O
sustained	B-MED
ventricular	I-MED
tachycardia	I-MED
or	O
ventricular	B-MED
fibrillation	I-MED
,	O
0.1	O
,	O
confirming	O
the	O
overall	B-MED
safety	I-MED
of	O
dse	B-MED
.	O
	
most	O
arrhythmias	B-MED
88%	O
occurred	O
in	O
patients	B-MED
with	O
normal	O
potassium	B-MED
levels	I-MED
,	O
and	O
arrhythmia	B-MED
rates	B-MED
remained	O
low	B-MED
in	O
patients	B-MED
with	O
potassium	B-MED
abnormalities	B-MED
.	O
	
patients	B-MED
with	O
hyperkalemia	B-MED
had	O
a	O
lower	O
risk	B-MED
of	O
developing	O
mild	B-MED
odds	B-MED
ratio	I-MED
or	B-MED
,	O
0.39	O
95%	O
ci	B-MED
,	O
0.22	O
and	O
severe	B-MED
or	B-MED
,	O
0.13	O
95%	O
ci	B-MED
,	O
0.01	O
supraventricular	B-MED
arrhythmias	I-MED
as	O
well	O
as	O
mild	B-MED
ventricular	B-MED
arrhythmias	I-MED
or	B-MED
,	O
0.58	O
95%	O
ci	B-MED
,	O
0.40	O
.	O
	
even	O
though	O
events	O
were	O
rare	B-MED
,	O
patients	B-MED
with	O
severe	B-MED
hypokalemia	B-MED
potassium	B-MED
levels	I-MED
3.1	O
mmol/l	O
had	O
an	O
increased	B-MED
risk	B-MED
of	O
supraventricular	B-MED
arrhythmia	I-MED
and	O
ventricular	B-MED
ectopy	I-MED
.	O
	
dse	B-MED
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-MED
in	O
blood	B-MED
potassium	I-MED
concentrations	I-MED
,	O
and	O
hence	O
cancellation	O
of	O
dse	B-MED
in	O
patients	B-MED
with	O
potassium	B-MED
abnormalities	B-MED
does	O
not	O
appear	O
warranted	O
.	O
	
elevated	B-MED
potassium	B-MED
levels	I-MED
are	O
associated	B-MED
with	I-MED
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B-MED
and	O
ventricular	B-MED
arrhythmias	I-MED
.	O
	
while	O
remaining	O
at	O
relatively	O
low	B-MED
risk	B-MED
,	O
patients	B-MED
with	O
very	O
low	B-MED
potassium	B-MED
levels	I-MED
3.1	O
mmol/l	O
at	O
the	O
time	O
of	O
dse	B-MED
have	O
a	O
modestly	O
increased	B-MED
risk	B-MED
of	O
arrhythmia	B-MED
.	O
	
consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	B-MED
hypokalemia	B-MED
prior	B-MED
to	O
anatomical	B-MED
subgroup	B-MED
analysis	B-MED
of	O
the	O
meridian	B-MED
cohort	B-MED
posterior	B-MED
fossa	I-MED
abnormalities	I-MED
to	O
assess	B-MED
the	O
diagnostic	B-MED
and	O
clinical	B-MED
contribution	B-MED
of	O
in	B-MED
utero	I-MED
magnetic	I-MED
resonance	I-MED
iumr	I-MED
imaging	I-MED
in	O
fetuses	B-MED
diagnosed	B-MED
with	O
abnormalities	B-MED
of	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
as	O
the	O
only	O
intracranial	B-MED
abnormality	I-MED
recognised	O
on	O
antenatal	B-MED
ultrasonography	I-MED
uss	B-MED
.	O
	
we	O
report	B-MED
a	O
sub-group	B-MED
analysis	B-MED
of	O
fetuses	B-MED
with	O
abnormalities	B-MED
of	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
diagnosed	B-MED
on	O
antenatal	B-MED
uss	I-MED
with	O
or	O
without	O
ventriculomegaly	B-MED
from	O
the	O
meridian	B-MED
cohort	B-MED
who	O
had	O
iumr	B-MED
imaging	I-MED
within	O
2	O
weeks	O
of	O
uss	B-MED
and	O
outcome	B-MED
reference	B-MED
data	I-MED
were	O
available	B-MED
.	O
	
the	O
diagnostic	B-MED
accuracy	I-MED
of	O
uss	B-MED
and	O
iumr	B-MED
are	O
reported	B-MED
as	O
well	O
as	O
indicators	B-MED
of	O
diagnostic	B-MED
confidence	I-MED
and	O
effects	B-MED
on	O
prognosis	B-MED
and	O
clinical	B-MED
management	I-MED
.	O
	
abnormalities	B-MED
confined	I-MED
to	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
according	O
to	O
uss	B-MED
were	O
found	O
in	O
81	O
fetuses	B-MED
67	O
with	O
parenchymal	B-MED
and	O
14	O
with	O
csf	B-MED
-containing	O
lesions	B-MED
.	O
	
the	O
overall	O
diagnostic	B-MED
accuracy	I-MED
for	O
detecting	B-MED
an	O
isolated	B-MED
posterior	B-MED
fossa	I-MED
abnormality	I-MED
was	O
65%	O
for	O
uss	B-MED
and	O
88%	O
for	O
iumr	B-MED
difference	B-MED
=	O
22%	O
,	O
95%	O
ci	O
14.0	O
to	O
30.5	O
,	O
p	O
<	O
0.0001	O
.	O
	
there	O
was	O
an	O
improvement	B-MED
in	O
'	O
appropriate	B-MED
'	O
diagnostic	B-MED
confidence	I-MED
as	O
assessed	B-MED
by	O
a	O
score	B-MED
-	O
based	B-MED
weighted	B-MED
average	B-MED
'	O
method	B-MED
p	O
<	O
0.0001	O
and	O
a	O
three-fold	O
reduction	B-MED
in	O
'high	B-MED
confidence	O
but	O
incorrect	B-MED
diagnoses	B-MED
'	O
was	O
achieved	O
by	O
using	O
iumr	B-MED
imaging	I-MED
.	O
	
the	O
prognostic	B-MED
information	I-MED
given	O
to	O
the	O
women	B-MED
after	O
iumr	B-MED
imaging	I-MED
changed	O
in	O
44%	O
of	O
cases	B-MED
and	O
the	O
overall	B-MED
effect	B-MED
of	O
iumr	B-MED
on	O
clinical	B-MED
management	I-MED
was	O
considered	O
to	O
be	O
'	O
significant	B-MED
'	O
,	O
'	O
major	B-MED
'	O
or	O
'	O
decisive	B-MED
'	O
in	O
35%	O
of	O
cases	B-MED
.	O
	
our	O
data	B-MED
suggests	O
that	O
any	O
woman	B-MED
whose	O
fetus	B-MED
has	O
a	O
posterior	B-MED
fossa	I-MED
abnormality	I-MED
as	O
the	O
only	O
intracranial	B-MED
finding	I-MED
on	O
uss	B-MED
should	O
have	O
iumr	B-MED
imaging	I-MED
for	O
further	O
evaluation	B-MED
.	O
	
this	O
is	O
on	O
the	O
basis	B-MED
of	O
improved	B-MED
diagnostic	B-MED
accuracy	I-MED
and	O
confidence	B-MED
which	O
has	O
substantial	B-MED
effects	B-MED
on	O
the	O
prognostic	B-MED
information	I-MED
given	O
to	O
women	B-MED
and	O
changes	O
in	O
clinical	B-MED
management	I-MED
.	O
	
design	B-MED
,	O
synthesis	B-MED
,	O
and	O
evaluation	B-MED
of	O
curcumin	B-MED
derivatives	B-MED
as	O
nrf2	B-MED
activators	B-MED
and	O
cytoprotectors	B-MED
against	O
oxidative	B-MED
death	I-MED
activation	B-MED
of	O
nuclear	B-MED
factor	I-MED
erythroid-2-related	I-MED
factor	I-MED
2	I-MED
nrf2	B-MED
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-MED
,	O
and	O
natural	O
curcumin	B-MED
stands	O
out	O
as	O
a	O
potent	O
nrf2	B-MED
activator	B-MED
and	O
cancer	B-MED
chemopreventive	B-MED
agent	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-MED
analogs	B-MED
by	O
introducing	O
the	O
geminal	B-MED
dimethyl	I-MED
substituents	I-MED
on	I-MED
the	I-MED
active	I-MED
methylene	I-MED
group	I-MED
to	O
find	O
more	O
potent	O
nrf2	B-MED
activators	B-MED
and	O
cytoprotectors	B-MED
against	O
oxidative	B-MED
death	I-MED
.	O
	
the	O
geminally	B-MED
dimethylated	I-MED
and	O
catechol	B-MED
-type	O
curcumin	B-MED
analog	B-MED
compound	B-MED
3	I-MED
was	O
identified	O
as	O
a	O
promising	O
lead	B-MED
molecule	I-MED
in	O
terms	O
of	O
its	O
increased	O
stability	B-MED
and	O
cytoprotective	B-MED
activity	B-MED
against	O
the	O
tert-butyl	B-MED
hydroperoxide	I-MED
t-bhp	B-MED
death	B-MED
of	O
hepg2	B-MED
cells	I-MED
.	O
	
mechanism	B-MED
studies	B-MED
indicate	O
that	O
its	O
cytoprotective	B-MED
effects	B-MED
are	O
mediated	O
by	O
activating	B-MED
the	O
nrf2	B-MED
signaling	B-MED
pathway	I-MED
in	O
the	O
michael	B-MED
acceptor	I-MED
-	O
and	O
catechol	B-MED
-dependent	O
manners	O
.	O
	
additionally	O
,	O
we	O
verified	O
by	O
using	O
copper	B-MED
and	O
iron	B-MED
ion	B-MED
chelators	B-MED
that	O
the	O
two	O
metal	B-MED
ion	B-MED
-mediated	O
oxidations	B-MED
of	O
compound	B-MED
3	I-MED
to	O
its	O
corresponding	O
electrophilic	O
o-quinone	B-MED
,	O
contribute	O
significantly	O
to	O
its	O
nrf2	B-MED
-dependent	O
cytoprotection	B-MED
.	O
	
this	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	B-MED
natural	B-MED
curcumin	B-MED
-directed	O
nrf2	B-MED
activators	B-MED
by	O
a	O
stability	B-MED
-increasing	O
and	O
proelectrophilic	B-MED
safe	B-MED
with	O
self-injury	B-MED
a	O
practical	B-MED
guide	I-MED
to	O
understanding	B-MED
,	O
responding	B-MED
and	O
harm-reduction	B-MED
inckle	B-MED
kay	I-MED
safe	B-MED
with	O
self-injury	B-MED
a	O
practical	B-MED
guide	I-MED
to	O
understanding	B-MED
,	O
responding	B-MED
and	O
harm-reduction	B-MED
274pp	O
23.99	O
pccs	O
books	O
9781910919163	O
1910919160	O
formula	O
see	O
text	O
the	O
author	B-MED
begins	O
her	O
book	B-MED
with	O
a	O
concise	B-MED
exploration	B-MED
of	O
the	O
stereotypes	B-MED
and	O
truths	B-MED
of	O
self-harm	B-MED
.	O
	
in	O
the	O
following	O
seven	O
chapters	B-MED
,	O
she	O
sets	O
out	O
a	O
grounded	B-MED
and	O
often	O
challenging	B-MED
view	I-MED
of	O
how	O
self-harm	B-MED
is	O
understood	B-MED
from	O
differing	O
pre-hospital	B-MED
policies	B-MED
for	O
the	O
care	B-MED
of	I-MED
patients	I-MED
with	O
acute	B-MED
coronary	I-MED
syndromes	I-MED
in	O
india	B-MED
a	O
policy	B-MED
document	B-MED
analysis	B-MED
ischemic	B-MED
heart	I-MED
disease	I-MED
is	O
the	O
leading	B-MED
cause	B-MED
of	I-MED
death	I-MED
in	O
india	B-MED
.	O
	
in	O
high-income	B-MED
countries	B-MED
,	O
pre-hospital	B-MED
systems	I-MED
of	I-MED
care	I-MED
have	O
been	O
developed	O
to	O
manage	B-MED
acute	B-MED
manifestations	B-MED
of	I-MED
ischemic	B-MED
heart	I-MED
disease	I-MED
,	O
such	O
as	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
acs	B-MED
.	O
	
however	O
,	O
it	O
is	O
unknown	B-MED
whether	O
guidelines	B-MED
,	O
policies	B-MED
,	O
regulations	B-MED
,	O
or	O
laws	B-MED
exist	B-MED
to	O
guide	O
pre-hospital	B-MED
acs	B-MED
care	B-MED
in	O
india	B-MED
.	O
	
we	O
undertook	O
a	O
nation-wide	B-MED
document	B-MED
analysis	B-MED
to	O
address	O
this	O
gap	O
in	O
knowledge	B-MED
.	O
	
from	O
november	B-MED
2014	O
to	O
may	B-MED
2016	O
,	O
we	O
searched	B-MED
for	O
publicly	B-MED
available	B-MED
emergency	B-MED
care	I-MED
guidelines	B-MED
and	O
legislation	B-MED
addressing	O
pre-hospital	B-MED
acs	B-MED
care	B-MED
in	O
all	O
29	O
indian	B-MED
states	B-MED
and	O
7	O
union	B-MED
territories	I-MED
via	O
internet	B-MED
search	B-MED
and	O
direct	B-MED
correspondence	B-MED
.	O
	
we	O
found	B-MED
two	O
documents	B-MED
addressing	O
pre-hospital	B-MED
acs	B-MED
care	B-MED
.	O
	
though	O
india	B-MED
has	O
legislation	B-MED
mandating	I-MED
acute	B-MED
care	I-MED
for	O
emergencies	B-MED
such	O
as	O
trauma	B-MED
,	O
regulations	B-MED
or	O
laws	B-MED
to	O
guide	O
pre-hospital	B-MED
acs	B-MED
care	B-MED
are	O
largely	O
absent	B-MED
.	O
	
policy	B-MED
makers	I-MED
urgently	B-MED
need	B-MED
to	O
develop	O
comprehensive	B-MED
,	O
multi-stakeholder	B-MED
policies	B-MED
for	O
pre-hospital	B-MED
emergency	B-MED
cardiovascular	B-MED
care	I-MED
in	O
lack	B-MED
of	O
antimicrobial	B-MED
efficacy	B-MED
of	O
mecetronium	B-MED
etilsulfate	I-MED
in	O
propanol	B-MED
-based	O
hand	B-MED
rubs	I-MED
for	O
surgical	B-MED
hand	B-MED
disinfection	I-MED
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
if	O
mecetronium	B-MED
etilsulfate	I-MED
mes	B-MED
contributes	O
to	O
overall	O
efficacy	B-MED
in	O
surgical	B-MED
hand	B-MED
disinfection	I-MED
.	O
	
three	O
blinded	O
hand	B-MED
rubs	I-MED
45%	O
iso-propanol	B-MED
,	O
30%	O
n-propanol	B-MED
were	O
applied	B-MED
for	O
1.5	O
min	O
and	O
compared	B-MED
with	O
the	O
en	B-MED
12791	I-MED
reference	O
procedure	B-MED
crossover	B-MED
design	I-MED
.	O
	
one	O
commercial	B-MED
hand	B-MED
rub	I-MED
contained	O
0.2	O
mes	B-MED
,	O
and	O
the	O
two	O
other	O
hand	B-MED
rubs	I-MED
were	O
identical	B-MED
apart	O
from	O
0.2	O
mes	B-MED
.	O
	
none	O
of	O
the	O
formulations	B-MED
had	O
a	O
log10	B-MED
reduction	B-MED
after	O
3	O
h	O
that	O
was	O
significantly	O
better	B-MED
compared	B-MED
with	O
the	O
reference	O
procedure	B-MED
mean	B-MED
1.72	O
standard	B-MED
deviation	I-MED
1.15	O
.	O
	
the	O
antimicrobial	B-MED
contribution	B-MED
of	O
mes	B-MED
in	O
hand	B-MED
rubs	I-MED
skin	B-MED
conductance	I-MED
responses	B-MED
and	O
neural	B-MED
activations	B-MED
during	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
recall	B-MED
across	O
anxiety	B-MED
disorders	I-MED
the	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
neurocircuitry	B-MED
has	O
been	O
extensively	B-MED
studied	B-MED
in	O
healthy	B-MED
and	O
clinical	B-MED
populations	B-MED
,	O
with	O
a	O
particular	B-MED
focus	I-MED
on	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
.	O
	
despite	O
significant	B-MED
overlap	B-MED
of	O
symptoms	B-MED
between	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
and	O
anxiety	B-MED
disorders	I-MED
,	O
the	O
latter	O
has	O
received	B-MED
less	B-MED
attention	B-MED
.	O
	
given	O
that	O
dysregulated	O
fear	B-MED
levels	B-MED
characterize	B-MED
anxiety	B-MED
disorders	I-MED
,	O
examining	B-MED
the	O
neural	B-MED
correlates	B-MED
of	O
fear	B-MED
and	O
extinction	B-MED
learning	B-MED
may	O
shed	O
light	O
on	O
the	O
pathogenesis	B-MED
of	O
underlying	O
anxiety	B-MED
disorders	I-MED
.	O
	
to	O
investigate	B-MED
the	O
psychophysiological	B-MED
and	O
neural	B-MED
correlates	B-MED
of	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
recall	B-MED
in	O
anxiety	B-MED
disorders	I-MED
and	O
to	O
document	B-MED
how	O
these	O
features	B-MED
differ	O
as	O
a	O
function	B-MED
of	O
multiple	B-MED
diagnoses	B-MED
or	O
anxiety	B-MED
severity	B-MED
.	O
	
this	O
investigation	B-MED
was	O
a	O
cross-sectional	B-MED
,	O
case-control	B-MED
,	O
functional	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
study	B-MED
at	O
an	O
academic	B-MED
medical	I-MED
center	I-MED
.	O
	
participants	B-MED
were	O
healthy	B-MED
controls	B-MED
and	O
individuals	B-MED
with	O
at	O
least	O
1	O
of	O
the	O
following	B-MED
anxiety	B-MED
disorders	I-MED
generalized	B-MED
anxiety	I-MED
disorder	I-MED
,	O
social	B-MED
anxiety	I-MED
disorder	I-MED
,	O
specific	B-MED
phobia	I-MED
,	O
and	O
panic	B-MED
disorder	I-MED
.	O
	
the	O
study	B-MED
dates	B-MED
were	O
between	O
march	O
2013	O
and	O
may	O
2015	O
.	O
	
two-day	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
paradigm	B-MED
.	O
	
skin	B-MED
conductance	I-MED
responses	B-MED
,	O
blood	B-MED
oxygenation	I-MED
level-dependent	I-MED
responses	B-MED
,	O
trait	B-MED
anxiety	B-MED
scores	I-MED
from	O
the	O
state	B-MED
trait	I-MED
anxiety	I-MED
inventory	I-MED
-	O
trait	B-MED
form	B-MED
,	O
and	O
functiona	B-MED
l	O
connectivity	B-MED
.	O
	
this	O
study	B-MED
included	B-MED
21	O
healthy	B-MED
controls	B-MED
10	O
women	B-MED
and	O
61	O
individuals	B-MED
with	O
anxiety	B-MED
disorders	I-MED
36	O
women	B-MED
.	O
	
p	B-MED
values	I-MED
reported	B-MED
for	O
the	O
neuroimaging	B-MED
results	B-MED
are	O
all	O
familywise	B-MED
error	B-MED
corrected	B-MED
.	O
	
skin	B-MED
conductance	I-MED
responses	B-MED
during	O
extinction	B-MED
recall	B-MED
did	O
not	O
differ	O
between	O
individuals	B-MED
with	O
anxiety	B-MED
disorders	I-MED
and	O
healthy	B-MED
controls	B-MED
ηp2	B-MED
=	O
0.001	O
,	O
p	O
=	O
79	O
,	O
where	O
ηp2	B-MED
is	O
partial	B-MED
eta	I-MED
squared	I-MED
.	O
	
the	O
anxiety	B-MED
group	B-MED
had	O
lower	B-MED
activation	B-MED
of	O
the	O
ventromedial	B-MED
prefrontal	I-MED
cortex	I-MED
vmpfc	B-MED
during	O
extinction	B-MED
recall	B-MED
ηp2	B-MED
=	O
0.178	O
,	O
p	O
=	O
02	O
.	O
	
a	O
similar	O
hypoactive	B-MED
pattern	B-MED
was	O
found	O
during	O
early	B-MED
conditioning	B-MED
ηp2	B-MED
=	O
0.106	O
,	O
p	O
=	O
009	O
.	O
	
the	O
vmpfc	B-MED
hypoactivation	B-MED
was	O
associated	B-MED
with	I-MED
anxiety	B-MED
symptom	I-MED
severity	B-MED
r	O
=	O
-0	O
,	O
p	O
=	O
01	O
for	O
conditioning	B-MED
and	O
r	O
=	O
-0	O
,	O
p	O
=	O
004	O
for	O
extinction	B-MED
recall	B-MED
and	O
the	O
number	B-MED
of	O
co-occuring	B-MED
anxiety	B-MED
disorders	I-MED
diagnosed	B-MED
ηp2	B-MED
=	O
0.137	O
,	O
p	O
=	O
009	O
for	O
conditioning	B-MED
and	O
ηp2	B-MED
=	O
0.227	O
,	O
p	O
=	O
004	O
for	O
extinction	B-MED
recall	B-MED
.	O
	
psychophysiological	B-MED
interaction	B-MED
analyses	I-MED
revealed	B-MED
that	O
the	O
fear	B-MED
network	B-MED
connectivity	I-MED
differed	O
between	O
healthy	B-MED
controls	B-MED
and	O
the	O
anxiety	B-MED
group	B-MED
during	O
fear	B-MED
learning	B-MED
ηp2	B-MED
range	B-MED
between	O
0.088	O
and	O
0.176	O
and	O
p	B-MED
range	B-MED
between	O
0.02	O
and	O
0.003	O
and	O
extinction	B-MED
recall	B-MED
ηp2	B-MED
range	B-MED
between	O
0.111	O
and	O
0.235	O
and	O
p	B-MED
range	B-MED
between	O
0.02	O
and	O
0.002	O
.	O
	
despite	O
no	O
skin	B-MED
conductance	I-MED
response	B-MED
group	B-MED
differences	B-MED
during	O
extinction	B-MED
recall	B-MED
,	O
brain	B-MED
activation	B-MED
patterns	B-MED
between	O
anxious	B-MED
and	O
healthy	B-MED
individuals	B-MED
differed	O
.	O
	
these	O
findings	B-MED
encourage	O
future	B-MED
studies	B-MED
to	O
examine	B-MED
the	O
conditions	B-MED
longitudinally	B-MED
and	O
in	O
the	O
context	B-MED
of	O
treatment	B-MED
trials	I-MED
to	O
improve	B-MED
and	O
guide	B-MED
therapeutics	I-MED
via	O
advanced	B-MED
neurobiological	B-MED
understanding	B-MED
of	O
each	O
extracellular	B-MED
vesicles	I-MED
from	O
bone	B-MED
marrow	I-MED
derived	O
mesenchymal	B-MED
stem	I-MED
cells	I-MED
protect	B-MED
against	O
murine	B-MED
hepatic	B-MED
ischemia	I-MED
-	O
reperfusion	O
injury	O
hepatic	O
ischemia-reperfusion	O
injury	O
iri	O
and	O
associated	O
inflammation	O
contributes	O
to	O
liver	O
dysfunction	O
and	O
complications	O
after	O
liver	O
surgery	O
and	O
transplantation	O
.	O
	
mesenchymal	O
stem	O
cells	O
msc	O
have	O
been	O
reported	O
to	O
reduce	O
hepatic	B-MED
iri	O
because	O
of	O
their	O
reparative	O
immunomodulatory	O
effects	O
in	O
injured	O
tissues	O
.	O
	
recent	O
studies	O
have	O
highlighted	O
beneficial	O
effects	O
of	O
extracellular	O
vesicles	O
from	O
mscs	O
msc	O
-	O
ev	O
on	O
tissue	O
injury	O
.	O
	
the	O
effects	O
of	O
systemically	O
administered	O
mouse	O
bone	O
marrow	O
derived	O
msc	O
-	O
ev	O
were	O
evaluated	O
in	O
an	O
experimental	O
murine	O
model	O
of	O
hepatic	O
iri	O
induced	O
by	O
cross	O
clamping	O
the	O
hepatic	O
artery	O
and	O
portal	O
vein	O
for	O
90	O
minutes	O
followed	O
by	O
reperfusion	O
for	O
periods	O
of	O
upto	O
6	O
hours	O
.	O
	
compared	O
with	O
controls	O
,	O
intravenous	O
administration	O
of	O
msc	O
-	O
ev	O
30	O
minutes	O
prior	O
to	O
iri	O
dramatically	O
reduced	O
the	O
extent	O
of	O
tissue	O
necrosis	O
,	O
decreased	O
caspase-3	O
positive	O
and	O
apoptotic	O
cells	O
,	O
and	O
reduced	O
serum	O
aminotransferase	O
levels	O
.	O
	
msc	O
-	O
ev	O
increased	O
hepatic	O
mrna	O
expression	O
of	O
nacht	O
,	O
lrr	O
and	O
pyd	O
domains-containing	O
protein	O
12	O
nlrp12	O
,	O
and	O
the	O
chemokine	O
c-x-c	O
motif	O
ligand	O
1	O
cxcl1	O
,	O
and	O
reduced	O
mrna	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
such	O
as	O
il-6	O
during	O
iri	O
.	O
	
msc	O
-	O
ev	O
increased	O
cell	O
viability	O
and	O
suppressed	O
both	O
oxidative	O
injury	O
and	O
nf-κb	O
activity	O
in	O
aml12	O
murine	O
hepatocytes	O
in	O
vitro	O
.	O
	
in	O
conclusion	O
,	O
the	O
administration	O
of	O
ev	O
derived	O
from	O
bone	O
marrow	O
derived	O
mscs	O
may	O
ameliorate	O
hepatic	O
iri	O
by	O
reducing	O
hepatic	O
injury	O
through	O
modulation	O
of	O
the	O
inflammatory	O
response	O
.	O
	
this	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
	
all	O
rights	O
nucleic	B-MED
acid	I-MED
detection	I-MED
with	O
crispr	B-MED
-	O
cas13a	B-MED
/	O
c2c2	B-MED
rapid	B-MED
,	O
inexpensive	O
,	O
and	O
sensitive	B-MED
nucleic	B-MED
acid	I-MED
detection	I-MED
may	O
aid	B-MED
point-of-care	B-MED
pathogen	B-MED
detection	B-MED
,	O
genotyping	B-MED
,	O
and	O
disease	B-MED
monitoring	B-MED
.	O
	
the	O
rna	B-MED
-guided	O
,	O
rna	B-MED
-	O
targeting	B-MED
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeats	I-MED
crispr	B-MED
effector	B-MED
cas13a	B-MED
previously	O
known	O
as	O
c2c2	B-MED
exhibits	O
a	O
""""	O
collateral	B-MED
effect	B-MED
""""	O
of	O
promiscuous	O
ribonuclease	B-MED
activity	I-MED
upon	O
target	B-MED
recognition	B-MED
.	O
	
we	O
combine	B-MED
the	O
collateral	B-MED
effect	B-MED
of	O
cas13a	B-MED
with	O
isothermal	B-MED
amplification	I-MED
to	O
establish	B-MED
a	O
crispr	B-MED
-based	O
diagnostic	B-MED
crispr	B-MED
-	O
dx	B-MED
,	O
providing	O
rapid	B-MED
dna	B-MED
or	O
rna	B-MED
detection	B-MED
with	O
attomolar	B-MED
sensitivity	I-MED
and	O
single-base	B-MED
mismatch	B-MED
specificity	B-MED
.	O
	
we	O
use	O
this	O
cas13a	B-MED
-based	O
molecular	B-MED
detection	B-MED
platform	B-MED
,	O
termed	O
specific	B-MED
high-sensitivity	I-MED
enzymatic	I-MED
reporter	I-MED
unlocking	I-MED
sherlock	B-MED
,	O
to	O
detect	B-MED
specific	B-MED
strains	B-MED
of	O
zika	B-MED
and	O
dengue	B-MED
virus	I-MED
,	O
distinguish	O
pathogenic	B-MED
bacteria	B-MED
,	O
genotype	B-MED
human	B-MED
dna	B-MED
,	O
and	O
identify	B-MED
mutations	B-MED
in	O
cell-free	B-MED
tumor	B-MED
dna	I-MED
.	O
	
furthermore	O
,	O
sherlock	B-MED
reaction	B-MED
reagents	B-MED
can	O
be	O
lyophilized	B-MED
for	O
cold-chain	B-MED
independence	O
and	O
long-term	B-MED
storage	B-MED
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	B-MED
applications	I-MED
.	O
	
a	O
plea	O
for	O
thoracoscopic	B-MED
resection	B-MED
of	O
solitary	B-MED
pulmonary	I-MED
nodule	I-MED
in	O
cancer	B-MED
patients	B-MED
solitary	B-MED
pulmonary	I-MED
nodules	I-MED
spn	B-MED
are	O
frequently	O
detected	B-MED
in	O
cancer	B-MED
patients	B-MED
.	O
	
these	O
lesions	B-MED
are	O
often	O
considered	O
as	O
pulmonary	B-MED
metastases	I-MED
and	O
increasingly	B-MED
treated	B-MED
by	O
non-surgical	B-MED
techniques	I-MED
without	O
histological	B-MED
confirmation	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	B-MED
nature	B-MED
of	O
spn	B-MED
resected	B-MED
by	O
thoracoscopy	B-MED
and	O
to	O
identify	O
risk	B-MED
factors	I-MED
of	O
malignancy	B-MED
.	O
	
single-institution	B-MED
retrospective	I-MED
analysis	I-MED
of	O
all	O
consecutive	B-MED
patients	B-MED
with	O
previously	O
known	O
malignancies	B-MED
who	O
underwent	O
thoracoscopic	B-MED
resection	B-MED
of	O
spn	B-MED
with	O
unknown	B-MED
diagnosis	B-MED
between	O
2001	O
and	O
2014	O
.	O
	
one	O
hundred	O
and	O
forty	O
cancer	B-MED
patients	B-MED
underwent	O
thoracoscopic	B-MED
resection	B-MED
of	O
a	O
spn	B-MED
.	O
	
the	O
resected	B-MED
spn	B-MED
was	O
benign	B-MED
in	O
34	O
patients	B-MED
24.3	O
and	O
malignant	B-MED
in	O
106	O
patients	B-MED
.	O
	
the	O
latter	O
were	O
metastasis	B-MED
in	O
70	O
patients	B-MED
50%	O
and	O
a	O
primary	B-MED
lung	B-MED
cancer	I-MED
in	O
36	O
patients	B-MED
25.7	O
.	O
	
upon	O
univariate	B-MED
analysis	I-MED
,	O
malignancy	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
age	B-MED
>60	O
years	B-MED
,	O
disease	B-MED
-free	O
interval	B-MED
24	O
months	B-MED
,	O
spn	B-MED
size	B-MED
>8	O
mm	O
,	O
upper	B-MED
lobe	I-MED
localization	B-MED
and	O
suvmax	B-MED
>	O
2.5	O
on	O
pet-ct	B-MED
.	O
	
upon	O
multivariate	B-MED
analysis	I-MED
,	O
upper	B-MED
lobe	I-MED
localization	B-MED
and	O
suvmax	B-MED
>	O
2.5	O
were	O
associated	B-MED
with	I-MED
malignancy	B-MED
.	O
	
smoking	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
spn	B-MED
containing	O
primary	B-MED
lung	B-MED
cancer	I-MED
.	O
	
in	O
this	O
series	B-MED
,	O
only	O
50%	O
of	O
spn	B-MED
in	O
patients	B-MED
with	O
known	O
malignant	B-MED
disease	I-MED
were	O
pulmonary	B-MED
metastases	I-MED
and	O
25%	O
had	O
a	O
newly	B-MED
diagnosed	I-MED
nsclc	B-MED
.	O
	
smoking	B-MED
was	O
associated	B-MED
with	I-MED
primary	B-MED
lung	B-MED
cancer	I-MED
but	O
no	B-MED
other	O
predictor	B-MED
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	B-MED
metastasis	I-MED
and	O
lung	B-MED
cancer	I-MED
.	O
	
these	O
results	O
endorse	O
the	O
need	O
of	O
histological	B-MED
confirmation	B-MED
of	O
spn	B-MED
in	O
patients	B-MED
with	O
previous	B-MED
malignancies	B-MED
to	O
avoid	O
diagnostic	B-MED
uncertainty	B-MED
and	O
suboptimal	B-MED
treatments	B-MED
.	O
	
reliability	B-MED
of	O
fear	B-MED
assessment	I-MED
in	O
growing	B-MED
pigs	B-MED
exposed	B-MED
to	I-MED
a	O
novel	B-MED
object	B-MED
test	B-MED
in	O
commercial	B-MED
conditions	B-MED
the	O
objective	B-MED
of	O
this	O
study	O
was	O
to	O
assess	B-MED
the	O
reliability	B-MED
and	O
feasibility	B-MED
of	O
a	O
novel	B-MED
object	B-MED
test	B-MED
assessing	B-MED
fear	I-MED
in	O
pigs	B-MED
in	O
commercial	B-MED
conditions	B-MED
.	O
	
a	O
total	O
of	O
18	O
commercial	B-MED
farms	B-MED
were	O
visited	O
,	O
and	O
321	O
pens	B-MED
housing	I-MED
4	O
growing	B-MED
pigs	B-MED
were	O
assessed	B-MED
.	O
	
three	O
balloons	B-MED
were	O
used	O
as	O
a	O
novel	B-MED
stimulus	B-MED
.	O
	
measures	B-MED
were	O
a	O
the	O
time	B-MED
it	O
took	O
for	O
the	O
first	O
pig	B-MED
to	O
contact	B-MED
1	O
of	O
the	O
balloons	B-MED
,	O
b	O
percentage	O
of	O
nonhuman	B-MED
animals	B-MED
watching	B-MED
the	O
balloons	B-MED
each	O
for	O
10	O
s	O
,	O
and	O
c	O
percentage	O
of	O
animals	B-MED
touching	B-MED
the	O
balloons	B-MED
during	O
periods	B-MED
of	O
5	O
s	O
.	O
	
the	O
time	B-MED
of	O
the	O
first	O
pig	B-MED
to	O
contact	B-MED
1	O
of	O
the	O
balloons	B-MED
ranged	B-MED
from	O
0	O
s	O
to	O
362	O
s	O
.	O
	
an	O
effect	B-MED
of	O
the	O
farm	B-MED
was	O
found	O
p	O
<	O
0001	O
for	O
contact	B-MED
latency	B-MED
,	O
ranging	B-MED
from	O
6.8	O
s	O
to	O
73.3	O
s	O
,	O
but	O
little	O
difference	B-MED
was	O
found	O
in	O
terms	O
of	O
intrafarm	B-MED
variability	B-MED
.	O
	
interobserver	B-MED
repeatability	I-MED
was	O
also	O
high	B-MED
in	O
this	O
measure	B-MED
,	O
ranging	B-MED
from	O
r	O
=	O
74	O
to	O
r	O
=	O
96	O
.	O
	
as	O
a	O
result	O
,	O
it	O
is	O
concluded	O
that	O
contact	B-MED
latency	B-MED
could	O
be	O
a	O
good	O
measure	B-MED
to	O
assess	B-MED
fear	B-MED
of	O
a	O
novel	O
stimulus	B-MED
in	O
commercial	B-MED
farms	B-MED
.	O
	
precise	O
prediction	B-MED
of	O
activators	B-MED
for	O
the	O
human	B-MED
constitutive	B-MED
androstane	I-MED
receptor	I-MED
using	O
structure	B-MED
-based	O
three-dimensional	B-MED
quantitative	I-MED
structure-activity	I-MED
relationship	I-MED
methods	B-MED
the	O
constitutive	B-MED
androstane	I-MED
receptor	I-MED
car	B-MED
,	O
nr1i3	B-MED
regulates	B-MED
the	I-MED
expression	I-MED
of	O
numerous	B-MED
drug-metabolizing	B-MED
enzymes	B-MED
and	O
transporters	B-MED
.	O
	
the	O
upregulation	B-MED
of	O
various	O
enzymes	B-MED
,	O
including	O
cyp2b6	B-MED
,	O
by	O
car	B-MED
activators	B-MED
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	B-MED
drug-drug	B-MED
interactions	I-MED
ddis	B-MED
.	O
	
to	O
date	O
,	O
however	O
,	O
few	O
effective	B-MED
computational	B-MED
approaches	I-MED
for	O
identifying	O
car	B-MED
activators	O
exist	O
.	O
	
in	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three-dimensional	B-MED
quantitative	I-MED
structure-activity	I-MED
relationship	I-MED
3d-qsar	B-MED
models	B-MED
to	O
predict	O
the	O
car	B-MED
activating	B-MED
potency	B-MED
of	O
compounds	B-MED
emerging	O
in	O
the	O
drug-discovery	B-MED
process	B-MED
.	O
	
models	B-MED
were	O
constructed	O
using	O
comparative	B-MED
molecular	I-MED
field	I-MED
analysis	I-MED
comfa	B-MED
based	O
on	O
the	O
molecular	B-MED
alignments	B-MED
of	O
ligands	B-MED
binding	I-MED
to	O
car	B-MED
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand-docking	B-MED
using	O
28	B-MED
compounds	I-MED
as	O
a	O
training	O
set	O
.	O
	
the	O
comfa	B-MED
model	B-MED
,	O
modified	B-MED
by	I-MED
adding	O
a	O
lipophilic	B-MED
parameter	B-MED
with	O
calculated	O
logd7.4	O
s+logd7	O
,	O
demonstrated	O
statistically	O
good	O
predictive	B-MED
ability	I-MED
r	O
=	O
0.99	O
,	O
q	O
=	O
0.74	O
.	O
	
we	O
also	O
confirmed	O
the	O
excellent	O
predictability	B-MED
of	O
the	O
3d-qsar	B-MED
model	B-MED
for	O
car	B-MED
activation	B-MED
r	O
=	O
0.71	O
using	O
seven	O
compounds	B-MED
as	O
a	O
test	O
set	O
for	O
external	B-MED
validation	I-MED
.	O
	
collectively	O
,	O
our	O
results	B-MED
indicate	O
that	O
the	O
3d-qsar	B-MED
model	B-MED
developed	O
in	O
this	O
study	O
provides	O
precise	B-MED
prediction	B-MED
of	O
car	B-MED
activating	B-MED
potency	B-MED
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B-MED
candidates	I-MED
with	O
minimized	B-MED
ddi	B-MED
risk	B-MED
related	O
to	O
enzyme-induction	B-MED
in	O
the	O
early	B-MED
drug-discovery	B-MED
stage	B-MED
.	O
	
effects	B-MED
of	I-MED
sirna	B-MED
-mediated	O
suppression	B-MED
of	O
hpv-11	B-MED
l1	I-MED
expression	B-MED
on	O
the	O
proliferation	B-MED
and	O
apoptosis	B-MED
of	O
vaginal	B-MED
epithelial	I-MED
cells	I-MED
the	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
human	B-MED
papillomavirus	I-MED
hpv	I-MED
infection	I-MED
on	O
the	O
gynecological	B-MED
disease	I-MED
of	O
vaginitis	B-MED
and	O
to	O
demonstrate	O
how	O
the	O
small	B-MED
interfering	I-MED
rna	I-MED
sirna	B-MED
method	O
may	O
be	O
used	O
for	O
hpv	B-MED
prevention	B-MED
in	O
the	O
clinic	B-MED
.	O
	
human	B-MED
vaginal	B-MED
epithelial	I-MED
cells	I-MED
were	O
transfected	B-MED
with	O
hpv-11	B-MED
l1	I-MED
expression	B-MED
vector	I-MED
and	O
sirna	B-MED
-	O
hpv-11	B-MED
l1	I-MED
vectors	B-MED
and	O
a	O
control	B-MED
group	I-MED
was	O
transfected	B-MED
with	O
scrambled	O
sirna	B-MED
.	O
	
cell	B-MED
proliferation	I-MED
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
mtt	B-MED
assay	I-MED
and	O
the	O
expression	B-MED
of	O
apoptosis	B-MED
-associated	O
proteins	B-MED
was	O
measured	B-MED
by	O
western	B-MED
blot	I-MED
analysis	I-MED
.	O
	
compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
,	O
hpv-11	B-MED
l1	I-MED
mrna	B-MED
and	O
protein	B-MED
levels	I-MED
were	O
significantly	O
increased	B-MED
following	O
transfection	B-MED
with	O
the	O
hpv-11	B-MED
l1	I-MED
expression	B-MED
vector	I-MED
in	O
cells	B-MED
p<0	O
,	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	B-MED
of	O
hpv-11	B-MED
l1	I-MED
p<0	O
.	O
	
in	O
addition	O
,	O
cell	B-MED
proliferation	I-MED
in	O
the	O
hpv-11	B-MED
group	I-MED
was	O
lower	B-MED
than	O
that	O
in	O
the	O
control	B-MED
group	I-MED
however	O
,	O
cell	B-MED
proliferation	I-MED
was	O
significantly	O
increased	B-MED
in	O
cells	B-MED
transfected	B-MED
with	O
silenced	B-MED
l1	B-MED
compared	O
with	O
that	O
in	O
the	O
control	B-MED
group	I-MED
p<0	O
.	O
	
furthermore	O
,	O
silencing	B-MED
of	O
hpv-11	B-MED
l1	I-MED
significantly	O
decreased	B-MED
caspase-3	B-MED
and	O
caspase-9	B-MED
expressions	B-MED
in	O
cells	B-MED
,	O
whereas	O
the	O
expression	B-MED
was	O
increased	B-MED
in	O
the	O
hpv-11	B-MED
l1	I-MED
group	O
p<0	O
.	O
	
the	O
present	O
study	B-MED
suggested	O
that	O
sirna	B-MED
-mediated	O
silencing	B-MED
of	O
hpv-11	B-MED
l1	I-MED
may	O
have	O
potential	O
therapeutic	B-MED
applications	I-MED
for	O
treating	O
gynecological	B-MED
diseases	I-MED
associated	B-MED
with	I-MED
hpv-11	B-MED
infection	B-MED
.	O
	
an	O
evaluation	B-MED
of	O
neuroendocrine	B-MED
dysfunction	B-MED
following	O
acute	B-MED
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
a	O
prospective	B-MED
study	I-MED
the	O
aim	B-MED
was	O
to	O
investigate	B-MED
the	O
incidence	O
and	O
pattern	B-MED
of	O
neuroendocrine	B-MED
changes	O
in	O
cases	B-MED
of	O
acute	B-MED
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
sah	B-MED
.	O
	
endocrine	B-MED
assessment	B-MED
was	O
performed	O
in	O
100	O
consecutive	O
cases	B-MED
of	O
acute	B-MED
aneurysmal	B-MED
sah	I-MED
presenting	O
within	O
7	O
days	B-MED
of	O
ictus	B-MED
.	O
	
the	O
gonadotropic	B-MED
,	O
somatotrophic	B-MED
,	O
thyrotropic	B-MED
,	O
and	O
corticotrophic	B-MED
axes	O
were	O
evaluated	B-MED
for	O
their	O
possible	O
dysfunction	B-MED
.	O
	
a	O
total	O
of	O
100	O
cases	B-MED
38	O
males	B-MED
,	O
62	O
females	B-MED
age	B-MED
range	B-MED
-	O
17-76	O
years	B-MED
mean	B-MED
age	B-MED
-	O
43.6	O
years	B-MED
of	O
acute	B-MED
sah	B-MED
were	O
studied	B-MED
.	O
	
the	O
aneurysms	B-MED
were	O
located	O
in	O
the	O
anterior	B-MED
circulation	I-MED
n	O
=	O
95	O
and	O
posterior	B-MED
circulation	I-MED
n	O
=	O
5	O
.	O
	
the	O
most	O
common	O
hormone	B-MED
deficiency	I-MED
was	O
of	O
growth	B-MED
hormone	I-MED
n	O
=	O
67	O
,	O
followed	O
by	O
gonadotrophin	B-MED
n	O
=	O
50	O
,	O
corticotrophin	B-MED
n	O
=	O
49	O
and	O
thyrotrophin	B-MED
n	O
=	O
35	O
.	O
	
hyperprolactinemia	B-MED
was	O
noted	O
in	O
10	O
cases	B-MED
.	O
	
one-pituitary	B-MED
hormone	I-MED
axis	I-MED
deficiency	I-MED
was	O
noted	O
in	O
26	O
cases	B-MED
while	O
67	O
cases	B-MED
had	O
two	O
or	O
more	O
pituitary	B-MED
hormone	I-MED
axes	O
dysfunction	B-MED
.	O
	
a	O
total	O
of	O
93	O
cases	B-MED
had	O
hormonal	B-MED
dysfunction	B-MED
in	O
one	O
or	O
more	O
pituitary	B-MED
hormone	I-MED
axes	I-MED
,	O
and	O
seven	O
cases	B-MED
had	O
no	O
hormonal	B-MED
dysfunction	B-MED
.	O
	
endocrine	B-MED
dysfunction	I-MED
occurs	O
in	O
93%	O
cases	B-MED
of	O
acute	B-MED
sah	B-MED
and	O
multiple	O
pituitary	B-MED
hormone	I-MED
axes	I-MED
dysfunction	B-MED
occurs	O
in	O
67%	O
cases	B-MED
.	O
	
it	O
is	O
suggested	O
that	O
hormonal	B-MED
evaluation	B-MED
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	B-MED
sah	B-MED
.	O
	
validity	B-MED
and	O
reliability	B-MED
of	O
fluoroscopy	B-MED
for	O
digital	B-MED
radiography	I-MED
a	O
new	O
way	O
to	O
evaluate	B-MED
diaphragmatic	B-MED
mobility	B-MED
fluoroscopy	B-MED
is	O
considered	O
the	O
most	O
accurate	O
method	B-MED
to	O
evaluate	B-MED
the	O
diaphragm	B-MED
,	O
yet	O
most	O
existing	O
methods	B-MED
for	O
measuring	O
diaphragmatic	B-MED
mobility	B-MED
using	O
fluoroscopy	B-MED
are	O
complex	O
.	O
	
to	O
assess	O
the	O
validity	B-MED
and	O
reliability	B-MED
of	O
a	O
new	O
evaluation	B-MED
method	I-MED
of	O
diaphragmatic	B-MED
motion	B-MED
using	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
of	O
healthy	B-MED
adults	B-MED
.	O
	
twenty-six	O
adults	B-MED
were	O
evaluated	B-MED
,	O
according	O
to	O
the	O
parameters	O
anthropometry	B-MED
and	O
pulmonary	B-MED
function	I-MED
test	I-MED
.	O
	
the	O
evaluation	B-MED
of	O
diaphragm	B-MED
mobility	B-MED
by	O
means	O
of	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
method	B-MED
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
a	O
and	O
b	O
.	O
	
the	O
pearson	B-MED
correlation	I-MED
coefficient	I-MED
and	O
the	O
intraclass	B-MED
correlation	I-MED
coefficient	I-MED
icc	B-MED
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	B-MED
.	O
	
the	O
inter-rater	O
and	O
intra-rater	O
reliability	B-MED
of	O
the	O
measurement	B-MED
of	O
diaphragmatic	B-MED
motion	B-MED
was	O
determined	O
using	O
icc	B-MED
and	O
a	O
confidence	O
interval	O
of	O
95%	O
.	O
	
there	O
was	O
a	O
relationship	B-MED
in	O
the	O
assessment	B-MED
of	O
the	O
concurrent	O
validity	B-MED
.	O
	
there	O
was	O
good	O
inter-rater	O
reliability	B-MED
for	O
right	O
hemidiaphragm	B-MED
mobility	B-MED
and	O
moderate	O
reliability	B-MED
for	O
left	B-MED
hemidiaphragm	I-MED
in	O
the	O
first	O
assessment	B-MED
.	O
	
in	O
the	O
second	O
assessment	B-MED
,	O
there	O
was	O
good	O
reliability	B-MED
for	O
the	O
mobility	B-MED
of	O
both	O
hemidiaphragms	B-MED
.	O
	
there	O
was	O
good	O
intra-rater	O
reliability	B-MED
in	O
the	O
mobility	B-MED
of	O
both	O
hemidiaphragms	B-MED
for	O
raters	O
a	O
and	O
b	O
.	O
	
the	O
evaluation	B-MED
of	O
diaphragmatic	B-MED
motion	B-MED
using	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
proved	O
to	O
be	O
a	O
valid	B-MED
and	O
reliable	B-MED
method	B-MED
of	O
healthy	B-MED
adults	B-MED
.	O
	
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
in	O
rats	B-MED
depends	O
on	O
individual	B-MED
vulnerability	B-MED
and	O
duration	O
of	O
alcohol	B-MED
consumption	I-MED
experience	O
alcohol	B-MED
use	I-MED
disorder	I-MED
aud	B-MED
is	O
characterized	O
by	O
excessive	B-MED
alcohol	I-MED
use	I-MED
and	O
persistent	B-MED
alcohol	B-MED
seeking	I-MED
despite	O
knowledge	O
of	O
its	O
negative	O
consequences	O
.	O
	
importantly	O
,	O
aud	B-MED
typically	O
develops	O
after	O
chronic	B-MED
excessive	B-MED
alcohol	I-MED
use	I-MED
in	O
a	O
subgroup	B-MED
of	O
individuals	B-MED
who	O
drink	B-MED
alcohol	I-MED
,	O
suggesting	O
that	O
aud	B-MED
results	O
from	O
an	O
interaction	B-MED
between	O
individual	B-MED
vulnerability	B-MED
and	O
prolonged	B-MED
alcohol	I-MED
exposure	I-MED
.	O
	
the	O
present	O
study	B-MED
assessed	B-MED
the	O
contribution	O
of	O
prolonged	B-MED
exposure	I-MED
to	I-MED
alcohol	I-MED
and	O
individual	B-MED
levels	I-MED
of	I-MED
alcohol	I-MED
intake	I-MED
to	O
the	O
development	B-MED
of	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
in	O
a	O
conditioned	B-MED
suppression	I-MED
model	I-MED
.	O
	
to	O
investigate	B-MED
the	O
impact	O
of	O
prolonged	B-MED
alcohol	I-MED
exposure	I-MED
,	O
conditioned	B-MED
suppression	I-MED
of	O
alcohol	B-MED
seeking	I-MED
was	O
assessed	B-MED
after	O
2	O
and	O
4	O
months	O
of	O
intermittent	B-MED
alcohol	I-MED
access	I-MED
iaa	B-MED
in	O
a	O
subgroup	B-MED
of	O
rats	B-MED
drinking	O
moderate	O
amounts	O
of	O
alcohol	O
.	O
	
we	O
observed	O
that	O
suppression	B-MED
of	O
alcohol	B-MED
seeking	I-MED
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
iaa	B-MED
.	O
	
the	O
influence	B-MED
of	O
individual	O
levels	O
of	O
alcohol	B-MED
intake	I-MED
on	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
was	O
subsequently	O
determined	B-MED
by	I-MED
assessing	B-MED
conditioned	B-MED
suppression	I-MED
in	O
subgroups	B-MED
of	O
low	B-MED
and	I-MED
high	I-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
.	O
	
unlike	O
the	O
low	B-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
,	O
the	O
high	B-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
showed	O
aversion-resistant	B-MED
alcohol	B-MED
seeking	I-MED
after	O
2	O
months	O
of	O
iaa	B-MED
,	O
although	O
both	O
groups	B-MED
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing	O
.	O
	
these	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
,	O
a	O
key	O
characteristic	O
of	O
aud	B-MED
in	O
humans	B-MED
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol	B-MED
exposure	I-MED
and	O
the	O
individual's	B-MED
neural	B-MED
correlates	B-MED
of	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
traumatic	B-MED
memories	B-MED
such	O
as	O
intrusions	B-MED
and	O
flashbacks	B-MED
play	O
a	O
major	O
role	O
in	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
post-traumatic	B-MED
stress	I-MED
disorder	I-MED
ptsd	B-MED
.	O
	
a	O
thorough	O
understanding	O
of	O
the	O
neural	B-MED
mechanisms	B-MED
underlying	O
traumatic	B-MED
memories	B-MED
is	O
indispensable	O
for	O
precise	O
diagnosis	B-MED
,	O
for	O
personalized	B-MED
treatment	B-MED
and	O
prevention	B-MED
.	O
	
in	O
particular	O
,	O
the	O
identification	B-MED
of	O
early	O
neural	B-MED
predictor	B-MED
variables	I-MED
for	O
intrusion	B-MED
development	B-MED
shortly	O
after	O
trauma	B-MED
exposure	B-MED
requires	O
detailed	O
investigation	B-MED
.	O
	
here	O
,	O
we	O
examined	B-MED
the	O
neural	B-MED
correlates	I-MED
of	O
early	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
in	O
a	O
traumatic	B-MED
film	I-MED
paradigm	I-MED
in	O
42	O
young	O
healthy	B-MED
females	B-MED
,	O
using	O
both	O
implicit	B-MED
and	O
explicit	B-MED
retrieval	B-MED
tasks	I-MED
.	O
	
we	O
show	O
that	O
implicit	B-MED
experimental	B-MED
trauma	B-MED
retrieval	B-MED
specifically	O
involved	O
the	O
retrosplenial	B-MED
cortex	I-MED
and	O
the	O
anterior	B-MED
cingulate	I-MED
cortex	I-MED
acc	B-MED
,	O
while	O
both	O
retrieval	B-MED
tasks	I-MED
resulted	O
in	O
trauma-related	B-MED
activity	B-MED
in	O
the	O
posterior	B-MED
cingulate	I-MED
cortex	I-MED
pcc	B-MED
and	O
the	O
precuneus	B-MED
.	O
	
importantly	O
,	O
neural	B-MED
activity	B-MED
early	O
after	O
experimental	B-MED
trauma	B-MED
exposure	B-MED
predicted	B-MED
later	O
intrusion	B-MED
development	B-MED
,	O
with	O
independent	B-MED
contributions	B-MED
from	O
activity	B-MED
in	O
the	O
retrosplenial	B-MED
cortex	I-MED
implicit	B-MED
retrieval	B-MED
and	O
the	O
pcc	B-MED
explicit	B-MED
retrieval	B-MED
.	O
	
additional	B-MED
analyses	B-MED
revealed	B-MED
a	O
stronger	O
connectivity	B-MED
between	O
the	O
bilateral	B-MED
amygdala	I-MED
and	O
the	O
supplementary	B-MED
motor	I-MED
area	I-MED
,	O
precentral	B-MED
and	O
paracentral	B-MED
lobule	I-MED
for	O
the	O
control	B-MED
group	I-MED
compared	O
to	O
the	O
experimental	B-MED
trauma	B-MED
group	B-MED
.	O
	
our	O
study	B-MED
gives	O
new	O
insights	O
in	O
the	O
neural	B-MED
correlates	B-MED
of	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
and	O
their	O
predictive	B-MED
value	I-MED
for	O
subsequent	B-MED
symptom	B-MED
development	B-MED
.	O
	
our	O
results	B-MED
could	O
provide	O
the	O
basis	O
for	O
personalized	B-MED
early	B-MED
treatment	I-MED
and	O
prevention	B-MED
of	O
ptsd	B-MED
.	O
	
targeting	B-MED
the	O
nrf2	B-MED
/	O
amyloid-beta	B-MED
liaison	I-MED
in	O
alzheimer's	B-MED
disease	I-MED
a	O
rational	B-MED
approach	I-MED
amyloid	B-MED
is	O
a	O
prominent	B-MED
feature	B-MED
of	O
alzheimer's	B-MED
disease	I-MED
ad	B-MED
.	O
	
yet	O
,	O
a	O
linear	B-MED
linkage	B-MED
between	O
amyloid-β	B-MED
peptide	I-MED
aβ	B-MED
and	O
the	O
disease	B-MED
onset	I-MED
and	O
progression	B-MED
has	O
recently	O
been	O
questioned	O
.	O
	
in	O
this	O
context	B-MED
,	O
the	O
crucial	O
partnership	B-MED
between	O
aβ	B-MED
and	O
nrf2	B-MED
pathways	I-MED
is	O
acquiring	B-MED
paramount	B-MED
importance	B-MED
,	O
offering	O
prospects	O
for	O
deciphering	B-MED
the	O
aβ	B-MED
-centered	O
disease	B-MED
network	B-MED
.	O
	
here	O
,	O
we	O
report	O
on	O
a	O
new	B-MED
class	O
of	O
antiaggregating	B-MED
agents	I-MED
rationally	O
designed	O
to	O
simultaneously	B-MED
activate	B-MED
transcription	I-MED
-based	O
antioxidant	B-MED
responses	B-MED
,	O
whose	O
lead	B-MED
1	I-MED
showed	O
interesting	O
properties	B-MED
in	O
a	O
preliminary	B-MED
investigation	O
.	O
	
relying	O
on	O
the	O
requirements	B-MED
of	O
aβ	B-MED
recognition	B-MED
,	O
we	O
identified	B-MED
the	O
catechol	B-MED
derivative	I-MED
12	I-MED
.	O
	
in	O
sh-sy5y	B-MED
neuroblastoma	I-MED
cells	I-MED
,	O
12	B-MED
combined	B-MED
remarkable	O
free	B-MED
radical	I-MED
scavenger	I-MED
properties	B-MED
to	O
the	O
ability	O
to	O
trigger	B-MED
the	O
nrf2	B-MED
pathway	I-MED
and	O
induce	B-MED
the	O
nrf2	B-MED
-	O
dependent	B-MED
defensive	B-MED
gene	B-MED
nqo1	I-MED
by	O
means	O
of	O
electrophilic	B-MED
activation	I-MED
of	O
the	O
transcriptional	B-MED
response	I-MED
.	O
	
moreover	O
,	O
12	O
prevented	O
the	O
formation	B-MED
of	O
cytotoxic	B-MED
stable	B-MED
oligomeric	B-MED
intermediates	I-MED
,	O
being	O
significantly	B-MED
more	B-MED
effective	B-MED
,	O
and	O
per	O
se	O
less	B-MED
toxic	I-MED
,	O
than	O
prototype	B-MED
1	I-MED
.	O
	
more	O
importantly	O
,	O
as	O
different	B-MED
chemical	B-MED
features	I-MED
were	O
exploited	O
to	O
regulate	B-MED
nrf2	I-MED
and	O
aβ	B-MED
activities	B-MED
,	O
the	O
two	O
pathways	B-MED
could	O
be	O
tuned	O
independently	O
.	O
	
these	O
findings	O
point	O
to	O
compound	B-MED
12	I-MED
and	O
its	O
derivatives	B-MED
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	B-MED
potential	B-MED
of	O
the	O
nrf2	B-MED
/	O
aβ	B-MED
cellular	B-MED
network	B-MED
,	O
laying	O
foundation	O
for	O
generating	B-MED
new	O
drug	B-MED
leads	I-MED
to	O
confront	O
young	B-MED
people	B-MED
,	O
mental	B-MED
health	I-MED
practitioners	B-MED
and	O
researchers	B-MED
co-produce	O
a	O
transition	B-MED
preparation	I-MED
programme	I-MED
to	O
improve	O
outcomes	B-MED
and	O
experience	B-MED
for	O
young	B-MED
people	B-MED
leaving	O
child	B-MED
and	I-MED
adolescent	I-MED
mental	I-MED
health	I-MED
services	I-MED
camhs	B-MED
in	O
the	O
uk	B-MED
young	B-MED
people	B-MED
attending	O
child	B-MED
and	I-MED
adolescent	I-MED
mental	I-MED
health	I-MED
services	I-MED
camhs	B-MED
are	O
required	O
to	O
move	O
on	O
,	O
either	O
through	O
discharge	B-MED
or	O
referral	B-MED
to	I-MED
an	O
adult	B-MED
service	I-MED
,	O
at	O
age	B-MED
17/18	O
,	O
a	O
period	B-MED
of	O
increased	B-MED
risk	B-MED
for	O
onset	B-MED
of	I-MED
mental	B-MED
health	I-MED
problems	I-MED
and	O
other	O
complex	B-MED
psychosocial	B-MED
and	O
physical	B-MED
changes	B-MED
.	O
	
camhs	B-MED
transitions	B-MED
are	O
often	O
poorly	O
managed	O
with	O
negative	B-MED
outcomes	B-MED
for	O
young	B-MED
people	B-MED
.	O
	
better	O
preparation	B-MED
may	O
improve	O
outcomes	B-MED
and	O
experience	B-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
co-produce	O
,	O
with	O
young	B-MED
people	B-MED
who	O
had	O
transitioned	B-MED
or	O
were	O
facing	O
transition	B-MED
from	O
camhs	B-MED
,	O
a	O
camhs	B-MED
transition	B-MED
preparation	I-MED
programme	I-MED
tpp	B-MED
,	O
deliverable	O
in	O
routine	B-MED
nhs	B-MED
settings	O
.	O
	
eighteen	O
young	B-MED
people	B-MED
,	O
aged	O
17-22	O
,	O
from	O
three	O
uk	B-MED
national	B-MED
health	I-MED
service	I-MED
nhs	B-MED
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative	O
,	O
participatory	B-MED
research	I-MED
workshops	I-MED
.	O
	
seven	O
parents	B-MED
completed	O
short	O
questionnaires	B-MED
.	O
	
thirty	O
clinical	B-MED
staff	I-MED
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	B-MED
to	O
ensure	O
deliverability	O
of	O
young	B-MED
people's	B-MED
ideas	B-MED
.	O
	
young	B-MED
people	B-MED
were	O
offered	O
co-research	B-MED
opportunities	I-MED
.	O
	
most	O
young	B-MED
people	B-MED
felt	O
anxious	B-MED
,	O
fearful	B-MED
and	O
uncertain	O
on	O
leaving	O
camhs	B-MED
and	O
perceived	B-MED
mental	B-MED
health	I-MED
services	I-MED
as	O
uncaring	O
.	O
	
participants	B-MED
outlined	O
transition	B-MED
procedures	B-MED
and	O
drafted	O
a	O
range	O
of	O
preparation	B-MED
activities	I-MED
,	O
centred	O
around	O
dedicated	O
transition	B-MED
peer	B-MED
support	I-MED
and	O
a	O
transition	B-MED
booklet	B-MED
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
camhs	B-MED
leavers	B-MED
,	O
irrespective	O
of	O
discharge	B-MED
or	O
transfer	B-MED
to	O
an	O
adult	B-MED
service	I-MED
.	O
	
preparation	B-MED
should	O
aim	O
to	O
build	O
confidence	B-MED
to	O
help	O
young	B-MED
people	B-MED
take	O
responsibility	B-MED
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	B-MED
world	B-MED
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough	O
.	O
	
some	O
clinicians	B-MED
also	O
felt	O
anxious	B-MED
at	O
transition	B-MED
and	O
recognised	O
the	O
potential	O
impact	B-MED
on	O
young	B-MED
people	B-MED
of	O
poor	O
communication	B-MED
and	O
lack	B-MED
of	O
understanding	O
between	O
services	B-MED
.	O
	
parents	B-MED
would	O
appreciate	O
help	O
to	O
support	B-MED
their	O
offspring	B-MED
during	O
the	O
transition	B-MED
period	B-MED
.	O
	
clinicians	B-MED
cited	O
lack	B-MED
of	O
funding	O
and	O
inflexible	O
nhs	B-MED
procedures	B-MED
and	O
policies	B-MED
as	O
potential	O
barriers	B-MED
to	O
the	O
implementation	B-MED
of	O
young	B-MED
people's	B-MED
ideas	B-MED
.	O
	
nine	O
young	B-MED
people	B-MED
took	O
up	O
co-research	B-MED
opportunities	I-MED
.	O
	
mental	B-MED
health	I-MED
services	I-MED
underestimate	O
the	O
anxiety	B-MED
of	O
camhs	B-MED
leavers	B-MED
.	O
	
young	B-MED
people	B-MED
have	O
clear	O
ideas	B-MED
about	O
the	O
preparation	B-MED
they	O
require	O
to	O
leave	O
camhs	B-MED
with	O
the	O
confidence	B-MED
to	O
take	O
responsibility	B-MED
for	O
their	O
own	O
health	B-MED
care	I-MED
.	O
	
close	O
collaboration	B-MED
of	O
nhs	B-MED
staff	B-MED
and	O
researchers	B-MED
facilitates	O
the	O
implementation	B-MED
of	O
research	B-MED
findings	B-MED
.	O
	
the	O
histone	B-MED
acetyltransferase	I-MED
gcn5	I-MED
positively	B-MED
regulates	I-MED
t	I-MED
cell	I-MED
activation	I-MED
histone	B-MED
acetyltransferases	I-MED
hats	B-MED
regulate	B-MED
inducible	I-MED
transcription	I-MED
in	O
multiple	B-MED
cellular	B-MED
processes	I-MED
and	O
during	O
inflammatory	B-MED
and	O
immune	B-MED
response	I-MED
.	O
	
however	O
,	O
the	O
functions	B-MED
of	O
general	B-MED
control	I-MED
nonrepressed-protein	I-MED
5	I-MED
gcn5	B-MED
,	O
an	O
evolutionarily	O
conserved	O
hat	B-MED
from	O
yeast	B-MED
to	O
human	B-MED
,	O
in	O
immune	B-MED
regulation	I-MED
remain	O
unappreciated	O
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
conditionally	O
deleted	B-MED
gcn5	B-MED
encoded	B-MED
by	O
the	O
kat2a	B-MED
gene	I-MED
specifically	O
in	O
t	B-MED
lymphocytes	I-MED
by	O
crossing	B-MED
floxed	B-MED
gcn5	I-MED
and	O
lck-cre	B-MED
mice	B-MED
,	O
and	O
demonstrated	O
that	O
gcn5	B-MED
plays	O
important	B-MED
roles	I-MED
in	O
multiple	O
stages	B-MED
of	O
t	B-MED
cell	I-MED
functions	I-MED
including	O
development	B-MED
,	O
clonal	B-MED
expansion	I-MED
,	O
and	O
differentiation	B-MED
.	O
	
loss	B-MED
of	I-MED
gcn5	B-MED
functions	O
impaired	B-MED
t	I-MED
cell	I-MED
proliferation	I-MED
,	O
il-2	B-MED
production	I-MED
,	O
and	O
th1	B-MED
/	O
th17	B-MED
,	O
but	O
not	O
th2	B-MED
and	O
regulatory	B-MED
t	I-MED
cell	I-MED
differentiation	I-MED
.	O
	
gcn5	B-MED
is	O
recruited	O
onto	O
the	O
il-2	B-MED
promoter	B-MED
by	O
interacting	B-MED
with	O
the	O
nfat	B-MED
in	O
t	B-MED
cells	I-MED
upon	O
tcr	B-MED
stimulation	O
.	O
	
interestingly	O
,	O
instead	O
of	O
directly	O
acetylating	O
nfat	O
,	O
gcn5	O
catalyzes	O
histone	O
h3	O
lysine	O
h9	O
acetylation	O
to	O
promote	O
il-2	O
production	O
.	O
	
t	O
cell	O
-specific	O
suppression	O
of	O
gcn5	O
partially	O
protected	O
mice	O
from	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-	O
induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
,	O
an	O
experimental	O
model	O
for	O
human	O
multiple	O
sclerosis	O
.	O
	
our	O
study	O
reveals	O
previously	O
unknown	O
physiological	O
functions	O
for	O
gcn5	O
and	O
a	O
molecular	O
mechanism	O
underlying	O
these	O
functions	O
in	O
regulating	O
t	O
cell	O
immunity	O
.	O
	
hence	O
gcn5	O
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune	O
disease	O
therapy	B-MED
minor	B-MED
physical	I-MED
anomalies	I-MED
and	O
dermatoglyphic	B-MED
signs	O
in	O
affective	B-MED
disorders	I-MED
a	O
systematic	B-MED
review	I-MED
the	O
increased	B-MED
prevalence	B-MED
of	O
minor	B-MED
physical	I-MED
anomalies	I-MED
mpas	B-MED
and	O
the	O
abnormalities	B-MED
of	I-MED
dermatoglyphic	I-MED
patterns	I-MED
may	O
be	O
physical	B-MED
manifestations	B-MED
of	O
neurodevelopmental	B-MED
disruption	I-MED
in	O
affective	B-MED
disorders	I-MED
.	O
	
this	O
paper	O
aims	O
to	O
review	B-MED
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	B-MED
of	O
mpas	B-MED
and	O
dermatoglyphic	B-MED
abnormalities	I-MED
in	O
mood	B-MED
disorders	I-MED
.	O
	
a	O
medline	B-MED
,	O
psychinfo	B-MED
and	O
web	B-MED
of	I-MED
science	I-MED
search	I-MED
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	B-MED
on	O
the	O
frequency	B-MED
of	O
mpas	B-MED
and	O
on	O
dermatoglyphic	B-MED
traits	I-MED
in	O
bipolar	B-MED
disorder	I-MED
and	O
unipolar	B-MED
depression	I-MED
.	O
	
24	O
studies	B-MED
on	O
mpas	B-MED
,	O
19	O
on	O
dermatoglyphics	B-MED
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-MED
findings	B-MED
.	O
	
the	O
relative	B-MED
contribution	B-MED
of	O
neurodevelopmental	B-MED
retardation	I-MED
to	O
the	O
aetiology	B-MED
of	O
affective	B-MED
disorders	I-MED
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	B-MED
.	O
	
increased	B-MED
recognition	B-MED
of	O
neurodevelopmental	B-MED
processes	B-MED
in	O
the	O
origin	B-MED
of	O
affective	B-MED
disorders	I-MED
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	B-MED
intervention	B-MED
and	O
novel	B-MED
strategy	I-MED
to	O
expand	O
super-charged	B-MED
nk	I-MED
cells	I-MED
with	O
significant	B-MED
potential	I-MED
to	O
lyse	B-MED
and	O
differentiate	B-MED
cancer	B-MED
stem	I-MED
cells	I-MED
differences	B-MED
in	O
nk	B-MED
expansion	I-MED
and	O
function	B-MED
between	O
healthy	B-MED
and	O
cancer	B-MED
patients	I-MED
natural	B-MED
killer	I-MED
nk	I-MED
cells	I-MED
are	O
known	O
to	O
target	O
cancer	B-MED
stem	I-MED
cells	I-MED
and	O
undifferentiated	B-MED
tumors	I-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
provide	O
a	O
novel	B-MED
strategy	I-MED
for	O
expanding	O
large	O
numbers	O
of	O
super-charged	B-MED
nk	I-MED
cells	I-MED
with	O
significant	B-MED
potential	I-MED
to	O
lyse	B-MED
and	O
differentiate	B-MED
cancer	B-MED
stem	I-MED
cells	I-MED
and	O
demonstrate	O
the	O
differences	B-MED
in	O
the	O
dynamics	B-MED
of	O
nk	B-MED
cell	I-MED
expansion	B-MED
between	O
healthy	B-MED
donors	I-MED
and	O
cancer	B-MED
patients	I-MED
.	O
	
decline	B-MED
in	I-MED
cytotoxicity	I-MED
and	O
lower	B-MED
interferon	B-MED
ifn	I-MED
secretion	I-MED
by	O
osteoclast	B-MED
oc	B-MED
nk	B-MED
cells	I-MED
from	O
cancer	B-MED
patients	I-MED
correlates	O
with	O
faster	B-MED
expansion	B-MED
of	O
residual	O
contaminating	B-MED
t	B-MED
cells	I-MED
within	O
purified	B-MED
nk	B-MED
cells	I-MED
,	O
whereas	O
healthy	B-MED
donors	I-MED
'	O
ocs	B-MED
continue	O
expanding	O
super-charged	B-MED
nk	I-MED
cells	I-MED
while	O
limiting	O
t	B-MED
cell	I-MED
expansion	B-MED
for	O
up	O
to	O
60	O
days	B-MED
.	O
	
similar	O
to	O
patient	B-MED
nk	B-MED
cells	I-MED
,	O
nk	B-MED
cells	I-MED
from	O
tumor	B-MED
-bearing	O
blt-humanized	B-MED
mice	I-MED
promote	O
faster	B-MED
expansion	B-MED
of	O
residual	O
t	B-MED
cells	I-MED
resulting	I-MED
in	I-MED
decreased	I-MED
numbers	I-MED
and	O
function	B-MED
of	O
nk	B-MED
cells	I-MED
,	O
whereas	O
nk	B-MED
cells	I-MED
from	O
mice	B-MED
with	O
no	B-MED
tumor	B-MED
continue	O
expanding	B-MED
nk	B-MED
cells	I-MED
and	O
retain	O
their	O
cytotoxicity	B-MED
.	O
	
in	O
addition	O
,	O
dendritic	B-MED
cells	I-MED
dcs	B-MED
in	O
contrast	O
to	O
ocs	B-MED
are	O
found	O
to	O
promote	O
faster	B-MED
expansion	B-MED
of	O
residual	O
t	B-MED
cells	I-MED
within	O
purified	B-MED
nk	B-MED
cells	I-MED
resulting	O
in	O
the	O
decline	B-MED
in	I-MED
nk	I-MED
cell	I-MED
numbers	I-MED
from	O
healthy	B-MED
individuals	I-MED
.	O
	
addition	O
of	O
anti-cd3	B-MED
mab	I-MED
inhibits	O
t	B-MED
cell	I-MED
proliferation	I-MED
while	O
enhancing	B-MED
nk	B-MED
cell	I-MED
expansion	B-MED
however	O
,	O
expanding	B-MED
nk	B-MED
cells	I-MED
have	O
lower	B-MED
cytotoxicity	B-MED
but	O
higher	B-MED
secretion	B-MED
of	I-MED
ifn-γ	I-MED
.	O
	
expansion	B-MED
and	O
functional	B-MED
activation	B-MED
of	O
super-charged	B-MED
nk	I-MED
cells	I-MED
by	O
ocs	B-MED
is	O
dependent	B-MED
on	O
interleukin	B-MED
il	I-MED
and	O
il-15	B-MED
.	O
	
thus	O
,	O
in	O
this	O
report	O
,	O
we	O
not	O
only	O
provide	O
a	O
novel	B-MED
strategy	I-MED
to	O
expand	B-MED
super-charged	B-MED
nk	I-MED
cells	I-MED
,	O
but	O
also	O
demonstrate	O
that	O
rapid	B-MED
and	I-MED
sustained	I-MED
expansion	I-MED
of	O
residual	O
t	B-MED
cells	I-MED
within	O
the	O
purified	B-MED
nk	B-MED
cells	I-MED
during	O
expansion	B-MED
with	O
dcs	B-MED
or	O
ocs	B-MED
could	O
be	O
a	O
potential	B-MED
mechanism	B-MED
by	O
which	O
the	O
numbers	B-MED
and	O
function	B-MED
of	O
nk	B-MED
cells	I-MED
decline	I-MED
in	O
cancer	B-MED
patients	I-MED
and	O
in	O
blt-humanized	B-MED
mice	I-MED
.	O
	
extremely	B-MED
giant	B-MED
liver	I-MED
hemangioma	I-MED
50	O
cm	O
with	O
kasabach-merritt	B-MED
syndrome	I-MED
a	O
33-	O
year	B-MED
-	O
old	B-MED
male	B-MED
has	O
been	O
found	B-MED
with	O
a	O
giant	B-MED
liver	I-MED
hemangioma	I-MED
of	O
initial	B-MED
size	B-MED
29	O
cm	O
for	O
5	O
years	B-MED
.	O
	
he	O
received	B-MED
arterial	B-MED
embolization	I-MED
twice	B-MED
in	O
order	O
to	O
shrink	B-MED
the	O
tumor	B-MED
however	O
,	O
no	B-MED
effect	I-MED
was	O
obtained	B-MED
.	O
	
the	O
tumor	B-MED
had	O
rapidly	B-MED
grown	B-MED
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-MED
in	O
the	O
hematological	B-MED
and	O
coagulative	B-MED
systems	B-MED
.	O
	
preoperative	B-MED
computed	B-MED
tomography	I-MED
revealed	B-MED
that	O
the	O
right	B-MED
hepatic	B-MED
vein	I-MED
,	O
right	B-MED
hepatic	B-MED
artery	I-MED
,	O
and	O
right	B-MED
portal	B-MED
vein	I-MED
were	O
not	B-MED
involved	I-MED
by	O
the	O
hemangioma	B-MED
.	O
	
resection	B-MED
of	O
the	O
giant	B-MED
liver	I-MED
hemangioma	I-MED
was	O
successfully	B-MED
performed	B-MED
after	O
intraoperative	B-MED
intentional	B-MED
bloodletting	B-MED
with	O
concurrent	B-MED
blood	B-MED
salvage	I-MED
.	O
	
all	O
hematological	B-MED
and	O
coagulative	B-MED
abnormalities	B-MED
had	O
returned	B-MED
to	O
normal	B-MED
after	O
the	O
role	B-MED
of	O
cysteine	B-MED
residues	B-MED
in	O
regulation	B-MED
of	O
peptidyl-prolyl	B-MED
cis-trans	I-MED
isomerase	I-MED
activity	I-MED
of	O
wheat	B-MED
cyclophilin	B-MED
tacypa-1	B-MED
oxidative	B-MED
conditions	B-MED
result	O
in	O
inhibition	B-MED
of	O
peptidyl-prolyl	B-MED
cis-trans	I-MED
isomerase	I-MED
ppiase	I-MED
activity	I-MED
of	O
several	O
cyclophilins	B-MED
.	O
	
thiol	B-MED
groups	O
have	O
been	O
implicated	O
in	O
redox	B-MED
regulation	B-MED
of	O
these	O
proteins	B-MED
.	O
	
in	O
our	O
previous	O
study	O
,	O
we	O
proposed	O
that	O
activity	B-MED
of	O
wheat	B-MED
cyclophilin	B-MED
,	O
tacypa-1	B-MED
,	O
may	O
be	O
modulated	B-MED
through	O
a	O
novel	O
dual	O
mechanism	B-MED
of	O
redox	B-MED
regulation	B-MED
.	O
	
to	O
further	O
understand	O
the	O
regulation	B-MED
of	O
ppiase	B-MED
activity	I-MED
of	O
tacypa-1	B-MED
,	O
we	O
generated	O
mutants	B-MED
of	O
tacypa-1	B-MED
by	O
substituting	B-MED
cysteine	B-MED
residues	B-MED
at	O
positions	B-MED
-40	O
and	O
-122	O
with	O
serine	B-MED
,	O
and	O
at	O
-126	O
with	O
proline	B-MED
.	O
	
comparative	B-MED
analysis	I-MED
of	O
their	O
ppiase	B-MED
activity	I-MED
revealed	O
that	O
catalytic	B-MED
efficiencies	B-MED
kcat/km	O
of	O
tacypa-1c40s	B-MED
0.37	O
x	O
106	O
m-1	O
s-1	O
and	O
tacypa-1c122s	B-MED
0.31	O
x	O
106	O
m-1	O
s-1	O
were	O
significantly	B-MED
lower	I-MED
as	O
compared	O
to	O
the	O
native	O
tacypa-1	B-MED
1.33	O
x	O
106	O
m-1	O
s-1	O
,	O
whereas	O
kcat/km	O
of	O
the	O
double	O
mutant	B-MED
tacypa-1c40s/c122s	B-MED
was	O
significantly	B-MED
higher	I-MED
2.36	O
x	O
106	O
m-1	O
s-1	O
.	O
	
compared	O
to	O
wild-type	B-MED
tacypa-1	B-MED
,	O
the	O
different	O
mutants	B-MED
also	O
showed	O
differential	B-MED
sensitivity	B-MED
to	O
cu2+	B-MED
.	O
	
furthermore	O
,	O
the	O
results	B-MED
of	O
this	O
study	B-MED
also	O
revealed	B-MED
that	O
despite	O
lacking	B-MED
ppiase	B-MED
activity	I-MED
,	O
the	O
mutant	B-MED
tacypa-1c126p	B-MED
was	O
able	O
to	O
confer	O
partial	B-MED
protection	B-MED
against	O
heat	B-MED
stress	I-MED
.	O
	
these	O
observations	B-MED
suggest	O
that	O
the	O
mechanism	B-MED
of	O
tacypa-1	B-MED
-induced	O
thermotolerance	B-MED
may	O
also	O
involve	O
other	O
activities	B-MED
besides	O
cis	B-MED
to	I-MED
trans	I-MED
isomerisation	I-MED
,	O
which	O
needs	O
to	O
be	O
identified	B-MED
association	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
duration	B-MED
with	O
systemic	B-MED
inflammation	I-MED
markers	B-MED
in	O
adolescents	B-MED
a	O
cross-sectional	B-MED
study	I-MED
breastfeeding	B-MED
duration	I-MED
has	O
been	O
associated	B-MED
with	I-MED
less	B-MED
low-grade	B-MED
inflammation	B-MED
in	O
healthy	B-MED
adolescents	B-MED
,	O
but	O
there	O
is	O
scarce	B-MED
information	B-MED
regarding	O
obese	B-MED
subjects	O
.	O
	
this	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	B-MED
breastfeeding	I-MED
is	O
related	O
to	O
serum	B-MED
concentrations	I-MED
of	O
inflammatory	B-MED
markers	B-MED
in	O
a	O
population	B-MED
of	O
spanish	B-MED
adolescents	B-MED
.	O
	
a	O
cross-sectional	B-MED
study	I-MED
was	O
performed	B-MED
on	O
1	O
adolescents	B-MED
13.2	O
1.2	O
years	O
randomly	O
recruited	O
from	O
schools	B-MED
in	O
southeast	B-MED
spain	B-MED
.	O
	
data	B-MED
on	O
breastfeeding	B-MED
duration	I-MED
were	O
collected	B-MED
via	O
a	O
parental	B-MED
questionnaire	I-MED
.	O
	
interleukin-6	B-MED
il-6	B-MED
and	O
tumor	B-MED
necrosis	I-MED
factor-alpha	I-MED
tnf-α	B-MED
were	O
determined	B-MED
by	I-MED
enzyme-linked	B-MED
immunosorbent	I-MED
assay	I-MED
.	O
	
c-reactive	B-MED
protein	I-MED
crp	B-MED
was	O
determined	B-MED
by	I-MED
solid-phase	B-MED
chemiluminescent	I-MED
immunometric	I-MED
assay	I-MED
.	O
	
nonadjusted	O
and	O
adjusted	O
multivariate	B-MED
correlation	B-MED
analyses	I-MED
confirmed	B-MED
a	O
strong	B-MED
association	B-MED
p	O
<	O
001	O
,	O
95%	O
confidence	B-MED
interval	I-MED
between	O
the	O
three	O
markers	B-MED
of	O
inflammation	B-MED
and	O
exclusive	B-MED
breastfeeding	I-MED
duration	B-MED
.	O
	
no	B-MED
significant	I-MED
differences	B-MED
were	O
observed	B-MED
for	O
il-6	B-MED
,	O
tnf-α	B-MED
,	O
and	O
crp	B-MED
serum	B-MED
concentrations	I-MED
among	O
normal	B-MED
weight	I-MED
,	O
overweight	B-MED
,	O
and	O
obese	B-MED
adolescents	B-MED
,	O
except	B-MED
for	I-MED
il-6	B-MED
between	O
normal	B-MED
weight	I-MED
and	O
obese	B-MED
subjects	B-MED
.	O
	
likewise	O
,	O
no	B-MED
significant	I-MED
association	B-MED
was	O
found	B-MED
between	O
these	O
markers	B-MED
of	O
inflammation	B-MED
and	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
z-score	B-MED
.	O
	
we	O
found	B-MED
a	O
possible	B-MED
association	B-MED
between	O
inflammatory	B-MED
markers	B-MED
and	O
exclusive	B-MED
breastfeeding	I-MED
duration	B-MED
in	O
adolescents	B-MED
,	O
regardless	B-MED
of	O
their	O
bmi	B-MED
.	O
	
this	O
finding	B-MED
suggests	B-MED
that	O
increased	B-MED
body	B-MED
weight	I-MED
or	O
obesity	B-MED
might	O
not	O
mediate	O
the	O
association	B-MED
between	O
breastfeeding	B-MED
and	O
inflammation	B-MED
.	O
	
these	O
results	B-MED
contribute	O
to	O
the	O
understanding	B-MED
of	O
the	O
relationship	B-MED
between	O
breastfeeding	B-MED
and	O
inflammatory	B-MED
markers	B-MED
in	O
effect	B-MED
of	O
ultrasound	B-MED
and	O
enzymatic	B-MED
pre-treatment	B-MED
on	O
yield	B-MED
and	O
properties	B-MED
of	O
banana	B-MED
juice	B-MED
effect	B-MED
of	O
ultrasound	B-MED
and	O
enzymatic	B-MED
pre-treatments	B-MED
with	O
cellulase	B-MED
and	O
pectinase	B-MED
on	O
yield	B-MED
and	O
properties	B-MED
of	O
banana	B-MED
juice	B-MED
were	O
investigated	B-MED
.	O
	
a	O
two-level	B-MED
full	I-MED
factorial	I-MED
design	I-MED
was	O
employed	O
.	O
	
the	O
factors	O
selected	O
were	O
ultrasonication	B-MED
time	I-MED
0	O
and	O
30	O
min	B-MED
,	O
cellulase	B-MED
concentration	B-MED
0	O
and	O
0.2	O
and	O
pectinase	B-MED
concentration	B-MED
0	O
and	O
0.2	O
.	O
	
the	O
responses	O
studied	O
were	O
yield	B-MED
,	O
viscosity	B-MED
,	O
clarity	B-MED
,	O
total	B-MED
soluble	I-MED
solids	I-MED
tss	B-MED
and	O
ph	B-MED
.	O
	
it	O
was	O
observed	O
that	O
pectinase	B-MED
was	O
more	O
effective	B-MED
in	O
increasing	B-MED
the	O
yield	B-MED
of	O
juice	B-MED
compared	O
to	O
cellulase	B-MED
.	O
	
ultrasonic	B-MED
pre-treatment	I-MED
alone	O
did	O
not	B-MED
significantly	B-MED
increase	I-MED
the	O
yield	B-MED
of	O
juice	B-MED
.	O
	
when	O
ultrasound	B-MED
was	O
combined	O
with	O
pre-treatment	B-MED
with	O
both	O
the	O
enzymes	B-MED
maximum	B-MED
yield	I-MED
of	O
89.40	O
was	O
obtained	O
compared	O
to	O
47.30	O
in	O
the	O
control	B-MED
.	O
	
the	O
viscosity	B-MED
of	O
the	O
juice	B-MED
decreased	B-MED
with	O
addition	O
of	O
enzymes	B-MED
and	O
with	O
application	O
of	O
ultrasound	B-MED
.	O
	
the	O
clarity	B-MED
of	O
the	O
juice	B-MED
was	O
not	O
affected	O
by	O
cellulase	B-MED
treatment	B-MED
,	O
but	O
improved	B-MED
with	O
pectinase	B-MED
treatment	B-MED
.	O
	
ultrasonication	B-MED
alone	O
was	O
found	O
to	O
be	O
more	O
effective	B-MED
than	O
pectinase	B-MED
or	O
cellulase	B-MED
treatment	B-MED
in	O
improving	B-MED
the	O
clarity	B-MED
of	O
the	O
juice	B-MED
.	O
	
the	O
tss	B-MED
increased	B-MED
with	O
enzymatic	B-MED
treatment	B-MED
,	O
ultrasonication	B-MED
and	O
their	O
combination	O
.	O
	
ph	B-MED
was	O
not	O
affected	O
by	O
treatment	B-MED
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	B-MED
juices	B-MED
.	O
	
significant	B-MED
correlations	I-MED
electrocardiographic	B-MED
appearance	I-MED
of	O
aortic	B-MED
stenosis	I-MED
before	O
and	O
after	O
aortic	B-MED
valve	I-MED
replacement	I-MED
so	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
qrs	B-MED
complex	I-MED
,	O
st-segment	B-MED
,	O
and	O
t	B-MED
wave	I-MED
was	O
observed	B-MED
in	O
aortic	B-MED
stenosis	I-MED
as	B-MED
.	O
	
s-wave	B-MED
dynamic	B-MED
change	B-MED
in	O
leads	B-MED
v1	I-MED
-	O
v3	B-MED
was	O
not	O
reported	O
in	O
as	B-MED
.	O
	
in	O
a	O
single-center	O
,	O
prospective	B-MED
study	I-MED
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	B-MED
who	O
underwent	O
surgical	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
avr	B-MED
.	O
	
we	O
conducted	O
3-year	O
gathering	O
of	O
patients	B-MED
with	O
symptomatic	B-MED
and	O
asymptomatic	B-MED
severe	O
as	B-MED
,	O
and	O
separated	O
them	O
by	O
hemodynamic	B-MED
stability	I-MED
into	O
groups	O
a	O
and	O
b	O
,	O
through	O
eflv	B-MED
of	O
more	O
or	O
less	O
than	O
50%	O
,	O
ava	B-MED
of	O
more	O
or	O
less	O
than	O
0.9	O
cm	O
,	O
pg	B-MED
between	O
55	O
and	O
75	O
mm	B-MED
hg	I-MED
or	O
over	O
75	O
mm	B-MED
hg	I-MED
,	O
and	O
end-diastolic	B-MED
lv	I-MED
dimension	I-MED
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
.	O
	
we	O
evaluated	B-MED
the	O
impact	B-MED
of	O
s-wave	B-MED
magnitude	B-MED
in	O
right	B-MED
precordial	I-MED
leads	O
before	O
and	O
after	O
avr	B-MED
in	O
all	O
patients	B-MED
.	O
	
we	O
followed	O
s-wave	B-MED
changes	B-MED
in	O
electrocardiogram	B-MED
altogether	O
with	O
hemodynamic	B-MED
measurements	I-MED
derived	O
from	O
echocardiography	B-MED
.	O
	
analysis	B-MED
of	O
echocardiographic	B-MED
parameters	B-MED
,	O
measured	B-MED
in	O
patients	B-MED
before	O
surgery	B-MED
,	O
did	O
not	O
show	O
statistical	B-MED
significance	I-MED
between	O
asymptomatic	B-MED
and	O
symptomatic	B-MED
group	O
.	O
	
the	O
statistical	B-MED
significance	I-MED
was	O
observed	B-MED
in	O
the	O
change	B-MED
in	O
s-wave	B-MED
magnitude	B-MED
in	O
the	O
right	B-MED
precordial	I-MED
leads	O
in	O
both	O
subsets	O
of	O
patients	B-MED
before	O
avr	B-MED
.	O
	
we	O
found	O
statistically	B-MED
significant	I-MED
predictive	B-MED
value	I-MED
of	O
s-wave	B-MED
magnitude	B-MED
in	O
leads	B-MED
v2	I-MED
-	O
v3	B-MED
for	O
dependent	B-MED
variables	I-MED
pg	B-MED
and	O
end-diastolic	B-MED
lv	I-MED
dimension	I-MED
.	O
	
s-wave	B-MED
changes	O
in	O
right	B-MED
precordial	I-MED
leads	O
can	O
predict	O
increase	B-MED
in	O
pg	B-MED
and	O
critical	O
narrowing	O
of	O
ava	B-MED
,	O
suggestive	B-MED
of	I-MED
timely	O
referral	B-MED
for	I-MED
avr	B-MED
.	O
	
anemia	B-MED
complicating	B-MED
type	B-MED
2	I-MED
diabetes	I-MED
prevalence	B-MED
,	O
risk	B-MED
factors	I-MED
and	O
prognosis	B-MED
to	O
determine	O
the	O
prevalence	B-MED
,	O
risk	B-MED
factors	I-MED
and	O
prognosis	B-MED
of	O
anemia	B-MED
in	O
representative	B-MED
community-based	O
patients	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
	
data	O
from	O
the	O
fremantle	B-MED
diabetes	I-MED
study	I-MED
phase	I-MED
ii	I-MED
fds2	B-MED
n=1551	O
,	O
mean	O
age	O
65.7years	O
,	O
51.9	O
males	B-MED
and	O
busselton	B-MED
diabetes	I-MED
study	I-MED
bds	B-MED
n=186	O
,	O
mean	O
age	O
70.2years	O
,	O
50.0	O
males	B-MED
cohorts	B-MED
,	O
and	O
from	O
186	O
matched	O
bds	B-MED
participants	B-MED
without	O
diabetes	B-MED
,	O
were	O
analyzed	B-MED
.	O
	
the	O
prevalence	B-MED
of	O
anemia	B-MED
hemoglobin	B-MED
130g/l	O
males	B-MED
,	O
120g/l	O
females	B-MED
was	O
determined	B-MED
in	O
each	O
sample	B-MED
.	O
	
in	O
fds2	B-MED
,	O
associates	O
of	O
anemia	B-MED
were	O
assessed	B-MED
using	O
multiple	O
logistic	B-MED
regression	I-MED
and	O
cox	B-MED
proportional	I-MED
hazards	I-MED
modeling	I-MED
identified	O
predictors	B-MED
of	O
death	B-MED
during	O
4.3	O
post-recruitment	O
.	O
	
the	O
prevalence	B-MED
of	O
anemia	B-MED
at	O
baseline	O
was	O
11.5	O
in	O
fds2	B-MED
participants	B-MED
,	O
17.8	O
in	O
bds	B-MED
type	O
2	O
patients	B-MED
and	O
5.4	O
in	O
bds	B-MED
participants	B-MED
without	O
diabetes	B-MED
.	O
	
in	O
fds2	B-MED
,	O
163	O
of	O
178	O
patients	B-MED
with	O
anemia	B-MED
91.6	O
had	O
at	O
least	O
one	O
other	O
risk	B-MED
factor	I-MED
serum	B-MED
vitamin	I-MED
b12	I-MED
<140pmol/l	O
,	O
serum	B-MED
ferritin	I-MED
<30μg/l	O
and/or	O
transferrin	B-MED
saturation	I-MED
<20%	O
,	O
serum	B-MED
testosterone	I-MED
<10nmol/l	O
males	B-MED
,	O
glitazone	B-MED
therapy	B-MED
,	O
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	I-MED
egfr	B-MED
<60ml/min	O
1.73m	O
,	O
malignancy	B-MED
,	O
hemoglobinopathy	B-MED
.	O
	
more	O
anemic	B-MED
than	O
non-anemic	B-MED
fds2	B-MED
patients	B-MED
died	O
28.7	O
versus	O
8.0	O
p<0	O
.	O
	
after	O
adjustment	O
for	O
other	O
independent	O
predictors	B-MED
age	O
as	O
time-scale	O
,	O
male	O
sex	O
,	O
aboriginality	B-MED
,	O
marital	B-MED
status	I-MED
,	O
smoking	B-MED
,	O
egfr	B-MED
,	O
anemia	B-MED
was	O
associated	B-MED
with	I-MED
a	O
57%	O
increase	B-MED
in	O
mortality	O
p=0	O
.	O
	
type	B-MED
2	I-MED
diabetes	I-MED
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-MED
but	O
other	O
mostly	O
modifiable	O
risk	B-MED
factors	I-MED
are	O
usually	O
present	B-MED
.	O
	
anemia	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	I-MED
of	I-MED
death	I-MED
after	O
adjustment	O
for	O
other	O
succinic	B-MED
acid	I-MED
production	B-MED
by	O
immobilized	B-MED
cultures	B-MED
using	O
spent	B-MED
sulphite	I-MED
liquor	I-MED
as	O
fermentation	B-MED
medium	B-MED
spent	B-MED
sulphite	I-MED
liquor	I-MED
ssl	B-MED
was	O
used	O
as	O
carbon	B-MED
source	B-MED
for	O
the	O
production	B-MED
of	O
succinic	B-MED
acid	I-MED
using	O
immobilized	B-MED
cultures	B-MED
of	O
actinobacillus	B-MED
succinogenes	I-MED
and	O
basfia	B-MED
succiniciproducens	I-MED
on	O
two	O
different	O
supports	B-MED
,	O
delignified	B-MED
cellulosic	I-MED
material	I-MED
dcm	B-MED
and	O
alginate	B-MED
beads	B-MED
.	O
	
fed-batch	B-MED
immobilized	I-MED
cultures	I-MED
with	O
a	B-MED
.	O
	
succinogenes	I-MED
in	O
alginates	B-MED
resulted	O
in	O
higher	B-MED
sugar	B-MED
to	O
succinic	B-MED
acid	I-MED
conversion	B-MED
yield	I-MED
0.81g	O
than	O
the	O
respective	O
yield	B-MED
achieved	O
0.65g	O
when	O
dcm	B-MED
immobilized	B-MED
cultures	B-MED
were	O
used	O
.	O
	
the	O
final	O
succinic	B-MED
acid	I-MED
concentration	B-MED
and	O
yield	B-MED
achieved	O
in	O
fed-batch	B-MED
with	O
immobilized	B-MED
cultures	B-MED
of	O
b	B-MED
.	O
	
succiniciproducens	I-MED
in	O
alginates	B-MED
45g/l	O
and	O
0.66g	O
were	O
higher	B-MED
than	O
a	B-MED
.	O
	
succinogenes	I-MED
immobilized	B-MED
cultures	B-MED
35.4g	O
and	O
0.61g	O
using	O
nano	B-MED
-	O
filtrated	B-MED
ssl	I-MED
as	O
fermentation	B-MED
medium	B-MED
.	O
	
immobilized	B-MED
cultures	B-MED
of	O
b	B-MED
.	O
	
succiniciproducens	I-MED
in	O
alginate	B-MED
beads	B-MED
were	O
reused	O
in	O
four	O
sequential	B-MED
fed-batch	I-MED
fermentations	B-MED
of	O
nano	B-MED
-	O
filtrated	B-MED
ssl	I-MED
leading	O
to	O
the	O
production	B-MED
of	O
64.7g	O
of	O
succinic	B-MED
acid	I-MED
with	O
a	O
yield	B-MED
range	O
of	O
0.42	O
and	O
productivity	B-MED
range	O
of	O
0.29	O
.	O
	
the	O
immobilized	B-MED
cultures	B-MED
improved	O
the	O
efficiency	B-MED
of	O
succinic	B-MED
acid	I-MED
production	B-MED
as	O
compared	B-MED
to	O
free	B-MED
cell	I-MED
cultures	I-MED
.	O
	
interventions	B-MED
to	O
improve	B-MED
grandparent	B-MED
caregivers'	B-MED
mental	B-MED
and	O
physical	B-MED
health	I-MED
an	O
integrative	B-MED
review	I-MED
the	O
aim	B-MED
of	O
this	O
integrative	B-MED
review	I-MED
is	O
to	O
appraise	O
grandparent	B-MED
caregiver	B-MED
interventions	B-MED
that	O
are	O
designed	O
to	O
improve	B-MED
their	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
.	O
	
a	O
database	B-MED
search	B-MED
was	O
performed	O
to	O
identify	O
relevant	B-MED
studies	B-MED
published	B-MED
between	O
january	O
1	O
,	O
1980	O
,	O
and	O
december	O
31	O
,	O
2014	O
.	O
	
thirteen	O
publications	B-MED
,	O
including	O
11	O
studies	B-MED
,	O
met	O
all	O
inclusion	B-MED
and	O
exclusion	B-MED
criteria	I-MED
.	O
	
all	O
studies	B-MED
included	O
grandparent	B-MED
mental	B-MED
health	I-MED
outcomes	B-MED
with	O
fewer	O
focusing	O
on	O
physical	B-MED
health	I-MED
and	O
social	B-MED
relations	I-MED
.	O
	
improvements	B-MED
were	O
found	O
in	O
all	O
three	O
areas	B-MED
with	O
fewer	O
improvements	B-MED
seen	O
in	O
physical	B-MED
health	I-MED
.	O
	
however	O
,	O
small	B-MED
effect	I-MED
sizes	I-MED
were	O
seen	O
with	O
most	O
measures	B-MED
of	O
these	O
outcomes	B-MED
.	O
	
although	O
the	O
interventions	B-MED
led	O
to	O
positive	O
grandparent	B-MED
caregiver	B-MED
outcomes	O
,	O
the	O
studies	B-MED
were	O
limited	B-MED
by	O
their	O
design	B-MED
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
	
also	O
,	O
interventions	B-MED
did	O
not	O
consider	O
variations	B-MED
in	O
the	O
grandchild's	B-MED
or	O
parent's	B-MED
ages	B-MED
or	O
if	O
the	O
grandparent	B-MED
provided	O
primary	B-MED
or	O
shared	B-MED
care	B-MED
.	O
	
these	O
gaps	O
should	O
be	O
addressed	O
in	O
future	B-MED
research	B-MED
.	O
	
an	O
attenuated	B-MED
mycobacterium	B-MED
tuberculosis	I-MED
clinical	B-MED
strain	B-MED
with	O
a	O
defect	B-MED
in	O
esx-1	B-MED
secretion	B-MED
induces	O
minimal	B-MED
host	B-MED
immune	B-MED
responses	I-MED
and	O
pathology	B-MED
although	O
mycobacterium	B-MED
tuberculosis	I-MED
m.tb	I-MED
dk9897	I-MED
is	O
an	O
attenuated	B-MED
strain	B-MED
,	O
it	O
was	O
isolated	B-MED
from	O
a	O
patient	B-MED
with	O
extrapulmonary	B-MED
tuberculosis	I-MED
and	O
vaccination	B-MED
with	O
a	O
subunit	B-MED
vaccine	I-MED
h56	B-MED
induced	B-MED
poor	B-MED
protection	B-MED
against	O
it	O
.	O
	
both	O
attenuation	B-MED
and	O
lack	B-MED
of	O
protection	B-MED
are	O
because	O
m.tb	B-MED
dk9897	I-MED
cannot	O
secrete	B-MED
the	O
esxa	B-MED
virulence	B-MED
factor	I-MED
nor	O
induce	O
a	O
host	B-MED
response	I-MED
against	O
it	O
.	O
	
genome	B-MED
sequencing	I-MED
identified	O
a	O
frameshift	B-MED
mutation	I-MED
in	O
the	O
eccca1	B-MED
gene	I-MED
.	O
	
since	O
the	O
encoded	B-MED
eccca1	B-MED
protein	I-MED
provides	O
energy	B-MED
for	O
esx-1	B-MED
secretion	B-MED
,	O
it	O
suggested	O
a	O
defect	B-MED
in	O
the	O
esx-1	B-MED
type	B-MED
vii	I-MED
secretion	I-MED
system	I-MED
.	O
	
genetic	B-MED
complementation	I-MED
with	O
a	O
plasmid	B-MED
carrying	O
the	O
m.tb	B-MED
h37rv	I-MED
sequence	O
of	O
eccca1-ecccb1-pe35	B-MED
re-established	O
esxa	B-MED
secretion	B-MED
,	O
host	B-MED
specific	O
esxa	B-MED
t-cell	B-MED
responses	B-MED
,	O
and	O
increased	B-MED
strain	B-MED
virulence	B-MED
.	O
	
the	O
esx-1	B-MED
secretion	B-MED
defect	B-MED
prevents	B-MED
several	O
virulence	B-MED
factors	I-MED
from	O
being	O
functional	O
during	O
infection	B-MED
and	O
therefore	O
attenuates	B-MED
m.tb	B-MED
.	O
	
it	O
precludes	O
specific	O
t-cell	B-MED
responses	B-MED
against	O
strong	O
antigens	B-MED
and	O
we	O
found	O
very	O
little	O
in	B-MED
vivo	I-MED
cytokine	B-MED
production	I-MED
,	O
gross	B-MED
pathology	I-MED
or	O
granuloma	B-MED
formation	I-MED
in	O
lungs	B-MED
from	O
m.tb	B-MED
dk9897	I-MED
infected	B-MED
animals	I-MED
.	O
	
this	O
coincides	O
with	O
m.tb	B-MED
dk9897	I-MED
being	O
unable	O
to	O
disrupt	O
the	O
phagosome	B-MED
membrane	I-MED
and	O
make	O
contact	O
to	O
the	O
results	B-MED
for	O
patients	B-MED
with	O
sarcoma	B-MED
not	B-MED
otherwise	I-MED
specified	I-MED
and	O
other	O
diagnoses	B-MED
than	O
ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
the	O
euro-ewing	B-MED
99	I-MED
trial	I-MED
euro-ewing	B-MED
99	I-MED
trial	I-MED
of	O
the	O
european	B-MED
ewing	B-MED
tumor	I-MED
working	B-MED
initiative	B-MED
of	O
national	B-MED
groups	B-MED
ee99	B-MED
was	O
an	O
international	B-MED
phase	B-MED
iii	I-MED
study	I-MED
in	O
patients	B-MED
with	O
ewing	B-MED
sarcoma	I-MED
.	O
	
the	O
german	B-MED
society	I-MED
of	I-MED
pediatric	I-MED
oncology	I-MED
and	I-MED
hematology	I-MED
gpoh	I-MED
data	I-MED
center	I-MED
registered	B-MED
and	O
followed	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
ewing	B-MED
sarcoma	I-MED
who	O
were	O
treated	B-MED
according	O
to	O
the	O
ee99	B-MED
protocol	I-MED
in	O
an	O
additional	O
non-ewing	B-MED
database	I-MED
.	O
	
data	B-MED
of	O
27	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
the	O
ee99	B-MED
protocol	I-MED
were	O
analyzed	B-MED
.	O
	
patients	B-MED
had	O
miscellaneous	B-MED
histologic	B-MED
diagnoses	B-MED
,	O
the	O
majority	B-MED
were	O
diagnosed	B-MED
with	O
sarcoma	B-MED
not	B-MED
otherwise	I-MED
specified	I-MED
nos	B-MED
arising	O
in	O
bone	B-MED
and	O
soft	B-MED
tissue	I-MED
63%	O
.	O
	
the	O
median	B-MED
age	B-MED
at	O
diagnosis	B-MED
was	O
16.9	O
years	O
range	O
4.5	O
.	O
	
localized	B-MED
disease	I-MED
was	O
diagnosed	B-MED
in	O
61.5	O
of	O
the	O
patients	B-MED
and	O
38.5	O
had	O
distant	B-MED
metastases	I-MED
at	O
time	O
of	O
primary	B-MED
diagnosis	B-MED
.	O
	
the	O
median	B-MED
follow-up	B-MED
time	B-MED
was	O
3.7	O
years	O
range	O
0.5	O
.	O
	
patients	B-MED
with	O
localized	B-MED
disease	I-MED
showed	O
a	O
3-year	O
event-free	B-MED
survival	I-MED
efs	B-MED
of	O
68%	O
,	O
compared	O
to	O
3-year	O
efs	B-MED
of	O
20%	O
in	O
patients	B-MED
with	O
metastases	B-MED
p	O
=	O
0.042	O
.	O
	
three-year	O
efs	B-MED
for	O
patients	B-MED
with	O
sarcoma	B-MED
nos	B-MED
was	O
52%	O
,	O
patients	B-MED
with	O
localized	B-MED
and	O
metastatic	B-MED
disease	I-MED
showed	O
3-year	O
efs	B-MED
of	O
66	O
and	O
20%	O
,	O
respectively	O
.	O
	
efs	B-MED
in	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
ee99	B-MED
was	O
significantly	B-MED
higher	O
in	O
patients	B-MED
with	O
localized	B-MED
than	O
metastatic	B-MED
disease	I-MED
.	O
	
sarcomas	B-MED
of	O
soft	B-MED
tissue	I-MED
and	O
bone	B-MED
that	O
cannot	O
be	O
classified	B-MED
to	O
current	B-MED
diagnostic	B-MED
categories	I-MED
constitute	O
a	O
therapeutic	B-MED
challenge	B-MED
.	O
	
capsular	B-MED
polysaccharide	I-MED
types	B-MED
and	O
virulence-related	B-MED
traits	B-MED
of	O
epidemic	B-MED
kpc	B-MED
-	O
producing	B-MED
klebsiella	B-MED
pneumoniae	I-MED
isolates	B-MED
in	O
a	O
chinese	B-MED
university	B-MED
hospital	I-MED
klebsiella	B-MED
pneumoniae	I-MED
is	O
an	O
important	B-MED
human	B-MED
pathogen	B-MED
associated	B-MED
with	I-MED
a	O
variety	B-MED
of	O
diseases	B-MED
and	O
the	O
prevalence	B-MED
of	O
blakpc	B-MED
carrying	O
k	B-MED
.	O
	
pneumoniae	I-MED
kpc-kp	B-MED
is	O
rapidly	B-MED
increasing	I-MED
.	O
	
capsule	B-MED
is	O
an	O
important	B-MED
virulence	B-MED
factor	I-MED
in	O
k	B-MED
.	O
	
pneumoniae	I-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
determined	O
to	O
first	O
systematically	B-MED
characterize	B-MED
capsular	B-MED
polysaccharide	I-MED
cps	B-MED
and	O
virulence	B-MED
traits	B-MED
in	O
kpc-kp	B-MED
strains	B-MED
.	O
	
a	O
total	O
of	O
56	O
kpc-kp	B-MED
isolates	B-MED
were	O
recovered	B-MED
from	O
clinical	B-MED
samples	I-MED
in	O
a	O
chinese	B-MED
hospital	I-MED
,	O
which	O
were	O
assigned	B-MED
to	O
clonal	B-MED
lineages	I-MED
by	O
multilocus	B-MED
sequence	I-MED
typing	I-MED
mlst	B-MED
.	O
	
capsule	B-MED
typing	B-MED
wzi	B-MED
sequencing	I-MED
and	O
wzc	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
pcr	B-MED
and	O
virulence	B-MED
genes	B-MED
were	O
characterized	B-MED
by	O
molecular	B-MED
approaches	I-MED
.	O
	
the	O
virulence	B-MED
of	O
these	O
strains	B-MED
was	O
determined	O
by	O
biofilm	B-MED
formation	I-MED
,	O
serum	B-MED
killing	B-MED
resistance	B-MED
,	O
phagocytosis	B-MED
,	O
and	O
infection	B-MED
models	B-MED
.	O
	
six	O
different	O
sts	B-MED
were	O
found	B-MED
among	O
56	O
kpc-kp	B-MED
isolates	B-MED
76.8	O
43	O
of	O
56	O
isolates	B-MED
belonged	O
to	O
st11	B-MED
,	O
6	B-MED
isolates	B-MED
belonged	O
to	O
st147	B-MED
,	O
4	O
isolates	B-MED
belonged	O
to	O
st15	B-MED
,	O
1	O
isolate	O
belonged	O
to	O
st1456	B-MED
,	O
1	O
isolate	O
belonged	O
to	O
st65	B-MED
,	O
and	O
1	O
isolate	O
was	O
st23	B-MED
.	O
	
based	O
on	O
the	O
wzi	B-MED
gene	I-MED
dna	I-MED
sequences	I-MED
and	O
wzc	B-MED
pcr	I-MED
,	O
these	O
56	O
strains	B-MED
were	O
classified	O
as	O
capsular	B-MED
type	B-MED
wzi47-k47	B-MED
n	O
=	O
37	O
,	O
wzi64-k64	B-MED
n	O
=	O
8	O
,	O
wzi8-k8	B-MED
n	O
=	O
4	O
,	O
wzi37-k37	B-MED
n	O
=	O
4	O
,	O
wzi53-k53	B-MED
n	O
=	O
1	O
,	O
wzi125-k2	B-MED
n	O
=	O
1	O
,	O
and	O
wzi1-k1	B-MED
n	O
=	O
1	O
.	O
	
heterogeneity	B-MED
was	O
detected	B-MED
in	O
biofilm	B-MED
formation	I-MED
and	O
phagocytosis	B-MED
among	O
different	O
cps	B-MED
types	B-MED
.	O
	
st11	B-MED
strains	B-MED
were	O
less	O
virulent	B-MED
than	O
other	O
st	B-MED
strains	B-MED
.	O
	
kpc-kp	B-MED
strains	B-MED
exhibit	O
variability	B-MED
of	O
virulence-associated	B-MED
traits	B-MED
.	O
	
differences	O
were	O
associated	O
with	O
the	O
st	B-MED
types	B-MED
and	O
interaction-driven	B-MED
distinctive	O
electronic	B-MED
states	I-MED
of	O
artificial	B-MED
atoms	I-MED
at	O
the	O
zno	B-MED
interface	B-MED
we	O
have	O
investigated	B-MED
the	O
electronic	B-MED
states	I-MED
of	O
planar	B-MED
quantum	I-MED
dots	I-MED
at	O
the	O
zno	B-MED
interface	B-MED
containing	O
a	O
few	O
interacting	B-MED
electrons	B-MED
in	O
an	O
externally	B-MED
applied	I-MED
magnetic	B-MED
field	I-MED
.	O
	
the	O
electron-electron	B-MED
interaction	B-MED
effects	B-MED
are	O
expected	O
to	O
be	O
much	B-MED
stronger	I-MED
in	O
this	O
case	B-MED
than	O
in	O
traditional	B-MED
semiconductor	I-MED
quantum	I-MED
systems	I-MED
,	O
such	O
as	O
in	O
gaas	B-MED
or	O
inas	B-MED
quantum	B-MED
dots	I-MED
.	O
	
in	O
order	O
to	O
highlight	O
that	O
stronger	B-MED
coulomb	B-MED
effects	I-MED
in	O
the	O
zno	B-MED
quantum	B-MED
dots	I-MED
,	O
we	O
have	O
compared	B-MED
the	O
energy	B-MED
spectra	I-MED
and	O
the	O
magnetization	B-MED
in	O
this	O
system	B-MED
to	O
those	O
of	O
the	O
inas	B-MED
quantum	B-MED
dots	I-MED
.	O
	
we	O
have	O
found	O
that	O
in	O
the	O
zno	B-MED
quantum	B-MED
dots	I-MED
the	O
signatures	O
of	O
stronger	B-MED
coulomb	B-MED
interaction	I-MED
manifests	B-MED
in	O
an	O
unique	B-MED
ground	B-MED
state	I-MED
that	O
has	O
very	O
different	B-MED
properties	B-MED
than	O
the	O
corresponding	O
ones	O
in	O
the	O
inas	B-MED
dot	B-MED
.	O
	
our	O
results	B-MED
for	O
the	O
magnetization	B-MED
also	O
exhibits	B-MED
behaviors	I-MED
never	B-MED
before	B-MED
observed	B-MED
in	O
a	O
quantum	B-MED
dot	I-MED
for	O
a	O
realistic	B-MED
set	I-MED
of	I-MED
parameters	I-MED
.	O
	
we	O
have	O
found	O
a	O
stronger	B-MED
temperature	B-MED
dependence	B-MED
and	O
other	O
unexpected	B-MED
features	I-MED
,	O
such	O
as	O
paramagnetic-like	B-MED
behavior	I-MED
at	O
high	B-MED
temperatures	I-MED
for	O
a	O
quantum-dot	B-MED
helium	B-MED
.	O
	
evaluation	B-MED
of	O
tobacco	B-MED
control	I-MED
policies	I-MED
in	O
san	B-MED
francisco	I-MED
homeless	B-MED
housing	B-MED
programs	I-MED
the	O
2014	O
surgeon	B-MED
general's	I-MED
report	I-MED
noted	B-MED
that	O
high	B-MED
smoking	B-MED
rates	I-MED
in	O
vulnerable	B-MED
populations	I-MED
such	O
as	O
the	O
homeless	B-MED
have	O
been	O
a	O
persistent	B-MED
public	B-MED
health	B-MED
problem	I-MED
smoking	B-MED
prevalence	B-MED
among	O
individuals	B-MED
experiencing	B-MED
homelessness	B-MED
exceeds	O
70%	O
.	O
	
historically	O
,	O
service	B-MED
providers	I-MED
for	O
the	O
homeless	B-MED
have	O
not	O
enacted	O
comprehensive	B-MED
tobacco	B-MED
control	I-MED
policies	I-MED
.	O
	
we	O
conducted	B-MED
a	O
qualitative	B-MED
study	I-MED
of	O
homeless	B-MED
housing	B-MED
programs	I-MED
in	O
san	B-MED
francisco	I-MED
.	O
	
administrators	B-MED
representing	B-MED
9	O
of	O
the	O
city's	O
11	O
homeless	B-MED
service	I-MED
agencies	I-MED
were	O
interviewed	B-MED
to	O
assess	B-MED
institutional	B-MED
smoking	B-MED
-related	O
policies	B-MED
and	O
cessation	B-MED
programs	B-MED
and	O
perceived	B-MED
barriers	B-MED
and	O
receptivity	B-MED
to	O
instituting	B-MED
tobacco	B-MED
control	B-MED
interventions	B-MED
.	O
	
respondents	B-MED
indicated	B-MED
that	O
although	O
most	O
programs	B-MED
had	O
adopted	B-MED
smoke	B-MED
-	O
free	B-MED
grounds	B-MED
and	O
some	O
had	O
eliminated	B-MED
evidence	B-MED
of	O
staff	B-MED
smoking	B-MED
,	O
the	O
smoking	B-MED
status	B-MED
of	O
clients	B-MED
was	O
assessed	B-MED
only	O
when	O
required	B-MED
by	O
funders	O
.	O
	
none	O
of	O
the	O
programs	B-MED
offered	B-MED
smoking	B-MED
cessation	I-MED
interventions	B-MED
.	O
	
most	O
administrators	B-MED
were	O
receptive	B-MED
to	O
adopting	B-MED
policies	B-MED
that	O
would	O
promote	B-MED
a	O
tobacco	B-MED
-	O
free	B-MED
culture	B-MED
however	O
,	O
they	O
noted	B-MED
that	O
their	O
clients	B-MED
had	O
unique	B-MED
challenges	B-MED
that	O
made	O
traditional	B-MED
smoking	B-MED
cessation	I-MED
programs	B-MED
unfeasible	O
.	O
	
homeless	B-MED
housing	B-MED
programs	I-MED
in	O
san	B-MED
francisco	I-MED
have	O
not	O
yet	O
adopted	B-MED
a	O
tobacco	B-MED
-	O
free	B-MED
culture	B-MED
.	O
	
existing	B-MED
policies	B-MED
were	O
created	B-MED
in	O
response	B-MED
to	O
external	B-MED
mandates	B-MED
,	O
and	O
smoking	B-MED
cessation	I-MED
programs	B-MED
may	O
need	O
to	O
be	O
modified	B-MED
in	O
order	O
to	O
effectively	B-MED
reach	O
identification	O
of	O
low	O
micromolar	B-MED
dual	O
inhibitors	B-MED
for	O
aldose	B-MED
reductase	I-MED
alr2	B-MED
and	O
poly	B-MED
adp-ribose	I-MED
polymerase	I-MED
parp-1	B-MED
using	O
structure	B-MED
based	O
design	B-MED
approach	O
clinical	B-MED
studies	I-MED
have	O
revealed	O
that	O
diabetic	B-MED
retinopathy	I-MED
is	O
a	O
multifactorial	O
disorder	B-MED
.	O
	
moreover	O
,	O
studies	O
also	O
suggest	O
that	O
alr2	B-MED
and	O
parp-1	B-MED
co-occur	O
in	O
retinal	B-MED
cells	B-MED
,	O
making	O
them	O
appropriate	O
targets	B-MED
for	O
the	O
treatment	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
.	O
	
to	O
find	O
the	O
dual	O
inhibitors	B-MED
of	O
alr2	B-MED
and	O
parp-1	B-MED
,	O
the	O
structure	B-MED
based	O
design	B-MED
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	B-MED
proteins	B-MED
.	O
	
a	O
series	O
of	O
novel	O
thiazolidine-2	B-MED
tzd	B-MED
derivatives	B-MED
were	O
therefore	O
rationally	O
designed	B-MED
,	O
synthesized	B-MED
and	O
their	O
in	B-MED
vitro	I-MED
inhibitory	B-MED
activities	I-MED
against	O
alr2	B-MED
and	O
parp-1	B-MED
were	O
evaluated	O
.	O
	
the	O
experimental	B-MED
results	I-MED
showed	O
that	O
compounds	B-MED
5b	I-MED
and	O
5f	B-MED
,	O
with	O
2-chloro	O
and	O
4-fluoro	O
substitutions	O
,	O
showed	O
biochemical	B-MED
activities	B-MED
in	O
micromolar	B-MED
and	O
submicromolar	B-MED
range	B-MED
ic50	B-MED
1.34	O
against	O
both	O
the	O
targeted	B-MED
enzymes	B-MED
.	O
	
the	O
structure-activity	B-MED
relationship	I-MED
elucidated	O
for	O
these	O
novel	O
inhibitors	B-MED
against	O
both	O
the	O
enzymes	B-MED
provide	O
new	O
insight	O
into	O
the	O
binding	B-MED
mode	B-MED
of	O
the	O
inhibitors	B-MED
to	O
the	O
active	B-MED
sites	I-MED
of	O
enzymes	B-MED
.	O
	
the	O
positive	B-MED
results	B-MED
of	O
the	O
biochemical	B-MED
assay	B-MED
suggest	O
that	O
these	O
compounds	B-MED
may	O
be	O
further	O
optimized	B-MED
and	O
utilized	B-MED
for	O
the	O
treatment	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
.	O
	
microbiology	B-MED
of	O
the	O
upper	B-MED
and	O
lower	B-MED
airways	I-MED
in	O
pediatric	B-MED
cystic	B-MED
fibrosis	I-MED
patients	B-MED
objective	O
to	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	B-MED
cystic	B-MED
fibrosis	I-MED
cf	B-MED
patients	B-MED
who	O
underwent	O
sinus	B-MED
surgery	I-MED
.	O
	
study	O
design	O
retrospective	B-MED
case	O
series	O
with	O
chart	O
review	O
.	O
	
setting	O
tertiary	B-MED
care	I-MED
children's	B-MED
hospital	I-MED
.	O
	
subjects	O
and	O
methods	O
a	O
total	O
of	O
201	O
paired	O
sinus	B-MED
and	O
pulmonary	B-MED
cultures	I-MED
from	O
105	O
cf	B-MED
patients	B-MED
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O
	
demographics	B-MED
and	O
culture	B-MED
results	B-MED
were	O
analyzed	B-MED
.	O
	
results	B-MED
the	O
mean	O
age	O
of	O
patients	B-MED
was	O
11.2	O
5.4	O
years	O
range	O
,	O
1-27	O
years	O
,	O
and	O
approximately	O
one-half	O
were	O
female	B-MED
.	O
	
methicillin	B-MED
-	O
sensitive	B-MED
staphylococcus	B-MED
aureus	I-MED
was	O
the	O
most	O
common	O
pathogen	B-MED
overall	O
.	O
	
a	O
significantly	O
higher	O
prevalence	B-MED
of	O
pseudomonas	B-MED
aeruginosa	I-MED
32%	O
for	O
pulmonary	B-MED
and	O
37%	O
for	O
sinus	B-MED
cultures	I-MED
was	O
observed	O
in	O
older	B-MED
patients	B-MED
versus	O
younger	B-MED
patients	B-MED
p	B-MED
<	O
001	O
.	O
	
there	O
was	O
low	O
to	O
moderate	B-MED
agreement	B-MED
between	O
sinus	B-MED
and	O
pulmonary	B-MED
cultures	I-MED
kappa	B-MED
statistic	B-MED
range	I-MED
,	O
0.03	O
.	O
	
the	O
prevalence	B-MED
of	O
methicillin-resistant	B-MED
s	I-MED
aureus	I-MED
mrsa	B-MED
increased	O
significantly	B-MED
for	O
lower	B-MED
respiratory	I-MED
tract	I-MED
culture	I-MED
from	O
5%	O
to	O
16%	O
and	O
sinus	B-MED
culture	I-MED
from	O
5%	O
to	O
27%	O
between	O
1996-2004	O
and	O
2010-2014	O
p	B-MED
=	O
016	O
and	O
p	B-MED
<	O
001	O
,	O
respectively	O
.	O
	
the	O
prevalence	B-MED
of	O
positive	B-MED
sinus	B-MED
cultures	I-MED
increased	O
from	O
40%	O
to	O
85%	O
between	O
1996-2004	O
and	O
2010-2014	O
p	B-MED
=	O
018	O
.	O
	
patients	B-MED
with	O
pulmonary	B-MED
mrsa	B-MED
were	O
more	O
likely	O
to	O
be	O
coinfected	B-MED
with	O
pulmonary	B-MED
p	B-MED
aeruginosa	I-MED
risk	B-MED
ratio	I-MED
,	O
2.4	O
95%	O
ci	B-MED
,	O
1.2	O
p	O
=	O
015	O
or	O
aspergillus	B-MED
fumigatus	I-MED
risk	B-MED
ratio	I-MED
,	O
2.2	O
95%	O
ci	B-MED
,	O
1.2	O
p	O
=	O
035	O
.	O
	
conclusions	O
there	O
is	O
low	O
to	O
moderate	B-MED
correlation	B-MED
between	O
pulmonary	B-MED
and	O
sinus	B-MED
pathogens	B-MED
in	O
cf	B-MED
patients	B-MED
.	O
	
this	O
is	O
important	O
to	O
consider	O
when	O
treating	B-MED
infections	B-MED
.	O
	
the	O
prevalence	B-MED
of	O
mrsa	B-MED
in	O
sinus	B-MED
cultures	I-MED
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
the	O
role	O
of	O
mir-451	B-MED
in	O
the	O
switching	O
between	O
proliferation	B-MED
and	O
migration	B-MED
in	O
malignant	B-MED
glioma	I-MED
cells	B-MED
ampk	B-MED
signaling	B-MED
,	O
mtor	B-MED
modulation	B-MED
and	O
rac1	B-MED
activation	B-MED
required	O
glioblastoma	B-MED
multiforme	I-MED
gbm	B-MED
,	O
who	B-MED
grade	I-MED
iv	I-MED
astrocytoma	I-MED
,	O
is	O
the	O
most	O
common	O
primary	B-MED
neoplasm	I-MED
of	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
cns	B-MED
and	O
has	O
the	O
highest	O
malignancy	B-MED
and	O
mortality	B-MED
rates	I-MED
.	O
	
the	O
invasive	B-MED
nature	I-MED
of	O
gbm	B-MED
complicates	O
surgical	B-MED
resection	I-MED
and	O
restricts	O
chemotherapeutic	B-MED
access	I-MED
,	O
contributing	O
to	O
poor	O
patient	B-MED
prognosis	B-MED
.	O
	
the	O
migration	B-MED
of	O
tumor	B-MED
cells	I-MED
is	O
closely	O
related	O
to	O
the	O
tumor	B-MED
cell	I-MED
proliferation	B-MED
.	O
	
the	O
acquisition	B-MED
of	O
migratory	B-MED
capability	B-MED
,	O
in	O
addition	O
to	O
intracellular	B-MED
factors	B-MED
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial	B-MED
mechanism	I-MED
during	O
the	O
progression	B-MED
of	O
invasion	B-MED
.	O
	
using	O
qrt-pcr	B-MED
analysis	B-MED
,	O
we	O
determined	O
that	O
the	O
expression	B-MED
of	O
mir-451	B-MED
in	O
glioma	B-MED
tissue	B-MED
was	O
lower	O
than	O
in	O
control	B-MED
brain	I-MED
tissue	I-MED
,	O
especially	O
in	O
the	O
central	B-MED
portions	B-MED
of	O
the	O
tumor	B-MED
.	O
	
in	O
glioma	B-MED
cell	B-MED
lines	I-MED
,	O
we	O
found	O
that	O
decreased	B-MED
mir-451	B-MED
expression	B-MED
suppressed	B-MED
tumor	B-MED
cell	I-MED
proliferation	B-MED
but	O
enhanced	O
migration	B-MED
with	O
a	O
concomitant	B-MED
low	O
level	O
of	O
cab39	B-MED
/	O
ampk	B-MED
/	O
mtor	B-MED
pathway	B-MED
activation	I-MED
and	O
high	O
level	O
of	O
rac1	B-MED
/	O
cofilin	B-MED
pathway	B-MED
activation	I-MED
,	O
respectively	O
.	O
	
notably	O
,	O
the	O
effect	O
of	O
mir-451	B-MED
on	O
cytological	B-MED
behavior	I-MED
and	O
on	O
the	O
activation	B-MED
of	O
mtor	B-MED
and	O
rac1	B-MED
was	O
limited	O
when	O
ampkα1	B-MED
expression	B-MED
was	O
knocked-down	O
with	O
a	O
synthetic	B-MED
shrna	B-MED
.	O
	
we	O
suggest	O
that	O
the	O
glioma	B-MED
microenvironment	B-MED
results	O
in	O
heterogeneity	B-MED
of	O
mir-451	B-MED
expression	B-MED
.	O
	
our	O
data	O
indicated	O
that	O
mir-451	B-MED
relays	O
environmental	O
signals	O
by	O
upregulating	B-MED
the	O
activity	O
of	O
ampk	B-MED
signaling	B-MED
,	O
thereby	O
modulating	B-MED
the	O
activation	B-MED
of	O
mtor	B-MED
and	O
rac1	B-MED
/	O
cofilin	B-MED
which	O
,	O
in	O
turn	O
,	O
play	O
key	O
roles	O
in	O
glioma	B-MED
cell	O
proliferation	B-MED
and	O
migration	B-MED
,	O
respectively	O
.	O
	
our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	B-MED
target	O
which	O
,	O
while	O
suppressing	B-MED
tumor	B-MED
cell	I-MED
proliferation	B-MED
,	O
could	O
also	O
promote	O
cell	B-MED
infiltration	B-MED
.	O
	
comparison	B-MED
of	O
gasoline	B-MED
direct-injection	I-MED
gdi	B-MED
and	O
port	B-MED
fuel	I-MED
injection	I-MED
pfi	B-MED
vehicle	B-MED
emissions	I-MED
emission	B-MED
certification	B-MED
standards	B-MED
,	O
cold-start	B-MED
,	O
secondary	O
organic	B-MED
aerosol	B-MED
formation	B-MED
potential	B-MED
,	O
and	O
potential	B-MED
climate	B-MED
impacts	B-MED
recent	O
increases	B-MED
in	O
the	O
corporate	B-MED
average	B-MED
fuel	I-MED
economy	I-MED
standards	B-MED
have	O
led	O
to	O
widespread	B-MED
adoption	O
of	O
vehicles	B-MED
equipped	O
with	O
gasoline	B-MED
direct-injection	I-MED
gdi	B-MED
engines	B-MED
.	O
	
changes	O
in	O
engine	B-MED
technologies	B-MED
can	O
alter	O
emissions	B-MED
.	O
	
to	O
quantify	B-MED
these	O
effects	B-MED
,	O
we	O
measured	B-MED
gas-	B-MED
and	O
particle-phase	B-MED
emissions	B-MED
from	O
82	O
light-duty	B-MED
gasoline	B-MED
vehicles	B-MED
recruited	O
from	O
the	O
california	B-MED
in-use	O
fleet	O
tested	B-MED
on	O
a	O
chassis	B-MED
dynamometer	B-MED
using	O
the	O
cold-start	B-MED
unified	O
cycle	O
.	O
	
the	O
fleet	O
included	O
15	O
gdi	B-MED
vehicles	B-MED
,	O
including	O
8	O
gdis	B-MED
certified	B-MED
to	O
the	O
most-stringent	O
emissions	B-MED
standard	B-MED
,	O
superultra-low-emission	B-MED
vehicles	I-MED
sulev	B-MED
.	O
	
we	O
quantified	B-MED
the	O
effects	B-MED
of	I-MED
engine	B-MED
technology	B-MED
,	O
emission	B-MED
certification	B-MED
standards	B-MED
,	O
and	O
cold-start	B-MED
on	O
emissions	B-MED
.	O
	
for	O
vehicles	B-MED
certified	B-MED
to	O
the	O
same	O
emissions	B-MED
standard	B-MED
,	O
there	O
is	O
no	O
statistical	B-MED
difference	B-MED
of	O
regulated	O
gas-phase	B-MED
pollutant	B-MED
emissions	B-MED
between	O
pfis	B-MED
and	O
gdis	B-MED
.	O
	
however	O
,	O
gdis	B-MED
had	O
,	O
on	O
average	B-MED
,	O
a	O
factor	B-MED
of	O
2	O
higher	O
particulate	B-MED
matter	I-MED
pm	B-MED
mass	O
emissions	B-MED
than	O
pfis	B-MED
due	O
to	O
higher	O
elemental	B-MED
carbon	I-MED
ec	B-MED
emissions	B-MED
.	O
	
sulev	B-MED
certified	B-MED
gdis	B-MED
have	O
a	O
factor	B-MED
of	O
2	O
lower	O
pm	B-MED
mass	O
emissions	B-MED
than	O
gdis	B-MED
certified	B-MED
as	O
ultralow-emission	B-MED
vehicles	I-MED
3.0	O
1.1	O
versus	O
6.3	O
1.1	O
mg/mi	O
,	O
suggesting	O
improvements	B-MED
in	O
engine	B-MED
design	B-MED
and	O
calibration	B-MED
.	O
	
comprehensive	B-MED
organic	B-MED
speciation	O
revealed	B-MED
no	O
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
composition	B-MED
of	O
the	O
volatile	B-MED
organic	B-MED
compounds	I-MED
emissions	B-MED
between	O
pfi	B-MED
and	O
gdis	B-MED
,	O
including	O
benzene	B-MED
,	O
toluene	B-MED
,	O
ethylbenzene	B-MED
,	O
and	O
xylenes	B-MED
btex	B-MED
.	O
	
therefore	O
,	O
the	O
secondary	O
organic	B-MED
aerosol	B-MED
and	O
ozone	B-MED
formation	B-MED
potential	B-MED
of	O
the	O
exhaust	B-MED
does	O
not	O
depend	O
on	O
engine	B-MED
technology	B-MED
.	O
	
cold-start	B-MED
contributes	B-MED
a	O
larger	B-MED
fraction	B-MED
of	I-MED
the	O
total	O
unified	O
cycle	O
emissions	B-MED
for	O
vehicles	B-MED
meeting	O
more-stringent	O
emission	B-MED
standards	B-MED
.	O
	
organic	B-MED
gas	B-MED
emissions	B-MED
were	O
the	O
most	O
sensitive	B-MED
to	O
cold-start	B-MED
compared	B-MED
to	O
the	O
other	O
pollutants	B-MED
tested	B-MED
here	O
.	O
	
there	O
were	O
no	O
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
effects	B-MED
of	I-MED
cold-start	B-MED
on	O
gdis	B-MED
and	O
pfis	B-MED
.	O
	
for	O
our	O
test	O
fleet	O
,	O
the	O
measured	B-MED
14.5	O
decrease	B-MED
in	O
co2	B-MED
emissions	B-MED
from	O
gdis	B-MED
was	O
much	O
greater	B-MED
than	O
the	O
potential	B-MED
climate	B-MED
forcing	O
associated	B-MED
with	I-MED
higher	O
black	B-MED
carbon	I-MED
emissions	B-MED
.	O
	
thus	O
,	O
switching	O
from	O
pfi	B-MED
to	O
gdi	B-MED
vehicles	B-MED
will	O
likely	O
lead	O
to	O
a	O
reduction	B-MED
in	O
net	O
global	B-MED
warming	I-MED
.	O
	
trib3	B-MED
downregulation	B-MED
enhances	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
cytotoxicity	B-MED
in	O
gastric	B-MED
cancer	I-MED
cells	B-MED
trib3	B-MED
,	O
which	O
is	O
a	O
pseudokinase	B-MED
known	O
to	O
regulate	B-MED
multiple	I-MED
pro-survival	I-MED
pathways	I-MED
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-MED
target	B-MED
for	O
the	O
treatment	B-MED
of	O
human	B-MED
tumors	B-MED
.	O
	
however	O
,	O
its	O
precise	O
role	O
in	O
cancer	B-MED
is	O
controversial	O
,	O
as	O
trib3	B-MED
protein	B-MED
levels	I-MED
have	O
been	O
associated	O
with	O
both	O
good	B-MED
and	O
poor	B-MED
prognosis	I-MED
in	O
cancer	B-MED
patients	I-MED
.	O
	
here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
trib3	B-MED
expression	B-MED
in	O
the	O
survival	B-MED
of	O
gastric	B-MED
cancer	I-MED
cells	B-MED
exposed	O
to	O
anticancer	B-MED
drugs	I-MED
.	O
	
we	O
found	O
that	O
the	O
tested	B-MED
anticancer	B-MED
drug	I-MED
,	O
doxorubicin	B-MED
,	O
induced	B-MED
cytotoxicity	B-MED
by	O
decreasing	O
trib3	B-MED
transcription	B-MED
,	O
which	O
was	O
followed	O
by	O
apoptotic	B-MED
cell	I-MED
death	I-MED
.	O
	
moreover	O
,	O
trib3	B-MED
sirna	I-MED
knockdown	B-MED
appeared	O
to	O
enhance	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
gastric	B-MED
cancer	I-MED
cells	B-MED
,	O
concurrently	O
with	O
altering	O
the	O
expression	B-MED
of	O
downstream	B-MED
apoptotic	B-MED
factors	I-MED
.	O
	
conversely	O
,	O
overexpression	B-MED
of	O
trib3	B-MED
significantly	O
protected	B-MED
cells	I-MED
against	O
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
.	O
	
our	O
results	O
indicate	O
that	O
downregulation	B-MED
of	O
trib3	B-MED
appears	O
to	O
promote	B-MED
cell	B-MED
death	I-MED
and	O
enhance	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
,	O
supporting	O
the	O
anti-apoptotic	B-MED
role	O
of	O
trib3	B-MED
.	O
	
the	O
inductions	B-MED
of	O
three	O
classes	O
of	O
mapks	B-MED
failed	O
to	O
affect	O
doxorubicin	B-MED
-mediated	O
trib3	B-MED
downregulation	B-MED
,	O
while	O
trib3	B-MED
overexpression	B-MED
did	O
not	O
affect	O
doxorubicin	B-MED
-	O
induced	B-MED
mapk	B-MED
activation	I-MED
.	O
	
in	O
sum	O
,	O
our	O
findings	B-MED
indicate	O
that	O
trib3	B-MED
plays	O
an	O
anti-apoptotic	B-MED
role	O
in	O
doxorubicin	B-MED
-treated	O
gastric	B-MED
cancer	I-MED
cell	B-MED
lines	I-MED
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
trib3	B-MED
expression	B-MED
in	O
response	O
to	O
anticancer	B-MED
drugs	I-MED
,	O
such	O
as	O
doxorubicin	B-MED
,	O
irinotecan	B-MED
or	O
oxaliplatin	B-MED
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B-MED
therapy	I-MED
.	O
	
digital	B-MED
myopericytoma	B-MED
a	O
case	B-MED
report	I-MED
and	O
systematic	B-MED
literature	I-MED
review	I-MED
a	O
myopericytoma	B-MED
mp	B-MED
is	O
an	O
exceedingly	O
rare	O
perivascular	B-MED
tumor	I-MED
of	O
unknown	B-MED
etiology	I-MED
.	O
	
given	O
their	O
potential	B-MED
for	O
mimicry	B-MED
and	O
malignancy	B-MED
,	O
mp	B-MED
tumors	I-MED
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	B-MED
and	O
may	O
be	O
overlooked	O
on	O
differential	B-MED
diagnosis	I-MED
.	O
	
we	O
present	O
a	O
case	B-MED
report	I-MED
of	O
an	O
otherwise	O
healthy	B-MED
33-year-old	O
right-hand	B-MED
dominant	I-MED
male	B-MED
who	O
presented	O
to	O
our	O
outpatient	B-MED
clinic	I-MED
with	O
a	O
2-month	O
history	O
of	O
painless	B-MED
swelling	B-MED
and	O
erythema	B-MED
of	I-MED
the	I-MED
pulp	I-MED
of	I-MED
his	I-MED
left	I-MED
index	I-MED
finger	I-MED
.	O
	
subsequent	O
plain	B-MED
film	I-MED
x-ray	I-MED
showed	O
near-complete	B-MED
bony	B-MED
destruction	I-MED
of	O
his	O
distal	B-MED
phalanx	I-MED
.	O
	
pathological	B-MED
evaluation	B-MED
of	O
an	O
incisional	B-MED
biopsy	I-MED
showed	O
a	O
benign	B-MED
variant	I-MED
of	O
mp	B-MED
.	O
	
the	O
lesion	B-MED
was	O
treated	O
by	O
excision	B-MED
with	O
tumor	B-MED
shelling	B-MED
,	O
and	O
there	O
was	O
no	B-MED
evidence	I-MED
of	I-MED
recurrence	B-MED
81	O
days	O
postoperatively	B-MED
.	O
	
a	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-MED
and	O
outcome	B-MED
of	O
all	O
known	O
cases	B-MED
of	O
hand	B-MED
and	I-MED
wrist	I-MED
mp	B-MED
gene	B-MED
expression	I-MED
reveals	O
evidence	B-MED
for	O
egfr	B-MED
-dependent	O
proximal-distal	B-MED
limb	I-MED
patterning	B-MED
in	O
a	O
myriapod	B-MED
evolution	B-MED
of	O
segmented	B-MED
limbs	I-MED
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
arthropoda	B-MED
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	B-MED
and	O
trunk	B-MED
appendages	B-MED
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success	O
.	O
	
proximodistal	B-MED
limb	I-MED
patterning	B-MED
is	O
controlled	O
by	O
two	O
regulatory	B-MED
networks	I-MED
in	O
the	O
vinegar	B-MED
fly	I-MED
drosophila	B-MED
melanogaster	I-MED
,	O
and	O
other	O
insects	B-MED
.	O
	
the	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	B-MED
wingless	B-MED
wg	B-MED
and	O
decapentaplegic	B-MED
dpp	B-MED
the	O
second	O
by	O
the	O
egfr-signaling	B-MED
cascade	I-MED
.	O
	
while	O
the	O
role	O
of	O
wg	B-MED
and	O
dpp	B-MED
has	O
been	O
studied	B-MED
in	O
a	O
wide	O
range	O
of	O
arthropods	B-MED
representing	O
all	O
main	O
branches	O
,	O
that	O
is	O
,	O
pancrustacea	B-MED
=	O
hexapoda	B-MED
+	O
crustacea	B-MED
,	O
myriapoda	B-MED
and	O
chelicerata	B-MED
,	O
investigation	B-MED
of	O
the	O
potential	O
role	O
of	O
egfr-signaling	B-MED
is	O
restricted	O
to	O
insects	B-MED
hexapoda	B-MED
.	O
	
gene	B-MED
expression	I-MED
analysis	I-MED
of	O
egfr	B-MED
,	O
its	O
potential	B-MED
ligands	B-MED
,	O
and	O
putative	B-MED
downstream	I-MED
factors	I-MED
in	O
the	O
pill	B-MED
millipede	I-MED
glomeris	B-MED
marginata	I-MED
myriapoda	B-MED
diplopoda	B-MED
,	O
reveals	O
that-in	O
at	O
least	O
mandibulate	B-MED
arthropods	B-MED
-	O
egfr-signaling	B-MED
is	O
likely	O
a	O
conserved	O
regulatory	B-MED
mechanism	I-MED
in	O
proximodistal	B-MED
limb	I-MED
patterning	B-MED
.	O
	
pirfenidone	B-MED
normalizes	B-MED
the	O
tumor	B-MED
microenvironment	I-MED
to	O
improve	O
chemotherapy	B-MED
normalization	B-MED
of	O
the	O
tumor	B-MED
microenvironment	I-MED
by	O
selectively	O
targeting	B-MED
components	B-MED
of	O
the	O
tumor	B-MED
extracellular	B-MED
matrix	I-MED
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	B-MED
to	O
decompress	B-MED
tumor	B-MED
blood	B-MED
vessels	I-MED
,	O
increase	B-MED
vessel	B-MED
perfusion	B-MED
and	O
thus	O
,	O
improve	O
drug	B-MED
delivery	I-MED
and	O
the	O
efficacy	B-MED
of	O
cancer	B-MED
therapy	I-MED
.	O
	
therefore	O
,	O
we	O
now	O
need	O
to	O
identify	B-MED
safe	O
and	O
well	O
tolerated	B-MED
pharmaceutical	B-MED
agents	I-MED
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	B-MED
of	O
solid	B-MED
tumors	I-MED
and	O
enhance	B-MED
chemotherapy	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
repurposed	O
pirfenidone	B-MED
,	O
a	O
clinically	B-MED
approved	B-MED
anti-fibrotic	B-MED
drug	I-MED
for	O
the	O
treatment	B-MED
of	O
idiopathic	B-MED
pulmonary	I-MED
fibrosis	I-MED
,	O
to	O
investigate	B-MED
its	O
possible	O
role	O
on	O
tumor	B-MED
microenvironment	I-MED
normalization	B-MED
.	O
	
using	O
two	O
orthotopic	B-MED
mammary	B-MED
tumor	B-MED
models	I-MED
we	O
demonstrate	O
that	O
pirfenidone	B-MED
reduces	B-MED
collagen	B-MED
and	O
hyaluronan	B-MED
levels	B-MED
and	O
,	O
as	O
a	O
result	B-MED
,	O
significantly	B-MED
increases	B-MED
blood	B-MED
vessel	I-MED
functionality	B-MED
and	O
perfusion	B-MED
and	O
improves	O
the	O
anti-tumor	B-MED
efficacy	I-MED
of	O
doxorubicin	B-MED
.	O
	
reduction	B-MED
of	O
extracellular	B-MED
matrix	I-MED
components	I-MED
were	O
mediated	O
via	O
tgfβ	B-MED
signaling	I-MED
pathway	I-MED
inhibition	B-MED
due	O
to	O
downregulation	B-MED
of	O
tgfβ1	B-MED
,	O
col1a1	B-MED
,	O
col3a1	B-MED
,	O
has2	B-MED
,	O
has3	B-MED
expression	B-MED
levels	B-MED
.	O
	
our	O
findings	B-MED
provide	O
evidence	B-MED
that	O
repurposing	O
pirfenidone	B-MED
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B-MED
to	O
enhance	B-MED
drug	B-MED
delivery	I-MED
to	O
solid	B-MED
tumors	I-MED
by	O
normalizing	B-MED
the	O
tumor	B-MED
microenvironment	I-MED
.	O
	
serum	B-MED
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
receptor-3	I-MED
levels	B-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
cancer	I-MED
esophageal	B-MED
cancer	I-MED
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-MED
of	I-MED
the	I-MED
gastrointestinal	I-MED
tract	I-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	B-MED
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor-3	I-MED
vegfr-3	B-MED
expression	B-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
escc	B-MED
to	O
evaluate	O
the	O
role	O
of	O
vegfr-3	B-MED
in	O
escc	B-MED
.	O
	
ninety	O
five	O
patients	B-MED
with	O
escc	B-MED
were	O
studied	O
.	O
	
pre-therapy	B-MED
and	O
preoperative	B-MED
samples	B-MED
were	O
stored	O
and	O
elisa	B-MED
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
vegfr-3	B-MED
.	O
	
the	O
serum	B-MED
values	I-MED
of	O
vegfr-3	B-MED
were	O
significantly	O
higher	O
in	O
patients	B-MED
with	O
escc	B-MED
than	O
in	O
healthy	B-MED
donors	B-MED
p<0	O
.	O
	
the	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	B-MED
of	O
vegfr-3	B-MED
in	O
escc	B-MED
.	O
	
vegfr-3	B-MED
may	O
be	O
a	O
good	O
diagnostic	B-MED
biomarker	B-MED
for	O
escc	B-MED
.	O
	
biomarker	B-MED
,	O
escc	B-MED
,	O
vegfr-3	B-MED
.	O
	
zinc	B-MED
and	O
wound	B-MED
healing	I-MED
a	O
review	B-MED
of	I-MED
zinc	B-MED
physiology	B-MED
and	O
clinical	B-MED
applications	I-MED
our	O
understanding	B-MED
of	O
the	O
role	O
of	O
zinc	B-MED
in	O
normal	O
human	B-MED
physiology	B-MED
is	O
constantly	B-MED
expanding	O
,	O
yet	O
there	O
are	O
major	O
gaps	B-MED
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	B-MED
of	O
zinc	B-MED
in	O
wound	B-MED
healing	I-MED
.	O
	
this	O
review	B-MED
aims	B-MED
to	O
provide	O
the	O
clinician	B-MED
with	O
sufficient	B-MED
understanding	O
of	O
zinc	B-MED
biology	B-MED
and	O
an	O
up-to-date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-MED
in	O
wound	B-MED
healing	I-MED
.	O
	
zinc	B-MED
is	O
an	O
essential	O
ion	B-MED
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	B-MED
,	O
and	O
zinc	B-MED
deficiency	I-MED
has	O
many	O
manifestations	B-MED
ranging	O
from	O
delayed	B-MED
wound	B-MED
healing	I-MED
to	O
immune	B-MED
dysfunction	I-MED
and	O
impairment	B-MED
of	O
multiple	B-MED
sensory	B-MED
systems	I-MED
.	O
	
while	O
consensus	B-MED
has	O
been	O
reached	O
regarding	O
the	O
detrimental	B-MED
effects	I-MED
of	O
zinc	B-MED
deficiency	I-MED
on	O
wound	B-MED
healing	I-MED
,	O
there	O
is	O
considerable	O
discord	B-MED
in	O
the	O
literature	B-MED
on	O
the	O
optimal	B-MED
methods	I-MED
and	O
true	B-MED
benefits	I-MED
of	O
zinc	B-MED
receipt	O
of	O
thyroid	B-MED
hormone	I-MED
deficiency	I-MED
treatment	B-MED
and	O
risk	B-MED
of	O
herpes	B-MED
zoster	I-MED
thyroid	B-MED
hormone	I-MED
th	B-MED
has	O
been	O
suggested	O
to	O
control	O
herpes	B-MED
virus	I-MED
gene	B-MED
expression	I-MED
and	O
replication	B-MED
in	O
neurons	B-MED
via	O
epigenetics	B-MED
through	O
its	O
nuclear	B-MED
receptors	I-MED
.	O
	
it	O
has	O
previously	O
been	O
shown	O
that	O
patients	B-MED
with	O
hypothyroidism	B-MED
are	O
predisposed	O
to	O
herpes	B-MED
zoster	I-MED
hz	B-MED
,	O
suggesting	O
that	O
the	O
th	B-MED
deficiency	I-MED
may	O
be	O
a	O
risk	B-MED
factor	I-MED
for	O
varicella	B-MED
zoster	I-MED
virus	I-MED
vzv	B-MED
reactivation	B-MED
.	O
	
the	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
test	O
the	O
hypothesis	B-MED
that	O
th	B-MED
treatment	I-MED
will	O
ameliorate	O
the	O
complication	B-MED
of	O
hz	B-MED
.	O
	
this	O
study	B-MED
investigated	B-MED
the	O
hypothesis	B-MED
by	O
enquiring	O
into	O
a	O
comprehensive	B-MED
medical	I-MED
database	I-MED
at	O
kaiser	B-MED
permanente	I-MED
southern	I-MED
california	I-MED
kpsc	B-MED
to	O
verify	O
whether	O
patients	B-MED
taking	O
th	B-MED
medication	B-MED
experience	O
a	O
reduction	O
in	O
hz	B-MED
occurrence	O
.	O
	
it	O
was	O
shown	O
by	O
kaplan-meier	B-MED
analysis	I-MED
that	O
hypothyroidism	B-MED
patients	B-MED
taking	O
th	B-MED
medicines	B-MED
had	O
a	O
lower	O
risk	B-MED
of	O
hz	B-MED
.	O
	
the	O
fully	O
adjusted	O
analysis	B-MED
indicated	O
that	O
patients	B-MED
receiving	O
medication	B-MED
for	O
the	O
treatment	B-MED
of	O
th	B-MED
deficiency	I-MED
exhibited	O
a	O
reduced	O
risk	B-MED
of	O
hz	B-MED
hazard	B-MED
ratio	I-MED
0.60	O
,	O
95%	O
confidence	B-MED
interval	I-MED
0.51	O
.	O
	
this	O
lower	O
risk	B-MED
of	O
hz	B-MED
was	O
significant	O
in	O
all	O
age	B-MED
groups	I-MED
except	O
the	O
18-39	O
years	B-MED
cohort	B-MED
.	O
	
in	O
addition	O
,	O
female	B-MED
patients	B-MED
taking	O
th	B-MED
treatment	I-MED
exhibited	O
a	O
lower	O
risk	B-MED
than	O
their	O
male	B-MED
counterparts	O
.	O
	
together	O
these	O
findings	B-MED
support	O
the	O
hypothesis	B-MED
that	O
a	O
constant	O
level	O
of	O
th	B-MED
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
hz	B-MED
.	O
	
more	O
studies	B-MED
are	O
underway	O
to	O
evaluate	B-MED
the	I-MED
laboratory	I-MED
data	I-MED
for	O
an	O
analysis	B-MED
of	O
hormonal	B-MED
effects	B-MED
on	O
peer	B-MED
exclusion	B-MED
during	O
the	O
pubertal	B-MED
transition	B-MED
the	O
role	O
of	O
social	B-MED
competence	I-MED
for	O
some	O
youth	B-MED
,	O
early	B-MED
puberty	I-MED
is	O
accompanied	O
by	O
peer	B-MED
exclusion	B-MED
.	O
	
yet	O
early	B-MED
developers	B-MED
may	O
experience	B-MED
less	O
peer	B-MED
exclusion	B-MED
if	O
they	O
have	O
social	B-MED
competence	I-MED
,	O
which	O
would	O
bolster	B-MED
their	O
ability	O
to	O
develop	B-MED
and	O
maintain	B-MED
positive	B-MED
relationships	B-MED
with	O
their	O
peers	B-MED
.	O
	
accordingly	O
,	O
the	O
present	B-MED
study	B-MED
tests	O
whether	O
pubertal	B-MED
timing	B-MED
and	O
tempo	B-MED
predicts	B-MED
decrements	B-MED
in	O
children's	B-MED
social	B-MED
competence	I-MED
and	O
whether	O
decrements	B-MED
in	O
social	B-MED
competence	I-MED
account	O
for	O
associations	B-MED
between	O
puberty	B-MED
timing	B-MED
and	O
tempo	B-MED
and	O
peer	B-MED
exclusion	B-MED
over	O
time	B-MED
.	O
	
longitudinal	B-MED
data	B-MED
were	O
drawn	O
from	O
1364	O
families	B-MED
48%	O
female	B-MED
76%	O
white	B-MED
m	O
=	O
9.32	O
years	B-MED
,	O
sd	O
=	O
48	O
,	O
at	O
wave	O
3	O
who	O
participated	B-MED
in	O
waves	O
3-5	O
i.e	O
,	O
grades	O
4-6	O
of	O
phase	B-MED
iii	I-MED
of	O
the	O
nichd	B-MED
-	O
seccyd	B-MED
.	O
	
the	O
results	B-MED
from	O
latent	B-MED
growth	I-MED
curve	I-MED
models	I-MED
indicated	O
that	O
earlier	B-MED
pubertal	B-MED
timing	B-MED
and	O
more	O
rapid	B-MED
pubertal	B-MED
tempo	B-MED
among	O
girls	B-MED
were	O
associated	B-MED
with	I-MED
high	B-MED
initial	B-MED
levels	B-MED
of	O
peer	B-MED
exclusion	B-MED
.	O
	
moreover	O
,	O
mediation	B-MED
analyses	I-MED
revealed	O
that	O
early	B-MED
developers'	B-MED
susceptibility	B-MED
to	O
peer	B-MED
exclusion	B-MED
was	O
associated	B-MED
with	I-MED
their	O
initial	B-MED
level	B-MED
of	O
social	B-MED
competence	I-MED
.	O
	
in	O
boys	B-MED
,	O
pubertal	B-MED
timing	B-MED
and	O
tempo	B-MED
were	O
not	O
directly	O
associated	B-MED
with	I-MED
peer	B-MED
exclusion	B-MED
instead	O
,	O
indirect	O
effects	B-MED
of	I-MED
pubertal	B-MED
timing	B-MED
on	O
peer	B-MED
exclusion	B-MED
intercept	B-MED
,	O
slope	B-MED
occurred	O
through	O
initial	B-MED
levels	B-MED
of	O
social	B-MED
competence	I-MED
.	O
	
on	O
average	B-MED
,	O
early	B-MED
developers'	B-MED
who	O
had	O
low	B-MED
levels	B-MED
of	O
social	B-MED
competence	I-MED
also	O
had	O
high	B-MED
initial	B-MED
levels	B-MED
of	O
peer	B-MED
exclusion	B-MED
but	O
experienced	B-MED
decrements	B-MED
in	O
peer	B-MED
exclusion	B-MED
over	O
time	O
.	O
	
the	O
association	B-MED
between	O
the	O
intercepts	B-MED
for	O
puberty	B-MED
and	O
peer	B-MED
exclusion	B-MED
and	O
the	O
slopes	B-MED
for	O
social	B-MED
competence	I-MED
and	O
peer	B-MED
exclusion	B-MED
were	O
stronger	B-MED
for	O
boys	B-MED
than	O
girls	B-MED
.	O
	
overall	O
,	O
our	O
findings	B-MED
suggest	O
that	O
early	B-MED
developers'	B-MED
susceptibility	B-MED
to	O
and	O
experiences	B-MED
of	O
peer	B-MED
exclusion	B-MED
are	O
associated	B-MED
with	I-MED
their	O
development	B-MED
of	O
social	B-MED
competence	I-MED
.	O
	
air	B-MED
pollution	I-MED
characteristics	B-MED
and	O
health	B-MED
risks	I-MED
in	O
henan	B-MED
province	I-MED
,	O
china	B-MED
events	O
of	O
severe	B-MED
air	B-MED
pollution	I-MED
occurred	O
frequently	O
in	O
china	B-MED
recently	O
,	O
thus	O
understanding	O
of	O
the	O
air	B-MED
pollution	I-MED
characteristics	B-MED
and	O
its	O
health	B-MED
risks	B-MED
is	O
very	O
important	O
.	O
	
in	O
this	O
work	O
,	O
we	O
analyzed	O
a	O
two-year	O
dataset	B-MED
march	O
2014	O
-	O
february	O
2016	O
including	O
daily	B-MED
concentrations	B-MED
of	O
six	O
criteria	O
pollutants	B-MED
pm2.5	B-MED
,	O
pm10	B-MED
,	O
co	B-MED
,	O
so2	B-MED
,	O
no2	B-MED
,	O
and	O
o3	B-MED
from	O
18	O
cities	O
in	O
henan	B-MED
province	I-MED
.	O
	
results	O
reveal	O
the	O
serious	O
air	B-MED
pollution	I-MED
status	B-MED
in	O
henan	B-MED
province	I-MED
,	O
especially	O
the	O
northern	B-MED
part	I-MED
,	O
and	O
zhengzhou	B-MED
is	O
the	O
city	B-MED
with	O
the	O
worst	B-MED
air	B-MED
quality	I-MED
.	O
	
annual	O
average	O
pm2.5	B-MED
concentrations	B-MED
exceed	O
the	O
second	O
grade	O
of	O
chinese	B-MED
ambient	I-MED
air	I-MED
quality	I-MED
standard	I-MED
75μg/m	O
at	O
both	O
2014	O
and	O
2015	O
.	O
	
pm2.5	B-MED
is	O
typically	O
the	O
major	O
pollutant	B-MED
,	O
but	O
ozone	B-MED
pollution	B-MED
can	O
be	O
significant	O
during	O
summer	B-MED
.	O
	
furthermore	O
,	O
as	O
the	O
commonly	O
used	O
air	B-MED
quality	I-MED
index	I-MED
aqi	B-MED
neglects	O
the	O
mutual	O
health	B-MED
effects	O
from	O
multiple	O
pollutants	B-MED
,	O
we	O
introduced	O
the	O
aggregate	B-MED
air	I-MED
quality	I-MED
index	I-MED
aaqi	B-MED
and	O
health-risk	B-MED
based	I-MED
air	I-MED
quality	I-MED
index	I-MED
haqi	B-MED
to	O
evaluate	B-MED
the	I-MED
health	I-MED
risks	I-MED
.	O
	
results	O
show	O
that	O
based	O
on	O
haqi	B-MED
,	O
the	O
current	O
aqi	B-MED
system	O
likely	O
significantly	O
underestimate	O
the	O
health	B-MED
risks	B-MED
of	O
air	B-MED
pollution	I-MED
,	O
highlighting	O
that	O
the	O
general	B-MED
public	I-MED
may	O
need	O
stricter	O
health	B-MED
protection	I-MED
measures	I-MED
.	O
	
the	O
population	B-MED
-weighted	O
two-year	O
average	O
haqi	B-MED
data	O
further	O
demonstrates	O
that	O
all	O
population	B-MED
in	O
the	O
studied	O
cities	B-MED
in	O
henan	B-MED
province	I-MED
live	O
with	O
polluted	B-MED
air	I-MED
-	O
72%	O
of	O
the	O
population	B-MED
is	O
exposed	B-MED
to	I-MED
air	B-MED
that	O
is	O
unhealthy	B-MED
for	O
sensitive	B-MED
people	B-MED
,	O
while	O
28%	O
of	O
people	B-MED
is	O
exposed	B-MED
to	I-MED
air	B-MED
that	O
can	O
be	O
harmful	O
to	O
healthy	B-MED
people	B-MED
and	O
the	O
health	B-MED
risks	B-MED
are	O
much	O
greater	O
during	O
winter	B-MED
than	O
during	O
other	O
seasons	B-MED
.	O
	
future	O
works	O
should	O
further	O
improve	O
the	O
haqi	B-MED
algorithm	B-MED
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	B-MED
/	O
epidemiologic	B-MED
data	B-MED
and	O
the	O
haqi	B-MED
increased	B-MED
risk	B-MED
of	O
ptld	B-MED
in	O
lung	B-MED
transplant	I-MED
recipients	I-MED
with	O
cystic	B-MED
fibrosis	I-MED
post-transplant	B-MED
lymphoproliferative	I-MED
disease	I-MED
ptld	B-MED
is	O
an	O
important	O
cause	O
of	O
morbidity	B-MED
and	O
mortality	B-MED
following	O
lung	B-MED
transplantation	I-MED
.	O
	
recipients	B-MED
with	O
cystic	B-MED
fibrosis	I-MED
cf	B-MED
may	O
have	O
an	O
increased	B-MED
risk	B-MED
of	O
ptld	B-MED
although	O
the	O
literature	B-MED
is	O
limited	O
to	O
single	B-MED
center	I-MED
cohorts	I-MED
.	O
	
our	O
primary	O
aim	O
is	O
to	O
examine	O
ptld	B-MED
in	O
an	O
adult	B-MED
lung	B-MED
transplant	I-MED
population	B-MED
by	O
utilizing	O
the	O
international	B-MED
society	I-MED
for	I-MED
heart	I-MED
and	I-MED
lung	I-MED
transplantation	I-MED
registry	I-MED
.	O
	
we	O
studied	B-MED
30	O
adult	B-MED
recipients	B-MED
of	O
lung	B-MED
transplants	I-MED
performed	O
between	O
1999	O
and	O
2011	O
.	O
	
the	O
primary	O
outcome	B-MED
was	O
development	B-MED
of	O
and	O
time	B-MED
to	O
ptld	B-MED
.	O
	
in	O
addition	O
to	O
indication	O
for	O
transplant	B-MED
,	O
other	O
predictors	B-MED
examined	O
included	O
epstein-barr	B-MED
virus	I-MED
ebv	B-MED
and	O
cytomegalovirus	B-MED
cmv	B-MED
serostatus	B-MED
,	O
gender	B-MED
,	O
and	O
age	B-MED
.	O
	
outcomes	B-MED
were	O
assessed	B-MED
with	O
univariable	B-MED
and	O
multivariable	B-MED
cox	I-MED
proportional	I-MED
hazard	I-MED
models	I-MED
to	O
obtain	O
hazard	B-MED
ratios	I-MED
hr	B-MED
.	O
	
17%	O
of	O
the	O
cohort	B-MED
had	O
a	O
diagnosis	B-MED
of	O
cf	B-MED
.	O
	
ptld	B-MED
developed	O
in	O
2%	O
of	O
cf	B-MED
recipients	B-MED
compared	O
to	O
1%	O
for	O
non-cf	B-MED
recipients	I-MED
p<0	O
.	O
	
compared	O
to	O
non-cf	B-MED
recipients	I-MED
,	O
cf	B-MED
recipients	B-MED
had	O
higher	B-MED
prevalence	I-MED
of	O
ebv	B-MED
and	O
cmv	B-MED
seronegativity	I-MED
and	O
higher	B-MED
prevalences	I-MED
of	O
high	B-MED
risk	I-MED
ebv	B-MED
and	O
cmv	B-MED
mismatch	O
d+/r-	O
.	O
	
there	O
is	O
a	O
significant	O
association	O
between	O
cf	B-MED
and	O
the	O
development	B-MED
of	O
ptld	B-MED
hr	B-MED
1.66	O
95%	O
ci	O
1.30	O
.	O
	
stratified	B-MED
multivariable	I-MED
analysis	I-MED
controlling	O
for	O
age	B-MED
revealed	O
ebv	B-MED
negative	B-MED
non-cf	B-MED
recipients	I-MED
have	O
an	O
almost	O
2	O
fold	O
increased	B-MED
risk	B-MED
of	O
developing	O
ptld	B-MED
,	O
whereas	O
ebv	B-MED
negative	O
cf	B-MED
recipients	B-MED
had	O
an	O
almost	O
6.5	O
fold	O
increased	B-MED
risk	B-MED
.	O
	
cf	B-MED
recipients	B-MED
have	O
a	O
higher	O
risk	B-MED
for	O
ptld	B-MED
compared	O
to	O
non-cf	B-MED
recipients	I-MED
.	O
	
further	O
studies	B-MED
are	O
needed	O
to	O
account	O
for	O
additional	O
risk	B-MED
factors	I-MED
and	O
management	B-MED
in	O
this	O
population	B-MED
post-transplant	I-MED
.	O
	
methods	B-MED
,	O
tools	B-MED
and	O
current	B-MED
perspectives	B-MED
in	O
proteogenomics	B-MED
with	O
combined	O
technological	B-MED
advancements	I-MED
in	O
high-throughput	B-MED
next-generation	I-MED
sequencing	I-MED
and	O
deep	B-MED
mass	I-MED
spectrometry	I-MED
-based	O
proteomics	B-MED
,	O
proteogenomics	B-MED
,	O
i.e	O
,	O
the	O
integrative	B-MED
analysis	I-MED
of	O
proteomic	B-MED
and	I-MED
genomic	I-MED
data	I-MED
,	O
has	O
emerged	O
as	O
a	O
new	O
research	B-MED
field	I-MED
.	O
	
early	O
efforts	O
in	O
the	O
field	B-MED
were	O
focused	O
on	O
improving	O
protein	B-MED
identification	B-MED
using	O
sample-specific	B-MED
genomic	I-MED
and	O
transcriptomic	B-MED
sequencing	I-MED
data	I-MED
.	O
	
more	O
recently	O
,	O
integrative	B-MED
analysis	I-MED
of	O
quantitative	B-MED
measurements	B-MED
from	O
genomic	B-MED
and	I-MED
proteomic	I-MED
studies	I-MED
have	O
identified	B-MED
novel	O
insights	O
into	O
gene	B-MED
expression	I-MED
regulation	I-MED
,	O
cell	B-MED
signaling	I-MED
,	O
and	O
disease	B-MED
.	O
	
many	O
methods	B-MED
and	O
tools	B-MED
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	B-MED
of	O
integrative	B-MED
proteogenomic	I-MED
approaches	I-MED
and	O
in	O
this	O
article	B-MED
,	O
we	O
systematically	B-MED
classify	B-MED
published	B-MED
methods	B-MED
and	O
tools	B-MED
into	O
four	O
major	B-MED
categories	I-MED
,	O
1	O
sequence	B-MED
-centric	O
proteogenomics	O
2	O
analysis	O
of	O
proteogenomic	O
relationships	O
3	O
integrative	O
modeling	O
of	O
proteogenomic	O
data	O
and	O
4	O
data	O
sharing	O
and	O
visualization	O
.	O
	
we	O
provide	O
a	O
comprehensive	O
review	O
of	O
methods	O
and	O
available	O
tools	O
in	O
each	O
category	O
and	O
highlight	O
their	O
typical	O
applications	B-MED
plasma	B-MED
dna	B-MED
and	O
rna	B-MED
differentially	B-MED
impact	B-MED
coagulation	B-MED
during	O
abdominal	B-MED
sepsis	I-MED
-an	O
explorative	B-MED
study	I-MED
cell-free	B-MED
dna	I-MED
cfdna	B-MED
and	O
extracellular	B-MED
rna	B-MED
exrna	B-MED
are	O
both	O
suspected	B-MED
to	O
activate	B-MED
coagulation	B-MED
cascades	I-MED
in	O
sepsis	B-MED
.	O
	
therefore	O
,	O
our	O
study	B-MED
investigated	B-MED
the	O
influence	B-MED
of	O
plasmatic	B-MED
nucleic	B-MED
acids	I-MED
on	O
coagulation	B-MED
in	O
septic	B-MED
patients	B-MED
in	O
comparison	B-MED
to	O
patients	B-MED
after	O
major	O
abdominal	B-MED
surgery	I-MED
.	O
	
a	O
total	O
of	O
15	O
patients	B-MED
with	O
sepsis	B-MED
,	O
10	O
postoperative	B-MED
patients	B-MED
,	O
and	O
10	O
healthy	B-MED
volunteers	I-MED
were	O
included	B-MED
in	O
this	O
longitudinal	B-MED
study	I-MED
.	O
	
blood	B-MED
was	O
collected	B-MED
at	O
sepsis	B-MED
onset	B-MED
and	O
after	O
surgery	B-MED
respectively	O
,	O
as	O
well	O
as	O
after	O
24	O
,	O
72	O
and	O
168	O
h	O
.	O
	
levels	B-MED
of	O
cfdna	B-MED
and	O
exrna	B-MED
were	O
measured	B-MED
by	O
quantitative	B-MED
probe-based	B-MED
polymerase	B-MED
chain	I-MED
reaction	I-MED
.	O
	
in	O
addition	O
,	O
thromboelastography	B-MED
for	O
coagulation	B-MED
as	O
well	O
as	O
thromboaggregometry	B-MED
for	O
platelet	B-MED
function	I-MED
was	O
conducted	O
.	O
	
both	O
cfdna	B-MED
and	O
exrna	B-MED
were	O
elevated	B-MED
in	O
patients	B-MED
with	O
sepsis	B-MED
compared	B-MED
with	O
postoperative	B-MED
patients	B-MED
and	O
healthy	B-MED
volunteers	I-MED
.	O
	
while	O
higher	B-MED
exrna	B-MED
levels	B-MED
correlated	B-MED
with	O
a	O
faster	B-MED
clotting	I-MED
time	I-MED
and	O
more	O
stable	B-MED
clots	I-MED
,	O
cfdna	B-MED
correlated	B-MED
with	O
a	O
shorter	B-MED
clotting	I-MED
time	I-MED
but	O
also	O
less	O
fibrinolysis	B-MED
.	O
	
in	O
addition	O
,	O
higher	B-MED
cfdna	B-MED
seems	O
to	O
be	O
associated	B-MED
with	I-MED
kidney	B-MED
dysfunction	I-MED
as	O
well	O
as	O
with	O
general	O
markers	B-MED
of	O
cell	B-MED
damage	I-MED
lactate	B-MED
dehydrogenase	I-MED
and	O
lactate	B-MED
.	O
	
both	O
nucleic	B-MED
acid	I-MED
species	O
might	O
be	O
associated	B-MED
with	I-MED
different	B-MED
effects	B-MED
on	O
coagulation	B-MED
during	O
sepsis	B-MED
,	O
with	O
an	O
overall	B-MED
procoagulatory	B-MED
influence	B-MED
.	O
	
for	O
this	O
reason	O
,	O
individualized	B-MED
therapeutic	B-MED
approaches	I-MED
in	O
patients	B-MED
suffering	B-MED
from	O
coagulation	B-MED
-	O
associated	B-MED
organ	B-MED
dysfunction	I-MED
association	B-MED
of	O
fat	B-MED
mass	I-MED
and	O
obesity	B-MED
-	O
associated	B-MED
gene	B-MED
variant	I-MED
with	O
lifestyle	B-MED
factors	B-MED
and	O
body	B-MED
fat	I-MED
in	O
indian	B-MED
children	B-MED
common	O
intronic	B-MED
variants	I-MED
of	O
the	O
fat	B-MED
mass	I-MED
and	O
obesity	B-MED
-	O
associated	B-MED
fto	B-MED
gene	I-MED
have	O
been	O
associated	B-MED
with	I-MED
obesity	B-MED
-related	O
traits	B-MED
in	O
humans	B-MED
.	O
	
1	O
the	O
aim	O
of	O
this	O
study	B-MED
is	O
to	O
study	B-MED
the	O
distribution	O
of	O
fto	B-MED
gene	I-MED
variants	B-MED
across	O
different	O
body	B-MED
mass	I-MED
index	I-MED
bmi	B-MED
categories	O
and	O
2	O
to	O
explore	O
the	O
association	B-MED
between	O
fto	B-MED
gene	I-MED
variants	B-MED
and	O
lifestyle	B-MED
factors	B-MED
in	O
obese	B-MED
and	O
normal	B-MED
weight	I-MED
indian	B-MED
children	B-MED
.	O
	
fifty-six	O
children	B-MED
26	O
boys	B-MED
,	O
mean	O
age	B-MED
10.3	O
2.2	O
years	B-MED
were	O
studied	B-MED
.	O
	
height	B-MED
,	O
weight	B-MED
,	O
and	O
waist	B-MED
and	O
hip	B-MED
circumference	I-MED
were	O
measured	B-MED
.	O
	
physical	B-MED
activity	I-MED
questionnaire	B-MED
and	O
food	B-MED
intake	B-MED
food	B-MED
frequency	I-MED
questionnaire	I-MED
were	O
assessed	B-MED
.	O
	
body	B-MED
fat	I-MED
percentage	I-MED
%bf	B-MED
was	O
measured	O
by	O
dual-energy	B-MED
x-ray	I-MED
absorptiometry	I-MED
.	O
	
fto	B-MED
allelic	I-MED
variants	I-MED
at	O
rs9939609	B-MED
site	I-MED
were	O
detected	O
by	O
sybr	B-MED
green	I-MED
amplification	I-MED
refractory	I-MED
mutation	I-MED
system	I-MED
real-time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
using	O
allele	B-MED
-	O
specific	B-MED
primers	B-MED
.	O
	
generalized	B-MED
linear	I-MED
model	I-MED
was	O
used	O
to	O
investigate	B-MED
the	O
simultaneous	B-MED
influence	B-MED
of	O
genetic	B-MED
and	O
lifestyle	B-MED
factors	B-MED
on	O
%bf	B-MED
.	O
	
mean	O
height	B-MED
,	O
weight	B-MED
,	O
and	O
bmi	B-MED
of	O
normal	B-MED
and	O
obese	B-MED
children	B-MED
were	O
130.6	O
7.1	O
versus	O
143.2	O
15.6	O
,	O
24.0	O
5.2	O
versus	O
53.1	O
15.8	O
,	O
and	O
13.9	O
2.1	O
versus	O
25.3	O
3.2	O
,	O
respectively	O
.	O
	
the	O
frequency	O
of	O
aa	B-MED
allele	I-MED
was	O
57%	O
among	O
obese	B-MED
children	B-MED
and	O
35%	O
in	O
normal	B-MED
weight	I-MED
children	B-MED
.	O
	
children	B-MED
with	O
the	O
aa	B-MED
allele	I-MED
who	O
were	O
obese	B-MED
had	O
least	O
physical	B-MED
activity	I-MED
,	O
whereas	O
children	B-MED
with	O
at	B-MED
allele	I-MED
and	O
obesity	B-MED
had	O
the	O
highest	B-MED
intake	B-MED
of	I-MED
calories	I-MED
when	O
compared	B-MED
to	O
children	B-MED
who	O
had	O
at	B-MED
allele	I-MED
and	O
were	O
normal	B-MED
.	O
	
%bf	B-MED
was	O
positively	O
associated	B-MED
with	I-MED
aa	B-MED
alleles	I-MED
and	O
junk	B-MED
food	I-MED
intake	B-MED
and	O
negatively	O
with	O
healthy	B-MED
food	B-MED
intake	B-MED
and	O
moderate	O
physical	B-MED
activity	I-MED
.	O
	
healthy	B-MED
lifestyle	I-MED
with	O
high	O
physical	B-MED
activity	I-MED
and	O
diet	B-MED
low	B-MED
in	O
calories	B-MED
and	O
fat	B-MED
may	O
help	O
in	O
modifying	B-MED
the	O
risk	B-MED
imposed	O
by	O
fto	B-MED
variants	I-MED
in	O
museum	B-MED
specimen	B-MED
data	B-MED
reveal	O
emergence	O
of	O
a	O
plant	B-MED
disease	I-MED
may	O
be	O
linked	O
to	O
increases	B-MED
in	O
the	O
insect	B-MED
vector	I-MED
population	O
the	O
emergence	O
rate	O
of	O
new	O
plant	O
diseases	O
is	O
increasing	O
due	O
to	O
novel	O
introductions	O
,	O
climate	O
change	O
,	O
and	O
changes	O
in	O
vector	O
populations	O
,	O
posing	O
risks	O
to	O
agricultural	O
sustainability	O
.	O
	
assessing	O
and	O
managing	O
future	O
disease	O
risks	O
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary	O
and	O
historical	O
emergence	O
events	O
.	O
	
since	O
the	O
mid-1990s	O
,	O
potato	O
growers	O
in	O
the	O
western	O
united	O
states	O
,	O
mexico	O
,	O
and	O
central	O
america	O
have	O
experienced	O
severe	O
yield	O
loss	O
from	O
zebra	O
chip	O
disease	O
and	O
have	O
responded	O
by	O
increasing	O
insecticide	O
use	O
to	O
suppress	O
populations	O
of	O
the	O
insect	B-MED
vector	I-MED
,	O
the	O
potato	O
psyllid	O
,	O
bactericera	O
cockerelli	O
hemiptera	O
triozidae	O
.	O
	
despite	O
the	O
severe	O
nature	O
of	O
zebra	O
chip	O
outbreaks	O
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown	O
.	O
	
we	O
tested	O
the	O
hypotheses	O
that	O
1	O
b	O
.	O
	
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
in	O
california	O
and	O
2	O
such	O
increases	O
are	O
related	O
to	O
climate	O
change	O
,	O
specifically	O
warmer	O
winters	O
.	O
	
we	O
compiled	O
a	O
dataset	O
of	O
87	O
museum	O
specimen	O
occurrence	O
records	O
across	O
the	O
order	O
hemiptera	O
collected	O
between	O
1900	O
and	O
2014	O
.	O
	
we	O
then	O
analyzed	O
changes	O
in	O
b	O
.	O
	
cockerelli	O
distribution	O
using	O
a	O
hierarchical	O
occupancy	O
model	O
using	O
changes	O
in	O
background	O
species	O
lists	O
to	O
correct	O
for	O
collecting	O
effort	O
.	O
	
we	O
found	O
evidence	O
that	O
b	O
.	O
	
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
.	O
	
however	O
,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate	O
changes	O
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	O
.	O
	
to	O
the	O
extent	O
that	O
species	O
occupancy	O
is	O
related	O
to	O
abundance	O
,	O
our	O
analysis	O
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	O
that	O
b	O
.	O
	
cockerelli	O
population	I-MED
abundance	O
has	O
increased	O
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
b	O
.	O
	
cockerelli	O
population	O
dynamics	O
to	O
zebra	O
chip	O
epidemics	O
.	O
	
finally	O
,	O
we	O
demonstrate	O
how	O
this	O
historical	O
macro-ecological	O
approach	O
provides	O
a	O
general	O
framework	O
for	O
comparative	O
risk	O
assessment	O
of	O
future	O
pest	O
and	O
insect	O
vector	O
outbreaks	O
.	O
	
this	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
	
all	O
rights	O
effect	B-MED
of	O
halotolerant	B-MED
rhizobacteria	I-MED
isolated	B-MED
from	O
halophytes	B-MED
on	O
the	O
growth	B-MED
of	O
sugar	B-MED
beet	I-MED
beta	B-MED
vulgaris	I-MED
l	I-MED
under	O
salt	B-MED
stress	I-MED
utilization	B-MED
of	O
rhizobacteria	B-MED
that	O
have	O
associated	B-MED
with	I-MED
plant	B-MED
roots	I-MED
in	O
harsh	B-MED
environments	B-MED
could	O
be	O
a	O
feasible	B-MED
strategy	I-MED
to	O
deal	O
with	O
limits	O
to	O
agricultural	B-MED
production	I-MED
caused	O
by	O
soil	B-MED
salinity	B-MED
.	O
	
halophytes	B-MED
occur	O
naturally	O
in	O
high	B-MED
-	O
salt	B-MED
environments	I-MED
,	O
and	O
their	O
roots	B-MED
may	O
be	O
associated	B-MED
with	I-MED
promising	O
microbial	B-MED
candidates	I-MED
for	O
promoting	B-MED
growth	B-MED
and	O
salt	B-MED
tolerance	I-MED
in	O
crops	B-MED
.	O
	
this	O
study	B-MED
aimed	O
to	O
isolate	B-MED
efficient	O
halotolerant	B-MED
plant	I-MED
-	O
growth	B-MED
-	O
promoting	B-MED
rhizobacterial	B-MED
strains	B-MED
from	O
halophytes	B-MED
and	O
evaluate	B-MED
their	O
activity	B-MED
and	O
effects	B-MED
on	O
sugar	B-MED
beet	I-MED
beta	B-MED
vulgaris	I-MED
l	I-MED
growth	B-MED
under	O
salinity	B-MED
stress	I-MED
.	O
	
a	O
total	O
of	O
23	O
isolates	B-MED
were	O
initially	O
screened	O
for	O
their	O
ability	B-MED
to	O
secrete	O
1-aminocyclopropane-1-carboxylate	B-MED
deaminase	I-MED
acd	B-MED
as	O
well	O
as	O
other	O
plant-growth	B-MED
-	O
promoting	B-MED
characteristics	B-MED
and	O
subsequently	O
identified	B-MED
by	O
sequencing	B-MED
the	O
16s	B-MED
rrna	I-MED
gene	B-MED
.	O
	
three	O
isolates	B-MED
,	O
identified	O
as	O
micrococcus	B-MED
yunnanensis	I-MED
,	O
planococcus	B-MED
rifietoensis	I-MED
and	O
variovorax	B-MED
paradoxus	I-MED
,	O
enhanced	B-MED
salt	B-MED
stress	I-MED
tolerance	B-MED
remarkably	O
in	O
sugar	B-MED
beet	I-MED
,	O
resulting	B-MED
in	I-MED
greater	B-MED
seed	B-MED
germination	I-MED
and	O
plant	B-MED
biomass	B-MED
,	O
higher	B-MED
photosynthetic	B-MED
capacity	B-MED
and	O
lower	B-MED
stress	B-MED
-	O
induced	B-MED
ethylene	B-MED
production	B-MED
at	O
different	B-MED
nacl	B-MED
concentrations	B-MED
50-125	O
mm	O
.	O
	
these	O
results	B-MED
demonstrate	O
that	O
salinity	B-MED
-	O
adapted	B-MED
,	O
acd	B-MED
-producing	O
bacteria	B-MED
isolated	B-MED
from	O
halophytes	B-MED
could	O
promote	B-MED
sugar	B-MED
beet	I-MED
growth	B-MED
under	O
saline	B-MED
stress	I-MED
conditions	I-MED
.	O
	
potential	B-MED
sunitinib	B-MED
-	O
induced	B-MED
coronary	B-MED
artery	I-MED
and	O
aortic	B-MED
dissections	I-MED
small-molecule	B-MED
multitargeted	I-MED
tyrosine	I-MED
kinase	I-MED
inhibitor	I-MED
tki	I-MED
therapy	I-MED
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-MED
.	O
	
these	O
drugs	B-MED
have	O
been	O
associated	B-MED
with	I-MED
cardiovascular	B-MED
toxicity	I-MED
,	O
including	O
aortic	B-MED
dissection	I-MED
.	O
	
to	O
our	O
knowledge	B-MED
,	O
this	O
is	O
the	O
first	B-MED
time	I-MED
that	O
a	O
coronary	B-MED
dissection	I-MED
potentially	B-MED
associated	B-MED
with	I-MED
a	O
tki	B-MED
treatment	I-MED
recovery	B-MED
of	I-MED
orthographic	B-MED
processing	B-MED
after	O
stroke	B-MED
a	O
longitudinal	B-MED
fmri	B-MED
study	O
an	O
intact	O
orthographic	B-MED
processing	B-MED
system	O
is	O
critical	O
for	O
normal	B-MED
reading	I-MED
and	I-MED
spelling	I-MED
.	O
	
here	O
we	O
investigate	O
the	O
neural	B-MED
changes	I-MED
associated	O
with	O
impairment	B-MED
and	O
subsequent	O
recovery	B-MED
of	O
the	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	B-MED
left	B-MED
posterior	I-MED
cerebral	I-MED
artery	I-MED
pca	I-MED
stroke	I-MED
.	O
	
this	O
work	O
describes	O
a	O
longitudinal	B-MED
case	I-MED
study	I-MED
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
mmy	B-MED
,	O
with	O
impairments	B-MED
in	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
for	O
reading	B-MED
and	I-MED
spelling	I-MED
at	O
stroke	B-MED
onset	B-MED
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-MED
.	O
	
we	O
tested	O
the	O
hypothesis	B-MED
that	O
this	O
acute	B-MED
impairment	B-MED
to	O
reading	B-MED
and	I-MED
spelling	I-MED
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	B-MED
of	I-MED
neural	B-MED
activation	I-MED
in	O
the	O
left	B-MED
fusiform	I-MED
gyrus	I-MED
fg	B-MED
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	B-MED
of	I-MED
neural	B-MED
activation	I-MED
in	O
this	O
region	O
.	O
	
mmy's	B-MED
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	B-MED
changes	I-MED
because	O
she	O
demonstrated	O
a	O
behavioral	B-MED
recovery	B-MED
of	I-MED
naming	I-MED
as	I-MED
well	I-MED
i.e	O
,	O
if	O
there	O
is	O
neural	B-MED
recovery	I-MED
for	O
reading	B-MED
and	I-MED
spelling	I-MED
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	B-MED
changes	I-MED
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	B-MED
processing	B-MED
.	O
	
to	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	B-MED
behavioral	I-MED
and	O
functional	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
fmri	B-MED
data	O
of	O
reading	B-MED
,	O
spelling	B-MED
,	O
and	O
visual	B-MED
object	I-MED
naming	I-MED
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	B-MED
.	O
	
in	O
confirmation	O
of	O
our	O
hypothesis	B-MED
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
was	O
associated	O
with	O
up-regulation	B-MED
of	O
neural	B-MED
activation	I-MED
in	O
areas	O
previously	O
associated	O
with	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
i.e	O
,	O
the	O
left	B-MED
mid-fg	I-MED
and	O
inferior	B-MED
frontal	I-MED
junction	I-MED
ifj	B-MED
.	O
	
furthermore	O
,	O
these	O
neural	B-MED
changes	I-MED
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	B-MED
processing	B-MED
,	O
as	O
they	O
were	O
observed	O
for	O
reading	B-MED
and	O
spelling	B-MED
,	O
but	O
not	O
for	O
visual	B-MED
object	I-MED
naming	I-MED
within	O
the	O
left	B-MED
mid-fg	I-MED
.	O
	
this	O
work	O
shows	O
that	O
left	B-MED
pca	I-MED
stroke	I-MED
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
system	O
,	O
not	O
only	O
in	O
the	O
posterior	B-MED
region	I-MED
adjacent	B-MED
to	O
the	O
stroke	B-MED
,	O
but	O
also	O
in	O
relatively	O
distant	B-MED
frontal	I-MED
orthographic	B-MED
processing	B-MED
nodal	B-MED
skip	B-MED
metastasis	B-MED
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
a	O
cohort	B-MED
study	I-MED
nodal	B-MED
skip	B-MED
metastasis	B-MED
is	O
a	O
prognostic	B-MED
factor	I-MED
in	O
some	O
sites	O
of	O
malignancies	B-MED
,	O
but	O
its	O
role	O
in	O
esophageal	B-MED
cancer	I-MED
is	O
still	O
unclear	B-MED
.	O
	
the	O
present	O
study	O
aimed	O
to	O
investigate	B-MED
occurrence	O
and	O
effect	B-MED
of	O
nodal	B-MED
skip	B-MED
metastases	O
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
.	O
	
all	O
578	O
patients	B-MED
undergoing	O
esophagectomy	B-MED
for	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
at	O
the	O
center	B-MED
for	I-MED
esophageal	I-MED
diseases	I-MED
located	O
in	O
padova	B-MED
between	O
january	B-MED
1992	O
and	O
december	B-MED
2010	O
were	O
retrospectively	B-MED
evaluated	I-MED
.	O
	
selection	B-MED
criteria	I-MED
were	O
r0	B-MED
resection	I-MED
,	O
pathological	B-MED
m0	B-MED
stage	I-MED
and	O
pathological	B-MED
lymph	B-MED
node	I-MED
involvement	I-MED
.	O
	
patients	B-MED
receiving	O
neoadjuvant	B-MED
therapy	I-MED
were	O
excluded	O
.	O
	
the	O
selection	O
identified	O
88	O
patients	B-MED
with	O
lymph	B-MED
node	I-MED
involvement	I-MED
confirmed	O
by	O
pathological	B-MED
evaluation	B-MED
.	O
	
sixteen	O
patients	B-MED
18.2	O
had	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
.	O
	
adjusting	O
for	O
the	O
number	O
of	O
lymph	B-MED
node	I-MED
metastases	I-MED
,	O
patient	B-MED
with	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
had	O
similar	O
5-year	O
overall	B-MED
survival	I-MED
14%	O
vs	O
.	O
	
13%	O
,	O
p	O
=	O
0.93	O
and	O
5-year	O
disease	B-MED
free	I-MED
survival	I-MED
14%	O
vs	O
.	O
	
9%	O
,	O
p	O
=	O
0.48	O
compared	O
to	O
patients	B-MED
with	O
both	O
peritumoral	B-MED
and	O
distant	B-MED
lymph	B-MED
node	I-MED
metastases	I-MED
.	O
	
the	O
risk	O
difference	O
of	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
was	O
-24	O
95%	O
c.i	B-MED
.	O
	
-43	O
to	O
-5	O
in	O
patients	B-MED
with	O
more	O
than	O
one	O
lymph	B-MED
node	I-MED
metastasis	I-MED
compared	O
to	O
those	O
with	O
one	O
lymph	B-MED
node	I-MED
metastasis	I-MED
-2	O
95%	O
c.i	B-MED
.	O
	
-29	O
to	O
25.2	O
in	O
middle	B-MED
thoracic	B-MED
esophagus	I-MED
and	O
-23	O
95%	O
c.i	B-MED
.	O
	
-47	O
to	O
1.8	O
in	O
lower	B-MED
thoracic	B-MED
esophagus	I-MED
compared	O
to	O
upper	B-MED
thoracic	B-MED
esophagus	I-MED
18.1	O
95%	O
c.i	B-MED
.	O
	
3.2	O
to	O
33.0	O
in	O
clinical	B-MED
n0	B-MED
stage	I-MED
vs	O
.	O
	
clinical	B-MED
n+	B-MED
stage	I-MED
.	O
	
nodal	B-MED
skip	B-MED
metastasis	B-MED
is	O
a	O
common	O
pattern	O
of	O
metastatic	B-MED
lymph	I-MED
involvement	I-MED
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
.	O
	
however	O
,	O
neither	B-MED
overall	B-MED
survival	I-MED
nor	O
disease	B-MED
free	I-MED
survival	I-MED
are	O
associated	B-MED
with	I-MED
nodal	B-MED
skip	B-MED
metastasis	B-MED
association	B-MED
of	O
leukemia	B-MED
inhibitory	I-MED
factor	I-MED
gene	I-MED
polymorphism	B-MED
and	O
in	B-MED
vitro	I-MED
fertilization	B-MED
outcome	B-MED
in	O
a	O
population	B-MED
in	O
northern	B-MED
iran	I-MED
several	O
studies	B-MED
have	O
been	O
demonstrated	O
that	O
endometrial	B-MED
leukemia	B-MED
inhibitory	I-MED
factor	I-MED
lif	B-MED
is	O
important	O
in	O
embryo	B-MED
implantation	I-MED
.	O
	
lif	B-MED
is	O
a	O
secreted	O
glycoprotein	B-MED
with	O
a	O
variety	O
of	O
biological	B-MED
functions	I-MED
including	O
stimulation	B-MED
of	O
cell	B-MED
proliferation	I-MED
,	O
differentiation	B-MED
and	O
survival	B-MED
that	O
are	O
all	O
essential	B-MED
for	O
blastocyete	B-MED
development	B-MED
and	O
implantation	B-MED
.	O
	
the	O
lif	B-MED
receptor	I-MED
activates	B-MED
several	O
signaling	B-MED
pathways	I-MED
in	O
diverse	B-MED
cell	I-MED
types	I-MED
,	O
including	O
jak/stat	B-MED
,	O
mapk	B-MED
and	O
pi3-kinase	B-MED
pathways	B-MED
in	O
the	O
endometrium	B-MED
of	O
fertile	B-MED
woman	B-MED
.	O
	
it	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	B-MED
of	O
lif	B-MED
in	O
proliferative	B-MED
phase	B-MED
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	B-MED
of	O
implantation	B-MED
.	O
	
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
association	B-MED
between	O
maternal	B-MED
genotype	B-MED
of	O
snp	B-MED
3951c/t	I-MED
lif	B-MED
and	O
in	B-MED
vitro	I-MED
fertilization	I-MED
and	O
embryo	B-MED
transfer	I-MED
ivf	B-MED
-	O
et	B-MED
outcome	B-MED
in	O
infertile	B-MED
women	B-MED
.	O
	
this	O
case-control	B-MED
study	I-MED
was	O
comprised	O
of	O
infertile	B-MED
patients	B-MED
n=70	O
and	O
women	B-MED
having	O
one	O
healthy	B-MED
child	I-MED
as	O
controls	B-MED
n=73	O
.	O
	
genotyping	B-MED
for	O
snp-3951c/t	B-MED
was	O
performed	O
by	O
pcr/rflp	B-MED
.	O
	
allele	B-MED
and	O
genotype	B-MED
distribution	B-MED
did	O
not	O
differ	O
significantly	O
between	O
patients	B-MED
and	O
controls	B-MED
p>0	O
.	O
	
the	O
lif	B-MED
genotype	B-MED
frequencies	B-MED
amongst	O
the	O
70	O
cases	B-MED
were	O
c/c	B-MED
=40%	O
,	O
c/t	B-MED
=52	O
and	O
t/t	B-MED
=7	O
the	O
c	O
and	O
t	O
allele	B-MED
frequencies	B-MED
were	O
66%	O
and	O
34%	O
,	O
respectively	O
.	O
	
the	O
lif	B-MED
genotype	B-MED
frequencies	B-MED
amongst	O
the	O
73	O
controls	B-MED
were	O
c/c	B-MED
=45	O
,	O
c/t	B-MED
=50	O
and	O
t/t	B-MED
=4	O
the	O
c	O
and	O
t	O
allele	B-MED
frequencies	B-MED
were	O
70%	O
and	O
30%	O
,	O
respectively	O
.	O
	
in	O
conclusion	O
,	O
the	O
results	B-MED
of	O
this	O
study	O
indicate	O
that	O
snp	B-MED
3951c/t	I-MED
of	O
lif	B-MED
may	O
not	O
be	O
associated	B-MED
with	I-MED
ivf	B-MED
-	O
et	B-MED
outcome	B-MED
in	O
this	O
population	B-MED
.	O
	
although	O
more	O
studies	B-MED
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	B-MED
and	O
control	B-MED
subjects	I-MED
to	O
confirm	B-MED
our	O
anti	B-MED
angiogenic	I-MED
effect	I-MED
of	O
chebulagic	B-MED
acid	I-MED
involves	O
inhibition	B-MED
of	O
vegfr2	B-MED
and	O
gsk3β	B-MED
dependent	I-MED
signaling	I-MED
pathways	I-MED
inhibition	B-MED
of	O
angiogenesis	B-MED
is	O
a	O
useful	O
strategy	B-MED
to	O
prevent	B-MED
cancer	B-MED
growth	I-MED
,	O
which	O
targets	B-MED
new	O
vessels	B-MED
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	B-MED
tumor	B-MED
cells	I-MED
.	O
	
endothelial	B-MED
cells	I-MED
can	O
use	O
a	O
number	O
of	O
different	O
pathways	B-MED
to	O
cause	O
angiogenesis	B-MED
and	O
each	O
step	O
in	O
these	O
pathways	B-MED
can	O
be	O
targeted	B-MED
.	O
	
the	O
use	O
of	O
multi	B-MED
targeted	I-MED
drugs	I-MED
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O
	
our	O
previous	O
results	O
have	O
shown	O
the	O
anti	B-MED
angiogenic	I-MED
effect	I-MED
of	O
chebulagic	B-MED
acid	I-MED
-	O
a	O
benzopyran	B-MED
tannin	B-MED
present	O
in	O
the	O
fruits	B-MED
of	O
terminalia	B-MED
chebula	I-MED
.	O
	
the	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	B-MED
mechanism	I-MED
of	O
the	O
anti	B-MED
angiogenic	I-MED
effect	I-MED
of	O
chebulagic	B-MED
acid	I-MED
.	O
	
results	O
of	O
our	O
investigations	O
using	O
molecular	B-MED
docking	I-MED
studies	I-MED
and	O
huvecs	B-MED
in	O
culture	B-MED
suggested	O
that	O
chebulagic	B-MED
acid	I-MED
inhibited	B-MED
gsk-3β	B-MED
dependent	B-MED
β-catenin	B-MED
phosphorylation	B-MED
,	O
an	O
important	O
mediator	O
of	O
ve-cadherin	B-MED
/	O
β-catenin	B-MED
signaling	B-MED
and	O
vegfr2	B-MED
phosphorylation	B-MED
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
vegf	B-MED
signaling	I-MED
.	O
	
chebulagic	B-MED
acid	I-MED
inhibits	B-MED
angiogenesis	B-MED
by	O
blocking	B-MED
both	O
vegf	B-MED
/	O
vegfr2	B-MED
and	O
cell-cell	B-MED
contact	I-MED
dependent	I-MED
downstream	I-MED
signaling	I-MED
pathway	I-MED
.	O
	
identification	O
of	O
protective	O
b-cell	B-MED
epitopes	I-MED
within	O
the	O
novel	O
malaria	B-MED
vaccine	I-MED
candidate	O
p	B-MED
.	O
	
falciparum	I-MED
schizont	I-MED
egress	I-MED
antigen-1	I-MED
naturally	B-MED
-acquired	O
antibodies	B-MED
to	O
pfsea-1a	B-MED
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-MED
in	O
children	B-MED
.	O
	
vaccination	B-MED
of	O
mice	B-MED
with	O
pbsea-1a	B-MED
decreases	O
parasitemia	B-MED
and	O
prolongs	O
survival	O
following	O
plasmodium	B-MED
berghei	I-MED
anka	I-MED
challenge	O
.	O
	
to	O
enhance	O
the	O
immunogenicity	B-MED
of	O
pfsea-1a	B-MED
,	O
we	O
identified	O
five	O
linear	O
,	O
b-cell	B-MED
epitopes	I-MED
using	O
peptide	B-MED
microarrays	B-MED
probed	O
with	O
anti-sera	B-MED
from	O
rpfsea-1a	B-MED
-	O
vaccinated	B-MED
non-human	O
primates	B-MED
.	O
	
we	O
evaluated	B-MED
the	O
relationship	O
between	O
epitope	B-MED
-specific	O
antibody	B-MED
levels	O
and	O
protection	O
from	O
parasitemia	B-MED
in	O
a	O
longitudinal	O
treatment	B-MED
-	O
reinfection	B-MED
cohort	B-MED
in	O
western	B-MED
kenya	I-MED
.	O
	
antibodies	B-MED
to	O
three	O
epitopes	B-MED
were	O
associated	O
with	O
16-17%	O
decreased	O
parasitemia	B-MED
over	O
an	O
18-	O
week	B-MED
high	O
transmission	B-MED
season	O
.	O
	
we	O
are	O
currently	O
designing	O
immunogens	B-MED
to	O
enhance	O
antibody	B-MED
responses	I-MED
to	O
these	O
three	O
estrogen	B-MED
deficiency	B-MED
accelerates	B-MED
lumbar	B-MED
facet	I-MED
joints	I-MED
arthritis	B-MED
dramatic	O
increase	B-MED
in	O
the	O
prevalence	B-MED
of	O
lumbar	B-MED
facet	I-MED
joint	I-MED
lfj	B-MED
arthritis	B-MED
in	O
women	B-MED
around	O
the	O
age	B-MED
of	O
menopause	B-MED
indicates	O
a	O
protective	B-MED
role	I-MED
for	O
estrogen	B-MED
in	O
lfj	B-MED
arthritis	B-MED
.	O
	
to	O
date	O
,	O
there	O
is	O
no	B-MED
evidence	I-MED
for	O
this	O
indication	B-MED
and	O
the	O
mechanism	B-MED
of	O
such	O
an	O
effect	B-MED
remains	O
poorly	O
understood	O
.	O
	
in	O
this	O
study	B-MED
,	O
ovariectomized	B-MED
ovx	I-MED
mice	I-MED
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-MED
-	O
deficient	B-MED
status	B-MED
of	O
post-menopausal	B-MED
women	B-MED
.	O
	
micro-ct	B-MED
and	O
immunohistochemistry	B-MED
was	O
employed	O
to	O
assess	B-MED
the	O
morphological	B-MED
and	O
molecular	B-MED
changes	B-MED
in	O
ovariectomy	B-MED
-	O
induced	B-MED
lfj	B-MED
arthritis	B-MED
.	O
	
the	O
results	B-MED
show	O
that	O
the	O
lfj	B-MED
subchondral	B-MED
bone	I-MED
mass	I-MED
was	O
significantly	O
decreased	B-MED
in	O
ovx	B-MED
mice	I-MED
,	O
with	O
increased	B-MED
cavities	B-MED
on	O
the	O
interface	B-MED
of	O
the	O
subchondral	B-MED
bone	I-MED
.	O
	
severe	B-MED
cartilage	B-MED
degradation	B-MED
was	O
observed	O
in	O
ovariectomy	B-MED
-	O
induced	B-MED
lfj	B-MED
arthritis	B-MED
.	O
	
increased	B-MED
blood	B-MED
vessels	I-MED
and	O
innervations	B-MED
were	O
also	O
found	O
in	O
degenerated	B-MED
lfj	B-MED
,	O
particularly	O
in	O
the	O
subchondral	B-MED
bone	I-MED
area	B-MED
.	O
	
17β-estradiol	B-MED
treatment	B-MED
efficiently	O
suppressed	B-MED
lfj	B-MED
subchondral	B-MED
bone	I-MED
turnover	I-MED
,	O
markedly	O
inhibited	B-MED
cartilage	B-MED
degradation	B-MED
,	O
and	O
increased	B-MED
blood	B-MED
vessel	I-MED
and	O
nerve	B-MED
ending	I-MED
growth	B-MED
in	O
degenerated	B-MED
lfj	B-MED
in	O
ovx	B-MED
mice	I-MED
.	O
	
our	O
study	B-MED
reveals	O
that	O
estrogen	B-MED
is	O
a	O
key	O
factor	B-MED
in	O
regulating	B-MED
lfj	I-MED
metabolism	I-MED
.	O
	
severe	B-MED
lfj	B-MED
degeneration	B-MED
occurs	O
when	O
estrogen	B-MED
is	O
absent	B-MED
in	B-MED
vivo	I-MED
.	O
	
collapsed	B-MED
subchondral	B-MED
bone	I-MED
may	O
be	O
the	O
initiation	B-MED
of	O
this	O
process	B-MED
,	O
and	O
estrogen	B-MED
replacement	I-MED
therapy	I-MED
can	O
effectively	O
prevent	O
degeneration	B-MED
of	O
lfj	B-MED
under	O
estrogen	B-MED
-	O
deficient	B-MED
conditions	B-MED
.	O
	
dexmedetomidine	B-MED
effect	B-MED
on	O
emergence	B-MED
agitation	I-MED
and	O
delirium	B-MED
in	O
children	B-MED
undergoing	O
laparoscopic	B-MED
hernia	I-MED
repair	I-MED
a	O
preliminary	B-MED
study	B-MED
objective	O
to	O
evaluate	O
the	O
safety	B-MED
and	O
efficacy	B-MED
of	O
dexmedetomidine	B-MED
dex	B-MED
to	O
prevent	O
emergence	B-MED
agitation	I-MED
ea	B-MED
and	O
delirium	B-MED
ed	B-MED
in	O
children	B-MED
undergoing	O
laparoscopic	B-MED
hernia	I-MED
repair	I-MED
under	O
general	B-MED
anesthesia	I-MED
.	O
	
methods	O
100	O
children	B-MED
1-5	O
years	B-MED
,	O
10-25	O
kg	O
were	O
randomized	B-MED
into	O
four	O
groups	B-MED
controls	B-MED
saline	B-MED
and	O
intravenous	B-MED
dex	B-MED
at	O
0.25	O
,	O
0.5	O
,	O
and	O
1.0	O
µg/kg	O
d1	B-MED
,	O
d2	B-MED
,	O
d3	B-MED
,	O
respectively	O
.	O
	
dex	B-MED
/	O
saline	B-MED
infusion	B-MED
was	O
started	O
following	O
anesthesia	B-MED
.	O
	
ea	B-MED
and	O
ed	B-MED
were	O
evaluated	O
on	O
a	O
5-point	B-MED
scale	I-MED
.	O
	
results	O
for	O
the	O
c	B-MED
,	O
d1	B-MED
,	O
d2	B-MED
,	O
and	O
d3	B-MED
groups	B-MED
,	O
respectively	O
,	O
ea	B-MED
frequencies	B-MED
were	O
45.8	O
,	O
30.4	O
,	O
12%	O
,	O
4%	O
ed	B-MED
frequencies	B-MED
29.1	O
,	O
13%	O
,	O
4%	O
,	O
4%	O
chipps	B-MED
scores	B-MED
8	O
,	O
6	O
,	O
3	O
,	O
3	O
sevoflurane	B-MED
doses	B-MED
from	O
13.2	O
3.4	O
controls	B-MED
to	O
9.4	O
3.5	O
ml	O
d3	B-MED
.	O
	
intervals	B-MED
until	O
mask	B-MED
removal	B-MED
/	O
spontaneous	B-MED
eye	I-MED
opening	I-MED
were	O
significantly	O
longer	B-MED
for	O
d2	B-MED
and	O
d3	B-MED
than	O
controls	B-MED
.	O
	
pacu	B-MED
stay	B-MED
was	O
longer	B-MED
for	O
d3	B-MED
.	O
	
conclusions	O
there	O
was	O
significantly	O
less	O
postoperative	B-MED
ea	B-MED
and	O
pain	B-MED
,	O
with	O
less	O
sevoflurane	B-MED
required	O
,	O
using	O
farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
lipid-polyethylene	B-MED
glycol-polymer	I-MED
hybrid	I-MED
nanoparticles	I-MED
for	O
treatment	B-MED
of	O
glioblastoma	B-MED
we	O
aimed	O
to	O
develop	O
lipid-polyethylene	B-MED
glycol	I-MED
peg	I-MED
hybrid	I-MED
nanoparticles	I-MED
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	B-MED
tissue	I-MED
with	O
active	B-MED
ingredient	I-MED
,	O
a	O
new	O
generation	B-MED
antineoplastic	B-MED
drug	I-MED
,	O
farnesylthiosalicylic	B-MED
acid	I-MED
fta	B-MED
for	O
treatment	B-MED
of	O
glioblastoma	B-MED
.	O
	
farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
poly	B-MED
acid	I-MED
distearoyl-glycerol-3-phospho-ethanolamine-n	I-MED
methoxy	I-MED
peg	I-MED
ammonium	I-MED
salt	I-MED
plga-dspe-peg	B-MED
with	O
or	O
without	O
1	B-MED
dotap	I-MED
hybrid	I-MED
nanoparticles	I-MED
has	O
been	O
prepared	B-MED
and	O
evaluated	B-MED
for	O
in-vitro	B-MED
characterization	I-MED
.	O
	
cytotoxicity	B-MED
of	O
fta-loaded	B-MED
nanoparticles	I-MED
along	O
with	O
its	O
efficacy	B-MED
on	O
rat	B-MED
glioma-2	I-MED
rg2	I-MED
cells	I-MED
was	O
also	O
evaluated	B-MED
both	O
in	B-MED
vitro	I-MED
in	O
comparison	O
with	O
non-malignant	B-MED
cell	I-MED
line	I-MED
,	O
l929	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
	
scanning	B-MED
electron	I-MED
microscopy	I-MED
studies	I-MED
showed	O
that	O
all	O
formulations	B-MED
prepared	I-MED
had	O
smooth	B-MED
surface	I-MED
and	O
spherical	B-MED
in	I-MED
shape	I-MED
.	O
	
fta	B-MED
and	O
fta-loaded	B-MED
nanoparticles	I-MED
have	O
cytotoxic	B-MED
activity	I-MED
against	O
rg2	B-MED
glioma	I-MED
cell	I-MED
lines	I-MED
in	O
cell	B-MED
culture	I-MED
studies	I-MED
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
dotap	B-MED
.	O
	
magnetic	B-MED
resonance	I-MED
imaging	I-MED
and	O
histopathologic	B-MED
evaluation	B-MED
on	O
rg2	B-MED
tumour	I-MED
cells	I-MED
in	O
rat	B-MED
glioma	I-MED
model	I-MED
49	O
female	O
wistar	B-MED
rats	I-MED
,	O
250-300	O
g	O
comparing	O
intravenous	B-MED
and	O
intratumoral	B-MED
injections	I-MED
of	O
the	O
drug	B-MED
have	O
been	O
performed	O
and	O
fta-loaded	B-MED
nanoparticles	I-MED
reduced	O
tumour	B-MED
size	I-MED
significantly	O
in	O
in-vivo	B-MED
studies	I-MED
,	O
with	O
higher	O
efficiency	B-MED
of	O
intratumoral	B-MED
administration	I-MED
than	O
intravenous	B-MED
route	I-MED
.	O
	
farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
plga-dspe-peg-dotap	B-MED
hybrid	I-MED
nanoparticles	I-MED
are	O
proven	O
to	O
be	O
effective	B-MED
against	O
glioblastoma	B-MED
in	O
both	O
in-vitro	B-MED
and	O
in-vivo	B-MED
experiments	I-MED
.	O
	
map	B-MED
learning	I-MED
and	O
working	B-MED
memory	I-MED
multimodal	O
learning	B-MED
strategies	I-MED
the	O
current	O
research	B-MED
investigated	O
whether	O
learning	B-MED
spatial	I-MED
information	B-MED
from	O
a	O
map	B-MED
involves	O
different	B-MED
modalities	I-MED
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	B-MED
memory	I-MED
.	O
	
in	O
four	O
experiments	O
,	O
participants	B-MED
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	B-MED
interference	B-MED
task	I-MED
high	O
cognitive	B-MED
load	I-MED
or	O
without	B-MED
interference	I-MED
low	O
cognitive	B-MED
load	I-MED
.	O
	
the	O
modality	B-MED
of	O
interference	B-MED
varied	O
between	O
experiments	O
.	O
	
experiment	O
1	O
used	O
a	O
tapping	B-MED
task	I-MED
visuospatial	B-MED
,	O
experiment	O
2	O
a	O
backwards	B-MED
counting	I-MED
task	I-MED
verbal	B-MED
,	O
experiment	O
3	O
an	O
articulatory	B-MED
suppression	B-MED
task	I-MED
verbal	B-MED
and	O
experiment	O
4	O
an	O
n-back	B-MED
task	I-MED
central	B-MED
executive	I-MED
.	O
	
spatial	B-MED
recall	I-MED
was	O
assessed	B-MED
in	O
two	O
tests	O
,	O
directional	B-MED
judgements	I-MED
and	O
map	B-MED
drawing	I-MED
.	O
	
cognitive	B-MED
load	I-MED
was	O
found	O
to	O
affect	O
spatial	B-MED
recall	I-MED
detrimentally	O
regardless	B-MED
of	O
interference	B-MED
modality	B-MED
.	O
	
the	O
findings	O
suggest	O
that	O
when	O
learning	B-MED
maps	I-MED
people	O
use	O
a	O
multimodal	O
learning	B-MED
strategy	I-MED
,	O
utilising	O
resources	B-MED
from	O
all	O
components	O
of	O
working	B-MED
memory	I-MED
.	O
	
4-anilino-2-pyridylquinazolines	B-MED
and	O
-	O
pyrimidines	B-MED
as	O
highly	O
potent	B-MED
and	O
nontoxic	B-MED
inhibitors	B-MED
of	O
breast	B-MED
cancer	I-MED
resistance	I-MED
protein	I-MED
abcg2	B-MED
multidrug	B-MED
resistance	I-MED
mdr	B-MED
mediated	O
by	O
atp-binding	B-MED
cassette	I-MED
abc	I-MED
transport	I-MED
proteins	I-MED
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B-MED
treatment	I-MED
of	O
cancer	B-MED
and	O
might	O
be	O
overcome	B-MED
by	O
inhibition	B-MED
of	O
the	O
transporter	B-MED
.	O
	
because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	B-MED
involved	O
in	O
the	O
transport	B-MED
process	I-MED
,	O
in	O
particular	O
for	O
breast	B-MED
cancer	I-MED
resistance	I-MED
protein	I-MED
bcrp	B-MED
/	O
abcg2	B-MED
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B-MED
of	O
abcg2	B-MED
.	O
	
in	O
this	O
study	O
,	O
we	O
investigated	B-MED
a	O
systematic	O
series	O
of	O
4-substituted-2-pyridylquinazolines	B-MED
in	O
terms	O
of	O
their	O
inhibitory	B-MED
potency	B-MED
as	O
well	O
as	O
selectivity	B-MED
toward	O
abcg2	B-MED
.	O
	
for	O
comparison	O
,	O
the	O
quinazoline	B-MED
scaffold	I-MED
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4-methylpyrimidine	B-MED
basic	O
structure	O
.	O
	
furthermore	O
,	O
the	O
cytotoxicity	B-MED
and	O
the	O
ability	O
to	O
reverse	B-MED
mdr	B-MED
was	O
tested	O
with	O
the	O
chemotherapeutic	B-MED
agents	I-MED
sn-38	B-MED
and	O
mitoxantrone	B-MED
mx	B-MED
.	O
	
interaction	B-MED
of	O
the	O
compounds	B-MED
with	O
abcg2	B-MED
was	O
investigated	B-MED
by	O
a	O
colorimetric	B-MED
atpase	B-MED
assay	B-MED
.	O
	
enzyme	B-MED
kinetic	I-MED
studies	I-MED
were	O
carried	O
out	O
with	O
hoechst	B-MED
33342	I-MED
as	O
fluorescent	B-MED
dye	I-MED
and	O
substrate	B-MED
of	O
abcg2	B-MED
to	O
elucidate	O
the	O
compounds	B-MED
binding	B-MED
modes	I-MED
.	O
	
the	O
value	O
of	O
biosamples	B-MED
in	O
smoking	B-MED
cessation	I-MED
trials	B-MED
a	O
review	O
of	O
genetic	B-MED
,	O
metabolomic	B-MED
,	O
and	O
epigenetic	B-MED
findings	B-MED
evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	B-MED
and	O
biomarkers	B-MED
are	O
associated	O
with	O
smoking	B-MED
cessation	I-MED
success	O
and	O
efficacy	O
of	O
smoking	B-MED
cessation	I-MED
treatments	I-MED
.	O
	
we	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking	B-MED
cessation	I-MED
treatment	I-MED
according	O
to	O
an	O
individual's	B-MED
genetic	B-MED
or	O
metabolic	B-MED
profile	I-MED
.	O
	
these	O
results	O
provide	O
important	O
incentive	B-MED
for	O
smoking	B-MED
cessation	I-MED
researchers	B-MED
to	O
collect	O
biosamples	B-MED
and	O
perform	O
genotyping	B-MED
in	O
research	B-MED
studies	I-MED
and	O
clinical	B-MED
trials	I-MED
.	O
	
acr	B-MED
appropriateness	B-MED
criteria	I-MED
radiologic	B-MED
management	B-MED
of	O
mesenteric	B-MED
ischemia	I-MED
mesenteric	B-MED
vascular	I-MED
insufficiency	I-MED
is	O
a	O
serious	O
medical	B-MED
condition	I-MED
that	O
may	O
lead	O
to	O
bowel	B-MED
infarction	I-MED
,	O
morbidity	B-MED
,	O
and	O
mortality	B-MED
that	O
may	O
approach	B-MED
50%	O
.	O
	
recommended	O
therapy	B-MED
for	O
acute	B-MED
mesenteric	I-MED
ischemia	I-MED
includes	O
aspiration	B-MED
embolectomy	B-MED
,	O
transcatheter	B-MED
thrombolysis	B-MED
,	O
and	O
angioplasty	B-MED
with	O
or	O
without	O
stenting	B-MED
for	O
the	O
treatment	B-MED
of	O
underlying	O
arterial	B-MED
stenosis	I-MED
.	O
	
nonocclusive	B-MED
mesenteric	I-MED
ischemia	I-MED
may	O
respond	O
to	O
transarterial	B-MED
infusion	I-MED
of	O
vasodilators	B-MED
such	O
as	O
nitroglycerin	B-MED
,	O
papaverine	B-MED
,	O
glucagon	B-MED
,	O
and	O
prostaglandin	B-MED
e1	I-MED
.	O
	
recommended	O
therapy	B-MED
for	O
chronic	B-MED
mesenteric	I-MED
ischemia	I-MED
includes	O
angioplasty	B-MED
with	O
or	O
without	O
stent	B-MED
placement	I-MED
and	O
,	O
if	O
an	O
endovascular	B-MED
approach	I-MED
is	O
not	O
possible	O
,	O
surgical	B-MED
bypass	I-MED
or	O
endarterectomy	B-MED
.	O
	
the	O
diagnosis	B-MED
of	O
median	B-MED
arcuate	I-MED
ligament	I-MED
syndrome	I-MED
is	O
controversial	O
,	O
but	O
surgical	B-MED
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	B-MED
situation	I-MED
.	O
	
venous	B-MED
mesenteric	B-MED
ischemia	I-MED
may	O
respond	O
to	O
systemic	B-MED
anticoagulation	B-MED
alone	O
.	O
	
transhepatic	B-MED
or	O
transjugular	B-MED
superior	B-MED
mesenteric	I-MED
vein	I-MED
catheterization	B-MED
and	I-MED
thrombolytic	I-MED
infusion	I-MED
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-MED
,	O
condition	B-MED
of	I-MED
the	I-MED
patient	I-MED
,	O
and	O
response	B-MED
to	O
systemic	B-MED
anticoagulation	B-MED
.	O
	
adjunct	B-MED
transjugular	B-MED
intrahepatic	I-MED
portosystemic	I-MED
shunt	I-MED
creation	I-MED
can	O
be	O
considered	O
for	O
outflow	O
improvement	B-MED
.	O
	
the	O
american	B-MED
college	I-MED
of	I-MED
radiology	I-MED
appropriateness	B-MED
criteria	I-MED
are	O
evidence-based	B-MED
guidelines	B-MED
for	O
specific	O
clinical	B-MED
conditions	I-MED
that	O
are	O
reviewed	B-MED
annually	B-MED
by	O
a	O
multidisciplinary	B-MED
expert	I-MED
panel	I-MED
.	O
	
the	O
guideline	B-MED
development	B-MED
and	O
revision	B-MED
include	O
an	O
extensive	B-MED
analysis	I-MED
of	O
current	O
medical	B-MED
literature	I-MED
from	O
peer-reviewed	B-MED
journals	I-MED
and	O
the	O
application	O
of	O
well-established	O
methodologies	B-MED
rand	B-MED
/	O
ucla	B-MED
appropriateness	B-MED
method	O
and	O
grading	B-MED
of	I-MED
recommendations	I-MED
assessment	I-MED
,	O
development	I-MED
,	O
and	I-MED
evaluation	I-MED
or	O
grade	B-MED
to	O
rate	O
the	O
appropriateness	B-MED
of	O
imaging	B-MED
and	O
treatment	B-MED
procedures	I-MED
for	O
specific	O
clinical	B-MED
scenarios	B-MED
.	O
	
in	O
those	O
instances	B-MED
where	O
evidence	B-MED
is	O
lacking	B-MED
or	O
equivocal	B-MED
,	O
expert	B-MED
opinion	I-MED
may	O
supplement	B-MED
the	O
available	O
evidence	B-MED
to	O
recommend	O
imaging	B-MED
or	O
blur	B-MED
perception	B-MED
throughout	O
the	O
visual	B-MED
field	I-MED
in	O
myopia	B-MED
and	O
emmetropia	B-MED
we	O
evaluated	B-MED
the	O
ability	B-MED
of	O
emmetropic	B-MED
and	O
myopic	B-MED
observers	B-MED
to	O
detect	B-MED
and	O
discriminate	B-MED
blur	B-MED
across	O
the	O
retina	B-MED
under	O
monocular	B-MED
or	O
binocular	B-MED
viewing	I-MED
conditions	B-MED
.	O
	
we	O
recruited	B-MED
39	O
young	B-MED
23-30	O
years	O
healthy	B-MED
adults	I-MED
n	O
=	O
19	O
myopes	B-MED
with	O
best-corrected	B-MED
visual	B-MED
acuity	I-MED
0.0	O
logmar	B-MED
20/20	I-MED
or	O
better	B-MED
in	O
each	O
eye	B-MED
and	O
no	B-MED
binocular	I-MED
or	O
accommodative	B-MED
dysfunction	I-MED
.	O
	
monocular	B-MED
and	O
binocular	B-MED
blur	B-MED
discrimination	B-MED
thresholds	B-MED
were	O
measured	B-MED
as	O
a	O
function	B-MED
of	O
pedestal	B-MED
blur	I-MED
using	O
naturalistic	B-MED
stimuli	B-MED
with	O
an	O
adaptive	B-MED
4afc	I-MED
procedure	I-MED
.	O
	
stimuli	B-MED
were	O
presented	B-MED
in	O
a	O
46	O
diameter	B-MED
window	O
at	O
40	O
cm	O
.	O
	
gaussian	B-MED
blur	I-MED
pedestals	I-MED
were	O
confined	B-MED
to	O
an	O
annulus	B-MED
at	O
either	O
0	O
,	O
4	O
,	O
8	O
,	O
or	O
12	O
eccentricity	B-MED
,	O
with	O
a	O
blur	B-MED
increment	B-MED
applied	B-MED
to	O
only	O
one	B-MED
quadrant	I-MED
of	O
the	O
image	B-MED
.	O
	
the	O
adaptive	B-MED
procedure	I-MED
efficiently	B-MED
estimated	B-MED
a	O
dipper	B-MED
shaped	I-MED
blur	B-MED
discrimination	B-MED
threshold	B-MED
function	B-MED
with	O
two	B-MED
parameters	B-MED
intrinsic	B-MED
blur	B-MED
and	O
blur	B-MED
sensitivity	B-MED
.	O
	
the	O
amount	B-MED
of	O
intrinsic	B-MED
blur	B-MED
increased	B-MED
for	O
retinal	B-MED
eccentricities	I-MED
beyond	O
4	O
p	O
<	O
0.001	O
and	O
was	O
lower	B-MED
in	O
binocular	B-MED
than	O
monocular	B-MED
conditions	B-MED
p	O
<	O
0.001	O
,	O
but	O
was	O
similar	B-MED
across	O
refractive	B-MED
groups	B-MED
p	O
=	O
0.47	O
.	O
	
blur	B-MED
sensitivity	B-MED
decreased	B-MED
with	O
retinal	B-MED
eccentricity	I-MED
p	O
<	O
0.001	O
and	O
was	O
highest	B-MED
for	O
binocular	B-MED
viewing	O
,	O
but	O
only	O
for	O
central	B-MED
vision	I-MED
p	O
<	O
0.05	O
.	O
	
myopes	B-MED
showed	O
worse	B-MED
blur	B-MED
sensitivity	B-MED
than	O
emmetropes	B-MED
monocularly	B-MED
p	O
<	O
0.05	O
but	O
not	O
binocularly	B-MED
p	O
=	O
0.66	O
.	O
	
as	O
expected	O
,	O
blur	B-MED
perception	B-MED
worsens	B-MED
in	O
the	O
visual	B-MED
periphery	I-MED
and	O
binocular	B-MED
summation	B-MED
is	O
most	O
evident	B-MED
in	O
central	B-MED
vision	I-MED
.	O
	
furthermore	O
,	O
myopes	B-MED
exhibit	O
a	O
monocular	B-MED
impairment	B-MED
in	O
blur	B-MED
sensitivity	B-MED
that	O
improves	B-MED
under	O
binocular	B-MED
conditions	B-MED
.	O
	
implications	B-MED
for	O
the	O
development	B-MED
of	O
myopia	B-MED
risk	B-MED
factors	I-MED
of	O
neurological	B-MED
deterioration	I-MED
in	O
patients	B-MED
with	O
cerebral	B-MED
infarction	I-MED
due	O
to	O
large-artery	B-MED
atherosclerosis	I-MED
in	O
some	O
patients	B-MED
with	O
acute	B-MED
ischemic	B-MED
stroke	I-MED
,	O
neurological	B-MED
deterioration	I-MED
nd	B-MED
is	O
observed	B-MED
,	O
and	O
it	O
is	O
difficult	B-MED
to	O
predict	B-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
.	O
	
especially	O
in	O
some	O
patients	B-MED
with	O
large-artery	B-MED
atherosclerosis	I-MED
laa	B-MED
,	O
aggressive	B-MED
medical	B-MED
treatments	I-MED
and	O
surgical	B-MED
interventions	I-MED
might	O
be	O
helpful	B-MED
to	O
prevent	O
nd	B-MED
.	O
	
therefore	O
,	O
we	O
investigated	B-MED
factors	B-MED
associated	B-MED
with	I-MED
nd	B-MED
in	O
patients	B-MED
with	O
laa	B-MED
.	O
	
we	O
studied	B-MED
patients	B-MED
with	O
laa	B-MED
who	O
were	O
admitted	B-MED
to	I-MED
our	I-MED
hospital	I-MED
.	O
	
we	O
divided	B-MED
them	O
into	O
2	O
groups	B-MED
with	O
group	B-MED
1	O
and	O
without	O
deterioration	B-MED
group	B-MED
2	O
,	O
and	O
evaluated	B-MED
their	O
medical	B-MED
records	I-MED
,	O
risk	B-MED
factors	I-MED
,	O
and	O
radiological	B-MED
findings	B-MED
,	O
such	O
as	O
number	O
of	O
diffusion	B-MED
-	O
positive	B-MED
lesion	B-MED
and	O
degree	B-MED
of	I-MED
stenosis	I-MED
.	O
	
our	O
study	B-MED
population	I-MED
consisted	O
of	O
171	O
patients	B-MED
71	O
41.5	O
did	O
and	O
100	O
58.5	O
did	O
not	O
suffer	B-MED
deterioration	B-MED
.	O
	
by	O
univariate	B-MED
analysis	I-MED
,	O
blood	B-MED
pressure	I-MED
bp	B-MED
,	O
heart	B-MED
rate	I-MED
,	O
national	B-MED
institutes	I-MED
of	I-MED
health	I-MED
stroke	I-MED
scale	I-MED
nihss	I-MED
score	I-MED
,	O
number	O
of	O
diffusion	B-MED
-	O
positive	B-MED
lesion	B-MED
,	O
count	B-MED
of	I-MED
red	I-MED
blood	I-MED
cell	I-MED
,	O
high-density	B-MED
lipoprotein	I-MED
,	O
and	O
degree	B-MED
of	I-MED
stenosis	I-MED
differed	O
significantly	B-MED
between	O
the	O
2	O
groups	B-MED
.	O
	
by	O
multivariate	B-MED
analysis	I-MED
,	O
systolic	B-MED
bp	I-MED
170	O
mm	O
hg	O
,	O
odds	B-MED
ratio	I-MED
7.20	O
,	O
p	O
<	O
was	O
associated	B-MED
with	I-MED
nd	B-MED
.	O
	
furthermore	O
,	O
number	O
of	O
diffusion-weighted	B-MED
image	I-MED
dwi	B-MED
positive	B-MED
lesion	B-MED
8	O
,	O
degree	B-MED
of	I-MED
stenosis	I-MED
>80	O
,	O
and	O
nihss	B-MED
score	I-MED
4	O
were	O
also	O
independent	B-MED
factors	B-MED
associated	B-MED
with	I-MED
nd	B-MED
.	O
	
high	B-MED
bp	I-MED
,	O
severity	B-MED
of	O
neurological	B-MED
deficit	I-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
,	O
and	O
radiological	B-MED
findings	B-MED
,	O
such	O
as	O
degree	B-MED
of	I-MED
stenosis	I-MED
and	O
number	O
of	O
dwi	B-MED
-	O
positive	B-MED
lesion	B-MED
,	O
are	O
independently	B-MED
associated	B-MED
with	I-MED
nd	B-MED
in	O
patients	B-MED
with	O
development	B-MED
and	O
validation	B-MED
of	O
an	O
easy-to-use	O
risk	B-MED
assessment	I-MED
tool	I-MED
for	O
cumulative	O
low	B-MED
back	I-MED
loading	B-MED
the	O
lifting	B-MED
fatigue	I-MED
failure	I-MED
tool	I-MED
lifft	B-MED
recent	O
evidence	O
suggests	O
that	O
musculoskeletal	B-MED
disorders	I-MED
msds	B-MED
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-MED
failure	B-MED
process	I-MED
in	O
affected	B-MED
tissues	B-MED
.	O
	
this	O
paper	O
describes	O
a	O
new	O
low	B-MED
back	I-MED
exposure	I-MED
assessment	B-MED
tool	I-MED
the	O
lifting	B-MED
fatigue	I-MED
failure	I-MED
tool	I-MED
lifft	B-MED
,	O
which	O
estimates	O
a	O
""""	O
daily	B-MED
dose	I-MED
""""	O
of	O
cumulative	B-MED
loading	B-MED
on	O
the	O
low	B-MED
back	I-MED
using	O
fatigue	B-MED
failure	B-MED
principles	B-MED
.	O
	
only	O
three	O
variables	B-MED
are	O
necessary	O
to	O
derive	O
the	O
cumulative	B-MED
load	B-MED
associated	B-MED
with	I-MED
a	O
lifting	B-MED
task	B-MED
the	O
weight	B-MED
of	I-MED
the	I-MED
load	I-MED
,	O
the	O
maximum	O
horizontal	B-MED
distance	I-MED
from	O
the	O
spine	B-MED
to	B-MED
the	I-MED
load	I-MED
,	O
and	O
the	O
number	O
of	O
repetitions	B-MED
for	O
tasks	B-MED
performed	I-MED
during	O
the	O
workday	B-MED
.	O
	
the	O
new	B-MED
tool	I-MED
was	O
validated	B-MED
using	O
two	O
existing	O
epidemiological	B-MED
databases	B-MED
the	O
lumbar	B-MED
motion	I-MED
monitor	O
lmm	O
database	O
,	O
and	O
a	O
database	O
from	O
a	O
u.s	O
.	O
	
automotive	O
manufacturer	O
.	O
	
the	O
lifft	O
cumulative	O
damage	O
metric	O
explained	O
92%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
disorders	O
lbds	O
in	O
the	O
lmm	O
database	O
and	O
72-95%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
outcomes	O
in	O
the	O
automotive	O
database	O
depending	O
on	O
the	O
outcome	O
measure	O
.	O
	
thus	O
,	O
lifft	O
is	O
practitioner	O
friendly	O
and	O
its	O
cumulative	O
damage	O
metric	O
highly	O
related	O
to	O
low	O
back	O
outcomes	I-MED
genetic	B-MED
diversity	I-MED
in	O
various	O
accessions	B-MED
of	O
pineapple	B-MED
ananas	B-MED
comosus	I-MED
l	I-MED
merr	I-MED
using	O
issr	B-MED
and	O
ssr	B-MED
markers	B-MED
inter	B-MED
simple	I-MED
sequence	I-MED
repeat	I-MED
issr	B-MED
and	O
simple	B-MED
sequence	I-MED
repeat	I-MED
ssr	B-MED
markers	B-MED
were	O
used	O
to	O
assess	O
the	O
genetic	B-MED
diversity	I-MED
of	O
36	O
pineapple	B-MED
accessions	B-MED
that	O
were	O
introduced	O
from	O
10	O
countries	B-MED
/	O
regions	B-MED
.	O
	
thirteen	O
issr	B-MED
primers	B-MED
amplified	B-MED
96	O
bands	O
,	O
of	O
which	O
91	O
93.65	O
were	O
polymorphic	B-MED
,	O
whereas	O
20	O
ssr	B-MED
primers	B-MED
amplified	B-MED
73	O
bands	O
,	O
of	O
which	O
70	O
96.50	O
were	O
polymorphic	B-MED
.	O
	
nei's	B-MED
gene	I-MED
diversity	I-MED
h	B-MED
=	O
0.28	O
,	O
shannon's	B-MED
information	I-MED
index	I-MED
i	B-MED
=	O
0.43	O
,	O
and	O
polymorphism	B-MED
information	I-MED
content	I-MED
pic	B-MED
=	O
0.29	O
generated	O
using	O
the	O
ssr	B-MED
primers	B-MED
were	O
higher	O
than	O
that	O
with	O
issr	B-MED
primers	B-MED
h	B-MED
=	O
0.23	O
,	O
i	B-MED
=	O
0.37	O
,	O
pic	B-MED
=	O
0.24	O
,	O
thereby	O
suggesting	O
that	O
the	O
ssr	B-MED
system	I-MED
is	O
more	O
efficient	O
than	O
the	O
issr	B-MED
system	I-MED
in	O
assessing	O
genetic	B-MED
diversity	I-MED
in	O
various	O
pineapple	B-MED
accessions	B-MED
.	O
	
mean	O
genetic	B-MED
similarities	B-MED
were	O
0.74	O
,	O
0.61	O
,	O
and	O
0.69	O
,	O
as	O
determined	O
using	O
issr	B-MED
,	O
ssr	B-MED
,	O
and	O
combined	O
issr	B-MED
/	O
ssr	B-MED
,	O
respectively	O
.	O
	
these	O
results	O
suggest	O
that	O
the	O
genetic	B-MED
diversity	I-MED
among	O
pineapple	B-MED
accessions	B-MED
is	O
very	O
high	O
.	O
	
we	O
clustered	B-MED
the	O
36	O
pineapple	B-MED
accessions	B-MED
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	B-MED
trees	I-MED
constructed	O
based	O
on	O
the	O
results	O
of	O
issr	B-MED
,	O
ssr	B-MED
,	O
and	O
combined	O
issr	B-MED
/	O
ssr	B-MED
analyses	B-MED
using	O
the	O
unweighted	B-MED
pair-group	I-MED
with	I-MED
arithmetic	I-MED
averaging	I-MED
upgma	I-MED
method	I-MED
.	O
	
the	O
results	O
of	O
principal	B-MED
components	I-MED
analysis	I-MED
pca	B-MED
also	O
supported	O
the	O
upgma	B-MED
clustering	B-MED
.	O
	
these	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	B-MED
germplasm	B-MED
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	B-MED
breeding	B-MED
strategies	I-MED
.	O
	
advanced	B-MED
age	I-MED
is	O
not	O
a	O
barrier	B-MED
to	O
creating	O
a	O
functional	B-MED
arteriovenous	B-MED
fistula	I-MED
a	O
retrospective	B-MED
study	I-MED
arteriovenous	B-MED
fistulas	I-MED
avfs	B-MED
are	O
the	O
recommended	O
form	O
of	O
vascular	B-MED
access	I-MED
for	O
hemodialysis	B-MED
.	O
	
however	O
,	O
controversy	B-MED
exists	O
regarding	O
whether	O
avfs	B-MED
are	O
suitable	O
for	O
elderly	B-MED
patients	B-MED
.	O
	
single-center	B-MED
retrospective	I-MED
review	I-MED
to	O
investigate	B-MED
the	O
impact	B-MED
of	O
age	B-MED
on	O
avf	B-MED
outcomes	B-MED
.	O
	
five	O
hundred	O
and	O
twenty-five	O
patients	B-MED
with	O
avf	B-MED
creation	B-MED
were	O
stratified	B-MED
based	O
on	O
age	B-MED
<65	B-MED
,	O
65-75	B-MED
,	O
and	O
>75	B-MED
years	B-MED
.	O
	
avf	B-MED
outcomes	B-MED
including	O
primary	B-MED
failure	B-MED
,	O
avf	B-MED
patency	B-MED
primary	B-MED
,	O
secondary	B-MED
,	O
and	O
functional	B-MED
,	O
and	O
avf	B-MED
complications	B-MED
were	O
studied	O
for	O
3	O
years	B-MED
following	O
avf	B-MED
creation	B-MED
.	O
	
the	O
cohort	B-MED
was	O
63%	O
male	B-MED
,	O
44%	O
caucasian	B-MED
,	O
and	O
55%	O
had	O
diabetes	B-MED
or	O
cardiovascular	B-MED
disease	I-MED
.	O
	
39%	O
were	O
aged	B-MED
<65	B-MED
years	B-MED
,	O
33%	O
65-75	B-MED
years	B-MED
,	O
and	O
28%	O
were	O
aged	B-MED
>75	B-MED
years	B-MED
.	O
	
no	O
differences	O
in	O
rates	O
of	O
primary	B-MED
failure	B-MED
,	O
loss	O
of	O
primary	B-MED
patency	B-MED
,	O
complications	B-MED
,	O
or	O
need	O
for	O
intervention	B-MED
were	O
observed	O
between	O
age	B-MED
groups	I-MED
.	O
	
there	O
was	O
a	O
significant	O
association	B-MED
of	O
age	B-MED
with	O
secondary	B-MED
patency	B-MED
and	O
functional	B-MED
patency	B-MED
,	O
with	O
age	B-MED
>75	B-MED
being	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
shortened	B-MED
lifespan	B-MED
of	O
the	O
fistula	O
.	O
	
for	O
patients	B-MED
aged	B-MED
>75	B-MED
years	B-MED
,	O
secondary	B-MED
patency	B-MED
at	O
3	O
years	B-MED
was	O
64%	O
compared	O
to	O
75%-78%	O
for	O
younger	B-MED
patients	B-MED
.	O
	
functional	B-MED
patency	B-MED
at	O
2	O
years	B-MED
was	O
69%	O
for	O
those	O
aged	B-MED
>75	B-MED
years	B-MED
compared	O
to	O
78%-81%	O
for	O
younger	B-MED
patients	B-MED
.	O
	
we	O
found	O
no	O
difference	O
in	O
avf	B-MED
maturation	B-MED
,	O
primary	B-MED
patency	B-MED
,	O
complications	B-MED
,	O
or	O
interventions	B-MED
in	O
those	O
over	O
the	O
age	B-MED
of	O
75	B-MED
compared	O
to	O
younger	B-MED
counterparts	O
.	O
	
while	O
secondary	B-MED
and	O
functional	B-MED
patency	B-MED
rates	B-MED
were	O
significantly	O
lower	O
in	O
those	O
aged	B-MED
>75	B-MED
years	B-MED
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O
	
therefore	O
,	O
we	O
recommend	O
that	O
advanced	B-MED
age	I-MED
alone	O
should	O
not	O
preclude	O
patients	B-MED
from	O
avf	B-MED
creation	B-MED
.	O
	
a	O
modified	B-MED
esbl	B-MED
nordmann/dortet/poirel-based	O
protocol	O
to	O
optimize	O
early	O
sepsis	O
management	O
we	O
evaluated	O
a	O
modification	O
of	O
a	O
colorimetric	O
test	O
recently	O
described	O
by	O
dortet	O
et	O
al	O
.	O
	
2015	O
for	O
the	O
rapid	O
detection	O
of	O
esbl	B-MED
-producing	O
enterobacteriaceae	O
directly	O
from	O
positive	O
blood	O
cultures	O
that	O
requires	O
less	O
manipulation	O
,	O
materials	O
and	O
hands-on	O
time	O
.	O
	
the	O
simplified	O
protocol	O
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100%	O
and	O
95.7	O
the	O
use	O
of	O
informativity	O
in	O
the	O
development	B-MED
of	O
robust	B-MED
viromics	I-MED
-based	O
examinations	B-MED
metagenomics	B-MED
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	B-MED
communities	I-MED
responsible	O
for	O
maintaining	B-MED
life	I-MED
on	I-MED
this	I-MED
planet	I-MED
.	O
	
sequencing	B-MED
efforts	O
often	O
uncover	O
novel	O
genetic	B-MED
content	I-MED
this	O
is	O
most	O
evident	O
for	O
phage	B-MED
communities	I-MED
,	O
in	O
which	O
upwards	O
of	O
90%	O
of	O
all	O
sequences	B-MED
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-MED
in	O
current	O
data	B-MED
repositories	I-MED
.	O
	
for	O
the	O
small	B-MED
fraction	I-MED
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
blast	B-MED
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	B-MED
of	O
a	O
viral	B-MED
taxon	I-MED
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O
	
homology	B-MED
-based	O
classification	B-MED
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	B-MED
repositories	I-MED
capture	O
but	O
a	O
small	B-MED
fraction	I-MED
of	O
phage	B-MED
diversity	I-MED
.	O
	
furthermore	O
,	O
lateral	B-MED
gene	B-MED
transfer	I-MED
is	O
pervasive	B-MED
within	O
phage	B-MED
communities	I-MED
.	O
	
as	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	B-MED
gene	I-MED
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	B-MED
viral	I-MED
species	I-MED
.	O
	
rather	O
,	O
it	O
is	O
just	O
that	O
an	O
indication	B-MED
of	O
the	O
presence	O
of	O
a	O
specific	B-MED
gene	I-MED
.	O
	
to	O
circumvent	O
this	O
limitation	B-MED
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-MED
of	I-MED
viral	I-MED
metagenomic	I-MED
datasets	I-MED
.	O
	
blast	B-MED
hits	O
are	O
weighted	O
,	O
integrating	B-MED
the	I-MED
sequence	I-MED
identity	I-MED
and	O
length	B-MED
of	I-MED
alignments	I-MED
as	O
well	O
as	O
a	O
taxonomic	B-MED
signal	I-MED
,	O
such	O
that	O
each	B-MED
gene	I-MED
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	B-MED
content	I-MED
.	O
	
through	O
this	O
quantifiable	B-MED
metric	I-MED
,	O
predictions	B-MED
of	O
viral	B-MED
community	I-MED
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O
	
as	O
a	O
proof-of-concept	B-MED
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	B-MED
and	O
applied	O
to	O
seven	O
freshwater	B-MED
viral	I-MED
metagenomes	I-MED
.	O
	
while	O
providing	O
a	O
robust	B-MED
method	I-MED
for	O
evaluating	O
viral	B-MED
metagenomic	I-MED
data	I-MED
,	O
the	O
tool	B-MED
is	O
versatile	B-MED
and	O
can	O
easily	O
be	O
customized	B-MED
to	O
investigations	B-MED
of	O
any	O
environment	B-MED
or	O
presence	B-MED
of	I-MED
citrinin	B-MED
in	O
grains	B-MED
and	O
its	O
possible	B-MED
health	B-MED
effects	B-MED
citrinin	B-MED
is	O
a	O
mycotoxin	B-MED
produced	B-MED
by	O
several	O
species	B-MED
of	O
the	O
genera	B-MED
aspergillus	I-MED
,	O
penicillium	B-MED
and	O
monascus	B-MED
and	O
it	O
occurs	B-MED
mainly	O
in	O
stored	B-MED
grain	I-MED
.	O
	
citrinin	B-MED
is	O
generally	O
formed	B-MED
after	O
harvest	B-MED
and	O
occurs	B-MED
mainly	O
in	O
stored	B-MED
grains	I-MED
,	O
it	O
also	O
occurs	B-MED
in	O
other	B-MED
plant	I-MED
products	I-MED
.	O
	
often	O
,	O
the	O
co-occurrence	B-MED
with	O
other	O
mycotoxins	B-MED
is	O
observed	B-MED
,	O
especially	O
ochratoxin	B-MED
a	I-MED
,	O
which	O
is	O
usually	O
associated	B-MED
with	I-MED
endemic	B-MED
nephropathy	I-MED
.	O
	
at	O
the	O
european	B-MED
union	I-MED
level	B-MED
,	O
systematic	B-MED
monitoring	B-MED
of	O
citrinin	B-MED
in	O
grains	B-MED
began	O
with	O
the	O
aim	B-MED
of	O
determining	B-MED
its	O
highest	O
permissible	B-MED
amount	I-MED
in	O
food	B-MED
.	O
	
thus	O
,	O
far	O
the	O
systematic	B-MED
monitoring	B-MED
of	O
the	O
above	B-MED
mentioned	I-MED
mycotoxin	I-MED
in	O
croatia	B-MED
is	O
yet	O
to	O
begin	B-MED
.	O
	
the	O
main	B-MED
goal	I-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	B-MED
the	O
presence	B-MED
of	I-MED
citrinin	B-MED
in	O
grains	B-MED
sampled	B-MED
in	O
the	O
area	B-MED
of	O
međimurje	B-MED
,	O
osijek-baranja	B-MED
,	O
vukovar-srijem	B-MED
and	O
brod-posavina	B-MED
county	I-MED
.	O
	
for	O
the	O
purpose	B-MED
of	O
identification	B-MED
and	O
quantification	B-MED
of	O
citrinin	B-MED
,	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatograph	I-MED
hplc	I-MED
with	I-MED
fluorescence	I-MED
was	O
used	B-MED
calibration	B-MED
curve	I-MED
k	O
>	O
0.999	O
intra	B-MED
assay	I-MED
cv	I-MED
=	O
2.1	O
inter	B-MED
assay	I-MED
cv	I-MED
=	O
4.3	O
loq	B-MED
<	O
1	O
μg/kg	O
.	O
	
from	O
the	O
area	B-MED
of	O
međimurje	B-MED
county	I-MED
,	O
10	O
samples	B-MED
of	O
corn	B-MED
and	O
10	O
samples	B-MED
of	O
wheat	B-MED
were	O
analyzed	B-MED
.	O
	
none	O
of	O
the	O
samples	B-MED
contained	B-MED
citrinin	B-MED
<1	O
μg/kg	O
.	O
	
from	O
the	O
area	B-MED
of	O
osijek-baranja	B-MED
and	O
vukovar-srijem	B-MED
county	I-MED
,	O
15	O
samples	B-MED
from	O
each	O
county	B-MED
were	O
analyzed	B-MED
.	O
	
the	O
mean	B-MED
value	I-MED
for	O
the	O
samples	B-MED
of	O
osijek-baranja	B-MED
county	I-MED
was	O
19.63	O
μg/kg	O
median	B-MED
=15	O
μg/kg	O
,	O
while	O
for	O
vukovar-srijem	B-MED
county	I-MED
the	O
mean	B-MED
value	I-MED
of	O
citrinin	B-MED
was	O
14	O
μg/kg	O
median	B-MED
=1	O
μg/kg	O
.	O
	
from	O
5	O
analyzed	B-MED
samples	B-MED
from	O
brod-posavina	B-MED
county	I-MED
,	O
one	O
of	O
the	O
samples	B-MED
contained	B-MED
citrinin	B-MED
in	O
the	O
amount	B-MED
of	O
23.8	O
μg/kg	O
,	O
while	O
the	O
registered	B-MED
amount	B-MED
s	O
in	O
the	O
other	O
samples	B-MED
were	O
<1	O
μg/kg	O
.	O
	
the	O
results	B-MED
show	O
that	O
grains	B-MED
from	O
several	B-MED
counties	B-MED
contain	B-MED
certain	O
amounts	B-MED
of	O
citrinin	B-MED
possibly	O
indicating	B-MED
a	O
significant	B-MED
intake	B-MED
of	O
citrinin	B-MED
in	O
humans	B-MED
.	O
	
it	O
must	O
be	O
stated	O
that	O
grains	B-MED
and	O
grain-based	B-MED
products	I-MED
are	O
the	O
basis	O
of	O
everyday	B-MED
diet	B-MED
of	O
all	O
age	B-MED
groups	I-MED
,	O
especially	O
small	B-MED
children	I-MED
,	O
where	O
higher	B-MED
intake	B-MED
of	O
citrinin	B-MED
can	O
occur	B-MED
.	O
	
consequently	O
,	O
we	O
emphasize	B-MED
the	O
need	O
for	O
systematic	B-MED
analysis	B-MED
of	O
larger	B-MED
amount	I-MED
of	O
samples	B-MED
,	O
from	O
both	O
large	B-MED
grains	I-MED
and	O
small	B-MED
grains	I-MED
,	O
especially	O
in	O
the	O
area	B-MED
of	O
brod-posavina	B-MED
county	I-MED
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-MED
contamination	B-MED
of	O
grains	B-MED
and	O
to	O
asses	B-MED
the	O
health	B-MED
risk	B-MED
in	O
recurrent	B-MED
noncoding	I-MED
regulatory	I-MED
mutations	I-MED
in	O
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
the	O
contributions	B-MED
of	O
coding	B-MED
mutations	I-MED
to	O
tumorigenesis	B-MED
are	O
relatively	O
well	O
known	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	B-MED
alterations	I-MED
in	O
noncoding	B-MED
dna	I-MED
.	O
	
here	O
we	O
describe	O
gecco	O
genomic	O
enrichment	O
computational	O
clustering	O
operation	O
to	O
analyze	O
somatic	B-MED
noncoding	I-MED
alterations	I-MED
in	O
308	O
pancreatic	B-MED
ductal	I-MED
adenocarcinomas	I-MED
pdas	B-MED
and	O
identify	O
commonly	O
mutated	B-MED
regulatory	I-MED
regions	I-MED
.	O
	
we	O
find	O
recurrent	B-MED
noncoding	I-MED
mutations	I-MED
to	O
be	O
enriched	O
in	O
pda	B-MED
pathways	B-MED
,	O
including	O
axon	B-MED
guidance	I-MED
and	O
cell	B-MED
adhesion	I-MED
,	O
and	O
newly	O
identified	B-MED
processes	B-MED
,	O
including	O
transcription	B-MED
and	O
homeobox	B-MED
genes	I-MED
.	O
	
we	O
identified	B-MED
mutations	B-MED
in	O
protein	B-MED
binding	I-MED
sites	I-MED
correlating	O
with	O
differential	B-MED
expression	B-MED
of	O
proximal	B-MED
genes	B-MED
and	O
experimentally	O
validated	O
effects	B-MED
of	I-MED
mutations	B-MED
on	O
expression	B-MED
.	O
	
we	O
developed	O
an	O
expression	B-MED
modulation	I-MED
score	I-MED
that	O
quantifies	B-MED
the	O
strength	B-MED
of	O
gene	B-MED
regulation	I-MED
imposed	O
by	O
each	O
class	O
of	O
regulatory	B-MED
elements	I-MED
,	O
and	O
found	O
the	O
strongest	O
elements	B-MED
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O
	
our	O
detailed	O
single-cancer	B-MED
analysis	I-MED
of	O
noncoding	B-MED
alterations	I-MED
identifies	O
regulatory	B-MED
mutations	I-MED
as	O
candidates	B-MED
for	O
diagnostic	B-MED
and	O
prognostic	B-MED
markers	I-MED
,	O
and	O
suggests	O
new	O
mechanisms	B-MED
for	O
tumor	B-MED
evolution	I-MED
.	O
	
distal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
revascularization	B-MED
for	O
a	O
fusiform	B-MED
pca	B-MED
aneurysm	B-MED
a	O
lesson	O
learned	O
the	O
need	O
for	O
revascularization	B-MED
with	O
proximal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
in	O
the	O
treatment	B-MED
of	O
giant	B-MED
and	O
fusiform	B-MED
aneurysms	I-MED
is	O
unclear	O
.	O
	
while	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10%	O
chance	O
of	O
infarction	B-MED
following	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
,	O
recently	O
several	O
authors	B-MED
have	O
advocated	O
a	O
bypass	B-MED
prior	O
to	O
parent	O
vessel	B-MED
sacrifice	O
in	O
all	O
cases	O
.	O
	
we	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	B-MED
aneurysm	I-MED
of	O
the	O
right	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
at	O
the	O
p2-p3	B-MED
junction	I-MED
.	O
	
he	O
clinically	B-MED
failed	I-MED
a	O
balloon	B-MED
test	I-MED
occlusion	I-MED
preoperatively	B-MED
and	O
therefore	O
underwent	O
an	O
occipital	B-MED
artery	I-MED
to	O
distal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
bypass	B-MED
with	O
subsequent	O
endovascular	B-MED
occlusion	I-MED
of	I-MED
the	I-MED
parent	I-MED
vessel	I-MED
and	O
aneurysm	B-MED
.	O
	
despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	B-MED
up	I-MED
cerebral	B-MED
angiography	I-MED
confirmed	O
a	O
patent	O
bypass	B-MED
,	O
the	O
patient	B-MED
still	O
developed	O
a	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
territory	B-MED
stroke	I-MED
.	O
	
we	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	B-MED
revascularization	B-MED
in	O
the	O
setting	O
of	O
proximal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
does	O
not	O
guarantee	O
against	O
cerebral	B-MED
ischemia	I-MED
and	O
infarction	B-MED
even	O
in	O
those	O
patients	B-MED
that	O
fail	O
a	O
test	B-MED
occlusion	I-MED
.	O
	
when	O
is	O
a	O
test	B-MED
score	I-MED
fair	B-MED
for	O
the	O
individual	B-MED
who	O
is	O
being	O
tested	B-MED
effects	B-MED
of	I-MED
different	O
scoring	B-MED
procedures	I-MED
across	O
multiple	B-MED
attempts	B-MED
when	O
testing	B-MED
a	O
motor	B-MED
skill	I-MED
task	B-MED
tests	B-MED
or	O
test	B-MED
batteries	I-MED
used	O
for	O
assessing	B-MED
motor	B-MED
skills	I-MED
,	O
either	O
in	O
research	B-MED
studies	I-MED
or	O
in	O
clinical	B-MED
settings	I-MED
,	O
apply	O
a	O
variety	O
of	O
procedures	B-MED
for	O
scoring	B-MED
performances	B-MED
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	B-MED
,	O
of	O
which	O
the	O
best	O
is	O
scored	B-MED
or	O
an	O
average	B-MED
is	O
computed	B-MED
.	O
	
the	O
rationale	O
behind	O
scoring	B-MED
procedures	B-MED
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	B-MED
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	B-MED
.	O
	
it	O
is	O
uncertain	O
whether	O
procedures	B-MED
fairly	O
capture	O
an	O
individual's	B-MED
skill	B-MED
level	B-MED
.	O
	
thus	O
,	O
the	O
validity	O
of	O
the	O
tests	B-MED
may	O
be	O
compromised	O
.	O
	
the	O
present	O
study	B-MED
tested	B-MED
24	O
young	O
female	B-MED
soccer	B-MED
players	B-MED
on	O
the	O
juggling	B-MED
of	O
a	O
soccer	B-MED
ball	I-MED
.	O
	
they	O
were	O
given	O
10	O
attempts	B-MED
,	O
and	O
trials	B-MED
were	O
scored	B-MED
according	O
to	O
nine	O
different	O
procedures	B-MED
including	O
the	O
'	O
best	B-MED
of	I-MED
'	O
or	O
'	O
mean	B-MED
of	I-MED
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	B-MED
.	O
	
individual	B-MED
raw	B-MED
scores	I-MED
differed	O
widely	O
across	O
trials	B-MED
,	O
but	O
no	B-MED
general	I-MED
effect	I-MED
of	O
trials	B-MED
was	O
found	O
.	O
	
the	O
mean	B-MED
sd	I-MED
percentage	I-MED
difference	I-MED
between	O
the	O
lowest	B-MED
and	O
highest	B-MED
scores	B-MED
was	O
27.7	O
,	O
with	O
17	O
players	B-MED
71%	O
demonstrating	O
a	O
significant	B-MED
change	O
from	O
lowest	B-MED
to	O
highest	B-MED
score	B-MED
.	O
	
correlations	B-MED
between	O
raw	B-MED
scores	I-MED
were	O
low	B-MED
across	O
trials	B-MED
,	O
while	O
they	O
were	O
generally	O
higher	B-MED
across	O
scoring	B-MED
procedures	B-MED
.	O
	
the	O
first	O
trial	B-MED
was	O
significantly	B-MED
different	B-MED
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	B-MED
score	I-MED
and	O
as	O
scoring	B-MED
procedure	B-MED
.	O
	
the	O
mean	B-MED
percentage	I-MED
difference	I-MED
between	O
best-of-two	B-MED
and	O
best-of-ten	B-MED
scores	I-MED
was	O
95%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	B-MED
demonstrating	O
a	O
significant	B-MED
difference	B-MED
between	O
the	O
two	O
scoring	B-MED
procedures	B-MED
.	O
	
no	B-MED
significant	I-MED
differences	I-MED
were	O
found	O
across	O
mean-of-rule	B-MED
scorings	I-MED
.	O
	
best-of-rule	B-MED
and	O
mean-of-rule	B-MED
scorings	I-MED
were	O
significantly	B-MED
different	B-MED
except	O
for	O
the	O
best-of-two	B-MED
vs	O
.	O
	
mean-of-two	B-MED
.	O
	
the	O
mean	B-MED
difference	I-MED
between	O
highest	B-MED
and	O
lowest	B-MED
rank	B-MED
across	O
players	B-MED
was	O
6.7	O
3.6	O
,	O
with	O
individual	B-MED
rankings	B-MED
within	O
the	O
group	B-MED
varying	O
33%	O
on	O
average	O
across	O
procedures	B-MED
.	O
	
one	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	B-MED
differences	B-MED
.	O
	
therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	B-MED
procedures	B-MED
affect	O
results	B-MED
and	O
may	O
have	O
an	O
impact	O
on	O
test	B-MED
outcomes	I-MED
.	O
	
this	O
may	O
present	O
consequences	O
for	O
decision-making	O
from	O
test	B-MED
results	I-MED
,	O
such	O
as	O
diagnosing	B-MED
and	O
selection	O
of	O
intervention	B-MED
groups	B-MED
.	O
	
we	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	B-MED
into	O
the	O
scoring	B-MED
procedures	B-MED
of	O
the	O
vast	O
amount	O
of	O
tests	B-MED
a	O
fast	B-MED
peak-searching	I-MED
algorithm	I-MED
for	O
ultrasonic	B-MED
elastography	I-MED
tissue	B-MED
axial	I-MED
strain	I-MED
estimation	I-MED
with	I-MED
ultrasound	I-MED
elastography	I-MED
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O
	
however	O
,	O
for	O
keypoints	O
tracking-based	B-MED
elastography	I-MED
algorithms	I-MED
,	O
locating	B-MED
extrema	B-MED
in	O
multimodal	O
ultrasonic	B-MED
radiofrequency	B-MED
signals	B-MED
is	O
still	O
a	O
challenging	O
problem	B-MED
.	O
	
in	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	B-MED
to	O
locate	B-MED
the	O
local	O
maxima	B-MED
and	O
minima	B-MED
of	O
the	O
rf	B-MED
signals	B-MED
directly	O
without	O
derivation	B-MED
operation	B-MED
.	O
	
this	O
algorithm	B-MED
can	O
accurately	O
locate	B-MED
extrema	B-MED
even	O
if	O
disturbed	O
peaks	B-MED
resulting	O
from	O
different	O
noise	B-MED
exist	O
.	O
	
furthermore	O
,	O
the	O
new	O
algorithm	B-MED
can	O
speed	O
up	O
approximately	O
79%	O
of	O
the	O
implementation	B-MED
process	O
as	O
compared	B-MED
with	O
the	O
standard	B-MED
cross-correlation	I-MED
method	I-MED
on	O
the	O
same	O
computing	B-MED
platform	O
.	O
	
in	O
addition	O
,	O
the	O
elastographic	O
signal-to-noise	B-MED
ratio	I-MED
and	O
the	O
contrast-to-noise	B-MED
ratio	I-MED
audiovisual	B-MED
integration	B-MED
supports	O
face	B-MED
-	O
name	B-MED
associative	B-MED
memory	B-MED
formation	I-MED
prior	O
multisensory	B-MED
experience	B-MED
influences	O
how	O
we	O
perceive	O
our	O
environment	B-MED
,	O
and	O
hence	O
how	O
memories	B-MED
are	O
encoded	O
for	O
subsequent	O
retrieval	B-MED
.	O
	
this	O
study	B-MED
investigated	O
if	O
audiovisual	B-MED
av	B-MED
integration	B-MED
and	O
associative	B-MED
memory	B-MED
formation	I-MED
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O
	
our	O
functional	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
results	O
demonstrate	O
that	O
the	O
neural	B-MED
mechanisms	B-MED
underlying	O
av	B-MED
integration	B-MED
and	O
associative	B-MED
memory	B-MED
overlap	B-MED
substantially	O
.	O
	
in	O
particular	O
,	O
activity	B-MED
in	O
anterior	B-MED
superior	I-MED
temporal	I-MED
sulcus	I-MED
sts	B-MED
is	O
increased	O
during	O
av	B-MED
integration	B-MED
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
av	B-MED
face	B-MED
-	O
name	B-MED
association	O
formation	O
.	O
	
dynamic	B-MED
causal	I-MED
modeling	I-MED
results	O
further	O
demonstrate	O
how	O
the	O
anterior	B-MED
sts	I-MED
interacts	O
with	O
the	O
associative	B-MED
memory	B-MED
system	I-MED
to	O
facilitate	O
successful	O
memory	B-MED
formation	I-MED
for	O
av	B-MED
face	B-MED
-	O
name	B-MED
associations	B-MED
.	O
	
specifically	O
,	O
the	O
connection	O
of	O
fusiform	B-MED
gyrus	I-MED
to	O
anterior	B-MED
sts	I-MED
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	B-MED
subsequently	O
remembered	B-MED
both	O
face	B-MED
and	O
name	B-MED
.	O
	
collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	B-MED
associative	B-MED
memories	B-MED
can	O
be	O
formed	O
for	O
subsequent	O
liquid	B-MED
chromatography-tandem	I-MED
mass	I-MED
spectrometry	I-MED
quantification	B-MED
of	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
residues	B-MED
in	O
butterbur	B-MED
grown	O
under	O
regulated	B-MED
conditions	I-MED
an	O
analytical	B-MED
method	I-MED
was	O
developed	O
to	O
quantify	B-MED
the	O
residual	B-MED
levels	B-MED
of	O
the	O
neonicotinoid	B-MED
insecticides	I-MED
,	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
,	O
in	O
field-incurred	B-MED
butterbur	B-MED
samples	B-MED
using	O
liquid	B-MED
chromatography-tandem	I-MED
mass	I-MED
spectrometry	I-MED
lc-ms/ms	B-MED
.	O
	
samples	B-MED
were	O
extracted	B-MED
with	O
acetonitrile	B-MED
and	O
partitioned	O
with	O
dichloromethane	B-MED
.	O
	
after	O
partitioning	O
,	O
purification	B-MED
was	O
conducted	O
using	O
a	O
florisil	B-MED
cartridge	I-MED
.	O
	
linearity	B-MED
of	O
a	O
matrix-matched	B-MED
calibration	I-MED
curve	I-MED
of	O
the	O
two	O
compounds	B-MED
over	O
a	O
concentration	B-MED
range	B-MED
of	O
0.004	O
was	O
excellent	O
,	O
with	O
determination	B-MED
coefficients	I-MED
r	B-MED
.	O
	
the	O
limits	B-MED
of	I-MED
detection	I-MED
lod	B-MED
and	O
quantitation	B-MED
loq	B-MED
for	O
both	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
were	O
0.0006	O
and	O
0.002mg	O
,	O
respectively	O
.	O
	
the	O
average	O
recoveries	O
for	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
at	O
two	O
spiking	B-MED
levels	I-MED
0.02	O
and	O
0.1mg	O
,	O
i.e	O
,	O
10	O
loq	B-MED
and	O
50	O
loq	B-MED
were	O
between	O
78.23	O
to	O
82.17	O
,	O
with	O
relative	B-MED
standard	I-MED
deviations	I-MED
rsds	B-MED
.	O
	
the	O
method	B-MED
was	O
successfully	O
applied	O
to	O
field-incurred	B-MED
samples	B-MED
treated	B-MED
with	O
a	O
commercial	B-MED
pesticide	B-MED
product	I-MED
,	O
either	O
once	O
zero	O
or	O
7	O
days	B-MED
before	O
harvest	B-MED
or	O
twice	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	B-MED
before	O
harvest	B-MED
.	O
	
the	O
highest	O
and	O
lowest	O
residues	B-MED
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	B-MED
'	O
treatment	B-MED
and	O
the	O
21	O
and	O
14	O
days	B-MED
'	O
treatment	B-MED
,	O
respectively	O
.	O
	
the	O
developed	O
method	B-MED
is	O
simple	O
and	O
accurate	B-MED
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	B-MED
vegetables	I-MED
.	O
	
percentile	B-MED
categorization	B-MED
of	O
qt	B-MED
interval	I-MED
as	O
an	O
approach	B-MED
for	O
identifying	B-MED
adult	B-MED
patients	B-MED
at	O
risk	B-MED
for	O
cardiovascular	B-MED
death	I-MED
the	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
qt	B-MED
prolongation	I-MED
with	O
cardiovascular	B-MED
death	I-MED
cvd	B-MED
have	O
been	O
inconsistent	B-MED
.	O
	
the	O
purpose	B-MED
of	I-MED
this	I-MED
study	I-MED
was	O
to	O
compare	B-MED
the	O
major	O
correction	B-MED
formulas	I-MED
to	O
percentile	B-MED
values	I-MED
of	O
qt	B-MED
for	O
heart	B-MED
rate	I-MED
ranges	B-MED
as	O
to	O
their	O
ability	B-MED
to	O
remove	B-MED
the	O
relationship	B-MED
of	O
qt	B-MED
to	O
heart	B-MED
rate	I-MED
and	O
to	O
predict	O
cvd	B-MED
.	O
	
participants	B-MED
were	O
16	O
veterans	B-MED
who	O
had	O
an	O
initial	O
ecg	B-MED
at	O
the	O
veterans	B-MED
affairs	I-MED
medical	I-MED
center	I-MED
,	O
palo	B-MED
alto	I-MED
,	O
between	O
march	B-MED
31	O
,	O
1987	O
,	O
and	O
december	B-MED
20	O
,	O
1999	O
,	O
and	O
were	O
followed	O
for	O
cvd	B-MED
.	O
	
the	O
4	O
major	O
correction	B-MED
formulas	I-MED
bazett	B-MED
,	O
fridericia	B-MED
,	O
framingham	B-MED
,	O
and	O
hodges	B-MED
were	O
used	O
to	O
correct	O
qt	B-MED
interval	I-MED
.	O
	
in	O
addition	O
,	O
the	O
percentiles	B-MED
for	O
heart	B-MED
rate	I-MED
ranges	B-MED
as	O
proposed	O
by	O
schwartz	B-MED
were	O
calculated	O
.	O
	
during	O
median	B-MED
follow-up	O
of	O
17.8	O
years	B-MED
,	O
455	O
cvd	B-MED
events	O
occurred	O
.	O
	
when	O
compared	O
to	O
the	O
other	O
equations	B-MED
,	O
qtc	O
bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart	B-MED
rate	I-MED
r	O
=	O
0.18	O
.	O
	
the	O
hazard	B-MED
ratio	I-MED
95%	O
confidence	B-MED
interval	I-MED
for	O
cvd	B-MED
was	O
2.08	O
1.28	O
for	O
the	O
98th	O
percentile	B-MED
of	O
qt	B-MED
interval	I-MED
by	O
heart	B-MED
rate	I-MED
ranges	B-MED
,	O
2.05	O
1.27	O
for	O
qtc	B-MED
bazett	I-MED
,	O
1.39	O
0.44	O
for	O
qtc	B-MED
fridericia	O
,	O
1.05	O
0.26	O
for	O
qtc	O
hodges	I-MED
,	O
and	O
1.12	O
0.28	O
for	O
qtc	B-MED
framingham	I-MED
.	O
	
the	O
hazard	O
ratio	O
of	O
qtc	B-MED
bazett	I-MED
was	O
significantly	B-MED
higher	I-MED
than	O
the	O
other	O
formulas	B-MED
except	O
for	O
the	O
98th	O
percentile	B-MED
method	O
.	O
	
the	O
framingham	B-MED
,	O
hodges	B-MED
,	O
and	O
fridericia	B-MED
equations	I-MED
remove	B-MED
the	O
effect	B-MED
of	O
heart	B-MED
rate	I-MED
on	O
qt	B-MED
interval	I-MED
significantly	O
better	O
than	O
the	O
bazett	B-MED
equation	I-MED
.	O
	
using	O
qt-interval	B-MED
percentiles	B-MED
based	O
on	O
heart	B-MED
rate	I-MED
provides	O
a	O
consistent	O
approach	B-MED
both	O
for	O
identifying	O
those	O
whose	O
qt	B-MED
intervals	I-MED
prolong	O
due	O
to	O
drugs	B-MED
or	O
other	O
stressors	B-MED
and	O
for	O
assessing	O
cvd	B-MED
risk	B-MED
.	O
	
how	O
should	O
i	O
study	O
for	O
the	O
exam	B-MED
self-regulated	B-MED
learning	I-MED
strategies	B-MED
and	O
achievement	B-MED
in	O
introductory	B-MED
biology	I-MED
in	O
college	B-MED
introductory	B-MED
science	I-MED
courses	B-MED
,	O
students	B-MED
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary	B-MED
content	I-MED
while	O
developing	O
as	O
autonomous	B-MED
and	O
effective	B-MED
learners	B-MED
.	O
	
self-regulated	B-MED
learning	I-MED
srl	B-MED
is	O
the	O
process	O
of	O
setting	O
learning	B-MED
goals	I-MED
,	O
monitoring	O
progress	B-MED
toward	O
them	O
,	O
and	O
applying	O
appropriate	O
study	B-MED
strategies	I-MED
.	O
	
srl	B-MED
characterizes	O
successful	O
,	O
"""expert"""	O
learners	B-MED
,	O
and	O
develops	O
with	O
time	O
and	O
practice	O
.	O
	
in	O
a	O
large	O
,	O
undergraduate	B-MED
introductory	B-MED
biology	I-MED
course	B-MED
,	O
we	O
investigated	O
1	O
what	O
srl	B-MED
strategies	B-MED
students	B-MED
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	B-MED
,	O
2	O
which	O
strategies	B-MED
were	O
associated	O
with	O
higher	O
achievement	B-MED
and	O
with	O
grade	B-MED
improvement	B-MED
on	O
exams	B-MED
,	O
and	O
3	O
what	O
study	O
approaches	O
students	B-MED
proposed	O
to	O
use	O
for	O
future	O
exams	B-MED
.	O
	
higher	B-MED
-	O
achieving	B-MED
students	B-MED
,	O
and	O
students	B-MED
whose	O
exam	B-MED
grades	B-MED
improved	B-MED
in	O
the	O
first	B-MED
half	I-MED
of	O
the	O
semester	B-MED
,	O
reported	O
using	O
specific	O
cognitive	B-MED
and	O
metacognitive	B-MED
strategies	I-MED
significantly	O
more	O
frequently	B-MED
than	O
their	O
lower	B-MED
-	O
achieving	B-MED
peers	B-MED
.	O
	
lower	B-MED
-	O
achieving	B-MED
students	B-MED
more	O
frequently	B-MED
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	B-MED
or	O
,	O
if	O
they	O
did	O
,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	B-MED
.	O
	
these	O
results	O
suggest	O
that	O
many	O
students	B-MED
entering	O
introductory	B-MED
biology	I-MED
have	O
limited	B-MED
knowledge	B-MED
of	O
srl	B-MED
strategies	B-MED
and/or	O
limited	B-MED
ability	O
to	O
implement	O
them	O
,	O
which	O
can	O
impact	B-MED
their	O
achievement	B-MED
.	O
	
course	B-MED
-specific	O
interventions	B-MED
that	O
promote	O
srl	B-MED
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical	B-MED
tools	I-MED
,	O
aimed	O
at	O
fostering	B-MED
development	O
of	O
students	B-MED
'	O
lifelong	B-MED
learning	B-MED
skills	I-MED
.	O
	
characterising	B-MED
bias	B-MED
in	O
regulatory	B-MED
risk	I-MED
and	O
decision	B-MED
analysis	I-MED
an	O
analysis	B-MED
of	O
heuristics	B-MED
applied	O
in	O
health	B-MED
technology	I-MED
appraisal	B-MED
,	O
chemicals	B-MED
regulation	B-MED
,	O
and	O
climate	B-MED
change	I-MED
governance	B-MED
in	O
many	O
environmental	B-MED
and	O
public	B-MED
health	I-MED
domains	I-MED
,	O
heuristic	B-MED
methods	I-MED
of	O
risk	B-MED
and	O
decision	B-MED
analysis	I-MED
must	O
be	O
relied	O
upon	O
,	O
either	O
because	O
problem	B-MED
structures	I-MED
are	O
ambiguous	O
,	O
reliable	O
data	B-MED
is	O
lacking	B-MED
,	O
or	O
decisions	B-MED
are	O
urgent	O
.	O
	
this	O
introduces	O
an	O
additional	O
source	B-MED
of	O
uncertainty	B-MED
beyond	O
model	B-MED
and	O
measurement	B-MED
error	I-MED
-	O
uncertainty	B-MED
stemming	O
from	O
relying	O
on	O
inexact	O
inference	B-MED
rules	I-MED
.	O
	
here	O
we	O
identify	B-MED
and	O
analyse	B-MED
heuristics	B-MED
used	O
to	O
prioritise	O
risk	B-MED
objects	B-MED
,	O
to	O
discriminate	B-MED
between	O
signal	B-MED
and	O
noise	B-MED
,	O
to	O
weight	B-MED
evidence	B-MED
,	O
to	O
construct	O
models	B-MED
,	O
to	O
extrapolate	O
beyond	O
datasets	B-MED
,	O
and	O
to	O
make	O
policy	B-MED
.	O
	
some	O
of	O
these	O
heuristics	B-MED
are	O
based	O
on	O
causal	O
generalisations	B-MED
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	B-MED
are	O
presumed	O
rather	O
than	O
tested	O
e.g	O
.	O
	
surrogates	B-MED
in	O
clinical	B-MED
trials	I-MED
.	O
	
others	O
are	O
conventions	B-MED
designed	O
to	O
confer	O
stability	B-MED
to	O
decision	B-MED
analysis	I-MED
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	B-MED
when	O
applied	O
ritualistically	O
e.g	O
.	O
	
significance	B-MED
testing	I-MED
.	O
	
some	O
heuristics	B-MED
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	B-MED
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	B-MED
that	O
are	O
often	O
violated	O
in	O
practical	B-MED
applications	I-MED
.	O
	
heuristic	B-MED
decision	B-MED
rules	I-MED
e.g	O
.	O
	
feasibility	B-MED
rules	I-MED
in	O
principle	O
act	O
as	O
surrogates	B-MED
for	O
utility	B-MED
maximisation	I-MED
or	O
distributional	B-MED
concerns	B-MED
,	O
yet	O
in	O
practice	B-MED
may	O
neglect	O
costs	B-MED
and	I-MED
benefits	I-MED
,	O
be	O
based	O
on	O
arbitrary	B-MED
thresholds	B-MED
,	O
and	O
be	O
prone	O
to	O
gaming	O
.	O
	
we	O
highlight	O
the	O
problem	B-MED
of	O
rule-entrenchment	B-MED
,	O
where	O
analytical	B-MED
choices	I-MED
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	B-MED
,	O
masking	O
uncertainty	B-MED
and	O
potentially	O
introducing	O
bias	B-MED
.	O
	
strategies	B-MED
for	O
making	O
risk	B-MED
and	O
decision	B-MED
analysis	I-MED
more	O
rigorous	O
include	O
formalising	O
the	O
assumptions	B-MED
and	O
scope	B-MED
conditions	B-MED
under	O
which	O
heuristics	B-MED
should	O
be	O
applied	O
testing	B-MED
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	B-MED
or	O
theoretical	B-MED
justifications	I-MED
using	O
sensitivity	B-MED
analysis	B-MED
,	O
simulations	B-MED
,	O
multiple	B-MED
bias	I-MED
analysis	I-MED
,	O
and	O
deductive	B-MED
systems	I-MED
of	I-MED
inference	I-MED
e.g	O
.	O
	
directed	B-MED
acyclic	I-MED
graphs	I-MED
to	O
characterise	O
rule	B-MED
uncertainty	B-MED
and	O
refine	O
heuristics	B-MED
adopting	O
""""	O
recovery	B-MED
schemes	I-MED
""""	O
to	O
correct	O
for	O
known	O
biases	B-MED
and	O
basing	O
decision	B-MED
rules	I-MED
on	O
clearly	O
articulated	O
values	B-MED
and	O
evidence	B-MED
,	O
rather	O
than	O
multicentric	B-MED
castleman	I-MED
disease	I-MED
of	O
hyaline	B-MED
vascular	B-MED
variant	B-MED
presenting	O
with	O
unusual	B-MED
systemic	B-MED
manifestations	B-MED
a	O
case	B-MED
report	I-MED
castleman	B-MED
disease	I-MED
is	O
a	O
rare	B-MED
lymphoproliferative	B-MED
disorder	I-MED
presenting	O
with	O
localized	B-MED
or	O
disseminated	B-MED
lymphadenopathy	B-MED
and	O
systemic	B-MED
manifestations	B-MED
.	O
	
it	O
can	O
be	O
categorized	B-MED
in	O
numerous	B-MED
ways	O
,	O
such	O
as	O
unicentric	B-MED
versus	O
multicentric	B-MED
,	O
histopathological	B-MED
variants	B-MED
hyaline	B-MED
-	O
vascular	B-MED
,	O
plasma	B-MED
cell	I-MED
,	O
and	O
mixed	B-MED
,	O
or	O
subtypes	B-MED
based	O
on	O
causative	B-MED
viral	B-MED
infections	I-MED
human	B-MED
immunodeficiency	I-MED
virus	I-MED
,	O
human	B-MED
herpesvirus-8	I-MED
,	O
or	O
kaposi	B-MED
sarcoma	I-MED
herpesvirus	I-MED
.	O
	
presentation	O
ranges	O
from	O
asymptomatic	B-MED
to	O
symptoms	B-MED
involving	O
multiple	B-MED
organs	B-MED
.	O
	
even	O
though	O
the	O
exact	O
mechanism	B-MED
of	O
pathogenesis	B-MED
is	O
unknown	O
,	O
treatment	B-MED
is	O
directed	B-MED
toward	O
possible	O
etiologies	B-MED
such	O
as	O
interleukin-6	B-MED
,	O
cluster	B-MED
of	I-MED
differentiation	I-MED
20	I-MED
,	O
and	O
viral	B-MED
agents	I-MED
.	O
	
a	O
36-	O
year	B-MED
-old	O
sri	B-MED
lankan	I-MED
woman	B-MED
presented	O
with	O
generalized	O
body	B-MED
swelling	I-MED
and	O
foamy	B-MED
urine	I-MED
of	O
2	O
weeks	B-MED
'	O
duration	B-MED
.	O
	
examination	B-MED
revealed	O
pallor	B-MED
generalized	B-MED
edema	I-MED
axillary	B-MED
,	O
cervical	B-MED
,	O
and	O
inguinal	B-MED
lymphadenopathy	I-MED
hypertension	B-MED
and	O
hepatomegaly	B-MED
.	O
	
investigations	B-MED
showed	O
bicytopenia	B-MED
,	O
nephrotic	B-MED
range	I-MED
proteinuria	I-MED
with	O
hypoalbuminemia	B-MED
,	O
hypogammaglobulinemia	B-MED
,	O
and	O
features	B-MED
of	O
hyaline	B-MED
-	O
vascular	B-MED
type	B-MED
castleman	B-MED
disease	I-MED
in	O
a	O
lymph	B-MED
node	I-MED
biopsy	I-MED
.	O
	
she	O
was	O
managed	B-MED
with	O
rituximab	B-MED
and	O
had	O
good	O
clinical	B-MED
improvement	B-MED
.	O
	
castleman	B-MED
disease	I-MED
has	O
a	O
broad	B-MED
spectrum	B-MED
of	O
clinical	B-MED
manifestations	B-MED
,	O
disease	B-MED
pathogeneses	B-MED
,	O
and	O
associations	B-MED
and/or	O
complications	B-MED
.	O
	
medical	B-MED
professionals	B-MED
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	B-MED
because	O
timely	O
diagnosis	B-MED
and	O
aggressive	B-MED
targeted	I-MED
therapy	I-MED
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
the	O
ages-reykjavik	B-MED
study	I-MED
atlases	I-MED
non-linear	B-MED
multi-spectral	B-MED
template	I-MED
and	O
atlases	B-MED
for	O
studies	B-MED
of	O
the	O
ageing	B-MED
brain	B-MED
quantitative	B-MED
analyses	I-MED
of	O
brain	B-MED
structures	B-MED
from	O
magnetic	B-MED
resonance	I-MED
mr	B-MED
image	B-MED
data	B-MED
are	O
often	O
performed	O
using	O
automatic	B-MED
segmentation	B-MED
algorithms	B-MED
.	O
	
many	O
of	O
these	O
algorithms	B-MED
rely	O
on	O
templates	B-MED
and	O
atlases	B-MED
in	O
a	O
common	O
coordinate	B-MED
space	I-MED
.	O
	
most	O
freely	B-MED
available	B-MED
brain	B-MED
atlases	B-MED
are	O
generated	O
from	O
relatively	O
young	B-MED
individuals	B-MED
and	O
not	O
always	O
derived	O
from	O
well-defined	O
cohort	B-MED
studies	I-MED
.	O
	
in	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	B-MED
available	B-MED
multi-spectral	B-MED
template	I-MED
with	O
corresponding	O
tissue	B-MED
probability	B-MED
atlases	B-MED
and	O
regional	B-MED
atlases	B-MED
,	O
optimised	B-MED
to	O
use	O
in	O
studies	B-MED
of	O
ageing	B-MED
cohorts	B-MED
mean	O
age	O
75	O
5	O
years	O
.	O
	
furthermore	O
,	O
we	O
provide	O
validation	B-MED
data	B-MED
from	O
a	O
regional	B-MED
segmentation	B-MED
pipeline	O
to	O
assure	O
the	O
integrity	B-MED
of	O
the	O
comparative	B-MED
and	O
evolutionary	B-MED
analysis	I-MED
of	O
an	O
adapter	B-MED
molecule	I-MED
myd88	I-MED
in	O
invertebrate	B-MED
metazoans	B-MED
the	O
myeloid	B-MED
differentiation	I-MED
factor	I-MED
88	I-MED
myd88	B-MED
is	O
an	O
essential	O
adapter	O
in	O
toll-like	B-MED
receptor	I-MED
tlr	B-MED
signalling	B-MED
pathways	I-MED
,	O
with	O
tlr	B-MED
the	O
first	O
pattern-recognition	B-MED
receptor	I-MED
prr	B-MED
that	O
was	O
discovered	O
in	O
drosophila	B-MED
.	O
	
in	O
the	O
present	O
study	B-MED
,	O
a	O
myd88	B-MED
gene	I-MED
was	O
identified	B-MED
and	O
characterized	B-MED
from	O
a	O
commercially	O
important	O
shellfish	B-MED
,	O
scapharca	B-MED
subcrenata	I-MED
,	O
including	O
a	O
death	B-MED
domain	I-MED
and	O
tir	B-MED
domain	I-MED
conserved	O
within	O
other	O
molluscs	B-MED
.	O
	
furthermore	O
,	O
comparative	B-MED
genomic	I-MED
evidence	I-MED
revealed	O
that	O
myd88	B-MED
was	O
of	O
different	B-MED
lengths	B-MED
and	O
contained	O
quantitative	B-MED
exon	B-MED
and	O
intron	B-MED
regions	I-MED
,	O
which	O
might	O
be	O
involved	O
in	O
specific	B-MED
mechanisms	I-MED
.	O
	
to	O
further	O
explore	O
the	O
phylogenetic	B-MED
relationships	I-MED
of	O
invertebrate	B-MED
metazoan	B-MED
myd88	B-MED
,	O
we	O
applied	O
mrbayes	B-MED
and	I-MED
phyml	I-MED
software	I-MED
to	O
construct	B-MED
phylogenetic	B-MED
trees	I-MED
using	O
bayesian	B-MED
and	O
maximum	B-MED
likelihood	I-MED
approaches	I-MED
,	O
respectively	O
,	O
which	O
suggested	O
that	O
the	O
myd88	B-MED
of	O
arthropoda	B-MED
was	O
closely	O
related	O
to	O
lower	B-MED
invertebrates	B-MED
,	O
in	O
contrast	B-MED
to	O
morphological	B-MED
taxonomy	B-MED
.	O
	
finally	O
,	O
we	O
investigated	B-MED
the	O
evolutionary	B-MED
patterns	I-MED
and	O
location	O
of	O
positive	B-MED
selection	I-MED
sites	I-MED
psss	B-MED
in	O
the	O
myd88	B-MED
gene	I-MED
from	O
arthropoda	B-MED
,	O
mollusca	B-MED
and	O
insecta	B-MED
using	O
paml	B-MED
software	I-MED
with	O
the	O
maximum	B-MED
likelihood	I-MED
method	I-MED
.	O
	
the	O
data	B-MED
showed	O
that	O
positive	B-MED
selection	I-MED
sites	I-MED
were	O
detected	B-MED
in	O
these	O
groups	B-MED
,	O
and	O
partial	B-MED
sites	I-MED
were	O
located	O
in	O
the	O
tir	B-MED
domain	I-MED
but	O
were	O
not	B-MED
found	I-MED
in	O
the	O
death	B-MED
domain	I-MED
.	O
	
to	O
summarize	O
,	O
in	O
this	O
study	B-MED
,	O
we	O
report	O
on	O
the	O
diversification	B-MED
of	O
myd88	B-MED
in	O
invertebrate	B-MED
metazoans	B-MED
,	O
the	O
specific	B-MED
evolutionary	B-MED
position	I-MED
of	O
arthropoda	B-MED
myd88	B-MED
,	O
and	O
the	O
positive	B-MED
selection	B-MED
pressures	I-MED
on	O
myd88	B-MED
of	O
arthropoda	B-MED
,	O
mollusca	B-MED
and	O
insecta	B-MED
.	O
	
these	O
results	B-MED
are	O
a	O
valuable	B-MED
contribution	I-MED
to	O
understand	O
and	O
clarify	B-MED
the	O
evolutionary	B-MED
pattern	I-MED
of	O
tlr	B-MED
/	O
myd88	B-MED
signalling	B-MED
pathways	I-MED
in	O
invertebrate	B-MED
and	O
vertebrate	B-MED
taxa	I-MED
.	O
	
rubinstein-taybi	B-MED
syndrome	I-MED
associated	B-MED
with	I-MED
pituitary	B-MED
macroadenoma	I-MED
a	O
case	B-MED
report	I-MED
rubinstein-taybi	B-MED
syndrome	I-MED
rsts	B-MED
is	O
an	O
autosomal	B-MED
dominant	I-MED
disorder	I-MED
that	O
is	O
classically	O
characterized	B-MED
by	O
prenatal	B-MED
and	O
postnatal	B-MED
growth	B-MED
restriction	I-MED
,	O
microcephaly	B-MED
,	O
dysmorphic	B-MED
craniofacial	I-MED
features	I-MED
,	O
broad	B-MED
thumbs	I-MED
and	O
toes	B-MED
,	O
and	O
intellectual	B-MED
disability	I-MED
.	O
	
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	B-MED
macroadenoma	I-MED
associated	B-MED
with	I-MED
rsts	B-MED
.	O
	
a	O
39-year-old	O
caucasian	B-MED
female	B-MED
with	O
a	O
past	B-MED
medical	I-MED
history	I-MED
of	O
rsts	B-MED
diagnosed	B-MED
at	O
age	B-MED
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	B-MED
-enhancing	O
pituitary	B-MED
mass	I-MED
on	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
mri	B-MED
of	O
the	O
brain	B-MED
three	O
years	B-MED
ago	O
during	O
workup	O
for	O
migraine-like	B-MED
headaches	I-MED
.	O
	
subsequent	O
serial	O
imaging	B-MED
showed	O
radiographic	B-MED
evidence	I-MED
of	O
growth	B-MED
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	B-MED
.	O
	
the	O
pituitary	B-MED
sellar	B-MED
lesion	I-MED
was	O
resected	B-MED
through	O
an	O
endoscopic	B-MED
transnasal	B-MED
transsphenoidal	B-MED
approach	I-MED
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	B-MED
adenoma	I-MED
.	O
	
rsts	B-MED
is	O
a	O
rare	B-MED
,	O
neurodevelopmental	B-MED
genetic	B-MED
disease	I-MED
where	O
most	O
patients	B-MED
with	I-MED
disabilities	I-MED
survive	B-MED
into	O
adulthood	B-MED
.	O
	
the	O
disorder	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
predisposition	B-MED
for	O
development	B-MED
of	O
nervous	B-MED
system	I-MED
tumors	I-MED
,	O
including	O
pituitary	B-MED
adenomas	I-MED
.	O
	
the	O
clinico-	O
radiological	B-MED
paradox	B-MED
of	O
cognitive	B-MED
function	I-MED
and	O
mri	B-MED
burden	B-MED
of	O
white	B-MED
matter	I-MED
lesions	B-MED
in	O
people	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
a	O
systematic	B-MED
review	I-MED
and	O
meta-analysis	B-MED
moderate	B-MED
correlation	B-MED
exists	O
between	O
the	O
imaging	B-MED
quantification	I-MED
of	O
brain	B-MED
white	B-MED
matter	I-MED
lesions	B-MED
and	O
cognitive	B-MED
performance	B-MED
in	O
people	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
ms	B-MED
.	O
	
this	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	B-MED
,	O
including	O
subvisible	O
pathology	B-MED
,	O
or	O
methodological	B-MED
limitations	B-MED
of	O
the	O
primary	B-MED
literature	B-MED
.	O
	
to	O
summarise	O
the	O
cognitive	B-MED
clinico-	O
radiological	B-MED
paradox	B-MED
and	O
explore	O
the	O
potential	B-MED
methodological	B-MED
factors	B-MED
that	O
could	O
influence	O
the	O
assessment	B-MED
of	O
this	O
relationship	B-MED
.	O
	
systematic	B-MED
review	I-MED
and	O
meta-analysis	B-MED
of	O
primary	B-MED
research	B-MED
relating	O
cognitive	B-MED
function	I-MED
to	O
white	B-MED
matter	I-MED
lesion	B-MED
burden	B-MED
.	O
	
fifty	O
papers	B-MED
met	O
eligibility	B-MED
criteria	I-MED
for	O
review	B-MED
,	O
and	O
meta-analysis	B-MED
of	O
overall	O
results	B-MED
was	O
possible	O
in	O
thirty-two	O
2050	O
participants	B-MED
.	O
	
aggregate	B-MED
correlation	B-MED
between	O
cognition	B-MED
and	O
t2	B-MED
lesion	B-MED
burden	B-MED
was	O
r	O
=	O
-0	O
95%	O
confidence	B-MED
interval	I-MED
-0	O
,	O
-0	O
.	O
	
wide	O
methodological	B-MED
variability	B-MED
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	B-MED
in	O
the	O
cognitive	B-MED
data	B-MED
capture	O
and	O
image	B-MED
analysis	I-MED
techniques	I-MED
.	O
	
resolving	O
the	O
persistent	O
clinico-	O
radiological	B-MED
paradox	B-MED
will	O
likely	O
require	O
simultaneous	O
evaluation	B-MED
of	O
multiple	B-MED
components	B-MED
of	O
the	O
complex	B-MED
pathology	B-MED
using	O
optimum	B-MED
measurement	B-MED
techniques	B-MED
for	O
both	O
cognitive	B-MED
and	O
mri	B-MED
feature	B-MED
quantification	B-MED
.	O
	
we	O
recommend	O
a	O
consensus	B-MED
initiative	O
to	O
support	O
common	O
standards	B-MED
for	O
image	B-MED
analysis	I-MED
in	O
ms	B-MED
,	O
enabling	O
benchmarking	B-MED
while	O
also	O
supporting	O
ongoing	O
long	B-MED
non-coding	I-MED
rna	I-MED
snhg6	B-MED
as	O
a	O
potential	O
biomarker	B-MED
for	O
hepatocellular	B-MED
carcinoma	I-MED
long	B-MED
non-coding	I-MED
rnas	I-MED
lncrnas	B-MED
refer	O
to	O
all	O
non-protein	B-MED
coding	I-MED
transcripts	B-MED
longer	O
than	O
200	O
nucleotides	B-MED
.	O
	
their	O
critical	O
roles	O
in	O
different	O
biological	B-MED
pathways	B-MED
have	O
been	O
already	O
well	O
established	O
.	O
	
altered	O
expression	B-MED
of	O
lncrnas	B-MED
can	O
be	O
involved	O
in	O
the	O
cancer	B-MED
initiation	I-MED
and/or	O
progression	B-MED
.	O
	
since	O
patients	B-MED
with	O
hepatocellular	B-MED
carcinoma	I-MED
hcc	B-MED
are	O
usually	O
diagnosed	B-MED
in	O
late	B-MED
stages	I-MED
,	O
developing	O
diagnostic	B-MED
methods	I-MED
seems	O
to	O
be	O
essential	O
.	O
	
in	O
this	O
study	B-MED
,	O
the	O
expression	B-MED
levels	O
of	O
different	O
lncrnas	B-MED
were	O
systematically	O
analysed	B-MED
in	O
different	O
genomic	B-MED
and	O
transcriptome	B-MED
datasets	I-MED
.	O
	
the	O
analyses	B-MED
showed	O
that	O
snhg6	B-MED
is	O
among	O
the	O
lncrnas	B-MED
with	O
distinctive	O
dysregulation	B-MED
of	O
expression	B-MED
and	O
copy	O
number	O
variation	O
in	O
hcc	B-MED
tumors	I-MED
compared	O
with	O
normal	B-MED
tissues	I-MED
.	O
	
the	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	B-MED
of	O
snhg6	B-MED
is	O
highly	O
cancer	B-MED
type	O
specific	O
.	O
	
through	O
co-occurrence	O
analyses	B-MED
,	O
we	O
found	O
that	O
snhg6	B-MED
and	O
its	O
related	O
co-expressed	B-MED
genes	B-MED
on	O
8q	B-MED
are	O
involved	O
in	O
the	O
structural	B-MED
integrity	B-MED
of	O
ribosome	B-MED
and	O
translation	B-MED
.	O
	
this	O
comprehensive	B-MED
in	B-MED
silico	I-MED
analysis	B-MED
,	O
provides	O
a	O
resource	O
for	O
investigating	B-MED
snhg6	B-MED
in	O
hepatocellular	B-MED
carcinoma	I-MED
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
expressional	B-MED
divergence	B-MED
of	O
insect	B-MED
gox	B-MED
genes	I-MED
from	O
specialist	O
to	O
generalist	O
glucose	B-MED
oxidase	I-MED
insect	B-MED
herbivores	I-MED
often	O
secrete	B-MED
glucose	B-MED
oxidase	I-MED
gox	B-MED
onto	O
plants	B-MED
to	O
counteract	B-MED
plant	B-MED
defenses	B-MED
and	O
potential	B-MED
pathogens	B-MED
.	O
	
whether	O
generalist	O
herbivores	B-MED
always	O
have	O
significantly	B-MED
higher	I-MED
gox	B-MED
activities	B-MED
than	O
their	O
specialist	O
counterparts	B-MED
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown	O
.	O
	
to	O
address	O
these	O
two	O
general	O
questions	O
,	O
we	O
subjected	O
larvae	B-MED
of	O
a	O
pair	O
of	O
sister	O
species	B-MED
differed	O
mainly	O
in	O
host	O
range	O
,	O
the	O
generalist	O
helicoverpa	B-MED
armigera	I-MED
and	O
its	O
specialist	O
counterpart	B-MED
helicoverpa	B-MED
assulta	I-MED
,	O
to	O
the	O
same	O
sets	O
of	O
stage	O
,	O
protein	B-MED
to	O
digestible	B-MED
carbohydrate	B-MED
p	O
ratio	O
,	O
allelochemical	B-MED
or	O
host	B-MED
plant	I-MED
treatments	B-MED
for	O
simultaneous	O
analyses	O
of	O
gox	B-MED
transcripts	B-MED
and	O
activities	B-MED
in	O
their	O
labial	B-MED
glands	I-MED
.	O
	
gox	B-MED
activity	B-MED
and	O
transcripts	B-MED
are	O
upregulated	B-MED
concurrently	O
with	O
food	B-MED
ingestion	B-MED
and	O
body	B-MED
growth	I-MED
,	O
downregulated	B-MED
with	O
stopping	O
ingestion	B-MED
and	O
wandering	B-MED
for	O
pupation	B-MED
in	O
both	O
species	B-MED
.	O
	
the	O
three	O
tested	O
host	B-MED
plants	I-MED
upregulated	B-MED
gox	B-MED
transcripts	B-MED
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
gox	B-MED
activity	B-MED
in	O
both	O
species	B-MED
.	O
	
there	O
were	O
significant	O
differences	O
in	O
both	O
gox	B-MED
transcripts	B-MED
and	O
activity	B-MED
elicited	O
by	O
allelochemicals	B-MED
,	O
but	O
only	O
in	O
gox	B-MED
transcripts	B-MED
by	O
p	O
ratios	O
in	O
both	O
species	B-MED
.	O
	
gox	B-MED
activities	B-MED
were	O
higher	O
in	O
h	B-MED
.	O
	
armigera	I-MED
than	O
h	B-MED
.	O
	
assulta	I-MED
in	O
all	O
the	O
comparable	O
treatments	O
,	O
but	O
gox	B-MED
transcripts	B-MED
were	O
significantly	B-MED
higher	I-MED
either	O
in	O
generalists	O
or	O
in	O
specialists	O
,	O
depending	O
on	O
the	O
developmental	B-MED
stages	I-MED
,	O
host	B-MED
plants	I-MED
,	O
p	O
ratio	O
and	O
allelochemicals	B-MED
they	O
encounter	B-MED
.	O
	
these	O
data	B-MED
indicate	O
that	O
the	O
greater	B-MED
gox	B-MED
activity	B-MED
in	O
generalist	O
herbivores	B-MED
is	O
not	O
achieved	O
by	O
greater	B-MED
transcription	B-MED
rate	O
,	O
but	O
by	O
greater	O
transcript	B-MED
stability	O
,	O
greater	O
translation	B-MED
rate	O
,	O
better	B-MED
enzyme	I-MED
stability	I-MED
propranolol	B-MED
effects	O
on	O
decompression	B-MED
sickness	I-MED
in	O
a	O
simulated	O
dissub	B-MED
rescue	B-MED
in	O
swine	B-MED
disabled	B-MED
submarine	I-MED
dissub	B-MED
survivors	B-MED
may	O
face	O
elevated	B-MED
co2	I-MED
levels	I-MED
and	O
inert	B-MED
gas	I-MED
saturation	I-MED
,	O
putting	O
them	O
at	O
risk	O
for	O
co2	B-MED
toxicity	B-MED
and	O
decompression	B-MED
sickness	I-MED
dcs	B-MED
.	O
	
propranolol	B-MED
was	O
shown	O
to	O
reduce	B-MED
co2	I-MED
production	I-MED
in	O
an	O
experimental	O
dissub	B-MED
model	B-MED
in	O
humans	B-MED
but	O
its	O
effects	O
on	O
dcs	B-MED
in	O
a	O
dissub	B-MED
rescue	B-MED
scenario	I-MED
are	O
unknown	O
.	O
	
a	O
100%	O
oxygen	B-MED
prebreathe	I-MED
opb	B-MED
reduces	O
dcs	B-MED
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
dissub	B-MED
rescue	B-MED
protocols	I-MED
.	O
	
we	O
used	O
a	O
swine	B-MED
model	I-MED
of	O
dissub	B-MED
rescue	B-MED
to	O
study	O
the	O
effect	O
of	O
propranolol	B-MED
on	O
dcs	B-MED
incidence	O
and	O
mortality	B-MED
with	O
and	O
without	O
an	O
opb	B-MED
.	O
	
in	O
experiment	O
1	O
,	O
male	B-MED
yorkshire	B-MED
swine	I-MED
70	O
kg	O
were	O
pressurized	B-MED
to	O
2.8	O
ata	O
for	O
22	O
h	O
.	O
	
propranolol	B-MED
1.0	O
mg	O
kg-1	O
iv	O
was	O
administered	B-MED
at	I-MED
21.25	O
h	O
.	O
	
at	O
22	O
h	O
,	O
the	O
animal	B-MED
was	O
rapidly	B-MED
decompressed	I-MED
and	O
observed	O
for	O
dcs	B-MED
type	O
,	O
onset	B-MED
time	I-MED
,	O
and	O
mortality	B-MED
.	O
	
experimental	O
animals	B-MED
n	O
=	O
21	O
69	O
4.1	O
kg	O
,	O
prop1.0	B-MED
,	O
were	O
compared	O
to	O
prop1.0	B-MED
-	O
opb45	B-MED
n	O
=	O
8	O
69	O
2.8	O
kg	O
with	O
the	O
same	O
dive	B-MED
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
opb	B-MED
prior	O
to	O
decompression	B-MED
.	O
	
in	O
experiment	O
2	O
,	O
the	O
same	O
methodology	B-MED
was	O
used	O
with	O
the	O
following	O
changes	O
swine	B-MED
pressurized	B-MED
to	O
2.8	O
ata	O
for	O
28	O
h	O
experimental	O
group	O
n	O
=	O
25	O
67	O
3.3	O
kg	O
,	O
prop0.5	B-MED
bis	O
,	O
propranolol	B-MED
0.5	O
mg	O
kg-1	O
bis	O
twice	O
iv	O
was	O
administered	B-MED
at	I-MED
22	O
h	O
and	O
26	O
h	O
.	O
	
control	B-MED
animals	I-MED
n	O
=	O
25	O
67	O
3.9	O
kg	O
received	O
normal	B-MED
saline	I-MED
.	O
	
opb	B-MED
reduced	B-MED
mortality	I-MED
in	O
prop1.0	B-MED
-	O
obp45	B-MED
compared	O
to	O
prop1.0	B-MED
0%	O
vs	O
.	O
	
71%	O
.	O
	
prop0.5	B-MED
bis	O
had	O
increased	B-MED
mortality	I-MED
compared	O
to	O
control	O
60-%	O
vs	O
.	O
	
4%	O
.	O
	
administration	O
of	O
beta	B-MED
blockers	I-MED
prior	O
to	O
saturation	B-MED
decompression	I-MED
appears	O
to	O
increase	O
dcs	B-MED
and	O
worsen	B-MED
mortality	I-MED
in	O
a	O
swine	B-MED
model	B-MED
however	O
,	O
their	O
effects	O
in	O
bounce	B-MED
diving	I-MED
gut	B-MED
microbiota	I-MED
-mediated	O
protection	B-MED
against	O
diarrheal	B-MED
infections	B-MED
the	O
mammalian	B-MED
gut	B-MED
microbiota	I-MED
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	B-MED
community	B-MED
that	O
resides	B-MED
in	O
the	O
gastrointestinal	B-MED
tract	I-MED
.	O
	
one	O
major	O
benefit	O
that	O
the	O
gut	B-MED
microbiota	I-MED
provides	O
to	O
its	O
host	B-MED
is	O
colonization	B-MED
resistance	B-MED
-the	O
ability	O
to	O
prevent	B-MED
colonization	B-MED
by	O
foreign	B-MED
microbes	I-MED
,	O
including	O
diarrheal	B-MED
pathogens	B-MED
such	O
as	O
clostridium	B-MED
difficile	I-MED
,	O
salmonella	B-MED
enterica	I-MED
serovar	I-MED
typhimurium	I-MED
and	O
diarrheagenic	B-MED
escherichia	I-MED
coli	I-MED
.	O
	
we	O
conducted	O
a	O
literature	B-MED
review	I-MED
of	O
the	O
effects	B-MED
of	I-MED
the	O
gut	B-MED
microbiota	I-MED
on	O
infection	B-MED
by	O
diarrheal	B-MED
pathogens	B-MED
.	O
	
we	O
used	O
pubmed	B-MED
to	O
search	O
for	O
relevant	O
articles	B-MED
published	O
before	O
july	O
2016	O
,	O
as	O
well	O
as	O
incorporated	O
data	B-MED
from	O
our	O
laboratory	B-MED
.	O
	
the	O
gut	B-MED
microbiota	I-MED
provides	O
protection	B-MED
from	O
diarrheal	B-MED
infections	B-MED
both	O
by	O
direct	B-MED
inhibition	B-MED
of	O
pathogens	B-MED
and	O
by	O
indirect	B-MED
effects	B-MED
on	O
host	B-MED
functions	B-MED
.	O
	
direct	B-MED
effects	B-MED
of	I-MED
the	O
microbiota	B-MED
on	O
diarrheal	B-MED
pathogens	B-MED
include	O
competing	O
for	O
nutrients	B-MED
and	O
producing	O
metabolites	B-MED
that	O
inhibit	B-MED
pathogen	B-MED
growth	B-MED
or	O
virulence	B-MED
.	O
	
indirect	B-MED
effects	B-MED
of	I-MED
the	O
gut	B-MED
microbiota	I-MED
include	O
promoting	O
maintenance	B-MED
of	O
the	O
gut	B-MED
mucosal	I-MED
barrier	I-MED
and	O
stimulating	O
innate	B-MED
and	O
adaptive	B-MED
immunity	I-MED
.	O
	
human	B-MED
epidemiological	B-MED
studies	I-MED
and	O
experimental	B-MED
infections	B-MED
of	O
laboratory	B-MED
animals	I-MED
both	O
demonstrate	O
that	O
antibiotic	B-MED
treatment	I-MED
can	O
alter	O
the	O
gut	B-MED
microbial	I-MED
community	B-MED
and	O
thereby	O
reduce	O
colonization	B-MED
resistance	B-MED
against	O
diarrheal	B-MED
pathogens	B-MED
.	O
	
further	O
research	B-MED
might	O
lead	O
to	O
the	O
development	B-MED
of	O
next-generation	B-MED
probiotics	I-MED
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-MED
resistance	B-MED
and	O
thus	O
prevent	B-MED
travellers'	B-MED
diarrheal	I-MED
.	O
	
ecotoxicity	B-MED
testing	B-MED
and	O
environmental	B-MED
risk	I-MED
assessment	I-MED
of	O
iron	B-MED
nanomaterials	B-MED
for	O
sub-surface	O
remediation	B-MED
-	O
recommendations	B-MED
from	O
the	O
fp7	B-MED
project	I-MED
nanorem	I-MED
nanoremediation	B-MED
with	O
iron	B-MED
fe	B-MED
nanomaterials	B-MED
opens	O
new	O
doors	O
for	O
treating	B-MED
contaminated	B-MED
soil	B-MED
and	O
groundwater	B-MED
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	B-MED
risks	I-MED
as	O
large	O
quantities	O
of	O
engineered	B-MED
nanomaterials	I-MED
are	O
introduced	O
into	O
the	O
environment	B-MED
.	O
	
in	O
this	O
study	B-MED
,	O
we	O
have	O
assessed	B-MED
the	O
ecotoxicity	B-MED
of	O
four	O
engineered	O
fe	B-MED
nanomaterials	B-MED
,	O
specifically	O
,	O
nano-goethite	B-MED
,	O
trap-ox	B-MED
fe-zeolites	I-MED
,	O
carbo-iron	B-MED
and	O
fermeg12	B-MED
,	O
developed	O
within	O
the	O
european	B-MED
fp7	I-MED
project	I-MED
nanorem	I-MED
for	O
sub-surface	O
remediation	B-MED
towards	O
a	O
test	B-MED
battery	I-MED
consisting	O
of	O
eight	O
ecotoxicity	B-MED
tests	B-MED
on	O
bacteria	B-MED
v	B-MED
.	O
	
fisheri	I-MED
,	O
e	B-MED
.	O
	
coli	I-MED
,	O
algae	B-MED
p	B-MED
.	O
	
subcapitata	I-MED
,	O
chlamydomonas	B-MED
sp	I-MED
,	O
crustaceans	B-MED
d	B-MED
.	O
	
magna	I-MED
,	O
worms	B-MED
e	B-MED
.	O
	
fetida	I-MED
,	O
l	B-MED
.	O
	
variegatus	I-MED
and	O
plants	B-MED
r	B-MED
.	O
	
sativus	I-MED
,	O
l	B-MED
.	O
	
multiflorum	I-MED
.	O
	
the	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
fe	B-MED
oxide	I-MED
and	O
nanoscale	B-MED
zero	I-MED
valent	I-MED
iron	I-MED
nzvi	B-MED
,	O
but	O
also	O
hybrid	O
products	O
with	O
fe	B-MED
loaded	O
into	O
a	O
matrix	B-MED
.	O
	
all	O
but	O
one	O
material	B-MED
,	O
a	O
ball	B-MED
milled	I-MED
nzvi	I-MED
fermeg12	B-MED
,	O
showed	O
no	B-MED
toxicity	I-MED
in	O
the	O
test	B-MED
battery	I-MED
when	O
tested	O
in	O
concentrations	B-MED
up	O
to	O
100	O
mg/l	O
,	O
which	O
is	O
the	O
cutoff	B-MED
for	O
hazard	B-MED
labeling	B-MED
in	O
chemicals	B-MED
regulation	I-MED
in	O
europe	B-MED
.	O
	
however	O
it	O
should	O
be	O
noted	O
that	O
fe	B-MED
nanomaterials	B-MED
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	B-MED
,	O
aggregation	B-MED
and	O
sedimentation	B-MED
behavior	I-MED
in	O
aqueous	B-MED
media	B-MED
.	O
	
this	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	B-MED
concerning	O
future	B-MED
testing	I-MED
of	O
fe	B-MED
nanomaterials	B-MED
and	O
discusses	O
environmental	B-MED
risk	I-MED
assessment	I-MED
grade	B-MED
group	I-MED
underestimation	B-MED
in	O
prostate	B-MED
biopsy	I-MED
predictive	B-MED
factors	I-MED
and	O
outcomes	B-MED
in	O
candidates	B-MED
for	O
active	B-MED
surveillance	I-MED
we	O
intended	O
to	O
analyze	O
the	O
outcomes	B-MED
and	O
predictive	B-MED
factors	I-MED
for	O
underestimating	O
the	O
prostate	B-MED
cancer	I-MED
pca	B-MED
grade	B-MED
group	I-MED
gg	B-MED
from	O
prostate	B-MED
biopsies	I-MED
in	O
a	O
large	O
monocentric	B-MED
cohort	I-MED
of	O
patients	B-MED
treated	B-MED
by	O
minimally	B-MED
invasive	I-MED
radical	I-MED
prostatectomy	I-MED
rp	B-MED
.	O
	
using	O
a	O
monocentric	B-MED
prospectively	I-MED
maintained	I-MED
database	I-MED
,	O
we	O
included	O
3062	O
patients	B-MED
who	O
underwent	O
minimally	B-MED
invasive	I-MED
rp	I-MED
between	O
2006	O
and	O
2013	O
.	O
	
we	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-MED
associated	B-MED
with	I-MED
a	O
gg	B-MED
upgrade	O
from	O
biopsy	B-MED
to	O
rp	B-MED
.	O
	
multivariate	B-MED
logistic	I-MED
regression	I-MED
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B-MED
to	O
predict	O
upgrading	O
for	O
gg1	B-MED
.	O
	
biopsy	B-MED
gg	B-MED
was	O
upgraded	O
after	O
rp	B-MED
in	O
51.5	O
of	O
cases	O
.	O
	
patients	B-MED
upgraded	O
from	O
gg1	B-MED
to	O
gg2	B-MED
or	O
gg3	B-MED
after	O
rp	B-MED
had	O
a	O
longer	B-MED
time	I-MED
to	O
biochemical	B-MED
recurrence	I-MED
than	O
those	O
with	O
gg2	B-MED
or	O
gg3	B-MED
respectively	O
,	O
on	O
both	O
biopsy	B-MED
and	O
rp	B-MED
,	O
but	O
a	O
shorter	B-MED
time	I-MED
to	O
biochemical	B-MED
recurrence	I-MED
than	O
those	O
who	O
remained	O
gg1	B-MED
after	O
rp	O
p	O
<	O
0001	O
.	O
	
in	O
multivariate	B-MED
analyses	I-MED
,	O
variables	B-MED
predicting	O
upgrading	O
for	O
gg1	B-MED
pca	B-MED
were	O
age	B-MED
p	O
=	O
0014	O
,	O
abnormal	B-MED
digital	I-MED
rectal	I-MED
examination	I-MED
p	O
<	O
0001	O
,	O
prostate	B-MED
-specific	O
antigen	O
density	O
p	O
<	O
0001	O
,	O
percentage	O
of	O
positive	O
cores	O
p	O
<	O
0001	O
,	O
and	O
body	O
mass	O
index	O
p	O
=	O
037	O
.	O
	
a	O
nomogram	O
was	O
generated	O
and	O
validated	O
internally	O
.	O
	
biopsy	O
grading	O
system	O
is	O
misleading	O
in	O
approximately	O
50%	O
of	O
cases	O
.	O
	
upgrading	O
gg	O
from	O
biopsy	O
to	O
rp	O
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	O
.	O
	
a	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
gg1	O
patients	O
at	O
their	O
initial	O
evaluation	B-MED
characterization	B-MED
of	O
electrocorticogram	B-MED
high	B-MED
-	O
gamma	B-MED
signal	B-MED
in	O
response	B-MED
to	O
varying	B-MED
upper	B-MED
extremity	I-MED
movement	B-MED
velocity	B-MED
the	O
mechanism	B-MED
by	O
which	O
the	O
human	B-MED
primary	B-MED
motor	I-MED
cortex	I-MED
m1	B-MED
encodes	B-MED
upper	B-MED
extremity	I-MED
movement	B-MED
kinematics	B-MED
is	O
not	O
fully	O
understood	O
.	O
	
for	O
example	O
,	O
human	B-MED
electrocorticogram	B-MED
ecog	B-MED
signals	B-MED
have	O
been	O
shown	O
to	O
modulate	B-MED
with	O
upper	B-MED
extremity	I-MED
movement	B-MED
s	O
however	O
,	O
this	O
relationship	B-MED
has	O
not	O
been	O
explicitly	B-MED
characterized	B-MED
.	O
	
to	O
address	O
this	O
issue	B-MED
,	O
we	O
recorded	B-MED
high	B-MED
-	O
density	B-MED
ecog	B-MED
signals	B-MED
from	O
patients	B-MED
undergoing	O
epilepsy	B-MED
surgery	B-MED
evaluation	B-MED
as	O
they	O
performed	B-MED
elementary	B-MED
upper	B-MED
extremity	I-MED
movements	B-MED
while	O
systematically	B-MED
varying	B-MED
movement	B-MED
speed	B-MED
and	O
duration	B-MED
.	O
	
specifically	B-MED
,	O
subjects	B-MED
performed	B-MED
intermittent	B-MED
pincer	B-MED
grasp	I-MED
/	O
release	B-MED
,	O
elbow	B-MED
flexion	I-MED
/	O
extension	B-MED
,	O
and	O
shoulder	B-MED
flexion	I-MED
/	O
extension	B-MED
at	O
slow	B-MED
,	O
moderate	B-MED
,	O
and	O
fast	B-MED
speeds	B-MED
.	O
	
in	O
all	O
movements	B-MED
,	O
bursts	B-MED
of	O
power	B-MED
in	O
the	O
high	B-MED
-	O
see	O
text	O
band	O
80-160	O
hz	O
were	O
observed	B-MED
in	O
m1	B-MED
.	O
	
in	O
addition	B-MED
,	O
the	O
amplitude	B-MED
of	O
these	O
power	B-MED
bursts	B-MED
and	O
the	O
area	B-MED
of	O
m1	B-MED
with	O
elevated	B-MED
high	B-MED
-	O
see	O
text	O
activity	B-MED
were	O
directly	B-MED
proportional	B-MED
to	O
the	O
movement	B-MED
speed	B-MED
.	O
	
likewise	O
,	O
the	O
duration	B-MED
of	O
elevated	B-MED
high	B-MED
-	O
see	O
text	O
activity	B-MED
increased	B-MED
with	O
movement	B-MED
duration	B-MED
.	O
	
based	B-MED
on	O
linear	B-MED
regression	I-MED
,	O
m1	B-MED
high	B-MED
-	O
see	O
text	O
power	B-MED
amplitude	B-MED
and	O
duration	B-MED
covaried	B-MED
with	O
movement	B-MED
speed	B-MED
and	O
duration	B-MED
,	O
respectively	O
,	O
with	O
an	O
average	B-MED
formula	O
see	O
text	O
of	O
formula	O
see	O
text	O
and	O
formula	O
see	O
text	O
.	O
	
these	O
findings	B-MED
indicate	B-MED
that	O
the	O
encoding	B-MED
of	O
upper	B-MED
extremity	I-MED
movement	B-MED
speed	B-MED
by	O
m1	B-MED
high	B-MED
-	O
see	O
text	O
activity	B-MED
is	O
primarily	B-MED
linear	B-MED
.	O
	
also	O
,	O
the	O
fact	O
that	O
this	O
activity	B-MED
remained	O
elevated	B-MED
throughout	O
a	O
movement	B-MED
suggests	O
that	O
m1	B-MED
does	O
not	O
merely	O
generate	O
transient	B-MED
instructions	B-MED
for	O
a	O
specific	B-MED
movement	B-MED
duration	B-MED
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	B-MED
of	O
the	O
movement	B-MED
.	O
	
finally	O
,	O
the	O
spatial	B-MED
distribution	I-MED
of	O
high	B-MED
-	O
see	O
text	O
activity	B-MED
suggests	O
the	O
presence	B-MED
of	O
a	O
recruitment	B-MED
phenomenon	B-MED
in	O
which	O
higher	B-MED
speeds	B-MED
or	O
increased	B-MED
muscle	B-MED
activity	B-MED
involve	O
activation	B-MED
of	O
larger	O
m1	B-MED
area	B-MED
fatty	B-MED
acids	I-MED
have	O
different	B-MED
adipogenic	B-MED
differentiation	I-MED
potentials	B-MED
in	O
stromal	B-MED
vascular	I-MED
cells	I-MED
isolated	B-MED
from	O
abdominal	B-MED
fat	I-MED
in	O
laying	B-MED
hens	B-MED
this	O
study	B-MED
was	O
conducted	O
to	O
examine	O
the	O
effects	B-MED
of	I-MED
fatty	B-MED
acids	I-MED
fa	B-MED
with/without	O
chicken	B-MED
serum	I-MED
cs	B-MED
on	O
the	O
expression	B-MED
of	O
adipogenic	B-MED
transcripts	B-MED
and	O
adipogenesis	B-MED
in	O
chicken	B-MED
stromal	B-MED
vascular	I-MED
cells	I-MED
svc	B-MED
.	O
	
in	O
experiment	O
1	O
,	O
svc	B-MED
were	O
grown	O
in	O
dmem	B-MED
containing	O
10%	O
fbs	B-MED
control	B-MED
and	O
treated	B-MED
with	O
300	O
µm	O
oleic	B-MED
acid	I-MED
ola	B-MED
+	O
fbs	B-MED
,	O
linoleic	B-MED
acid	I-MED
lna	B-MED
+	O
fbs	B-MED
,	O
palmitic	B-MED
acid	I-MED
pam	B-MED
+	O
fbs	B-MED
,	O
or	O
stearic	B-MED
acid	I-MED
sta	B-MED
+	O
fbs	B-MED
for	O
48	O
h	O
.	O
	
in	O
experiment	O
2	O
,	O
cells	B-MED
were	O
grown	O
in	O
dmem	B-MED
containing	O
5%	O
cs	B-MED
and	O
treated	B-MED
with	O
300	O
µm	O
ola	B-MED
cs	B-MED
+	O
ola	B-MED
,	O
pam	B-MED
cs	B-MED
+	O
pam	B-MED
,	O
sta	B-MED
cs	B-MED
+	O
sta	B-MED
or	O
200	O
µm	O
lna	B-MED
cs	B-MED
+	O
lna	B-MED
for	O
48	O
h	O
.	O
	
adipogenesis	B-MED
was	O
determined	O
using	O
oil	B-MED
red	I-MED
o	I-MED
staining	I-MED
and	O
glycerol-3-phosphate	B-MED
dehydrogenase	I-MED
gpdh	I-MED
activity	I-MED
.	O
	
the	O
proportion	O
of	O
ola	B-MED
,	O
pam	B-MED
,	O
or	O
sta	B-MED
was	O
increased	B-MED
p	O
<	O
0.05	O
in	O
svc	B-MED
grown	O
in	O
either	O
fbs	B-MED
or	O
cs	B-MED
with	O
ola	B-MED
,	O
pam	B-MED
or	O
sta	B-MED
.	O
	
adipogenesis	B-MED
was	O
induced	B-MED
in	O
fbs	B-MED
+	O
ola	B-MED
,	O
fbs	B-MED
+	O
lna	B-MED
,	O
fbs	B-MED
+	O
pam	B-MED
,	O
fbs	B-MED
+	O
sta	B-MED
,	O
cs	B-MED
+	O
ola	B-MED
,	O
cs	B-MED
+	O
lna	B-MED
,	O
cs	B-MED
+	O
pam	B-MED
,	O
or	O
cs	B-MED
+	O
sta	B-MED
compared	O
to	O
fbs	B-MED
.	O
	
gpdh	B-MED
activity	I-MED
was	O
significantly	B-MED
higher	I-MED
in	O
fbs	B-MED
+	O
ola	B-MED
and	O
fbs	B-MED
+	O
lna	B-MED
than	O
one	O
in	O
fbs	B-MED
.	O
	
compared	O
to	O
fbs	B-MED
,	O
the	O
expression	B-MED
of	O
fabp4	B-MED
mrna	B-MED
increased	B-MED
p	O
<	O
0.05	O
in	O
fbs	B-MED
+	O
ola	B-MED
,	O
fbs	B-MED
+	O
lna	B-MED
,	O
or	O
fbs	B-MED
+	O
pam	B-MED
,	O
whereas	O
that	O
of	O
c/ebpα	B-MED
,	O
c/ebpβ	B-MED
,	O
and	O
atgl	B-MED
increased	B-MED
p	O
<	O
0.05	O
in	O
fbs	B-MED
+	O
ola	B-MED
or	O
fbs	B-MED
+	O
lna	B-MED
cells	B-MED
.	O
	
expression	B-MED
of	O
fabp4	B-MED
and	O
c/ebpβ	B-MED
mrna	B-MED
was	O
higher	B-MED
in	O
cs	B-MED
,	O
cs	B-MED
+	O
ola	B-MED
,	O
cs	B-MED
+	O
lna	B-MED
,	O
cs	B-MED
+	O
pam	B-MED
,	O
or	O
cs	B-MED
+	O
sta	B-MED
compared	B-MED
with	O
fbs	B-MED
,	O
whereas	O
the	O
expression	B-MED
of	O
atgl	B-MED
and	O
c/ebpα	B-MED
was	O
higher	B-MED
in	O
cs	B-MED
,	O
cs	B-MED
+	O
ola	B-MED
,	O
or	O
cs	B-MED
+	O
lna	B-MED
than	O
fbs	B-MED
cells	B-MED
.	O
	
in	O
conclusion	O
,	O
these	O
results	B-MED
showed	O
that	O
fa	B-MED
have	O
different	B-MED
potentials	B-MED
to	O
induce	B-MED
adipogenesis	B-MED
,	O
lna	B-MED
is	O
the	O
most	O
potent	B-MED
among	O
the	O
tested	O
fa	B-MED
,	O
and	O
these	O
potentials	B-MED
can	O
be	O
improved	O
in	O
the	O
presence	B-MED
of	O
a	O
novel	B-MED
rapid	B-MED
analysis	B-MED
using	O
mass	B-MED
spectrometry	I-MED
to	O
evaluate	O
downstream	B-MED
refolding	B-MED
of	O
recombinant	B-MED
human	I-MED
insulin-like	I-MED
growth	I-MED
factor-1	I-MED
mecasermin	B-MED
mecasermin	B-MED
is	O
used	O
to	O
treat	O
elevated	B-MED
blood	I-MED
sugar	I-MED
as	O
well	O
as	O
growth	B-MED
hormone	I-MED
-	O
resistant	B-MED
laron-type	B-MED
dwarfism	I-MED
.	O
	
mecasermin	B-MED
isolated	O
from	O
inclusion	B-MED
bodies	I-MED
in	O
extracts	O
of	O
e.coli	B-MED
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O
	
however	O
,	O
there	O
is	O
no	O
rapid	B-MED
analytical	B-MED
method	I-MED
for	O
monitoring	O
refolding	B-MED
during	O
the	O
purification	B-MED
process	O
.	O
	
we	O
prepared	O
mecasermin	B-MED
drug	B-MED
product	I-MED
,	O
in-process	O
samples	B-MED
during	O
the	O
oxidation	B-MED
of	O
mecasermin	B-MED
,	O
forced-reduced	O
mecasermin	B-MED
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-MED
after	O
forced	O
reduction	B-MED
.	O
	
desalted	O
mecasermin	B-MED
samples	B-MED
were	O
analyzed	O
using	O
maldi-isd	B-MED
.	O
	
the	O
peak	B-MED
intensity	I-MED
ratio	I-MED
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O
	
the	O
charge	B-MED
state	I-MED
distribution	I-MED
csd	B-MED
of	O
mecasermin	B-MED
ions	O
was	O
evaluated	O
using	O
esi-ms	B-MED
coupled	O
with	O
sec-mode	O
hplc	B-MED
.	O
	
the	O
drift	B-MED
time	I-MED
and	O
collision	B-MED
cross-sectional	I-MED
areas	I-MED
ccs	B-MED
of	O
mecasermin	B-MED
ions	O
were	O
evaluated	O
using	O
esi-ims-ms	B-MED
coupled	B-MED
with	O
sec-mode	O
hplc	B-MED
.	O
	
maldi-isd	B-MED
data	O
,	O
csd	B-MED
values	I-MED
determined	O
using	O
esi-ms	B-MED
,	O
and	O
the	O
ccs	B-MED
acquired	O
using	O
esi-ims-ms	B-MED
revealed	O
the	O
relationship	B-MED
between	O
the	O
folded	B-MED
and	O
unfolded	B-MED
proteoforms	B-MED
of	O
forced-reduced	O
mecasermin	B-MED
and	O
aerially	O
oxidized	O
mecasermin	B-MED
with	O
the	O
free-sh	B-MED
protein	I-MED
ratio	I-MED
of	O
mecasermin	B-MED
drug	B-MED
product	I-MED
.	O
	
the	O
collision	B-MED
cross-sectional	I-MED
area	I-MED
,	O
which	O
is	O
determined	O
using	O
esi-ims-ms	B-MED
,	O
provided	O
proteoform	B-MED
information	O
through	O
rapid	B-MED
monitoring	O
<2	O
min	O
of	O
in-process	O
samples	B-MED
during	O
the	O
manufacture	O
of	O
mecasermin	B-MED
.	O
	
esi-ims-ms	B-MED
coupled	O
with	O
sec-mode	O
hplc	B-MED
is	O
a	O
rapid	B-MED
and	O
robust	B-MED
method	O
for	O
analyzing	O
the	O
free-sh	B-MED
protein	I-MED
ratio	I-MED
of	O
mecasermin	B-MED
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B-MED
changes	O
during	O
the	O
oxidation	B-MED
of	O
mecasermin	B-MED
.	O
	
esi-ims-ms	B-MED
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
""""	O
critical	B-MED
quality	B-MED
attributes	B-MED
""""	O
and	O
implementing	O
""""	O
quality	B-MED
by	O
design	B-MED
""""	O
for	O
manufacturing	O
regulated	B-MED
intron	B-MED
removal	B-MED
integrates	O
motivational	B-MED
state	I-MED
and	O
experience	B-MED
myriad	O
experiences	B-MED
produce	O
transient	B-MED
memory	I-MED
,	O
yet	O
,	O
contingent	O
on	O
the	O
internal	B-MED
state	I-MED
of	O
the	O
organism	B-MED
and	O
the	O
saliency	O
of	O
the	O
experience	B-MED
,	O
only	O
some	O
memories	B-MED
persist	O
over	O
time	B-MED
.	O
	
how	O
experience	B-MED
and	O
internal	B-MED
state	I-MED
influence	B-MED
the	O
duration	B-MED
of	O
memory	B-MED
at	O
the	O
molecular	O
level	O
remains	O
unknown	O
.	O
	
a	O
self-assembled	B-MED
aggregated	I-MED
state	O
of	O
drosophila	B-MED
orb2a	I-MED
protein	I-MED
is	O
required	O
specifically	O
for	O
long-lasting	B-MED
memory	I-MED
.	O
	
we	O
report	O
that	O
in	O
the	O
adult	B-MED
fly	I-MED
brain	B-MED
the	O
mrna	B-MED
encoding	B-MED
orb2a	B-MED
protein	I-MED
exists	O
in	O
an	O
unspliced	B-MED
non-protein-coding	I-MED
form	I-MED
.	O
	
the	O
convergence	B-MED
of	O
experience	B-MED
and	O
internal	B-MED
drive	I-MED
transiently	O
increases	B-MED
the	O
spliced	B-MED
protein-coding	I-MED
orb2a	I-MED
mrna	I-MED
.	O
	
a	O
screen	O
identified	O
pasilla	B-MED
,	O
the	O
fly	B-MED
ortholog	O
of	O
mammalian	B-MED
nova-1	B-MED
/	O
2	B-MED
,	O
as	O
a	O
mediator	B-MED
of	O
orb2a	B-MED
mrna	I-MED
processing	B-MED
.	O
	
a	O
single-nucleotide	B-MED
substitution	B-MED
in	O
the	O
intronic	B-MED
region	O
that	O
reduces	B-MED
pasilla	B-MED
binding	B-MED
and	O
intron	B-MED
removal	B-MED
selectively	O
impairs	B-MED
long-term	B-MED
memory	I-MED
.	O
	
we	O
posit	O
that	O
pasilla	B-MED
-mediated	O
processing	B-MED
of	O
unspliced	B-MED
orb2a	I-MED
mrna	I-MED
integrates	O
experience	B-MED
and	O
internal	B-MED
state	I-MED
to	O
control	O
orb2a	B-MED
protein	I-MED
abundance	B-MED
and	O
long-term	B-MED
memory	I-MED
formation	B-MED
.	O
	
the	O
flashe	B-MED
study	I-MED
survey	B-MED
development	B-MED
,	O
dyadic	B-MED
perspectives	O
,	O
and	O
participant	B-MED
characteristics	B-MED
the	O
national	B-MED
cancer	I-MED
institute	I-MED
developed	O
the	O
family	B-MED
life	I-MED
,	O
activity	B-MED
,	O
sun	B-MED
,	O
health	B-MED
,	O
and	O
eating	B-MED
flashe	B-MED
study	B-MED
to	O
examine	O
multiple	O
cancer	B-MED
preventive	I-MED
behaviors	B-MED
within	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
.	O
	
the	O
purpose	O
of	O
creating	O
flashe	B-MED
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	B-MED
activity	I-MED
,	O
diet	B-MED
,	O
and	O
other	O
cancer	B-MED
preventive	I-MED
behaviors	I-MED
and	O
potential	O
correlates	O
among	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
.	O
	
flashe	B-MED
surveys	I-MED
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	B-MED
reviews	I-MED
,	O
scientific	B-MED
input	B-MED
from	O
experts	B-MED
in	O
the	O
field	O
,	O
cognitive	B-MED
testing	I-MED
,	O
and	O
usability	O
testing	O
.	O
	
this	O
cross-sectional	B-MED
,	O
web-based	B-MED
study	I-MED
of	O
parents	B-MED
and	O
their	O
adolescent	B-MED
children	B-MED
aged	O
12-17	O
years	O
was	O
administered	B-MED
between	O
april	B-MED
and	O
october	B-MED
2014	O
.	O
	
the	O
nationwide	O
sample	O
consisted	O
of	O
1	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
1	O
parents	B-MED
and	O
1	O
adolescents	B-MED
who	O
returned	O
all	O
flashe	B-MED
surveys	I-MED
.	O
	
flashe	B-MED
assessed	O
parent	B-MED
and	O
adolescent	B-MED
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	B-MED
domains	O
including	O
psychosocial	B-MED
variables	I-MED
,	O
parenting	B-MED
,	O
and	O
the	O
community	B-MED
and	O
home	B-MED
environments	I-MED
.	O
	
on	O
a	O
subset	O
of	O
example	O
flashe	B-MED
items	O
across	O
these	O
domains	O
,	O
responses	B-MED
of	O
parents	B-MED
and	O
adolescents	B-MED
within	O
the	O
same	O
dyads	B-MED
were	O
positively	O
and	O
significantly	O
correlated	B-MED
r	O
=0	O
.	O
	
analyses	O
were	O
run	O
in	O
2015-2016	O
.	O
	
flashe	B-MED
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	B-MED
questions	I-MED
among	O
individuals	B-MED
or	O
dyads	B-MED
,	O
including	O
the	O
ability	B-MED
to	O
examine	O
similarity	B-MED
between	O
parents	B-MED
and	O
adolescents	B-MED
on	O
many	O
constructs	O
relevant	O
to	O
cancer	B-MED
preventive	I-MED
behaviors	I-MED
.	O
	
flashe	B-MED
data	O
are	O
publicly	O
available	O
for	O
researchers	B-MED
and	O
practitioners	B-MED
to	O
help	O
advance	O
research	B-MED
on	O
cancer	B-MED
preventive	I-MED
health	B-MED
behaviors	I-MED
.	O
	
sex	B-MED
differences	I-MED
in	O
the	O
effect	B-MED
of	I-MED
chronic	B-MED
mild	I-MED
stress	I-MED
on	O
mouse	B-MED
prefrontal	B-MED
cortical	I-MED
bdnf	B-MED
levels	O
a	O
role	O
of	O
major	O
ovarian	B-MED
hormones	I-MED
depression	B-MED
induced	B-MED
by	O
stress	B-MED
is	O
affected	O
by	O
sex	B-MED
,	O
age	B-MED
and	O
hormonal	B-MED
status	O
of	O
the	O
animal	B-MED
and	O
also	O
by	O
duration	B-MED
and	O
type	O
of	O
the	O
stressors	B-MED
.	O
	
moreover	O
,	O
higher	O
prevalence	O
of	O
depression	B-MED
and	O
comorbidities	B-MED
in	O
women	B-MED
than	O
men	B-MED
implies	O
the	O
need	O
to	O
include	O
the	O
sex	B-MED
variable	O
in	O
studies	O
on	O
animal	B-MED
models	I-MED
of	O
depression	B-MED
.	O
	
the	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect	B-MED
of	I-MED
sex	B-MED
and	O
ovarian	B-MED
hormones	I-MED
on	O
depression	B-MED
-like	O
phenotypes	B-MED
in	O
mice	B-MED
exposed	O
to	O
a	O
21-day	O
chronic	B-MED
variable	I-MED
mild	I-MED
stress	I-MED
cvms	B-MED
paradigm	B-MED
.	O
	
adult	B-MED
male	B-MED
,	O
intact	B-MED
female	I-MED
and	O
,	O
ovariectomized	B-MED
ovx	I-MED
female	I-MED
mice	B-MED
exposed	O
to	O
cvms	B-MED
displayed	O
despair	O
behavior	B-MED
,	O
a	O
depression	B-MED
-like	O
phenotype	B-MED
,	O
in	O
all	O
the	O
groups	O
.	O
	
however	O
,	O
intact	B-MED
females	I-MED
alone	O
,	O
but	O
not	O
males	B-MED
and	O
ovx	B-MED
females	I-MED
,	O
showed	O
anhedonia	B-MED
,	O
another	O
depression	B-MED
-like	O
phenotype	B-MED
.	O
	
at	O
the	O
molecular	B-MED
level	I-MED
,	O
the	O
expression	B-MED
of	O
brain-derived	B-MED
neurotrophic	I-MED
factor	I-MED
bdnf	B-MED
,	O
a	O
neuropeptide	B-MED
associated	B-MED
with	I-MED
depression	B-MED
,	O
and	O
few	O
other	O
stress	B-MED
-specific	O
genes	B-MED
crh	B-MED
,	O
nr3c1	B-MED
,	O
cart	B-MED
,	O
and	O
npy	B-MED
were	O
measured	O
in	O
the	O
prefrontal	B-MED
cortex	I-MED
pfc	B-MED
region	O
of	O
the	O
reward	O
circuitry	O
.	O
	
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
bdnf	B-MED
protein	B-MED
expression	I-MED
along	O
with	O
an	O
increase	O
in	O
the	O
mrna	B-MED
expression	I-MED
of	O
crh	B-MED
,	O
nr3c1	B-MED
,	O
cart	B-MED
,	O
and	O
npy	B-MED
in	O
intact	B-MED
females	I-MED
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	B-MED
.	O
	
ovx	B-MED
females	I-MED
resembled	O
males	B-MED
in	O
behavioral	B-MED
and	O
molecular	B-MED
responses	I-MED
to	O
cvms	B-MED
.	O
	
17β-estradiol	B-MED
e2	B-MED
administration	B-MED
,	O
not	O
progesterone	B-MED
p4	B-MED
,	O
to	O
ovx	B-MED
female	I-MED
stress	B-MED
mice	B-MED
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	B-MED
of	O
bdnf	B-MED
in	O
pfc	B-MED
.	O
	
this	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects	B-MED
of	I-MED
e2	B-MED
administration	B-MED
in	O
stress	B-MED
development	B-MED
and	O
evaluation	B-MED
of	O
the	O
adhd	B-MED
cognitions	O
scale	O
for	O
adults	O
the	O
clinical	O
literature	O
on	O
adhd	B-MED
in	O
adults	O
suggests	O
that	O
""""	O
overly	O
positive	O
""""	O
or	O
optimistic	O
cognitions	O
may	O
contribute	O
to	O
impairment	O
and	O
failure	O
to	O
use	O
self-regulation	O
skills	O
in	O
this	O
population	O
,	O
yet	O
the	O
research	O
literature	O
on	O
this	O
topic	O
is	O
limited	O
.	O
	
we	O
developed	O
the	O
adhd	O
cognitions	I-MED
scale	I-MED
acs	O
,	O
a	O
brief	O
self-report	O
measure	O
of	O
adhd	O
-related	O
thoughts	O
,	O
and	O
evaluated	O
its	O
psychometric	O
properties	O
.	O
	
we	O
collected	O
self-report	O
measures	O
,	O
inculding	O
the	O
acs	O
,	O
from	O
two	O
large	O
community	O
samples	O
ns	O
=	O
262	O
,	O
304	O
.	O
	
the	O
measure	O
demonstrated	O
a	O
one-factor	O
solution	O
that	O
replicated	O
in	O
the	O
second	O
sample	O
.	O
	
evidence	O
of	O
good	O
internal	O
consistency	O
and	O
also	O
convergent	O
and	O
divergent	O
validity	O
was	O
obtained	O
for	O
both	O
samples	O
.	O
	
scores	O
on	O
the	O
acs	O
correlated	O
with	O
functional	O
impairment	O
,	O
time	O
management	O
problems	O
,	O
and	O
avoidant	O
coping	O
strategies	O
.	O
	
with	O
additional	O
study	O
,	O
the	O
acs	O
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	O
adhd	O
-related	O
cognitions	O
during	O
cognitive-behavioral	O
treatment	O
,	O
and	O
to	O
further	O
study	O
the	O
role	O
of	O
these	O
thoughts	O
in	O
adhd	O
-related	O
impairment	B-MED
visual	B-MED
confidence	B-MED
visual	B-MED
confidence	B-MED
refers	O
to	O
an	O
observer's	B-MED
ability	B-MED
to	O
judge	B-MED
the	O
accuracy	B-MED
of	O
her	O
perceptual	B-MED
decisions	I-MED
.	O
	
even	O
though	O
confidence	B-MED
judgments	B-MED
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	B-MED
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual	B-MED
perception	I-MED
.	O
	
the	O
reluctance	O
to	O
study	O
visual	B-MED
confidence	B-MED
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental	B-MED
evidence	I-MED
in	O
favor	O
of	O
metacognitive	B-MED
abilities	I-MED
rather	O
than	O
just	O
perceptual	B-MED
sensitivity	I-MED
.	O
	
some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental	B-MED
paradigms	I-MED
to	O
study	B-MED
visual	B-MED
confidence	B-MED
in	O
humans	B-MED
and	O
nonhuman	B-MED
animals	I-MED
.	O
	
to	O
understand	O
the	O
origins	B-MED
of	O
confidence	B-MED
judgments	B-MED
,	O
investigators	B-MED
have	O
developed	O
two	O
competing	O
frameworks	O
.	O
	
the	O
approach	O
based	O
on	O
signal	B-MED
decision	I-MED
theory	I-MED
is	O
popular	O
but	O
fails	B-MED
to	O
account	O
for	O
response	B-MED
times	I-MED
.	O
	
in	O
contrast	O
,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	B-MED
models	B-MED
naturally	O
includes	O
the	O
dynamics	B-MED
of	O
perceptual	B-MED
decisions	I-MED
.	O
	
these	O
models	B-MED
can	O
explain	O
a	O
range	O
of	O
results	B-MED
,	O
including	O
the	O
apparently	O
paradoxical	B-MED
dissociation	B-MED
between	O
performance	B-MED
and	O
confidence	B-MED
grapevine	B-MED
subtilase	B-MED
family	I-MED
update	O
on	O
new	O
sequences	B-MED
and	O
nomenclature	B-MED
proposal	I-MED
in	O
grapevine	B-MED
,	O
serine	B-MED
peptidases	I-MED
from	O
the	O
subtilase	B-MED
family	I-MED
were	O
recently	O
associated	O
to	O
plasmopara	B-MED
viticola	I-MED
resistance	B-MED
.	O
	
this	O
family	O
in	O
grapevine	B-MED
,	O
first	O
characterized	O
in	O
2014	O
,	O
was	O
re-analyzed	B-MED
last	O
year	O
and	O
82	O
subtilase	B-MED
genes	B-MED
were	O
identified	O
.	O
	
however	O
,	O
in	O
november	O
of	O
2016	O
,	O
the	O
national	B-MED
center	I-MED
for	I-MED
biotechnology	I-MED
information	I-MED
database	B-MED
ncbi	B-MED
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	B-MED
genome	B-MED
annotation	I-MED
based	O
on	O
new	O
sequencing	B-MED
data	I-MED
and	O
better	O
prediction	B-MED
algorithms	B-MED
.	O
	
as	O
a	O
consequence	B-MED
,	O
some	O
gene	B-MED
annotations	I-MED
and	O
lengths	O
changed	O
.	O
	
here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	B-MED
subtilase	B-MED
gene	B-MED
family	I-MED
sequences	B-MED
sbt	B-MED
,	O
namely	O
sequence	B-MED
identifiers	I-MED
,	O
bioinformatic	B-MED
predictions	B-MED
and	O
recommend	O
a	O
nomenclature	B-MED
for	O
the	O
grapevine	B-MED
sbt	B-MED
genes	B-MED
.	O
	
our	O
results	B-MED
show	O
that	O
grapevine	B-MED
subtilase	B-MED
gene	B-MED
family	I-MED
is	O
now	O
constituted	O
by	O
87	O
subtilase	B-MED
genes	B-MED
encoding	B-MED
for	O
109	O
subtilase	B-MED
proteins	I-MED
and	O
,	O
despite	O
the	O
reported	O
alterations	B-MED
,	O
expression	B-MED
data	B-MED
on	O
subtilases	B-MED
associated	O
to	O
grapevine	B-MED
resistance	B-MED
to	O
p	B-MED
.	O
	
viticola	I-MED
pathosystem	B-MED
did	O
not	O
suffer	O
any	O
shared	B-MED
decision	I-MED
making	I-MED
and	O
the	O
promise	B-MED
of	O
a	O
respectful	O
and	O
equitable	O
healthcare	B-MED
system	I-MED
in	O
peru	B-MED
peru	B-MED
has	O
achieved	O
sustained	B-MED
development	I-MED
in	O
the	O
last	O
two	O
decades	B-MED
.	O
	
however	O
,	O
despite	O
this	O
achievement	O
,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	B-MED
in	O
the	O
quality	B-MED
of	I-MED
education	I-MED
and	O
health	B-MED
investment	O
in	O
both	O
sectors	B-MED
is	O
among	O
the	O
lowest	O
in	O
the	O
region	B-MED
.	O
	
this	O
situation	O
perpetuates	O
huge	O
gaps	B-MED
in	O
infrastructure	B-MED
and	O
also	O
conditions	O
a	O
poor	B-MED
literacy	I-MED
level	I-MED
of	O
the	O
population	B-MED
specifically	O
in	O
health	B-MED
.	O
	
currently	O
,	O
there	O
is	O
a	O
fragmented	O
model	B-MED
of	O
patient	B-MED
care	I-MED
,	O
in	O
which	O
the	O
systems	B-MED
are	O
exclusive	O
of	O
each	O
other	O
.	O
	
they	O
do	O
not	O
cooperate	B-MED
or	O
communicate	B-MED
with	O
each	O
other	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	B-MED
within	O
the	O
system	B-MED
,	O
preventing	O
referral	B-MED
of	I-MED
patients	I-MED
directly	O
from	O
the	O
basic	B-MED
level	I-MED
to	O
the	O
complex	B-MED
level	I-MED
of	O
care	B-MED
when	O
needed	O
.	O
	
in	O
addition	O
,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	B-MED
of	O
an	O
empathetic	O
,	O
respectful	O
or	O
person-centered	B-MED
clinical	I-MED
practice	I-MED
instead	O
,	O
economic	B-MED
,	O
social	B-MED
and	O
educational	B-MED
differences	O
perpetuate	O
a	O
paternalistic	O
clinical	B-MED
practice	I-MED
.	O
	
the	O
task	O
of	O
orienting	O
medical	B-MED
training	I-MED
towards	O
the	O
development	B-MED
of	O
humanism	B-MED
is	O
pending	O
.	O
	
the	O
patient	B-MED
is	O
the	O
center	O
of	O
the	O
medical	B-MED
act	I-MED
and	O
the	O
main	O
objective	O
of	O
doctors'	B-MED
actions	O
.	O
	
a	O
humanistic	B-MED
care	I-MED
approach	I-MED
will	O
not	O
only	O
empower	O
the	O
person	B-MED
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his/her	O
health	B-MED
care	I-MED
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic	O
,	O
caring	B-MED
,	O
respectful	B-MED
and	O
kind	O
model	B-MED
of	O
clinical	B-MED
practice	I-MED
.	O
	
identification	O
of	O
markers	B-MED
for	O
quiescent	B-MED
pancreatic	B-MED
stellate	I-MED
cells	I-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
pancreatic	B-MED
stellate	I-MED
cells	I-MED
pscs	B-MED
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	B-MED
cells	I-MED
in	O
pancreatic	B-MED
cancer	I-MED
and	O
chronic	B-MED
pancreatitis	I-MED
.	O
	
in	O
contrast	O
to	O
quiescent	B-MED
hepatic	B-MED
stellate	I-MED
cells	I-MED
qhscs	B-MED
,	O
a	O
specific	O
marker	B-MED
for	O
quiescent	B-MED
pscs	B-MED
qpscs	B-MED
that	O
can	O
be	O
used	O
in	O
formalin-fixed	B-MED
and	I-MED
paraffin	I-MED
embedded	I-MED
ffpe	I-MED
normal	I-MED
human	I-MED
pancreatic	I-MED
tissue	I-MED
has	O
not	O
been	O
identified	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qpscs	B-MED
in	O
normal	B-MED
human	B-MED
ffpe	B-MED
pancreatic	I-MED
tissue	I-MED
.	O
	
immunohistochemical	B-MED
ihc	B-MED
,	O
double-ihc	B-MED
,	O
immunofluorescence	B-MED
if	B-MED
and	O
double-if	B-MED
analyses	I-MED
were	O
carried	O
out	O
using	O
a	O
tissue	B-MED
microarray	I-MED
consisting	O
of	O
cores	O
with	O
normal	B-MED
human	B-MED
pancreatic	B-MED
tissue	I-MED
.	O
	
cores	O
with	O
normal	B-MED
human	B-MED
liver	B-MED
served	O
as	O
control	B-MED
.	O
	
antibodies	B-MED
directed	O
against	O
adipophilin	B-MED
,	O
α-sma	B-MED
,	O
cd146	B-MED
,	O
crbp-1	B-MED
,	O
cytoglobin	B-MED
,	O
desmin	B-MED
,	O
gfap	B-MED
,	O
nestin	B-MED
,	O
s100a4	B-MED
and	O
vinculin	B-MED
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	B-MED
cells	B-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
and	O
perisinusoidal	B-MED
cells	I-MED
in	O
the	O
normal	B-MED
human	B-MED
liver	B-MED
.	O
	
the	O
immunolabelling	B-MED
capacity	B-MED
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	B-MED
scoring	I-MED
system	I-MED
.	O
	
double-if	B-MED
of	O
the	O
markers	B-MED
of	O
interest	O
together	O
with	O
markers	B-MED
for	O
other	O
periacinar	B-MED
cells	B-MED
was	O
performed	O
.	O
	
moreover	O
,	O
the	O
utility	O
of	O
histochemical	B-MED
stains	I-MED
for	O
the	O
identification	O
of	O
human	B-MED
qpscs	B-MED
was	O
examined	O
,	O
and	O
their	O
ultrastructure	B-MED
was	O
revisited	O
by	O
electron	B-MED
microscopy	I-MED
.	O
	
adipophilin	B-MED
,	O
crbp-1	B-MED
,	O
cytoglobin	B-MED
and	O
vinculin	B-MED
were	O
expressed	O
in	O
qhscs	B-MED
in	O
the	O
liver	B-MED
,	O
whereas	O
cytoglobin	B-MED
and	O
adipophilin	B-MED
were	O
expressed	O
in	O
qpscs	B-MED
in	O
the	O
pancreas	B-MED
.	O
	
adipophilin	B-MED
immunohistochemistry	B-MED
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	B-MED
time	I-MED
interval	I-MED
pati	B-MED
from	O
removal	O
of	O
the	O
tissue	B-MED
to	O
formalin	B-MED
fixation	I-MED
.	O
	
cytoglobin	B-MED
,	O
s100a4	B-MED
and	O
vinculin	B-MED
were	O
expressed	O
in	O
periacinar	B-MED
fibroblasts	B-MED
fbs	B-MED
.	O
	
the	O
other	O
examined	O
markers	B-MED
were	O
negative	O
in	O
human	B-MED
qpscs	B-MED
.	O
	
our	O
data	O
indicate	O
that	O
cytoglobin	B-MED
and	O
adipophilin	B-MED
are	O
markers	B-MED
of	O
qpscs	B-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
.	O
	
however	O
,	O
the	O
use	O
of	O
adipophilin	B-MED
as	O
a	O
qpsc	B-MED
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
pati	B-MED
.	O
	
cytoglobin	B-MED
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	B-MED
for	O
qpscs	B-MED
but	O
is	O
expressed	O
in	O
fbs	B-MED
biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
a	O
review	B-MED
of	I-MED
magnetic	B-MED
signatures	O
from	O
biological	B-MED
sensors	I-MED
biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	B-MED
magnetism	B-MED
.	O
	
particulate	B-MED
matter	I-MED
pm	B-MED
in	O
atmospheric	B-MED
pollution	I-MED
contains	O
readily-	O
measurable	B-MED
concentrations	O
of	O
magnetic	B-MED
minerals	I-MED
.	O
	
biological	B-MED
surfaces	B-MED
,	O
exposed	O
to	O
atmospheric	B-MED
pollution	I-MED
,	O
accumulate	O
magnetic	B-MED
particles	B-MED
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	B-MED
-	O
specific	B-MED
,	O
time-integrated	B-MED
air	B-MED
quality	I-MED
information	B-MED
.	O
	
this	O
review	B-MED
summarizes	O
current	O
knowledge	O
of	O
biological	B-MED
material	I-MED
'	O
sensors	B-MED
'	O
used	O
for	O
biomagnetic	B-MED
monitoring	I-MED
purposes	O
.	O
	
our	O
work	O
addresses	O
the	O
range	O
of	O
magnetic	B-MED
properties	I-MED
reported	O
for	O
lichens	B-MED
,	O
mosses	B-MED
,	O
leaves	B-MED
,	O
bark	B-MED
,	O
trunk	B-MED
wood	I-MED
,	O
insects	B-MED
,	O
crustaceans	B-MED
,	O
mammal	B-MED
and	O
human	B-MED
tissues	I-MED
their	O
associations	O
with	O
atmospheric	B-MED
pollutant	I-MED
species	I-MED
pm	B-MED
,	O
nox	B-MED
,	O
trace	B-MED
elements	I-MED
,	O
pahs	B-MED
the	O
pros	B-MED
and	I-MED
cons	I-MED
of	O
biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
current	O
challenges	O
for	O
large-scale	B-MED
implementation	I-MED
of	O
biomagnetic	B-MED
monitoring	I-MED
and	O
future	B-MED
perspectives	O
.	O
	
a	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	B-MED
and	O
policy	B-MED
makers	I-MED
in	O
selecting	O
the	O
most	O
suitable	O
biological	B-MED
sensor	I-MED
for	O
their	O
intended	O
biomagnetic	B-MED
monitoring	I-MED
role	O
of	O
infrared	B-MED
spectroscopy	I-MED
and	O
imaging	B-MED
in	O
cancer	B-MED
diagnosis	B-MED
ftir	B-MED
imaging	B-MED
has	O
been	O
used	O
to	O
diagnose	B-MED
and	O
differentiate	B-MED
the	O
molecular	B-MED
differences	B-MED
between	O
normal	B-MED
and	O
diseased	B-MED
tissues	B-MED
.	O
	
the	O
differences	B-MED
correspond	O
to	O
the	O
distribution	B-MED
and	O
structure	B-MED
of	O
lipids	B-MED
,	O
proteins	B-MED
,	O
nucleic	B-MED
acids	I-MED
as	O
well	O
as	O
other	O
metabolites	B-MED
.	O
	
these	O
differences	B-MED
depended	O
on	O
the	O
type	B-MED
and	O
the	O
grade	O
of	O
cancer	B-MED
.	O
	
the	O
sensitivity	B-MED
of	O
chemotherapy	B-MED
drugs	B-MED
on	O
individual	B-MED
specific	O
was	O
also	O
discussed	O
.	O
	
here	O
,	O
we	O
emphasize	O
that	O
ftir	B-MED
spectroscopy	I-MED
and	O
imaging	B-MED
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	B-MED
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-MED
of	O
this	O
dreadful	B-MED
disease	I-MED
because	O
of	O
high	B-MED
sensitivity	I-MED
,	O
accuracy	B-MED
and	O
inexpensive	O
technique	B-MED
.	O
	
now	O
the	O
medical	B-MED
community	I-MED
started	O
using	O
and	O
accepting	O
this	O
technique	B-MED
for	O
early	B-MED
stage	I-MED
cancer	B-MED
detection	B-MED
.	O
	
but	O
,	O
this	O
technique	B-MED
endures	O
several	O
challenges	B-MED
on	O
its	O
application	O
into	O
the	O
diagnosis	B-MED
of	O
cancer	B-MED
in	O
regards	O
of	O
sample	B-MED
preparations	I-MED
,	O
data	B-MED
interpretation	I-MED
,	O
and	O
data	B-MED
analysis	I-MED
.	O
	
in	O
general	O
,	O
more	O
research	B-MED
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	B-MED
and	O
biology	B-MED
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	B-MED
and	O
imaging	B-MED
because	O
invaluable	B-MED
information	B-MED
the	O
clasp2	B-MED
protein	B-MED
interaction	I-MED
network	I-MED
in	O
adipocytes	B-MED
links	O
clip2	B-MED
to	O
agap3	B-MED
,	O
clasp2	B-MED
to	O
g2l1	B-MED
,	O
mark2	B-MED
,	O
and	O
soga1	B-MED
,	O
and	O
identifies	O
soga1	B-MED
as	O
a	O
microtubule-associated	B-MED
protein	I-MED
clasp2	B-MED
is	O
a	O
microtubule-associated	B-MED
protein	I-MED
that	O
undergoes	O
insulin	B-MED
-	O
stimulated	B-MED
phosphorylation	B-MED
and	O
co-localization	B-MED
with	O
reorganized	B-MED
actin	B-MED
and	O
glut4	B-MED
at	O
the	O
plasma	B-MED
membrane	I-MED
.	O
	
to	O
gain	B-MED
insight	B-MED
to	O
the	O
role	B-MED
of	O
clasp2	B-MED
in	O
this	O
system	B-MED
,	O
we	O
developed	B-MED
and	O
successfully	B-MED
executed	B-MED
a	O
streamlined	B-MED
interactome	B-MED
approach	B-MED
and	O
built	O
a	O
clasp2	B-MED
protein	B-MED
network	I-MED
in	O
3t3-l1	B-MED
adipocytes	I-MED
.	O
	
using	O
two	O
different	B-MED
commercially	B-MED
available	B-MED
antibodies	B-MED
for	O
clasp2	B-MED
and	O
an	O
antibody	B-MED
for	O
epitope	B-MED
-tagged	O
,	O
overexpressed	B-MED
clasp2	B-MED
,	O
we	O
performed	B-MED
multiple	B-MED
affinity	B-MED
purification	I-MED
coupled	B-MED
with	O
mass	B-MED
spectrometry	I-MED
ap	B-MED
-	O
ms	B-MED
experiments	B-MED
in	O
combination	B-MED
with	O
label-free	B-MED
quantitative	B-MED
proteomics	B-MED
and	O
analyzed	B-MED
the	O
data	B-MED
with	O
the	O
bioinformatics	B-MED
tool	B-MED
significance	B-MED
analysis	I-MED
of	I-MED
interactome	I-MED
saint	B-MED
.	O
	
we	O
discovered	B-MED
that	O
clasp2	B-MED
co-immunoprecipitates	B-MED
co-ips	B-MED
the	O
novel	O
protein	B-MED
soga1	B-MED
,	O
the	O
microtubule-associated	B-MED
protein	I-MED
kinase	I-MED
mark2	B-MED
,	O
and	O
the	O
microtubule	B-MED
/	O
actin	B-MED
-	O
regulating	B-MED
protein	B-MED
g2l1	B-MED
.	O
	
the	O
gtpase-activating	B-MED
proteins	I-MED
agap1	B-MED
and	O
agap3	B-MED
were	O
also	O
enriched	O
in	O
the	O
clasp2	B-MED
interactome	B-MED
,	O
although	O
subsequent	B-MED
agap3	B-MED
and	O
clip2	B-MED
interactome	B-MED
analysis	B-MED
suggests	O
a	O
preference	B-MED
of	O
agap3	B-MED
for	O
clip2	B-MED
.	O
	
follow-up	O
mark2	B-MED
interactome	B-MED
analysis	B-MED
confirmed	B-MED
reciprocal	B-MED
co-ip	B-MED
of	O
clasp2	B-MED
and	O
also	O
revealed	O
mark2	B-MED
can	O
co-ip	B-MED
soga1	B-MED
,	O
glycogen	B-MED
synthase	I-MED
,	O
and	O
glycogenin	B-MED
.	O
	
investigating	B-MED
the	O
soga1	B-MED
interactome	B-MED
confirmed	B-MED
soga1	B-MED
can	O
reciprocal	B-MED
co-ip	B-MED
both	O
clasp2	B-MED
and	O
mark2	B-MED
as	O
well	O
as	O
glycogen	B-MED
synthase	I-MED
and	O
glycogenin	B-MED
.	O
	
soga1	B-MED
was	O
confirmed	B-MED
to	O
colocalize	B-MED
with	O
clasp2	B-MED
and	O
also	O
with	O
tubulin	B-MED
,	O
which	O
identifies	O
soga1	B-MED
as	O
a	O
new	O
microtubule-associated	B-MED
protein	I-MED
.	O
	
these	O
results	B-MED
introduce	O
the	O
metabolic	B-MED
function	I-MED
of	O
these	O
proposed	B-MED
novel	O
protein	B-MED
networks	I-MED
and	O
their	O
relationship	B-MED
with	O
microtubules	B-MED
as	O
new	O
fields	O
of	O
cytoskeleton	B-MED
-	O
associated	B-MED
protein	B-MED
biology	I-MED
.	O
	
